,Broader,N,PUBMEDID,AUTHOR,DiseaseOrTrait,STAGE,DATE,STUDY ACCESSION,parentterm,color
2,European,36745.0,31413261.0,Deelen J,Longevity (age >90th survival percentile),initial,2019-08-14,GCST008598,Other measurement,#d53e4f
3,European,7544.0,31413261.0,Deelen J,Longevity (age >90th survival percentile),replication,2019-08-14,GCST008598,Other measurement,#d53e4f
4,European,28967.0,31413261.0,Deelen J,Longevity (age >99th survival percentile),initial,2019-08-14,GCST008599,Other measurement,#d53e4f
5,European,6898.0,31413261.0,Deelen J,Longevity (age >99th survival percentile),replication,2019-08-14,GCST008599,Other measurement,#d53e4f
6,Asian,4477.0,31413261.0,Deelen J,Longevity (age >90th survival percentile),initial,2019-08-14,GCST008600,Other measurement,#3288bd
7,African Am./Caribbean,388.0,31413261.0,Deelen J,Longevity (age >90th survival percentile),initial,2019-08-14,GCST008600,Other measurement,#fee08b
8,European,36745.0,31413261.0,Deelen J,Longevity (age >90th survival percentile),initial,2019-08-14,GCST008600,Other measurement,#d53e4f
9,Asian,4477.0,31413261.0,Deelen J,Longevity (age >99th survival percentile),initial,2019-08-14,GCST008601,Other measurement,#3288bd
10,European,28967.0,31413261.0,Deelen J,Longevity (age >99th survival percentile),initial,2019-08-14,GCST008601,Other measurement,#d53e4f
11,Hispanic/Latin American,11103.0,31393916.0,Andaleon A,High density lipoprotein cholesterol levels,initial,2019-08-08,GCST008592,Lipid or lipoprotein measurement,#807dba
12,Hispanic/Latin American,11103.0,31393916.0,Andaleon A,Total cholesterol levels,initial,2019-08-08,GCST008594,Lipid or lipoprotein measurement,#807dba
13,Hispanic/Latin American,11103.0,31393916.0,Andaleon A,Low density lipoprotein cholesterol levels,initial,2019-08-08,GCST008593,Lipid or lipoprotein measurement,#807dba
14,Hispanic/Latin American,11103.0,31393916.0,Andaleon A,Triglyceride levels,initial,2019-08-08,GCST008591,Lipid or lipoprotein measurement,#807dba
15,European,120552.0,31374203.0,Lam M,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)",initial,2019-08-01,GCST008595,Neurological disorder,#d53e4f
17,European,120552.0,31374203.0,Lam M,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)",initial,2019-08-01,GCST008595,Biological process,#d53e4f
19,European,120552.0,31374203.0,Lam M,"Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)",initial,2019-08-01,GCST008595,Other measurement,#d53e4f
21,European,146660.0,31358989.0,Gelernter J,Post-traumatic stress disorder (re-experiencing symptoms),initial,2019-07-29,GCST008490,Other measurement,#d53e4f
22,European,117900.0,31358989.0,Gelernter J,Post-traumatic stress disorder (re-experiencing symptoms),replication,2019-07-29,GCST008490,Other measurement,#d53e4f
23,African Am./Caribbean,19983.0,31358989.0,Gelernter J,Post-traumatic stress disorder (re-experiencing symptoms),initial,2019-07-29,GCST008490,Other measurement,#fee08b
24,Asian,6264.0,31345160.0,Jia H,Coffee consumption,initial,2019-07-26,GCST008487,Other measurement,#3288bd
25,Asian,5975.0,31345160.0,Jia H,Coffee consumption,replication,2019-07-26,GCST008487,Other measurement,#3288bd
26,African Am./Caribbean,1158.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (adjusted lung density),initial,2019-07-19,GCST008477,Other measurement,#fee08b
27,European,4427.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (adjusted lung density),initial,2019-07-19,GCST008477,Other measurement,#d53e4f
28,African Am./Caribbean,1158.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (adjusted lung density),initial,2019-07-19,GCST008477,Other measurement,#fee08b
29,European,4427.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (adjusted lung density),initial,2019-07-19,GCST008477,Other measurement,#d53e4f
30,African,2578.0,31324766.0,Adeyemo AA,Type 2 diabetes,replication,2019-07-19,GCST008463,Metabolic disorder,#fc8d59
31,African,5231.0,31324766.0,Adeyemo AA,Type 2 diabetes,initial,2019-07-19,GCST008463,Metabolic disorder,#fc8d59
32,African Am./Caribbean,1158.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (percent low attenuation area),initial,2019-07-19,GCST008476,Other measurement,#fee08b
33,European,4427.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (percent low attenuation area),initial,2019-07-19,GCST008476,Other measurement,#d53e4f
34,African Am./Caribbean,1158.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (percent low attenuation area),initial,2019-07-19,GCST008476,Other measurement,#fee08b
35,European,4427.0,31324189.0,Kim W,Emphysema annual change measurement in smokers (percent low attenuation area),initial,2019-07-19,GCST008476,Other measurement,#d53e4f
36,African Am./Caribbean,8599.0,31324766.0,Adeyemo AA,Type 2 diabetes,initial,2019-07-19,GCST008464,Metabolic disorder,#fee08b
37,African,5231.0,31324766.0,Adeyemo AA,Type 2 diabetes,initial,2019-07-19,GCST008464,Metabolic disorder,#fc8d59
38,European,750.0,31320639.0,Hillary RF,Neurological blood protein biomarker levels,initial,2019-07-18,GCST008478,Other measurement,#d53e4f
39,Hispanic/Latin American,1047.0,31315583.0,Lona-Durazo F,Skin pigmentation (conditioned on rs1426654 and rs35397),initial,2019-07-17,GCST008516,Other measurement,#807dba
40,African Am./Caribbean,373.0,31315583.0,Lona-Durazo F,Skin pigmentation (conditioned on rs1426654 and rs35397),initial,2019-07-17,GCST008516,Other measurement,#fee08b
41,Other/Mixed,684.0,31315583.0,Lona-Durazo F,Skin pigmentation (conditioned on rs1426654 and rs35397),initial,2019-07-17,GCST008516,Other measurement,#99d594
42,European,9677.0,31311600.0,Namjou B,Nonalcoholic fatty liver disease (SNP x SNP interaction),initial,2019-07-17,GCST008470,Digestive system disorder,#d53e4f
43,European,1075.0,31311600.0,Namjou B,Alanine aminotransferase levels in non-alcoholic fatty liver disease,initial,2019-07-17,GCST008466,Liver enzyme measurement,#d53e4f
44,European,1075.0,31311600.0,Namjou B,Alanine aminotransferase levels in non-alcoholic fatty liver disease,initial,2019-07-17,GCST008466,Digestive system disorder,#d53e4f
45,European,1075.0,31311600.0,Namjou B,Aspartate aminotransferase levels in non-alcoholic fatty liver disease,initial,2019-07-17,GCST008467,Liver enzyme measurement,#d53e4f
46,European,1075.0,31311600.0,Namjou B,Aspartate aminotransferase levels in non-alcoholic fatty liver disease,initial,2019-07-17,GCST008467,Digestive system disorder,#d53e4f
47,European,235.0,31311600.0,Namjou B,Liver fibrosis in non-alcoholic fatty acid liver disease,initial,2019-07-17,GCST008469,Digestive system disorder,#d53e4f
48,European,235.0,31311600.0,Namjou B,Liver fibrosis in non-alcoholic fatty acid liver disease,initial,2019-07-17,GCST008469,Other trait,#d53e4f
49,European,235.0,31311600.0,Namjou B,Non-alcoholic fatty liver disease activity score,initial,2019-07-17,GCST008471,Other measurement,#d53e4f
50,European,9677.0,31311600.0,Namjou B,Nonalcoholic fatty liver disease,initial,2019-07-17,GCST008468,Digestive system disorder,#d53e4f
51,Hispanic/Latin American,1047.0,31315583.0,Lona-Durazo F,Skin pigmentation,initial,2019-07-17,GCST008519,Other measurement,#807dba
52,Other/Mixed,684.0,31315583.0,Lona-Durazo F,Skin pigmentation,initial,2019-07-17,GCST008519,Other measurement,#99d594
53,African Am./Caribbean,373.0,31315583.0,Lona-Durazo F,Skin pigmentation,initial,2019-07-17,GCST008519,Other measurement,#fee08b
54,European,5628.0,31346403.0,Massrali A,Autistic traits score (Social and Communication Disorders Checklist),initial,2019-07-17,GCST008484,Other measurement,#d53e4f
55,Hispanic/Latin American,762.0,31315583.0,Lona-Durazo F,Skin pigmentation,initial,2019-07-17,GCST008518,Other measurement,#807dba
56,European,72517.0,31308545.0,Watson HJ,Anorexia nervosa,initial,2019-07-15,GCST008465,Metabolic disorder,#d53e4f
57,European,545.0,31295725.0,Wang ZT,Change in neurofilament light levels,initial,2019-07-11,GCST008497,Other measurement,#d53e4f
58,European,19431.0,31294817.0,Chen J,Fagerstrӧm test for nicotine dependence,initial,2019-07-11,GCST008548,Other measurement,#d53e4f
59,European,7010.0,31294817.0,Chen J,Fagerstrӧm test for nicotine dependence,replication,2019-07-11,GCST008548,Other measurement,#d53e4f
60,Asian,4061.0,31289104.0,Kawamura Y,Gout vs. Hyperuricemia,replication,2019-07-08,GCST008460,Metabolic disorder,#3288bd
61,Asian,1948.0,31289104.0,Kawamura Y,Gout vs. Hyperuricemia,initial,2019-07-08,GCST008460,Metabolic disorder,#3288bd
62,Asian,4061.0,31289104.0,Kawamura Y,Gout vs. Hyperuricemia,replication,2019-07-08,GCST008460,Metabolic disorder,#3288bd
63,Asian,1948.0,31289104.0,Kawamura Y,Gout vs. Hyperuricemia,initial,2019-07-08,GCST008460,Metabolic disorder,#3288bd
64,European,13382.0,31285632.0,Klarin D,Minimum ankle–brachial index,initial,2019-07-08,GCST008475,Cardiovascular measurement,#d53e4f
65,African,3284.0,31285632.0,Klarin D,Minimum ankle–brachial index,initial,2019-07-08,GCST008475,Cardiovascular measurement,#fc8d59
66,Hispanic/Latin American,998.0,31285632.0,Klarin D,Minimum ankle–brachial index,initial,2019-07-08,GCST008475,Cardiovascular measurement,#807dba
67,European,174992.0,31285632.0,Klarin D,Peripheral artery disease,initial,2019-07-08,GCST008474,Cardiovascular disease,#d53e4f
68,African,47858.0,31285632.0,Klarin D,Peripheral artery disease,initial,2019-07-08,GCST008474,Cardiovascular disease,#fc8d59
69,Hispanic/Latin American,20210.0,31285632.0,Klarin D,Peripheral artery disease,initial,2019-07-08,GCST008474,Cardiovascular disease,#807dba
70,European,394408.0,31285632.0,Klarin D,Peripheral artery disease,replication,2019-07-08,GCST008474,Cardiovascular disease,#d53e4f
71,European,504.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other measurement,#d53e4f
72,Asian,73.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other measurement,#3288bd
73,Other/Mixed,18.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other measurement,#99d594
75,African Am./Caribbean,5.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other measurement,#fee08b
76,European,504.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Response to drug,#d53e4f
77,Asian,73.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Response to drug,#3288bd
78,Other/Mixed,18.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Response to drug,#99d594
80,African Am./Caribbean,5.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Response to drug,#fee08b
81,European,504.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other disease,#d53e4f
82,Asian,73.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other disease,#3288bd
83,Other/Mixed,18.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other disease,#99d594
85,African Am./Caribbean,5.0,31295674.0,Condreay LD,Exacerbation frequency in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008269,Other disease,#fee08b
86,European,504.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other measurement,#d53e4f
87,Asian,73.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other measurement,#3288bd
88,Other/Mixed,18.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other measurement,#99d594
89,African Am./Caribbean,5.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other measurement,#fee08b
91,European,504.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Response to drug,#d53e4f
92,Asian,73.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Response to drug,#3288bd
93,Other/Mixed,18.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Response to drug,#99d594
94,African Am./Caribbean,5.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Response to drug,#fee08b
96,European,504.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other disease,#d53e4f
97,Asian,73.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other disease,#3288bd
98,Other/Mixed,18.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other disease,#99d594
99,African Am./Caribbean,5.0,31295674.0,Condreay LD,Frequency of exacerbations requiring hospitalisation in mepolizumab-treated chronic obstructive pulmonary disease,initial,2019-07-05,GCST008268,Other disease,#fee08b
101,European,510.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis,initial,2019-07-04,GCST008461,Other measurement,#d53e4f
102,European,1156.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis,replication,2019-07-04,GCST008461,Other measurement,#d53e4f
103,European,510.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis,initial,2019-07-04,GCST008461,Cardiovascular disease,#d53e4f
104,European,1156.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis,replication,2019-07-04,GCST008461,Cardiovascular disease,#d53e4f
105,European,510.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis (conditioned on rs6027),initial,2019-07-04,GCST008462,Other measurement,#d53e4f
106,European,1156.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis (conditioned on rs6027),replication,2019-07-04,GCST008462,Other measurement,#d53e4f
107,European,510.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis (conditioned on rs6027),initial,2019-07-04,GCST008462,Cardiovascular disease,#d53e4f
108,European,1156.0,31271701.0,Thibord F,Plasma factor V levels in venous thrombosis (conditioned on rs6027),replication,2019-07-04,GCST008462,Cardiovascular disease,#d53e4f
109,Asian,218.0,31269844.0,Wu NN,Diabetes (gestational),initial,2019-07-03,GCST008448,Metabolic disorder,#3288bd
110,European,4723.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (long-term average),initial,2019-07-03,GCST008447,Biological process,#d53e4f
111,African Am./Caribbean,1527.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (long-term average),initial,2019-07-03,GCST008447,Biological process,#fee08b
112,European,306.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (long-term average),replication,2019-07-03,GCST008447,Biological process,#d53e4f
113,African Am./Caribbean,169.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (long-term average),replication,2019-07-03,GCST008447,Biological process,#fee08b
114,African Am./Caribbean,1527.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (first five times drinking),initial,2019-07-03,GCST008446,Biological process,#fee08b
115,European,306.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (first five times drinking),replication,2019-07-03,GCST008446,Biological process,#d53e4f
116,African Am./Caribbean,169.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (first five times drinking),replication,2019-07-03,GCST008446,Biological process,#fee08b
117,European,4723.0,31270906.0,Lai D,Number of alcoholic drinks required to feel an effect (first five times drinking),initial,2019-07-03,GCST008446,Biological process,#d53e4f
119,Asian,3092.0,31268507.0,Periyasamy S,Schizophrenia,initial,2019-07-03,GCST008459,Neurological disorder,#3288bd
120,European,1843.0,31264924.0,Meng W,Diabetic maculopathy with decreased visual acuity in type 2 diabetes,initial,2019-07-02,GCST008545,Other measurement,#d53e4f
121,European,1843.0,31264924.0,Meng W,Diabetic maculopathy with decreased visual acuity in type 2 diabetes,initial,2019-07-02,GCST008545,Metabolic disorder,#d53e4f
122,European,2614.0,31264924.0,Meng W,Diabetic maculopathy in type 2 diabetes,initial,2019-07-02,GCST008546,Metabolic disorder,#d53e4f
123,Other/Mixed,1498.0,31260374.0,Pedergnana V,Pre-treatment viral load in hepatitis C virus genotype 3,initial,2019-07-01,GCST008515,Digestive system disorder,#99d594
124,Other/Mixed,409.0,31260374.0,Pedergnana V,Response to direct-acting antiviral treatment in hepatitis C virus genotype 3,initial,2019-07-01,GCST008520,Digestive system disorder,#99d594
125,European,6064.0,31263063.0,Dufek S,Childhood steroid-sensitive nephrotic syndrome,initial,2019-07-01,GCST008456,Other disease,#d53e4f
126,Other/Mixed,1258.0,31260374.0,Pedergnana V,Response to interferon treatment in hepatitis C virus genotype 3,initial,2019-07-01,GCST008517,Response to drug,#99d594
127,Other/Mixed,1258.0,31260374.0,Pedergnana V,Response to interferon treatment in hepatitis C virus genotype 3,initial,2019-07-01,GCST008517,Digestive system disorder,#99d594
128,European,935.0,31262040.0,Pujol-Moix N,Platelet reactivity measurement (collagen-ADP),initial,2019-06-30,GCST008458,Cardiovascular measurement,#d53e4f
129,European,935.0,31262040.0,Pujol-Moix N,Platelet reactivity measurement (collagen-epinephrine),initial,2019-06-30,GCST008457,Cardiovascular measurement,#d53e4f
130,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Other disease,#99d594
131,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Other disease,#99d594
132,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Response to drug,#99d594
133,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Response to drug,#99d594
134,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Response to drug,#99d594
135,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Response to drug,#99d594
136,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Other measurement,#99d594
137,Other/Mixed,1209.0,31299468.0,Condreay LD,Change in quality of life in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008292,Other measurement,#99d594
138,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#3288bd
139,Asian,1.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#3288bd
140,Other/Mixed,3.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#99d594
141,Other/Mixed,4.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#99d594
142,Other/Mixed,7.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#99d594
143,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#3288bd
145,European,1869.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other measurement,#d53e4f
146,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#3288bd
147,Asian,1.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#3288bd
148,Other/Mixed,3.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#99d594
149,Other/Mixed,4.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#99d594
150,Other/Mixed,7.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#99d594
151,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#3288bd
153,European,1869.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Other disease,#d53e4f
154,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
155,Asian,1.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
156,Other/Mixed,3.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
157,Other/Mixed,4.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
158,Other/Mixed,7.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
159,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
161,European,1869.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#d53e4f
162,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
163,Asian,1.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
164,Other/Mixed,3.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
165,Other/Mixed,4.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
166,Other/Mixed,7.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#99d594
167,Asian,33.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#3288bd
169,European,1869.0,31299468.0,Condreay LD,Change in trough FEV1 in response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008293,Response to drug,#d53e4f
170,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Other measurement,#99d594
171,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Other measurement,#99d594
172,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Other disease,#99d594
173,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Other disease,#99d594
174,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Response to drug,#99d594
175,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Response to drug,#99d594
176,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Response to drug,#99d594
177,Other/Mixed,1188.0,31299468.0,Condreay LD,Response to fluticasone propionate/salmeterol in chronic obstructive pulmonary disease,initial,2019-06-29,GCST008294,Response to drug,#99d594
178,Hispanic/Latin American,15124.0,31251759.0,Swenson BR,QRS duration,initial,2019-06-28,GCST008422,Cardiovascular measurement,#807dba
180,European,2384.0,31246245.0,Khawaja AP,Corneal resistance factor,replication,2019-06-27,GCST008276,Other measurement,#d53e4f
181,Asian,6867.0,31243853.0,Chung S,Response to hepatitis B vaccine,initial,2019-06-27,GCST008435,Other measurement,#3288bd
182,Asian,2610.0,31243853.0,Chung S,Response to hepatitis B vaccine,replication,2019-06-27,GCST008435,Other measurement,#3288bd
183,Asian,6867.0,31243853.0,Chung S,Response to hepatitis B vaccine,initial,2019-06-27,GCST008435,Response to drug,#3288bd
184,Asian,2610.0,31243853.0,Chung S,Response to hepatitis B vaccine,replication,2019-06-27,GCST008435,Response to drug,#3288bd
186,European,2384.0,31246245.0,Khawaja AP,Corneal hysteresis,replication,2019-06-27,GCST008277,Other measurement,#d53e4f
187,Hispanic/Latin American,11816.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces or use of dentures",initial,2019-06-24,GCST008295,Digestive system disorder,#807dba
188,European,476007.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces or use of dentures",initial,2019-06-24,GCST008295,Digestive system disorder,#d53e4f
189,Hispanic/Latin American,11816.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces or use of dentures",initial,2019-06-24,GCST008295,Other trait,#807dba
190,European,476007.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces or use of dentures",initial,2019-06-24,GCST008295,Other trait,#d53e4f
191,European,495646.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Digestive system disorder,#d53e4f
192,Asian,17350.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Digestive system disorder,#3288bd
193,Hispanic/Latin American,10948.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Digestive system disorder,#807dba
194,European,495646.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Other measurement,#d53e4f
195,Asian,17350.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Other measurement,#3288bd
196,Hispanic/Latin American,10948.0,31235808.0,Shungin D,Periodontitis or loose teeth,initial,2019-06-24,GCST008296,Other measurement,#807dba
197,European,127121.0,31235810.0,Fung K,Arterial stiffness index,initial,2019-06-24,GCST008403,Cardiovascular measurement,#d53e4f
198,European,461031.0,31235808.0,Shungin D,Loose teeth,initial,2019-06-24,GCST008297,Other measurement,#d53e4f
199,European,16133.0,31235808.0,Shungin D,Number of natural teeth,initial,2019-06-24,GCST008298,Other measurement,#d53e4f
200,Hispanic/Latin American,11816.0,31235808.0,Shungin D,Number of natural teeth,initial,2019-06-24,GCST008298,Other measurement,#807dba
201,European,461031.0,31235808.0,Shungin D,Mouth ulcers,initial,2019-06-24,GCST008304,Other trait,#d53e4f
202,European,461031.0,31235808.0,Shungin D,Toothache,initial,2019-06-24,GCST008305,Other trait,#d53e4f
203,European,461031.0,31235808.0,Shungin D,Dentures,initial,2019-06-24,GCST008306,Other trait,#d53e4f
204,European,461031.0,31235808.0,Shungin D,Painful gums,initial,2019-06-24,GCST008303,Other measurement,#d53e4f
205,European,461031.0,31235808.0,Shungin D,Bleeding gums,initial,2019-06-24,GCST008301,Other trait,#d53e4f
206,Hispanic/Latin American,10948.0,31235808.0,Shungin D,Periodontitis,initial,2019-06-24,GCST008300,Digestive system disorder,#807dba
207,Asian,17350.0,31235808.0,Shungin D,Periodontitis,initial,2019-06-24,GCST008300,Digestive system disorder,#3288bd
208,European,17353.0,31235808.0,Shungin D,Periodontitis,initial,2019-06-24,GCST008300,Digestive system disorder,#d53e4f
209,European,14717.0,31235808.0,Shungin D,Number of decayed and filled tooth surfaces per available tooth surface,initial,2019-06-24,GCST008299,Digestive system disorder,#d53e4f
210,Hispanic/Latin American,11816.0,31235808.0,Shungin D,Number of decayed and filled tooth surfaces per available tooth surface,initial,2019-06-24,GCST008299,Digestive system disorder,#807dba
211,European,14976.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces",initial,2019-06-24,GCST008302,Digestive system disorder,#d53e4f
212,Hispanic/Latin American,11816.0,31235808.0,Shungin D,"Number of decayed, missing and filled tooth surfaces",initial,2019-06-24,GCST008302,Digestive system disorder,#807dba
213,European,2974.0,31231134.0,Laskar RS,Renal cell carcinoma,replication,2019-06-23,GCST008225,Cancer,#d53e4f
214,European,5087.0,31231134.0,Laskar RS,Renal cell carcinoma,initial,2019-06-23,GCST008225,Cancer,#d53e4f
215,European,8143.0,31231134.0,Laskar RS,Renal cell carcinoma,initial,2019-06-23,GCST008226,Cancer,#d53e4f
216,European,8113.0,31231134.0,Laskar RS,Renal cell carcinoma,replication,2019-06-23,GCST008226,Cancer,#d53e4f
217,European,13230.0,31231134.0,Laskar RS,Renal cell carcinoma x sex interaction,initial,2019-06-23,GCST008224,Other measurement,#d53e4f
218,European,11087.0,31231134.0,Laskar RS,Renal cell carcinoma x sex interaction,replication,2019-06-23,GCST008224,Other measurement,#d53e4f
219,European,13230.0,31231134.0,Laskar RS,Renal cell carcinoma x sex interaction,initial,2019-06-23,GCST008224,Cancer,#d53e4f
220,European,11087.0,31231134.0,Laskar RS,Renal cell carcinoma x sex interaction,replication,2019-06-23,GCST008224,Cancer,#d53e4f
221,Hispanic/Latin American,7953.0,31226226.0,Du Z,Prostate cancer,initial,2019-06-21,GCST008231,Cancer,#807dba
223,European,85.0,31220337.0,Carr DF,Simvastatin-induced myopathy,initial,2019-06-20,GCST008551,Response to drug,#d53e4f
225,European,85.0,31220337.0,Carr DF,Simvastatin-induced myopathy,initial,2019-06-20,GCST008551,Other disease,#d53e4f
226,Hispanic/Latin American,3644.0,31219225.0,Young KA,Aspartate aminotransferase levels,initial,2019-06-20,GCST008174,Liver enzyme measurement,#807dba
228,European,128.0,31220337.0,Carr DF,Statin-induced myopathy,initial,2019-06-20,GCST008552,Response to drug,#d53e4f
230,European,128.0,31220337.0,Carr DF,Statin-induced myopathy,initial,2019-06-20,GCST008552,Other disease,#d53e4f
231,Hispanic/Latin American,1577.0,31219225.0,Young KA,Gamma glutamyl transferase levels,initial,2019-06-20,GCST008175,Liver enzyme measurement,#807dba
232,Hispanic/Latin American,3595.0,31219225.0,Young KA,Alanine aminotransferase levels,initial,2019-06-20,GCST008173,Liver enzyme measurement,#807dba
234,European,32.0,31220337.0,Carr DF,Statin-induced myopathy (severe),initial,2019-06-20,GCST008553,Response to drug,#d53e4f
236,European,32.0,31220337.0,Carr DF,Statin-induced myopathy (severe),initial,2019-06-20,GCST008553,Other disease,#d53e4f
238,European,28.0,31220337.0,Carr DF,Atorvastatin-induced myopathy,initial,2019-06-20,GCST008554,Other disease,#d53e4f
240,Other/Mixed,645.0,31217584.0,Wojcik GL,Body mass index,initial,2019-06-19,GCST008025,Body measurement,#99d594
241,Other/Mixed,3936.0,31217584.0,Wojcik GL,Body mass index,initial,2019-06-19,GCST008025,Body measurement,#99d594
242,Asian,4647.0,31217584.0,Wojcik GL,Body mass index,initial,2019-06-19,GCST008025,Body measurement,#3288bd
243,African Am./Caribbean,17127.0,31217584.0,Wojcik GL,Body mass index,initial,2019-06-19,GCST008025,Body measurement,#fee08b
244,Hispanic/Latin American,21955.0,31217584.0,Wojcik GL,Body mass index,initial,2019-06-19,GCST008025,Body measurement,#807dba
245,European,13577.0,31217265.0,Sliz E,Tumor necrosis factor alpha levels,initial,2019-06-19,GCST008211,Inflammatory measurement,#d53e4f
246,European,13577.0,31217265.0,Sliz E,Interferon gamma-induced protein 10 levels,initial,2019-06-19,GCST008199,Other measurement,#d53e4f
247,European,13577.0,31217265.0,Sliz E,Interleukin-8 levels,initial,2019-06-19,GCST008197,Other measurement,#d53e4f
248,European,13577.0,31217265.0,Sliz E,Interleukin-6 levels,initial,2019-06-19,GCST008200,Inflammatory measurement,#d53e4f
249,European,13577.0,31217265.0,Sliz E,Interleukin-4 levels,initial,2019-06-19,GCST008201,Other measurement,#d53e4f
250,European,13577.0,31217265.0,Sliz E,Interleukin-1-receptor antagonist levels,initial,2019-06-19,GCST008203,Inflammatory measurement,#d53e4f
251,European,13577.0,31217265.0,Sliz E,Interleukin-1-beta levels,initial,2019-06-19,GCST008209,Inflammatory measurement,#d53e4f
252,European,13577.0,31217265.0,Sliz E,Monocyte chemoattractant protein-1 levels,initial,2019-06-19,GCST008204,Other measurement,#d53e4f
253,European,13577.0,31217265.0,Sliz E,Interleukin-17 levels,initial,2019-06-19,GCST008205,Other measurement,#d53e4f
254,European,13577.0,31217265.0,Sliz E,Vascular endothelial growth factor levels,initial,2019-06-19,GCST008198,Cardiovascular measurement,#d53e4f
255,European,5284.0,31217265.0,Sliz E,Plasminogen activator inhibitor-1 (PAI-1) levels,initial,2019-06-19,GCST008206,Other measurement,#d53e4f
256,European,5284.0,31217265.0,Sliz E,Soluble CD40 ligand levels,initial,2019-06-19,GCST008208,Inflammatory measurement,#d53e4f
257,European,5284.0,31217265.0,Sliz E,Interleukin-1-alpha levels,initial,2019-06-19,GCST008207,Other measurement,#d53e4f
258,European,5284.0,31217265.0,Sliz E,Soluble VCAM-1 levels,initial,2019-06-19,GCST008196,Other measurement,#d53e4f
259,European,5284.0,31217265.0,Sliz E,Soluble ICAM-1,initial,2019-06-19,GCST008210,Cardiovascular measurement,#d53e4f
260,European,5284.0,31217265.0,Sliz E,Soluble E-selectin levels,initial,2019-06-19,GCST008202,Inflammatory measurement,#d53e4f
262,Other/Mixed,574.0,31217584.0,Wojcik GL,C-reactive protein levels,initial,2019-06-19,GCST008055,Inflammatory measurement,#99d594
263,Other/Mixed,1777.0,31217584.0,Wojcik GL,C-reactive protein levels,initial,2019-06-19,GCST008055,Inflammatory measurement,#99d594
264,Asian,1811.0,31217584.0,Wojcik GL,C-reactive protein levels,initial,2019-06-19,GCST008055,Inflammatory measurement,#3288bd
265,African Am./Caribbean,8349.0,31217584.0,Wojcik GL,C-reactive protein levels,initial,2019-06-19,GCST008055,Inflammatory measurement,#fee08b
266,Hispanic/Latin American,15912.0,31217584.0,Wojcik GL,C-reactive protein levels,initial,2019-06-19,GCST008055,Inflammatory measurement,#807dba
267,Other/Mixed,226.0,31217584.0,Wojcik GL,QRS duration,initial,2019-06-19,GCST008054,Cardiovascular measurement,#99d594
268,African Am./Caribbean,3274.0,31217584.0,Wojcik GL,QRS duration,initial,2019-06-19,GCST008054,Cardiovascular measurement,#fee08b
269,Hispanic/Latin American,13420.0,31217584.0,Wojcik GL,QRS duration,initial,2019-06-19,GCST008054,Cardiovascular measurement,#807dba
270,Asian,126.0,31217584.0,Wojcik GL,QRS duration,initial,2019-06-19,GCST008054,Cardiovascular measurement,#3288bd
271,Asian,4680.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#3288bd
273,Other/Mixed,647.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#99d594
274,Other/Mixed,3939.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#99d594
275,African Am./Caribbean,17286.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#fee08b
276,Hispanic/Latin American,22192.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#807dba
277,European,253288.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008041,Body measurement,#d53e4f
278,European,303288.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008040,Body measurement,#d53e4f
280,Other/Mixed,647.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008053,Body measurement,#99d594
281,Other/Mixed,3939.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008053,Body measurement,#99d594
282,Asian,4680.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008053,Body measurement,#3288bd
283,Hispanic/Latin American,22192.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008053,Body measurement,#807dba
284,African Am./Caribbean,17286.0,31217584.0,Wojcik GL,Height,initial,2019-06-19,GCST008053,Body measurement,#fee08b
285,Hispanic/Latin American,16472.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008052,Body measurement,#807dba
286,Other/Mixed,585.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008052,Body measurement,#99d594
287,Other/Mixed,3061.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008052,Body measurement,#99d594
288,Asian,3500.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008052,Body measurement,#3288bd
289,African Am./Caribbean,10286.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008052,Body measurement,#fee08b
290,Other/Mixed,1346.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008051,Body measurement,#99d594
291,Asian,1657.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008051,Body measurement,#3288bd
292,Hispanic/Latin American,4917.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008051,Body measurement,#807dba
293,African Am./Caribbean,1146.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008051,Body measurement,#fee08b
294,Other/Mixed,585.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008050,Body measurement,#99d594
295,Other/Mixed,1715.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008050,Body measurement,#99d594
296,Asian,1843.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008050,Body measurement,#3288bd
297,African Am./Caribbean,9140.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008050,Body measurement,#fee08b
298,Hispanic/Latin American,11555.0,31217584.0,Wojcik GL,Waist-hip ratio,initial,2019-06-19,GCST008050,Body measurement,#807dba
299,Hispanic/Latin American,18251.0,31217584.0,Wojcik GL,White blood cell count,initial,2019-06-19,GCST008049,Hematological measurement,#807dba
300,African Am./Caribbean,8825.0,31217584.0,Wojcik GL,White blood cell count,initial,2019-06-19,GCST008049,Hematological measurement,#fee08b
301,Asian,543.0,31217584.0,Wojcik GL,White blood cell count,initial,2019-06-19,GCST008049,Hematological measurement,#3288bd
303,Other/Mixed,606.0,31217584.0,Wojcik GL,White blood cell count,initial,2019-06-19,GCST008049,Hematological measurement,#99d594
305,Other/Mixed,619.0,31217584.0,Wojcik GL,Type 2 diabetes,initial,2019-06-19,GCST008048,Metabolic disorder,#99d594
306,Other/Mixed,3551.0,31217584.0,Wojcik GL,Type 2 diabetes,initial,2019-06-19,GCST008048,Metabolic disorder,#99d594
307,Asian,4576.0,31217584.0,Wojcik GL,Type 2 diabetes,initial,2019-06-19,GCST008048,Metabolic disorder,#3288bd
308,Hispanic/Latin American,20480.0,31217584.0,Wojcik GL,Type 2 diabetes,initial,2019-06-19,GCST008048,Metabolic disorder,#807dba
309,African Am./Caribbean,15601.0,31217584.0,Wojcik GL,Type 2 diabetes,initial,2019-06-19,GCST008048,Metabolic disorder,#fee08b
311,Other/Mixed,604.0,31217584.0,Wojcik GL,Triglyceride levels,initial,2019-06-19,GCST008046,Lipid or lipoprotein measurement,#99d594
312,Asian,2381.0,31217584.0,Wojcik GL,Triglyceride levels,initial,2019-06-19,GCST008046,Lipid or lipoprotein measurement,#3288bd
313,African Am./Caribbean,9980.0,31217584.0,Wojcik GL,Triglyceride levels,initial,2019-06-19,GCST008046,Lipid or lipoprotein measurement,#fee08b
314,Hispanic/Latin American,17856.0,31217584.0,Wojcik GL,Triglyceride levels,initial,2019-06-19,GCST008046,Lipid or lipoprotein measurement,#807dba
315,Other/Mixed,1915.0,31217584.0,Wojcik GL,Triglyceride levels,initial,2019-06-19,GCST008046,Lipid or lipoprotein measurement,#99d594
317,Other/Mixed,604.0,31217584.0,Wojcik GL,Total cholesterol levels,initial,2019-06-19,GCST008045,Lipid or lipoprotein measurement,#99d594
318,Other/Mixed,1915.0,31217584.0,Wojcik GL,Total cholesterol levels,initial,2019-06-19,GCST008045,Lipid or lipoprotein measurement,#99d594
319,Asian,2387.0,31217584.0,Wojcik GL,Total cholesterol levels,initial,2019-06-19,GCST008045,Lipid or lipoprotein measurement,#3288bd
320,African Am./Caribbean,10137.0,31217584.0,Wojcik GL,Total cholesterol levels,initial,2019-06-19,GCST008045,Lipid or lipoprotein measurement,#fee08b
321,Hispanic/Latin American,17802.0,31217584.0,Wojcik GL,Total cholesterol levels,initial,2019-06-19,GCST008045,Lipid or lipoprotein measurement,#807dba
323,Hispanic/Latin American,21549.0,31217584.0,Wojcik GL,Systolic blood pressure,initial,2019-06-19,GCST008044,Other measurement,#807dba
324,African Am./Caribbean,11380.0,31217584.0,Wojcik GL,Systolic blood pressure,initial,2019-06-19,GCST008044,Other measurement,#fee08b
325,Other/Mixed,636.0,31217584.0,Wojcik GL,Systolic blood pressure,initial,2019-06-19,GCST008044,Other measurement,#99d594
326,Asian,1086.0,31217584.0,Wojcik GL,Systolic blood pressure,initial,2019-06-19,GCST008044,Other measurement,#3288bd
327,Other/Mixed,230.0,31217584.0,Wojcik GL,QT interval,initial,2019-06-19,GCST008043,Cardiovascular measurement,#99d594
328,Asian,127.0,31217584.0,Wojcik GL,QT interval,initial,2019-06-19,GCST008043,Cardiovascular measurement,#3288bd
329,African Am./Caribbean,3293.0,31217584.0,Wojcik GL,QT interval,initial,2019-06-19,GCST008043,Cardiovascular measurement,#fee08b
330,Hispanic/Latin American,13698.0,31217584.0,Wojcik GL,QT interval,initial,2019-06-19,GCST008043,Cardiovascular measurement,#807dba
331,Other/Mixed,231.0,31217584.0,Wojcik GL,PR interval,initial,2019-06-19,GCST008042,Cardiovascular measurement,#99d594
332,Asian,129.0,31217584.0,Wojcik GL,PR interval,initial,2019-06-19,GCST008042,Cardiovascular measurement,#3288bd
333,African Am./Caribbean,3360.0,31217584.0,Wojcik GL,PR interval,initial,2019-06-19,GCST008042,Cardiovascular measurement,#fee08b
334,Hispanic/Latin American,13702.0,31217584.0,Wojcik GL,PR interval,initial,2019-06-19,GCST008042,Cardiovascular measurement,#807dba
336,Other/Mixed,603.0,31217584.0,Wojcik GL,Platelet count,initial,2019-06-19,GCST008039,Hematological measurement,#99d594
337,Asian,541.0,31217584.0,Wojcik GL,Platelet count,initial,2019-06-19,GCST008039,Hematological measurement,#3288bd
338,African Am./Caribbean,8850.0,31217584.0,Wojcik GL,Platelet count,initial,2019-06-19,GCST008039,Hematological measurement,#fee08b
339,Hispanic/Latin American,18949.0,31217584.0,Wojcik GL,Platelet count,initial,2019-06-19,GCST008039,Hematological measurement,#807dba
341,Other/Mixed,20.0,31217584.0,Wojcik GL,Mean corpuscular hemoglobin concentration,initial,2019-06-19,GCST008038,Hematological measurement,#99d594
342,Asian,128.0,31217584.0,Wojcik GL,Mean corpuscular hemoglobin concentration,initial,2019-06-19,GCST008038,Hematological measurement,#3288bd
343,African Am./Caribbean,3750.0,31217584.0,Wojcik GL,Mean corpuscular hemoglobin concentration,initial,2019-06-19,GCST008038,Hematological measurement,#fee08b
344,Hispanic/Latin American,15522.0,31217584.0,Wojcik GL,Mean corpuscular hemoglobin concentration,initial,2019-06-19,GCST008038,Hematological measurement,#807dba
345,Hispanic/Latin American,17373.0,31217584.0,Wojcik GL,Low density lipoprotein cholesterol levels,initial,2019-06-19,GCST008037,Lipid or lipoprotein measurement,#807dba
346,African Am./Caribbean,9720.0,31217584.0,Wojcik GL,Low density lipoprotein cholesterol levels,initial,2019-06-19,GCST008037,Lipid or lipoprotein measurement,#fee08b
347,Asian,2316.0,31217584.0,Wojcik GL,Low density lipoprotein cholesterol levels,initial,2019-06-19,GCST008037,Lipid or lipoprotein measurement,#3288bd
348,Other/Mixed,591.0,31217584.0,Wojcik GL,Low density lipoprotein cholesterol levels,initial,2019-06-19,GCST008037,Lipid or lipoprotein measurement,#99d594
349,Other/Mixed,1900.0,31217584.0,Wojcik GL,Low density lipoprotein cholesterol levels,initial,2019-06-19,GCST008037,Lipid or lipoprotein measurement,#99d594
352,Other/Mixed,635.0,31217584.0,Wojcik GL,Hypertension,initial,2019-06-19,GCST008036,Cardiovascular disease,#99d594
353,Other/Mixed,3705.0,31217584.0,Wojcik GL,Hypertension,initial,2019-06-19,GCST008036,Cardiovascular disease,#99d594
354,Asian,4663.0,31217584.0,Wojcik GL,Hypertension,initial,2019-06-19,GCST008036,Cardiovascular disease,#3288bd
355,African Am./Caribbean,17152.0,31217584.0,Wojcik GL,Hypertension,initial,2019-06-19,GCST008036,Cardiovascular disease,#fee08b
356,Hispanic/Latin American,21936.0,31217584.0,Wojcik GL,Hypertension,initial,2019-06-19,GCST008036,Cardiovascular disease,#807dba
358,Other/Mixed,604.0,31217584.0,Wojcik GL,High density lipoprotein cholesterol levels,initial,2019-06-19,GCST008035,Lipid or lipoprotein measurement,#99d594
359,Asian,2378.0,31217584.0,Wojcik GL,High density lipoprotein cholesterol levels,initial,2019-06-19,GCST008035,Lipid or lipoprotein measurement,#3288bd
360,African Am./Caribbean,10085.0,31217584.0,Wojcik GL,High density lipoprotein cholesterol levels,initial,2019-06-19,GCST008035,Lipid or lipoprotein measurement,#fee08b
361,Other/Mixed,1912.0,31217584.0,Wojcik GL,High density lipoprotein cholesterol levels,initial,2019-06-19,GCST008035,Lipid or lipoprotein measurement,#99d594
362,Hispanic/Latin American,17751.0,31217584.0,Wojcik GL,High density lipoprotein cholesterol levels,initial,2019-06-19,GCST008035,Lipid or lipoprotein measurement,#807dba
363,Other/Mixed,4.0,31217584.0,Wojcik GL,Hemoglobin A1c levels,initial,2019-06-19,GCST008034,Other measurement,#99d594
364,Asian,92.0,31217584.0,Wojcik GL,Hemoglobin A1c levels,initial,2019-06-19,GCST008034,Other measurement,#3288bd
365,African Am./Caribbean,559.0,31217584.0,Wojcik GL,Hemoglobin A1c levels,initial,2019-06-19,GCST008034,Other measurement,#fee08b
366,Hispanic/Latin American,10408.0,31217584.0,Wojcik GL,Hemoglobin A1c levels,initial,2019-06-19,GCST008034,Other measurement,#807dba
368,Other/Mixed,395.0,31217584.0,Wojcik GL,Fasting blood insulin,initial,2019-06-19,GCST008033,Other measurement,#99d594
369,Other/Mixed,1397.0,31217584.0,Wojcik GL,Fasting blood insulin,initial,2019-06-19,GCST008033,Other measurement,#99d594
370,Asian,1547.0,31217584.0,Wojcik GL,Fasting blood insulin,initial,2019-06-19,GCST008033,Other measurement,#3288bd
371,Hispanic/Latin American,12687.0,31217584.0,Wojcik GL,Fasting blood insulin,initial,2019-06-19,GCST008033,Other measurement,#807dba
372,African Am./Caribbean,5525.0,31217584.0,Wojcik GL,Fasting blood insulin,initial,2019-06-19,GCST008033,Other measurement,#fee08b
374,Other/Mixed,412.0,31217584.0,Wojcik GL,Fasting blood glucose,initial,2019-06-19,GCST008032,Other measurement,#99d594
375,Other/Mixed,1400.0,31217584.0,Wojcik GL,Fasting blood glucose,initial,2019-06-19,GCST008032,Other measurement,#99d594
376,Asian,1918.0,31217584.0,Wojcik GL,Fasting blood glucose,initial,2019-06-19,GCST008032,Other measurement,#3288bd
377,African Am./Caribbean,6457.0,31217584.0,Wojcik GL,Fasting blood glucose,initial,2019-06-19,GCST008032,Other measurement,#fee08b
378,Hispanic/Latin American,13556.0,31217584.0,Wojcik GL,Fasting blood glucose,initial,2019-06-19,GCST008032,Other measurement,#807dba
380,Other/Mixed,53.0,31217584.0,Wojcik GL,End-stage renal disease,initial,2019-06-19,GCST008031,Other disease,#99d594
381,Asian,3600.0,31217584.0,Wojcik GL,End-stage renal disease,initial,2019-06-19,GCST008031,Other disease,#3288bd
382,Hispanic/Latin American,16405.0,31217584.0,Wojcik GL,End-stage renal disease,initial,2019-06-19,GCST008031,Other disease,#807dba
383,African Am./Caribbean,9065.0,31217584.0,Wojcik GL,End-stage renal disease,initial,2019-06-19,GCST008031,Other disease,#fee08b
384,Other/Mixed,2946.0,31217584.0,Wojcik GL,End-stage renal disease,initial,2019-06-19,GCST008031,Other disease,#99d594
386,Other/Mixed,602.0,31217584.0,Wojcik GL,Estimated glomerular filtration rate,initial,2019-06-19,GCST008030,Other measurement,#99d594
387,Asian,150.0,31217584.0,Wojcik GL,Estimated glomerular filtration rate,initial,2019-06-19,GCST008030,Other measurement,#3288bd
388,African Am./Caribbean,8261.0,31217584.0,Wojcik GL,Estimated glomerular filtration rate,initial,2019-06-19,GCST008030,Other measurement,#fee08b
389,Hispanic/Latin American,18548.0,31217584.0,Wojcik GL,Estimated glomerular filtration rate,initial,2019-06-19,GCST008030,Other measurement,#807dba
390,Hispanic/Latin American,21549.0,31217584.0,Wojcik GL,Diastolic blood pressure,initial,2019-06-19,GCST008029,Other measurement,#807dba
391,African Am./Caribbean,11380.0,31217584.0,Wojcik GL,Diastolic blood pressure,initial,2019-06-19,GCST008029,Other measurement,#fee08b
392,Asian,1086.0,31217584.0,Wojcik GL,Diastolic blood pressure,initial,2019-06-19,GCST008029,Other measurement,#3288bd
394,Other/Mixed,636.0,31217584.0,Wojcik GL,Diastolic blood pressure,initial,2019-06-19,GCST008029,Other measurement,#99d594
395,Other/Mixed,582.0,31217584.0,Wojcik GL,Coffee consumption (cups per day),initial,2019-06-19,GCST008028,Other measurement,#99d594
396,Other/Mixed,3857.0,31217584.0,Wojcik GL,Coffee consumption (cups per day),initial,2019-06-19,GCST008028,Other measurement,#99d594
397,Asian,3764.0,31217584.0,Wojcik GL,Coffee consumption (cups per day),initial,2019-06-19,GCST008028,Other measurement,#3288bd
398,African Am./Caribbean,11862.0,31217584.0,Wojcik GL,Coffee consumption (cups per day),initial,2019-06-19,GCST008028,Other measurement,#fee08b
399,Hispanic/Latin American,15837.0,31217584.0,Wojcik GL,Coffee consumption (cups per day),initial,2019-06-19,GCST008028,Other measurement,#807dba
401,Other/Mixed,288.0,31217584.0,Wojcik GL,Smoking behaviour (cigarettes smoked per day),initial,2019-06-19,GCST008027,Other measurement,#99d594
402,Asian,1918.0,31217584.0,Wojcik GL,Smoking behaviour (cigarettes smoked per day),initial,2019-06-19,GCST008027,Other measurement,#3288bd
403,African Am./Caribbean,7171.0,31217584.0,Wojcik GL,Smoking behaviour (cigarettes smoked per day),initial,2019-06-19,GCST008027,Other measurement,#fee08b
404,Hispanic/Latin American,4198.0,31217584.0,Wojcik GL,Smoking behaviour (cigarettes smoked per day),initial,2019-06-19,GCST008027,Other measurement,#807dba
405,Other/Mixed,2176.0,31217584.0,Wojcik GL,Smoking behaviour (cigarettes smoked per day),initial,2019-06-19,GCST008027,Other measurement,#99d594
407,Other/Mixed,639.0,31217584.0,Wojcik GL,Chronic kidney disease,initial,2019-06-19,GCST008026,Other disease,#99d594
408,Other/Mixed,3500.0,31217584.0,Wojcik GL,Chronic kidney disease,initial,2019-06-19,GCST008026,Other disease,#99d594
409,Asian,4124.0,31217584.0,Wojcik GL,Chronic kidney disease,initial,2019-06-19,GCST008026,Other disease,#3288bd
410,African Am./Caribbean,15522.0,31217584.0,Wojcik GL,Chronic kidney disease,initial,2019-06-19,GCST008026,Other disease,#fee08b
411,Hispanic/Latin American,20920.0,31217584.0,Wojcik GL,Chronic kidney disease,initial,2019-06-19,GCST008026,Other disease,#807dba
412,European,152.0,31209788.0,Li HQ,Cerebral microbleed progression,initial,2019-06-18,GCST008274,Other trait,#d53e4f
413,European,152.0,31209788.0,Li HQ,Cerebral microbleed progression,initial,2019-06-18,GCST008274,Other measurement,#d53e4f
414,European,8289.0,31226389.0,Wilman HR,Liver iron content,initial,2019-06-18,GCST008172,Other measurement,#d53e4f
415,European,1513.0,31226389.0,Wilman HR,Liver iron content,replication,2019-06-18,GCST008172,Other measurement,#d53e4f
416,European,454.0,31209788.0,Li HQ,Cerebral microbleeds,initial,2019-06-18,GCST008275,Other trait,#d53e4f
417,Hispanic/Latin American,4777.0,31213470.0,Moon JY,Glycated hemoglobin levels,replication,2019-06-18,GCST008398,Other measurement,#807dba
418,Hispanic/Latin American,9636.0,31213470.0,Moon JY,Glycated hemoglobin levels,initial,2019-06-18,GCST008398,Other measurement,#807dba
419,Other/Mixed,2700.0,31211820.0,Deek R,High density lipoprotein cholesterol levels,initial,2019-06-18,GCST008444,Lipid or lipoprotein measurement,#99d594
420,European,51372.0,31209380.0,Demontis D,Psychiatric disorder,initial,2019-06-17,GCST008417,Neurological disorder,#d53e4f
421,European,51372.0,31209380.0,Demontis D,Psychiatric disorder,initial,2019-06-17,GCST008417,Neurological disorder,#d53e4f
422,European,51372.0,31209380.0,Demontis D,Psychiatric disorder,initial,2019-06-17,GCST008417,Neurological disorder,#d53e4f
423,European,51372.0,31209380.0,Demontis D,Psychiatric disorder,initial,2019-06-17,GCST008417,Neurological disorder,#d53e4f
424,European,51372.0,31209380.0,Demontis D,Psychiatric disorder,initial,2019-06-17,GCST008417,Neurological disorder,#d53e4f
425,European,306542.0,31209380.0,Demontis D,Cannabis use disorder,replication,2019-06-17,GCST008414,Neurological disorder,#d53e4f
426,European,51372.0,31209380.0,Demontis D,Cannabis use disorder,initial,2019-06-17,GCST008414,Neurological disorder,#d53e4f
427,European,306542.0,31209380.0,Demontis D,Cannabis use disorder,replication,2019-06-17,GCST008414,Other disease,#d53e4f
428,European,51372.0,31209380.0,Demontis D,Cannabis use disorder,initial,2019-06-17,GCST008414,Other disease,#d53e4f
429,European,3034.0,31206164.0,Richards AL,Cognitive ability in schizophrenia,initial,2019-06-17,GCST008387,Neurological disorder,#d53e4f
430,European,3034.0,31206164.0,Richards AL,Cognitive ability in schizophrenia,initial,2019-06-17,GCST008387,Biological process,#d53e4f
431,European,4176.0,31209380.0,Demontis D,Cannabis use disorder vs schizophrenia,initial,2019-06-17,GCST008415,Neurological disorder,#d53e4f
432,European,4176.0,31209380.0,Demontis D,Cannabis use disorder vs schizophrenia,initial,2019-06-17,GCST008415,Neurological disorder,#d53e4f
433,European,4176.0,31209380.0,Demontis D,Cannabis use disorder vs schizophrenia,initial,2019-06-17,GCST008415,Other disease,#d53e4f
434,European,48985.0,31209380.0,Demontis D,Psychiatric disorder without cannabis use disorder,initial,2019-06-17,GCST008416,Neurological disorder,#d53e4f
435,European,48985.0,31209380.0,Demontis D,Psychiatric disorder without cannabis use disorder,initial,2019-06-17,GCST008416,Neurological disorder,#d53e4f
436,European,48985.0,31209380.0,Demontis D,Psychiatric disorder without cannabis use disorder,initial,2019-06-17,GCST008416,Neurological disorder,#d53e4f
437,European,48985.0,31209380.0,Demontis D,Psychiatric disorder without cannabis use disorder,initial,2019-06-17,GCST008416,Neurological disorder,#d53e4f
438,European,48985.0,31209380.0,Demontis D,Psychiatric disorder without cannabis use disorder,initial,2019-06-17,GCST008416,Neurological disorder,#d53e4f
440,Other/Mixed,327.0,31163085.0,Sharapov SZ,N-glycan levels,replication,2019-06-15,GCST008108,Other measurement,#99d594
441,European,294.0,31163085.0,Sharapov SZ,N-glycan levels,replication,2019-06-15,GCST008108,Other measurement,#d53e4f
443,European,6378.0,31212010.0,Cabana-Dominguez J,Cocaine dependence,initial,2019-06-15,GCST008399,Neurological disorder,#d53e4f
444,Hispanic/Latin American,3693.0,31207883.0,Rivera-Paredez B,Serum uric acid levels,replication,2019-06-14,GCST008445,Cardiovascular measurement,#807dba
445,Hispanic/Latin American,396.0,31207883.0,Rivera-Paredez B,Serum uric acid levels,initial,2019-06-14,GCST008445,Cardiovascular measurement,#807dba
446,European,666.0,31194736.0,Tiensuu H,Gestational age at birth (child effect),initial,2019-06-13,GCST008176,Other measurement,#d53e4f
448,Other/Mixed,30.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#99d594
449,Hispanic/Latin American,138.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#807dba
450,Asian,100.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#3288bd
451,African Am./Caribbean,53.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#fee08b
452,European,4175.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#d53e4f
453,Other/Mixed,11.0,31194788.0,Read RW,Platelet count,initial,2019-06-13,GCST008168,Hematological measurement,#99d594
454,Other/Mixed,11.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#99d594
455,Other/Mixed,30.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#99d594
456,Hispanic/Latin American,138.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#807dba
457,European,4175.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#d53e4f
458,Asian,100.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#3288bd
459,African Am./Caribbean,53.0,31194788.0,Read RW,Mean corpuscular volume,initial,2019-06-13,GCST008166,Hematological measurement,#fee08b
461,European,4175.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#d53e4f
463,Asian,100.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#3288bd
464,African Am./Caribbean,53.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#fee08b
465,Other/Mixed,11.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#99d594
466,Other/Mixed,30.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#99d594
467,Hispanic/Latin American,138.0,31194788.0,Read RW,Mean platelet volume,initial,2019-06-13,GCST008167,Hematological measurement,#807dba
468,European,520.0,31194736.0,Tiensuu H,Spontaneous preterm birth without premature rupture of membranes,initial,2019-06-13,GCST008181,Other trait,#d53e4f
469,European,552.0,31194736.0,Tiensuu H,Spontaneous preterm birth with premature rupture of membranes,initial,2019-06-13,GCST008180,Other disease,#d53e4f
470,European,552.0,31194736.0,Tiensuu H,Spontaneous preterm birth with premature rupture of membranes,initial,2019-06-13,GCST008180,Other trait,#d53e4f
471,European,494.0,31194736.0,Tiensuu H,Moderate-to-late spontaneous preterm birth,initial,2019-06-13,GCST008179,Other trait,#d53e4f
472,European,591.0,31194736.0,Tiensuu H,Early spontaneous preterm birth,initial,2019-06-13,GCST008178,Other trait,#d53e4f
473,European,666.0,31194736.0,Tiensuu H,Spontaneous preterm birth (preterm birth),initial,2019-06-13,GCST008177,Other trait,#d53e4f
474,Other/Mixed,58.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Biological process,#99d594
476,European,357.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Biological process,#d53e4f
477,Hispanic/Latin American,401.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Biological process,#807dba
478,Other/Mixed,58.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Other trait,#99d594
480,European,357.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Other trait,#d53e4f
481,Hispanic/Latin American,401.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Other trait,#807dba
482,Other/Mixed,58.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Cancer,#99d594
484,European,357.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Cancer,#d53e4f
485,Hispanic/Latin American,401.0,31196165.0,Lee E,Acute post-radiotherapy pain in breast cancer,initial,2019-06-13,GCST008388,Cancer,#807dba
486,European,73302.0,31249589.0,Edwards TL,Uterine fibroids,initial,2019-06-12,GCST008423,Cancer,#d53e4f
487,African,3192.0,31249589.0,Edwards TL,Uterine fibroids,replication,2019-06-12,GCST008423,Cancer,#fc8d59
488,European,150588.0,31249589.0,Edwards TL,Uterine fibroids,replication,2019-06-12,GCST008423,Cancer,#d53e4f
490,Asian,1402.0,31186284.0,Liu Y,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention),initial,2019-06-11,GCST008433,Lipid or lipoprotein measurement,#3288bd
491,Asian,1402.0,31186284.0,Liu Y,Lipoprotein (a) levels in coronary artery disease (percutaneous coronary intervention),initial,2019-06-11,GCST008433,Cardiovascular disease,#3288bd
493,European,7611.0,31188284.0,Bae H,Age at menopause,initial,2019-06-10,GCST008149,Other measurement,#d53e4f
494,Asian,2118.0,31170924.0,Kong S,Metabolic syndrome,replication,2019-06-06,GCST008140,Metabolic disorder,#3288bd
495,Asian,1850.0,31170924.0,Kong S,Metabolic syndrome,initial,2019-06-06,GCST008140,Metabolic disorder,#3288bd
496,Asian,2857.0,31170924.0,Kong S,Metabolic syndrome,initial,2019-06-06,GCST008146,Metabolic disorder,#3288bd
497,Asian,5273.0,31170924.0,Kong S,Waist circumference,replication,2019-06-06,GCST008145,Body measurement,#3288bd
498,Asian,4659.0,31170924.0,Kong S,Waist circumference,initial,2019-06-06,GCST008145,Body measurement,#3288bd
499,Asian,5273.0,31170924.0,Kong S,Fasting plasma glucose,replication,2019-06-06,GCST008144,Other measurement,#3288bd
500,Asian,4659.0,31170924.0,Kong S,Fasting plasma glucose,initial,2019-06-06,GCST008144,Other measurement,#3288bd
501,Asian,5273.0,31170924.0,Kong S,Diastolic blood pressure,replication,2019-06-06,GCST008143,Other measurement,#3288bd
502,Asian,4659.0,31170924.0,Kong S,Diastolic blood pressure,initial,2019-06-06,GCST008143,Other measurement,#3288bd
503,Asian,4659.0,31170924.0,Kong S,Systolic blood pressure,initial,2019-06-06,GCST008142,Other measurement,#3288bd
504,Asian,5273.0,31170924.0,Kong S,Systolic blood pressure,replication,2019-06-06,GCST008142,Other measurement,#3288bd
505,Asian,5273.0,31170924.0,Kong S,HDL cholesterol,replication,2019-06-06,GCST008141,Lipid or lipoprotein measurement,#3288bd
506,Asian,4659.0,31170924.0,Kong S,HDL cholesterol,initial,2019-06-06,GCST008141,Lipid or lipoprotein measurement,#3288bd
507,Asian,5273.0,31170924.0,Kong S,Triglyceride levels,replication,2019-06-06,GCST008150,Lipid or lipoprotein measurement,#3288bd
508,Asian,4659.0,31170924.0,Kong S,Triglyceride levels,initial,2019-06-06,GCST008150,Lipid or lipoprotein measurement,#3288bd
509,European,37505.0,31171785.0,Dorajoo R,Leukocyte telomere length,replication,2019-06-06,GCST008366,Other measurement,#d53e4f
510,Asian,6337.0,31171785.0,Dorajoo R,Leukocyte telomere length,replication,2019-06-06,GCST008366,Other measurement,#3288bd
511,Asian,16759.0,31171785.0,Dorajoo R,Leukocyte telomere length,initial,2019-06-06,GCST008366,Other measurement,#3288bd
512,European,363705.0,31168069.0,Ward J,Mood instability,initial,2019-06-05,GCST008357,Other measurement,#d53e4f
513,European,13393.0,31164008.0,Mullins N,Suicide attempts in bipolar disorder or schizophrenia,initial,2019-06-05,GCST008122,Neurological disorder,#d53e4f
514,European,13393.0,31164008.0,Mullins N,Suicide attempts in bipolar disorder or schizophrenia,initial,2019-06-05,GCST008122,Neurological disorder,#d53e4f
515,European,13393.0,31164008.0,Mullins N,Suicide attempts in bipolar disorder or schizophrenia,initial,2019-06-05,GCST008122,Biological process,#d53e4f
516,European,19172.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,initial,2019-06-05,GCST008121,Neurological disorder,#d53e4f
517,European,58853.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,replication,2019-06-05,GCST008121,Neurological disorder,#d53e4f
518,European,19172.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,initial,2019-06-05,GCST008121,Neurological disorder,#d53e4f
519,European,58853.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,replication,2019-06-05,GCST008121,Neurological disorder,#d53e4f
520,European,19172.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,initial,2019-06-05,GCST008121,Biological process,#d53e4f
521,European,58853.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder,replication,2019-06-05,GCST008121,Biological process,#d53e4f
522,European,4629.0,31164008.0,Mullins N,Suicide attempts in schizophrenia,initial,2019-06-05,GCST008120,Neurological disorder,#d53e4f
523,European,4629.0,31164008.0,Mullins N,Suicide attempts in schizophrenia,initial,2019-06-05,GCST008120,Biological process,#d53e4f
524,European,8764.0,31164008.0,Mullins N,Suicide attempts in bipolar disorder,initial,2019-06-05,GCST008119,Neurological disorder,#d53e4f
525,European,8764.0,31164008.0,Mullins N,Suicide attempts in bipolar disorder,initial,2019-06-05,GCST008119,Biological process,#d53e4f
526,European,6704.0,31167214.0,Osazuwa-Peters OL,DIastolic blood pressure x physical activity interaction (2df),initial,2019-06-05,GCST008390,Other measurement,#d53e4f
527,European,6704.0,31167214.0,Osazuwa-Peters OL,DIastolic blood pressure x physical activity interaction (2df),initial,2019-06-05,GCST008390,Other measurement,#d53e4f
528,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity interaction (1df),initial,2019-06-05,GCST008389,Other measurement,#d53e4f
529,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity interaction (1df),initial,2019-06-05,GCST008389,Other measurement,#d53e4f
530,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity interaction (1df),initial,2019-06-05,GCST008392,Other measurement,#d53e4f
531,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity interaction (1df),initial,2019-06-05,GCST008392,Other measurement,#d53e4f
532,European,3984.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least vs most active quartile) interaction (1df),initial,2019-06-05,GCST008400,Other measurement,#d53e4f
533,European,3984.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least vs most active quartile) interaction (1df),initial,2019-06-05,GCST008400,Biological process,#d53e4f
534,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (less vs more active half) interaction (1df),initial,2019-06-05,GCST008401,Other measurement,#d53e4f
535,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (less vs more active half) interaction (1df),initial,2019-06-05,GCST008401,Biological process,#d53e4f
536,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least active quartile vs others) interaction (1df),initial,2019-06-05,GCST008404,Other measurement,#d53e4f
537,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least active quartile vs others) interaction (1df),initial,2019-06-05,GCST008404,Biological process,#d53e4f
538,European,3984.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (1df),initial,2019-06-05,GCST008405,Other measurement,#d53e4f
539,European,3984.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (1df),initial,2019-06-05,GCST008405,Biological process,#d53e4f
540,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (less vs more active half) interaction (1df),initial,2019-06-05,GCST008406,Other measurement,#d53e4f
541,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (less vs more active half) interaction (1df),initial,2019-06-05,GCST008406,Biological process,#d53e4f
542,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (1df),initial,2019-06-05,GCST008407,Other measurement,#d53e4f
543,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (1df),initial,2019-06-05,GCST008407,Biological process,#d53e4f
544,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity interaction (2df),initial,2019-06-05,GCST008393,Other measurement,#d53e4f
545,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity interaction (2df),initial,2019-06-05,GCST008393,Other measurement,#d53e4f
546,European,3984.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least vs most active quartile) interaction (2df),initial,2019-06-05,GCST008402,Other measurement,#d53e4f
547,European,3984.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least vs most active quartile) interaction (2df),initial,2019-06-05,GCST008402,Biological process,#d53e4f
548,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (less vs more active half) interaction (2df),initial,2019-06-05,GCST008408,Other measurement,#d53e4f
549,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (less vs more active half) interaction (2df),initial,2019-06-05,GCST008408,Biological process,#d53e4f
550,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least active quartile vs others) interaction (2df),initial,2019-06-05,GCST008409,Other measurement,#d53e4f
551,European,6705.0,31167214.0,Osazuwa-Peters OL,Systolic blood pressure x physical activity (least active quartile vs others) interaction (2df),initial,2019-06-05,GCST008409,Biological process,#d53e4f
552,European,3984.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (2df),initial,2019-06-05,GCST008410,Other measurement,#d53e4f
553,European,3984.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least vs most active quartile) interaction (2df),initial,2019-06-05,GCST008410,Biological process,#d53e4f
554,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (less vs more active half) interaction (2df),initial,2019-06-05,GCST008411,Other measurement,#d53e4f
555,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (less vs more active half) interaction (2df),initial,2019-06-05,GCST008411,Biological process,#d53e4f
556,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (2df),initial,2019-06-05,GCST008412,Other measurement,#d53e4f
557,European,6704.0,31167214.0,Osazuwa-Peters OL,Diastolic blood pressure x physical activity (least active quartile vs others) interaction (2df),initial,2019-06-05,GCST008412,Biological process,#d53e4f
558,European,23801.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,initial,2019-06-05,GCST008123,Neurological disorder,#d53e4f
559,European,23801.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,initial,2019-06-05,GCST008123,Neurological disorder,#d53e4f
560,European,23801.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,initial,2019-06-05,GCST008123,Neurological disorder,#d53e4f
561,European,23801.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder or bipolar disorder or schizophrenia,initial,2019-06-05,GCST008123,Biological process,#d53e4f
562,European,10408.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder,initial,2019-06-05,GCST008118,Neurological disorder,#d53e4f
563,European,10408.0,31164008.0,Mullins N,Suicide attempts in major depressive disorder,initial,2019-06-05,GCST008118,Biological process,#d53e4f
564,European,199.0,31155012.0,Nakahara S,Dentate gyrus volume x schizophrenia interaction,initial,2019-06-03,GCST008557,Neurological disorder,#d53e4f
566,Asian,31.0,31155012.0,Nakahara S,Dentate gyrus volume x schizophrenia interaction,initial,2019-06-03,GCST008557,Neurological disorder,#3288bd
567,Other/Mixed,2.0,31155012.0,Nakahara S,Dentate gyrus volume x schizophrenia interaction,initial,2019-06-03,GCST008557,Neurological disorder,#99d594
568,Other/Mixed,3.0,31155012.0,Nakahara S,Dentate gyrus volume x schizophrenia interaction,initial,2019-06-03,GCST008557,Neurological disorder,#99d594
569,European,1203.0,31189108.0,O'Connor D,Meningococcal C IgG concentrations post childhood immunization,initial,2019-06-01,GCST008498,Response to drug,#d53e4f
570,European,980.0,31189108.0,O'Connor D,Meningococcal C IgG concentrations post childhood immunization,replication,2019-06-01,GCST008498,Response to drug,#d53e4f
571,European,967.0,31189108.0,O'Connor D,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization,initial,2019-06-01,GCST008501,Response to drug,#d53e4f
572,European,1011.0,31189108.0,O'Connor D,Haemophilus influenza type b polyribosylribitol phosphate IgG concentrations post childhood immunization,replication,2019-06-01,GCST008501,Response to drug,#d53e4f
573,European,549.0,31189108.0,O'Connor D,Tetanus toxoid IgG concentrations post childhood immunization,initial,2019-06-01,GCST008500,Response to drug,#d53e4f
574,European,1303.0,31189108.0,O'Connor D,Tetanus toxoid IgG concentrations post childhood immunization,replication,2019-06-01,GCST008500,Response to drug,#d53e4f
575,European,1585.0,31189108.0,O'Connor D,Meningococcal C functional antibody titers post childhood immunization,initial,2019-06-01,GCST008499,Response to drug,#d53e4f
576,European,779.0,31189108.0,O'Connor D,Meningococcal C functional antibody titers post childhood immunization,replication,2019-06-01,GCST008499,Response to drug,#d53e4f
577,European,567460.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008058,Other measurement,#d53e4f
578,Asian,165726.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008058,Other measurement,#3288bd
579,African Am./Caribbean,13842.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008058,Other measurement,#fee08b
580,Asian,13359.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008058,Other measurement,#3288bd
581,Hispanic/Latin American,4961.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008058,Other measurement,#807dba
582,European,216518.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,replication,2019-05-31,GCST008058,Other measurement,#d53e4f
583,African,64204.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,replication,2019-05-31,GCST008058,Other measurement,#fc8d59
584,African Am./Caribbean,13842.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008066,Other measurement,#fee08b
585,European,625219.0,31152163.0,Wuttke M,Chronic kidney disease,initial,2019-05-31,GCST008065,Other disease,#d53e4f
587,European,243029.0,31152163.0,Wuttke M,Blood urea nitrogen levels,initial,2019-05-31,GCST008063,Other measurement,#d53e4f
589,Asian,13359.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008061,Other measurement,#3288bd
590,Asian,165726.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008060,Other measurement,#3288bd
591,European,567460.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,initial,2019-05-31,GCST008059,Other measurement,#d53e4f
592,European,216518.0,31152163.0,Wuttke M,Estimated glomerular filtration rate,replication,2019-05-31,GCST008059,Other measurement,#d53e4f
593,Asian,2262.0,31152121.0,Zhu M,Type 1 diabetes,initial,2019-05-31,GCST008377,Metabolic disorder,#3288bd
594,Asian,5152.0,31152121.0,Zhu M,Type 1 diabetes,replication,2019-05-31,GCST008377,Metabolic disorder,#3288bd
595,African Am./Caribbean,9013.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#fee08b
596,Hispanic/Latin American,16134.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#807dba
597,Asian,3648.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#3288bd
598,Other/Mixed,2988.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#99d594
599,Other/Mixed,966.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#99d594
600,Other/Mixed,50.0,31178898.0,Lin BM,End-stage kidney disease,initial,2019-05-24,GCST008395,Other disease,#99d594
601,European,5168.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,initial,2019-05-24,GCST008223,Neurological disorder,#d53e4f
602,African Am./Caribbean,1345.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,replication,2019-05-24,GCST008223,Neurological disorder,#fee08b
603,European,949.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,replication,2019-05-24,GCST008223,Neurological disorder,#d53e4f
604,European,5168.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,initial,2019-05-24,GCST008223,Metabolic disorder,#d53e4f
605,African Am./Caribbean,1345.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,replication,2019-05-24,GCST008223,Metabolic disorder,#fee08b
606,European,949.0,31127053.0,Tang Y,Diabetic peripheral neuropathy in type 2 diabetes,replication,2019-05-24,GCST008223,Metabolic disorder,#d53e4f
607,African Am./Caribbean,15293.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#fee08b
608,Hispanic/Latin American,20653.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#807dba
609,Asian,4115.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#3288bd
610,Other/Mixed,3500.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#99d594
611,Other/Mixed,637.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#99d594
612,Other/Mixed,993.0,31178898.0,Lin BM,Mild to moderate chronic kidney disease,initial,2019-05-24,GCST008394,Other disease,#99d594
613,European,935.0,31120506.0,Grassmann F,Geographic atrophy lesion growth rate in age-related macular degeneration,initial,2019-05-23,GCST008356,Other measurement,#d53e4f
614,European,935.0,31120506.0,Grassmann F,Geographic atrophy lesion growth rate in age-related macular degeneration,initial,2019-05-23,GCST008356,Neurological disorder,#d53e4f
617,European,972.0,31123309.0,Rayner C,Response to cognitive-behavioural therapy in anxiety disorder,initial,2019-05-23,GCST008360,Neurological disorder,#d53e4f
618,European,972.0,31123309.0,Rayner C,Response to cognitive-behavioural therapy in anxiety disorder,initial,2019-05-23,GCST008360,Other trait,#d53e4f
622,European,972.0,31123309.0,Rayner C,Response to cognitive-behavioural therapy in anxiety and major depressive disorders,initial,2019-05-23,GCST008358,Neurological disorder,#d53e4f
624,European,972.0,31123309.0,Rayner C,Response to cognitive-behavioural therapy in anxiety and major depressive disorders,initial,2019-05-23,GCST008358,Neurological disorder,#d53e4f
626,European,972.0,31123309.0,Rayner C,Response to cognitive-behavioural therapy in anxiety and major depressive disorders,initial,2019-05-23,GCST008358,Other trait,#d53e4f
627,European,31880.0,31116379.0,Meier SM,Anxiety and stress-related disorders,initial,2019-05-22,GCST008559,Neurological disorder,#d53e4f
628,European,23198.0,31116379.0,Meier SM,Anxiety and stress-related disorders (propensity-score-matching design),initial,2019-05-22,GCST008560,Neurological disorder,#d53e4f
629,European,54311.0,31116379.0,Meier SM,Anxiety and stress-related disorders (psychiatric co-morbidity covariate model),initial,2019-05-22,GCST008561,Neurological disorder,#d53e4f
630,European,29536.0,31116379.0,Meier SM,Anxiety and stress-related disorders (psychiatric co-morbidity weighting design),initial,2019-05-22,GCST008562,Neurological disorder,#d53e4f
631,European,32758.0,31116379.0,Meier SM,Anxiety and stress-related disorders (including obsessive-compulsive disorder),initial,2019-05-22,GCST008563,Neurological disorder,#d53e4f
632,European,30785.0,31116379.0,Meier SM,Anxiety and stress-related disorders (excluding co-morbid schizophrenia),initial,2019-05-22,GCST008564,Neurological disorder,#d53e4f
633,European,27742.0,31116379.0,Meier SM,Anxiety and stress-related disorders (excluding adjustment disorder),initial,2019-05-22,GCST008565,Neurological disorder,#d53e4f
634,European,23809.0,31116379.0,Meier SM,Anxiety disorders,initial,2019-05-22,GCST008566,Neurological disorder,#d53e4f
635,African Am./Caribbean,520.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Other trait,#fee08b
636,European,523.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Other trait,#d53e4f
637,African Am./Caribbean,520.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Cardiovascular disease,#fee08b
638,European,523.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Cardiovascular disease,#d53e4f
639,African Am./Caribbean,520.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Cardiovascular measurement,#fee08b
640,European,523.0,31113495.0,Evans KL,Heart rate in heart failure with reduced ejection fraction,initial,2019-05-21,GCST007999,Cardiovascular measurement,#d53e4f
641,Asian,318.0,31109976.0,Suvichapanich S,Liver injury in anti-tuberculosis drug treatment,initial,2019-05-20,GCST007897,Other disease,#3288bd
642,Asian,318.0,31109976.0,Suvichapanich S,Liver injury in anti-tuberculosis drug treatment,initial,2019-05-20,GCST007897,Response to drug,#3288bd
643,Asian,318.0,31109976.0,Suvichapanich S,Liver injury in anti-tuberculosis drug treatment,initial,2019-05-20,GCST007897,Digestive system disorder,#3288bd
644,European,1609.0,31102405.0,Labreche K,Primary central nervous system lymphoma,initial,2019-05-17,GCST007896,Cancer,#d53e4f
645,European,3379.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),initial,2019-05-16,GCST008381,Biological process,#d53e4f
646,European,3379.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),initial,2019-05-16,GCST008381,Cancer,#d53e4f
647,European,3379.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),initial,2019-05-16,GCST008381,Other trait,#d53e4f
648,European,3782.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event),initial,2019-05-16,GCST008382,Biological process,#d53e4f
649,European,3782.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event),initial,2019-05-16,GCST008382,Cancer,#d53e4f
650,European,3782.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (increased urinary frequency) (time to event),initial,2019-05-16,GCST008382,Other trait,#d53e4f
651,European,3871.0,31095341.0,Kerns SL,Response to radiotherapy in prostate cancer (overall toxicity),initial,2019-05-16,GCST008379,Biological process,#d53e4f
652,European,3871.0,31095341.0,Kerns SL,Response to radiotherapy in prostate cancer (overall toxicity),initial,2019-05-16,GCST008379,Other disease,#d53e4f
653,European,3871.0,31095341.0,Kerns SL,Response to radiotherapy in prostate cancer (overall toxicity),initial,2019-05-16,GCST008379,Cancer,#d53e4f
654,Asian,538.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),replication,2019-05-16,GCST008380,Biological process,#3288bd
655,European,3619.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),initial,2019-05-16,GCST008380,Biological process,#d53e4f
656,Asian,538.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),replication,2019-05-16,GCST008380,Other trait,#3288bd
657,European,3619.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),initial,2019-05-16,GCST008380,Other trait,#d53e4f
658,Asian,538.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),replication,2019-05-16,GCST008380,Cancer,#3288bd
659,European,3619.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (hematuria) (time to event),initial,2019-05-16,GCST008380,Cancer,#d53e4f
660,European,3470.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event),initial,2019-05-16,GCST008378,Biological process,#d53e4f
661,European,3470.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event),initial,2019-05-16,GCST008378,Other trait,#d53e4f
662,European,3470.0,31095341.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event),initial,2019-05-16,GCST008378,Cancer,#d53e4f
663,African Am./Caribbean,10409.0,31092297.0,Guan M,Type 2 diabetes and end-stage kidney disease,initial,2019-05-15,GCST007949,Metabolic disorder,#fee08b
664,African Am./Caribbean,8827.0,31092297.0,Guan M,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals,initial,2019-05-15,GCST007950,Other measurement,#fee08b
665,African Am./Caribbean,8827.0,31092297.0,Guan M,Type 2 diabetes and end-stage kidney disease in APOL1 risk genotype negative individuals,initial,2019-05-15,GCST007950,Metabolic disorder,#fee08b
666,European,92967.0,31089142.0,Law PJ,Colorectal cancer,initial,2019-05-14,GCST007992,Cancer,#d53e4f
667,African Am./Caribbean,2939.0,31090166.0,Lai D,Alcohol dependence (drinking despite problems),replication,2019-05-14,GCST008291,Other measurement,#fee08b
668,African Am./Caribbean,3135.0,31090166.0,Lai D,Alcohol dependence (drinking despite problems),initial,2019-05-14,GCST008291,Other measurement,#fee08b
669,European,7307.0,31090166.0,Lai D,Alcohol dependence (drinking despite problems),initial,2019-05-14,GCST008291,Other measurement,#d53e4f
670,European,5052.0,31090166.0,Lai D,Alcohol dependence (drinking despite problems),replication,2019-05-14,GCST008291,Other measurement,#d53e4f
671,European,5053.0,31090166.0,Lai D,Alcohol dependence (time spent drinking),replication,2019-05-14,GCST008290,Other measurement,#d53e4f
672,African Am./Caribbean,3136.0,31090166.0,Lai D,Alcohol dependence (time spent drinking),initial,2019-05-14,GCST008290,Other measurement,#fee08b
673,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence (time spent drinking),replication,2019-05-14,GCST008290,Other measurement,#fee08b
674,European,7309.0,31090166.0,Lai D,Alcohol dependence (time spent drinking),initial,2019-05-14,GCST008290,Other measurement,#d53e4f
675,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence (giving up activities),replication,2019-05-14,GCST008289,Other measurement,#fee08b
676,European,5053.0,31090166.0,Lai D,Alcohol dependence (giving up activities),replication,2019-05-14,GCST008289,Other measurement,#d53e4f
677,African Am./Caribbean,3136.0,31090166.0,Lai D,Alcohol dependence (giving up activities),initial,2019-05-14,GCST008289,Other measurement,#fee08b
678,European,7308.0,31090166.0,Lai D,Alcohol dependence (giving up activities),initial,2019-05-14,GCST008289,Other measurement,#d53e4f
679,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence (desire to cut drinking),replication,2019-05-14,GCST008288,Other measurement,#fee08b
680,European,5053.0,31090166.0,Lai D,Alcohol dependence (desire to cut drinking),replication,2019-05-14,GCST008288,Other measurement,#d53e4f
681,African Am./Caribbean,3137.0,31090166.0,Lai D,Alcohol dependence (desire to cut drinking),initial,2019-05-14,GCST008288,Other measurement,#fee08b
682,European,7309.0,31090166.0,Lai D,Alcohol dependence (desire to cut drinking),initial,2019-05-14,GCST008288,Other measurement,#d53e4f
683,European,7306.0,31090166.0,Lai D,Alcohol dependence (drinking more than intended),initial,2019-05-14,GCST008287,Other measurement,#d53e4f
684,African Am./Caribbean,3134.0,31090166.0,Lai D,Alcohol dependence (drinking more than intended),initial,2019-05-14,GCST008287,Other measurement,#fee08b
685,African Am./Caribbean,2938.0,31090166.0,Lai D,Alcohol dependence (drinking more than intended),replication,2019-05-14,GCST008287,Other measurement,#fee08b
686,European,5050.0,31090166.0,Lai D,Alcohol dependence (drinking more than intended),replication,2019-05-14,GCST008287,Other measurement,#d53e4f
687,African Am./Caribbean,3130.0,31090166.0,Lai D,Alcohol dependence (withdrawal),initial,2019-05-14,GCST008286,Other measurement,#fee08b
688,European,5053.0,31090166.0,Lai D,Alcohol dependence (withdrawal),replication,2019-05-14,GCST008286,Other measurement,#d53e4f
689,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence (withdrawal),replication,2019-05-14,GCST008286,Other measurement,#fee08b
690,European,7305.0,31090166.0,Lai D,Alcohol dependence (withdrawal),initial,2019-05-14,GCST008286,Other measurement,#d53e4f
691,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence (tolerance),replication,2019-05-14,GCST008285,Other measurement,#fee08b
692,African Am./Caribbean,3134.0,31090166.0,Lai D,Alcohol dependence (tolerance),initial,2019-05-14,GCST008285,Other measurement,#fee08b
693,European,5052.0,31090166.0,Lai D,Alcohol dependence (tolerance),replication,2019-05-14,GCST008285,Other measurement,#d53e4f
694,European,7306.0,31090166.0,Lai D,Alcohol dependence (tolerance),initial,2019-05-14,GCST008285,Other measurement,#d53e4f
695,African Am./Caribbean,2940.0,31090166.0,Lai D,Alcohol dependence symptom count,replication,2019-05-14,GCST008283,Other measurement,#fee08b
696,European,5053.0,31090166.0,Lai D,Alcohol dependence symptom count,replication,2019-05-14,GCST008283,Other measurement,#d53e4f
697,African Am./Caribbean,3175.0,31090166.0,Lai D,Alcohol dependence symptom count,initial,2019-05-14,GCST008283,Other measurement,#fee08b
698,European,7418.0,31090166.0,Lai D,Alcohol dependence symptom count,initial,2019-05-14,GCST008283,Other measurement,#d53e4f
699,Asian,651.0,31089239.0,Choe EK,Right-sided colonic diverticulosis,replication,2019-05-14,GCST007921,Other trait,#3288bd
700,Asian,1968.0,31089239.0,Choe EK,Right-sided colonic diverticulosis,initial,2019-05-14,GCST007921,Other trait,#3288bd
701,African Am./Caribbean,2726.0,31090166.0,Lai D,Alcohol dependence,replication,2019-05-14,GCST008284,Neurological disorder,#fee08b
702,European,4244.0,31090166.0,Lai D,Alcohol dependence,replication,2019-05-14,GCST008284,Neurological disorder,#d53e4f
703,African Am./Caribbean,1831.0,31090166.0,Lai D,Alcohol dependence,initial,2019-05-14,GCST008284,Neurological disorder,#fee08b
704,European,4849.0,31090166.0,Lai D,Alcohol dependence,initial,2019-05-14,GCST008284,Neurological disorder,#d53e4f
705,European,581.0,31081985.0,Stein MB,Psychological resilience (outcome-based) in high deployment stress exposure,initial,2019-05-13,GCST007945,Other measurement,#d53e4f
706,European,581.0,31081985.0,Stein MB,Psychological resilience (outcome-based) in high deployment stress exposure,initial,2019-05-13,GCST007945,Other measurement,#d53e4f
707,European,1939.0,31081985.0,Stein MB,Psychological resilience (outcome-based),initial,2019-05-13,GCST007947,Other measurement,#d53e4f
708,European,11473.0,31081985.0,Stein MB,Psychological resilience (self-assessed),initial,2019-05-13,GCST007946,Other measurement,#d53e4f
709,European,563.0,31085060.0,Gisbert L,Emotional lability in attention deficit hyperactivity disorder,initial,2019-05-10,GCST007880,Neurological disorder,#d53e4f
710,European,563.0,31085060.0,Gisbert L,Emotional lability in attention deficit hyperactivity disorder,initial,2019-05-10,GCST007880,Other measurement,#d53e4f
711,European,19112.0,31070104.0,Jia Q,Glycine levels,initial,2019-05-09,GCST007838,Other measurement,#d53e4f
712,European,30118.0,31070104.0,Jia Q,Glycine levels,initial,2019-05-09,GCST007836,Other measurement,#d53e4f
713,European,11006.0,31070104.0,Jia Q,Glycine levels,initial,2019-05-09,GCST007837,Other measurement,#d53e4f
714,European,8450.0,31066027.0,Nicoletti P,Carbamazepine-induced liver injury,initial,2019-05-07,GCST008383,Digestive system disorder,#d53e4f
715,European,8450.0,31066027.0,Nicoletti P,Carbamazepine-induced liver injury,initial,2019-05-07,GCST008383,Response to drug,#d53e4f
716,European,10744.0,31066027.0,Nicoletti P,Carbamazepine-induced serious cutaneous adverse reaction,initial,2019-05-07,GCST008386,Other disease,#d53e4f
717,European,10744.0,31066027.0,Nicoletti P,Carbamazepine-induced serious cutaneous adverse reaction,initial,2019-05-07,GCST008386,Response to drug,#d53e4f
718,European,7310.0,31065058.0,Rongve A,Dementia with Lewy bodies,initial,2019-05-07,GCST007881,Other trait,#d53e4f
719,European,75653.0,31065058.0,Rongve A,Dementia with Lewy bodies,replication,2019-05-07,GCST007881,Other trait,#d53e4f
720,European,8454.0,31066027.0,Nicoletti P,Carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2019-05-07,GCST008385,Other disease,#d53e4f
721,European,8454.0,31066027.0,Nicoletti P,Carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2019-05-07,GCST008385,Other disease,#d53e4f
722,European,8454.0,31066027.0,Nicoletti P,Carbamazepine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2019-05-07,GCST008385,Response to drug,#d53e4f
723,European,10726.0,31066027.0,Nicoletti P,Carbamazepine-induced reaction with eosinophilia and systemic symptoms,initial,2019-05-07,GCST008384,Immune system disorder,#d53e4f
724,European,10726.0,31066027.0,Nicoletti P,Carbamazepine-induced reaction with eosinophilia and systemic symptoms,initial,2019-05-07,GCST008384,Response to drug,#d53e4f
726,European,4755.0,31059154.0,Chen Z,Progressive supranuclear palsy,initial,2019-05-06,GCST007845,Neurological disorder,#d53e4f
727,European,4806.0,31055733.0,Nazarian A,Alzheimer's disease in hypertension-negative individuals,initial,2019-05-05,GCST008437,Neurological disorder,#d53e4f
728,European,10870.0,31055733.0,Nazarian A,Alzheimer's disease in hypertension,initial,2019-05-05,GCST008438,Neurological disorder,#d53e4f
729,European,10870.0,31055733.0,Nazarian A,Alzheimer's disease in hypertension,initial,2019-05-05,GCST008438,Cardiovascular disease,#d53e4f
730,Asian,9383.0,31053729.0,Styrkarsdottir U,Femoral neck size,replication,2019-05-03,GCST008278,Body measurement,#3288bd
731,European,28954.0,31053729.0,Styrkarsdottir U,Femoral neck size,initial,2019-05-03,GCST008278,Body measurement,#d53e4f
732,European,6351.0,31053729.0,Styrkarsdottir U,Femoral neck size,replication,2019-05-03,GCST008278,Body measurement,#d53e4f
733,European,28900.0,31053729.0,Styrkarsdottir U,Hip bone size,initial,2019-05-03,GCST008281,Body measurement,#d53e4f
734,European,7912.0,31053729.0,Styrkarsdottir U,Hip bone size,replication,2019-05-03,GCST008281,Body measurement,#d53e4f
735,Asian,5699.0,31053729.0,Styrkarsdottir U,Hip bone size,replication,2019-05-03,GCST008281,Body measurement,#3288bd
736,Asian,2331.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis and Graves disease,initial,2019-05-03,GCST008365,Immune system disorder,#3288bd
737,Asian,1451.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis and Graves disease,replication,2019-05-03,GCST008365,Immune system disorder,#3288bd
738,Asian,2331.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis and Graves disease,initial,2019-05-03,GCST008365,Metabolic disorder,#3288bd
739,Asian,1451.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis and Graves disease,replication,2019-05-03,GCST008365,Metabolic disorder,#3288bd
740,European,29059.0,31053729.0,Styrkarsdottir U,Spine bone size,initial,2019-05-03,GCST008282,Other measurement,#d53e4f
741,Asian,6345.0,31053729.0,Styrkarsdottir U,Spine bone size,replication,2019-05-03,GCST008282,Other measurement,#3288bd
742,European,14932.0,31053729.0,Styrkarsdottir U,Spine bone size,replication,2019-05-03,GCST008282,Other measurement,#d53e4f
743,European,7912.0,31053729.0,Styrkarsdottir U,Intertrochanteric region size,replication,2019-05-03,GCST008280,Body measurement,#d53e4f
744,Asian,5696.0,31053729.0,Styrkarsdottir U,Intertrochanteric region size,replication,2019-05-03,GCST008280,Body measurement,#3288bd
745,European,28936.0,31053729.0,Styrkarsdottir U,Intertrochanteric region size,initial,2019-05-03,GCST008280,Body measurement,#d53e4f
746,Asian,1575.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis in Graves disease,initial,2019-05-03,GCST008364,Immune system disorder,#3288bd
747,Asian,1575.0,31050781.0,Zhao SX,Thyrotoxic hypokalemic periodic paralysis in Graves disease,initial,2019-05-03,GCST008364,Metabolic disorder,#3288bd
748,European,28944.0,31053729.0,Styrkarsdottir U,Trochanter size,initial,2019-05-03,GCST008279,Body measurement,#d53e4f
749,European,8065.0,31053729.0,Styrkarsdottir U,Trochanter size,replication,2019-05-03,GCST008279,Body measurement,#d53e4f
750,Asian,5711.0,31053729.0,Styrkarsdottir U,Trochanter size,replication,2019-05-03,GCST008279,Body measurement,#3288bd
751,European,62.0,31043678.0,Aterido A,Anti-adalimumab antibody production in response to treatment in Crohn's disease,initial,2019-05-02,GCST008271,Response to drug,#d53e4f
752,European,88.0,31043678.0,Aterido A,Anti-adalimumab antibody production in response to treatment in Crohn's disease,replication,2019-05-02,GCST008271,Response to drug,#d53e4f
753,European,62.0,31043678.0,Aterido A,Anti-adalimumab antibody production in response to treatment in Crohn's disease,initial,2019-05-02,GCST008271,Digestive system disorder,#d53e4f
754,European,88.0,31043678.0,Aterido A,Anti-adalimumab antibody production in response to treatment in Crohn's disease,replication,2019-05-02,GCST008271,Digestive system disorder,#d53e4f
755,African,4347.0,31049640.0,Chen J,Type 2 diabetes,initial,2019-05-02,GCST008114,Metabolic disorder,#fc8d59
756,European,39924.0,31046077.0,Zhong VW,Coffee consumption,replication,2019-05-02,GCST008526,Other measurement,#d53e4f
757,European,335909.0,31046077.0,Zhong VW,Coffee consumption,initial,2019-05-02,GCST008526,Other measurement,#d53e4f
758,European,46237.0,31043756.0,Stahl EA,Bipolar I disorder,initial,2019-05-01,GCST008115,Neurological disorder,#d53e4f
759,European,4064.0,31250797.0,Brick LA,Opioid dependence,initial,2019-05-01,GCST008424,Neurological disorder,#d53e4f
760,Asian,157.0,31058715.0,St Jean PL,Response to belimumab (SLE response index) in systemic lupus erythematosus,initial,2019-05-01,GCST008307,Response to drug,#3288bd
761,Asian,204.0,31058715.0,St Jean PL,Response to belimumab (SLE response index) in systemic lupus erythematosus,replication,2019-05-01,GCST008307,Response to drug,#3288bd
763,Asian,157.0,31058715.0,St Jean PL,Response to belimumab (SLE response index) in systemic lupus erythematosus,initial,2019-05-01,GCST008307,Immune system disorder,#3288bd
764,Asian,204.0,31058715.0,St Jean PL,Response to belimumab (SLE response index) in systemic lupus erythematosus,replication,2019-05-01,GCST008307,Immune system disorder,#3288bd
766,European,1030.0,31118946.0,Jiao H,Obesity (extreme) (SNP x SNP interaction),initial,2019-05-01,GCST007997,Metabolic disorder,#d53e4f
767,African Am./Caribbean,7687.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#fee08b
769,Asian,2629.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#3288bd
770,Asian,840.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#3288bd
771,Other/Mixed,815.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#99d594
772,Hispanic/Latin American,612.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#807dba
773,European,298142.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#d53e4f
774,Other/Mixed,365.0,31043758.0,Warrington NM,Birth weight,initial,2019-05-01,GCST008362,Body measurement,#99d594
775,European,51710.0,31043756.0,Stahl EA,Bipolar disorder,initial,2019-05-01,GCST008103,Neurological disorder,#d53e4f
776,European,147172.0,31043756.0,Stahl EA,Bipolar disorder,replication,2019-05-01,GCST008103,Neurological disorder,#d53e4f
778,European,210267.0,31043758.0,Warrington NM,Offspring birth weight,initial,2019-05-01,GCST008363,Body measurement,#d53e4f
780,European,210267.0,31043758.0,Warrington NM,Offspring birth weight,initial,2019-05-01,GCST008363,Other measurement,#d53e4f
781,European,32335.0,31043756.0,Stahl EA,Schizoaffective disorder-bipolar type,initial,2019-05-01,GCST008117,Neurological disorder,#d53e4f
782,European,34779.0,31043756.0,Stahl EA,Bipolar II disorder,initial,2019-05-01,GCST008116,Neurological disorder,#d53e4f
783,Asian,54.0,31039275.0,Park SH,Infliximab-induced mucosal healing in Crohn's disease,replication,2019-04-30,GCST008397,Response to drug,#3288bd
784,Asian,58.0,31039275.0,Park SH,Infliximab-induced mucosal healing in Crohn's disease,initial,2019-04-30,GCST008397,Response to drug,#3288bd
785,Asian,54.0,31039275.0,Park SH,Infliximab-induced mucosal healing in Crohn's disease,replication,2019-04-30,GCST008397,Digestive system disorder,#3288bd
786,Asian,58.0,31039275.0,Park SH,Infliximab-induced mucosal healing in Crohn's disease,initial,2019-04-30,GCST008397,Digestive system disorder,#3288bd
787,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
788,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
789,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
790,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
791,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
792,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Inflammatory measurement,#fc8d59
793,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
794,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
795,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
796,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
797,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
798,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
799,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
800,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
801,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008338,Hematological measurement,#fc8d59
802,European,328113.0,31036433.0,Pividori M,Chronic obstructive pulmonary disease,initial,2019-04-26,GCST007996,Other disease,#d53e4f
803,European,37846.0,31036433.0,Pividori M,Asthma (age of onset),initial,2019-04-26,GCST007994,Other disease,#d53e4f
804,European,327670.0,31036433.0,Pividori M,Asthma (childhood onset),initial,2019-04-26,GCST007995,Other disease,#d53e4f
805,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
806,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
807,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
808,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
809,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
810,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
811,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
812,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Inflammatory measurement,#fc8d59
813,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
814,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
815,African,6407.0,31080455.0,Fatumo S,Blood cell traits (multivariate analysis),initial,2019-04-26,GCST008337,Hematological measurement,#fc8d59
816,African,1624.0,31080455.0,Fatumo S,Mean platelet volume,initial,2019-04-26,GCST008336,Hematological measurement,#fc8d59
817,European,339801.0,31036433.0,Pividori M,Asthma (adult onset),initial,2019-04-26,GCST007993,Other disease,#d53e4f
818,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,initial,2019-04-26,GCST008273,Other disease,#d53e4f
819,African Am./Caribbean,88.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,replication,2019-04-26,GCST008273,Other disease,#fee08b
820,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,initial,2019-04-26,GCST008273,Other measurement,#d53e4f
821,African Am./Caribbean,88.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,replication,2019-04-26,GCST008273,Other measurement,#fee08b
822,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,initial,2019-04-26,GCST008273,Other measurement,#d53e4f
823,African Am./Caribbean,88.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (NO2) interaction in childhood asthma,replication,2019-04-26,GCST008273,Other measurement,#fee08b
824,African,1555.0,31080455.0,Fatumo S,Eosinophil counts,initial,2019-04-26,GCST008335,Hematological measurement,#fc8d59
825,African,1565.0,31080455.0,Fatumo S,Basophil count,initial,2019-04-26,GCST008328,Inflammatory measurement,#fc8d59
826,African,1565.0,31080455.0,Fatumo S,Monocyte count,initial,2019-04-26,GCST008327,Hematological measurement,#fc8d59
827,African,1565.0,31080455.0,Fatumo S,Lymphocyte counts,initial,2019-04-26,GCST008326,Hematological measurement,#fc8d59
828,African,1625.0,31080455.0,Fatumo S,Platelet count,initial,2019-04-26,GCST008325,Hematological measurement,#fc8d59
829,African,1415.0,31080455.0,Fatumo S,Neutrophil count,initial,2019-04-26,GCST008334,Hematological measurement,#fc8d59
830,African,1625.0,31080455.0,Fatumo S,Hemoglobin,initial,2019-04-26,GCST008324,Hematological measurement,#fc8d59
831,African,1625.0,31080455.0,Fatumo S,Hematocrit,initial,2019-04-26,GCST008323,Hematological measurement,#fc8d59
832,African,1625.0,31080455.0,Fatumo S,Red cell distribution width,initial,2019-04-26,GCST008333,Hematological measurement,#fc8d59
833,African,1625.0,31080455.0,Fatumo S,Mean corpuscular hemoglobin concentration,initial,2019-04-26,GCST008332,Hematological measurement,#fc8d59
834,African,1625.0,31080455.0,Fatumo S,Mean corpuscular hemoglobin,initial,2019-04-26,GCST008331,Hematological measurement,#fc8d59
835,African,1625.0,31080455.0,Fatumo S,Mean corpuscular volume,initial,2019-04-26,GCST008330,Hematological measurement,#fc8d59
836,African,1625.0,31080455.0,Fatumo S,Red blood cell count,initial,2019-04-26,GCST008329,Hematological measurement,#fc8d59
837,African,1625.0,31080455.0,Fatumo S,White blood cell count,initial,2019-04-26,GCST008322,Hematological measurement,#fc8d59
838,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma,initial,2019-04-26,GCST008272,Other disease,#d53e4f
839,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma,initial,2019-04-26,GCST008272,Other measurement,#d53e4f
840,European,522.0,31028280.0,Ierodiakonou D,Post-bronchodilator FEV1 x air pollution (CO) interaction in childhood asthma,initial,2019-04-26,GCST008272,Other measurement,#d53e4f
841,European,10395.0,31014085.0,Welsh P,Cardiac Troponin-T levels,initial,2019-04-24,GCST008310,Cardiovascular measurement,#d53e4f
842,European,152.0,31241743.0,Jaeger M,Candidemia,replication,2019-04-24,GCST008106,Other disease,#d53e4f
843,European,161.0,31241743.0,Jaeger M,Candidemia,initial,2019-04-24,GCST008106,Other disease,#d53e4f
844,Asian,419.0,31020675.0,Omae Y,KANNO antigen negativity,initial,2019-04-24,GCST007948,Other measurement,#3288bd
845,European,14579.0,31014085.0,Welsh P,Cardiac troponin-I levels,initial,2019-04-24,GCST008309,Cardiovascular measurement,#d53e4f
846,Asian,143658.0,31015462.0,Graham SE,Estimated glomerular filtration rate,initial,2019-04-23,GCST007876,Other measurement,#3288bd
847,European,206856.0,31015462.0,Graham SE,Estimated glomerular filtration rate,initial,2019-04-23,GCST007876,Other measurement,#d53e4f
848,European,67619.0,31015462.0,Graham SE,Chronic kidney disease,initial,2019-04-23,GCST007879,Other disease,#d53e4f
849,European,20700.0,31015462.0,Graham SE,Urea levels,initial,2019-04-23,GCST007878,Other measurement,#d53e4f
850,European,69591.0,31015462.0,Graham SE,Creatinine levels,initial,2019-04-23,GCST007877,Other measurement,#d53e4f
851,European,100868.0,31015401.0,Wu Y,Medication use (antiglaucoma preparations and miotics),initial,2019-04-23,GCST007944,Other measurement,#d53e4f
852,European,151636.0,31015401.0,Wu Y,Medication use (antihistamines for systemic use),initial,2019-04-23,GCST007943,Other measurement,#d53e4f
853,European,205700.0,31015401.0,Wu Y,Medication use (glucocorticoids),initial,2019-04-23,GCST007942,Other measurement,#d53e4f
854,European,176445.0,31015401.0,Wu Y,"Medication use (adrenergics, inhalants)",initial,2019-04-23,GCST007941,Other measurement,#d53e4f
855,European,304162.0,31015401.0,Wu Y,Medication use (antidepressants),initial,2019-04-23,GCST007940,Other measurement,#d53e4f
856,European,119844.0,31015401.0,Wu Y,Medication use (antimigraine preparations),initial,2019-04-23,GCST007939,Other measurement,#d53e4f
857,European,179810.0,31015401.0,Wu Y,Medication use (anilides),initial,2019-04-23,GCST007938,Other measurement,#d53e4f
858,European,112010.0,31015401.0,Wu Y,Medication use (salicylic acid and derivatives),initial,2019-04-23,GCST007937,Other measurement,#d53e4f
859,European,78808.0,31015401.0,Wu Y,Medication use (opioids),initial,2019-04-23,GCST007936,Other measurement,#d53e4f
860,European,215668.0,31015401.0,Wu Y,Medication use (drugs affecting bone structure and mineralization),initial,2019-04-23,GCST007935,Other measurement,#d53e4f
861,European,164520.0,31015401.0,Wu Y,"Medication use (anti-inflammatory and antirheumatic products, non-steroids)",initial,2019-04-23,GCST007934,Other measurement,#d53e4f
862,European,272602.0,31015401.0,Wu Y,Medication use (immunosuppressants),initial,2019-04-23,GCST007933,Other measurement,#d53e4f
863,European,305582.0,31015401.0,Wu Y,Medication use (thyroid preparations),initial,2019-04-23,GCST007932,Other measurement,#d53e4f
864,European,290385.0,31015401.0,Wu Y,Medication use (HMG CoA reductase inhibitors),initial,2019-04-23,GCST007931,Other measurement,#d53e4f
865,European,237530.0,31015401.0,Wu Y,Medication use (agents acting on the renin-angiotensin system),initial,2019-04-23,GCST007930,Other measurement,#d53e4f
866,European,204378.0,31015401.0,Wu Y,Medication use (calcium channel blockers),initial,2019-04-23,GCST007929,Other measurement,#d53e4f
867,European,224024.0,31015401.0,Wu Y,Medication use (beta blocking agents),initial,2019-04-23,GCST007927,Other measurement,#d53e4f
868,European,229086.0,31015401.0,Wu Y,Medication use (diuretics),initial,2019-04-23,GCST007928,Other measurement,#d53e4f
869,European,152380.0,31015401.0,Wu Y,Medication use (antihypertensives),initial,2019-04-23,GCST007926,Other measurement,#d53e4f
870,European,242659.0,31015401.0,Wu Y,Medication use (vasodilators used in cardiac diseases),initial,2019-04-23,GCST007925,Other measurement,#d53e4f
871,European,153639.0,31015401.0,Wu Y,Medication use (antithrombotic agents),initial,2019-04-23,GCST007924,Other measurement,#d53e4f
872,European,305913.0,31015401.0,Wu Y,Medication use (drugs used in diabetes),initial,2019-04-23,GCST007923,Other measurement,#d53e4f
873,European,132367.0,31015401.0,Wu Y,Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),initial,2019-04-23,GCST007922,Other measurement,#d53e4f
882,Hispanic/Latin American,1.0,31006051.0,Kharazmi M,Bisphosphonate-associated atypical femoral fracture,initial,2019-04-20,GCST008097,Other disease,#807dba
883,European,4941.0,31006051.0,Kharazmi M,Bisphosphonate-associated atypical femoral fracture,initial,2019-04-20,GCST008097,Other disease,#d53e4f
884,Hispanic/Latin American,1.0,31006051.0,Kharazmi M,Bisphosphonate-associated atypical femoral fracture,initial,2019-04-20,GCST008097,Response to drug,#807dba
885,European,4941.0,31006051.0,Kharazmi M,Bisphosphonate-associated atypical femoral fracture,initial,2019-04-20,GCST008097,Response to drug,#d53e4f
886,Hispanic/Latin American,1.0,31006051.0,Kharazmi M,Atypical femoral fracture in phosphonate treatment,initial,2019-04-20,GCST008098,Other disease,#807dba
887,European,374.0,31006051.0,Kharazmi M,Atypical femoral fracture in phosphonate treatment,initial,2019-04-20,GCST008098,Other disease,#d53e4f
888,Hispanic/Latin American,1.0,31006051.0,Kharazmi M,Atypical femoral fracture in phosphonate treatment,initial,2019-04-20,GCST008098,Response to drug,#807dba
889,European,374.0,31006051.0,Kharazmi M,Atypical femoral fracture in phosphonate treatment,initial,2019-04-20,GCST008098,Response to drug,#d53e4f
890,European,7192.0,31009812.0,Hung RJ,Adenocarcinoma in never smokers,initial,2019-04-19,GCST008375,Other measurement,#d53e4f
891,European,1612.0,31009812.0,Hung RJ,Adenocarcinoma in never smokers,replication,2019-04-19,GCST008375,Other measurement,#d53e4f
892,European,7192.0,31009812.0,Hung RJ,Adenocarcinoma in never smokers,initial,2019-04-19,GCST008375,Cancer,#d53e4f
893,European,1612.0,31009812.0,Hung RJ,Adenocarcinoma in never smokers,replication,2019-04-19,GCST008375,Cancer,#d53e4f
894,European,8031.0,31009812.0,Hung RJ,Lung cancer in never smokers,initial,2019-04-19,GCST008376,Other measurement,#d53e4f
895,European,1900.0,31009812.0,Hung RJ,Lung cancer in never smokers,replication,2019-04-19,GCST008376,Other measurement,#d53e4f
896,European,8031.0,31009812.0,Hung RJ,Lung cancer in never smokers,initial,2019-04-19,GCST008376,Cancer,#d53e4f
897,European,1900.0,31009812.0,Hung RJ,Lung cancer in never smokers,replication,2019-04-19,GCST008376,Cancer,#d53e4f
898,European,408455.0,30998689.0,Shadrina AS,Varicose veins,initial,2019-04-18,GCST008057,Other trait,#d53e4f
899,African Am./Caribbean,441.0,30995994.0,Truong DT,Latent naming speed,initial,2019-04-17,GCST007862,Biological process,#fee08b
900,Hispanic/Latin American,883.0,30995994.0,Truong DT,Rapid alternating stimulus test for letters/numbers,initial,2019-04-17,GCST007863,Biological process,#807dba
901,African Am./Caribbean,441.0,30995994.0,Truong DT,Rapid alternating stimulus test for letters/numbers,initial,2019-04-17,GCST007863,Biological process,#fee08b
902,Hispanic/Latin American,883.0,30995994.0,Truong DT,Rapid automised naming of letters,initial,2019-04-17,GCST007864,Biological process,#807dba
903,African Am./Caribbean,441.0,30995994.0,Truong DT,Rapid automised naming of letters,initial,2019-04-17,GCST007864,Biological process,#fee08b
904,African Am./Caribbean,441.0,30995994.0,Truong DT,Rapid automised naming of objects,initial,2019-04-17,GCST007865,Biological process,#fee08b
905,Hispanic/Latin American,883.0,30995994.0,Truong DT,Rapid automised naming of objects,initial,2019-04-17,GCST007865,Biological process,#807dba
906,Hispanic/Latin American,883.0,30995994.0,Truong DT,Latent naming speed,initial,2019-04-17,GCST007860,Biological process,#807dba
907,African Am./Caribbean,441.0,30995994.0,Truong DT,Latent naming speed,initial,2019-04-17,GCST007860,Biological process,#fee08b
908,Hispanic/Latin American,883.0,30995994.0,Truong DT,Rapid automised naming and rapid alternating stimulus test performance,initial,2019-04-17,GCST007859,Biological process,#807dba
909,African Am./Caribbean,441.0,30995994.0,Truong DT,Rapid automised naming and rapid alternating stimulus test performance,initial,2019-04-17,GCST007859,Biological process,#fee08b
910,Hispanic/Latin American,883.0,30995994.0,Truong DT,Latent naming speed,initial,2019-04-17,GCST007861,Biological process,#807dba
911,European,6879.0,30992453.0,Bjornsdottir G,Sural nerve amplitude potential,initial,2019-04-16,GCST008312,Other measurement,#d53e4f
912,European,6979.0,30992453.0,Bjornsdottir G,Sural nerve conduction velocity,initial,2019-04-16,GCST008313,Other measurement,#d53e4f
913,Other/Mixed,497.0,31040861.0,Thomson RJ,Urinary albumin-to-creatinine ratio,replication,2019-04-16,GCST007832,Other measurement,#99d594
914,Other/Mixed,249.0,31040861.0,Thomson RJ,Urinary albumin-to-creatinine ratio,initial,2019-04-16,GCST007832,Other measurement,#99d594
916,European,8857.0,30988330.0,Hellwege JN,Benign prostatic hyperplasia,initial,2019-04-15,GCST008169,Other disease,#d53e4f
917,European,331037.0,30980028.0,de Kovel CGF,Handedness (Left-handed vs. non-left-handed),initial,2019-04-12,GCST007592,Other trait,#d53e4f
918,European,331037.0,30980028.0,de Kovel CGF,Ambidextrousness,initial,2019-04-12,GCST007593,Other trait,#d53e4f
919,European,331037.0,30980028.0,de Kovel CGF,Handedness (Right-handed vs. non-right-handed),initial,2019-04-12,GCST007594,Other trait,#d53e4f
920,Asian,296.0,30971808.0,Kim JJ,Response to intravenous immunoglobulin treatment in Kawasaki disease,initial,2019-04-11,GCST008314,Immune system disorder,#3288bd
921,Asian,1242.0,30971808.0,Kim JJ,Response to intravenous immunoglobulin treatment in Kawasaki disease,replication,2019-04-11,GCST008314,Immune system disorder,#3288bd
922,Asian,296.0,30971808.0,Kim JJ,Response to intravenous immunoglobulin treatment in Kawasaki disease,initial,2019-04-11,GCST008314,Other trait,#3288bd
923,Asian,1242.0,30971808.0,Kim JJ,Response to intravenous immunoglobulin treatment in Kawasaki disease,replication,2019-04-11,GCST008314,Other trait,#3288bd
924,European,6692.0,31070471.0,Akinkuolie AO,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP,initial,2019-04-11,GCST008260,Other measurement,#d53e4f
925,European,6692.0,31070471.0,Akinkuolie AO,group IIA secretory phospholipase A2 levels in individuals with elevated hsCRP,initial,2019-04-11,GCST008260,Inflammatory measurement,#d53e4f
926,European,131686.0,31070453.0,Zekavat SM,Arterial stiffness,initial,2019-04-11,GCST007846,Cardiovascular measurement,#d53e4f
927,Asian,6106.0,30975718.0,Tanikawa C,Urolithiasis,replication,2019-04-11,GCST007833,Other disease,#3288bd
928,Asian,198769.0,30975718.0,Tanikawa C,Urolithiasis,initial,2019-04-11,GCST007833,Other disease,#3288bd
930,European,465.0,30972912.0,Wei L,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,initial,2019-04-10,GCST008514,Digestive system disorder,#d53e4f
931,Asian,1108.0,30972912.0,Wei L,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,initial,2019-04-10,GCST008514,Digestive system disorder,#3288bd
932,European,2481.0,30999091.0,Wang Y,Post-traumatic stress disorder symptoms in trauma-exposed soldiers,initial,2019-04-09,GCST008270,Biological process,#d53e4f
933,European,2481.0,30999091.0,Wang Y,Post-traumatic stress disorder symptoms in trauma-exposed soldiers,initial,2019-04-09,GCST008270,Other measurement,#d53e4f
934,Asian,121745.0,30993211.0,Nakatochi M,Serum uric acid levels,initial,2019-04-08,GCST007725,Cardiovascular measurement,#3288bd
935,European,101293.0,30993211.0,Nakatochi M,Serum uric acid levels,replication,2019-04-08,GCST007725,Cardiovascular measurement,#d53e4f
936,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing index (total score),initial,2019-04-08,GCST008267,Other measurement,#3288bd
937,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing (health and vitality),initial,2019-04-08,GCST008266,Other measurement,#3288bd
938,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing (depressiveness),initial,2019-04-08,GCST008261,Other measurement,#3288bd
939,European,88461.0,30993211.0,Nakatochi M,Serum uric acid levels,initial,2019-04-08,GCST007733,Cardiovascular measurement,#d53e4f
940,Asian,121745.0,30993211.0,Nakatochi M,Serum uric acid levels,initial,2019-04-08,GCST007733,Cardiovascular measurement,#3288bd
941,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing (social role performance and self-confidence),initial,2019-04-08,GCST008265,Other measurement,#3288bd
942,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing index 12 (lack of enjoying daily life),initial,2019-04-08,GCST008264,Other measurement,#3288bd
943,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing index 3 (fatigue and loss of appetite),initial,2019-04-08,GCST008263,Other measurement,#3288bd
944,Asian,12680.0,31003110.0,Kim S,Psychological wellbeing index 1 (lack of subjective wellbeing and health),initial,2019-04-08,GCST008262,Other measurement,#3288bd
949,Asian,3617.0,30955190.0,Yun S,Incident chronic kidney disease,initial,2019-04-06,GCST007734,Other disease,#3288bd
950,European,762.0,30952644.0,El Charif O,Tinnitus in cisplatin-treated testicular cancer,initial,2019-04-05,GCST007796,Cancer,#d53e4f
951,European,762.0,30952644.0,El Charif O,Tinnitus in cisplatin-treated testicular cancer,initial,2019-04-05,GCST007796,Response to drug,#d53e4f
952,European,762.0,30952644.0,El Charif O,Tinnitus in cisplatin-treated testicular cancer,initial,2019-04-05,GCST007796,Other trait,#d53e4f
953,European,4401.0,30952852.0,Jones SE,Diurnal inactivity,replication,2019-04-05,GCST007808,Other measurement,#d53e4f
954,European,84757.0,30952852.0,Jones SE,Diurnal inactivity,initial,2019-04-05,GCST007808,Other measurement,#d53e4f
955,European,5819.0,30952852.0,Jones SE,Sleep (time to midpoint),replication,2019-04-05,GCST007807,Other measurement,#d53e4f
956,European,84810.0,30952852.0,Jones SE,Sleep (time to midpoint),initial,2019-04-05,GCST007807,Other measurement,#d53e4f
957,European,85670.0,30952852.0,Jones SE,Time to most active 10 hours,initial,2019-04-05,GCST007806,Other measurement,#d53e4f
958,European,5819.0,30952852.0,Jones SE,Time to most active 10 hours,replication,2019-04-05,GCST007806,Other measurement,#d53e4f
959,European,5819.0,30952852.0,Jones SE,Sleep (time to least active 5 hours),replication,2019-04-05,GCST007805,Other measurement,#d53e4f
960,European,85205.0,30952852.0,Jones SE,Sleep (time to least active 5 hours),initial,2019-04-05,GCST007805,Other measurement,#d53e4f
961,European,84810.0,30952852.0,Jones SE,Sleep (number of episodes),initial,2019-04-05,GCST007804,Other measurement,#d53e4f
962,European,4401.0,30952852.0,Jones SE,Sleep (number of episodes),replication,2019-04-05,GCST007804,Other measurement,#d53e4f
963,European,5819.0,30952852.0,Jones SE,Sleep efficiency,replication,2019-04-05,GCST007803,Other measurement,#d53e4f
964,European,84810.0,30952852.0,Jones SE,Sleep efficiency,initial,2019-04-05,GCST007803,Other measurement,#d53e4f
965,European,5819.0,30952852.0,Jones SE,Sleep duration (variability),replication,2019-04-05,GCST007802,Other measurement,#d53e4f
966,European,84441.0,30952852.0,Jones SE,Sleep duration (variability),initial,2019-04-05,GCST007802,Other measurement,#d53e4f
967,European,85449.0,30952852.0,Jones SE,Sleep duration,initial,2019-04-05,GCST007801,Other measurement,#d53e4f
968,European,5819.0,30952852.0,Jones SE,Sleep duration,replication,2019-04-05,GCST007801,Other measurement,#d53e4f
969,Asian,367.0,30945699.0,Wei J,Postoperative survival time in hepatocellular carcinoma,initial,2019-04-04,GCST007731,Other measurement,#3288bd
970,Asian,758.0,30945699.0,Wei J,Postoperative survival time in hepatocellular carcinoma,replication,2019-04-04,GCST007731,Other measurement,#3288bd
971,Asian,367.0,30945699.0,Wei J,Postoperative survival time in hepatocellular carcinoma,initial,2019-04-04,GCST007731,Cancer,#3288bd
972,Asian,758.0,30945699.0,Wei J,Postoperative survival time in hepatocellular carcinoma,replication,2019-04-04,GCST007731,Cancer,#3288bd
973,European,3921.0,30946739.0,Hu B,Facial attractiveness (male raters),initial,2019-04-04,GCST007819,Other measurement,#d53e4f
974,European,2062.0,30946739.0,Hu B,Facial attractiveness (female raters),initial,2019-04-04,GCST007820,Other measurement,#d53e4f
975,European,1792.0,30946739.0,Hu B,Facial attractiveness (female raters),initial,2019-04-04,GCST007821,Other measurement,#d53e4f
976,European,2062.0,30946739.0,Hu B,Facial attractiveness (male raters),initial,2019-04-04,GCST007822,Other measurement,#d53e4f
977,European,213.0,30946739.0,Hu B,Facial attractiveness (male raters),replication,2019-04-04,GCST007822,Other measurement,#d53e4f
978,European,1792.0,30946739.0,Hu B,Facial attractiveness (male raters),initial,2019-04-04,GCST007823,Other measurement,#d53e4f
979,European,3928.0,30946739.0,Hu B,Facial attractiveness (male raters),initial,2019-04-04,GCST007817,Other measurement,#d53e4f
980,Asian,8839.0,31006500.0,Liu M,Low HDL-cholesterol levels,initial,2019-04-04,GCST007840,Lipid or lipoprotein measurement,#3288bd
981,Other/Mixed,1828.0,30946743.0,Li Z,Ankylosing spondylitis,initial,2019-04-04,GCST007844,Immune system disorder,#99d594
982,Other/Mixed,1176.0,30946743.0,Li Z,Ankylosing spondylitis,initial,2019-04-04,GCST007844,Immune system disorder,#99d594
983,European,3928.0,30946739.0,Hu B,Facial attractiveness (female raters),initial,2019-04-04,GCST007818,Other measurement,#d53e4f
984,European,455.0,30946739.0,Hu B,Facial attractiveness (female raters),replication,2019-04-04,GCST007818,Other measurement,#d53e4f
985,European,471.0,30958311.0,Tao F,Neuropathy in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008530,Neurological disorder,#d53e4f
986,European,471.0,30958311.0,Tao F,Neuropathy in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008530,Neurological disorder,#d53e4f
987,European,406.0,30958311.0,Tao F,Burning or tingling in extremities in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008532,Neurological disorder,#d53e4f
988,European,406.0,30958311.0,Tao F,Burning or tingling in extremities in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008532,Neurological disorder,#d53e4f
989,European,409.0,30958311.0,Tao F,Arthritic-like pain in Charcot-Marie-Tooth type 1A,initial,2019-04-03,GCST008535,Neurological disorder,#d53e4f
990,European,409.0,30958311.0,Tao F,Arthritic-like pain in Charcot-Marie-Tooth type 1A,initial,2019-04-03,GCST008535,Other trait,#d53e4f
991,European,409.0,30958311.0,Tao F,Scoliosis in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008536,Neurological disorder,#d53e4f
992,European,409.0,30958311.0,Tao F,Scoliosis in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008536,Other disease,#d53e4f
993,European,412.0,30958311.0,Tao F,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008539,Neurological disorder,#d53e4f
994,European,412.0,30958311.0,Tao F,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008539,Other measurement,#d53e4f
995,European,417.0,30958311.0,Tao F,Foot deformity in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008541,Neurological disorder,#d53e4f
996,European,417.0,30958311.0,Tao F,Foot deformity in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008541,Other trait,#d53e4f
997,European,200.0,30958311.0,Tao F,First dorsal interosseous strength in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008542,Neurological disorder,#d53e4f
998,European,200.0,30958311.0,Tao F,First dorsal interosseous strength in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008542,Other measurement,#d53e4f
999,European,291.0,30958311.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008544,Neurological disorder,#d53e4f
1000,European,291.0,30958311.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008544,Other measurement,#d53e4f
1001,European,424.0,30958311.0,Tao F,Walking difficulty in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008543,Neurological disorder,#d53e4f
1002,European,423.0,30958311.0,Tao F,"Decreased fine motor function in Charcot-Marie-Tooth disease 1A (buttons, zippers, fasteners, bottles)",initial,2019-04-03,GCST008540,Neurological disorder,#d53e4f
1003,European,413.0,30958311.0,Tao F,Balance difficulty in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008538,Neurological disorder,#d53e4f
1004,European,413.0,30958311.0,Tao F,Balance difficulty in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008538,Other trait,#d53e4f
1005,European,8736.0,30944420.0,Liu L,Trunk fat mass adjusted for trunk lean mass,initial,2019-04-03,GCST007816,Other measurement,#d53e4f
1006,African Am./Caribbean,847.0,30944420.0,Liu L,Trunk fat mass adjusted for trunk lean mass,initial,2019-04-03,GCST007816,Other measurement,#fee08b
1007,Hispanic/Latin American,445.0,30944420.0,Liu L,Trunk fat mass adjusted for trunk lean mass,initial,2019-04-03,GCST007816,Other measurement,#807dba
1008,Asian,1541.0,30944420.0,Liu L,Trunk fat mass adjusted for trunk lean mass,initial,2019-04-03,GCST007816,Other measurement,#3288bd
1009,European,1589.0,30942860.0,Shin J,Visceral fat,initial,2019-04-03,GCST008473,Other measurement,#d53e4f
1012,European,420.0,30958311.0,Tao F,Decreased sensory function in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008537,Other trait,#d53e4f
1013,European,420.0,30958311.0,Tao F,Decreased sensory function in Charcot-Marie-Tooth disease type 1A,initial,2019-04-03,GCST008537,Neurological disorder,#d53e4f
1014,European,364.0,30958311.0,Tao F,Hearing loss in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008534,Neurological disorder,#d53e4f
1015,European,364.0,30958311.0,Tao F,Hearing loss in Charcot-Marie-Tooth disease 1A,initial,2019-04-03,GCST008534,Neurological disorder,#d53e4f
1016,European,420.0,30958311.0,Tao F,Decreased fine motor function in Charcot-Marie-Tooth disease 1A (eating with utensils),initial,2019-04-03,GCST008533,Neurological disorder,#d53e4f
1017,European,200680.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#d53e4f
1018,African Am./Caribbean,56495.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#fee08b
1019,Hispanic/Latin American,14112.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#807dba
1020,Asian,1366.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#3288bd
1021,Asian,189.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#3288bd
1022,European,200680.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#d53e4f
1023,African Am./Caribbean,56495.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#fee08b
1024,Hispanic/Latin American,14112.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#807dba
1025,Asian,1366.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#3288bd
1026,Asian,189.0,30940813.0,Kranzler HR,Alcohol use disorder (consumption score),initial,2019-04-02,GCST008258,Other measurement,#3288bd
1028,European,458969.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy),initial,2019-04-02,GCST007656,Cardiovascular measurement,#d53e4f
1030,European,458969.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or resting heart rate (pleiotropy),initial,2019-04-02,GCST007656,Other disease,#d53e4f
1031,European,202004.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Other measurement,#d53e4f
1032,African Am./Caribbean,56648.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Other measurement,#fee08b
1033,Asian,1374.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Other measurement,#3288bd
1034,Asian,190.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Other measurement,#3288bd
1035,Hispanic/Latin American,14175.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Other measurement,#807dba
1036,European,202004.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Neurological disorder,#d53e4f
1037,African Am./Caribbean,56648.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Neurological disorder,#fee08b
1038,Asian,1374.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Neurological disorder,#3288bd
1039,Asian,190.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Neurological disorder,#3288bd
1040,Hispanic/Latin American,14175.0,30940813.0,Kranzler HR,Alcohol use disorder,initial,2019-04-02,GCST008259,Neurological disorder,#807dba
1042,European,446696.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or stroke (pleiotropy),initial,2019-04-02,GCST007613,Cardiovascular disease,#d53e4f
1044,European,446696.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or stroke (pleiotropy),initial,2019-04-02,GCST007613,Other disease,#d53e4f
1048,European,458554.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy),initial,2019-04-02,GCST007611,Cardiovascular disease,#d53e4f
1050,European,458554.0,30940143.0,Zhu Z,Chronic obstructive pulmonary disease or high blood pressure (pleiotropy),initial,2019-04-02,GCST007611,Other disease,#d53e4f
1051,European,458554.0,30940143.0,Zhu Z,Hypertension,initial,2019-04-02,GCST007610,Cardiovascular disease,#d53e4f
1052,European,458969.0,30940143.0,Zhu Z,Resting heart rate,initial,2019-04-02,GCST007609,Cardiovascular measurement,#d53e4f
1053,European,146369.0,30476138.0,Benonisdottir S,Glucosuria,initial,2019-04-01,GCST008614,Other trait,#d53e4f
1054,European,87742.0,30476138.0,Benonisdottir S,Hematuria (mild),initial,2019-04-01,GCST008618,Other trait,#d53e4f
1055,European,118115.0,30476138.0,Benonisdottir S,Hematuria (moderate to severe),initial,2019-04-01,GCST008617,Other trait,#d53e4f
1056,European,136954.0,30476138.0,Benonisdottir S,Hematuria,initial,2019-04-01,GCST008613,Other trait,#d53e4f
1057,European,120230.0,30476138.0,Benonisdottir S,Proteinuria (mild),initial,2019-04-01,GCST008612,Other trait,#d53e4f
1058,European,116855.0,30476138.0,Benonisdottir S,Proteinuria (moderate to severe),initial,2019-04-01,GCST008611,Other trait,#d53e4f
1059,European,145547.0,30476138.0,Benonisdottir S,Proteinuria,initial,2019-04-01,GCST008610,Other trait,#d53e4f
1060,European,140260.0,30476138.0,Benonisdottir S,Glucosuria (mild),initial,2019-04-01,GCST008606,Other trait,#d53e4f
1061,European,141621.0,30476138.0,Benonisdottir S,Glucosuria (moderate to severe),initial,2019-04-01,GCST008605,Other trait,#d53e4f
1062,European,1094.0,30929638.0,Matana A,Thyroglobulin plasma levels,initial,2019-03-30,GCST008170,Other measurement,#d53e4f
1063,European,2989.0,30922102.0,Pardinas AF,Plasma norclozapine levels in treatment-resistant schizophrenia,initial,2019-03-29,GCST007686,Neurological disorder,#d53e4f
1064,European,2989.0,30922102.0,Pardinas AF,Plasma norclozapine levels in treatment-resistant schizophrenia,initial,2019-03-29,GCST007686,Response to drug,#d53e4f
1065,European,405.0,30926877.0,Brcic L,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007851,Immune system disorder,#d53e4f
1066,European,405.0,30926877.0,Brcic L,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007851,Other measurement,#d53e4f
1067,European,405.0,30926877.0,Brcic L,Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007851,Other measurement,#d53e4f
1068,European,405.0,30926877.0,Brcic L,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007831,Immune system disorder,#d53e4f
1069,European,405.0,30926877.0,Brcic L,Anti-thyroglobulin (TgAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007831,Other measurement,#d53e4f
1070,European,405.0,30926877.0,Brcic L,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007830,Immune system disorder,#d53e4f
1071,European,405.0,30926877.0,Brcic L,Anti-thyroid peroxidase (TPOAb) levels in Hashimoto's thyroiditis,initial,2019-03-29,GCST007830,Other measurement,#d53e4f
1072,European,2989.0,30922102.0,Pardinas AF,Plasma clozapine levels in treatment-resistant schizophrenia,initial,2019-03-29,GCST007685,Neurological disorder,#d53e4f
1073,European,2989.0,30922102.0,Pardinas AF,Plasma clozapine levels in treatment-resistant schizophrenia,initial,2019-03-29,GCST007685,Response to drug,#d53e4f
1074,European,2989.0,30922102.0,Pardinas AF,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia,initial,2019-03-29,GCST007684,Neurological disorder,#d53e4f
1075,European,2989.0,30922102.0,Pardinas AF,Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia,initial,2019-03-29,GCST007684,Response to drug,#d53e4f
1076,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Response to drug,#d53e4f
1077,European,355.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008148,Response to drug,#d53e4f
1078,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Response to drug,#3288bd
1079,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Response to drug,#807dba
1080,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Response to drug,#fee08b
1081,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Metabolic disorder,#d53e4f
1082,European,355.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008148,Metabolic disorder,#d53e4f
1083,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Metabolic disorder,#3288bd
1084,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Metabolic disorder,#807dba
1085,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Metabolic disorder,#fee08b
1086,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Cardiovascular measurement,#d53e4f
1087,European,355.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008148,Cardiovascular measurement,#d53e4f
1088,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Cardiovascular measurement,#3288bd
1089,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Cardiovascular measurement,#807dba
1090,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008148,Cardiovascular measurement,#fee08b
1091,European,47299.0,30929738.0,Ferreira MAR,Asthma onset (childhood vs adult),replication,2019-03-28,GCST007797,Other measurement,#d53e4f
1092,European,28835.0,30929738.0,Ferreira MAR,Asthma onset (childhood vs adult),initial,2019-03-28,GCST007797,Other measurement,#d53e4f
1093,European,47299.0,30929738.0,Ferreira MAR,Asthma onset (childhood vs adult),replication,2019-03-28,GCST007797,Other disease,#d53e4f
1094,European,28835.0,30929738.0,Ferreira MAR,Asthma onset (childhood vs adult),initial,2019-03-28,GCST007797,Other disease,#d53e4f
1095,European,341215.0,30929738.0,Ferreira MAR,Asthma,initial,2019-03-28,GCST007798,Other disease,#d53e4f
1096,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Response to drug,#d53e4f
1097,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Response to drug,#3288bd
1098,European,820.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008147,Response to drug,#d53e4f
1099,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Response to drug,#807dba
1100,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Response to drug,#fee08b
1101,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Metabolic disorder,#d53e4f
1102,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Metabolic disorder,#3288bd
1103,European,820.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008147,Metabolic disorder,#d53e4f
1104,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Metabolic disorder,#807dba
1105,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Metabolic disorder,#fee08b
1106,European,2647.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Cardiovascular measurement,#d53e4f
1107,Asian,303.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Cardiovascular measurement,#3288bd
1108,European,820.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),replication,2019-03-28,GCST008147,Cardiovascular measurement,#d53e4f
1109,Hispanic/Latin American,114.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Cardiovascular measurement,#807dba
1110,African Am./Caribbean,115.0,30924126.0,Brackman DJ,Response to allopurinol in gout (change in serum uric acid levels),initial,2019-03-28,GCST008147,Cardiovascular measurement,#fee08b
1111,Asian,400.0,30921371.0,Choi SY,Severe coronary artery calcification,initial,2019-03-28,GCST007711,Other trait,#3288bd
1112,Asian,1288.0,30921371.0,Choi SY,Severe coronary artery calcification,replication,2019-03-28,GCST007711,Other trait,#3288bd
1113,Other/Mixed,631.0,30921485.0,Bejaoui Y,Psoriasis,initial,2019-03-28,GCST008096,Immune system disorder,#99d594
1114,Other/Mixed,574.0,30921485.0,Bejaoui Y,Psoriasis,replication,2019-03-28,GCST008096,Immune system disorder,#99d594
1115,European,327253.0,30929738.0,Ferreira MAR,Asthma (adult onset),initial,2019-03-28,GCST007799,Other disease,#d53e4f
1116,European,234008.0,30929738.0,Ferreira MAR,Asthma (adult onset),replication,2019-03-28,GCST007799,Other disease,#d53e4f
1117,European,246649.0,30929738.0,Ferreira MAR,Asthma (childhood onset),replication,2019-03-28,GCST007800,Other disease,#d53e4f
1118,European,314633.0,30929738.0,Ferreira MAR,Asthma (childhood onset),initial,2019-03-28,GCST007800,Other disease,#d53e4f
1119,Asian,1036.0,30911093.0,Bandesh K,Low density lipoprotein cholesterol levels,initial,2019-03-25,GCST007689,Lipid or lipoprotein measurement,#3288bd
1120,Asian,4235.0,30911093.0,Bandesh K,Low density lipoprotein cholesterol levels,replication,2019-03-25,GCST007689,Lipid or lipoprotein measurement,#3288bd
1121,European,188577.0,30911093.0,Bandesh K,Low density lipoprotein cholesterol levels,replication,2019-03-25,GCST007689,Lipid or lipoprotein measurement,#d53e4f
1122,Other/Mixed,7898.0,30911093.0,Bandesh K,Low density lipoprotein cholesterol levels,replication,2019-03-25,GCST007689,Lipid or lipoprotein measurement,#99d594
1123,Asian,4235.0,30911093.0,Bandesh K,Total cholesterol levels,replication,2019-03-25,GCST007688,Lipid or lipoprotein measurement,#3288bd
1124,Asian,1036.0,30911093.0,Bandesh K,Total cholesterol levels,initial,2019-03-25,GCST007688,Lipid or lipoprotein measurement,#3288bd
1125,European,188577.0,30911093.0,Bandesh K,Total cholesterol levels,replication,2019-03-25,GCST007688,Lipid or lipoprotein measurement,#d53e4f
1126,Other/Mixed,7898.0,30911093.0,Bandesh K,Total cholesterol levels,replication,2019-03-25,GCST007688,Lipid or lipoprotein measurement,#99d594
1127,Asian,1036.0,30911093.0,Bandesh K,Triglyceride levels,initial,2019-03-25,GCST007702,Lipid or lipoprotein measurement,#3288bd
1128,Asian,4235.0,30911093.0,Bandesh K,Triglyceride levels,replication,2019-03-25,GCST007702,Lipid or lipoprotein measurement,#3288bd
1129,European,188577.0,30911093.0,Bandesh K,Triglyceride levels,replication,2019-03-25,GCST007702,Lipid or lipoprotein measurement,#d53e4f
1130,Other/Mixed,7898.0,30911093.0,Bandesh K,Triglyceride levels,replication,2019-03-25,GCST007702,Lipid or lipoprotein measurement,#99d594
1131,Asian,4235.0,30911093.0,Bandesh K,High density lipoprotein cholesterol levels,replication,2019-03-25,GCST007701,Lipid or lipoprotein measurement,#3288bd
1132,Asian,1036.0,30911093.0,Bandesh K,High density lipoprotein cholesterol levels,initial,2019-03-25,GCST007701,Lipid or lipoprotein measurement,#3288bd
1133,European,188577.0,30911093.0,Bandesh K,High density lipoprotein cholesterol levels,replication,2019-03-25,GCST007701,Lipid or lipoprotein measurement,#d53e4f
1134,Other/Mixed,7898.0,30911093.0,Bandesh K,High density lipoprotein cholesterol levels,replication,2019-03-25,GCST007701,Lipid or lipoprotein measurement,#99d594
1135,Asian,7094.0,30899057.0,Lee MG,Gout,initial,2019-03-21,GCST008139,Metabolic disorder,#3288bd
1136,Asian,7830.0,30899057.0,Lee MG,Gout,replication,2019-03-21,GCST008139,Metabolic disorder,#3288bd
1137,Asian,329.0,30895295.0,Jonnalagadda M,Iris heterochromicity,initial,2019-03-21,GCST007742,Other measurement,#3288bd
1138,Asian,329.0,30895295.0,Jonnalagadda M,Iris color (L* coordinate),initial,2019-03-21,GCST007743,Other measurement,#3288bd
1139,Asian,329.0,30895295.0,Jonnalagadda M,Iris color (b* coordinate),initial,2019-03-21,GCST007741,Other measurement,#3288bd
1140,Asian,329.0,30895295.0,Jonnalagadda M,Iris color (a* coordinate),initial,2019-03-21,GCST007740,Other measurement,#3288bd
1141,Asian,720.0,30895295.0,Jonnalagadda M,Skin reflectance (Melanin index),initial,2019-03-21,GCST007739,Other measurement,#3288bd
1142,Asian,3417.0,30899065.0,Wang M,Photic sneeze reflex,initial,2019-03-21,GCST007687,Other trait,#3288bd
1143,European,6125.0,30894546.0,Ivarsdottir EV,Corneal hysteresis,initial,2019-03-20,GCST008315,Other measurement,#d53e4f
1144,European,6125.0,30894546.0,Ivarsdottir EV,Corneal endothelial cell shape (percentage of hexagonally shaped cells),initial,2019-03-20,GCST008321,Other measurement,#d53e4f
1145,European,6125.0,30894546.0,Ivarsdottir EV,Corneal endothelial cell size variation coefficient,initial,2019-03-20,GCST008316,Other measurement,#d53e4f
1146,European,6125.0,30894546.0,Ivarsdottir EV,Corneal endothelial cell density,initial,2019-03-20,GCST008339,Other measurement,#d53e4f
1147,European,1459.0,30894546.0,Ivarsdottir EV,Central corneal thickness,replication,2019-03-20,GCST008317,Other measurement,#d53e4f
1148,European,6125.0,30894546.0,Ivarsdottir EV,Central corneal thickness,initial,2019-03-20,GCST008317,Other measurement,#d53e4f
1149,European,6125.0,30894546.0,Ivarsdottir EV,Intraocular pressure (Goldman correlated),initial,2019-03-20,GCST008320,Other measurement,#d53e4f
1150,European,6125.0,30894546.0,Ivarsdottir EV,Intraocular pressure (corneal compensated),initial,2019-03-20,GCST008319,Other measurement,#d53e4f
1151,European,6125.0,30894546.0,Ivarsdottir EV,Corneal resistance factor,initial,2019-03-20,GCST008318,Other measurement,#d53e4f
1160,Asian,7321.0,30898391.0,Lawrenson K,Epithelial ovarian cancer,initial,2019-03-19,GCST007728,Cancer,#3288bd
1161,European,1758.0,30886212.0,Eszlari N,Rumination (response to stress),initial,2019-03-18,GCST007677,Biological process,#d53e4f
1162,European,1758.0,30886212.0,Eszlari N,Reflection (response to stress),initial,2019-03-18,GCST007679,Biological process,#d53e4f
1163,European,1758.0,30886212.0,Eszlari N,Brooding (response to stress),initial,2019-03-18,GCST007678,Biological process,#d53e4f
1164,European,294.0,30889042.0,Innocenti F,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer,initial,2019-03-18,GCST007643,Immune system disorder,#d53e4f
1165,European,294.0,30889042.0,Innocenti F,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer,initial,2019-03-18,GCST007643,Response to drug,#d53e4f
1166,European,294.0,30889042.0,Innocenti F,Gemcitabine-induced early high-grade neutropenia in pancreatic cancer,initial,2019-03-18,GCST007643,Cancer,#d53e4f
1167,European,270059.0,30867560.0,Hill WD,Worry/vulnerability (special factor of neuroticism),initial,2019-03-13,GCST007708,Other measurement,#d53e4f
1168,European,270059.0,30867560.0,Hill WD,General factor of neuroticism,initial,2019-03-13,GCST007709,Other measurement,#d53e4f
1169,European,270059.0,30867560.0,Hill WD,Anxiety/tension (special factor of neuroticism),initial,2019-03-13,GCST007710,Other measurement,#d53e4f
1170,European,218759.0,30910378.0,Zanetti D,Urinary albumin-to-creatinine ratio,initial,2019-03-12,GCST007718,Other measurement,#d53e4f
1171,European,109530.0,30910378.0,Zanetti D,Urinary albumin-to-creatinine ratio,replication,2019-03-12,GCST007718,Other measurement,#d53e4f
1172,European,217634.0,30910378.0,Zanetti D,Albuminuria,initial,2019-03-12,GCST007719,Other trait,#d53e4f
1173,European,108800.0,30910378.0,Zanetti D,Albuminuria,replication,2019-03-12,GCST007719,Other trait,#d53e4f
1174,European,108942.0,30910378.0,Zanetti D,Urinary sodium to potassium ratio,replication,2019-03-12,GCST007717,Other measurement,#d53e4f
1175,European,217996.0,30910378.0,Zanetti D,Urinary sodium to potassium ratio,initial,2019-03-12,GCST007717,Other measurement,#d53e4f
1176,European,109166.0,30910378.0,Zanetti D,Urinary sodium to creatinine ratio,replication,2019-03-12,GCST007778,Other measurement,#d53e4f
1177,European,218450.0,30910378.0,Zanetti D,Urinary sodium to creatinine ratio,initial,2019-03-12,GCST007778,Other measurement,#d53e4f
1178,European,218435.0,30910378.0,Zanetti D,Urinary potassium to creatinine ratio,initial,2019-03-12,GCST007721,Other measurement,#d53e4f
1179,European,109178.0,30910378.0,Zanetti D,Urinary potassium to creatinine ratio,replication,2019-03-12,GCST007721,Other measurement,#d53e4f
1180,Asian,1252.0,30854688.0,Wang C,Anti-sp100 seropositivity in primary biliary cholangitis,replication,2019-03-10,GCST007737,Cancer,#3288bd
1181,Asian,922.0,30854688.0,Wang C,Anti-sp100 seropositivity in primary biliary cholangitis,initial,2019-03-10,GCST007737,Cancer,#3288bd
1182,Asian,1252.0,30854688.0,Wang C,Anti-sp100 seropositivity in primary biliary cholangitis,replication,2019-03-10,GCST007737,Other measurement,#3288bd
1183,Asian,922.0,30854688.0,Wang C,Anti-sp100 seropositivity in primary biliary cholangitis,initial,2019-03-10,GCST007737,Other measurement,#3288bd
1184,Asian,1252.0,30854688.0,Wang C,Anti-gp210 seropositivity in primary biliary cholangitis,replication,2019-03-10,GCST007736,Cancer,#3288bd
1185,Asian,912.0,30854688.0,Wang C,Anti-gp210 seropositivity in primary biliary cholangitis,initial,2019-03-10,GCST007736,Cancer,#3288bd
1186,Asian,1252.0,30854688.0,Wang C,Anti-gp210 seropositivity in primary biliary cholangitis,replication,2019-03-10,GCST007736,Other measurement,#3288bd
1187,Asian,912.0,30854688.0,Wang C,Anti-gp210 seropositivity in primary biliary cholangitis,initial,2019-03-10,GCST007736,Other measurement,#3288bd
1188,European,369.0,30852652.0,Schlicht K,Metabolic coherence (transcriptomic),initial,2019-03-09,GCST007690,Other measurement,#d53e4f
1189,European,3783.0,30852652.0,Schlicht K,Metabolic coherence (transcriptomic),replication,2019-03-09,GCST007690,Other measurement,#d53e4f
1190,European,369.0,30852652.0,Schlicht K,Metabolic coherence (transcriptomic),initial,2019-03-09,GCST007690,Other measurement,#d53e4f
1191,European,3783.0,30852652.0,Schlicht K,Metabolic coherence (transcriptomic),replication,2019-03-09,GCST007690,Other measurement,#d53e4f
1192,European,5161.0,30850646.0,Tziotzios C,Frontal fibrosing alopecia,initial,2019-03-08,GCST007713,Other disease,#d53e4f
1193,European,432.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,initial,2019-03-07,GCST008240,Other measurement,#d53e4f
1194,European,432.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,initial,2019-03-07,GCST008240,Other measurement,#d53e4f
1195,European,5070.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,initial,2019-03-07,GCST008246,Other measurement,#d53e4f
1196,European,1966.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,replication,2019-03-07,GCST008246,Other measurement,#d53e4f
1197,European,5070.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,initial,2019-03-07,GCST008246,Other measurement,#d53e4f
1198,European,1966.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,replication,2019-03-07,GCST008246,Other measurement,#d53e4f
1199,European,4855.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,initial,2019-03-07,GCST008245,Other measurement,#d53e4f
1200,European,3134.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,replication,2019-03-07,GCST008245,Other measurement,#d53e4f
1201,European,4855.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,initial,2019-03-07,GCST008245,Other measurement,#d53e4f
1202,European,3134.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,replication,2019-03-07,GCST008245,Other measurement,#d53e4f
1203,European,5070.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,initial,2019-03-07,GCST008247,Other measurement,#d53e4f
1204,European,1966.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,replication,2019-03-07,GCST008247,Other measurement,#d53e4f
1205,European,5070.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,initial,2019-03-07,GCST008247,Other measurement,#d53e4f
1206,European,1966.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in never smokers,replication,2019-03-07,GCST008247,Other measurement,#d53e4f
1207,European,1729.0,30843173.0,Popovic M,Triiodothyronine levels and thyroxine levels,initial,2019-03-07,GCST007680,Other measurement,#d53e4f
1208,European,1729.0,30843173.0,Popovic M,Triiodothyronine levels and thyroxine levels,initial,2019-03-07,GCST007680,Other measurement,#d53e4f
1209,European,1731.0,30843173.0,Popovic M,Thyroid stimulating hormone levels,initial,2019-03-07,GCST007681,Other measurement,#d53e4f
1210,European,1715.0,30843173.0,Popovic M,Thyroxine levels,initial,2019-03-07,GCST007682,Other measurement,#d53e4f
1211,European,446118.0,30846698.0,Dashti HS,Sleep duration,initial,2019-03-07,GCST007561,Other measurement,#d53e4f
1213,European,339926.0,30846698.0,Dashti HS,Sleep duration (long sleep),initial,2019-03-07,GCST007560,Other measurement,#d53e4f
1215,European,4855.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,initial,2019-03-07,GCST008244,Other measurement,#d53e4f
1216,European,3134.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,replication,2019-03-07,GCST008244,Other measurement,#d53e4f
1217,European,4855.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,initial,2019-03-07,GCST008244,Other measurement,#d53e4f
1218,European,3134.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,replication,2019-03-07,GCST008244,Other measurement,#d53e4f
1219,European,1729.0,30843173.0,Popovic M,Triiodothyronine levels,initial,2019-03-07,GCST007683,Other measurement,#d53e4f
1220,European,446118.0,30846698.0,Dashti HS,Sleep duration (short sleep),initial,2019-03-07,GCST007559,Other measurement,#d53e4f
1222,Asian,2197.0,30866520.0,Er LK,Chemerin levels,initial,2019-03-07,GCST007900,Cardiovascular measurement,#3288bd
1223,European,823.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,initial,2019-03-07,GCST008243,Other measurement,#d53e4f
1224,European,823.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<70%) in ever smokers,initial,2019-03-07,GCST008243,Other measurement,#d53e4f
1225,European,432.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,initial,2019-03-07,GCST008241,Other measurement,#d53e4f
1226,European,432.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in never smokers,initial,2019-03-07,GCST008241,Other measurement,#d53e4f
1227,European,823.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,initial,2019-03-07,GCST008242,Other measurement,#d53e4f
1228,European,823.0,30845926.0,van der Plaat DA,Airway obstruction (FEV1/FVC<lower limit of normal) in ever smokers,initial,2019-03-07,GCST008242,Other measurement,#d53e4f
1229,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and C-reactive protein levels (pleiotropy),initial,2019-03-06,GCST008234,Other trait,#d53e4f
1230,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and C-reactive protein levels (pleiotropy),initial,2019-03-06,GCST008234,Inflammatory measurement,#d53e4f
1231,European,6545.0,31201950.0,Lutz MW,Serum total cholesterol levels,initial,2019-03-06,GCST008239,Lipid or lipoprotein measurement,#d53e4f
1232,European,6545.0,31201950.0,Lutz MW,Low density lipoprotein cholesterol levels,initial,2019-03-06,GCST008238,Lipid or lipoprotein measurement,#d53e4f
1233,European,6545.0,31201950.0,Lutz MW,High density lipoprotein cholesterol levels,initial,2019-03-06,GCST008237,Lipid or lipoprotein measurement,#d53e4f
1234,European,6545.0,31201950.0,Lutz MW,C-reactive protein levels,initial,2019-03-06,GCST008236,Inflammatory measurement,#d53e4f
1235,European,6545.0,31201950.0,Lutz MW,Cognitive impairment,initial,2019-03-06,GCST008235,Other trait,#d53e4f
1236,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and total cholesterol levels (pleiotropy),initial,2019-03-06,GCST008232,Other trait,#d53e4f
1237,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and total cholesterol levels (pleiotropy),initial,2019-03-06,GCST008232,Lipid or lipoprotein measurement,#d53e4f
1238,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and LDL levels (pleiotropy),initial,2019-03-06,GCST008233,Other trait,#d53e4f
1239,European,6545.0,31201950.0,Lutz MW,Cognitive impairment and LDL levels (pleiotropy),initial,2019-03-06,GCST008233,Lipid or lipoprotein measurement,#d53e4f
1240,European,80003.0,30837465.0,Wittemans LBL,Glycine levels,initial,2019-03-05,GCST007638,Other measurement,#d53e4f
1243,European,401656.0,30833571.0,Wiberg A,Carpal tunnel syndrome,initial,2019-03-04,GCST007581,Neurological disorder,#d53e4f
1245,European,77997.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy),initial,2019-03-01,GCST007587,Neurological disorder,#d53e4f
1247,European,77997.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or hippocampal volume (pleiotropy),initial,2019-03-01,GCST007587,Other measurement,#d53e4f
1248,European,64987.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy),initial,2019-03-01,GCST007584,Neurological disorder,#d53e4f
1250,European,64987.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or thalamus volume (pleiotropy),initial,2019-03-01,GCST007584,Other measurement,#d53e4f
1252,European,64933.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy),initial,2019-03-01,GCST007585,Neurological disorder,#d53e4f
1254,European,64933.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or pallidum volume (pleiotropy),initial,2019-03-01,GCST007585,Other measurement,#d53e4f
1256,European,65050.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy),initial,2019-03-01,GCST007588,Neurological disorder,#d53e4f
1258,European,65050.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or amygdala volume (pleiotropy),initial,2019-03-01,GCST007588,Other measurement,#d53e4f
1261,European,64939.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or putamen volume (pleiotropy),initial,2019-03-01,GCST007582,Neurological disorder,#d53e4f
1263,European,64939.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or putamen volume (pleiotropy),initial,2019-03-01,GCST007582,Other measurement,#d53e4f
1264,European,77317.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy),initial,2019-03-01,GCST007586,Neurological disorder,#d53e4f
1266,European,77317.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or intracranial volume (pleiotropy),initial,2019-03-01,GCST007586,Other measurement,#d53e4f
1268,European,24024.0,30818988.0,Klein M,Intracranial volume,initial,2019-03-01,GCST007589,Other measurement,#d53e4f
1269,European,24704.0,30818988.0,Klein M,Hippocampal volume,initial,2019-03-01,GCST007590,Other measurement,#d53e4f
1271,European,65065.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy),initial,2019-03-01,GCST007591,Neurological disorder,#d53e4f
1273,European,65065.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or caudate nucleus volume (pleiotropy),initial,2019-03-01,GCST007591,Other measurement,#d53e4f
1274,European,67083.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy),initial,2019-03-01,GCST007583,Neurological disorder,#d53e4f
1276,European,67083.0,30818988.0,Klein M,Attention deficit hyperactivity disorder or nucleus accumbens volume (pleiotropy),initial,2019-03-01,GCST007583,Other measurement,#d53e4f
1278,Asian,367.0,30945673.0,Prasad G,Postoperative survival time in hepatocellular carcinoma,initial,2019-03-01,GCST007650,Other measurement,#3288bd
1279,Asian,758.0,30945673.0,Prasad G,Postoperative survival time in hepatocellular carcinoma,replication,2019-03-01,GCST007650,Other measurement,#3288bd
1280,Asian,367.0,30945673.0,Prasad G,Postoperative survival time in hepatocellular carcinoma,initial,2019-03-01,GCST007650,Cancer,#3288bd
1281,Asian,758.0,30945673.0,Prasad G,Postoperative survival time in hepatocellular carcinoma,replication,2019-03-01,GCST007650,Cancer,#3288bd
1282,European,623.0,30824882.0,Gunjaca I,Triiodothyronine/thyroxine ratio,initial,2019-03-01,GCST007427,Other measurement,#d53e4f
1283,European,623.0,30824882.0,Gunjaca I,Triiodothyronine levels,initial,2019-03-01,GCST007426,Other measurement,#d53e4f
1284,European,6774.0,30818990.0,Yu D,Tourette syndrome,replication,2019-03-01,GCST007277,Neurological disorder,#d53e4f
1285,European,14307.0,30818990.0,Yu D,Tourette syndrome,initial,2019-03-01,GCST007277,Neurological disorder,#d53e4f
1286,European,1121.0,30824882.0,Gunjaca I,Thyroxine levels,initial,2019-03-01,GCST007428,Other measurement,#d53e4f
1289,European,30511.0,30820047.0,Kunkle BW,Alzheimer's disease (late onset),replication,2019-02-28,GCST007511,Neurological disorder,#d53e4f
1290,European,63926.0,30820047.0,Kunkle BW,Alzheimer's disease (late onset),initial,2019-02-28,GCST007511,Neurological disorder,#d53e4f
1291,European,4475.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect),initial,2019-02-27,GCST007644,Other measurement,#d53e4f
1292,European,4475.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect),initial,2019-02-27,GCST007644,Other measurement,#d53e4f
1293,European,4475.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 1 year in renal transplantation (donor effect),initial,2019-02-27,GCST007644,Other measurement,#d53e4f
1294,European,5935.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect),initial,2019-02-27,GCST007645,Other measurement,#d53e4f
1295,European,5935.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 1 year in renal transplantation (recipient effect),initial,2019-02-27,GCST007645,Other measurement,#d53e4f
1296,European,2298.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate change in renal transplantation (donor effect),initial,2019-02-27,GCST007646,Other measurement,#d53e4f
1297,European,2298.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate change in renal transplantation (donor effect),initial,2019-02-27,GCST007646,Other measurement,#d53e4f
1298,European,2298.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate change in renal transplantation (donor effect),initial,2019-02-27,GCST007646,Other measurement,#d53e4f
1299,European,2298.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate change in renal transplantation (recipient effect),initial,2019-02-27,GCST007647,Other measurement,#d53e4f
1300,European,2298.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate change in renal transplantation (recipient effect),initial,2019-02-27,GCST007647,Other measurement,#d53e4f
1301,European,2921.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect),initial,2019-02-27,GCST007648,Other measurement,#d53e4f
1302,European,2921.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect),initial,2019-02-27,GCST007648,Other measurement,#d53e4f
1303,European,2921.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 5 years in renal transplantation (donor effect),initial,2019-02-27,GCST007648,Other measurement,#d53e4f
1304,European,2921.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect),initial,2019-02-27,GCST007649,Other measurement,#d53e4f
1305,European,2921.0,30920136.0,Stapleton CP,Estimated glomerular filtration rate after 5 years in renal transplantation (recipient effect),initial,2019-02-27,GCST007649,Other measurement,#d53e4f
1306,European,6770.0,30807572.0,Gong J,Meconium ileus in cystic fibrosis,initial,2019-02-26,GCST007367,Digestive system disorder,#d53e4f
1307,European,499.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,initial,2019-02-26,GCST007495,Other measurement,#d53e4f
1308,European,574.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,replication,2019-02-26,GCST007495,Other measurement,#d53e4f
1309,European,499.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,initial,2019-02-26,GCST007495,Other disease,#d53e4f
1310,European,574.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,replication,2019-02-26,GCST007495,Other disease,#d53e4f
1311,European,499.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,initial,2019-02-26,GCST007495,Cardiovascular disease,#d53e4f
1312,European,574.0,30809046.0,Schmitz B,Estimated glomerular filtration rate in coronary artery disease and impaired kidney function,replication,2019-02-26,GCST007495,Cardiovascular disease,#d53e4f
1313,European,1829.0,30808802.0,Freidin M,Modic changes,initial,2019-02-26,GCST007537,Other trait,#d53e4f
1314,European,112209.0,30805717.0,Zhu Z,Alzheimer's disease or fasting glucose levels (pleiotropy),initial,2019-02-25,GCST007825,Neurological disorder,#d53e4f
1315,European,112209.0,30805717.0,Zhu Z,Alzheimer's disease or fasting glucose levels (pleiotropy),initial,2019-02-25,GCST007825,Other measurement,#d53e4f
1316,European,114974.0,30805717.0,Zhu Z,Alzheimer's disease or HDL levels (pleiotropy),initial,2019-02-25,GCST007827,Neurological disorder,#d53e4f
1317,European,114974.0,30805717.0,Zhu Z,Alzheimer's disease or HDL levels (pleiotropy),initial,2019-02-25,GCST007827,Lipid or lipoprotein measurement,#d53e4f
1318,European,105912.0,30805717.0,Zhu Z,Alzheimer's disease or fasting insulin levels (pleiotropy),initial,2019-02-25,GCST007826,Neurological disorder,#d53e4f
1319,European,105912.0,30805717.0,Zhu Z,Alzheimer's disease or fasting insulin levels (pleiotropy),initial,2019-02-25,GCST007826,Other measurement,#d53e4f
1320,European,359916.0,30804565.0,Jansen PR,Snoring,initial,2019-02-25,GCST007985,Other measurement,#d53e4f
1321,European,386548.0,30804565.0,Jansen PR,Daytime sleepiness,initial,2019-02-25,GCST007984,Other measurement,#d53e4f
1322,European,385949.0,30804565.0,Jansen PR,Ease of getting up in the morning,initial,2019-02-25,GCST007986,Other measurement,#d53e4f
1323,European,384317.0,30804565.0,Jansen PR,Sleep duration,initial,2019-02-25,GCST007982,Other measurement,#d53e4f
1324,European,434835.0,30804565.0,Jansen PR,Morningness,initial,2019-02-25,GCST007983,Other measurement,#d53e4f
1326,European,46350.0,30804558.0,Grove J,Autism and educational attainment (MTAG),initial,2019-02-25,GCST007554,Neurological disorder,#d53e4f
1328,European,46350.0,30804558.0,Grove J,Autism and educational attainment (MTAG),initial,2019-02-25,GCST007554,Other measurement,#d53e4f
1330,European,46350.0,30804558.0,Grove J,Autism and schizophrenia (MTAG),initial,2019-02-25,GCST007555,Neurological disorder,#d53e4f
1332,European,46350.0,30804558.0,Grove J,Autism and schizophrenia (MTAG),initial,2019-02-25,GCST007555,Neurological disorder,#d53e4f
1334,European,46350.0,30804558.0,Grove J,Autism and major depressive disorder (MTAG),initial,2019-02-25,GCST007553,Neurological disorder,#d53e4f
1336,European,46350.0,30804558.0,Grove J,Autism and major depressive disorder (MTAG),initial,2019-02-25,GCST007553,Neurological disorder,#d53e4f
1337,European,237627.0,30804566.0,Lane JM,Insomnia symptoms (never/rarely vs. usually),initial,2019-02-25,GCST007388,Other measurement,#d53e4f
1338,European,78990.0,30804566.0,Lane JM,Insomnia symptoms (never/rarely vs. usually),replication,2019-02-25,GCST007388,Other measurement,#d53e4f
1339,European,386577.0,30804565.0,Jansen PR,Daytime nap,initial,2019-02-25,GCST007987,Other measurement,#d53e4f
1340,European,1263.0,30801121.0,O'Donnell S,Crohn's disease (indolent vs progressive),initial,2019-02-25,GCST007499,Other measurement,#d53e4f
1341,European,1263.0,30801121.0,O'Donnell S,Crohn's disease (indolent vs progressive),initial,2019-02-25,GCST007499,Digestive system disorder,#d53e4f
1342,European,1360.0,30801121.0,O'Donnell S,Crohn's disease (time to first abdominal surgery),initial,2019-02-25,GCST007498,Other measurement,#d53e4f
1343,European,1360.0,30801121.0,O'Donnell S,Crohn's disease (time to first abdominal surgery),initial,2019-02-25,GCST007498,Digestive system disorder,#d53e4f
1344,European,24218.0,30804560.0,Shrine N,Peak expiratory flow,initial,2019-02-25,GCST007430,Other measurement,#d53e4f
1345,European,321047.0,30804560.0,Shrine N,Peak expiratory flow,initial,2019-02-25,GCST007430,Other measurement,#d53e4f
1346,European,79005.0,30804560.0,Shrine N,Lung function (FEV1/FVC),initial,2019-02-25,GCST007431,Other measurement,#d53e4f
1347,European,321047.0,30804560.0,Shrine N,Lung function (FEV1/FVC),initial,2019-02-25,GCST007431,Other measurement,#d53e4f
1348,European,79005.0,30804560.0,Shrine N,FEV1,initial,2019-02-25,GCST007432,Other measurement,#d53e4f
1349,European,321047.0,30804560.0,Shrine N,FEV1,initial,2019-02-25,GCST007432,Other measurement,#d53e4f
1350,Asian,546.0,30823506.0,Hong EP,Intracranial aneurysm,initial,2019-02-25,GCST007354,Cardiovascular disease,#3288bd
1351,European,78990.0,30804566.0,Lane JM,Insomnia symptoms (never/rarely vs. sometimes/usually),replication,2019-02-25,GCST007387,Other measurement,#d53e4f
1352,European,453379.0,30804566.0,Lane JM,Insomnia symptoms (never/rarely vs. sometimes/usually),initial,2019-02-25,GCST007387,Other measurement,#d53e4f
1354,European,144498.0,30804558.0,Grove J,Autism spectrum disorder,replication,2019-02-25,GCST007556,Neurological disorder,#d53e4f
1355,European,46350.0,30804558.0,Grove J,Autism spectrum disorder,initial,2019-02-25,GCST007556,Neurological disorder,#d53e4f
1356,European,1331010.0,30804565.0,Jansen PR,Insomnia,initial,2019-02-25,GCST007988,Other measurement,#d53e4f
1357,European,79005.0,30804560.0,Shrine N,Lung function (FVC),initial,2019-02-25,GCST007429,Other measurement,#d53e4f
1358,European,321047.0,30804560.0,Shrine N,Lung function (FVC),initial,2019-02-25,GCST007429,Other measurement,#d53e4f
1359,European,662.0,30801121.0,O'Donnell S,Crohn's disease (time to progression),initial,2019-02-25,GCST007497,Other measurement,#d53e4f
1360,European,662.0,30801121.0,O'Donnell S,Crohn's disease (time to progression),initial,2019-02-25,GCST007497,Digestive system disorder,#d53e4f
1371,European,96661.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in breast cancer,initial,2019-02-21,GCST007477,Cancer,#d53e4f
1372,European,96661.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in breast cancer,initial,2019-02-21,GCST007477,Other measurement,#d53e4f
1373,European,64171.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in estrogen receptor positive breast cancer,initial,2019-02-21,GCST007475,Cancer,#d53e4f
1374,European,64171.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in estrogen receptor positive breast cancer,initial,2019-02-21,GCST007475,Other measurement,#d53e4f
1375,European,16172.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in estrogen receptor negative breast cancer,initial,2019-02-21,GCST007476,Cancer,#d53e4f
1376,European,16172.0,30787463.0,Escala-Garcia M,Breast cancer specific mortality in estrogen receptor negative breast cancer,initial,2019-02-21,GCST007476,Other measurement,#d53e4f
1377,Hispanic/Latin American,5136.0,30787307.0,Daya M,Adult asthma,initial,2019-02-20,GCST007266,Other disease,#807dba
1378,African Am./Caribbean,9518.0,30787307.0,Daya M,Adult asthma,initial,2019-02-20,GCST007266,Other disease,#fee08b
1379,African Am./Caribbean,299.0,30801552.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,initial,2019-02-19,GCST008577,Other measurement,#fee08b
1380,European,609.0,30801552.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,replication,2019-02-19,GCST008577,Other measurement,#d53e4f
1381,European,1363.0,30801552.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,initial,2019-02-19,GCST008577,Other measurement,#d53e4f
1382,African Am./Caribbean,171.0,30801552.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,replication,2019-02-19,GCST008577,Other measurement,#fee08b
1383,Asian,2955.0,30779856.0,Lu HF,Calcaneus stiffness index,replication,2019-02-19,GCST007616,Other measurement,#3288bd
1384,Asian,7742.0,30779856.0,Lu HF,Calcaneus stiffness index,initial,2019-02-19,GCST007616,Other measurement,#3288bd
1385,European,1235.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),initial,2019-02-19,GCST008578,Response to drug,#d53e4f
1386,African Am./Caribbean,256.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),initial,2019-02-19,GCST008578,Response to drug,#fee08b
1387,European,487.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),replication,2019-02-19,GCST008578,Response to drug,#d53e4f
1388,African Am./Caribbean,94.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),replication,2019-02-19,GCST008578,Response to drug,#fee08b
1389,European,1235.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),initial,2019-02-19,GCST008578,Metabolic disorder,#d53e4f
1390,African Am./Caribbean,256.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),initial,2019-02-19,GCST008578,Metabolic disorder,#fee08b
1391,European,487.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),replication,2019-02-19,GCST008578,Metabolic disorder,#d53e4f
1392,African Am./Caribbean,94.0,30801552.0,Oetting WS,New onset diabetes in calcineurin inhibitor treated kidney transplant patients (time to event),replication,2019-02-19,GCST008578,Metabolic disorder,#fee08b
1393,European,1785.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008579,Other trait,#d53e4f
1394,African Am./Caribbean,338.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008579,Other trait,#fee08b
1395,European,657.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008579,Other trait,#d53e4f
1396,African Am./Caribbean,171.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008579,Other trait,#fee08b
1397,European,1785.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008579,Response to drug,#d53e4f
1398,African Am./Caribbean,338.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008579,Response to drug,#fee08b
1399,European,657.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008579,Response to drug,#d53e4f
1400,African Am./Caribbean,171.0,30801552.0,Oetting WS,Leukopenia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008579,Response to drug,#fee08b
1401,European,438.0,30801552.0,Oetting WS,Anemia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008580,Other trait,#d53e4f
1402,European,1785.0,30801552.0,Oetting WS,Anemia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008580,Other trait,#d53e4f
1403,European,438.0,30801552.0,Oetting WS,Anemia in mycophenolic acid treated kidney transplant patients (time to event),replication,2019-02-19,GCST008580,Response to drug,#d53e4f
1404,European,1785.0,30801552.0,Oetting WS,Anemia in mycophenolic acid treated kidney transplant patients (time to event),initial,2019-02-19,GCST008580,Response to drug,#d53e4f
1405,European,475.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008581,Other measurement,#d53e4f
1406,European,63.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008581,Other measurement,#d53e4f
1407,European,475.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008581,Response to drug,#d53e4f
1408,European,63.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008581,Response to drug,#d53e4f
1409,European,475.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008581,Other trait,#d53e4f
1410,European,63.0,30801552.0,Oetting WS,Nephrotoxicity in cyclosporine-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008581,Other trait,#d53e4f
1411,European,1352.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008582,Other measurement,#d53e4f
1412,European,609.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008582,Other measurement,#d53e4f
1413,European,1352.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008582,Other trait,#d53e4f
1414,European,609.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008582,Other trait,#d53e4f
1415,European,1352.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),initial,2019-02-19,GCST008582,Response to drug,#d53e4f
1416,European,609.0,30801552.0,Oetting WS,Nephrotoxicity in tacrolimus-treated kidney transplant patients (time to event),replication,2019-02-19,GCST008582,Response to drug,#d53e4f
1417,European,132177.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007484,Body measurement,#d53e4f
1418,Hispanic/Latin American,4075.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007484,Body measurement,#807dba
1419,Asian,6800.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007484,Body measurement,#3288bd
1420,Asian,29315.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007484,Body measurement,#3288bd
1421,African Am./Caribbean,15687.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007484,Body measurement,#fee08b
1422,European,288492.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007484,Body measurement,#d53e4f
1423,European,157516.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007503,Body measurement,#d53e4f
1424,European,62368.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007503,Body measurement,#d53e4f
1425,European,62368.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007502,Body measurement,#d53e4f
1426,European,157516.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007502,Body measurement,#d53e4f
1427,European,62368.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007501,Body measurement,#d53e4f
1428,Other/Mixed,180131.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007501,Body measurement,#99d594
1429,European,157516.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007501,Body measurement,#d53e4f
1430,Other/Mixed,180131.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007500,Body measurement,#99d594
1431,European,157516.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007500,Body measurement,#d53e4f
1432,European,62368.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007500,Body measurement,#d53e4f
1433,European,130976.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007496,Body measurement,#d53e4f
1434,European,62500.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007496,Body measurement,#d53e4f
1435,European,130976.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007494,Body measurement,#d53e4f
1436,European,62500.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007494,Body measurement,#d53e4f
1437,European,62500.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007493,Body measurement,#d53e4f
1438,Other/Mixed,164238.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007493,Body measurement,#99d594
1439,European,130976.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007493,Body measurement,#d53e4f
1440,European,62500.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007492,Body measurement,#d53e4f
1441,Other/Mixed,164238.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007492,Body measurement,#99d594
1442,European,130976.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007492,Body measurement,#d53e4f
1443,European,288492.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),initial,2019-02-18,GCST007491,Body measurement,#d53e4f
1444,European,132177.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (recessive genetic model),replication,2019-02-18,GCST007491,Body measurement,#d53e4f
1445,European,132177.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007483,Body measurement,#d53e4f
1446,Asian,6800.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007483,Body measurement,#3288bd
1447,Asian,29315.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007483,Body measurement,#3288bd
1448,African Am./Caribbean,15687.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007483,Body measurement,#fee08b
1449,European,288492.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007483,Body measurement,#d53e4f
1450,Hispanic/Latin American,4075.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007483,Body measurement,#807dba
1451,European,132177.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),replication,2019-02-18,GCST007487,Body measurement,#d53e4f
1452,European,288492.0,30778226.0,Justice AE,Waist-to-hip ratio adjusted for BMI (additive genetic model),initial,2019-02-18,GCST007487,Body measurement,#d53e4f
1453,Asian,74.0,30767168.0,Shin JH,Cellular nuclear factor (erythroid-derived 2)-like 2 levels,initial,2019-02-14,GCST007538,Other measurement,#3288bd
1454,European,418553.0,30760885.0,Mbarek H,Number of twin births,initial,2019-02-13,GCST007280,Other measurement,#d53e4f
1455,European,2563.0,30741946.0,Gialluisi A,Rapid automised naming of digits,initial,2019-02-11,GCST007469,Biological process,#d53e4f
1456,European,2563.0,30741946.0,Gialluisi A,Rapid automised naming of letters,initial,2019-02-11,GCST007470,Biological process,#d53e4f
1457,European,3468.0,30741946.0,Gialluisi A,Reading ability (multivariate),initial,2019-02-11,GCST007479,Biological process,#d53e4f
1458,European,3093.0,30741946.0,Gialluisi A,Phoneme awareness,initial,2019-02-11,GCST007465,Biological process,#d53e4f
1459,European,3468.0,30741946.0,Gialluisi A,Word reading,initial,2019-02-11,GCST007466,Biological process,#d53e4f
1460,European,3399.0,30741946.0,Gialluisi A,Word spelling,initial,2019-02-11,GCST007467,Biological process,#d53e4f
1461,European,3409.0,30741946.0,Gialluisi A,Non-word reading,initial,2019-02-11,GCST007478,Biological process,#d53e4f
1462,European,2591.0,30741946.0,Gialluisi A,Short-term memory (digit-span task),initial,2019-02-11,GCST007471,Biological process,#d53e4f
1463,European,2562.0,30741946.0,Gialluisi A,Rapid automised naming of pictures,initial,2019-02-11,GCST007473,Biological process,#d53e4f
1464,European,379.0,30738427.0,Penney ME,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event),initial,2019-02-09,GCST007434,Other measurement,#d53e4f
1465,European,379.0,30738427.0,Penney ME,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event),initial,2019-02-09,GCST007434,Cancer,#d53e4f
1466,European,379.0,30738427.0,Penney ME,Metastasis in stage I-III microsatellite instability low/stable colorectal cancer (time to event),initial,2019-02-09,GCST007434,Other measurement,#d53e4f
1467,European,3902.0,30737484.0,Thomsen H,Monoclonal gammopathy of undetermined significance,initial,2019-02-08,GCST007824,Other disease,#d53e4f
1468,European,100234.0,30745170.0,Strawbridge RJ,Deliberate self-harm,initial,2019-02-07,GCST007391,Other measurement,#d53e4f
1469,European,122808.0,30745170.0,Strawbridge RJ,Suicidality,initial,2019-02-07,GCST007389,Other measurement,#d53e4f
1470,European,108090.0,30745170.0,Strawbridge RJ,Suicidality (suicidal ideation/attempts),initial,2019-02-07,GCST007390,Other measurement,#d53e4f
1471,Asian,5479.0,30714141.0,Chen H,Glioma,replication,2019-02-04,GCST007842,Cancer,#3288bd
1472,Asian,2000.0,30714141.0,Chen H,Glioma,initial,2019-02-04,GCST007842,Cancer,#3288bd
1473,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x independent stressful life events interaction (2df test),initial,2019-02-04,GCST007413,Other measurement,#d53e4f
1474,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x independent stressful life events interaction (2df test),initial,2019-02-04,GCST007413,Other measurement,#d53e4f
1475,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x independent stressful life events interaction (1df test),initial,2019-02-04,GCST007412,Other measurement,#d53e4f
1476,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x independent stressful life events interaction (1df test),initial,2019-02-04,GCST007412,Other measurement,#d53e4f
1477,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x dependent stressful life events interaction (2df test),initial,2019-02-04,GCST007411,Other measurement,#d53e4f
1478,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x dependent stressful life events interaction (2df test),initial,2019-02-04,GCST007411,Other measurement,#d53e4f
1479,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x dependent stressful life events interaction (1df test),initial,2019-02-04,GCST007410,Other measurement,#d53e4f
1480,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x dependent stressful life events interaction (1df test),initial,2019-02-04,GCST007410,Other measurement,#d53e4f
1481,European,99057.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (2df test),initial,2019-02-04,GCST007409,Other measurement,#d53e4f
1482,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (2df test),initial,2019-02-04,GCST007409,Other measurement,#d53e4f
1483,European,99057.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (2df test),initial,2019-02-04,GCST007409,Other measurement,#d53e4f
1484,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (2df test),initial,2019-02-04,GCST007409,Other measurement,#d53e4f
1485,European,99057.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (1df test),initial,2019-02-04,GCST007408,Other measurement,#d53e4f
1486,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (1df test),initial,2019-02-04,GCST007408,Other measurement,#d53e4f
1487,European,99057.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (1df test),initial,2019-02-04,GCST007408,Other measurement,#d53e4f
1488,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms x stressful life events interaction (1df test),initial,2019-02-04,GCST007408,Other measurement,#d53e4f
1489,European,22572.0,30718321.0,Sanchez-Roige S,Drug experimentation measurement,initial,2019-02-04,GCST007630,Other measurement,#d53e4f
1490,European,21786.0,30718321.0,Sanchez-Roige S,Impulsivity (non-planning),initial,2019-02-04,GCST007629,Other measurement,#d53e4f
1491,European,21806.0,30718321.0,Sanchez-Roige S,Impulsivity (motor),initial,2019-02-04,GCST007628,Other measurement,#d53e4f
1492,European,21876.0,30718321.0,Sanchez-Roige S,Impulsivity (attentional),initial,2019-02-04,GCST007627,Other measurement,#d53e4f
1493,European,22861.0,30718321.0,Sanchez-Roige S,Lack of perseverance,initial,2019-02-04,GCST007626,Other measurement,#d53e4f
1494,European,22795.0,30718321.0,Sanchez-Roige S,Negative urgency,initial,2019-02-04,GCST007625,Other measurement,#d53e4f
1495,European,22738.0,30718321.0,Sanchez-Roige S,Positive urgency,initial,2019-02-04,GCST007624,Other measurement,#d53e4f
1496,European,22774.0,30718321.0,Sanchez-Roige S,Lack of premeditation,initial,2019-02-04,GCST007623,Other measurement,#d53e4f
1497,European,21495.0,30718321.0,Sanchez-Roige S,Impulsivity,initial,2019-02-04,GCST007622,Other measurement,#d53e4f
1498,Asian,6000.0,30718733.0,Moon S,Alanine aminotransferase levels,replication,2019-02-04,GCST007440,Liver enzyme measurement,#3288bd
1499,Asian,6949.0,30718733.0,Moon S,Alanine aminotransferase levels,initial,2019-02-04,GCST007440,Liver enzyme measurement,#3288bd
1500,Asian,6949.0,30718733.0,Moon S,Aspartate aminotransferase levels,initial,2019-02-04,GCST007439,Liver enzyme measurement,#3288bd
1501,Asian,6000.0,30718733.0,Moon S,Aspartate aminotransferase levels,replication,2019-02-04,GCST007439,Liver enzyme measurement,#3288bd
1502,Asian,6000.0,30718733.0,Moon S,Total cholesterol levels,replication,2019-02-04,GCST007441,Lipid or lipoprotein measurement,#3288bd
1503,Asian,6949.0,30718733.0,Moon S,Total cholesterol levels,initial,2019-02-04,GCST007441,Lipid or lipoprotein measurement,#3288bd
1504,Asian,6000.0,30718733.0,Moon S,High density lipoprotein cholesterol levels,replication,2019-02-04,GCST007438,Lipid or lipoprotein measurement,#3288bd
1505,Asian,6949.0,30718733.0,Moon S,High density lipoprotein cholesterol levels,initial,2019-02-04,GCST007438,Lipid or lipoprotein measurement,#3288bd
1506,Asian,6000.0,30718733.0,Moon S,Low density lipoprotein cholesterol levels,replication,2019-02-04,GCST007442,Lipid or lipoprotein measurement,#3288bd
1507,Asian,6949.0,30718733.0,Moon S,Low density lipoprotein cholesterol levels,initial,2019-02-04,GCST007442,Lipid or lipoprotein measurement,#3288bd
1508,Asian,6000.0,30718733.0,Moon S,Triglyceride levels,replication,2019-02-04,GCST007437,Lipid or lipoprotein measurement,#3288bd
1509,Asian,6949.0,30718733.0,Moon S,Triglyceride levels,initial,2019-02-04,GCST007437,Lipid or lipoprotein measurement,#3288bd
1510,Asian,191764.0,30718926.0,Suzuki K,Type 2 diabetes,initial,2019-02-04,GCST007847,Metabolic disorder,#3288bd
1511,European,4919.0,30718454.0,Arnau-Soler A,Depressive symptoms,initial,2019-02-04,GCST007407,Other measurement,#d53e4f
1512,European,99057.0,30718454.0,Arnau-Soler A,Depressive symptoms,initial,2019-02-04,GCST007407,Other measurement,#d53e4f
1513,European,446238.0,30718901.0,Howard DM,Depression,initial,2019-02-04,GCST007342,Neurological disorder,#d53e4f
1514,European,1306354.0,30718901.0,Howard DM,Depression,replication,2019-02-04,GCST007342,Neurological disorder,#d53e4f
1516,European,22745.0,30718321.0,Sanchez-Roige S,Sensation seeking,initial,2019-02-04,GCST007621,Other measurement,#d53e4f
1517,European,3514.0,30794219.0,MacInnes SJ,Osteolysis in total hip arthroplasty,initial,2019-02-01,GCST007549,Other disease,#d53e4f
1518,European,3514.0,30794219.0,MacInnes SJ,Osteolysis in total hip arthroplasty,initial,2019-02-01,GCST007549,Other trait,#d53e4f
1519,European,1096.0,30794219.0,MacInnes SJ,Osteolysis in total hip arthroplasty (time to prosthesis revision),initial,2019-02-01,GCST007550,Other disease,#d53e4f
1520,European,1096.0,30794219.0,MacInnes SJ,Osteolysis in total hip arthroplasty (time to prosthesis revision),initial,2019-02-01,GCST007550,Other trait,#d53e4f
1521,European,1096.0,30794219.0,MacInnes SJ,Osteolysis in total hip arthroplasty (time to prosthesis revision),initial,2019-02-01,GCST007550,Other measurement,#d53e4f
1523,European,3452.0,30700811.0,Wigmore EM,Antidepressant treatment resistance (number of drugs prescribed),initial,2019-01-31,GCST007356,Response to drug,#d53e4f
1525,European,3452.0,30700811.0,Wigmore EM,Antidepressant treatment resistance (> 2 drugs prescribed),initial,2019-01-31,GCST007355,Response to drug,#d53e4f
1526,Asian,10330.0,30705256.0,Koshimizu H,Psychological distress,initial,2019-01-31,GCST007297,Other measurement,#3288bd
1527,European,5461.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number,initial,2019-01-31,GCST007399,Other measurement,#d53e4f
1529,European,330.0,30706531.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,initial,2019-01-31,GCST007304,Neurological disorder,#d53e4f
1530,Asian,80.0,30706531.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,replication,2019-01-31,GCST007304,Neurological disorder,#3288bd
1531,European,330.0,30706531.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,initial,2019-01-31,GCST007304,Other measurement,#d53e4f
1532,Asian,80.0,30706531.0,Tao F,Reduced foot dorsiflexion strength in Charcot-Marie-Tooth disease type 1A,replication,2019-01-31,GCST007304,Other measurement,#3288bd
1534,European,3405.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number (white blood cells),initial,2019-01-31,GCST007398,Other measurement,#d53e4f
1536,European,3405.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number (white blood cells),initial,2019-01-31,GCST007396,Other measurement,#d53e4f
1537,European,5461.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number,initial,2019-01-31,GCST007395,Other measurement,#d53e4f
1538,European,2102.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number,initial,2019-01-31,GCST007394,Other measurement,#d53e4f
1539,European,3647.0,30704525.0,Guyatt AL,Mitochondrial DNA copy number,initial,2019-01-31,GCST007393,Other measurement,#d53e4f
1540,European,4932.0,30711515.0,Hallberg P,Pandemrix-induced narcolepsy,initial,2019-01-30,GCST007779,Neurological disorder,#d53e4f
1541,European,31.0,30711515.0,Hallberg P,Pandemrix-induced narcolepsy,replication,2019-01-30,GCST007779,Neurological disorder,#d53e4f
1545,European,4932.0,30711515.0,Hallberg P,Pandemrix-induced narcolepsy,initial,2019-01-30,GCST007779,Response to drug,#d53e4f
1546,European,31.0,30711515.0,Hallberg P,Pandemrix-induced narcolepsy,replication,2019-01-30,GCST007779,Response to drug,#d53e4f
1550,African,3073.0,30729179.0,Zenin A,Healthspan,replication,2019-01-30,GCST007406,Other measurement,#fc8d59
1551,Asian,1422.0,30729179.0,Zenin A,Healthspan,replication,2019-01-30,GCST007406,Other measurement,#3288bd
1552,Asian,6921.0,30729179.0,Zenin A,Healthspan,replication,2019-01-30,GCST007406,Other measurement,#3288bd
1553,African Am./Caribbean,3799.0,30729179.0,Zenin A,Healthspan,replication,2019-01-30,GCST007406,Other measurement,#fee08b
1554,European,300447.0,30729179.0,Zenin A,Healthspan,initial,2019-01-30,GCST007406,Other measurement,#d53e4f
1555,European,81099.0,30729179.0,Zenin A,Healthspan,replication,2019-01-30,GCST007406,Other measurement,#d53e4f
1556,Asian,2169.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#3288bd
1557,Asian,11706.0,30698716.0,de Vries PS,HDL cholesterol levels,initial,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#3288bd
1558,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#807dba
1559,Asian,9986.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#3288bd
1560,African Am./Caribbean,4475.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#fee08b
1561,European,136986.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#d53e4f
1562,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,HDL cholesterol levels,initial,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#807dba
1563,Asian,744.0,30698716.0,de Vries PS,HDL cholesterol levels,initial,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#3288bd
1564,African Am./Caribbean,20989.0,30698716.0,de Vries PS,HDL cholesterol levels,initial,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#fee08b
1565,European,89893.0,30698716.0,de Vries PS,HDL cholesterol levels,initial,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#d53e4f
1566,Asian,96276.0,30698716.0,de Vries PS,HDL cholesterol levels,replication,2019-01-29,GCST008070,Lipid or lipoprotein measurement,#3288bd
1567,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#3288bd
1568,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#3288bd
1569,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#807dba
1570,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#3288bd
1571,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#fee08b
1572,European,107548.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#d53e4f
1573,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#807dba
1574,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#fee08b
1575,European,56505.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#d53e4f
1576,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#3288bd
1577,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Lipid or lipoprotein measurement,#3288bd
1578,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#3288bd
1579,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Other measurement,#3288bd
1580,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#807dba
1581,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#3288bd
1582,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#fee08b
1583,European,107548.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#d53e4f
1584,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Other measurement,#807dba
1585,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Other measurement,#fee08b
1586,European,56505.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Other measurement,#d53e4f
1587,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008071,Other measurement,#3288bd
1588,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008071,Other measurement,#3288bd
1589,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Other measurement,#3288bd
1590,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Other measurement,#d53e4f
1591,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Other measurement,#fee08b
1592,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Other measurement,#3288bd
1593,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#3288bd
1594,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#3288bd
1595,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#807dba
1596,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#3288bd
1597,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#fee08b
1598,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Other measurement,#d53e4f
1599,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Other measurement,#807dba
1600,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#3288bd
1601,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#d53e4f
1602,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#fee08b
1603,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#3288bd
1604,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#3288bd
1605,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#3288bd
1606,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#807dba
1607,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#3288bd
1608,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#fee08b
1609,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#d53e4f
1610,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008072,Lipid or lipoprotein measurement,#807dba
1611,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#3288bd
1612,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#3288bd
1613,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#3288bd
1614,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#807dba
1615,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#3288bd
1616,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#fee08b
1617,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#d53e4f
1618,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#807dba
1619,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#fee08b
1620,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#d53e4f
1621,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Lipid or lipoprotein measurement,#3288bd
1622,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#3288bd
1623,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#3288bd
1624,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Other measurement,#3288bd
1625,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#807dba
1626,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#3288bd
1627,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#fee08b
1628,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),replication,2019-01-29,GCST008073,Other measurement,#d53e4f
1629,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Other measurement,#807dba
1630,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Other measurement,#fee08b
1631,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Other measurement,#d53e4f
1632,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (1df),initial,2019-01-29,GCST008073,Other measurement,#3288bd
1633,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#3288bd
1634,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#3288bd
1635,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#3288bd
1636,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#807dba
1637,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#fee08b
1638,European,107548.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#d53e4f
1639,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#807dba
1640,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#fee08b
1641,European,56505.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#d53e4f
1642,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#3288bd
1643,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Lipid or lipoprotein measurement,#3288bd
1644,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#3288bd
1645,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#3288bd
1646,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Other measurement,#3288bd
1647,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#807dba
1648,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#fee08b
1649,European,107548.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#d53e4f
1650,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Other measurement,#807dba
1651,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Other measurement,#fee08b
1652,European,56505.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Other measurement,#d53e4f
1653,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008074,Other measurement,#3288bd
1654,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008074,Other measurement,#3288bd
1655,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#3288bd
1656,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#3288bd
1657,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Other measurement,#d53e4f
1658,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#807dba
1659,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#3288bd
1660,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#fee08b
1661,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Other measurement,#d53e4f
1662,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Other measurement,#807dba
1663,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Other measurement,#fee08b
1664,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Other measurement,#3288bd
1665,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Other measurement,#3288bd
1666,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#3288bd
1667,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#3288bd
1668,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#d53e4f
1669,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#807dba
1670,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#3288bd
1671,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#fee08b
1672,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#d53e4f
1673,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#807dba
1674,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#fee08b
1675,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#3288bd
1676,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008075,Lipid or lipoprotein measurement,#3288bd
1677,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#807dba
1678,Asian,9986.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#3288bd
1679,African Am./Caribbean,4475.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#fee08b
1680,European,136986.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#d53e4f
1681,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,Triglyceride levels,initial,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#807dba
1682,Asian,744.0,30698716.0,de Vries PS,Triglyceride levels,initial,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#3288bd
1683,African Am./Caribbean,20989.0,30698716.0,de Vries PS,Triglyceride levels,initial,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#fee08b
1684,European,89893.0,30698716.0,de Vries PS,Triglyceride levels,initial,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#d53e4f
1685,Asian,11706.0,30698716.0,de Vries PS,Triglyceride levels,initial,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#3288bd
1686,Asian,96276.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#3288bd
1687,Asian,2169.0,30698716.0,de Vries PS,Triglyceride levels,replication,2019-01-29,GCST008076,Lipid or lipoprotein measurement,#3288bd
1688,Asian,9986.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#3288bd
1689,European,89893.0,30698716.0,de Vries PS,LDL cholesterol levels,initial,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#d53e4f
1690,Asian,2169.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#3288bd
1691,Asian,96276.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#3288bd
1692,Asian,11706.0,30698716.0,de Vries PS,LDL cholesterol levels,initial,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#3288bd
1693,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#807dba
1694,African Am./Caribbean,4475.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#fee08b
1695,European,136986.0,30698716.0,de Vries PS,LDL cholesterol levels,replication,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#d53e4f
1696,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,LDL cholesterol levels,initial,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#807dba
1697,Asian,744.0,30698716.0,de Vries PS,LDL cholesterol levels,initial,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#3288bd
1698,African Am./Caribbean,20989.0,30698716.0,de Vries PS,LDL cholesterol levels,initial,2019-01-29,GCST008077,Lipid or lipoprotein measurement,#fee08b
1699,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#3288bd
1700,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#3288bd
1701,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#3288bd
1702,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#807dba
1703,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#3288bd
1704,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#fee08b
1705,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#d53e4f
1706,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#807dba
1707,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#fee08b
1708,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#d53e4f
1709,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Lipid or lipoprotein measurement,#3288bd
1710,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#3288bd
1711,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#3288bd
1712,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Other measurement,#3288bd
1713,Hispanic/Latin American,6622.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#807dba
1714,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#3288bd
1715,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#fee08b
1716,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),replication,2019-01-29,GCST008078,Other measurement,#d53e4f
1717,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Other measurement,#807dba
1718,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Other measurement,#fee08b
1719,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Other measurement,#d53e4f
1720,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df),initial,2019-01-29,GCST008078,Other measurement,#3288bd
1721,African Am./Caribbean,1349.0,30694715.0,Sakornsakolpat P,Diffusing capacity of carbon monoxide,initial,2019-01-29,GCST007637,Other measurement,#fee08b
1722,European,5586.0,30694715.0,Sakornsakolpat P,Diffusing capacity of carbon monoxide,initial,2019-01-29,GCST007637,Other measurement,#d53e4f
1723,European,89893.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#d53e4f
1724,African Am./Caribbean,20989.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#fee08b
1725,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#807dba
1726,Asian,744.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#3288bd
1727,Asian,2169.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#3288bd
1728,Asian,96276.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#3288bd
1729,Asian,11706.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#3288bd
1730,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#807dba
1731,Asian,9986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#3288bd
1732,African Am./Caribbean,4475.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#fee08b
1733,European,136986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Lipid or lipoprotein measurement,#d53e4f
1734,European,89893.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Biological process,#d53e4f
1735,African Am./Caribbean,20989.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Biological process,#fee08b
1736,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Biological process,#807dba
1737,Asian,744.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Biological process,#3288bd
1738,Asian,2169.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#3288bd
1739,Asian,96276.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#3288bd
1740,Asian,11706.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008079,Biological process,#3288bd
1741,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#807dba
1742,Asian,9986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#3288bd
1743,African Am./Caribbean,4475.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#fee08b
1744,European,136986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008079,Biological process,#d53e4f
1745,African Am./Caribbean,493.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,initial,2019-01-29,GCST007100,Other measurement,#fee08b
1746,Hispanic/Latin American,854.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,initial,2019-01-29,GCST007100,Other measurement,#807dba
1747,European,1697.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,replication,2019-01-29,GCST007100,Other measurement,#d53e4f
1748,African Am./Caribbean,493.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,initial,2019-01-29,GCST007100,Response to drug,#fee08b
1749,Hispanic/Latin American,854.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,initial,2019-01-29,GCST007100,Response to drug,#807dba
1750,European,1697.0,30697902.0,Hernandez-Pacheco N,Asthma exacerbations in inhaled corticosteroid treatment,replication,2019-01-29,GCST007100,Response to drug,#d53e4f
1751,European,248098.0,30696823.0,Jones SE,Chronotype,replication,2019-01-29,GCST007576,Other measurement,#d53e4f
1752,European,449734.0,30696823.0,Jones SE,Chronotype,initial,2019-01-29,GCST007576,Other measurement,#d53e4f
1753,European,403195.0,30696823.0,Jones SE,Morning person,initial,2019-01-29,GCST007565,Other measurement,#d53e4f
1754,European,248100.0,30696823.0,Jones SE,Morning person,replication,2019-01-29,GCST007565,Other measurement,#d53e4f
1755,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#807dba
1756,Asian,9986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#3288bd
1757,African Am./Caribbean,4475.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#fee08b
1758,European,136986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#d53e4f
1759,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#807dba
1760,Asian,744.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#3288bd
1761,European,89893.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#d53e4f
1762,Asian,11706.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#3288bd
1763,Asian,96276.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#3288bd
1764,African Am./Caribbean,20989.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#fee08b
1765,Asian,2169.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Lipid or lipoprotein measurement,#3288bd
1766,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#807dba
1767,Asian,9986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#3288bd
1768,African Am./Caribbean,4475.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#fee08b
1769,European,136986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#d53e4f
1770,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Biological process,#807dba
1771,Asian,744.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Biological process,#3288bd
1772,European,89893.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Biological process,#d53e4f
1773,Asian,11706.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Biological process,#3288bd
1774,Asian,96276.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#3288bd
1775,African Am./Caribbean,20989.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008080,Biological process,#fee08b
1776,Asian,2169.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008080,Biological process,#3288bd
1777,European,89893.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Biological process,#d53e4f
1778,Asian,2169.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#3288bd
1779,Asian,96276.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#3288bd
1780,Asian,11706.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Biological process,#3288bd
1781,African Am./Caribbean,20989.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Biological process,#fee08b
1782,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#807dba
1783,Asian,9986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#3288bd
1784,African Am./Caribbean,4475.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#fee08b
1785,European,136986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Biological process,#d53e4f
1786,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Biological process,#807dba
1787,Asian,744.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Biological process,#3288bd
1788,European,89893.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#d53e4f
1789,Asian,2169.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#3288bd
1790,Asian,96276.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#3288bd
1791,Asian,11706.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#3288bd
1792,African Am./Caribbean,20989.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#fee08b
1793,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#807dba
1794,Asian,9986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#3288bd
1795,African Am./Caribbean,4475.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#fee08b
1796,European,136986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#d53e4f
1797,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#807dba
1798,Asian,744.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008081,Lipid or lipoprotein measurement,#3288bd
1799,Asian,2169.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#3288bd
1800,Asian,11706.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#3288bd
1801,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#807dba
1802,Asian,9986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#3288bd
1803,African Am./Caribbean,4475.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#fee08b
1804,European,136986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#d53e4f
1805,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#807dba
1806,Asian,744.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#3288bd
1807,African Am./Caribbean,20989.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#fee08b
1808,Asian,96276.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#3288bd
1809,European,89893.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Lipid or lipoprotein measurement,#d53e4f
1810,Asian,2169.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#3288bd
1811,Asian,11706.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Biological process,#3288bd
1812,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#807dba
1813,Asian,9986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#3288bd
1814,African Am./Caribbean,4475.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#fee08b
1815,European,136986.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#d53e4f
1816,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Biological process,#807dba
1817,Asian,744.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Biological process,#3288bd
1818,African Am./Caribbean,20989.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Biological process,#fee08b
1819,Asian,96276.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),replication,2019-01-29,GCST008082,Biological process,#3288bd
1820,European,89893.0,30698716.0,de Vries PS,LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (1df),initial,2019-01-29,GCST008082,Biological process,#d53e4f
1821,Asian,2169.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#3288bd
1822,Asian,96276.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#3288bd
1823,Asian,11706.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#3288bd
1824,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#807dba
1825,Asian,9986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#3288bd
1826,African Am./Caribbean,4475.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#fee08b
1827,European,136986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#d53e4f
1828,Asian,744.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#3288bd
1829,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#807dba
1830,African Am./Caribbean,20989.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#fee08b
1831,European,89893.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Lipid or lipoprotein measurement,#d53e4f
1832,Asian,2169.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#3288bd
1833,Asian,96276.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#3288bd
1834,Asian,11706.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Biological process,#3288bd
1835,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#807dba
1836,Asian,9986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#3288bd
1837,African Am./Caribbean,4475.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#fee08b
1838,European,136986.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008083,Biological process,#d53e4f
1839,Asian,744.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Biological process,#3288bd
1840,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Biological process,#807dba
1841,African Am./Caribbean,20989.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Biological process,#fee08b
1842,European,89893.0,30698716.0,de Vries PS,Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008083,Biological process,#d53e4f
1843,Asian,2169.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#3288bd
1844,Asian,96276.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#3288bd
1845,Asian,11706.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Biological process,#3288bd
1846,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#807dba
1847,Asian,9986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#3288bd
1848,European,136986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#d53e4f
1849,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Biological process,#807dba
1850,Asian,744.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Biological process,#3288bd
1851,African Am./Caribbean,20989.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Biological process,#fee08b
1852,European,89893.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Biological process,#d53e4f
1853,African Am./Caribbean,4475.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Biological process,#fee08b
1854,Asian,2169.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#3288bd
1855,Asian,96276.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#3288bd
1856,Asian,11706.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#3288bd
1857,Hispanic/Latin American,17366.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#807dba
1858,Asian,9986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#3288bd
1859,European,136986.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#d53e4f
1860,Hispanic/Latin American,3994.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#807dba
1861,Asian,744.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#3288bd
1862,African Am./Caribbean,20989.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#fee08b
1863,European,89893.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),initial,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#d53e4f
1864,African Am./Caribbean,4475.0,30698716.0,de Vries PS,HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df),replication,2019-01-29,GCST008084,Lipid or lipoprotein measurement,#fee08b
1865,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#fee08b
1866,European,107548.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#d53e4f
1867,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#807dba
1868,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#fee08b
1869,European,56505.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#d53e4f
1870,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#3288bd
1871,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#3288bd
1872,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#807dba
1873,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#3288bd
1874,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#3288bd
1875,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Lipid or lipoprotein measurement,#3288bd
1876,African Am./Caribbean,2028.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#fee08b
1877,European,107548.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#d53e4f
1878,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Biological process,#807dba
1879,African Am./Caribbean,9870.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Biological process,#fee08b
1880,European,56505.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Biological process,#d53e4f
1881,Asian,267.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Biological process,#3288bd
1882,Asian,3905.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#3288bd
1883,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#807dba
1884,Asian,36673.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#3288bd
1885,Asian,2224.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,initial,2019-01-29,GCST008087,Biological process,#3288bd
1886,Asian,662.0,30698716.0,de Vries PS,Triglyceride levels in current drinkers,replication,2019-01-29,GCST008087,Biological process,#3288bd
1887,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Biological process,#3288bd
1888,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#3288bd
1889,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#807dba
1890,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#3288bd
1891,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#fee08b
1892,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#d53e4f
1893,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Biological process,#807dba
1894,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Biological process,#fee08b
1895,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Biological process,#d53e4f
1896,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Biological process,#3288bd
1897,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Biological process,#3288bd
1898,Asian,2224.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#3288bd
1899,Asian,36673.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#3288bd
1900,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#807dba
1901,Asian,3905.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#3288bd
1902,African Am./Caribbean,2028.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#fee08b
1903,European,107548.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#d53e4f
1904,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#807dba
1905,African Am./Caribbean,9870.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#fee08b
1906,European,56505.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#d53e4f
1907,Asian,267.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#3288bd
1908,Asian,662.0,30698716.0,de Vries PS,HDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008085,Lipid or lipoprotein measurement,#3288bd
1909,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#3288bd
1910,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#3288bd
1911,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#807dba
1912,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#3288bd
1913,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#fee08b
1914,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#d53e4f
1915,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#807dba
1916,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#fee08b
1917,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#d53e4f
1918,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#3288bd
1919,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Lipid or lipoprotein measurement,#3288bd
1920,Asian,662.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#3288bd
1921,Asian,2224.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Biological process,#3288bd
1922,Hispanic/Latin American,8606.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#807dba
1923,Asian,3905.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#3288bd
1924,African Am./Caribbean,2028.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#fee08b
1925,European,107548.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#d53e4f
1926,Hispanic/Latin American,2528.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Biological process,#807dba
1927,African Am./Caribbean,9870.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Biological process,#fee08b
1928,European,56505.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Biological process,#d53e4f
1929,Asian,267.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,initial,2019-01-29,GCST008086,Biological process,#3288bd
1930,Asian,36673.0,30698716.0,de Vries PS,LDL cholesterol levels in current drinkers,replication,2019-01-29,GCST008086,Biological process,#3288bd
1931,Hispanic/Latin American,1095.0,30692554.0,Bustos BI,Gallstone disease,initial,2019-01-28,GCST007050,Digestive system disorder,#807dba
1932,European,6092.0,30692554.0,Bustos BI,Gallstone disease,replication,2019-01-28,GCST007050,Digestive system disorder,#d53e4f
1933,Hispanic/Latin American,1643.0,30692554.0,Bustos BI,Gallstone disease,replication,2019-01-28,GCST007050,Digestive system disorder,#807dba
1934,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Metabolic disorder,#d53e4f
1936,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1938,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1940,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1942,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1944,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1946,European,65534.0,30692689.0,Schork AJ,Psychiatric disorder,initial,2019-01-28,GCST007777,Neurological disorder,#d53e4f
1960,European,28698.0,30679814.0,van Setten J,RR interval (heart rate),initial,2019-01-24,GCST007217,Cardiovascular measurement,#d53e4f
1961,African Am./Caribbean,2048.0,30679814.0,van Setten J,QT interval,replication,2019-01-24,GCST007218,Cardiovascular measurement,#fee08b
1962,European,26794.0,30679814.0,van Setten J,QT interval,initial,2019-01-24,GCST007218,Cardiovascular measurement,#d53e4f
1963,European,32597.0,30679814.0,van Setten J,QT interval,replication,2019-01-24,GCST007218,Cardiovascular measurement,#d53e4f
1964,European,25509.0,30679814.0,van Setten J,QRS duration,initial,2019-01-24,GCST007227,Cardiovascular measurement,#d53e4f
1965,European,32132.0,30679814.0,van Setten J,QRS duration,replication,2019-01-24,GCST007227,Cardiovascular measurement,#d53e4f
1966,African Am./Caribbean,2048.0,30679814.0,van Setten J,QRS duration,replication,2019-01-24,GCST007227,Cardiovascular measurement,#fee08b
1967,European,31695.0,30679814.0,van Setten J,PR interval,initial,2019-01-24,GCST007226,Cardiovascular measurement,#d53e4f
1968,European,32405.0,30679814.0,van Setten J,PR interval,replication,2019-01-24,GCST007226,Cardiovascular measurement,#d53e4f
1969,African Am./Caribbean,2070.0,30679814.0,van Setten J,PR interval,replication,2019-01-24,GCST007226,Cardiovascular measurement,#fee08b
1970,European,7931.0,30677029.0,Riveros-McKay F,Normal body mass index vs. thin,initial,2019-01-24,GCST007242,Body measurement,#d53e4f
1971,European,24252.0,30677029.0,Riveros-McKay F,Normal body mass index vs. thin,replication,2019-01-24,GCST007242,Body measurement,#d53e4f
1972,European,28246.0,30677029.0,Riveros-McKay F,Obesity (extreme),replication,2019-01-24,GCST007241,Body measurement,#d53e4f
1974,European,7916.0,30677029.0,Riveros-McKay F,Obesity (extreme),initial,2019-01-24,GCST007241,Body measurement,#d53e4f
1975,European,2927.0,30677029.0,Riveros-McKay F,Obese vs. thin,initial,2019-01-24,GCST007240,Body measurement,#d53e4f
1976,European,11058.0,30677029.0,Riveros-McKay F,Obese vs. thin,replication,2019-01-24,GCST007240,Body measurement,#d53e4f
1978,European,20623.0,30674883.0,Jin Y,Vitiligo (late onset),initial,2019-01-23,GCST007112,Immune system disorder,#d53e4f
1979,European,1704.0,30674883.0,Jin Y,Vitiligo (late onset),replication,2019-01-23,GCST007112,Immune system disorder,#d53e4f
1980,Other/Mixed,920.0,30674050.0,Spiegel AM,Maternal chorioamnionitis,initial,2019-01-23,GCST007956,Other disease,#99d594
1981,European,4622.0,30674623.0,Syreeni A,Glycated hemoglobin levels in type 1 diabetes,initial,2019-01-23,GCST007605,Metabolic disorder,#d53e4f
1983,European,4622.0,30674623.0,Syreeni A,Glycated hemoglobin levels in type 1 diabetes,initial,2019-01-23,GCST007605,Other measurement,#d53e4f
1985,European,19860.0,30674883.0,Jin Y,Vitiligo (early onset),initial,2019-01-23,GCST007111,Immune system disorder,#d53e4f
1986,European,1830.0,30674883.0,Jin Y,Vitiligo (early onset),replication,2019-01-23,GCST007111,Immune system disorder,#d53e4f
1987,European,84902.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#d53e4f
1988,Asian,4441.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#3288bd
1989,Hispanic/Latin American,11421.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#807dba
1990,European,107617.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#d53e4f
1991,African Am./Caribbean,3778.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#fee08b
1992,Hispanic/Latin American,9187.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#807dba
1993,Asian,6403.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#3288bd
1994,African Am./Caribbean,20487.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#fee08b
1995,Asian,2149.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#3288bd
1996,African,1606.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Lipid or lipoprotein measurement,#fc8d59
1997,European,84902.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Biological process,#d53e4f
1998,Asian,4441.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#3288bd
1999,Hispanic/Latin American,11421.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#807dba
2000,European,107617.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#d53e4f
2001,African Am./Caribbean,3778.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#fee08b
2002,Hispanic/Latin American,9187.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Biological process,#807dba
2003,Asian,6403.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Biological process,#3288bd
2004,African Am./Caribbean,20487.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007282,Biological process,#fee08b
2005,Asian,2149.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#3288bd
2006,African,1606.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007282,Biological process,#fc8d59
2007,Hispanic/Latin American,5652.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#807dba
2008,African Am./Caribbean,2120.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#fee08b
2009,European,81966.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#d53e4f
2010,Hispanic/Latin American,11422.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#807dba
2011,European,72102.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#d53e4f
2012,Asian,4401.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#3288bd
2013,Asian,2148.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#3288bd
2014,Asian,2579.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#3288bd
2015,African,1606.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#fc8d59
2016,African Am./Caribbean,20126.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Lipid or lipoprotein measurement,#fee08b
2017,Hispanic/Latin American,5652.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Biological process,#807dba
2018,African Am./Caribbean,2120.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#fee08b
2019,European,81966.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#d53e4f
2020,Hispanic/Latin American,11422.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#807dba
2021,European,72102.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Biological process,#d53e4f
2022,Asian,4401.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Biological process,#3288bd
2023,Asian,2148.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#3288bd
2024,Asian,2579.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#3288bd
2025,African,1606.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),replication,2019-01-22,GCST007285,Biological process,#fc8d59
2026,African Am./Caribbean,20126.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (1df test),initial,2019-01-22,GCST007285,Biological process,#fee08b
2027,African,1606.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#fc8d59
2028,Asian,6403.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Biological process,#3288bd
2029,Hispanic/Latin American,9187.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Biological process,#807dba
2030,Asian,2149.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#3288bd
2031,African Am./Caribbean,20487.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Biological process,#fee08b
2032,European,84902.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Biological process,#d53e4f
2033,Asian,4441.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#3288bd
2034,African Am./Caribbean,3778.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#fee08b
2035,European,107617.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#d53e4f
2036,Hispanic/Latin American,11421.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Biological process,#807dba
2037,African,1606.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#fc8d59
2038,Asian,6403.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#3288bd
2039,Hispanic/Latin American,9187.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#807dba
2040,Asian,2149.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#3288bd
2041,African Am./Caribbean,20487.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#fee08b
2042,European,84902.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#d53e4f
2043,Asian,4441.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#3288bd
2044,African Am./Caribbean,3778.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#fee08b
2045,European,107617.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#d53e4f
2046,Hispanic/Latin American,11421.0,30670697.0,Kilpelainen TO,HDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007281,Lipid or lipoprotein measurement,#807dba
2047,African,1606.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#fc8d59
2048,Asian,4442.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#3288bd
2049,African Am./Caribbean,20021.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#fee08b
2050,Asian,6355.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#3288bd
2051,European,77688.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#d53e4f
2052,Hispanic/Latin American,5624.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#807dba
2053,Asian,2149.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#3288bd
2054,European,84608.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#d53e4f
2055,Hispanic/Latin American,11239.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#807dba
2056,African Am./Caribbean,2092.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Lipid or lipoprotein measurement,#fee08b
2057,African,1606.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#fc8d59
2058,Asian,4442.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#3288bd
2059,African Am./Caribbean,20021.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Biological process,#fee08b
2060,Asian,6355.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Biological process,#3288bd
2061,European,77688.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Biological process,#d53e4f
2062,Hispanic/Latin American,5624.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),initial,2019-01-22,GCST007283,Biological process,#807dba
2063,Asian,2149.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#3288bd
2064,European,84608.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#d53e4f
2065,Hispanic/Latin American,11239.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#807dba
2066,African Am./Caribbean,2092.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (1df test),replication,2019-01-22,GCST007283,Biological process,#fee08b
2067,Hispanic/Latin American,11422.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#807dba
2068,European,81966.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#d53e4f
2069,African Am./Caribbean,2120.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#fee08b
2070,Hispanic/Latin American,5652.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#807dba
2071,European,72102.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#d53e4f
2072,African Am./Caribbean,20126.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#fee08b
2073,Asian,4401.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#3288bd
2074,Asian,2148.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#3288bd
2075,African,1606.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#fc8d59
2076,Asian,2579.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Lipid or lipoprotein measurement,#3288bd
2077,Hispanic/Latin American,11422.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#807dba
2078,European,81966.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#d53e4f
2079,African Am./Caribbean,2120.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#fee08b
2080,Hispanic/Latin American,5652.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Biological process,#807dba
2081,European,72102.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Biological process,#d53e4f
2082,African Am./Caribbean,20126.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Biological process,#fee08b
2083,Asian,4401.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),initial,2019-01-22,GCST007286,Biological process,#3288bd
2084,Asian,2148.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#3288bd
2085,African,1606.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#fc8d59
2086,Asian,2579.0,30670697.0,Kilpelainen TO,Triglycerides x physical activity interaction (2df test),replication,2019-01-22,GCST007286,Biological process,#3288bd
2087,African Am./Caribbean,20021.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#fee08b
2088,Hispanic/Latin American,11239.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#807dba
2089,European,84608.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#d53e4f
2090,African Am./Caribbean,2092.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#fee08b
2091,Hispanic/Latin American,5624.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#807dba
2092,European,77688.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#d53e4f
2093,Asian,6355.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#3288bd
2094,Asian,2149.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#3288bd
2095,Asian,4442.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#3288bd
2096,African,1606.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Lipid or lipoprotein measurement,#fc8d59
2097,African Am./Caribbean,20021.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Biological process,#fee08b
2098,Hispanic/Latin American,11239.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#807dba
2099,European,84608.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#d53e4f
2100,African Am./Caribbean,2092.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#fee08b
2101,Hispanic/Latin American,5624.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Biological process,#807dba
2102,European,77688.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Biological process,#d53e4f
2103,Asian,6355.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),initial,2019-01-22,GCST007284,Biological process,#3288bd
2104,Asian,2149.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#3288bd
2105,Asian,4442.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#3288bd
2106,African,1606.0,30670697.0,Kilpelainen TO,LDL cholesterol x physical activity interaction (2df test),replication,2019-01-22,GCST007284,Biological process,#fc8d59
2107,European,116138.0,30664634.0,Rask-Andersen M,Body fat distribution (arm fat ratio),initial,2019-01-21,GCST007293,Body measurement,#d53e4f
2108,European,246360.0,30664634.0,Rask-Andersen M,Body fat distribution (arm fat ratio),replication,2019-01-21,GCST007293,Body measurement,#d53e4f
2109,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,"Skin, hair and eye pigmentation (multivariate analysis)",initial,2019-01-21,GCST007451,Other measurement,#807dba
2110,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,"Skin, hair and eye pigmentation (multivariate analysis)",initial,2019-01-21,GCST007451,Other measurement,#807dba
2111,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,"Skin, hair and eye pigmentation (multivariate analysis)",initial,2019-01-21,GCST007451,Other measurement,#807dba
2112,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Eye color (hue),initial,2019-01-21,GCST007456,Other measurement,#807dba
2113,European,116138.0,30664634.0,Rask-Andersen M,Body fat distribution (trunk fat ratio),initial,2019-01-21,GCST007294,Body measurement,#d53e4f
2114,European,246360.0,30664634.0,Rask-Andersen M,Body fat distribution (trunk fat ratio),replication,2019-01-21,GCST007294,Body measurement,#d53e4f
2115,European,116138.0,30664634.0,Rask-Andersen M,Body fat distribution (leg fat ratio),initial,2019-01-21,GCST007295,Body measurement,#d53e4f
2116,European,246360.0,30664634.0,Rask-Andersen M,Body fat distribution (leg fat ratio),replication,2019-01-21,GCST007295,Body measurement,#d53e4f
2117,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Eye color (brightness),initial,2019-01-21,GCST007455,Other measurement,#807dba
2118,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Hair color,initial,2019-01-21,GCST007454,Other measurement,#807dba
2119,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Eye color,initial,2019-01-21,GCST007453,Other measurement,#807dba
2120,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Eye color (saturation),initial,2019-01-21,GCST007457,Other measurement,#807dba
2121,European,455221.0,30664745.0,Tachmazidou I,Osteoarthritis,initial,2019-01-21,GCST007093,Other disease,#d53e4f
2122,European,417596.0,30664745.0,Tachmazidou I,Osteoarthritis of the hip or knee,initial,2019-01-21,GCST007092,Other disease,#d53e4f
2123,European,417596.0,30664745.0,Tachmazidou I,Osteoarthritis of the hip or knee,initial,2019-01-21,GCST007092,Other disease,#d53e4f
2124,European,393873.0,30664745.0,Tachmazidou I,Osteoarthritis (hip),initial,2019-01-21,GCST007091,Other disease,#d53e4f
2125,European,403124.0,30664745.0,Tachmazidou I,Knee osteoarthritis,initial,2019-01-21,GCST007090,Other disease,#d53e4f
2126,Hispanic/Latin American,6236.0,30664655.0,Adhikari K,Skin pigmentation,initial,2019-01-21,GCST007452,Other measurement,#807dba
2127,European,7032.0,30661239.0,Nicoletti P,Drug-induced liver injury (flucloxacillin),initial,2019-01-19,GCST007606,Digestive system disorder,#d53e4f
2128,European,10603.0,30661239.0,Nicoletti P,Drug-induced liver injury (amoxicillin),initial,2019-01-19,GCST007607,Digestive system disorder,#d53e4f
2129,European,10594.0,30661239.0,Nicoletti P,Drug-induced liver injury (isoxazolyl penicillins),initial,2019-01-19,GCST007608,Digestive system disorder,#d53e4f
2130,European,451099.0,30661054.0,Schafmayer C,Diverticular disease,initial,2019-01-19,GCST008105,Digestive system disorder,#d53e4f
2131,European,36089.0,30661054.0,Schafmayer C,Diverticular disease,replication,2019-01-19,GCST008105,Digestive system disorder,#d53e4f
2132,Asian,1338.0,30659259.0,Imaizumi A,Plasma free amino acid levels (adjusted for twenty other PFAAs),initial,2019-01-18,GCST007382,Other measurement,#3288bd
2133,Other/Mixed,815.0,30713548.0,Schurz H,Tuberculosis (SNP x SNP interaction),initial,2019-01-18,GCST007232,Other disease,#99d594
2134,Asian,1338.0,30659259.0,Imaizumi A,Plasma free amino acid levels,initial,2019-01-18,GCST007385,Other measurement,#3288bd
2135,European,1145.0,30654714.0,Hurst Z,Radioiodine-refractory disease in thyroid cancer,initial,2019-01-18,GCST008107,Biological process,#d53e4f
2136,African Am./Caribbean,55.0,30654714.0,Hurst Z,Radioiodine-refractory disease in thyroid cancer,initial,2019-01-18,GCST008107,Biological process,#fee08b
2137,European,1145.0,30654714.0,Hurst Z,Radioiodine-refractory disease in thyroid cancer,initial,2019-01-18,GCST008107,Cancer,#d53e4f
2138,African Am./Caribbean,55.0,30654714.0,Hurst Z,Radioiodine-refractory disease in thyroid cancer,initial,2019-01-18,GCST008107,Cancer,#fee08b
2139,Asian,1338.0,30659259.0,Imaizumi A,Plasma free asparagine levels,initial,2019-01-18,GCST007386,Other measurement,#3288bd
2140,Asian,665.0,30659259.0,Imaizumi A,Plasma free asparagine levels,replication,2019-01-18,GCST007386,Other measurement,#3288bd
2141,Asian,6143.0,30657218.0,Park SY,Asthma-chronic obstructive  pulmonary disease overlap syndrome,initial,2019-01-18,GCST007521,Other disease,#3288bd
2143,European,14689.0,30659475.0,Arias-Vasquez A,Attention deficit hyperactivity disorder symptom score,initial,2019-01-18,GCST007279,Other measurement,#d53e4f
2144,European,11226.0,30659137.0,Traylor M,White matter hyperintensity volume,initial,2019-01-18,GCST007305,Other measurement,#d53e4f
2145,European,1202.0,30659137.0,Traylor M,White matter hyperintensity volume,replication,2019-01-18,GCST007305,Other measurement,#d53e4f
2147,European,2062.0,30891314.0,Saad MN,Rheumatoid arthritis,initial,2019-01-18,GCST007843,Immune system disorder,#d53e4f
2148,Asian,1338.0,30659259.0,Imaizumi A,Plasma free proline levels,initial,2019-01-18,GCST007384,Other measurement,#3288bd
2149,Asian,665.0,30659259.0,Imaizumi A,Plasma free proline levels,replication,2019-01-18,GCST007384,Other measurement,#3288bd
2150,Asian,959.0,30657218.0,Park SY,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma,initial,2019-01-18,GCST007520,Other disease,#3288bd
2151,Asian,959.0,30657218.0,Park SY,Asthma-chronic obstructive pulmonary disease overlap syndrome in asthma,initial,2019-01-18,GCST007520,Other disease,#3288bd
2152,Asian,7271.0,30657218.0,Park SY,Adult asthma,initial,2019-01-18,GCST007519,Other disease,#3288bd
2153,Other/Mixed,815.0,30713548.0,Schurz H,Tuberculosis,initial,2019-01-18,GCST007231,Other disease,#99d594
2154,African Am./Caribbean,1447.0,30664875.0,Cirulli ET,Drug-induced liver injury,initial,2019-01-18,GCST007774,Digestive system disorder,#fee08b
2155,European,12203.0,30664875.0,Cirulli ET,Drug-induced liver injury,initial,2019-01-18,GCST007774,Digestive system disorder,#d53e4f
2156,Hispanic/Latin American,827.0,30664875.0,Cirulli ET,Drug-induced liver injury,initial,2019-01-18,GCST007774,Digestive system disorder,#807dba
2157,European,239417.0,30664875.0,Cirulli ET,Drug-induced liver injury,replication,2019-01-18,GCST007774,Digestive system disorder,#d53e4f
2158,Asian,1338.0,30659259.0,Imaizumi A,Plasma free amino acid levels (adjusted for one other PFAA),initial,2019-01-18,GCST007383,Other measurement,#3288bd
2159,European,1252.0,30868120.0,Berghuis B,Sodium levels in epilepsy,initial,2019-01-17,GCST007814,Other measurement,#d53e4f
2160,European,1252.0,30868120.0,Berghuis B,Sodium levels in epilepsy,initial,2019-01-17,GCST007814,Neurological disorder,#d53e4f
2161,European,468.0,30868120.0,Berghuis B,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy",initial,2019-01-17,GCST007813,Other measurement,#d53e4f
2162,European,468.0,30868120.0,Berghuis B,"Carbamazepine metabolism (carbamazepine-10,11-diol to carbamazepine ratio) in epilepsy",initial,2019-01-17,GCST007813,Neurological disorder,#d53e4f
2163,European,297.0,30868120.0,Berghuis B,Oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007812,Response to drug,#d53e4f
2164,European,297.0,30868120.0,Berghuis B,Oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007812,Other trait,#d53e4f
2165,European,297.0,30868120.0,Berghuis B,Oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007812,Neurological disorder,#d53e4f
2166,European,1031.0,30868120.0,Berghuis B,Carbamazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007811,Other trait,#d53e4f
2167,European,1031.0,30868120.0,Berghuis B,Carbamazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007811,Neurological disorder,#d53e4f
2168,European,1031.0,30868120.0,Berghuis B,Carbamazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007811,Response to drug,#d53e4f
2169,European,804.0,30868120.0,Berghuis B,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007810,Other trait,#d53e4f
2170,European,804.0,30868120.0,Berghuis B,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007810,Response to drug,#d53e4f
2171,European,804.0,30868120.0,Berghuis B,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007810,Other trait,#d53e4f
2172,European,804.0,30868120.0,Berghuis B,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007810,Neurological disorder,#d53e4f
2173,European,804.0,30868120.0,Berghuis B,Severe carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007810,Response to drug,#d53e4f
2174,European,1252.0,30868120.0,Berghuis B,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007809,Other trait,#d53e4f
2175,European,1252.0,30868120.0,Berghuis B,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007809,Response to drug,#d53e4f
2176,European,1252.0,30868120.0,Berghuis B,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007809,Other trait,#d53e4f
2177,European,1252.0,30868120.0,Berghuis B,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007809,Neurological disorder,#d53e4f
2178,European,1252.0,30868120.0,Berghuis B,Carbamazepine- or oxcarbazepine-induced hyponatremia in epilepsy,initial,2019-01-17,GCST007809,Response to drug,#d53e4f
2179,African Am./Caribbean,3881.0,30655502.0,Levey DF,Suicide attempt severity,initial,2019-01-17,GCST007019,Other measurement,#fee08b
2180,African Am./Caribbean,1488.0,30655502.0,Levey DF,Suicide attempt severity,replication,2019-01-17,GCST007019,Other measurement,#fee08b
2181,Hispanic/Latin American,2963.0,30655502.0,Levey DF,Suicide attempt severity,replication,2019-01-17,GCST007019,Other measurement,#807dba
2182,European,2439.0,30655502.0,Levey DF,Suicide attempt severity,initial,2019-01-17,GCST007019,Other measurement,#d53e4f
2183,European,9382.0,30655502.0,Levey DF,Suicide attempt severity,replication,2019-01-17,GCST007019,Other measurement,#d53e4f
2184,European,15464.0,30651383.0,Chauhan G,Small subcortical brain infarct,initial,2019-01-16,GCST007729,Cardiovascular disease,#d53e4f
2185,African Am./Caribbean,994.0,30651383.0,Chauhan G,Small subcortical brain infarct,initial,2019-01-16,GCST007729,Cardiovascular disease,#fee08b
2186,Hispanic/Latin American,699.0,30651383.0,Chauhan G,Small subcortical brain infarct,initial,2019-01-16,GCST007729,Cardiovascular disease,#807dba
2187,Asian,196.0,30651383.0,Chauhan G,Small subcortical brain infarct,initial,2019-01-16,GCST007729,Cardiovascular disease,#3288bd
2188,Asian,208.0,30651383.0,Chauhan G,Small subcortical brain infarct,initial,2019-01-16,GCST007729,Cardiovascular disease,#3288bd
2189,European,5748.0,30651383.0,Chauhan G,Small subcortical brain infarct,replication,2019-01-16,GCST007729,Cardiovascular disease,#d53e4f
2190,Asian,13.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Response to drug,#3288bd
2191,European,634.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Response to drug,#d53e4f
2192,African Am./Caribbean,40.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Response to drug,#fee08b
2193,Asian,13.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Cancer,#3288bd
2194,European,634.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Cancer,#d53e4f
2195,African Am./Caribbean,40.0,30648747.0,Dudenkov TM,Plasma anastrozole concentration in anastrozole-treated estrogen receptor positive breast cancer,initial,2019-01-16,GCST007664,Cancer,#fee08b
2196,European,6932.0,30649180.0,Luo Q,Voxel-wise structural brain imaging measurements,initial,2019-01-16,GCST007357,Other measurement,#d53e4f
2197,European,1721.0,30649180.0,Luo Q,Voxel-wise structural brain imaging measurements,initial,2019-01-16,GCST007357,Other measurement,#d53e4f
2198,Asian,521.0,30651383.0,Chauhan G,Brain infarct,replication,2019-01-16,GCST007730,Cardiovascular disease,#3288bd
2199,European,17956.0,30651383.0,Chauhan G,Brain infarct,initial,2019-01-16,GCST007730,Cardiovascular disease,#d53e4f
2200,African Am./Caribbean,1834.0,30651383.0,Chauhan G,Brain infarct,initial,2019-01-16,GCST007730,Cardiovascular disease,#fee08b
2201,Hispanic/Latin American,737.0,30651383.0,Chauhan G,Brain infarct,initial,2019-01-16,GCST007730,Cardiovascular disease,#807dba
2202,Asian,207.0,30651383.0,Chauhan G,Brain infarct,initial,2019-01-16,GCST007730,Cardiovascular disease,#3288bd
2203,Asian,215.0,30651383.0,Chauhan G,Brain infarct,initial,2019-01-16,GCST007730,Cardiovascular disease,#3288bd
2204,European,6341.0,30651383.0,Chauhan G,Brain infarct,replication,2019-01-16,GCST007730,Cardiovascular disease,#d53e4f
2205,African,552.0,30647433.0,Legge SE,Neutrophil level response to clozapine in treatment-resistant schizophrenia,initial,2019-01-15,GCST006987,Hematological measurement,#fc8d59
2206,African,552.0,30647433.0,Legge SE,Neutrophil level response to clozapine in treatment-resistant schizophrenia,initial,2019-01-15,GCST006987,Neurological disorder,#fc8d59
2207,African,552.0,30647433.0,Legge SE,Neutrophil level response to clozapine in treatment-resistant schizophrenia,initial,2019-01-15,GCST006987,Response to drug,#fc8d59
2208,European,557923.0,30643258.0,Karlsson Linner R,Adventurousness,initial,2019-01-14,GCST007324,Biological process,#d53e4f
2211,European,1039210.0,30643251.0,Liu M,Alcohol consumption (drinks per week) (MTAG),initial,2019-01-14,GCST007472,Other measurement,#d53e4f
2212,European,1359002.0,30643251.0,Liu M,Smoking initiation (ever regular vs never regular) (MTAG),initial,2019-01-14,GCST007468,Other measurement,#d53e4f
2213,European,820192.0,30643251.0,Liu M,Smoking cessation (MTAG),initial,2019-01-14,GCST007464,Biological process,#d53e4f
2214,European,403928.0,30643251.0,Liu M,Cigarettes smoked per day (MTAG),initial,2019-01-14,GCST007463,Other measurement,#d53e4f
2215,European,931815.0,30643251.0,Liu M,Age of smoking initiation (MTAG),initial,2019-01-14,GCST007462,Biological process,#d53e4f
2216,European,941280.0,30643251.0,Liu M,Alcohol consumption (drinks per week),initial,2019-01-14,GCST007461,Other measurement,#d53e4f
2217,European,1232091.0,30643251.0,Liu M,Smoking initiation (ever regular vs never regular),initial,2019-01-14,GCST007474,Other measurement,#d53e4f
2218,European,547219.0,30643251.0,Liu M,Smoking cessation,initial,2019-01-14,GCST007460,Biological process,#d53e4f
2219,European,377334.0,30643251.0,Liu M,Smoking behaviour (cigarettes smoked per day),initial,2019-01-14,GCST007459,Other measurement,#d53e4f
2220,European,341427.0,30643251.0,Liu M,Age of smoking initiation,initial,2019-01-14,GCST007458,Biological process,#d53e4f
2221,European,3344.0,30649302.0,Ruth KS,Anti-Mullerian hormone levels in pre-menopausal women of late reproductive age,initial,2019-01-14,GCST007363,Other measurement,#d53e4f
2222,European,719047.0,30643255.0,Kristjansson RP,Nasal polyps,initial,2019-01-14,GCST007443,Cancer,#d53e4f
2223,Asian,3574.0,30643196.0,Hitomi Y,Primary biliary cholangitis,initial,2019-01-14,GCST007036,Cancer,#3288bd
2224,African Am./Caribbean,3420.0,30642921.0,de Vries PS,Factor VII activity,initial,2019-01-14,GCST007401,Other measurement,#fee08b
2225,European,20014.0,30642921.0,de Vries PS,Factor VII activity,initial,2019-01-14,GCST007401,Other measurement,#d53e4f
2226,Hispanic/Latin American,8801.0,30642363.0,Hoffman J,Breast cancer,initial,2019-01-14,GCST006985,Cancer,#807dba
2227,African Am./Caribbean,5984.0,30642363.0,Hoffman J,Breast cancer,replication,2019-01-14,GCST006985,Cancer,#fee08b
2229,Hispanic/Latin American,3992.0,30642363.0,Hoffman J,Breast cancer,replication,2019-01-14,GCST006985,Cancer,#807dba
2230,Asian,8719.0,30642363.0,Hoffman J,Breast cancer,replication,2019-01-14,GCST006985,Cancer,#3288bd
2231,European,2083151.0,30643256.0,Baselmans BML,Well-being spectrum (multivariate analysis),initial,2019-01-14,GCST007341,Other measurement,#d53e4f
2232,European,287239.0,30643256.0,Baselmans BML,Well-being spectrum (multivariate analysis),replication,2019-01-14,GCST007341,Other measurement,#d53e4f
2233,European,939908.0,30643258.0,Karlsson Linner R,General risk tolerance,initial,2019-01-14,GCST007322,Biological process,#d53e4f
2234,European,35445.0,30643258.0,Karlsson Linner R,General risk tolerance,replication,2019-01-14,GCST007322,Biological process,#d53e4f
2237,European,315894.0,30643258.0,Karlsson Linner R,Risk-taking tendency (4-domain principal component model),initial,2019-01-14,GCST007323,Biological process,#d53e4f
2238,European,975353.0,30643258.0,Karlsson Linner R,General risk tolerance (MTAG),initial,2019-01-14,GCST007325,Biological process,#d53e4f
2239,European,228033.0,30643256.0,Baselmans BML,Depressive symptoms,replication,2019-01-14,GCST007340,Other measurement,#d53e4f
2240,European,1067913.0,30643256.0,Baselmans BML,Depressive symptoms,initial,2019-01-14,GCST007340,Other measurement,#d53e4f
2241,European,523783.0,30643256.0,Baselmans BML,Neuroticism,initial,2019-01-14,GCST007339,Other measurement,#d53e4f
2242,European,59206.0,30643256.0,Baselmans BML,Neuroticism,replication,2019-01-14,GCST007339,Other measurement,#d53e4f
2243,European,410603.0,30643256.0,Baselmans BML,Positive affect,initial,2019-01-14,GCST007338,Other measurement,#d53e4f
2244,European,80852.0,30643256.0,Baselmans BML,Life satisfaction,initial,2019-01-14,GCST007337,Other measurement,#d53e4f
2245,European,24075.0,30642921.0,de Vries PS,Factor VII activity or levels,initial,2019-01-14,GCST007402,Other measurement,#d53e4f
2246,African Am./Caribbean,3420.0,30642921.0,de Vries PS,Factor VII activity or levels,initial,2019-01-14,GCST007402,Other measurement,#fee08b
2247,European,765694.0,30643255.0,Kristjansson RP,Chronic rhinosinusitis,initial,2019-01-14,GCST007444,Neurological disorder,#d53e4f
2248,European,370711.0,30643258.0,Karlsson Linner R,Number of sexual partners,initial,2019-01-14,GCST007326,Other measurement,#d53e4f
2249,European,518633.0,30643258.0,Karlsson Linner R,Smoking status (ever vs never smokers),initial,2019-01-14,GCST007327,Biological process,#d53e4f
2250,European,414343.0,30643258.0,Karlsson Linner R,Alcohol consumption (drinks per week),initial,2019-01-14,GCST007328,Other measurement,#d53e4f
2251,European,404291.0,30643258.0,Karlsson Linner R,Automobile speeding propensity,initial,2019-01-14,GCST007329,Biological process,#d53e4f
2252,European,17480.0,30636644.0,Nazarian A,Alzheimer's disease,initial,2019-01-12,GCST007600,Neurological disorder,#d53e4f
2253,European,377371.0,30626913.0,Amare AT,Broad depression or major depressive disorder (self-reported),initial,2019-01-09,GCST007254,Neurological disorder,#d53e4f
2255,European,70017.0,30626913.0,Amare AT,Broad depression or schizophrenia,initial,2019-01-09,GCST007257,Neurological disorder,#d53e4f
2258,European,70017.0,30626913.0,Amare AT,Broad depression or schizophrenia,initial,2019-01-09,GCST007257,Neurological disorder,#d53e4f
2262,European,86748.0,30626913.0,Amare AT,Broad depression or bipolar disorder,initial,2019-01-09,GCST007255,Neurological disorder,#d53e4f
2264,European,86748.0,30626913.0,Amare AT,Broad depression or bipolar disorder,initial,2019-01-09,GCST007255,Neurological disorder,#d53e4f
2265,European,70017.0,30626913.0,Amare AT,Broad depression or major depressive disorder (recurrent),initial,2019-01-09,GCST007256,Neurological disorder,#d53e4f
2267,Asian,10640.0,30626913.0,Amare AT,Broad depression or major depressive disorder (recurrent),initial,2019-01-09,GCST007256,Neurological disorder,#3288bd
2268,European,324851.0,30617275.0,Erzurumluoglu AM,Smoking initiation,initial,2019-01-07,GCST007603,Biological process,#d53e4f
2269,Asian,21962.0,30617275.0,Erzurumluoglu AM,Smoking initiation,initial,2019-01-07,GCST007603,Biological process,#3288bd
2270,European,275596.0,30617275.0,Erzurumluoglu AM,Smoking initiation,replication,2019-01-07,GCST007603,Biological process,#d53e4f
2271,Other/Mixed,121543.0,30617275.0,Erzurumluoglu AM,Smoking cessation,initial,2019-01-07,GCST007604,Biological process,#99d594
2272,European,275596.0,30617275.0,Erzurumluoglu AM,Smoking cessation,replication,2019-01-07,GCST007604,Biological process,#d53e4f
2273,Other/Mixed,131892.0,30617275.0,Erzurumluoglu AM,Smoking behaviour (cigarette pack-years),initial,2019-01-07,GCST007601,Other measurement,#99d594
2274,European,275596.0,30617275.0,Erzurumluoglu AM,Smoking behaviour (cigarette pack-years),replication,2019-01-07,GCST007601,Other measurement,#d53e4f
2275,Other/Mixed,128746.0,30617275.0,Erzurumluoglu AM,Smoking behaviour (cigarettes smoked per day),initial,2019-01-07,GCST007602,Other measurement,#99d594
2276,European,275596.0,30617275.0,Erzurumluoglu AM,Smoking behaviour (cigarettes smoked per day),replication,2019-01-07,GCST007602,Other measurement,#d53e4f
2277,European,455258.0,30617256.0,Jansen IE,Alzheimer's disease or family history of Alzheimer's disease,initial,2019-01-07,GCST007320,Neurological disorder,#d53e4f
2278,European,455258.0,30617256.0,Jansen IE,Alzheimer's disease or family history of Alzheimer's disease,initial,2019-01-07,GCST007320,Other measurement,#d53e4f
2279,European,376113.0,30617256.0,Jansen IE,Family history of Alzheimer's disease,initial,2019-01-07,GCST007321,Other measurement,#d53e4f
2280,European,79145.0,30617256.0,Jansen IE,Alzheimer's disease (late onset),initial,2019-01-07,GCST007319,Neurological disorder,#d53e4f
2281,European,430.0,30621171.0,Coltell O,Serum bilirubin levels in metabolic syndrome,initial,2019-01-04,GCST007018,Other measurement,#d53e4f
2282,European,430.0,30621171.0,Coltell O,Serum bilirubin levels in metabolic syndrome,initial,2019-01-04,GCST007018,Metabolic disorder,#d53e4f
2283,European,24546.0,30610202.0,Ruderfer DM,Predicted suicide risk,initial,2019-01-04,GCST006977,Other measurement,#d53e4f
2284,European,418.0,30621171.0,Coltell O,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,initial,2019-01-04,GCST007017,Other measurement,#d53e4f
2285,European,418.0,30621171.0,Coltell O,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,initial,2019-01-04,GCST007017,Other measurement,#d53e4f
2286,European,418.0,30621171.0,Coltell O,Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,initial,2019-01-04,GCST007017,Metabolic disorder,#d53e4f
2287,European,430.0,30621171.0,Coltell O,Serum bilirubin levels x sex interaction in metabolic syndrome,initial,2019-01-04,GCST007016,Other measurement,#d53e4f
2288,European,430.0,30621171.0,Coltell O,Serum bilirubin levels x sex interaction in metabolic syndrome,initial,2019-01-04,GCST007016,Other measurement,#d53e4f
2289,European,430.0,30621171.0,Coltell O,Serum bilirubin levels x sex interaction in metabolic syndrome,initial,2019-01-04,GCST007016,Metabolic disorder,#d53e4f
2290,Other/Mixed,82315.0,30610197.0,Smeland OB,Schizophrenia or intelligence (pleiotropy),initial,2019-01-04,GCST007782,Neurological disorder,#99d594
2292,Other/Mixed,82315.0,30610197.0,Smeland OB,Schizophrenia or intelligence (pleiotropy),initial,2019-01-04,GCST007782,Biological process,#99d594
2294,European,51710.0,30610197.0,Smeland OB,Bipolar disorder or intelligence (pleiotropy),initial,2019-01-04,GCST007781,Biological process,#d53e4f
2296,European,51710.0,30610197.0,Smeland OB,Bipolar disorder or intelligence (pleiotropy),initial,2019-01-04,GCST007781,Neurological disorder,#d53e4f
2298,European,83129.0,30610198.0,Soler Artigas M,Attention deficit hyperactivity disorder or cannabis use,initial,2019-01-04,GCST006983,Neurological disorder,#d53e4f
2299,European,83129.0,30610198.0,Soler Artigas M,Attention deficit hyperactivity disorder or cannabis use,initial,2019-01-04,GCST006983,Biological process,#d53e4f
2300,European,337199.0,30610202.0,Ruderfer DM,Suicide attempts,initial,2019-01-04,GCST006978,Biological process,#d53e4f
2301,Asian,143658.0,30604766.0,Morris AP,Estimated glomerular filtration rate,initial,2019-01-03,GCST007344,Other measurement,#3288bd
2302,European,134070.0,30604766.0,Morris AP,Estimated glomerular filtration rate,initial,2019-01-03,GCST007344,Other measurement,#d53e4f
2303,Hispanic/Latin American,26344.0,30604766.0,Morris AP,Estimated glomerular filtration rate,initial,2019-01-03,GCST007344,Other measurement,#807dba
2304,African Am./Caribbean,8224.0,30604766.0,Morris AP,Estimated glomerular filtration rate,initial,2019-01-03,GCST007344,Other measurement,#fee08b
2305,African Am./Caribbean,285.0,30610941.0,Wang AW,Anti-Toxoplasma gondii IgG seropositivity,initial,2019-01-02,GCST007726,Other measurement,#fee08b
2306,European,790.0,30610941.0,Wang AW,Anti-Toxoplasma gondii IgG seropositivity,initial,2019-01-02,GCST007726,Other measurement,#d53e4f
2307,European,1791.0,30582445.0,Mola-Caminal M,3-month functional outcome in ischaemic stroke (modified Rankin score),replication,2019-01-01,GCST006935,Other trait,#d53e4f
2308,European,1225.0,30582445.0,Mola-Caminal M,3-month functional outcome in ischaemic stroke (modified Rankin score),initial,2019-01-01,GCST006935,Other trait,#d53e4f
2309,European,1791.0,30582445.0,Mola-Caminal M,3-month functional outcome in ischaemic stroke (modified Rankin score),replication,2019-01-01,GCST006935,Other measurement,#d53e4f
2310,European,1225.0,30582445.0,Mola-Caminal M,3-month functional outcome in ischaemic stroke (modified Rankin score),initial,2019-01-01,GCST006935,Other measurement,#d53e4f
2311,European,426824.0,30598549.0,Morris JA,Heel bone mineral density,initial,2018-12-31,GCST006979,Other measurement,#d53e4f
2312,European,731819.0,30598549.0,Morris JA,Fractures,replication,2018-12-31,GCST006980,Other disease,#d53e4f
2313,European,426795.0,30598549.0,Morris JA,Fractures,initial,2018-12-31,GCST006980,Other disease,#d53e4f
2314,European,155961.0,30593698.0,Hubel C,Body fat percentage,initial,2018-12-28,GCST007064,Body measurement,#d53e4f
2315,European,155961.0,30593698.0,Hubel C,Fat-free mass,initial,2018-12-28,GCST007063,Other measurement,#d53e4f
2316,European,2900.0,30685440.0,Silbernagel G,Low density lipoprotein triglyceride levels,initial,2018-12-28,GCST007955,Lipid or lipoprotein measurement,#d53e4f
2317,European,455000.0,30595370.0,Kichaev G,Educational attainment (years of education),initial,2018-12-27,GCST007037,Other measurement,#d53e4f
2328,European,665.0,30595539.0,Wallace HJ,Postburn scar pliability,initial,2018-12-27,GCST007252,Other measurement,#d53e4f
2329,European,665.0,30595539.0,Wallace HJ,Postburn scar height,initial,2018-12-27,GCST007251,Other measurement,#d53e4f
2330,European,422000.0,30595370.0,Kichaev G,Systolic blood pressure,initial,2018-12-27,GCST007087,Other measurement,#d53e4f
2331,European,344000.0,30595370.0,Kichaev G,Sunburns,initial,2018-12-27,GCST007086,Other disease,#d53e4f
2332,European,458000.0,30595370.0,Kichaev G,Smoking status,initial,2018-12-27,GCST007085,Other measurement,#d53e4f
2333,European,372000.0,30595370.0,Kichaev G,Neuroticism,initial,2018-12-27,GCST007084,Other measurement,#d53e4f
2334,European,410000.0,30595370.0,Kichaev G,Morning person,initial,2018-12-27,GCST007083,Other measurement,#d53e4f
2335,European,452000.0,30595370.0,Kichaev G,Hair color,initial,2018-12-27,GCST007082,Other measurement,#d53e4f
2336,European,372000.0,30595370.0,Kichaev G,Lung function (FVC),initial,2018-12-27,GCST007081,Other measurement,#d53e4f
2337,European,370000.0,30595370.0,Kichaev G,Lung function (FEV1/FVC),initial,2018-12-27,GCST007080,Other measurement,#d53e4f
2338,European,143000.0,30595370.0,Kichaev G,Age at menopause,initial,2018-12-27,GCST007079,Other measurement,#d53e4f
2339,European,242000.0,30595370.0,Kichaev G,Menarche (age at onset),initial,2018-12-27,GCST007078,Other measurement,#d53e4f
2340,European,459000.0,30595370.0,Kichaev G,Type 2 diabetes,initial,2018-12-27,GCST007077,Metabolic disorder,#d53e4f
2341,European,459000.0,30595370.0,Kichaev G,Respiratory diseases,initial,2018-12-27,GCST007076,Other disease,#d53e4f
2342,European,459000.0,30595370.0,Kichaev G,Hypothyroidism,initial,2018-12-27,GCST007073,Other disease,#d53e4f
2343,European,459000.0,30595370.0,Kichaev G,Eczema,initial,2018-12-27,GCST007075,Other trait,#d53e4f
2344,European,459000.0,30595370.0,Kichaev G,Cardiovascular disease,initial,2018-12-27,GCST007072,Other disease,#d53e4f
2345,European,459000.0,30595370.0,Kichaev G,Autoimmune traits,initial,2018-12-27,GCST007071,Immune system disorder,#d53e4f
2346,European,444000.0,30595370.0,Kichaev G,White blood cell count,initial,2018-12-27,GCST007070,Hematological measurement,#d53e4f
2347,European,445000.0,30595370.0,Kichaev G,Red cell distribution width,initial,2018-12-27,GCST007074,Hematological measurement,#d53e4f
2348,European,445000.0,30595370.0,Kichaev G,Red blood cell count,initial,2018-12-27,GCST007069,Hematological measurement,#d53e4f
2349,European,443000.0,30595370.0,Kichaev G,Mean corpuscular hemoglobin,initial,2018-12-27,GCST007068,Hematological measurement,#d53e4f
2350,European,440000.0,30595370.0,Kichaev G,Eosinophil counts,initial,2018-12-27,GCST007065,Hematological measurement,#d53e4f
2351,European,458000.0,30595370.0,Kichaev G,Waist-hip ratio,initial,2018-12-27,GCST007067,Body measurement,#d53e4f
2352,European,458000.0,30595370.0,Kichaev G,Height,initial,2018-12-27,GCST007841,Body measurement,#d53e4f
2353,European,446000.0,30595370.0,Kichaev G,Heel bone mineral density,initial,2018-12-27,GCST007066,Other measurement,#d53e4f
2354,European,458000.0,30595370.0,Kichaev G,Body mass index,initial,2018-12-27,GCST007039,Body measurement,#d53e4f
2355,European,208000.0,30595370.0,Kichaev G,Balding type 1,initial,2018-12-27,GCST007038,Other measurement,#d53e4f
2358,Hispanic/Latin American,486.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Other trait,#807dba
2359,European,1736.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Other trait,#d53e4f
2360,African Am./Caribbean,2201.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Other trait,#fee08b
2361,Hispanic/Latin American,486.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Digestive system disorder,#807dba
2362,European,1736.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Digestive system disorder,#d53e4f
2363,African Am./Caribbean,2201.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007631,Digestive system disorder,#fee08b
2364,Hispanic/Latin American,486.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007634,Other trait,#807dba
2365,Hispanic/Latin American,486.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007634,Digestive system disorder,#807dba
2366,European,1736.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007633,Other trait,#d53e4f
2367,European,1736.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007633,Digestive system disorder,#d53e4f
2368,African Am./Caribbean,2201.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007632,Other trait,#fee08b
2369,African Am./Caribbean,2201.0,30593799.0,Vergara C,Hepatitis C (spontaneous viral clearance),initial,2018-12-26,GCST007632,Digestive system disorder,#fee08b
2370,Asian,2981.0,30591961.0,Huang L,Intraocular pressure,initial,2018-12-24,GCST007998,Other measurement,#3288bd
2371,Asian,5571.0,30591961.0,Huang L,Intraocular pressure,initial,2018-12-24,GCST007998,Other measurement,#3288bd
2372,European,493.0,30583557.0,Loohuis LM,B6 vitamer levels (multivariate analysis),initial,2018-12-22,GCST007260,Other measurement,#d53e4f
2373,European,493.0,30583557.0,Loohuis LM,Plasma pyridoxic acid to pyridoxal phosphate ratio,initial,2018-12-22,GCST007265,Other measurement,#d53e4f
2374,European,493.0,30583557.0,Loohuis LM,Plasma pyridoxal phosphate to pyridoxal ratio,initial,2018-12-22,GCST007264,Other measurement,#d53e4f
2375,European,493.0,30583557.0,Loohuis LM,Cerebrospinal fluid pyridoxal phosphate to pyridoxal ratio,initial,2018-12-22,GCST007263,Other measurement,#d53e4f
2376,European,493.0,30583557.0,Loohuis LM,Plasma pyridoxal phosphate levels,initial,2018-12-22,GCST007262,Other measurement,#d53e4f
2377,European,493.0,30583557.0,Loohuis LM,Cerebrospinal fluid pyridoxal phosphate levels,initial,2018-12-22,GCST007261,Other measurement,#d53e4f
2378,European,223805.0,30583798.0,Bovijn J,Erectile dysfunction,initial,2018-12-21,GCST006956,Other disease,#d53e4f
2380,Asian,4792.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007272,Cardiovascular measurement,#3288bd
2381,Hispanic/Latin American,22802.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007272,Cardiovascular measurement,#807dba
2382,African,63490.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007272,Cardiovascular measurement,#fc8d59
2383,European,225112.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007272,Cardiovascular measurement,#d53e4f
2384,Other/Mixed,2695.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007272,Cardiovascular measurement,#99d594
2386,Other/Mixed,2695.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007271,Other measurement,#99d594
2387,Asian,4792.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007271,Other measurement,#3288bd
2388,African,63490.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007271,Other measurement,#fc8d59
2389,European,225112.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007271,Other measurement,#d53e4f
2390,Hispanic/Latin American,22802.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007271,Other measurement,#807dba
2391,Other/Mixed,2695.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007270,Other measurement,#99d594
2392,Asian,4792.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007270,Other measurement,#3288bd
2393,Hispanic/Latin American,22802.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007270,Other measurement,#807dba
2394,African,63490.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007270,Other measurement,#fc8d59
2395,European,225112.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007270,Other measurement,#d53e4f
2397,European,365998.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007269,Cardiovascular measurement,#d53e4f
2398,Hispanic/Latin American,22802.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007269,Cardiovascular measurement,#807dba
2400,European,299024.0,30578418.0,Giri A,Pulse pressure,replication,2018-12-21,GCST007269,Cardiovascular measurement,#d53e4f
2401,Other/Mixed,2695.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007269,Cardiovascular measurement,#99d594
2402,Asian,4792.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007269,Cardiovascular measurement,#3288bd
2403,African,63490.0,30578418.0,Giri A,Pulse pressure,initial,2018-12-21,GCST007269,Cardiovascular measurement,#fc8d59
2405,European,299024.0,30578418.0,Giri A,Diastolic blood pressure,replication,2018-12-21,GCST007268,Other measurement,#d53e4f
2406,Asian,4792.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007268,Other measurement,#3288bd
2407,Hispanic/Latin American,22802.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007268,Other measurement,#807dba
2408,African,63490.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007268,Other measurement,#fc8d59
2409,European,365998.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007268,Other measurement,#d53e4f
2410,Other/Mixed,2695.0,30578418.0,Giri A,Diastolic blood pressure,initial,2018-12-21,GCST007268,Other measurement,#99d594
2412,European,299024.0,30578418.0,Giri A,Systolic blood pressure,replication,2018-12-21,GCST007267,Other measurement,#d53e4f
2413,Other/Mixed,2695.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007267,Other measurement,#99d594
2414,Asian,4792.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007267,Other measurement,#3288bd
2415,Hispanic/Latin American,22802.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007267,Other measurement,#807dba
2416,African,63490.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007267,Other measurement,#fc8d59
2417,European,365998.0,30578418.0,Giri A,Systolic blood pressure,initial,2018-12-21,GCST007267,Other measurement,#d53e4f
2418,European,7155.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008506,Neurological disorder,#d53e4f
2419,European,7155.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008506,Other measurement,#d53e4f
2420,European,30247.0,30571770.0,Arnau-Soler A,Neuroticism,initial,2018-12-20,GCST008510,Other measurement,#d53e4f
2421,European,30247.0,30571770.0,Arnau-Soler A,Major depressive disorder,initial,2018-12-20,GCST008509,Neurological disorder,#d53e4f
2422,European,30247.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008508,Neurological disorder,#d53e4f
2423,European,30247.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008508,Other measurement,#d53e4f
2424,European,31382.0,30573655.0,Acosta-Herrera M,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),initial,2018-12-20,GCST007278,Neurological disorder,#d53e4f
2425,European,31382.0,30573655.0,Acosta-Herrera M,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),initial,2018-12-20,GCST007278,Immune system disorder,#d53e4f
2426,European,31382.0,30573655.0,Acosta-Herrera M,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),initial,2018-12-20,GCST007278,Immune system disorder,#d53e4f
2427,European,31382.0,30573655.0,Acosta-Herrera M,Systemic seropositive rheumatic diseases (Systemic sclerosis or systemic lupus erythematosus or rheumatoid arthritis or idiopathic inflammatory myopathies),initial,2018-12-20,GCST007278,Immune system disorder,#d53e4f
2428,European,205327.0,30573740.0,Yap CX,Male-pattern baldness,initial,2018-12-20,GCST007020,Other measurement,#d53e4f
2429,European,23092.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008507,Neurological disorder,#d53e4f
2430,European,23092.0,30571770.0,Arnau-Soler A,Stress sensitivity (neuroticism score x major depressive disorder status interaction),initial,2018-12-20,GCST008507,Other measurement,#d53e4f
2431,European,54543.0,30578877.0,Dahlin A,Adult asthma,initial,2018-12-19,GCST007596,Other disease,#d53e4f
2432,European,26475.0,30578877.0,Dahlin A,Adult asthma,replication,2018-12-19,GCST007596,Other disease,#d53e4f
2433,Asian,8401.0,30566433.0,Taira M,Type 2 diabetes nephropathy including microalbuminuria,initial,2018-12-19,GCST007022,Other trait,#3288bd
2434,Asian,4634.0,30566433.0,Taira M,Type 2 diabetes nephropathy including microalbuminuria,replication,2018-12-19,GCST007022,Other trait,#3288bd
2435,Asian,8401.0,30566433.0,Taira M,Type 2 diabetes nephropathy including microalbuminuria,initial,2018-12-19,GCST007022,Metabolic disorder,#3288bd
2436,Asian,4634.0,30566433.0,Taira M,Type 2 diabetes nephropathy including microalbuminuria,replication,2018-12-19,GCST007022,Metabolic disorder,#3288bd
2437,Hispanic/Latin American,5327.0,30578877.0,Dahlin A,Adult asthma,initial,2018-12-19,GCST007597,Other disease,#807dba
2438,European,26475.0,30578877.0,Dahlin A,Adult asthma,replication,2018-12-19,GCST007597,Other disease,#d53e4f
2439,Asian,6227.0,30578877.0,Dahlin A,Adult asthma,initial,2018-12-19,GCST007598,Other disease,#3288bd
2440,European,26475.0,30578877.0,Dahlin A,Adult asthma,replication,2018-12-19,GCST007598,Other disease,#d53e4f
2441,African Am./Caribbean,2526.0,30578877.0,Dahlin A,Adult asthma,initial,2018-12-19,GCST007599,Other disease,#fee08b
2442,European,26475.0,30578877.0,Dahlin A,Adult asthma,replication,2018-12-19,GCST007599,Other disease,#d53e4f
2443,European,113238.0,30566500.0,Day F,Polycystic ovary syndrome,initial,2018-12-19,GCST007089,Other disease,#d53e4f
2444,Asian,8401.0,30566433.0,Taira M,Type 2 diabetes nephropathy,initial,2018-12-19,GCST007021,Metabolic disorder,#3288bd
2445,Asian,4634.0,30566433.0,Taira M,Type 2 diabetes nephropathy,replication,2018-12-19,GCST007021,Metabolic disorder,#3288bd
2446,European,3186.0,30631343.0,Rolfe S,Normal facial asymmetry (angle of surface orientation score),initial,2018-12-18,GCST007448,Other measurement,#d53e4f
2447,European,3186.0,30631343.0,Rolfe S,Normal facial asymmetry (deformation magnitude),initial,2018-12-18,GCST007450,Other measurement,#d53e4f
2448,European,1688.0,30563984.0,Hawi Z,Attention deficit hyperactivity disorder,initial,2018-12-18,GCST006916,Neurological disorder,#d53e4f
2449,Asian,408.0,30662464.0,Yang C,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma,initial,2018-12-18,GCST008104,Cancer,#3288bd
2450,Asian,408.0,30662464.0,Yang C,Nucleoside diphosphate kinase A levels in hepatocellular carcinoma,initial,2018-12-18,GCST008104,Other measurement,#3288bd
2451,European,3186.0,30631343.0,Rolfe S,Normal facial asymmetry (angle of deformation score),initial,2018-12-18,GCST007449,Other measurement,#d53e4f
2452,Asian,18173.0,30557369.0,Yodsurang V,Ovarian cancer,initial,2018-12-17,GCST007239,Cancer,#3288bd
2456,European,520.0,30556296.0,Alblooshi H,Substance use disorder,replication,2018-12-16,GCST007700,Neurological disorder,#d53e4f
2457,Other/Mixed,502.0,30556296.0,Alblooshi H,Substance use disorder,initial,2018-12-16,GCST007700,Neurological disorder,#99d594
2458,European,157.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (antidepressant effects),initial,2018-12-14,GCST007316,Neurological disorder,#d53e4f
2459,European,157.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (antidepressant effects),initial,2018-12-14,GCST007316,Other measurement,#d53e4f
2460,European,157.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (antidepressant effects),initial,2018-12-14,GCST007316,Response to drug,#d53e4f
2461,European,157.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (antidepressant effects),initial,2018-12-14,GCST007316,Neurological disorder,#d53e4f
2463,European,2198.0,30552173.0,Aterido A,Psoriatic arthritis,initial,2018-12-14,GCST007043,Immune system disorder,#d53e4f
2464,Asian,676.0,30552108.0,Kawabata Y,Fulminant type 1 diabetes,initial,2018-12-14,GCST007433,Metabolic disorder,#3288bd
2465,European,90.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (dissociation effects),initial,2018-12-14,GCST007317,Neurological disorder,#d53e4f
2466,European,90.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (dissociation effects),initial,2018-12-14,GCST007317,Response to drug,#d53e4f
2467,European,90.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (dissociation effects),initial,2018-12-14,GCST007317,Other measurement,#d53e4f
2468,European,90.0,30552317.0,Guo W,Response to ketamine in bipolar disorder or major depression (dissociation effects),initial,2018-12-14,GCST007317,Neurological disorder,#d53e4f
2469,European,21536.0,30541042.0,Walsh N,Pancreatic ductal adenocarcinoma,initial,2018-12-12,GCST007235,Cancer,#d53e4f
2470,European,708.0,30584014.0,Huang M,Whole-brain volume,initial,2018-12-12,GCST008491,Other measurement,#d53e4f
2471,European,26722.0,30542056.0,Petridis C,Acne (severe),initial,2018-12-12,GCST007234,Other disease,#d53e4f
2472,European,26885.0,30552067.0,Shrine N,Asthma (moderate or severe),replication,2018-12-11,GCST006911,Other disease,#d53e4f
2473,European,30810.0,30552067.0,Shrine N,Asthma (moderate or severe),initial,2018-12-11,GCST006911,Other disease,#d53e4f
2474,European,299651.0,30531825.0,Morgan MD,Red vs. brown/black hair color,initial,2018-12-10,GCST006986,Other trait,#d53e4f
2475,European,91105.0,30531941.0,Doherty A,Physical activity (overall physical activity time),initial,2018-12-10,GCST006912,Other measurement,#d53e4f
2476,European,91105.0,30531941.0,Doherty A,Physical activity (moderate intensity activity duration),initial,2018-12-10,GCST006915,Other measurement,#d53e4f
2477,European,91105.0,30531941.0,Doherty A,Physical activity (walking duration),initial,2018-12-10,GCST007110,Other measurement,#d53e4f
2478,European,91105.0,30531941.0,Doherty A,Sedentary behaviour duration,initial,2018-12-10,GCST006913,Other measurement,#d53e4f
2479,European,91105.0,30531941.0,Doherty A,Sleep duration,initial,2018-12-10,GCST006914,Other measurement,#d53e4f
2480,African Am./Caribbean,2645.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Generalized epilepsy,initial,2018-12-10,GCST007353,Neurological disorder,#fee08b
2481,Asian,2875.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Generalized epilepsy,initial,2018-12-10,GCST007353,Neurological disorder,#3288bd
2482,European,27926.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Generalized epilepsy,initial,2018-12-10,GCST007353,Neurological disorder,#d53e4f
2483,European,33313.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy,initial,2018-12-10,GCST007352,Neurological disorder,#d53e4f
2484,Asian,3365.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy,initial,2018-12-10,GCST007352,Neurological disorder,#3288bd
2485,African Am./Caribbean,2670.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy,initial,2018-12-10,GCST007352,Neurological disorder,#fee08b
2486,European,26969.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy (with lesion other than hippocampal sclerosis),initial,2018-12-10,GCST007351,Neurological disorder,#d53e4f
2487,European,24927.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy (with hippocampal sclerosis),initial,2018-12-10,GCST007350,Neurological disorder,#d53e4f
2488,European,26878.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Focal epilepsy (lesion negative),initial,2018-12-10,GCST007349,Neurological disorder,#d53e4f
2489,European,24443.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,"Epilepsy (generalized, with tonic-clonic seizures alone)",initial,2018-12-10,GCST007348,Neurological disorder,#d53e4f
2490,European,25395.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Juvenile myoclonic epilepsy,initial,2018-12-10,GCST007347,Neurological disorder,#d53e4f
2491,European,24633.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Juvenile absence epilepsy,initial,2018-12-10,GCST007346,Neurological disorder,#d53e4f
2492,European,24996.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Childhood absence epilepsy,initial,2018-12-10,GCST007345,Neurological disorder,#d53e4f
2493,European,283920.0,30531825.0,Morgan MD,Brown vs. black hair color,initial,2018-12-10,GCST006989,Other trait,#d53e4f
2494,European,323317.0,30531825.0,Morgan MD,Blond vs. brown/black hair color,initial,2018-12-10,GCST006988,Other trait,#d53e4f
2495,European,38752.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Epilepsy,initial,2018-12-10,GCST007343,Neurological disorder,#d53e4f
2496,Asian,3406.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Epilepsy,initial,2018-12-10,GCST007343,Neurological disorder,#3288bd
2497,African Am./Caribbean,2731.0,30531953.0,International League Against Epilepsy Consortium on Complex Epilepsies,Epilepsy,initial,2018-12-10,GCST007343,Neurological disorder,#fee08b
2498,European,59814.0,30535121.0,Gao XR,Macular thickness,initial,2018-12-07,GCST006976,Other measurement,#d53e4f
2499,European,8609.0,30535121.0,Gao XR,Macular thickness,replication,2018-12-07,GCST006976,Other measurement,#d53e4f
2501,European,346.0,30531935.0,Crowley JJ,Fragile X syndrome,initial,2018-12-07,GCST007233,Metabolic disorder,#d53e4f
2502,Asian,70506.0,30529582.0,Lu Y,Colorectal cancer,initial,2018-12-06,GCST007552,Cancer,#3288bd
2503,European,11744.0,30527956.0,Rhodes CJ,Pulmonary arterial hypertension,initial,2018-12-05,GCST007228,Cardiovascular disease,#d53e4f
2504,European,342.0,30563176.0,Westermair AL,Severe depressive disorders in coronary artery disease,initial,2018-12-05,GCST007230,Neurological disorder,#d53e4f
2505,European,342.0,30563176.0,Westermair AL,Severe depressive disorders in coronary artery disease,initial,2018-12-05,GCST007230,Cardiovascular disease,#d53e4f
2506,European,4554.0,30514930.0,Mukherjee S,Alzheimer's disease with memory domain impairment,initial,2018-12-04,GCST007330,Neurological disorder,#d53e4f
2507,European,4554.0,30514930.0,Mukherjee S,Alzheimer's disease with memory domain impairment,initial,2018-12-04,GCST007330,Other trait,#d53e4f
2508,European,5878.0,30514930.0,Mukherjee S,Alzheimer's disease,initial,2018-12-04,GCST007331,Neurological disorder,#d53e4f
2509,European,5031.0,30514930.0,Mukherjee S,Alzheimer's disease with no specific cognitive domain impairment,initial,2018-12-04,GCST007333,Neurological disorder,#d53e4f
2510,European,3695.0,30514930.0,Mukherjee S,Alzheimer's disease with multiple cognitive domain impairments,initial,2018-12-04,GCST007332,Other trait,#d53e4f
2511,European,3695.0,30514930.0,Mukherjee S,Alzheimer's disease with multiple cognitive domain impairments,initial,2018-12-04,GCST007332,Neurological disorder,#d53e4f
2512,European,3944.0,30514930.0,Mukherjee S,Alzheimer's disease with visuospatial domain impairment,initial,2018-12-04,GCST007318,Neurological disorder,#d53e4f
2513,European,3944.0,30514930.0,Mukherjee S,Alzheimer's disease with visuospatial domain impairment,initial,2018-12-04,GCST007318,Neurological disorder,#d53e4f
2514,European,3957.0,30514930.0,Mukherjee S,Alzheimer's disease with language domain impairment,initial,2018-12-04,GCST007334,Neurological disorder,#d53e4f
2515,European,3957.0,30514930.0,Mukherjee S,Alzheimer's disease with language domain impairment,initial,2018-12-04,GCST007334,Neurological disorder,#d53e4f
2516,European,120184.0,30510241.0,Huyghe JR,Colorectal cancer or advanced adenoma,initial,2018-12-03,GCST007856,Cancer,#d53e4f
2517,Asian,5294.0,30510241.0,Huyghe JR,Colorectal cancer or advanced adenoma,initial,2018-12-03,GCST007856,Cancer,#3288bd
2518,European,120184.0,30510241.0,Huyghe JR,Colorectal cancer or advanced adenoma,initial,2018-12-03,GCST007856,Cancer,#d53e4f
2519,Asian,5294.0,30510241.0,Huyghe JR,Colorectal cancer or advanced adenoma,initial,2018-12-03,GCST007856,Cancer,#3288bd
2520,European,48434.0,30510157.0,Franceschini N,Carotid plaque,initial,2018-12-03,GCST007435,Cardiovascular disease,#d53e4f
2521,European,71128.0,30510157.0,Franceschini N,Carotid intima media thickness,initial,2018-12-03,GCST007436,Cardiovascular measurement,#d53e4f
2522,Asian,1143.0,30511388.0,Yan W,Developmental dysplasia of the hip,replication,2018-12-03,GCST007699,Other disease,#3288bd
2523,Asian,886.0,30511388.0,Yan W,Developmental dysplasia of the hip,initial,2018-12-03,GCST007699,Other disease,#3288bd
2524,European,4367.0,30510082.0,Qian M,Acute lymphoblastic leukemia (B-cell precursor),replication,2018-12-03,GCST007276,Cancer,#d53e4f
2525,Hispanic/Latin American,1521.0,30510082.0,Qian M,Acute lymphoblastic leukemia (B-cell precursor),initial,2018-12-03,GCST007276,Cancer,#807dba
2526,Hispanic/Latin American,585.0,30510082.0,Qian M,Acute lymphoblastic leukemia (B-cell precursor),replication,2018-12-03,GCST007276,Cancer,#807dba
2527,African Am./Caribbean,1607.0,30510082.0,Qian M,Acute lymphoblastic leukemia (B-cell precursor),replication,2018-12-03,GCST007276,Cancer,#fee08b
2528,African Am./Caribbean,130.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,replication,2018-12-01,GCST007210,Neurological disorder,#fee08b
2529,African Am./Caribbean,267.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2018-12-01,GCST007210,Neurological disorder,#fee08b
2530,African Am./Caribbean,130.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,replication,2018-12-01,GCST007210,Biological process,#fee08b
2531,African Am./Caribbean,267.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2018-12-01,GCST007210,Biological process,#fee08b
2532,African Am./Caribbean,130.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,replication,2018-12-01,GCST007210,Biological process,#fee08b
2533,African Am./Caribbean,267.0,30578281.0,Williams LM,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2018-12-01,GCST007210,Biological process,#fee08b
2542,European,337536.0,30566020.0,Fukaya E,Varicose veins,initial,2018-12-01,GCST007225,Other trait,#d53e4f
2543,European,764012.0,30504769.0,Ferkingstad E,Gallstone disease,initial,2018-11-30,GCST007209,Digestive system disorder,#d53e4f
2544,Asian,2569.0,30498034.0,Terao C,Takayasu arteritis,initial,2018-11-29,GCST006984,Cardiovascular disease,#3288bd
2545,Asian,3989.0,30498034.0,Terao C,Takayasu arteritis,replication,2018-11-29,GCST006984,Cardiovascular disease,#3288bd
2546,Asian,1622.0,30500874.0,Kakuta Y,Crohn's disease,replication,2018-11-29,GCST007216,Digestive system disorder,#3288bd
2547,Asian,2796.0,30500874.0,Kakuta Y,Crohn's disease,initial,2018-11-29,GCST007216,Digestive system disorder,#3288bd
2548,European,105253.0,30487518.0,Takeuchi F,Systolic blood pressure,replication,2018-11-28,GCST007703,Other measurement,#d53e4f
2549,Asian,53008.0,30487518.0,Takeuchi F,Systolic blood pressure,replication,2018-11-28,GCST007703,Other measurement,#3288bd
2550,Asian,130777.0,30487518.0,Takeuchi F,Systolic blood pressure,initial,2018-11-28,GCST007703,Other measurement,#3288bd
2551,Asian,22472.0,30487518.0,Takeuchi F,Hypertension,replication,2018-11-28,GCST007707,Cardiovascular disease,#3288bd
2552,European,53008.0,30487518.0,Takeuchi F,Hypertension,replication,2018-11-28,GCST007707,Cardiovascular disease,#d53e4f
2553,Asian,50792.0,30487518.0,Takeuchi F,Hypertension,initial,2018-11-28,GCST007707,Cardiovascular disease,#3288bd
2554,European,53008.0,30487518.0,Takeuchi F,Mean arterial pressure,replication,2018-11-28,GCST007706,Other measurement,#d53e4f
2555,Asian,130777.0,30487518.0,Takeuchi F,Mean arterial pressure,initial,2018-11-28,GCST007706,Other measurement,#3288bd
2556,Asian,105253.0,30487518.0,Takeuchi F,Mean arterial pressure,replication,2018-11-28,GCST007706,Other measurement,#3288bd
2557,Asian,105253.0,30487518.0,Takeuchi F,Pulse pressure,replication,2018-11-28,GCST007705,Cardiovascular measurement,#3288bd
2558,European,53008.0,30487518.0,Takeuchi F,Pulse pressure,replication,2018-11-28,GCST007705,Cardiovascular measurement,#d53e4f
2559,Asian,130777.0,30487518.0,Takeuchi F,Pulse pressure,initial,2018-11-28,GCST007705,Cardiovascular measurement,#3288bd
2560,Asian,53008.0,30487518.0,Takeuchi F,Diastolic blood pressure,replication,2018-11-28,GCST007704,Other measurement,#3288bd
2561,European,105253.0,30487518.0,Takeuchi F,Diastolic blood pressure,replication,2018-11-28,GCST007704,Other measurement,#d53e4f
2562,Asian,130777.0,30487518.0,Takeuchi F,Diastolic blood pressure,initial,2018-11-28,GCST007704,Other measurement,#3288bd
2563,European,3094.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),initial,2018-11-28,GCST007292,Metabolic disorder,#d53e4f
2564,Asian,771.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),replication,2018-11-28,GCST007292,Metabolic disorder,#3288bd
2565,African Am./Caribbean,1852.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),initial,2018-11-28,GCST007292,Metabolic disorder,#fee08b
2566,European,15918.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),replication,2018-11-28,GCST007292,Metabolic disorder,#d53e4f
2567,Hispanic/Latin American,2710.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),replication,2018-11-28,GCST007292,Metabolic disorder,#807dba
2568,Asian,13703.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),replication,2018-11-28,GCST007292,Metabolic disorder,#3288bd
2569,Asian,984.0,30487263.0,Pollack S,Diabetic retinopathy (all NPDR and PDR),replication,2018-11-28,GCST007292,Metabolic disorder,#3288bd
2570,Asian,2484.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs no DR),replication,2018-11-28,GCST007291,Metabolic disorder,#3288bd
2571,Hispanic/Latin American,1280.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs no DR),replication,2018-11-28,GCST007291,Metabolic disorder,#807dba
2572,European,3731.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs no DR),replication,2018-11-28,GCST007291,Metabolic disorder,#d53e4f
2573,African Am./Caribbean,2038.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs no DR),initial,2018-11-28,GCST007291,Metabolic disorder,#fee08b
2574,European,2368.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs no DR),initial,2018-11-28,GCST007291,Metabolic disorder,#d53e4f
2575,Asian,8607.0,30487263.0,Pollack S,Diabetic retinopathy (moderate NPDR and PDR),replication,2018-11-28,GCST007290,Metabolic disorder,#3288bd
2576,Hispanic/Latin American,2254.0,30487263.0,Pollack S,Diabetic retinopathy (moderate NPDR and PDR),replication,2018-11-28,GCST007290,Metabolic disorder,#807dba
2577,African Am./Caribbean,1709.0,30487263.0,Pollack S,Diabetic retinopathy (moderate NPDR and PDR),initial,2018-11-28,GCST007290,Metabolic disorder,#fee08b
2578,European,2614.0,30487263.0,Pollack S,Diabetic retinopathy (moderate NPDR and PDR),initial,2018-11-28,GCST007290,Metabolic disorder,#d53e4f
2579,European,4677.0,30487263.0,Pollack S,Diabetic retinopathy (moderate NPDR and PDR),replication,2018-11-28,GCST007290,Metabolic disorder,#d53e4f
2580,Hispanic/Latin American,2426.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs NPDR and no DR),replication,2018-11-28,GCST007289,Metabolic disorder,#807dba
2581,Asian,2085.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs NPDR and no DR),replication,2018-11-28,GCST007289,Metabolic disorder,#3288bd
2582,European,8821.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs NPDR and no DR),replication,2018-11-28,GCST007289,Metabolic disorder,#d53e4f
2583,African Am./Caribbean,2611.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs NPDR and no DR),initial,2018-11-28,GCST007289,Metabolic disorder,#fee08b
2584,European,3246.0,30487263.0,Pollack S,Proliferative diabetic retinopathy (vs NPDR and no DR),initial,2018-11-28,GCST007289,Metabolic disorder,#d53e4f
2585,European,678.0,30488612.0,Xiang B,Alcohol and nicotine co-dependence,replication,2018-11-28,GCST007657,Neurological disorder,#d53e4f
2586,African Am./Caribbean,2094.0,30488612.0,Xiang B,Alcohol and nicotine co-dependence,initial,2018-11-28,GCST007657,Neurological disorder,#fee08b
2587,European,1207.0,30488612.0,Xiang B,Alcohol and nicotine co-dependence,initial,2018-11-28,GCST007657,Neurological disorder,#d53e4f
2589,European,136207.0,30478444.0,Demontis D,Attention deficit hyperactivity disorder,replication,2018-11-26,GCST007543,Neurological disorder,#d53e4f
2591,European,53293.0,30478444.0,Demontis D,Attention deficit hyperactivity disorder,initial,2018-11-26,GCST007543,Neurological disorder,#d53e4f
2592,Asian,1937.0,30478444.0,Demontis D,Attention deficit hyperactivity disorder,initial,2018-11-26,GCST007543,Neurological disorder,#3288bd
2593,European,8232.0,30475886.0,Mekli K,Frailty index,initial,2018-11-26,GCST007716,Other measurement,#d53e4f
2594,European,5248.0,30475886.0,Mekli K,Frailty index,replication,2018-11-26,GCST007716,Other measurement,#d53e4f
2595,European,3226.0,30468137.0,Fabbri C,Treatment resistant depression,initial,2018-11-23,GCST007665,Neurological disorder,#d53e4f
2596,European,3226.0,30468137.0,Fabbri C,Treatment resistant depression,initial,2018-11-23,GCST007665,Response to drug,#d53e4f
2597,European,1429.0,30470734.0,Hackinger S,Schizophrenia vs schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007222,Neurological disorder,#d53e4f
2598,European,1429.0,30470734.0,Hackinger S,Schizophrenia vs schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007222,Metabolic disorder,#d53e4f
2599,European,1630.0,30470734.0,Hackinger S,Schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007220,Neurological disorder,#d53e4f
2600,European,1630.0,30470734.0,Hackinger S,Schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007220,Metabolic disorder,#d53e4f
2601,European,2312.0,30468137.0,Fabbri C,Depressive symptom improvement,initial,2018-11-23,GCST007666,Other measurement,#d53e4f
2602,European,2312.0,30468137.0,Fabbri C,Depressive symptom improvement,initial,2018-11-23,GCST007666,Response to drug,#d53e4f
2603,European,1327.0,30470734.0,Hackinger S,Type 2 diabetes vs schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007224,Neurological disorder,#d53e4f
2604,European,1327.0,30470734.0,Hackinger S,Type 2 diabetes vs schizophrenia and type 2 diabetes,initial,2018-11-23,GCST007224,Metabolic disorder,#d53e4f
2605,European,2312.0,30468137.0,Fabbri C,Treatment resistant depression,initial,2018-11-23,GCST007667,Neurological disorder,#d53e4f
2606,European,2312.0,30468137.0,Fabbri C,Treatment resistant depression,initial,2018-11-23,GCST007667,Response to drug,#d53e4f
2607,European,1746.0,30470734.0,Hackinger S,Schizophrenia vs type 2 diabetes,initial,2018-11-23,GCST007223,Neurological disorder,#d53e4f
2608,European,1746.0,30470734.0,Hackinger S,Schizophrenia vs type 2 diabetes,initial,2018-11-23,GCST007223,Metabolic disorder,#d53e4f
2609,European,1947.0,30470734.0,Hackinger S,Type 2 diabetes,initial,2018-11-23,GCST007221,Metabolic disorder,#d53e4f
2610,European,2049.0,30470734.0,Hackinger S,Schizophrenia,initial,2018-11-23,GCST007219,Neurological disorder,#d53e4f
2611,African,371.0,30467376.0,Wilker S,Post-traumatic stress disorder,replication,2018-11-22,GCST007651,Neurological disorder,#fc8d59
2612,African,924.0,30467376.0,Wilker S,Post-traumatic stress disorder,initial,2018-11-22,GCST007651,Neurological disorder,#fc8d59
2613,European,9870.0,30456828.0,Khramtsova EA,Obsessive-compulsive disorder,initial,2018-11-20,GCST007208,Neurological disorder,#d53e4f
2614,African Am./Caribbean,4500.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#fee08b
2615,European,42379.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#d53e4f
2616,Hispanic/Latin American,1440.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#807dba
2617,Asian,773.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#3288bd
2618,African Am./Caribbean,4500.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#fee08b
2619,European,42379.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#d53e4f
2620,Hispanic/Latin American,1440.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#807dba
2621,Asian,773.0,30586737.0,Sabater-Lleal M,vWF and FVIII levels,initial,2018-11-20,GCST007447,Hematological measurement,#3288bd
2622,European,42379.0,30586737.0,Sabater-Lleal M,vWF levels,initial,2018-11-20,GCST007446,Hematological measurement,#d53e4f
2623,Hispanic/Latin American,275.0,30586737.0,Sabater-Lleal M,vWF levels,initial,2018-11-20,GCST007446,Hematological measurement,#807dba
2624,African Am./Caribbean,3700.0,30586737.0,Sabater-Lleal M,vWF levels,initial,2018-11-20,GCST007446,Hematological measurement,#fee08b
2625,European,9870.0,30456828.0,Khramtsova EA,Obsessive-compulsive disorder x sex interaction,initial,2018-11-20,GCST007207,Neurological disorder,#d53e4f
2626,European,9870.0,30456828.0,Khramtsova EA,Obsessive-compulsive disorder x sex interaction,initial,2018-11-20,GCST007207,Other measurement,#d53e4f
2627,African Am./Caribbean,4500.0,30586737.0,Sabater-Lleal M,Factor VIII levels,initial,2018-11-20,GCST007445,Hematological measurement,#fee08b
2628,European,25897.0,30586737.0,Sabater-Lleal M,Factor VIII levels,initial,2018-11-20,GCST007445,Hematological measurement,#d53e4f
2629,Hispanic/Latin American,1440.0,30586737.0,Sabater-Lleal M,Factor VIII levels,initial,2018-11-20,GCST007445,Hematological measurement,#807dba
2630,Asian,773.0,30586737.0,Sabater-Lleal M,Factor VIII levels,initial,2018-11-20,GCST007445,Hematological measurement,#3288bd
2631,African,3073.0,30452639.0,Butali A,Cleft lip with or without cleft palate,initial,2018-11-19,GCST007510,Other trait,#fc8d59
2632,African,1049.0,30452639.0,Butali A,Cleft lip with or without cleft palate,replication,2018-11-19,GCST007510,Other trait,#fc8d59
2633,African Am./Caribbean,307.0,30452639.0,Butali A,Cleft lip with or without cleft palate,replication,2018-11-19,GCST007510,Other trait,#fee08b
2634,European,534.0,30453346.0,Tunjungputri RN,Platelet count and reactivity phenotypes,initial,2018-11-19,GCST007652,Cardiovascular measurement,#d53e4f
2635,European,534.0,30453346.0,Tunjungputri RN,Platelet count and reactivity phenotypes,initial,2018-11-19,GCST007652,Hematological measurement,#d53e4f
2636,African,2364.0,30452639.0,Butali A,Cleft palate,initial,2018-11-19,GCST007509,Other trait,#fc8d59
2637,African,748.0,30452639.0,Butali A,Cleft palate,replication,2018-11-19,GCST007509,Other trait,#fc8d59
2638,African Am./Caribbean,265.0,30452639.0,Butali A,Cleft palate,replication,2018-11-19,GCST007509,Other trait,#fee08b
2639,European,831.0,30450575.0,Hojfeldt SG,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia,initial,2018-11-18,GCST007540,Response to drug,#d53e4f
2640,European,831.0,30450575.0,Hojfeldt SG,PEG-asparaginase hypersensitivity without enzyme activity in childhood acute lymphoblastic leukaemia,initial,2018-11-18,GCST007540,Cancer,#d53e4f
2641,European,878.0,30450575.0,Hojfeldt SG,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more),initial,2018-11-18,GCST007541,Response to drug,#d53e4f
2642,European,878.0,30450575.0,Hojfeldt SG,PEG-asparaginase hypersensitivity in childhood acute lymphoblastic leukaemia (allergic reaction grade 2 or more),initial,2018-11-18,GCST007541,Cancer,#d53e4f
2643,European,803.0,30450575.0,Hojfeldt SG,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia,initial,2018-11-18,GCST007539,Other measurement,#d53e4f
2644,European,803.0,30450575.0,Hojfeldt SG,Silent asparaginase inactivation in childhood acute lymphoblastic leukaemia,initial,2018-11-18,GCST007539,Cancer,#d53e4f
2645,European,1453.0,30453627.0,Marklund M,Fatty acid desaturase activity (serum),initial,2018-11-17,GCST007635,Other measurement,#d53e4f
2646,European,783.0,30453627.0,Marklund M,Fatty acid desaturase activity (adipose tissue),initial,2018-11-17,GCST007636,Other measurement,#d53e4f
2647,Asian,278.0,30498476.0,Liu H,Total cholesterol levels,initial,2018-11-15,GCST007203,Lipid or lipoprotein measurement,#3288bd
2648,Asian,278.0,30498476.0,Liu H,Low density lipoprotein cholesterol levels,initial,2018-11-15,GCST007204,Lipid or lipoprotein measurement,#3288bd
2649,Asian,278.0,30498476.0,Liu H,High density lipoprotein cholesterol levels,initial,2018-11-15,GCST007202,Lipid or lipoprotein measurement,#3288bd
2650,European,88583.0,30429480.0,Duffy DL,Nevus count or cutaneous melanoma,initial,2018-11-14,GCST007505,Other measurement,#d53e4f
2651,European,88583.0,30429480.0,Duffy DL,Nevus count or cutaneous melanoma,initial,2018-11-14,GCST007505,Cancer,#d53e4f
2652,European,52506.0,30429480.0,Duffy DL,Nevus count,initial,2018-11-14,GCST007504,Other measurement,#d53e4f
2654,Other/Mixed,4.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#99d594
2655,European,144750.0,30431558.0,Smith SB,Temporomandibular joint disorder,replication,2018-11-13,GCST007619,Other disease,#d53e4f
2656,European,1859.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#d53e4f
2657,Hispanic/Latin American,159.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#807dba
2658,Hispanic/Latin American,11975.0,30431558.0,Smith SB,Temporomandibular joint disorder,replication,2018-11-13,GCST007619,Other disease,#807dba
2659,Other/Mixed,8.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#99d594
2660,African Am./Caribbean,701.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#fee08b
2662,Asian,223.0,30431558.0,Smith SB,Temporomandibular joint disorder,initial,2018-11-13,GCST007619,Other disease,#3288bd
2663,European,22708.0,30699873.0,van der Merwe C,Post-traumatic stress disorder or brain volume (pleiotropy),initial,2018-11-13,GCST007776,Neurological disorder,#d53e4f
2664,European,22708.0,30699873.0,van der Merwe C,Post-traumatic stress disorder or brain volume (pleiotropy),initial,2018-11-13,GCST007776,Other measurement,#d53e4f
2665,European,34932.0,30699873.0,van der Merwe C,Anxiety disorder or brain volume (pleiotropy),initial,2018-11-13,GCST007775,Neurological disorder,#d53e4f
2666,European,34932.0,30699873.0,van der Merwe C,Anxiety disorder or brain volume (pleiotropy),initial,2018-11-13,GCST007775,Other measurement,#d53e4f
2667,European,80888.0,30423114.0,Laufer VA,Rheumatoid arthritis,replication,2018-11-13,GCST006959,Immune system disorder,#d53e4f
2668,Asian,22514.0,30423114.0,Laufer VA,Rheumatoid arthritis,replication,2018-11-13,GCST006959,Immune system disorder,#3288bd
2669,African Am./Caribbean,2308.0,30423114.0,Laufer VA,Rheumatoid arthritis,initial,2018-11-13,GCST006959,Immune system disorder,#fee08b
2670,European,12819.0,30586722.0,Aragam KG,Heart failure,replication,2018-11-11,GCST007715,Cardiovascular disease,#d53e4f
2671,European,394156.0,30586722.0,Aragam KG,Heart failure,initial,2018-11-11,GCST007715,Cardiovascular disease,#d53e4f
2672,European,17195.0,30586722.0,Aragam KG,Nonischemic cardiomyopathy,replication,2018-11-11,GCST007714,Cardiovascular disease,#d53e4f
2673,European,390142.0,30586722.0,Aragam KG,Nonischemic cardiomyopathy,initial,2018-11-11,GCST007714,Cardiovascular disease,#d53e4f
2674,Asian,4756.0,30412241.0,Takeuchi F,Cervical cancer,replication,2018-11-09,GCST007119,Cancer,#3288bd
2675,Asian,7321.0,30412241.0,Takeuchi F,Cervical cancer,initial,2018-11-09,GCST007119,Cancer,#3288bd
2676,European,6507.0,28540843.0,Mbarek H,Major depressive disorder,initial,2017-05-25,GCST004486,Neurological disorder,#d53e4f
2677,European,287323.0,28537254.0,Tsoi LC,Psoriasis,initial,2017-05-24,GCST004346,Immune system disorder,#d53e4f
2678,European,18478.0,28537254.0,Tsoi LC,Psoriasis,replication,2017-05-24,GCST004346,Immune system disorder,#d53e4f
2679,Asian,1.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Other trait,#3288bd
2680,European,337.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Other trait,#d53e4f
2681,African Am./Caribbean,30.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Other trait,#fee08b
2682,Hispanic/Latin American,4.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Other trait,#807dba
2683,European,152.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Other trait,#d53e4f
2684,African Am./Caribbean,23.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Other trait,#fee08b
2685,Asian,3.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Other trait,#3288bd
2688,Asian,1.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Response to drug,#3288bd
2689,European,337.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Response to drug,#d53e4f
2690,African Am./Caribbean,30.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Response to drug,#fee08b
2691,Hispanic/Latin American,4.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,initial,2017-05-24,GCST004353,Response to drug,#807dba
2692,European,152.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Response to drug,#d53e4f
2693,African Am./Caribbean,23.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Response to drug,#fee08b
2694,Asian,3.0,28542097.0,Wells QS,Left ventricular function change in anthracycline treatment,replication,2017-05-24,GCST004353,Response to drug,#3288bd
2697,European,204641.0,28537267.0,Sapkota Y,Endometriosis,initial,2017-05-24,GCST004549,Other disease,#d53e4f
2698,Asian,4262.0,28537267.0,Sapkota Y,Endometriosis,initial,2017-05-24,GCST004549,Other disease,#3288bd
2699,European,4664.0,28533516.0,Cantor RM,Restricted and repetitive behaviours in autism spectrum disorder,initial,2017-05-23,GCST004377,Neurological disorder,#d53e4f
2700,European,4664.0,28533516.0,Cantor RM,Restricted and repetitive behaviours in autism spectrum disorder,initial,2017-05-23,GCST004377,Other measurement,#d53e4f
2701,European,13574.0,28540026.0,Anney RJL,Autism spectrum disorder or schizophrenia,initial,2017-05-22,GCST004521,Neurological disorder,#d53e4f
2703,European,13574.0,28540026.0,Anney RJL,Autism spectrum disorder or schizophrenia,initial,2017-05-22,GCST004521,Neurological disorder,#d53e4f
2705,European,78308.0,28530673.0,Sniekers S,Intelligence,initial,2017-05-22,GCST004364,Biological process,#d53e4f
2706,European,155828.0,28540026.0,Anney RJL,Autism spectrum disorder,replication,2017-05-22,GCST004520,Neurological disorder,#d53e4f
2709,European,13574.0,28540026.0,Anney RJL,Autism spectrum disorder,initial,2017-05-22,GCST004520,Neurological disorder,#d53e4f
2710,European,3967.0,28525603.0,Ortega-Alonso A,Psychosis proneness (hypomanic personality scale),initial,2017-05-19,GCST004678,Other measurement,#d53e4f
2711,European,3820.0,28525603.0,Ortega-Alonso A,Psychosis proneness (revised physical anhedonia scale and revised social anhedonia scale),initial,2017-05-19,GCST004684,Other measurement,#d53e4f
2712,European,3868.0,28525603.0,Ortega-Alonso A,Psychosis proneness (perceptual aberration scale and revised social anhedonia scale),initial,2017-05-19,GCST004683,Other measurement,#d53e4f
2713,European,3812.0,28525603.0,Ortega-Alonso A,Psychosis proneness (perceptual aberration scale and revised physical anhedonia scale),initial,2017-05-19,GCST004688,Other measurement,#d53e4f
2714,European,3837.0,28525603.0,Ortega-Alonso A,Psychosis proneness (hypomanic personality scale and revised social anhedonia scale),initial,2017-05-19,GCST004682,Other measurement,#d53e4f
2715,European,3787.0,28525603.0,Ortega-Alonso A,Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale),initial,2017-05-19,GCST004681,Other measurement,#d53e4f
2716,European,4191.0,28525603.0,Ortega-Alonso A,Psychosis proneness (schizoidia scale),initial,2017-05-19,GCST004687,Other measurement,#d53e4f
2717,European,3824.0,28525603.0,Ortega-Alonso A,Psychosis proneness (hypomanic personality scale and perceptual aberration scale),initial,2017-05-19,GCST004679,Other measurement,#d53e4f
2718,European,4025.0,28525603.0,Ortega-Alonso A,Psychosis proneness (revised social anhedonia scale),initial,2017-05-19,GCST004686,Other measurement,#d53e4f
2719,European,3988.0,28525603.0,Ortega-Alonso A,Psychosis proneness (revised physical anhedonia scale),initial,2017-05-19,GCST004680,Other measurement,#d53e4f
2720,European,4057.0,28525603.0,Ortega-Alonso A,Psychosis proneness (perceptual aberration scale),initial,2017-05-19,GCST004685,Other measurement,#d53e4f
2721,European,2434.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004526,Other measurement,#d53e4f
2722,African Am./Caribbean,2470.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004526,Other measurement,#fee08b
2723,Hispanic/Latin American,2065.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004526,Other measurement,#807dba
2724,Asian,702.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004526,Other measurement,#3288bd
2725,European,3013.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar percentage of high attenuation areas on CT scan),replication,2017-05-18,GCST004526,Other measurement,#d53e4f
2726,African Am./Caribbean,2856.0,28545128.0,McDaniel LD,Sporadic neuroblastoma,replication,2017-05-18,GCST004510,Cancer,#fee08b
2727,European,6303.0,28545128.0,McDaniel LD,Sporadic neuroblastoma,initial,2017-05-18,GCST004510,Cancer,#d53e4f
2729,European,1210.0,28545128.0,McDaniel LD,Sporadic neuroblastoma,replication,2017-05-18,GCST004510,Cancer,#d53e4f
2730,Asian,702.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004527,Other measurement,#3288bd
2731,European,2434.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004527,Other measurement,#d53e4f
2732,African Am./Caribbean,2470.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004527,Other measurement,#fee08b
2733,Hispanic/Latin American,2065.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan),initial,2017-05-18,GCST004527,Other measurement,#807dba
2734,European,3013.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (percentage of high attenuation areas on CT scan),replication,2017-05-18,GCST004527,Other measurement,#d53e4f
2735,European,2434.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),initial,2017-05-18,GCST004525,Other measurement,#d53e4f
2736,African Am./Caribbean,2470.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),initial,2017-05-18,GCST004525,Other measurement,#fee08b
2737,Hispanic/Latin American,2065.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),initial,2017-05-18,GCST004525,Other measurement,#807dba
2738,Asian,702.0,28521775.0,Manichaikul A,Subclinical trait of interstitial lung disease (basilar peel-core ratio of high attentuation areas on CT scan),initial,2017-05-18,GCST004525,Other measurement,#3288bd
2739,Hispanic/Latin American,2564.0,28520984.0,Saccone NL,Smoking status (daily vs non-daily),initial,2017-05-17,GCST004511,Other measurement,#807dba
2740,African Am./Caribbean,1264.0,28520984.0,Saccone NL,Smoking status (daily vs non-daily),replication,2017-05-17,GCST004511,Other measurement,#fee08b
2741,Hispanic/Latin American,428.0,28520984.0,Saccone NL,Smoking status (daily vs non-daily),replication,2017-05-17,GCST004511,Other measurement,#807dba
2742,European,1548.0,28520984.0,Saccone NL,Smoking status (daily vs non-daily),replication,2017-05-17,GCST004511,Other measurement,#d53e4f
2743,Hispanic/Latin American,12735.0,28520984.0,Saccone NL,Smoking status (ever vs never smokers),initial,2017-05-17,GCST004514,Other measurement,#807dba
2744,Hispanic/Latin American,5119.0,28520984.0,Saccone NL,Smoking status (current vs former),initial,2017-05-17,GCST004513,Other measurement,#807dba
2745,Hispanic/Latin American,5085.0,28520984.0,Saccone NL,Smoking status (heavy vs light),initial,2017-05-17,GCST004512,Other measurement,#807dba
2746,European,13781.0,28512139.0,Mack S,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms,initial,2017-05-16,GCST004399,Lipid or lipoprotein measurement,#d53e4f
2747,European,13781.0,28512139.0,Mack S,Lipoprotein(a) levels adjusted for apolipoprotein(a) isoforms,initial,2017-05-16,GCST004399,Lipid or lipoprotein measurement,#d53e4f
2748,Asian,711.0,28512992.0,Joo YB,Bone erosion in rheumatoid arthritis,initial,2017-05-16,GCST004400,Other measurement,#3288bd
2749,European,13781.0,28512139.0,Mack S,Lipoprotein (a) levels,initial,2017-05-16,GCST004398,Lipid or lipoprotein measurement,#d53e4f
2750,Hispanic/Latin American,12375.0,28334935.0,Raffield LM,Iron status biomarkers (ferritin levels),initial,2017-05-15,GCST004573,Other measurement,#807dba
2751,European,843.0,28641921.0,Li J,Cerebrospinal fluid t-tau:AB1-42 ratio,initial,2017-05-15,GCST004490,Other measurement,#d53e4f
2752,European,843.0,28641921.0,Li J,Cerebrospinal fluid AB1-42 levels,initial,2017-05-15,GCST004492,Other measurement,#d53e4f
2753,Hispanic/Latin American,12589.0,28334935.0,Raffield LM,Iron status biomarkers (transferrin saturation),initial,2017-05-15,GCST004572,Other measurement,#807dba
2754,European,843.0,28641921.0,Li J,Cerebrospinal fluid t-tau levels,initial,2017-05-15,GCST004491,Other measurement,#d53e4f
2755,Hispanic/Latin American,12586.0,28334935.0,Raffield LM,Iron status biomarkers (total iron binding capacity),initial,2017-05-15,GCST004571,Other measurement,#807dba
2756,Hispanic/Latin American,12580.0,28334935.0,Raffield LM,Iron status biomarkers (iron levels),initial,2017-05-15,GCST004570,Other measurement,#807dba
2761,African,31155.0,28498854.0,Liang J,Systolic blood pressure,initial,2017-05-12,GCST004385,Other measurement,#fc8d59
2762,African,4187.0,28498854.0,Liang J,Systolic blood pressure,replication,2017-05-12,GCST004385,Other measurement,#fc8d59
2763,Asian,14016.0,28498854.0,Liang J,Systolic blood pressure,replication,2017-05-12,GCST004385,Other measurement,#3288bd
2764,European,23914.0,28498854.0,Liang J,Systolic blood pressure,replication,2017-05-12,GCST004385,Other measurement,#d53e4f
2765,Hispanic/Latin American,12278.0,28498854.0,Liang J,Systolic blood pressure,replication,2017-05-12,GCST004385,Other measurement,#807dba
2766,European,237.0,28500057.0,Bluett J,Methotrexate-induced interstitial lung disease in rheumatoid arthritis,initial,2017-05-12,GCST004358,Response to drug,#d53e4f
2767,European,237.0,28500057.0,Bluett J,Methotrexate-induced interstitial lung disease in rheumatoid arthritis,initial,2017-05-12,GCST004358,Immune system disorder,#d53e4f
2768,European,237.0,28500057.0,Bluett J,Methotrexate-induced interstitial lung disease in rheumatoid arthritis,initial,2017-05-12,GCST004358,Other disease,#d53e4f
2769,African,31155.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),initial,2017-05-12,GCST004388,Cardiovascular measurement,#fc8d59
2770,African,4187.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular measurement,#fc8d59
2771,Asian,14016.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular measurement,#3288bd
2772,European,23914.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular measurement,#d53e4f
2773,Hispanic/Latin American,12278.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular measurement,#807dba
2774,African,31155.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),initial,2017-05-12,GCST004388,Other measurement,#fc8d59
2775,African,4187.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#fc8d59
2776,Asian,14016.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#3288bd
2777,European,23914.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#d53e4f
2778,Hispanic/Latin American,12278.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#807dba
2779,African,31155.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),initial,2017-05-12,GCST004388,Other measurement,#fc8d59
2780,African,4187.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#fc8d59
2781,Asian,14016.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#3288bd
2782,European,23914.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#d53e4f
2783,Hispanic/Latin American,12278.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Other measurement,#807dba
2784,African,31155.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),initial,2017-05-12,GCST004388,Cardiovascular disease,#fc8d59
2785,African,4187.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular disease,#fc8d59
2786,Asian,14016.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular disease,#3288bd
2787,European,23914.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular disease,#d53e4f
2788,Hispanic/Latin American,12278.0,28498854.0,Liang J,Blood pressure traits (multi-trait analysis),replication,2017-05-12,GCST004388,Cardiovascular disease,#807dba
2789,African,2375.0,28498854.0,Liang J,Hypertension,replication,2017-05-12,GCST004384,Cardiovascular disease,#fc8d59
2790,African,18440.0,28498854.0,Liang J,Hypertension,initial,2017-05-12,GCST004384,Cardiovascular disease,#fc8d59
2791,European,9348.0,28498854.0,Liang J,Hypertension,replication,2017-05-12,GCST004384,Cardiovascular disease,#d53e4f
2792,Asian,3718.0,28498854.0,Liang J,Hypertension,replication,2017-05-12,GCST004384,Cardiovascular disease,#3288bd
2793,Hispanic/Latin American,3445.0,28498854.0,Liang J,Hypertension,replication,2017-05-12,GCST004384,Cardiovascular disease,#807dba
2794,European,23914.0,28498854.0,Liang J,Pulse pressure,replication,2017-05-12,GCST004387,Cardiovascular measurement,#d53e4f
2795,Asian,14016.0,28498854.0,Liang J,Pulse pressure,replication,2017-05-12,GCST004387,Cardiovascular measurement,#3288bd
2796,African,4187.0,28498854.0,Liang J,Pulse pressure,replication,2017-05-12,GCST004387,Cardiovascular measurement,#fc8d59
2797,African,31155.0,28498854.0,Liang J,Pulse pressure,initial,2017-05-12,GCST004387,Cardiovascular measurement,#fc8d59
2798,Hispanic/Latin American,12278.0,28498854.0,Liang J,Pulse pressure,replication,2017-05-12,GCST004387,Cardiovascular measurement,#807dba
2799,Hispanic/Latin American,12278.0,28498854.0,Liang J,Diastolic blood pressure,replication,2017-05-12,GCST004386,Other measurement,#807dba
2800,European,23914.0,28498854.0,Liang J,Diastolic blood pressure,replication,2017-05-12,GCST004386,Other measurement,#d53e4f
2801,African,4187.0,28498854.0,Liang J,Diastolic blood pressure,replication,2017-05-12,GCST004386,Other measurement,#fc8d59
2802,African,31155.0,28498854.0,Liang J,Diastolic blood pressure,initial,2017-05-12,GCST004386,Other measurement,#fc8d59
2803,Asian,14016.0,28498854.0,Liang J,Diastolic blood pressure,replication,2017-05-12,GCST004386,Other measurement,#3288bd
2804,European,14477.0,28494655.0,Duncan L,Anorexia nervosa,initial,2017-05-12,GCST004367,Metabolic disorder,#d53e4f
2805,Asian,319.0,28492228.0,Parks T,Rheumatic heart disease,initial,2017-05-11,GCST004366,Cardiovascular disease,#3288bd
2806,Other/Mixed,307.0,28492228.0,Parks T,Rheumatic heart disease,initial,2017-05-11,GCST004366,Cardiovascular disease,#99d594
2807,Other/Mixed,2229.0,28492228.0,Parks T,Rheumatic heart disease,initial,2017-05-11,GCST004366,Cardiovascular disease,#99d594
2809,Hispanic/Latin American,2337.0,28490609.0,Wood AR,Peak insulin response,initial,2017-05-10,GCST004487,Other measurement,#807dba
2810,European,2159.0,28490609.0,Wood AR,Peak insulin response,initial,2017-05-10,GCST004487,Other measurement,#d53e4f
2811,Other/Mixed,332.0,28490609.0,Wood AR,Peak insulin response,initial,2017-05-10,GCST004487,Other measurement,#99d594
2812,European,739.0,28490609.0,Wood AR,Peak insulin response,replication,2017-05-10,GCST004487,Other measurement,#d53e4f
2813,European,527.0,28490609.0,Wood AR,insulin secretion rate (BMI adjusted),initial,2017-05-10,GCST006679,Other measurement,#d53e4f
2814,European,2087.0,28490609.0,Wood AR,Acute insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006677,Other measurement,#d53e4f
2815,Hispanic/Latin American,2346.0,28490609.0,Wood AR,Acute insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006677,Other measurement,#807dba
2816,Other/Mixed,332.0,28490609.0,Wood AR,Acute insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006677,Other measurement,#99d594
2817,European,741.0,28490609.0,Wood AR,Acute insulin response (insulin secretion adjusted),replication,2017-05-10,GCST006677,Other measurement,#d53e4f
2818,European,2087.0,28490609.0,Wood AR,Acute insulin response (insulin secretion and BMI adjusted),initial,2017-05-10,GCST006678,Other measurement,#d53e4f
2819,Hispanic/Latin American,2346.0,28490609.0,Wood AR,Acute insulin response (insulin secretion and BMI adjusted),initial,2017-05-10,GCST006678,Other measurement,#807dba
2820,Other/Mixed,332.0,28490609.0,Wood AR,Acute insulin response (insulin secretion and BMI adjusted),initial,2017-05-10,GCST006678,Other measurement,#99d594
2821,European,741.0,28490609.0,Wood AR,Acute insulin response (insulin secretion and BMI adjusted),replication,2017-05-10,GCST006678,Other measurement,#d53e4f
2822,Hispanic/Latin American,2337.0,28490609.0,Wood AR,Peak insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006676,Other measurement,#807dba
2823,European,2159.0,28490609.0,Wood AR,Peak insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006676,Other measurement,#d53e4f
2824,Other/Mixed,332.0,28490609.0,Wood AR,Peak insulin response (insulin secretion adjusted),initial,2017-05-10,GCST006676,Other measurement,#99d594
2825,European,739.0,28490609.0,Wood AR,Peak insulin response (insulin secretion adjusted),replication,2017-05-10,GCST006676,Other measurement,#d53e4f
2826,European,739.0,28490609.0,Wood AR,Peak insulin response (BMI and insulin secretion adjusted),replication,2017-05-10,GCST006675,Other measurement,#d53e4f
2827,Other/Mixed,332.0,28490609.0,Wood AR,Peak insulin response (BMI and insulin secretion adjusted),initial,2017-05-10,GCST006675,Other measurement,#99d594
2828,European,2159.0,28490609.0,Wood AR,Peak insulin response (BMI and insulin secretion adjusted),initial,2017-05-10,GCST006675,Other measurement,#d53e4f
2829,Hispanic/Latin American,2337.0,28490609.0,Wood AR,Peak insulin response (BMI and insulin secretion adjusted),initial,2017-05-10,GCST006675,Other measurement,#807dba
2830,European,741.0,28490609.0,Wood AR,Insulin disposition index (BMI adjusted),replication,2017-05-10,GCST006681,Other measurement,#d53e4f
2831,European,2042.0,28490609.0,Wood AR,Insulin disposition index (BMI adjusted),initial,2017-05-10,GCST006681,Other measurement,#d53e4f
2832,Hispanic/Latin American,2345.0,28490609.0,Wood AR,Insulin disposition index (BMI adjusted),initial,2017-05-10,GCST006681,Other measurement,#807dba
2833,Other/Mixed,332.0,28490609.0,Wood AR,Insulin disposition index (BMI adjusted),initial,2017-05-10,GCST006681,Other measurement,#99d594
2834,European,741.0,28490609.0,Wood AR,Insulin disposition index,replication,2017-05-10,GCST004489,Other measurement,#d53e4f
2835,Other/Mixed,332.0,28490609.0,Wood AR,Insulin disposition index,initial,2017-05-10,GCST004489,Other measurement,#99d594
2836,European,2042.0,28490609.0,Wood AR,Insulin disposition index,initial,2017-05-10,GCST004489,Other measurement,#d53e4f
2837,Hispanic/Latin American,2345.0,28490609.0,Wood AR,Insulin disposition index,initial,2017-05-10,GCST004489,Other measurement,#807dba
2838,European,527.0,28490609.0,Wood AR,Insulin secretion rate,initial,2017-05-10,GCST004488,Other measurement,#d53e4f
2839,Other/Mixed,332.0,28490609.0,Wood AR,Acute insulin response,initial,2017-05-10,GCST004575,Other measurement,#99d594
2840,Hispanic/Latin American,2346.0,28490609.0,Wood AR,Acute insulin response,initial,2017-05-10,GCST004575,Other measurement,#807dba
2841,European,2087.0,28490609.0,Wood AR,Acute insulin response,initial,2017-05-10,GCST004575,Other measurement,#d53e4f
2842,European,741.0,28490609.0,Wood AR,Acute insulin response,replication,2017-05-10,GCST004575,Other measurement,#d53e4f
2843,European,71071.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Other measurement,#d53e4f
2844,Hispanic/Latin American,7047.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Other measurement,#807dba
2845,Asian,6034.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Other measurement,#3288bd
2846,African Am./Caribbean,2475.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Other measurement,#fee08b
2847,European,71071.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Biological process,#d53e4f
2848,Hispanic/Latin American,7047.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Biological process,#807dba
2849,Asian,6034.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Biological process,#3288bd
2850,African Am./Caribbean,2475.0,28485404.0,Jorgenson E,Alcohol consumption (drinks per week),initial,2017-05-09,GCST004405,Biological process,#fee08b
2851,European,71071.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Other measurement,#d53e4f
2852,Hispanic/Latin American,7047.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Other measurement,#807dba
2853,Asian,6034.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Other measurement,#3288bd
2854,African Am./Caribbean,2475.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Other measurement,#fee08b
2855,European,71071.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Biological process,#d53e4f
2856,Hispanic/Latin American,7047.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Biological process,#807dba
2857,Asian,6034.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Biological process,#3288bd
2858,African Am./Caribbean,2475.0,28485404.0,Jorgenson E,Alcohol consumption (drinkers vs non-drinkers),initial,2017-05-09,GCST004404,Biological process,#fee08b
2859,Other/Mixed,419.0,28476931.0,Piaggi P,Energy expenditure (24h),initial,2017-05-05,GCST004524,Other measurement,#99d594
2860,Other/Mixed,509.0,28476931.0,Piaggi P,Resting metabolic rate,initial,2017-05-05,GCST004523,Other measurement,#99d594
2861,European,16627.0,28472463.0,Mullin BH,Bone ultrasound measurement (velocity of sound),initial,2017-05-04,GCST004350,Other measurement,#d53e4f
2862,European,16627.0,28472463.0,Mullin BH,Bone ultrasound measurement (broadband ultrasound attenuation),initial,2017-05-04,GCST004351,Other measurement,#d53e4f
2863,Asian,1283.0,28471803.0,Choe EK,Elevated serum prostate-specific antigen levels in healthy men,replication,2017-05-03,GCST004345,Other measurement,#3288bd
2864,Asian,2841.0,28471803.0,Choe EK,Elevated serum prostate-specific antigen levels in healthy men,initial,2017-05-03,GCST004345,Other measurement,#3288bd
2865,European,820.0,28470677.0,Tang H,Survival in pancreatic cancer,replication,2017-05-03,GCST004485,Other measurement,#d53e4f
2866,European,868.0,28470677.0,Tang H,Survival in pancreatic cancer,initial,2017-05-03,GCST004485,Other measurement,#d53e4f
2867,European,820.0,28470677.0,Tang H,Survival in pancreatic cancer,replication,2017-05-03,GCST004485,Cancer,#d53e4f
2868,European,868.0,28470677.0,Tang H,Survival in pancreatic cancer,initial,2017-05-03,GCST004485,Cancer,#d53e4f
2869,Hispanic/Latin American,5037.0,28461288.0,Yan Q,Asthma,initial,2017-05-01,GCST004390,Other disease,#807dba
2870,European,24063.0,28452372.0,Gorski M,Glomerular filtration rate (cystatin C),initial,2017-04-28,GCST004293,Other measurement,#d53e4f
2871,European,24063.0,28452372.0,Gorski M,Glomerular filtration rate (cystatin C),initial,2017-04-28,GCST004293,Other measurement,#d53e4f
2872,European,84.0,28453389.0,Koga A,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction),initial,2017-04-28,GCST004374,Other measurement,#d53e4f
2873,European,84.0,28453389.0,Koga A,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction),initial,2017-04-28,GCST004374,Neurological disorder,#d53e4f
2874,European,84.0,28453389.0,Koga A,Resistance to antipsychotic treatment in schizophrenia (childhood trauma interaction),initial,2017-04-28,GCST004374,Response to drug,#d53e4f
2875,Hispanic/Latin American,4772.0,28453575.0,Hodonsky CJ,Mean corpuscular volume,replication,2017-04-28,GCST004335,Hematological measurement,#807dba
2876,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Mean corpuscular volume,initial,2017-04-28,GCST004335,Hematological measurement,#807dba
2877,Hispanic/Latin American,4772.0,28453575.0,Hodonsky CJ,Mean corpuscular hemoglobin,replication,2017-04-28,GCST004334,Hematological measurement,#807dba
2878,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Mean corpuscular hemoglobin,initial,2017-04-28,GCST004334,Hematological measurement,#807dba
2879,European,84.0,28453389.0,Koga A,Resistance to antipsychotic treatment in schizophrenia,initial,2017-04-28,GCST004375,Neurological disorder,#d53e4f
2880,European,84.0,28453389.0,Koga A,Resistance to antipsychotic treatment in schizophrenia,initial,2017-04-28,GCST004375,Response to drug,#d53e4f
2881,Hispanic/Latin American,4772.0,28453575.0,Hodonsky CJ,Red cell distribution width,replication,2017-04-28,GCST004333,Hematological measurement,#807dba
2882,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Red cell distribution width,initial,2017-04-28,GCST004333,Hematological measurement,#807dba
2883,Hispanic/Latin American,7106.0,28453575.0,Hodonsky CJ,Hemoglobin,replication,2017-04-28,GCST004331,Hematological measurement,#807dba
2884,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Hemoglobin,initial,2017-04-28,GCST004331,Hematological measurement,#807dba
2885,Hispanic/Latin American,4772.0,28453575.0,Hodonsky CJ,Red blood cell count,replication,2017-04-28,GCST004332,Hematological measurement,#807dba
2886,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Red blood cell count,initial,2017-04-28,GCST004332,Hematological measurement,#807dba
2887,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Mean corpuscular hemoglobin concentration,initial,2017-04-28,GCST004329,Hematological measurement,#807dba
2888,Hispanic/Latin American,4772.0,28453575.0,Hodonsky CJ,Mean corpuscular hemoglobin concentration,replication,2017-04-28,GCST004329,Hematological measurement,#807dba
2889,Hispanic/Latin American,12502.0,28453575.0,Hodonsky CJ,Hematocrit,initial,2017-04-28,GCST004330,Hematological measurement,#807dba
2890,Hispanic/Latin American,7106.0,28453575.0,Hodonsky CJ,Hematocrit,replication,2017-04-28,GCST004330,Hematological measurement,#807dba
2891,European,110517.0,28452372.0,Gorski M,Glomerular filtration rate (creatinine),initial,2017-04-28,GCST004292,Other measurement,#d53e4f
2892,European,110517.0,28452372.0,Gorski M,Glomerular filtration rate (creatinine),initial,2017-04-28,GCST004292,Other measurement,#d53e4f
2893,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-27,GCST004576,Body measurement,#fee08b
2894,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Body measurement,#d53e4f
2895,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Body measurement,#fee08b
2896,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Body measurement,#3288bd
2897,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-27,GCST004576,Body measurement,#d53e4f
2898,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Body measurement,#3288bd
2899,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-27,GCST004576,Other measurement,#fee08b
2900,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Other measurement,#d53e4f
2901,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Other measurement,#fee08b
2902,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Other measurement,#3288bd
2903,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-27,GCST004576,Other measurement,#d53e4f
2904,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-27,GCST004576,Other measurement,#3288bd
2905,European,10600.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004577,Body measurement,#d53e4f
2906,European,31133.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Body measurement,#d53e4f
2907,African Am./Caribbean,1501.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004577,Body measurement,#fee08b
2908,African Am./Caribbean,812.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Body measurement,#fee08b
2909,Asian,352.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Body measurement,#3288bd
2910,Asian,5379.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Body measurement,#3288bd
2911,European,10600.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004577,Other measurement,#d53e4f
2912,European,31133.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Other measurement,#d53e4f
2913,African Am./Caribbean,1501.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004577,Other measurement,#fee08b
2914,African Am./Caribbean,812.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Other measurement,#fee08b
2915,Asian,352.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Other measurement,#3288bd
2916,Asian,5379.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004577,Other measurement,#3288bd
2917,African Am./Caribbean,5072.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,replication,2017-04-27,GCST004578,Body measurement,#fee08b
2918,European,112031.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Body measurement,#d53e4f
2919,African Am./Caribbean,3163.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Body measurement,#fee08b
2920,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Body measurement,#3288bd
2921,European,26887.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,replication,2017-04-27,GCST004578,Body measurement,#d53e4f
2922,Asian,2334.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Body measurement,#3288bd
2923,African Am./Caribbean,5072.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,replication,2017-04-27,GCST004578,Other measurement,#fee08b
2924,European,112031.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Other measurement,#d53e4f
2925,African Am./Caribbean,3163.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Other measurement,#fee08b
2926,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Other measurement,#3288bd
2927,European,26887.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,replication,2017-04-27,GCST004578,Other measurement,#d53e4f
2928,Asian,2334.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI in active individuals,initial,2017-04-27,GCST004578,Other measurement,#3288bd
2929,European,26887.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,replication,2017-04-27,GCST004564,Body measurement,#d53e4f
2930,African Am./Caribbean,3163.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Body measurement,#fee08b
2931,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Body measurement,#3288bd
2932,Asian,2334.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Body measurement,#3288bd
2933,African Am./Caribbean,5072.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,replication,2017-04-27,GCST004564,Body measurement,#fee08b
2934,European,115058.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Body measurement,#d53e4f
2935,European,26887.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,replication,2017-04-27,GCST004564,Other measurement,#d53e4f
2936,African Am./Caribbean,3163.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Other measurement,#fee08b
2937,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Other measurement,#3288bd
2938,Asian,2334.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Other measurement,#3288bd
2939,African Am./Caribbean,5072.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,replication,2017-04-27,GCST004564,Other measurement,#fee08b
2940,European,115058.0,28448500.0,Graff M,Waist circumference adjusted for BMI in active individuals,initial,2017-04-27,GCST004564,Other measurement,#d53e4f
2941,African Am./Caribbean,1501.0,28448500.0,Graff M,Body mass index in physically inactive individuals,replication,2017-04-27,GCST004560,Other measurement,#fee08b
2942,Asian,5379.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Other measurement,#3288bd
2943,European,32052.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Other measurement,#d53e4f
2944,African Am./Caribbean,812.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Other measurement,#fee08b
2945,Asian,352.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Other measurement,#3288bd
2946,European,10600.0,28448500.0,Graff M,Body mass index in physically inactive individuals,replication,2017-04-27,GCST004560,Other measurement,#d53e4f
2947,African Am./Caribbean,1501.0,28448500.0,Graff M,Body mass index in physically inactive individuals,replication,2017-04-27,GCST004560,Body measurement,#fee08b
2948,Asian,5379.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Body measurement,#3288bd
2949,European,32052.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Body measurement,#d53e4f
2950,African Am./Caribbean,812.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Body measurement,#fee08b
2951,Asian,352.0,28448500.0,Graff M,Body mass index in physically inactive individuals,initial,2017-04-27,GCST004560,Body measurement,#3288bd
2952,European,10600.0,28448500.0,Graff M,Body mass index in physically inactive individuals,replication,2017-04-27,GCST004560,Body measurement,#d53e4f
2953,African Am./Caribbean,3163.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Other measurement,#fee08b
2954,European,26887.0,28448500.0,Graff M,Body mass index in physically active individuals,replication,2017-04-27,GCST004559,Other measurement,#d53e4f
2955,African Am./Caribbean,5072.0,28448500.0,Graff M,Body mass index in physically active individuals,replication,2017-04-27,GCST004559,Other measurement,#fee08b
2956,European,115827.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Other measurement,#d53e4f
2957,Asian,1773.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Other measurement,#3288bd
2958,Asian,2334.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Other measurement,#3288bd
2959,African Am./Caribbean,3163.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Body measurement,#fee08b
2960,European,26887.0,28448500.0,Graff M,Body mass index in physically active individuals,replication,2017-04-27,GCST004559,Body measurement,#d53e4f
2961,African Am./Caribbean,5072.0,28448500.0,Graff M,Body mass index in physically active individuals,replication,2017-04-27,GCST004559,Body measurement,#fee08b
2962,European,115827.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Body measurement,#d53e4f
2963,Asian,1773.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Body measurement,#3288bd
2964,Asian,2334.0,28448500.0,Graff M,Body mass index in physically active individuals,initial,2017-04-27,GCST004559,Body measurement,#3288bd
2965,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Body measurement,#3288bd
2966,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Body measurement,#d53e4f
2967,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Body measurement,#fee08b
2968,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Body measurement,#3288bd
2969,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004563,Body measurement,#d53e4f
2970,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004563,Body measurement,#fee08b
2971,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Other measurement,#3288bd
2972,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Other measurement,#d53e4f
2973,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Other measurement,#fee08b
2974,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004563,Other measurement,#3288bd
2975,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004563,Other measurement,#d53e4f
2976,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004563,Other measurement,#fee08b
2977,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index (physical activity interaction),replication,2017-04-27,GCST004568,Other measurement,#fee08b
2978,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Other measurement,#fee08b
2979,Asian,1773.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Other measurement,#3288bd
2980,European,37487.0,28448500.0,Graff M,Body mass index (physical activity interaction),replication,2017-04-27,GCST004568,Other measurement,#d53e4f
2981,European,146942.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Other measurement,#d53e4f
2982,Asian,7713.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Other measurement,#3288bd
2983,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index (physical activity interaction),replication,2017-04-27,GCST004568,Body measurement,#fee08b
2984,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Body measurement,#fee08b
2985,Asian,1773.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Body measurement,#3288bd
2986,European,37487.0,28448500.0,Graff M,Body mass index (physical activity interaction),replication,2017-04-27,GCST004568,Body measurement,#d53e4f
2987,European,146942.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Body measurement,#d53e4f
2988,Asian,7713.0,28448500.0,Graff M,Body mass index (physical activity interaction),initial,2017-04-27,GCST004568,Body measurement,#3288bd
2989,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004566,Body measurement,#d53e4f
2990,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Body measurement,#d53e4f
2991,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004566,Body measurement,#fee08b
2992,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Body measurement,#fee08b
2993,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Body measurement,#3288bd
2994,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Body measurement,#3288bd
2995,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004566,Other measurement,#d53e4f
2996,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Other measurement,#d53e4f
2997,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004566,Other measurement,#fee08b
2998,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Other measurement,#fee08b
2999,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Other measurement,#3288bd
3000,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004566,Other measurement,#3288bd
3001,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,replication,2017-04-27,GCST004562,Body measurement,#fee08b
3002,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Body measurement,#d53e4f
3003,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Body measurement,#fee08b
3004,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Body measurement,#3288bd
3005,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Body measurement,#3288bd
3006,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,replication,2017-04-27,GCST004562,Body measurement,#d53e4f
3007,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,replication,2017-04-27,GCST004562,Other measurement,#fee08b
3008,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Other measurement,#d53e4f
3009,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Other measurement,#fee08b
3010,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Other measurement,#3288bd
3011,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,initial,2017-04-27,GCST004562,Other measurement,#3288bd
3012,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for body mass index,replication,2017-04-27,GCST004562,Other measurement,#d53e4f
3013,European,146942.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Other measurement,#d53e4f
3014,Asian,7713.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Other measurement,#3288bd
3015,European,37487.0,28448500.0,Graff M,Body mass index,replication,2017-04-27,GCST004557,Other measurement,#d53e4f
3016,Asian,1773.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Other measurement,#3288bd
3017,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Other measurement,#fee08b
3018,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index,replication,2017-04-27,GCST004557,Other measurement,#fee08b
3019,European,146942.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Body measurement,#d53e4f
3020,Asian,7713.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Body measurement,#3288bd
3021,European,37487.0,28448500.0,Graff M,Body mass index,replication,2017-04-27,GCST004557,Body measurement,#d53e4f
3022,Asian,1773.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Body measurement,#3288bd
3023,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index,initial,2017-04-27,GCST004557,Body measurement,#fee08b
3024,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index,replication,2017-04-27,GCST004557,Body measurement,#fee08b
3025,European,14789.0,28445677.0,Steri M,Multiple sclerosis,replication,2017-04-27,GCST004290,Immune system disorder,#d53e4f
3027,European,4421.0,28445677.0,Steri M,Multiple sclerosis,initial,2017-04-27,GCST004290,Immune system disorder,#d53e4f
3028,Asian,2012.0,28460022.0,Lee JY,Early onset atrial fibrillation,replication,2017-04-27,GCST004352,Cardiovascular disease,#3288bd
3029,Asian,4372.0,28460022.0,Lee JY,Early onset atrial fibrillation,initial,2017-04-27,GCST004352,Cardiovascular disease,#3288bd
3030,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Body measurement,#3288bd
3031,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Body measurement,#3288bd
3032,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),replication,2017-04-27,GCST004567,Body measurement,#fee08b
3033,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Body measurement,#fee08b
3034,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Body measurement,#d53e4f
3035,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),replication,2017-04-27,GCST004567,Body measurement,#d53e4f
3036,Asian,1773.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Other measurement,#3288bd
3037,Asian,7713.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Other measurement,#3288bd
3038,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),replication,2017-04-27,GCST004567,Other measurement,#fee08b
3039,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Other measurement,#fee08b
3040,European,142227.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),initial,2017-04-27,GCST004567,Other measurement,#d53e4f
3041,European,37487.0,28448500.0,Graff M,Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),replication,2017-04-27,GCST004567,Other measurement,#d53e4f
3042,European,37487.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004558,Other measurement,#d53e4f
3043,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004558,Other measurement,#fee08b
3044,European,146942.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Other measurement,#d53e4f
3045,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Other measurement,#fee08b
3046,Asian,1773.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Other measurement,#3288bd
3047,Asian,7713.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Other measurement,#3288bd
3048,European,37487.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004558,Body measurement,#d53e4f
3049,African Am./Caribbean,6573.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),replication,2017-04-27,GCST004558,Body measurement,#fee08b
3050,European,146942.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Body measurement,#d53e4f
3051,African Am./Caribbean,3975.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Body measurement,#fee08b
3052,Asian,1773.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Body measurement,#3288bd
3053,Asian,7713.0,28448500.0,Graff M,Body mass index (joint analysis main effects and physical activity interaction),initial,2017-04-27,GCST004558,Body measurement,#3288bd
3054,Asian,5379.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Body measurement,#3288bd
3055,African Am./Caribbean,1501.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004565,Body measurement,#fee08b
3056,European,31928.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Body measurement,#d53e4f
3057,African Am./Caribbean,812.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Body measurement,#fee08b
3058,Asian,352.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Body measurement,#3288bd
3059,European,10600.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004565,Body measurement,#d53e4f
3060,Asian,5379.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Other measurement,#3288bd
3061,African Am./Caribbean,1501.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004565,Other measurement,#fee08b
3062,European,31928.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Other measurement,#d53e4f
3063,African Am./Caribbean,812.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Other measurement,#fee08b
3064,Asian,352.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,initial,2017-04-27,GCST004565,Other measurement,#3288bd
3065,European,10600.0,28448500.0,Graff M,Waist circumference adjusted for BMI in inactive individuals,replication,2017-04-27,GCST004565,Other measurement,#d53e4f
3066,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Body measurement,#3288bd
3067,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004561,Body measurement,#fee08b
3068,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Body measurement,#d53e4f
3069,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Body measurement,#fee08b
3070,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Body measurement,#3288bd
3071,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004561,Body measurement,#d53e4f
3072,Asian,7713.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Other measurement,#3288bd
3073,African Am./Caribbean,6573.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004561,Other measurement,#fee08b
3074,European,146049.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Other measurement,#d53e4f
3075,African Am./Caribbean,3975.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Other measurement,#fee08b
3076,Asian,1773.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),initial,2017-04-27,GCST004561,Other measurement,#3288bd
3077,European,37487.0,28448500.0,Graff M,Waist circumference adjusted for BMI (physical activity interaction),replication,2017-04-27,GCST004561,Other measurement,#d53e4f
3078,European,168375.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Biological process,#d53e4f
3079,African Am./Caribbean,13206.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Biological process,#fee08b
3080,Asian,8678.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Biological process,#3288bd
3081,Hispanic/Latin American,4708.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Biological process,#807dba
3082,Asian,1793.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Biological process,#3288bd
3083,European,164513.0,28443625.0,Justice AE,BMI (smoking interaction),replication,2017-04-26,GCST004496,Biological process,#d53e4f
3084,African Am./Caribbean,3181.0,28443625.0,Justice AE,BMI (smoking interaction),replication,2017-04-26,GCST004496,Biological process,#fee08b
3085,European,168375.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Body measurement,#d53e4f
3086,African Am./Caribbean,13206.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Body measurement,#fee08b
3087,Asian,8678.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Body measurement,#3288bd
3088,Hispanic/Latin American,4708.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Body measurement,#807dba
3089,Asian,1793.0,28443625.0,Justice AE,BMI (smoking interaction),initial,2017-04-26,GCST004496,Body measurement,#3288bd
3090,European,164513.0,28443625.0,Justice AE,BMI (smoking interaction),replication,2017-04-26,GCST004496,Body measurement,#d53e4f
3091,African Am./Caribbean,3181.0,28443625.0,Justice AE,BMI (smoking interaction),replication,2017-04-26,GCST004496,Body measurement,#fee08b
3092,African Am./Caribbean,461.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,replication,2017-04-26,GCST004509,Biological process,#fee08b
3093,European,25372.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,replication,2017-04-26,GCST004509,Biological process,#d53e4f
3094,European,36054.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Biological process,#d53e4f
3095,African Am./Caribbean,2602.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Biological process,#fee08b
3096,Asian,967.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Biological process,#3288bd
3097,Hispanic/Latin American,921.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Biological process,#807dba
3098,Asian,267.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Biological process,#3288bd
3099,African Am./Caribbean,461.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,replication,2017-04-26,GCST004509,Body measurement,#fee08b
3100,European,25372.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,replication,2017-04-26,GCST004509,Body measurement,#d53e4f
3101,European,36054.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Body measurement,#d53e4f
3102,African Am./Caribbean,2602.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Body measurement,#fee08b
3103,Asian,967.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Body measurement,#3288bd
3104,Hispanic/Latin American,921.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Body measurement,#807dba
3105,Asian,267.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in smokers,initial,2017-04-26,GCST004509,Body measurement,#3288bd
3106,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004507,Biological process,#fee08b
3107,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Biological process,#d53e4f
3108,African Am./Caribbean,10602.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Biological process,#fee08b
3109,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Biological process,#3288bd
3110,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Biological process,#807dba
3111,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Biological process,#3288bd
3112,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004507,Biological process,#d53e4f
3113,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004507,Body measurement,#fee08b
3114,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Body measurement,#d53e4f
3115,African Am./Caribbean,10602.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Body measurement,#fee08b
3116,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Body measurement,#3288bd
3117,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Body measurement,#807dba
3118,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004507,Body measurement,#3288bd
3119,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004507,Body measurement,#d53e4f
3120,Asian,1793.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Biological process,#3288bd
3121,African Am./Caribbean,3181.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004495,Biological process,#fee08b
3122,European,164513.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004495,Biological process,#d53e4f
3123,European,168375.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Biological process,#d53e4f
3124,African Am./Caribbean,13206.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Biological process,#fee08b
3125,Asian,8678.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Biological process,#3288bd
3126,Hispanic/Latin American,4708.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Biological process,#807dba
3127,Asian,1793.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Body measurement,#3288bd
3128,African Am./Caribbean,3181.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004495,Body measurement,#fee08b
3129,European,164513.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004495,Body measurement,#d53e4f
3130,European,168375.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Body measurement,#d53e4f
3131,African Am./Caribbean,13206.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Body measurement,#fee08b
3132,Asian,8678.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Body measurement,#3288bd
3133,Hispanic/Latin American,4708.0,28443625.0,Justice AE,BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004495,Body measurement,#807dba
3134,African Am./Caribbean,10602.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,initial,2017-04-26,GCST004508,Body measurement,#fee08b
3135,Asian,7711.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,initial,2017-04-26,GCST004508,Body measurement,#3288bd
3136,Hispanic/Latin American,3787.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,initial,2017-04-26,GCST004508,Body measurement,#807dba
3137,Asian,1526.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,initial,2017-04-26,GCST004508,Body measurement,#3288bd
3138,European,126046.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,initial,2017-04-26,GCST004508,Body measurement,#d53e4f
3139,African Am./Caribbean,2720.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,replication,2017-04-26,GCST004508,Body measurement,#fee08b
3140,European,139141.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI in non-smokers,replication,2017-04-26,GCST004508,Body measurement,#d53e4f
3141,African Am./Caribbean,461.0,28443625.0,Justice AE,BMI in smokers,replication,2017-04-26,GCST004498,Biological process,#fee08b
3142,European,25372.0,28443625.0,Justice AE,BMI in smokers,replication,2017-04-26,GCST004498,Biological process,#d53e4f
3143,Asian,967.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Biological process,#3288bd
3144,African Am./Caribbean,2604.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Biological process,#fee08b
3145,Hispanic/Latin American,921.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Biological process,#807dba
3146,Asian,267.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Biological process,#3288bd
3147,European,37784.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Biological process,#d53e4f
3148,African Am./Caribbean,461.0,28443625.0,Justice AE,BMI in smokers,replication,2017-04-26,GCST004498,Body measurement,#fee08b
3149,European,25372.0,28443625.0,Justice AE,BMI in smokers,replication,2017-04-26,GCST004498,Body measurement,#d53e4f
3150,Asian,967.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Body measurement,#3288bd
3151,African Am./Caribbean,2604.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Body measurement,#fee08b
3152,Hispanic/Latin American,921.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Body measurement,#807dba
3153,Asian,267.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Body measurement,#3288bd
3154,European,37784.0,28443625.0,Justice AE,BMI in smokers,initial,2017-04-26,GCST004498,Body measurement,#d53e4f
3155,European,25372.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,replication,2017-04-26,GCST004503,Biological process,#d53e4f
3156,African Am./Caribbean,461.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,replication,2017-04-26,GCST004503,Biological process,#fee08b
3157,African Am./Caribbean,2604.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Biological process,#fee08b
3158,Asian,267.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Biological process,#3288bd
3159,Hispanic/Latin American,921.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Biological process,#807dba
3160,Asian,967.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Biological process,#3288bd
3161,European,36657.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Biological process,#d53e4f
3162,European,25372.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,replication,2017-04-26,GCST004503,Body measurement,#d53e4f
3163,African Am./Caribbean,461.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,replication,2017-04-26,GCST004503,Body measurement,#fee08b
3164,African Am./Caribbean,2604.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Body measurement,#fee08b
3165,Asian,267.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Body measurement,#3288bd
3166,Hispanic/Latin American,921.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Body measurement,#807dba
3167,Asian,967.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Body measurement,#3288bd
3168,European,36657.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in smokers,initial,2017-04-26,GCST004503,Body measurement,#d53e4f
3169,Asian,1526.0,28443625.0,Justice AE,BMI in non-smokers,initial,2017-04-26,GCST004499,Body measurement,#3288bd
3170,Hispanic/Latin American,3787.0,28443625.0,Justice AE,BMI in non-smokers,initial,2017-04-26,GCST004499,Body measurement,#807dba
3171,Asian,7711.0,28443625.0,Justice AE,BMI in non-smokers,initial,2017-04-26,GCST004499,Body measurement,#3288bd
3172,African Am./Caribbean,10602.0,28443625.0,Justice AE,BMI in non-smokers,initial,2017-04-26,GCST004499,Body measurement,#fee08b
3173,European,129415.0,28443625.0,Justice AE,BMI in non-smokers,initial,2017-04-26,GCST004499,Body measurement,#d53e4f
3174,European,139141.0,28443625.0,Justice AE,BMI in non-smokers,replication,2017-04-26,GCST004499,Body measurement,#d53e4f
3175,African Am./Caribbean,2720.0,28443625.0,Justice AE,BMI in non-smokers,replication,2017-04-26,GCST004499,Body measurement,#fee08b
3176,Asian,1526.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,initial,2017-04-26,GCST004504,Body measurement,#3288bd
3177,Hispanic/Latin American,3787.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,initial,2017-04-26,GCST004504,Body measurement,#807dba
3178,Asian,7711.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,initial,2017-04-26,GCST004504,Body measurement,#3288bd
3179,African Am./Caribbean,10602.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,initial,2017-04-26,GCST004504,Body measurement,#fee08b
3180,European,129288.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,initial,2017-04-26,GCST004504,Body measurement,#d53e4f
3181,European,139141.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,replication,2017-04-26,GCST004504,Body measurement,#d53e4f
3182,African Am./Caribbean,2720.0,28443625.0,Justice AE,Waist circumference adjusted for BMI in non-smokers,replication,2017-04-26,GCST004504,Body measurement,#fee08b
3183,African Am./Caribbean,452.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#fee08b
3185,Hispanic/Latin American,78.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#807dba
3186,European,380.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#d53e4f
3187,African Am./Caribbean,452.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#fee08b
3189,Hispanic/Latin American,78.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#807dba
3190,European,380.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment),initial,2017-04-26,GCST004410,Other measurement,#d53e4f
3191,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Biological process,#fee08b
3192,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Biological process,#d53e4f
3193,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004505,Biological process,#d53e4f
3194,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004505,Biological process,#fee08b
3195,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Biological process,#3288bd
3196,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Biological process,#807dba
3197,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Biological process,#3288bd
3198,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Body measurement,#fee08b
3199,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Body measurement,#d53e4f
3200,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004505,Body measurement,#d53e4f
3201,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004505,Body measurement,#fee08b
3202,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Body measurement,#3288bd
3203,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Body measurement,#807dba
3204,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004505,Body measurement,#3288bd
3205,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004502,Biological process,#fee08b
3206,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Biological process,#3288bd
3207,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Biological process,#807dba
3208,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Biological process,#3288bd
3209,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Biological process,#fee08b
3210,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Biological process,#d53e4f
3211,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004502,Biological process,#d53e4f
3212,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004502,Body measurement,#fee08b
3213,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Body measurement,#3288bd
3214,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Body measurement,#807dba
3215,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Body measurement,#3288bd
3216,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Body measurement,#fee08b
3217,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004502,Body measurement,#d53e4f
3218,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004502,Body measurement,#d53e4f
3219,Asian,1793.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Biological process,#3288bd
3220,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Biological process,#807dba
3221,Asian,8678.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Biological process,#3288bd
3222,African Am./Caribbean,13206.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Biological process,#fee08b
3223,European,168375.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Biological process,#d53e4f
3224,European,164513.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004497,Biological process,#d53e4f
3225,African Am./Caribbean,3181.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004497,Biological process,#fee08b
3226,Asian,1793.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Body measurement,#3288bd
3227,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Body measurement,#807dba
3228,Asian,8678.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Body measurement,#3288bd
3229,African Am./Caribbean,13206.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Body measurement,#fee08b
3230,European,168375.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004497,Body measurement,#d53e4f
3231,European,164513.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004497,Body measurement,#d53e4f
3232,African Am./Caribbean,3181.0,28443625.0,Justice AE,Body mass index (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004497,Body measurement,#fee08b
3233,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Biological process,#3288bd
3234,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Biological process,#807dba
3235,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Biological process,#3288bd
3236,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Biological process,#fee08b
3237,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Biological process,#d53e4f
3238,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004501,Biological process,#d53e4f
3239,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004501,Biological process,#fee08b
3240,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Body measurement,#3288bd
3241,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Body measurement,#807dba
3242,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Body measurement,#3288bd
3243,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Body measurement,#fee08b
3244,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),initial,2017-04-26,GCST004501,Body measurement,#d53e4f
3245,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004501,Body measurement,#d53e4f
3246,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),replication,2017-04-26,GCST004501,Body measurement,#fee08b
3247,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Biological process,#3288bd
3248,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Biological process,#fee08b
3249,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Biological process,#d53e4f
3250,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004506,Biological process,#d53e4f
3251,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004506,Biological process,#fee08b
3252,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Biological process,#807dba
3253,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Biological process,#3288bd
3254,Asian,8678.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Body measurement,#3288bd
3255,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Body measurement,#fee08b
3256,European,163276.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Body measurement,#d53e4f
3257,European,164513.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004506,Body measurement,#d53e4f
3258,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),replication,2017-04-26,GCST004506,Body measurement,#fee08b
3259,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Body measurement,#807dba
3260,Asian,1793.0,28443625.0,Justice AE,Waist-to-hip ratio adjusted for BMI (smoking interaction),initial,2017-04-26,GCST004506,Body measurement,#3288bd
3261,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004500,Biological process,#fee08b
3262,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Biological process,#807dba
3263,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Biological process,#3288bd
3264,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Biological process,#fee08b
3265,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004500,Biological process,#d53e4f
3266,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Biological process,#3288bd
3267,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Biological process,#d53e4f
3268,African Am./Caribbean,3181.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004500,Body measurement,#fee08b
3269,Hispanic/Latin American,4708.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Body measurement,#807dba
3270,Asian,8678.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Body measurement,#3288bd
3271,African Am./Caribbean,13206.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Body measurement,#fee08b
3272,European,164513.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),replication,2017-04-26,GCST004500,Body measurement,#d53e4f
3273,Asian,1793.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Body measurement,#3288bd
3274,European,167121.0,28443625.0,Justice AE,Waist circumference adjusted for BMI (adjusted for smoking behaviour),initial,2017-04-26,GCST004500,Body measurement,#d53e4f
3276,Hispanic/Latin American,99.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other disease,#807dba
3277,European,443.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other disease,#d53e4f
3278,African Am./Caribbean,490.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other disease,#fee08b
3280,Hispanic/Latin American,99.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other measurement,#807dba
3281,European,443.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other measurement,#d53e4f
3282,African Am./Caribbean,490.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (dichotomous),initial,2017-04-26,GCST004407,Other measurement,#fee08b
3283,European,443.0,28447399.0,Jia P,HIV-associated neurocognitive disorder,initial,2017-04-26,GCST004409,Other measurement,#d53e4f
3285,Hispanic/Latin American,99.0,28447399.0,Jia P,HIV-associated neurocognitive disorder,initial,2017-04-26,GCST004409,Other measurement,#807dba
3286,African Am./Caribbean,489.0,28447399.0,Jia P,HIV-associated neurocognitive disorder,initial,2017-04-26,GCST004409,Other measurement,#fee08b
3287,European,275.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#d53e4f
3288,Hispanic/Latin American,46.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#807dba
3289,African Am./Caribbean,327.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#fee08b
3291,European,275.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#d53e4f
3292,Hispanic/Latin American,46.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#807dba
3293,African Am./Caribbean,327.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder),initial,2017-04-26,GCST004408,Other measurement,#fee08b
3295,African Am./Caribbean,482.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#fee08b
3296,Hispanic/Latin American,95.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#807dba
3297,European,425.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#d53e4f
3299,African Am./Caribbean,482.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#fee08b
3300,Hispanic/Latin American,95.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#807dba
3301,European,425.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#d53e4f
3303,African Am./Caribbean,482.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#fee08b
3304,Hispanic/Latin American,95.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#807dba
3305,European,425.0,28447399.0,Jia P,HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment),initial,2017-04-26,GCST004411,Other measurement,#d53e4f
3308,European,443.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other disease,#d53e4f
3309,African Am./Caribbean,490.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other disease,#fee08b
3310,Hispanic/Latin American,99.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other disease,#807dba
3312,European,443.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other measurement,#d53e4f
3313,African Am./Caribbean,490.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other measurement,#fee08b
3314,Hispanic/Latin American,99.0,28447399.0,Jia P,Neurocognitive impairment in HIV-1 infection (continuous),initial,2017-04-26,GCST004406,Other measurement,#807dba
3315,European,14713.0,28440896.0,Yin X,Nicotine dependence,initial,2017-04-25,GCST004294,Neurological disorder,#d53e4f
3316,African Am./Caribbean,3369.0,28440896.0,Yin X,Nicotine dependence,initial,2017-04-25,GCST004294,Neurological disorder,#fee08b
3317,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 23),initial,2017-04-25,GCST004327,Other measurement,#d53e4f
3318,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 22),initial,2017-04-25,GCST004326,Other measurement,#d53e4f
3319,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 21, depth of nasal alae)",initial,2017-04-25,GCST004325,Other measurement,#d53e4f
3320,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 14, intercanthal width)",initial,2017-04-25,GCST004318,Other measurement,#d53e4f
3321,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)",initial,2017-04-25,GCST004317,Other measurement,#d53e4f
3322,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 13, vertical position of alar curvature relative to upper lip)",initial,2017-04-25,GCST004317,Other measurement,#d53e4f
3323,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface)",initial,2017-04-25,GCST004316,Other measurement,#d53e4f
3324,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 11, projection of the nose)",initial,2017-04-25,GCST004315,Other measurement,#d53e4f
3325,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 9, facial height related to vertical position of nasion)",initial,2017-04-25,GCST004313,Other measurement,#d53e4f
3326,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion)",initial,2017-04-25,GCST004312,Other measurement,#d53e4f
3327,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 7, width of cartilaginous portion of nose)",initial,2017-04-25,GCST004311,Other measurement,#d53e4f
3328,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 6, height of vermillion lower lip)",initial,2017-04-25,GCST004310,Other measurement,#d53e4f
3329,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 5, width of mouth relative to central midface)",initial,2017-04-25,GCST004309,Other measurement,#d53e4f
3330,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 4, facial height related to vertical position of gnathion)",initial,2017-04-25,GCST004308,Other measurement,#d53e4f
3331,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 2, vertical position of orbits relative to midface)",initial,2017-04-25,GCST004306,Other measurement,#d53e4f
3332,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 20),initial,2017-04-25,GCST004324,Other measurement,#d53e4f
3333,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 19),initial,2017-04-25,GCST004323,Other measurement,#d53e4f
3334,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 18),initial,2017-04-25,GCST004322,Other measurement,#d53e4f
3335,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 17, height of vermillion upper lip)",initial,2017-04-25,GCST004321,Other measurement,#d53e4f
3336,European,2187.0,28441456.0,Lee MK,Facial morphology (factor 16),initial,2017-04-25,GCST004320,Other measurement,#d53e4f
3337,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 15, philtrum width)",initial,2017-04-25,GCST004319,Other measurement,#d53e4f
3338,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 3, length of philtrum)",initial,2017-04-25,GCST004307,Other measurement,#d53e4f
3339,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 10, width of nasal floor)",initial,2017-04-25,GCST004314,Other measurement,#d53e4f
3340,European,979.0,28441426.0,White CC,Residual cognition,initial,2017-04-25,GCST004291,Biological process,#d53e4f
3341,European,979.0,28441426.0,White CC,Residual cognition,initial,2017-04-25,GCST004291,Biological process,#d53e4f
3342,Other/Mixed,787.0,28449029.0,Munz M,Aggressive periodontitis,initial,2017-04-25,GCST004303,Digestive system disorder,#99d594
3343,European,7687.0,28449029.0,Munz M,Aggressive periodontitis,initial,2017-04-25,GCST004303,Digestive system disorder,#d53e4f
3344,European,2187.0,28441456.0,Lee MK,"Facial morphology (factor 1, breadth of lateral portion of upper face)",initial,2017-04-25,GCST004328,Other measurement,#d53e4f
3345,European,242.0,28560309.0,Lee E,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),initial,2017-04-23,GCST004253,Other trait,#d53e4f
3346,European,242.0,28560309.0,Lee E,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),initial,2017-04-23,GCST004253,Neurological disorder,#d53e4f
3347,European,242.0,28560309.0,Lee E,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),initial,2017-04-23,GCST004253,Other measurement,#d53e4f
3348,European,210086.0,28430825.0,Ng MCY,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-21,GCST004518,Body measurement,#d53e4f
3349,African Am./Caribbean,2711.0,28430825.0,Ng MCY,Waist-to-hip ratio adjusted for body mass index,replication,2017-04-21,GCST004518,Body measurement,#fee08b
3350,African Am./Caribbean,20384.0,28430825.0,Ng MCY,Waist-to-hip ratio adjusted for body mass index,initial,2017-04-21,GCST004518,Body measurement,#fee08b
3351,European,322154.0,28430825.0,Ng MCY,Body mass index (adult),replication,2017-04-21,GCST004519,Body measurement,#d53e4f
3352,African,10143.0,28430825.0,Ng MCY,Body mass index (adult),replication,2017-04-21,GCST004519,Body measurement,#fc8d59
3353,African Am./Caribbean,46696.0,28430825.0,Ng MCY,Body mass index (adult),initial,2017-04-21,GCST004519,Body measurement,#fee08b
3354,African,1056.0,28430825.0,Ng MCY,Body mass index (adult),initial,2017-04-21,GCST004519,Body measurement,#fc8d59
3355,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#fee08b
3356,European,707.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#d53e4f
3357,Asian,15.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#3288bd
3358,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Cancer,#fee08b
3359,European,707.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Cancer,#d53e4f
3360,Asian,15.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Cancer,#3288bd
3361,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#fee08b
3362,European,707.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#d53e4f
3363,Asian,15.0,28429243.0,Dudenkov TM,Estrone conjugates/estrone ratio in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004360,Other measurement,#3288bd
3364,Asian,15.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Other measurement,#3288bd
3365,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Other measurement,#fee08b
3366,European,707.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Other measurement,#d53e4f
3367,Asian,15.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Cancer,#3288bd
3368,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Cancer,#fee08b
3369,European,707.0,28429243.0,Dudenkov TM,Plasma estrone conjugates levels in resected early stage estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004359,Cancer,#d53e4f
3370,Asian,3034.0,28425483.0,Qiu F,Primary biliary cholangitis,replication,2017-04-20,GCST004302,Cancer,#3288bd
3371,Asian,5158.0,28425483.0,Qiu F,Primary biliary cholangitis,initial,2017-04-20,GCST004302,Cancer,#3288bd
3372,Asian,534.0,28424481.0,Sugiura-Ogasawara M,Obstetric antiphospholipid syndrome,initial,2017-04-20,GCST004227,Immune system disorder,#3288bd
3373,European,707.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Other measurement,#d53e4f
3374,Asian,15.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Other measurement,#3288bd
3375,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Other measurement,#fee08b
3376,European,707.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Cancer,#d53e4f
3377,Asian,15.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Cancer,#3288bd
3378,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma androstenedione levels in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004363,Cancer,#fee08b
3379,Asian,15.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Cancer,#3288bd
3380,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Cancer,#fee08b
3381,European,707.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Cancer,#d53e4f
3382,Asian,15.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Other measurement,#3288bd
3383,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Other measurement,#fee08b
3384,European,707.0,28429243.0,Dudenkov TM,Plasma estrone levels in resected estrogen-receptor positive breast cancer,initial,2017-04-20,GCST004362,Other measurement,#d53e4f
3385,Asian,15.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#3288bd
3386,European,707.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#d53e4f
3387,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#fee08b
3388,Asian,15.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Cancer,#3288bd
3389,European,707.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Cancer,#d53e4f
3390,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Cancer,#fee08b
3391,Asian,15.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#3288bd
3392,European,707.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#d53e4f
3393,African Am./Caribbean,52.0,28429243.0,Dudenkov TM,Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,initial,2017-04-20,GCST004361,Other measurement,#fee08b
3394,Asian,922.0,28416812.0,Yang L,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder,replication,2017-04-18,GCST004336,Neurological disorder,#3288bd
3395,Asian,780.0,28416812.0,Yang L,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder,initial,2017-04-18,GCST004336,Neurological disorder,#3288bd
3396,Asian,922.0,28416812.0,Yang L,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder,replication,2017-04-18,GCST004336,Other measurement,#3288bd
3397,Asian,780.0,28416812.0,Yang L,Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder,initial,2017-04-18,GCST004336,Other measurement,#3288bd
3398,European,251.0,28421636.0,Dennis J,Tissue factor pathway inhibitor levels,initial,2017-04-18,GCST004344,Other measurement,#d53e4f
3399,European,1033.0,28421636.0,Dennis J,Tissue factor pathway inhibitor levels,replication,2017-04-18,GCST004344,Other measurement,#d53e4f
3400,European,129712.0,28416822.0,Low SK,Atrial fibrillation,replication,2017-04-17,GCST004373,Cardiovascular disease,#d53e4f
3401,Asian,36792.0,28416822.0,Low SK,Atrial fibrillation,initial,2017-04-17,GCST004373,Cardiovascular disease,#3288bd
3402,Asian,128184.0,28416822.0,Low SK,Atrial fibrillation,replication,2017-04-17,GCST004373,Cardiovascular disease,#3288bd
3403,European,111432.0,28416818.0,Christophersen IE,Prevalent atrial fibrillation,initial,2017-04-17,GCST004301,Cardiovascular disease,#d53e4f
3404,European,110099.0,28416818.0,Christophersen IE,Incident atrial fibrillation,initial,2017-04-17,GCST004300,Cardiovascular disease,#d53e4f
3405,African Am./Caribbean,5875.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004295,Cardiovascular disease,#fee08b
3406,Hispanic/Latin American,3358.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004295,Cardiovascular disease,#807dba
3407,European,118755.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004295,Cardiovascular disease,#d53e4f
3408,Asian,4130.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004295,Cardiovascular disease,#3288bd
3409,Asian,36792.0,28416818.0,Christophersen IE,Atrial fibrillation,replication,2017-04-17,GCST004295,Cardiovascular disease,#3288bd
3410,African Am./Caribbean,889.0,28416818.0,Christophersen IE,Atrial fibrillation,replication,2017-04-17,GCST004299,Cardiovascular disease,#fee08b
3411,African Am./Caribbean,5875.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004299,Cardiovascular disease,#fee08b
3412,Asian,4133.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004298,Cardiovascular disease,#3288bd
3413,Asian,36792.0,28416818.0,Christophersen IE,Atrial fibrillation,replication,2017-04-17,GCST004298,Cardiovascular disease,#3288bd
3414,European,118755.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004297,Cardiovascular disease,#d53e4f
3415,European,118755.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004296,Cardiovascular disease,#d53e4f
3416,Hispanic/Latin American,3358.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004296,Cardiovascular disease,#807dba
3417,African Am./Caribbean,5875.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004296,Cardiovascular disease,#fee08b
3419,Asian,4130.0,28416818.0,Christophersen IE,Atrial fibrillation,initial,2017-04-17,GCST004296,Cardiovascular disease,#3288bd
3420,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks),initial,2017-04-14,GCST004271,Response to drug,#d53e4f
3421,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks),initial,2017-04-14,GCST004271,Neurological disorder,#d53e4f
3422,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks),initial,2017-04-14,GCST004275,Response to drug,#d53e4f
3423,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 24 weeks),initial,2017-04-14,GCST004275,Neurological disorder,#d53e4f
3424,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks),initial,2017-04-14,GCST004274,Response to drug,#d53e4f
3425,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks),initial,2017-04-14,GCST004274,Neurological disorder,#d53e4f
3426,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks),initial,2017-04-14,GCST004273,Response to drug,#d53e4f
3427,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks),initial,2017-04-14,GCST004273,Neurological disorder,#d53e4f
3428,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks),initial,2017-04-14,GCST004270,Response to drug,#d53e4f
3429,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (responders vs non-responders after 12 weeks),initial,2017-04-14,GCST004270,Neurological disorder,#d53e4f
3430,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks),initial,2017-04-14,GCST004272,Response to drug,#d53e4f
3431,European,98.0,28437668.0,Jung J,Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 12 weeks),initial,2017-04-14,GCST004272,Neurological disorder,#d53e4f
3432,Asian,7935.0,28406950.0,Kim J,Prevalent type 2 diabetes,initial,2017-04-13,GCST004304,Metabolic disorder,#3288bd
3433,Asian,7935.0,28406950.0,Kim J,Type 2 diabetes,initial,2017-04-13,GCST004305,Metabolic disorder,#3288bd
3434,European,21852.0,28394258.0,Wild PS,Peak velocity of the mitral E-wave,initial,2017-04-10,GCST004653,Cardiovascular measurement,#d53e4f
3435,European,14787.0,28394258.0,Wild PS,Peak velocity of the mitral E-wave,replication,2017-04-10,GCST004653,Cardiovascular measurement,#d53e4f
3436,European,30201.0,28394258.0,Wild PS,Left  ventricle systolic dysfunction,initial,2017-04-10,GCST004648,Cardiovascular measurement,#d53e4f
3437,European,30201.0,28394258.0,Wild PS,Left ventricular fractional shortening,initial,2017-04-10,GCST004645,Cardiovascular measurement,#d53e4f
3438,European,14002.0,28394258.0,Wild PS,Left ventricular fractional shortening,replication,2017-04-10,GCST004645,Cardiovascular measurement,#d53e4f
3439,European,30201.0,28394258.0,Wild PS,Left ventricular mass,initial,2017-04-10,GCST004659,Cardiovascular measurement,#d53e4f
3440,European,14002.0,28394258.0,Wild PS,Left ventricular mass,replication,2017-04-10,GCST004659,Cardiovascular measurement,#d53e4f
3441,European,30201.0,28394258.0,Wild PS,Left ventricle wall thickness,initial,2017-04-10,GCST004646,Cardiovascular measurement,#d53e4f
3442,European,14002.0,28394258.0,Wild PS,Left ventricle diastolic internal dimension,replication,2017-04-10,GCST004655,Cardiovascular measurement,#d53e4f
3443,European,30201.0,28394258.0,Wild PS,Left ventricle diastolic internal dimension,initial,2017-04-10,GCST004655,Cardiovascular measurement,#d53e4f
3444,European,30201.0,28394258.0,Wild PS,Left atrial antero-posterior diameter,initial,2017-04-10,GCST004647,Cardiovascular measurement,#d53e4f
3445,European,30201.0,28394258.0,Wild PS,Aortic root size,initial,2017-04-10,GCST004651,Cardiovascular measurement,#d53e4f
3446,European,14002.0,28394258.0,Wild PS,Aortic root size,replication,2017-04-10,GCST004651,Cardiovascular measurement,#d53e4f
3447,European,21852.0,28394258.0,Wild PS,Heart failure with preserved ejection fraction,initial,2017-04-10,GCST004660,Cardiovascular measurement,#d53e4f
3448,European,14787.0,28394258.0,Wild PS,Heart failure with preserved ejection fraction,replication,2017-04-10,GCST004660,Cardiovascular measurement,#d53e4f
3449,European,21852.0,28394258.0,Wild PS,Diastolic dysfunction with preserved ejection pressure,initial,2017-04-10,GCST004650,Cardiovascular measurement,#d53e4f
3450,European,14787.0,28394258.0,Wild PS,Diastolic dysfunction with preserved ejection pressure,replication,2017-04-10,GCST004650,Cardiovascular measurement,#d53e4f
3451,European,21852.0,28394258.0,Wild PS,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave,initial,2017-04-10,GCST004657,Cardiovascular measurement,#d53e4f
3452,European,14787.0,28394258.0,Wild PS,Ratio of the peak velocity of the excursion of the lateral mitral annulus in the early diastolic phase and the peak velocity of the mitral E-wave,replication,2017-04-10,GCST004657,Cardiovascular measurement,#d53e4f
3453,European,21852.0,28394258.0,Wild PS,Deceleration time of the mitral E-wave,initial,2017-04-10,GCST004654,Cardiovascular measurement,#d53e4f
3454,European,14787.0,28394258.0,Wild PS,Deceleration time of the mitral E-wave,replication,2017-04-10,GCST004654,Cardiovascular measurement,#d53e4f
3455,European,21852.0,28394258.0,Wild PS,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.,initial,2017-04-10,GCST004656,Cardiovascular measurement,#d53e4f
3456,European,14787.0,28394258.0,Wild PS,Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.,replication,2017-04-10,GCST004656,Cardiovascular measurement,#d53e4f
3457,European,21852.0,28394258.0,Wild PS,Peak velocity of the mitral A-wave,initial,2017-04-10,GCST004652,Cardiovascular measurement,#d53e4f
3458,European,14787.0,28394258.0,Wild PS,Peak velocity of the mitral A-wave,replication,2017-04-10,GCST004652,Cardiovascular measurement,#d53e4f
3459,European,21852.0,28394258.0,Wild PS,Peak velocity of excursion of lateral mitral annulus in early diastolic phase,initial,2017-04-10,GCST004658,Cardiovascular measurement,#d53e4f
3460,European,14787.0,28394258.0,Wild PS,Peak velocity of excursion of lateral mitral annulus in early diastolic phase,replication,2017-04-10,GCST004658,Cardiovascular measurement,#d53e4f
3461,European,14787.0,28394258.0,Wild PS,Isovolumetric relaxation time,replication,2017-04-10,GCST004649,Cardiovascular measurement,#d53e4f
3462,European,21852.0,28394258.0,Wild PS,Isovolumetric relaxation time,initial,2017-04-10,GCST004649,Cardiovascular measurement,#d53e4f
3464,European,1528.0,28375557.0,Thomsen H,Monoclonal gammopathy of undetermined significance,initial,2017-04-04,GCST004287,Other disease,#d53e4f
3465,European,4942.0,28374850.0,Ellinghaus E,Chronic venous disease,initial,2017-04-04,GCST004343,Other trait,#d53e4f
3466,European,5092.0,28374850.0,Ellinghaus E,Chronic venous disease,replication,2017-04-04,GCST004343,Other trait,#d53e4f
3467,European,4942.0,28374850.0,Ellinghaus E,Chronic venous disease,initial,2017-04-04,GCST004343,Other trait,#d53e4f
3468,European,5092.0,28374850.0,Ellinghaus E,Chronic venous disease,replication,2017-04-04,GCST004343,Other trait,#d53e4f
3469,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#99d594
3470,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#fee08b
3471,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#d53e4f
3472,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#3288bd
3473,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#807dba
3474,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#3288bd
3475,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#99d594
3476,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#fee08b
3477,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#d53e4f
3478,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#3288bd
3479,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#807dba
3480,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides,initial,2017-04-03,GCST004281,Other measurement,#3288bd
3481,Asian,10295.0,28373541.0,Yang J,High altitude adaptation,initial,2017-04-03,GCST006054,Biological process,#3288bd
3482,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#807dba
3483,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#d53e4f
3484,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#3288bd
3485,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#fee08b
3486,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#99d594
3487,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#3288bd
3488,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#807dba
3489,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#d53e4f
3490,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#3288bd
3491,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#fee08b
3492,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#99d594
3493,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs,initial,2017-04-03,GCST004283,Other measurement,#3288bd
3494,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect),initial,2017-04-03,GCST004282,Other measurement,#99d594
3495,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect),initial,2017-04-03,GCST004282,Other measurement,#99d594
3496,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of organochlorine pesticides (fetal genetic effect),initial,2017-04-03,GCST004282,Other measurement,#99d594
3497,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs (fetal genetic effect),initial,2017-04-03,GCST004286,Other measurement,#99d594
3498,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs (fetal genetic effect),initial,2017-04-03,GCST004286,Other measurement,#99d594
3499,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs (fetal genetic effect),initial,2017-04-03,GCST004286,Other measurement,#99d594
3500,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs (fetal genetic effect),initial,2017-04-03,GCST004286,Other measurement,#99d594
3501,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#807dba
3502,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3503,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3504,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#99d594
3505,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#fee08b
3506,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#d53e4f
3507,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#807dba
3508,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3509,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3510,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#99d594
3511,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#fee08b
3512,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#d53e4f
3513,Hispanic/Latin American,329.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#807dba
3514,Asian,122.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3515,Asian,23.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#3288bd
3516,Other/Mixed,22.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#99d594
3517,African Am./Caribbean,21.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#fee08b
3518,European,273.0,28235828.0,Traglia M,Midgestational circulating levels of PBDEs,initial,2017-04-03,GCST004285,Other measurement,#d53e4f
3519,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs (fetal genetic effect),initial,2017-04-03,GCST004284,Other measurement,#99d594
3520,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs (fetal genetic effect),initial,2017-04-03,GCST004284,Other measurement,#99d594
3521,Other/Mixed,764.0,28235828.0,Traglia M,Midgestational circulating levels of PCBs (fetal genetic effect),initial,2017-04-03,GCST004284,Other measurement,#99d594
3522,European,513.0,28207573.0,Backman JD,Clopidogrel active metabolite levels,initial,2017-04-01,GCST004264,Other measurement,#d53e4f
3523,European,69057.0,28199695.0,Jones AV,Itch intensity from mosquito bite adjusted by bite size,initial,2017-04-01,GCST004865,Other measurement,#d53e4f
3524,European,69057.0,28199695.0,Jones AV,Itch intensity from mosquito bite adjusted by bite size,initial,2017-04-01,GCST004865,Other measurement,#d53e4f
3525,European,16576.0,28199695.0,Jones AV,Perceived unattractiveness to mosquitoes,initial,2017-04-01,GCST004864,Other measurement,#d53e4f
3526,European,84724.0,28199695.0,Jones AV,Mosquito bite size,initial,2017-04-01,GCST004863,Other measurement,#d53e4f
3527,European,84724.0,28199695.0,Jones AV,Itch intensity from mosquito bite adjusted by bite size,initial,2017-04-01,GCST004862,Other measurement,#d53e4f
3528,European,84724.0,28199695.0,Jones AV,Itch intensity from mosquito bite adjusted by bite size,initial,2017-04-01,GCST004862,Other measurement,#d53e4f
3529,African,186.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,initial,2017-04-01,GCST004262,Response to drug,#fc8d59
3530,African,116.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,replication,2017-04-01,GCST004262,Response to drug,#fc8d59
3531,African,186.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,initial,2017-04-01,GCST004262,Other disease,#fc8d59
3532,African,116.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,replication,2017-04-01,GCST004262,Other disease,#fc8d59
3533,African,186.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,initial,2017-04-01,GCST004262,Response to drug,#fc8d59
3534,African,116.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,replication,2017-04-01,GCST004262,Response to drug,#fc8d59
3535,African,186.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,initial,2017-04-01,GCST004262,Other disease,#fc8d59
3536,African,116.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,replication,2017-04-01,GCST004262,Other disease,#fc8d59
3537,African,186.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,initial,2017-04-01,GCST004262,Digestive system disorder,#fc8d59
3538,African,116.0,28388302.0,Petros Z,Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis,replication,2017-04-01,GCST004262,Digestive system disorder,#fc8d59
3539,European,46629.0,28348047.0,Li C,Mean arterial pressure (long-term average),replication,2017-04-01,GCST004259,Other measurement,#d53e4f
3540,Asian,18422.0,28348047.0,Li C,Mean arterial pressure (long-term average),initial,2017-04-01,GCST004259,Other measurement,#3288bd
3541,Asian,18422.0,28348047.0,Li C,Pulse pressure (long-term average),initial,2017-04-01,GCST004260,Cardiovascular measurement,#3288bd
3542,European,46629.0,28348047.0,Li C,Pulse pressure (long-term average),replication,2017-04-01,GCST004260,Cardiovascular measurement,#d53e4f
3543,Asian,18422.0,28348047.0,Li C,Diastolic blood pressure (long-term average),initial,2017-04-01,GCST004258,Other measurement,#3288bd
3544,European,46629.0,28348047.0,Li C,Diastolic blood pressure (long-term average),replication,2017-04-01,GCST004258,Other measurement,#d53e4f
3545,European,8424.0,28333195.0,Uimari O,Deep ovarian and/or rectovaginal disease with dense adhesions,initial,2017-04-01,GCST004370,Other disease,#d53e4f
3546,European,8746.0,28333195.0,Uimari O,Ovarian disease with few adhesions,initial,2017-04-01,GCST004369,Other disease,#d53e4f
3547,European,84724.0,28199695.0,Jones AV,Itch intensity from mosquito bite,initial,2017-04-01,GCST004861,Other measurement,#d53e4f
3548,European,2555.0,28289848.0,Haralambieva IH,Immune response to measles vaccine (measles-induced IFN gamma),initial,2017-04-01,GCST004268,Response to drug,#d53e4f
3549,African Am./Caribbean,317.0,28289848.0,Haralambieva IH,Immune response to measles vaccine (measles-induced IFN gamma),initial,2017-04-01,GCST004268,Response to drug,#fee08b
3550,European,513.0,28207573.0,Backman JD,Response to clopidogrel therapy,initial,2017-04-01,GCST004266,Cardiovascular measurement,#d53e4f
3551,European,513.0,28207573.0,Backman JD,Response to clopidogrel therapy,initial,2017-04-01,GCST004266,Response to drug,#d53e4f
3552,European,10254.0,28333195.0,Uimari O,Endometriosis,initial,2017-04-01,GCST004368,Other disease,#d53e4f
3554,European,120158.0,28373160.0,Klarin D,Venous thromboembolism,initial,2017-04-01,GCST004256,Cardiovascular disease,#d53e4f
3555,African,307.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,initial,2017-04-01,GCST004261,Response to drug,#fc8d59
3556,African,73.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,replication,2017-04-01,GCST004261,Response to drug,#fc8d59
3557,African,307.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,initial,2017-04-01,GCST004261,Other disease,#fc8d59
3558,African,73.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,replication,2017-04-01,GCST004261,Other disease,#fc8d59
3559,African,307.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,initial,2017-04-01,GCST004261,Digestive system disorder,#fc8d59
3560,African,73.0,28388302.0,Petros Z,Liver injury in anti-retroviral drug treated HIV,replication,2017-04-01,GCST004261,Digestive system disorder,#fc8d59
3561,European,46629.0,28348047.0,Li C,Systolic blood pressure (long-term average),replication,2017-04-01,GCST004257,Other measurement,#d53e4f
3562,Asian,18422.0,28348047.0,Li C,Systolic blood pressure (long-term average),initial,2017-04-01,GCST004257,Other measurement,#3288bd
3563,African Am./Caribbean,317.0,28289848.0,Haralambieva IH,Immune response to measles vaccine (measles-specific neutralising antibody titre),initial,2017-04-01,GCST004269,Response to drug,#fee08b
3564,European,2555.0,28289848.0,Haralambieva IH,Immune response to measles vaccine (measles-specific neutralising antibody titre),initial,2017-04-01,GCST004269,Response to drug,#d53e4f
3565,Asian,1742.0,28371326.0,Zhu Y,Metabolic syndrome,initial,2017-03-30,GCST004239,Metabolic disorder,#3288bd
3566,Asian,10978.0,28371326.0,Zhu Y,Metabolic syndrome,replication,2017-03-30,GCST004239,Metabolic disorder,#3288bd
3567,Asian,1742.0,28371326.0,Zhu Y,Body mass index,initial,2017-03-30,GCST004245,Body measurement,#3288bd
3568,Asian,4219.0,28371326.0,Zhu Y,Body mass index,replication,2017-03-30,GCST004245,Body measurement,#3288bd
3569,European,83264.0,28358823.0,Kim SK,Anterior cruciate ligament rupture,initial,2017-03-30,GCST004265,Other disease,#d53e4f
3570,Hispanic/Latin American,8560.0,28358823.0,Kim SK,Anterior cruciate ligament rupture,initial,2017-03-30,GCST004265,Other disease,#807dba
3571,Asian,7518.0,28358823.0,Kim SK,Anterior cruciate ligament rupture,initial,2017-03-30,GCST004265,Other disease,#3288bd
3572,European,83264.0,28358823.0,Kim SK,Achilles tendinopathy,initial,2017-03-30,GCST004263,Other disease,#d53e4f
3573,Asian,7518.0,28358823.0,Kim SK,Achilles tendinopathy,initial,2017-03-30,GCST004263,Other disease,#3288bd
3574,African Am./Caribbean,3161.0,28358823.0,Kim SK,Achilles tendinopathy,initial,2017-03-30,GCST004263,Other disease,#fee08b
3575,Asian,476.0,28358823.0,Kim SK,Achilles tendinopathy,initial,2017-03-30,GCST004263,Other disease,#3288bd
3576,Hispanic/Latin American,8560.0,28358823.0,Kim SK,Achilles tendinopathy,initial,2017-03-30,GCST004263,Other disease,#807dba
3577,Asian,4219.0,28371326.0,Zhu Y,Waist-hip ratio,replication,2017-03-30,GCST004244,Body measurement,#3288bd
3578,Asian,1742.0,28371326.0,Zhu Y,Waist-hip ratio,initial,2017-03-30,GCST004244,Body measurement,#3288bd
3579,Asian,1742.0,28371326.0,Zhu Y,LDL cholesterol levels,initial,2017-03-30,GCST004243,Lipid or lipoprotein measurement,#3288bd
3580,Asian,1589.0,28371326.0,Zhu Y,LDL cholesterol levels,replication,2017-03-30,GCST004243,Lipid or lipoprotein measurement,#3288bd
3581,Asian,10978.0,28371326.0,Zhu Y,HDL cholesterol,replication,2017-03-30,GCST004242,Lipid or lipoprotein measurement,#3288bd
3582,Asian,1742.0,28371326.0,Zhu Y,HDL cholesterol,initial,2017-03-30,GCST004242,Lipid or lipoprotein measurement,#3288bd
3583,Asian,1742.0,28371326.0,Zhu Y,Triglyceride levels,initial,2017-03-30,GCST004241,Lipid or lipoprotein measurement,#3288bd
3584,Asian,10978.0,28371326.0,Zhu Y,Triglyceride levels,replication,2017-03-30,GCST004241,Lipid or lipoprotein measurement,#3288bd
3585,Asian,1742.0,28371326.0,Zhu Y,Fasting blood glucose,initial,2017-03-30,GCST004240,Other measurement,#3288bd
3586,Asian,1589.0,28371326.0,Zhu Y,Fasting blood glucose,replication,2017-03-30,GCST004240,Other measurement,#3288bd
3587,African Am./Caribbean,7215.0,28360221.0,Boger CA,Blood osmolality (transformed sodium),initial,2017-03-30,GCST004267,Other measurement,#fee08b
3588,Asian,8765.0,28360221.0,Boger CA,Blood osmolality (transformed sodium),initial,2017-03-30,GCST004267,Other measurement,#3288bd
3589,European,45889.0,28360221.0,Boger CA,Blood osmolality (transformed sodium),initial,2017-03-30,GCST004267,Other measurement,#d53e4f
3590,European,17637.0,28360221.0,Boger CA,Blood osmolality (transformed sodium),replication,2017-03-30,GCST004267,Other measurement,#d53e4f
3591,European,3968.0,28358029.0,Afshari NA,Fuchs's corneal dystrophy,initial,2017-03-30,GCST004217,Neurological disorder,#d53e4f
3592,European,1449.0,28358029.0,Afshari NA,Fuchs's corneal dystrophy,replication,2017-03-30,GCST004217,Neurological disorder,#d53e4f
3593,European,1562.0,28355232.0,Ward-Caviness CK,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),initial,2017-03-29,GCST004224,Other measurement,#d53e4f
3594,African Am./Caribbean,538.0,28355232.0,Ward-Caviness CK,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),initial,2017-03-29,GCST004224,Other measurement,#fee08b
3595,European,1562.0,28355232.0,Ward-Caviness CK,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),initial,2017-03-29,GCST004224,Other measurement,#d53e4f
3596,African Am./Caribbean,538.0,28355232.0,Ward-Caviness CK,Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),initial,2017-03-29,GCST004224,Other measurement,#fee08b
3597,Asian,1790.0,28355295.0,Hong EP,Tuberculosis,initial,2017-03-29,GCST004226,Other disease,#3288bd
3598,Asian,679.0,28355295.0,Hong EP,Tuberculosis,replication,2017-03-29,GCST004226,Other disease,#3288bd
3599,European,30659.0,28346443.0,Melin BS,Glioma,initial,2017-03-27,GCST004347,Cancer,#d53e4f
3600,European,30659.0,28346443.0,Melin BS,Glioma,initial,2017-03-27,GCST004347,Cancer,#d53e4f
3601,Asian,1908.0,28346466.0,Chen G,Type 2 diabetes,initial,2017-03-27,GCST007620,Metabolic disorder,#3288bd
3602,African,10401.0,28346466.0,Chen G,Type 2 diabetes,replication,2017-03-27,GCST007620,Metabolic disorder,#fc8d59
3603,European,5161.0,28030426.0,Mahmoudpour SH,Angiotensin-converting enzyme inhibitor intolerance,initial,2017-03-27,GCST004029,Response to drug,#d53e4f
3604,European,63347.0,28346442.0,Phelan CM,Invasive epithelial ovarian cancer,initial,2017-03-27,GCST004415,Cancer,#d53e4f
3605,European,19036.0,28346442.0,Phelan CM,Ovarian cancer in BRCA1 mutation carriers,initial,2017-03-27,GCST004414,Other measurement,#d53e4f
3606,European,19036.0,28346442.0,Phelan CM,Ovarian cancer in BRCA1 mutation carriers,initial,2017-03-27,GCST004414,Cancer,#d53e4f
3607,European,41953.0,28346442.0,Phelan CM,Low-grade serous ovarian cancer,initial,2017-03-27,GCST004461,Cancer,#d53e4f
3608,European,53978.0,28346442.0,Phelan CM,High-grade serous ovarian cancer,initial,2017-03-27,GCST004480,Cancer,#d53e4f
3609,European,42895.0,28346442.0,Phelan CM,Serous borderline ovarian cancer,initial,2017-03-27,GCST004479,Cancer,#d53e4f
3610,European,54990.0,28346442.0,Phelan CM,Serous invasive ovarian cancer,initial,2017-03-27,GCST004478,Cancer,#d53e4f
3611,European,43507.0,28346442.0,Phelan CM,Mucinous ovarian carcinoma,initial,2017-03-27,GCST004419,Cancer,#d53e4f
3612,European,43751.0,28346442.0,Phelan CM,Endometrioid ovarian cancer,initial,2017-03-27,GCST004418,Cancer,#d53e4f
3613,European,42307.0,28346442.0,Phelan CM,Ovarian clear cell cancer,initial,2017-03-27,GCST004417,Cancer,#d53e4f
3614,European,85426.0,28346442.0,Phelan CM,Epithelial ovarian cancer,initial,2017-03-27,GCST004462,Cancer,#d53e4f
3615,European,24381.0,28346443.0,Melin BS,Glioblastoma,initial,2017-03-27,GCST004349,Cancer,#d53e4f
3616,European,24381.0,28346443.0,Melin BS,Glioblastoma,initial,2017-03-27,GCST004349,Cancer,#d53e4f
3617,European,12412.0,28346442.0,Phelan CM,Ovarian cancer in BRCA2 mutation carriers,initial,2017-03-27,GCST004416,Other measurement,#d53e4f
3618,European,12412.0,28346442.0,Phelan CM,Ovarian cancer in BRCA2 mutation carriers,initial,2017-03-27,GCST004416,Cancer,#d53e4f
3619,European,24009.0,28346443.0,Melin BS,Non-glioblastoma glioma,initial,2017-03-27,GCST004348,Cancer,#d53e4f
3620,European,24009.0,28346443.0,Melin BS,Non-glioblastoma glioma,initial,2017-03-27,GCST004348,Cancer,#d53e4f
3621,European,43907.0,28346442.0,Phelan CM,Low-grade serous and serous borderline ovarian cancer,initial,2017-03-27,GCST004481,Cancer,#d53e4f
3622,Asian,98.0,28352666.0,Liu TC,Paneth cell defects in Crohn's disease,initial,2017-03-23,GCST004251,Other measurement,#3288bd
3623,Asian,98.0,28352666.0,Liu TC,Paneth cell defects in Crohn's disease,initial,2017-03-23,GCST004251,Digestive system disorder,#3288bd
3624,European,1680.0,28333968.0,Nielsen TR,Free thyroxine concentration,initial,2017-03-23,GCST004277,Other measurement,#d53e4f
3625,European,2129.0,28333968.0,Nielsen TR,Free thyroxine concentration,replication,2017-03-23,GCST004277,Other measurement,#d53e4f
3626,European,2998.0,28386217.0,Ritter ML,Attention deficit hyperactivity disorder and obsessive compulsive disorder,initial,2017-03-23,GCST004223,Neurological disorder,#d53e4f
3628,European,2998.0,28386217.0,Ritter ML,Attention deficit hyperactivity disorder and obsessive compulsive disorder,initial,2017-03-23,GCST004223,Neurological disorder,#d53e4f
3630,European,2129.0,28333968.0,Nielsen TR,Plasma thyroid-stimulating hormone levels,replication,2017-03-23,GCST004276,Other measurement,#d53e4f
3631,European,1680.0,28333968.0,Nielsen TR,Plasma thyroid-stimulating hormone levels,initial,2017-03-23,GCST004276,Other measurement,#d53e4f
3632,European,1000.0,28322352.0,Ran S,Lean body mass,initial,2017-03-21,GCST004218,Other measurement,#d53e4f
3633,European,2283.0,28322352.0,Ran S,Lean body mass,replication,2017-03-21,GCST004218,Other measurement,#d53e4f
3634,European,32241.0,28322246.0,McLaughlin RL,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy),initial,2017-03-21,GCST004252,Neurological disorder,#d53e4f
3635,Other/Mixed,79845.0,28322246.0,McLaughlin RL,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy),initial,2017-03-21,GCST004252,Neurological disorder,#99d594
3636,European,32241.0,28322246.0,McLaughlin RL,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy),initial,2017-03-21,GCST004252,Neurological disorder,#d53e4f
3637,Other/Mixed,79845.0,28322246.0,McLaughlin RL,Amyotrophic lateral sclerosis or schizophrenia (pleiotropy),initial,2017-03-21,GCST004252,Neurological disorder,#99d594
3638,European,212171.0,28319091.0,Styrkarsdottir U,Osteoarthritis (with total hip replacement),initial,2017-03-20,GCST004199,Other measurement,#d53e4f
3639,European,212171.0,28319091.0,Styrkarsdottir U,Osteoarthritis (with total hip replacement),initial,2017-03-20,GCST004199,Other disease,#d53e4f
3640,European,696.0,28317342.0,Hivert MF,Adiponectin levels in pregnancy,replication,2017-03-20,GCST004289,Other measurement,#d53e4f
3641,European,1322.0,28317342.0,Hivert MF,Adiponectin levels in pregnancy,initial,2017-03-20,GCST004289,Other measurement,#d53e4f
3642,Asian,152.0,28415562.0,Li X,High-altitude pulmonary edema,initial,2017-03-18,GCST004200,Other disease,#3288bd
3643,Asian,503.0,28415562.0,Li X,High-altitude pulmonary edema,replication,2017-03-18,GCST004200,Other disease,#3288bd
3644,Asian,2497.0,28314753.0,Terao C,Systemic sclerosis,initial,2017-03-17,GCST004202,Neurological disorder,#3288bd
3645,Asian,2427.0,28314753.0,Terao C,Systemic sclerosis,replication,2017-03-17,GCST004202,Neurological disorder,#3288bd
3646,European,11907.0,28314753.0,Terao C,Systemic sclerosis,replication,2017-03-17,GCST004202,Neurological disorder,#d53e4f
3647,European,2340.0,28314753.0,Terao C,Systemic sclerosis,initial,2017-03-17,GCST004202,Neurological disorder,#d53e4f
3648,African Am./Caribbean,373.0,28300201.0,Hernandez-Pacheco N,Skin pigmentation,replication,2017-03-16,GCST004219,Other trait,#fee08b
3649,Hispanic/Latin American,285.0,28300201.0,Hernandez-Pacheco N,Skin pigmentation,initial,2017-03-16,GCST004219,Other trait,#807dba
3650,Asian,3521.0,28298293.0,Hu Y,Palmitoleic acid (16:1n-7) levels,initial,2017-03-15,GCST004339,Lipid or lipoprotein measurement,#3288bd
3651,Asian,3521.0,28298293.0,Hu Y,Nervonic acid (24:1n-9) levels,initial,2017-03-15,GCST004341,Lipid or lipoprotein measurement,#3288bd
3652,European,12020.0,28298293.0,Hu Y,Nervonic acid (24:1n-9) levels,initial,2017-03-15,GCST004341,Lipid or lipoprotein measurement,#d53e4f
3653,Asian,3521.0,28298293.0,Hu Y,Erucic acid (22:1n-9) levels,initial,2017-03-15,GCST004340,Lipid or lipoprotein measurement,#3288bd
3654,European,12020.0,28298293.0,Hu Y,Erucic acid (22:1n-9) levels,initial,2017-03-15,GCST004340,Lipid or lipoprotein measurement,#d53e4f
3655,European,12020.0,28298293.0,Hu Y,Gondoic acid (20:1n-9) levels,initial,2017-03-15,GCST004337,Lipid or lipoprotein measurement,#d53e4f
3656,Asian,3521.0,28298293.0,Hu Y,Gondoic acid (20:1n-9) levels,initial,2017-03-15,GCST004337,Lipid or lipoprotein measurement,#3288bd
3657,Asian,3521.0,28298293.0,Hu Y,Oleic acid (18:1n-9) levels,initial,2017-03-15,GCST004338,Lipid or lipoprotein measurement,#3288bd
3658,Asian,3521.0,28298293.0,Hu Y,Vaccenic acid (18:1n-7) levels,initial,2017-03-15,GCST004342,Lipid or lipoprotein measurement,#3288bd
3659,European,12020.0,28298293.0,Hu Y,Vaccenic acid (18:1n-7) levels,initial,2017-03-15,GCST004342,Lipid or lipoprotein measurement,#d53e4f
3660,European,396.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#d53e4f
3661,Asian,349.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#3288bd
3662,African Am./Caribbean,327.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#fee08b
3663,European,396.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#d53e4f
3664,Asian,349.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#3288bd
3665,African Am./Caribbean,327.0,28292921.0,Boldry EJ,"Urinary 1,3-butadiene metabolite levels in smokers",initial,2017-03-14,GCST004254,Other measurement,#fee08b
3666,European,157.0,28179588.0,Fagerholm R,Survival in TP53 positive breast cancer,initial,2017-03-14,GCST004228,Other measurement,#d53e4f
3667,European,157.0,28179588.0,Fagerholm R,Survival in TP53 positive breast cancer,initial,2017-03-14,GCST004228,Cancer,#d53e4f
3668,European,4610.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),replication,2017-03-14,GCST004229,Other measurement,#d53e4f
3669,European,572.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),initial,2017-03-14,GCST004229,Other measurement,#d53e4f
3670,European,4610.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),replication,2017-03-14,GCST004229,Cancer,#d53e4f
3671,European,572.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),initial,2017-03-14,GCST004229,Cancer,#d53e4f
3672,European,4610.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),replication,2017-03-14,GCST004229,Other measurement,#d53e4f
3673,European,572.0,28179588.0,Fagerholm R,Survival in breast cancer (TP53 expression interaction),initial,2017-03-14,GCST004229,Other measurement,#d53e4f
3674,African Am./Caribbean,2041.0,28295283.0,Wang H,Colorectal cancer,replication,2017-03-13,GCST004168,Cancer,#fee08b
3675,African Am./Caribbean,6597.0,28295283.0,Wang H,Colorectal cancer,initial,2017-03-13,GCST004168,Cancer,#fee08b
3676,Hispanic/Latin American,5941.0,28295283.0,Wang H,Colorectal cancer,replication,2017-03-13,GCST004168,Cancer,#807dba
3677,African Am./Caribbean,1753.0,28295283.0,Wang H,Colon cancer,replication,2017-03-13,GCST004167,Cancer,#fee08b
3678,African Am./Caribbean,6154.0,28295283.0,Wang H,Colon cancer,initial,2017-03-13,GCST004167,Cancer,#fee08b
3679,African Am./Caribbean,1434.0,28295283.0,Wang H,Rectal cancer,replication,2017-03-13,GCST004169,Cancer,#fee08b
3680,African Am./Caribbean,5146.0,28295283.0,Wang H,Rectal cancer,initial,2017-03-13,GCST004169,Cancer,#fee08b
3681,African Am./Caribbean,9020.0,28296344.0,Chen G,Body mass index,replication,2017-03-13,GCST004255,Body measurement,#fee08b
3682,African,1411.0,28296344.0,Chen G,Body mass index,replication,2017-03-13,GCST004255,Body measurement,#fc8d59
3683,African,1570.0,28296344.0,Chen G,Body mass index,initial,2017-03-13,GCST004255,Body measurement,#fc8d59
3685,European,339.0,28283553.0,Srinivasan L,Sepsis in extremely premature infants,initial,2017-03-10,GCST004230,Other trait,#d53e4f
3686,European,460.0,28781888.0,Mobuchon L,Uveal melanoma,replication,2017-03-10,GCST004661,Cancer,#d53e4f
3687,European,660.0,28781888.0,Mobuchon L,Uveal melanoma,initial,2017-03-10,GCST004661,Cancer,#d53e4f
3688,European,626.0,28439531.0,Aslibekyan S,Plasma trimethylamine N-oxide levels,initial,2017-03-08,GCST004484,Other measurement,#d53e4f
3689,European,22518.0,28272467.0,Heilmann-Heimbach S,Male-pattern baldness,initial,2017-03-08,GCST007815,Other measurement,#d53e4f
3690,European,19546.0,28270201.0,Nagy R,Diastolic blood pressure,initial,2017-03-07,GCST004203,Other measurement,#d53e4f
3691,European,19695.0,28270201.0,Nagy R,Waist-to-hip ratio adjusted for body mass index,initial,2017-03-07,GCST004216,Body measurement,#d53e4f
3692,European,19293.0,28270201.0,Nagy R,Urea levels,initial,2017-03-07,GCST004215,Other measurement,#d53e4f
3693,European,16347.0,28270201.0,Nagy R,Creatinine levels,initial,2017-03-07,GCST004214,Other measurement,#d53e4f
3694,European,19920.0,28270201.0,Nagy R,Resting heart rate,initial,2017-03-07,GCST004213,Cardiovascular measurement,#d53e4f
3695,European,19965.0,28270201.0,Nagy R,Height,initial,2017-03-07,GCST004212,Body measurement,#d53e4f
3696,European,2077.0,28270201.0,Nagy R,Urate levels,initial,2017-03-07,GCST004211,Other measurement,#d53e4f
3697,European,19480.0,28270201.0,Nagy R,Body fat percentage,initial,2017-03-07,GCST004210,Body measurement,#d53e4f
3698,European,19259.0,28270201.0,Nagy R,"Cholesterol, total",initial,2017-03-07,GCST004209,Lipid or lipoprotein measurement,#d53e4f
3699,European,19900.0,28270201.0,Nagy R,Body mass index,initial,2017-03-07,GCST004208,Body measurement,#d53e4f
3700,European,19223.0,28270201.0,Nagy R,HDL cholesterol,initial,2017-03-07,GCST004207,Lipid or lipoprotein measurement,#d53e4f
3701,European,16174.0,28270201.0,Nagy R,Fasting plasma glucose,initial,2017-03-07,GCST004206,Other measurement,#d53e4f
3702,European,19546.0,28270201.0,Nagy R,Pulse pressure,initial,2017-03-07,GCST004205,Cardiovascular measurement,#d53e4f
3703,European,19547.0,28270201.0,Nagy R,Systolic blood pressure,initial,2017-03-07,GCST004204,Other measurement,#d53e4f
3704,Hispanic/Latin American,3238.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#807dba
3705,European,10732.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#d53e4f
3706,European,3755.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),replication,2017-03-07,GCST004225,Other measurement,#d53e4f
3707,African Am./Caribbean,4329.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),replication,2017-03-07,GCST004225,Other measurement,#fee08b
3708,African Am./Caribbean,2391.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#fee08b
3709,Hispanic/Latin American,3238.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#807dba
3710,European,10732.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#d53e4f
3711,European,3755.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),replication,2017-03-07,GCST004225,Other measurement,#d53e4f
3712,African Am./Caribbean,4329.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),replication,2017-03-07,GCST004225,Other measurement,#fee08b
3713,African Am./Caribbean,2391.0,28265120.0,Polimanti R,Alcohol misuse (trauma interaction),initial,2017-03-07,GCST004225,Other measurement,#fee08b
3714,Other/Mixed,258.0,28262088.0,Melroy-Greif WE,Post traumatic stress disorder symptom count in trauma-exposed individuals,initial,2017-03-06,GCST005550,Biological process,#99d594
3715,Hispanic/Latin American,254.0,28262088.0,Melroy-Greif WE,Post traumatic stress disorder symptom count in trauma-exposed individuals,initial,2017-03-06,GCST005550,Biological process,#807dba
3716,Other/Mixed,258.0,28262088.0,Melroy-Greif WE,Post traumatic stress disorder symptom count in trauma-exposed individuals,initial,2017-03-06,GCST005550,Other measurement,#99d594
3717,Hispanic/Latin American,254.0,28262088.0,Melroy-Greif WE,Post traumatic stress disorder symptom count in trauma-exposed individuals,initial,2017-03-06,GCST005550,Other measurement,#807dba
3718,Asian,1354.0,28265093.0,Malik R,Large artery stroke,initial,2017-03-06,GCST007991,Cardiovascular disease,#3288bd
3719,European,11170.0,28265093.0,Malik R,Large artery stroke,initial,2017-03-06,GCST007991,Cardiovascular disease,#d53e4f
3720,Asian,8839.0,28273873.0,Park YM,Hypertension,initial,2017-03-05,GCST004143,Cardiovascular disease,#3288bd
3721,Asian,848.0,28274756.0,Mhatre S,Gallbladder cancer,replication,2017-03-03,GCST004201,Cancer,#3288bd
3722,Asian,2751.0,28274756.0,Mhatre S,Gallbladder cancer,initial,2017-03-03,GCST004201,Cancer,#3288bd
3723,European,4057.0,28253294.0,Vonk JM,Adult onset asthma (smoking interaction),initial,2017-03-02,GCST004220,Biological process,#d53e4f
3724,European,12475.0,28253294.0,Vonk JM,Adult onset asthma (smoking interaction),replication,2017-03-02,GCST004220,Biological process,#d53e4f
3725,European,4057.0,28253294.0,Vonk JM,Adult onset asthma (smoking interaction),initial,2017-03-02,GCST004220,Other disease,#d53e4f
3726,European,12475.0,28253294.0,Vonk JM,Adult onset asthma (smoking interaction),replication,2017-03-02,GCST004220,Other disease,#d53e4f
3727,European,2107.0,28253294.0,Vonk JM,Adult onset asthma in ever-smokers,initial,2017-03-02,GCST004222,Biological process,#d53e4f
3728,European,7496.0,28253294.0,Vonk JM,Adult onset asthma in ever-smokers,replication,2017-03-02,GCST004222,Biological process,#d53e4f
3729,European,2107.0,28253294.0,Vonk JM,Adult onset asthma in ever-smokers,initial,2017-03-02,GCST004222,Other disease,#d53e4f
3730,European,7496.0,28253294.0,Vonk JM,Adult onset asthma in ever-smokers,replication,2017-03-02,GCST004222,Other disease,#d53e4f
3731,European,1950.0,28253294.0,Vonk JM,Adult onset asthma in non-smokers,initial,2017-03-02,GCST004221,Other disease,#d53e4f
3732,European,4979.0,28253294.0,Vonk JM,Adult onset asthma in non-smokers,replication,2017-03-02,GCST004221,Other disease,#d53e4f
3733,Hispanic/Latin American,7746.0,28254843.0,Qi Q,Type 2 diabetes,initial,2017-03-02,GCST004758,Metabolic disorder,#807dba
3737,Asian,10464.0,28334814.0,Zhu Z,Adolescent idiopathic scoliosis,replication,2017-02-28,GCST004288,Other disease,#3288bd
3738,Asian,3560.0,28334814.0,Zhu Z,Adolescent idiopathic scoliosis,initial,2017-02-28,GCST004288,Other disease,#3288bd
3739,European,2209.0,28250457.0,Scerri TS,Macular telangiectasia type 2,initial,2017-02-27,GCST004171,Neurological disorder,#d53e4f
3740,European,1306.0,28250457.0,Scerri TS,Macular telangiectasia type 2,replication,2017-02-27,GCST004171,Neurological disorder,#d53e4f
3741,European,997.0,28240269.0,Suhre K,Blood protein levels,initial,2017-02-27,GCST004365,Other measurement,#d53e4f
3742,Other/Mixed,338.0,28240269.0,Suhre K,Blood protein levels,replication,2017-02-27,GCST004365,Other measurement,#99d594
3743,Asian,1001.0,28334792.0,Nongmaithem SS,Vitamin B12 levels,initial,2017-02-27,GCST004161,Other measurement,#3288bd
3744,Asian,3418.0,28334792.0,Nongmaithem SS,Vitamin B12 levels,replication,2017-02-27,GCST004161,Other measurement,#3288bd
3745,Asian,6084.0,28232668.0,Yu Y,Nonsyndromic cleft lip with cleft palate,initial,2017-02-24,GCST004166,Other trait,#3288bd
3746,Asian,5888.0,28232668.0,Yu Y,Nonsyndromic cleft lip with cleft palate,replication,2017-02-24,GCST004166,Other trait,#3288bd
3747,Asian,6084.0,28232668.0,Yu Y,Nonsyndromic cleft lip with cleft palate,initial,2017-02-24,GCST004166,Other trait,#3288bd
3748,Asian,5888.0,28232668.0,Yu Y,Nonsyndromic cleft lip with cleft palate,replication,2017-02-24,GCST004166,Other trait,#3288bd
3749,European,7189.0,28282560.0,Pott J,Carotid plaque burden,initial,2017-02-24,GCST004162,Cardiovascular measurement,#d53e4f
3750,European,8703.0,28649644.0,Pivot X,HER2 status in breast cancer,initial,2017-02-23,GCST004528,Other measurement,#d53e4f
3751,European,8703.0,28649644.0,Pivot X,HER2 status in breast cancer,initial,2017-02-23,GCST004528,Cancer,#d53e4f
3752,European,287338.0,28223688.0,Bjornsdottir G,Sciatica caused by lumbar disc herniation (treated with microdiscectomy),initial,2017-02-22,GCST004098,Other disease,#d53e4f
3753,European,287338.0,28223688.0,Bjornsdottir G,Sciatica caused by lumbar disc herniation (treated with microdiscectomy),initial,2017-02-22,GCST004098,Other trait,#d53e4f
3754,European,287338.0,28223688.0,Bjornsdottir G,Sciatica caused by lumbar disc herniation (treated with microdiscectomy),initial,2017-02-22,GCST004098,Other measurement,#d53e4f
3755,European,304241.0,28177523.0,Lin Y,Basal cell carcinoma,initial,2017-02-22,GCST004113,Cancer,#d53e4f
3756,European,9179.0,28224759.0,Pei YF,Body fat mass,initial,2017-02-22,GCST004141,Other measurement,#d53e4f
3757,Asian,22814.0,28334899.0,Spracklen CN,Total cholesterol levels,initial,2017-02-21,GCST004231,Lipid or lipoprotein measurement,#3288bd
3758,Asian,57490.0,28334899.0,Spracklen CN,Total cholesterol levels,replication,2017-02-21,GCST004231,Lipid or lipoprotein measurement,#3288bd
3759,Asian,8741.0,28334899.0,Spracklen CN,HDL cholesterol levels,replication,2017-02-21,GCST004232,Lipid or lipoprotein measurement,#3288bd
3760,Asian,34930.0,28334899.0,Spracklen CN,HDL cholesterol levels,initial,2017-02-21,GCST004232,Lipid or lipoprotein measurement,#3288bd
3761,European,187167.0,28334899.0,Spracklen CN,HDL cholesterol levels,initial,2017-02-21,GCST004232,Lipid or lipoprotein measurement,#d53e4f
3762,Asian,18421.0,28334899.0,Spracklen CN,Triglyceride levels,initial,2017-02-21,GCST004238,Lipid or lipoprotein measurement,#3288bd
3763,Asian,38060.0,28334899.0,Spracklen CN,Triglyceride levels,replication,2017-02-21,GCST004238,Lipid or lipoprotein measurement,#3288bd
3764,European,177861.0,28334899.0,Spracklen CN,Triglyceride levels,initial,2017-02-21,GCST004237,Lipid or lipoprotein measurement,#d53e4f
3765,Asian,28183.0,28334899.0,Spracklen CN,Triglyceride levels,initial,2017-02-21,GCST004237,Lipid or lipoprotein measurement,#3288bd
3766,Asian,10857.0,28334899.0,Spracklen CN,Triglyceride levels,replication,2017-02-21,GCST004237,Lipid or lipoprotein measurement,#3288bd
3767,Asian,37842.0,28334899.0,Spracklen CN,LDL cholesterol levels,replication,2017-02-21,GCST004236,Lipid or lipoprotein measurement,#3288bd
3768,Asian,22526.0,28334899.0,Spracklen CN,LDL cholesterol levels,initial,2017-02-21,GCST004236,Lipid or lipoprotein measurement,#3288bd
3769,Asian,32576.0,28334899.0,Spracklen CN,Total cholesterol levels,initial,2017-02-21,GCST004235,Lipid or lipoprotein measurement,#3288bd
3770,European,187365.0,28334899.0,Spracklen CN,Total cholesterol levels,initial,2017-02-21,GCST004235,Lipid or lipoprotein measurement,#d53e4f
3771,Asian,10855.0,28334899.0,Spracklen CN,Total cholesterol levels,replication,2017-02-21,GCST004235,Lipid or lipoprotein measurement,#3288bd
3772,Asian,25169.0,28334899.0,Spracklen CN,HDL cholesterol levels,initial,2017-02-21,GCST004234,Lipid or lipoprotein measurement,#3288bd
3773,Asian,45953.0,28334899.0,Spracklen CN,HDL cholesterol levels,replication,2017-02-21,GCST004234,Lipid or lipoprotein measurement,#3288bd
3774,European,173082.0,28334899.0,Spracklen CN,LDL cholesterol levels,initial,2017-02-21,GCST004233,Lipid or lipoprotein measurement,#d53e4f
3775,Asian,32285.0,28334899.0,Spracklen CN,LDL cholesterol levels,initial,2017-02-21,GCST004233,Lipid or lipoprotein measurement,#3288bd
3776,Asian,8478.0,28334899.0,Spracklen CN,LDL cholesterol levels,replication,2017-02-21,GCST004233,Lipid or lipoprotein measurement,#3288bd
3777,African Am./Caribbean,5334.0,28203683.0,Heit JA,Venous thromboembolism adjusted for sickle cell variant rs77121243-T,initial,2017-02-16,GCST004068,Cardiovascular disease,#fee08b
3778,European,5892.0,28193307.0,Lin BD,Monocyte-lymphocyte ratio,initial,2017-02-14,GCST004170,Hematological measurement,#d53e4f
3779,European,52874.0,28196072.0,Hagenaars SP,Male-pattern baldness,initial,2017-02-14,GCST006661,Other disease,#d53e4f
3780,European,5892.0,28193307.0,Lin BD,Monocyte count,initial,2017-02-14,GCST004164,Hematological measurement,#d53e4f
3781,European,108976.0,28194004.0,Deary V,Self-reported tiredness,initial,2017-02-14,GCST004158,Other measurement,#d53e4f
3782,European,290551.0,28195142.0,Gudmundsson J,Thyroid cancer,initial,2017-02-14,GCST004144,Cancer,#d53e4f
3783,European,245.0,28187132.0,Kiryluk K,Serum galactose-deficient IgA1 levels,initial,2017-02-10,GCST004159,Other measurement,#d53e4f
3784,Asian,653.0,28187132.0,Kiryluk K,Serum galactose-deficient IgA1 levels,replication,2017-02-10,GCST004159,Other measurement,#3288bd
3785,European,785.0,28187132.0,Kiryluk K,Serum galactose-deficient IgA1 levels,replication,2017-02-10,GCST004159,Other measurement,#d53e4f
3786,Asian,950.0,28187132.0,Kiryluk K,Serum galactose-deficient IgA1 levels,initial,2017-02-10,GCST004159,Other measurement,#3288bd
3787,European,291407.0,28212542.0,Ransohoff KJ,Melanoma,initial,2017-02-09,GCST004142,Cancer,#d53e4f
3788,European,2830.0,28212542.0,Ransohoff KJ,Melanoma,replication,2017-02-09,GCST004142,Cancer,#d53e4f
3789,European,933.0,28181694.0,Chesi A,Pediatric bone mineral content (hip),initial,2017-02-09,GCST004180,Other measurement,#d53e4f
3790,European,486.0,28181694.0,Chesi A,Pediatric bone mineral content (hip),replication,2017-02-09,GCST004180,Other measurement,#d53e4f
3791,European,933.0,28181694.0,Chesi A,Pediatric bone mineral content (spine),initial,2017-02-09,GCST004182,Other measurement,#d53e4f
3792,European,486.0,28181694.0,Chesi A,Pediatric bone mineral content (spine),replication,2017-02-09,GCST004182,Other measurement,#d53e4f
3793,European,933.0,28181694.0,Chesi A,Pediatric bone mineral content (radius),initial,2017-02-09,GCST004175,Other measurement,#d53e4f
3794,European,486.0,28181694.0,Chesi A,Pediatric bone mineral content (radius),replication,2017-02-09,GCST004175,Other measurement,#d53e4f
3795,European,933.0,28181694.0,Chesi A,Pediatric bone mineral density (hip),initial,2017-02-09,GCST004178,Other measurement,#d53e4f
3796,European,486.0,28181694.0,Chesi A,Pediatric bone mineral density (hip),replication,2017-02-09,GCST004178,Other measurement,#d53e4f
3797,European,933.0,28181694.0,Chesi A,Pediatric bone mineral density (femoral neck),initial,2017-02-09,GCST004177,Other measurement,#d53e4f
3798,European,486.0,28181694.0,Chesi A,Pediatric bone mineral density (femoral neck),replication,2017-02-09,GCST004177,Other measurement,#d53e4f
3799,European,933.0,28181694.0,Chesi A,Pediatric bone mineral content (femoral neck),initial,2017-02-09,GCST004179,Other measurement,#d53e4f
3800,European,486.0,28181694.0,Chesi A,Pediatric bone mineral content (femoral neck),replication,2017-02-09,GCST004179,Other measurement,#d53e4f
3801,European,933.0,28181694.0,Chesi A,Pediatric bone mineral density (spine),initial,2017-02-09,GCST004181,Other measurement,#d53e4f
3802,European,486.0,28181694.0,Chesi A,Pediatric bone mineral density (spine),replication,2017-02-09,GCST004181,Other measurement,#d53e4f
3803,European,933.0,28181694.0,Chesi A,Pediatric areal bone mineral density (radius),initial,2017-02-09,GCST004176,Other measurement,#d53e4f
3804,European,486.0,28181694.0,Chesi A,Pediatric areal bone mineral density (radius),replication,2017-02-09,GCST004176,Other measurement,#d53e4f
3805,European,6392.0,28167838.0,Deckert J,Agoraphobic traits,replication,2017-02-07,GCST004109,Other measurement,#d53e4f
3806,European,1370.0,28167838.0,Deckert J,Agoraphobic traits,initial,2017-02-07,GCST004109,Other measurement,#d53e4f
3807,European,17691.0,28165464.0,Law PJ,Chronic lymphocytic leukemia,initial,2017-02-06,GCST004146,Cancer,#d53e4f
3808,European,6107.0,28165464.0,Law PJ,Chronic lymphocytic leukemia,replication,2017-02-06,GCST004146,Cancer,#d53e4f
3809,European,14569.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4- carriers,initial,2017-02-06,GCST004249,Neurological disorder,#d53e4f
3810,African Am./Caribbean,2877.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4- carriers,initial,2017-02-06,GCST004249,Neurological disorder,#fee08b
3811,Other/Mixed,115.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4- carriers,initial,2017-02-06,GCST004249,Neurological disorder,#99d594
3812,European,14248.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4- carriers,replication,2017-02-06,GCST004249,Neurological disorder,#d53e4f
3813,Asian,1159.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4- carriers,initial,2017-02-06,GCST004249,Neurological disorder,#3288bd
3814,European,12039.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4+ carriers,replication,2017-02-06,GCST004248,Neurological disorder,#d53e4f
3815,European,11751.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4+ carriers,initial,2017-02-06,GCST004248,Neurological disorder,#d53e4f
3816,African Am./Caribbean,2106.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4+ carriers,initial,2017-02-06,GCST004248,Neurological disorder,#fee08b
3817,Asian,686.0,28183528.0,Jun GR,Alzheimer's disease in APOE e4+ carriers,initial,2017-02-06,GCST004248,Neurological disorder,#3288bd
3818,European,57176.0,28166213.0,Wain LV,Lung function (FEV1/FVC),replication,2017-02-06,GCST004185,Other measurement,#d53e4f
3820,European,48943.0,28166213.0,Wain LV,Lung function (FEV1/FVC),initial,2017-02-06,GCST004185,Other measurement,#d53e4f
3821,European,26320.0,28183528.0,Jun GR,Alzheimer's disease (APOE e4 interaction),initial,2017-02-06,GCST004247,Neurological disorder,#d53e4f
3822,African Am./Caribbean,4983.0,28183528.0,Jun GR,Alzheimer's disease (APOE e4 interaction),initial,2017-02-06,GCST004247,Neurological disorder,#fee08b
3823,Asian,1845.0,28183528.0,Jun GR,Alzheimer's disease (APOE e4 interaction),initial,2017-02-06,GCST004247,Neurological disorder,#3288bd
3824,Other/Mixed,115.0,28183528.0,Jun GR,Alzheimer's disease (APOE e4 interaction),initial,2017-02-06,GCST004247,Neurological disorder,#99d594
3825,European,26287.0,28183528.0,Jun GR,Alzheimer's disease (APOE e4 interaction),replication,2017-02-06,GCST004247,Neurological disorder,#d53e4f
3827,European,48943.0,28166213.0,Wain LV,Lung function (FVC),initial,2017-02-06,GCST004184,Other measurement,#d53e4f
3828,European,57176.0,28166213.0,Wain LV,Lung function (FVC),replication,2017-02-06,GCST004184,Other measurement,#d53e4f
3829,African Am./Caribbean,4983.0,28183528.0,Jun GR,Alzheimer's disease,initial,2017-02-06,GCST004246,Neurological disorder,#fee08b
3830,Asian,1845.0,28183528.0,Jun GR,Alzheimer's disease,initial,2017-02-06,GCST004246,Neurological disorder,#3288bd
3831,Other/Mixed,115.0,28183528.0,Jun GR,Alzheimer's disease,initial,2017-02-06,GCST004246,Neurological disorder,#99d594
3832,European,26287.0,28183528.0,Jun GR,Alzheimer's disease,replication,2017-02-06,GCST004246,Neurological disorder,#d53e4f
3833,European,26320.0,28183528.0,Jun GR,Alzheimer's disease,initial,2017-02-06,GCST004246,Neurological disorder,#d53e4f
3834,African Am./Caribbean,3522.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,initial,2017-02-06,GCST004147,Other disease,#fee08b
3835,Hispanic/Latin American,600.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,initial,2017-02-06,GCST004147,Other disease,#807dba
3836,Asian,6940.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,initial,2017-02-06,GCST004147,Other disease,#3288bd
3837,European,23162.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,replication,2017-02-06,GCST004147,Other disease,#d53e4f
3838,Asian,358.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,replication,2017-02-06,GCST004147,Other disease,#3288bd
3839,European,47856.0,28166215.0,Hobbs BD,Chronic obstructive pulmonary disease,initial,2017-02-06,GCST004147,Other disease,#d53e4f
3841,European,48943.0,28166213.0,Wain LV,Lung function (FEV1),initial,2017-02-06,GCST004183,Other measurement,#d53e4f
3842,European,57176.0,28166213.0,Wain LV,Lung function (FEV1),replication,2017-02-06,GCST004183,Other measurement,#d53e4f
3843,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004108,Other measurement,#807dba
3844,European,497.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other measurement,#d53e4f
3845,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other measurement,#807dba
3846,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004108,Other disease,#807dba
3847,European,497.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other disease,#d53e4f
3848,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other disease,#807dba
3849,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004108,Other measurement,#807dba
3850,European,497.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other measurement,#d53e4f
3851,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1/FVC) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004108,Other measurement,#807dba
3852,European,497.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other measurement,#d53e4f
3853,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004107,Other measurement,#807dba
3854,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other measurement,#807dba
3855,European,497.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other measurement,#d53e4f
3856,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004107,Other measurement,#807dba
3857,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other measurement,#807dba
3858,European,497.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other disease,#d53e4f
3859,Hispanic/Latin American,440.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),initial,2017-02-04,GCST004107,Other disease,#807dba
3860,Hispanic/Latin American,605.0,28167095.0,Forno E,Lung function (FEV1) in asthma (dust mite allergen exposure interaction),replication,2017-02-04,GCST004107,Other disease,#807dba
3861,Asian,599.0,28155865.0,Chen H,Mathematical ability,replication,2017-02-03,GCST004123,Biological process,#3288bd
3862,Asian,998.0,28155865.0,Chen H,Mathematical ability,initial,2017-02-03,GCST004123,Biological process,#3288bd
3863,European,2053.0,28256260.0,Siitonen A,Early-onset Parkinson's disease,initial,2017-02-02,GCST004138,Neurological disorder,#d53e4f
3864,Asian,457.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,initial,2017-02-02,GCST004160,Response to drug,#3288bd
3865,Asian,340.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,replication,2017-02-02,GCST004160,Response to drug,#3288bd
3866,Asian,457.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,initial,2017-02-02,GCST004160,Cancer,#3288bd
3867,Asian,340.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,replication,2017-02-02,GCST004160,Cancer,#3288bd
3868,Asian,457.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,initial,2017-02-02,GCST004160,Other measurement,#3288bd
3869,Asian,340.0,28163062.0,Matsuura K,Hepatocellular carcinoma in post hepatitis C eradication by interferon therapy,replication,2017-02-02,GCST004160,Other measurement,#3288bd
3870,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count,replication,2017-02-01,GCST004126,Hematological measurement,#807dba
3871,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count,initial,2017-02-01,GCST004126,Hematological measurement,#807dba
3872,European,16169.0,28053049.0,Sennblad B,Factor XI,initial,2017-02-01,GCST004124,Hematological measurement,#d53e4f
3873,European,2045.0,28053049.0,Sennblad B,Factor XI,replication,2017-02-01,GCST004124,Hematological measurement,#d53e4f
3874,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count (neutrophil),initial,2017-02-01,GCST004128,Hematological measurement,#807dba
3875,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count (neutrophil),replication,2017-02-01,GCST004128,Hematological measurement,#807dba
3876,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count (monocyte),initial,2017-02-01,GCST004129,Hematological measurement,#807dba
3877,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count (monocyte),replication,2017-02-01,GCST004129,Hematological measurement,#807dba
3878,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count (lymphocyte),initial,2017-02-01,GCST004130,Hematological measurement,#807dba
3879,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count (lymphocyte),replication,2017-02-01,GCST004130,Hematological measurement,#807dba
3880,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count (eosinophil),initial,2017-02-01,GCST004135,Hematological measurement,#807dba
3881,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count (eosinophil),replication,2017-02-01,GCST004135,Hematological measurement,#807dba
3882,Hispanic/Latin American,7200.0,28158719.0,Jain D,White blood cell count (basophil),replication,2017-02-01,GCST004127,Inflammatory measurement,#807dba
3883,Hispanic/Latin American,11809.0,28158719.0,Jain D,White blood cell count (basophil),initial,2017-02-01,GCST004127,Inflammatory measurement,#807dba
3884,European,28503.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels,initial,2017-01-31,GCST004093,Other measurement,#d53e4f
3885,Hispanic/Latin American,2716.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels,replication,2017-01-31,GCST004093,Other measurement,#807dba
3886,Asian,2518.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels,replication,2017-01-31,GCST004093,Other measurement,#3288bd
3887,European,11796.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels,replication,2017-01-31,GCST004093,Other measurement,#d53e4f
3888,African Am./Caribbean,1585.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels,replication,2017-01-31,GCST004093,Other measurement,#fee08b
3889,European,995.0,28139761.0,Pasanen A,Bronchiolitis,initial,2017-01-31,GCST004140,Other trait,#d53e4f
3890,European,1936.0,28139761.0,Pasanen A,Bronchiolitis,replication,2017-01-31,GCST004140,Other trait,#d53e4f
3891,European,28503.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels (conditioned on lead SNPs),initial,2017-01-31,GCST004094,Other measurement,#d53e4f
3892,Hispanic/Latin American,2716.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels (conditioned on lead SNPs),replication,2017-01-31,GCST004094,Other measurement,#807dba
3893,Asian,2518.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels (conditioned on lead SNPs),replication,2017-01-31,GCST004094,Other measurement,#3288bd
3894,African Am./Caribbean,1585.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels (conditioned on lead SNPs),replication,2017-01-31,GCST004094,Other measurement,#fee08b
3895,European,6193.0,28139693.0,Hoffmann TJ,Prostate-specific antigen levels (conditioned on lead SNPs),replication,2017-01-31,GCST004094,Other measurement,#d53e4f
3896,European,393.0,27903959.0,Lv H,Core binding factor acute myeloid leukemia,initial,2017-01-31,GCST008413,Cancer,#d53e4f
3897,European,190318.0,28135244.0,Warren HR,Diastolic blood pressure,replication,2017-01-30,GCST004280,Other measurement,#d53e4f
3898,European,140886.0,28135244.0,Warren HR,Diastolic blood pressure,initial,2017-01-30,GCST004280,Other measurement,#d53e4f
3899,European,190318.0,28135244.0,Warren HR,Systolic blood pressure,replication,2017-01-30,GCST004279,Other measurement,#d53e4f
3900,European,140882.0,28135244.0,Warren HR,Systolic blood pressure,initial,2017-01-30,GCST004279,Other measurement,#d53e4f
3901,European,190318.0,28135244.0,Warren HR,Pulse pressure,replication,2017-01-30,GCST004278,Cardiovascular measurement,#d53e4f
3902,European,140886.0,28135244.0,Warren HR,Pulse pressure,initial,2017-01-30,GCST004278,Cardiovascular measurement,#d53e4f
3903,Asian,2587.0,28130311.0,Tan W,Acute-on-chronic liver failure in hepatitis B,replication,2017-01-27,GCST004165,Digestive system disorder,#3288bd
3904,Asian,780.0,28130311.0,Tan W,Acute-on-chronic liver failure in hepatitis B,initial,2017-01-27,GCST004165,Digestive system disorder,#3288bd
3905,Asian,2587.0,28130311.0,Tan W,Acute-on-chronic liver failure in hepatitis B,replication,2017-01-27,GCST004165,Digestive system disorder,#3288bd
3906,Asian,780.0,28130311.0,Tan W,Acute-on-chronic liver failure in hepatitis B,initial,2017-01-27,GCST004165,Digestive system disorder,#3288bd
3907,Asian,370.0,28120872.0,Li X,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,replication,2017-01-25,GCST004097,Cancer,#3288bd
3908,Asian,226.0,28120872.0,Li X,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,initial,2017-01-25,GCST004097,Cancer,#3288bd
3909,Asian,370.0,28120872.0,Li X,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,replication,2017-01-25,GCST004097,Response to drug,#3288bd
3910,Asian,226.0,28120872.0,Li X,Response to platinum-based neoadjuvant chemotherapy in cervical cancer,initial,2017-01-25,GCST004097,Response to drug,#3288bd
3911,Other/Mixed,863.0,28118524.0,Saxena R,Rheumatoid arthritis,initial,2017-01-24,GCST004172,Immune system disorder,#99d594
3912,Other/Mixed,504.0,28118524.0,Saxena R,Rheumatoid arthritis,replication,2017-01-24,GCST004172,Immune system disorder,#99d594
3913,Other/Mixed,506.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative),initial,2017-01-24,GCST004173,Immune system disorder,#99d594
3914,Other/Mixed,279.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and anti-cyclic citrullinated peptide seronegative),replication,2017-01-24,GCST004173,Immune system disorder,#99d594
3915,Other/Mixed,459.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),replication,2017-01-24,GCST004174,Immune system disorder,#99d594
3916,Other/Mixed,709.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),initial,2017-01-24,GCST004174,Immune system disorder,#99d594
3917,Other/Mixed,459.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),replication,2017-01-24,GCST004174,Other measurement,#99d594
3918,Other/Mixed,709.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),initial,2017-01-24,GCST004174,Other measurement,#99d594
3919,Other/Mixed,459.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),replication,2017-01-24,GCST004174,Other measurement,#99d594
3920,Other/Mixed,709.0,28118524.0,Saxena R,Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive),initial,2017-01-24,GCST004174,Other measurement,#99d594
3921,Asian,64851.0,28115744.0,Ikeda M,Bipolar disorder,initial,2017-01-24,GCST004139,Neurological disorder,#3288bd
3922,European,16731.0,28115744.0,Ikeda M,Bipolar disorder,initial,2017-01-24,GCST004139,Neurological disorder,#d53e4f
3923,European,1027.0,28115739.0,Smith AH,Methadone dose in opioid dependence,initial,2017-01-24,GCST004136,Neurological disorder,#d53e4f
3924,African Am./Caribbean,383.0,28115739.0,Smith AH,Methadone dose in opioid dependence,initial,2017-01-24,GCST004136,Neurological disorder,#fee08b
3925,European,1027.0,28115739.0,Smith AH,Methadone dose in opioid dependence,initial,2017-01-24,GCST004136,Other measurement,#d53e4f
3926,African Am./Caribbean,383.0,28115739.0,Smith AH,Methadone dose in opioid dependence,initial,2017-01-24,GCST004136,Other measurement,#fee08b
3927,European,411.0,28128768.0,Ferrari R,Frontotemporal dementia (age at onset),initial,2017-01-23,GCST004096,Other measurement,#d53e4f
3928,European,411.0,28128768.0,Ferrari R,Frontotemporal dementia (age at onset),initial,2017-01-23,GCST004096,Neurological disorder,#d53e4f
3929,European,14421.0,28112199.0,Law PJ,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",initial,2017-01-23,GCST004099,Cancer,#d53e4f
3930,European,14421.0,28112199.0,Law PJ,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",initial,2017-01-23,GCST004099,Cancer,#d53e4f
3931,European,14421.0,28112199.0,Law PJ,"B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",initial,2017-01-23,GCST004099,Cancer,#d53e4f
3932,European,91953.0,28107422.0,de Vries PS,Fibrinogen levels,initial,2017-01-20,GCST004122,Hematological measurement,#d53e4f
3933,European,91953.0,28107422.0,de Vries PS,Fibrinogen levels,initial,2017-01-20,GCST004121,Hematological measurement,#d53e4f
3934,Asian,354.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,replication,2017-01-19,GCST004072,Other disease,#3288bd
3935,Asian,805.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,initial,2017-01-19,GCST004072,Other disease,#3288bd
3936,Asian,354.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,replication,2017-01-19,GCST004072,Other disease,#3288bd
3937,Asian,805.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,initial,2017-01-19,GCST004072,Other disease,#3288bd
3938,Asian,354.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,replication,2017-01-19,GCST004072,Response to drug,#3288bd
3939,Asian,805.0,28100913.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications,initial,2017-01-19,GCST004072,Response to drug,#3288bd
3940,European,229.0,28109725.0,Fuchs O,Exhaled nitric oxide output,initial,2017-01-18,GCST004060,Other measurement,#d53e4f
3941,European,229.0,28109725.0,Fuchs O,Exhaled nitric oxide levels,initial,2017-01-18,GCST004059,Other measurement,#d53e4f
3942,European,463.0,28100725.0,Chen J,Plasma t-tau levels,initial,2017-01-18,GCST004092,Other measurement,#d53e4f
3944,Asian,886.0,28098162.0,Hibar DP,Hippocampal volume,replication,2017-01-18,GCST003961,Other measurement,#3288bd
3945,African Am./Caribbean,562.0,28098162.0,Hibar DP,Hippocampal volume,replication,2017-01-18,GCST003961,Other measurement,#fee08b
3946,Hispanic/Latin American,1411.0,28098162.0,Hibar DP,Hippocampal volume,replication,2017-01-18,GCST003961,Other measurement,#807dba
3947,European,26814.0,28098162.0,Hibar DP,Hippocampal volume,initial,2017-01-18,GCST003961,Other measurement,#d53e4f
3948,European,3863.0,28098162.0,Hibar DP,Hippocampal volume,replication,2017-01-18,GCST003961,Other measurement,#d53e4f
3949,Hispanic/Latin American,768.0,28095793.0,Chittoor G,Glomerular load of uric acid,initial,2017-01-17,GCST004054,Cardiovascular measurement,#807dba
3950,European,35298.0,28093568.0,Trampush JW,Cognitive function,initial,2017-01-17,GCST004077,Biological process,#d53e4f
3951,Hispanic/Latin American,768.0,28095793.0,Chittoor G,Urinary uric acid to urinary creatinine ratio,initial,2017-01-17,GCST004056,Other measurement,#807dba
3952,Hispanic/Latin American,768.0,28095793.0,Chittoor G,Creatinine clearance,initial,2017-01-17,GCST004057,Other measurement,#807dba
3953,Hispanic/Latin American,768.0,28095793.0,Chittoor G,Fractional excretion of uric acid,initial,2017-01-17,GCST004055,Cardiovascular measurement,#807dba
3954,Hispanic/Latin American,768.0,28095793.0,Chittoor G,Uric acid clearance,initial,2017-01-17,GCST004058,Cardiovascular measurement,#807dba
3955,European,3409.0,28060188.0,Hamet P,Type 2 diabetes (age of onset),initial,2017-01-16,GCST004125,Metabolic disorder,#d53e4f
3956,African Am./Caribbean,111.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Liver enzyme measurement,#fee08b
3957,European,488.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Liver enzyme measurement,#d53e4f
3958,Hispanic/Latin American,60.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Liver enzyme measurement,#807dba
3959,Other/Mixed,56.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Liver enzyme measurement,#99d594
3960,African Am./Caribbean,111.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Response to drug,#fee08b
3961,European,488.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Response to drug,#d53e4f
3962,Hispanic/Latin American,60.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Response to drug,#807dba
3963,Other/Mixed,56.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Response to drug,#99d594
3964,African Am./Caribbean,111.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Cancer,#fee08b
3965,European,488.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Cancer,#d53e4f
3966,Hispanic/Latin American,60.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Cancer,#807dba
3967,Other/Mixed,56.0,28090653.0,Liu Y,Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL),initial,2017-01-16,GCST004250,Cancer,#99d594
3969,European,96.0,28108127.0,Eitel I,Takotsubo syndrome,initial,2017-01-15,GCST004095,Cardiovascular disease,#d53e4f
3970,Other/Mixed,589.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#99d594
3971,Hispanic/Latin American,475.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#807dba
3972,European,1145.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#d53e4f
3973,Asian,2385.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,initial,2017-01-13,GCST004088,Other trait,#3288bd
3974,European,3715.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,initial,2017-01-13,GCST004088,Other trait,#d53e4f
3975,Other/Mixed,589.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#99d594
3976,Hispanic/Latin American,475.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#807dba
3977,European,1145.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,replication,2017-01-13,GCST004088,Other trait,#d53e4f
3978,Asian,2385.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,initial,2017-01-13,GCST004088,Other trait,#3288bd
3979,European,3715.0,28087736.0,Ludwig KU,Nonsyndromic cleft lip with or without cleft palate,initial,2017-01-13,GCST004088,Other trait,#d53e4f
3981,Other/Mixed,1.0,28084903.0,Hallberg P,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2017-01-13,GCST004049,Response to drug,#99d594
3982,European,123.0,28084903.0,Hallberg P,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2017-01-13,GCST004049,Response to drug,#d53e4f
3984,Other/Mixed,1.0,28084903.0,Hallberg P,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2017-01-13,GCST004049,Other trait,#99d594
3985,European,123.0,28084903.0,Hallberg P,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2017-01-13,GCST004049,Other trait,#d53e4f
3987,European,10778.0,28082259.0,Pankow JS,Protein C levels,initial,2017-01-12,GCST006119,Hematological measurement,#d53e4f
3988,African Am./Caribbean,2706.0,28082259.0,Pankow JS,Protein C levels,initial,2017-01-12,GCST006119,Hematological measurement,#fee08b
3989,European,4167.0,28081215.0,Pardo LM,Multiple keratinocyte cancers,initial,2017-01-12,GCST004134,Cancer,#d53e4f
3991,European,4167.0,28081215.0,Pardo LM,Multiple keratinocyte cancers,initial,2017-01-12,GCST004134,Other measurement,#d53e4f
3993,European,4167.0,28081215.0,Pardo LM,Multiple keratinocyte cancers,initial,2017-01-12,GCST004134,Cancer,#d53e4f
3997,European,5613.0,28081371.0,Sanders AE,Temporomandibular joint disorder,replication,2017-01-12,GCST004034,Other disease,#d53e4f
3998,Hispanic/Latin American,636.0,28081371.0,Sanders AE,Temporomandibular joint disorder,replication,2017-01-12,GCST004034,Other disease,#807dba
3999,Hispanic/Latin American,10153.0,28081371.0,Sanders AE,Temporomandibular joint disorder,initial,2017-01-12,GCST004034,Other disease,#807dba
4000,European,170.0,27883235.0,Martino DJ,Peanut allergy,initial,2017-01-11,GCST003881,Other measurement,#d53e4f
4001,Asian,24.0,27883235.0,Martino DJ,Peanut allergy,initial,2017-01-11,GCST003881,Other measurement,#3288bd
4002,Other/Mixed,27.0,27883235.0,Martino DJ,Peanut allergy,initial,2017-01-11,GCST003881,Other measurement,#99d594
4003,European,5212.0,27883235.0,Martino DJ,Peanut allergy,replication,2017-01-11,GCST003881,Other measurement,#d53e4f
4004,Other/Mixed,74.0,27883235.0,Martino DJ,Peanut allergy,replication,2017-01-11,GCST003881,Other measurement,#99d594
4005,Asian,1585.0,28076899.0,Taylor KE,Sjögren's syndrome,initial,2017-01-11,GCST004062,Neurological disorder,#3288bd
4006,Asian,876.0,28076899.0,Taylor KE,Sjögren's syndrome,initial,2017-01-11,GCST004061,Neurological disorder,#3288bd
4007,European,4131.0,28076899.0,Taylor KE,Sjögren's syndrome,initial,2017-01-11,GCST004061,Neurological disorder,#d53e4f
4008,African,546.0,28076899.0,Taylor KE,Sjögren's syndrome,initial,2017-01-11,GCST004061,Neurological disorder,#fc8d59
4009,Other/Mixed,401.0,28076899.0,Taylor KE,Sjögren's syndrome,initial,2017-01-11,GCST004061,Neurological disorder,#99d594
4011,Asian,7333.0,28073927.0,Springelkamp H,Optic cup area,replication,2017-01-10,GCST004137,Other measurement,#3288bd
4012,European,22484.0,28073927.0,Springelkamp H,Optic cup area,initial,2017-01-10,GCST004137,Other measurement,#d53e4f
4013,European,2588.0,28077804.0,Ben-Avraham D,Gait speed in old age,replication,2017-01-10,GCST004110,Other measurement,#d53e4f
4014,European,31478.0,28077804.0,Ben-Avraham D,Gait speed in old age,initial,2017-01-10,GCST004110,Other measurement,#d53e4f
4015,Asian,8352.0,28073927.0,Springelkamp H,Intraocular pressure,replication,2017-01-10,GCST004074,Other measurement,#3288bd
4016,European,29578.0,28073927.0,Springelkamp H,Intraocular pressure,initial,2017-01-10,GCST004074,Other measurement,#d53e4f
4017,European,6789.0,28073367.0,Zeng X,Cough,replication,2017-01-10,GCST004073,Other measurement,#d53e4f
4018,European,7976.0,28073367.0,Zeng X,Cough,initial,2017-01-10,GCST004073,Other measurement,#d53e4f
4019,African Am./Caribbean,2382.0,28070124.0,Meyers JL,Fast beta electroencephalogram,initial,2017-01-10,GCST004048,Other measurement,#fee08b
4020,European,33181.0,28072414.0,Charney AW,Bipolar disorder,initial,2017-01-10,GCST003962,Neurological disorder,#d53e4f
4021,European,6789.0,28073367.0,Zeng X,Dyspnea,replication,2017-01-10,GCST004112,Other measurement,#d53e4f
4022,European,7976.0,28073367.0,Zeng X,Dyspnea,initial,2017-01-10,GCST004112,Other measurement,#d53e4f
4023,European,7976.0,28073367.0,Zeng X,Phlegm,initial,2017-01-10,GCST004111,Other measurement,#d53e4f
4024,European,6789.0,28073367.0,Zeng X,Phlegm,replication,2017-01-10,GCST004111,Other measurement,#d53e4f
4025,Asian,7302.0,28073927.0,Springelkamp H,Optic disc area,replication,2017-01-10,GCST004076,Other measurement,#3288bd
4026,European,22504.0,28073927.0,Springelkamp H,Optic disc area,initial,2017-01-10,GCST004076,Other measurement,#d53e4f
4027,Asian,8168.0,28073927.0,Springelkamp H,Vertical cup-disc ratio,replication,2017-01-10,GCST004075,Other measurement,#3288bd
4028,European,23899.0,28073927.0,Springelkamp H,Vertical cup-disc ratio,initial,2017-01-10,GCST004075,Other measurement,#d53e4f
4030,European,2734.0,28067912.0,Lee JC,Poor prognosis in Crohn's disease,initial,2017-01-09,GCST004053,Digestive system disorder,#d53e4f
4031,European,2734.0,28067912.0,Lee JC,Poor prognosis in Crohn's disease,initial,2017-01-09,GCST004053,Other measurement,#d53e4f
4034,European,1377.0,28056976.0,Paziewska A,Primary biliary cholangitis,initial,2017-01-06,GCST004120,Cancer,#d53e4f
4035,Asian,90.0,28059113.0,Hao J,Palmar length-width ratio in Kashin-Beck disease,initial,2017-01-06,GCST004091,Other disease,#3288bd
4036,Asian,403.0,28059113.0,Hao J,Palmar length-width ratio in Kashin-Beck disease,replication,2017-01-06,GCST004091,Other disease,#3288bd
4037,European,1054.0,28056976.0,Paziewska A,Primary sclerosing cholangitis,initial,2017-01-06,GCST004119,Digestive system disorder,#d53e4f
4038,African,76.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Response to drug,#fc8d59
4039,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Response to drug,#fc8d59
4040,African,203.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),initial,2017-01-05,GCST004114,Response to drug,#fc8d59
4041,African,76.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Other disease,#fc8d59
4042,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Other disease,#fc8d59
4043,African,203.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),initial,2017-01-05,GCST004114,Other disease,#fc8d59
4044,African,76.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Digestive system disorder,#fc8d59
4045,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),replication,2017-01-05,GCST004114,Digestive system disorder,#fc8d59
4046,African,203.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (drug-induced liver injury),initial,2017-01-05,GCST004114,Digestive system disorder,#fc8d59
4047,Asian,2886.0,28062665.0,Kawashima M,Primary biliary cholangitis,initial,2017-01-05,GCST004145,Cancer,#3288bd
4048,Asian,7024.0,28062665.0,Kawashima M,Primary biliary cholangitis,replication,2017-01-05,GCST004145,Cancer,#3288bd
4049,Asian,261.0,28065765.0,Nagao Y,Lichen planus in hepatitis C,initial,2017-01-05,GCST004090,Other disease,#3288bd
4050,European,45.0,28065765.0,Nagao Y,Lichen planus in hepatitis C,replication,2017-01-05,GCST004090,Other disease,#d53e4f
4051,Asian,261.0,28065765.0,Nagao Y,Lichen planus in hepatitis C,initial,2017-01-05,GCST004090,Digestive system disorder,#3288bd
4052,European,45.0,28065765.0,Nagao Y,Lichen planus in hepatitis C,replication,2017-01-05,GCST004090,Digestive system disorder,#d53e4f
4053,African,333.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,initial,2017-01-05,GCST004118,Response to drug,#fc8d59
4054,African,122.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,replication,2017-01-05,GCST004118,Response to drug,#fc8d59
4055,African,333.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,initial,2017-01-05,GCST004118,Immune system disorder,#fc8d59
4056,African,122.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,replication,2017-01-05,GCST004118,Immune system disorder,#fc8d59
4057,African,333.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,initial,2017-01-05,GCST004118,Other disease,#fc8d59
4058,African,122.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV,replication,2017-01-05,GCST004118,Other disease,#fc8d59
4059,African,398.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),initial,2017-01-05,GCST004117,Response to drug,#fc8d59
4060,African,87.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),replication,2017-01-05,GCST004117,Response to drug,#fc8d59
4061,African,398.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),initial,2017-01-05,GCST004117,Other disease,#fc8d59
4062,African,87.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),replication,2017-01-05,GCST004117,Other disease,#fc8d59
4063,African,398.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),initial,2017-01-05,GCST004117,Other disease,#fc8d59
4064,African,87.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (rash),replication,2017-01-05,GCST004117,Other disease,#fc8d59
4065,African,205.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome),initial,2017-01-05,GCST004116,Response to drug,#fc8d59
4066,African,205.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome),initial,2017-01-05,GCST004116,Immune system disorder,#fc8d59
4067,African,205.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (hypersensitivity syndrome),initial,2017-01-05,GCST004116,Other disease,#fc8d59
4068,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Response to drug,#fc8d59
4069,African,233.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),initial,2017-01-05,GCST004115,Response to drug,#fc8d59
4070,African,71.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Response to drug,#fc8d59
4071,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4072,African,233.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),initial,2017-01-05,GCST004115,Other disease,#fc8d59
4073,African,71.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4074,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4075,African,233.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),initial,2017-01-05,GCST004115,Other disease,#fc8d59
4076,African,71.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4077,African,35.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4078,African,233.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),initial,2017-01-05,GCST004115,Other disease,#fc8d59
4079,African,71.0,28062682.0,Carr DF,Nevirapine-induced hypersensitivity in HIV (Stevens-Johnson syndrome or toxic epidermal necrosis),replication,2017-01-05,GCST004115,Other disease,#fc8d59
4081,Asian,3763.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#3288bd
4082,European,3969.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#d53e4f
4083,Other/Mixed,3161.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#99d594
4085,Asian,3763.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#3288bd
4086,European,3969.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#d53e4f
4087,Other/Mixed,3161.0,28054174.0,Leslie EJ,Cleft lip with or without cleft palate,initial,2017-01-04,GCST004050,Other trait,#99d594
4091,European,4865.0,28054174.0,Leslie EJ,Orofacial clefts,initial,2017-01-04,GCST004051,Other trait,#d53e4f
4092,Asian,4579.0,28054174.0,Leslie EJ,Orofacial clefts,initial,2017-01-04,GCST004051,Other trait,#3288bd
4093,Other/Mixed,3303.0,28054174.0,Leslie EJ,Orofacial clefts,initial,2017-01-04,GCST004051,Other trait,#99d594
4094,Asian,977.0,28054174.0,Leslie EJ,Cleft palate,initial,2017-01-04,GCST004052,Other trait,#3288bd
4095,Other/Mixed,846.0,28054174.0,Leslie EJ,Cleft palate,initial,2017-01-04,GCST004052,Other trait,#99d594
4096,European,1761.0,28054174.0,Leslie EJ,Cleft palate,initial,2017-01-04,GCST004052,Other trait,#d53e4f
4098,Asian,2567.0,28046027.0,Kim T,NHDL cholesterol to HDL cholesterol ratio,replication,2017-01-03,GCST004035,Lipid or lipoprotein measurement,#3288bd
4099,Asian,5292.0,28046027.0,Kim T,NHDL cholesterol to HDL cholesterol ratio,initial,2017-01-03,GCST004035,Lipid or lipoprotein measurement,#3288bd
4100,Asian,725.0,28045058.0,Kim SW,Behcet's disease,replication,2017-01-03,GCST004019,Cardiovascular disease,#3288bd
4101,Asian,796.0,28045058.0,Kim SW,Behcet's disease,initial,2017-01-03,GCST004019,Cardiovascular disease,#3288bd
4102,Asian,2567.0,28046027.0,Kim T,Triglyceride to HDL cholesterol ratio,replication,2017-01-03,GCST004037,Lipid or lipoprotein measurement,#3288bd
4103,Asian,5292.0,28046027.0,Kim T,Triglyceride to HDL cholesterol ratio,initial,2017-01-03,GCST004037,Lipid or lipoprotein measurement,#3288bd
4104,Asian,2567.0,28046027.0,Kim T,LDL cholesterol to HDL cholesterol ratio,replication,2017-01-03,GCST004036,Lipid or lipoprotein measurement,#3288bd
4105,Asian,5292.0,28046027.0,Kim T,LDL cholesterol to HDL cholesterol ratio,initial,2017-01-03,GCST004036,Lipid or lipoprotein measurement,#3288bd
4123,Other/Mixed,1279.0,28222112.0,Dumitrescu L,Resistance to antihypertensive treatment in hypertension,initial,2017-01-01,GCST004163,Cardiovascular disease,#99d594
4124,European,2427.0,28222112.0,Dumitrescu L,Resistance to antihypertensive treatment in hypertension,initial,2017-01-01,GCST004163,Cardiovascular disease,#d53e4f
4125,Hispanic/Latin American,3596.0,28061514.0,Nannini DR,Optic nerve measurement (cup-to-disc ratio),initial,2017-01-01,GCST004047,Other measurement,#807dba
4126,Hispanic/Latin American,941.0,28061514.0,Nannini DR,Optic nerve measurement (cup-to-disc ratio),replication,2017-01-01,GCST004047,Other measurement,#807dba
4127,Asian,2058.0,28952330.0,Chen SP,Migraine without aura,initial,2017-01-01,GCST004900,Cardiovascular disease,#3288bd
4128,Asian,1724.0,28952330.0,Chen SP,Migraine without aura,replication,2017-01-01,GCST004900,Cardiovascular disease,#3288bd
4129,European,646.0,28317148.0,Campo C,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2017-01-01,GCST003964,Neurological disorder,#d53e4f
4130,European,646.0,28317148.0,Campo C,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2017-01-01,GCST003964,Cancer,#d53e4f
4131,European,646.0,28317148.0,Campo C,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2017-01-01,GCST003964,Response to drug,#d53e4f
4132,European,10602.0,28043905.0,Nicoletti P,Drug-induced liver injury (terbinafine),initial,2016-12-30,GCST004078,Digestive system disorder,#d53e4f
4133,European,10602.0,28043905.0,Nicoletti P,Drug-induced liver injury (terbinafine),initial,2016-12-30,GCST004078,Response to drug,#d53e4f
4134,African Am./Caribbean,10235.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Cardiovascular measurement,#fee08b
4135,Hispanic/Latin American,13808.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Cardiovascular measurement,#807dba
4136,European,45706.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Cardiovascular measurement,#d53e4f
4137,African Am./Caribbean,10235.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#fee08b
4138,Hispanic/Latin American,13808.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#807dba
4139,European,45706.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#d53e4f
4140,African Am./Caribbean,10235.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#fee08b
4141,Hispanic/Latin American,13808.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#807dba
4142,European,45706.0,28039329.0,Noordam R,RR interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004011,Response to drug,#d53e4f
4143,European,11450.0,28043905.0,Nicoletti P,Drug-induced liver injury,initial,2016-12-30,GCST004086,Digestive system disorder,#d53e4f
4145,European,511.0,28039263.0,Wheeler HE,Cisplatin-induced ototoxicity,initial,2016-12-30,GCST003898,Other trait,#d53e4f
4147,European,511.0,28039263.0,Wheeler HE,Cisplatin-induced ototoxicity,initial,2016-12-30,GCST003898,Response to drug,#d53e4f
4148,European,41951.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#d53e4f
4149,Hispanic/Latin American,69749.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#807dba
4150,African Am./Caribbean,10235.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#fee08b
4151,European,41951.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Cardiovascular measurement,#d53e4f
4152,Hispanic/Latin American,69749.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Cardiovascular measurement,#807dba
4153,African Am./Caribbean,10235.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Cardiovascular measurement,#fee08b
4154,European,41951.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#d53e4f
4155,Hispanic/Latin American,69749.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#807dba
4156,African Am./Caribbean,10235.0,28039329.0,Noordam R,QT interval (tricyclic/tetracyclic antidepressant use interaction),initial,2016-12-30,GCST004010,Response to drug,#fee08b
4157,European,10732.0,28043905.0,Nicoletti P,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs),initial,2016-12-30,GCST004087,Response to drug,#d53e4f
4158,European,10732.0,28043905.0,Nicoletti P,Drug-induced liver injury (nonsteroidal anti-inflammatory drugs),initial,2016-12-30,GCST004087,Digestive system disorder,#d53e4f
4159,European,10631.0,28043905.0,Nicoletti P,Drug-induced liver injury (fluoroquinolones),initial,2016-12-30,GCST004085,Response to drug,#d53e4f
4160,European,10631.0,28043905.0,Nicoletti P,Drug-induced liver injury (fluoroquinolones),initial,2016-12-30,GCST004085,Digestive system disorder,#d53e4f
4161,European,10655.0,28043905.0,Nicoletti P,Drug-induced liver injury (anti-tuberculosis drugs),initial,2016-12-30,GCST004084,Response to drug,#d53e4f
4162,European,10655.0,28043905.0,Nicoletti P,Drug-induced liver injury (anti-tuberculosis drugs),initial,2016-12-30,GCST004084,Digestive system disorder,#d53e4f
4163,European,10655.0,28043905.0,Nicoletti P,Drug-induced liver injury (diclofenac),initial,2016-12-30,GCST004083,Response to drug,#d53e4f
4164,European,10655.0,28043905.0,Nicoletti P,Drug-induced liver injury (diclofenac),initial,2016-12-30,GCST004083,Digestive system disorder,#d53e4f
4165,European,10652.0,28043905.0,Nicoletti P,Drug-induced liver injury (nitrofurantoin),initial,2016-12-30,GCST004082,Response to drug,#d53e4f
4166,European,10652.0,28043905.0,Nicoletti P,Drug-induced liver injury (nitrofurantoin),initial,2016-12-30,GCST004082,Digestive system disorder,#d53e4f
4167,European,10911.0,28043905.0,Nicoletti P,Drug-induced cholestatic/mixed liver injury,initial,2016-12-30,GCST004081,Digestive system disorder,#d53e4f
4168,European,10647.0,28043905.0,Nicoletti P,Drug-induced liver injury (statins),initial,2016-12-30,GCST004080,Response to drug,#d53e4f
4169,European,10647.0,28043905.0,Nicoletti P,Drug-induced liver injury (statins),initial,2016-12-30,GCST004080,Digestive system disorder,#d53e4f
4170,European,11062.0,28043905.0,Nicoletti P,Drug-induced hepatocellular liver injury,initial,2016-12-30,GCST004079,Digestive system disorder,#d53e4f
4171,European,11259.0,28041642.0,Carmona FD,Giant cell arteritis,initial,2016-12-29,GCST003928,Cardiovascular disease,#d53e4f
4172,European,1519.0,28029757.0,Merkel PA,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase,initial,2016-12-28,GCST003977,Immune system disorder,#d53e4f
4173,European,3582.0,28029757.0,Merkel PA,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to myeloperoxidase,initial,2016-12-28,GCST003977,Immune system disorder,#d53e4f
4174,European,1564.0,28040410.0,Meyers JL,Fast beta electroencephalogram,initial,2016-12-28,GCST003902,Other measurement,#d53e4f
4175,European,1564.0,28040410.0,Meyers JL,Fast beta electroencephalogram,initial,2016-12-28,GCST003902,Other measurement,#d53e4f
4176,European,2036.0,28029757.0,Merkel PA,Antineutrophil cytoplasmic antibody-associated vasculitis,initial,2016-12-28,GCST003976,Immune system disorder,#d53e4f
4177,European,4479.0,28029757.0,Merkel PA,Antineutrophil cytoplasmic antibody-associated vasculitis,initial,2016-12-28,GCST003976,Immune system disorder,#d53e4f
4178,European,1944.0,28029757.0,Merkel PA,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3,initial,2016-12-28,GCST003978,Immune system disorder,#d53e4f
4179,European,4140.0,28029757.0,Merkel PA,Vasculitis associated with antineutrophil cytoplasmic antibody reactive to proteinase-3,initial,2016-12-28,GCST003978,Immune system disorder,#d53e4f
4181,European,523.0,28008999.0,Ostrowski J,Crohn's disease,replication,2016-12-23,GCST003959,Digestive system disorder,#d53e4f
4182,European,1172.0,28008999.0,Ostrowski J,Crohn's disease,initial,2016-12-23,GCST003959,Digestive system disorder,#d53e4f
4183,European,2059.0,28012008.0,Lu S,Spine bone mineral density and alcohol drinking,initial,2016-12-23,GCST003919,Other measurement,#d53e4f
4184,European,2059.0,28012008.0,Lu S,Spine bone mineral density and alcohol drinking,initial,2016-12-23,GCST003919,Other measurement,#d53e4f
4185,European,729.0,28008999.0,Ostrowski J,Inflammatory bowel disease,replication,2016-12-23,GCST003958,Digestive system disorder,#d53e4f
4186,European,1700.0,28008999.0,Ostrowski J,Inflammatory bowel disease,initial,2016-12-23,GCST003958,Digestive system disorder,#d53e4f
4187,European,636.0,28011674.0,Ruhle F,Venous thromboembolism,initial,2016-12-23,GCST004012,Cardiovascular disease,#d53e4f
4188,European,2059.0,28012008.0,Lu S,Hip bone mineral density and alcohol drinking,initial,2016-12-23,GCST003920,Other measurement,#d53e4f
4189,European,2059.0,28012008.0,Lu S,Hip bone mineral density and alcohol drinking,initial,2016-12-23,GCST003920,Other measurement,#d53e4f
4190,European,2059.0,28012008.0,Lu S,Whole body bone mineral density and alcohol drinking,initial,2016-12-23,GCST003921,Other measurement,#d53e4f
4191,European,2059.0,28012008.0,Lu S,Whole body bone mineral density and alcohol drinking,initial,2016-12-23,GCST003921,Other measurement,#d53e4f
4192,European,1110.0,28008999.0,Ostrowski J,Ulcerative colitis,initial,2016-12-23,GCST003960,Immune system disorder,#d53e4f
4193,European,558.0,28008999.0,Ostrowski J,Ulcerative colitis,replication,2016-12-23,GCST003960,Immune system disorder,#d53e4f
4194,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Mean corpuscular volume,replication,2016-12-22,GCST004004,Hematological measurement,#99d594
4195,European,29646.0,28017375.0,van Rooij FJA,Mean corpuscular volume,initial,2016-12-22,GCST004004,Hematological measurement,#d53e4f
4196,Asian,15074.0,28017375.0,van Rooij FJA,Mean corpuscular volume,initial,2016-12-22,GCST004004,Hematological measurement,#3288bd
4197,African Am./Caribbean,6150.0,28017375.0,van Rooij FJA,Mean corpuscular volume,initial,2016-12-22,GCST004004,Hematological measurement,#fee08b
4198,European,433.0,28002826.0,D'Adamo CR,Retinol levels,initial,2016-12-22,GCST003937,Other measurement,#d53e4f
4199,European,433.0,28002826.0,D'Adamo CR,Vitamin E levels (gamma-tocopherol),initial,2016-12-22,GCST003936,Other measurement,#d53e4f
4200,European,433.0,28002826.0,D'Adamo CR,Carotenoid levels (zeaxanthin),initial,2016-12-22,GCST003933,Other measurement,#d53e4f
4201,European,433.0,28002826.0,D'Adamo CR,Carotenoid levels (lutein),initial,2016-12-22,GCST003932,Other measurement,#d53e4f
4202,European,433.0,28002826.0,D'Adamo CR,Carotenoid levels (beta-carotene),initial,2016-12-22,GCST003931,Other measurement,#d53e4f
4203,European,433.0,28002826.0,D'Adamo CR,Vitamin E levels (alpha-tocopherol),initial,2016-12-22,GCST003935,Other measurement,#d53e4f
4204,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hematocrit,replication,2016-12-22,GCST004003,Hematological measurement,#99d594
4205,African Am./Caribbean,16128.0,28017375.0,van Rooij FJA,Hematocrit,initial,2016-12-22,GCST004003,Hematological measurement,#fee08b
4206,Asian,15252.0,28017375.0,van Rooij FJA,Hematocrit,initial,2016-12-22,GCST004003,Hematological measurement,#3288bd
4207,European,40258.0,28017375.0,van Rooij FJA,Hematocrit,initial,2016-12-22,GCST004003,Hematological measurement,#d53e4f
4208,Asian,455.0,28011712.0,Foo JN,Parkinson's disease,replication,2016-12-22,GCST003922,Neurological disorder,#3288bd
4209,Asian,22274.0,28011712.0,Foo JN,Parkinson's disease,replication,2016-12-22,GCST003922,Neurological disorder,#3288bd
4210,Asian,14006.0,28011712.0,Foo JN,Parkinson's disease,initial,2016-12-22,GCST003922,Neurological disorder,#3288bd
4212,Other/Mixed,540.0,28011710.0,Benyamin B,Circulating chromogranin peptide levels,initial,2016-12-22,GCST004038,Other measurement,#99d594
4214,Other/Mixed,540.0,28011710.0,Benyamin B,Circulating chromogranin peptide levels,initial,2016-12-22,GCST004038,Other measurement,#99d594
4215,European,433.0,28002826.0,D'Adamo CR,Carotenoid levels (alpha-carotene),initial,2016-12-22,GCST003938,Other measurement,#d53e4f
4216,European,433.0,28002826.0,D'Adamo CR,Carotenoid levels (cryptoxanthin),initial,2016-12-22,GCST003934,Other measurement,#d53e4f
4217,European,21020.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin,initial,2016-12-22,GCST004006,Hematological measurement,#d53e4f
4218,Asian,15062.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin,initial,2016-12-22,GCST004006,Hematological measurement,#3288bd
4219,African Am./Caribbean,3621.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin,initial,2016-12-22,GCST004006,Hematological measurement,#fee08b
4220,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin,replication,2016-12-22,GCST004006,Hematological measurement,#99d594
4221,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Red blood cell count,replication,2016-12-22,GCST004008,Hematological measurement,#99d594
4222,European,40258.0,28017375.0,van Rooij FJA,Red blood cell count,initial,2016-12-22,GCST004008,Hematological measurement,#d53e4f
4223,Asian,15252.0,28017375.0,van Rooij FJA,Red blood cell count,initial,2016-12-22,GCST004008,Hematological measurement,#3288bd
4224,African Am./Caribbean,16128.0,28017375.0,van Rooij FJA,Red blood cell count,initial,2016-12-22,GCST004008,Hematological measurement,#fee08b
4225,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin concentration,replication,2016-12-22,GCST004007,Hematological measurement,#99d594
4226,European,21020.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin concentration,initial,2016-12-22,GCST004007,Hematological measurement,#d53e4f
4227,Asian,15062.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin concentration,initial,2016-12-22,GCST004007,Hematological measurement,#3288bd
4228,African Am./Caribbean,3621.0,28017375.0,van Rooij FJA,Mean corpuscular hemoglobin concentration,initial,2016-12-22,GCST004007,Hematological measurement,#fee08b
4229,European,40258.0,28017375.0,van Rooij FJA,Hemoglobin levels,initial,2016-12-22,GCST004005,Hematological measurement,#d53e4f
4230,African Am./Caribbean,16128.0,28017375.0,van Rooij FJA,Hemoglobin levels,initial,2016-12-22,GCST004005,Hematological measurement,#fee08b
4231,Other/Mixed,16389.0,28017375.0,van Rooij FJA,Hemoglobin levels,replication,2016-12-22,GCST004005,Hematological measurement,#99d594
4232,Asian,15252.0,28017375.0,van Rooij FJA,Hemoglobin levels,initial,2016-12-22,GCST004005,Hematological measurement,#3288bd
4233,Asian,366.0,28011148.0,Zhang M,Trans-epidermal water loss,replication,2016-12-21,GCST003940,Other measurement,#3288bd
4234,Asian,611.0,28011148.0,Zhang M,Trans-epidermal water loss,initial,2016-12-21,GCST003940,Other measurement,#3288bd
4235,African Am./Caribbean,3964.0,28078323.0,Raj T,Cognitive decline (age-related),initial,2016-12-21,GCST003901,Other trait,#fee08b
4236,European,25713.0,27997041.0,Traylor M,Ischemic stroke,replication,2016-12-20,GCST004023,Other trait,#d53e4f
4237,European,22495.0,27997041.0,Traylor M,Ischemic stroke,initial,2016-12-20,GCST004023,Other trait,#d53e4f
4238,European,14162.0,27997041.0,Traylor M,Large artery stroke,initial,2016-12-20,GCST004022,Cardiovascular disease,#d53e4f
4239,European,19100.0,27997041.0,Traylor M,Large artery stroke,replication,2016-12-20,GCST004022,Cardiovascular disease,#d53e4f
4240,European,40371.0,27997041.0,Traylor M,Small vessel stroke,replication,2016-12-20,GCST004020,Cardiovascular disease,#d53e4f
4241,European,14560.0,27997041.0,Traylor M,Small vessel stroke,initial,2016-12-20,GCST004020,Cardiovascular disease,#d53e4f
4242,European,14000.0,27997041.0,Traylor M,Ischemic stroke (cardioembolic),initial,2016-12-20,GCST004021,Cardiovascular disease,#d53e4f
4243,European,41544.0,27997041.0,Traylor M,Ischemic stroke (cardioembolic),replication,2016-12-20,GCST004021,Cardiovascular disease,#d53e4f
4244,European,111648.0,27992416.0,Lane JM,Excessive daytime sleepiness,initial,2016-12-19,GCST003979,Other measurement,#d53e4f
4245,European,775.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,replication,2016-12-19,GCST003939,Response to drug,#d53e4f
4246,European,845.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,initial,2016-12-19,GCST003939,Response to drug,#d53e4f
4247,European,775.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,replication,2016-12-19,GCST003939,Cardiovascular disease,#d53e4f
4248,European,845.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,initial,2016-12-19,GCST003939,Cardiovascular disease,#d53e4f
4249,European,775.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,replication,2016-12-19,GCST003939,Cancer,#d53e4f
4250,European,845.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,initial,2016-12-19,GCST003939,Cancer,#d53e4f
4251,European,775.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,replication,2016-12-19,GCST003939,Response to drug,#d53e4f
4252,European,845.0,27993963.0,Schneider BP,Adverse response to chemotherapy (congestive heart failure) in breast cancer,initial,2016-12-19,GCST003939,Response to drug,#d53e4f
4253,European,59128.0,27992416.0,Lane JM,Insomnia,initial,2016-12-19,GCST003981,Other measurement,#d53e4f
4254,European,9861.0,27992413.0,Ji SG,Primary sclerosing cholangitis,replication,2016-12-19,GCST004030,Digestive system disorder,#d53e4f
4255,European,14890.0,27992413.0,Ji SG,Primary sclerosing cholangitis,initial,2016-12-19,GCST004030,Digestive system disorder,#d53e4f
4256,European,112586.0,27992416.0,Lane JM,Sleep traits (multi-trait analysis),initial,2016-12-19,GCST003982,Other measurement,#d53e4f
4257,European,112586.0,27992416.0,Lane JM,Sleep traits (multi-trait analysis),initial,2016-12-19,GCST003982,Biological process,#d53e4f
4258,European,112586.0,27992416.0,Lane JM,Sleep traits (multi-trait analysis),initial,2016-12-19,GCST003982,Other measurement,#d53e4f
4259,European,112586.0,27992416.0,Lane JM,Sleep traits (multi-trait analysis),initial,2016-12-19,GCST003982,Other measurement,#d53e4f
4260,European,111975.0,27992416.0,Lane JM,Sleep duration,initial,2016-12-19,GCST003980,Other measurement,#d53e4f
4261,Asian,115.0,27981573.0,Zhong WP,Response to clopidogrel therapy in coronary heart disease,initial,2016-12-16,GCST003899,Cardiovascular measurement,#3288bd
4262,Asian,115.0,27981573.0,Zhong WP,Response to clopidogrel therapy in coronary heart disease,initial,2016-12-16,GCST003899,Response to drug,#3288bd
4263,Asian,115.0,27981573.0,Zhong WP,Response to clopidogrel therapy in coronary heart disease,initial,2016-12-16,GCST003899,Cardiovascular disease,#3288bd
4264,Asian,17450.0,27976721.0,Wang Z,Leprosy,replication,2016-12-15,GCST004009,Neurological disorder,#3288bd
4265,Asian,6316.0,27976721.0,Wang Z,Leprosy,initial,2016-12-15,GCST004009,Neurological disorder,#3288bd
4266,Asian,434.0,28000841.0,Baek SH,Idiopathic osteonecrosis of the femoral head,initial,2016-12-14,GCST003918,Other disease,#3288bd
4267,European,458.0,27957625.0,Bacchelli E,Cluster headache,initial,2016-12-13,GCST003900,Other measurement,#d53e4f
4268,European,458.0,27957625.0,Bacchelli E,Cluster headache,initial,2016-12-13,GCST003900,Other trait,#d53e4f
4269,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Cardiovascular measurement,#807dba
4270,European,45002.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Cardiovascular measurement,#d53e4f
4271,African Am./Caribbean,11731.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Cardiovascular measurement,#fee08b
4272,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Response to drug,#807dba
4273,European,45002.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Response to drug,#d53e4f
4274,African Am./Caribbean,11731.0,27958378.0,Floyd JS,QRS interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004033,Response to drug,#fee08b
4275,European,8186.0,27989323.0,Ahola-Olli AV,TRAIL levels,initial,2016-12-13,GCST004424,Other measurement,#d53e4f
4276,European,1559.0,27989323.0,Ahola-Olli AV,Tumor necrosis factor beta levels,initial,2016-12-13,GCST004425,Other measurement,#d53e4f
4277,European,3454.0,27989323.0,Ahola-Olli AV,Tumor necrosis factor alpha levels,initial,2016-12-13,GCST004426,Inflammatory measurement,#d53e4f
4278,European,5998.0,27989323.0,Ahola-Olli AV,Stromal-cell-derived factor 1 alpha levels,initial,2016-12-13,GCST004427,Other measurement,#d53e4f
4279,European,3682.0,27989323.0,Ahola-Olli AV,Stem cell growth factor beta levels,initial,2016-12-13,GCST004428,Other measurement,#d53e4f
4280,European,8290.0,27989323.0,Ahola-Olli AV,Stem cell factor levels,initial,2016-12-13,GCST004429,Other measurement,#d53e4f
4281,European,3421.0,27989323.0,Ahola-Olli AV,RANTES levels,initial,2016-12-13,GCST004431,Inflammatory measurement,#d53e4f
4282,European,8293.0,27989323.0,Ahola-Olli AV,Platelet-derived growth factor BB levels,initial,2016-12-13,GCST004432,Other measurement,#d53e4f
4283,European,8243.0,27989323.0,Ahola-Olli AV,Macrophage inflammatory protein 1b levels,initial,2016-12-13,GCST004433,Other measurement,#d53e4f
4284,European,3522.0,27989323.0,Ahola-Olli AV,Macrophage inflammatory protein 1a levels,initial,2016-12-13,GCST004434,Other measurement,#d53e4f
4285,European,3685.0,27989323.0,Ahola-Olli AV,Monokine induced by gamma interferon levels,initial,2016-12-13,GCST004435,Other measurement,#d53e4f
4286,European,840.0,27989323.0,Ahola-Olli AV,Macrophage colony stimulating factor levels,initial,2016-12-13,GCST004436,Other measurement,#d53e4f
4287,European,843.0,27989323.0,Ahola-Olli AV,Monocyte chemoattractant protein-3 levels,initial,2016-12-13,GCST004437,Other measurement,#d53e4f
4288,European,8293.0,27989323.0,Ahola-Olli AV,Monocyte chemoattractant protein-1 levels,initial,2016-12-13,GCST004438,Other measurement,#d53e4f
4289,European,3483.0,27989323.0,Ahola-Olli AV,Interleukin-16 levels,initial,2016-12-13,GCST004430,Other measurement,#d53e4f
4290,European,8270.0,27989323.0,Ahola-Olli AV,Interleukin-12p70 levels,initial,2016-12-13,GCST004439,Other measurement,#d53e4f
4291,European,3685.0,27989323.0,Ahola-Olli AV,Interferon gamma-induced protein 10 levels,initial,2016-12-13,GCST004440,Other measurement,#d53e4f
4292,European,3494.0,27989323.0,Ahola-Olli AV,Macrophage Migration Inhibitory Factor levels,initial,2016-12-13,GCST004423,Other measurement,#d53e4f
4293,European,3636.0,27989323.0,Ahola-Olli AV,Interleukin-18 levels,initial,2016-12-13,GCST004441,Inflammatory measurement,#d53e4f
4294,European,7760.0,27989323.0,Ahola-Olli AV,Interleukin-17 levels,initial,2016-12-13,GCST004442,Other measurement,#d53e4f
4295,European,3557.0,27989323.0,Ahola-Olli AV,Interleukin-13 levels,initial,2016-12-13,GCST004443,Other measurement,#d53e4f
4296,European,7681.0,27989323.0,Ahola-Olli AV,Interleukin-10 levels,initial,2016-12-13,GCST004444,Inflammatory measurement,#d53e4f
4297,European,3634.0,27989323.0,Ahola-Olli AV,Interleukin-9 levels,initial,2016-12-13,GCST004450,Other measurement,#d53e4f
4298,European,3526.0,27989323.0,Ahola-Olli AV,Interleukin-8 levels,initial,2016-12-13,GCST004445,Inflammatory measurement,#d53e4f
4299,European,3409.0,27989323.0,Ahola-Olli AV,Interleukin-7 levels,initial,2016-12-13,GCST004451,Other measurement,#d53e4f
4300,European,8189.0,27989323.0,Ahola-Olli AV,Interleukin-6 levels,initial,2016-12-13,GCST004446,Inflammatory measurement,#d53e4f
4301,European,3364.0,27989323.0,Ahola-Olli AV,Interleukin-5 levels,initial,2016-12-13,GCST004452,Other measurement,#d53e4f
4302,European,8124.0,27989323.0,Ahola-Olli AV,Interleukin-4 levels,initial,2016-12-13,GCST004453,Other measurement,#d53e4f
4303,European,3677.0,27989323.0,Ahola-Olli AV,Interleukin-2 receptor antagonist levels,initial,2016-12-13,GCST004454,Other measurement,#d53e4f
4304,European,3475.0,27989323.0,Ahola-Olli AV,Interleukin-2 levels,initial,2016-12-13,GCST004455,Other measurement,#d53e4f
4305,European,3638.0,27989323.0,Ahola-Olli AV,Interleukin-1-receptor antagonist levels,initial,2016-12-13,GCST004447,Inflammatory measurement,#d53e4f
4306,European,3309.0,27989323.0,Ahola-Olli AV,Interleukin-1-beta levels,initial,2016-12-13,GCST004448,Inflammatory measurement,#d53e4f
4307,European,7701.0,27989323.0,Ahola-Olli AV,Interferon gamma levels,initial,2016-12-13,GCST004456,Other measurement,#d53e4f
4308,European,8292.0,27989323.0,Ahola-Olli AV,Hepatocyte growth factor levels,initial,2016-12-13,GCST004449,Cardiovascular measurement,#d53e4f
4309,European,3505.0,27989323.0,Ahola-Olli AV,Growth-regulated protein alpha levels,initial,2016-12-13,GCST004457,Other measurement,#d53e4f
4310,European,7904.0,27989323.0,Ahola-Olli AV,Granulocyte-colony stimulating factor levels,initial,2016-12-13,GCST004458,Other measurement,#d53e4f
4311,European,7565.0,27989323.0,Ahola-Olli AV,Fibroblast growth factor basic levels,initial,2016-12-13,GCST004459,Other measurement,#d53e4f
4312,European,8153.0,27989323.0,Ahola-Olli AV,Eotaxin levels,initial,2016-12-13,GCST004460,Other measurement,#d53e4f
4313,European,3631.0,27989323.0,Ahola-Olli AV,CTACK levels,initial,2016-12-13,GCST004420,Other measurement,#d53e4f
4314,European,7118.0,27989323.0,Ahola-Olli AV,Vascular endothelial growth factor levels,initial,2016-12-13,GCST004422,Cardiovascular measurement,#d53e4f
4315,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Response to drug,#807dba
4316,African Am./Caribbean,11731.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Response to drug,#fee08b
4317,European,45002.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Response to drug,#d53e4f
4318,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Cardiovascular measurement,#807dba
4319,African Am./Caribbean,11731.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Cardiovascular measurement,#fee08b
4320,European,45002.0,27958378.0,Floyd JS,QT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004031,Cardiovascular measurement,#d53e4f
4321,European,3531.0,27989323.0,Ahola-Olli AV,beta-nerve growth factor levels,initial,2016-12-13,GCST004421,Other measurement,#d53e4f
4322,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Cardiovascular measurement,#807dba
4323,African Am./Caribbean,11731.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Cardiovascular measurement,#fee08b
4324,European,45002.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Cardiovascular measurement,#d53e4f
4325,Hispanic/Latin American,15124.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Response to drug,#807dba
4326,African Am./Caribbean,11731.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Response to drug,#fee08b
4327,European,45002.0,27958378.0,Floyd JS,JT interval (sulfonylurea treatment interaction),initial,2016-12-13,GCST004032,Response to drug,#d53e4f
4328,European,2942.0,27941131.0,Feenstra B,Tonsillectomy,replication,2016-12-09,GCST003974,Other measurement,#d53e4f
4329,European,13483.0,27941131.0,Feenstra B,Tonsillectomy,initial,2016-12-09,GCST003974,Other measurement,#d53e4f
4330,Asian,504.0,27936112.0,Kalsi G,Heroin dependence,initial,2016-12-09,GCST003878,Neurological disorder,#3288bd
4331,Asian,10640.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,replication,2016-12-08,GCST004024,Neurological disorder,#3288bd
4332,European,28489.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,replication,2016-12-08,GCST004024,Neurological disorder,#d53e4f
4333,European,70017.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,initial,2016-12-08,GCST004024,Neurological disorder,#d53e4f
4334,Asian,10640.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,replication,2016-12-08,GCST004024,Other measurement,#3288bd
4335,European,28489.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,replication,2016-12-08,GCST004024,Other measurement,#d53e4f
4336,European,70017.0,28049566.0,Direk N,Depressive symptom measurement or major depressive disorder,initial,2016-12-08,GCST004024,Other measurement,#d53e4f
4338,European,6502.0,27927781.0,Robinson-Cohen C,Serum parathyroid hormone levels,replication,2016-12-07,GCST003879,Other measurement,#d53e4f
4339,European,22653.0,27927781.0,Robinson-Cohen C,Serum parathyroid hormone levels,initial,2016-12-07,GCST003879,Other measurement,#d53e4f
4340,Asian,10154.0,27922604.0,Yu H,Schizophrenia,initial,2016-12-06,GCST003880,Neurological disorder,#3288bd
4341,Asian,11382.0,27922604.0,Yu H,Schizophrenia,replication,2016-12-06,GCST003880,Neurological disorder,#3288bd
4342,African Am./Caribbean,3467.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST003965,Other measurement,#fee08b
4343,European,14780.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST003965,Other measurement,#d53e4f
4344,African Am./Caribbean,1324.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006554,Body measurement,#fee08b
4345,European,7050.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006554,Body measurement,#d53e4f
4346,African Am./Caribbean,1324.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006554,Other measurement,#fee08b
4347,European,7050.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006554,Other measurement,#d53e4f
4348,African Am./Caribbean,3529.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006553,Body measurement,#fee08b
4349,European,7618.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006553,Body measurement,#d53e4f
4350,African Am./Caribbean,3529.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006553,Other measurement,#fee08b
4351,European,7618.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST006553,Other measurement,#d53e4f
4352,African Am./Caribbean,2205.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST006551,Other measurement,#fee08b
4353,European,7618.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST006551,Other measurement,#d53e4f
4354,African Am./Caribbean,1324.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST006552,Other measurement,#fee08b
4355,European,7050.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST006552,Other measurement,#d53e4f
4356,African Am./Caribbean,592.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST006548,Other measurement,#fee08b
4357,European,5729.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST006548,Other measurement,#d53e4f
4358,African Am./Caribbean,449.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST006547,Other measurement,#fee08b
4359,European,5749.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST006547,Other measurement,#d53e4f
4360,Asian,390.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006546,Other measurement,#3288bd
4361,Hispanic/Latin American,746.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006546,Other measurement,#807dba
4362,African Am./Caribbean,1284.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006546,Other measurement,#fee08b
4363,European,3978.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006546,Other measurement,#d53e4f
4364,European,3888.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006545,Other measurement,#d53e4f
4365,African Am./Caribbean,877.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006545,Other measurement,#fee08b
4366,Asian,378.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006545,Other measurement,#3288bd
4367,Hispanic/Latin American,699.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST006545,Other measurement,#807dba
4368,African Am./Caribbean,449.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST006549,Other measurement,#fee08b
4369,European,5699.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST006549,Other measurement,#d53e4f
4370,African Am./Caribbean,592.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST006550,Other measurement,#fee08b
4371,European,5699.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST006550,Other measurement,#d53e4f
4372,Asian,390.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Other measurement,#3288bd
4373,Hispanic/Latin American,746.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Other measurement,#807dba
4374,African Am./Caribbean,1284.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Other measurement,#fee08b
4375,European,3978.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Other measurement,#d53e4f
4376,Asian,390.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#3288bd
4377,Hispanic/Latin American,746.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#807dba
4378,African Am./Caribbean,1284.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#fee08b
4379,European,3978.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#d53e4f
4380,Asian,390.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#3288bd
4381,Hispanic/Latin American,746.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#807dba
4382,African Am./Caribbean,1284.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#fee08b
4383,European,3978.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006544,Body measurement,#d53e4f
4384,Asian,378.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Other measurement,#3288bd
4385,Hispanic/Latin American,699.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Other measurement,#807dba
4386,European,3888.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Other measurement,#d53e4f
4387,African Am./Caribbean,877.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Other measurement,#fee08b
4388,Asian,378.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#3288bd
4389,Hispanic/Latin American,699.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#807dba
4390,European,3888.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#d53e4f
4391,African Am./Caribbean,877.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#fee08b
4392,Asian,378.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#3288bd
4393,Hispanic/Latin American,699.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#807dba
4394,European,3888.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#d53e4f
4395,African Am./Caribbean,877.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST006543,Body measurement,#fee08b
4396,African Am./Caribbean,2163.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST006542,Other measurement,#fee08b
4397,European,7431.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST006542,Other measurement,#d53e4f
4398,African Am./Caribbean,1036.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST006540,Other measurement,#fee08b
4399,European,7432.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST006540,Other measurement,#d53e4f
4400,African Am./Caribbean,1034.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST006538,Other measurement,#fee08b
4401,European,7381.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST006538,Other measurement,#d53e4f
4402,African Am./Caribbean,2163.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST006537,Other measurement,#fee08b
4403,European,7399.0,27918534.0,Chu AY,Subcutaneous adipose tissue,initial,2016-12-05,GCST006537,Other measurement,#d53e4f
4404,European,7431.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006533,Other measurement,#d53e4f
4405,African Am./Caribbean,2163.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006533,Other measurement,#fee08b
4406,European,7431.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006533,Body measurement,#d53e4f
4407,African Am./Caribbean,2163.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006533,Body measurement,#fee08b
4408,European,7432.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006534,Other measurement,#d53e4f
4409,African Am./Caribbean,1036.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006534,Other measurement,#fee08b
4410,European,7432.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006534,Body measurement,#d53e4f
4411,African Am./Caribbean,1036.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST006534,Body measurement,#fee08b
4412,African Am./Caribbean,3529.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST003973,Body measurement,#fee08b
4413,European,14668.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST003973,Body measurement,#d53e4f
4414,African Am./Caribbean,3529.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST003973,Other measurement,#fee08b
4415,European,14668.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2016-12-05,GCST003973,Other measurement,#d53e4f
4416,African Am./Caribbean,3529.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST003972,Other measurement,#fee08b
4417,European,14668.0,27918534.0,Chu AY,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2016-12-05,GCST003972,Other measurement,#d53e4f
4418,African Am./Caribbean,1041.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST003969,Other measurement,#fee08b
4419,European,11478.0,27918534.0,Chu AY,Visceral adipose tissue attenuation (Hounslow unit scale),initial,2016-12-05,GCST003969,Other measurement,#d53e4f
4420,European,11398.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST003970,Other measurement,#d53e4f
4421,African Am./Caribbean,1041.0,27918534.0,Chu AY,Subcutaneous adipose tissue attenuation (Hounsfield unit scale),initial,2016-12-05,GCST003970,Other measurement,#fee08b
4422,Hispanic/Latin American,1445.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST003971,Other measurement,#807dba
4423,Asian,768.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST003971,Other measurement,#3288bd
4424,African Am./Caribbean,2161.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST003971,Other measurement,#fee08b
4425,European,7866.0,27918534.0,Chu AY,Pericardial fat,initial,2016-12-05,GCST003971,Other measurement,#d53e4f
4426,European,76581.0,27918536.0,Lo MT,Openness,initial,2016-12-05,GCST004016,Other measurement,#d53e4f
4427,European,122867.0,27918536.0,Lo MT,Neuroticism,initial,2016-12-05,GCST004017,Other measurement,#d53e4f
4428,European,137994.0,27918536.0,Lo MT,Neuroticism,replication,2016-12-05,GCST004017,Other measurement,#d53e4f
4429,European,122886.0,27918536.0,Lo MT,Extraversion,initial,2016-12-05,GCST004015,Biological process,#d53e4f
4430,European,46621.0,27918536.0,Lo MT,Extraversion,replication,2016-12-05,GCST004015,Biological process,#d53e4f
4431,European,76551.0,27918536.0,Lo MT,Conscientiousness,initial,2016-12-05,GCST004014,Other measurement,#d53e4f
4432,European,46581.0,27918536.0,Lo MT,Conscientiousness,replication,2016-12-05,GCST004014,Other measurement,#d53e4f
4433,European,14863.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST003967,Other measurement,#d53e4f
4434,African Am./Caribbean,3469.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST003967,Other measurement,#fee08b
4435,European,14863.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST003967,Body measurement,#d53e4f
4436,African Am./Caribbean,3469.0,27918534.0,Chu AY,Visceral adipose tissue adjusted for BMI,initial,2016-12-05,GCST003967,Body measurement,#fee08b
4437,Hispanic/Latin American,1445.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Other measurement,#807dba
4438,African Am./Caribbean,1261.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Other measurement,#fee08b
4439,European,7866.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Other measurement,#d53e4f
4440,Asian,768.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Other measurement,#3288bd
4441,Hispanic/Latin American,1445.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#807dba
4442,African Am./Caribbean,1261.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#fee08b
4443,European,7866.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#d53e4f
4444,Asian,768.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#3288bd
4445,Hispanic/Latin American,1445.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#807dba
4446,African Am./Caribbean,1261.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#fee08b
4447,European,7866.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#d53e4f
4448,Asian,768.0,27918534.0,Chu AY,Pericardial adipose tissue adjusted for height and weight,initial,2016-12-05,GCST003968,Body measurement,#3288bd
4449,African Am./Caribbean,3469.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST003966,Other measurement,#fee08b
4450,European,14863.0,27918534.0,Chu AY,Visceral adipose tissue,initial,2016-12-05,GCST003966,Other measurement,#d53e4f
4451,European,76551.0,27918536.0,Lo MT,Agreeableness,initial,2016-12-05,GCST004013,Other measurement,#d53e4f
4452,European,9320.0,27915449.0,Corre T,Urinary electrolytes (magnesium/calcium ratio),initial,2016-12-03,GCST003929,Other measurement,#d53e4f
4453,European,1788.0,27901618.0,Gref A,Childhood onset asthma (traffic air pollution exposure interaction),replication,2016-11-30,GCST003975,Other disease,#d53e4f
4454,European,1534.0,27901618.0,Gref A,Childhood onset asthma (traffic air pollution exposure interaction),initial,2016-11-30,GCST003975,Other disease,#d53e4f
4455,European,1788.0,27901618.0,Gref A,Childhood onset asthma (traffic air pollution exposure interaction),replication,2016-11-30,GCST003975,Other measurement,#d53e4f
4456,European,1534.0,27901618.0,Gref A,Childhood onset asthma (traffic air pollution exposure interaction),initial,2016-11-30,GCST003975,Other measurement,#d53e4f
4457,European,5127.0,27899403.0,Jones GT,Abdominal aortic aneurysm,replication,2016-11-29,GCST003877,Cardiovascular disease,#d53e4f
4459,European,104830.0,27899403.0,Jones GT,Abdominal aortic aneurysm,initial,2016-11-29,GCST003877,Cardiovascular disease,#d53e4f
4460,Asian,1886.0,27899376.0,Nakayama A,Renal overload gout,replication,2016-11-29,GCST003924,Metabolic disorder,#3288bd
4461,Asian,1773.0,27899376.0,Nakayama A,Renal overload gout,initial,2016-11-29,GCST003924,Metabolic disorder,#3288bd
4462,Other/Mixed,1536.0,27899376.0,Nakayama A,Gout,replication,2016-11-29,GCST003925,Metabolic disorder,#99d594
4463,European,1833.0,27899376.0,Nakayama A,Gout,replication,2016-11-29,GCST003925,Metabolic disorder,#d53e4f
4464,Asian,2664.0,27899376.0,Nakayama A,Gout,replication,2016-11-29,GCST003925,Metabolic disorder,#3288bd
4465,Asian,2158.0,27899376.0,Nakayama A,Gout,initial,2016-11-29,GCST003925,Metabolic disorder,#3288bd
4466,European,19596.0,27898682.0,Lotta LA,Branched-chain amino acid levels (Valine),initial,2016-11-29,GCST006078,Other measurement,#d53e4f
4467,European,19596.0,27898682.0,Lotta LA,Branched-chain amino acid levels (Leucine),initial,2016-11-29,GCST006076,Other measurement,#d53e4f
4468,European,19596.0,27898682.0,Lotta LA,Branched-chain amino acid levels (Isoleucine),initial,2016-11-29,GCST006077,Other measurement,#d53e4f
4469,Asian,1964.0,27899376.0,Nakayama A,Renal underexcretion gout,replication,2016-11-29,GCST003926,Metabolic disorder,#3288bd
4470,Asian,1832.0,27899376.0,Nakayama A,Renal underexcretion gout,initial,2016-11-29,GCST003926,Metabolic disorder,#3288bd
4471,European,70460.0,27911795.0,Schumann G,Alcohol consumption,initial,2016-11-28,GCST004026,Other measurement,#d53e4f
4472,European,35438.0,27911795.0,Schumann G,Alcohol consumption,replication,2016-11-28,GCST004026,Other measurement,#d53e4f
4473,European,74711.0,27911795.0,Schumann G,Alcohol consumption (heavy vs. light/non-drinkers),initial,2016-11-28,GCST004027,Other measurement,#d53e4f
4474,European,31021.0,27911795.0,Schumann G,Alcohol consumption (heavy vs. light/non-drinkers),replication,2016-11-28,GCST004027,Other measurement,#d53e4f
4475,Asian,133.0,28031287.0,Sasayama D,Cerebrospinal fluid biomarker levels,initial,2016-11-26,GCST004000,Other measurement,#3288bd
4476,European,172378.0,27863252.0,Astle WJ,Eosinophil percentage of white cells,initial,2016-11-17,GCST004600,Hematological measurement,#d53e4f
4477,European,172952.0,27863252.0,Astle WJ,Red blood cell count,initial,2016-11-17,GCST004601,Hematological measurement,#d53e4f
4478,European,164454.0,27863252.0,Astle WJ,Mean platelet volume,initial,2016-11-17,GCST004599,Hematological measurement,#d53e4f
4479,European,170223.0,27863252.0,Astle WJ,Basophil percentage of granulocytes,initial,2016-11-17,GCST004634,Inflammatory measurement,#d53e4f
4480,European,171542.0,27863252.0,Astle WJ,Neutrophil percentage of white cells,initial,2016-11-17,GCST004633,Hematological measurement,#d53e4f
4481,European,171748.0,27863252.0,Astle WJ,Lymphocyte percentage of white cells,initial,2016-11-17,GCST004632,Hematological measurement,#d53e4f
4482,European,171996.0,27863252.0,Astle WJ,Basophil percentage of white cells,initial,2016-11-17,GCST004631,Inflammatory measurement,#d53e4f
4483,European,172332.0,27863252.0,Astle WJ,Mean corpuscular hemoglobin,initial,2016-11-17,GCST004630,Hematological measurement,#d53e4f
4484,European,170702.0,27863252.0,Astle WJ,Neutrophil count,initial,2016-11-17,GCST004629,Hematological measurement,#d53e4f
4485,European,170548.0,27863252.0,Astle WJ,Immature fraction of reticulocytes,initial,2016-11-17,GCST004628,Hematological measurement,#d53e4f
4486,European,171643.0,27863252.0,Astle WJ,Lymphocyte counts,initial,2016-11-17,GCST004627,Hematological measurement,#d53e4f
4487,European,169219.0,27863252.0,Astle WJ,Myeloid white cell count,initial,2016-11-17,GCST004626,Hematological measurement,#d53e4f
4488,European,170721.0,27863252.0,Astle WJ,Monocyte count,initial,2016-11-17,GCST004625,Hematological measurement,#d53e4f
4489,European,171771.0,27863252.0,Astle WJ,Sum eosinophil basophil counts,initial,2016-11-17,GCST004624,Hematological measurement,#d53e4f
4490,European,170672.0,27863252.0,Astle WJ,Neutrophil percentage of granulocytes,initial,2016-11-17,GCST004623,Hematological measurement,#d53e4f
4491,European,170641.0,27863252.0,Astle WJ,Reticulocyte count,initial,2016-11-17,GCST004622,Hematological measurement,#d53e4f
4492,European,171529.0,27863252.0,Astle WJ,Red cell distribution width,initial,2016-11-17,GCST004621,Hematological measurement,#d53e4f
4493,European,170143.0,27863252.0,Astle WJ,Sum basophil neutrophil counts,initial,2016-11-17,GCST004620,Hematological measurement,#d53e4f
4494,European,170690.0,27863252.0,Astle WJ,Reticulocyte fraction of red cells,initial,2016-11-17,GCST004619,Hematological measurement,#d53e4f
4495,European,171846.0,27863252.0,Astle WJ,White blood cell count (basophil),initial,2016-11-17,GCST004618,Inflammatory measurement,#d53e4f
4496,European,170536.0,27863252.0,Astle WJ,Eosinophil percentage of granulocytes,initial,2016-11-17,GCST004617,Hematological measurement,#d53e4f
4497,European,164433.0,27863252.0,Astle WJ,Platelet distribution width,initial,2016-11-17,GCST004616,Hematological measurement,#d53e4f
4498,European,172925.0,27863252.0,Astle WJ,Hemoglobin concentration,initial,2016-11-17,GCST004615,Hematological measurement,#d53e4f
4499,European,170763.0,27863252.0,Astle WJ,High light scatter reticulocyte percentage of red cells,initial,2016-11-17,GCST004612,Hematological measurement,#d53e4f
4500,European,169822.0,27863252.0,Astle WJ,Granulocyte count,initial,2016-11-17,GCST004614,Hematological measurement,#d53e4f
4501,European,170384.0,27863252.0,Astle WJ,Sum neutrophil eosinophil counts,initial,2016-11-17,GCST004613,Hematological measurement,#d53e4f
4502,European,170761.0,27863252.0,Astle WJ,High light scatter reticulocyte count,initial,2016-11-17,GCST004611,Hematological measurement,#d53e4f
4503,European,172435.0,27863252.0,Astle WJ,White blood cell count,initial,2016-11-17,GCST004610,Hematological measurement,#d53e4f
4504,European,170494.0,27863252.0,Astle WJ,Monocyte percentage of white cells,initial,2016-11-17,GCST004609,Hematological measurement,#d53e4f
4505,European,169545.0,27863252.0,Astle WJ,Granulocyte percentage of myeloid white cells,initial,2016-11-17,GCST004608,Hematological measurement,#d53e4f
4506,European,164339.0,27863252.0,Astle WJ,Plateletcrit,initial,2016-11-17,GCST004607,Hematological measurement,#d53e4f
4507,European,172275.0,27863252.0,Astle WJ,Eosinophil counts,initial,2016-11-17,GCST004606,Hematological measurement,#d53e4f
4508,European,172851.0,27863252.0,Astle WJ,Mean corpuscular hemoglobin concentration,initial,2016-11-17,GCST004605,Hematological measurement,#d53e4f
4509,European,173039.0,27863252.0,Astle WJ,Hematocrit,initial,2016-11-17,GCST004604,Hematological measurement,#d53e4f
4510,European,166066.0,27863252.0,Astle WJ,Platelet count,initial,2016-11-17,GCST004603,Hematological measurement,#d53e4f
4511,European,172433.0,27863252.0,Astle WJ,Mean corpuscular volume,initial,2016-11-17,GCST004602,Hematological measurement,#d53e4f
4512,Hispanic/Latin American,3584.0,28171582.0,Gao X,Central corneal thickness,initial,2016-11-15,GCST003856,Other measurement,#807dba
4513,Hispanic/Latin American,931.0,28171582.0,Gao X,Central corneal thickness,replication,2016-11-15,GCST003856,Other measurement,#807dba
4514,European,3299.0,27846281.0,Galesloot TE,Hepcidin levels,initial,2016-11-15,GCST003943,Other measurement,#d53e4f
4515,European,1018.0,27846281.0,Galesloot TE,Hepcidin levels,replication,2016-11-15,GCST003943,Other measurement,#d53e4f
4518,European,3299.0,27846281.0,Galesloot TE,Hepcidin/ferritin ratio,initial,2016-11-15,GCST003944,Other measurement,#d53e4f
4520,European,3299.0,27846281.0,Galesloot TE,Hepcidin/transferrin saturation ratio,initial,2016-11-15,GCST003945,Other measurement,#d53e4f
4522,Asian,2735.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#3288bd
4524,African,2029.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#fc8d59
4525,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#fee08b
4526,Asian,7701.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#3288bd
4527,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#807dba
4528,European,295529.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007094,Other measurement,#d53e4f
4529,Asian,7243.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007095,Other measurement,#3288bd
4530,Asian,461.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007095,Other measurement,#3288bd
4531,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007095,Other measurement,#fee08b
4532,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007095,Other measurement,#807dba
4533,European,80792.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007095,Other measurement,#d53e4f
4534,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007097,Cardiovascular measurement,#807dba
4535,Asian,7243.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007097,Cardiovascular measurement,#3288bd
4536,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007097,Cardiovascular measurement,#fee08b
4537,Asian,461.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007097,Cardiovascular measurement,#3288bd
4538,European,80792.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007097,Cardiovascular measurement,#d53e4f
4539,European,80792.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007098,Other measurement,#d53e4f
4540,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007098,Other measurement,#807dba
4541,Asian,7243.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007098,Other measurement,#3288bd
4542,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007098,Other measurement,#fee08b
4543,Asian,461.0,27841878.0,Hoffmann TJ,Diastolic blood pressure,initial,2016-11-14,GCST007098,Other measurement,#3288bd
4544,European,295529.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#d53e4f
4545,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#807dba
4546,Asian,7701.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#3288bd
4547,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#fee08b
4548,African,2029.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#fc8d59
4550,Asian,2735.0,27841878.0,Hoffmann TJ,Systolic blood pressure,initial,2016-11-14,GCST007099,Other measurement,#3288bd
4552,European,295529.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#d53e4f
4553,Hispanic/Latin American,8231.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#807dba
4554,Asian,7701.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#3288bd
4555,African Am./Caribbean,3058.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#fee08b
4556,African,2029.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#fc8d59
4557,Asian,2735.0,27841878.0,Hoffmann TJ,Pulse pressure,initial,2016-11-14,GCST007096,Cardiovascular measurement,#3288bd
4558,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (positive Marder score),initial,2016-11-11,GCST004040,Neurological disorder,#d53e4f
4559,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (positive Marder score),initial,2016-11-11,GCST004040,Response to drug,#d53e4f
4560,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (positive Marder score),initial,2016-11-11,GCST004040,Other measurement,#d53e4f
4561,European,1016.0,27839851.0,Lind L,"DDT metabolite (p,p'-DDE levels)",initial,2016-11-11,GCST003923,Other measurement,#d53e4f
4562,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (CGI-S score),initial,2016-11-11,GCST004039,Neurological disorder,#d53e4f
4563,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (CGI-S score),initial,2016-11-11,GCST004039,Response to drug,#d53e4f
4564,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (CGI-S score),initial,2016-11-11,GCST004039,Other measurement,#d53e4f
4565,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (Multivariate),initial,2016-11-11,GCST004043,Neurological disorder,#d53e4f
4566,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (Multivariate),initial,2016-11-11,GCST004043,Response to drug,#d53e4f
4567,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (Multivariate),initial,2016-11-11,GCST004043,Other measurement,#d53e4f
4568,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (PANSS score),initial,2016-11-11,GCST004042,Neurological disorder,#d53e4f
4569,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (PANSS score),initial,2016-11-11,GCST004042,Response to drug,#d53e4f
4570,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (PANSS score),initial,2016-11-11,GCST004042,Other measurement,#d53e4f
4571,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (negative Marder score),initial,2016-11-11,GCST004041,Neurological disorder,#d53e4f
4572,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (negative Marder score),initial,2016-11-11,GCST004041,Response to drug,#d53e4f
4573,European,1390.0,27846195.0,Li Q,Response to paliperidone in schizophrenia (negative Marder score),initial,2016-11-11,GCST004041,Other measurement,#d53e4f
4574,European,117109.0,27824142.0,Lin H,Atrial fibrillation (SNPxSNP interaction),replication,2016-11-08,GCST004018,Cardiovascular disease,#d53e4f
4575,European,73410.0,27824142.0,Lin H,Atrial fibrillation (SNPxSNP interaction),initial,2016-11-08,GCST004018,Cardiovascular disease,#d53e4f
4577,African Am./Caribbean,682.0,27816938.0,Tanaka T,Parental longevity (at least one long-lived parent),initial,2016-11-05,GCST003882,Other measurement,#fee08b
4578,European,5034.0,27816938.0,Tanaka T,Parental longevity (at least one long-lived parent),initial,2016-11-05,GCST003882,Other measurement,#d53e4f
4579,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Cancer,#d53e4f
4580,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Cancer,#d53e4f
4581,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4582,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4583,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Metabolic disorder,#d53e4f
4584,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Metabolic disorder,#d53e4f
4585,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4586,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4587,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4588,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4589,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4590,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Cardiovascular disease,#d53e4f
4591,European,9618.0,27790247.0,He L,Age-related diseases and mortality,initial,2016-11-03,GCST004044,Other measurement,#d53e4f
4592,European,19796.0,27790247.0,He L,Age-related diseases and mortality,replication,2016-11-03,GCST004044,Other measurement,#d53e4f
4593,European,112005.0,27818178.0,Hill WD,Social deprivation,initial,2016-11-03,GCST007156,Other trait,#d53e4f
4594,European,96900.0,27818178.0,Hill WD,Household income,initial,2016-11-03,GCST007155,Other trait,#d53e4f
4595,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4596,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4597,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Other measurement,#d53e4f
4598,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Other measurement,#d53e4f
4599,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4600,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4601,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Other measurement,#d53e4f
4602,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Other measurement,#d53e4f
4603,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Hematological measurement,#d53e4f
4604,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Hematological measurement,#d53e4f
4605,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Cardiovascular measurement,#d53e4f
4606,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Cardiovascular measurement,#d53e4f
4607,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Other measurement,#d53e4f
4608,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Other measurement,#d53e4f
4609,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Body measurement,#d53e4f
4610,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Body measurement,#d53e4f
4611,European,19796.0,27790247.0,He L,Age-related disease endophenotypes,replication,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4612,European,9618.0,27790247.0,He L,Age-related disease endophenotypes,initial,2016-11-03,GCST004046,Lipid or lipoprotein measurement,#d53e4f
4613,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4614,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4615,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Hematological measurement,#d53e4f
4616,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Hematological measurement,#d53e4f
4617,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4618,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4619,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cardiovascular measurement,#d53e4f
4620,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cardiovascular measurement,#d53e4f
4621,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4622,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4623,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Body measurement,#d53e4f
4624,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Body measurement,#d53e4f
4625,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4626,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4627,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4628,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4629,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cancer,#d53e4f
4630,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cancer,#d53e4f
4631,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Other measurement,#d53e4f
4632,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Other measurement,#d53e4f
4633,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4634,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Lipid or lipoprotein measurement,#d53e4f
4635,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Other measurement,#d53e4f
4636,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Other measurement,#d53e4f
4637,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4638,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Cardiovascular disease,#d53e4f
4639,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Metabolic disorder,#d53e4f
4640,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Metabolic disorder,#d53e4f
4641,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Other measurement,#d53e4f
4642,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Other measurement,#d53e4f
4643,European,9618.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",initial,2016-11-03,GCST004045,Other measurement,#d53e4f
4644,European,19796.0,27790247.0,He L,"Age-related diseases, mortality and associated endophenotypes",replication,2016-11-03,GCST004045,Other measurement,#d53e4f
4645,European,4008.0,27723757.0,Jin Y,Vitiligo,replication,2016-11-01,GCST004785,Immune system disorder,#d53e4f
4646,European,40258.0,27723757.0,Jin Y,Vitiligo,initial,2016-11-01,GCST004785,Immune system disorder,#d53e4f
4647,Other/Mixed,709.0,27487801.0,Wu S,Straight vs curly hair,replication,2016-11-01,GCST006468,Other trait,#99d594
4648,Asian,2899.0,27487801.0,Wu S,Straight vs curly hair,initial,2016-11-01,GCST006468,Other trait,#3288bd
4649,European,11891.0,27454463.0,Jones AV,Dysmenorrheic pain,initial,2016-11-01,GCST003927,Other measurement,#d53e4f
4650,European,102505.0,27668658.0,Iotchkova V,Cardiometabolic and hematological traits,replication,2016-11-01,GCST006101,Other measurement,#d53e4f
4651,European,35981.0,27668658.0,Iotchkova V,Cardiometabolic and hematological traits,initial,2016-11-01,GCST006101,Other measurement,#d53e4f
4652,European,1739.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003805,Response to drug,#d53e4f
4653,African Am./Caribbean,430.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003805,Response to drug,#fee08b
4654,European,1739.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003805,Other measurement,#d53e4f
4655,African Am./Caribbean,430.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003805,Other measurement,#fee08b
4656,European,1739.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003805,Cardiovascular disease,#d53e4f
4657,African Am./Caribbean,430.0,27802415.0,Salvi E,Diastolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003805,Cardiovascular disease,#fee08b
4658,European,189656.0,27798627.0,Barban N,Age at first birth,initial,2016-10-31,GCST006045,Other measurement,#d53e4f
4659,European,48408.0,27798627.0,Barban N,Age at first birth,initial,2016-10-31,GCST006044,Other measurement,#d53e4f
4660,European,225230.0,27798627.0,Barban N,Number of children ever born,initial,2016-10-31,GCST006047,Other measurement,#d53e4f
4661,European,103909.0,27798627.0,Barban N,Number of children ever born,initial,2016-10-31,GCST006046,Other measurement,#d53e4f
4662,European,238064.0,27798627.0,Barban N,Age at first birth,initial,2016-10-31,GCST003795,Other measurement,#d53e4f
4663,Asian,2478.0,27798624.0,Eppinga RN,Resting heart rate,initial,2016-10-31,GCST003818,Cardiovascular measurement,#3288bd
4664,European,130795.0,27798624.0,Eppinga RN,Resting heart rate,replication,2016-10-31,GCST003818,Cardiovascular measurement,#d53e4f
4666,European,127919.0,27798624.0,Eppinga RN,Resting heart rate,initial,2016-10-31,GCST003818,Cardiovascular measurement,#d53e4f
4667,Other/Mixed,684.0,27798624.0,Eppinga RN,Resting heart rate,initial,2016-10-31,GCST003818,Cardiovascular measurement,#99d594
4668,African,1734.0,27798624.0,Eppinga RN,Resting heart rate,initial,2016-10-31,GCST003818,Cardiovascular measurement,#fc8d59
4669,African Am./Caribbean,430.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003807,Response to drug,#fee08b
4670,European,1739.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003807,Response to drug,#d53e4f
4671,African Am./Caribbean,430.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003807,Cardiovascular disease,#fee08b
4672,European,1739.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003807,Cardiovascular disease,#d53e4f
4673,African Am./Caribbean,430.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,replication,2016-10-31,GCST003807,Other measurement,#fee08b
4674,European,1739.0,27802415.0,Salvi E,Systolic blood pressure response to hydrochlorothiazide in hypertension,initial,2016-10-31,GCST003807,Other measurement,#d53e4f
4675,European,329139.0,27798627.0,Barban N,Number of children ever born,initial,2016-10-31,GCST003796,Other measurement,#d53e4f
4676,African Am./Caribbean,811.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Other measurement,#fee08b
4677,European,5766.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Other measurement,#d53e4f
4678,African Am./Caribbean,811.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Response to drug,#fee08b
4679,European,5766.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Response to drug,#d53e4f
4680,African Am./Caribbean,811.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Other disease,#fee08b
4681,European,5766.0,26503814.0,Hardin M,Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),initial,2016-10-27,GCST003830,Other disease,#d53e4f
4682,Hispanic/Latin American,399.0,27777418.0,Wong ML,Major depressive disorder,initial,2016-10-25,GCST005547,Neurological disorder,#807dba
4683,European,1212.0,27770449.0,Tamm R,Thiopurine S-methyltransferase activity,initial,2016-10-22,GCST003841,Other measurement,#d53e4f
4684,European,2094.0,27797806.0,Muller SH,Essential tremor,replication,2016-10-20,GCST003762,Other trait,#d53e4f
4685,European,7154.0,27797806.0,Muller SH,Essential tremor,initial,2016-10-20,GCST003762,Other trait,#d53e4f
4686,African Am./Caribbean,5609.0,27770636.0,Mez J,Late-onset Alzheimer's disease,initial,2016-10-20,GCST003815,Neurological disorder,#fee08b
4687,African Am./Caribbean,2279.0,27764096.0,Hoffmann TJ,Age-related hearing impairment,replication,2016-10-20,GCST003763,Neurological disorder,#fee08b
4688,Asian,5438.0,27764096.0,Hoffmann TJ,Age-related hearing impairment,replication,2016-10-20,GCST003763,Neurological disorder,#3288bd
4689,Hispanic/Latin American,5696.0,27764096.0,Hoffmann TJ,Age-related hearing impairment,replication,2016-10-20,GCST003763,Neurological disorder,#807dba
4690,European,52409.0,27764096.0,Hoffmann TJ,Age-related hearing impairment,initial,2016-10-20,GCST003763,Neurological disorder,#d53e4f
4691,European,3962.0,27764105.0,Lemmela S,Sciatica,initial,2016-10-20,GCST003869,Other trait,#d53e4f
4692,European,19265.0,27764105.0,Lemmela S,Sciatica,replication,2016-10-20,GCST003869,Other trait,#d53e4f
4694,European,24442.0,27890468.0,van Hulzen KJE,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder,initial,2016-10-18,GCST004002,Neurological disorder,#d53e4f
4697,European,24442.0,27890468.0,van Hulzen KJE,Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder,initial,2016-10-18,GCST004002,Neurological disorder,#d53e4f
4699,Hispanic/Latin American,683.0,27980656.0,Justice AE,Systolic blood pressure change trajectories,initial,2016-10-18,GCST003825,Other measurement,#807dba
4701,European,28925.0,27890468.0,van Hulzen KJE,Bipolar disorder or attention deficit hyperactivity disorder,initial,2016-10-18,GCST004001,Neurological disorder,#d53e4f
4704,European,28925.0,27890468.0,van Hulzen KJE,Bipolar disorder or attention deficit hyperactivity disorder,initial,2016-10-18,GCST004001,Neurological disorder,#d53e4f
4711,European,8701.0,27749845.0,Lesseur C,Oral cavity cancer,initial,2016-10-17,GCST003858,Cancer,#d53e4f
4712,European,8490.0,27749845.0,Lesseur C,Oropharynx cancer,initial,2016-10-17,GCST003859,Cancer,#d53e4f
4714,European,8727.0,27764800.0,Cox DG,Estrogen receptor status in breast cancer,initial,2016-10-14,GCST003821,Other measurement,#d53e4f
4715,European,8727.0,27764800.0,Cox DG,Estrogen receptor status in breast cancer,initial,2016-10-14,GCST003821,Cancer,#d53e4f
4716,Asian,2961.0,27964859.0,Zhang M,Petaloid toenail,initial,2016-10-14,GCST003843,Other trait,#3288bd
4717,Other/Mixed,721.0,27964859.0,Zhang M,Petaloid toenail,initial,2016-10-14,GCST003843,Other trait,#99d594
4718,European,5452.0,27764800.0,Cox DG,Estrogen receptor status in HER2 negative breast cancer,initial,2016-10-14,GCST003823,Other measurement,#d53e4f
4719,European,5452.0,27764800.0,Cox DG,Estrogen receptor status in HER2 negative breast cancer,initial,2016-10-14,GCST003823,Other measurement,#d53e4f
4720,European,5452.0,27764800.0,Cox DG,Estrogen receptor status in HER2 negative breast cancer,initial,2016-10-14,GCST003823,Cancer,#d53e4f
4721,European,3275.0,27764800.0,Cox DG,Estrogen receptor status in HER2 positive breast cancer,initial,2016-10-14,GCST003822,Other measurement,#d53e4f
4722,European,3275.0,27764800.0,Cox DG,Estrogen receptor status in HER2 positive breast cancer,initial,2016-10-14,GCST003822,Other measurement,#d53e4f
4723,European,3275.0,27764800.0,Cox DG,Estrogen receptor status in HER2 positive breast cancer,initial,2016-10-14,GCST003822,Cancer,#d53e4f
4724,Other/Mixed,420.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#99d594
4725,Asian,840.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#3288bd
4726,Asian,1449.0,27680694.0,Horikoshi M,Birth weight,replication,2016-10-13,GCST005146,Body measurement,#3288bd
4727,European,16288.0,27680694.0,Horikoshi M,Birth weight,replication,2016-10-13,GCST005146,Body measurement,#d53e4f
4728,Other/Mixed,365.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#99d594
4729,African Am./Caribbean,6635.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#fee08b
4730,Other/Mixed,395.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#99d594
4731,European,133903.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST005146,Body measurement,#d53e4f
4732,Hispanic/Latin American,19706.0,27736895.0,Franceschini N,Systolic blood pressure,initial,2016-10-13,GCST007237,Other measurement,#807dba
4733,African Am./Caribbean,18744.0,27736895.0,Franceschini N,Systolic blood pressure,initial,2016-10-13,GCST007237,Other measurement,#fee08b
4734,European,16288.0,27680694.0,Horikoshi M,Birth weight,replication,2016-10-13,GCST007557,Body measurement,#d53e4f
4735,European,133903.0,27680694.0,Horikoshi M,Birth weight,initial,2016-10-13,GCST007557,Body measurement,#d53e4f
4736,Hispanic/Latin American,19706.0,27736895.0,Franceschini N,Diastolic blood pressure,initial,2016-10-13,GCST007238,Other measurement,#807dba
4737,African Am./Caribbean,18744.0,27736895.0,Franceschini N,Diastolic blood pressure,initial,2016-10-13,GCST007238,Other measurement,#fee08b
4738,European,1812.0,27723756.0,Wang J,Gut microbiota (beta diversity),initial,2016-10-10,GCST003876,Other measurement,#d53e4f
4739,European,371.0,27723756.0,Wang J,Gut microbiota (beta diversity),replication,2016-10-10,GCST003876,Other measurement,#d53e4f
4740,European,1812.0,27723756.0,Wang J,Gut microbiota (bacterial taxa),initial,2016-10-10,GCST003875,Other measurement,#d53e4f
4741,European,1812.0,27723756.0,Wang J,Gut microbiota (bacterial taxa),initial,2016-10-10,GCST003875,Other measurement,#d53e4f
4742,European,22601.0,27723779.0,Gong J,Colorectal cancer (smoking interaction),initial,2016-10-10,GCST003874,Other measurement,#d53e4f
4743,European,22601.0,27723779.0,Gong J,Colorectal cancer (smoking interaction),initial,2016-10-10,GCST003874,Cancer,#d53e4f
4744,European,16823.0,27723779.0,Gong J,Colorectal cancer (alcohol consumption interaction),initial,2016-10-10,GCST003873,Cancer,#d53e4f
4745,European,16823.0,27723779.0,Gong J,Colorectal cancer (alcohol consumption interaction),initial,2016-10-10,GCST003873,Other measurement,#d53e4f
4746,Asian,160.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,replication,2016-10-10,GCST003824,Digestive system disorder,#3288bd
4747,Asian,224.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,initial,2016-10-10,GCST003824,Digestive system disorder,#3288bd
4748,Asian,160.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,replication,2016-10-10,GCST003824,Response to drug,#3288bd
4749,Asian,224.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,initial,2016-10-10,GCST003824,Response to drug,#3288bd
4750,Asian,160.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,replication,2016-10-10,GCST003824,Other measurement,#3288bd
4751,Asian,224.0,27723809.0,Matsunami K,Depression in response to interferon-based therapy in chronic hepatitis C,initial,2016-10-10,GCST003824,Other measurement,#3288bd
4752,European,6487.0,27723758.0,Bronson PG,Selective IgA deficiency,initial,2016-10-10,GCST003814,Immune system disorder,#d53e4f
4753,African Am./Caribbean,140.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Other measurement,#fee08b
4754,European,4459.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Other measurement,#d53e4f
4755,Asian,59.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Other measurement,#3288bd
4756,African Am./Caribbean,140.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Response to drug,#fee08b
4757,European,4459.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Response to drug,#d53e4f
4758,Asian,59.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Response to drug,#3288bd
4759,African Am./Caribbean,140.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Cancer,#fee08b
4760,European,4459.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Cancer,#d53e4f
4761,Asian,59.0,27758888.0,Ingle JN,Breast cancer-free interval (treatment with aromatase inhibitor),initial,2016-10-10,GCST003816,Cancer,#3288bd
4762,European,577.0,28364478.0,Sulkava S,Job-related exhaustion in shift workers,replication,2016-10-10,GCST003868,Other measurement,#d53e4f
4763,European,176.0,28364478.0,Sulkava S,Job-related exhaustion in shift workers,initial,2016-10-10,GCST003868,Other measurement,#d53e4f
4764,Hispanic/Latin American,18.0,27704462.0,Moura Rodrigues R,Response to dendritic cell-based immunotherapy in HIV infection,initial,2016-10-04,GCST003852,Response to drug,#807dba
4765,European,15.0,27704462.0,Moura Rodrigues R,Response to dendritic cell-based immunotherapy in HIV infection,initial,2016-10-04,GCST003852,Response to drug,#d53e4f
4766,Hispanic/Latin American,18.0,27704462.0,Moura Rodrigues R,Response to dendritic cell-based immunotherapy in HIV infection,initial,2016-10-04,GCST003852,Other disease,#807dba
4767,European,15.0,27704462.0,Moura Rodrigues R,Response to dendritic cell-based immunotherapy in HIV infection,initial,2016-10-04,GCST003852,Other disease,#d53e4f
4770,European,1572.0,27701424.0,Castano-Betancourt MC,Hip minimal joint space width,replication,2016-10-04,GCST003853,Other measurement,#d53e4f
4771,European,6523.0,27701424.0,Castano-Betancourt MC,Hip minimal joint space width,initial,2016-10-04,GCST003853,Other measurement,#d53e4f
4772,European,3562.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,3,7-trimethyluric acid level)",initial,2016-10-03,GCST003850,Other measurement,#d53e4f
4773,European,824.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)",replication,2016-10-03,GCST003851,Other measurement,#d53e4f
4774,European,5323.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)",initial,2016-10-03,GCST003851,Other measurement,#d53e4f
4775,European,826.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)",replication,2016-10-03,GCST003848,Other measurement,#d53e4f
4776,European,5261.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level)",initial,2016-10-03,GCST003848,Other measurement,#d53e4f
4777,European,414.0,27702942.0,Tang CS,Hirschsprung disease,initial,2016-10-03,GCST003764,Digestive system disorder,#d53e4f
4778,Asian,1294.0,27702942.0,Tang CS,Hirschsprung disease,initial,2016-10-03,GCST003764,Digestive system disorder,#3288bd
4779,European,8882.0,27694927.0,Vijayakrishnan J,Acute lymphoblastic leukemia in childhood (B cell precursor),initial,2016-10-03,GCST003798,Cancer,#d53e4f
4781,European,2891.0,27694927.0,Vijayakrishnan J,Acute lymphoblastic leukemia in childhood (B cell precursor),replication,2016-10-03,GCST003798,Cancer,#d53e4f
4782,European,984.0,27694959.0,Bonder MJ,Gut microbiota (bacterial taxa),initial,2016-10-03,GCST003855,Other measurement,#d53e4f
4783,European,530.0,27694959.0,Bonder MJ,Gut microbiota (bacterial taxa),replication,2016-10-03,GCST003855,Other measurement,#d53e4f
4784,European,26577.0,27694991.0,Adams HH,Intracranial volume,initial,2016-10-03,GCST003834,Other measurement,#d53e4f
4785,European,2362.0,27694991.0,Adams HH,Intracranial volume,replication,2016-10-03,GCST003834,Other measurement,#d53e4f
4786,African Am./Caribbean,938.0,27694991.0,Adams HH,Intracranial volume,replication,2016-10-03,GCST003834,Other measurement,#fee08b
4787,Asian,955.0,27694991.0,Adams HH,Intracranial volume,replication,2016-10-03,GCST003834,Other measurement,#3288bd
4788,Hispanic/Latin American,1605.0,27694991.0,Adams HH,Intracranial volume,replication,2016-10-03,GCST003834,Other measurement,#807dba
4789,European,822.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)",replication,2016-10-03,GCST003846,Other measurement,#d53e4f
4790,European,9054.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level)",initial,2016-10-03,GCST003846,Other measurement,#d53e4f
4791,European,984.0,27694959.0,Bonder MJ,Gut microbiota (functional units),initial,2016-10-03,GCST003854,Other measurement,#d53e4f
4792,European,530.0,27694959.0,Bonder MJ,Gut microbiota (functional units),replication,2016-10-03,GCST003854,Other measurement,#d53e4f
4793,European,824.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)",replication,2016-10-03,GCST003849,Other measurement,#d53e4f
4794,European,8911.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)",initial,2016-10-03,GCST003849,Other measurement,#d53e4f
4795,European,5353.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)",initial,2016-10-03,GCST003847,Other measurement,#d53e4f
4796,European,833.0,27702941.0,Cornelis MC,"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)",replication,2016-10-03,GCST003847,Other measurement,#d53e4f
4797,European,154543.0,27618448.0,Liu C,Systolic blood pressure,replication,2016-10-01,GCST006228,Other measurement,#d53e4f
4798,Hispanic/Latin American,4586.0,27618448.0,Liu C,Systolic blood pressure,initial,2016-10-01,GCST006228,Other measurement,#807dba
4799,African Am./Caribbean,21503.0,27618448.0,Liu C,Systolic blood pressure,initial,2016-10-01,GCST006228,Other measurement,#fee08b
4800,Asian,26183.0,27618448.0,Liu C,Systolic blood pressure,replication,2016-10-01,GCST006228,Other measurement,#3288bd
4801,European,120473.0,27618448.0,Liu C,Systolic blood pressure,initial,2016-10-01,GCST006228,Other measurement,#d53e4f
4802,Hispanic/Latin American,4586.0,27618448.0,Liu C,Hypertension,initial,2016-10-01,GCST006229,Cardiovascular disease,#807dba
4803,African Am./Caribbean,21503.0,27618448.0,Liu C,Hypertension,initial,2016-10-01,GCST006229,Cardiovascular disease,#fee08b
4804,European,120473.0,27618448.0,Liu C,Hypertension,initial,2016-10-01,GCST006229,Cardiovascular disease,#d53e4f
4805,Asian,26183.0,27618448.0,Liu C,Hypertension,replication,2016-10-01,GCST006229,Cardiovascular disease,#3288bd
4806,European,154543.0,27618448.0,Liu C,Hypertension,replication,2016-10-01,GCST006229,Cardiovascular disease,#d53e4f
4807,Asian,26183.0,27618448.0,Liu C,Pulse pressure,replication,2016-10-01,GCST006230,Cardiovascular measurement,#3288bd
4808,European,120473.0,27618448.0,Liu C,Pulse pressure,initial,2016-10-01,GCST006230,Cardiovascular measurement,#d53e4f
4809,African Am./Caribbean,21503.0,27618448.0,Liu C,Pulse pressure,initial,2016-10-01,GCST006230,Cardiovascular measurement,#fee08b
4810,European,154543.0,27618448.0,Liu C,Pulse pressure,replication,2016-10-01,GCST006230,Cardiovascular measurement,#d53e4f
4811,Hispanic/Latin American,4586.0,27618448.0,Liu C,Pulse pressure,initial,2016-10-01,GCST006230,Cardiovascular measurement,#807dba
4812,Hispanic/Latin American,4586.0,27618448.0,Liu C,Diastolic blood pressure,initial,2016-10-01,GCST006227,Other measurement,#807dba
4813,African Am./Caribbean,21503.0,27618448.0,Liu C,Diastolic blood pressure,initial,2016-10-01,GCST006227,Other measurement,#fee08b
4814,European,120473.0,27618448.0,Liu C,Diastolic blood pressure,initial,2016-10-01,GCST006227,Other measurement,#d53e4f
4815,Asian,26183.0,27618448.0,Liu C,Diastolic blood pressure,replication,2016-10-01,GCST006227,Other measurement,#3288bd
4816,European,154543.0,27618448.0,Liu C,Diastolic blood pressure,replication,2016-10-01,GCST006227,Other measurement,#d53e4f
4817,African Am./Caribbean,22077.0,27618447.0,Surendran P,Hypertension,replication,2016-10-01,GCST006023,Cardiovascular disease,#fee08b
4818,Asian,2641.0,27618447.0,Surendran P,Hypertension,replication,2016-10-01,GCST006023,Cardiovascular disease,#3288bd
4819,European,125713.0,27618447.0,Surendran P,Hypertension,replication,2016-10-01,GCST006023,Cardiovascular disease,#d53e4f
4820,Asian,26183.0,27618447.0,Surendran P,Hypertension,initial,2016-10-01,GCST006023,Cardiovascular disease,#3288bd
4821,European,157090.0,27618447.0,Surendran P,Hypertension,initial,2016-10-01,GCST006023,Cardiovascular disease,#d53e4f
4822,Hispanic/Latin American,4632.0,27618447.0,Surendran P,Hypertension,replication,2016-10-01,GCST006023,Cardiovascular disease,#807dba
4823,African Am./Caribbean,22077.0,27618447.0,Surendran P,Pulse pressure,replication,2016-10-01,GCST006022,Cardiovascular measurement,#fee08b
4824,Hispanic/Latin American,4632.0,27618447.0,Surendran P,Pulse pressure,replication,2016-10-01,GCST006022,Cardiovascular measurement,#807dba
4825,Asian,2641.0,27618447.0,Surendran P,Pulse pressure,replication,2016-10-01,GCST006022,Cardiovascular measurement,#3288bd
4826,European,125713.0,27618447.0,Surendran P,Pulse pressure,replication,2016-10-01,GCST006022,Cardiovascular measurement,#d53e4f
4827,Asian,27487.0,27618447.0,Surendran P,Pulse pressure,initial,2016-10-01,GCST006022,Cardiovascular measurement,#3288bd
4828,European,165276.0,27618447.0,Surendran P,Pulse pressure,initial,2016-10-01,GCST006022,Cardiovascular measurement,#d53e4f
4829,African Am./Caribbean,22077.0,27618447.0,Surendran P,Systolic blood pressure,replication,2016-10-01,GCST006021,Other measurement,#fee08b
4830,Hispanic/Latin American,4632.0,27618447.0,Surendran P,Systolic blood pressure,replication,2016-10-01,GCST006021,Other measurement,#807dba
4831,Asian,2641.0,27618447.0,Surendran P,Systolic blood pressure,replication,2016-10-01,GCST006021,Other measurement,#3288bd
4832,European,125713.0,27618447.0,Surendran P,Systolic blood pressure,replication,2016-10-01,GCST006021,Other measurement,#d53e4f
4833,Asian,27487.0,27618447.0,Surendran P,Systolic blood pressure,initial,2016-10-01,GCST006021,Other measurement,#3288bd
4834,European,165276.0,27618447.0,Surendran P,Systolic blood pressure,initial,2016-10-01,GCST006021,Other measurement,#d53e4f
4835,European,165276.0,27618447.0,Surendran P,Diastolic blood pressure,initial,2016-10-01,GCST006020,Other measurement,#d53e4f
4836,Asian,2641.0,27618447.0,Surendran P,Diastolic blood pressure,replication,2016-10-01,GCST006020,Other measurement,#3288bd
4837,African Am./Caribbean,22077.0,27618447.0,Surendran P,Diastolic blood pressure,replication,2016-10-01,GCST006020,Other measurement,#fee08b
4838,Hispanic/Latin American,4632.0,27618447.0,Surendran P,Diastolic blood pressure,replication,2016-10-01,GCST006020,Other measurement,#807dba
4839,Asian,27487.0,27618447.0,Surendran P,Diastolic blood pressure,initial,2016-10-01,GCST006020,Other measurement,#3288bd
4840,European,125713.0,27618447.0,Surendran P,Diastolic blood pressure,replication,2016-10-01,GCST006020,Other measurement,#d53e4f
4841,European,4448.0,27696742.0,Yau MS,Knee osteoarthritis,initial,2016-10-01,GCST003820,Other disease,#d53e4f
4842,European,2618.0,27696742.0,Yau MS,Knee osteoarthritis,replication,2016-10-01,GCST003820,Other disease,#d53e4f
4843,European,120473.0,27618448.0,Liu C,Mean arterial pressure,initial,2016-10-01,GCST006231,Other measurement,#d53e4f
4844,African Am./Caribbean,21503.0,27618448.0,Liu C,Mean arterial pressure,initial,2016-10-01,GCST006231,Other measurement,#fee08b
4845,Hispanic/Latin American,4586.0,27618448.0,Liu C,Mean arterial pressure,initial,2016-10-01,GCST006231,Other measurement,#807dba
4846,European,1846.0,27769005.0,Nassan M,Bipolar disorder (early onset),replication,2016-09-30,GCST003742,Neurological disorder,#d53e4f
4847,European,2411.0,27769005.0,Nassan M,Bipolar disorder (early onset),initial,2016-09-30,GCST003742,Neurological disorder,#d53e4f
4848,European,958.0,27670397.0,Reyes-Gibby CC,Pre-treatment pain in head and neck squamous cell carcinoma,initial,2016-09-27,GCST003760,Other trait,#d53e4f
4849,European,410.0,27670397.0,Reyes-Gibby CC,Pre-treatment pain in head and neck squamous cell carcinoma,replication,2016-09-27,GCST003760,Other trait,#d53e4f
4850,European,958.0,27670397.0,Reyes-Gibby CC,Pre-treatment pain in head and neck squamous cell carcinoma,initial,2016-09-27,GCST003760,Cancer,#d53e4f
4851,European,410.0,27670397.0,Reyes-Gibby CC,Pre-treatment pain in head and neck squamous cell carcinoma,replication,2016-09-27,GCST003760,Cancer,#d53e4f
4852,European,54993.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),initial,2016-09-27,GCST003870,Cardiovascular measurement,#d53e4f
4853,European,13263.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#d53e4f
4854,Asian,4619.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#3288bd
4855,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#fee08b
4856,European,54993.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),initial,2016-09-27,GCST003870,Cardiovascular measurement,#d53e4f
4857,European,13263.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#d53e4f
4858,Asian,4619.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#3288bd
4859,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (Sokolow-Lyon),replication,2016-09-27,GCST003870,Cardiovascular measurement,#fee08b
4860,European,58862.0,27659466.0,van der Harst P,QRS complex (Cornell),initial,2016-09-27,GCST003871,Cardiovascular measurement,#d53e4f
4861,European,13263.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#d53e4f
4862,Asian,4619.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#3288bd
4863,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#fee08b
4864,European,58862.0,27659466.0,van der Harst P,QRS complex (Cornell),initial,2016-09-27,GCST003871,Cardiovascular measurement,#d53e4f
4865,European,13263.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#d53e4f
4866,Asian,4619.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#3288bd
4867,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (Cornell),replication,2016-09-27,GCST003871,Cardiovascular measurement,#fee08b
4868,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#fee08b
4869,Asian,4619.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#3288bd
4870,European,48632.0,27659466.0,van der Harst P,QRS complex (12-leadsum),initial,2016-09-27,GCST003872,Cardiovascular measurement,#d53e4f
4871,European,13263.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#d53e4f
4872,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#fee08b
4873,Asian,4619.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#3288bd
4874,European,48632.0,27659466.0,van der Harst P,QRS complex (12-leadsum),initial,2016-09-27,GCST003872,Cardiovascular measurement,#d53e4f
4875,European,13263.0,27659466.0,van der Harst P,QRS complex (12-leadsum),replication,2016-09-27,GCST003872,Cardiovascular measurement,#d53e4f
4876,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#fee08b
4877,Asian,4619.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#3288bd
4878,European,60255.0,27659466.0,van der Harst P,QRS duration,initial,2016-09-27,GCST003844,Cardiovascular measurement,#d53e4f
4879,European,13263.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#d53e4f
4880,African Am./Caribbean,3603.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#fee08b
4881,Asian,4619.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#3288bd
4882,European,60255.0,27659466.0,van der Harst P,QRS duration,initial,2016-09-27,GCST003844,Cardiovascular measurement,#d53e4f
4883,European,13263.0,27659466.0,van der Harst P,QRS duration,replication,2016-09-27,GCST003844,Cardiovascular measurement,#d53e4f
4884,European,552.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),initial,2016-09-27,GCST003797,Response to drug,#d53e4f
4885,Hispanic/Latin American,471.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#807dba
4886,African Am./Caribbean,117.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#fee08b
4887,European,552.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),initial,2016-09-27,GCST003797,Metabolic disorder,#d53e4f
4888,Hispanic/Latin American,471.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Metabolic disorder,#807dba
4889,African Am./Caribbean,117.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Metabolic disorder,#fee08b
4890,European,552.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),initial,2016-09-27,GCST003797,Cardiovascular disease,#d53e4f
4891,Hispanic/Latin American,471.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Cardiovascular disease,#807dba
4892,African Am./Caribbean,117.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Cardiovascular disease,#fee08b
4893,European,552.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),initial,2016-09-27,GCST003797,Response to drug,#d53e4f
4894,Hispanic/Latin American,471.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#807dba
4895,African Am./Caribbean,117.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#fee08b
4896,European,552.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),initial,2016-09-27,GCST003797,Response to drug,#d53e4f
4897,Hispanic/Latin American,471.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#807dba
4898,African Am./Caribbean,117.0,27670767.0,Chang SW,Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),replication,2016-09-27,GCST003797,Response to drug,#fee08b
4899,Asian,70.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,replication,2016-09-26,GCST003794,Other measurement,#3288bd
4901,Asian,128.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,initial,2016-09-26,GCST003794,Other measurement,#3288bd
4902,Asian,70.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,replication,2016-09-26,GCST003794,Response to drug,#3288bd
4904,Asian,128.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,initial,2016-09-26,GCST003794,Response to drug,#3288bd
4905,Asian,70.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,replication,2016-09-26,GCST003794,Response to drug,#3288bd
4907,Asian,128.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,initial,2016-09-26,GCST003794,Response to drug,#3288bd
4908,Asian,70.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,replication,2016-09-26,GCST003794,Cancer,#3288bd
4910,Asian,128.0,27669169.0,Chang IS,Progression free survival in EGFR-mutation-positive never-smoking lung adenocarcinoma treated with gefitinib or erlotinib,initial,2016-09-26,GCST003794,Cancer,#3288bd
4911,Asian,302.0,27665939.0,Liang KH,Hepatitis B (viral clearance),replication,2016-09-26,GCST003718,Biological process,#3288bd
4912,Asian,57.0,27665939.0,Liang KH,Hepatitis B (viral clearance),initial,2016-09-26,GCST003718,Biological process,#3288bd
4913,Asian,302.0,27665939.0,Liang KH,Hepatitis B (viral clearance),replication,2016-09-26,GCST003718,Digestive system disorder,#3288bd
4914,Asian,57.0,27665939.0,Liang KH,Hepatitis B (viral clearance),initial,2016-09-26,GCST003718,Digestive system disorder,#3288bd
4915,European,6215.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Biological process,#d53e4f
4917,African Am./Caribbean,2955.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Biological process,#fee08b
4918,European,824.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Biological process,#d53e4f
4919,European,6215.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Other measurement,#d53e4f
4921,African Am./Caribbean,2955.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Other measurement,#fee08b
4922,European,824.0,27669027.0,Boueiz A,Emphysema distribution in smoking,initial,2016-09-26,GCST003761,Other measurement,#d53e4f
4923,African,244.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,replication,2016-09-26,GCST003792,Response to drug,#fc8d59
4924,African,402.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,initial,2016-09-26,GCST003792,Response to drug,#fc8d59
4925,African,244.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,replication,2016-09-26,GCST003792,Other disease,#fc8d59
4926,African,402.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,initial,2016-09-26,GCST003792,Other disease,#fc8d59
4927,African,244.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,replication,2016-09-26,GCST003792,Digestive system disorder,#fc8d59
4928,African,402.0,27671213.0,Petros Z,Liver injury in anti-tuberculosis drug treatment,initial,2016-09-26,GCST003792,Digestive system disorder,#fc8d59
4929,European,679.0,27671502.0,Blokland GAM,Brain activation in response to working memory task,initial,2016-09-23,GCST003698,Other measurement,#d53e4f
4931,European,679.0,27671502.0,Blokland GAM,Brain activation in response to working memory task,initial,2016-09-23,GCST003698,Other measurement,#d53e4f
4933,European,679.0,27671502.0,Blokland GAM,Brain activation in response to working memory task,initial,2016-09-23,GCST003698,Biological process,#d53e4f
4935,Asian,4059.0,27664181.0,Kawamura R,Resistin levels,replication,2016-09-23,GCST003759,Other measurement,#3288bd
4936,Asian,448.0,27664181.0,Kawamura R,Resistin levels,initial,2016-09-23,GCST003759,Other measurement,#3288bd
4937,European,1655.0,27656889.0,Alemany S,Attention function,initial,2016-09-22,GCST003719,Other measurement,#d53e4f
4938,European,546.0,27656889.0,Alemany S,Attention function,replication,2016-09-22,GCST003719,Other measurement,#d53e4f
4939,European,901.0,27656708.0,Zhang W,L-arginine levels,initial,2016-09-22,GCST003793,Other measurement,#d53e4f
4940,Asian,1394.0,27656708.0,Zhang W,L-arginine levels,initial,2016-09-22,GCST003793,Other measurement,#3288bd
4942,European,1000.0,27656708.0,Zhang W,L-arginine levels,replication,2016-09-22,GCST003793,Other measurement,#d53e4f
4943,Hispanic/Latin American,12226.0,27650483.0,Kramer HJ,Urinary albumin-to-creatinine ratio,initial,2016-09-20,GCST003774,Other measurement,#807dba
4945,European,1087.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes,replication,2016-09-19,GCST003862,Metabolic disorder,#d53e4f
4947,European,4019.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes,initial,2016-09-19,GCST003862,Metabolic disorder,#d53e4f
4949,European,1087.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes,replication,2016-09-19,GCST003862,Other disease,#d53e4f
4951,European,4019.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs non-end stage renal disease) in type 1 diabetes,initial,2016-09-19,GCST003862,Other disease,#d53e4f
4952,European,3584.0,27647854.0,Sandholm N,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes,initial,2016-09-19,GCST003867,Metabolic disorder,#d53e4f
4955,European,3584.0,27647854.0,Sandholm N,Chronic kidney disease (chronic kidney disease vs normal or mildly reduced eGFR) in type 1 diabetes,initial,2016-09-19,GCST003867,Other disease,#d53e4f
4960,European,3410.0,27647854.0,Sandholm N,Kidney disease (late stage) in type 1 diabetes,initial,2016-09-19,GCST003866,Metabolic disorder,#d53e4f
4963,European,3410.0,27647854.0,Sandholm N,Kidney disease (late stage) in type 1 diabetes,initial,2016-09-19,GCST003866,Other disease,#d53e4f
4964,European,2458.0,27647854.0,Sandholm N,Kidney disease (early stage) in type 1 diabetes,initial,2016-09-19,GCST003865,Metabolic disorder,#d53e4f
4967,European,2458.0,27647854.0,Sandholm N,Kidney disease (early stage) in type 1 diabetes,initial,2016-09-19,GCST003865,Other disease,#d53e4f
4970,European,3971.0,27647854.0,Sandholm N,Kidney disease (early and late stages) in type 1 diabetes,initial,2016-09-19,GCST003864,Metabolic disorder,#d53e4f
4973,European,883.0,27647854.0,Sandholm N,Kidney disease (early and late stages) in type 1 diabetes,replication,2016-09-19,GCST003864,Metabolic disorder,#d53e4f
4974,European,3971.0,27647854.0,Sandholm N,Kidney disease (early and late stages) in type 1 diabetes,initial,2016-09-19,GCST003864,Other disease,#d53e4f
4977,European,883.0,27647854.0,Sandholm N,Kidney disease (early and late stages) in type 1 diabetes,replication,2016-09-19,GCST003864,Other disease,#d53e4f
4979,European,2568.0,27647854.0,Sandholm N,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes,initial,2016-09-19,GCST003863,Metabolic disorder,#d53e4f
4982,European,2568.0,27647854.0,Sandholm N,Chronic kidney disease (severe chronic kidney disease vs normal kidney function) in type 1 diabetes,initial,2016-09-19,GCST003863,Other disease,#d53e4f
4986,European,721.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes,replication,2016-09-19,GCST003861,Metabolic disorder,#d53e4f
4987,European,2632.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes,initial,2016-09-19,GCST003861,Metabolic disorder,#d53e4f
4990,European,721.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes,replication,2016-09-19,GCST003861,Other disease,#d53e4f
4991,European,2632.0,27647854.0,Sandholm N,Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes,initial,2016-09-19,GCST003861,Other disease,#d53e4f
4992,European,2876.0,27632927.0,Einarsdottir E,Otitis media,initial,2016-09-16,GCST003827,Neurological disorder,#d53e4f
4993,European,2775.0,27632927.0,Einarsdottir E,Otitis media (recurrent),initial,2016-09-16,GCST003829,Neurological disorder,#d53e4f
4994,European,2585.0,27632927.0,Einarsdottir E,Otitis media (chronic),initial,2016-09-16,GCST003828,Neurological disorder,#d53e4f
4997,Hispanic/Latin American,867.0,27629369.0,Gao J,Loneliness (multivariate analysis),initial,2016-09-15,GCST003773,Other measurement,#807dba
4998,African Am./Caribbean,1228.0,27629369.0,Gao J,Loneliness (multivariate analysis),initial,2016-09-15,GCST003773,Other measurement,#fee08b
4999,European,8490.0,27629369.0,Gao J,Loneliness (multivariate analysis),initial,2016-09-15,GCST003773,Other measurement,#d53e4f
5000,European,740.0,27639821.0,Scherag A,Mortality in sepsis,initial,2016-09-15,GCST003817,Other trait,#d53e4f
5002,European,740.0,27639821.0,Scherag A,Mortality in sepsis,initial,2016-09-15,GCST003817,Other measurement,#d53e4f
5004,European,8490.0,27629369.0,Gao J,Loneliness (linear analysis),initial,2016-09-15,GCST003772,Other measurement,#d53e4f
5006,Hispanic/Latin American,867.0,27629369.0,Gao J,Loneliness (linear analysis),initial,2016-09-15,GCST003772,Other measurement,#807dba
5007,African Am./Caribbean,1228.0,27629369.0,Gao J,Loneliness (linear analysis),initial,2016-09-15,GCST003772,Other measurement,#fee08b
5008,African Am./Caribbean,825.0,27629369.0,Gao J,Loneliness,initial,2016-09-15,GCST003771,Other measurement,#fee08b
5010,Hispanic/Latin American,621.0,27629369.0,Gao J,Loneliness,initial,2016-09-15,GCST003771,Other measurement,#807dba
5011,European,5950.0,27629369.0,Gao J,Loneliness,initial,2016-09-15,GCST003771,Other measurement,#d53e4f
5012,Asian,10390.0,27623749.0,Hwang JY,Body mass index,replication,2016-09-14,GCST003789,Body measurement,#3288bd
5013,Asian,484.0,27623749.0,Hwang JY,Body mass index,initial,2016-09-14,GCST003789,Body measurement,#3288bd
5014,European,4782.0,27629089.0,Sailer A,Multiple system atrophy,initial,2016-09-14,GCST003784,Neurological disorder,#d53e4f
5015,European,4159.0,27629089.0,Sailer A,Multiple system atrophy (pathologically confirmed),initial,2016-09-14,GCST003783,Neurological disorder,#d53e4f
5016,European,4536.0,27622933.0,Li QS,Response to bupropion in depression,initial,2016-09-13,GCST003800,Neurological disorder,#d53e4f
5017,European,4536.0,27622933.0,Li QS,Response to bupropion in depression,initial,2016-09-13,GCST003800,Response to drug,#d53e4f
5018,European,4536.0,27622933.0,Li QS,Response to bupropion in depression,initial,2016-09-13,GCST003800,Neurological disorder,#d53e4f
5019,Other/Mixed,154.0,27623284.0,Verma SS,Glaucoma (primary open-angle),initial,2016-09-13,GCST003745,Neurological disorder,#99d594
5020,European,4840.0,27623284.0,Verma SS,Glaucoma (primary open-angle),initial,2016-09-13,GCST003745,Neurological disorder,#d53e4f
5021,African,96.0,27623284.0,Verma SS,Glaucoma (primary open-angle),initial,2016-09-13,GCST003745,Neurological disorder,#fc8d59
5022,European,198990.0,27622933.0,Li QS,Response to antidepressants and depression,initial,2016-09-13,GCST003813,Neurological disorder,#d53e4f
5023,European,198990.0,27622933.0,Li QS,Response to antidepressants and depression,initial,2016-09-13,GCST003813,Neurological disorder,#d53e4f
5024,European,198990.0,27622933.0,Li QS,Response to antidepressants and depression,initial,2016-09-13,GCST003813,Response to drug,#d53e4f
5025,European,195222.0,27622933.0,Li QS,Non-response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003808,Neurological disorder,#d53e4f
5026,European,195222.0,27622933.0,Li QS,Non-response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003808,Response to drug,#d53e4f
5027,European,195222.0,27622933.0,Li QS,Non-response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003808,Neurological disorder,#d53e4f
5028,European,193489.0,27622933.0,Li QS,Non-response to antidepressants and depression,initial,2016-09-13,GCST003812,Neurological disorder,#d53e4f
5029,European,193489.0,27622933.0,Li QS,Non-response to antidepressants and depression,initial,2016-09-13,GCST003812,Neurological disorder,#d53e4f
5030,European,193489.0,27622933.0,Li QS,Non-response to antidepressants and depression,initial,2016-09-13,GCST003812,Response to drug,#d53e4f
5031,European,194909.0,27622933.0,Li QS,Response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003811,Neurological disorder,#d53e4f
5032,European,194909.0,27622933.0,Li QS,Response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003811,Response to drug,#d53e4f
5033,European,194909.0,27622933.0,Li QS,Response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003811,Response to drug,#d53e4f
5034,European,194909.0,27622933.0,Li QS,Response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003811,Neurological disorder,#d53e4f
5035,European,194088.0,27622933.0,Li QS,Non-response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003810,Neurological disorder,#d53e4f
5036,European,194088.0,27622933.0,Li QS,Non-response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003810,Response to drug,#d53e4f
5037,European,194088.0,27622933.0,Li QS,Non-response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003810,Response to drug,#d53e4f
5038,European,194088.0,27622933.0,Li QS,Non-response to citalopram or escitalopram and depression,initial,2016-09-13,GCST003810,Neurological disorder,#d53e4f
5039,European,197744.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003809,Neurological disorder,#d53e4f
5040,European,197744.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003809,Response to drug,#d53e4f
5041,European,197744.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors and depression,initial,2016-09-13,GCST003809,Neurological disorder,#d53e4f
5042,European,194673.0,27622933.0,Li QS,Response to bupropion and depression,initial,2016-09-13,GCST003806,Neurological disorder,#d53e4f
5043,European,194673.0,27622933.0,Li QS,Response to bupropion and depression,initial,2016-09-13,GCST003806,Response to drug,#d53e4f
5044,European,194673.0,27622933.0,Li QS,Response to bupropion and depression,initial,2016-09-13,GCST003806,Neurological disorder,#d53e4f
5045,European,193931.0,27622933.0,Li QS,Non-response to bupropion and depression,initial,2016-09-13,GCST003804,Neurological disorder,#d53e4f
5046,European,193931.0,27622933.0,Li QS,Non-response to bupropion and depression,initial,2016-09-13,GCST003804,Response to drug,#d53e4f
5047,European,193931.0,27622933.0,Li QS,Non-response to bupropion and depression,initial,2016-09-13,GCST003804,Neurological disorder,#d53e4f
5048,European,9106.0,27622933.0,Li QS,Response to antidepressants in depression,initial,2016-09-13,GCST003803,Neurological disorder,#d53e4f
5049,European,9106.0,27622933.0,Li QS,Response to antidepressants in depression,initial,2016-09-13,GCST003803,Neurological disorder,#d53e4f
5050,European,9106.0,27622933.0,Li QS,Response to antidepressants in depression,initial,2016-09-13,GCST003803,Response to drug,#d53e4f
5051,European,4698.0,27622933.0,Li QS,Response to citalopram or escitalopram in depression,initial,2016-09-13,GCST003802,Neurological disorder,#d53e4f
5052,European,4698.0,27622933.0,Li QS,Response to citalopram or escitalopram in depression,initial,2016-09-13,GCST003802,Response to drug,#d53e4f
5053,European,4698.0,27622933.0,Li QS,Response to citalopram or escitalopram in depression,initial,2016-09-13,GCST003802,Response to drug,#d53e4f
5054,European,4698.0,27622933.0,Li QS,Response to citalopram or escitalopram in depression,initial,2016-09-13,GCST003802,Neurological disorder,#d53e4f
5055,European,9688.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors in depression,initial,2016-09-13,GCST003801,Neurological disorder,#d53e4f
5056,European,9688.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors in depression,initial,2016-09-13,GCST003801,Response to drug,#d53e4f
5057,European,9688.0,27622933.0,Li QS,Response to selective serotonin reuptake inhibitors in depression,initial,2016-09-13,GCST003801,Neurological disorder,#d53e4f
5058,European,201529.0,27618452.0,Ehret GB,Diastolic blood pressure,initial,2016-09-12,GCST006258,Other measurement,#d53e4f
5059,European,140886.0,27618452.0,Ehret GB,Diastolic blood pressure,replication,2016-09-12,GCST006258,Other measurement,#d53e4f
5060,European,201529.0,27618452.0,Ehret GB,Systolic blood pressure,initial,2016-09-12,GCST006259,Other measurement,#d53e4f
5061,European,140886.0,27618452.0,Ehret GB,Systolic blood pressure,replication,2016-09-12,GCST006259,Other measurement,#d53e4f
5062,Asian,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Other measurement,#3288bd
5063,African Am./Caribbean,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Other measurement,#fee08b
5064,European,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Other measurement,#d53e4f
5065,Asian,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Response to drug,#3288bd
5066,African Am./Caribbean,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Response to drug,#fee08b
5067,European,96.0,28173075.0,Niu N,Response to metformin (IC50),initial,2016-09-11,GCST003791,Response to drug,#d53e4f
5068,African Am./Caribbean,2600.0,27643478.0,Powers A,Emotional dysregulation,initial,2016-09-09,GCST003765,Other measurement,#fee08b
5069,African Am./Caribbean,5372.0,27611488.0,Almoguera B,Asthma (childhood onset),initial,2016-09-09,GCST003832,Other disease,#fee08b
5070,European,5277.0,27611488.0,Almoguera B,Asthma (childhood onset),initial,2016-09-09,GCST003832,Other disease,#d53e4f
5071,European,14247.0,27611488.0,Almoguera B,Asthma,initial,2016-09-09,GCST003831,Other disease,#d53e4f
5072,African Am./Caribbean,7397.0,27611488.0,Almoguera B,Asthma,initial,2016-09-09,GCST003831,Other disease,#fee08b
5073,African Am./Caribbean,2025.0,27611488.0,Almoguera B,Adult asthma,initial,2016-09-09,GCST003833,Other disease,#fee08b
5074,European,8970.0,27611488.0,Almoguera B,Adult asthma,initial,2016-09-09,GCST003833,Other disease,#d53e4f
5075,Other/Mixed,1415.0,27599772.0,Ram R,Hypertriglyceridemia,replication,2016-09-07,GCST003743,Metabolic disorder,#99d594
5076,Other/Mixed,4086.0,27599772.0,Ram R,Hypertriglyceridemia,initial,2016-09-07,GCST003743,Metabolic disorder,#99d594
5077,African Am./Caribbean,908.0,27601451.0,Sanders AE,Chronic periodontitis (mean interproximal clinical attachment level),replication,2016-09-06,GCST003744,Other measurement,#fee08b
5078,European,4402.0,27601451.0,Sanders AE,Chronic periodontitis (mean interproximal clinical attachment level),replication,2016-09-06,GCST003744,Other measurement,#d53e4f
5079,Hispanic/Latin American,10935.0,27601451.0,Sanders AE,Chronic periodontitis (mean interproximal clinical attachment level),initial,2016-09-06,GCST003744,Other measurement,#807dba
5080,European,11080.0,27476799.0,Nielson CM,Lumbar spine bone mineral density (integral),initial,2016-09-06,GCST007015,Other measurement,#d53e4f
5082,European,12287.0,27476799.0,Nielson CM,Lumbar spine bone mineral density (trabecular),initial,2016-09-06,GCST007014,Other measurement,#d53e4f
5087,European,579.0,27595289.0,Goyal RK,Acute graft versus host disease in bone marrow transplantation (recipient effect),initial,2016-09-05,GCST003941,Immune system disorder,#d53e4f
5088,European,656.0,27595289.0,Goyal RK,Acute graft versus host disease in bone marrow transplantation (donor effect),initial,2016-09-05,GCST003942,Immune system disorder,#d53e4f
5089,European,656.0,27595289.0,Goyal RK,Acute graft versus host disease in bone marrow transplantation (donor effect),initial,2016-09-05,GCST003942,Other measurement,#d53e4f
5090,African,1335.0,28171663.0,Huo D,Breast cancer,initial,2016-09-04,GCST003782,Cancer,#fc8d59
5091,African Am./Caribbean,8112.0,28171663.0,Huo D,Breast cancer,initial,2016-09-04,GCST003782,Cancer,#fee08b
5092,African Am./Caribbean,4923.0,28171663.0,Huo D,Breast cancer,replication,2016-09-04,GCST003782,Cancer,#fee08b
5093,African,666.0,28171663.0,Huo D,Breast cancer (estrogen-receptor negative),initial,2016-09-04,GCST003780,Cancer,#fc8d59
5094,African Am./Caribbean,3512.0,28171663.0,Huo D,Breast cancer (estrogen-receptor negative),replication,2016-09-04,GCST003780,Cancer,#fee08b
5095,African Am./Caribbean,5499.0,28171663.0,Huo D,Breast cancer (estrogen-receptor negative),initial,2016-09-04,GCST003780,Cancer,#fee08b
5096,African Am./Caribbean,4032.0,28171663.0,Huo D,Breast cancer (estrogen-receptor positive),replication,2016-09-04,GCST003781,Cancer,#fee08b
5097,African,723.0,28171663.0,Huo D,Breast cancer (estrogen-receptor positive),initial,2016-09-04,GCST003781,Cancer,#fc8d59
5098,African Am./Caribbean,5945.0,28171663.0,Huo D,Breast cancer (estrogen-receptor positive),initial,2016-09-04,GCST003781,Cancer,#fee08b
5099,European,10951.0,27587472.0,Postmus I,Response to statins (HDL cholesterol change),replication,2016-09-01,GCST003617,Lipid or lipoprotein measurement,#d53e4f
5100,European,16769.0,27587472.0,Postmus I,Response to statins (HDL cholesterol change),initial,2016-09-01,GCST003617,Lipid or lipoprotein measurement,#d53e4f
5101,European,10951.0,27587472.0,Postmus I,Response to statins (HDL cholesterol change),replication,2016-09-01,GCST003617,Response to drug,#d53e4f
5102,European,16769.0,27587472.0,Postmus I,Response to statins (HDL cholesterol change),initial,2016-09-01,GCST003617,Response to drug,#d53e4f
5103,European,1373.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),initial,2016-09-01,GCST004522,Other measurement,#d53e4f
5104,Hispanic/Latin American,743.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Other measurement,#807dba
5105,Asian,627.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Other measurement,#3288bd
5106,African Am./Caribbean,1196.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Other measurement,#fee08b
5107,European,9184.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Other measurement,#d53e4f
5108,European,1373.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),initial,2016-09-01,GCST004522,Metabolic disorder,#d53e4f
5109,Hispanic/Latin American,743.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Metabolic disorder,#807dba
5110,Asian,627.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Metabolic disorder,#3288bd
5111,African Am./Caribbean,1196.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Metabolic disorder,#fee08b
5112,European,9184.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Metabolic disorder,#d53e4f
5113,European,1373.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),initial,2016-09-01,GCST004522,Response to drug,#d53e4f
5114,Hispanic/Latin American,743.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Response to drug,#807dba
5115,Asian,627.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Response to drug,#3288bd
5116,African Am./Caribbean,1196.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Response to drug,#fee08b
5117,European,9184.0,27500523.0,Zhou K,Response to metformin in type 2 diabetes (HbA1c reduction),replication,2016-09-01,GCST004522,Response to drug,#d53e4f
5118,African Am./Caribbean,8224.0,27588450.0,Mahajan A,Glomerular filtration rate,initial,2016-09-01,GCST003790,Other measurement,#fee08b
5119,Hispanic/Latin American,16325.0,27588450.0,Mahajan A,Glomerular filtration rate,initial,2016-09-01,GCST003790,Other measurement,#807dba
5120,Asian,23536.0,27588450.0,Mahajan A,Glomerular filtration rate,initial,2016-09-01,GCST003790,Other measurement,#3288bd
5121,European,23553.0,27588450.0,Mahajan A,Glomerular filtration rate,initial,2016-09-01,GCST003790,Other measurement,#d53e4f
5122,European,1612.0,27576016.0,Zhao B,Acute kidney injury in critical illness,replication,2016-08-30,GCST003656,Other trait,#d53e4f
5123,European,1328.0,27576016.0,Zhao B,Acute kidney injury in critical illness,initial,2016-08-30,GCST003656,Other trait,#d53e4f
5124,European,1612.0,27576016.0,Zhao B,Acute kidney injury in critical illness,replication,2016-08-30,GCST003656,Other measurement,#d53e4f
5125,European,1328.0,27576016.0,Zhao B,Acute kidney injury in critical illness,initial,2016-08-30,GCST003656,Other measurement,#d53e4f
5126,European,40407.0,27577874.0,Evans DS,QRS duration,initial,2016-08-29,GCST003598,Cardiovascular measurement,#d53e4f
5127,African Am./Caribbean,13031.0,27577874.0,Evans DS,QRS duration,initial,2016-08-29,GCST003598,Cardiovascular measurement,#fee08b
5128,African Am./Caribbean,10305.0,28580392.0,Taylor KC,Bone fracture in osteoporosis,initial,2016-08-27,GCST004403,Other disease,#fee08b
5129,African Am./Caribbean,10305.0,28580392.0,Taylor KC,Bone fracture in osteoporosis,initial,2016-08-27,GCST004403,Other disease,#fee08b
5131,Asian,57.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Other measurement,#3288bd
5132,Hispanic/Latin American,251.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Other measurement,#807dba
5133,African,138.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Other measurement,#fc8d59
5134,European,407.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Other measurement,#d53e4f
5136,Asian,57.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Response to drug,#3288bd
5137,Hispanic/Latin American,251.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Response to drug,#807dba
5138,African,138.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Response to drug,#fc8d59
5139,European,407.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Response to drug,#d53e4f
5141,Asian,57.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Cancer,#3288bd
5142,Hispanic/Latin American,251.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Cancer,#807dba
5143,African,138.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Cancer,#fc8d59
5144,European,407.0,27564568.0,Liu C,Thiopurine methyltransferase activity in acute lymphoblastic leukemia patients treated with mercaptopurines,initial,2016-08-26,GCST003609,Cancer,#d53e4f
5145,European,2447.0,27560520.0,Shaffer JR,Cranial base width,initial,2016-08-25,GCST003641,Other measurement,#d53e4f
5146,European,671.0,27560520.0,Shaffer JR,Cranial base width,replication,2016-08-25,GCST003641,Other measurement,#d53e4f
5147,European,671.0,27560520.0,Shaffer JR,Facial depth,replication,2016-08-25,GCST003646,Other measurement,#d53e4f
5148,European,2447.0,27560520.0,Shaffer JR,Facial depth,initial,2016-08-25,GCST003646,Other measurement,#d53e4f
5149,European,671.0,27560520.0,Shaffer JR,Lower facial height,replication,2016-08-25,GCST003645,Other measurement,#d53e4f
5150,European,2447.0,27560520.0,Shaffer JR,Lower facial height,initial,2016-08-25,GCST003645,Other measurement,#d53e4f
5151,European,671.0,27560520.0,Shaffer JR,Lip morphology,replication,2016-08-25,GCST003644,Other measurement,#d53e4f
5152,European,2447.0,27560520.0,Shaffer JR,Lip morphology,initial,2016-08-25,GCST003644,Other measurement,#d53e4f
5153,European,671.0,27560520.0,Shaffer JR,Nose morphology,replication,2016-08-25,GCST003643,Other measurement,#d53e4f
5154,European,2447.0,27560520.0,Shaffer JR,Nose morphology,initial,2016-08-25,GCST003643,Other measurement,#d53e4f
5155,European,671.0,27560520.0,Shaffer JR,Eye morphology,replication,2016-08-25,GCST003642,Other measurement,#d53e4f
5156,European,2447.0,27560520.0,Shaffer JR,Eye morphology,initial,2016-08-25,GCST003642,Other measurement,#d53e4f
5157,Asian,5480.0,27569725.0,Yang SK,Inflammatory bowel disease,replication,2016-08-25,GCST003602,Digestive system disorder,#3288bd
5158,Asian,5546.0,27569725.0,Yang SK,Inflammatory bowel disease,initial,2016-08-25,GCST003602,Digestive system disorder,#3288bd
5159,European,1713.0,27561104.0,Pirastu N,Coffee consumption,replication,2016-08-25,GCST003621,Biological process,#d53e4f
5160,European,1213.0,27561104.0,Pirastu N,Coffee consumption,initial,2016-08-25,GCST003621,Biological process,#d53e4f
5161,European,1713.0,27561104.0,Pirastu N,Coffee consumption,replication,2016-08-25,GCST003621,Other measurement,#d53e4f
5162,European,1213.0,27561104.0,Pirastu N,Coffee consumption,initial,2016-08-25,GCST003621,Other measurement,#d53e4f
5163,Asian,767.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,replication,2016-08-24,GCST003603,Other trait,#3288bd
5164,Asian,267.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2016-08-24,GCST003603,Other trait,#3288bd
5165,Asian,767.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,replication,2016-08-24,GCST003603,Response to drug,#3288bd
5166,Asian,267.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2016-08-24,GCST003603,Response to drug,#3288bd
5167,Asian,767.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,replication,2016-08-24,GCST003603,Digestive system disorder,#3288bd
5168,Asian,267.0,27558924.0,Kim HS,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2016-08-24,GCST003603,Digestive system disorder,#3288bd
5169,European,3768.0,27559109.0,Bustamante M,diarrhoeal disease at age 1,replication,2016-08-23,GCST003626,Other trait,#d53e4f
5170,European,5758.0,27559109.0,Bustamante M,diarrhoeal disease at age 1,initial,2016-08-23,GCST003626,Other trait,#d53e4f
5171,European,7722.0,27559109.0,Bustamante M,diarrhoeal disease at age 2 with doctor diagnosis,replication,2016-08-23,GCST003624,Other trait,#d53e4f
5172,European,6233.0,27559109.0,Bustamante M,diarrhoeal disease at age 2 with doctor diagnosis,initial,2016-08-23,GCST003624,Other trait,#d53e4f
5173,European,3516.0,27559109.0,Bustamante M,diarrhoeal disease at age 2,replication,2016-08-23,GCST003623,Other trait,#d53e4f
5174,European,5608.0,27559109.0,Bustamante M,diarrhoeal disease at age 2,initial,2016-08-23,GCST003623,Other trait,#d53e4f
5175,European,7465.0,27559109.0,Bustamante M,diarrhoeal disease at age 1 with doctor diagnosis,replication,2016-08-23,GCST003625,Other trait,#d53e4f
5176,European,6403.0,27559109.0,Bustamante M,diarrhoeal disease at age 1 with doctor diagnosis,initial,2016-08-23,GCST003625,Other trait,#d53e4f
5177,Asian,700.0,27545300.0,Hao J,Joint destruction and growth retardation,replication,2016-08-22,GCST003727,Other disease,#3288bd
5178,Asian,1717.0,27545300.0,Hao J,Joint destruction and growth retardation,initial,2016-08-22,GCST003727,Other disease,#3288bd
5179,Asian,700.0,27545300.0,Hao J,Joint destruction and growth retardation,replication,2016-08-22,GCST003727,Other measurement,#3288bd
5180,Asian,1717.0,27545300.0,Hao J,Joint destruction and growth retardation,initial,2016-08-22,GCST003727,Other measurement,#3288bd
5181,Asian,700.0,27545300.0,Hao J,Joint destruction and growth retardation,replication,2016-08-22,GCST003727,Body measurement,#3288bd
5182,Asian,1717.0,27545300.0,Hao J,Joint destruction and growth retardation,initial,2016-08-22,GCST003727,Body measurement,#3288bd
5183,European,735.0,27548383.0,Ortiz-Fernandez L,Behcet's disease,replication,2016-08-22,GCST007551,Cardiovascular disease,#d53e4f
5184,European,1795.0,27548383.0,Ortiz-Fernandez L,Behcet's disease,initial,2016-08-22,GCST007551,Cardiovascular disease,#d53e4f
5185,European,1250.0,27568811.0,Marinelli M,Sleep duration,replication,2016-08-19,GCST003741,Other measurement,#d53e4f
5186,European,10554.0,27568811.0,Marinelli M,Sleep duration,initial,2016-08-19,GCST003741,Other measurement,#d53e4f
5187,European,17044.0,27539887.0,Chahal HS,Basal cell carcinoma,replication,2016-08-19,GCST003726,Cancer,#d53e4f
5188,European,287197.0,27539887.0,Chahal HS,Basal cell carcinoma,initial,2016-08-19,GCST003726,Cancer,#d53e4f
5189,European,1751.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Other measurement,#d53e4f
5190,African Am./Caribbean,2173.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Other measurement,#fee08b
5191,European,1751.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Neurological disorder,#d53e4f
5192,African Am./Caribbean,2173.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Neurological disorder,#fee08b
5193,European,1751.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Other measurement,#d53e4f
5194,African Am./Caribbean,2173.0,27531626.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2016-08-17,GCST003860,Other measurement,#fee08b
5195,Asian,439.0,27529621.0,Otowa T,Depressive symptoms,replication,2016-08-16,GCST003836,Other measurement,#3288bd
5196,Asian,320.0,27529621.0,Otowa T,Depressive symptoms,initial,2016-08-16,GCST003836,Other measurement,#3288bd
5197,Asian,439.0,27529621.0,Otowa T,Depressive symptoms (stressful life events interaction),replication,2016-08-16,GCST003835,Other measurement,#3288bd
5198,Asian,320.0,27529621.0,Otowa T,Depressive symptoms (stressful life events interaction),initial,2016-08-16,GCST003835,Other measurement,#3288bd
5199,Asian,439.0,27529621.0,Otowa T,Depressive symptoms (stressful life events interaction),replication,2016-08-16,GCST003835,Other measurement,#3288bd
5200,Asian,320.0,27529621.0,Otowa T,Depressive symptoms (stressful life events interaction),initial,2016-08-16,GCST003835,Other measurement,#3288bd
5201,European,23326.0,27527254.0,Gharahkhani P,Barrett's esophagus,initial,2016-08-12,GCST003738,Digestive system disorder,#d53e4f
5202,European,27438.0,27527254.0,Gharahkhani P,Barrett's esophagus  or Esophageal adenocarcinoma,initial,2016-08-12,GCST003740,Cancer,#d53e4f
5203,European,27438.0,27527254.0,Gharahkhani P,Barrett's esophagus  or Esophageal adenocarcinoma,initial,2016-08-12,GCST003740,Digestive system disorder,#d53e4f
5204,European,21271.0,27527254.0,Gharahkhani P,Esophageal adenocarcinoma,initial,2016-08-12,GCST003739,Cancer,#d53e4f
5205,Asian,5030.0,27501781.0,Shiraishi K,EGFR mutation-positive lung adenocarcinoma,initial,2016-08-09,GCST003605,Cancer,#3288bd
5206,Asian,13301.0,27501781.0,Shiraishi K,EGFR mutation-positive lung adenocarcinoma,replication,2016-08-09,GCST003605,Cancer,#3288bd
5207,Asian,100.0,27506219.0,Wang W,Endometriosis,initial,2016-08-09,GCST003819,Other disease,#3288bd
5208,Asian,2876.0,27506219.0,Wang W,Endometriosis,replication,2016-08-09,GCST003819,Other disease,#3288bd
5209,Asian,14610.0,27503288.0,Song IW,Sjögren's syndrome,replication,2016-08-08,GCST003604,Neurological disorder,#3288bd
5210,Asian,1686.0,27503288.0,Song IW,Sjögren's syndrome,initial,2016-08-08,GCST003604,Neurological disorder,#3288bd
5212,European,127898.0,27494321.0,Jones SE,Chronotype,initial,2016-08-05,GCST003837,Biological process,#d53e4f
5213,European,110188.0,27494321.0,Jones SE,Sleep duration (undersleepers),initial,2016-08-05,GCST006686,Other measurement,#d53e4f
5214,European,91306.0,27494321.0,Jones SE,Sleep duration (oversleepers),initial,2016-08-05,GCST006685,Other measurement,#d53e4f
5215,European,39082.0,27494321.0,Jones SE,Sleep duration (oversleepers vs undersleepers),initial,2016-08-05,GCST003840,Other measurement,#d53e4f
5216,European,114765.0,27494321.0,Jones SE,Morning vs. evening chronotype,initial,2016-08-05,GCST003838,Biological process,#d53e4f
5217,European,127573.0,27494321.0,Jones SE,Sleep duration,initial,2016-08-05,GCST003839,Other measurement,#d53e4f
5220,European,1743.0,27490719.0,Bacelis J,Gestational age at birth (maternal effect),initial,2016-08-04,GCST003688,Other measurement,#d53e4f
5221,European,1743.0,27490719.0,Bacelis J,Gestational age at birth (maternal effect),initial,2016-08-04,GCST003688,Other measurement,#d53e4f
5222,European,1109.0,27490719.0,Bacelis J,Gestational age at birth (child effect),initial,2016-08-04,GCST003686,Other measurement,#d53e4f
5223,European,1109.0,27490719.0,Bacelis J,Gestational age at birth (child effect),initial,2016-08-04,GCST003686,Other measurement,#d53e4f
5224,European,336.0,27490719.0,Bacelis J,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect),initial,2016-08-04,GCST003685,Other measurement,#d53e4f
5225,European,336.0,27490719.0,Bacelis J,Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect),initial,2016-08-04,GCST003685,Other measurement,#d53e4f
5226,European,1407.0,27490719.0,Bacelis J,Gestational age at birth in labor-initiated deliveries (maternal effect),initial,2016-08-04,GCST003684,Other measurement,#d53e4f
5227,European,1407.0,27490719.0,Bacelis J,Gestational age at birth in labor-initiated deliveries (maternal effect),initial,2016-08-04,GCST003684,Other measurement,#d53e4f
5228,European,225.0,27490719.0,Bacelis J,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect),initial,2016-08-04,GCST003689,Other measurement,#d53e4f
5229,European,225.0,27490719.0,Bacelis J,Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect),initial,2016-08-04,GCST003689,Other measurement,#d53e4f
5230,European,884.0,27490719.0,Bacelis J,Gestational age at birth in labor-initiated deliveries (child effect),initial,2016-08-04,GCST003687,Other measurement,#d53e4f
5231,European,884.0,27490719.0,Bacelis J,Gestational age at birth in labor-initiated deliveries (child effect),initial,2016-08-04,GCST003687,Other measurement,#d53e4f
5235,European,437.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Biological process,#d53e4f
5236,Hispanic/Latin American,453.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Biological process,#807dba
5237,Asian,674.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Biological process,#3288bd
5238,Other/Mixed,311.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Biological process,#99d594
5239,African Am./Caribbean,364.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Biological process,#fee08b
5240,European,437.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Other measurement,#d53e4f
5241,Hispanic/Latin American,453.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Other measurement,#807dba
5242,Asian,674.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Other measurement,#3288bd
5243,Other/Mixed,311.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Other measurement,#99d594
5244,African Am./Caribbean,364.0,27488534.0,Patel YM,nicotine metabolite ratio in current smokers,initial,2016-08-03,GCST003629,Other measurement,#fee08b
5245,Asian,21472.0,27480026.0,Liu X,Hypertension,replication,2016-08-02,GCST003613,Cardiovascular disease,#3288bd
5246,Asian,518.0,27480026.0,Liu X,Hypertension,initial,2016-08-02,GCST003613,Cardiovascular disease,#3288bd
5247,European,5374.0,27492634.0,Du Y,Neuroendocrine tumor,initial,2016-08-01,GCST003785,Cancer,#d53e4f
5248,Asian,775.0,27271309.0,Li C,Pulse pressure x sodium interaction (2df test),replication,2016-08-01,GCST006118,Cardiovascular measurement,#3288bd
5249,Asian,1876.0,27271309.0,Li C,Pulse pressure x sodium interaction (2df test),initial,2016-08-01,GCST006118,Cardiovascular measurement,#3288bd
5250,Asian,775.0,27271309.0,Li C,Pulse pressure x sodium interaction (2df test),replication,2016-08-01,GCST006118,Other measurement,#3288bd
5251,Asian,1876.0,27271309.0,Li C,Pulse pressure x sodium interaction (2df test),initial,2016-08-01,GCST006118,Other measurement,#3288bd
5252,Asian,1876.0,27271309.0,Li C,Pulse pressure x sodium interaction (1df test),initial,2016-08-01,GCST006117,Cardiovascular measurement,#3288bd
5253,Asian,775.0,27271309.0,Li C,Pulse pressure x sodium interaction (1df test),replication,2016-08-01,GCST006117,Cardiovascular measurement,#3288bd
5254,Asian,1876.0,27271309.0,Li C,Pulse pressure x sodium interaction (1df test),initial,2016-08-01,GCST006117,Other measurement,#3288bd
5255,Asian,775.0,27271309.0,Li C,Pulse pressure x sodium interaction (1df test),replication,2016-08-01,GCST006117,Other measurement,#3288bd
5256,European,326113.0,27479909.0,Hyde CL,Major depressive disorder,initial,2016-08-01,GCST006041,Neurological disorder,#d53e4f
5257,European,152127.0,27479909.0,Hyde CL,Major depressive disorder,replication,2016-08-01,GCST006041,Neurological disorder,#d53e4f
5258,Asian,775.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (1df test),replication,2016-08-01,GCST006116,Other measurement,#3288bd
5259,Asian,1876.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (1df test),initial,2016-08-01,GCST006116,Other measurement,#3288bd
5260,Asian,775.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (1df test),replication,2016-08-01,GCST006116,Other measurement,#3288bd
5261,Asian,1876.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (1df test),initial,2016-08-01,GCST006116,Other measurement,#3288bd
5262,Asian,775.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (1df test),replication,2016-08-01,GCST006115,Other measurement,#3288bd
5263,Asian,1876.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (1df test),initial,2016-08-01,GCST006115,Other measurement,#3288bd
5264,Asian,775.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (1df test),replication,2016-08-01,GCST006115,Other measurement,#3288bd
5265,Asian,1876.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (1df test),initial,2016-08-01,GCST006115,Other measurement,#3288bd
5266,Asian,1876.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (2df test),initial,2016-08-01,GCST006114,Other measurement,#3288bd
5267,Asian,775.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (2df test),replication,2016-08-01,GCST006114,Other measurement,#3288bd
5268,Asian,1876.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (2df test),initial,2016-08-01,GCST006114,Other measurement,#3288bd
5269,Asian,775.0,27271309.0,Li C,Mean arterial pressure x sodium interaction (2df test),replication,2016-08-01,GCST006114,Other measurement,#3288bd
5270,Asian,1876.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (2df test),initial,2016-08-01,GCST006111,Other measurement,#3288bd
5271,Asian,775.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (2df test),replication,2016-08-01,GCST006111,Other measurement,#3288bd
5272,Asian,1876.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (2df test),initial,2016-08-01,GCST006111,Other measurement,#3288bd
5273,Asian,775.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (2df test),replication,2016-08-01,GCST006111,Other measurement,#3288bd
5274,Asian,775.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (2df test),replication,2016-08-01,GCST006113,Other measurement,#3288bd
5275,Asian,1876.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (2df test),initial,2016-08-01,GCST006113,Other measurement,#3288bd
5276,Asian,775.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (2df test),replication,2016-08-01,GCST006113,Other measurement,#3288bd
5277,Asian,1876.0,27271309.0,Li C,Systolic blood pressure x sodium interaction (2df test),initial,2016-08-01,GCST006113,Other measurement,#3288bd
5279,European,13952.0,27579533.0,Zhang M,Pancreatic cancer,initial,2016-08-01,GCST003758,Cancer,#d53e4f
5280,European,4670.0,27492634.0,Du Y,Bronchial neuroendocrine tumor,initial,2016-08-01,GCST003787,Cancer,#d53e4f
5281,European,4698.0,27492634.0,Du Y,Pancreatic neuroendocrine tumor,initial,2016-08-01,GCST003788,Cancer,#d53e4f
5283,European,4835.0,27492634.0,Du Y,Small intestine neuroendocrine tumor,initial,2016-08-01,GCST003786,Cancer,#d53e4f
5284,Asian,775.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (1df test),replication,2016-08-01,GCST006112,Other measurement,#3288bd
5285,Asian,1876.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (1df test),initial,2016-08-01,GCST006112,Other measurement,#3288bd
5286,Asian,775.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (1df test),replication,2016-08-01,GCST006112,Other measurement,#3288bd
5287,Asian,1876.0,27271309.0,Li C,Diastolic blood pressure x sodium interaction (1df test),initial,2016-08-01,GCST006112,Other measurement,#3288bd
5288,European,289.0,27339598.0,Ulveling D,Liver fibrosis severity in HIV/hepatitis C co-infection,initial,2016-07-29,GCST003606,Other disease,#d53e4f
5289,European,289.0,27339598.0,Ulveling D,Liver fibrosis severity in HIV/hepatitis C co-infection,initial,2016-07-29,GCST003606,Other trait,#d53e4f
5290,European,289.0,27339598.0,Ulveling D,Liver fibrosis severity in HIV/hepatitis C co-infection,initial,2016-07-29,GCST003606,Digestive system disorder,#d53e4f
5291,Other/Mixed,2102.0,27455349.0,Minster RL,Body mass index,replication,2016-07-25,GCST005181,Body measurement,#99d594
5292,Other/Mixed,3072.0,27455349.0,Minster RL,Body mass index,initial,2016-07-25,GCST005181,Body measurement,#99d594
5293,European,5346.0,27455348.0,van Rheenen W,Amyotrophic lateral sclerosis,replication,2016-07-25,GCST004692,Neurological disorder,#d53e4f
5294,European,36052.0,27455348.0,van Rheenen W,Amyotrophic lateral sclerosis,initial,2016-07-25,GCST004692,Neurological disorder,#d53e4f
5295,African Am./Caribbean,3742.0,26202629.0,Johnson EO,Drug abuse,initial,2016-07-23,GCST003601,Neurological disorder,#fee08b
5296,European,6845.0,26202629.0,Johnson EO,Drug abuse,initial,2016-07-23,GCST003601,Neurological disorder,#d53e4f
5297,European,1131.0,26202629.0,Johnson EO,Drug abuse,replication,2016-07-23,GCST003601,Neurological disorder,#d53e4f
5298,African Am./Caribbean,755.0,26202629.0,Johnson EO,Drug abuse,replication,2016-07-23,GCST003601,Neurological disorder,#fee08b
5300,European,9291.0,27439200.0,Nieuwenhuis MA,Bronchial hyperresponsiveness in asthma,replication,2016-07-20,GCST003589,Other disease,#d53e4f
5302,European,1487.0,27515689.0,Kerns SL,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)",initial,2016-07-20,GCST003584,Biological process,#d53e4f
5303,European,1487.0,27515689.0,Kerns SL,"Response to radiotherapy in prostate cancer (toxicity, rectal bleeding)",initial,2016-07-20,GCST003584,Cancer,#d53e4f
5304,European,1346.0,27515689.0,Kerns SL,Response to radiotherapy in prostate cancer (overall toxicity),initial,2016-07-20,GCST003583,Biological process,#d53e4f
5305,European,1346.0,27515689.0,Kerns SL,Response to radiotherapy in prostate cancer (overall toxicity),initial,2016-07-20,GCST003583,Cancer,#d53e4f
5306,European,1245.0,27515689.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event),initial,2016-07-20,GCST003581,Biological process,#d53e4f
5307,European,1245.0,27515689.0,Kerns SL,Toxicity response to radiotherapy in prostate cancer (decreased urine stream) (time to event),initial,2016-07-20,GCST003581,Cancer,#d53e4f
5308,European,1409.0,27515689.0,Kerns SL,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)",initial,2016-07-20,GCST003582,Biological process,#d53e4f
5309,European,1409.0,27515689.0,Kerns SL,"Response to radiotherapy in prostate cancer (toxicity, urinary frequency)",initial,2016-07-20,GCST003582,Cancer,#d53e4f
5310,Asian,11054.0,27436580.0,Cui Q,Nasopharyngeal carcinoma,replication,2016-07-19,GCST003578,Cancer,#3288bd
5311,Asian,4562.0,27436580.0,Cui Q,Nasopharyngeal carcinoma,initial,2016-07-19,GCST003578,Cancer,#3288bd
5312,European,12343.0,27424798.0,Chahal HS,Cutaneous squamous cell carcinoma,replication,2016-07-18,GCST003655,Cancer,#d53e4f
5313,European,287137.0,27424798.0,Chahal HS,Cutaneous squamous cell carcinoma,initial,2016-07-18,GCST003655,Cancer,#d53e4f
5314,Asian,1547.0,27424934.0,Choi HJ,Bone mineral density (femoral neck),replication,2016-07-15,GCST003612,Other measurement,#3288bd
5315,European,3237.0,27424934.0,Choi HJ,Bone mineral density (femoral neck),replication,2016-07-15,GCST003612,Other measurement,#d53e4f
5316,Asian,2729.0,27424934.0,Choi HJ,Bone mineral density (femoral neck),initial,2016-07-15,GCST003612,Other measurement,#3288bd
5317,Asian,2729.0,27424934.0,Choi HJ,Bone mineral density (spine),initial,2016-07-15,GCST003610,Other measurement,#3288bd
5318,European,3237.0,27424934.0,Choi HJ,Bone mineral density (spine),replication,2016-07-15,GCST003610,Other measurement,#d53e4f
5319,Asian,1547.0,27424934.0,Choi HJ,Bone mineral density (spine),replication,2016-07-15,GCST003610,Other measurement,#3288bd
5320,Asian,2729.0,27424934.0,Choi HJ,Bone mineral density (total hip),initial,2016-07-15,GCST003611,Other measurement,#3288bd
5321,European,3237.0,27424934.0,Choi HJ,Bone mineral density (total hip),replication,2016-07-15,GCST003611,Other measurement,#d53e4f
5322,Asian,1547.0,27424934.0,Choi HJ,Bone mineral density (total hip),replication,2016-07-15,GCST003611,Other measurement,#3288bd
5323,European,12601.0,27418160.0,van 't Hof FN,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)",initial,2016-07-14,GCST003683,Cardiovascular disease,#d53e4f
5324,European,12601.0,27418160.0,van 't Hof FN,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)",initial,2016-07-14,GCST003683,Cardiovascular disease,#d53e4f
5325,European,12601.0,27418160.0,van 't Hof FN,"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)",initial,2016-07-14,GCST003683,Cardiovascular disease,#d53e4f
5326,European,13354.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI),replication,2016-07-14,GCST003658,Other measurement,#d53e4f
5327,European,16753.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI),initial,2016-07-14,GCST003658,Other measurement,#d53e4f
5328,European,13354.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI),replication,2016-07-14,GCST003658,Body measurement,#d53e4f
5329,European,16753.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI),initial,2016-07-14,GCST003658,Body measurement,#d53e4f
5330,European,13354.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index,replication,2016-07-14,GCST005178,Other measurement,#d53e4f
5331,European,16753.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index,initial,2016-07-14,GCST005178,Other measurement,#d53e4f
5332,European,13354.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),replication,2016-07-14,GCST003659,Other measurement,#d53e4f
5333,European,16753.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),initial,2016-07-14,GCST003659,Other measurement,#d53e4f
5334,European,13354.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),replication,2016-07-14,GCST003659,Body measurement,#d53e4f
5335,European,16753.0,27416945.0,Walford GA,Modified Stumvoll Insulin Sensitivity Index (BMI interaction),initial,2016-07-14,GCST003659,Body measurement,#d53e4f
5336,European,917.0,27412988.0,Tise CG,Serum sulfate level,initial,2016-07-13,GCST003723,Other measurement,#d53e4f
5337,European,5649.0,27400856.0,Legge SE,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-07-12,GCST003628,Other trait,#d53e4f
5339,European,5649.0,27400856.0,Legge SE,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-07-12,GCST003628,Neurological disorder,#d53e4f
5341,European,5649.0,27400856.0,Legge SE,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-07-12,GCST003628,Response to drug,#d53e4f
5343,European,2267.0,27412012.0,Lamina C,Apolipoprotein A-IV levels,replication,2016-07-12,GCST003590,Lipid or lipoprotein measurement,#d53e4f
5344,European,13813.0,27412012.0,Lamina C,Apolipoprotein A-IV levels,initial,2016-07-12,GCST003590,Lipid or lipoprotein measurement,#d53e4f
5345,European,2363.0,27402877.0,Hill-Burns EM,"Parkinson's disease (non-familial, age at onset)",replication,2016-07-11,GCST003651,Neurological disorder,#d53e4f
5346,European,1554.0,27402877.0,Hill-Burns EM,"Parkinson's disease (non-familial, age at onset)",initial,2016-07-11,GCST003651,Neurological disorder,#d53e4f
5347,European,2363.0,27402877.0,Hill-Burns EM,"Parkinson's disease (non-familial, age at onset)",replication,2016-07-11,GCST003651,Other measurement,#d53e4f
5348,European,1554.0,27402877.0,Hill-Burns EM,"Parkinson's disease (non-familial, age at onset)",initial,2016-07-11,GCST003651,Other measurement,#d53e4f
5349,European,11675.0,27399966.0,Morris DL,Systemic lupus erythematosus,replication,2016-07-11,GCST003622,Immune system disorder,#d53e4f
5350,European,10995.0,27399966.0,Morris DL,Systemic lupus erythematosus,initial,2016-07-11,GCST003622,Immune system disorder,#d53e4f
5351,Asian,8117.0,27399966.0,Morris DL,Systemic lupus erythematosus,replication,2016-07-11,GCST003622,Immune system disorder,#3288bd
5352,Asian,5057.0,27399966.0,Morris DL,Systemic lupus erythematosus,initial,2016-07-11,GCST003622,Immune system disorder,#3288bd
5353,European,737.0,27402877.0,Hill-Burns EM,"Parkinson's disease (familial, age at onset)",replication,2016-07-11,GCST003652,Neurological disorder,#d53e4f
5354,European,431.0,27402877.0,Hill-Burns EM,"Parkinson's disease (familial, age at onset)",initial,2016-07-11,GCST003652,Neurological disorder,#d53e4f
5355,European,737.0,27402877.0,Hill-Burns EM,"Parkinson's disease (familial, age at onset)",replication,2016-07-11,GCST003652,Other measurement,#d53e4f
5356,European,431.0,27402877.0,Hill-Burns EM,"Parkinson's disease (familial, age at onset)",initial,2016-07-11,GCST003652,Other measurement,#d53e4f
5357,European,3100.0,27402877.0,Hill-Burns EM,Parkinson's disease (age of onset),replication,2016-07-11,GCST003653,Neurological disorder,#d53e4f
5358,European,1985.0,27402877.0,Hill-Burns EM,Parkinson's disease (age of onset),initial,2016-07-11,GCST003653,Neurological disorder,#d53e4f
5359,European,3100.0,27402877.0,Hill-Burns EM,Parkinson's disease (age of onset),replication,2016-07-11,GCST003653,Other measurement,#d53e4f
5360,European,1985.0,27402877.0,Hill-Burns EM,Parkinson's disease (age of onset),initial,2016-07-11,GCST003653,Other measurement,#d53e4f
5361,European,1625.0,27387956.0,Murk W,Asthma (SNP x SNP interaction),initial,2016-07-07,GCST003682,Other disease,#d53e4f
5362,European,1634.0,27387956.0,Murk W,Asthma (SNP x SNP interaction),replication,2016-07-07,GCST003682,Other disease,#d53e4f
5365,Asian,1579.0,27397699.0,Pei YF,Bone mineral density (Ward's triangle area),initial,2016-07-07,GCST003654,Other measurement,#3288bd
5366,African Am./Caribbean,845.0,27397699.0,Pei YF,Bone mineral density (Ward's triangle area),initial,2016-07-07,GCST003654,Other measurement,#fee08b
5367,European,4305.0,27397699.0,Pei YF,Bone mineral density (Ward's triangle area),initial,2016-07-07,GCST003654,Other measurement,#d53e4f
5368,Hispanic/Latin American,446.0,27397699.0,Pei YF,Bone mineral density (Ward's triangle area),initial,2016-07-07,GCST003654,Other measurement,#807dba
5369,Other/Mixed,2672.0,27523435.0,Mosteller M,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2016-07-05,GCST003567,Other measurement,#99d594
5370,Other/Mixed,2672.0,27523435.0,Mosteller M,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2016-07-05,GCST003567,Response to drug,#99d594
5371,Other/Mixed,2672.0,27523435.0,Mosteller M,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2016-07-05,GCST003567,Other disease,#99d594
5372,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),replication,2016-07-01,GCST003485,Lipid or lipoprotein measurement,#fee08b
5373,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),replication,2016-07-01,GCST003485,Lipid or lipoprotein measurement,#807dba
5374,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),initial,2016-07-01,GCST003485,Lipid or lipoprotein measurement,#d53e4f
5375,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),replication,2016-07-01,GCST003485,Response to drug,#fee08b
5376,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),replication,2016-07-01,GCST003485,Response to drug,#807dba
5377,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (HDL cholesterol levels),initial,2016-07-01,GCST003485,Response to drug,#d53e4f
5378,European,241704.0,27363682.0,Mitchell JS,Multiple myeloma,initial,2016-07-01,GCST004483,Cancer,#d53e4f
5379,European,7350.0,27363682.0,Mitchell JS,Multiple myeloma,replication,2016-07-01,GCST004483,Cancer,#d53e4f
5380,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),replication,2016-07-01,GCST003488,Lipid or lipoprotein measurement,#fee08b
5381,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),initial,2016-07-01,GCST003488,Lipid or lipoprotein measurement,#d53e4f
5382,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),replication,2016-07-01,GCST003488,Lipid or lipoprotein measurement,#807dba
5383,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),replication,2016-07-01,GCST003488,Response to drug,#fee08b
5384,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),initial,2016-07-01,GCST003488,Response to drug,#d53e4f
5385,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (triglyceride levels),replication,2016-07-01,GCST003488,Response to drug,#807dba
5386,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),initial,2016-07-01,GCST003487,Lipid or lipoprotein measurement,#d53e4f
5387,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),replication,2016-07-01,GCST003487,Lipid or lipoprotein measurement,#807dba
5388,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),replication,2016-07-01,GCST003487,Lipid or lipoprotein measurement,#fee08b
5389,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),initial,2016-07-01,GCST003487,Response to drug,#d53e4f
5390,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),replication,2016-07-01,GCST003487,Response to drug,#807dba
5391,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (total cholesterol levels),replication,2016-07-01,GCST003487,Response to drug,#fee08b
5392,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),replication,2016-07-01,GCST003486,Lipid or lipoprotein measurement,#fee08b
5393,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),initial,2016-07-01,GCST003486,Lipid or lipoprotein measurement,#d53e4f
5394,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),replication,2016-07-01,GCST003486,Lipid or lipoprotein measurement,#807dba
5395,African Am./Caribbean,138.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),replication,2016-07-01,GCST003486,Response to drug,#fee08b
5396,European,1594.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),initial,2016-07-01,GCST003486,Response to drug,#d53e4f
5397,Hispanic/Latin American,350.0,27002377.0,Irvin MR,Response to fenofibrate (LDL cholesterol levels),replication,2016-07-01,GCST003486,Response to drug,#807dba
5398,European,130990.0,27362418.0,Zhang H,Type 2 diabetes,initial,2016-06-30,GCST005716,Metabolic disorder,#d53e4f
5399,Asian,18817.0,27362418.0,Zhang H,Type 2 diabetes,replication,2016-06-30,GCST005716,Metabolic disorder,#3288bd
5400,European,1546.0,27347659.0,Vaysse A,Breslow thickness in cutaneous melanoma,replication,2016-06-27,GCST003639,Cancer,#d53e4f
5401,European,966.0,27347659.0,Vaysse A,Breslow thickness in cutaneous melanoma,initial,2016-06-27,GCST003639,Cancer,#d53e4f
5402,European,1546.0,27347659.0,Vaysse A,Breslow thickness in cutaneous melanoma,replication,2016-06-27,GCST003639,Other measurement,#d53e4f
5403,European,966.0,27347659.0,Vaysse A,Breslow thickness in cutaneous melanoma,initial,2016-06-27,GCST003639,Other measurement,#d53e4f
5404,Asian,13905.0,27354352.0,Han MR,Breast cancer,initial,2016-06-27,GCST003520,Cancer,#3288bd
5405,Asian,15148.0,27354352.0,Han MR,Breast cancer,replication,2016-06-27,GCST003520,Cancer,#3288bd
5406,European,34950.0,27329760.0,Hou L,Bipolar disorder,initial,2016-06-21,GCST003724,Neurological disorder,#d53e4f
5407,European,5305.0,27329760.0,Hou L,Bipolar disorder,replication,2016-06-21,GCST003724,Neurological disorder,#d53e4f
5408,European,9822.0,27325353.0,Matteini AM,Lower body strength,initial,2016-06-21,GCST004493,Other measurement,#d53e4f
5410,European,27581.0,27325353.0,Matteini AM,Hand grip strength,initial,2016-06-21,GCST004494,Other measurement,#d53e4f
5411,European,502.0,27327535.0,Laville V,Severity of facial solar lentigines,initial,2016-06-21,GCST003591,Other measurement,#d53e4f
5412,European,375752.0,27322543.0,Gormley P,Migraine,initial,2016-06-20,GCST003720,Cardiovascular disease,#d53e4f
5413,European,151215.0,27322543.0,Gormley P,Migraine with aura,initial,2016-06-20,GCST003722,Cardiovascular disease,#d53e4f
5414,European,147790.0,27322543.0,Gormley P,Migraine without aura,initial,2016-06-20,GCST003721,Cardiovascular disease,#d53e4f
5415,European,6226.0,27386562.0,Andlauer TF,Multiple sclerosis,replication,2016-06-17,GCST003566,Immune system disorder,#d53e4f
5416,European,15283.0,27386562.0,Andlauer TF,Multiple sclerosis,initial,2016-06-17,GCST003566,Immune system disorder,#d53e4f
5417,European,6912.0,27311723.0,Pei YF,Bone mineral density (hip),initial,2016-06-16,GCST003559,Other measurement,#d53e4f
5418,African Am./Caribbean,845.0,27311723.0,Pei YF,Bone mineral density (hip),replication,2016-06-16,GCST003559,Other measurement,#fee08b
5419,European,971.0,27311723.0,Pei YF,Bone mineral density (hip),replication,2016-06-16,GCST003559,Other measurement,#d53e4f
5420,Hispanic/Latin American,446.0,27311723.0,Pei YF,Bone mineral density (hip),replication,2016-06-16,GCST003559,Other measurement,#807dba
5421,European,1431.0,27315593.0,Lang M,Pathological gambling,initial,2016-06-14,GCST003648,Neurological disorder,#d53e4f
5422,African Am./Caribbean,6871.0,27296613.0,Salinas YD,Body mass index,replication,2016-06-13,GCST003647,Body measurement,#fee08b
5423,Hispanic/Latin American,3379.0,27296613.0,Salinas YD,Body mass index,replication,2016-06-13,GCST003647,Body measurement,#807dba
5424,European,2395.0,27296613.0,Salinas YD,Body mass index,initial,2016-06-13,GCST003647,Body measurement,#d53e4f
5425,African Am./Caribbean,1549.0,27296613.0,Salinas YD,Body mass index,initial,2016-06-13,GCST003647,Body measurement,#fee08b
5426,Asian,706.0,27296613.0,Salinas YD,Body mass index,initial,2016-06-13,GCST003647,Body measurement,#3288bd
5427,Hispanic/Latin American,1235.0,27296613.0,Salinas YD,Body mass index,initial,2016-06-13,GCST003647,Body measurement,#807dba
5432,Other/Mixed,230.0,28025368.0,Janicki PK,Complex regional pain syndrome,initial,2016-06-10,GCST003930,Neurological disorder,#99d594
5433,Other/Mixed,230.0,28025368.0,Janicki PK,Complex regional pain syndrome,replication,2016-06-10,GCST003930,Neurological disorder,#99d594
5438,European,2671.0,27285765.0,Chen D,Cervical cancer,replication,2016-06-07,GCST003565,Cancer,#d53e4f
5439,European,6076.0,27285765.0,Chen D,Cervical cancer,initial,2016-06-07,GCST003565,Cancer,#d53e4f
5440,European,3893.0,27262462.0,Teerlink CC,Prostate cancer,initial,2016-06-04,GCST003586,Cancer,#d53e4f
5441,European,2511.0,27262462.0,Teerlink CC,Aggressive prostate cancer,initial,2016-06-04,GCST003585,Other measurement,#d53e4f
5442,European,2511.0,27262462.0,Teerlink CC,Aggressive prostate cancer,initial,2016-06-04,GCST003585,Cancer,#d53e4f
5443,African,3106.0,27236921.0,Rautanen A,Pneumococcal bacteremia,initial,2016-06-02,GCST003649,Other disease,#fc8d59
5444,African,1449.0,27236921.0,Rautanen A,Pneumococcal bacteremia,replication,2016-06-02,GCST003649,Other disease,#fc8d59
5445,African,4213.0,27236921.0,Rautanen A,Bacteremia,initial,2016-06-02,GCST003650,Other disease,#fc8d59
5446,African,1770.0,27236921.0,Rautanen A,Bacteremia,replication,2016-06-02,GCST003650,Other disease,#fc8d59
5447,European,539.0,27304844.0,Khong JJ,Thyroid-associated orbitopathy in graves' disease,replication,2016-06-01,GCST003640,Immune system disorder,#d53e4f
5448,European,412.0,27304844.0,Khong JJ,Thyroid-associated orbitopathy in graves' disease,initial,2016-06-01,GCST003640,Immune system disorder,#d53e4f
5449,European,539.0,27304844.0,Khong JJ,Thyroid-associated orbitopathy in graves' disease,replication,2016-06-01,GCST003640,Neurological disorder,#d53e4f
5450,European,412.0,27304844.0,Khong JJ,Thyroid-associated orbitopathy in graves' disease,initial,2016-06-01,GCST003640,Neurological disorder,#d53e4f
5451,Asian,7261.0,27244555.0,Li Y,Susceptibility to persistent hepatitis B virus infection,replication,2016-05-31,GCST003615,Digestive system disorder,#3288bd
5452,Asian,2308.0,27244555.0,Li Y,Susceptibility to persistent hepatitis B virus infection,initial,2016-05-31,GCST003615,Digestive system disorder,#3288bd
5453,Asian,7261.0,27244555.0,Li Y,Susceptibility to persistent hepatitis B virus infection,replication,2016-05-31,GCST003615,Immune system disorder,#3288bd
5454,Asian,2308.0,27244555.0,Li Y,Susceptibility to persistent hepatitis B virus infection,initial,2016-05-31,GCST003615,Immune system disorder,#3288bd
5455,European,4256.0,27244217.0,Fogh I,Survival in sporadic amyotrophic lateral sclerosis,initial,2016-05-31,GCST003632,Neurological disorder,#d53e4f
5456,European,4256.0,27244217.0,Fogh I,Survival in sporadic amyotrophic lateral sclerosis,initial,2016-05-31,GCST003632,Other measurement,#d53e4f
5457,European,405072.0,27225129.0,Okbay A,Educational attainment (years of education),initial,2016-05-26,GCST003676,Other measurement,#d53e4f
5458,European,161.0,28090565.0,Tsai EA,Liver disease severity in Alagille syndrome,initial,2016-05-26,GCST003616,Neurological disorder,#d53e4f
5459,European,161.0,28090565.0,Tsai EA,Liver disease severity in Alagille syndrome,initial,2016-05-26,GCST003616,Digestive system disorder,#d53e4f
5460,European,280007.0,27225129.0,Okbay A,Educational attainment (college completion),initial,2016-05-26,GCST003677,Other measurement,#d53e4f
5461,European,104402.0,27519822.0,Power RA,Major depressive disorder,replication,2016-05-24,GCST003558,Neurological disorder,#d53e4f
5462,European,11611.0,27519822.0,Power RA,Major depressive disorder,initial,2016-05-24,GCST003558,Neurological disorder,#d53e4f
5466,Asian,5537.0,27519822.0,Power RA,Major depressive disorder,replication,2016-05-24,GCST003558,Neurological disorder,#3288bd
5467,European,525.0,27203581.0,Sousa I,Primary spontaneous pneumothorax,replication,2016-05-20,GCST003618,Other trait,#d53e4f
5468,European,221.0,27203581.0,Sousa I,Primary spontaneous pneumothorax,initial,2016-05-20,GCST003618,Other trait,#d53e4f
5469,Hispanic/Latin American,501.0,27193062.0,Adhikari K,middle facial morphology traits (ordinal measurement),replication,2016-05-19,GCST003633,Other measurement,#807dba
5470,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,middle facial morphology traits (ordinal measurement),initial,2016-05-19,GCST003633,Other measurement,#807dba
5471,Hispanic/Latin American,501.0,27193062.0,Adhikari K,middle facial morphology traits (ordinal measurement),replication,2016-05-19,GCST003633,Other measurement,#807dba
5472,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,middle facial morphology traits (ordinal measurement),initial,2016-05-19,GCST003633,Other measurement,#807dba
5473,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,upper facial morphology traits (ordinal measurement),initial,2016-05-19,GCST003638,Other measurement,#807dba
5474,Asian,2941.0,27195777.0,Sano M,Left ventricular QRS voltage,replication,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5475,Asian,2994.0,27195777.0,Sano M,Left ventricular QRS voltage,initial,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5476,Asian,2941.0,27195777.0,Sano M,Left ventricular QRS voltage,replication,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5477,Asian,2994.0,27195777.0,Sano M,Left ventricular QRS voltage,initial,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5478,Asian,2941.0,27195777.0,Sano M,Left ventricular QRS voltage,replication,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5479,Asian,2994.0,27195777.0,Sano M,Left ventricular QRS voltage,initial,2016-05-19,GCST003630,Cardiovascular measurement,#3288bd
5480,Asian,1922.0,27195708.0,Scott WR,Waist-to-hip ratio adjusted for body mass index,replication,2016-05-19,GCST003564,Body measurement,#3288bd
5481,Asian,10318.0,27195708.0,Scott WR,Waist-to-hip ratio adjusted for body mass index,initial,2016-05-19,GCST003564,Body measurement,#3288bd
5482,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,facial morphology traits (multivariate analysis),initial,2016-05-19,GCST003637,Other measurement,#807dba
5483,Hispanic/Latin American,2955.0,27193062.0,Adhikari K,lower facial morphology traits (quantitative measurement),initial,2016-05-19,GCST003636,Other measurement,#807dba
5484,Hispanic/Latin American,2955.0,27193062.0,Adhikari K,lower facial morphology traits (quantitative measurement),initial,2016-05-19,GCST003636,Other measurement,#807dba
5485,Hispanic/Latin American,2955.0,27193062.0,Adhikari K,middle facial morphology traits (quantitative measurement),initial,2016-05-19,GCST003635,Other measurement,#807dba
5486,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,lower facial morphology traits (ordinal measurement),initial,2016-05-19,GCST003634,Other measurement,#807dba
5487,Hispanic/Latin American,5958.0,27193062.0,Adhikari K,lower facial morphology traits (ordinal measurement),initial,2016-05-19,GCST003634,Other measurement,#807dba
5488,European,56799.0,27189021.0,Cook JP,Type 2 diabetes,initial,2016-05-18,GCST003619,Metabolic disorder,#d53e4f
5489,African Am./Caribbean,3571.0,27189021.0,Cook JP,Type 2 diabetes,initial,2016-05-18,GCST003619,Metabolic disorder,#fee08b
5490,Hispanic/Latin American,6499.0,27189021.0,Cook JP,Type 2 diabetes,initial,2016-05-18,GCST003619,Metabolic disorder,#807dba
5491,Asian,4735.0,27189021.0,Cook JP,Type 2 diabetes,initial,2016-05-18,GCST003619,Metabolic disorder,#3288bd
5492,European,69033.0,27189021.0,Cook JP,Type 2 diabetes,replication,2016-05-18,GCST003619,Metabolic disorder,#d53e4f
5493,European,52107.0,27193031.0,Marquez A,Systemic lupus erythematosus or rheumatoid arthritis,replication,2016-05-18,GCST003620,Immune system disorder,#d53e4f
5494,European,16546.0,27193031.0,Marquez A,Systemic lupus erythematosus or rheumatoid arthritis,initial,2016-05-18,GCST003620,Immune system disorder,#d53e4f
5495,European,52107.0,27193031.0,Marquez A,Systemic lupus erythematosus or rheumatoid arthritis,replication,2016-05-18,GCST003620,Immune system disorder,#d53e4f
5496,European,16546.0,27193031.0,Marquez A,Systemic lupus erythematosus or rheumatoid arthritis,initial,2016-05-18,GCST003620,Immune system disorder,#d53e4f
5497,European,334141.0,27182965.0,Pickrell JK,Parkinson's disease,initial,2016-05-16,GCST003984,Neurological disorder,#d53e4f
5498,European,134641.0,27182965.0,Pickrell JK,Hypothyroidism,initial,2016-05-16,GCST003988,Other disease,#d53e4f
5499,European,17500.0,27182965.0,Pickrell JK,Male-pattern baldness,initial,2016-05-16,GCST003983,Other disease,#d53e4f
5500,European,67023.0,27182965.0,Pickrell JK,Nose size,initial,2016-05-16,GCST003999,Other measurement,#d53e4f
5501,European,64143.0,27182965.0,Pickrell JK,Joint mobility (Beighton score),initial,2016-05-16,GCST003998,Other measurement,#d53e4f
5502,European,191843.0,27182965.0,Pickrell JK,Myopia,initial,2016-05-16,GCST003997,Other trait,#d53e4f
5503,European,69284.0,27182965.0,Pickrell JK,Monobrow,initial,2016-05-16,GCST003996,Other measurement,#d53e4f
5504,European,173421.0,27182965.0,Pickrell JK,Tonsillectomy,initial,2016-05-16,GCST003995,Other measurement,#d53e4f
5505,European,55871.0,27182965.0,Pickrell JK,Age at voice drop,initial,2016-05-16,GCST003994,Other measurement,#d53e4f
5506,European,76831.0,27182965.0,Pickrell JK,Menarche (age at onset),initial,2016-05-16,GCST003993,Other measurement,#d53e4f
5507,European,99695.0,27182965.0,Pickrell JK,Photic sneeze reflex,initial,2016-05-16,GCST003992,Other trait,#d53e4f
5508,European,121810.0,27182965.0,Pickrell JK,Childhood ear infection,initial,2016-05-16,GCST003991,Other measurement,#d53e4f
5509,European,180741.0,27182965.0,Pickrell JK,Allergy,initial,2016-05-16,GCST003990,Immune system disorder,#d53e4f
5510,European,71489.0,27182965.0,Pickrell JK,Chin dimples,initial,2016-05-16,GCST003989,Other measurement,#d53e4f
5511,European,157242.0,27182965.0,Pickrell JK,Asthma,initial,2016-05-16,GCST003987,Other disease,#d53e4f
5512,European,283985.0,27182965.0,Pickrell JK,Migraine,initial,2016-05-16,GCST003986,Cardiovascular disease,#d53e4f
5513,European,33790.0,27182965.0,Pickrell JK,Breast size,initial,2016-05-16,GCST003985,Body measurement,#d53e4f
5514,African Am./Caribbean,5339.0,27393504.0,Zanetti KA,Lung cancer,initial,2016-05-13,GCST003775,Cancer,#fee08b
5515,African Am./Caribbean,1662.0,27393504.0,Zanetti KA,Lung cancer,replication,2016-05-13,GCST003775,Cancer,#fee08b
5516,African Am./Caribbean,4001.0,27393504.0,Zanetti KA,Squamous cell lung carcinoma,initial,2016-05-13,GCST003777,Cancer,#fee08b
5517,African Am./Caribbean,1329.0,27393504.0,Zanetti KA,Squamous cell lung carcinoma,replication,2016-05-13,GCST003777,Cancer,#fee08b
5518,African Am./Caribbean,1448.0,27393504.0,Zanetti KA,Lung adenocarcinoma,replication,2016-05-13,GCST003776,Cancer,#fee08b
5519,African Am./Caribbean,4340.0,27393504.0,Zanetti KA,Lung adenocarcinoma,initial,2016-05-13,GCST003776,Cancer,#fee08b
5520,Asian,786.0,27191271.0,Hu Q,Coronary artery disease,initial,2016-05-13,GCST003561,Cardiovascular disease,#3288bd
5521,Asian,9127.0,27191271.0,Hu Q,Coronary artery disease,replication,2016-05-13,GCST003561,Cardiovascular disease,#3288bd
5522,African Am./Caribbean,4737.0,27393504.0,Zanetti KA,Smoking behaviour (cigarettes smoked per day),initial,2016-05-13,GCST003779,Other measurement,#fee08b
5523,African Am./Caribbean,3777.0,27393504.0,Zanetti KA,Smoking status (current vs former),initial,2016-05-13,GCST003778,Other measurement,#fee08b
5524,Asian,157.0,27171184.0,Kuo HC,Coronary artery aneurysm in Kawasaki disease,initial,2016-05-12,GCST003560,Immune system disorder,#3288bd
5525,Asian,157.0,27171184.0,Kuo HC,Coronary artery aneurysm in Kawasaki disease,initial,2016-05-12,GCST003560,Cardiovascular disease,#3288bd
5526,Hispanic/Latin American,1242.0,27167565.0,Stein MB,Post-traumatic stress disorder,replication,2016-05-11,GCST003495,Neurological disorder,#807dba
5527,African Am./Caribbean,667.0,27167565.0,Stein MB,Post-traumatic stress disorder,replication,2016-05-11,GCST003495,Neurological disorder,#fee08b
5528,European,4007.0,27167565.0,Stein MB,Post-traumatic stress disorder,replication,2016-05-11,GCST003495,Neurological disorder,#d53e4f
5529,Hispanic/Latin American,1413.0,27167565.0,Stein MB,Post-traumatic stress disorder,initial,2016-05-11,GCST003495,Neurological disorder,#807dba
5530,African Am./Caribbean,1312.0,27167565.0,Stein MB,Post-traumatic stress disorder,initial,2016-05-11,GCST003495,Neurological disorder,#fee08b
5531,European,5049.0,27167565.0,Stein MB,Post-traumatic stress disorder,initial,2016-05-11,GCST003495,Neurological disorder,#d53e4f
5532,Asian,57.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Cancer,#3288bd
5533,Other/Mixed,26.0,27173062.0,Azad AK,Survival in head and neck cancer,initial,2016-05-09,GCST003541,Cancer,#99d594
5534,African Am./Caribbean,11.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Cancer,#fee08b
5535,European,489.0,27173062.0,Azad AK,Survival in head and neck cancer,initial,2016-05-09,GCST003541,Cancer,#d53e4f
5536,European,470.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Cancer,#d53e4f
5537,Other/Mixed,28.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Cancer,#99d594
5538,Asian,57.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Other measurement,#3288bd
5539,Other/Mixed,26.0,27173062.0,Azad AK,Survival in head and neck cancer,initial,2016-05-09,GCST003541,Other measurement,#99d594
5540,African Am./Caribbean,11.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Other measurement,#fee08b
5541,European,489.0,27173062.0,Azad AK,Survival in head and neck cancer,initial,2016-05-09,GCST003541,Other measurement,#d53e4f
5542,European,470.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Other measurement,#d53e4f
5543,Other/Mixed,28.0,27173062.0,Azad AK,Survival in head and neck cancer,replication,2016-05-09,GCST003541,Other measurement,#99d594
5544,Hispanic/Latin American,12282.0,27159506.0,Dunn EC,Anxiety,initial,2016-05-09,GCST003562,Other measurement,#807dba
5545,Hispanic/Latin American,8195.0,27159506.0,Dunn EC,Anxiety,replication,2016-05-09,GCST003562,Other measurement,#807dba
5546,Asian,1693.0,27153935.0,Zhang CE,Dermatomyositis,initial,2016-05-06,GCST003522,Neurological disorder,#3288bd
5547,European,14933.0,27132594.0,Mbarek H,Spontaneous dizygotic twinning,initial,2016-05-05,GCST004413,Biological process,#d53e4f
5548,European,300945.0,27132594.0,Mbarek H,Spontaneous dizygotic twinning,replication,2016-05-05,GCST004413,Biological process,#d53e4f
5549,European,2605.0,27151647.0,Chen G,Alcohol dependence symptom count,initial,2016-05-05,GCST003538,Other measurement,#d53e4f
5550,African Am./Caribbean,1233.0,27151647.0,Chen G,Alcohol dependence symptom count,initial,2016-05-05,GCST003538,Other measurement,#fee08b
5551,Asian,2329.0,27145994.0,Wang M,Colorectal cancer,initial,2016-05-05,GCST003494,Cancer,#3288bd
5552,European,2122.0,27145994.0,Wang M,Colorectal cancer,replication,2016-05-05,GCST003494,Cancer,#d53e4f
5553,Asian,12204.0,27145994.0,Wang M,Colorectal cancer,replication,2016-05-05,GCST003494,Cancer,#3288bd
5554,European,2828.0,27149122.0,Smith JG,Mortality in heart failure,initial,2016-05-05,GCST003539,Cardiovascular disease,#d53e4f
5555,European,1870.0,27149122.0,Smith JG,Mortality in heart failure,replication,2016-05-05,GCST003539,Cardiovascular disease,#d53e4f
5556,European,2828.0,27149122.0,Smith JG,Mortality in heart failure,initial,2016-05-05,GCST003539,Other measurement,#d53e4f
5557,European,1870.0,27149122.0,Smith JG,Mortality in heart failure,replication,2016-05-05,GCST003539,Other measurement,#d53e4f
5558,European,1300.0,27149984.0,Degenhardt F,Coenzyme Q10 levels,initial,2016-05-05,GCST003523,Other measurement,#d53e4f
5559,European,958.0,27445529.0,Berube JC,Asthma,replication,2016-05-04,GCST003521,Other disease,#d53e4f
5560,European,360.0,27445529.0,Berube JC,Asthma,initial,2016-05-04,GCST003521,Other disease,#d53e4f
5561,European,30377.0,27142678.0,Amin N,Sleep latency,replication,2016-05-04,GCST003481,Other measurement,#d53e4f
5562,European,4242.0,27142678.0,Amin N,Sleep latency,initial,2016-05-04,GCST003481,Other measurement,#d53e4f
5563,European,5208.0,27157822.0,Hallberg P,Anti-thyroid drug induced agranulocytosis,initial,2016-05-03,GCST003527,Other trait,#d53e4f
5565,European,5208.0,27157822.0,Hallberg P,Anti-thyroid drug induced agranulocytosis,initial,2016-05-03,GCST003527,Response to drug,#d53e4f
5567,European,5392.0,27157822.0,Hallberg P,Non-chemotherapy drug induced agranulocytosis,initial,2016-05-03,GCST003526,Other trait,#d53e4f
5569,European,5392.0,27157822.0,Hallberg P,Non-chemotherapy drug induced agranulocytosis,initial,2016-05-03,GCST003526,Biological process,#d53e4f
5571,African Am./Caribbean,1227.0,27142222.0,White MJ,Asthma (childhood onset),initial,2016-05-03,GCST003482,Other disease,#fee08b
5572,European,623.0,27143689.0,Hertz DL,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,initial,2016-05-03,GCST003672,Neurological disorder,#d53e4f
5573,European,623.0,27143689.0,Hertz DL,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,initial,2016-05-03,GCST003672,Response to drug,#d53e4f
5574,European,623.0,27143689.0,Hertz DL,Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,initial,2016-05-03,GCST003672,Cancer,#d53e4f
5575,European,11626.0,27135401.0,Cheng TH,Endometrial endometrioid carcinoma,initial,2016-05-02,GCST003525,Cancer,#d53e4f
5576,European,32153.0,27135401.0,Cheng TH,Endometrial endometrioid carcinoma,replication,2016-05-02,GCST003525,Cancer,#d53e4f
5577,European,11756.0,27135401.0,Cheng TH,Endometrial cancer,initial,2016-05-02,GCST003524,Cancer,#d53e4f
5578,European,33125.0,27135401.0,Cheng TH,Endometrial cancer,replication,2016-05-02,GCST003524,Cancer,#d53e4f
5579,Asian,2561.0,26663301.0,Lessard CJ,Systemic lupus erythematosus,replication,2016-05-01,GCST003599,Immune system disorder,#3288bd
5580,Asian,5420.0,26663301.0,Lessard CJ,Systemic lupus erythematosus,initial,2016-05-01,GCST003599,Immune system disorder,#3288bd
5581,European,2370.0,26651848.0,Rivera NV,Sarcoidosis (Lofgren's syndrome),initial,2016-05-01,GCST005540,Other disease,#d53e4f
5582,European,5152.0,26651848.0,Rivera NV,Sarcoidosis (Lofgren's syndrome),replication,2016-05-01,GCST005540,Other disease,#d53e4f
5583,European,1048.0,26651848.0,Rivera NV,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome),initial,2016-05-01,GCST005541,Other disease,#d53e4f
5584,European,477.0,26651848.0,Rivera NV,Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome),replication,2016-05-01,GCST005541,Other disease,#d53e4f
5585,European,2537.0,26651848.0,Rivera NV,Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations),initial,2016-05-01,GCST005542,Other disease,#d53e4f
5586,European,5664.0,26651848.0,Rivera NV,Sarcoidosis (non-Lofgren's syndrome),replication,2016-05-01,GCST005543,Other disease,#d53e4f
5587,European,2593.0,26651848.0,Rivera NV,Sarcoidosis (non-Lofgren's syndrome),initial,2016-05-01,GCST005543,Other disease,#d53e4f
5588,African Am./Caribbean,1657.0,26651848.0,Rivera NV,Sarcoidosis (non-Lofgren's syndrome),replication,2016-05-01,GCST005543,Other disease,#fee08b
5589,European,874.0,27126917.0,Spada J,Daytime sleep phenotypes,initial,2016-04-29,GCST003518,Other measurement,#d53e4f
5590,European,941.0,27126917.0,Spada J,Night sleep phenotypes,initial,2016-04-29,GCST003542,Other measurement,#d53e4f
5591,European,941.0,27126917.0,Spada J,Night sleep phenotypes,initial,2016-04-29,GCST003542,Other measurement,#d53e4f
5592,European,941.0,27126917.0,Spada J,Night sleep phenotypes,initial,2016-04-29,GCST003542,Other measurement,#d53e4f
5593,European,941.0,27126917.0,Spada J,Night sleep phenotypes,initial,2016-04-29,GCST003542,Other measurement,#d53e4f
5594,European,65053.0,27117709.0,Couch FJ,Breast cancer,replication,2016-04-27,GCST003845,Cancer,#d53e4f
5595,European,19291.0,27117709.0,Couch FJ,Breast cancer,initial,2016-04-27,GCST003845,Cancer,#d53e4f
5596,European,49801.0,27117709.0,Couch FJ,Breast cancer (estrogen-receptor negative),replication,2016-04-27,GCST003842,Cancer,#d53e4f
5597,European,19291.0,27117709.0,Couch FJ,Breast cancer (estrogen-receptor negative),initial,2016-04-27,GCST003842,Cancer,#d53e4f
5601,Asian,99.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Digestive system disorder,#3288bd
5602,Hispanic/Latin American,1177.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Digestive system disorder,#807dba
5603,African,350.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Digestive system disorder,#fc8d59
5604,European,3069.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Digestive system disorder,#d53e4f
5606,Asian,99.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Cancer,#3288bd
5607,Hispanic/Latin American,1177.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Cancer,#807dba
5608,African,350.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Cancer,#fc8d59
5609,European,3069.0,27114598.0,Liu C,Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),initial,2016-04-25,GCST003501,Cancer,#d53e4f
5610,European,9314.0,27106561.0,Cornelis MC,Food addiction,initial,2016-04-23,GCST003489,Biological process,#d53e4f
5611,European,9314.0,27106561.0,Cornelis MC,Food addiction,initial,2016-04-23,GCST003489,Other measurement,#d53e4f
5612,European,4163.0,27098658.0,Muller-Calleja N,Presence of antiphospholipid antibodies,initial,2016-04-21,GCST003563,Other measurement,#d53e4f
5613,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5614,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5615,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5616,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5617,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5618,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5619,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5620,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5621,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5622,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5623,European,123671.0,27197191.0,Fehringer G,Cancer (pleiotropy),initial,2016-04-20,GCST003588,Cancer,#d53e4f
5624,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5625,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5626,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5627,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5628,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5629,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5630,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5631,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5632,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5633,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5634,European,123671.0,27197191.0,Fehringer G,Cancer,initial,2016-04-20,GCST003587,Cancer,#d53e4f
5635,European,4077.0,28459102.0,Zhang S,Severe gingival inflammation,initial,2016-04-20,GCST004198,Other trait,#d53e4f
5636,European,298420.0,27089181.0,Okbay A,Subjective well-being,initial,2016-04-18,GCST003766,Other measurement,#d53e4f
5637,European,125667.0,27089180.0,Day FR,Age at first sexual intercourse,initial,2016-04-18,GCST007335,Other measurement,#d53e4f
5638,European,262097.0,27089180.0,Day FR,Age at first birth,replication,2016-04-18,GCST007336,Other measurement,#d53e4f
5639,European,66310.0,27089180.0,Day FR,Age at first birth,initial,2016-04-18,GCST007336,Other measurement,#d53e4f
5640,European,170911.0,27089181.0,Okbay A,Neuroticism,initial,2016-04-18,GCST003770,Other measurement,#d53e4f
5641,European,180866.0,27089181.0,Okbay A,Depression,initial,2016-04-18,GCST003769,Neurological disorder,#d53e4f
5642,European,368890.0,27089181.0,Okbay A,Depression,replication,2016-04-18,GCST003769,Neurological disorder,#d53e4f
5643,European,180866.0,27089181.0,Okbay A,Depression,initial,2016-04-18,GCST003769,Other measurement,#d53e4f
5644,European,368890.0,27089181.0,Okbay A,Depression,replication,2016-04-18,GCST003769,Other measurement,#d53e4f
5645,Hispanic/Latin American,5941.0,27207650.0,Schmit SL,Colorectal cancer,initial,2016-04-18,GCST003420,Cancer,#807dba
5646,European,180281.0,27089181.0,Okbay A,Positive affect,initial,2016-04-18,GCST003768,Other measurement,#d53e4f
5647,European,166205.0,27089181.0,Okbay A,Life satisfaction,initial,2016-04-18,GCST003767,Other measurement,#d53e4f
5648,European,63872.0,27094239.0,Joshi AD,Gallstone disease,initial,2016-04-16,GCST003725,Digestive system disorder,#d53e4f
5649,Hispanic/Latin American,3459.0,27094239.0,Joshi AD,Gallstone disease,replication,2016-04-16,GCST003725,Digestive system disorder,#807dba
5650,African Am./Caribbean,10644.0,27094239.0,Joshi AD,Gallstone disease,replication,2016-04-16,GCST003725,Digestive system disorder,#fee08b
5651,European,69286.0,27094239.0,Joshi AD,Gallstone disease,replication,2016-04-16,GCST003725,Digestive system disorder,#d53e4f
5652,European,1623.0,27082954.0,Ward-Caviness CK,Peripheral arterial disease (traffic-related air pollution interaction),initial,2016-04-15,GCST004482,Cardiovascular disease,#d53e4f
5653,African Am./Caribbean,554.0,27082954.0,Ward-Caviness CK,Peripheral arterial disease (traffic-related air pollution interaction),initial,2016-04-15,GCST004482,Cardiovascular disease,#fee08b
5654,European,1623.0,27082954.0,Ward-Caviness CK,Peripheral arterial disease (traffic-related air pollution interaction),initial,2016-04-15,GCST004482,Other measurement,#d53e4f
5655,African Am./Caribbean,554.0,27082954.0,Ward-Caviness CK,Peripheral arterial disease (traffic-related air pollution interaction),initial,2016-04-15,GCST004482,Other measurement,#fee08b
5656,European,91370.0,27067015.0,Smith DJ,Neuroticism,initial,2016-04-12,GCST003447,Other measurement,#d53e4f
5658,European,1359.0,27207532.0,Roshandel D,Skin fluorescence in type 1 diabetes,initial,2016-04-12,GCST003418,Other measurement,#d53e4f
5659,European,1359.0,27207532.0,Roshandel D,Skin fluorescence in type 1 diabetes,initial,2016-04-12,GCST003418,Metabolic disorder,#d53e4f
5661,African,296.0,27064253.0,Zhou W,Mosaic loss of chromosome Y,initial,2016-04-11,GCST003421,Other measurement,#fc8d59
5662,European,11749.0,27064253.0,Zhou W,Mosaic loss of chromosome Y,initial,2016-04-11,GCST003421,Other measurement,#d53e4f
5663,European,114.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,replication,2016-04-08,GCST003438,Neurological disorder,#d53e4f
5664,European,469.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2016-04-08,GCST003438,Neurological disorder,#d53e4f
5665,European,114.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,replication,2016-04-08,GCST003438,Cancer,#d53e4f
5666,European,469.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2016-04-08,GCST003438,Cancer,#d53e4f
5667,European,114.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,replication,2016-04-08,GCST003438,Response to drug,#d53e4f
5668,European,469.0,27060151.0,Magrangeas F,Bortezomib-induced peripheral neuropathy in multiple myeloma,initial,2016-04-08,GCST003438,Response to drug,#d53e4f
5669,European,3028.0,27068588.0,Chauhan G,Ischemic stroke,initial,2016-04-07,GCST003492,Other trait,#d53e4f
5670,Other/Mixed,49324.0,27068588.0,Chauhan G,Ischemic stroke,replication,2016-04-07,GCST003492,Other trait,#99d594
5671,European,19468.0,27068588.0,Chauhan G,Ischemic stroke,replication,2016-04-07,GCST003492,Other trait,#d53e4f
5673,European,1931.0,27018472.0,Leslie EJ,Cleft palate,replication,2016-04-07,GCST005947,Other trait,#d53e4f
5674,European,1215.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#d53e4f
5675,Hispanic/Latin American,737.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#807dba
5676,Asian,41.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#3288bd
5677,African,98.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#fc8d59
5678,African Am./Caribbean,7.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#fee08b
5679,African,1.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#fc8d59
5680,Asian,242.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005947,Other trait,#3288bd
5681,African,15.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005948,Other trait,#fc8d59
5682,Asian,117.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005948,Other trait,#3288bd
5683,European,342.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005948,Other trait,#d53e4f
5684,Hispanic/Latin American,90.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005948,Other trait,#807dba
5685,Asian,3.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005948,Other trait,#3288bd
5686,Hispanic/Latin American,647.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#807dba
5687,Asian,125.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#3288bd
5688,Asian,38.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#3288bd
5689,African,83.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#fc8d59
5690,African Am./Caribbean,7.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#fee08b
5691,African,1.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#fc8d59
5693,European,1931.0,27018472.0,Leslie EJ,Cleft palate,replication,2016-04-07,GCST005946,Other trait,#d53e4f
5694,European,873.0,27018472.0,Leslie EJ,Cleft palate,initial,2016-04-07,GCST005946,Other trait,#d53e4f
5695,European,2012.0,27068588.0,Chauhan G,Stroke,replication,2016-04-07,GCST003491,Cardiovascular disease,#d53e4f
5696,European,4348.0,27068588.0,Chauhan G,Stroke,initial,2016-04-07,GCST003491,Cardiovascular disease,#d53e4f
5697,European,82383.0,27068588.0,Chauhan G,Ischemic stroke (non-cardioembolic),initial,2016-04-07,GCST003493,Other trait,#d53e4f
5698,European,19215.0,27068588.0,Chauhan G,Ischemic stroke (non-cardioembolic),replication,2016-04-07,GCST003493,Other trait,#d53e4f
5699,Other/Mixed,37969.0,27068588.0,Chauhan G,Ischemic stroke (non-cardioembolic),replication,2016-04-07,GCST003493,Other trait,#99d594
5700,European,602.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),initial,2016-04-07,GCST003490,Other trait,#d53e4f
5701,European,19094.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),replication,2016-04-07,GCST003490,Other trait,#d53e4f
5702,Other/Mixed,35900.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),replication,2016-04-07,GCST003490,Other trait,#99d594
5703,European,602.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),initial,2016-04-07,GCST003490,Cardiovascular disease,#d53e4f
5704,European,19094.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),replication,2016-04-07,GCST003490,Cardiovascular disease,#d53e4f
5705,Other/Mixed,35900.0,27068588.0,Chauhan G,Ischemic stroke (cardioembolic),replication,2016-04-07,GCST003490,Cardiovascular disease,#99d594
5706,European,112067.0,27046643.0,Davies G,Memory performance,initial,2016-04-05,GCST003497,Other measurement,#d53e4f
5707,European,111483.0,27046643.0,Davies G,Reaction time,initial,2016-04-05,GCST003499,Other measurement,#d53e4f
5709,European,111114.0,27046643.0,Davies G,Educational attainment,initial,2016-04-05,GCST003496,Other measurement,#d53e4f
5710,European,36035.0,27046643.0,Davies G,Verbal-numerical reasoning,initial,2016-04-05,GCST003498,Biological process,#d53e4f
5711,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Neurological disorder,#d53e4f
5712,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Lipid or lipoprotein measurement,#d53e4f
5713,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Lipid or lipoprotein measurement,#d53e4f
5714,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Lipid or lipoprotein measurement,#d53e4f
5715,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Body measurement,#d53e4f
5716,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Metabolic disorder,#d53e4f
5717,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Body measurement,#d53e4f
5718,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Lipid or lipoprotein measurement,#d53e4f
5719,European,1432180.0,30413934.0,Broce IJ,Alzheimer's disease or cardiovascular risk factors (pleiotropy),initial,2018-11-09,GCST007303,Cardiovascular disease,#d53e4f
5720,European,301162.0,30410027.0,Gudmundsson J,Benign prostatic hyperplasia and lower urinary tract symptoms,initial,2018-11-08,GCST007507,Other trait,#d53e4f
5721,European,301162.0,30410027.0,Gudmundsson J,Benign prostatic hyperplasia and lower urinary tract symptoms,initial,2018-11-08,GCST007507,Other disease,#d53e4f
5722,European,33572.0,30410027.0,Gudmundsson J,Prostate-specific antigen levels,initial,2018-11-08,GCST007513,Other measurement,#d53e4f
5723,European,295892.0,30410027.0,Gudmundsson J,Prostate cancer,initial,2018-11-08,GCST007506,Cancer,#d53e4f
5724,European,295351.0,30410027.0,Gudmundsson J,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded),initial,2018-11-08,GCST007512,Other trait,#d53e4f
5725,European,295351.0,30410027.0,Gudmundsson J,Benign prostatic hyperplasia and lower urinary tract symptoms (prostate cancer excluded),initial,2018-11-08,GCST007512,Other disease,#d53e4f
5726,European,340793.0,30392061.0,Orlova E,Appendicitis,replication,2018-11-03,GCST007595,Immune system disorder,#d53e4f
5727,European,133680.0,30392061.0,Orlova E,Appendicitis,initial,2018-11-03,GCST007595,Immune system disorder,#d53e4f
5728,European,222.0,30596066.0,Kong LL,Brain glucose metabolism (fluorodeoxyglucose uptake),initial,2018-11-01,GCST007206,Other measurement,#d53e4f
5729,European,148164.0,30388399.0,Ligthart S,C-reactive protein levels,initial,2018-11-01,GCST007615,Inflammatory measurement,#d53e4f
5730,European,204402.0,30388399.0,Ligthart S,C-reactive protein levels,initial,2018-11-01,GCST007614,Inflammatory measurement,#d53e4f
5731,Asian,7198.0,30382898.0,Moon S,Metabolic syndrome,initial,2018-11-01,GCST007738,Metabolic disorder,#3288bd
5732,Asian,2838.0,30382898.0,Moon S,Metabolic syndrome,replication,2018-11-01,GCST007738,Metabolic disorder,#3288bd
5733,European,821100.0,30383316.0,Malik R,Stroke,initial,2018-11-01,GCST007248,Cardiovascular disease,#d53e4f
5734,Other/Mixed,101040.0,30383316.0,Malik R,Stroke,initial,2018-11-01,GCST007248,Cardiovascular disease,#99d594
5735,European,813375.0,30383316.0,Malik R,Ischemic stroke,initial,2018-11-01,GCST007249,Other trait,#d53e4f
5736,Other/Mixed,74463.0,30383316.0,Malik R,Ischemic stroke,initial,2018-11-01,GCST007249,Other trait,#99d594
5737,Asian,13379.0,30395268.0,Khanshour AM,Adolescent idiopathic scoliosis,initial,2018-11-01,GCST006902,Other disease,#3288bd
5738,European,20097.0,30395268.0,Khanshour AM,Adolescent idiopathic scoliosis,initial,2018-11-01,GCST006902,Other disease,#d53e4f
5739,Asian,59552.0,30395268.0,Khanshour AM,Adolescent idiopathic scoliosis,replication,2018-11-01,GCST006902,Other disease,#3288bd
5740,European,3387.0,30395268.0,Khanshour AM,Adolescent idiopathic scoliosis,replication,2018-11-01,GCST006902,Other disease,#d53e4f
5741,Asian,1311.0,30480742.0,Miki A,Chronic central serous retinopathy,initial,2018-11-01,GCST007296,Neurological disorder,#3288bd
5742,Asian,2254.0,30480742.0,Miki A,Chronic central serous retinopathy,replication,2018-11-01,GCST007296,Neurological disorder,#3288bd
5743,European,2421.0,30378284.0,Smajlagic D,Verbal intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007403,Other trait,#d53e4f
5744,European,2421.0,30378284.0,Smajlagic D,Verbal intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007403,Biological process,#d53e4f
5745,European,2421.0,30378284.0,Smajlagic D,Full scale intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007405,Other trait,#d53e4f
5746,European,2421.0,30378284.0,Smajlagic D,Full scale intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007405,Biological process,#d53e4f
5747,European,2421.0,30378284.0,Smajlagic D,Performance intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007404,Other trait,#d53e4f
5748,European,2421.0,30378284.0,Smajlagic D,Performance intelligence quotient (cesarean section interaction),initial,2018-10-31,GCST007404,Biological process,#d53e4f
5749,Asian,139.0,30377885.0,Fujimori S,Non-steroidal anti-inflammatory drug-induced enteropathy,initial,2018-10-30,GCST007258,Response to drug,#3288bd
5750,Asian,139.0,30377885.0,Fujimori S,Non-steroidal anti-inflammatory drug-induced enteropathy,initial,2018-10-30,GCST007258,Digestive system disorder,#3288bd
5751,European,586030.0,30374069.0,Styrkarsdottir U,Knee osteoarthritis,initial,2018-10-29,GCST006925,Other disease,#d53e4f
5752,European,613790.0,30374069.0,Styrkarsdottir U,Osteoarthritis (hip),initial,2018-10-29,GCST006926,Other disease,#d53e4f
5753,African Am./Caribbean,2667.0,30373671.0,Hayden LP,Self-reported childhood asthma in adult smokers,initial,2018-10-29,GCST007508,Other disease,#fee08b
5754,European,5364.0,30373671.0,Hayden LP,Self-reported childhood asthma in adult smokers,initial,2018-10-29,GCST007508,Other disease,#d53e4f
5755,African Am./Caribbean,2667.0,30373671.0,Hayden LP,Self-reported childhood asthma in adult smokers,initial,2018-10-29,GCST007508,Other measurement,#fee08b
5756,European,5364.0,30373671.0,Hayden LP,Self-reported childhood asthma in adult smokers,initial,2018-10-29,GCST007508,Other measurement,#d53e4f
5757,European,49269.0,30367059.0,Teumer A,Free thyroxine concentration,initial,2018-10-26,GCST006896,Other measurement,#d53e4f
5758,European,22383.0,30367059.0,Teumer A,Free thyroxine concentration,replication,2018-10-26,GCST006896,Other measurement,#d53e4f
5759,European,51823.0,30367059.0,Teumer A,Hyperthyroidism,initial,2018-10-26,GCST006897,Other disease,#d53e4f
5760,European,53323.0,30367059.0,Teumer A,Hypothyroidism,initial,2018-10-26,GCST006898,Other disease,#d53e4f
5761,European,54288.0,30367059.0,Teumer A,Thyroid stimulating hormone levels,initial,2018-10-26,GCST006899,Other measurement,#d53e4f
5762,European,22383.0,30367059.0,Teumer A,Thyroid stimulating hormone levels,replication,2018-10-26,GCST006899,Other measurement,#d53e4f
5763,European,983.0,30361487.0,Yan Q,Cerebral amyloid deposition (PET imaging),initial,2018-10-25,GCST006904,Other measurement,#d53e4f
5764,European,98.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Other measurement,#d53e4f
5765,African Am./Caribbean,244.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),initial,2018-10-24,GCST008230,Other measurement,#fee08b
5766,African Am./Caribbean,1366.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Other measurement,#fee08b
5767,Hispanic/Latin American,1461.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Other measurement,#807dba
5768,European,98.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Response to drug,#d53e4f
5769,African Am./Caribbean,244.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),initial,2018-10-24,GCST008230,Response to drug,#fee08b
5770,African Am./Caribbean,1366.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Response to drug,#fee08b
5771,Hispanic/Latin American,1461.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (2df),replication,2018-10-24,GCST008230,Response to drug,#807dba
5772,African Am./Caribbean,1366.0,30367910.0,Levin AM,Asthma control,replication,2018-10-24,GCST008228,Other measurement,#fee08b
5773,African Am./Caribbean,244.0,30367910.0,Levin AM,Asthma control,initial,2018-10-24,GCST008228,Other measurement,#fee08b
5774,Hispanic/Latin American,1461.0,30367910.0,Levin AM,Asthma control,replication,2018-10-24,GCST008228,Other measurement,#807dba
5775,European,98.0,30367910.0,Levin AM,Asthma control,replication,2018-10-24,GCST008228,Other measurement,#d53e4f
5776,European,98.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Other measurement,#d53e4f
5777,Hispanic/Latin American,1461.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Other measurement,#807dba
5778,African Am./Caribbean,1366.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Other measurement,#fee08b
5779,African Am./Caribbean,244.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),initial,2018-10-24,GCST008229,Other measurement,#fee08b
5780,European,98.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Response to drug,#d53e4f
5781,Hispanic/Latin American,1461.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Response to drug,#807dba
5782,African Am./Caribbean,1366.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),replication,2018-10-24,GCST008229,Response to drug,#fee08b
5783,African Am./Caribbean,244.0,30367910.0,Levin AM,Asthma control x inhaled corticosteroid treatment interaction (1df),initial,2018-10-24,GCST008229,Response to drug,#fee08b
5784,European,290.0,30353303.0,Seo M,Response to long-term oxygen therapy in chronic obstructive pulmonary disease,initial,2018-10-23,GCST007558,Response to drug,#d53e4f
5785,European,290.0,30353303.0,Seo M,Response to long-term oxygen therapy in chronic obstructive pulmonary disease,initial,2018-10-23,GCST007558,Other disease,#d53e4f
5787,European,141932.0,30336701.0,Sanchez-Roige S,Alcohol use disorder (total score),initial,2018-10-19,GCST006716,Other measurement,#d53e4f
5788,Asian,422.0,30343302.0,Kim SH,Polycystic ovary syndrome,initial,2018-10-19,GCST006659,Other disease,#3288bd
5789,European,121604.0,30336701.0,Sanchez-Roige S,Alcohol use disorder (dependence and problematic use scores),initial,2018-10-19,GCST006717,Other measurement,#d53e4f
5790,European,121604.0,30336701.0,Sanchez-Roige S,Alcohol use disorder (consumption score),initial,2018-10-19,GCST006718,Other measurement,#d53e4f
5791,European,2232.0,30339177.0,Shane B,Plasma homocysteine levels,initial,2018-10-19,GCST007578,Cardiovascular measurement,#d53e4f
5792,European,2232.0,30339177.0,Shane B,Serum folate levels,initial,2018-10-19,GCST007579,Other measurement,#d53e4f
5793,European,2232.0,30339177.0,Shane B,Red blood cell folate levels,initial,2018-10-19,GCST007580,Other measurement,#d53e4f
5794,Asian,301.0,30326835.0,Li Z,Mitochondrial DNA levels,initial,2018-10-16,GCST006936,Other measurement,#3288bd
5795,European,1087.0,30327367.0,Jung SY,Hyperinsulinemia in less-fat diet,initial,2018-10-16,GCST007773,Lipid or lipoprotein measurement,#d53e4f
5796,European,1087.0,30327367.0,Jung SY,Hyperinsulinemia in less-fat diet,initial,2018-10-16,GCST007773,Other measurement,#d53e4f
5797,European,10707.0,30327367.0,Jung SY,Hyperinsulinemia in more-fat diet,initial,2018-10-16,GCST007772,Lipid or lipoprotein measurement,#d53e4f
5798,European,10707.0,30327367.0,Jung SY,Hyperinsulinemia in more-fat diet,initial,2018-10-16,GCST007772,Other measurement,#d53e4f
5799,European,6818.0,30327367.0,Jung SY,Hyperinsulinemia in lower physical activity,initial,2018-10-16,GCST007771,Other measurement,#d53e4f
5800,European,6818.0,30327367.0,Jung SY,Hyperinsulinemia in lower physical activity,initial,2018-10-16,GCST007771,Other measurement,#d53e4f
5801,European,4976.0,30327367.0,Jung SY,Hyperinsulinemia in higher physical activity,initial,2018-10-16,GCST007770,Other measurement,#d53e4f
5802,European,4976.0,30327367.0,Jung SY,Hyperinsulinemia in higher physical activity,initial,2018-10-16,GCST007770,Other measurement,#d53e4f
5803,European,8363.0,30327367.0,Jung SY,Hyperinsulinemia in non-obese individuals,initial,2018-10-16,GCST007769,Other measurement,#d53e4f
5804,European,3431.0,30327367.0,Jung SY,Hyperinsulinemia in obesity,initial,2018-10-16,GCST007768,Metabolic disorder,#d53e4f
5805,European,3431.0,30327367.0,Jung SY,Hyperinsulinemia in obesity,initial,2018-10-16,GCST007768,Other measurement,#d53e4f
5806,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction,initial,2018-10-16,GCST007767,Lipid or lipoprotein measurement,#d53e4f
5807,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x saturated fatty acids interaction,initial,2018-10-16,GCST007767,Other trait,#d53e4f
5808,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x saturated fatty acids interaction,initial,2018-10-16,GCST007766,Lipid or lipoprotein measurement,#d53e4f
5809,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x saturated fatty acids interaction,initial,2018-10-16,GCST007766,Other measurement,#d53e4f
5810,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x physical activity interaction,initial,2018-10-16,GCST007765,Other trait,#d53e4f
5811,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x physical activity interaction,initial,2018-10-16,GCST007765,Other measurement,#d53e4f
5812,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x physical activity interaction,initial,2018-10-16,GCST007764,Other measurement,#d53e4f
5813,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x physical activity interaction,initial,2018-10-16,GCST007764,Other measurement,#d53e4f
5814,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x BMI interaction,initial,2018-10-16,GCST007763,Other trait,#d53e4f
5815,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance x BMI interaction,initial,2018-10-16,GCST007763,Body measurement,#d53e4f
5816,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x BMI interaction,initial,2018-10-16,GCST007762,Body measurement,#d53e4f
5817,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia x BMI interaction,initial,2018-10-16,GCST007762,Other measurement,#d53e4f
5818,European,11794.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance,initial,2018-10-16,GCST007761,Other trait,#d53e4f
5819,European,11794.0,30327367.0,Jung SY,Hyperinsulinemia,initial,2018-10-16,GCST007760,Other measurement,#d53e4f
5820,European,11794.0,30327367.0,Jung SY,Hyperglycemia x saturated fatty acids interaction,initial,2018-10-16,GCST007759,Lipid or lipoprotein measurement,#d53e4f
5821,European,11794.0,30327367.0,Jung SY,Hyperglycemia x saturated fatty acids interaction,initial,2018-10-16,GCST007759,Other measurement,#d53e4f
5822,European,11794.0,30327367.0,Jung SY,Hyperglycemia x physical activity interaction,initial,2018-10-16,GCST007758,Other measurement,#d53e4f
5823,European,11794.0,30327367.0,Jung SY,Hyperglycemia x physical activity interaction,initial,2018-10-16,GCST007758,Other measurement,#d53e4f
5824,European,11794.0,30327367.0,Jung SY,Hyperglycemia x BMI interaction,initial,2018-10-16,GCST007757,Body measurement,#d53e4f
5825,European,11794.0,30327367.0,Jung SY,Hyperglycemia x BMI interaction,initial,2018-10-16,GCST007757,Other measurement,#d53e4f
5826,European,1087.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in less-fat diet,initial,2018-10-16,GCST007756,Lipid or lipoprotein measurement,#d53e4f
5827,European,1087.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in less-fat diet,initial,2018-10-16,GCST007756,Other trait,#d53e4f
5828,European,10707.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in more-fat diet,initial,2018-10-16,GCST007755,Lipid or lipoprotein measurement,#d53e4f
5829,European,10707.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in more-fat diet,initial,2018-10-16,GCST007755,Other trait,#d53e4f
5830,European,6818.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in lower physical activity,initial,2018-10-16,GCST007754,Other trait,#d53e4f
5831,European,6818.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in lower physical activity,initial,2018-10-16,GCST007754,Other measurement,#d53e4f
5832,European,4976.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in higher physical activity,initial,2018-10-16,GCST007753,Other trait,#d53e4f
5833,European,4976.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in higher physical activity,initial,2018-10-16,GCST007753,Other measurement,#d53e4f
5834,European,8363.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in non-obese individuals,initial,2018-10-16,GCST007752,Other trait,#d53e4f
5835,European,3431.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in obesity,initial,2018-10-16,GCST007751,Other trait,#d53e4f
5836,European,3431.0,30327367.0,Jung SY,Homeostasis model assessment of insulin resistance in obesity,initial,2018-10-16,GCST007751,Metabolic disorder,#d53e4f
5837,European,1087.0,30327367.0,Jung SY,Hyperglycemia in less-fat diet,initial,2018-10-16,GCST007750,Lipid or lipoprotein measurement,#d53e4f
5838,European,1087.0,30327367.0,Jung SY,Hyperglycemia in less-fat diet,initial,2018-10-16,GCST007750,Other measurement,#d53e4f
5839,European,10707.0,30327367.0,Jung SY,Hyperglycemia in more-fat diet,initial,2018-10-16,GCST007749,Lipid or lipoprotein measurement,#d53e4f
5840,European,10707.0,30327367.0,Jung SY,Hyperglycemia in more-fat diet,initial,2018-10-16,GCST007749,Other measurement,#d53e4f
5841,European,4976.0,30327367.0,Jung SY,Hyperglycemia in higher physical activity,initial,2018-10-16,GCST007748,Other measurement,#d53e4f
5842,European,4976.0,30327367.0,Jung SY,Hyperglycemia in higher physical activity,initial,2018-10-16,GCST007748,Other measurement,#d53e4f
5843,European,6818.0,30327367.0,Jung SY,Hyperglycemia in lower physical activity,initial,2018-10-16,GCST007747,Other measurement,#d53e4f
5844,European,6818.0,30327367.0,Jung SY,Hyperglycemia in lower physical activity,initial,2018-10-16,GCST007747,Other measurement,#d53e4f
5845,European,8363.0,30327367.0,Jung SY,Hyperglycemia in non-obese individuals,initial,2018-10-16,GCST007746,Other measurement,#d53e4f
5846,European,3431.0,30327367.0,Jung SY,Hyperglycemia in obesity,initial,2018-10-16,GCST007745,Other measurement,#d53e4f
5847,European,3431.0,30327367.0,Jung SY,Hyperglycemia in obesity,initial,2018-10-16,GCST007745,Metabolic disorder,#d53e4f
5848,European,11794.0,30327367.0,Jung SY,Hyperglycemia,initial,2018-10-16,GCST007744,Other measurement,#d53e4f
5849,European,337208.0,30325047.0,Gellert-Kristensen H,Gallstone disease,initial,2018-10-16,GCST007364,Digestive system disorder,#d53e4f
5850,European,19788.0,30325047.0,Gellert-Kristensen H,Gallstone disease,replication,2018-10-16,GCST007364,Digestive system disorder,#d53e4f
5851,European,337208.0,30325047.0,Gellert-Kristensen H,Gallstone disease,initial,2018-10-16,GCST007364,Digestive system disorder,#d53e4f
5852,European,19788.0,30325047.0,Gellert-Kristensen H,Gallstone disease,replication,2018-10-16,GCST007364,Digestive system disorder,#d53e4f
5854,European,10217.0,30320955.0,Baird DA,Hip shape (DXA scan),initial,2018-10-15,GCST006903,Body measurement,#d53e4f
5855,Asian,7448.0,30323354.0,Lee JY,BRCA1/2-negative high-risk breast cancer,initial,2018-10-15,GCST006719,Cancer,#3288bd
5856,African,864.0,30317457.0,Bonnemaijer PWM,Glaucoma (primary open-angle),initial,2018-10-13,GCST007199,Neurological disorder,#fc8d59
5857,African Am./Caribbean,1800.0,30317457.0,Bonnemaijer PWM,Glaucoma (primary open-angle),initial,2018-10-13,GCST007199,Neurological disorder,#fee08b
5858,African Am./Caribbean,5408.0,30317457.0,Bonnemaijer PWM,Glaucoma (primary open-angle),replication,2018-10-13,GCST007199,Neurological disorder,#fee08b
5859,African,3723.0,30317457.0,Bonnemaijer PWM,Glaucoma (primary open-angle),replication,2018-10-13,GCST007199,Neurological disorder,#fc8d59
5860,Other/Mixed,275.0,30317457.0,Bonnemaijer PWM,Glaucoma (primary open-angle),initial,2018-10-13,GCST007199,Neurological disorder,#99d594
5862,European,86335.0,30306274.0,Shah RL,Corneal astigmatism,initial,2018-10-10,GCST007157,Neurological disorder,#d53e4f
5863,European,88005.0,30306274.0,Shah RL,Refractive astigmatism,initial,2018-10-10,GCST007160,Other trait,#d53e4f
5864,European,86335.0,30306274.0,Shah RL,Corneal astigmatism,initial,2018-10-10,GCST007159,Neurological disorder,#d53e4f
5865,European,4015.0,30305637.0,McMaster ML,Waldenström macroglobulinemia / lymphoplasmacytic lymphoma,initial,2018-10-10,GCST006982,Cancer,#d53e4f
5866,European,877.0,30305637.0,McMaster ML,Waldenström macroglobulinemia / lymphoplasmacytic lymphoma,replication,2018-10-10,GCST006982,Cancer,#d53e4f
5867,European,8428.0,30305740.0,Elliott LT,Brain imaging measurements,initial,2018-10-10,GCST006777,Other measurement,#d53e4f
5868,European,4386.0,30305740.0,Elliott LT,Brain imaging measurements,replication,2018-10-10,GCST006777,Other measurement,#d53e4f
5869,European,88005.0,30306274.0,Shah RL,Refractive astigmatism,initial,2018-10-10,GCST007158,Other trait,#d53e4f
5870,European,29859.0,30297428.0,Jorgenson E,Erectile dysfunction,initial,2018-10-08,GCST007118,Other disease,#d53e4f
5871,European,209758.0,30297428.0,Jorgenson E,Erectile dysfunction,replication,2018-10-08,GCST007118,Other disease,#d53e4f
5872,Hispanic/Latin American,2970.0,30297428.0,Jorgenson E,Erectile dysfunction,initial,2018-10-08,GCST007118,Other disease,#807dba
5873,Asian,2737.0,30297428.0,Jorgenson E,Erectile dysfunction,initial,2018-10-08,GCST007118,Other disease,#3288bd
5874,African Am./Caribbean,1083.0,30297428.0,Jorgenson E,Erectile dysfunction,initial,2018-10-08,GCST007118,Other disease,#fee08b
5875,Asian,5304.0,30297428.0,Jorgenson E,Erectile dysfunction,replication,2018-10-08,GCST007118,Other disease,#3288bd
5876,African,3634.0,30297428.0,Jorgenson E,Erectile dysfunction,replication,2018-10-08,GCST007118,Other disease,#fc8d59
5877,Asian,680.0,30297428.0,Jorgenson E,Erectile dysfunction,replication,2018-10-08,GCST007118,Other disease,#3288bd
5885,African Am./Caribbean,6831.0,30298529.0,Stanaway IB,Shingles,initial,2018-10-08,GCST007139,Other disease,#fee08b
5886,European,38763.0,30298529.0,Stanaway IB,Shingles,initial,2018-10-08,GCST007139,Other disease,#d53e4f
5887,Asian,756.0,30298529.0,Stanaway IB,Shingles,initial,2018-10-08,GCST007139,Other disease,#3288bd
5888,European,1950.0,30338293.0,Wallen ZD,Parkinson's disease (age at diagnosis),initial,2018-10-05,GCST007198,Neurological disorder,#d53e4f
5889,European,726.0,30338293.0,Wallen ZD,Parkinson's disease (age at diagnosis),replication,2018-10-05,GCST007198,Neurological disorder,#d53e4f
5890,European,1950.0,30338293.0,Wallen ZD,Parkinson's disease (age at diagnosis),initial,2018-10-05,GCST007198,Other measurement,#d53e4f
5891,European,726.0,30338293.0,Wallen ZD,Parkinson's disease (age at diagnosis),replication,2018-10-05,GCST007198,Other measurement,#d53e4f
5897,European,630791.0,30289880.0,Qi G,Social science traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006665,Other measurement,#d53e4f
5898,European,630791.0,30289880.0,Qi G,Social science traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006665,Other measurement,#d53e4f
5899,European,630791.0,30289880.0,Qi G,Social science traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006665,Other measurement,#d53e4f
5900,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 2),initial,2018-10-05,GCST006667,Lipid or lipoprotein measurement,#d53e4f
5901,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 2),initial,2018-10-05,GCST006667,Lipid or lipoprotein measurement,#d53e4f
5902,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 2),initial,2018-10-05,GCST006667,Lipid or lipoprotein measurement,#d53e4f
5903,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 2),initial,2018-10-05,GCST006667,Lipid or lipoprotein measurement,#d53e4f
5904,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006666,Lipid or lipoprotein measurement,#d53e4f
5905,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006666,Lipid or lipoprotein measurement,#d53e4f
5906,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006666,Lipid or lipoprotein measurement,#d53e4f
5907,European,188577.0,30289880.0,Qi G,Lipid traits (pleiotropy) (HIPO component 1),initial,2018-10-05,GCST006666,Lipid or lipoprotein measurement,#d53e4f
5908,European,857.0,30287865.0,Pinar A,Intra-individual response time variability (response selection),initial,2018-10-04,GCST007244,Other measurement,#d53e4f
5909,African Am./Caribbean,3724.0,30287806.0,Zhou H,Nicotine dependence and major depression (severity of comorbidity),initial,2018-10-04,GCST006631,Other measurement,#fee08b
5910,African Am./Caribbean,3724.0,30287806.0,Zhou H,Nicotine dependence and major depression (severity of comorbidity),initial,2018-10-04,GCST006631,Other measurement,#fee08b
5911,European,857.0,30287865.0,Pinar A,Intra-individual response time variability (selective attention),initial,2018-10-04,GCST007243,Other measurement,#d53e4f
5912,European,367.0,30284742.0,Bevilacqua L,Chronic periodontitis (localised),initial,2018-10-04,GCST007197,Digestive system disorder,#d53e4f
5913,Asian,2053.0,30287856.0,Zheng R,Tuberculosis,initial,2018-10-04,GCST006619,Other disease,#3288bd
5914,Asian,5986.0,30287856.0,Zheng R,Tuberculosis,replication,2018-10-04,GCST006619,Other disease,#3288bd
5915,European,395.0,30284742.0,Bevilacqua L,Chronic periodontitis (generalised),initial,2018-10-04,GCST007193,Digestive system disorder,#d53e4f
5916,European,329.0,30284742.0,Bevilacqua L,Chronic periodontitis (severe),initial,2018-10-04,GCST007194,Digestive system disorder,#d53e4f
5917,European,433.0,30284742.0,Bevilacqua L,Chronic periodontitis (slight),initial,2018-10-04,GCST007195,Digestive system disorder,#d53e4f
5918,European,602.0,30284742.0,Bevilacqua L,Chronic periodontitis,initial,2018-10-04,GCST007196,Digestive system disorder,#d53e4f
5919,Asian,33349.0,30281874.0,Tanikawa C,Gastric cancer,initial,2018-10-03,GCST006707,Cancer,#3288bd
5920,Asian,17062.0,30281874.0,Tanikawa C,Gastric cancer,replication,2018-10-03,GCST006707,Cancer,#3288bd
5927,Asian,45528.0,30285260.0,Ikeda M,Schizophrenia,initial,2018-10-03,GCST007201,Neurological disorder,#3288bd
5928,European,77096.0,30285260.0,Ikeda M,Schizophrenia,replication,2018-10-03,GCST007201,Neurological disorder,#d53e4f
5929,European,838.0,30284222.0,Brcic L,Hashimoto thyroiditis,initial,2018-10-03,GCST007138,Immune system disorder,#d53e4f
5930,European,605.0,30284222.0,Brcic L,Hashimoto thyroiditis,replication,2018-10-03,GCST007138,Immune system disorder,#d53e4f
5931,Asian,9348.0,30285260.0,Ikeda M,Schizophrenia,initial,2018-10-03,GCST007205,Neurological disorder,#3288bd
5932,Asian,58541.0,30285260.0,Ikeda M,Schizophrenia,replication,2018-10-03,GCST007205,Neurological disorder,#3288bd
5933,European,108154.0,30279531.0,Baselmans BML,Eudaimonic well-being,initial,2018-10-02,GCST006635,Other measurement,#d53e4f
5934,European,21297.0,30279459.0,van der Meer D,Parasubiculum volume,initial,2018-10-02,GCST006895,Other measurement,#d53e4f
5935,European,21297.0,30279459.0,van der Meer D,HATA volume,initial,2018-10-02,GCST006894,Other measurement,#d53e4f
5936,European,21297.0,30279459.0,van der Meer D,Fimbria volume,initial,2018-10-02,GCST006893,Other measurement,#d53e4f
5937,European,21297.0,30279459.0,van der Meer D,Hippocampal tail volume,initial,2018-10-02,GCST006870,Other measurement,#d53e4f
5938,European,21297.0,30279459.0,van der Meer D,Hippocampal fissure volume,initial,2018-10-02,GCST006892,Other measurement,#d53e4f
5939,European,21297.0,30279459.0,van der Meer D,Dentate gyrus molecular layer volume,initial,2018-10-02,GCST006891,Other measurement,#d53e4f
5940,European,21297.0,30279459.0,van der Meer D,Dentate gyrus granule cell layer volume,initial,2018-10-02,GCST006890,Other measurement,#d53e4f
5941,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA4 volume,initial,2018-10-02,GCST006889,Other measurement,#d53e4f
5942,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA3 volume,initial,2018-10-02,GCST006888,Other measurement,#d53e4f
5943,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA1 volume,initial,2018-10-02,GCST006887,Other measurement,#d53e4f
5944,European,21297.0,30279459.0,van der Meer D,Subiculum volume,initial,2018-10-02,GCST006886,Other measurement,#d53e4f
5945,European,21297.0,30279459.0,van der Meer D,Presubiculum volume,initial,2018-10-02,GCST006885,Other measurement,#d53e4f
5946,European,21297.0,30279459.0,van der Meer D,Parasubiculum volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006884,Other measurement,#d53e4f
5947,European,21297.0,30279459.0,van der Meer D,HATA volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006883,Other measurement,#d53e4f
5948,European,21297.0,30279459.0,van der Meer D,Fimbria volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006882,Other measurement,#d53e4f
5949,European,21297.0,30279459.0,van der Meer D,Hippocampal tail volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006881,Other measurement,#d53e4f
5950,European,21297.0,30279459.0,van der Meer D,Hippocampal fissure volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006880,Other measurement,#d53e4f
5951,European,21297.0,30279459.0,van der Meer D,Dentate gyrus molecular layer volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006878,Other measurement,#d53e4f
5952,European,21297.0,30279459.0,van der Meer D,Dentate gyrus granule cell layer volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006877,Other measurement,#d53e4f
5953,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA4 volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006876,Other measurement,#d53e4f
5954,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA3 volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006875,Other measurement,#d53e4f
5955,European,21297.0,30279459.0,van der Meer D,Hippocampal subfield CA1 volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006874,Other measurement,#d53e4f
5956,European,21297.0,30279459.0,van der Meer D,Subiculum volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006873,Other measurement,#d53e4f
5957,European,21297.0,30279459.0,van der Meer D,Presubiculum volume (corrected for total hippocampal volume),initial,2018-10-02,GCST006872,Other measurement,#d53e4f
5958,European,221575.0,30279531.0,Baselmans BML,Hedonic well-being,initial,2018-10-02,GCST006634,Other measurement,#d53e4f
5959,European,21297.0,30279459.0,van der Meer D,Total hippocampal volume,initial,2018-10-02,GCST006871,Other measurement,#d53e4f
5960,Hispanic/Latin American,1266.0,30281099.0,Fadista J,Infantile hypertrophic pyloric stenosis,replication,2018-10-02,GCST006705,Digestive system disorder,#807dba
5961,European,3669.0,30281099.0,Fadista J,Infantile hypertrophic pyloric stenosis,replication,2018-10-02,GCST006705,Digestive system disorder,#d53e4f
5962,European,5833.0,30281099.0,Fadista J,Infantile hypertrophic pyloric stenosis,initial,2018-10-02,GCST006705,Digestive system disorder,#d53e4f
5963,Hispanic/Latin American,2153.0,30305239.0,Macias-Kauffer LR,Serum uric acid levels,initial,2018-10-01,GCST006905,Cardiovascular measurement,#807dba
5964,African Am./Caribbean,188.0,30357299.0,De T,Warfarin-associated bleeding,replication,2018-10-01,GCST007137,Response to drug,#fee08b
5965,African Am./Caribbean,215.0,30357299.0,De T,Warfarin-associated bleeding,initial,2018-10-01,GCST007137,Response to drug,#fee08b
5966,European,215551.0,30275531.0,Klarin D,Total cholesterol levels,initial,2018-10-01,GCST006614,Lipid or lipoprotein measurement,#d53e4f
5967,African Am./Caribbean,57332.0,30275531.0,Klarin D,Total cholesterol levels,initial,2018-10-01,GCST006614,Lipid or lipoprotein measurement,#fee08b
5968,Hispanic/Latin American,24743.0,30275531.0,Klarin D,Total cholesterol levels,initial,2018-10-01,GCST006614,Lipid or lipoprotein measurement,#807dba
5970,African Am./Caribbean,57332.0,30275531.0,Klarin D,Triglycerides,initial,2018-10-01,GCST006613,Lipid or lipoprotein measurement,#fee08b
5971,European,215551.0,30275531.0,Klarin D,Triglycerides,initial,2018-10-01,GCST006613,Lipid or lipoprotein measurement,#d53e4f
5972,Hispanic/Latin American,24743.0,30275531.0,Klarin D,Triglycerides,initial,2018-10-01,GCST006613,Lipid or lipoprotein measurement,#807dba
5974,European,215551.0,30275531.0,Klarin D,LDL cholesterol,initial,2018-10-01,GCST006612,Lipid or lipoprotein measurement,#d53e4f
5976,Hispanic/Latin American,24743.0,30275531.0,Klarin D,LDL cholesterol,initial,2018-10-01,GCST006612,Lipid or lipoprotein measurement,#807dba
5977,African Am./Caribbean,57332.0,30275531.0,Klarin D,LDL cholesterol,initial,2018-10-01,GCST006612,Lipid or lipoprotein measurement,#fee08b
5979,Hispanic/Latin American,24743.0,30275531.0,Klarin D,HDL cholesterol,initial,2018-10-01,GCST006611,Lipid or lipoprotein measurement,#807dba
5980,European,215551.0,30275531.0,Klarin D,HDL cholesterol,initial,2018-10-01,GCST006611,Lipid or lipoprotein measurement,#d53e4f
5981,African Am./Caribbean,57332.0,30275531.0,Klarin D,HDL cholesterol,initial,2018-10-01,GCST006611,Lipid or lipoprotein measurement,#fee08b
5982,African,892.0,30276832.0,Edwards AC,Initial alcohol sensitivity,initial,2018-10-01,GCST006633,Biological process,#fc8d59
5983,Hispanic/Latin American,408.0,30276832.0,Edwards AC,Initial alcohol sensitivity,initial,2018-10-01,GCST006633,Biological process,#807dba
5984,European,6039.0,30276832.0,Edwards AC,Initial alcohol sensitivity,initial,2018-10-01,GCST006633,Biological process,#d53e4f
5985,African Am./Caribbean,2509.0,30266756.0,Chang X,Paediatric migraine,initial,2018-09-28,GCST007154,Cardiovascular disease,#fee08b
5986,European,7926.0,30266756.0,Chang X,Paediatric migraine,initial,2018-09-28,GCST007154,Cardiovascular disease,#d53e4f
5987,African Am./Caribbean,4271.0,30266756.0,Chang X,Paediatric migraine,replication,2018-09-28,GCST007154,Cardiovascular disease,#fee08b
5992,Asian,1701.0,30266950.0,Miyagawa T,Hypersomnia (HLA-DQB1*06:02 negative),initial,2018-09-28,GCST007191,Neurological disorder,#3288bd
5993,Asian,716.0,30266950.0,Miyagawa T,Hypersomnia (HLA-DQB1*06:02 negative),replication,2018-09-28,GCST007191,Neurological disorder,#3288bd
5994,European,158025.0,30261039.0,Suri P,Chronic back pain,initial,2018-09-27,GCST007152,Other trait,#d53e4f
5995,European,283752.0,30261039.0,Suri P,Chronic back pain,replication,2018-09-27,GCST007152,Other trait,#d53e4f
5996,European,2545.0,30363675.0,Cha EDK,visceral adipose tissue/total adipose tissue ratio,initial,2018-09-27,GCST007189,Other measurement,#d53e4f
5997,European,2545.0,30363675.0,Cha EDK,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2018-09-27,GCST007188,Other measurement,#d53e4f
5998,European,2545.0,30363675.0,Cha EDK,Visceral adipose tissue,initial,2018-09-27,GCST007187,Other measurement,#d53e4f
5999,European,2545.0,30363675.0,Cha EDK,Subcutaneous adipose tissue,initial,2018-09-27,GCST007190,Other measurement,#d53e4f
6000,European,986.0,30265060.0,MacKillop J,Delayed reward discounting,initial,2018-09-27,GCST007153,Other measurement,#d53e4f
6001,African Am./Caribbean,1488.0,30258056.0,Vojinovic D,Lateral ventricular volume in normal aging,initial,2018-09-26,GCST007147,Other measurement,#fee08b
6002,European,22045.0,30258056.0,Vojinovic D,Lateral ventricular volume in normal aging,initial,2018-09-26,GCST007147,Other measurement,#d53e4f
6003,African Am./Caribbean,1231.0,30252935.0,Smith AH,Alcohol withdrawal symptoms,initial,2018-09-25,GCST008136,Neurological disorder,#fee08b
6004,European,3422.0,30254083.0,Cousminer DL,Latent autoimmune diabetes vs. type 1 diabetes,initial,2018-09-25,GCST007247,Metabolic disorder,#d53e4f
6005,European,3422.0,30254083.0,Cousminer DL,Latent autoimmune diabetes vs. type 1 diabetes,initial,2018-09-25,GCST007247,Metabolic disorder,#d53e4f
6006,European,13175.0,30254083.0,Cousminer DL,Latent autoimmune diabetes vs. type 2 diabetes,initial,2018-09-25,GCST007246,Metabolic disorder,#d53e4f
6007,European,13175.0,30254083.0,Cousminer DL,Latent autoimmune diabetes vs. type 2 diabetes,initial,2018-09-25,GCST007246,Metabolic disorder,#d53e4f
6008,European,1297.0,30252935.0,Smith AH,Alcohol withdrawal symptoms,initial,2018-09-25,GCST008137,Neurological disorder,#d53e4f
6009,European,181.0,30252935.0,Smith AH,Alcohol withdrawal symptoms,replication,2018-09-25,GCST008137,Neurological disorder,#d53e4f
6010,European,8581.0,30254083.0,Cousminer DL,Latent autoimmune diabetes,initial,2018-09-25,GCST007245,Metabolic disorder,#d53e4f
6011,European,2009.0,30254083.0,Cousminer DL,Latent autoimmune diabetes,replication,2018-09-25,GCST007245,Metabolic disorder,#d53e4f
6013,European,1355.0,30251476.0,Lopez-Mejias R,Carotid plaques in rheumatoid arthritis,initial,2018-09-24,GCST007425,Immune system disorder,#d53e4f
6014,European,1355.0,30251476.0,Lopez-Mejias R,Carotid plaques in rheumatoid arthritis,initial,2018-09-24,GCST007425,Cardiovascular disease,#d53e4f
6015,European,2989.0,30251476.0,Lopez-Mejias R,Ischemic heart disease in rheumatoid arthritis,initial,2018-09-24,GCST007088,Immune system disorder,#d53e4f
6016,European,2989.0,30251476.0,Lopez-Mejias R,Ischemic heart disease in rheumatoid arthritis,initial,2018-09-24,GCST007088,Cardiovascular disease,#d53e4f
6017,European,2989.0,30251476.0,Lopez-Mejias R,Cardiovascular event in rheumatoid arthritis,initial,2018-09-24,GCST007041,Immune system disorder,#d53e4f
6018,European,2989.0,30251476.0,Lopez-Mejias R,Cardiovascular event in rheumatoid arthritis,initial,2018-09-24,GCST007041,Other disease,#d53e4f
6019,European,1355.0,30251476.0,Lopez-Mejias R,Carotid intima media thickness in rheumatoid arthritis,initial,2018-09-24,GCST007040,Immune system disorder,#d53e4f
6020,European,1355.0,30251476.0,Lopez-Mejias R,Carotid intima media thickness in rheumatoid arthritis,initial,2018-09-24,GCST007040,Other measurement,#d53e4f
6021,Other/Mixed,721.0,30248107.0,Wu S,Eyebrow thickness,initial,2018-09-24,GCST006706,Other measurement,#99d594
6022,Hispanic/Latin American,2301.0,30248107.0,Wu S,Eyebrow thickness,initial,2018-09-24,GCST006706,Other measurement,#807dba
6023,European,4411.0,30248107.0,Wu S,Eyebrow thickness,replication,2018-09-24,GCST006706,Other measurement,#d53e4f
6024,Asian,2961.0,30248107.0,Wu S,Eyebrow thickness,initial,2018-09-24,GCST006706,Other measurement,#3288bd
6028,Other/Mixed,2107.0,30247649.0,Gonzalez-Serna D,Systemic sclerosis,initial,2018-09-21,GCST006493,Neurological disorder,#99d594
6029,Asian,4527.0,30242241.0,Hachiya T,Diastolic blood pressure x sodium interaction (1df test),initial,2018-09-21,GCST007107,Other measurement,#3288bd
6030,Asian,4241.0,30242241.0,Hachiya T,Diastolic blood pressure x sodium interaction (1df test),replication,2018-09-21,GCST007107,Other measurement,#3288bd
6031,Asian,4527.0,30242241.0,Hachiya T,Diastolic blood pressure x sodium interaction (1df test),initial,2018-09-21,GCST007107,Other measurement,#3288bd
6032,Asian,4241.0,30242241.0,Hachiya T,Diastolic blood pressure x sodium interaction (1df test),replication,2018-09-21,GCST007107,Other measurement,#3288bd
6033,Asian,4527.0,30242241.0,Hachiya T,Systolic blood pressure x sodium interaction (1df test),initial,2018-09-21,GCST007108,Other measurement,#3288bd
6034,Asian,4241.0,30242241.0,Hachiya T,Systolic blood pressure x sodium interaction (1df test),replication,2018-09-21,GCST007108,Other measurement,#3288bd
6035,Asian,4527.0,30242241.0,Hachiya T,Systolic blood pressure x sodium interaction (1df test),initial,2018-09-21,GCST007108,Other measurement,#3288bd
6036,Asian,4241.0,30242241.0,Hachiya T,Systolic blood pressure x sodium interaction (1df test),replication,2018-09-21,GCST007108,Other measurement,#3288bd
6037,Asian,2097.0,30242048.0,Chen B,Perceptual rivalry (binocular rivalry task),initial,2018-09-21,GCST007177,Other measurement,#3288bd
6038,Asian,870.0,30242048.0,Chen B,Perceptual rivalry (binocular rivalry task),replication,2018-09-21,GCST007177,Other measurement,#3288bd
6039,Asian,744.0,30242048.0,Chen B,Perceptual rivalry (voluntary modulation strength),replication,2018-09-21,GCST007178,Other measurement,#3288bd
6040,Asian,1876.0,30242048.0,Chen B,Perceptual rivalry (voluntary modulation strength),initial,2018-09-21,GCST007178,Other measurement,#3288bd
6041,Asian,1880.0,30242048.0,Chen B,Perceptual rivalry (Necker cube stimulus),initial,2018-09-21,GCST007176,Other measurement,#3288bd
6042,Asian,748.0,30242048.0,Chen B,Perceptual rivalry (Necker cube stimulus),replication,2018-09-21,GCST007176,Other measurement,#3288bd
6043,Hispanic/Latin American,859.0,30237584.0,El Rouby N,Resistant hypertension,initial,2018-09-20,GCST007135,Cardiovascular disease,#807dba
6044,European,2417.0,30237584.0,El Rouby N,Resistant hypertension,replication,2018-09-20,GCST007135,Cardiovascular disease,#d53e4f
6045,European,920.0,30237584.0,El Rouby N,Resistant hypertension,initial,2018-09-20,GCST007135,Cardiovascular disease,#d53e4f
6046,Hispanic/Latin American,537.0,30237584.0,El Rouby N,Resistant hypertension,initial,2018-09-20,GCST007136,Cardiovascular disease,#807dba
6047,Hispanic/Latin American,322.0,30237584.0,El Rouby N,Resistant hypertension,replication,2018-09-20,GCST007136,Cardiovascular disease,#807dba
6048,European,657.0,30237584.0,El Rouby N,Resistant hypertension,initial,2018-09-20,GCST007136,Cardiovascular disease,#d53e4f
6049,European,263.0,30237584.0,El Rouby N,Resistant hypertension,replication,2018-09-20,GCST007136,Cardiovascular disease,#d53e4f
6050,Asian,636.0,30230522.0,Zhang S,Pemphigus foliaceus,replication,2018-09-19,GCST008067,Immune system disorder,#3288bd
6051,Asian,573.0,30230522.0,Zhang S,Pemphigus foliaceus,initial,2018-09-19,GCST008067,Immune system disorder,#3288bd
6052,Asian,715.0,30230522.0,Zhang S,Pemphigus vulgaris,replication,2018-09-19,GCST008068,Immune system disorder,#3288bd
6053,Asian,756.0,30230522.0,Zhang S,Pemphigus vulgaris,initial,2018-09-19,GCST008068,Immune system disorder,#3288bd
6054,Asian,750.0,30230522.0,Zhang S,Pemphigus,replication,2018-09-19,GCST008069,Immune system disorder,#3288bd
6055,Asian,851.0,30230522.0,Zhang S,Pemphigus,initial,2018-09-19,GCST008069,Immune system disorder,#3288bd
6056,European,517.0,30324795.0,Moen GH,Fasting glucose in pregnancy (gestational week 14-16),initial,2018-09-18,GCST007179,Other measurement,#d53e4f
6057,European,424481.0,30226466.0,Valimaki N,Uterine fibroids,initial,2018-09-18,GCST007548,Cancer,#d53e4f
6058,European,21637.0,30226466.0,Valimaki N,Uterine fibroids,replication,2018-09-18,GCST007548,Cancer,#d53e4f
6059,African,1552.0,30226466.0,Valimaki N,Uterine fibroids,replication,2018-09-18,GCST007548,Cancer,#fc8d59
6060,African Am./Caribbean,2709.0,30226466.0,Valimaki N,Uterine fibroids,replication,2018-09-18,GCST007548,Cancer,#fee08b
6061,Asian,2770.0,30226466.0,Valimaki N,Uterine fibroids,replication,2018-09-18,GCST007548,Cancer,#3288bd
6062,Asian,744.0,30228239.0,Wojcik GL,Diarrhoea-associated Entamoeba histolytica infection,initial,2018-09-18,GCST007109,Other disease,#3288bd
6063,European,506.0,30324795.0,Moen GH,Timing of glucose curve peak in pregnancy (gestational week 30-32),initial,2018-09-18,GCST007186,Other measurement,#d53e4f
6064,European,497.0,30324795.0,Moen GH,Timing of glucose curve peak in pregnancy (gestational week 14-16),initial,2018-09-18,GCST007185,Other measurement,#d53e4f
6065,European,506.0,30324795.0,Moen GH,General glucose level in pregnancy (gestational week 30-32),initial,2018-09-18,GCST007184,Other measurement,#d53e4f
6066,European,497.0,30324795.0,Moen GH,General glucose level in pregnancy (gestational week 14-16),initial,2018-09-18,GCST007183,Other measurement,#d53e4f
6067,European,512.0,30324795.0,Moen GH,Two-hour glucose in pregnancy (gestational week 30-32),initial,2018-09-18,GCST007182,Other measurement,#d53e4f
6068,European,506.0,30324795.0,Moen GH,Two-hour glucose in pregnancy (gestational week 14-16),initial,2018-09-18,GCST007181,Other measurement,#d53e4f
6069,European,521.0,30324795.0,Moen GH,Fasting glucose in pregnancy (gestational week 30-32),initial,2018-09-18,GCST007180,Other measurement,#d53e4f
6070,European,1999.0,30223776.0,Hwang LD,Bitter taste perception (multivariate analysis),initial,2018-09-17,GCST006703,Biological process,#d53e4f
6071,European,757601.0,30224653.0,Evangelou E,Pulse pressure,initial,2018-09-17,GCST006626,Cardiovascular measurement,#d53e4f
6072,European,757601.0,30224653.0,Evangelou E,Diastolic blood pressure,initial,2018-09-17,GCST006627,Other measurement,#d53e4f
6073,European,757601.0,30224653.0,Evangelou E,Systolic blood pressure,initial,2018-09-17,GCST006628,Other measurement,#d53e4f
6074,European,757601.0,30224653.0,Evangelou E,Pulse pressure,initial,2018-09-17,GCST006629,Cardiovascular measurement,#d53e4f
6075,European,249262.0,30224653.0,Evangelou E,Pulse pressure,replication,2018-09-17,GCST006629,Cardiovascular measurement,#d53e4f
6076,European,757601.0,30224653.0,Evangelou E,Diastolic blood pressure,initial,2018-09-17,GCST006630,Other measurement,#d53e4f
6077,European,249262.0,30224653.0,Evangelou E,Diastolic blood pressure,replication,2018-09-17,GCST006630,Other measurement,#d53e4f
6078,European,823.0,30255771.0,Sarnowski C,Triglyceride change in response to fenofibrate treatment,initial,2018-09-17,GCST007663,Lipid or lipoprotein measurement,#d53e4f
6079,European,823.0,30255771.0,Sarnowski C,Triglyceride change in response to fenofibrate treatment,initial,2018-09-17,GCST007663,Response to drug,#d53e4f
6080,European,823.0,30255771.0,Sarnowski C,Triglyceride levels in response to fenofibrate,initial,2018-09-17,GCST007662,Lipid or lipoprotein measurement,#d53e4f
6081,European,823.0,30255771.0,Sarnowski C,Triglyceride levels in response to fenofibrate,initial,2018-09-17,GCST007662,Response to drug,#d53e4f
6082,European,823.0,30255771.0,Sarnowski C,Triglyceride levels,initial,2018-09-17,GCST007661,Lipid or lipoprotein measurement,#d53e4f
6088,European,1999.0,30223776.0,Hwang LD,Bitter taste perception,initial,2018-09-17,GCST006704,Biological process,#d53e4f
6089,European,757601.0,30224653.0,Evangelou E,Systolic blood pressure,initial,2018-09-17,GCST006624,Other measurement,#d53e4f
6090,European,249262.0,30224653.0,Evangelou E,Systolic blood pressure,replication,2018-09-17,GCST006624,Other measurement,#d53e4f
6091,European,823.0,30255771.0,Sarnowski C,Triglyceride change in response to fenofibrate (parental genotype effect),initial,2018-09-17,GCST007659,Lipid or lipoprotein measurement,#d53e4f
6092,European,823.0,30255771.0,Sarnowski C,Triglyceride change in response to fenofibrate (parental genotype effect),initial,2018-09-17,GCST007659,Response to drug,#d53e4f
6093,European,823.0,30255771.0,Sarnowski C,Triglyceride change in response to fenofibrate (parental genotype effect),initial,2018-09-17,GCST007659,Other measurement,#d53e4f
6094,European,823.0,30255771.0,Sarnowski C,Triglyceride levels in response to fenofibrate treatment (parental genotype effect),initial,2018-09-17,GCST007660,Lipid or lipoprotein measurement,#d53e4f
6095,European,823.0,30255771.0,Sarnowski C,Triglyceride levels in response to fenofibrate treatment (parental genotype effect),initial,2018-09-17,GCST007660,Response to drug,#d53e4f
6096,European,823.0,30255771.0,Sarnowski C,Triglyceride levels in response to fenofibrate treatment (parental genotype effect),initial,2018-09-17,GCST007660,Other measurement,#d53e4f
6104,European,823.0,30255771.0,Sarnowski C,Triglyceride levels (parental genotype effect),initial,2018-09-17,GCST007658,Lipid or lipoprotein measurement,#d53e4f
6105,European,823.0,30255771.0,Sarnowski C,Triglyceride levels (parental genotype effect),initial,2018-09-17,GCST007658,Other measurement,#d53e4f
6107,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis,initial,2018-09-15,GCST008217,Cancer,#d53e4f
6108,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis,replication,2018-09-15,GCST008217,Cancer,#d53e4f
6109,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis,initial,2018-09-15,GCST008217,Other measurement,#d53e4f
6110,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis,replication,2018-09-15,GCST008217,Other measurement,#d53e4f
6111,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer EORTC risk category,initial,2018-09-15,GCST008222,Cancer,#d53e4f
6112,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer EORTC risk category,initial,2018-09-15,GCST008222,Other measurement,#d53e4f
6113,European,643.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1),initial,2018-09-15,GCST008221,Cancer,#d53e4f
6114,European,1323.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1),replication,2018-09-15,GCST008221,Cancer,#d53e4f
6115,European,643.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1),initial,2018-09-15,GCST008221,Other measurement,#d53e4f
6116,European,1323.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1),replication,2018-09-15,GCST008221,Other measurement,#d53e4f
6117,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta),initial,2018-09-15,GCST008220,Cancer,#d53e4f
6118,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta),replication,2018-09-15,GCST008220,Cancer,#d53e4f
6119,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta),initial,2018-09-15,GCST008220,Other measurement,#d53e4f
6120,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta),replication,2018-09-15,GCST008220,Other measurement,#d53e4f
6121,European,633.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs ≥ 3 cm),initial,2018-09-15,GCST008219,Cancer,#d53e4f
6122,European,302.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs ≥ 3 cm),replication,2018-09-15,GCST008219,Cancer,#d53e4f
6123,European,633.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs ≥ 3 cm),initial,2018-09-15,GCST008219,Other measurement,#d53e4f
6124,European,302.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size (< 3 cm vs ≥ 3 cm),replication,2018-09-15,GCST008219,Other measurement,#d53e4f
6125,European,633.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size,initial,2018-09-15,GCST008216,Cancer,#d53e4f
6126,European,302.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size,replication,2018-09-15,GCST008216,Cancer,#d53e4f
6127,European,633.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size,initial,2018-09-15,GCST008216,Other measurement,#d53e4f
6128,European,302.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer tumour size,replication,2018-09-15,GCST008216,Other measurement,#d53e4f
6129,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs ≥ 70 years),replication,2018-09-15,GCST008218,Cancer,#d53e4f
6130,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs ≥ 70 years),initial,2018-09-15,GCST008218,Cancer,#d53e4f
6131,European,1470.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs ≥ 70 years),replication,2018-09-15,GCST008218,Other measurement,#d53e4f
6132,European,653.0,31277774.0,Lipunova N,Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs ≥ 70 years),initial,2018-09-15,GCST008218,Other measurement,#d53e4f
6133,European,3844.0,30217971.0,Ho KWD,Seasonality in depression,initial,2018-09-14,GCST007101,Neurological disorder,#d53e4f
6134,European,3844.0,30217971.0,Ho KWD,Seasonality in depression,initial,2018-09-14,GCST007101,Other measurement,#d53e4f
6135,European,3844.0,30217971.0,Ho KWD,Seasonality in depression,initial,2018-09-14,GCST007101,Neurological disorder,#d53e4f
6136,Asian,71.0,30277654.0,Yokoshima Y,Response to opioid analgesics in cancer (pain decrease),initial,2018-09-14,GCST007106,Cancer,#3288bd
6137,Asian,71.0,30277654.0,Yokoshima Y,Response to opioid analgesics in cancer (pain decrease),initial,2018-09-14,GCST007106,Response to drug,#3288bd
6138,European,2412.0,30218097.0,Munz M,Periodontitis,replication,2018-09-14,GCST006486,Digestive system disorder,#d53e4f
6139,European,12591.0,30218097.0,Munz M,Periodontitis,initial,2018-09-14,GCST006486,Digestive system disorder,#d53e4f
6140,African,4443.0,30217807.0,Robinson-Cohen C,Circulating fibroblast growth factor 23 levels,replication,2018-09-14,GCST006491,Other measurement,#fc8d59
6141,European,16624.0,30217807.0,Robinson-Cohen C,Circulating fibroblast growth factor 23 levels,initial,2018-09-14,GCST006491,Other measurement,#d53e4f
6142,European,4317.0,30217971.0,Ho KWD,Seasonality and depression,initial,2018-09-14,GCST007102,Neurological disorder,#d53e4f
6143,European,4317.0,30217971.0,Ho KWD,Seasonality and depression,initial,2018-09-14,GCST007102,Other measurement,#d53e4f
6144,European,4317.0,30217971.0,Ho KWD,Seasonality and depression,initial,2018-09-14,GCST007102,Neurological disorder,#d53e4f
6145,European,249665.0,30213928.0,Went M,Multiple myeloma,initial,2018-09-13,GCST006432,Cancer,#d53e4f
6146,European,7865.0,30213928.0,Went M,Multiple myeloma,replication,2018-09-13,GCST006432,Cancer,#d53e4f
6147,Asian,16533.0,30219835.0,Lin WY,Blood pressure (smoking interaction),initial,2018-09-13,GCST007618,Other measurement,#3288bd
6148,Asian,16533.0,30219835.0,Lin WY,Blood pressure (smoking interaction),initial,2018-09-13,GCST007618,Other measurement,#3288bd
6149,Asian,16543.0,30219835.0,Lin WY,Blood pressure x alcohol consumption interaction,initial,2018-09-13,GCST007617,Other measurement,#3288bd
6150,Asian,16543.0,30219835.0,Lin WY,Blood pressure x alcohol consumption interaction,initial,2018-09-13,GCST007617,Other measurement,#3288bd
6151,Hispanic/Latin American,416.0,30206298.0,Spear ML,Bronchodilator response in asthma,replication,2018-09-12,GCST007360,Response to drug,#807dba
6152,African Am./Caribbean,1615.0,30206298.0,Spear ML,Bronchodilator response in asthma,replication,2018-09-12,GCST007360,Response to drug,#fee08b
6153,Hispanic/Latin American,1830.0,30206298.0,Spear ML,Bronchodilator response in asthma,initial,2018-09-12,GCST007360,Response to drug,#807dba
6154,African Am./Caribbean,949.0,30206298.0,Spear ML,Bronchodilator response in asthma,initial,2018-09-12,GCST007360,Response to drug,#fee08b
6155,Hispanic/Latin American,416.0,30206298.0,Spear ML,Bronchodilator response in asthma,replication,2018-09-12,GCST007360,Other disease,#807dba
6156,African Am./Caribbean,1615.0,30206298.0,Spear ML,Bronchodilator response in asthma,replication,2018-09-12,GCST007360,Other disease,#fee08b
6157,Hispanic/Latin American,1830.0,30206298.0,Spear ML,Bronchodilator response in asthma,initial,2018-09-12,GCST007360,Other disease,#807dba
6158,African Am./Caribbean,949.0,30206298.0,Spear ML,Bronchodilator response in asthma,initial,2018-09-12,GCST007360,Other disease,#fee08b
6159,European,4910.0,30206230.0,Offenbacher S,High IL-1beta levels in gingival crevicular fluid,initial,2018-09-11,GCST007542,Inflammatory measurement,#d53e4f
6163,European,454.0,30201983.0,Tulstrup M,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007149,Other measurement,#d53e4f
6164,European,454.0,30201983.0,Tulstrup M,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007149,Response to drug,#d53e4f
6165,European,454.0,30201983.0,Tulstrup M,Erythrocyte methylated 6-mercaptopurine metabolite concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007149,Cancer,#d53e4f
6166,European,452.0,30201983.0,Tulstrup M,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007148,Other measurement,#d53e4f
6167,European,452.0,30201983.0,Tulstrup M,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007148,Response to drug,#d53e4f
6168,European,452.0,30201983.0,Tulstrup M,Erythrocyte thioguanine concentration in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007148,Cancer,#d53e4f
6169,European,1533.0,30202041.0,Otani T,Homocysteine level response to multivitamin in cerebral infarction,initial,2018-09-10,GCST007366,Cardiovascular disease,#d53e4f
6170,European,1533.0,30202041.0,Otani T,Homocysteine level response to multivitamin in cerebral infarction,initial,2018-09-10,GCST007366,Cardiovascular measurement,#d53e4f
6171,European,1533.0,30202041.0,Otani T,Homocysteine level response to multivitamin in cerebral infarction,initial,2018-09-10,GCST007366,Biological process,#d53e4f
6172,European,11165.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008102,Lipid or lipoprotein measurement,#d53e4f
6173,African,797.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008102,Lipid or lipoprotein measurement,#fc8d59
6174,European,1141.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008102,Lipid or lipoprotein measurement,#d53e4f
6175,African,546.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008102,Lipid or lipoprotein measurement,#fc8d59
6176,European,11165.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008102,Other measurement,#d53e4f
6177,African,797.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008102,Other measurement,#fc8d59
6178,European,1141.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008102,Other measurement,#d53e4f
6179,African,546.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008102,Other measurement,#fc8d59
6180,European,11165.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008099,Lipid or lipoprotein measurement,#d53e4f
6181,African,797.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008099,Lipid or lipoprotein measurement,#fc8d59
6182,African,546.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008099,Lipid or lipoprotein measurement,#fc8d59
6183,European,1141.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008099,Lipid or lipoprotein measurement,#d53e4f
6184,European,11165.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008099,Other measurement,#d53e4f
6185,African,797.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),initial,2018-09-10,GCST008099,Other measurement,#fc8d59
6186,African,546.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008099,Other measurement,#fc8d59
6187,European,1141.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosahexaenoic acid) interaction (2df),replication,2018-09-10,GCST008099,Other measurement,#d53e4f
6188,African,797.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008100,Lipid or lipoprotein measurement,#fc8d59
6189,European,11165.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008100,Lipid or lipoprotein measurement,#d53e4f
6190,African,546.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008100,Lipid or lipoprotein measurement,#fc8d59
6191,European,1141.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008100,Lipid or lipoprotein measurement,#d53e4f
6192,African,797.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008100,Other measurement,#fc8d59
6193,European,11165.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008100,Other measurement,#d53e4f
6194,African,546.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008100,Other measurement,#fc8d59
6195,European,1141.0,30199657.0,Xu J,Pulmonary function (FVC) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008100,Other measurement,#d53e4f
6196,African,546.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008101,Other measurement,#fc8d59
6197,African,797.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008101,Other measurement,#fc8d59
6198,European,11165.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008101,Other measurement,#d53e4f
6199,European,1141.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008101,Other measurement,#d53e4f
6200,African,546.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008101,Lipid or lipoprotein measurement,#fc8d59
6201,African,797.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008101,Lipid or lipoprotein measurement,#fc8d59
6202,European,11165.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),initial,2018-09-10,GCST008101,Lipid or lipoprotein measurement,#d53e4f
6203,European,1141.0,30199657.0,Xu J,Pulmonary function (FEV1) x omega-3 PUFA (docosapentaenoic acid) interaction (2df),replication,2018-09-10,GCST008101,Lipid or lipoprotein measurement,#d53e4f
6207,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007151,Other measurement,#d53e4f
6208,European,136.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,replication,2018-09-10,GCST007151,Other measurement,#d53e4f
6209,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007151,Response to drug,#d53e4f
6210,European,136.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,replication,2018-09-10,GCST007151,Response to drug,#d53e4f
6211,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007151,Cancer,#d53e4f
6212,European,136.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine to erythrocyte thioguanine ratio in 6-mercaptopurine-treated acute lymphoblastic leukaemia,replication,2018-09-10,GCST007151,Cancer,#d53e4f
6213,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007150,Other measurement,#d53e4f
6214,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007150,Response to drug,#d53e4f
6215,European,443.0,30201983.0,Tulstrup M,DNA-incorporated thioguanine levels in 6-mercaptopurine-treated acute lymphoblastic leukaemia,initial,2018-09-10,GCST007150,Cancer,#d53e4f
6216,European,156028.0,30270018.0,Zhang Q,Type 2 diabetes or coronary artery disease (pleiotropy),initial,2018-09-09,GCST007359,Metabolic disorder,#d53e4f
6217,European,156028.0,30270018.0,Zhang Q,Type 2 diabetes or coronary artery disease (pleiotropy),initial,2018-09-09,GCST007359,Cardiovascular disease,#d53e4f
6218,European,44871.0,30202859.0,Laisk T,Length of menstrual cycle,initial,2018-09-07,GCST006958,Other measurement,#d53e4f
6219,European,6576.0,30219690.0,Heinzman JT,Depression in smokers,initial,2018-09-07,GCST006427,Biological process,#d53e4f
6220,African Am./Caribbean,3140.0,30219690.0,Heinzman JT,Depression in smokers,initial,2018-09-07,GCST006427,Biological process,#fee08b
6221,European,6576.0,30219690.0,Heinzman JT,Depression in smokers,initial,2018-09-07,GCST006427,Neurological disorder,#d53e4f
6222,African Am./Caribbean,3140.0,30219690.0,Heinzman JT,Depression in smokers,initial,2018-09-07,GCST006427,Neurological disorder,#fee08b
6223,European,27750.0,30194254.0,Sud A,Hodgkin's lymphoma,initial,2018-09-07,GCST007062,Cancer,#d53e4f
6224,European,539925.0,30194396.0,Rafnar T,Uterine fibroids,initial,2018-09-07,GCST006462,Cancer,#d53e4f
6226,European,382500.0,30220432.0,Haas ME,Urinary albumin excretion,initial,2018-09-06,GCST006586,Other trait,#d53e4f
6274,European,302687.0,30220432.0,Haas ME,Urinary albumin excretion (no hypertensive medication),initial,2018-09-06,GCST006463,Other trait,#d53e4f
6284,African Am./Caribbean,492.0,30185882.0,Zeiger AM,Telomere length,initial,2018-09-05,GCST006485,Other measurement,#fee08b
6285,European,4666.0,30178632.0,Meng W,Severe diabetic retinopathy in type 2 diabetes,initial,2018-09-04,GCST006424,Metabolic disorder,#d53e4f
6286,European,4666.0,30178632.0,Meng W,Severe diabetic retinopathy in type 2 diabetes,initial,2018-09-04,GCST006424,Metabolic disorder,#d53e4f
6287,European,4941.0,30181573.0,Jing J,Gout in chronic kidney disease,initial,2018-09-04,GCST006425,Metabolic disorder,#d53e4f
6288,European,4941.0,30181573.0,Jing J,Gout in chronic kidney disease,initial,2018-09-04,GCST006425,Other disease,#d53e4f
6290,European,47983.0,30181555.0,Strawbridge RJ,Self-reported risk-taking behaviour,replication,2018-09-04,GCST006461,Biological process,#d53e4f
6291,African Am./Caribbean,7480.0,30181555.0,Strawbridge RJ,Self-reported risk-taking behaviour,replication,2018-09-04,GCST006461,Biological process,#fee08b
6292,Asian,7031.0,30181555.0,Strawbridge RJ,Self-reported risk-taking behaviour,replication,2018-09-04,GCST006461,Biological process,#3288bd
6293,European,328339.0,30181555.0,Strawbridge RJ,Self-reported risk-taking behaviour,initial,2018-09-04,GCST006461,Biological process,#d53e4f
6294,European,4941.0,30181573.0,Jing J,Serum urate levels in chronic kidney disease,initial,2018-09-04,GCST006426,Other measurement,#d53e4f
6295,European,4941.0,30181573.0,Jing J,Serum urate levels in chronic kidney disease,initial,2018-09-04,GCST006426,Other disease,#d53e4f
6296,European,409728.0,30177863.0,Maguire LH,Diverticular disease,initial,2018-09-03,GCST006479,Digestive system disorder,#d53e4f
6299,Other/Mixed,1301.0,30196971.0,Bray MJ,Uterine fibroid size (maximum dimension),initial,2018-09-01,GCST006618,Other measurement,#99d594
6300,Asian,190.0,30088374.0,Park HW,Severe cutaneous adverse drug reactions,replication,2018-09-01,GCST008492,Other disease,#3288bd
6301,Asian,340.0,30088374.0,Park HW,Severe cutaneous adverse drug reactions,initial,2018-09-01,GCST008492,Other disease,#3288bd
6302,European,1514.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate),initial,2018-08-31,GCST006607,Immune system disorder,#d53e4f
6303,European,1514.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate),initial,2018-08-31,GCST006607,Response to drug,#d53e4f
6304,European,1514.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (erythrocyte sedimentation rate),initial,2018-08-31,GCST006607,Inflammatory measurement,#d53e4f
6305,Asian,909.0,30169916.0,Sun Y,Pemphigus foliaceus,initial,2018-08-31,GCST006520,Immune system disorder,#3288bd
6306,Asian,1045.0,30169916.0,Sun Y,Pemphigus foliaceus,replication,2018-08-31,GCST006520,Immune system disorder,#3288bd
6307,Asian,1052.0,30169916.0,Sun Y,Pemphigus vulgaris,replication,2018-08-31,GCST006521,Immune system disorder,#3288bd
6308,Asian,945.0,30169916.0,Sun Y,Pemphigus vulgaris,initial,2018-08-31,GCST006521,Immune system disorder,#3288bd
6309,European,1569.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score),initial,2018-08-31,GCST006610,Immune system disorder,#d53e4f
6310,European,1569.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score),initial,2018-08-31,GCST006610,Response to drug,#d53e4f
6311,European,1569.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in disease activity score),initial,2018-08-31,GCST006610,Other measurement,#d53e4f
6312,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count),initial,2018-08-31,GCST006609,Immune system disorder,#d53e4f
6313,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count),initial,2018-08-31,GCST006609,Response to drug,#d53e4f
6314,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count),initial,2018-08-31,GCST006609,Other measurement,#d53e4f
6315,European,1709.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score),initial,2018-08-31,GCST006608,Immune system disorder,#d53e4f
6316,European,1709.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score),initial,2018-08-31,GCST006608,Other trait,#d53e4f
6317,European,1709.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in patient global heath assessment score),initial,2018-08-31,GCST006608,Response to drug,#d53e4f
6318,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),initial,2018-08-31,GCST006606,Immune system disorder,#d53e4f
6319,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),initial,2018-08-31,GCST006606,Response to drug,#d53e4f
6320,European,1723.0,30166627.0,Massey J,Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),initial,2018-08-31,GCST006606,Other measurement,#d53e4f
6321,European,212444.0,30172742.0,Hu Y,Femoral neck bone mineral density or type 2 diabetes (pleiotropy),initial,2018-08-30,GCST006861,Metabolic disorder,#d53e4f
6322,European,212444.0,30172742.0,Hu Y,Femoral neck bone mineral density or type 2 diabetes (pleiotropy),initial,2018-08-30,GCST006861,Other measurement,#d53e4f
6323,European,4988.0,30166351.0,Galvan-Femenia I,Heart rate,initial,2018-08-30,GCST007481,Cardiovascular measurement,#d53e4f
6324,European,4988.0,30166351.0,Galvan-Femenia I,Handedness,initial,2018-08-30,GCST007482,Other trait,#d53e4f
6325,European,4988.0,30166351.0,Galvan-Femenia I,Hair morphology traits,initial,2018-08-30,GCST007486,Other measurement,#d53e4f
6326,European,4988.0,30166351.0,Galvan-Femenia I,Skin pigmentation traits,initial,2018-08-30,GCST007488,Other trait,#d53e4f
6327,European,4988.0,30166351.0,Galvan-Femenia I,Eye color traits,initial,2018-08-30,GCST007489,Other trait,#d53e4f
6328,European,4988.0,30166351.0,Galvan-Femenia I,Disorders of lipid metabolism,initial,2018-08-30,GCST007480,Other trait,#d53e4f
6329,Asian,72.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,replication,2018-08-30,GCST006615,Response to drug,#3288bd
6330,Asian,275.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,initial,2018-08-30,GCST006615,Response to drug,#3288bd
6331,Asian,72.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,replication,2018-08-30,GCST006615,Other measurement,#3288bd
6332,Asian,275.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,initial,2018-08-30,GCST006615,Other measurement,#3288bd
6333,Asian,72.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,replication,2018-08-30,GCST006615,Cancer,#3288bd
6334,Asian,275.0,30161160.0,Onishi H,Response to tamoxifen in oestrogen receptor positive/HER2 negative breast cancer,initial,2018-08-30,GCST006615,Cancer,#3288bd
6335,Other/Mixed,1.0,30160337.0,Asleh R,Glomerular filtration rate change in heart transplantation,initial,2018-08-30,GCST006496,Biological process,#99d594
6337,European,243.0,30160337.0,Asleh R,Glomerular filtration rate change in heart transplantation,initial,2018-08-30,GCST006496,Biological process,#d53e4f
6338,Other/Mixed,1.0,30160337.0,Asleh R,Glomerular filtration rate change in heart transplantation,initial,2018-08-30,GCST006496,Other measurement,#99d594
6340,European,243.0,30160337.0,Asleh R,Glomerular filtration rate change in heart transplantation,initial,2018-08-30,GCST006496,Other measurement,#d53e4f
6341,European,2286.0,30172743.0,Liang X,Bone mineral density (spine),initial,2018-08-30,GCST006447,Other measurement,#d53e4f
6342,European,2286.0,30172743.0,Liang X,Ulna and radius bone mineral density,initial,2018-08-30,GCST006446,Other measurement,#d53e4f
6343,European,2286.0,30172743.0,Liang X,Femoral neck bone mineral density,initial,2018-08-30,GCST006445,Other measurement,#d53e4f
6344,European,2286.0,30172743.0,Liang X,Bone mineral density (hip),initial,2018-08-30,GCST006444,Other measurement,#d53e4f
6345,European,4988.0,30166351.0,Galvan-Femenia I,Anthropometric traits,initial,2018-08-30,GCST007485,Other measurement,#d53e4f
6346,European,336107.0,30166351.0,Galvan-Femenia I,Anthropometric traits,replication,2018-08-30,GCST007485,Other measurement,#d53e4f
6347,European,336107.0,30166351.0,Galvan-Femenia I,Anthropometric traits (multi-trait analysis),replication,2018-08-30,GCST007490,Other measurement,#d53e4f
6348,European,4988.0,30166351.0,Galvan-Femenia I,Anthropometric traits (multi-trait analysis),initial,2018-08-30,GCST007490,Other measurement,#d53e4f
6349,European,2286.0,30172743.0,Liang X,Total body bone mineral density,initial,2018-08-30,GCST006443,Other measurement,#d53e4f
6350,European,264173.0,30158200.0,Trajanoska K,Fractures,initial,2018-08-29,GCST006423,Other disease,#d53e4f
6351,European,297285.0,30158200.0,Trajanoska K,Fractures,replication,2018-08-29,GCST006423,Other disease,#d53e4f
6352,Asian,800.0,30158200.0,Trajanoska K,Fractures,initial,2018-08-29,GCST006423,Other disease,#3288bd
6353,Asian,5281.0,30158200.0,Trajanoska K,Fractures,replication,2018-08-29,GCST006422,Other disease,#3288bd
6354,Other/Mixed,1468.0,30158200.0,Trajanoska K,Fractures,replication,2018-08-29,GCST006422,Other disease,#99d594
6355,European,264173.0,30158200.0,Trajanoska K,Fractures,initial,2018-08-29,GCST006422,Other disease,#d53e4f
6356,European,44108.0,30158200.0,Trajanoska K,Fractures,replication,2018-08-29,GCST006422,Other disease,#d53e4f
6357,Asian,800.0,30158200.0,Trajanoska K,Fractures,initial,2018-08-29,GCST006422,Other disease,#3288bd
6358,European,3146.0,30153862.0,Maxwell TJ,Cerebrospinal fluid t-tau:AB1-42 ratio,initial,2018-08-28,GCST007130,Other measurement,#d53e4f
6359,European,3146.0,30153862.0,Maxwell TJ,Cerebrospinal fluid t-tau:AB1-42 ratio,initial,2018-08-28,GCST007129,Other measurement,#d53e4f
6360,African Am./Caribbean,328.0,30169657.0,Ashar FN,Sudden cardiac arrest,replication,2018-08-28,GCST006401,Cardiovascular disease,#fee08b
6361,Other/Mixed,40333.0,30169657.0,Ashar FN,Sudden cardiac arrest,replication,2018-08-28,GCST006401,Cardiovascular disease,#99d594
6362,Asian,424.0,30169657.0,Ashar FN,Sudden cardiac arrest,replication,2018-08-28,GCST006401,Cardiovascular disease,#3288bd
6363,European,29928.0,30169657.0,Ashar FN,Sudden cardiac arrest,initial,2018-08-28,GCST006401,Cardiovascular disease,#d53e4f
6364,European,184756.0,30150663.0,Pasman JA,Cannabis use,initial,2018-08-27,GCST006421,Biological process,#d53e4f
6367,Asian,4477.0,30294719.0,Zeng Y,Longevity,initial,2018-08-24,GCST006658,Other measurement,#3288bd
6368,Asian,2148.0,30132804.0,Kim M,Low HDL-cholesterol levels,initial,2018-08-22,GCST006860,Lipid or lipoprotein measurement,#3288bd
6369,Other/Mixed,764.0,30134952.0,Traglia M,Neonatal cytokine/chemokine levels (fetal genetic effect),initial,2018-08-22,GCST006622,Other measurement,#99d594
6370,Other/Mixed,764.0,30134952.0,Traglia M,Neonatal cytokine/chemokine levels (fetal genetic effect),initial,2018-08-22,GCST006622,Other measurement,#99d594
6371,Other/Mixed,764.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (fetal genetic effect),initial,2018-08-22,GCST006623,Other measurement,#99d594
6372,Other/Mixed,764.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (fetal genetic effect),initial,2018-08-22,GCST006623,Other measurement,#99d594
6373,Other/Mixed,764.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (fetal genetic effect),initial,2018-08-22,GCST006623,Other measurement,#99d594
6374,Other/Mixed,790.0,30134952.0,Traglia M,Neonatal cytokine/chemokine levels (maternal genetic effect),initial,2018-08-22,GCST006625,Other measurement,#99d594
6375,Other/Mixed,790.0,30134952.0,Traglia M,Neonatal cytokine/chemokine levels (maternal genetic effect),initial,2018-08-22,GCST006625,Other measurement,#99d594
6376,Other/Mixed,790.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (maternal genetic effect),initial,2018-08-22,GCST006621,Other measurement,#99d594
6377,Other/Mixed,790.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (maternal genetic effect),initial,2018-08-22,GCST006621,Other measurement,#99d594
6378,Other/Mixed,790.0,30134952.0,Traglia M,Midgestational cytokine/chemokine levels (maternal genetic effect),initial,2018-08-22,GCST006621,Other measurement,#99d594
6379,Other/Mixed,92.0,30130595.0,Dominguez-Cruz MG,Type 2 diabetes,initial,2018-08-18,GCST006484,Metabolic disorder,#99d594
6380,Asian,502.0,30120420.0,Sun R,Motor composite score,initial,2018-08-17,GCST006440,Other measurement,#3288bd
6381,Hispanic/Latin American,462.0,30120420.0,Sun R,Motor composite score,initial,2018-08-17,GCST006440,Other measurement,#807dba
6382,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (horizontal position gain),initial,2018-08-17,GCST006448,Other measurement,#3288bd
6383,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (horizontal position gain),initial,2018-08-17,GCST006448,Neurological disorder,#3288bd
6384,European,70.0,30120429.0,Schlauch KA,Obesity without metabolic disease,initial,2018-08-17,GCST006492,Metabolic disorder,#d53e4f
6385,Asian,502.0,30120420.0,Sun R,Mental composite score,initial,2018-08-17,GCST006441,Other measurement,#3288bd
6386,Hispanic/Latin American,462.0,30120420.0,Sun R,Mental composite score,initial,2018-08-17,GCST006441,Other measurement,#807dba
6387,Asian,226.0,30120336.0,Kikuchi M,Eye movement (integrated eye movement score),initial,2018-08-17,GCST006449,Other measurement,#3288bd
6388,Asian,166.0,30120336.0,Kikuchi M,Eye movement (integrated eye movement score),initial,2018-08-17,GCST006450,Other measurement,#3288bd
6389,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (integrated eye movement score),initial,2018-08-17,GCST006451,Other measurement,#3288bd
6390,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (integrated eye movement score),initial,2018-08-17,GCST006451,Neurological disorder,#3288bd
6391,Asian,226.0,30120336.0,Kikuchi M,Eye movement (duration of fixations),initial,2018-08-17,GCST006452,Other measurement,#3288bd
6392,Asian,166.0,30120336.0,Kikuchi M,Eye movement (duration of fixations),initial,2018-08-17,GCST006453,Other measurement,#3288bd
6393,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (duration of fixations),initial,2018-08-17,GCST006454,Other measurement,#3288bd
6394,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (duration of fixations),initial,2018-08-17,GCST006454,Neurological disorder,#3288bd
6395,Asian,226.0,30120336.0,Kikuchi M,Eye movement (scanpath length),initial,2018-08-17,GCST006455,Other measurement,#3288bd
6396,Asian,166.0,30120336.0,Kikuchi M,Eye movement (scanpath length),initial,2018-08-17,GCST006456,Other measurement,#3288bd
6397,Asian,226.0,30120336.0,Kikuchi M,Eye movement (horizontal position gain),initial,2018-08-17,GCST006457,Other measurement,#3288bd
6398,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (scanpath length),initial,2018-08-17,GCST006459,Other measurement,#3288bd
6399,Asian,60.0,30120336.0,Kikuchi M,Eye movement in schizophrenia (scanpath length),initial,2018-08-17,GCST006459,Neurological disorder,#3288bd
6400,Asian,166.0,30120336.0,Kikuchi M,Eye movement (horizontal position gain),initial,2018-08-17,GCST006458,Other measurement,#3288bd
6402,European,456426.0,30124842.0,Yengo L,Body mass index,initial,2018-08-16,GCST006900,Body measurement,#d53e4f
6403,Other/Mixed,694.0,30174134.0,Qiao L,Mouth morphology (partial least square model),initial,2018-08-16,GCST006518,Other measurement,#99d594
6404,Other/Mixed,171.0,30174134.0,Qiao L,Mouth morphology (partial least square model),replication,2018-08-16,GCST006518,Other measurement,#99d594
6405,Asian,1504.0,30174134.0,Qiao L,Mouth morphology (partial least square model),replication,2018-08-16,GCST006518,Other measurement,#3288bd
6406,Other/Mixed,694.0,30174134.0,Qiao L,Nose morphology (partial least square model),initial,2018-08-16,GCST006517,Other measurement,#99d594
6407,Other/Mixed,171.0,30174134.0,Qiao L,Nose morphology (partial least square model),replication,2018-08-16,GCST006517,Other measurement,#99d594
6408,Asian,1504.0,30174134.0,Qiao L,Nose morphology (partial least square model),replication,2018-08-16,GCST006517,Other measurement,#3288bd
6409,Other/Mixed,171.0,30174134.0,Qiao L,Cheek morphology (partial least square model),replication,2018-08-16,GCST006516,Other measurement,#99d594
6410,Asian,1504.0,30174134.0,Qiao L,Cheek morphology (partial least square model),replication,2018-08-16,GCST006516,Other measurement,#3288bd
6411,Other/Mixed,694.0,30174134.0,Qiao L,Cheek morphology (partial least square model),initial,2018-08-16,GCST006516,Other measurement,#99d594
6412,Other/Mixed,694.0,30174134.0,Qiao L,Side of face morphology (partial least square model),initial,2018-08-16,GCST006515,Other measurement,#99d594
6413,Other/Mixed,171.0,30174134.0,Qiao L,Side of face morphology (partial least square model),replication,2018-08-16,GCST006515,Other measurement,#99d594
6414,Asian,1504.0,30174134.0,Qiao L,Side of face morphology (partial least square model),replication,2018-08-16,GCST006515,Other measurement,#3288bd
6415,Asian,1504.0,30174134.0,Qiao L,Eye morphology (partial least square model),replication,2018-08-16,GCST006514,Other measurement,#3288bd
6416,Other/Mixed,694.0,30174134.0,Qiao L,Eye morphology (partial least square model),initial,2018-08-16,GCST006514,Other measurement,#99d594
6417,Other/Mixed,171.0,30174134.0,Qiao L,Eye morphology (partial least square model),replication,2018-08-16,GCST006514,Other measurement,#99d594
6418,Asian,1504.0,30174134.0,Qiao L,Brow ridge morphology (partial least square model),replication,2018-08-16,GCST006513,Other measurement,#3288bd
6419,Other/Mixed,171.0,30174134.0,Qiao L,Brow ridge morphology (partial least square model),replication,2018-08-16,GCST006513,Other measurement,#99d594
6420,Other/Mixed,694.0,30174134.0,Qiao L,Brow ridge morphology (partial least square model),initial,2018-08-16,GCST006513,Other measurement,#99d594
6421,Other/Mixed,694.0,30174134.0,Qiao L,Mouth morphology (principal component model),initial,2018-08-16,GCST006512,Other measurement,#99d594
6422,Other/Mixed,171.0,30174134.0,Qiao L,Mouth morphology (principal component model),replication,2018-08-16,GCST006512,Other measurement,#99d594
6423,Asian,1504.0,30174134.0,Qiao L,Mouth morphology (principal component model),replication,2018-08-16,GCST006512,Other measurement,#3288bd
6424,Other/Mixed,694.0,30174134.0,Qiao L,Nose morphology (principal component model),initial,2018-08-16,GCST006511,Other measurement,#99d594
6425,Other/Mixed,171.0,30174134.0,Qiao L,Nose morphology (principal component model),replication,2018-08-16,GCST006511,Other measurement,#99d594
6426,Asian,1504.0,30174134.0,Qiao L,Nose morphology (principal component model),replication,2018-08-16,GCST006511,Other measurement,#3288bd
6427,Other/Mixed,694.0,30174134.0,Qiao L,Cheek morphology (principal component model),initial,2018-08-16,GCST006510,Other measurement,#99d594
6428,Other/Mixed,171.0,30174134.0,Qiao L,Cheek morphology (principal component model),replication,2018-08-16,GCST006510,Other measurement,#99d594
6429,Asian,1504.0,30174134.0,Qiao L,Cheek morphology (principal component model),replication,2018-08-16,GCST006510,Other measurement,#3288bd
6430,Other/Mixed,694.0,30174134.0,Qiao L,Side of face morphology (principal component model),initial,2018-08-16,GCST006509,Other measurement,#99d594
6431,Other/Mixed,171.0,30174134.0,Qiao L,Side of face morphology (principal component model),replication,2018-08-16,GCST006509,Other measurement,#99d594
6432,Asian,1504.0,30174134.0,Qiao L,Side of face morphology (principal component model),replication,2018-08-16,GCST006509,Other measurement,#3288bd
6433,Other/Mixed,694.0,30174134.0,Qiao L,Eye morphology (principal component model),initial,2018-08-16,GCST006508,Other measurement,#99d594
6434,Other/Mixed,171.0,30174134.0,Qiao L,Eye morphology (principal component model),replication,2018-08-16,GCST006508,Other measurement,#99d594
6435,Asian,1504.0,30174134.0,Qiao L,Eye morphology (principal component model),replication,2018-08-16,GCST006508,Other measurement,#3288bd
6436,Other/Mixed,694.0,30174134.0,Qiao L,Brow ridge morphology (principal component model),initial,2018-08-16,GCST006498,Other measurement,#99d594
6437,Other/Mixed,171.0,30174134.0,Qiao L,Brow ridge morphology (principal component model),replication,2018-08-16,GCST006498,Other measurement,#99d594
6438,Asian,1504.0,30174134.0,Qiao L,Brow ridge morphology (principal component model),replication,2018-08-16,GCST006498,Other measurement,#3288bd
6439,Other/Mixed,171.0,30174134.0,Qiao L,Lower face length,replication,2018-08-16,GCST006507,Other measurement,#99d594
6440,Other/Mixed,694.0,30174134.0,Qiao L,Lower face length,initial,2018-08-16,GCST006507,Other measurement,#99d594
6441,Asian,1504.0,30174134.0,Qiao L,Lower face length,replication,2018-08-16,GCST006507,Other measurement,#3288bd
6442,Other/Mixed,694.0,30174134.0,Qiao L,Lip thickness,initial,2018-08-16,GCST006506,Other measurement,#99d594
6443,Other/Mixed,171.0,30174134.0,Qiao L,Lip thickness,replication,2018-08-16,GCST006506,Other measurement,#99d594
6444,Asian,1504.0,30174134.0,Qiao L,Lip thickness,replication,2018-08-16,GCST006506,Other measurement,#3288bd
6445,Other/Mixed,171.0,30174134.0,Qiao L,Labial fissure length,replication,2018-08-16,GCST006505,Other measurement,#99d594
6446,Asian,1504.0,30174134.0,Qiao L,Labial fissure length,replication,2018-08-16,GCST006505,Other measurement,#3288bd
6447,Other/Mixed,694.0,30174134.0,Qiao L,Labial fissure length,initial,2018-08-16,GCST006505,Other measurement,#99d594
6448,Other/Mixed,694.0,30174134.0,Qiao L,Interorbital distance,initial,2018-08-16,GCST006504,Other measurement,#99d594
6449,Asian,1504.0,30174134.0,Qiao L,Interorbital distance,replication,2018-08-16,GCST006504,Other measurement,#3288bd
6450,Other/Mixed,171.0,30174134.0,Qiao L,Interorbital distance,replication,2018-08-16,GCST006504,Other measurement,#99d594
6451,Other/Mixed,694.0,30174134.0,Qiao L,Eye length,initial,2018-08-16,GCST006503,Other measurement,#99d594
6452,Other/Mixed,171.0,30174134.0,Qiao L,Eye length,replication,2018-08-16,GCST006503,Other measurement,#99d594
6453,Asian,1504.0,30174134.0,Qiao L,Eye length,replication,2018-08-16,GCST006503,Other measurement,#3288bd
6454,Other/Mixed,694.0,30174134.0,Qiao L,Nasal root height,initial,2018-08-16,GCST006502,Other measurement,#99d594
6455,Other/Mixed,171.0,30174134.0,Qiao L,Nasal root height,replication,2018-08-16,GCST006502,Other measurement,#99d594
6456,Asian,1504.0,30174134.0,Qiao L,Nasal root height,replication,2018-08-16,GCST006502,Other measurement,#3288bd
6457,Asian,1504.0,30174134.0,Qiao L,Nasal root breadth,replication,2018-08-16,GCST006501,Other measurement,#3288bd
6458,Other/Mixed,694.0,30174134.0,Qiao L,Nasal root breadth,initial,2018-08-16,GCST006501,Other measurement,#99d594
6459,Other/Mixed,171.0,30174134.0,Qiao L,Nasal root breadth,replication,2018-08-16,GCST006501,Other measurement,#99d594
6460,Other/Mixed,171.0,30174134.0,Qiao L,Nosetip height,replication,2018-08-16,GCST006500,Other measurement,#99d594
6461,Asian,1504.0,30174134.0,Qiao L,Nosetip height,replication,2018-08-16,GCST006500,Other measurement,#3288bd
6462,Other/Mixed,694.0,30174134.0,Qiao L,Nosetip height,initial,2018-08-16,GCST006500,Other measurement,#99d594
6463,Other/Mixed,694.0,30174134.0,Qiao L,Nose length,initial,2018-08-16,GCST006499,Other measurement,#99d594
6464,Other/Mixed,171.0,30174134.0,Qiao L,Nose length,replication,2018-08-16,GCST006499,Other measurement,#99d594
6465,Asian,1504.0,30174134.0,Qiao L,Nose length,replication,2018-08-16,GCST006499,Other measurement,#3288bd
6467,European,456426.0,30124842.0,Yengo L,Height,initial,2018-08-16,GCST006901,Body measurement,#d53e4f
6468,European,177.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other disease,#d53e4f
6469,African Am./Caribbean,133.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other disease,#fee08b
6470,Hispanic/Latin American,42.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other disease,#807dba
6471,European,177.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other trait,#d53e4f
6472,African Am./Caribbean,133.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other trait,#fee08b
6473,Hispanic/Latin American,42.0,30113228.0,Torgerson DG,Bronchopulmonary dysplasia in preterm infants,initial,2018-08-16,GCST006460,Other trait,#807dba
6474,European,50264.0,30116032.0,Erlangsen A,Suicide attempts,initial,2018-08-16,GCST006419,Biological process,#d53e4f
6475,European,17596.0,30116032.0,Erlangsen A,Affective disorder and suicide attempts,initial,2018-08-16,GCST006420,Biological process,#d53e4f
6476,European,17596.0,30116032.0,Erlangsen A,Affective disorder and suicide attempts,initial,2018-08-16,GCST006420,Neurological disorder,#d53e4f
6477,Other/Mixed,694.0,30174134.0,Qiao L,Nose wing breadth,initial,2018-08-16,GCST006497,Other measurement,#99d594
6478,Other/Mixed,171.0,30174134.0,Qiao L,Nose wing breadth,replication,2018-08-16,GCST006497,Other measurement,#99d594
6479,Asian,1504.0,30174134.0,Qiao L,Nose wing breadth,replication,2018-08-16,GCST006497,Other measurement,#3288bd
6480,European,6861.0,30111768.0,Yao C,Blood protein levels,initial,2018-08-15,GCST007128,Other measurement,#d53e4f
6481,European,4298.0,30111768.0,Yao C,Blood protein levels,replication,2018-08-15,GCST007128,Other measurement,#d53e4f
6483,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Pulse rate,initial,2018-08-14,GCST007051,Cardiovascular measurement,#99d594
6484,European,330.0,30108209.0,Ganjgahi H,Brain imaging measurements,initial,2018-08-14,GCST006389,Other measurement,#d53e4f
6485,Other/Mixed,1176.0,30108155.0,Hebbar P,Triglyceride levels,replication,2018-08-14,GCST006436,Lipid or lipoprotein measurement,#99d594
6486,Other/Mixed,1353.0,30108155.0,Hebbar P,Triglyceride levels,initial,2018-08-14,GCST006436,Lipid or lipoprotein measurement,#99d594
6487,European,71500.0,30120083.0,Ferguson A,Disrupted circadian rhythm (low relative amplitude of rest-activity cycles),initial,2018-08-14,GCST006396,Biological process,#d53e4f
6488,Asian,1822.0,30108127.0,Hoffmann TJ,Body mass index,replication,2018-08-14,GCST006368,Body measurement,#3288bd
6489,African,8261.0,30108127.0,Hoffmann TJ,Body mass index,replication,2018-08-14,GCST006368,Body measurement,#fc8d59
6490,Asian,9275.0,30108127.0,Hoffmann TJ,Body mass index,replication,2018-08-14,GCST006368,Body measurement,#3288bd
6491,European,431743.0,30108127.0,Hoffmann TJ,Body mass index,replication,2018-08-14,GCST006368,Body measurement,#d53e4f
6492,Asian,459.0,30108127.0,Hoffmann TJ,Body mass index,initial,2018-08-14,GCST006368,Body measurement,#3288bd
6493,African Am./Caribbean,3069.0,30108127.0,Hoffmann TJ,Body mass index,initial,2018-08-14,GCST006368,Body measurement,#fee08b
6494,Asian,7290.0,30108127.0,Hoffmann TJ,Body mass index,initial,2018-08-14,GCST006368,Body measurement,#3288bd
6495,European,315347.0,30108127.0,Hoffmann TJ,Body mass index,initial,2018-08-14,GCST006368,Body measurement,#d53e4f
6497,Hispanic/Latin American,8322.0,30108127.0,Hoffmann TJ,Body mass index,initial,2018-08-14,GCST006368,Body measurement,#807dba
6498,European,77440.0,30120083.0,Ferguson A,Relative amplitude of rest-activity cycles,initial,2018-08-14,GCST006397,Biological process,#d53e4f
6500,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Hip circumference,initial,2018-08-14,GCST007058,Body measurement,#99d594
6502,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Height,initial,2018-08-14,GCST007057,Body measurement,#99d594
6504,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Waist-hip ratio,initial,2018-08-14,GCST007056,Body measurement,#99d594
6506,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Waist circumference,initial,2018-08-14,GCST007055,Body measurement,#99d594
6508,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Weight,initial,2018-08-14,GCST007054,Body measurement,#99d594
6510,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Body mass index,initial,2018-08-14,GCST007053,Body measurement,#99d594
6511,Other/Mixed,901.0,30108283.0,Granot-Hershkovitz E,Lipoprotein (a) levels,initial,2018-08-14,GCST007052,Lipid or lipoprotein measurement,#99d594
6512,Other/Mixed,1176.0,30108155.0,Hebbar P,Total cholesterol levels,replication,2018-08-14,GCST006439,Lipid or lipoprotein measurement,#99d594
6513,Other/Mixed,1353.0,30108155.0,Hebbar P,Total cholesterol levels,initial,2018-08-14,GCST006439,Lipid or lipoprotein measurement,#99d594
6514,Other/Mixed,1176.0,30108155.0,Hebbar P,Low density lipoprotein cholesterol levels,replication,2018-08-14,GCST006437,Lipid or lipoprotein measurement,#99d594
6515,Other/Mixed,1353.0,30108155.0,Hebbar P,Low density lipoprotein cholesterol levels,initial,2018-08-14,GCST006437,Lipid or lipoprotein measurement,#99d594
6516,Other/Mixed,1176.0,30108155.0,Hebbar P,High density lipoprotein cholesterol levels,replication,2018-08-14,GCST006438,Lipid or lipoprotein measurement,#99d594
6517,Other/Mixed,1353.0,30108155.0,Hebbar P,High density lipoprotein cholesterol levels,initial,2018-08-14,GCST006438,Lipid or lipoprotein measurement,#99d594
6518,European,8669.0,30104567.0,Ji X,Lung cancer in ever smokers,initial,2018-08-13,GCST006400,Other measurement,#d53e4f
6519,European,26271.0,30104567.0,Ji X,Lung cancer in ever smokers,replication,2018-08-13,GCST006400,Other measurement,#d53e4f
6520,European,8669.0,30104567.0,Ji X,Lung cancer in ever smokers,initial,2018-08-13,GCST006400,Cancer,#d53e4f
6521,European,26271.0,30104567.0,Ji X,Lung cancer in ever smokers,replication,2018-08-13,GCST006400,Cancer,#d53e4f
6522,European,387318.0,30104761.0,Zhou W,Colorectal cancer,initial,2018-08-13,GCST008372,Cancer,#d53e4f
6523,European,402223.0,30104761.0,Zhou W,Glaucoma,initial,2018-08-13,GCST008373,Neurological disorder,#d53e4f
6524,European,408458.0,30104761.0,Zhou W,Coronary artery disease,initial,2018-08-13,GCST008370,Cardiovascular disease,#d53e4f
6525,European,759.0,30104601.0,Ren H,Anhedonia in major depressive disorder,initial,2018-08-13,GCST006927,Neurological disorder,#d53e4f
6527,European,759.0,30104601.0,Ren H,Anhedonia in major depressive disorder,initial,2018-08-13,GCST006927,Other measurement,#d53e4f
6529,European,407757.0,30104761.0,Zhou W,Thyroid cancer,initial,2018-08-13,GCST008371,Cancer,#d53e4f
6530,European,368.0,30102696.0,Chen Y,Biliary atresia,replication,2018-08-13,GCST006390,Digestive system disorder,#d53e4f
6531,European,2059.0,30102696.0,Chen Y,Biliary atresia,initial,2018-08-13,GCST006390,Digestive system disorder,#d53e4f
6532,European,10473.0,30104567.0,Ji X,Lung cancer,initial,2018-08-13,GCST006399,Cancer,#d53e4f
6533,European,32465.0,30104567.0,Ji X,Lung cancer,replication,2018-08-13,GCST006399,Cancer,#d53e4f
6534,European,444.0,30103242.0,Karhausen JA,Thrombocytopenia in coronary artery bypass surgery,initial,2018-08-13,GCST006435,Other trait,#d53e4f
6535,European,164.0,30103242.0,Karhausen JA,Thrombocytopenia in coronary artery bypass surgery,initial,2018-08-13,GCST006435,Other trait,#d53e4f
6536,European,444.0,30103242.0,Karhausen JA,Thrombocytopenia in coronary artery bypass surgery,initial,2018-08-13,GCST006435,Other trait,#d53e4f
6537,European,164.0,30103242.0,Karhausen JA,Thrombocytopenia in coronary artery bypass surgery,initial,2018-08-13,GCST006435,Other trait,#d53e4f
6538,European,10473.0,30104567.0,Ji X,Lung cancer (SNP x SNP interaction),initial,2018-08-13,GCST006398,Cancer,#d53e4f
6539,Asian,2036.0,30102679.0,Hara M,Leisure-time exercise behaviour,initial,2018-08-10,GCST006857,Biological process,#3288bd
6540,Asian,13980.0,30102679.0,Hara M,Leisure-time exercise behaviour,initial,2018-08-10,GCST006857,Biological process,#3288bd
6541,Asian,2036.0,30102679.0,Hara M,Leisure-time exercise behaviour (age-stratified),initial,2018-08-10,GCST006858,Biological process,#3288bd
6542,Asian,13980.0,30102679.0,Hara M,Leisure-time exercise behaviour (age-stratified),initial,2018-08-10,GCST006858,Biological process,#3288bd
6543,European,54884.0,30093612.0,O'Mara TA,Endometrial cancer (endometrioid histology),initial,2018-08-09,GCST006465,Cancer,#d53e4f
6544,European,121885.0,30093612.0,O'Mara TA,Endometrial cancer,initial,2018-08-09,GCST006464,Cancer,#d53e4f
6545,European,2079.0,30093639.0,Machiela MJ,Ewing sarcoma,initial,2018-08-09,GCST006467,Cancer,#d53e4f
6546,European,4735.0,30093639.0,Machiela MJ,Ewing sarcoma,replication,2018-08-09,GCST006467,Cancer,#d53e4f
6549,European,36677.0,30093612.0,O'Mara TA,Endometrial cancer (Non-endometrioid histology),initial,2018-08-09,GCST006466,Cancer,#d53e4f
6550,European,12308.0,30089514.0,Chen JA,Progressive supranuclear palsy,initial,2018-08-08,GCST006418,Neurological disorder,#d53e4f
6551,European,98.0,30087447.0,Aubart M,Severe aortic features in Marfan syndrome,initial,2018-08-07,GCST006957,Neurological disorder,#d53e4f
6552,European,98.0,30087447.0,Aubart M,Severe aortic features in Marfan syndrome,initial,2018-08-07,GCST006957,Cardiovascular disease,#d53e4f
6553,European,24196.0,30087453.0,Yilmaz Z,Anorexia nervosa or obsessive-compulsive disorder,initial,2018-08-07,GCST006576,Metabolic disorder,#d53e4f
6554,European,24196.0,30087453.0,Yilmaz Z,Anorexia nervosa or obsessive-compulsive disorder,initial,2018-08-07,GCST006576,Neurological disorder,#d53e4f
6555,African Am./Caribbean,24.0,30092369.0,Mainali B,Infection persistence (>18 months) in genital human papillomavirus 16 infection,initial,2018-08-06,GCST008308,Other disease,#fee08b
6556,European,90.0,30092369.0,Mainali B,Infection persistence (>18 months) in genital human papillomavirus 16 infection,initial,2018-08-06,GCST008308,Other disease,#d53e4f
6557,Hispanic/Latin American,77.0,30092369.0,Mainali B,Infection persistence (>18 months) in genital human papillomavirus 16 infection,initial,2018-08-06,GCST008308,Other disease,#807dba
6558,Asian,5081.0,30099483.0,Hwangbo Y,Thyroid nodules,replication,2018-08-06,GCST006387,Other disease,#3288bd
6559,Asian,1502.0,30099483.0,Hwangbo Y,Thyroid nodules,initial,2018-08-06,GCST006387,Other disease,#3288bd
6560,European,3200.0,30072576.0,Emilsson V,Blood protein levels,initial,2018-08-02,GCST006585,Other measurement,#d53e4f
6561,European,18770.0,30071075.0,Jiang L,Energy intake,initial,2018-08-02,GCST006402,Other measurement,#d53e4f
6562,European,4098.0,30073298.0,Schellevis RL,Chronic central serous retinopathy,initial,2018-08-02,GCST006416,Neurological disorder,#d53e4f
6563,European,3126.0,30070759.0,Olsson M,Plasma factor VII activating protease levels,initial,2018-08-02,GCST006417,Other measurement,#d53e4f
6564,European,18770.0,30071075.0,Jiang L,Energy expenditure,initial,2018-08-02,GCST006403,Other measurement,#d53e4f
6565,European,830.0,30196823.0,Blum S,Guillain-Barré syndrome,initial,2018-08-02,GCST006836,Immune system disorder,#d53e4f
6566,European,1645.0,30068317.0,Li X,Post bronchodilator percent predicted FEV1 in smoking,initial,2018-08-01,GCST006309,Biological process,#d53e4f
6567,European,1645.0,30068317.0,Li X,Post bronchodilator percent predicted FEV1 in smoking,initial,2018-08-01,GCST006309,Other measurement,#d53e4f
6568,European,5293.0,30369316.0,Low-Kam C,Cholesterol efflux capacity (BHK stimulated assay),initial,2018-08-01,GCST007117,Lipid or lipoprotein measurement,#d53e4f
6569,European,5293.0,30369316.0,Low-Kam C,Cholesterol efflux capacity (ABCA-1 dependent assay),initial,2018-08-01,GCST007116,Lipid or lipoprotein measurement,#d53e4f
6570,European,5293.0,30369316.0,Low-Kam C,Cholesterol efflux capacity (cAMP stimulated assay),initial,2018-08-01,GCST007115,Lipid or lipoprotein measurement,#d53e4f
6571,European,5293.0,30369316.0,Low-Kam C,Cholesterol efflux capacity,initial,2018-08-01,GCST007114,Lipid or lipoprotein measurement,#d53e4f
6572,European,1645.0,30068317.0,Li X,Post bronchodilator FEV1/FVC ratio in smoking,initial,2018-08-01,GCST006310,Biological process,#d53e4f
6573,European,1645.0,30068317.0,Li X,Post bronchodilator FEV1/FVC ratio in smoking,initial,2018-08-01,GCST006310,Other measurement,#d53e4f
6575,European,2270.0,30067744.0,Howe LJ,Nonsyndromic cleft lip with or without cleft palate,initial,2018-08-01,GCST006415,Other trait,#d53e4f
6577,European,2270.0,30067744.0,Howe LJ,Nonsyndromic cleft lip with or without cleft palate,initial,2018-08-01,GCST006415,Other trait,#d53e4f
6578,Asian,447.0,30067105.0,Chang LC,Adverse response to antithyroid drugs in Graves disease,initial,2018-08-01,GCST006278,Immune system disorder,#3288bd
6579,Asian,182.0,30067105.0,Chang LC,Adverse response to antithyroid drugs in Graves disease,replication,2018-08-01,GCST006278,Immune system disorder,#3288bd
6580,Asian,447.0,30067105.0,Chang LC,Adverse response to antithyroid drugs in Graves disease,initial,2018-08-01,GCST006278,Response to drug,#3288bd
6581,Asian,182.0,30067105.0,Chang LC,Adverse response to antithyroid drugs in Graves disease,replication,2018-08-01,GCST006278,Response to drug,#3288bd
6582,European,6136.0,30067744.0,Howe LJ,Philtrum width,initial,2018-08-01,GCST006407,Other measurement,#d53e4f
6583,European,497.0,30066433.0,Jabbari E,Non-Richardson's syndrome vs Richardson's syndrome in progressive supranuclear palsy,initial,2018-07-31,GCST006276,Neurological disorder,#d53e4f
6584,European,60552.0,30061609.0,Wyss AB,Lung function (FEV1),initial,2018-07-30,GCST006481,Other measurement,#d53e4f
6585,African,8429.0,30061609.0,Wyss AB,Lung function (FEV1),initial,2018-07-30,GCST006481,Other measurement,#fc8d59
6586,Hispanic/Latin American,11775.0,30061609.0,Wyss AB,Lung function (FEV1),initial,2018-07-30,GCST006481,Other measurement,#807dba
6587,Asian,9959.0,30061609.0,Wyss AB,Lung function (FEV1),initial,2018-07-30,GCST006481,Other measurement,#3288bd
6588,European,60552.0,30061609.0,Wyss AB,Lung function (FVC),initial,2018-07-30,GCST006483,Other measurement,#d53e4f
6589,African,8429.0,30061609.0,Wyss AB,Lung function (FVC),initial,2018-07-30,GCST006483,Other measurement,#fc8d59
6590,Asian,9959.0,30061609.0,Wyss AB,Lung function (FVC),initial,2018-07-30,GCST006483,Other measurement,#3288bd
6591,Hispanic/Latin American,11775.0,30061609.0,Wyss AB,Lung function (FVC),initial,2018-07-30,GCST006483,Other measurement,#807dba
6592,European,1030836.0,30061737.0,Nielsen JB,Atrial fibrillation,initial,2018-07-30,GCST006414,Cardiovascular disease,#d53e4f
6593,European,60552.0,30061609.0,Wyss AB,Lung function (FEV1/FVC),initial,2018-07-30,GCST006482,Other measurement,#d53e4f
6594,African,8429.0,30061609.0,Wyss AB,Lung function (FEV1/FVC),initial,2018-07-30,GCST006482,Other measurement,#fc8d59
6595,Hispanic/Latin American,11775.0,30061609.0,Wyss AB,Lung function (FEV1/FVC),initial,2018-07-30,GCST006482,Other measurement,#807dba
6596,Asian,9959.0,30061609.0,Wyss AB,Lung function (FEV1/FVC),initial,2018-07-30,GCST006482,Other measurement,#3288bd
6597,Asian,485.0,30054556.0,Akiyama M,Response to ranibizumab in age-related macular degeneration (exudative),replication,2018-07-27,GCST006277,Response to drug,#3288bd
6598,Asian,434.0,30054556.0,Akiyama M,Response to ranibizumab in age-related macular degeneration (exudative),initial,2018-07-27,GCST006277,Response to drug,#3288bd
6599,Asian,485.0,30054556.0,Akiyama M,Response to ranibizumab in age-related macular degeneration (exudative),replication,2018-07-27,GCST006277,Neurological disorder,#3288bd
6600,Asian,434.0,30054556.0,Akiyama M,Response to ranibizumab in age-related macular degeneration (exudative),initial,2018-07-27,GCST006277,Neurological disorder,#3288bd
6601,Asian,344.0,30060048.0,Wang SC,Methadone dose in opioid dependence,initial,2018-07-27,GCST006856,Neurological disorder,#3288bd
6602,Asian,344.0,30060048.0,Wang SC,Methadone dose in opioid dependence,initial,2018-07-27,GCST006856,Other measurement,#3288bd
6603,European,455607.0,30054458.0,Xue A,Type 2 diabetes,initial,2018-07-27,GCST006868,Metabolic disorder,#d53e4f
6604,European,15.0,30053915.0,Scepanovic P,Anti-hepatitis B virus core antigen (HBc) IgG levels,initial,2018-07-27,GCST006355,Other measurement,#d53e4f
6605,European,508.0,30053915.0,Scepanovic P,Anti-hepatitis B virus surface antigen (HBs) IgG levels,initial,2018-07-27,GCST006354,Other measurement,#d53e4f
6606,European,935.0,30053915.0,Scepanovic P,Anti-rubella virus IgG levels,initial,2018-07-27,GCST006353,Other measurement,#d53e4f
6607,European,912.0,30053915.0,Scepanovic P,Anti-mumps virus IgG levels,initial,2018-07-27,GCST006352,Other measurement,#d53e4f
6608,European,885.0,30053915.0,Scepanovic P,Anti-measles virus IgG levels,initial,2018-07-27,GCST006351,Other measurement,#d53e4f
6609,European,777.0,30053915.0,Scepanovic P,Anti-influenza A virus IgG levels,initial,2018-07-27,GCST006350,Other measurement,#d53e4f
6610,European,559.0,30053915.0,Scepanovic P,Anti-Toxoplasma gondii IgG levels,initial,2018-07-27,GCST006349,Other measurement,#d53e4f
6611,European,175.0,30053915.0,Scepanovic P,Anti-Helicobacter pylori IgG levels,initial,2018-07-27,GCST006363,Other measurement,#d53e4f
6612,European,931.0,30053915.0,Scepanovic P,Anti-varicella zoster virus IgG levels,initial,2018-07-27,GCST006348,Other measurement,#d53e4f
6613,European,208.0,30053915.0,Scepanovic P,Anti-herpes simplex virus 2 IgG levels,initial,2018-07-27,GCST006347,Other measurement,#d53e4f
6614,European,645.0,30053915.0,Scepanovic P,Anti-herpes simplex virus 1 IgG levels,initial,2018-07-27,GCST006346,Other measurement,#d53e4f
6615,European,91.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus early antigen (EA) IgG levels,initial,2018-07-27,GCST006345,Other measurement,#d53e4f
6616,European,956.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG levels,initial,2018-07-27,GCST006362,Other measurement,#d53e4f
6617,European,914.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG levels,initial,2018-07-27,GCST006361,Other measurement,#d53e4f
6618,European,347.0,30053915.0,Scepanovic P,Anti-cytomegalovirus IgG levels,initial,2018-07-27,GCST006344,Other measurement,#d53e4f
6619,European,1000.0,30053915.0,Scepanovic P,IgE levels,initial,2018-07-27,GCST006358,Other measurement,#d53e4f
6620,European,1000.0,30053915.0,Scepanovic P,IgA levels,initial,2018-07-27,GCST006360,Other measurement,#d53e4f
6621,European,1000.0,30053915.0,Scepanovic P,IgM levels,initial,2018-07-27,GCST006359,Other measurement,#d53e4f
6622,European,1000.0,30053915.0,Scepanovic P,IgG levels,initial,2018-07-27,GCST006357,Other measurement,#d53e4f
6623,European,1000.0,30053915.0,Scepanovic P,Anti-hepatitis B virus core antigen (HBc) IgG seropositivity,initial,2018-07-27,GCST006343,Other measurement,#d53e4f
6624,European,1000.0,30053915.0,Scepanovic P,Anti-hepatitis B virus surface antigen (HBs) IgG seropositivity,initial,2018-07-27,GCST006356,Other measurement,#d53e4f
6625,European,1000.0,30053915.0,Scepanovic P,Anti-rubella virus IgG seropositivity,initial,2018-07-27,GCST006342,Other measurement,#d53e4f
6626,European,1000.0,30053915.0,Scepanovic P,Anti-mumps virus IgG seropositivity,initial,2018-07-27,GCST006341,Other measurement,#d53e4f
6627,European,1000.0,30053915.0,Scepanovic P,Anti-measles virus IgG seropositivity,initial,2018-07-27,GCST006340,Other measurement,#d53e4f
6628,European,1000.0,30053915.0,Scepanovic P,Anti-influenza A virus IgG seropositivity,initial,2018-07-27,GCST006339,Other measurement,#d53e4f
6629,European,1000.0,30053915.0,Scepanovic P,Anti-Toxoplasma gondii IgG seropositivity,initial,2018-07-27,GCST006338,Other measurement,#d53e4f
6630,European,1000.0,30053915.0,Scepanovic P,Anti-Helicobacter pylori IgG seropositivity,initial,2018-07-27,GCST006337,Other measurement,#d53e4f
6631,European,1000.0,30053915.0,Scepanovic P,Anti-varicella zoster virus IgG seropositivity,initial,2018-07-27,GCST006336,Other measurement,#d53e4f
6632,European,1000.0,30053915.0,Scepanovic P,Anti-herpes simplex virus 2 IgG seropositivity,initial,2018-07-27,GCST006335,Other measurement,#d53e4f
6633,European,1000.0,30053915.0,Scepanovic P,Anti-herpes simplex virus 1 IgG seropositivity,initial,2018-07-27,GCST006334,Other measurement,#d53e4f
6634,European,1000.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus early antigen (EA) IgG seropositivity,initial,2018-07-27,GCST006330,Other measurement,#d53e4f
6635,European,1000.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus viral capsid antigen (VCA) IgG seropositivity,initial,2018-07-27,GCST006333,Other measurement,#d53e4f
6636,European,1000.0,30053915.0,Scepanovic P,Anti-Epstein-Barr virus nuclear antigen (EBNA) IgG seropositivity,initial,2018-07-27,GCST006332,Other measurement,#d53e4f
6637,European,137086.0,30054594.0,MacGregor S,Glaucoma,initial,2018-07-27,GCST006395,Neurological disorder,#d53e4f
6638,European,1000.0,30053915.0,Scepanovic P,Anti-cytomegalovirus IgG seropositivity,initial,2018-07-27,GCST006331,Other measurement,#d53e4f
6639,European,133492.0,30054594.0,MacGregor S,Intraocular pressure,initial,2018-07-27,GCST006394,Other measurement,#d53e4f
6640,European,655666.0,30054458.0,Xue A,Type 2 diabetes,initial,2018-07-27,GCST006867,Metabolic disorder,#d53e4f
6641,Asian,3650.0,30054458.0,Xue A,Type 2 diabetes,initial,2018-07-27,GCST006867,Metabolic disorder,#3288bd
6642,European,394929.0,30048462.0,Kim SK,Heel bone mineral density,initial,2018-07-26,GCST006433,Other measurement,#d53e4f
6643,European,8372.0,30049742.0,Terzikhan N,Diffusing capacity of the lung for carbon monoxide traits,initial,2018-07-26,GCST006473,Other measurement,#d53e4f
6644,European,92340.0,30046033.0,van Setten J,PR interval,initial,2018-07-25,GCST007045,Cardiovascular measurement,#d53e4f
6645,European,1131881.0,30038396.0,Lee JJ,Educational attainment (years of education),initial,2018-07-23,GCST006442,Other measurement,#d53e4f
6646,European,811539.0,30038396.0,Lee JJ,Highest math class taken (MTAG),initial,2018-07-23,GCST006568,Biological process,#d53e4f
6647,European,430445.0,30038396.0,Lee JJ,Highest math class taken,initial,2018-07-23,GCST006574,Biological process,#d53e4f
6648,European,670471.0,30038396.0,Lee JJ,Self-reported math ability (MTAG),initial,2018-07-23,GCST006569,Biological process,#d53e4f
6649,European,564698.0,30038396.0,Lee JJ,Self-reported math ability,initial,2018-07-23,GCST006573,Biological process,#d53e4f
6650,European,402382.0,30038396.0,Lee JJ,Cognitive performance (MTAG),initial,2018-07-23,GCST006570,Other measurement,#d53e4f
6651,European,257841.0,30038396.0,Lee JJ,Cognitive performance,initial,2018-07-23,GCST006572,Other measurement,#d53e4f
6652,European,1131438.0,30038396.0,Lee JJ,Educational attainment (MTAG),initial,2018-07-23,GCST006571,Other measurement,#d53e4f
6653,European,2740.0,30079052.0,Rujescu D,Vestibular neuritis,initial,2018-07-20,GCST006275,Neurological disorder,#d53e4f
6654,European,331.0,30031151.0,Virtanen VB,Hirschsprung disease,replication,2018-07-18,GCST006272,Digestive system disorder,#d53e4f
6655,European,491.0,30031151.0,Virtanen VB,Hirschsprung disease,initial,2018-07-18,GCST006272,Digestive system disorder,#d53e4f
6656,European,454.0,30031151.0,Virtanen VB,Hirschsprung disease,initial,2018-07-18,GCST006271,Digestive system disorder,#d53e4f
6657,African Am./Caribbean,7695.0,30012220.0,Prins BP,QRS duration,initial,2018-07-17,GCST007104,Cardiovascular measurement,#fee08b
6658,European,77898.0,30012220.0,Prins BP,QRS duration,initial,2018-07-17,GCST007104,Cardiovascular measurement,#d53e4f
6659,European,111874.0,30012220.0,Prins BP,QRS duration,replication,2018-07-17,GCST007104,Cardiovascular measurement,#d53e4f
6660,African Am./Caribbean,7695.0,30012220.0,Prins BP,QRS duration,initial,2018-07-17,GCST007105,Cardiovascular measurement,#fee08b
6661,European,77898.0,30012220.0,Prins BP,QRS duration,initial,2018-07-17,GCST007103,Cardiovascular measurement,#d53e4f
6662,European,732.0,30145303.0,Kimbrel NA,Suicide attempts,initial,2018-07-17,GCST006428,Biological process,#d53e4f
6665,European,733.0,30145303.0,Kimbrel NA,Suicidal ideation,initial,2018-07-17,GCST006429,Biological process,#d53e4f
6667,European,31.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,replication,2018-07-16,GCST006270,Immune system disorder,#d53e4f
6668,European,151.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,initial,2018-07-16,GCST006270,Immune system disorder,#d53e4f
6669,European,31.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,replication,2018-07-16,GCST006270,Response to drug,#d53e4f
6670,European,151.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,initial,2018-07-16,GCST006270,Response to drug,#d53e4f
6671,European,31.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,replication,2018-07-16,GCST006270,Digestive system disorder,#d53e4f
6672,European,151.0,30013178.0,Kowalec K,Drug-induced liver injury in interferon-beta-treated multiple sclerosis,initial,2018-07-16,GCST006270,Digestive system disorder,#d53e4f
6675,European,243.0,30014611.0,Weiss RB,Age at loss of ambulation in Duchenne muscular dystrophy,initial,2018-07-16,GCST006286,Neurological disorder,#d53e4f
6677,European,243.0,30014611.0,Weiss RB,Age at loss of ambulation in Duchenne muscular dystrophy,initial,2018-07-16,GCST006286,Other measurement,#d53e4f
6679,Asian,636.0,30012571.0,Jia X,Childhood steroid-sensitive nephrotic syndrome,initial,2018-07-16,GCST006246,Other disease,#3288bd
6680,Asian,935.0,30012571.0,Jia X,Childhood steroid-sensitive nephrotic syndrome,initial,2018-07-16,GCST006246,Other disease,#3288bd
6685,European,3735.0,30003630.0,Minica CC,Cannabis use (age at onset),replication,2018-07-13,GCST006386,Biological process,#d53e4f
6686,European,24953.0,30003630.0,Minica CC,Cannabis use (age at onset),initial,2018-07-13,GCST006386,Biological process,#d53e4f
6687,European,3735.0,30003630.0,Minica CC,Cannabis use (age at onset),replication,2018-07-13,GCST006386,Other measurement,#d53e4f
6688,European,24953.0,30003630.0,Minica CC,Cannabis use (age at onset),initial,2018-07-13,GCST006386,Other measurement,#d53e4f
6689,European,15666.0,30003307.0,Fall T,Coronary artery disease in diabetes,initial,2018-07-12,GCST006405,Metabolic disorder,#d53e4f
6690,European,15666.0,30003307.0,Fall T,Coronary artery disease in diabetes,initial,2018-07-12,GCST006405,Cardiovascular disease,#d53e4f
6691,European,177315.0,29988085.0,Merino J,Dietary macronutrient intake,replication,2018-07-09,GCST006388,Biological process,#d53e4f
6692,European,91114.0,29988085.0,Merino J,Dietary macronutrient intake,initial,2018-07-09,GCST006388,Biological process,#d53e4f
6693,European,1053.0,30289108.0,Li W,Prostate cancer mortality,initial,2018-07-07,GCST008493,Other measurement,#d53e4f
6694,European,1552.0,30289108.0,Li W,Prostate cancer mortality,replication,2018-07-07,GCST008493,Other measurement,#d53e4f
6695,European,1053.0,30289108.0,Li W,Prostate cancer mortality,initial,2018-07-07,GCST008493,Cancer,#d53e4f
6696,European,1552.0,30289108.0,Li W,Prostate cancer mortality,replication,2018-07-07,GCST008493,Cancer,#d53e4f
6697,Asian,421.0,30034349.0,Lin E,Response to selective serotonin reuptake inhibitors in depression,initial,2018-07-06,GCST006267,Neurological disorder,#3288bd
6698,Asian,421.0,30034349.0,Lin E,Response to selective serotonin reuptake inhibitors in depression,initial,2018-07-06,GCST006267,Response to drug,#3288bd
6699,Asian,421.0,30034349.0,Lin E,Remission after SSRI treatment in major depression,initial,2018-07-06,GCST006266,Neurological disorder,#3288bd
6700,Asian,421.0,30034349.0,Lin E,Remission after SSRI treatment in major depression,initial,2018-07-06,GCST006266,Response to drug,#3288bd
6701,European,434.0,29981864.0,Mohammadnejad A,Allergic rhinitis x sex interaction,initial,2018-07-05,GCST008138,Other measurement,#d53e4f
6702,European,434.0,29981864.0,Mohammadnejad A,Allergic rhinitis x sex interaction,initial,2018-07-05,GCST008138,Immune system disorder,#d53e4f
6703,Asian,200.0,29975729.0,Kim TH,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection,initial,2018-07-05,GCST006364,Other measurement,#3288bd
6704,Asian,200.0,29975729.0,Kim TH,Hepatitis B surface antigen seroclearance in chronic hepatitis B infection,initial,2018-07-05,GCST006364,Digestive system disorder,#3288bd
6705,European,204.0,29973135.0,Rimpela JM,Systolic blood pressure night-to-day ratio in hypertension,initial,2018-07-04,GCST006274,Cardiovascular disease,#d53e4f
6706,European,204.0,29973135.0,Rimpela JM,Systolic blood pressure night-to-day ratio in hypertension,initial,2018-07-04,GCST006274,Other measurement,#d53e4f
6707,European,204.0,29973135.0,Rimpela JM,Diastolic blood pressure night-to-day ratio in hypertension,initial,2018-07-04,GCST006273,Other measurement,#d53e4f
6708,European,204.0,29973135.0,Rimpela JM,Diastolic blood pressure night-to-day ratio in hypertension,initial,2018-07-04,GCST006273,Cardiovascular disease,#d53e4f
6709,European,445024.0,29970889.0,Day FR,Loneliness,initial,2018-07-03,GCST006923,Other measurement,#d53e4f
6710,Asian,1522.0,29970928.0,Zhu Z,Long-term memory (delayed word recall task),initial,2018-07-03,GCST006256,Other measurement,#3288bd
6711,Asian,1862.0,29970928.0,Zhu Z,Long-term memory (delayed word recall task),replication,2018-07-03,GCST006256,Other measurement,#3288bd
6712,European,487647.0,29970889.0,Day FR,Loneliness (MTAG),initial,2018-07-03,GCST006924,Other measurement,#d53e4f
6713,European,28599.0,29971594.0,Rosenberger A,Lung cancer x radon exposure interaction (1df),initial,2018-07-03,GCST006413,Cancer,#d53e4f
6714,European,28599.0,29971594.0,Rosenberger A,Lung cancer x radon exposure interaction (1df),initial,2018-07-03,GCST006413,Other measurement,#d53e4f
6715,Asian,2790.0,29970928.0,Zhu Z,Short-term memory (shared component of digit-span and visuospatial tasks),replication,2018-07-03,GCST006255,Other measurement,#3288bd
6716,Asian,1623.0,29970928.0,Zhu Z,Short-term memory (shared component of digit-span and visuospatial tasks),initial,2018-07-03,GCST006255,Other measurement,#3288bd
6717,Asian,1623.0,29970928.0,Zhu Z,Short-term memory (visuospatial task),initial,2018-07-03,GCST006254,Other measurement,#3288bd
6718,Asian,2790.0,29970928.0,Zhu Z,Short-term memory (visuospatial task),replication,2018-07-03,GCST006254,Other measurement,#3288bd
6719,Asian,1621.0,29970928.0,Zhu Z,Short-term memory (digit-span task),initial,2018-07-03,GCST006253,Other measurement,#3288bd
6720,Asian,2788.0,29970928.0,Zhu Z,Short-term memory (digit-span task),replication,2018-07-03,GCST006253,Other measurement,#3288bd
6721,European,452302.0,29970889.0,Day FR,Regular attendance at a religious group,initial,2018-07-03,GCST006922,Other measurement,#d53e4f
6722,European,452302.0,29970889.0,Day FR,Regular attendance at a pub or social club,initial,2018-07-03,GCST006921,Other measurement,#d53e4f
6723,European,452302.0,29970889.0,Day FR,Regular attendance at a gym or sports club,initial,2018-07-03,GCST006920,Other measurement,#d53e4f
6724,European,302567.0,29970889.0,Day FR,Ability to confide in someone,initial,2018-07-03,GCST006919,Other measurement,#d53e4f
6725,European,288950.0,29970889.0,Day FR,Social isolation,initial,2018-07-03,GCST006918,Other measurement,#d53e4f
6726,Asian,781.0,29967481.0,Joo YB,Childhood onset systemic lupus erythematosus,initial,2018-07-02,GCST006260,Other measurement,#3288bd
6727,Asian,781.0,29967481.0,Joo YB,Childhood onset systemic lupus erythematosus,initial,2018-07-02,GCST006260,Immune system disorder,#3288bd
6728,Asian,511.0,30004843.0,Ge S,Elevated fasting plasma glucose,initial,2018-07-01,GCST006257,Other measurement,#3288bd
6729,African Am./Caribbean,2589.0,30134085.0,Zhang H,Cognitive flexibility,initial,2018-07-01,GCST006406,Other measurement,#fee08b
6730,European,2284.0,30134085.0,Zhang H,Cognitive flexibility,initial,2018-07-01,GCST006406,Other measurement,#d53e4f
6731,Asian,8832.0,30045251.0,Lee MR,Body mass index,initial,2018-07-01,GCST006369,Body measurement,#3288bd
6732,Asian,13112.0,30304924.0,Kim HJ,Kawasaki disease,replication,2018-06-30,GCST006809,Immune system disorder,#3288bd
6733,Asian,1296.0,30304924.0,Kim HJ,Kawasaki disease,initial,2018-06-30,GCST006809,Immune system disorder,#3288bd
6734,European,209.0,29959729.0,Zhong XL,Cerebrospinal fluid α-synuclein levels,initial,2018-06-29,GCST006279,Other measurement,#d53e4f
6735,European,209.0,29959729.0,Zhong XL,Cerebrospinal fluid α-synuclein levels,initial,2018-06-29,GCST006279,Other measurement,#d53e4f
6736,Asian,100.0,30065583.0,Choi MR,Skin hydration,initial,2018-06-28,GCST006939,Other measurement,#3288bd
6738,European,688809.0,29942085.0,Nagel M,Depression,initial,2018-06-25,GCST006477,Neurological disorder,#d53e4f
6739,Asian,1999.0,29953918.0,Deng C,Serum folate levels,initial,2018-06-25,GCST006137,Other measurement,#3288bd
6740,European,269867.0,29942086.0,Savage JE,Intelligence,initial,2018-06-25,GCST006250,Biological process,#d53e4f
6741,European,449484.0,29942085.0,Nagel M,Neuroticism,initial,2018-06-25,GCST006476,Other measurement,#d53e4f
6742,European,348219.0,29942085.0,Nagel M,Worry,initial,2018-06-25,GCST006478,Other measurement,#d53e4f
6743,European,357957.0,29942085.0,Nagel M,Depressed affect,initial,2018-06-25,GCST006475,Neurological disorder,#d53e4f
6744,European,357957.0,29942085.0,Nagel M,Depressed affect,initial,2018-06-25,GCST006475,Neurological disorder,#d53e4f
6745,European,456426.0,29936532.0,Colodro-Conde L,Socioeconomic status of place of residence,initial,2018-06-23,GCST007422,Other measurement,#d53e4f
6746,European,504130.0,29936532.0,Colodro-Conde L,Population density of place of residence,initial,2018-06-23,GCST007421,Other measurement,#d53e4f
6747,European,172.0,29934777.0,Witten A,Heparin-induced thrombocytopenia,initial,2018-06-22,GCST006144,Response to drug,#d53e4f
6748,European,192.0,29934777.0,Witten A,Heparin-induced thrombocytopenia,initial,2018-06-22,GCST006144,Response to drug,#d53e4f
6749,European,172.0,29934777.0,Witten A,Heparin-induced thrombocytopenia,initial,2018-06-22,GCST006144,Other trait,#d53e4f
6750,European,192.0,29934777.0,Witten A,Heparin-induced thrombocytopenia,initial,2018-06-22,GCST006144,Other trait,#d53e4f
6752,European,17037.0,29931343.0,Haworth S,Childhood dental caries in primary teeth,initial,2018-06-20,GCST006312,Digestive system disorder,#d53e4f
6753,European,13353.0,29931343.0,Haworth S,Childhood dental caries in permanent teeth,initial,2018-06-20,GCST006311,Digestive system disorder,#d53e4f
6754,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006200,Other trait,#3288bd
6755,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006200,Response to drug,#3288bd
6756,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006200,Digestive system disorder,#3288bd
6757,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006199,Other disease,#3288bd
6758,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006199,Response to drug,#3288bd
6759,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006199,Digestive system disorder,#3288bd
6760,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006215,Other trait,#3288bd
6761,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006215,Response to drug,#3288bd
6762,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006215,Digestive system disorder,#3288bd
6763,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006214,Other disease,#3288bd
6764,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006214,Response to drug,#3288bd
6765,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006214,Digestive system disorder,#3288bd
6766,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced skin symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006213,Other disease,#3288bd
6767,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced skin symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006213,Response to drug,#3288bd
6768,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced skin symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006213,Digestive system disorder,#3288bd
6769,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced liver dysfunction in inflammatory bowel disease,initial,2018-06-19,GCST006212,Response to drug,#3288bd
6770,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced liver dysfunction in inflammatory bowel disease,initial,2018-06-19,GCST006212,Digestive system disorder,#3288bd
6771,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced liver dysfunction in inflammatory bowel disease,initial,2018-06-19,GCST006212,Digestive system disorder,#3288bd
6772,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced infection in inflammatory bowel disease,initial,2018-06-19,GCST006211,Response to drug,#3288bd
6773,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced infection in inflammatory bowel disease,initial,2018-06-19,GCST006211,Digestive system disorder,#3288bd
6774,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced infection in inflammatory bowel disease,initial,2018-06-19,GCST006211,Other measurement,#3288bd
6775,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced digestive symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006210,Other disease,#3288bd
6776,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced digestive symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006210,Response to drug,#3288bd
6777,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced digestive symptoms in inflammatory bowel disease,initial,2018-06-19,GCST006210,Digestive system disorder,#3288bd
6778,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced fever in inflammatory bowel disease,initial,2018-06-19,GCST006209,Other trait,#3288bd
6779,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced fever in inflammatory bowel disease,initial,2018-06-19,GCST006209,Response to drug,#3288bd
6780,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced fever in inflammatory bowel disease,initial,2018-06-19,GCST006209,Digestive system disorder,#3288bd
6781,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced pancreatitis in inflammatory bowel disease,initial,2018-06-19,GCST006208,Digestive system disorder,#3288bd
6782,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced pancreatitis in inflammatory bowel disease,initial,2018-06-19,GCST006208,Response to drug,#3288bd
6783,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced pancreatitis in inflammatory bowel disease,initial,2018-06-19,GCST006208,Digestive system disorder,#3288bd
6784,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006207,Other disease,#3288bd
6785,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006207,Response to drug,#3288bd
6786,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006207,Digestive system disorder,#3288bd
6787,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006206,Other disease,#3288bd
6788,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006206,Response to drug,#3288bd
6789,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced alopecia in inflammatory bowel disease,initial,2018-06-19,GCST006206,Digestive system disorder,#3288bd
6790,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006205,Other trait,#3288bd
6791,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006205,Response to drug,#3288bd
6792,Asian,1215.0,29923122.0,Kakuta Y,Thiopurine-induced acute severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006205,Digestive system disorder,#3288bd
6793,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006204,Other trait,#3288bd
6794,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006204,Response to drug,#3288bd
6795,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced severe leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006204,Digestive system disorder,#3288bd
6796,Asian,5634.0,29921221.0,Cha S,Upper eyelid morphology,initial,2018-06-19,GCST006107,Other measurement,#3288bd
6797,Asian,1926.0,29921221.0,Cha S,Upper eyelid morphology,replication,2018-06-19,GCST006107,Other measurement,#3288bd
6798,Asian,5634.0,29921221.0,Cha S,Lip morphology,initial,2018-06-19,GCST006109,Other measurement,#3288bd
6799,Asian,1926.0,29921221.0,Cha S,Lip morphology,replication,2018-06-19,GCST006109,Other measurement,#3288bd
6800,Asian,1940.0,29921221.0,Cha S,Nose morphology,replication,2018-06-19,GCST006110,Other measurement,#3288bd
6801,Asian,5634.0,29921221.0,Cha S,Nose morphology,initial,2018-06-19,GCST006110,Other measurement,#3288bd
6802,Asian,1926.0,29921221.0,Cha S,Eye morphology,replication,2018-06-19,GCST006105,Other measurement,#3288bd
6803,Asian,5634.0,29921221.0,Cha S,Eye morphology,initial,2018-06-19,GCST006105,Other measurement,#3288bd
6804,Asian,1926.0,29921221.0,Cha S,Forehead morphology,replication,2018-06-19,GCST006106,Other measurement,#3288bd
6805,Asian,5634.0,29921221.0,Cha S,Forehead morphology,initial,2018-06-19,GCST006106,Other measurement,#3288bd
6806,European,31930.0,29924316.0,Byun J,Familial squamous cell lung carcinoma,initial,2018-06-19,GCST006088,Cancer,#d53e4f
6807,European,31930.0,29924316.0,Byun J,Familial squamous cell lung carcinoma,initial,2018-06-19,GCST006088,Other measurement,#d53e4f
6808,European,32338.0,29924316.0,Byun J,Familial lung adenocarcinoma,initial,2018-06-19,GCST006087,Cancer,#d53e4f
6809,European,32338.0,29924316.0,Byun J,Familial lung adenocarcinoma,initial,2018-06-19,GCST006087,Other measurement,#d53e4f
6810,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006202,Other trait,#3288bd
6811,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006202,Response to drug,#3288bd
6812,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease (conditioned on rs116855232),initial,2018-06-19,GCST006202,Digestive system disorder,#3288bd
6813,European,35953.0,29924316.0,Byun J,Familial lung cancer,initial,2018-06-19,GCST006086,Cancer,#d53e4f
6814,European,35953.0,29924316.0,Byun J,Familial lung cancer,initial,2018-06-19,GCST006086,Other measurement,#d53e4f
6815,Asian,1926.0,29921221.0,Cha S,Facial morphology,replication,2018-06-19,GCST006108,Other trait,#3288bd
6816,Asian,5634.0,29921221.0,Cha S,Facial morphology,initial,2018-06-19,GCST006108,Other trait,#3288bd
6817,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006201,Other trait,#3288bd
6818,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006201,Response to drug,#3288bd
6819,Asian,1220.0,29923122.0,Kakuta Y,Thiopurine-induced leukopenia in inflammatory bowel disease,initial,2018-06-19,GCST006201,Digestive system disorder,#3288bd
6820,European,228.0,29915124.0,Marini S,Hematoma volume in lobar spontaneous intracerebral hemorrhage,initial,2018-06-18,GCST006139,Cardiovascular disease,#d53e4f
6821,European,71.0,29915124.0,Marini S,Hematoma volume in lobar spontaneous intracerebral hemorrhage,replication,2018-06-18,GCST006139,Cardiovascular disease,#d53e4f
6822,European,56705.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Cardiovascular measurement,#d53e4f
6823,African,9725.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Cardiovascular measurement,#fc8d59
6824,Asian,1789.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Cardiovascular measurement,#3288bd
6825,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Cardiovascular measurement,#807dba
6826,European,116835.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Cardiovascular measurement,#d53e4f
6827,Asian,306423.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Cardiovascular measurement,#3288bd
6828,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Cardiovascular measurement,#807dba
6829,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Cardiovascular measurement,#fee08b
6830,European,56705.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Other measurement,#d53e4f
6831,African,9725.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Other measurement,#fc8d59
6832,Asian,1789.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Other measurement,#3288bd
6833,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006171,Other measurement,#807dba
6834,European,116835.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Other measurement,#d53e4f
6835,Asian,306423.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Other measurement,#3288bd
6836,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Other measurement,#807dba
6837,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006171,Other measurement,#fee08b
6838,Hispanic/Latin American,13371.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Other measurement,#807dba
6839,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Other measurement,#fee08b
6840,European,281376.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Other measurement,#d53e4f
6841,Asian,141024.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Other measurement,#3288bd
6842,European,91099.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Other measurement,#d53e4f
6843,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Other measurement,#fee08b
6844,Asian,12365.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Other measurement,#3288bd
6845,Hispanic/Latin American,8471.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Other measurement,#807dba
6846,Hispanic/Latin American,13371.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Biological process,#807dba
6847,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Biological process,#fee08b
6848,European,281376.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Biological process,#d53e4f
6849,Asian,141024.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006166,Biological process,#3288bd
6850,European,91099.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Biological process,#d53e4f
6851,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Biological process,#fee08b
6852,Asian,12365.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Biological process,#3288bd
6853,Hispanic/Latin American,8471.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006166,Biological process,#807dba
6854,Asian,306423.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#3288bd
6855,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#fee08b
6856,European,116778.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#d53e4f
6857,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#807dba
6858,Asian,1789.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#3288bd
6859,African Am./Caribbean,9725.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#fee08b
6860,European,56705.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#d53e4f
6861,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#807dba
6862,Asian,306423.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#3288bd
6863,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#fee08b
6864,European,116778.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#d53e4f
6865,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#807dba
6866,Asian,1789.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#3288bd
6867,African Am./Caribbean,9725.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#fee08b
6868,European,56705.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006172,Other measurement,#d53e4f
6869,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006172,Other measurement,#807dba
6870,European,281311.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Other measurement,#d53e4f
6871,Hispanic/Latin American,8470.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Other measurement,#807dba
6872,Asian,12365.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Other measurement,#3288bd
6873,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Other measurement,#fee08b
6874,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Other measurement,#fee08b
6875,European,91110.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Other measurement,#d53e4f
6876,Asian,141023.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Other measurement,#3288bd
6877,Hispanic/Latin American,13371.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Other measurement,#807dba
6878,European,281311.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Biological process,#d53e4f
6879,Hispanic/Latin American,8470.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Biological process,#807dba
6880,Asian,12365.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Biological process,#3288bd
6881,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Biological process,#fee08b
6882,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Biological process,#fee08b
6883,European,91110.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006167,Biological process,#d53e4f
6884,Asian,141023.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Biological process,#3288bd
6885,Hispanic/Latin American,13371.0,29912962.0,Feitosa MF,Mean arterial pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006167,Biological process,#807dba
6886,Asian,141023.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Cardiovascular measurement,#3288bd
6887,European,91099.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Cardiovascular measurement,#d53e4f
6888,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Cardiovascular measurement,#fee08b
6889,Asian,12365.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Cardiovascular measurement,#3288bd
6890,Hispanic/Latin American,8470.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Cardiovascular measurement,#807dba
6891,European,281371.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Cardiovascular measurement,#d53e4f
6892,Hispanic/Latin American,13370.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Cardiovascular measurement,#807dba
6893,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Cardiovascular measurement,#fee08b
6894,Asian,141023.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Biological process,#3288bd
6895,European,91099.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Biological process,#d53e4f
6896,African Am./Caribbean,21416.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Biological process,#fee08b
6897,Asian,12365.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Biological process,#3288bd
6898,Hispanic/Latin American,8470.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006168,Biological process,#807dba
6899,European,281371.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Biological process,#d53e4f
6900,Hispanic/Latin American,13370.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Biological process,#807dba
6901,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Pulse pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006168,Biological process,#fee08b
6902,European,56705.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#d53e4f
6903,Asian,1789.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#3288bd
6904,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#807dba
6905,European,116784.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#d53e4f
6906,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#fee08b
6907,Asian,306423.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#3288bd
6908,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#807dba
6909,African Am./Caribbean,9565.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#fee08b
6910,European,56705.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#d53e4f
6911,Asian,1789.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#3288bd
6912,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#807dba
6913,European,116784.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#d53e4f
6914,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#fee08b
6915,Asian,306423.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006170,Other measurement,#3288bd
6916,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#807dba
6917,African Am./Caribbean,9565.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006170,Other measurement,#fee08b
6918,European,281318.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Other measurement,#d53e4f
6919,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Other measurement,#fee08b
6920,Asian,141026.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Other measurement,#3288bd
6921,Hispanic/Latin American,13377.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Other measurement,#807dba
6922,Hispanic/Latin American,8471.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Other measurement,#807dba
6923,Asian,12365.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Other measurement,#3288bd
6924,European,91102.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Other measurement,#d53e4f
6925,African Am./Caribbean,21417.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Other measurement,#fee08b
6926,European,281318.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Biological process,#d53e4f
6927,African Am./Caribbean,5041.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Biological process,#fee08b
6928,Asian,141026.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Biological process,#3288bd
6929,Hispanic/Latin American,13377.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),replication,2018-06-18,GCST006434,Biological process,#807dba
6930,Hispanic/Latin American,8471.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Biological process,#807dba
6931,Asian,12365.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Biological process,#3288bd
6932,European,91102.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Biological process,#d53e4f
6933,African Am./Caribbean,21417.0,29912962.0,Feitosa MF,Systolic blood pressure x alcohol consumption interaction (2df test),initial,2018-06-18,GCST006434,Biological process,#fee08b
6934,European,166.0,29915124.0,Marini S,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage,initial,2018-06-18,GCST006140,Cardiovascular disease,#d53e4f
6935,European,169.0,29915124.0,Marini S,Hematoma volume in non-lobar spontaneous intracerebral hemorrhage,replication,2018-06-18,GCST006140,Cardiovascular disease,#d53e4f
6936,European,56705.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#d53e4f
6937,Asian,1789.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#3288bd
6938,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#807dba
6939,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#fee08b
6940,European,116836.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#d53e4f
6941,Asian,306423.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#3288bd
6942,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#807dba
6943,African Am./Caribbean,9565.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#fee08b
6944,European,56705.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#d53e4f
6945,Asian,1789.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#3288bd
6946,Hispanic/Latin American,4812.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#807dba
6947,African Am./Caribbean,1062.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#fee08b
6948,European,116836.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#d53e4f
6949,Asian,306423.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#3288bd
6950,Hispanic/Latin American,535.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),replication,2018-06-18,GCST006169,Other measurement,#807dba
6951,African Am./Caribbean,9565.0,29912962.0,Feitosa MF,Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),initial,2018-06-18,GCST006169,Other measurement,#fee08b
6952,European,67812.0,29917119.0,Schmit SL,Colorectal cancer,initial,2018-06-16,GCST006131,Cancer,#d53e4f
6953,European,61335.0,29917119.0,Schmit SL,Colorectal cancer,replication,2018-06-16,GCST006131,Cancer,#d53e4f
6954,Hispanic/Latin American,5941.0,29917119.0,Schmit SL,Colorectal cancer,replication,2018-06-16,GCST006131,Cancer,#807dba
6955,Asian,21630.0,29917119.0,Schmit SL,Colorectal cancer,replication,2018-06-16,GCST006131,Cancer,#3288bd
6956,African Am./Caribbean,6597.0,29917119.0,Schmit SL,Colorectal cancer,initial,2018-06-16,GCST006131,Cancer,#fee08b
6957,Other/Mixed,346.0,29903748.0,Debiec H,Childhood steroid-sensitive nephrotic syndrome,initial,2018-06-14,GCST006252,Other disease,#99d594
6958,African,510.0,29903748.0,Debiec H,Childhood steroid-sensitive nephrotic syndrome,initial,2018-06-14,GCST006252,Other disease,#fc8d59
6959,European,2796.0,29903748.0,Debiec H,Childhood steroid-sensitive nephrotic syndrome,initial,2018-06-14,GCST006252,Other disease,#d53e4f
6960,European,1944.0,29898447.0,Alaraudanjoki VK,Erosive tooth wear (severe vs non-severe),initial,2018-06-13,GCST006218,Other measurement,#d53e4f
6961,European,1147.0,29898447.0,Alaraudanjoki VK,Erosive tooth wear (severe vs none or mild),initial,2018-06-13,GCST006226,Other measurement,#d53e4f
6962,European,505.0,29942513.0,Penney ME,Mucinous adenocarcinoma in colorectal cancer,initial,2018-06-13,GCST006411,Cancer,#d53e4f
6963,European,505.0,29942513.0,Penney ME,Mucinous adenocarcinoma in colorectal cancer,initial,2018-06-13,GCST006411,Cancer,#d53e4f
6964,European,91084.0,29899525.0,Klimentidis YC,Accelerometer-based physical activity measurement (average acceleration),initial,2018-06-13,GCST006099,Other measurement,#d53e4f
6965,European,350492.0,29899525.0,Klimentidis YC,Strenuous sports or other exercises,initial,2018-06-13,GCST006100,Other measurement,#d53e4f
6966,European,261055.0,29899525.0,Klimentidis YC,Vigorous physical activity,initial,2018-06-13,GCST006098,Other measurement,#d53e4f
6967,European,377234.0,29899525.0,Klimentidis YC,Moderate to vigorous physical activity levels,initial,2018-06-13,GCST006097,Other measurement,#d53e4f
6968,European,90667.0,29899525.0,Klimentidis YC,Accelerometer-based physical activity measurement (fraction of time with accelerations >425 milli-gravities),initial,2018-06-13,GCST006079,Other measurement,#d53e4f
6969,Other/Mixed,4.0,29907492.0,Nakahara S,Attention function,initial,2018-06-12,GCST006929,Other measurement,#99d594
6970,Other/Mixed,2.0,29907492.0,Nakahara S,Attention function,initial,2018-06-12,GCST006929,Other measurement,#99d594
6971,African Am./Caribbean,37.0,29907492.0,Nakahara S,Attention function,initial,2018-06-12,GCST006929,Other measurement,#fee08b
6972,Asian,28.0,29907492.0,Nakahara S,Attention function,initial,2018-06-12,GCST006929,Other measurement,#3288bd
6973,European,192.0,29907492.0,Nakahara S,Attention function,initial,2018-06-12,GCST006929,Other measurement,#d53e4f
6974,Asian,11253.0,29895819.0,Endo C,Age spots,initial,2018-06-12,GCST006096,Other measurement,#3288bd
6975,European,192.0,29907492.0,Nakahara S,Information processing speed,initial,2018-06-12,GCST006934,Biological process,#d53e4f
6976,African Am./Caribbean,37.0,29907492.0,Nakahara S,Information processing speed,initial,2018-06-12,GCST006934,Biological process,#fee08b
6977,Asian,28.0,29907492.0,Nakahara S,Information processing speed,initial,2018-06-12,GCST006934,Biological process,#3288bd
6978,Other/Mixed,4.0,29907492.0,Nakahara S,Information processing speed,initial,2018-06-12,GCST006934,Biological process,#99d594
6979,Other/Mixed,2.0,29907492.0,Nakahara S,Information processing speed,initial,2018-06-12,GCST006934,Biological process,#99d594
6980,Asian,4538.0,29895819.0,Endo C,Excessive sweating,initial,2018-06-12,GCST006090,Other trait,#3288bd
6981,Asian,11244.0,29895819.0,Endo C,Excessive hairiness,initial,2018-06-12,GCST006095,Other trait,#3288bd
6982,Asian,4878.0,29895819.0,Endo C,Straight vs curly hair,initial,2018-06-12,GCST006094,Other measurement,#3288bd
6983,Asian,3941.0,29895819.0,Endo C,Thick vs thin eyebrows,initial,2018-06-12,GCST006093,Other measurement,#3288bd
6984,Asian,5614.0,29895819.0,Endo C,Double-edged eyelids,initial,2018-06-12,GCST006092,Other measurement,#3288bd
6985,Asian,11182.0,29895819.0,Endo C,Freckles,initial,2018-06-12,GCST006091,Other trait,#3288bd
6986,Asian,28.0,29907492.0,Nakahara S,Cognitive function,initial,2018-06-12,GCST006933,Other measurement,#3288bd
6987,Other/Mixed,4.0,29907492.0,Nakahara S,Cognitive function,initial,2018-06-12,GCST006933,Other measurement,#99d594
6988,African Am./Caribbean,37.0,29907492.0,Nakahara S,Cognitive function,initial,2018-06-12,GCST006933,Other measurement,#fee08b
6989,Other/Mixed,2.0,29907492.0,Nakahara S,Cognitive function,initial,2018-06-12,GCST006933,Other measurement,#99d594
6990,European,192.0,29907492.0,Nakahara S,Cognitive function,initial,2018-06-12,GCST006933,Other measurement,#d53e4f
6991,Other/Mixed,4.0,29907492.0,Nakahara S,Reasoning,initial,2018-06-12,GCST006932,Biological process,#99d594
6992,Asian,28.0,29907492.0,Nakahara S,Reasoning,initial,2018-06-12,GCST006932,Biological process,#3288bd
6993,African Am./Caribbean,37.0,29907492.0,Nakahara S,Reasoning,initial,2018-06-12,GCST006932,Biological process,#fee08b
6994,Other/Mixed,2.0,29907492.0,Nakahara S,Reasoning,initial,2018-06-12,GCST006932,Biological process,#99d594
6995,European,192.0,29907492.0,Nakahara S,Reasoning,initial,2018-06-12,GCST006932,Biological process,#d53e4f
6996,Other/Mixed,2.0,29907492.0,Nakahara S,Visual memory,initial,2018-06-12,GCST006928,Other measurement,#99d594
6997,European,192.0,29907492.0,Nakahara S,Visual memory,initial,2018-06-12,GCST006928,Other measurement,#d53e4f
6998,Other/Mixed,4.0,29907492.0,Nakahara S,Visual memory,initial,2018-06-12,GCST006928,Other measurement,#99d594
6999,Asian,28.0,29907492.0,Nakahara S,Visual memory,initial,2018-06-12,GCST006928,Other measurement,#3288bd
7000,African Am./Caribbean,37.0,29907492.0,Nakahara S,Visual memory,initial,2018-06-12,GCST006928,Other measurement,#fee08b
7001,European,192.0,29907492.0,Nakahara S,Verbal memory,initial,2018-06-12,GCST006931,Other measurement,#d53e4f
7002,Other/Mixed,2.0,29907492.0,Nakahara S,Verbal memory,initial,2018-06-12,GCST006931,Other measurement,#99d594
7003,African Am./Caribbean,37.0,29907492.0,Nakahara S,Verbal memory,initial,2018-06-12,GCST006931,Other measurement,#fee08b
7004,Asian,28.0,29907492.0,Nakahara S,Verbal memory,initial,2018-06-12,GCST006931,Other measurement,#3288bd
7005,Other/Mixed,4.0,29907492.0,Nakahara S,Verbal memory,initial,2018-06-12,GCST006931,Other measurement,#99d594
7006,Other/Mixed,2.0,29907492.0,Nakahara S,Working memory,initial,2018-06-12,GCST006930,Biological process,#99d594
7007,African Am./Caribbean,37.0,29907492.0,Nakahara S,Working memory,initial,2018-06-12,GCST006930,Biological process,#fee08b
7008,Asian,28.0,29907492.0,Nakahara S,Working memory,initial,2018-06-12,GCST006930,Biological process,#3288bd
7009,European,192.0,29907492.0,Nakahara S,Working memory,initial,2018-06-12,GCST006930,Biological process,#d53e4f
7010,Other/Mixed,4.0,29907492.0,Nakahara S,Working memory,initial,2018-06-12,GCST006930,Biological process,#99d594
7011,Hispanic/Latin American,5022.0,29892015.0,Roselli C,Atrial fibrillation,initial,2018-06-11,GCST006061,Cardiovascular disease,#807dba
7012,African Am./Caribbean,8967.0,29892015.0,Roselli C,Atrial fibrillation,initial,2018-06-11,GCST006061,Cardiovascular disease,#fee08b
7013,Asian,36792.0,29892015.0,Roselli C,Atrial fibrillation,initial,2018-06-11,GCST006061,Cardiovascular disease,#3288bd
7014,European,537409.0,29892015.0,Roselli C,Atrial fibrillation,initial,2018-06-11,GCST006061,Cardiovascular disease,#d53e4f
7015,African,5103.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#fc8d59
7016,Other/Mixed,3571.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#99d594
7017,Asian,5120.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#3288bd
7018,European,214102.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#d53e4f
7019,Asian,5370.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#3288bd
7020,Hispanic/Latin American,5189.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#807dba
7021,African Am./Caribbean,1847.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006065,Neurological disorder,#fee08b
7022,European,140254.0,29892016.0,Schumacher FR,Prostate cancer,initial,2018-06-11,GCST006085,Cancer,#d53e4f
7023,European,1528.0,30134812.0,Chattopadhyay S,Monoclonal gammopathy of undetermined significance,initial,2018-06-11,GCST006917,Other disease,#d53e4f
7024,Hispanic/Latin American,5189.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006067,Neurological disorder,#807dba
7025,European,51901.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006067,Neurological disorder,#d53e4f
7026,Asian,4475.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006067,Neurological disorder,#3288bd
7027,African Am./Caribbean,1847.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006067,Neurological disorder,#fee08b
7028,European,162201.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006067,Neurological disorder,#d53e4f
7029,African,5103.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006067,Neurological disorder,#fc8d59
7030,Asian,5120.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006067,Neurological disorder,#3288bd
7031,Other/Mixed,3571.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006067,Neurological disorder,#99d594
7032,Asian,895.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006067,Neurological disorder,#3288bd
7033,Other/Mixed,3571.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006066,Neurological disorder,#99d594
7034,Asian,895.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006066,Neurological disorder,#3288bd
7035,African,5103.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006066,Neurological disorder,#fc8d59
7036,European,162201.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006066,Neurological disorder,#d53e4f
7037,African Am./Caribbean,1847.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006066,Neurological disorder,#fee08b
7038,Asian,4475.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006066,Neurological disorder,#3288bd
7039,Hispanic/Latin American,5189.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006066,Neurological disorder,#807dba
7040,European,51901.0,29891935.0,Choquet H,Glaucoma (primary open-angle),initial,2018-06-11,GCST006066,Neurological disorder,#d53e4f
7041,Asian,5120.0,29891935.0,Choquet H,Glaucoma (primary open-angle),replication,2018-06-11,GCST006066,Neurological disorder,#3288bd
7042,European,61978.0,29892016.0,Schumacher FR,Prostate cancer (Gleason score),initial,2018-06-11,GCST006084,Cancer,#d53e4f
7043,European,51244.0,29892016.0,Schumacher FR,Prostate cancer (early onset),initial,2018-06-11,GCST006089,Cancer,#d53e4f
7044,European,73475.0,29892016.0,Schumacher FR,Prostate cancer (advanced),initial,2018-06-11,GCST006083,Cancer,#d53e4f
7045,European,76581.0,29892016.0,Schumacher FR,Prostate cancer (advanced vs non-advanced),initial,2018-06-11,GCST006081,Cancer,#d53e4f
7046,European,58751.0,29892016.0,Schumacher FR,Prostate cancer aggressiveness (high vs low/intermediate),initial,2018-06-11,GCST006082,Cancer,#d53e4f
7047,European,25300.0,29892016.0,Schumacher FR,Prostate cancer aggressiveness (high vs low),initial,2018-06-11,GCST006080,Cancer,#d53e4f
7048,European,1043.0,29884837.0,Reyes-Gibby CC,Neuropathic pain in head and neck cancer,initial,2018-06-08,GCST005934,Cancer,#d53e4f
7049,European,1043.0,29884837.0,Reyes-Gibby CC,Neuropathic pain in head and neck cancer,initial,2018-06-08,GCST005934,Other trait,#d53e4f
7050,European,3301.0,29875488.0,Sun BB,Blood protein levels,initial,2018-06-06,GCST005806,Other measurement,#d53e4f
7051,African Am./Caribbean,4306.0,29885931.0,Langefeld CD,End-stage renal disease,initial,2018-06-06,GCST006814,Other disease,#fee08b
7052,African Am./Caribbean,89.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,replication,2018-06-06,GCST006175,Biological process,#fee08b
7053,European,2546.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,initial,2018-06-06,GCST006175,Biological process,#d53e4f
7054,African Am./Caribbean,3269.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,initial,2018-06-06,GCST006175,Biological process,#fee08b
7055,African Am./Caribbean,89.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,replication,2018-06-06,GCST006175,Biological process,#fee08b
7056,European,2546.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,initial,2018-06-06,GCST006175,Biological process,#d53e4f
7057,African Am./Caribbean,3269.0,29875475.0,Montalvo-Ortiz JL,Cannabis-related aggression,initial,2018-06-06,GCST006175,Biological process,#fee08b
7058,African Am./Caribbean,1229.0,29885931.0,Langefeld CD,End stage renal disease in APOL1 risk genotype-positive individuals,initial,2018-06-06,GCST006816,Other disease,#fee08b
7059,African Am./Caribbean,1229.0,29885931.0,Langefeld CD,End stage renal disease in APOL1 risk genotype-positive individuals,initial,2018-06-06,GCST006816,Other measurement,#fee08b
7060,African Am./Caribbean,3076.0,29885931.0,Langefeld CD,End stage renal disease in APOL1 risk genotype-negative individuals,initial,2018-06-06,GCST006815,Other disease,#fee08b
7061,African Am./Caribbean,3076.0,29885931.0,Langefeld CD,End stage renal disease in APOL1 risk genotype-negative individuals,initial,2018-06-06,GCST006815,Other measurement,#fee08b
7062,African Am./Caribbean,2649.0,29885931.0,Langefeld CD,End stage renal disease x APOL1 genotype interaction,initial,2018-06-06,GCST006813,Other disease,#fee08b
7063,African Am./Caribbean,2649.0,29885931.0,Langefeld CD,End stage renal disease x APOL1 genotype interaction,initial,2018-06-06,GCST006813,Other measurement,#fee08b
7064,European,2110.0,29883787.0,Gregson CL,Bone mineral density (total hip),initial,2018-06-05,GCST006143,Other measurement,#d53e4f
7066,European,1380.0,29883787.0,Gregson CL,Lumbar spine bone mineral density,initial,2018-06-05,GCST006142,Other measurement,#d53e4f
7067,European,5899.0,29883787.0,Gregson CL,High bone mineral density,initial,2018-06-05,GCST006141,Other measurement,#d53e4f
7068,European,240.0,29967566.0,Roberts CH,Chlamydia trachomatis seropositivity,initial,2018-06-03,GCST006225,Other measurement,#d53e4f
7095,Asian,5734.0,29855537.0,Hirata T,Dysmenorrheic pain severity,initial,2018-05-31,GCST006656,Other measurement,#3288bd
7096,Asian,5614.0,29855537.0,Hirata T,Dysmenorrheic pain severity,replication,2018-05-31,GCST006656,Other measurement,#3288bd
7097,Hispanic/Latin American,36.0,29855589.0,Chernus J,Velopharyngeal dysfunction,initial,2018-05-31,GCST006280,Other trait,#807dba
7100,European,678.0,29852030.0,Lores-Motta L,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity),initial,2018-05-31,GCST006808,Other measurement,#d53e4f
7102,European,678.0,29852030.0,Lores-Motta L,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity),initial,2018-05-31,GCST006808,Response to drug,#d53e4f
7104,European,678.0,29852030.0,Lores-Motta L,Response to anti-VEGF treatment in neovascular age-related macular degeneration (visual acuity),initial,2018-05-31,GCST006808,Neurological disorder,#d53e4f
7105,Asian,5609.0,29855537.0,Hirata T,Breast size,initial,2018-05-31,GCST006655,Body measurement,#3288bd
7106,European,4134.0,30273415.0,Hatzikotoulas K,Developmental dysplasia of the hip,initial,2018-05-31,GCST006566,Other disease,#d53e4f
7107,European,5781.0,30273415.0,Hatzikotoulas K,Developmental dysplasia of the hip,replication,2018-05-31,GCST006566,Other disease,#d53e4f
7108,Asian,5614.0,29855537.0,Hirata T,Vaginal discharge (smell),replication,2018-05-31,GCST006654,Other trait,#3288bd
7109,Asian,5734.0,29855537.0,Hirata T,Vaginal discharge (smell),initial,2018-05-31,GCST006654,Other trait,#3288bd
7110,Asian,5734.0,29855537.0,Hirata T,Vaginal discharge (metrorrhagia),initial,2018-05-31,GCST006657,Other trait,#3288bd
7111,Asian,5734.0,29855537.0,Hirata T,Vaginal discharge (metrorrhagia),initial,2018-05-31,GCST006657,Other trait,#3288bd
7112,Asian,5614.0,29855537.0,Hirata T,Vaginal discharge (itching),replication,2018-05-31,GCST006653,Other trait,#3288bd
7113,Asian,5734.0,29855537.0,Hirata T,Vaginal discharge (itching),initial,2018-05-31,GCST006653,Other trait,#3288bd
7114,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (stiff neck),replication,2018-05-31,GCST006652,Other measurement,#3288bd
7115,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (stiff neck),initial,2018-05-31,GCST006652,Other measurement,#3288bd
7116,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (stiff neck),replication,2018-05-31,GCST006652,Other trait,#3288bd
7117,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (stiff neck),initial,2018-05-31,GCST006652,Other trait,#3288bd
7118,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (sleepiness),initial,2018-05-31,GCST006651,Other measurement,#3288bd
7119,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (sleepiness),replication,2018-05-31,GCST006651,Other measurement,#3288bd
7120,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (sleepiness),initial,2018-05-31,GCST006651,Neurological disorder,#3288bd
7121,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (sleepiness),replication,2018-05-31,GCST006651,Neurological disorder,#3288bd
7122,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (pressure in breast),replication,2018-05-31,GCST006650,Other measurement,#3288bd
7123,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (pressure in breast),initial,2018-05-31,GCST006650,Other measurement,#3288bd
7124,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (pressure in breast),replication,2018-05-31,GCST006650,Body measurement,#3288bd
7125,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (pressure in breast),initial,2018-05-31,GCST006650,Body measurement,#3288bd
7126,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (nervousness),initial,2018-05-31,GCST006649,Neurological disorder,#3288bd
7127,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (nervousness),initial,2018-05-31,GCST006649,Other measurement,#3288bd
7128,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (loss of concentration),initial,2018-05-31,GCST006648,Other measurement,#3288bd
7129,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (loss of concentration),initial,2018-05-31,GCST006648,Neurological disorder,#3288bd
7130,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (joint pain),initial,2018-05-31,GCST006647,Other measurement,#3288bd
7131,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (joint pain),replication,2018-05-31,GCST006647,Other measurement,#3288bd
7132,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (joint pain),initial,2018-05-31,GCST006647,Other trait,#3288bd
7133,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (joint pain),replication,2018-05-31,GCST006647,Other trait,#3288bd
7134,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (headache),initial,2018-05-31,GCST006646,Other measurement,#3288bd
7135,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (headache),replication,2018-05-31,GCST006646,Other measurement,#3288bd
7136,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (headache),initial,2018-05-31,GCST006646,Other trait,#3288bd
7137,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (headache),replication,2018-05-31,GCST006646,Other trait,#3288bd
7138,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (edema),replication,2018-05-31,GCST006645,Other measurement,#3288bd
7139,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (edema),initial,2018-05-31,GCST006645,Other measurement,#3288bd
7140,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (edema),replication,2018-05-31,GCST006645,Other disease,#3288bd
7141,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (edema),initial,2018-05-31,GCST006645,Other disease,#3288bd
7142,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (depression),replication,2018-05-31,GCST006644,Other measurement,#3288bd
7143,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (depression),initial,2018-05-31,GCST006644,Other measurement,#3288bd
7144,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (depression),replication,2018-05-31,GCST006644,Neurological disorder,#3288bd
7145,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (depression),initial,2018-05-31,GCST006644,Neurological disorder,#3288bd
7146,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (bowel movement),replication,2018-05-31,GCST006643,Other measurement,#3288bd
7147,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (bowel movement),initial,2018-05-31,GCST006643,Other measurement,#3288bd
7148,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (bowel movement),replication,2018-05-31,GCST006643,Other trait,#3288bd
7149,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (bowel movement),initial,2018-05-31,GCST006643,Other trait,#3288bd
7150,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (increased appetite),replication,2018-05-31,GCST006642,Other measurement,#3288bd
7151,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (increased appetite),initial,2018-05-31,GCST006642,Other measurement,#3288bd
7152,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (increased appetite),replication,2018-05-31,GCST006642,Biological process,#3288bd
7153,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (increased appetite),initial,2018-05-31,GCST006642,Biological process,#3288bd
7154,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (aggressiveness),initial,2018-05-31,GCST006641,Other measurement,#3288bd
7155,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (aggressiveness),replication,2018-05-31,GCST006641,Other measurement,#3288bd
7156,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (aggressiveness),initial,2018-05-31,GCST006641,Biological process,#3288bd
7157,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (aggressiveness),replication,2018-05-31,GCST006641,Biological process,#3288bd
7158,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (acne),replication,2018-05-31,GCST006640,Other measurement,#3288bd
7159,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (acne),initial,2018-05-31,GCST006640,Other measurement,#3288bd
7160,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (acne),replication,2018-05-31,GCST006640,Other disease,#3288bd
7161,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (acne),initial,2018-05-31,GCST006640,Other disease,#3288bd
7162,Asian,5614.0,29855537.0,Hirata T,Heavy vaginal discharge,replication,2018-05-31,GCST006639,Other measurement,#3288bd
7163,Asian,5734.0,29855537.0,Hirata T,Heavy vaginal discharge,initial,2018-05-31,GCST006639,Other measurement,#3288bd
7164,Asian,5614.0,29855537.0,Hirata T,Heavy vaginal discharge,replication,2018-05-31,GCST006639,Other trait,#3288bd
7165,Asian,5734.0,29855537.0,Hirata T,Heavy vaginal discharge,initial,2018-05-31,GCST006639,Other trait,#3288bd
7166,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (fever),replication,2018-05-31,GCST006638,Other measurement,#3288bd
7167,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (fever),initial,2018-05-31,GCST006638,Other measurement,#3288bd
7168,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (fever),replication,2018-05-31,GCST006638,Other trait,#3288bd
7169,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (fever),initial,2018-05-31,GCST006638,Other trait,#3288bd
7170,Asian,5614.0,29855537.0,Hirata T,Pain medicine use during menstruation,replication,2018-05-31,GCST006637,Other measurement,#3288bd
7171,Asian,5734.0,29855537.0,Hirata T,Pain medicine use during menstruation,initial,2018-05-31,GCST006637,Other measurement,#3288bd
7172,Asian,5614.0,29855537.0,Hirata T,Pain medicine use during menstruation,replication,2018-05-31,GCST006637,Other measurement,#3288bd
7173,Asian,5734.0,29855537.0,Hirata T,Pain medicine use during menstruation,initial,2018-05-31,GCST006637,Other measurement,#3288bd
7174,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (dysmenorrhea),replication,2018-05-31,GCST006636,Other measurement,#3288bd
7175,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (dysmenorrhea),initial,2018-05-31,GCST006636,Other measurement,#3288bd
7176,Asian,5614.0,29855537.0,Hirata T,Menstruation quality of life impact (dysmenorrhea),replication,2018-05-31,GCST006636,Other measurement,#3288bd
7177,Asian,5734.0,29855537.0,Hirata T,Menstruation quality of life impact (dysmenorrhea),initial,2018-05-31,GCST006636,Other measurement,#3288bd
7178,European,926.0,29860282.0,Scelsi MA,Hippocampal volume,initial,2018-05-30,GCST006134,Other measurement,#d53e4f
7179,European,16966.0,29848360.0,Julia A,Systemic lupus erythematosus,initial,2018-05-30,GCST005831,Immune system disorder,#d53e4f
7180,European,944.0,29860282.0,Scelsi MA,Alzheimer's disease progression score,initial,2018-05-30,GCST006136,Other measurement,#d53e4f
7181,European,936.0,29860282.0,Scelsi MA,Cortical amyloid beta load,initial,2018-05-30,GCST006135,Other measurement,#d53e4f
7182,European,1760.0,30680360.0,McCoy TH Jr,Nonunion in individuals with fractures,initial,2018-05-29,GCST007250,Other disease,#d53e4f
7183,European,1760.0,30680360.0,McCoy TH Jr,Nonunion in individuals with fractures,initial,2018-05-29,GCST007250,Other disease,#d53e4f
7184,European,7647.0,29844224.0,Loomis SJ,Fructosamine levels,initial,2018-05-29,GCST006056,Other measurement,#d53e4f
7185,African,2104.0,29844224.0,Loomis SJ,Fructosamine levels,initial,2018-05-29,GCST006056,Other measurement,#fc8d59
7186,European,1304.0,29844224.0,Loomis SJ,Fructosamine levels,replication,2018-05-29,GCST006056,Other measurement,#d53e4f
7187,African,608.0,29844224.0,Loomis SJ,Fructosamine levels,replication,2018-05-29,GCST006056,Other measurement,#fc8d59
7188,Asian,1271.0,29857070.0,Gao J,Pemphigus vulgaris,initial,2018-05-29,GCST006584,Immune system disorder,#3288bd
7189,Asian,2104.0,29857070.0,Gao J,Pemphigus vulgaris,replication,2018-05-29,GCST006584,Immune system disorder,#3288bd
7190,Asian,3418.0,29844195.0,Hosoda Y,Sub-foveal choroidal thickness,initial,2018-05-29,GCST006068,Other measurement,#3288bd
7191,Asian,2692.0,29844195.0,Hosoda Y,Sub-foveal choroidal thickness,replication,2018-05-29,GCST006068,Other measurement,#3288bd
7192,European,300486.0,29844566.0,Davies G,General cognitive ability,initial,2018-05-29,GCST006269,Biological process,#d53e4f
7193,African,2104.0,29844224.0,Loomis SJ,Hemoglobin A1c levels,initial,2018-05-29,GCST006060,Hematological measurement,#fc8d59
7194,European,7647.0,29844224.0,Loomis SJ,Hemoglobin A1c levels,initial,2018-05-29,GCST006060,Hematological measurement,#d53e4f
7195,European,7647.0,29844224.0,Loomis SJ,Fasting blood glucose,initial,2018-05-29,GCST006059,Other measurement,#d53e4f
7196,African,2104.0,29844224.0,Loomis SJ,Fasting blood glucose,initial,2018-05-29,GCST006059,Other measurement,#fc8d59
7197,European,7647.0,29844224.0,Loomis SJ,Total glycated albumin levels,initial,2018-05-29,GCST006058,Other measurement,#d53e4f
7198,African,2104.0,29844224.0,Loomis SJ,Total glycated albumin levels,initial,2018-05-29,GCST006058,Other measurement,#fc8d59
7199,European,7647.0,29844224.0,Loomis SJ,Percent glycated albumin,initial,2018-05-29,GCST006057,Other measurement,#d53e4f
7200,African,2104.0,29844224.0,Loomis SJ,Percent glycated albumin,initial,2018-05-29,GCST006057,Other measurement,#fc8d59
7201,European,1304.0,29844224.0,Loomis SJ,Percent glycated albumin,replication,2018-05-29,GCST006057,Other measurement,#d53e4f
7202,African,608.0,29844224.0,Loomis SJ,Percent glycated albumin,replication,2018-05-29,GCST006057,Other measurement,#fc8d59
7203,European,330069.0,29844566.0,Davies G,Reaction time,initial,2018-05-29,GCST006268,Other measurement,#d53e4f
7204,Asian,2110.0,29808027.0,Tedja MS,Spherical equivalent,initial,2018-05-28,GCST006289,Other measurement,#3288bd
7205,Asian,2506.0,29808027.0,Tedja MS,Spherical equivalent,initial,2018-05-28,GCST006289,Other measurement,#3288bd
7206,European,44192.0,29808027.0,Tedja MS,Spherical equivalent,initial,2018-05-28,GCST006289,Other measurement,#d53e4f
7207,Asian,15044.0,29808027.0,Tedja MS,Spherical equivalent,initial,2018-05-28,GCST006289,Other measurement,#3288bd
7208,Asian,2275.0,29808027.0,Tedja MS,Spherical equivalent,initial,2018-05-28,GCST006289,Other measurement,#3288bd
7209,Asian,2506.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7210,Asian,2275.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7211,Asian,15044.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7212,European,95505.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),replication,2018-05-28,GCST006291,Other measurement,#d53e4f
7213,European,148485.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#d53e4f
7214,Asian,2110.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7215,Asian,2506.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other trait,#3288bd
7216,Asian,2275.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other trait,#3288bd
7217,Asian,15044.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other trait,#3288bd
7218,European,95505.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),replication,2018-05-28,GCST006291,Other trait,#d53e4f
7219,European,148485.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other trait,#d53e4f
7220,Asian,2110.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other trait,#3288bd
7221,Asian,2506.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7222,Asian,2275.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7223,Asian,15044.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7224,European,95505.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),replication,2018-05-28,GCST006291,Other measurement,#d53e4f
7225,European,148485.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#d53e4f
7226,Asian,2110.0,29808027.0,Tedja MS,Spherical equivalent or myopia (age of diagnosis),initial,2018-05-28,GCST006291,Other measurement,#3288bd
7227,European,104293.0,29808027.0,Tedja MS,Myopia (age of diagnosis),initial,2018-05-28,GCST006290,Other measurement,#d53e4f
7228,European,104293.0,29808027.0,Tedja MS,Myopia (age of diagnosis),initial,2018-05-28,GCST006290,Other trait,#d53e4f
7229,European,790.0,29786918.0,Vonk JM,Clinical remission in asthma,initial,2018-05-22,GCST007423,Other trait,#d53e4f
7230,European,456.0,29786918.0,Vonk JM,Clinical remission in asthma,replication,2018-05-22,GCST007423,Other trait,#d53e4f
7231,European,790.0,29786918.0,Vonk JM,Clinical remission in asthma,initial,2018-05-22,GCST007423,Other disease,#d53e4f
7232,European,456.0,29786918.0,Vonk JM,Clinical remission in asthma,replication,2018-05-22,GCST007423,Other disease,#d53e4f
7233,European,667.0,29786918.0,Vonk JM,Complete remission in asthma,initial,2018-05-22,GCST007424,Other trait,#d53e4f
7234,European,342.0,29786918.0,Vonk JM,Complete remission in asthma,replication,2018-05-22,GCST007424,Other trait,#d53e4f
7235,European,667.0,29786918.0,Vonk JM,Complete remission in asthma,initial,2018-05-22,GCST007424,Other disease,#d53e4f
7236,European,342.0,29786918.0,Vonk JM,Complete remission in asthma,replication,2018-05-22,GCST007424,Other disease,#d53e4f
7237,European,90853.0,29785011.0,Zhu Z,Asthma,initial,2018-05-21,GCST007562,Other disease,#d53e4f
7242,European,884.0,29787419.0,Hrdlickova B,Refractory celiac disease type II,initial,2018-05-21,GCST005928,Digestive system disorder,#d53e4f
7243,European,1341.0,29787419.0,Hrdlickova B,Refractory celiac disease type II,replication,2018-05-21,GCST005928,Digestive system disorder,#d53e4f
7244,European,253288.0,29782485.0,Rueger S,Height,initial,2018-05-21,GCST005908,Body measurement,#d53e4f
7245,European,336474.0,29782485.0,Rueger S,Height,replication,2018-05-21,GCST005908,Body measurement,#d53e4f
7246,European,116538.0,29785011.0,Zhu Z,Asthma or allergic disease (pleiotropy),initial,2018-05-21,GCST007564,Immune system disorder,#d53e4f
7247,European,116538.0,29785011.0,Zhu Z,Asthma or allergic disease (pleiotropy),initial,2018-05-21,GCST007564,Other disease,#d53e4f
7248,Asian,989.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,initial,2018-05-21,GCST005746,Cancer,#3288bd
7249,Asian,1048.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,replication,2018-05-21,GCST005746,Cancer,#3288bd
7250,Asian,383.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,replication,2018-05-21,GCST005746,Cancer,#3288bd
7251,Asian,989.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,initial,2018-05-21,GCST005746,Digestive system disorder,#3288bd
7252,Asian,1048.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,replication,2018-05-21,GCST005746,Digestive system disorder,#3288bd
7253,Asian,383.0,29784950.0,Sawai H,Hepatocellular carcinoma in hepatitis B infection,replication,2018-05-21,GCST005746,Digestive system disorder,#3288bd
7255,European,139555.0,29785010.0,Khawaja AP,Intraocular pressure,initial,2018-05-21,GCST006412,Other measurement,#d53e4f
7256,European,102453.0,29785011.0,Zhu Z,"Allergic disease (asthma, hay fever or eczema)",initial,2018-05-21,GCST007563,Immune system disorder,#d53e4f
7257,European,102453.0,29785011.0,Zhu Z,"Allergic disease (asthma, hay fever or eczema)",initial,2018-05-21,GCST007563,Other disease,#d53e4f
7258,European,260279.0,29777097.0,Marioni RE,Paternal history of Alzheimer's disease,initial,2018-05-18,GCST005920,Other measurement,#d53e4f
7259,Asian,11283.0,29779033.0,Hishida A,Serum creatinine levels,initial,2018-05-18,GCST006393,Other measurement,#3288bd
7260,Asian,148829.0,29779033.0,Hishida A,Serum creatinine levels,initial,2018-05-18,GCST006393,Other measurement,#3288bd
7261,Asian,11283.0,29779033.0,Hishida A,Estimated glomerular filtration rate,initial,2018-05-18,GCST006392,Other measurement,#3288bd
7262,Asian,148829.0,29779033.0,Hishida A,Estimated glomerular filtration rate,initial,2018-05-18,GCST006392,Other measurement,#3288bd
7263,European,288676.0,29777097.0,Marioni RE,Maternal history of Alzheimer's disease,initial,2018-05-18,GCST005923,Other measurement,#d53e4f
7264,Asian,11283.0,29779033.0,Hishida A,Chronic kidney disease,initial,2018-05-18,GCST006391,Other disease,#3288bd
7265,Asian,148829.0,29779033.0,Hishida A,Chronic kidney disease,initial,2018-05-18,GCST006391,Other disease,#3288bd
7266,European,314278.0,29777097.0,Marioni RE,Alzheimer's disease or family history of Alzheimer's disease,initial,2018-05-18,GCST005922,Neurological disorder,#d53e4f
7268,European,314278.0,29777097.0,Marioni RE,Alzheimer's disease or family history of Alzheimer's disease,initial,2018-05-18,GCST005922,Other measurement,#d53e4f
7270,European,314278.0,29777097.0,Marioni RE,Family history of Alzheimer's disease,initial,2018-05-18,GCST005921,Other measurement,#d53e4f
7271,Asian,43861.0,29773799.0,Horikoshi M,Menopause (age at onset),initial,2018-05-17,GCST005863,Other measurement,#3288bd
7272,European,32545.0,29773799.0,Horikoshi M,Menopause (age at onset),replication,2018-05-17,GCST005863,Other measurement,#d53e4f
7273,European,4187.0,30271932.0,Oskarsson GR,Serum erythropoietin levels,initial,2018-05-17,GCST006536,Other measurement,#d53e4f
7274,European,68.0,30271932.0,Oskarsson GR,Serum erythropoietin levels,replication,2018-05-17,GCST006536,Other measurement,#d53e4f
7275,Asian,25432.0,29773799.0,Horikoshi M,Late age at menarche,initial,2018-05-17,GCST005864,Other measurement,#3288bd
7276,Asian,30266.0,29773799.0,Horikoshi M,Early age at menarche,initial,2018-05-17,GCST005865,Other measurement,#3288bd
7277,Asian,67029.0,29773799.0,Horikoshi M,Menarche (age at onset),initial,2018-05-17,GCST005867,Other measurement,#3288bd
7278,European,73397.0,29773799.0,Horikoshi M,Menarche (age at onset),replication,2018-05-17,GCST005867,Other measurement,#d53e4f
7279,European,67257.0,29769521.0,Ramirez J,Heart rate response to exercise,initial,2018-05-16,GCST005787,Cardiovascular measurement,#d53e4f
7280,Asian,278.0,29868124.0,Wu Y,Body mass index and waist-hip ratio (pleiotropy),initial,2018-05-16,GCST006430,Body measurement,#3288bd
7281,Asian,278.0,29868124.0,Wu Y,Body mass index and waist-hip ratio (pleiotropy),initial,2018-05-16,GCST006430,Body measurement,#3288bd
7282,European,847.0,29769526.0,Estrada K,Neuromyelitis optica (AQP4-IgG-negative),initial,2018-05-16,GCST006938,Immune system disorder,#d53e4f
7283,European,480.0,29769526.0,Estrada K,Neuromyelitis optica (AQP4-IgG-negative),replication,2018-05-16,GCST006938,Immune system disorder,#d53e4f
7284,European,850.0,29769526.0,Estrada K,Neuromyelitis optica (AQP4-IgG-positive),initial,2018-05-16,GCST006937,Immune system disorder,#d53e4f
7285,European,526.0,29769526.0,Estrada K,Neuromyelitis optica (AQP4-IgG-positive),replication,2018-05-16,GCST006937,Immune system disorder,#d53e4f
7286,European,913.0,29769526.0,Estrada K,Neuromyelitis optica,initial,2018-05-16,GCST005964,Immune system disorder,#d53e4f
7287,European,546.0,29769526.0,Estrada K,Neuromyelitis optica,replication,2018-05-16,GCST005964,Immune system disorder,#d53e4f
7288,Asian,547.0,29769613.0,Sun X,Executive function in ADHD,initial,2018-05-16,GCST006219,Neurological disorder,#3288bd
7289,Asian,547.0,29769613.0,Sun X,Executive function in ADHD,initial,2018-05-16,GCST006219,Other measurement,#3288bd
7290,European,73265.0,29771307.0,Aponte JL,Rosacea symptom severity,initial,2018-05-16,GCST005790,Other measurement,#d53e4f
7291,European,67062.0,29769521.0,Ramirez J,Resting heart rate,initial,2018-05-16,GCST005789,Cardiovascular measurement,#d53e4f
7292,European,67257.0,29769521.0,Ramirez J,Heart rate response to recovery post exercise,initial,2018-05-16,GCST005788,Cardiovascular measurement,#d53e4f
7293,African Am./Caribbean,3280.0,29767774.0,Lutz SM,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-05-15,GCST006042,Other disease,#fee08b
7294,European,6658.0,29767774.0,Lutz SM,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-05-15,GCST006042,Other disease,#d53e4f
7296,African Am./Caribbean,3280.0,29767774.0,Lutz SM,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-05-15,GCST006042,Other measurement,#fee08b
7297,European,6658.0,29767774.0,Lutz SM,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-05-15,GCST006042,Other measurement,#d53e4f
7299,European,95.0,29766673.0,Fusco JP,Non-small cell lung cancer in heavy smokers,initial,2018-05-15,GCST005747,Biological process,#d53e4f
7300,European,133.0,29766673.0,Fusco JP,Non-small cell lung cancer in heavy smokers,replication,2018-05-15,GCST005747,Biological process,#d53e4f
7301,European,95.0,29766673.0,Fusco JP,Non-small cell lung cancer in heavy smokers,initial,2018-05-15,GCST005747,Cancer,#d53e4f
7302,European,133.0,29766673.0,Fusco JP,Non-small cell lung cancer in heavy smokers,replication,2018-05-15,GCST005747,Cancer,#d53e4f
7303,Asian,8107.0,29760442.0,Iglesias AI,Central corneal thickness,initial,2018-05-14,GCST005667,Other measurement,#3288bd
7304,European,17803.0,29760442.0,Iglesias AI,Central corneal thickness,initial,2018-05-14,GCST005667,Other measurement,#d53e4f
7305,Asian,8107.0,29760442.0,Iglesias AI,Central corneal thickness,initial,2018-05-14,GCST006367,Other measurement,#3288bd
7306,European,17803.0,29760442.0,Iglesias AI,Central corneal thickness,initial,2018-05-14,GCST006366,Other measurement,#d53e4f
7307,European,520.0,29762745.0,Claus EB,Meningioma,replication,2018-05-12,GCST005870,Cancer,#d53e4f
7309,European,11429.0,29762745.0,Claus EB,Meningioma,initial,2018-05-12,GCST005870,Cancer,#d53e4f
7310,Hispanic/Latin American,374.0,29750799.0,Chao MJ,Huntington's disease (age at onset),initial,2018-05-11,GCST007113,Neurological disorder,#807dba
7311,European,4061.0,29750799.0,Chao MJ,Huntington's disease (age at onset),initial,2018-05-11,GCST007113,Neurological disorder,#d53e4f
7312,Hispanic/Latin American,374.0,29750799.0,Chao MJ,Huntington's disease (age at onset),initial,2018-05-11,GCST007113,Other measurement,#807dba
7313,European,4061.0,29750799.0,Chao MJ,Huntington's disease (age at onset),initial,2018-05-11,GCST007113,Other measurement,#d53e4f
7314,European,8429.0,29752348.0,Rutten-Jacobs LCA,White matter hyperintensity volume,initial,2018-05-11,GCST006062,Other measurement,#d53e4f
7315,European,8239.0,29752348.0,Rutten-Jacobs LCA,White matter integrity (mean diffusivity),initial,2018-05-11,GCST006064,Other measurement,#d53e4f
7316,European,8239.0,29752348.0,Rutten-Jacobs LCA,White matter integrity (fractional anisotropy),initial,2018-05-11,GCST006063,Other measurement,#d53e4f
7317,European,340.0,29751835.0,Hu H,Cerebrospinal fluid beta-site APP cleaving enzyme levels,initial,2018-05-11,GCST005714,Other measurement,#d53e4f
7318,European,527.0,29747637.0,Li JQ,Plasma neurofilament light levels,initial,2018-05-10,GCST005713,Other measurement,#d53e4f
7319,European,18723.0,29743610.0,Ostrom QT,Glioma,initial,2018-05-09,GCST005931,Cancer,#d53e4f
7320,European,13722.0,29743610.0,Ostrom QT,Non-glioblastoma glioma,initial,2018-05-09,GCST005933,Cancer,#d53e4f
7321,European,15203.0,29743610.0,Ostrom QT,Glioblastoma,initial,2018-05-09,GCST005932,Cancer,#d53e4f
7322,European,705.0,29739359.0,Graham PS,Diabetic macular edema in type 2 diabetes,initial,2018-05-08,GCST006282,Metabolic disorder,#d53e4f
7323,European,705.0,29739359.0,Graham PS,Diabetic macular edema in type 2 diabetes,initial,2018-05-08,GCST006282,Metabolic disorder,#d53e4f
7324,European,611.0,29739359.0,Graham PS,Proliferative diabetic retinopathy in type 2 diabetes,initial,2018-05-08,GCST006283,Metabolic disorder,#d53e4f
7325,European,611.0,29739359.0,Graham PS,Proliferative diabetic retinopathy in type 2 diabetes,initial,2018-05-08,GCST006283,Metabolic disorder,#d53e4f
7326,European,7582.0,29738550.0,de Oliveira Otto MC,Circulating odd-numbered chain saturated fatty acid levels (C23:0),initial,2018-05-08,GCST005861,Lipid or lipoprotein measurement,#d53e4f
7327,European,1910.0,29738550.0,de Oliveira Otto MC,Circulating odd-numbered chain saturated fatty acid levels (C19:0),initial,2018-05-08,GCST005862,Lipid or lipoprotein measurement,#d53e4f
7328,European,6016.0,29738550.0,de Oliveira Otto MC,Circulating odd-numbered chain saturated fatty acid levels (C15:0+C17:0),initial,2018-05-08,GCST005866,Lipid or lipoprotein measurement,#d53e4f
7329,European,6016.0,29738550.0,de Oliveira Otto MC,Circulating odd-numbered chain saturated fatty acid levels (C17:0),initial,2018-05-08,GCST005868,Lipid or lipoprotein measurement,#d53e4f
7331,European,55382.0,29739929.0,Visconti A,Low tan response,replication,2018-05-08,GCST005897,Other trait,#d53e4f
7332,European,121296.0,29739929.0,Visconti A,Low tan response,initial,2018-05-08,GCST005897,Other trait,#d53e4f
7333,European,11494.0,29738550.0,de Oliveira Otto MC,Circulating odd-numbered chain saturated fatty acid levels (C15:0),initial,2018-05-08,GCST005869,Lipid or lipoprotein measurement,#d53e4f
7334,European,119.0,29998114.0,Gadad BS,Remission after antidepressant treatment in major depression,initial,2018-05-03,GCST006818,Neurological disorder,#d53e4f
7335,European,119.0,29998114.0,Gadad BS,Remission after antidepressant treatment in major depression,initial,2018-05-03,GCST006818,Response to drug,#d53e4f
7336,Asian,4476.0,29725004.0,Hosoda Y,Myopic maculopathy,initial,2018-05-03,GCST005715,Other measurement,#3288bd
7337,Asian,3279.0,29725004.0,Hosoda Y,Myopic maculopathy,replication,2018-05-03,GCST005715,Other measurement,#3288bd
7338,European,450406.0,30271922.0,Clifton EAD,Smoking status (ever vs never smokers),initial,2018-05-03,GCST006812,Other measurement,#d53e4f
7340,European,436236.0,30271922.0,Clifton EAD,Self-reported risk-taking behaviour,initial,2018-05-03,GCST006810,Biological process,#d53e4f
7341,European,210.0,29998114.0,Gadad BS,Response to antidepressants in depression,initial,2018-05-03,GCST006817,Neurological disorder,#d53e4f
7342,European,210.0,29998114.0,Gadad BS,Response to antidepressants in depression,initial,2018-05-03,GCST006817,Response to drug,#d53e4f
7343,African Am./Caribbean,158.0,29730043.0,Li J,Response to lurasidone in schizophrenia,initial,2018-05-02,GCST006248,Neurological disorder,#fee08b
7344,European,264.0,29730043.0,Li J,Response to lurasidone in schizophrenia,initial,2018-05-02,GCST006248,Neurological disorder,#d53e4f
7345,African Am./Caribbean,158.0,29730043.0,Li J,Response to lurasidone in schizophrenia,initial,2018-05-02,GCST006248,Response to drug,#fee08b
7346,European,264.0,29730043.0,Li J,Response to lurasidone in schizophrenia,initial,2018-05-02,GCST006248,Response to drug,#d53e4f
7347,European,3290.0,29748315.0,Pott J,Plasma proprotein convertase subtilisin/kexin type 9 levels in stable coronary artery disease,initial,2018-05-01,GCST006284,Other measurement,#d53e4f
7348,Hispanic/Latin American,4038.0,29847655.0,Fan BJ,Central corneal thickness,replication,2018-05-01,GCST006049,Other measurement,#807dba
7349,European,4806.0,29847655.0,Fan BJ,Central corneal thickness,replication,2018-05-01,GCST006049,Other measurement,#d53e4f
7350,Asian,195.0,29847655.0,Fan BJ,Central corneal thickness,initial,2018-05-01,GCST006049,Other measurement,#3288bd
7353,Asian,195.0,29847655.0,Fan BJ,Central corneal thickness,initial,2018-05-01,GCST006050,Other measurement,#3288bd
7354,Asian,1520.0,29847655.0,Fan BJ,Central corneal thickness,replication,2018-05-01,GCST006050,Other measurement,#3288bd
7355,European,6911.0,29847655.0,Fan BJ,Central corneal thickness,replication,2018-05-01,GCST006050,Other measurement,#d53e4f
7356,Hispanic/Latin American,4038.0,29847655.0,Fan BJ,Central corneal thickness,replication,2018-05-01,GCST006050,Other measurement,#807dba
7357,European,382.0,29724592.0,Pottier C,Behavioural changes in frontotemporal lobe dementia,initial,2018-04-30,GCST006146,Neurological disorder,#d53e4f
7358,European,382.0,29724592.0,Pottier C,Behavioural changes in frontotemporal lobe dementia,initial,2018-04-30,GCST006146,Biological process,#d53e4f
7359,European,1528.0,29724592.0,Pottier C,Frontotemporal dementia,initial,2018-04-30,GCST006154,Neurological disorder,#d53e4f
7360,European,2008.0,29724592.0,Pottier C,Frontotemporal dementia,replication,2018-04-30,GCST006154,Neurological disorder,#d53e4f
7361,European,382.0,29724592.0,Pottier C,Parkinsonism in frontotemporal lobe dementia,initial,2018-04-30,GCST006153,Neurological disorder,#d53e4f
7362,European,382.0,29724592.0,Pottier C,Parkinsonism in frontotemporal lobe dementia,initial,2018-04-30,GCST006153,Neurological disorder,#d53e4f
7363,European,382.0,29724592.0,Pottier C,Language impairment in frontotemporal lobe dementia,initial,2018-04-30,GCST006152,Neurological disorder,#d53e4f
7364,European,382.0,29724592.0,Pottier C,Language impairment in frontotemporal lobe dementia,initial,2018-04-30,GCST006152,Neurological disorder,#d53e4f
7365,European,382.0,29724592.0,Pottier C,Memory dysfunction in frontotemporal lobe dementia,initial,2018-04-30,GCST006151,Other trait,#d53e4f
7366,European,382.0,29724592.0,Pottier C,Memory dysfunction in frontotemporal lobe dementia,initial,2018-04-30,GCST006151,Neurological disorder,#d53e4f
7367,European,1941.0,29724592.0,Pottier C,Frontotemporal dementia,replication,2018-04-30,GCST006150,Neurological disorder,#d53e4f
7368,European,1528.0,29724592.0,Pottier C,Frontotemporal dementia,initial,2018-04-30,GCST006150,Neurological disorder,#d53e4f
7369,European,382.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation (age at onset),initial,2018-04-30,GCST006149,Other measurement,#d53e4f
7370,European,67.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation (age at onset),replication,2018-04-30,GCST006149,Other measurement,#d53e4f
7371,European,382.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation (age at onset),initial,2018-04-30,GCST006149,Neurological disorder,#d53e4f
7372,European,67.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation (age at onset),replication,2018-04-30,GCST006149,Neurological disorder,#d53e4f
7373,European,1528.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation,initial,2018-04-30,GCST006148,Neurological disorder,#d53e4f
7374,European,1865.0,29724592.0,Pottier C,Frontotemporal dementia with GRN mutation,replication,2018-04-30,GCST006148,Neurological disorder,#d53e4f
7375,European,210.0,29724592.0,Pottier C,Frontotemporal dementia (age at onset),replication,2018-04-30,GCST006147,Other measurement,#d53e4f
7376,European,1528.0,29724592.0,Pottier C,Frontotemporal dementia (age at onset),initial,2018-04-30,GCST006147,Other measurement,#d53e4f
7377,European,210.0,29724592.0,Pottier C,Frontotemporal dementia (age at onset),replication,2018-04-30,GCST006147,Neurological disorder,#d53e4f
7378,European,1528.0,29724592.0,Pottier C,Frontotemporal dementia (age at onset),initial,2018-04-30,GCST006147,Neurological disorder,#d53e4f
7379,European,10875.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,initial,2018-04-27,GCST005881,Metabolic disorder,#d53e4f
7380,European,12356.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#d53e4f
7381,Asian,16047.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7382,Asian,619.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7383,Asian,222.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7384,Asian,223.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7385,European,10875.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,initial,2018-04-27,GCST005881,Metabolic disorder,#d53e4f
7386,European,12356.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#d53e4f
7387,Asian,16047.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7388,Asian,619.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7389,Asian,222.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7390,Asian,223.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes,replication,2018-04-27,GCST005881,Metabolic disorder,#3288bd
7391,Asian,222.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7392,European,5717.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005895,Metabolic disorder,#d53e4f
7393,European,12356.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#d53e4f
7394,Asian,16047.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7395,Asian,619.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7396,Asian,223.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7397,Asian,222.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7398,European,5717.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005895,Metabolic disorder,#d53e4f
7399,European,12356.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#d53e4f
7400,Asian,16047.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7401,Asian,619.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7402,Asian,223.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005895,Metabolic disorder,#3288bd
7403,European,10674.0,29703846.0,Wei WQ,Coronary heart disease events during statin therapy,initial,2018-04-27,GCST006217,Response to drug,#d53e4f
7406,European,1129.0,29703846.0,Wei WQ,Coronary heart disease events during statin therapy,replication,2018-04-27,GCST006217,Response to drug,#d53e4f
7407,European,10674.0,29703846.0,Wei WQ,Coronary heart disease events during statin therapy,initial,2018-04-27,GCST006217,Cardiovascular measurement,#d53e4f
7410,European,1129.0,29703846.0,Wei WQ,Coronary heart disease events during statin therapy,replication,2018-04-27,GCST006217,Cardiovascular measurement,#d53e4f
7411,European,1877.0,29703947.0,Jawinski P,Resting-state electroencephalogram vigilance,initial,2018-04-27,GCST006138,Other measurement,#d53e4f
7412,European,326113.0,29728651.0,Li X,Major depressive disorder,initial,2018-04-27,GCST005907,Neurological disorder,#d53e4f
7413,Asian,10640.0,29728651.0,Li X,Major depressive disorder,initial,2018-04-27,GCST005907,Neurological disorder,#3288bd
7414,European,19896.0,29728651.0,Li X,Major depressive disorder,replication,2018-04-27,GCST005907,Neurological disorder,#d53e4f
7415,Asian,418.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#3288bd
7416,Asian,5387.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#3288bd
7417,European,9650.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),initial,2018-04-27,GCST005894,Metabolic disorder,#d53e4f
7418,European,9443.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#d53e4f
7419,Asian,418.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#3288bd
7420,Asian,5387.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#3288bd
7421,European,9650.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),initial,2018-04-27,GCST005894,Metabolic disorder,#d53e4f
7422,European,9443.0,29703844.0,van Zuydam NR,Diabetic kidney disease in diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005894,Metabolic disorder,#d53e4f
7423,European,4842.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),initial,2018-04-27,GCST005893,Other disease,#d53e4f
7424,European,9443.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Other disease,#d53e4f
7425,Asian,5387.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Other disease,#3288bd
7426,Asian,418.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Other disease,#3288bd
7427,European,4842.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),initial,2018-04-27,GCST005893,Metabolic disorder,#d53e4f
7428,European,9443.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Metabolic disorder,#d53e4f
7429,Asian,5387.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Metabolic disorder,#3288bd
7430,Asian,418.0,29703844.0,van Zuydam NR,Diabetic kidney disease in type 2 diabetes (ESRD vs. no ESRD),replication,2018-04-27,GCST005893,Metabolic disorder,#3288bd
7431,European,13158.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,initial,2018-04-27,GCST005891,Other measurement,#d53e4f
7432,European,9333.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Other measurement,#d53e4f
7433,Asian,7405.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Other measurement,#3288bd
7434,Asian,975.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Other measurement,#3288bd
7435,Asian,307.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Other measurement,#3288bd
7436,Asian,384.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Other measurement,#3288bd
7437,European,13158.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,initial,2018-04-27,GCST005891,Metabolic disorder,#d53e4f
7438,European,9333.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Metabolic disorder,#d53e4f
7439,Asian,7405.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Metabolic disorder,#3288bd
7440,Asian,975.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Metabolic disorder,#3288bd
7441,Asian,307.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Metabolic disorder,#3288bd
7442,Asian,384.0,29703844.0,van Zuydam NR,Glomerular filtration rate in diabetes,replication,2018-04-27,GCST005891,Metabolic disorder,#3288bd
7443,European,9197.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,initial,2018-04-27,GCST005892,Other measurement,#d53e4f
7444,European,9333.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Other measurement,#d53e4f
7445,Asian,7405.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Other measurement,#3288bd
7446,Asian,975.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Other measurement,#3288bd
7447,Asian,384.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Other measurement,#3288bd
7448,Asian,307.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Other measurement,#3288bd
7449,European,9197.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,initial,2018-04-27,GCST005892,Metabolic disorder,#d53e4f
7450,European,9333.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Metabolic disorder,#d53e4f
7451,Asian,7405.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Metabolic disorder,#3288bd
7452,Asian,975.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Metabolic disorder,#3288bd
7453,Asian,384.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Metabolic disorder,#3288bd
7454,Asian,307.0,29703844.0,van Zuydam NR,Glomerular filtration rate in type 2 diabetes,replication,2018-04-27,GCST005892,Metabolic disorder,#3288bd
7455,European,7626.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,initial,2018-04-27,GCST005890,Metabolic disorder,#d53e4f
7456,European,3485.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#d53e4f
7457,Asian,5508.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7458,Asian,440.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7459,Asian,137.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7460,Asian,180.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7461,European,7626.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,initial,2018-04-27,GCST005890,Metabolic disorder,#d53e4f
7462,European,3485.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#d53e4f
7463,Asian,5508.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7464,Asian,440.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7465,Asian,137.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7466,Asian,180.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in diabetes,replication,2018-04-27,GCST005890,Metabolic disorder,#3288bd
7467,European,4227.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005889,Metabolic disorder,#d53e4f
7468,European,3485.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#d53e4f
7469,Asian,5508.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7470,Asian,440.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7471,Asian,180.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7472,Asian,137.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7473,European,4227.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005889,Metabolic disorder,#d53e4f
7474,European,3485.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#d53e4f
7475,Asian,5508.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7476,Asian,440.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7477,Asian,180.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7478,Asian,137.0,29703844.0,van Zuydam NR,Early diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005889,Metabolic disorder,#3288bd
7479,European,9853.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#d53e4f
7480,European,8063.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,initial,2018-04-27,GCST005888,Metabolic disorder,#d53e4f
7481,Asian,332.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7482,Asian,103.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7483,Asian,13915.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7484,European,9853.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#d53e4f
7485,European,8063.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,initial,2018-04-27,GCST005888,Metabolic disorder,#d53e4f
7486,Asian,332.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7487,Asian,103.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7488,Asian,13915.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in diabetes,replication,2018-04-27,GCST005888,Metabolic disorder,#3288bd
7489,European,9853.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#d53e4f
7490,Asian,13915.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7491,Asian,332.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7492,Asian,103.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7493,European,3711.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005887,Metabolic disorder,#d53e4f
7494,European,9853.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#d53e4f
7495,Asian,13915.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7496,Asian,332.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7497,Asian,103.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005887,Metabolic disorder,#3288bd
7498,European,3711.0,29703844.0,van Zuydam NR,Late diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005887,Metabolic disorder,#d53e4f
7499,European,5655.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,initial,2018-04-27,GCST005886,Other disease,#d53e4f
7500,European,6400.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Other disease,#d53e4f
7501,Asian,5738.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Other disease,#3288bd
7502,Asian,169.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Other disease,#3288bd
7503,European,5655.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,initial,2018-04-27,GCST005886,Metabolic disorder,#d53e4f
7504,European,6400.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Metabolic disorder,#d53e4f
7505,Asian,5738.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Metabolic disorder,#3288bd
7506,Asian,169.0,29703844.0,van Zuydam NR,End-stage renal disease in diabetes,replication,2018-04-27,GCST005886,Metabolic disorder,#3288bd
7507,Asian,169.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Other disease,#3288bd
7508,European,6400.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Other disease,#d53e4f
7509,Asian,5738.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Other disease,#3288bd
7510,European,2447.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,initial,2018-04-27,GCST005885,Other disease,#d53e4f
7511,Asian,169.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Metabolic disorder,#3288bd
7512,European,6400.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Metabolic disorder,#d53e4f
7513,Asian,5738.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,replication,2018-04-27,GCST005885,Metabolic disorder,#3288bd
7514,European,2447.0,29703844.0,van Zuydam NR,End-stage renal disease in type 2 diabetes,initial,2018-04-27,GCST005885,Metabolic disorder,#d53e4f
7515,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Other disease,#3288bd
7516,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Other disease,#3288bd
7517,European,5433.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,initial,2018-04-27,GCST005884,Other disease,#d53e4f
7518,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Other disease,#d53e4f
7519,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#3288bd
7520,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#3288bd
7521,European,5433.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,initial,2018-04-27,GCST005884,Metabolic disorder,#d53e4f
7522,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#d53e4f
7523,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#3288bd
7524,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#3288bd
7525,European,5433.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,initial,2018-04-27,GCST005884,Metabolic disorder,#d53e4f
7526,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in diabetes,replication,2018-04-27,GCST005884,Metabolic disorder,#d53e4f
7527,European,2298.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005883,Other disease,#d53e4f
7528,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Other disease,#d53e4f
7529,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Other disease,#3288bd
7530,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Other disease,#3288bd
7531,European,2298.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005883,Metabolic disorder,#d53e4f
7532,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#d53e4f
7533,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#3288bd
7534,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#3288bd
7535,European,2298.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005883,Metabolic disorder,#d53e4f
7536,European,5248.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#d53e4f
7537,Asian,900.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#3288bd
7538,Asian,194.0,29703844.0,van Zuydam NR,Chronic kidney disease and diabetic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005883,Metabolic disorder,#3288bd
7539,European,10164.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,initial,2018-04-27,GCST005880,Other disease,#d53e4f
7540,European,14150.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Other disease,#d53e4f
7541,Asian,6287.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Other disease,#3288bd
7542,Asian,480.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Other disease,#3288bd
7543,Asian,165.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Other disease,#3288bd
7544,Asian,159.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Other disease,#3288bd
7545,European,10164.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,initial,2018-04-27,GCST005880,Metabolic disorder,#d53e4f
7546,European,14150.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Metabolic disorder,#d53e4f
7547,Asian,6287.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Metabolic disorder,#3288bd
7548,Asian,480.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Metabolic disorder,#3288bd
7549,Asian,165.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Metabolic disorder,#3288bd
7550,Asian,159.0,29703844.0,van Zuydam NR,Chronic kidney disease in diabetes,replication,2018-04-27,GCST005880,Metabolic disorder,#3288bd
7551,European,6000.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005882,Other disease,#d53e4f
7552,European,14150.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Other disease,#d53e4f
7553,Asian,6287.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Other disease,#3288bd
7554,Asian,480.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Other disease,#3288bd
7555,Asian,165.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Other disease,#3288bd
7556,Asian,159.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Other disease,#3288bd
7557,European,6000.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,initial,2018-04-27,GCST005882,Metabolic disorder,#d53e4f
7558,European,14150.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Metabolic disorder,#d53e4f
7559,Asian,6287.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Metabolic disorder,#3288bd
7560,Asian,480.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Metabolic disorder,#3288bd
7561,Asian,165.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Metabolic disorder,#3288bd
7562,Asian,159.0,29703844.0,van Zuydam NR,Chronic kidney disease in type 2 diabetes,replication,2018-04-27,GCST005882,Metabolic disorder,#3288bd
7563,European,4419.0,29698431.0,Roosenboom J,Maximum cranial length,initial,2018-04-26,GCST005938,Other measurement,#d53e4f
7564,European,480359.0,29700475.0,Wray NR,Depression,initial,2018-04-26,GCST005839,Neurological disorder,#d53e4f
7565,European,2754.0,29698419.0,Pande M,Breast cancer and/or colorectal cancer,initial,2018-04-26,GCST006035,Cancer,#d53e4f
7566,European,2754.0,29698419.0,Pande M,Breast cancer and/or colorectal cancer,initial,2018-04-26,GCST006035,Cancer,#d53e4f
7567,European,4419.0,29698431.0,Roosenboom J,Maximum cranial width,initial,2018-04-26,GCST005940,Other measurement,#d53e4f
7568,European,4419.0,29698431.0,Roosenboom J,Cephalic index,initial,2018-04-26,GCST005939,Other measurement,#d53e4f
7570,European,3557.0,29695241.0,Charmet R,Coronary artery disease in type 1 diabetes,initial,2018-04-25,GCST006281,Metabolic disorder,#d53e4f
7572,European,3557.0,29695241.0,Charmet R,Coronary artery disease in type 1 diabetes,initial,2018-04-25,GCST006281,Cardiovascular disease,#d53e4f
7573,European,334825.0,29691431.0,Tikkanen E,Hand grip strength,initial,2018-04-24,GCST005830,Other measurement,#d53e4f
7574,African Am./Caribbean,6224.0,29691896.0,Keaton JM,"Type 2 diabetes (SNP x SNP interaction, 1df)",initial,2018-04-24,GCST006494,Metabolic disorder,#fee08b
7575,African Am./Caribbean,6224.0,29691896.0,Keaton JM,"Type 2 diabetes (SNP x SNP interaction, 2df)",initial,2018-04-24,GCST006495,Metabolic disorder,#fee08b
7576,European,111610.0,29691431.0,Tikkanen E,Hand grip strength,replication,2018-04-24,GCST005829,Other measurement,#d53e4f
7577,European,223215.0,29691431.0,Tikkanen E,Hand grip strength,initial,2018-04-24,GCST005829,Other measurement,#d53e4f
7578,European,581.0,29682794.0,Szekely E,Basal ganglia growth,initial,2018-04-22,GCST006220,Other measurement,#d53e4f
7579,Asian,8.0,29682794.0,Szekely E,Basal ganglia growth,initial,2018-04-22,GCST006220,Other measurement,#3288bd
7580,Other/Mixed,15.0,29682794.0,Szekely E,Basal ganglia growth,initial,2018-04-22,GCST006220,Other measurement,#99d594
7582,African Am./Caribbean,31.0,29682794.0,Szekely E,Basal ganglia growth,initial,2018-04-22,GCST006220,Other measurement,#fee08b
7583,European,581.0,29682794.0,Szekely E,Right lateral prefrontal cortical growth,initial,2018-04-22,GCST006224,Other measurement,#d53e4f
7584,African Am./Caribbean,31.0,29682794.0,Szekely E,Right lateral prefrontal cortical growth,initial,2018-04-22,GCST006224,Other measurement,#fee08b
7585,Asian,8.0,29682794.0,Szekely E,Right lateral prefrontal cortical growth,initial,2018-04-22,GCST006224,Other measurement,#3288bd
7586,Other/Mixed,15.0,29682794.0,Szekely E,Right lateral prefrontal cortical growth,initial,2018-04-22,GCST006224,Other measurement,#99d594
7588,European,581.0,29682794.0,Szekely E,Cerebral cortical growth,initial,2018-04-22,GCST006223,Other measurement,#d53e4f
7589,Asian,8.0,29682794.0,Szekely E,Cerebral cortical growth,initial,2018-04-22,GCST006223,Other measurement,#3288bd
7590,Other/Mixed,15.0,29682794.0,Szekely E,Cerebral cortical growth,initial,2018-04-22,GCST006223,Other measurement,#99d594
7591,African Am./Caribbean,31.0,29682794.0,Szekely E,Cerebral cortical growth,initial,2018-04-22,GCST006223,Other measurement,#fee08b
7593,Other/Mixed,15.0,29682794.0,Szekely E,Cerebellum growth,initial,2018-04-22,GCST006222,Other measurement,#99d594
7594,African Am./Caribbean,31.0,29682794.0,Szekely E,Cerebellum growth,initial,2018-04-22,GCST006222,Other measurement,#fee08b
7595,Asian,8.0,29682794.0,Szekely E,Cerebellum growth,initial,2018-04-22,GCST006222,Other measurement,#3288bd
7596,European,581.0,29682794.0,Szekely E,Cerebellum growth,initial,2018-04-22,GCST006222,Other measurement,#d53e4f
7598,Asian,8.0,29682794.0,Szekely E,White matter growth,initial,2018-04-22,GCST006221,Other measurement,#3288bd
7599,Other/Mixed,15.0,29682794.0,Szekely E,White matter growth,initial,2018-04-22,GCST006221,Other measurement,#99d594
7601,European,581.0,29682794.0,Szekely E,White matter growth,initial,2018-04-22,GCST006221,Other measurement,#d53e4f
7602,African Am./Caribbean,31.0,29682794.0,Szekely E,White matter growth,initial,2018-04-22,GCST006221,Other measurement,#fee08b
7603,European,11103.0,29673008.0,Bonfiglio F,Irritable bowel syndrome,initial,2018-04-19,GCST006535,Digestive system disorder,#d53e4f
7604,European,2618.0,29678681.0,Matana A,Plasma anti-thyroid peroxidase levels,initial,2018-04-18,GCST008368,Other measurement,#d53e4f
7605,European,2629.0,29678681.0,Matana A,Plasma anti-thyroglobulin levels,initial,2018-04-18,GCST008369,Other measurement,#d53e4f
7606,European,360838.0,29679657.0,Ferreira MA,"Allergic disease (asthma, hay fever or eczema)",initial,2018-04-18,GCST007732,Immune system disorder,#d53e4f
7607,European,2629.0,29678681.0,Matana A,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis),initial,2018-04-18,GCST008367,Other measurement,#d53e4f
7608,European,2629.0,29678681.0,Matana A,Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis),initial,2018-04-18,GCST008367,Other measurement,#d53e4f
7609,Asian,6403.0,29665250.0,Shimanoe C,Emotional support seeking,initial,2018-04-17,GCST006819,Other measurement,#3288bd
7610,Asian,7685.0,29665250.0,Shimanoe C,Emotional support seeking,replication,2018-04-17,GCST006819,Other measurement,#3288bd
7611,Asian,6403.0,29665250.0,Shimanoe C,Emotional expression,initial,2018-04-17,GCST006826,Other measurement,#3288bd
7612,Asian,7685.0,29665250.0,Shimanoe C,Emotional expression,replication,2018-04-17,GCST006826,Other measurement,#3288bd
7613,Asian,6403.0,29665250.0,Shimanoe C,Perceived stress,initial,2018-04-17,GCST006825,Other measurement,#3288bd
7614,Asian,7685.0,29665250.0,Shimanoe C,Perceived stress,replication,2018-04-17,GCST006825,Other measurement,#3288bd
7615,Asian,6403.0,29665250.0,Shimanoe C,Approach coping (positive reappraisal/problem solving),initial,2018-04-17,GCST006824,Other measurement,#3288bd
7616,Asian,7685.0,29665250.0,Shimanoe C,Approach coping (positive reappraisal/problem solving),replication,2018-04-17,GCST006824,Other measurement,#3288bd
7617,Asian,7685.0,29665250.0,Shimanoe C,Emotional coping (emotional expression/emotional support seeking),replication,2018-04-17,GCST006823,Other measurement,#3288bd
7618,Asian,6403.0,29665250.0,Shimanoe C,Emotional coping (emotional expression/emotional support seeking),initial,2018-04-17,GCST006823,Other measurement,#3288bd
7619,Asian,6403.0,29665250.0,Shimanoe C,Disengagement,initial,2018-04-17,GCST006822,Other measurement,#3288bd
7620,Asian,7685.0,29665250.0,Shimanoe C,Disengagement,replication,2018-04-17,GCST006822,Other measurement,#3288bd
7621,Asian,6403.0,29665250.0,Shimanoe C,Problem solving,initial,2018-04-17,GCST006821,Other measurement,#3288bd
7622,Asian,7685.0,29665250.0,Shimanoe C,Problem solving,replication,2018-04-17,GCST006821,Other measurement,#3288bd
7623,Asian,6403.0,29665250.0,Shimanoe C,Positive reappraisal,initial,2018-04-17,GCST006820,Other measurement,#3288bd
7624,Asian,7685.0,29665250.0,Shimanoe C,Positive reappraisal,replication,2018-04-17,GCST006820,Other measurement,#3288bd
7625,European,174519.0,29662059.0,Howard DM,Major depressive disorder (probable),initial,2018-04-16,GCST005904,Neurological disorder,#d53e4f
7627,European,322580.0,29662059.0,Howard DM,Depression (broad),initial,2018-04-16,GCST005902,Neurological disorder,#d53e4f
7628,European,290891.0,29662168.0,Hysi PG,Hair color,initial,2018-04-16,GCST006075,Other measurement,#d53e4f
7629,European,27865.0,29662168.0,Hysi PG,Hair color,replication,2018-04-16,GCST006075,Other measurement,#d53e4f
7630,European,217584.0,29662059.0,Howard DM,Major depressive disorder (ICD-10 coded),initial,2018-04-16,GCST005903,Neurological disorder,#d53e4f
7631,European,502.0,29654602.0,Laville V,Upper eyelid sagging severity,initial,2018-04-13,GCST006365,Other measurement,#d53e4f
7632,European,12636.0,29659830.0,Warrington NM,Digit length ratio (right hand),initial,2018-04-12,GCST005748,Body measurement,#d53e4f
7633,Asian,607.0,29674289.0,Cheon EJ,Cholesterol efflux capacity,initial,2018-04-12,GCST005671,Lipid or lipoprotein measurement,#3288bd
7634,Asian,158.0,29674289.0,Cheon EJ,Cholesterol efflux capacity,replication,2018-04-12,GCST005671,Lipid or lipoprotein measurement,#3288bd
7635,European,845.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Other measurement,#d53e4f
7636,African Am./Caribbean,222.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Other measurement,#fee08b
7637,European,6963.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Other measurement,#d53e4f
7638,African Am./Caribbean,1015.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Other measurement,#fee08b
7641,European,845.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Metabolic disorder,#d53e4f
7642,African Am./Caribbean,222.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Metabolic disorder,#fee08b
7643,European,6963.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Metabolic disorder,#d53e4f
7644,African Am./Caribbean,1015.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Metabolic disorder,#fee08b
7647,European,845.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Response to drug,#d53e4f
7648,African Am./Caribbean,222.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,initial,2018-04-12,GCST005753,Response to drug,#fee08b
7649,European,6963.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Response to drug,#d53e4f
7650,African Am./Caribbean,1015.0,29650774.0,Rotroff DM,Change in HbA1c levels in response to metformin treatment in type 2 diabetes,replication,2018-04-12,GCST005753,Response to drug,#fee08b
7653,European,14382.0,29659830.0,Warrington NM,Digit length ratio (left hand),initial,2018-04-12,GCST005749,Body measurement,#d53e4f
7655,European,12586.0,29659830.0,Warrington NM,Digit length ratio,initial,2018-04-12,GCST005750,Body measurement,#d53e4f
7656,European,2596.0,30134803.0,Matana A,Plasma parathyroid hormone levels,initial,2018-04-11,GCST006431,Other measurement,#d53e4f
7657,European,4024.0,29631575.0,Obeidat M,Cotinine levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005916,Other measurement,#d53e4f
7658,European,4024.0,29631575.0,Obeidat M,Cotinine levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005916,Other measurement,#d53e4f
7659,European,4024.0,29631575.0,Obeidat M,Cotinine levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005916,Other disease,#d53e4f
7660,European,2706.0,29631575.0,Obeidat M,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005919,Other measurement,#d53e4f
7661,European,2706.0,29631575.0,Obeidat M,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005919,Other disease,#d53e4f
7662,European,2706.0,29631575.0,Obeidat M,Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease,initial,2018-04-10,GCST005919,Other measurement,#d53e4f
7663,European,2892.0,29631575.0,Obeidat M,Smoking cessation in chronic obstructive pulmonary disease,initial,2018-04-10,GCST005918,Other disease,#d53e4f
7664,European,2892.0,29631575.0,Obeidat M,Smoking cessation in chronic obstructive pulmonary disease,initial,2018-04-10,GCST005918,Biological process,#d53e4f
7665,European,2854.0,29631575.0,Obeidat M,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-04-10,GCST005917,Other disease,#d53e4f
7666,European,2854.0,29631575.0,Obeidat M,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2018-04-10,GCST005917,Other measurement,#d53e4f
7667,European,298957.0,29632382.0,Mahajan A,Type 2 diabetes,initial,2018-04-09,GCST007515,Metabolic disorder,#d53e4f
7668,Other/Mixed,153287.0,29632382.0,Mahajan A,Type 2 diabetes,initial,2018-04-09,GCST007515,Metabolic disorder,#99d594
7669,European,298957.0,29632382.0,Mahajan A,Type 2 diabetes (adjusted for BMI),initial,2018-04-09,GCST007518,Metabolic disorder,#d53e4f
7670,European,298957.0,29632382.0,Mahajan A,Type 2 diabetes (adjusted for BMI),initial,2018-04-09,GCST007516,Metabolic disorder,#d53e4f
7671,Other/Mixed,153287.0,29632382.0,Mahajan A,Type 2 diabetes (adjusted for BMI),initial,2018-04-09,GCST007516,Metabolic disorder,#99d594
7672,European,298957.0,29632382.0,Mahajan A,Type 2 diabetes,initial,2018-04-09,GCST007517,Metabolic disorder,#d53e4f
7673,European,17051.0,29632299.0,Vijayakrishnan J,Acute lymphoblastic leukemia in childhood (B cell precursor),initial,2018-04-09,GCST005832,Cancer,#d53e4f
7674,Asian,8373.0,29632305.0,Lee HS,Metabolic syndrome (multivariate analysis),initial,2018-04-09,GCST005878,Metabolic disorder,#3288bd
7675,Asian,3694.0,29632305.0,Lee HS,Metabolic syndrome (multivariate analysis),replication,2018-04-09,GCST005878,Metabolic disorder,#3288bd
7676,African,3057.0,29622589.0,Tereshchenko LG,Global electrical heterogeneity phenotypes,initial,2018-04-05,GCST005905,Cardiovascular measurement,#fc8d59
7677,European,10769.0,29622589.0,Tereshchenko LG,Global electrical heterogeneity phenotypes,initial,2018-04-05,GCST005905,Cardiovascular measurement,#d53e4f
7678,Asian,5731.0,29621232.0,Spracklen CN,Type 2 diabetes,initial,2018-04-05,GCST005912,Metabolic disorder,#3288bd
7679,Asian,6943.0,29621232.0,Spracklen CN,Glycated hemoglobin levels,initial,2018-04-05,GCST005914,Other measurement,#3288bd
7680,Asian,5786.0,29621232.0,Spracklen CN,Fasting blood insulin,initial,2018-04-05,GCST005915,Other measurement,#3288bd
7681,Asian,5786.0,29621232.0,Spracklen CN,Fasting blood glucose,initial,2018-04-05,GCST005913,Other measurement,#3288bd
7682,European,139.0,29670602.0,Moreau K,Infective endocarditis in Staphylococcus aureus infection,initial,2018-04-04,GCST006805,Cardiovascular disease,#d53e4f
7683,European,180.0,29670602.0,Moreau K,Infective endocarditis in Staphylococcus aureus infection,replication,2018-04-04,GCST006805,Cardiovascular disease,#d53e4f
7684,European,139.0,29670602.0,Moreau K,Infective endocarditis in Staphylococcus aureus infection,initial,2018-04-04,GCST006805,Other disease,#d53e4f
7685,European,180.0,29670602.0,Moreau K,Infective endocarditis in Staphylococcus aureus infection,replication,2018-04-04,GCST006805,Other disease,#d53e4f
7686,Hispanic/Latin American,11185.0,29618737.0,Napier MD,Supraventricular ectopy,initial,2018-04-04,GCST005936,Cardiovascular disease,#807dba
7687,European,22517.0,29618737.0,Napier MD,Supraventricular ectopy,initial,2018-04-04,GCST005936,Cardiovascular disease,#d53e4f
7688,African,9274.0,29618737.0,Napier MD,Supraventricular ectopy,initial,2018-04-04,GCST005936,Cardiovascular disease,#fc8d59
7689,European,23672.0,29618737.0,Napier MD,Ventricular ectopy,initial,2018-04-04,GCST005937,Cardiovascular disease,#d53e4f
7690,Hispanic/Latin American,11185.0,29618737.0,Napier MD,Ventricular ectopy,initial,2018-04-04,GCST005937,Cardiovascular disease,#807dba
7691,African,9274.0,29618737.0,Napier MD,Ventricular ectopy,initial,2018-04-04,GCST005937,Cardiovascular disease,#fc8d59
7692,European,346075.0,29626450.0,Bonfiglio F,Irritable bowel syndrome,initial,2018-04-04,GCST006304,Digestive system disorder,#d53e4f
7693,European,23672.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#d53e4f
7694,Hispanic/Latin American,11185.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#807dba
7695,African,9274.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#fc8d59
7696,European,23672.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#d53e4f
7697,Hispanic/Latin American,11185.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#807dba
7698,African,9274.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#fc8d59
7699,European,23672.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#d53e4f
7700,Hispanic/Latin American,11185.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#807dba
7701,African,9274.0,29618737.0,Napier MD,Ventricular ectopy or supraventricular ectopy (pleiotropy),initial,2018-04-04,GCST005935,Cardiovascular disease,#fc8d59
7704,European,150.0,29650764.0,McDonough CW,Plasma renin activity levels,replication,2018-04-01,GCST006043,Cardiovascular measurement,#d53e4f
7705,African Am./Caribbean,297.0,29650764.0,McDonough CW,Plasma renin activity levels,initial,2018-04-01,GCST006043,Cardiovascular measurement,#fee08b
7706,European,461.0,29650764.0,McDonough CW,Plasma renin activity levels,initial,2018-04-01,GCST006043,Cardiovascular measurement,#d53e4f
7707,European,6579.0,29603866.0,Pain O,Anhedonia,initial,2018-03-31,GCST005718,Other measurement,#d53e4f
7708,European,2359.0,29603866.0,Pain O,Anhedonia,replication,2018-03-31,GCST005718,Other measurement,#d53e4f
7709,European,8665.0,29603866.0,Pain O,Paranoia and hallucinations,initial,2018-03-31,GCST005717,Other measurement,#d53e4f
7710,European,10098.0,29603866.0,Pain O,Parent-rated negative symptoms,initial,2018-03-31,GCST005720,Other measurement,#d53e4f
7711,European,6297.0,29603866.0,Pain O,Cognitive disorganisation,initial,2018-03-31,GCST005719,Other measurement,#d53e4f
7712,Asian,254.0,29603369.0,Naito T,Bone mineral density (lumbar spine) in inflammatory bowel disease,initial,2018-03-30,GCST005783,Digestive system disorder,#3288bd
7713,Asian,254.0,29603369.0,Naito T,Bone mineral density (lumbar spine) in inflammatory bowel disease,initial,2018-03-30,GCST005783,Other measurement,#3288bd
7714,Asian,254.0,29603369.0,Naito T,Bone mineral density (femoral neck) in inflammatory bowel disease,initial,2018-03-30,GCST005784,Digestive system disorder,#3288bd
7715,Asian,254.0,29603369.0,Naito T,Bone mineral density (femoral neck) in inflammatory bowel disease,initial,2018-03-30,GCST005784,Other measurement,#3288bd
7717,Asian,2.0,29608535.0,Kuehn MH,Idiopathic intracranial hypertension,initial,2018-03-30,GCST005688,Cardiovascular disease,#3288bd
7718,Other/Mixed,7.0,29608535.0,Kuehn MH,Idiopathic intracranial hypertension,initial,2018-03-30,GCST005688,Cardiovascular disease,#99d594
7719,African Am./Caribbean,42.0,29608535.0,Kuehn MH,Idiopathic intracranial hypertension,initial,2018-03-30,GCST005688,Cardiovascular disease,#fee08b
7720,European,124.0,29608535.0,Kuehn MH,Idiopathic intracranial hypertension,initial,2018-03-30,GCST005688,Cardiovascular disease,#d53e4f
7721,African Am./Caribbean,1997.0,29596498.0,Charles BA,Low white blood cell count,initial,2018-03-29,GCST005579,Hematological measurement,#fee08b
7722,African Am./Caribbean,1178.0,29596498.0,Charles BA,Low white blood cell count (conditioned on rs2814778),initial,2018-03-29,GCST005578,Hematological measurement,#fee08b
7723,European,115486.0,29617998.0,Gao XR,Intraocular pressure,initial,2018-03-28,GCST005580,Other measurement,#d53e4f
7724,European,646.0,29594489.0,Apewokin S,Clostridium difficile infection in multiple myeloma,initial,2018-03-28,GCST005686,Other disease,#d53e4f
7725,European,646.0,29594489.0,Apewokin S,Clostridium difficile infection in multiple myeloma,initial,2018-03-28,GCST005686,Cancer,#d53e4f
7726,European,465.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,replication,2018-03-27,GCST005646,Response to drug,#d53e4f
7727,European,214.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,initial,2018-03-27,GCST005646,Response to drug,#d53e4f
7728,European,465.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,replication,2018-03-27,GCST005646,Cardiovascular disease,#d53e4f
7729,European,214.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,initial,2018-03-27,GCST005646,Cardiovascular disease,#d53e4f
7730,European,465.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,replication,2018-03-27,GCST005646,Cardiovascular measurement,#d53e4f
7731,European,214.0,29580174.0,Ala-Mutka EM,Change in serum uric acid levels in response to thiazide diuretic treatment (hydrochlorothiazide) in hypertension,initial,2018-03-27,GCST005646,Cardiovascular measurement,#d53e4f
7732,European,140700.0,29590334.0,Bjornsson T,Aortic coarctation,initial,2018-03-24,GCST005687,Cardiovascular disease,#d53e4f
7733,European,214493.0,29590334.0,Bjornsson T,Aortic coarctation,replication,2018-03-24,GCST005687,Cardiovascular disease,#d53e4f
7734,Asian,236.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,initial,2018-03-23,GCST005807,Hematological measurement,#3288bd
7735,Asian,512.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005807,Hematological measurement,#3288bd
7736,Asian,57.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005807,Hematological measurement,#3288bd
7737,Asian,236.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,initial,2018-03-23,GCST005807,Metabolic disorder,#3288bd
7738,Asian,512.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005807,Metabolic disorder,#3288bd
7739,Asian,57.0,29572449.0,Gurung RL,Urinary haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005807,Metabolic disorder,#3288bd
7740,Asian,236.0,29572449.0,Gurung RL,Plasma haptoglobin levels in type 2 diabetes,initial,2018-03-23,GCST005808,Hematological measurement,#3288bd
7741,Asian,57.0,29572449.0,Gurung RL,Plasma haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005808,Hematological measurement,#3288bd
7742,Asian,236.0,29572449.0,Gurung RL,Plasma haptoglobin levels in type 2 diabetes,initial,2018-03-23,GCST005808,Metabolic disorder,#3288bd
7743,Asian,57.0,29572449.0,Gurung RL,Plasma haptoglobin levels in type 2 diabetes,replication,2018-03-23,GCST005808,Metabolic disorder,#3288bd
7744,European,4633.0,29628937.0,Jiang J,Growth differentiation factor-15 levels,initial,2018-03-23,GCST005711,Hematological measurement,#d53e4f
7745,European,807.0,29628937.0,Jiang J,Growth differentiation factor-15 levels,replication,2018-03-23,GCST005711,Hematological measurement,#d53e4f
7746,European,4633.0,29628937.0,Jiang J,Growth differentiation factor-15 levels (conditioned on rs888663),initial,2018-03-23,GCST005712,Hematological measurement,#d53e4f
7747,European,807.0,29628937.0,Jiang J,Growth differentiation factor-15 levels (conditioned on rs888663),replication,2018-03-23,GCST005712,Hematological measurement,#d53e4f
7748,European,1297.0,29563342.0,Li XS,Plasma trimethyllysine levels,initial,2018-03-22,GCST005670,Hematological measurement,#d53e4f
7749,European,53731.0,29563502.0,Fejzo MS,Severity of nausea and vomiting of pregnancy,initial,2018-03-21,GCST005929,Other measurement,#d53e4f
7751,European,80610.0,29566793.0,Nicolas A,Amyotrophic lateral sclerosis,initial,2018-03-21,GCST005647,Neurological disorder,#d53e4f
7752,European,1648.0,29563502.0,Fejzo MS,Hyperemesis gravidarum,replication,2018-03-21,GCST005930,Other disease,#d53e4f
7753,European,17062.0,29563502.0,Fejzo MS,Hyperemesis gravidarum,initial,2018-03-21,GCST005930,Other disease,#d53e4f
7754,Asian,7064.0,29558500.0,Lee J,Creatinine levels,initial,2018-03-20,GCST005791,Other measurement,#3288bd
7755,Asian,6509.0,29558500.0,Lee J,Creatinine levels,replication,2018-03-20,GCST005791,Other measurement,#3288bd
7756,Asian,11409.0,29559738.0,Sasayama D,Photic sneeze reflex,initial,2018-03-20,GCST005809,Other trait,#3288bd
7757,Other/Mixed,7064.0,29558500.0,Lee J,Blood urea nitrogen levels,initial,2018-03-20,GCST005794,Other measurement,#99d594
7758,Asian,6509.0,29558500.0,Lee J,Blood urea nitrogen levels,replication,2018-03-20,GCST005794,Other measurement,#3288bd
7759,European,63556.0,29559693.0,Zengini E,Osteoarthritis (self-reported),initial,2018-03-20,GCST005811,Other disease,#d53e4f
7760,European,32970.0,29559693.0,Zengini E,Osteoarthritis of the hip or knee (hospital diagnosed),initial,2018-03-20,GCST005812,Other disease,#d53e4f
7761,European,208850.0,29559693.0,Zengini E,Osteoarthritis of the hip or knee (hospital diagnosed),replication,2018-03-20,GCST005812,Other disease,#d53e4f
7762,European,32970.0,29559693.0,Zengini E,Osteoarthritis of the hip or knee (hospital diagnosed),initial,2018-03-20,GCST005812,Other disease,#d53e4f
7763,European,208850.0,29559693.0,Zengini E,Osteoarthritis of the hip or knee (hospital diagnosed),replication,2018-03-20,GCST005812,Other disease,#d53e4f
7764,European,22347.0,29559693.0,Zengini E,Osteoarthritis of the knee (hospital diagnosed),initial,2018-03-20,GCST005813,Other disease,#d53e4f
7765,European,177463.0,29559693.0,Zengini E,Osteoarthritis of the knee (hospital diagnosed),replication,2018-03-20,GCST005813,Other disease,#d53e4f
7766,European,50508.0,29559693.0,Zengini E,Osteoarthritis (hospital diagnosed),initial,2018-03-20,GCST005814,Other disease,#d53e4f
7767,European,264362.0,29559693.0,Zengini E,Osteoarthritis (hospital diagnosed),replication,2018-03-20,GCST005814,Other disease,#d53e4f
7768,European,205135.0,29559693.0,Zengini E,Osteoarthritis of the hip (hospital diagnosed),replication,2018-03-20,GCST005810,Other disease,#d53e4f
7769,European,11989.0,29559693.0,Zengini E,Osteoarthritis of the hip (hospital diagnosed),initial,2018-03-20,GCST005810,Other disease,#d53e4f
7770,Asian,3703.0,29558500.0,Lee J,Uric acid levels,replication,2018-03-20,GCST005793,Cardiovascular measurement,#3288bd
7771,Asian,7064.0,29558500.0,Lee J,Uric acid levels,initial,2018-03-20,GCST005793,Cardiovascular measurement,#3288bd
7772,Asian,6509.0,29558500.0,Lee J,Glomerular filtration rate,replication,2018-03-20,GCST005792,Other measurement,#3288bd
7773,Asian,7064.0,29558500.0,Lee J,Glomerular filtration rate,initial,2018-03-20,GCST005792,Other measurement,#3288bd
7774,European,5947.0,29743933.0,Wu B,Glycemic traits (multi-trait analysis),initial,2018-03-18,GCST006404,Other measurement,#d53e4f
7775,European,5947.0,29743933.0,Wu B,Glycemic traits (multi-trait analysis),initial,2018-03-18,GCST006404,Other measurement,#d53e4f
7776,European,5947.0,29743933.0,Wu B,Glycemic traits (multi-trait analysis),initial,2018-03-18,GCST006404,Other measurement,#d53e4f
7777,European,599.0,29555444.0,Hamer MA,Facial wrinkles,replication,2018-03-16,GCST006981,Other trait,#d53e4f
7778,European,3513.0,29555444.0,Hamer MA,Facial wrinkles,initial,2018-03-16,GCST006981,Other trait,#d53e4f
7779,European,1143.0,29545352.0,Li Y,Serum metabolite concentrations in chronic kidney disease,initial,2018-03-15,GCST005648,Other disease,#d53e4f
7780,European,1143.0,29545352.0,Li Y,Serum metabolite concentrations in chronic kidney disease,initial,2018-03-15,GCST005648,Other measurement,#d53e4f
7781,European,407.0,29551627.0,Hawcutt DB,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L),initial,2018-03-15,GCST005927,Other measurement,#d53e4f
7783,European,407.0,29551627.0,Hawcutt DB,Corticosteroid-induced adrenal suppression (peak cortisol < 350 nmol/L),initial,2018-03-15,GCST005927,Response to drug,#d53e4f
7785,European,407.0,29551627.0,Hawcutt DB,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005926,Other disease,#d53e4f
7786,European,407.0,29551627.0,Hawcutt DB,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005926,Other measurement,#d53e4f
7787,European,407.0,29551627.0,Hawcutt DB,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005926,Response to drug,#d53e4f
7788,European,407.0,29551627.0,Hawcutt DB,Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005926,Response to drug,#d53e4f
7789,European,407.0,29551627.0,Hawcutt DB,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005925,Other disease,#d53e4f
7790,European,407.0,29551627.0,Hawcutt DB,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005925,Other measurement,#d53e4f
7791,European,407.0,29551627.0,Hawcutt DB,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005925,Response to drug,#d53e4f
7792,European,407.0,29551627.0,Hawcutt DB,Baseline cortisol levels in response to low dose short synacthen test in corticosteroid treated asthma,initial,2018-03-15,GCST005925,Response to drug,#d53e4f
7793,European,407.0,29551627.0,Hawcutt DB,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L),initial,2018-03-15,GCST005924,Other measurement,#d53e4f
7795,European,407.0,29551627.0,Hawcutt DB,Corticosteroid-induced adrenal suppression (peak cortisol < 500 nmol/L),initial,2018-03-15,GCST005924,Response to drug,#d53e4f
7797,European,1143.0,29545352.0,Li Y,Fractional excretion of metabolites in chronic kidney disease,initial,2018-03-15,GCST005666,Other disease,#d53e4f
7798,European,1143.0,29545352.0,Li Y,Fractional excretion of metabolites in chronic kidney disease,initial,2018-03-15,GCST005666,Other measurement,#d53e4f
7799,European,1143.0,29545352.0,Li Y,Urinary metabolite concentrations in chronic kidney disease,initial,2018-03-15,GCST005651,Other disease,#d53e4f
7800,European,1143.0,29545352.0,Li Y,Urinary metabolite concentrations in chronic kidney disease,initial,2018-03-15,GCST005651,Other measurement,#d53e4f
7801,European,5286.0,29551738.0,Dong J,Barrett's esophagus x gastroesophageal reflux disease interaction,initial,2018-03-15,GCST006526,Digestive system disorder,#d53e4f
7802,European,5286.0,29551738.0,Dong J,Barrett's esophagus x gastroesophageal reflux disease interaction,initial,2018-03-15,GCST006526,Digestive system disorder,#d53e4f
7803,European,5286.0,29551738.0,Dong J,Barrett's esophagus x smoking interaction,initial,2018-03-15,GCST006527,Other measurement,#d53e4f
7804,European,5286.0,29551738.0,Dong J,Barrett's esophagus x smoking interaction,initial,2018-03-15,GCST006527,Digestive system disorder,#d53e4f
7805,European,5286.0,29551738.0,Dong J,Barrett's esophagus x pack-years of smoking exposure interaction,initial,2018-03-15,GCST006528,Other measurement,#d53e4f
7806,European,5286.0,29551738.0,Dong J,Barrett's esophagus x pack-years of smoking exposure interaction,initial,2018-03-15,GCST006528,Digestive system disorder,#d53e4f
7807,European,5286.0,29551738.0,Dong J,Barrett's esophagus x BMI interaction,initial,2018-03-15,GCST006529,Digestive system disorder,#d53e4f
7808,European,5286.0,29551738.0,Dong J,Barrett's esophagus x BMI interaction,initial,2018-03-15,GCST006529,Body measurement,#d53e4f
7809,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction,initial,2018-03-15,GCST006531,Cancer,#d53e4f
7810,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x gastroesophageal reflux disease interaction,initial,2018-03-15,GCST006531,Digestive system disorder,#d53e4f
7811,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x pack-years of smoking exposure interaction,initial,2018-03-15,GCST006532,Cancer,#d53e4f
7812,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x pack-years of smoking exposure interaction,initial,2018-03-15,GCST006532,Other measurement,#d53e4f
7813,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x smoking interaction,initial,2018-03-15,GCST006530,Cancer,#d53e4f
7814,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x smoking interaction,initial,2018-03-15,GCST006530,Other measurement,#d53e4f
7815,European,1143.0,29545352.0,Li Y,Serum metabolite ratios in chronic kidney disease,initial,2018-03-15,GCST005650,Other disease,#d53e4f
7816,European,1143.0,29545352.0,Li Y,Serum metabolite ratios in chronic kidney disease,initial,2018-03-15,GCST005650,Other measurement,#d53e4f
7817,European,1143.0,29545352.0,Li Y,Urinary metabolite ratios in chronic kidney disease,initial,2018-03-15,GCST005649,Other disease,#d53e4f
7818,European,1143.0,29545352.0,Li Y,Urinary metabolite ratios in chronic kidney disease,initial,2018-03-15,GCST005649,Other measurement,#d53e4f
7819,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x BMI interaction,initial,2018-03-15,GCST006525,Cancer,#d53e4f
7820,European,4466.0,29551738.0,Dong J,Esophageal adenocarcinoma x BMI interaction,initial,2018-03-15,GCST006525,Body measurement,#d53e4f
7821,Hispanic/Latin American,136.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Digestive system disorder,#807dba
7822,African Am./Caribbean,303.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Digestive system disorder,#fee08b
7823,European,137.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Digestive system disorder,#d53e4f
7824,Hispanic/Latin American,136.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Other trait,#807dba
7825,African Am./Caribbean,303.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Other trait,#fee08b
7826,European,137.0,29538362.0,Jilling T,Surgical necrotising enterocolitis in extremely premature birth,initial,2018-03-14,GCST005800,Other trait,#d53e4f
7827,European,3002.0,29547969.0,Chen X,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels,initial,2018-03-14,GCST005761,Other measurement,#d53e4f
7828,European,646.0,29547969.0,Chen X,Immunoglobulin M against phosphorylcholine (IgM anti-PC) levels,replication,2018-03-14,GCST005761,Other measurement,#d53e4f
7829,European,7344.0,29532581.0,Hallfors J,Smoking behaviour (cigarettes smoked per day),replication,2018-03-13,GCST006299,Other measurement,#d53e4f
7830,European,1715.0,29532581.0,Hallfors J,Smoking behaviour (cigarettes smoked per day),initial,2018-03-13,GCST006299,Other measurement,#d53e4f
7831,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed),initial,2018-03-13,GCST008590,Biological process,#d53e4f
7832,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed),initial,2018-03-13,GCST008590,Other measurement,#d53e4f
7833,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) in major depressive disorder,initial,2018-03-13,GCST008589,Neurological disorder,#d53e4f
7834,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) in major depressive disorder,initial,2018-03-13,GCST008589,Biological process,#d53e4f
7835,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) in major depressive disorder,initial,2018-03-13,GCST008589,Other measurement,#d53e4f
7836,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (language ability),initial,2018-03-13,GCST008588,Other measurement,#d53e4f
7837,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (language ability),initial,2018-03-13,GCST008588,Other measurement,#d53e4f
7838,European,7012.0,29531327.0,Meijsen JJ,Cognitive performance (language ability),initial,2018-03-13,GCST008587,Other measurement,#d53e4f
7839,European,7012.0,29531327.0,Meijsen JJ,Cognitive performance (language ability),initial,2018-03-13,GCST008587,Other measurement,#d53e4f
7840,Hispanic/Latin American,8560.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Other trait,#807dba
7841,Asian,7518.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Other trait,#3288bd
7842,African Am./Caribbean,3166.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Other trait,#fee08b
7843,European,83264.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Other trait,#d53e4f
7844,Hispanic/Latin American,8560.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Cancer,#807dba
7845,Asian,7518.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Cancer,#3288bd
7846,African Am./Caribbean,3166.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Cancer,#fee08b
7847,European,83264.0,29534260.0,Kim SK,Plantar fascial disorders,initial,2018-03-13,GCST005558,Cancer,#d53e4f
7848,European,1703.0,29532581.0,Hallfors J,Nicotine withdrawal,initial,2018-03-13,GCST006869,Other measurement,#d53e4f
7849,European,1703.0,29532581.0,Hallfors J,Nicotine withdrawal symptom count,initial,2018-03-13,GCST006303,Other measurement,#d53e4f
7850,European,1715.0,29532581.0,Hallfors J,Nicotine dependence,initial,2018-03-13,GCST006302,Neurological disorder,#d53e4f
7851,European,1715.0,29532581.0,Hallfors J,Nicotine dependence symptom count,initial,2018-03-13,GCST006301,Other measurement,#d53e4f
7852,European,1711.0,29532581.0,Hallfors J,Smoking behaviour (maximum cigarettes in a 24 hour period),initial,2018-03-13,GCST006300,Other measurement,#d53e4f
7853,Asian,1193.0,29534301.0,Nishida N,Response to hepatitis B vaccine,initial,2018-03-13,GCST005606,Response to drug,#3288bd
7854,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder type interaction,initial,2018-03-13,GCST008586,Neurological disorder,#d53e4f
7855,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder type interaction,initial,2018-03-13,GCST008586,Biological process,#d53e4f
7856,European,1021.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder type interaction,initial,2018-03-13,GCST008586,Other measurement,#d53e4f
7857,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008585,Neurological disorder,#d53e4f
7858,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008585,Other measurement,#d53e4f
7859,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008585,Other measurement,#d53e4f
7860,European,7012.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008584,Neurological disorder,#d53e4f
7861,European,7012.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008584,Other measurement,#d53e4f
7862,European,7012.0,29531327.0,Meijsen JJ,Cognitive performance (language ability) x major depressive disorder status interaction,initial,2018-03-13,GCST008584,Other measurement,#d53e4f
7863,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder status interaction,initial,2018-03-13,GCST008583,Neurological disorder,#d53e4f
7864,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder status interaction,initial,2018-03-13,GCST008583,Biological process,#d53e4f
7865,European,6524.0,29531327.0,Meijsen JJ,Cognitive performance (processing speed) x major depressive disorder status interaction,initial,2018-03-13,GCST008583,Other measurement,#d53e4f
7866,European,46861.0,29527006.0,Warrier V,Empathy quotient,initial,2018-03-12,GCST005751,Other measurement,#d53e4f
7867,European,211763.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST006910,Cardiovascular disease,#d53e4f
7868,European,198048.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST006909,Cardiovascular disease,#d53e4f
7869,Asian,45564.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#3288bd
7870,Asian,555.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#3288bd
7871,African Am./Caribbean,20687.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#fee08b
7872,Asian,9144.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#3288bd
7873,European,440328.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#d53e4f
7874,Hispanic/Latin American,1247.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST005843,Other trait,#807dba
7875,Hispanic/Latin American,791.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#807dba
7876,Asian,364.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#3288bd
7877,Asian,29042.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#3288bd
7878,African Am./Caribbean,15560.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#fee08b
7879,Asian,7129.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#3288bd
7880,European,211763.0,29531354.0,Malik R,Ischemic stroke (cardioembolic),initial,2018-03-12,GCST005842,Cardiovascular disease,#d53e4f
7881,European,198048.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#d53e4f
7882,Asian,33291.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#3288bd
7883,Asian,7021.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#3288bd
7884,African Am./Caribbean,15840.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#fee08b
7885,Hispanic/Latin American,778.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#807dba
7886,Asian,467.0,29531354.0,Malik R,Ischemic stroke (small-vessel),initial,2018-03-12,GCST005841,Cardiovascular disease,#3288bd
7887,African Am./Caribbean,15405.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#fee08b
7888,Asian,29821.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#3288bd
7889,Asian,7062.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#3288bd
7890,European,150765.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#d53e4f
7891,Asian,367.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#3288bd
7892,Hispanic/Latin American,733.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST005840,Cardiovascular disease,#807dba
7893,European,440328.0,29531354.0,Malik R,Ischemic stroke,initial,2018-03-12,GCST006908,Other trait,#d53e4f
7894,European,150765.0,29531354.0,Malik R,Ischemic stroke (large artery atherosclerosis),initial,2018-03-12,GCST006907,Cardiovascular disease,#d53e4f
7895,Hispanic/Latin American,1557.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#807dba
7896,Asian,698.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#3288bd
7897,African Am./Caribbean,20695.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#fee08b
7898,Asian,9144.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#3288bd
7899,Asian,45564.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#3288bd
7900,European,446696.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST005838,Cardiovascular disease,#d53e4f
7902,European,1945.0,29531279.0,Zhou S,Intracranial aneurysm,initial,2018-03-12,GCST005576,Cardiovascular disease,#d53e4f
7903,European,446696.0,29531354.0,Malik R,Stroke,initial,2018-03-12,GCST006906,Cardiovascular disease,#d53e4f
7904,European,6035.0,29631748.0,McCoy TH Jr.,Delirium,initial,2018-03-10,GCST005851,Neurological disorder,#d53e4f
7905,European,222.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Response to drug,#d53e4f
7906,African Am./Caribbean,140.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Response to drug,#fee08b
7907,European,175.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Response to drug,#d53e4f
7908,African Am./Caribbean,135.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Response to drug,#fee08b
7909,European,222.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Cardiovascular disease,#d53e4f
7910,African Am./Caribbean,140.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Cardiovascular disease,#fee08b
7911,European,175.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Cardiovascular disease,#d53e4f
7912,African Am./Caribbean,135.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Cardiovascular disease,#fee08b
7913,European,222.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Other measurement,#d53e4f
7914,African Am./Caribbean,140.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,replication,2018-03-09,GCST005577,Other measurement,#fee08b
7915,European,175.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Other measurement,#d53e4f
7916,African Am./Caribbean,135.0,29523524.0,Singh S,Change in glucose in response to thiazide diuretic treatment in hypertension,initial,2018-03-09,GCST005577,Other measurement,#fee08b
7917,African,2857.0,29523850.0,Gilchrist JJ,Nontyphoidal Salmonella bacteraemia,initial,2018-03-09,GCST005590,Cardiovascular disease,#fc8d59
7918,African,734.0,29523850.0,Gilchrist JJ,Nontyphoidal Salmonella bacteraemia,replication,2018-03-09,GCST005590,Cardiovascular disease,#fc8d59
7919,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (2df test),initial,2018-03-08,GCST006133,Biological process,#3288bd
7920,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (2df test),initial,2018-03-08,GCST006133,Other measurement,#3288bd
7921,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (2df test),initial,2018-03-08,GCST006133,Other measurement,#3288bd
7922,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (1df test),initial,2018-03-08,GCST006132,Biological process,#3288bd
7923,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (1df test),initial,2018-03-08,GCST006132,Other measurement,#3288bd
7924,Asian,119.0,29518117.0,Lee HS,Bone mineral density x blood lead interaction in current smokers (1df test),initial,2018-03-08,GCST006132,Other measurement,#3288bd
7925,European,87740.0,29520040.0,Coleman JRI,Extremely high intelligence,initial,2018-03-08,GCST007044,Biological process,#d53e4f
7926,Hispanic/Latin American,3499.0,29520036.0,Stein MB,Insomnia,initial,2018-03-08,GCST005566,Neurological disorder,#807dba
7927,European,11473.0,29520036.0,Stein MB,Insomnia,initial,2018-03-08,GCST005566,Neurological disorder,#d53e4f
7928,African Am./Caribbean,2679.0,29520036.0,Stein MB,Insomnia,initial,2018-03-08,GCST005566,Neurological disorder,#fee08b
7929,European,2026.0,29511167.0,Theriault S,Calcific aortic valve stenosis,initial,2018-03-07,GCST005785,Cardiovascular disease,#d53e4f
7930,European,353586.0,29511167.0,Theriault S,Calcific aortic valve stenosis,replication,2018-03-07,GCST005785,Cardiovascular disease,#d53e4f
7931,European,2026.0,29511167.0,Theriault S,Calcific aortic valve stenosis,initial,2018-03-07,GCST005785,Cardiovascular disease,#d53e4f
7932,European,353586.0,29511167.0,Theriault S,Calcific aortic valve stenosis,replication,2018-03-07,GCST005785,Cardiovascular disease,#d53e4f
7933,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (infant genotype effect),initial,2018-03-07,GCST005587,Lipid or lipoprotein measurement,#3288bd
7934,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (infant genotype effect),initial,2018-03-07,GCST005587,Other measurement,#3288bd
7935,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (infant genotype effect),initial,2018-03-07,GCST005587,Other measurement,#3288bd
7936,European,522.0,29513936.0,Haasnoot AJW,Uveitis in juvenile idiopathic arthritis,initial,2018-03-07,GCST006126,Neurological disorder,#d53e4f
7937,European,522.0,29513936.0,Haasnoot AJW,Uveitis in juvenile idiopathic arthritis,initial,2018-03-07,GCST006126,Immune system disorder,#d53e4f
7938,European,590.0,29513936.0,Haasnoot AJW,Uveitis (juvenile idiopathic arthritis-associated),initial,2018-03-07,GCST006127,Neurological disorder,#d53e4f
7939,European,590.0,29513936.0,Haasnoot AJW,Uveitis (juvenile idiopathic arthritis-associated),initial,2018-03-07,GCST006127,Immune system disorder,#d53e4f
7940,European,920.0,29513936.0,Haasnoot AJW,Arthritis (juvenile idiopathic),initial,2018-03-07,GCST006128,Immune system disorder,#d53e4f
7941,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (maternal genotype effect),initial,2018-03-07,GCST005586,Lipid or lipoprotein measurement,#3288bd
7942,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (maternal genotype effect),initial,2018-03-07,GCST005586,Other measurement,#3288bd
7943,Asian,1142.0,29514873.0,Mychaleckyj JC,Breast milk fatty acid composition (maternal genotype effect),initial,2018-03-07,GCST005586,Other measurement,#3288bd
7944,European,456581.0,29511194.0,Helgadottir A,Aortic valve stenosis,replication,2018-03-07,GCST005561,Cardiovascular disease,#d53e4f
7945,European,351799.0,29511194.0,Helgadottir A,Aortic valve stenosis,initial,2018-03-07,GCST005561,Cardiovascular disease,#d53e4f
7952,Asian,278.0,29559957.0,Wang W,Serum uric acid levels,initial,2018-03-06,GCST005557,Cardiovascular measurement,#3288bd
7959,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007131,Lipid or lipoprotein measurement,#fee08b
7960,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007131,Lipid or lipoprotein measurement,#807dba
7961,European,265204.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007131,Lipid or lipoprotein measurement,#d53e4f
7962,Asian,439.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007131,Lipid or lipoprotein measurement,#3288bd
7963,Asian,439.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007143,Lipid or lipoprotein measurement,#3288bd
7964,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007143,Lipid or lipoprotein measurement,#807dba
7965,European,76627.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007143,Lipid or lipoprotein measurement,#d53e4f
7966,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007143,Lipid or lipoprotein measurement,#fee08b
7967,Asian,439.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007142,Lipid or lipoprotein measurement,#3288bd
7968,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007142,Lipid or lipoprotein measurement,#fee08b
7969,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007142,Lipid or lipoprotein measurement,#807dba
7970,European,76627.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007142,Lipid or lipoprotein measurement,#d53e4f
7971,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007134,Lipid or lipoprotein measurement,#807dba
7972,European,265204.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007134,Lipid or lipoprotein measurement,#d53e4f
7973,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007134,Lipid or lipoprotein measurement,#fee08b
7974,Asian,439.0,29507422.0,Hoffmann TJ,Total cholesterol levels,initial,2018-03-05,GCST007134,Lipid or lipoprotein measurement,#3288bd
7975,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007133,Lipid or lipoprotein measurement,#807dba
7976,European,265204.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007133,Lipid or lipoprotein measurement,#d53e4f
7977,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007133,Lipid or lipoprotein measurement,#fee08b
7978,Asian,439.0,29507422.0,Hoffmann TJ,Triglycerides,initial,2018-03-05,GCST007133,Lipid or lipoprotein measurement,#3288bd
7979,Asian,439.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007132,Lipid or lipoprotein measurement,#3288bd
7980,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007132,Lipid or lipoprotein measurement,#fee08b
7981,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007132,Lipid or lipoprotein measurement,#807dba
7982,European,265204.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007132,Lipid or lipoprotein measurement,#d53e4f
7983,Asian,439.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007141,Lipid or lipoprotein measurement,#3288bd
7984,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007141,Lipid or lipoprotein measurement,#fee08b
7985,European,76627.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007141,Lipid or lipoprotein measurement,#d53e4f
7986,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,Low density lipoprotein cholesterol levels,initial,2018-03-05,GCST007141,Lipid or lipoprotein measurement,#807dba
7987,Asian,439.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007140,Lipid or lipoprotein measurement,#3288bd
7988,African Am./Caribbean,2958.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007140,Lipid or lipoprotein measurement,#fee08b
7989,Hispanic/Latin American,7795.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007140,Lipid or lipoprotein measurement,#807dba
7990,European,76627.0,29507422.0,Hoffmann TJ,High density lipoprotein cholesterol levels,initial,2018-03-05,GCST007140,Lipid or lipoprotein measurement,#d53e4f
7991,Asian,9599.0,29495898.0,Peterson RE,Major depressive disorder,initial,2018-03-02,GCST005691,Neurological disorder,#3288bd
7992,Asian,6971.0,29495898.0,Peterson RE,Major depressive disorder (unexposed to adversity),initial,2018-03-02,GCST005689,Neurological disorder,#3288bd
7993,Asian,2628.0,29495898.0,Peterson RE,Major depressive disorder (exposed to adversity),initial,2018-03-02,GCST005690,Neurological disorder,#3288bd
7994,European,371318.0,29500382.0,Nagel M,Feeling tense,initial,2018-03-02,GCST006952,Other measurement,#d53e4f
7995,European,372047.0,29500382.0,Nagel M,Feeling hurt,initial,2018-03-02,GCST006951,Other measurement,#d53e4f
7996,European,372869.0,29500382.0,Nagel M,Feeling worry,initial,2018-03-02,GCST006950,Other measurement,#d53e4f
7997,European,369499.0,29500382.0,Nagel M,Suffering from nerves,initial,2018-03-02,GCST006949,Neurological disorder,#d53e4f
7998,European,373121.0,29500382.0,Nagel M,Feeling nervous,initial,2018-03-02,GCST006948,Other measurement,#d53e4f
7999,European,374971.0,29500382.0,Nagel M,Feeling fed-up,initial,2018-03-02,GCST006947,Other measurement,#d53e4f
8000,European,367725.0,29500382.0,Nagel M,Worry too long after an embarrassing experience,initial,2018-03-02,GCST006946,Other measurement,#d53e4f
8001,European,373380.0,29500382.0,Nagel M,Feeling guilty,initial,2018-03-02,GCST006945,Other measurement,#d53e4f
8002,European,373733.0,29500382.0,Nagel M,Experiencing mood swings,initial,2018-03-02,GCST006944,Other measurement,#d53e4f
8003,European,376097.0,29500382.0,Nagel M,Feeling miserable,initial,2018-03-02,GCST006943,Other measurement,#d53e4f
8004,European,376352.0,29500382.0,Nagel M,Feeling lonely,initial,2018-03-02,GCST006942,Other measurement,#d53e4f
8005,European,366726.0,29500382.0,Nagel M,Irritable mood,initial,2018-03-02,GCST006941,Other measurement,#d53e4f
8006,European,380506.0,29500382.0,Nagel M,Neurociticism,initial,2018-03-02,GCST006940,Other measurement,#d53e4f
8008,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate increase in response to exercise,initial,2018-03-01,GCST005845,Cardiovascular measurement,#99d594
8009,African,1445.0,29497042.0,Verweij N,Heart rate increase in response to exercise,initial,2018-03-01,GCST005845,Cardiovascular measurement,#fc8d59
8010,Asian,1744.0,29497042.0,Verweij N,Heart rate increase in response to exercise,initial,2018-03-01,GCST005845,Cardiovascular measurement,#3288bd
8011,European,54137.0,29497042.0,Verweij N,Heart rate increase in response to exercise,initial,2018-03-01,GCST005845,Cardiovascular measurement,#d53e4f
8013,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (10 sec),initial,2018-03-01,GCST005846,Cardiovascular measurement,#99d594
8014,African,1445.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (10 sec),initial,2018-03-01,GCST005846,Cardiovascular measurement,#fc8d59
8015,Asian,1744.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (10 sec),initial,2018-03-01,GCST005846,Cardiovascular measurement,#3288bd
8016,European,54137.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (10 sec),initial,2018-03-01,GCST005846,Cardiovascular measurement,#d53e4f
8018,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (20 sec),initial,2018-03-01,GCST005847,Cardiovascular measurement,#99d594
8019,African,1445.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (20 sec),initial,2018-03-01,GCST005847,Cardiovascular measurement,#fc8d59
8020,Asian,1744.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (20 sec),initial,2018-03-01,GCST005847,Cardiovascular measurement,#3288bd
8021,European,54137.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (20 sec),initial,2018-03-01,GCST005847,Cardiovascular measurement,#d53e4f
8022,European,770.0,29489655.0,Liu X,Milk allergy (maternal genetic effects),initial,2018-03-01,GCST005722,Other measurement,#d53e4f
8023,European,770.0,29489655.0,Liu X,Milk allergy (maternal genetic effects),initial,2018-03-01,GCST005722,Other measurement,#d53e4f
8024,European,835.0,29489655.0,Liu X,Peanut allergy (maternal genetic effects),initial,2018-03-01,GCST005723,Other measurement,#d53e4f
8025,European,835.0,29489655.0,Liu X,Peanut allergy (maternal genetic effects),initial,2018-03-01,GCST005723,Other measurement,#d53e4f
8026,European,1630.0,29489655.0,Liu X,Food allergy (maternal genetic effects),initial,2018-03-01,GCST005724,Other measurement,#d53e4f
8027,European,1630.0,29489655.0,Liu X,Food allergy (maternal genetic effects),initial,2018-03-01,GCST005724,Other measurement,#d53e4f
8028,European,563.0,29489655.0,Liu X,Egg allergy (parent-of-origin effect),initial,2018-03-01,GCST005725,Other measurement,#d53e4f
8029,European,563.0,29489655.0,Liu X,Egg allergy (parent-of-origin effect),initial,2018-03-01,GCST005725,Other measurement,#d53e4f
8030,European,770.0,29489655.0,Liu X,Milk allergy (parent-of-origin effect),initial,2018-03-01,GCST005726,Other measurement,#d53e4f
8031,European,770.0,29489655.0,Liu X,Milk allergy (parent-of-origin effect),initial,2018-03-01,GCST005726,Other measurement,#d53e4f
8032,European,835.0,29489655.0,Liu X,Peanut allergy (parent-of-origin effect),initial,2018-03-01,GCST005727,Other measurement,#d53e4f
8033,European,835.0,29489655.0,Liu X,Peanut allergy (parent-of-origin effect),initial,2018-03-01,GCST005727,Other measurement,#d53e4f
8034,African Am./Caribbean,134.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,initial,2018-03-01,GCST005729,Other measurement,#fee08b
8035,European,1576.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,initial,2018-03-01,GCST005729,Other measurement,#d53e4f
8036,Other/Mixed,38.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,initial,2018-03-01,GCST005729,Other measurement,#99d594
8037,Hispanic/Latin American,81.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,initial,2018-03-01,GCST005729,Other measurement,#807dba
8038,European,2722.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,replication,2018-03-01,GCST005729,Other measurement,#d53e4f
8039,African Am./Caribbean,204.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,replication,2018-03-01,GCST005729,Other measurement,#fee08b
8040,Hispanic/Latin American,113.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,replication,2018-03-01,GCST005729,Other measurement,#807dba
8041,Other/Mixed,84.0,29545823.0,O'Brien KM,Serum 25-Hydroxyvitamin D levels,replication,2018-03-01,GCST005729,Other measurement,#99d594
8042,Asian,11755.0,29494758.0,Liu L,Systemic lupus erythematosus,replication,2018-03-01,GCST005754,Immune system disorder,#3288bd
8043,Asian,2252.0,29494758.0,Liu L,Systemic lupus erythematosus,initial,2018-03-01,GCST005754,Immune system disorder,#3288bd
8044,European,563.0,29489655.0,Liu X,Egg allergy (maternal genetic effects),initial,2018-03-01,GCST005728,Other measurement,#d53e4f
8045,European,563.0,29489655.0,Liu X,Egg allergy (maternal genetic effects),initial,2018-03-01,GCST005728,Other measurement,#d53e4f
8047,African,1445.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (50 sec),initial,2018-03-01,GCST005848,Cardiovascular measurement,#fc8d59
8048,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (50 sec),initial,2018-03-01,GCST005848,Cardiovascular measurement,#99d594
8049,European,54137.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (50 sec),initial,2018-03-01,GCST005848,Cardiovascular measurement,#d53e4f
8050,Asian,1744.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (50 sec),initial,2018-03-01,GCST005848,Cardiovascular measurement,#3288bd
8052,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (40 sec),initial,2018-03-01,GCST005849,Cardiovascular measurement,#99d594
8053,African,1445.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (40 sec),initial,2018-03-01,GCST005849,Cardiovascular measurement,#fc8d59
8054,Asian,1744.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (40 sec),initial,2018-03-01,GCST005849,Cardiovascular measurement,#3288bd
8055,European,54137.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (40 sec),initial,2018-03-01,GCST005849,Cardiovascular measurement,#d53e4f
8057,Other/Mixed,468.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (30 sec),initial,2018-03-01,GCST005850,Cardiovascular measurement,#99d594
8058,African,1445.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (30 sec),initial,2018-03-01,GCST005850,Cardiovascular measurement,#fc8d59
8059,Asian,1744.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (30 sec),initial,2018-03-01,GCST005850,Cardiovascular measurement,#3288bd
8060,European,54137.0,29497042.0,Verweij N,Heart rate response to recovery post exercise (30 sec),initial,2018-03-01,GCST005850,Cardiovascular measurement,#d53e4f
8061,European,1630.0,29489655.0,Liu X,Food allergy (parent-of-origin effect),initial,2018-03-01,GCST005721,Other measurement,#d53e4f
8062,European,1630.0,29489655.0,Liu X,Food allergy (parent-of-origin effect),initial,2018-03-01,GCST005721,Other measurement,#d53e4f
8063,European,223.0,29535370.0,Kleinstein SE,Virologic severity in Herpes simplex virus type 2 infection,initial,2018-02-28,GCST005559,Other measurement,#d53e4f
8064,European,37657.0,29499414.0,Pei YF,Femoral neck bone mineral density,initial,2018-02-27,GCST005795,Other measurement,#d53e4f
8065,Asian,1539.0,29499414.0,Pei YF,Femoral neck bone mineral density,initial,2018-02-27,GCST005795,Other measurement,#3288bd
8066,African Am./Caribbean,849.0,29499414.0,Pei YF,Femoral neck bone mineral density,initial,2018-02-27,GCST005795,Other measurement,#fee08b
8067,Hispanic/Latin American,446.0,29499414.0,Pei YF,Femoral neck bone mineral density,initial,2018-02-27,GCST005795,Other measurement,#807dba
8068,African Am./Caribbean,849.0,29499414.0,Pei YF,Lumbar spine bone mineral density,initial,2018-02-27,GCST005796,Other measurement,#fee08b
8069,European,37657.0,29499414.0,Pei YF,Lumbar spine bone mineral density,initial,2018-02-27,GCST005796,Other measurement,#d53e4f
8070,Asian,1539.0,29499414.0,Pei YF,Lumbar spine bone mineral density,initial,2018-02-27,GCST005796,Other measurement,#3288bd
8071,Hispanic/Latin American,446.0,29499414.0,Pei YF,Lumbar spine bone mineral density,initial,2018-02-27,GCST005796,Other measurement,#807dba
8072,African Am./Caribbean,1800.0,29495422.0,Xu H,Idiopathic dilated cardiomyopathy,initial,2018-02-26,GCST005588,Cardiovascular disease,#fee08b
8073,European,105318.0,29483656.0,Pardinas AF,Schizophrenia,initial,2018-02-26,GCST006803,Neurological disorder,#d53e4f
8075,European,144368.0,29483656.0,Pardinas AF,Schizophrenia,replication,2018-02-26,GCST006803,Neurological disorder,#d53e4f
8076,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other trait,#d53e4f
8077,Asian,3027.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other trait,#3288bd
8078,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other trait,#99d594
8079,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other measurement,#d53e4f
8080,Asian,3027.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other measurement,#3288bd
8081,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional alcohol intake interaction),initial,2018-02-26,GCST005653,Other measurement,#99d594
8082,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other measurement,#d53e4f
8083,Asian,3027.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other measurement,#3288bd
8084,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other measurement,#99d594
8085,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other trait,#d53e4f
8086,Asian,3027.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other trait,#3288bd
8087,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional cigarette smoking interaction),initial,2018-02-26,GCST005654,Other trait,#99d594
8088,European,1823.0,29535710.0,Wahl A,IgG glycosylation patterns,initial,2018-02-26,GCST005656,Other measurement,#d53e4f
8089,European,1836.0,29535710.0,Wahl A,IgG glycosylation patterns,replication,2018-02-26,GCST005656,Other measurement,#d53e4f
8090,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other measurement,#d53e4f
8091,Asian,3072.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other measurement,#3288bd
8092,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other measurement,#99d594
8093,European,2475.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other trait,#d53e4f
8094,Asian,3072.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other trait,#3288bd
8095,Other/Mixed,177.0,29535761.0,Haaland OA,Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),initial,2018-02-26,GCST005652,Other trait,#99d594
8096,European,228.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol monotherapy),initial,2018-02-24,GCST005521,Response to drug,#d53e4f
8097,African Am./Caribbean,146.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol monotherapy),initial,2018-02-24,GCST005521,Response to drug,#fee08b
8098,European,228.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol monotherapy),initial,2018-02-24,GCST005521,Cardiovascular measurement,#d53e4f
8099,African Am./Caribbean,146.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol monotherapy),initial,2018-02-24,GCST005521,Cardiovascular measurement,#fee08b
8100,European,426.0,29478026.0,Shahin MH,Heart rate response to beta blockers,initial,2018-02-24,GCST005519,Response to drug,#d53e4f
8101,European,200.0,29478026.0,Shahin MH,Heart rate response to beta blockers,replication,2018-02-24,GCST005519,Response to drug,#d53e4f
8102,African Am./Caribbean,168.0,29478026.0,Shahin MH,Heart rate response to beta blockers,replication,2018-02-24,GCST005519,Response to drug,#fee08b
8103,African Am./Caribbean,273.0,29478026.0,Shahin MH,Heart rate response to beta blockers,initial,2018-02-24,GCST005519,Response to drug,#fee08b
8104,European,426.0,29478026.0,Shahin MH,Heart rate response to beta blockers,initial,2018-02-24,GCST005519,Cardiovascular measurement,#d53e4f
8105,European,200.0,29478026.0,Shahin MH,Heart rate response to beta blockers,replication,2018-02-24,GCST005519,Cardiovascular measurement,#d53e4f
8106,African Am./Caribbean,168.0,29478026.0,Shahin MH,Heart rate response to beta blockers,replication,2018-02-24,GCST005519,Cardiovascular measurement,#fee08b
8107,African Am./Caribbean,273.0,29478026.0,Shahin MH,Heart rate response to beta blockers,initial,2018-02-24,GCST005519,Cardiovascular measurement,#fee08b
8108,European,198.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol add-on therapy),initial,2018-02-24,GCST005520,Response to drug,#d53e4f
8109,African Am./Caribbean,127.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol add-on therapy),initial,2018-02-24,GCST005520,Response to drug,#fee08b
8110,European,198.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol add-on therapy),initial,2018-02-24,GCST005520,Cardiovascular measurement,#d53e4f
8111,African Am./Caribbean,127.0,29478026.0,Shahin MH,Heart rate response to beta blockers (atenolol add-on therapy),initial,2018-02-24,GCST005520,Cardiovascular measurement,#fee08b
8112,Asian,21198.0,29472232.0,Li Y,Coronary artery disease,replication,2018-02-22,GCST005582,Cardiovascular disease,#3288bd
8113,Asian,630.0,29472232.0,Li Y,Coronary artery disease,initial,2018-02-22,GCST005582,Cardiovascular disease,#3288bd
8114,European,4577.0,29472613.0,Warrier V,Theory of mind score in adolescence (Emotional Triangles Task),initial,2018-02-22,GCST005797,Other measurement,#d53e4f
8115,Asian,1045.0,29460428.0,Gelernter J,Alcohol dependence symptom count,initial,2018-02-20,GCST005440,Other measurement,#3288bd
8116,European,3598.0,29458411.0,Chung J,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005517,Metabolic disorder,#d53e4f
8117,European,3598.0,29458411.0,Chung J,Neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005517,Other measurement,#d53e4f
8118,European,3598.0,29458411.0,Chung J,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005515,Other measurement,#d53e4f
8119,European,3598.0,29458411.0,Chung J,Neuritic plaques or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005515,Metabolic disorder,#d53e4f
8120,European,3598.0,29458411.0,Chung J,Neuritic plaques or neurofibrillary tangles (pleiotropy),initial,2018-02-20,GCST005516,Other measurement,#d53e4f
8121,European,3598.0,29458411.0,Chung J,Neuritic plaques or neurofibrillary tangles (pleiotropy),initial,2018-02-20,GCST005516,Other measurement,#d53e4f
8122,European,4687.0,29496196.0,McCoy TH Jr.,Dimensional psychopathology (Cognitive),initial,2018-02-20,GCST005760,Other measurement,#d53e4f
8123,European,4687.0,29496196.0,McCoy TH Jr.,Dimensional psychopathology (Social),initial,2018-02-20,GCST005759,Other measurement,#d53e4f
8124,European,4687.0,29496196.0,McCoy TH Jr.,Dimensional psychopathology (Arousal),initial,2018-02-20,GCST005758,Other measurement,#d53e4f
8125,European,4687.0,29496196.0,McCoy TH Jr.,Dimensional psychopathology (Positive),initial,2018-02-20,GCST005757,Other measurement,#d53e4f
8126,Asian,1045.0,29460428.0,Gelernter J,Response to alcohol consumption (flushing response),initial,2018-02-20,GCST005439,Biological process,#3288bd
8127,Asian,1045.0,29460428.0,Gelernter J,Alcohol consumption (max-drinks),initial,2018-02-20,GCST005441,Other measurement,#3288bd
8128,European,4687.0,29496196.0,McCoy TH Jr.,Dimensional psychopathology (Negative),initial,2018-02-20,GCST005756,Other measurement,#d53e4f
8129,European,3598.0,29458411.0,Chung J,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005514,Other measurement,#d53e4f
8130,European,3598.0,29458411.0,Chung J,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005514,Metabolic disorder,#d53e4f
8131,European,3598.0,29458411.0,Chung J,Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),initial,2018-02-20,GCST005514,Other measurement,#d53e4f
8132,European,1719.0,29459680.0,Claes P,Facial morphology traits (63 three-dimensional facial segments),replication,2018-02-19,GCST007989,Other measurement,#d53e4f
8133,European,2329.0,29459680.0,Claes P,Facial morphology traits (63 three-dimensional facial segments),initial,2018-02-19,GCST007989,Other measurement,#d53e4f
8134,Asian,33870.0,29471430.0,Tanikawa C,Colorectal cancer,initial,2018-02-17,GCST005591,Cancer,#3288bd
8135,Asian,11046.0,29471430.0,Tanikawa C,Colorectal cancer,replication,2018-02-17,GCST005591,Cancer,#3288bd
8136,Asian,779.0,29453196.0,Sato Y,Sperm motility,replication,2018-02-16,GCST005798,Other measurement,#3288bd
8137,Asian,811.0,29453196.0,Sato Y,Sperm motility,initial,2018-02-16,GCST005798,Other measurement,#3288bd
8138,Asian,2818.0,29453348.0,Chen CJ,Hyperuricemia,initial,2018-02-16,GCST005802,Metabolic disorder,#3288bd
8139,Asian,1494.0,29453348.0,Chen CJ,Gout vs. Hyperuricemia,initial,2018-02-16,GCST005801,Metabolic disorder,#3288bd
8140,Asian,1494.0,29453348.0,Chen CJ,Gout vs. Hyperuricemia,initial,2018-02-16,GCST005801,Metabolic disorder,#3288bd
8141,Asian,2818.0,29453348.0,Chen CJ,Gout,initial,2018-02-16,GCST005799,Metabolic disorder,#3288bd
8142,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#3288bd
8143,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#3288bd
8144,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8145,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#fc8d59
8146,European,80542.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#d53e4f
8147,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#fee08b
8148,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#807dba
8149,European,300070.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#d53e4f
8150,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#fee08b
8151,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8152,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8153,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#807dba
8154,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#3288bd
8155,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#3288bd
8156,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8157,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#fc8d59
8158,European,80542.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#d53e4f
8159,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#fee08b
8160,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006186,Other measurement,#807dba
8161,European,300070.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#d53e4f
8162,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#fee08b
8163,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8164,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#3288bd
8165,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006186,Other measurement,#807dba
8166,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#fc8d59
8167,European,80552.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#d53e4f
8168,Asian,13438.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#3288bd
8169,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#807dba
8170,European,305832.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#d53e4f
8171,African Am./Caribbean,7786.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#fee08b
8172,Asian,136451.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#3288bd
8173,Asian,12481.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#3288bd
8174,Hispanic/Latin American,17947.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#807dba
8175,African Am./Caribbean,25889.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#fee08b
8176,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#fc8d59
8177,European,80552.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#d53e4f
8178,Asian,13438.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#3288bd
8179,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#807dba
8180,European,305832.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#d53e4f
8181,African Am./Caribbean,7786.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#fee08b
8182,Asian,136451.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#3288bd
8183,Asian,12481.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#3288bd
8184,Hispanic/Latin American,17947.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006187,Other measurement,#807dba
8185,African Am./Caribbean,25889.0,29455858.0,Sung YJ,Diastolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006187,Other measurement,#fee08b
8186,Hispanic/Latin American,17947.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#807dba
8187,Asian,12481.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#3288bd
8188,African Am./Caribbean,7786.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#fee08b
8189,Asian,136451.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#3288bd
8190,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#fc8d59
8191,European,80552.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#d53e4f
8192,African Am./Caribbean,25889.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#fee08b
8193,Asian,13438.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#3288bd
8194,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#807dba
8195,European,305832.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#d53e4f
8196,Hispanic/Latin American,17947.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#807dba
8197,Asian,12481.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#3288bd
8198,African Am./Caribbean,7786.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#fee08b
8199,Asian,136451.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#3288bd
8200,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#fc8d59
8201,European,80552.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#d53e4f
8202,African Am./Caribbean,25889.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#fee08b
8203,Asian,13438.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#3288bd
8204,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),initial,2018-02-15,GCST006188,Other measurement,#807dba
8205,European,305832.0,29455858.0,Sung YJ,Systolic blood pressure (cigarette smoking interaction),replication,2018-02-15,GCST006188,Other measurement,#d53e4f
8206,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8207,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8208,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#fee08b
8209,European,285041.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#d53e4f
8210,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#807dba
8211,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8212,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#fee08b
8213,European,80551.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#d53e4f
8214,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#807dba
8215,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#3288bd
8216,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#3288bd
8217,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8218,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8219,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#fee08b
8220,European,285041.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#d53e4f
8221,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#807dba
8222,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#3288bd
8223,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#fee08b
8224,European,80551.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#d53e4f
8225,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006189,Other measurement,#807dba
8226,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#3288bd
8227,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006189,Other measurement,#3288bd
8228,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#3288bd
8229,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#807dba
8230,European,80551.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#d53e4f
8231,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#fee08b
8232,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#3288bd
8233,European,285041.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#d53e4f
8234,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#fee08b
8235,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8236,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8237,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#807dba
8238,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8239,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#3288bd
8240,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#807dba
8241,European,80551.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#d53e4f
8242,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#fee08b
8243,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006190,Other measurement,#3288bd
8244,European,285041.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#d53e4f
8245,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#fee08b
8246,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8247,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8248,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#807dba
8249,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006190,Other measurement,#3288bd
8250,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#3288bd
8251,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#3288bd
8252,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8253,European,80551.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#d53e4f
8254,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#fee08b
8255,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#807dba
8256,European,285041.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#d53e4f
8257,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8258,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#fee08b
8259,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8260,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#807dba
8261,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#3288bd
8262,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#3288bd
8263,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8264,European,80551.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#d53e4f
8265,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#fee08b
8266,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),initial,2018-02-15,GCST006191,Other measurement,#807dba
8267,European,285041.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#d53e4f
8268,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8269,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#fee08b
8270,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#3288bd
8271,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),replication,2018-02-15,GCST006191,Other measurement,#807dba
8272,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#3288bd
8273,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8274,European,80551.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#d53e4f
8275,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#fee08b
8276,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#3288bd
8277,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#807dba
8278,European,285041.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#d53e4f
8279,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#fee08b
8280,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8281,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8282,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#807dba
8283,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#3288bd
8284,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8285,European,80551.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#d53e4f
8286,African Am./Caribbean,25814.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#fee08b
8287,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#3288bd
8288,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),initial,2018-02-15,GCST006192,Other measurement,#807dba
8289,European,285041.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#d53e4f
8290,African Am./Caribbean,6180.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#fee08b
8291,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8292,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#3288bd
8293,Hispanic/Latin American,17943.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (ever vs never) interaction (2df test),replication,2018-02-15,GCST006192,Other measurement,#807dba
8294,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#3288bd
8295,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#fc8d59
8296,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8297,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8298,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#fee08b
8299,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#807dba
8300,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#807dba
8301,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#3288bd
8302,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#fee08b
8303,European,80542.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#d53e4f
8304,European,300070.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#d53e4f
8305,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8306,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#3288bd
8307,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#fc8d59
8308,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8309,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8310,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#fee08b
8311,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#807dba
8312,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#807dba
8313,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#3288bd
8314,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#fee08b
8315,European,80542.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006193,Other measurement,#d53e4f
8316,European,300070.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#d53e4f
8317,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006193,Other measurement,#3288bd
8318,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#fee08b
8319,European,300070.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#d53e4f
8320,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8321,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8322,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#807dba
8323,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#807dba
8324,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#3288bd
8325,European,80542.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#d53e4f
8326,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#fee08b
8327,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8328,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#3288bd
8329,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#fc8d59
8330,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#fee08b
8331,European,300070.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#d53e4f
8332,Asian,135505.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8333,Asian,12475.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8334,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#807dba
8335,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#807dba
8336,Asian,11603.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#3288bd
8337,European,80542.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#d53e4f
8338,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#fee08b
8339,Asian,952.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),replication,2018-02-15,GCST006194,Other measurement,#3288bd
8340,Asian,1835.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#3288bd
8341,African,1229.0,29455858.0,Sung YJ,Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),initial,2018-02-15,GCST006194,Other measurement,#fc8d59
8342,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#3288bd
8343,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8344,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#fc8d59
8345,European,80542.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#d53e4f
8346,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#fee08b
8347,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#3288bd
8348,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#807dba
8349,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#fee08b
8350,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8351,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8352,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#807dba
8353,European,300070.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#d53e4f
8354,Asian,1835.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#3288bd
8355,Asian,952.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8356,African,1229.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#fc8d59
8357,European,80542.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#d53e4f
8358,African Am./Caribbean,25887.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#fee08b
8359,Asian,11603.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#3288bd
8360,Hispanic/Latin American,8805.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),initial,2018-02-15,GCST006195,Other measurement,#807dba
8361,African Am./Caribbean,7785.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#fee08b
8362,Asian,135505.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8363,Asian,12475.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#3288bd
8364,Hispanic/Latin American,17936.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#807dba
8365,European,300070.0,29455858.0,Sung YJ,Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),replication,2018-02-15,GCST006195,Other measurement,#d53e4f
8366,European,9821.0,29449654.0,Gharahkhani P,Glaucoma (primary open-angle),initial,2018-02-15,GCST005407,Neurological disorder,#d53e4f
8368,European,39399.0,29449654.0,Gharahkhani P,Open-angle glaucoma and intra-ocular pressure,initial,2018-02-15,GCST005408,Neurological disorder,#d53e4f
8369,Asian,8352.0,29449654.0,Gharahkhani P,Open-angle glaucoma and intra-ocular pressure,initial,2018-02-15,GCST005408,Neurological disorder,#3288bd
8370,European,39399.0,29449654.0,Gharahkhani P,Open-angle glaucoma and intra-ocular pressure,initial,2018-02-15,GCST005408,Other measurement,#d53e4f
8371,Asian,8352.0,29449654.0,Gharahkhani P,Open-angle glaucoma and intra-ocular pressure,initial,2018-02-15,GCST005408,Other measurement,#3288bd
8372,European,33720.0,29449654.0,Gharahkhani P,Open-angle glaucoma and vertical cup-disc ratio,initial,2018-02-15,GCST005409,Other measurement,#d53e4f
8373,Asian,8373.0,29449654.0,Gharahkhani P,Open-angle glaucoma and vertical cup-disc ratio,initial,2018-02-15,GCST005409,Other measurement,#3288bd
8374,European,33720.0,29449654.0,Gharahkhani P,Open-angle glaucoma and vertical cup-disc ratio,initial,2018-02-15,GCST005409,Neurological disorder,#d53e4f
8375,Asian,8373.0,29449654.0,Gharahkhani P,Open-angle glaucoma and vertical cup-disc ratio,initial,2018-02-15,GCST005409,Neurological disorder,#3288bd
8376,European,32325.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic disc area,initial,2018-02-15,GCST005410,Neurological disorder,#d53e4f
8377,Asian,7307.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic disc area,initial,2018-02-15,GCST005410,Neurological disorder,#3288bd
8378,European,32325.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic disc area,initial,2018-02-15,GCST005410,Other measurement,#d53e4f
8379,Asian,7307.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic disc area,initial,2018-02-15,GCST005410,Other measurement,#3288bd
8380,Asian,6340.0,29246937.0,Li Y,Hepatitis B virus-related hepatocellular carcinoma,replication,2018-02-15,GCST005570,Cancer,#3288bd
8381,Asian,1274.0,29246937.0,Li Y,Hepatitis B virus-related hepatocellular carcinoma,initial,2018-02-15,GCST005570,Cancer,#3288bd
8382,Asian,6340.0,29246937.0,Li Y,Hepatitis B virus-related hepatocellular carcinoma,replication,2018-02-15,GCST005570,Digestive system disorder,#3288bd
8383,Asian,1274.0,29246937.0,Li Y,Hepatitis B virus-related hepatocellular carcinoma,initial,2018-02-15,GCST005570,Digestive system disorder,#3288bd
8384,European,32310.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic cup area,initial,2018-02-15,GCST005406,Other measurement,#d53e4f
8385,Asian,7339.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic cup area,initial,2018-02-15,GCST005406,Other measurement,#3288bd
8386,European,32310.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic cup area,initial,2018-02-15,GCST005406,Neurological disorder,#d53e4f
8387,Asian,7339.0,29449654.0,Gharahkhani P,Open-angle glaucoma and optic cup area,initial,2018-02-15,GCST005406,Neurological disorder,#3288bd
8388,African Am./Caribbean,1432.0,29452408.0,Shiga Y,Glaucoma (primary open-angle),replication,2018-02-14,GCST005388,Neurological disorder,#fee08b
8389,African,2946.0,29452408.0,Shiga Y,Glaucoma (primary open-angle),replication,2018-02-14,GCST005388,Neurological disorder,#fc8d59
8390,European,40480.0,29452408.0,Shiga Y,Glaucoma (primary open-angle),replication,2018-02-14,GCST005388,Neurological disorder,#d53e4f
8391,Asian,22567.0,29452408.0,Shiga Y,Glaucoma (primary open-angle),replication,2018-02-14,GCST005388,Neurological disorder,#3288bd
8392,Asian,22795.0,29452408.0,Shiga Y,Glaucoma (primary open-angle),initial,2018-02-14,GCST005388,Neurological disorder,#3288bd
8393,European,607.0,29425463.0,Bime C,Acute respiratory distress syndrome,replication,2018-02-09,GCST005805,Other disease,#d53e4f
8394,African Am./Caribbean,362.0,29425463.0,Bime C,Acute respiratory distress syndrome,replication,2018-02-09,GCST005805,Other disease,#fee08b
8395,African Am./Caribbean,394.0,29425463.0,Bime C,Acute respiratory distress syndrome,initial,2018-02-09,GCST005805,Other disease,#fee08b
8396,European,685.0,29432556.0,Brooke RJ,Premature menopause in childhood cancer survivors,initial,2018-02-08,GCST005518,Other disease,#d53e4f
8397,African,114.0,29432556.0,Brooke RJ,Premature menopause in childhood cancer survivors,initial,2018-02-08,GCST005518,Other disease,#fc8d59
8398,European,21536.0,29422604.0,Klein AP,Pancreatic cancer,initial,2018-02-08,GCST005434,Cancer,#d53e4f
8400,European,107364.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee (with total joint replacement),replication,2018-02-07,GCST005571,Other disease,#d53e4f
8401,European,15353.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee (with total joint replacement),initial,2018-02-07,GCST005571,Other disease,#d53e4f
8402,European,107364.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee (with total joint replacement),replication,2018-02-07,GCST005571,Other disease,#d53e4f
8403,European,15353.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee (with total joint replacement),initial,2018-02-07,GCST005571,Other disease,#d53e4f
8404,European,11475.0,29436472.0,Casalone E,Osteoarthritis of the knee (with total joint replacement),replication,2018-02-07,GCST005574,Other disease,#d53e4f
8405,European,12127.0,29436472.0,Casalone E,Osteoarthritis of the knee (with total joint replacement),initial,2018-02-07,GCST005574,Other disease,#d53e4f
8406,European,11475.0,29436472.0,Casalone E,Osteoarthritis of the hip (with total joint replacement),replication,2018-02-07,GCST005572,Other disease,#d53e4f
8407,European,12456.0,29436472.0,Casalone E,Osteoarthritis of the hip (with total joint replacement),initial,2018-02-07,GCST005572,Other disease,#d53e4f
8408,European,63556.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee,replication,2018-02-07,GCST005573,Other disease,#d53e4f
8409,European,15353.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee,initial,2018-02-07,GCST005573,Other disease,#d53e4f
8410,European,63556.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee,replication,2018-02-07,GCST005573,Other disease,#d53e4f
8411,European,15353.0,29436472.0,Casalone E,Osteoarthritis of the hip or knee,initial,2018-02-07,GCST005573,Other disease,#d53e4f
8412,European,1303.0,29404672.0,Roshandel D,Stimulated C-peptide levels in type I diabetes,initial,2018-02-05,GCST005435,Other measurement,#d53e4f
8413,European,1303.0,29404672.0,Roshandel D,Stimulated C-peptide levels in type I diabetes,initial,2018-02-05,GCST005435,Metabolic disorder,#d53e4f
8414,Asian,75391.0,29403010.0,Kanai M,C-reactive protein levels,initial,2018-02-05,GCST006012,Inflammatory measurement,#3288bd
8415,Asian,126319.0,29403010.0,Kanai M,Lactate dehydrogenase levels,initial,2018-02-05,GCST006013,Hematological measurement,#3288bd
8416,Asian,106080.0,29403010.0,Kanai M,Creatine kinase levels,initial,2018-02-05,GCST006014,Cardiovascular measurement,#3288bd
8417,Asian,18348.0,29403010.0,Kanai M,Fibrinogen levels,initial,2018-02-05,GCST006015,Hematological measurement,#3288bd
8418,Asian,58110.0,29403010.0,Kanai M,Prothrombin time,initial,2018-02-05,GCST006017,Hematological measurement,#3288bd
8419,Asian,37767.0,29403010.0,Kanai M,Activated partial thromboplastin time,initial,2018-02-05,GCST006018,Hematological measurement,#3288bd
8420,Asian,118309.0,29403010.0,Kanai M,Gamma glutamyl transferase levels,initial,2018-02-05,GCST006019,Liver enzyme measurement,#3288bd
8421,Asian,105030.0,29403010.0,Kanai M,Serum alkaline phosphatase levels,initial,2018-02-05,GCST006016,Liver enzyme measurement,#3288bd
8422,Asian,134182.0,29403010.0,Kanai M,Alanine transaminase levels,initial,2018-02-05,GCST005998,Liver enzyme measurement,#3288bd
8423,Asian,134154.0,29403010.0,Kanai M,Aspartate aminotransferase levels,initial,2018-02-05,GCST005999,Liver enzyme measurement,#3288bd
8424,Asian,12303.0,29403010.0,Kanai M,Immunoglobulin measurement (zinc sulfate turbidity test),initial,2018-02-05,GCST006000,Other measurement,#3288bd
8425,Asian,42790.0,29403010.0,Kanai M,Hemoglobin A1c levels,initial,2018-02-05,GCST006001,Other measurement,#3288bd
8426,Asian,93146.0,29403010.0,Kanai M,Blood sugar levels,initial,2018-02-05,GCST006002,Other measurement,#3288bd
8427,Asian,105597.0,29403010.0,Kanai M,Triglyceride levels,initial,2018-02-05,GCST006003,Lipid or lipoprotein measurement,#3288bd
8428,Asian,72866.0,29403010.0,Kanai M,Low density lipoprotein cholesterol levels,initial,2018-02-05,GCST006004,Lipid or lipoprotein measurement,#3288bd
8429,Asian,70657.0,29403010.0,Kanai M,High density lipoprotein cholesterol levels,initial,2018-02-05,GCST006005,Lipid or lipoprotein measurement,#3288bd
8430,Asian,8600.0,29403010.0,Kanai M,E/A ratio,initial,2018-02-05,GCST006024,Cardiovascular measurement,#3288bd
8431,Asian,17837.0,29403010.0,Kanai M,Left ventricular mass index,initial,2018-02-05,GCST006025,Cardiovascular measurement,#3288bd
8432,Asian,19076.0,29403010.0,Kanai M,Left ventricular mass,initial,2018-02-05,GCST006026,Cardiovascular measurement,#3288bd
8433,Asian,19373.0,29403010.0,Kanai M,Posterior wall thickness,initial,2018-02-05,GCST006027,Cardiovascular measurement,#3288bd
8434,Asian,19318.0,29403010.0,Kanai M,Interventricular septum thickness,initial,2018-02-05,GCST006028,Cardiovascular measurement,#3288bd
8435,Asian,19516.0,29403010.0,Kanai M,Ejection fraction,initial,2018-02-05,GCST006006,Cardiovascular measurement,#3288bd
8436,Asian,19580.0,29403010.0,Kanai M,Fractional shortening,initial,2018-02-05,GCST006029,Cardiovascular measurement,#3288bd
8437,Asian,19311.0,29403010.0,Kanai M,Relative wall thickness,initial,2018-02-05,GCST006033,Cardiovascular measurement,#3288bd
8438,Asian,19586.0,29403010.0,Kanai M,Left ventricular internal dimension in systole,initial,2018-02-05,GCST006007,Cardiovascular measurement,#3288bd
8439,Asian,19676.0,29403010.0,Kanai M,Left ventricular internal dimension in diastole,initial,2018-02-05,GCST006008,Cardiovascular measurement,#3288bd
8440,Asian,136249.0,29403010.0,Kanai M,Pulse pressure,initial,2018-02-05,GCST006009,Cardiovascular measurement,#3288bd
8441,Asian,136482.0,29403010.0,Kanai M,Mean arterial pressure,initial,2018-02-05,GCST006010,Other measurement,#3288bd
8442,Asian,136615.0,29403010.0,Kanai M,Diastolic blood pressure,initial,2018-02-05,GCST005978,Other measurement,#3288bd
8443,Asian,136597.0,29403010.0,Kanai M,Systolic blood pressure,initial,2018-02-05,GCST005979,Other measurement,#3288bd
8444,Asian,110207.0,29403010.0,Kanai M,Total bilirubin levels,initial,2018-02-05,GCST005980,Other measurement,#3288bd
8445,Asian,42793.0,29403010.0,Kanai M,Phosphorus levels,initial,2018-02-05,GCST005981,Other measurement,#3288bd
8446,Asian,71701.0,29403010.0,Kanai M,Calcium levels,initial,2018-02-05,GCST005982,Other measurement,#3288bd
8447,Asian,126402.0,29403010.0,Kanai M,Chloride levels,initial,2018-02-05,GCST006030,Other measurement,#3288bd
8448,Asian,132938.0,29403010.0,Kanai M,Potassium levels,initial,2018-02-05,GCST006031,Other measurement,#3288bd
8449,Asian,127304.0,29403010.0,Kanai M,Sodium levels,initial,2018-02-05,GCST006032,Other measurement,#3288bd
8450,Asian,109029.0,29403010.0,Kanai M,Serum uric acid levels,initial,2018-02-05,GCST005983,Cardiovascular measurement,#3288bd
8451,Asian,143658.0,29403010.0,Kanai M,Glomerular filtration rate,initial,2018-02-05,GCST005984,Other measurement,#3288bd
8452,Asian,142097.0,29403010.0,Kanai M,Creatinine levels,initial,2018-02-05,GCST005985,Other measurement,#3288bd
8453,Asian,139818.0,29403010.0,Kanai M,Blood urea nitrogen levels,initial,2018-02-05,GCST005986,Other measurement,#3288bd
8454,Asian,98626.0,29403010.0,Kanai M,Albumin-globulin ratio,initial,2018-02-05,GCST005987,Cardiovascular measurement,#3288bd
8455,Asian,102223.0,29403010.0,Kanai M,Serum albumin level,initial,2018-02-05,GCST005988,Other measurement,#3288bd
8456,Asian,113509.0,29403010.0,Kanai M,Serum total protein level,initial,2018-02-05,GCST005989,Other measurement,#3288bd
8457,Asian,98538.0,29403010.0,Kanai M,Non-albumin protein levels,initial,2018-02-05,GCST005990,Other measurement,#3288bd
8458,Asian,108208.0,29403010.0,Kanai M,Platelet count,initial,2018-02-05,GCST005991,Hematological measurement,#3288bd
8459,Asian,108728.0,29403010.0,Kanai M,Mean corpuscular hemoglobin concentration,initial,2018-02-05,GCST005992,Hematological measurement,#3288bd
8460,Asian,108054.0,29403010.0,Kanai M,Mean corpuscular hemoglobin,initial,2018-02-05,GCST005993,Hematological measurement,#3288bd
8461,Asian,108256.0,29403010.0,Kanai M,Mean corpuscular volume,initial,2018-02-05,GCST006011,Hematological measurement,#3288bd
8462,Asian,108757.0,29403010.0,Kanai M,Hematocrit,initial,2018-02-05,GCST005994,Hematological measurement,#3288bd
8463,Asian,108769.0,29403010.0,Kanai M,Hemoglobin,initial,2018-02-05,GCST005995,Hematological measurement,#3288bd
8464,Asian,108794.0,29403010.0,Kanai M,Red blood cell count,initial,2018-02-05,GCST005996,Hematological measurement,#3288bd
8465,Asian,62076.0,29403010.0,Kanai M,Lymphocyte counts,initial,2018-02-05,GCST005997,Hematological measurement,#3288bd
8466,Asian,62076.0,29403010.0,Kanai M,Monocyte count,initial,2018-02-05,GCST005977,Hematological measurement,#3288bd
8467,Asian,62076.0,29403010.0,Kanai M,White blood cell count (basophil),initial,2018-02-05,GCST005976,Inflammatory measurement,#3288bd
8468,Asian,62076.0,29403010.0,Kanai M,Eosinophil counts,initial,2018-02-05,GCST005975,Hematological measurement,#3288bd
8469,Asian,62076.0,29403010.0,Kanai M,Neutrophil count,initial,2018-02-05,GCST005974,Hematological measurement,#3288bd
8470,Asian,107964.0,29403010.0,Kanai M,White blood cell count,initial,2018-02-05,GCST005973,Hematological measurement,#3288bd
8471,European,3479.0,29404672.0,Roshandel D,C-peptide levels in type I diabetes,initial,2018-02-05,GCST005436,Other measurement,#d53e4f
8472,European,3479.0,29404672.0,Roshandel D,C-peptide levels in type I diabetes,initial,2018-02-05,GCST005436,Metabolic disorder,#d53e4f
8473,European,1497.0,29404672.0,Roshandel D,Random C-peptide levels in type I diabetes,initial,2018-02-05,GCST005437,Other measurement,#d53e4f
8474,European,1497.0,29404672.0,Roshandel D,Random C-peptide levels in type I diabetes,initial,2018-02-05,GCST005437,Metabolic disorder,#d53e4f
8475,European,2019.0,29404672.0,Roshandel D,Fasting C-peptide levels in type I diabetes,initial,2018-02-05,GCST005438,Other measurement,#d53e4f
8476,European,2019.0,29404672.0,Roshandel D,Fasting C-peptide levels in type I diabetes,initial,2018-02-05,GCST005438,Metabolic disorder,#d53e4f
8477,Asian,9120.0,29422769.0,Shah RL,Corneal astigmatism,initial,2018-02-05,GCST005803,Neurological disorder,#3288bd
8478,European,22250.0,29422769.0,Shah RL,Corneal astigmatism,initial,2018-02-05,GCST005803,Neurological disorder,#d53e4f
8479,Asian,128305.0,29403010.0,Kanai M,Total cholesterol levels,initial,2018-02-05,GCST006034,Lipid or lipoprotein measurement,#3288bd
8480,Asian,1634.0,29408531.0,Zhang D,Serum uric acid levels,initial,2018-02-02,GCST005369,Cardiovascular measurement,#3288bd
8481,Asian,2818.0,29408531.0,Zhang D,Serum uric acid levels,replication,2018-02-02,GCST005369,Cardiovascular measurement,#3288bd
8482,Hispanic/Latin American,5616.0,29394082.0,Burkart KM,Chronic obstructive pulmonary disease,initial,2018-02-02,GCST005417,Other disease,#807dba
8483,Hispanic/Latin American,10403.0,29394082.0,Burkart KM,Airflow obstruction,initial,2018-02-02,GCST005416,Other measurement,#807dba
8484,Hispanic/Latin American,4162.0,29394082.0,Burkart KM,Lung function (FEV1/FVC),replication,2018-02-02,GCST005419,Other measurement,#807dba
8485,Hispanic/Latin American,11822.0,29394082.0,Burkart KM,Lung function (FEV1/FVC),initial,2018-02-02,GCST005419,Other measurement,#807dba
8486,European,94612.0,29394082.0,Burkart KM,Lung function (FEV1/FVC),replication,2018-02-02,GCST005419,Other measurement,#d53e4f
8487,African Am./Caribbean,876.0,29394082.0,Burkart KM,Lung function (FEV1/FVC),replication,2018-02-02,GCST005419,Other measurement,#fee08b
8488,Hispanic/Latin American,4162.0,29394082.0,Burkart KM,FEV1,replication,2018-02-02,GCST005418,Other measurement,#807dba
8489,African Am./Caribbean,876.0,29394082.0,Burkart KM,FEV1,replication,2018-02-02,GCST005418,Other measurement,#fee08b
8490,European,94612.0,29394082.0,Burkart KM,FEV1,replication,2018-02-02,GCST005418,Other measurement,#d53e4f
8491,Hispanic/Latin American,11822.0,29394082.0,Burkart KM,FEV1,initial,2018-02-02,GCST005418,Other measurement,#807dba
8492,European,2209.0,29391396.0,McElroy SL,Binge eating behaviour and bipolar disorder,initial,2018-02-02,GCST005386,Metabolic disorder,#d53e4f
8493,European,2209.0,29391396.0,McElroy SL,Binge eating behaviour and bipolar disorder,initial,2018-02-02,GCST005386,Neurological disorder,#d53e4f
8494,European,1610.0,29391396.0,McElroy SL,Binge eating behaviour in bipolar disorder,initial,2018-02-02,GCST005387,Metabolic disorder,#d53e4f
8495,European,1610.0,29391396.0,McElroy SL,Binge eating behaviour in bipolar disorder,initial,2018-02-02,GCST005387,Neurological disorder,#d53e4f
8496,European,116255.0,29391395.0,Strawbridge RJ,Self-reported risk-taking behaviour,initial,2018-02-02,GCST005415,Biological process,#d53e4f
8497,European,139473.0,29391395.0,Strawbridge RJ,Self-reported risk-taking behaviour,replication,2018-02-02,GCST005415,Biological process,#d53e4f
8498,European,3116.0,29378355.0,Stanne TM,Thrombin-activatable fibrinolysis inhibitor levels,initial,2018-02-01,GCST005412,Other measurement,#d53e4f
8499,Asian,731.0,29581620.0,Fujii R,Pollinosis,initial,2018-02-01,GCST005556,Immune system disorder,#3288bd
8500,Asian,560.0,29581620.0,Fujii R,Pollinosis,replication,2018-02-01,GCST005556,Immune system disorder,#3288bd
8501,European,1098.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor-recipient interaction),initial,2018-02-01,GCST005433,Other measurement,#d53e4f
8502,European,3148.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor-recipient interaction),replication,2018-02-01,GCST005433,Other measurement,#d53e4f
8503,European,1098.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor-recipient interaction),initial,2018-02-01,GCST005433,Other measurement,#d53e4f
8504,European,3148.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor-recipient interaction),replication,2018-02-01,GCST005433,Other measurement,#d53e4f
8505,European,2318.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor effect),initial,2018-02-01,GCST005432,Other measurement,#d53e4f
8506,European,3148.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor effect),replication,2018-02-01,GCST005432,Other measurement,#d53e4f
8507,European,2318.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor effect),initial,2018-02-01,GCST005432,Other measurement,#d53e4f
8508,European,3148.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (donor effect),replication,2018-02-01,GCST005432,Other measurement,#d53e4f
8509,European,2695.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (recipient effect),initial,2018-02-01,GCST005431,Other measurement,#d53e4f
8510,European,3148.0,29392897.0,Hernandez-Fuentes MP,Acute graft rejection in renal transplantation (recipient effect),replication,2018-02-01,GCST005431,Other measurement,#d53e4f
8511,European,4188.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor-recipient interaction),initial,2018-02-01,GCST005430,Other measurement,#d53e4f
8512,European,11218.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor-recipient interaction),replication,2018-02-01,GCST005430,Other measurement,#d53e4f
8513,European,4188.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor-recipient interaction),initial,2018-02-01,GCST005430,Other measurement,#d53e4f
8514,European,11218.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor-recipient interaction),replication,2018-02-01,GCST005430,Other measurement,#d53e4f
8515,European,5027.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor effect),replication,2018-02-01,GCST005429,Other measurement,#d53e4f
8516,European,2204.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor effect),initial,2018-02-01,GCST005429,Other measurement,#d53e4f
8517,European,5027.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor effect),replication,2018-02-01,GCST005429,Other measurement,#d53e4f
8518,European,2204.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (donor effect),initial,2018-02-01,GCST005429,Other measurement,#d53e4f
8519,European,5866.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (recipient effect),replication,2018-02-01,GCST005428,Other measurement,#d53e4f
8520,European,2689.0,29392897.0,Hernandez-Fuentes MP,Graft survival time in renal transplantation (recipient effect),initial,2018-02-01,GCST005428,Other measurement,#d53e4f
8521,European,5866.0,29392897.0,Hernandez-Fuentes MP,End stage renal failure in renal transplantation (recipient effect),replication,2018-02-01,GCST005427,Other measurement,#d53e4f
8522,European,10088.0,29392897.0,Hernandez-Fuentes MP,End stage renal failure in renal transplantation (recipient effect),initial,2018-02-01,GCST005427,Other measurement,#d53e4f
8523,European,5866.0,29392897.0,Hernandez-Fuentes MP,End stage renal failure in renal transplantation (recipient effect),replication,2018-02-01,GCST005427,Other disease,#d53e4f
8524,European,10088.0,29392897.0,Hernandez-Fuentes MP,End stage renal failure in renal transplantation (recipient effect),initial,2018-02-01,GCST005427,Other disease,#d53e4f
8525,European,5027.0,29392897.0,Hernandez-Fuentes MP,Intracranial haemorrhage in renal transplantation (donors),replication,2018-02-01,GCST005426,Cardiovascular disease,#d53e4f
8526,European,10088.0,29392897.0,Hernandez-Fuentes MP,Intracranial haemorrhage in renal transplantation (donors),initial,2018-02-01,GCST005426,Cardiovascular disease,#d53e4f
8527,European,697.0,29398083.0,Lores-Motta L,Serum C3d:C3 ratio (systemic complement activation),replication,2018-02-01,GCST005365,Hematological measurement,#d53e4f
8528,European,1548.0,29398083.0,Lores-Motta L,Serum C3d:C3 ratio (systemic complement activation),initial,2018-02-01,GCST005365,Hematological measurement,#d53e4f
8529,European,3124.0,29378355.0,Stanne TM,Thrombin-activatable fibrinolysis inhibitor activation peptide,initial,2018-02-01,GCST005411,Hematological measurement,#d53e4f
8530,European,2123.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Neurological disorder,#d53e4f
8531,African Am./Caribbean,139.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Neurological disorder,#fee08b
8532,European,2123.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Cancer,#d53e4f
8533,African Am./Caribbean,139.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Cancer,#fee08b
8534,European,2123.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Response to drug,#d53e4f
8535,African Am./Caribbean,139.0,29278617.0,Sucheston-Campbell LE,Taxane-induced peripheral neuropathy in breast cancer,initial,2018-02-01,GCST005804,Response to drug,#fee08b
8536,Asian,7730.0,29385134.0,Kawaguchi T,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma,initial,2018-01-31,GCST005309,Cancer,#3288bd
8537,Asian,7730.0,29385134.0,Kawaguchi T,Nonalcoholic steatohepatitis-derived hepatocellular carcinoma,initial,2018-01-31,GCST005309,Digestive system disorder,#3288bd
8538,European,223782.0,29397368.0,Meng W,Headache,initial,2018-01-31,GCST005337,Other trait,#d53e4f
8539,Asian,8574.0,29385134.0,Kawaguchi T,Nonalcoholic fatty liver disease,initial,2018-01-31,GCST005308,Digestive system disorder,#3288bd
8540,Asian,834.0,29385134.0,Kawaguchi T,Hepatocyte fat droplet content in nonalcoholic fatty liver disease,initial,2018-01-31,GCST005311,Other measurement,#3288bd
8541,Asian,567.0,29385134.0,Kawaguchi T,Brunt grade in nonalcoholic fatty liver disease,initial,2018-01-31,GCST005310,Other measurement,#3288bd
8542,Asian,474.0,29385134.0,Kawaguchi T,Brunt stage in nonalcoholic fatty liver disease,initial,2018-01-31,GCST005307,Other measurement,#3288bd
8543,African,914.0,29381699.0,Ravenhall M,Severe malaria (adjusted for sickle cell variant rs334),initial,2018-01-30,GCST005357,Digestive system disorder,#fc8d59
8544,African,914.0,29381699.0,Ravenhall M,Severe malaria,initial,2018-01-30,GCST005356,Digestive system disorder,#fc8d59
8545,Hispanic/Latin American,189.0,29382897.0,Pagerols M,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder,replication,2018-01-30,GCST005318,Neurological disorder,#807dba
8546,European,173.0,29382897.0,Pagerols M,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder,initial,2018-01-30,GCST005318,Neurological disorder,#d53e4f
8547,Hispanic/Latin American,189.0,29382897.0,Pagerols M,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder,replication,2018-01-30,GCST005318,Response to drug,#807dba
8548,European,173.0,29382897.0,Pagerols M,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder,initial,2018-01-30,GCST005318,Response to drug,#d53e4f
8549,Asian,1765.0,29404214.0,Andaleon A,"Cholesterol, total",initial,2018-01-29,GCST006305,Lipid or lipoprotein measurement,#3288bd
8550,African,1017.0,29404214.0,Andaleon A,"Cholesterol, total",initial,2018-01-29,GCST006305,Lipid or lipoprotein measurement,#fc8d59
8551,Asian,1765.0,29404214.0,Andaleon A,Triglyceride levels,initial,2018-01-29,GCST006472,Lipid or lipoprotein measurement,#3288bd
8552,African,1017.0,29404214.0,Andaleon A,Triglyceride levels,initial,2018-01-29,GCST006472,Lipid or lipoprotein measurement,#fc8d59
8554,Asian,1765.0,29404214.0,Andaleon A,LDL cholesterol,initial,2018-01-29,GCST006471,Lipid or lipoprotein measurement,#3288bd
8556,African,1017.0,29404214.0,Andaleon A,LDL cholesterol,initial,2018-01-29,GCST006471,Lipid or lipoprotein measurement,#fc8d59
8557,African,1017.0,29404214.0,Andaleon A,HDL cholesterol,initial,2018-01-29,GCST006470,Lipid or lipoprotein measurement,#fc8d59
8559,Asian,1765.0,29404214.0,Andaleon A,HDL cholesterol,initial,2018-01-29,GCST006470,Lipid or lipoprotein measurement,#3288bd
8561,African,1017.0,29404214.0,Andaleon A,"Cholesterol, total",initial,2018-01-29,GCST006469,Lipid or lipoprotein measurement,#fc8d59
8562,Asian,1765.0,29404214.0,Andaleon A,"Cholesterol, total",initial,2018-01-29,GCST006469,Lipid or lipoprotein measurement,#3288bd
8563,Asian,1765.0,29404214.0,Andaleon A,Triglycerides,initial,2018-01-29,GCST006308,Lipid or lipoprotein measurement,#3288bd
8564,African,1017.0,29404214.0,Andaleon A,Triglycerides,initial,2018-01-29,GCST006308,Lipid or lipoprotein measurement,#fc8d59
8565,Asian,1765.0,29404214.0,Andaleon A,LDL cholesterol,initial,2018-01-29,GCST006307,Lipid or lipoprotein measurement,#3288bd
8566,African,1017.0,29404214.0,Andaleon A,LDL cholesterol,initial,2018-01-29,GCST006307,Lipid or lipoprotein measurement,#fc8d59
8567,African,1017.0,29404214.0,Andaleon A,HDL cholesterol,initial,2018-01-29,GCST006306,Lipid or lipoprotein measurement,#fc8d59
8568,Asian,1765.0,29404214.0,Andaleon A,HDL cholesterol,initial,2018-01-29,GCST006306,Lipid or lipoprotein measurement,#3288bd
8569,European,4887.0,29379196.0,Fadista J,Hirschsprung disease,initial,2018-01-29,GCST005289,Digestive system disorder,#d53e4f
8570,European,1319.0,29379196.0,Fadista J,Hirschsprung disease,replication,2018-01-29,GCST005289,Digestive system disorder,#d53e4f
8571,Hispanic/Latin American,491.0,29374233.0,Lu AT,Extrinsic epigenetic age acceleration,replication,2018-01-26,GCST005288,Biological process,#807dba
8572,African Am./Caribbean,1023.0,29374233.0,Lu AT,Extrinsic epigenetic age acceleration,replication,2018-01-26,GCST005288,Biological process,#fee08b
8573,European,8393.0,29374233.0,Lu AT,Extrinsic epigenetic age acceleration,initial,2018-01-26,GCST005288,Biological process,#d53e4f
8574,Hispanic/Latin American,491.0,29374233.0,Lu AT,Intrinsic epigenetic age acceleration,replication,2018-01-26,GCST005287,Biological process,#807dba
8575,African Am./Caribbean,1023.0,29374233.0,Lu AT,Intrinsic epigenetic age acceleration,replication,2018-01-26,GCST005287,Biological process,#fee08b
8576,European,8393.0,29374233.0,Lu AT,Intrinsic epigenetic age acceleration,initial,2018-01-26,GCST005287,Biological process,#d53e4f
8577,European,66.0,29367611.0,Gao B,Paclitaxel disposition in epithelial ovarian cancer,initial,2018-01-24,GCST005352,Cancer,#d53e4f
8578,Asian,14.0,29367611.0,Gao B,Paclitaxel disposition in epithelial ovarian cancer,initial,2018-01-24,GCST005352,Cancer,#3288bd
8579,European,66.0,29367611.0,Gao B,Paclitaxel disposition in epithelial ovarian cancer,initial,2018-01-24,GCST005352,Response to drug,#d53e4f
8580,Asian,14.0,29367611.0,Gao B,Paclitaxel disposition in epithelial ovarian cancer,initial,2018-01-24,GCST005352,Response to drug,#3288bd
8581,Asian,11261.0,29367735.0,Nakagawa-Senda H,Coffee consumption,initial,2018-01-24,GCST005330,Other measurement,#3288bd
8582,Asian,4949.0,29367735.0,Nakagawa-Senda H,Coffee consumption,replication,2018-01-24,GCST005329,Other measurement,#3288bd
8583,Asian,6312.0,29367735.0,Nakagawa-Senda H,Coffee consumption,initial,2018-01-24,GCST005329,Other measurement,#3288bd
8584,Asian,14.0,29367611.0,Gao B,Carboplatin disposition in epthelial ovarian cancer,initial,2018-01-24,GCST005351,Cancer,#3288bd
8585,European,42.0,29367611.0,Gao B,Carboplatin disposition in epthelial ovarian cancer,initial,2018-01-24,GCST005351,Cancer,#d53e4f
8586,Asian,14.0,29367611.0,Gao B,Carboplatin disposition in epthelial ovarian cancer,initial,2018-01-24,GCST005351,Response to drug,#3288bd
8587,European,42.0,29367611.0,Gao B,Carboplatin disposition in epthelial ovarian cancer,initial,2018-01-24,GCST005351,Response to drug,#d53e4f
8590,European,127001.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005414,Metabolic disorder,#d53e4f
8591,Hispanic/Latin American,2583.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005414,Metabolic disorder,#807dba
8592,Asian,20019.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005414,Metabolic disorder,#3288bd
8593,Asian,18817.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005414,Metabolic disorder,#3288bd
8594,European,20979.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005898,Metabolic disorder,#d53e4f
8596,Hispanic/Latin American,3490.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,replication,2018-01-22,GCST005898,Metabolic disorder,#807dba
8597,European,9253.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,replication,2018-01-22,GCST005898,Metabolic disorder,#d53e4f
8598,European,57968.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005899,Metabolic disorder,#d53e4f
8599,European,75670.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,replication,2018-01-22,GCST005899,Metabolic disorder,#d53e4f
8600,Other/Mixed,16857.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,replication,2018-01-22,GCST005899,Metabolic disorder,#99d594
8601,European,70127.0,29358691.0,Bonas-Guarch S,Type 2 diabetes,initial,2018-01-22,GCST005413,Metabolic disorder,#d53e4f
8602,African,1040.0,29356057.0,Du Z,Prostate cancer,initial,2018-01-21,GCST005786,Cancer,#fc8d59
8603,European,1943.0,29360470.0,Miron J,Late-onset Alzheimer's disease,initial,2018-01-19,GCST006806,Neurological disorder,#d53e4f
8605,Hispanic/Latin American,1041.0,29348612.0,Wiemels JL,Acute lymphoblastic leukemia (childhood),replication,2018-01-18,GCST005315,Cancer,#807dba
8606,European,3583.0,29348612.0,Wiemels JL,Acute lymphoblastic leukemia (childhood),replication,2018-01-18,GCST005315,Cancer,#d53e4f
8607,African Am./Caribbean,3972.0,29348612.0,Wiemels JL,Acute lymphoblastic leukemia (childhood),initial,2018-01-18,GCST005315,Cancer,#fee08b
8608,Hispanic/Latin American,10533.0,29348612.0,Wiemels JL,Acute lymphoblastic leukemia (childhood),initial,2018-01-18,GCST005315,Cancer,#807dba
8609,European,4735.0,29348612.0,Wiemels JL,Acute lymphoblastic leukemia (childhood),initial,2018-01-18,GCST005315,Cancer,#d53e4f
8610,European,2113.0,29343764.0,Jiang X,Vitamin D levels (dietary vitamin D intake interaction),replication,2018-01-17,GCST005366,Other measurement,#d53e4f
8611,European,39868.0,29343764.0,Jiang X,Vitamin D levels (dietary vitamin D intake interaction),initial,2018-01-17,GCST005366,Other measurement,#d53e4f
8612,European,2113.0,29343764.0,Jiang X,Vitamin D levels (dietary vitamin D intake interaction),replication,2018-01-17,GCST005366,Other measurement,#d53e4f
8613,European,39868.0,29343764.0,Jiang X,Vitamin D levels (dietary vitamin D intake interaction),initial,2018-01-17,GCST005366,Other measurement,#d53e4f
8615,European,79366.0,29343764.0,Jiang X,Vitamin D levels,initial,2018-01-17,GCST005367,Other measurement,#d53e4f
8616,European,2721.0,29346644.0,Yan Q,Disease progression in age-related macular degeneration,initial,2018-01-15,GCST005359,Neurological disorder,#d53e4f
8617,European,2721.0,29346644.0,Yan Q,Disease progression in age-related macular degeneration,initial,2018-01-15,GCST005359,Other measurement,#d53e4f
8618,European,2721.0,29346644.0,Yan Q,Disease progression to choroidal neovascularization form in age-related macular degeneration,initial,2018-01-15,GCST005358,Other measurement,#d53e4f
8619,European,2721.0,29346644.0,Yan Q,Disease progression to choroidal neovascularization form in age-related macular degeneration,initial,2018-01-15,GCST005358,Neurological disorder,#d53e4f
8620,European,2721.0,29346644.0,Yan Q,Disease progression to geographic atrophy form in age-related macular degeneration,initial,2018-01-15,GCST005360,Neurological disorder,#d53e4f
8621,European,2721.0,29346644.0,Yan Q,Disease progression to geographic atrophy form in age-related macular degeneration,initial,2018-01-15,GCST005360,Other measurement,#d53e4f
8622,Asian,6846.0,29331962.0,Kochi Y,Idiopathic inflammatory myopathy,initial,2018-01-13,GCST005341,Immune system disorder,#3288bd
8623,European,105.0,29331962.0,Kochi Y,Clinically amyopathic dermatomyositis,replication,2018-01-13,GCST005338,Neurological disorder,#d53e4f
8624,Asian,6303.0,29331962.0,Kochi Y,Clinically amyopathic dermatomyositis,initial,2018-01-13,GCST005338,Neurological disorder,#3288bd
8625,Asian,6610.0,29331962.0,Kochi Y,Dermatomyositis,initial,2018-01-13,GCST005339,Neurological disorder,#3288bd
8626,Asian,6506.0,29331962.0,Kochi Y,Polymyositis,initial,2018-01-13,GCST005340,Neurological disorder,#3288bd
8633,European,3058.0,29478698.0,Cheng Z,Opioid dependence,initial,2018-01-11,GCST005368,Neurological disorder,#d53e4f
8634,African Am./Caribbean,2014.0,29478698.0,Cheng Z,Opioid dependence,replication,2018-01-11,GCST005368,Neurological disorder,#fee08b
8636,European,120934.0,29326435.0,Hill WD,Intelligence (MTAG),initial,2018-01-11,GCST005316,Biological process,#d53e4f
8640,European,43055.0,29317602.0,Hall LS,Major depressive disorder,initial,2018-01-10,GCST005231,Neurological disorder,#d53e4f
8641,European,39556.0,29317602.0,Hall LS,Recurrent major depressive disorder,initial,2018-01-10,GCST005230,Neurological disorder,#d53e4f
8642,European,290.0,29317604.0,Liu D,Plasma kynurenine to tryptophan ratio in major depressive disorder,initial,2018-01-10,GCST005343,Neurological disorder,#d53e4f
8643,European,290.0,29317604.0,Liu D,Plasma kynurenine to tryptophan ratio in major depressive disorder,initial,2018-01-10,GCST005343,Other measurement,#d53e4f
8644,European,290.0,29317604.0,Liu D,Plasma kynurenine levels in major depressive disorder,initial,2018-01-10,GCST005342,Neurological disorder,#d53e4f
8645,European,290.0,29317604.0,Liu D,Plasma kynurenine levels in major depressive disorder,initial,2018-01-10,GCST005342,Other measurement,#d53e4f
8652,European,7570.0,29325096.0,Eriksson AL,Estrone levels,initial,2018-01-09,GCST005827,Other measurement,#d53e4f
8674,Hispanic/Latin American,130.0,29315502.0,Tamraz B,Atazanavir levels,initial,2018-01-09,GCST006203,Other measurement,#807dba
8675,African Am./Caribbean,194.0,29315502.0,Tamraz B,Atazanavir levels,initial,2018-01-09,GCST006203,Other measurement,#fee08b
8676,European,64.0,29315502.0,Tamraz B,Atazanavir levels,initial,2018-01-09,GCST006203,Other measurement,#d53e4f
8677,Asian,10.0,29315502.0,Tamraz B,Atazanavir levels,initial,2018-01-09,GCST006203,Other measurement,#3288bd
8679,Hispanic/Latin American,3485.0,29325163.0,Hong J,Serum 25-Hydroxyvitamin D levels,initial,2018-01-09,GCST005782,Other measurement,#807dba
8680,African Am./Caribbean,8541.0,29325163.0,Hong J,Serum 25-Hydroxyvitamin D levels,initial,2018-01-09,GCST005782,Other measurement,#fee08b
8681,European,16124.0,29325163.0,Hong J,Serum 25-Hydroxyvitamin D levels,initial,2018-01-09,GCST005782,Other measurement,#d53e4f
8682,European,11097.0,29325096.0,Eriksson AL,Estradiol levels,initial,2018-01-09,GCST005828,Other measurement,#d53e4f
8683,European,9890.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),initial,2018-01-09,GCST005313,Other trait,#d53e4f
8684,Hispanic/Latin American,1847.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),initial,2018-01-09,GCST005313,Other trait,#807dba
8685,European,331.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),replication,2018-01-09,GCST005313,Other trait,#d53e4f
8686,Hispanic/Latin American,3133.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),replication,2018-01-09,GCST005313,Other trait,#807dba
8687,Asian,59.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),initial,2018-01-09,GCST005313,Other trait,#3288bd
8688,Asian,249.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),initial,2018-01-09,GCST005313,Other trait,#3288bd
8689,African Am./Caribbean,1874.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),initial,2018-01-09,GCST005313,Other trait,#fee08b
8690,African Am./Caribbean,1419.0,29317701.0,Rappoport N,Spontaneous preterm birth (preterm birth),replication,2018-01-09,GCST005313,Other trait,#fee08b
8691,European,5086.0,29310926.0,Sharma A,Type 1 diabetes in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006196,Other measurement,#d53e4f
8692,European,5086.0,29310926.0,Sharma A,Type 1 diabetes in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006196,Metabolic disorder,#d53e4f
8693,European,5086.0,29310926.0,Sharma A,Type 1 diabetes in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006196,Other measurement,#d53e4f
8694,European,5086.0,29310926.0,Sharma A,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006197,Other measurement,#d53e4f
8695,European,5086.0,29310926.0,Sharma A,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006197,Metabolic disorder,#d53e4f
8696,European,5086.0,29310926.0,Sharma A,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006197,Other measurement,#d53e4f
8697,European,5086.0,29310926.0,Sharma A,Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),initial,2018-01-05,GCST006197,Other measurement,#d53e4f
8698,European,67944.0,29290336.0,Nielsen JB,Atrial fibrillation,initial,2018-01-04,GCST005306,Cardiovascular disease,#d53e4f
8699,European,309574.0,29290336.0,Nielsen JB,Atrial fibrillation,replication,2018-01-04,GCST005306,Cardiovascular disease,#d53e4f
8701,European,18805.0,29304378.0,Medina-Gomez C,Total body bone mineral density (age 45-60),initial,2018-01-04,GCST005350,Other measurement,#d53e4f
8705,European,56284.0,29304378.0,Medina-Gomez C,Total body bone mineral density,initial,2018-01-04,GCST005348,Other measurement,#d53e4f
8706,African Am./Caribbean,1333.0,29304378.0,Medina-Gomez C,Total body bone mineral density,initial,2018-01-04,GCST005348,Other measurement,#fee08b
8708,European,18319.0,29309628.0,Beaumont RN,Offspring birth weight,replication,2018-01-03,GCST005314,Body measurement,#d53e4f
8709,European,68258.0,29309628.0,Beaumont RN,Offspring birth weight,initial,2018-01-03,GCST005314,Body measurement,#d53e4f
8710,European,18319.0,29309628.0,Beaumont RN,Offspring birth weight,replication,2018-01-03,GCST005314,Other measurement,#d53e4f
8711,European,68258.0,29309628.0,Beaumont RN,Offspring birth weight,initial,2018-01-03,GCST005314,Other measurement,#d53e4f
8713,European,100.0,29293525.0,Gudmundsdottir V,GLP-1-stimulated insulin secretion,replication,2018-01-02,GCST005353,Other measurement,#d53e4f
8714,European,3813.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-topoisomerase-positive),initial,2018-01-02,GCST005551,Neurological disorder,#d53e4f
8715,African Am./Caribbean,329.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-topoisomerase-positive),initial,2018-01-02,GCST005551,Neurological disorder,#fee08b
8716,European,4137.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-centromere-positive),initial,2018-01-02,GCST005552,Neurological disorder,#d53e4f
8717,African Am./Caribbean,281.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-centromere-positive),initial,2018-01-02,GCST005552,Neurological disorder,#fee08b
8718,European,4040.0,29293537.0,Gorlova OY,Diffuse cutaneous systemic sclerosis,initial,2018-01-02,GCST005553,Neurological disorder,#d53e4f
8719,African Am./Caribbean,461.0,29293537.0,Gorlova OY,Diffuse cutaneous systemic sclerosis,initial,2018-01-02,GCST005553,Neurological disorder,#fee08b
8720,European,4553.0,29293537.0,Gorlova OY,Limited cutaneous systemic scleroderma,initial,2018-01-02,GCST005555,Neurological disorder,#d53e4f
8721,African Am./Caribbean,342.0,29293537.0,Gorlova OY,Limited cutaneous systemic scleroderma,initial,2018-01-02,GCST005555,Neurological disorder,#fee08b
8722,European,5299.0,29293537.0,Gorlova OY,Systemic sclerosis,initial,2018-01-02,GCST005554,Neurological disorder,#d53e4f
8723,African Am./Caribbean,551.0,29293537.0,Gorlova OY,Systemic sclerosis,initial,2018-01-02,GCST005554,Neurological disorder,#fee08b
8724,European,3813.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-topoisomerase-positive),initial,2018-01-02,GCST005332,Neurological disorder,#d53e4f
8725,African Am./Caribbean,329.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-topoisomerase-positive),initial,2018-01-02,GCST005332,Neurological disorder,#fee08b
8726,African Am./Caribbean,281.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-centromere-positive),initial,2018-01-02,GCST005333,Neurological disorder,#fee08b
8727,European,4137.0,29293537.0,Gorlova OY,Systemic sclerosis (anti-centromere-positive),initial,2018-01-02,GCST005333,Neurological disorder,#d53e4f
8728,African Am./Caribbean,461.0,29293537.0,Gorlova OY,Diffuse cutaneous systemic sclerosis,initial,2018-01-02,GCST005335,Neurological disorder,#fee08b
8729,European,4040.0,29293537.0,Gorlova OY,Diffuse cutaneous systemic sclerosis,initial,2018-01-02,GCST005335,Neurological disorder,#d53e4f
8730,African Am./Caribbean,342.0,29293537.0,Gorlova OY,Limited cutaneous systemic scleroderma,initial,2018-01-02,GCST005334,Neurological disorder,#fee08b
8731,European,4553.0,29293537.0,Gorlova OY,Limited cutaneous systemic scleroderma,initial,2018-01-02,GCST005334,Neurological disorder,#d53e4f
8732,African Am./Caribbean,551.0,29293537.0,Gorlova OY,Systemic sclerosis,initial,2018-01-02,GCST005336,Neurological disorder,#fee08b
8733,European,5299.0,29293537.0,Gorlova OY,Systemic sclerosis,initial,2018-01-02,GCST005336,Neurological disorder,#d53e4f
8735,European,340498.0,29364747.0,Jonsson L,Tooth agenesis,initial,2018-01-01,GCST005389,Digestive system disorder,#d53e4f
8736,European,6170.0,29364747.0,Jonsson L,Tooth agenesis,replication,2018-01-01,GCST005389,Digestive system disorder,#d53e4f
8737,European,339154.0,29364747.0,Jonsson L,Tooth agenesis (maxillary second premolars),initial,2018-01-01,GCST005392,Digestive system disorder,#d53e4f
8738,European,306.0,29364747.0,Jonsson L,Tooth agenesis (maxillary lateral incisors),replication,2018-01-01,GCST005391,Digestive system disorder,#d53e4f
8739,European,339154.0,29364747.0,Jonsson L,Tooth agenesis (maxillary lateral incisors),initial,2018-01-01,GCST005391,Digestive system disorder,#d53e4f
8742,European,339750.0,29364747.0,Jonsson L,Tooth agenesis (mandibular second premolars),initial,2018-01-01,GCST005390,Digestive system disorder,#d53e4f
8743,European,4733.0,29364747.0,Jonsson L,Tooth agenesis (mandibular second premolars),replication,2018-01-01,GCST005390,Digestive system disorder,#d53e4f
8744,Asian,1424.0,29354237.0,Kim HA,Lumbar spondylosis (Kellgren-Lawrence grade),initial,2018-01-01,GCST005277,Other disease,#3288bd
8745,Asian,1426.0,29354237.0,Kim HA,Lumbar spondylosis (presence and severity of osteophytes),initial,2018-01-01,GCST005278,Other disease,#3288bd
8746,European,388538.0,29292387.0,Turley P,Subjective well-being,initial,2018-01-01,GCST005328,Other measurement,#d53e4f
8747,European,354862.0,29292387.0,Turley P,Depressive symptoms,initial,2018-01-01,GCST005324,Other measurement,#d53e4f
8748,European,1190.0,29263008.0,Guerreiro R,Dementia with Lewy bodies,replication,2018-01-01,GCST005276,Other trait,#d53e4f
8749,European,5007.0,29263008.0,Guerreiro R,Dementia with Lewy bodies,initial,2018-01-01,GCST005276,Other trait,#d53e4f
8750,Asian,1425.0,29354237.0,Kim HA,Lumbar spondylosis (disc space narrowing),initial,2018-01-01,GCST005279,Other disease,#3288bd
8751,European,168105.0,29292387.0,Turley P,Neuroticism,initial,2018-01-01,GCST005327,Other measurement,#d53e4f
8752,European,168105.0,29292387.0,Turley P,Neuroticism (MTAG),initial,2018-01-01,GCST005326,Other measurement,#d53e4f
8753,European,388538.0,29292387.0,Turley P,Subjective well-being (MTAG),initial,2018-01-01,GCST005325,Other measurement,#d53e4f
8754,European,354862.0,29292387.0,Turley P,Depressive symptoms (MTAG),initial,2018-01-01,GCST005323,Other measurement,#d53e4f
8755,European,1238.0,29288229.0,McCormack M,Antiepileptic drug-induced maculopapular exanthema,initial,2017-12-29,GCST005197,Other disease,#d53e4f
8756,Asian,458.0,29288229.0,McCormack M,Antiepileptic drug-induced maculopapular exanthema,initial,2017-12-29,GCST005197,Other disease,#3288bd
8757,European,1238.0,29288229.0,McCormack M,Antiepileptic drug-induced maculopapular exanthema,initial,2017-12-29,GCST005197,Response to drug,#d53e4f
8758,Asian,458.0,29288229.0,McCormack M,Antiepileptic drug-induced maculopapular exanthema,initial,2017-12-29,GCST005197,Response to drug,#3288bd
8759,European,524.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,initial,2017-12-29,GCST005200,Other disease,#d53e4f
8760,Asian,80.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,initial,2017-12-29,GCST005200,Other disease,#3288bd
8761,European,101.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,replication,2017-12-29,GCST005200,Other disease,#d53e4f
8762,European,524.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,initial,2017-12-29,GCST005200,Response to drug,#d53e4f
8763,Asian,80.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,initial,2017-12-29,GCST005200,Response to drug,#3288bd
8764,European,101.0,29288229.0,McCormack M,Phenytoin-induced maculopapular exanthema,replication,2017-12-29,GCST005200,Response to drug,#d53e4f
8765,Asian,48.0,29288229.0,McCormack M,Lamotrigine-induced maculopapular exanthema,initial,2017-12-29,GCST005199,Response to drug,#3288bd
8766,European,930.0,29288229.0,McCormack M,Lamotrigine-induced maculopapular exanthema,initial,2017-12-29,GCST005199,Response to drug,#d53e4f
8767,Asian,48.0,29288229.0,McCormack M,Lamotrigine-induced maculopapular exanthema,initial,2017-12-29,GCST005199,Other disease,#3288bd
8768,European,930.0,29288229.0,McCormack M,Lamotrigine-induced maculopapular exanthema,initial,2017-12-29,GCST005199,Other disease,#d53e4f
8769,European,964.0,29288229.0,McCormack M,Carbamazepine-induced maculopapular exanthema,initial,2017-12-29,GCST005198,Other disease,#d53e4f
8770,Asian,282.0,29288229.0,McCormack M,Carbamazepine-induced maculopapular exanthema,initial,2017-12-29,GCST005198,Other disease,#3288bd
8771,European,964.0,29288229.0,McCormack M,Carbamazepine-induced maculopapular exanthema,initial,2017-12-29,GCST005198,Response to drug,#d53e4f
8772,Asian,282.0,29288229.0,McCormack M,Carbamazepine-induced maculopapular exanthema,initial,2017-12-29,GCST005198,Response to drug,#3288bd
8773,Asian,1881.0,29271184.0,Chung GE,Nonalcoholic fatty liver disease,replication,2017-12-26,GCST005190,Digestive system disorder,#3288bd
8774,Asian,4409.0,29271184.0,Chung GE,Nonalcoholic fatty liver disease,initial,2017-12-26,GCST005190,Digestive system disorder,#3288bd
8775,European,209.0,29278698.0,Zagajewska K,Pseudoexfoliation syndrome,initial,2017-12-23,GCST005347,Neurological disorder,#d53e4f
8776,Asian,2786.0,29273593.0,Duan L,Moyamoya disease,initial,2017-12-22,GCST005575,Cardiovascular disease,#3288bd
8777,Asian,3767.0,29273593.0,Duan L,Moyamoya disease,replication,2017-12-22,GCST005575,Cardiovascular disease,#3288bd
8778,Hispanic/Latin American,10772.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008125,Body measurement,#807dba
8779,Asian,29398.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008127,Body measurement,#3288bd
8780,Asian,8839.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008126,Body measurement,#3288bd
8781,African Am./Caribbean,27610.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008124,Body measurement,#fee08b
8782,European,192226.0,29273807.0,Turcot V,Body mass index,replication,2017-12-22,GCST008124,Body measurement,#d53e4f
8783,European,449886.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008128,Body measurement,#d53e4f
8784,European,192226.0,29273807.0,Turcot V,Body mass index,replication,2017-12-22,GCST008128,Body measurement,#d53e4f
8785,European,449889.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008129,Body measurement,#d53e4f
8786,Asian,29398.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008129,Body measurement,#3288bd
8787,Asian,8839.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008129,Body measurement,#3288bd
8788,African Am./Caribbean,27610.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008129,Body measurement,#fee08b
8789,European,196766.0,29273807.0,Turcot V,Body mass index,replication,2017-12-22,GCST008129,Body measurement,#d53e4f
8790,Hispanic/Latin American,10772.0,29273807.0,Turcot V,Body mass index,initial,2017-12-22,GCST008129,Body measurement,#807dba
8791,European,127669.0,29273806.0,Demenais F,Asthma,initial,2017-12-22,GCST006862,Other disease,#d53e4f
8792,Hispanic/Latin American,1398.0,29273806.0,Demenais F,Asthma (childhood onset),initial,2017-12-22,GCST005213,Other disease,#807dba
8793,European,20762.0,29273806.0,Demenais F,Asthma (childhood onset),initial,2017-12-22,GCST005213,Other disease,#d53e4f
8794,Asian,5215.0,29273806.0,Demenais F,Asthma (childhood onset),initial,2017-12-22,GCST005213,Other disease,#3288bd
8795,Hispanic/Latin American,1398.0,29273806.0,Demenais F,Asthma,initial,2017-12-22,GCST005212,Other disease,#807dba
8796,European,127669.0,29273806.0,Demenais F,Asthma,initial,2017-12-22,GCST005212,Other disease,#d53e4f
8798,Asian,5215.0,29273806.0,Demenais F,Asthma,initial,2017-12-22,GCST005212,Other disease,#3288bd
8799,Asian,6942.0,29263402.0,Han Y,Coronary artery disease,initial,2017-12-20,GCST005172,Cardiovascular disease,#3288bd
8800,Asian,2139.0,29263402.0,Han Y,Coronary artery disease,replication,2017-12-20,GCST005172,Cardiovascular disease,#3288bd
8801,Asian,2603.0,29263402.0,Han Y,Coronary artery disease,initial,2017-12-20,GCST005172,Cardiovascular disease,#3288bd
8802,European,581.0,29274321.0,Chung J,Hippocampal volume in mild cognitive impairment,initial,2017-12-20,GCST007013,Other measurement,#d53e4f
8803,European,581.0,29274321.0,Chung J,Hippocampal volume in mild cognitive impairment,initial,2017-12-20,GCST007013,Other measurement,#d53e4f
8804,European,1076.0,29274321.0,Chung J,Cerebrospinal fluid AB1-42 levels,initial,2017-12-20,GCST007012,Other measurement,#d53e4f
8805,European,305.0,29274321.0,Chung J,Logical memory (delayed recall) in normal cognition,initial,2017-12-20,GCST007006,Other measurement,#d53e4f
8806,European,581.0,29274321.0,Chung J,Cerebrospinal AB1-42 levels in mild cognitive impairment,initial,2017-12-20,GCST006996,Other measurement,#d53e4f
8807,European,581.0,29274321.0,Chung J,Cerebrospinal AB1-42 levels in mild cognitive impairment,initial,2017-12-20,GCST006996,Other measurement,#d53e4f
8808,European,1076.0,29274321.0,Chung J,Logical memory (immediate recall),initial,2017-12-20,GCST007011,Other measurement,#d53e4f
8809,European,1076.0,29274321.0,Chung J,Logical memory (delayed recall),initial,2017-12-20,GCST007010,Other measurement,#d53e4f
8810,European,1076.0,29274321.0,Chung J,Hippocampal volume,initial,2017-12-20,GCST007009,Other measurement,#d53e4f
8811,European,1076.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels,initial,2017-12-20,GCST007008,Other measurement,#d53e4f
8812,European,1076.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels,initial,2017-12-20,GCST007007,Other measurement,#d53e4f
8813,European,305.0,29274321.0,Chung J,Logical memory (immediate recall) in normal cognition,initial,2017-12-20,GCST007005,Other measurement,#d53e4f
8814,European,305.0,29274321.0,Chung J,Hippocampal volume in normal cognition,initial,2017-12-20,GCST007004,Other measurement,#d53e4f
8815,European,305.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels in normal cognition,initial,2017-12-20,GCST007003,Other measurement,#d53e4f
8816,European,305.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels in normal cognition,initial,2017-12-20,GCST007002,Other measurement,#d53e4f
8817,European,305.0,29274321.0,Chung J,Cerebrospinal AB1-42 levels in normal cognition,initial,2017-12-20,GCST007001,Other measurement,#d53e4f
8818,European,581.0,29274321.0,Chung J,Logical memory (delayed recall) in mild cognitive impairment,initial,2017-12-20,GCST007000,Other measurement,#d53e4f
8819,European,581.0,29274321.0,Chung J,Logical memory (delayed recall) in mild cognitive impairment,initial,2017-12-20,GCST007000,Other measurement,#d53e4f
8820,European,581.0,29274321.0,Chung J,Logical memory (immediate recall) in mild cognitive impairment,initial,2017-12-20,GCST006999,Other measurement,#d53e4f
8821,European,581.0,29274321.0,Chung J,Logical memory (immediate recall) in mild cognitive impairment,initial,2017-12-20,GCST006999,Other measurement,#d53e4f
8822,European,581.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels in mild cognitive impairment,initial,2017-12-20,GCST006998,Other measurement,#d53e4f
8823,European,581.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels in mild cognitive impairment,initial,2017-12-20,GCST006998,Other measurement,#d53e4f
8824,European,581.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels in mild cognitive impairment,initial,2017-12-20,GCST006997,Other measurement,#d53e4f
8825,European,581.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels in mild cognitive impairment,initial,2017-12-20,GCST006997,Other measurement,#d53e4f
8826,European,190.0,29274321.0,Chung J,Logical memory (delayed recall) in Alzheimer's disease dementia,initial,2017-12-20,GCST006995,Neurological disorder,#d53e4f
8827,European,190.0,29274321.0,Chung J,Logical memory (delayed recall) in Alzheimer's disease dementia,initial,2017-12-20,GCST006995,Other measurement,#d53e4f
8828,European,190.0,29274321.0,Chung J,Logical memory (immediate recall) in Alzheimer's disease dementia,initial,2017-12-20,GCST006994,Neurological disorder,#d53e4f
8829,European,190.0,29274321.0,Chung J,Logical memory (immediate recall) in Alzheimer's disease dementia,initial,2017-12-20,GCST006994,Other measurement,#d53e4f
8830,European,190.0,29274321.0,Chung J,Hippocampal volume in Alzheimer's disease dementia,initial,2017-12-20,GCST006993,Neurological disorder,#d53e4f
8831,European,190.0,29274321.0,Chung J,Hippocampal volume in Alzheimer's disease dementia,initial,2017-12-20,GCST006993,Other measurement,#d53e4f
8832,European,190.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006992,Neurological disorder,#d53e4f
8833,European,190.0,29274321.0,Chung J,Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006992,Other measurement,#d53e4f
8834,European,190.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006991,Neurological disorder,#d53e4f
8835,European,190.0,29274321.0,Chung J,Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006991,Other measurement,#d53e4f
8836,European,190.0,29274321.0,Chung J,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006990,Neurological disorder,#d53e4f
8837,European,190.0,29274321.0,Chung J,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,initial,2017-12-20,GCST006990,Other measurement,#d53e4f
8838,European,235.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Other measurement,#d53e4f
8840,African Am./Caribbean,48.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Other measurement,#fee08b
8841,European,235.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Response to drug,#d53e4f
8843,African Am./Caribbean,48.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Response to drug,#fee08b
8844,European,235.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Cancer,#d53e4f
8846,African Am./Caribbean,48.0,29266176.0,Inaba H,Bone mineral density change response to combined chemotherapy in acute lymphoblastic leukemia,initial,2017-12-19,GCST005214,Cancer,#fee08b
8847,European,782.0,29253858.0,Bohman A,Chronic rhinosinusitis with nasal polyps,initial,2017-12-18,GCST005268,Neurological disorder,#d53e4f
8848,European,122867.0,29255261.0,Luciano M,Neuroticism,replication,2017-12-18,GCST005232,Other measurement,#d53e4f
8849,European,329821.0,29255261.0,Luciano M,Neuroticism,initial,2017-12-18,GCST005232,Other measurement,#d53e4f
8850,Hispanic/Latin American,8048.0,29505938.0,Dunn EC,Depressive symptoms,replication,2017-12-16,GCST006174,Neurological disorder,#807dba
8851,Hispanic/Latin American,12310.0,29505938.0,Dunn EC,Depressive symptoms,initial,2017-12-16,GCST006174,Neurological disorder,#807dba
8852,African Am./Caribbean,202.0,29253144.0,Voigt EA,Rubella-specific interferon-gamma secretion,initial,2017-12-14,GCST005177,Other measurement,#fee08b
8853,European,1643.0,29253144.0,Voigt EA,Rubella-specific interferon-gamma secretion,initial,2017-12-14,GCST005177,Other measurement,#d53e4f
8854,African Am./Caribbean,202.0,29253144.0,Voigt EA,Rubella-specific interferon-gamma secretion,initial,2017-12-14,GCST005177,Response to drug,#fee08b
8855,European,1643.0,29253144.0,Voigt EA,Rubella-specific interferon-gamma secretion,initial,2017-12-14,GCST005177,Response to drug,#d53e4f
8856,European,933.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (concordant skeletal phenotype),initial,2017-12-14,GCST006130,Other measurement,#d53e4f
8857,Other/Mixed,466.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (concordant skeletal phenotype),initial,2017-12-14,GCST006130,Other measurement,#99d594
8858,European,486.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (concordant skeletal phenotype),replication,2017-12-14,GCST006130,Other measurement,#d53e4f
8859,European,933.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype),initial,2017-12-14,GCST006129,Other measurement,#d53e4f
8860,European,486.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype),replication,2017-12-14,GCST006129,Other measurement,#d53e4f
8861,Other/Mixed,466.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (spine vs radius & hip discordant skeletal phenotype),initial,2017-12-14,GCST006129,Other measurement,#99d594
8862,European,933.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype),initial,2017-12-14,GCST006247,Other measurement,#d53e4f
8863,Other/Mixed,466.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype),initial,2017-12-14,GCST006247,Other measurement,#99d594
8864,European,486.0,29240982.0,Mitchell JA,Pediatric areal bone mineral density (radius vs spine & hip discordant skeletal phenotype),replication,2017-12-14,GCST006247,Other measurement,#d53e4f
8865,European,1643.0,29253144.0,Voigt EA,Rubella-specific interleukin-6 secretion,initial,2017-12-14,GCST005176,Inflammatory measurement,#d53e4f
8866,African Am./Caribbean,202.0,29253144.0,Voigt EA,Rubella-specific interleukin-6 secretion,initial,2017-12-14,GCST005176,Inflammatory measurement,#fee08b
8867,European,1643.0,29253144.0,Voigt EA,Rubella-specific interleukin-6 secretion,initial,2017-12-14,GCST005176,Response to drug,#d53e4f
8868,African Am./Caribbean,202.0,29253144.0,Voigt EA,Rubella-specific interleukin-6 secretion,initial,2017-12-14,GCST005176,Response to drug,#fee08b
8869,Other/Mixed,37930.0,29235454.0,Choquet H,Intraocular pressure,replication,2017-12-13,GCST005170,Other measurement,#99d594
8870,African Am./Caribbean,2070.0,29235454.0,Choquet H,Intraocular pressure,initial,2017-12-13,GCST005170,Other measurement,#fee08b
8871,Asian,5119.0,29235454.0,Choquet H,Intraocular pressure,initial,2017-12-13,GCST005170,Other measurement,#3288bd
8872,Hispanic/Latin American,5748.0,29235454.0,Choquet H,Intraocular pressure,initial,2017-12-13,GCST005170,Other measurement,#807dba
8873,European,56819.0,29235454.0,Choquet H,Intraocular pressure,initial,2017-12-13,GCST005170,Other measurement,#d53e4f
8874,European,928.0,29230059.0,Sanchez-Roige S,Delayed reward discounting,replication,2017-12-11,GCST005248,Other measurement,#d53e4f
8875,European,23127.0,29230059.0,Sanchez-Roige S,Delayed reward discounting,initial,2017-12-11,GCST005248,Other measurement,#d53e4f
8876,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,replication,2017-12-08,GCST005173,Other trait,#fee08b
8877,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,initial,2017-12-08,GCST005173,Other trait,#fee08b
8878,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,replication,2017-12-08,GCST005173,Metabolic disorder,#fee08b
8879,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,initial,2017-12-08,GCST005173,Metabolic disorder,#fee08b
8880,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,replication,2017-12-08,GCST005175,Other trait,#fee08b
8881,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,initial,2017-12-08,GCST005175,Other trait,#fee08b
8882,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,replication,2017-12-08,GCST005175,Metabolic disorder,#fee08b
8883,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,initial,2017-12-08,GCST005175,Metabolic disorder,#fee08b
8884,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,initial,2017-12-08,GCST005174,Other trait,#fee08b
8885,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,replication,2017-12-08,GCST005174,Other trait,#fee08b
8886,African Am./Caribbean,691.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,initial,2017-12-08,GCST005174,Metabolic disorder,#fee08b
8887,African Am./Caribbean,205.0,29221444.0,Divers J,Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,replication,2017-12-08,GCST005174,Metabolic disorder,#fee08b
8888,European,2308.0,29217827.0,Sanders AR,Male sexual orientation,initial,2017-12-07,GCST005247,Other trait,#d53e4f
8889,Asian,2146.0,29208002.0,Kim M,Diastolic blood pressure,initial,2017-12-06,GCST005169,Other measurement,#3288bd
8893,Asian,1876.0,29212900.0,Li C,Mean arterial pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005203,Other measurement,#3288bd
8894,Asian,775.0,29212900.0,Li C,Mean arterial pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005203,Other measurement,#3288bd
8895,Asian,1876.0,29212900.0,Li C,Mean arterial pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005203,Other measurement,#3288bd
8896,Asian,775.0,29212900.0,Li C,Mean arterial pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005203,Other measurement,#3288bd
8897,Asian,1876.0,29212900.0,Li C,Diastolic blood pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005202,Other measurement,#3288bd
8898,Asian,775.0,29212900.0,Li C,Diastolic blood pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005202,Other measurement,#3288bd
8899,Asian,1876.0,29212900.0,Li C,Diastolic blood pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005202,Other measurement,#3288bd
8900,Asian,775.0,29212900.0,Li C,Diastolic blood pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005202,Other measurement,#3288bd
8901,European,523.0,29210060.0,Koster R,Overall survival in osteosarcoma,initial,2017-12-06,GCST005158,Cancer,#d53e4f
8902,Hispanic/Latin American,109.0,29210060.0,Koster R,Overall survival in osteosarcoma,replication,2017-12-06,GCST005158,Cancer,#807dba
8903,European,523.0,29210060.0,Koster R,Overall survival in osteosarcoma,initial,2017-12-06,GCST005158,Other measurement,#d53e4f
8904,Hispanic/Latin American,109.0,29210060.0,Koster R,Overall survival in osteosarcoma,replication,2017-12-06,GCST005158,Other measurement,#807dba
8905,Other/Mixed,15.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#99d594
8906,Other/Mixed,15.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#99d594
8907,European,16763.0,29220522.0,Liu F,Hair shape,initial,2017-12-06,GCST005191,Other measurement,#d53e4f
8908,Asian,2899.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#3288bd
8909,European,2340.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#d53e4f
8910,Hispanic/Latin American,6238.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#807dba
8911,Other/Mixed,709.0,29220522.0,Liu F,Hair shape,replication,2017-12-06,GCST005191,Other measurement,#99d594
8914,Asian,2146.0,29208002.0,Kim M,Systolic blood pressure,initial,2017-12-06,GCST005168,Other measurement,#3288bd
8915,Hispanic/Latin American,15997.0,29213071.0,Mendez-Giraldez R,QT interval,initial,2017-12-06,GCST005171,Cardiovascular measurement,#807dba
8916,Asian,117.0,29207912.0,Nishizawa D,Opioid requirements during laparoscopic-assisted colectomy,initial,2017-12-06,GCST005364,Response to drug,#3288bd
8917,Asian,234.0,29207912.0,Nishizawa D,Opioid requirements during laparoscopic-assisted colectomy,replication,2017-12-06,GCST005364,Response to drug,#3288bd
8918,Asian,117.0,29207912.0,Nishizawa D,Opioid requirements during laparoscopic-assisted colectomy,initial,2017-12-06,GCST005364,Other measurement,#3288bd
8919,Asian,234.0,29207912.0,Nishizawa D,Opioid requirements during laparoscopic-assisted colectomy,replication,2017-12-06,GCST005364,Other measurement,#3288bd
8920,Asian,775.0,29212900.0,Li C,Systolic blood pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005204,Other measurement,#3288bd
8921,Asian,1876.0,29212900.0,Li C,Systolic blood pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005204,Other measurement,#3288bd
8922,Asian,775.0,29212900.0,Li C,Systolic blood pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005204,Other measurement,#3288bd
8923,Asian,1876.0,29212900.0,Li C,Systolic blood pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005204,Other measurement,#3288bd
8924,Asian,1876.0,29212900.0,Li C,Pulse pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005201,Cardiovascular measurement,#3288bd
8925,Asian,775.0,29212900.0,Li C,Pulse pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005201,Cardiovascular measurement,#3288bd
8926,Asian,1876.0,29212900.0,Li C,Pulse pressure (dietary potassium intake interaction),initial,2017-12-06,GCST005201,Other measurement,#3288bd
8927,Asian,775.0,29212900.0,Li C,Pulse pressure (dietary potassium intake interaction),replication,2017-12-06,GCST005201,Other measurement,#3288bd
8928,African Am./Caribbean,288.0,29206233.0,Shendre A,Common carotid intima-media thickness in HIV negative individuals,initial,2017-12-04,GCST005182,Cardiovascular measurement,#fee08b
8929,African Am./Caribbean,970.0,29206233.0,Shendre A,Common carotid intima-media thickness,initial,2017-12-04,GCST005183,Cardiovascular measurement,#fee08b
8930,African Am./Caribbean,682.0,29206233.0,Shendre A,Common carotid intima-media thickness in HIV infection,initial,2017-12-04,GCST005184,Cardiovascular measurement,#fee08b
8931,African Am./Caribbean,682.0,29206233.0,Shendre A,Common carotid intima-media thickness in HIV infection,initial,2017-12-04,GCST005184,Other disease,#fee08b
8932,European,53293.0,29325848.0,Martin J,Attention deficit hyperactivity disorder (sex interaction),initial,2017-12-02,GCST005361,Neurological disorder,#d53e4f
8933,European,53293.0,29325848.0,Martin J,Attention deficit hyperactivity disorder (sex interaction),initial,2017-12-02,GCST005361,Other measurement,#d53e4f
8934,European,53293.0,29325848.0,Martin J,Attention deficit hyperactivity disorder,initial,2017-12-02,GCST005362,Neurological disorder,#d53e4f
8936,European,19099.0,29325848.0,Martin J,Sex difference in attention deficit hyperactivity disorder,initial,2017-12-02,GCST005363,Neurological disorder,#d53e4f
8937,European,19099.0,29325848.0,Martin J,Sex difference in attention deficit hyperactivity disorder,initial,2017-12-02,GCST005363,Other trait,#d53e4f
8939,European,15603.0,29196614.0,Sud A,Nodular sclerosis Hodgkin lymphoma,initial,2017-12-01,GCST005211,Cancer,#d53e4f
8940,European,120286.0,29237688.0,Weng LC,Atrial fibrillation,initial,2017-12-01,GCST008486,Cardiovascular disease,#d53e4f
8941,European,208118.0,29227965.0,Pilling LC,Parental longevity (combined parental age at death),initial,2017-12-01,GCST006702,Other measurement,#d53e4f
8942,European,415311.0,29227965.0,Pilling LC,Parental longevity (father's attained age),initial,2017-12-01,GCST006701,Other measurement,#d53e4f
8943,European,317652.0,29227965.0,Pilling LC,Parental longevity (father's age at death),initial,2017-12-01,GCST006700,Other measurement,#d53e4f
8944,European,412937.0,29227965.0,Pilling LC,Parental longevity (mother's attained age),initial,2017-12-01,GCST006696,Other measurement,#d53e4f
8945,European,246941.0,29227965.0,Pilling LC,Parental longevity (mother's age at death),initial,2017-12-01,GCST006699,Other measurement,#d53e4f
8946,European,86949.0,29227965.0,Pilling LC,Parental longevity (both parents in top 10%),initial,2017-12-01,GCST006698,Other measurement,#d53e4f
8947,European,389166.0,29227965.0,Pilling LC,"Parental longevity (combined parental attained age, Martingale residuals)",initial,2017-12-01,GCST006697,Other measurement,#d53e4f
8948,European,4932.0,29237677.0,Salo PP,B-type natriuretic peptide levels,initial,2017-12-01,GCST005206,Cardiovascular measurement,#d53e4f
8949,European,1373.0,29237677.0,Salo PP,B-type natriuretic peptide levels,replication,2017-12-01,GCST005206,Cardiovascular measurement,#d53e4f
8950,European,934.0,29251981.0,Weafer J,Inhibitory control,initial,2017-12-01,GCST005246,Other measurement,#d53e4f
8951,European,6049.0,29212897.0,Salminen A,Matrix metalloproteinase-8 levels,initial,2017-12-01,GCST005187,Inflammatory measurement,#d53e4f
8952,European,1373.0,29237677.0,Salo PP,N-terminal pro B-type natriuretic peptide levels,replication,2017-12-01,GCST005205,Cardiovascular measurement,#d53e4f
8953,European,4932.0,29237677.0,Salo PP,N-terminal pro B-type natriuretic peptide levels,initial,2017-12-01,GCST005205,Cardiovascular measurement,#d53e4f
8954,European,1373.0,29237677.0,Salo PP,Midregional pro atrial natriuretic peptide levels,replication,2017-12-01,GCST005207,Cardiovascular measurement,#d53e4f
8955,European,4932.0,29237677.0,Salo PP,Midregional pro atrial natriuretic peptide levels,initial,2017-12-01,GCST005207,Cardiovascular measurement,#d53e4f
8956,European,1373.0,29237677.0,Salo PP,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio,replication,2017-12-01,GCST005208,Cardiovascular measurement,#d53e4f
8957,European,4932.0,29237677.0,Salo PP,B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio,initial,2017-12-01,GCST005208,Cardiovascular measurement,#d53e4f
8958,European,16757.0,29196614.0,Sud A,Hodgkin's lymphoma,initial,2017-12-01,GCST005209,Cancer,#d53e4f
8961,European,15143.0,29196614.0,Sud A,Mixed cellularity Hodgkin lymphoma,initial,2017-12-01,GCST005210,Cancer,#d53e4f
8962,European,66741.0,29198719.0,Shaffer JR,Lobe attachment (rater-scored or self-reported),initial,2017-11-30,GCST005192,Other trait,#d53e4f
8963,Hispanic/Latin American,5062.0,29198719.0,Shaffer JR,Lobe attachment (rater-scored or self-reported),initial,2017-11-30,GCST005192,Other trait,#807dba
8964,Asian,2857.0,29198719.0,Shaffer JR,Lobe attachment (rater-scored or self-reported),initial,2017-11-30,GCST005192,Other trait,#3288bd
8965,Hispanic/Latin American,5062.0,29198719.0,Shaffer JR,Lobe attachment (rater scored),initial,2017-11-30,GCST005193,Other trait,#807dba
8966,Asian,2857.0,29198719.0,Shaffer JR,Lobe attachment (rater scored),initial,2017-11-30,GCST005193,Other trait,#3288bd
8967,European,1791.0,29198719.0,Shaffer JR,Lobe attachment (rater scored),initial,2017-11-30,GCST005193,Other trait,#d53e4f
8968,African,216.0,29195075.0,Martin AR,Skin pigmentation,initial,2017-11-30,GCST005188,Other measurement,#fc8d59
8969,African,240.0,29195075.0,Martin AR,Skin pigmentation,replication,2017-11-30,GCST005188,Other measurement,#fc8d59
8970,African Am./Caribbean,74.0,29187748.0,Morey RA,Thalamus volume in trauma-exposed individuals,initial,2017-11-30,GCST005245,Biological process,#fee08b
8971,European,83.0,29187748.0,Morey RA,Thalamus volume in trauma-exposed individuals,initial,2017-11-30,GCST005245,Biological process,#d53e4f
8972,African Am./Caribbean,74.0,29187748.0,Morey RA,Thalamus volume in trauma-exposed individuals,initial,2017-11-30,GCST005245,Other measurement,#fee08b
8973,European,83.0,29187748.0,Morey RA,Thalamus volume in trauma-exposed individuals,initial,2017-11-30,GCST005245,Other measurement,#d53e4f
8974,African Am./Caribbean,74.0,29187748.0,Morey RA,Lateral ventricle volume in trauma-exposed individuals,initial,2017-11-30,GCST005286,Other measurement,#fee08b
8975,European,83.0,29187748.0,Morey RA,Lateral ventricle volume in trauma-exposed individuals,initial,2017-11-30,GCST005286,Other measurement,#d53e4f
8976,African Am./Caribbean,74.0,29187748.0,Morey RA,Lateral ventricle volume in trauma-exposed individuals,initial,2017-11-30,GCST005286,Biological process,#fee08b
8977,European,83.0,29187748.0,Morey RA,Lateral ventricle volume in trauma-exposed individuals,initial,2017-11-30,GCST005286,Biological process,#d53e4f
8978,African Am./Caribbean,74.0,29187748.0,Morey RA,Putamen volume in trauma-exposed individuals,initial,2017-11-30,GCST005244,Biological process,#fee08b
8979,European,83.0,29187748.0,Morey RA,Putamen volume in trauma-exposed individuals,initial,2017-11-30,GCST005244,Biological process,#d53e4f
8980,African Am./Caribbean,74.0,29187748.0,Morey RA,Putamen volume in trauma-exposed individuals,initial,2017-11-30,GCST005244,Other measurement,#fee08b
8981,European,83.0,29187748.0,Morey RA,Putamen volume in trauma-exposed individuals,initial,2017-11-30,GCST005244,Other measurement,#d53e4f
8982,African Am./Caribbean,74.0,29187748.0,Morey RA,Hippocampal volume in trauma-exposed individuals,initial,2017-11-30,GCST005243,Biological process,#fee08b
8983,European,83.0,29187748.0,Morey RA,Hippocampal volume in trauma-exposed individuals,initial,2017-11-30,GCST005243,Biological process,#d53e4f
8984,African Am./Caribbean,74.0,29187748.0,Morey RA,Hippocampal volume in trauma-exposed individuals,initial,2017-11-30,GCST005243,Other measurement,#fee08b
8985,European,83.0,29187748.0,Morey RA,Hippocampal volume in trauma-exposed individuals,initial,2017-11-30,GCST005243,Other measurement,#d53e4f
8986,European,83.0,29187748.0,Morey RA,Amygdala volume in trauma-exposed individuals,initial,2017-11-30,GCST005239,Biological process,#d53e4f
8987,African Am./Caribbean,74.0,29187748.0,Morey RA,Amygdala volume in trauma-exposed individuals,initial,2017-11-30,GCST005239,Biological process,#fee08b
8988,European,83.0,29187748.0,Morey RA,Amygdala volume in trauma-exposed individuals,initial,2017-11-30,GCST005239,Other measurement,#d53e4f
8989,African Am./Caribbean,74.0,29187748.0,Morey RA,Amygdala volume in trauma-exposed individuals,initial,2017-11-30,GCST005239,Other measurement,#fee08b
8990,African Am./Caribbean,74.0,29187748.0,Morey RA,Pallidum volume in trauma-exposed individuals,initial,2017-11-30,GCST005242,Other measurement,#fee08b
8991,European,83.0,29187748.0,Morey RA,Pallidum volume in trauma-exposed individuals,initial,2017-11-30,GCST005242,Other measurement,#d53e4f
8992,African Am./Caribbean,74.0,29187748.0,Morey RA,Pallidum volume in trauma-exposed individuals,initial,2017-11-30,GCST005242,Biological process,#fee08b
8993,European,83.0,29187748.0,Morey RA,Pallidum volume in trauma-exposed individuals,initial,2017-11-30,GCST005242,Biological process,#d53e4f
8994,European,83.0,29187748.0,Morey RA,Nucleus accumbens volume in trauma-exposed individuals,initial,2017-11-30,GCST005241,Biological process,#d53e4f
8995,African Am./Caribbean,74.0,29187748.0,Morey RA,Nucleus accumbens volume in trauma-exposed individuals,initial,2017-11-30,GCST005241,Biological process,#fee08b
8996,European,83.0,29187748.0,Morey RA,Nucleus accumbens volume in trauma-exposed individuals,initial,2017-11-30,GCST005241,Other measurement,#d53e4f
8997,African Am./Caribbean,74.0,29187748.0,Morey RA,Nucleus accumbens volume in trauma-exposed individuals,initial,2017-11-30,GCST005241,Other measurement,#fee08b
8998,European,104103.0,29187730.0,Ward J,Mood instability,initial,2017-11-30,GCST005237,Other measurement,#d53e4f
8999,African,216.0,29195075.0,Martin AR,Tanning,initial,2017-11-30,GCST005189,Other trait,#fc8d59
9000,African,240.0,29195075.0,Martin AR,Tanning,replication,2017-11-30,GCST005189,Other trait,#fc8d59
9001,European,83.0,29187748.0,Morey RA,Caudate volume in trauma-exposed individuals,initial,2017-11-30,GCST005240,Biological process,#d53e4f
9002,African Am./Caribbean,74.0,29187748.0,Morey RA,Caudate volume in trauma-exposed individuals,initial,2017-11-30,GCST005240,Biological process,#fee08b
9003,European,83.0,29187748.0,Morey RA,Caudate volume in trauma-exposed individuals,initial,2017-11-30,GCST005240,Other measurement,#d53e4f
9004,African Am./Caribbean,74.0,29187748.0,Morey RA,Caudate volume in trauma-exposed individuals,initial,2017-11-30,GCST005240,Other measurement,#fee08b
9005,European,18773.0,29187746.0,Howard DM,Major depressive disorder,initial,2017-11-30,GCST005108,Neurological disorder,#d53e4f
9006,European,25035.0,29187746.0,Howard DM,Major depressive disorder,replication,2017-11-30,GCST005108,Neurological disorder,#d53e4f
9007,European,113968.0,29187730.0,Ward J,Mood instability,initial,2017-11-30,GCST005238,Other measurement,#d53e4f
9010,European,4213.0,29185836.0,Chen MH,Platelet aggregation,initial,2017-11-29,GCST008171,Biological process,#d53e4f
9011,European,1184.0,29185836.0,Chen MH,Platelet aggregation,replication,2017-11-29,GCST008171,Biological process,#d53e4f
9012,African Am./Caribbean,613.0,29185836.0,Chen MH,Platelet aggregation,replication,2017-11-29,GCST008171,Biological process,#fee08b
9013,European,107207.0,29186694.0,Lam M,Cognitive ability,initial,2017-11-28,GCST005142,Biological process,#d53e4f
9014,European,2629.0,29423119.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2017-11-28,GCST005900,Other measurement,#d53e4f
9016,European,2629.0,29423119.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2017-11-28,GCST005900,Cancer,#d53e4f
9018,European,2629.0,29423119.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2017-11-28,GCST005900,Response to drug,#d53e4f
9020,European,2971.0,29423119.0,Khan S,Survival in breast cancer (estrogen-receptor positive),initial,2017-11-28,GCST005901,Other measurement,#d53e4f
9022,European,2971.0,29423119.0,Khan S,Survival in breast cancer (estrogen-receptor positive),initial,2017-11-28,GCST005901,Cancer,#d53e4f
9024,European,436124.0,29186694.0,Lam M,Cognitive ability (MTAG),initial,2017-11-28,GCST005141,Biological process,#d53e4f
9025,European,436124.0,29186694.0,Lam M,Cognitive ability (MTAG),initial,2017-11-28,GCST005141,Other measurement,#d53e4f
9026,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue (sex interaction),initial,2017-11-27,GCST005086,Other measurement,#807dba
9027,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue (sex interaction),replication,2017-11-27,GCST005086,Other measurement,#807dba
9028,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue (sex interaction),initial,2017-11-27,GCST005086,Other measurement,#807dba
9029,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue (sex interaction),replication,2017-11-27,GCST005086,Other measurement,#807dba
9030,African,1473.0,29868224.0,Sallah N,Epstein-Barr virus immune response (multivariate analysis),initial,2017-11-27,GCST005943,Other measurement,#fc8d59
9031,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue,initial,2017-11-27,GCST005085,Other measurement,#807dba
9032,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue,replication,2017-11-27,GCST005085,Other measurement,#807dba
9033,African,1562.0,29868224.0,Sallah N,Viral capsid antigen IgG seropositivity,initial,2017-11-27,GCST005944,Other measurement,#fc8d59
9034,African,1473.0,29868224.0,Sallah N,Viral capsid antigen IgG levels,initial,2017-11-27,GCST005942,Other measurement,#fc8d59
9035,African,1562.0,29868224.0,Sallah N,Epstein Barr virus nuclear antigen 1 IgG seropositivity,initial,2017-11-27,GCST005941,Other measurement,#fc8d59
9036,European,2162.0,29868224.0,Sallah N,Epstein Barr virus nuclear antigen 1 IgG levels,initial,2017-11-27,GCST005963,Other measurement,#d53e4f
9037,African,1473.0,29868224.0,Sallah N,Epstein Barr virus nuclear antigen 1 IgG levels,initial,2017-11-27,GCST005963,Other measurement,#fc8d59
9038,European,2811.0,29186428.0,Tonjes A,Progranulin levels,initial,2017-11-27,GCST005109,Other measurement,#d53e4f
9039,European,1800.0,29186428.0,Tonjes A,Progranulin levels,replication,2017-11-27,GCST005109,Other measurement,#d53e4f
9040,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI,initial,2017-11-27,GCST005087,Other measurement,#807dba
9041,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI,replication,2017-11-27,GCST005087,Other measurement,#807dba
9042,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI (sex interaction),replication,2017-11-27,GCST005088,Other measurement,#807dba
9043,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI (sex interaction),initial,2017-11-27,GCST005088,Other measurement,#807dba
9044,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI (sex interaction),replication,2017-11-27,GCST005088,Other measurement,#807dba
9045,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue adjusted for BMI (sex interaction),initial,2017-11-27,GCST005088,Other measurement,#807dba
9046,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio,replication,2017-11-27,GCST005089,Other measurement,#807dba
9047,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2017-11-27,GCST005089,Other measurement,#807dba
9048,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction),initial,2017-11-27,GCST005090,Other measurement,#807dba
9049,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction),replication,2017-11-27,GCST005090,Other measurement,#807dba
9050,Hispanic/Latin American,983.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction),initial,2017-11-27,GCST005090,Other measurement,#807dba
9051,Hispanic/Latin American,707.0,29178545.0,Gao C,Visceral adipose tissue/subcutaneous adipose tissue ratio (sex interaction),replication,2017-11-27,GCST005090,Other measurement,#807dba
9052,Hispanic/Latin American,983.0,29178545.0,Gao C,Subcutaneous adipose tissue,initial,2017-11-27,GCST005091,Other measurement,#807dba
9053,Hispanic/Latin American,983.0,29178545.0,Gao C,Subcutaneous adipose tissue (sex interaction),initial,2017-11-27,GCST005092,Other measurement,#807dba
9054,Hispanic/Latin American,983.0,29178545.0,Gao C,Subcutaneous adipose tissue (sex interaction),initial,2017-11-27,GCST005092,Other measurement,#807dba
9055,European,338460.0,29413154.0,Shadrin AA,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy),initial,2017-11-26,GCST006216,Neurological disorder,#d53e4f
9056,European,338460.0,29413154.0,Shadrin AA,Attention deficit hyperactivity disorder or educational attainment (years of education) (pleiotropy),initial,2017-11-26,GCST006216,Other measurement,#d53e4f
9057,European,19136.0,29299148.0,Liu W,Cancer,initial,2017-11-25,GCST005275,Cancer,#d53e4f
9058,Asian,7704.0,29170429.0,Hachiya T,Glycated hemoglobin levels,initial,2017-11-23,GCST005145,Other measurement,#3288bd
9060,European,2799.0,29170203.0,Alonso N,Fractures (vertebral),replication,2017-11-23,GCST005097,Other disease,#d53e4f
9061,European,5893.0,29170203.0,Alonso N,Fractures (vertebral),initial,2017-11-23,GCST005097,Other disease,#d53e4f
9062,European,946.0,29168253.0,Seielstad M,Alloimmunization response to pregnancy (HLA class I and II),initial,2017-11-22,GCST005154,Biological process,#d53e4f
9063,European,1505.0,29168253.0,Seielstad M,Alloimmunization response to pregnancy,initial,2017-11-22,GCST005155,Biological process,#d53e4f
9064,European,1085.0,29168253.0,Seielstad M,Alloimmunization response to pregnancy (HLA class II),initial,2017-11-22,GCST005157,Biological process,#d53e4f
9065,European,1000.0,29168253.0,Seielstad M,Alloimmunization response to pregnancy (HLA class I),initial,2017-11-22,GCST005156,Biological process,#d53e4f
9067,European,4739.0,29158497.0,Kadalayil L,Breast cancer (survival),initial,2017-11-21,GCST005106,Other measurement,#d53e4f
9068,European,1301.0,29158497.0,Kadalayil L,Breast cancer (survival),replication,2017-11-21,GCST005106,Other measurement,#d53e4f
9070,European,4739.0,29158497.0,Kadalayil L,Breast cancer (survival),initial,2017-11-21,GCST005106,Cancer,#d53e4f
9071,European,1301.0,29158497.0,Kadalayil L,Breast cancer (survival),replication,2017-11-21,GCST005106,Cancer,#d53e4f
9072,European,2145.0,29160301.0,Fabbri C,Response to antidepressants (symptom remission),initial,2017-11-21,GCST007061,Response to drug,#d53e4f
9073,European,1828.0,29160301.0,Fabbri C,Response to SSRI (symptom remission),initial,2017-11-21,GCST007060,Response to drug,#d53e4f
9074,European,2145.0,29160301.0,Fabbri C,Response to antidepressants (symptom improvement),initial,2017-11-21,GCST007059,Response to drug,#d53e4f
9075,European,1828.0,29160301.0,Fabbri C,Response to SSRI (symptom improvement),initial,2017-11-21,GCST007042,Response to drug,#d53e4f
9076,European,1472.0,29160301.0,Fabbri C,Response to SSRI (symptom improvement),replication,2017-11-21,GCST007042,Response to drug,#d53e4f
9077,European,1345.0,29160300.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,initial,2017-11-21,GCST005144,Other measurement,#d53e4f
9078,European,1345.0,29160300.0,Oetting WS,Tacrolimus trough concentration in kidney transplant patients,initial,2017-11-21,GCST005144,Other measurement,#d53e4f
9079,European,286.0,29158487.0,Heckerman D,Activities of daily living score,initial,2017-11-20,GCST005117,Other measurement,#d53e4f
9080,European,286.0,29158487.0,Heckerman D,Hand grip strength,initial,2017-11-20,GCST005122,Other measurement,#d53e4f
9081,European,286.0,29158487.0,Heckerman D,Calf circumference,initial,2017-11-20,GCST005119,Other measurement,#d53e4f
9082,European,286.0,29158487.0,Heckerman D,Cognitive performance,initial,2017-11-20,GCST005123,Other measurement,#d53e4f
9083,European,1055.0,29158487.0,Heckerman D,Four meter walk test score,replication,2017-11-20,GCST005120,Other measurement,#d53e4f
9084,European,286.0,29158487.0,Heckerman D,Four meter walk test score,initial,2017-11-20,GCST005120,Other measurement,#d53e4f
9085,European,286.0,29158487.0,Heckerman D,Mid-arm muscle circumference,initial,2017-11-20,GCST005118,Other measurement,#d53e4f
9086,European,286.0,29158487.0,Heckerman D,Short physical performance battery score,initial,2017-11-20,GCST005121,Other measurement,#d53e4f
9087,Asian,5075.0,29151059.0,Delgado DA,Telomere length,initial,2017-11-18,GCST005143,Other measurement,#3288bd
9089,European,25218.0,29146897.0,Pirastu N,Male-pattern baldness,replication,2017-11-17,GCST005116,Other disease,#d53e4f
9090,European,43590.0,29146897.0,Pirastu N,Male-pattern baldness,initial,2017-11-17,GCST005116,Other disease,#d53e4f
9091,European,12596.0,29147026.0,Chen CH,Putamen volume,initial,2017-11-16,GCST005083,Other measurement,#d53e4f
9092,European,585478.0,29145611.0,Hu Y,Osteoporosis or obesity (pleiotropy),initial,2017-11-14,GCST005114,Metabolic disorder,#d53e4f
9094,European,585478.0,29145611.0,Hu Y,Osteoporosis or obesity (pleiotropy),initial,2017-11-14,GCST005114,Other disease,#d53e4f
9096,European,606.0,29130521.0,Christopher L,Decline in glucose metabolism in posterior cingulate cortex,initial,2017-11-11,GCST006632,Other measurement,#d53e4f
9097,European,606.0,29130521.0,Christopher L,Decline in glucose metabolism in posterior cingulate cortex,initial,2017-11-11,GCST006632,Other measurement,#d53e4f
9098,European,4296.0,29127183.0,Seyerle AA,PR interval,replication,2017-11-10,GCST005080,Cardiovascular measurement,#d53e4f
9099,African Am./Caribbean,3763.0,29127183.0,Seyerle AA,PR interval,replication,2017-11-10,GCST005080,Cardiovascular measurement,#fee08b
9100,Asian,6805.0,29127183.0,Seyerle AA,PR interval,replication,2017-11-10,GCST005080,Cardiovascular measurement,#3288bd
9101,Hispanic/Latin American,14756.0,29127183.0,Seyerle AA,PR interval,initial,2017-11-10,GCST005080,Cardiovascular measurement,#807dba
9102,Hispanic/Latin American,463.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#807dba
9103,Asian,542.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#3288bd
9105,Asian,927.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#3288bd
9107,Asian,367.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#3288bd
9108,Hispanic/Latin American,1050.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#807dba
9109,European,576.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#d53e4f
9110,European,598.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#d53e4f
9111,African,147.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#fc8d59
9112,Hispanic/Latin American,463.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other disease,#807dba
9113,Asian,542.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other disease,#3288bd
9115,Asian,927.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other disease,#3288bd
9117,Asian,367.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other disease,#3288bd
9118,Hispanic/Latin American,1050.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other disease,#807dba
9119,European,576.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other disease,#d53e4f
9120,European,598.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other disease,#d53e4f
9121,African,147.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other disease,#fc8d59
9122,Hispanic/Latin American,463.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#807dba
9123,Asian,542.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#3288bd
9125,Asian,927.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#3288bd
9127,Asian,367.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#3288bd
9128,Hispanic/Latin American,1050.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#807dba
9129,European,576.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#d53e4f
9130,European,598.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),replication,2017-11-10,GCST005079,Other trait,#d53e4f
9131,African,147.0,29124805.0,Carlson JC,Orofacial clefts (cleft lip vs. cleft lip and palate),initial,2017-11-10,GCST005079,Other trait,#fc8d59
9132,Asian,2073.0,29123153.0,Lee TH,Small vessel stroke,initial,2017-11-09,GCST005057,Cardiovascular disease,#3288bd
9133,Asian,1453.0,29123153.0,Lee TH,Small vessel stroke,replication,2017-11-09,GCST005057,Cardiovascular disease,#3288bd
9134,Asian,5636.0,29124443.0,Yasukochi Y,Creatinine levels,initial,2017-11-09,GCST007919,Other measurement,#3288bd
9135,Asian,5636.0,29124443.0,Yasukochi Y,Estimated glomerular filtration rate,initial,2017-11-09,GCST007917,Other measurement,#3288bd
9136,Asian,5847.0,29124443.0,Yasukochi Y,Serum uric acid levels,initial,2017-11-09,GCST007918,Cardiovascular measurement,#3288bd
9137,Asian,5556.0,29124443.0,Yasukochi Y,Hyperuricemia,replication,2017-11-09,GCST007916,Metabolic disorder,#3288bd
9138,Asian,5487.0,29124443.0,Yasukochi Y,Hyperuricemia,initial,2017-11-09,GCST007916,Metabolic disorder,#3288bd
9139,Asian,3402.0,29124443.0,Yasukochi Y,Chronic kidney disease,replication,2017-11-09,GCST007920,Other disease,#3288bd
9140,Asian,1646.0,29124443.0,Yasukochi Y,Chronic kidney disease,initial,2017-11-09,GCST007920,Other disease,#3288bd
9141,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Neurological disorder,#d53e4f
9142,Asian,226.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Neurological disorder,#3288bd
9144,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Neurological disorder,#d53e4f
9145,Asian,226.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Neurological disorder,#3288bd
9147,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Response to drug,#d53e4f
9148,Asian,226.0,29121268.0,Amare AT,Bipolar disorder lithium response (categorical) or schizophrenia,initial,2017-11-09,GCST005082,Response to drug,#3288bd
9150,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Neurological disorder,#d53e4f
9151,Asian,220.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Neurological disorder,#3288bd
9153,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Neurological disorder,#d53e4f
9154,Asian,220.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Neurological disorder,#3288bd
9156,European,2366.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Response to drug,#d53e4f
9157,Asian,220.0,29121268.0,Amare AT,Bipolar disorder lithium response (continuous) or schizophrenia,initial,2017-11-09,GCST005081,Response to drug,#3288bd
9159,Asian,60650.0,29118346.0,Sakamoto Y,Idiopathic osteonecrosis of the femoral head,initial,2017-11-08,GCST005048,Other disease,#3288bd
9160,European,8050.0,29112194.0,Agrawal A,Cannabis dependence symptom count,initial,2017-11-07,GCST005128,Other measurement,#d53e4f
9161,European,2372.0,29112194.0,Agrawal A,Cannabis dependence,replication,2017-11-07,GCST005133,Neurological disorder,#d53e4f
9162,European,8515.0,29112194.0,Agrawal A,Cannabis dependence,initial,2017-11-07,GCST005133,Neurological disorder,#d53e4f
9163,African Am./Caribbean,2801.0,29112194.0,Agrawal A,Cannabis dependence,replication,2017-11-07,GCST005133,Neurological disorder,#fee08b
9164,Asian,2928.0,29209388.0,Cho CH,Restless legs syndrome,initial,2017-11-07,GCST005107,Neurological disorder,#3288bd
9165,Asian,456.0,29209388.0,Cho CH,Restless legs syndrome,replication,2017-11-07,GCST005107,Neurological disorder,#3288bd
9166,European,2192.0,29097723.0,Darlow JM,Primary vesicoureteric reflux,initial,2017-11-06,GCST005044,Other disease,#d53e4f
9167,European,4936.0,29097723.0,Darlow JM,Primary vesicoureteric reflux,initial,2017-11-06,GCST005045,Other disease,#d53e4f
9168,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Other measurement,#807dba
9169,European,221.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Other measurement,#d53e4f
9170,European,314.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005039,Other measurement,#d53e4f
9171,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Response to drug,#807dba
9172,European,221.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Response to drug,#d53e4f
9173,European,314.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005039,Response to drug,#d53e4f
9174,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Response to drug,#807dba
9175,European,221.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005039,Response to drug,#d53e4f
9176,European,314.0,29097388.0,Magvanjav O,Uncontrolled blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005039,Response to drug,#d53e4f
9181,Asian,377.0,29109912.0,Rawofi L,Iris color (a* coordinate),initial,2017-11-02,GCST005093,Other trait,#3288bd
9182,Asian,377.0,29109912.0,Rawofi L,Iris color (L* coordinate),initial,2017-11-02,GCST005094,Other trait,#3288bd
9183,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Other measurement,#807dba
9184,European,221.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Other measurement,#d53e4f
9185,European,314.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005041,Other measurement,#d53e4f
9186,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Response to drug,#807dba
9187,European,221.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Response to drug,#d53e4f
9188,European,314.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005041,Response to drug,#d53e4f
9189,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Response to drug,#807dba
9190,European,221.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005041,Response to drug,#d53e4f
9191,European,314.0,29097388.0,Magvanjav O,Diastolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005041,Response to drug,#d53e4f
9192,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Other measurement,#807dba
9193,European,221.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Other measurement,#d53e4f
9194,European,314.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005040,Other measurement,#d53e4f
9195,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Response to drug,#807dba
9196,European,221.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Response to drug,#d53e4f
9197,European,314.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005040,Response to drug,#d53e4f
9198,Hispanic/Latin American,193.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Response to drug,#807dba
9199,European,221.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),replication,2017-11-02,GCST005040,Response to drug,#d53e4f
9200,European,314.0,29097388.0,Magvanjav O,Systolic blood pressure in combination therapy (beta blocker and thiazide diuretic),initial,2017-11-02,GCST005040,Response to drug,#d53e4f
9201,Asian,377.0,29109912.0,Rawofi L,Skin pigmentation,initial,2017-11-02,GCST005084,Other measurement,#3288bd
9202,Asian,568.0,29109912.0,Rawofi L,Skin pigmentation,replication,2017-11-02,GCST005084,Other measurement,#3288bd
9203,European,3344.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005163,Other measurement,#d53e4f
9204,European,4905.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005163,Other measurement,#d53e4f
9205,European,3344.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005163,Other measurement,#d53e4f
9206,European,4905.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005163,Other measurement,#d53e4f
9207,European,4905.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005166,Other measurement,#d53e4f
9208,European,3344.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005166,Other measurement,#d53e4f
9209,European,4905.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005166,Other measurement,#d53e4f
9210,European,3344.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005166,Other measurement,#d53e4f
9211,European,3344.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005165,Other measurement,#d53e4f
9212,European,4905.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005165,Other measurement,#d53e4f
9213,European,3344.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005165,Other measurement,#d53e4f
9214,European,4905.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (120 minutes),replication,2017-11-02,GCST005165,Other measurement,#d53e4f
9215,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005161,Other measurement,#d53e4f
9216,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005161,Other measurement,#d53e4f
9217,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005161,Other measurement,#d53e4f
9218,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (120 minutes),initial,2017-11-02,GCST005161,Other measurement,#d53e4f
9219,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (30 minutes),initial,2017-11-02,GCST005160,Other measurement,#d53e4f
9220,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (30 minutes),replication,2017-11-02,GCST005160,Other measurement,#d53e4f
9221,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (30 minutes),initial,2017-11-02,GCST005160,Other measurement,#d53e4f
9222,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (30 minutes),replication,2017-11-02,GCST005160,Other measurement,#d53e4f
9223,European,3344.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005164,Other measurement,#d53e4f
9224,European,4905.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005164,Other measurement,#d53e4f
9225,European,3344.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005164,Other measurement,#d53e4f
9226,European,4905.0,29093273.0,Almgren P,GLP-1 levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005164,Other measurement,#d53e4f
9227,European,4905.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005167,Other measurement,#d53e4f
9228,European,3344.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005167,Other measurement,#d53e4f
9229,European,4905.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005167,Other measurement,#d53e4f
9230,European,3344.0,29093273.0,Almgren P,GIP levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005167,Other measurement,#d53e4f
9231,European,4905.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005162,Other measurement,#d53e4f
9232,European,3344.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005162,Other measurement,#d53e4f
9233,European,4905.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005162,Other measurement,#d53e4f
9234,European,3344.0,29093273.0,Almgren P,Glucagon levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005162,Other measurement,#d53e4f
9235,Asian,377.0,29109912.0,Rawofi L,Iris heterochromicity,initial,2017-11-02,GCST005095,Other trait,#3288bd
9236,Asian,377.0,29109912.0,Rawofi L,Iris color (b* coordinate),initial,2017-11-02,GCST005096,Other trait,#3288bd
9237,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005159,Other measurement,#d53e4f
9238,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005159,Other measurement,#d53e4f
9239,European,4905.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (fasting),replication,2017-11-02,GCST005159,Other measurement,#d53e4f
9240,European,3344.0,29093273.0,Almgren P,Insulin levels in response to oral glucose tolerance test (fasting),initial,2017-11-02,GCST005159,Other measurement,#d53e4f
9241,Asian,428.0,29104669.0,Chen L,Polycystic ovary syndrome,initial,2017-11-01,GCST005043,Other disease,#3288bd
9242,Asian,1600.0,29104669.0,Chen L,Polycystic ovary syndrome,replication,2017-11-01,GCST005043,Other disease,#3288bd
9243,European,5901.0,29066854.0,Lin BD,Neutrophil-to-lymphocyte ratio,initial,2017-11-01,GCST005053,Hematological measurement,#d53e4f
9245,European,5901.0,29066854.0,Lin BD,Platelet count,initial,2017-11-01,GCST005054,Hematological measurement,#d53e4f
9247,European,5901.0,29066854.0,Lin BD,Lymphocyte counts,initial,2017-11-01,GCST005055,Hematological measurement,#d53e4f
9249,European,5901.0,29066854.0,Lin BD,Neutrophil count,initial,2017-11-01,GCST005056,Hematological measurement,#d53e4f
9251,European,5901.0,29066854.0,Lin BD,Platelet-to-lymphocyte ratio,initial,2017-11-01,GCST005052,Hematological measurement,#d53e4f
9253,Asian,8842.0,29095316.0,Suh Y,Lung function (FEV1/FVC),initial,2017-11-01,GCST005130,Other measurement,#3288bd
9254,Asian,8842.0,29095316.0,Suh Y,Lung function (forced vital capacity),initial,2017-11-01,GCST005131,Other measurement,#3288bd
9255,Asian,8842.0,29095316.0,Suh Y,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity),initial,2017-11-01,GCST005129,Other measurement,#3288bd
9256,European,317683.0,29029846.0,Schormair B,Restless legs syndrome,replication,2017-11-01,GCST005042,Neurological disorder,#d53e4f
9257,European,110851.0,29029846.0,Schormair B,Restless legs syndrome,initial,2017-11-01,GCST005042,Neurological disorder,#d53e4f
9258,European,7976.0,29093028.0,Corre T,Serum magnesium levels,initial,2017-11-01,GCST005125,Other measurement,#d53e4f
9259,European,7976.0,29093028.0,Corre T,Fractional excretion of magnesium,initial,2017-11-01,GCST005126,Other measurement,#d53e4f
9260,European,2981.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors,initial,2017-11-01,GCST005111,Cancer,#d53e4f
9261,European,2981.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors,initial,2017-11-01,GCST005111,Cancer,#d53e4f
9262,European,624.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy,initial,2017-11-01,GCST005112,Biological process,#d53e4f
9263,European,624.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy,initial,2017-11-01,GCST005112,Cancer,#d53e4f
9264,European,624.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors treated with more than 10 gray radiotherapy,initial,2017-11-01,GCST005112,Cancer,#d53e4f
9265,European,2213.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy,initial,2017-11-01,GCST005110,Cancer,#d53e4f
9266,European,2213.0,29059430.0,Morton LM,Breast cancer in childhood cancer survivors treated with less than 10 gray radiotherapy,initial,2017-11-01,GCST005110,Cancer,#d53e4f
9267,Asian,8842.0,29095316.0,Suh Y,Lung function (forced expiratory volume in 1 second),initial,2017-11-01,GCST005132,Other measurement,#3288bd
9268,European,9099.0,29093028.0,Corre T,Urinary magnesium-to-creatinine ratio,initial,2017-11-01,GCST005124,Other measurement,#d53e4f
9269,Asian,8842.0,29095316.0,Suh Y,Lung function (maximal voluntary ventilation),initial,2017-11-01,GCST005127,Other measurement,#3288bd
9270,Asian,8842.0,29095316.0,Suh Y,Lung function (maximal voluntary ventilation),initial,2017-11-01,GCST005127,Other measurement,#3288bd
9271,Other/Mixed,282.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Biological process,#99d594
9272,African Am./Caribbean,1036.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,initial,2017-10-30,GCST005236,Biological process,#fee08b
9273,European,828.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Biological process,#d53e4f
9274,African,108.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Biological process,#fc8d59
9276,Asian,6.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Biological process,#3288bd
9277,Other/Mixed,282.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Other measurement,#99d594
9278,African Am./Caribbean,1036.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,initial,2017-10-30,GCST005236,Other measurement,#fee08b
9279,European,828.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Other measurement,#d53e4f
9280,African,108.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Other measurement,#fc8d59
9282,Asian,6.0,29082582.0,Almli LM,Problematic alcohol use in trauma-exposed individuals,replication,2017-10-30,GCST005236,Other measurement,#3288bd
9283,European,8372.0,29084231.0,Davis JP,Apolipoprotein A1 levels,initial,2017-10-30,GCST005513,Lipid or lipoprotein measurement,#d53e4f
9284,European,8372.0,29084231.0,Davis JP,Triglyceride levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005512,Lipid or lipoprotein measurement,#d53e4f
9285,European,8372.0,29084231.0,Davis JP,Triglyceride levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005512,Lipid or lipoprotein measurement,#d53e4f
9286,European,8372.0,29084231.0,Davis JP,Triglyceride levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005512,Lipid or lipoprotein measurement,#d53e4f
9287,European,8372.0,29084231.0,Davis JP,Phospholipid levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005511,Lipid or lipoprotein measurement,#d53e4f
9288,European,8372.0,29084231.0,Davis JP,Phospholipid levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005511,Lipid or lipoprotein measurement,#d53e4f
9289,European,8372.0,29084231.0,Davis JP,Phospholipid levels in chylomicrons and largest VLDL,initial,2017-10-30,GCST005511,Lipid or lipoprotein measurement,#d53e4f
9290,European,8372.0,29084231.0,Davis JP,Chylomicron and largest VLDL particle concentration,initial,2017-10-30,GCST005510,Lipid or lipoprotein measurement,#d53e4f
9291,European,8372.0,29084231.0,Davis JP,Chylomicron and largest VLDL particle concentration,initial,2017-10-30,GCST005510,Lipid or lipoprotein measurement,#d53e4f
9292,European,8372.0,29084231.0,Davis JP,Triglyceride levels in small HDL,initial,2017-10-30,GCST005509,Lipid or lipoprotein measurement,#d53e4f
9293,European,8372.0,29084231.0,Davis JP,Triglyceride levels in small HDL,initial,2017-10-30,GCST005509,Lipid or lipoprotein measurement,#d53e4f
9294,European,8372.0,29084231.0,Davis JP,Small HDL particle concentration,initial,2017-10-30,GCST005508,Lipid or lipoprotein measurement,#d53e4f
9295,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in medium HDL,initial,2017-10-30,GCST005507,Lipid or lipoprotein measurement,#d53e4f
9296,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium HDL,initial,2017-10-30,GCST005506,Lipid or lipoprotein measurement,#d53e4f
9297,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium HDL,initial,2017-10-30,GCST005506,Lipid or lipoprotein measurement,#d53e4f
9298,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in medium HDL,initial,2017-10-30,GCST005505,Lipid or lipoprotein measurement,#d53e4f
9299,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium HDL,initial,2017-10-30,GCST005504,Lipid or lipoprotein measurement,#d53e4f
9300,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium HDL,initial,2017-10-30,GCST005504,Lipid or lipoprotein measurement,#d53e4f
9301,European,8372.0,29084231.0,Davis JP,Medium HDL particle concentration,initial,2017-10-30,GCST005503,Lipid or lipoprotein measurement,#d53e4f
9302,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large HDL,initial,2017-10-30,GCST005502,Lipid or lipoprotein measurement,#d53e4f
9303,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large HDL,initial,2017-10-30,GCST005502,Lipid or lipoprotein measurement,#d53e4f
9304,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in very large HDL,initial,2017-10-30,GCST005501,Lipid or lipoprotein measurement,#d53e4f
9305,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in very large HDL,initial,2017-10-30,GCST005501,Lipid or lipoprotein measurement,#d53e4f
9306,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in large HDL,initial,2017-10-30,GCST005500,Lipid or lipoprotein measurement,#d53e4f
9307,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large HDL,initial,2017-10-30,GCST005499,Lipid or lipoprotein measurement,#d53e4f
9308,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large HDL,initial,2017-10-30,GCST005499,Lipid or lipoprotein measurement,#d53e4f
9309,European,8372.0,29084231.0,Davis JP,Large HDL particle concentration,initial,2017-10-30,GCST005497,Lipid or lipoprotein measurement,#d53e4f
9310,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very large HDL,initial,2017-10-30,GCST005498,Lipid or lipoprotein measurement,#d53e4f
9311,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very large HDL,initial,2017-10-30,GCST005498,Lipid or lipoprotein measurement,#d53e4f
9312,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in very large HDL,initial,2017-10-30,GCST005496,Lipid or lipoprotein measurement,#d53e4f
9313,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in very large HDL,initial,2017-10-30,GCST005496,Lipid or lipoprotein measurement,#d53e4f
9314,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in very large HDL,initial,2017-10-30,GCST005495,Lipid or lipoprotein measurement,#d53e4f
9315,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in very large HDL,initial,2017-10-30,GCST005495,Lipid or lipoprotein measurement,#d53e4f
9316,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in very large HDL,initial,2017-10-30,GCST005494,Lipid or lipoprotein measurement,#d53e4f
9317,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very large HDL,initial,2017-10-30,GCST005493,Lipid or lipoprotein measurement,#d53e4f
9318,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very large HDL,initial,2017-10-30,GCST005493,Lipid or lipoprotein measurement,#d53e4f
9319,European,8372.0,29084231.0,Davis JP,Very large HDL particle concentration,initial,2017-10-30,GCST005492,Lipid or lipoprotein measurement,#d53e4f
9320,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in small LDL,initial,2017-10-30,GCST005491,Lipid or lipoprotein measurement,#d53e4f
9321,European,8372.0,29084231.0,Davis JP,Small LDL particle concentration,initial,2017-10-30,GCST005490,Lipid or lipoprotein measurement,#d53e4f
9322,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium LDL,initial,2017-10-30,GCST005489,Lipid or lipoprotein measurement,#d53e4f
9323,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium LDL,initial,2017-10-30,GCST005489,Lipid or lipoprotein measurement,#d53e4f
9324,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in medium LDL,initial,2017-10-30,GCST005488,Lipid or lipoprotein measurement,#d53e4f
9325,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium LDL,initial,2017-10-30,GCST005487,Lipid or lipoprotein measurement,#d53e4f
9326,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium LDL,initial,2017-10-30,GCST005487,Lipid or lipoprotein measurement,#d53e4f
9327,European,8372.0,29084231.0,Davis JP,Medium LDL particle concentration,initial,2017-10-30,GCST005486,Lipid or lipoprotein measurement,#d53e4f
9328,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large LDL,initial,2017-10-30,GCST005485,Lipid or lipoprotein measurement,#d53e4f
9329,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large LDL,initial,2017-10-30,GCST005485,Lipid or lipoprotein measurement,#d53e4f
9330,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in large LDL,initial,2017-10-30,GCST005484,Lipid or lipoprotein measurement,#d53e4f
9331,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in large LDL,initial,2017-10-30,GCST005484,Lipid or lipoprotein measurement,#d53e4f
9332,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in large LDL,initial,2017-10-30,GCST005483,Lipid or lipoprotein measurement,#d53e4f
9333,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large LDL,initial,2017-10-30,GCST005482,Lipid or lipoprotein measurement,#d53e4f
9334,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large LDL,initial,2017-10-30,GCST005482,Lipid or lipoprotein measurement,#d53e4f
9335,European,8372.0,29084231.0,Davis JP,Large LDL particle concentration,initial,2017-10-30,GCST005481,Lipid or lipoprotein measurement,#d53e4f
9336,European,8372.0,29084231.0,Davis JP,Triglyceride levels in IDL,initial,2017-10-30,GCST005480,Lipid or lipoprotein measurement,#d53e4f
9337,European,8372.0,29084231.0,Davis JP,Triglyceride levels in IDL,initial,2017-10-30,GCST005480,Lipid or lipoprotein measurement,#d53e4f
9338,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in IDL,initial,2017-10-30,GCST005479,Lipid or lipoprotein measurement,#d53e4f
9339,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in IDL,initial,2017-10-30,GCST005479,Lipid or lipoprotein measurement,#d53e4f
9340,European,8372.0,29084231.0,Davis JP,IDL particle concentration,initial,2017-10-30,GCST005478,Lipid or lipoprotein measurement,#d53e4f
9341,European,8372.0,29084231.0,Davis JP,Phospholipid levels in IDL,initial,2017-10-30,GCST005477,Lipid or lipoprotein measurement,#d53e4f
9342,European,8372.0,29084231.0,Davis JP,Phospholipid levels in IDL,initial,2017-10-30,GCST005477,Lipid or lipoprotein measurement,#d53e4f
9343,European,8372.0,29084231.0,Davis JP,IDL particle concentration,initial,2017-10-30,GCST005476,Lipid or lipoprotein measurement,#d53e4f
9344,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very small VLDL,initial,2017-10-30,GCST005475,Lipid or lipoprotein measurement,#d53e4f
9345,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very small VLDL,initial,2017-10-30,GCST005475,Lipid or lipoprotein measurement,#d53e4f
9346,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very small VLDL,initial,2017-10-30,GCST005474,Lipid or lipoprotein measurement,#d53e4f
9347,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very small VLDL,initial,2017-10-30,GCST005474,Lipid or lipoprotein measurement,#d53e4f
9348,European,8372.0,29084231.0,Davis JP,Very small VLDL particle concentration,initial,2017-10-30,GCST005473,Lipid or lipoprotein measurement,#d53e4f
9349,European,8372.0,29084231.0,Davis JP,Triglyceride levels in small VLDL,initial,2017-10-30,GCST005472,Lipid or lipoprotein measurement,#d53e4f
9350,European,8372.0,29084231.0,Davis JP,Triglyceride levels in small VLDL,initial,2017-10-30,GCST005472,Lipid or lipoprotein measurement,#d53e4f
9351,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in small VLDL,initial,2017-10-30,GCST005471,Lipid or lipoprotein measurement,#d53e4f
9352,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in small VLDL,initial,2017-10-30,GCST005471,Lipid or lipoprotein measurement,#d53e4f
9353,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in small VLDL,initial,2017-10-30,GCST005470,Lipid or lipoprotein measurement,#d53e4f
9354,European,8372.0,29084231.0,Davis JP,Phospholipid levels in small VLDL,initial,2017-10-30,GCST005469,Lipid or lipoprotein measurement,#d53e4f
9355,European,8372.0,29084231.0,Davis JP,Phospholipid levels in small VLDL,initial,2017-10-30,GCST005469,Lipid or lipoprotein measurement,#d53e4f
9356,European,8372.0,29084231.0,Davis JP,Small VLDL particle concentration,initial,2017-10-30,GCST005468,Lipid or lipoprotein measurement,#d53e4f
9357,European,8372.0,29084231.0,Davis JP,Triglyceride levels in medium VLDL,initial,2017-10-30,GCST005467,Lipid or lipoprotein measurement,#d53e4f
9358,European,8372.0,29084231.0,Davis JP,Triglyceride levels in medium VLDL,initial,2017-10-30,GCST005467,Lipid or lipoprotein measurement,#d53e4f
9359,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in medium VLDL,initial,2017-10-30,GCST005466,Lipid or lipoprotein measurement,#d53e4f
9360,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in medium VLDL,initial,2017-10-30,GCST005466,Lipid or lipoprotein measurement,#d53e4f
9361,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium VLDL,initial,2017-10-30,GCST005465,Lipid or lipoprotein measurement,#d53e4f
9362,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in medium VLDL,initial,2017-10-30,GCST005465,Lipid or lipoprotein measurement,#d53e4f
9363,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in medium VLDL,initial,2017-10-30,GCST005464,Lipid or lipoprotein measurement,#d53e4f
9364,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium VLDL,initial,2017-10-30,GCST005463,Lipid or lipoprotein measurement,#d53e4f
9365,European,8372.0,29084231.0,Davis JP,Phospholipid levels in medium VLDL,initial,2017-10-30,GCST005463,Lipid or lipoprotein measurement,#d53e4f
9366,European,8372.0,29084231.0,Davis JP,Medium VLDL particle concentration,initial,2017-10-30,GCST005462,Lipid or lipoprotein measurement,#d53e4f
9367,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in large VLDL,initial,2017-10-30,GCST005461,Lipid or lipoprotein measurement,#d53e4f
9368,European,8372.0,29084231.0,Davis JP,Cholesterol ester levels in large VLDL,initial,2017-10-30,GCST005461,Lipid or lipoprotein measurement,#d53e4f
9369,European,8372.0,29084231.0,Davis JP,Triglyceride levels in large VLDL,initial,2017-10-30,GCST005460,Lipid or lipoprotein measurement,#d53e4f
9370,European,8372.0,29084231.0,Davis JP,Triglyceride levels in large VLDL,initial,2017-10-30,GCST005460,Lipid or lipoprotein measurement,#d53e4f
9371,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large VLDL,initial,2017-10-30,GCST005459,Lipid or lipoprotein measurement,#d53e4f
9372,European,8372.0,29084231.0,Davis JP,Free cholesterol levels in large VLDL,initial,2017-10-30,GCST005459,Lipid or lipoprotein measurement,#d53e4f
9373,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in large VLDL,initial,2017-10-30,GCST005458,Lipid or lipoprotein measurement,#d53e4f
9374,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large VLDL,initial,2017-10-30,GCST005454,Lipid or lipoprotein measurement,#d53e4f
9375,European,8372.0,29084231.0,Davis JP,Phospholipid levels in large VLDL,initial,2017-10-30,GCST005454,Lipid or lipoprotein measurement,#d53e4f
9376,European,8372.0,29084231.0,Davis JP,Very large VLDL particle concentration,initial,2017-10-30,GCST005453,Lipid or lipoprotein measurement,#d53e4f
9377,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very large VLDL,initial,2017-10-30,GCST005452,Lipid or lipoprotein measurement,#d53e4f
9378,European,8372.0,29084231.0,Davis JP,Triglyceride levels in very large VLDL,initial,2017-10-30,GCST005452,Lipid or lipoprotein measurement,#d53e4f
9379,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very large VLDL,initial,2017-10-30,GCST005451,Lipid or lipoprotein measurement,#d53e4f
9380,European,8372.0,29084231.0,Davis JP,Phospholipid levels in very large VLDL,initial,2017-10-30,GCST005451,Lipid or lipoprotein measurement,#d53e4f
9381,European,8372.0,29084231.0,Davis JP,Very large VLDL particle concentration,initial,2017-10-30,GCST005450,Lipid or lipoprotein measurement,#d53e4f
9382,European,8372.0,29084231.0,Davis JP,Mean diameter of VLDL particles,initial,2017-10-30,GCST005457,Lipid or lipoprotein measurement,#d53e4f
9383,European,8372.0,29084231.0,Davis JP,Mean diameter of LDL particles,initial,2017-10-30,GCST005456,Lipid or lipoprotein measurement,#d53e4f
9384,European,8372.0,29084231.0,Davis JP,Mean diameter of HDL particles,initial,2017-10-30,GCST005455,Lipid or lipoprotein measurement,#d53e4f
9385,European,8372.0,29084231.0,Davis JP,Total triglycerides levels,initial,2017-10-30,GCST005449,Lipid or lipoprotein measurement,#d53e4f
9386,European,8372.0,29084231.0,Davis JP,Serum total cholesterol levels,initial,2017-10-30,GCST005448,Lipid or lipoprotein measurement,#d53e4f
9387,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in LDL,initial,2017-10-30,GCST005447,Lipid or lipoprotein measurement,#d53e4f
9388,European,8372.0,29084231.0,Davis JP,Total cholesterol levels in HDL,initial,2017-10-30,GCST005446,Lipid or lipoprotein measurement,#d53e4f
9389,European,8372.0,29084231.0,Davis JP,Free cholesterol levels,initial,2017-10-30,GCST005445,Lipid or lipoprotein measurement,#d53e4f
9390,European,8372.0,29084231.0,Davis JP,Esterified cholesterol levels,initial,2017-10-30,GCST005444,Lipid or lipoprotein measurement,#d53e4f
9391,European,8372.0,29084231.0,Davis JP,Ratio of apolipoprotein A1 to apolipoprotein B,initial,2017-10-30,GCST005443,Lipid or lipoprotein measurement,#d53e4f
9392,European,8372.0,29084231.0,Davis JP,Ratio of apolipoprotein A1 to apolipoprotein B,initial,2017-10-30,GCST005443,Lipid or lipoprotein measurement,#d53e4f
9393,European,8372.0,29084231.0,Davis JP,Apolipoprotein B levels,initial,2017-10-30,GCST005442,Lipid or lipoprotein measurement,#d53e4f
9394,European,360838.0,29083406.0,Ferreira MA,"Allergic disease (asthma, hay fever or eczema)",initial,2017-10-30,GCST005038,Immune system disorder,#d53e4f
9395,African Am./Caribbean,1221.0,29077507.0,Chen H,Obstructive sleep apnea trait (apnea hypopnea index),initial,2017-10-27,GCST005051,Other measurement,#fee08b
9396,Asian,228.0,29077507.0,Chen H,Obstructive sleep apnea trait (apnea hypopnea index),initial,2017-10-27,GCST005051,Other measurement,#3288bd
9397,European,5727.0,29077507.0,Chen H,Obstructive sleep apnea trait (apnea hypopnea index),initial,2017-10-27,GCST005051,Other measurement,#d53e4f
9398,Hispanic/Latin American,12557.0,29077507.0,Chen H,Obstructive sleep apnea trait (apnea hypopnea index),initial,2017-10-27,GCST005051,Other measurement,#807dba
9399,Asian,228.0,29077507.0,Chen H,Obstructive sleep apnea during REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005050,Other measurement,#3288bd
9400,African Am./Caribbean,1221.0,29077507.0,Chen H,Obstructive sleep apnea during REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005050,Other measurement,#fee08b
9401,European,5727.0,29077507.0,Chen H,Obstructive sleep apnea during REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005050,Other measurement,#d53e4f
9402,Hispanic/Latin American,12557.0,29077507.0,Chen H,Obstructive sleep apnea during REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005050,Other measurement,#807dba
9403,African Am./Caribbean,1221.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005049,Other measurement,#fee08b
9404,Asian,228.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005049,Other measurement,#3288bd
9405,European,5727.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005049,Other measurement,#d53e4f
9406,Hispanic/Latin American,12557.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),initial,2017-10-27,GCST005049,Other measurement,#807dba
9407,African Am./Caribbean,206.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),replication,2017-10-27,GCST005049,Other measurement,#fee08b
9408,Asian,2792.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),replication,2017-10-27,GCST005049,Other measurement,#3288bd
9409,European,5382.0,29077507.0,Chen H,Obstructive sleep apnea during non-REM sleep (apnea hypopnea index),replication,2017-10-27,GCST005049,Other measurement,#d53e4f
9410,European,16063.0,29107063.0,Yashin AI,Alzheimer's disease,initial,2017-10-26,GCST006121,Neurological disorder,#d53e4f
9411,African,2329.0,29107063.0,Yashin AI,Alzheimer's disease,initial,2017-10-26,GCST006121,Neurological disorder,#fc8d59
9414,African,2078.0,29107063.0,Yashin AI,Alzheimer's disease (age of onset),initial,2017-10-26,GCST006120,Neurological disorder,#fc8d59
9415,European,12169.0,29107063.0,Yashin AI,Alzheimer's disease (age of onset),initial,2017-10-26,GCST006120,Neurological disorder,#d53e4f
9417,African,2078.0,29107063.0,Yashin AI,Alzheimer's disease (age of onset),initial,2017-10-26,GCST006120,Other measurement,#fc8d59
9418,European,12169.0,29107063.0,Yashin AI,Alzheimer's disease (age of onset),initial,2017-10-26,GCST006120,Other measurement,#d53e4f
9419,European,820.0,29229094.0,Condreay L,Response to mepolizumab in severe asthma,initial,2017-10-26,GCST005115,Response to drug,#d53e4f
9420,European,820.0,29229094.0,Condreay L,Response to mepolizumab in severe asthma,initial,2017-10-26,GCST005115,Other disease,#d53e4f
9421,European,1551.0,29071344.0,Zhou H,Major depression and alcohol dependence,replication,2017-10-25,GCST005022,Neurological disorder,#d53e4f
9422,African Am./Caribbean,1612.0,29071344.0,Zhou H,Major depression and alcohol dependence,replication,2017-10-25,GCST005022,Neurological disorder,#fee08b
9423,European,1618.0,29071344.0,Zhou H,Major depression and alcohol dependence,initial,2017-10-25,GCST005022,Neurological disorder,#d53e4f
9424,African Am./Caribbean,3041.0,29071344.0,Zhou H,Major depression and alcohol dependence,initial,2017-10-25,GCST005022,Neurological disorder,#fee08b
9425,European,1551.0,29071344.0,Zhou H,Major depression and alcohol dependence,replication,2017-10-25,GCST005022,Neurological disorder,#d53e4f
9426,African Am./Caribbean,1612.0,29071344.0,Zhou H,Major depression and alcohol dependence,replication,2017-10-25,GCST005022,Neurological disorder,#fee08b
9427,European,1618.0,29071344.0,Zhou H,Major depression and alcohol dependence,initial,2017-10-25,GCST005022,Neurological disorder,#d53e4f
9428,African Am./Caribbean,3041.0,29071344.0,Zhou H,Major depression and alcohol dependence,initial,2017-10-25,GCST005022,Neurological disorder,#fee08b
9429,Asian,238.0,29065906.0,Joo YB,Severe progression in rheumatoid arthritis,initial,2017-10-25,GCST004998,Immune system disorder,#3288bd
9430,Asian,238.0,29065906.0,Joo YB,Severe progression in rheumatoid arthritis,initial,2017-10-25,GCST004998,Other measurement,#3288bd
9431,African,224.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#fc8d59
9432,European,367.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#d53e4f
9433,African,224.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Other measurement,#fc8d59
9434,European,367.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Other measurement,#d53e4f
9435,African,224.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#fc8d59
9436,European,367.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#d53e4f
9437,African,224.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#fc8d59
9438,European,367.0,29064472.0,Lencer R,Pursuit maintenance gain in psychotic disorders,initial,2017-10-24,GCST005028,Neurological disorder,#d53e4f
9439,African,224.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Other measurement,#fc8d59
9440,European,367.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Other measurement,#d53e4f
9441,African,224.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#fc8d59
9442,European,367.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#d53e4f
9443,African,224.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#fc8d59
9444,European,367.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#d53e4f
9445,African,224.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#fc8d59
9446,European,367.0,29064472.0,Lencer R,Anti-saccade error rate in psychotic disorders,initial,2017-10-24,GCST005027,Neurological disorder,#d53e4f
9447,European,367.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#d53e4f
9448,African,224.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#fc8d59
9449,European,367.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Other measurement,#d53e4f
9450,African,224.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Other measurement,#fc8d59
9451,European,367.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#d53e4f
9452,African,224.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#fc8d59
9453,European,367.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#d53e4f
9454,African,224.0,29064472.0,Lencer R,Initial pursuit acceleration in psychotic disorders,initial,2017-10-24,GCST005026,Neurological disorder,#fc8d59
9455,European,4134.0,29065852.0,Hallengren E,Fasting growth hormone levels,initial,2017-10-24,GCST005035,Other measurement,#d53e4f
9456,European,5262.0,29065852.0,Hallengren E,Fasting growth hormone levels,replication,2017-10-24,GCST005035,Other measurement,#d53e4f
9457,African,300.0,29064472.0,Lencer R,Anti-saccade response,initial,2017-10-24,GCST005025,Other measurement,#fc8d59
9458,European,549.0,29064472.0,Lencer R,Anti-saccade response,initial,2017-10-24,GCST005025,Other measurement,#d53e4f
9459,African,300.0,29064472.0,Lencer R,Pursuit maintenance gain,initial,2017-10-24,GCST005024,Other measurement,#fc8d59
9460,European,549.0,29064472.0,Lencer R,Pursuit maintenance gain,initial,2017-10-24,GCST005024,Other measurement,#d53e4f
9461,European,549.0,29064472.0,Lencer R,Initial pursuit acceleration,initial,2017-10-24,GCST005023,Other measurement,#d53e4f
9462,African,300.0,29064472.0,Lencer R,Initial pursuit acceleration,initial,2017-10-24,GCST005023,Other measurement,#fc8d59
9463,European,139274.0,29059683.0,Michailidou K,Breast cancer,initial,2017-10-23,GCST004988,Cancer,#d53e4f
9464,Asian,14068.0,29059683.0,Michailidou K,Breast cancer,replication,2017-10-23,GCST004988,Cancer,#3288bd
9465,European,89677.0,29059683.0,Michailidou K,Breast cancer,replication,2017-10-23,GCST004988,Cancer,#d53e4f
9466,European,434.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Neurological disorder,#d53e4f
9467,African,202.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Neurological disorder,#fc8d59
9469,European,434.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Cardiovascular measurement,#d53e4f
9470,African,202.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Cardiovascular measurement,#fc8d59
9472,European,434.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Response to drug,#d53e4f
9473,African,202.0,29064910.0,Kure Fischer E,Antipsychotic drug-induced QTc interval change in schizophrenia,initial,2017-10-23,GCST004987,Response to drug,#fc8d59
9475,Asian,295.0,29058489.0,Ogata S,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure),initial,2017-10-23,GCST004985,Other measurement,#3288bd
9476,Asian,236.0,29058489.0,Ogata S,White coat effect (clinic diastolic blood pressure minus home diastolic blood pressure),replication,2017-10-23,GCST004985,Other measurement,#3288bd
9477,European,15566.0,29058716.0,Milne RL,Breast Cancer in BRCA1 mutation carriers,initial,2017-10-23,GCST005075,Other measurement,#d53e4f
9478,European,3342.0,29058716.0,Milne RL,Breast Cancer in BRCA1 mutation carriers,replication,2017-10-23,GCST005075,Other measurement,#d53e4f
9479,European,15566.0,29058716.0,Milne RL,Breast Cancer in BRCA1 mutation carriers,initial,2017-10-23,GCST005075,Cancer,#d53e4f
9480,European,3342.0,29058716.0,Milne RL,Breast Cancer in BRCA1 mutation carriers,replication,2017-10-23,GCST005075,Cancer,#d53e4f
9481,European,87827.0,29058716.0,Milne RL,Breast cancer,initial,2017-10-23,GCST005077,Cancer,#d53e4f
9482,European,53143.0,29058716.0,Milne RL,Breast cancer,replication,2017-10-23,GCST005077,Cancer,#d53e4f
9483,Hispanic/Latin American,74.0,29057527.0,Ballantine JL,Early childhood caries,initial,2017-10-23,GCST004989,Digestive system disorder,#807dba
9484,African Am./Caribbean,67.0,29057527.0,Ballantine JL,Early childhood caries,initial,2017-10-23,GCST004989,Digestive system disorder,#fee08b
9487,Other/Mixed,21.0,29057527.0,Ballantine JL,Early childhood caries,initial,2017-10-23,GCST004989,Digestive system disorder,#99d594
9488,European,49.0,29057527.0,Ballantine JL,Early childhood caries,initial,2017-10-23,GCST004989,Digestive system disorder,#d53e4f
9489,European,20328.0,29058377.0,Sanchez-Roige S,Alcohol consumption over the past year,initial,2017-10-23,GCST004990,Other measurement,#d53e4f
9490,Asian,236.0,29058489.0,Ogata S,White coat effect (clinic systolic blood pressure minus home systolic blood pressure),replication,2017-10-23,GCST004984,Other measurement,#3288bd
9491,Asian,295.0,29058489.0,Ogata S,White coat effect (clinic systolic blood pressure minus home systolic blood pressure),initial,2017-10-23,GCST004984,Other measurement,#3288bd
9492,European,49801.0,29058716.0,Milne RL,Breast cancer (estrogen-receptor negative),replication,2017-10-23,GCST005076,Cancer,#d53e4f
9493,European,72261.0,29058716.0,Milne RL,Breast cancer (estrogen-receptor negative),initial,2017-10-23,GCST005076,Cancer,#d53e4f
9494,European,2556.0,29051540.0,Marenholz I,Cow's milk allergy,initial,2017-10-20,GCST004978,Other measurement,#d53e4f
9495,European,2900.0,29051540.0,Marenholz I,Cow's milk allergy,replication,2017-10-20,GCST004978,Other measurement,#d53e4f
9496,European,4529.0,29059373.0,Li Y,Smoking interaction in squamous cell lung cancer (1df test),initial,2017-10-20,GCST005911,Biological process,#d53e4f
9497,European,4529.0,29059373.0,Li Y,Smoking interaction in squamous cell lung cancer (1df test),initial,2017-10-20,GCST005911,Cancer,#d53e4f
9498,European,7015.0,29059373.0,Li Y,Smoking interaction in lung adenocarcinoma (1df test),initial,2017-10-20,GCST005909,Biological process,#d53e4f
9499,European,7015.0,29059373.0,Li Y,Smoking interaction in lung adenocarcinoma (1df test),initial,2017-10-20,GCST005909,Cancer,#d53e4f
9500,European,2675.0,29051540.0,Marenholz I,Hen's egg allergy,initial,2017-10-20,GCST004977,Other measurement,#d53e4f
9501,European,2926.0,29051540.0,Marenholz I,Hen's egg allergy,replication,2017-10-20,GCST004977,Other measurement,#d53e4f
9502,European,2948.0,29051540.0,Marenholz I,Peanut allergy,replication,2017-10-20,GCST004980,Other measurement,#d53e4f
9503,European,2617.0,29051540.0,Marenholz I,Peanut allergy,initial,2017-10-20,GCST004980,Other measurement,#d53e4f
9504,European,2884.0,29051540.0,Marenholz I,Food allergy,initial,2017-10-20,GCST004979,Other measurement,#d53e4f
9505,European,3560.0,29051540.0,Marenholz I,Food allergy,replication,2017-10-20,GCST004979,Other measurement,#d53e4f
9506,European,3968.0,29066090.0,Allen RJ,Idiopathic pulmonary fibrosis,initial,2017-10-20,GCST004986,Cancer,#d53e4f
9507,European,7353.0,29066090.0,Allen RJ,Idiopathic pulmonary fibrosis,replication,2017-10-20,GCST004986,Cancer,#d53e4f
9508,European,13336.0,29059373.0,Li Y,Smoking interaction in non-small cell lung cancer (1df test),initial,2017-10-20,GCST005910,Biological process,#d53e4f
9509,European,13336.0,29059373.0,Li Y,Smoking interaction in non-small cell lung cancer (1df test),initial,2017-10-20,GCST005910,Cancer,#d53e4f
9510,Other/Mixed,1158.0,29045471.0,Robiou-du-Pont S,Blood pressure (parental or offspring effect),initial,2017-10-18,GCST007577,Other measurement,#99d594
9511,Asian,606.0,29016859.0,Ogura Y,Curve progression in adolescent idiopathic scoliosis,replication,2017-10-15,GCST004981,Other disease,#3288bd
9512,Asian,1937.0,29016859.0,Ogura Y,Curve progression in adolescent idiopathic scoliosis,initial,2017-10-15,GCST004981,Other disease,#3288bd
9513,Asian,606.0,29016859.0,Ogura Y,Curve progression in adolescent idiopathic scoliosis,replication,2017-10-15,GCST004981,Other measurement,#3288bd
9514,Asian,1937.0,29016859.0,Ogura Y,Curve progression in adolescent idiopathic scoliosis,initial,2017-10-15,GCST004981,Other measurement,#3288bd
9515,European,586626.0,29030599.0,Joshi PK,Parental lifespan,initial,2017-10-13,GCST004983,Other measurement,#d53e4f
9516,African Am./Caribbean,19433.0,29030599.0,Joshi PK,Parental lifespan,initial,2017-10-13,GCST004983,Other measurement,#fee08b
9517,Asian,1942.0,29031612.0,Hirata J,Psoriasis vulgaris,replication,2017-10-12,GCST006036,Immune system disorder,#3288bd
9518,Asian,708.0,29031612.0,Hirata J,Psoriasis vulgaris,initial,2017-10-12,GCST006036,Immune system disorder,#3288bd
9520,European,4395.0,29030101.0,Asai Y,Peanut allergy,initial,2017-10-10,GCST006039,Other measurement,#d53e4f
9522,European,4506.0,29030101.0,Asai Y,Food allergy,initial,2017-10-10,GCST006038,Other measurement,#d53e4f
9523,European,4792.0,29018042.0,Schierding W,Post-term birth,initial,2017-10-10,GCST004951,Other measurement,#d53e4f
9524,European,2469.0,29228715.0,Hofer P,Colorectal cancer,initial,2017-10-09,GCST005148,Cancer,#d53e4f
9525,European,10555.0,28990592.0,Warrington NM,Gestational weight gain (maternal effect),initial,2017-10-09,GCST005033,Other measurement,#d53e4f
9526,European,11280.0,28990592.0,Warrington NM,Gestational weight gain (maternal effect),replication,2017-10-09,GCST005033,Other measurement,#d53e4f
9527,European,7681.0,28990592.0,Warrington NM,Late gestational weight gain (maternal effect),initial,2017-10-09,GCST005034,Other measurement,#d53e4f
9528,European,1646.0,28990592.0,Warrington NM,Late gestational weight gain (maternal effect),replication,2017-10-09,GCST005034,Other measurement,#d53e4f
9529,European,1854.0,28990592.0,Warrington NM,Early gestation weight gain (maternal effect),replication,2017-10-09,GCST005029,Other measurement,#d53e4f
9530,European,7704.0,28990592.0,Warrington NM,Early gestation weight gain (maternal effect),initial,2017-10-09,GCST005029,Other measurement,#d53e4f
9531,Asian,10154.0,28991256.0,Li Z,Schizophrenia,replication,2017-10-09,GCST004946,Neurological disorder,#3288bd
9532,Asian,26026.0,28991256.0,Li Z,Schizophrenia,initial,2017-10-09,GCST004946,Neurological disorder,#3288bd
9533,European,82315.0,28991256.0,Li Z,Schizophrenia,initial,2017-10-09,GCST004946,Neurological disorder,#d53e4f
9534,European,1436.0,28990359.0,Polimanti R,Risky sexual behaviors in alcohol dependence,initial,2017-10-09,GCST004955,Neurological disorder,#d53e4f
9535,African Am./Caribbean,1541.0,28990359.0,Polimanti R,Risky sexual behaviors in alcohol dependence,initial,2017-10-09,GCST004955,Neurological disorder,#fee08b
9536,European,1436.0,28990359.0,Polimanti R,Risky sexual behaviors in alcohol dependence,initial,2017-10-09,GCST004955,Other measurement,#d53e4f
9537,African Am./Caribbean,1541.0,28990359.0,Polimanti R,Risky sexual behaviors in alcohol dependence,initial,2017-10-09,GCST004955,Other measurement,#fee08b
9538,European,4294.0,29228715.0,Hofer P,Colonoscopy-negative controls vs population controls,initial,2017-10-09,GCST005147,Other trait,#d53e4f
9539,European,1491.0,29228715.0,Hofer P,Colorectal adenoma (advanced),initial,2017-10-09,GCST005153,Cancer,#d53e4f
9540,European,1833.0,29228715.0,Hofer P,Colorectal cancer,initial,2017-10-09,GCST005152,Cancer,#d53e4f
9541,African Am./Caribbean,2173.0,28990359.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2017-10-09,GCST004956,Neurological disorder,#fee08b
9542,European,1751.0,28990359.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2017-10-09,GCST004956,Neurological disorder,#d53e4f
9543,African Am./Caribbean,2173.0,28990359.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2017-10-09,GCST004956,Other measurement,#fee08b
9544,European,1751.0,28990359.0,Polimanti R,Risky sexual behaviors (alcohol dependence interaction),initial,2017-10-09,GCST004956,Other measurement,#d53e4f
9545,European,8641.0,28990592.0,Warrington NM,Late gestational weight gain (fetal effect),initial,2017-10-09,GCST005030,Other measurement,#d53e4f
9546,European,779.0,28990592.0,Warrington NM,Late gestational weight gain (fetal effect),replication,2017-10-09,GCST005030,Other measurement,#d53e4f
9547,European,8641.0,28990592.0,Warrington NM,Late gestational weight gain (fetal effect),initial,2017-10-09,GCST005030,Other measurement,#d53e4f
9548,European,779.0,28990592.0,Warrington NM,Late gestational weight gain (fetal effect),replication,2017-10-09,GCST005030,Other measurement,#d53e4f
9549,European,16434.0,28990592.0,Warrington NM,Gestational weight gain (fetal effect),initial,2017-10-09,GCST005031,Other measurement,#d53e4f
9550,European,7827.0,28990592.0,Warrington NM,Gestational weight gain (fetal effect),replication,2017-10-09,GCST005031,Other measurement,#d53e4f
9551,European,16434.0,28990592.0,Warrington NM,Gestational weight gain (fetal effect),initial,2017-10-09,GCST005031,Other measurement,#d53e4f
9552,European,7827.0,28990592.0,Warrington NM,Gestational weight gain (fetal effect),replication,2017-10-09,GCST005031,Other measurement,#d53e4f
9553,European,8559.0,28990592.0,Warrington NM,Early gestational weight gain (fetal effect),initial,2017-10-09,GCST005032,Other measurement,#d53e4f
9554,European,3289.0,28990592.0,Warrington NM,Early gestational weight gain (fetal effect),replication,2017-10-09,GCST005032,Other measurement,#d53e4f
9555,European,8559.0,28990592.0,Warrington NM,Early gestational weight gain (fetal effect),initial,2017-10-09,GCST005032,Other measurement,#d53e4f
9556,European,3289.0,28990592.0,Warrington NM,Early gestational weight gain (fetal effect),replication,2017-10-09,GCST005032,Other measurement,#d53e4f
9557,European,4930.0,29228715.0,Hofer P,Colorectal adenoma (advanced),initial,2017-10-09,GCST005151,Cancer,#d53e4f
9558,European,5908.0,29228715.0,Hofer P,Colorectal cancer,initial,2017-10-09,GCST005150,Cancer,#d53e4f
9559,European,5272.0,29228715.0,Hofer P,Colorectal cancer,initial,2017-10-09,GCST005149,Cancer,#d53e4f
9560,Asian,469.0,28983962.0,Cheung JPY,Lumbar spinal stenosis,initial,2017-10-06,GCST004945,Other disease,#3288bd
9561,European,14980.0,28979981.0,Tielbeek JJ,Antisocial behavior,initial,2017-10-04,GCST004954,Other measurement,#d53e4f
9562,European,7054.0,28979981.0,Tielbeek JJ,Antisocial behavior,initial,2017-10-04,GCST006489,Other measurement,#d53e4f
9563,European,7926.0,28979981.0,Tielbeek JJ,Antisocial behavior,initial,2017-10-04,GCST006490,Other measurement,#d53e4f
9564,African Am./Caribbean,9925.0,28972577.0,Hancock DB,Nicotine dependence,initial,2017-10-03,GCST008496,Neurological disorder,#fee08b
9565,European,28677.0,28972577.0,Hancock DB,Nicotine dependence,initial,2017-10-03,GCST008496,Neurological disorder,#d53e4f
9578,European,24003.0,28960316.0,Tanskanen T,Colorectal cancer,replication,2017-09-28,GCST004895,Cancer,#d53e4f
9579,European,15783.0,28960316.0,Tanskanen T,Colorectal cancer,initial,2017-09-28,GCST004895,Cancer,#d53e4f
9580,European,116666.0,28957414.0,Pilling LC,Red cell distribution width,initial,2017-09-28,GCST006804,Hematological measurement,#d53e4f
9583,European,83264.0,28957384.0,Kim SK,Ankle injury,initial,2017-09-28,GCST004952,Other disease,#d53e4f
9584,Asian,7518.0,28957384.0,Kim SK,Ankle injury,initial,2017-09-28,GCST004952,Other disease,#3288bd
9585,Hispanic/Latin American,8560.0,28957384.0,Kim SK,Ankle injury,initial,2017-09-28,GCST004952,Other disease,#807dba
9586,African,2698.0,29036319.0,Qi H,Tuberculosis,initial,2017-09-26,GCST004922,Other disease,#fc8d59
9587,Asian,2509.0,29036319.0,Qi H,Tuberculosis,initial,2017-09-26,GCST004922,Other disease,#3288bd
9588,Asian,2509.0,29036319.0,Qi H,Tuberculosis,initial,2017-09-26,GCST004923,Other disease,#3288bd
9589,Asian,8187.0,29036319.0,Qi H,Tuberculosis,replication,2017-09-26,GCST004923,Other disease,#3288bd
9590,European,17675.0,28941034.0,Smith CE,BMI x dairy intake interaction (1df interaction test),replication,2017-09-21,GCST006173,Biological process,#d53e4f
9591,European,25513.0,28941034.0,Smith CE,BMI x dairy intake interaction (1df interaction test),initial,2017-09-21,GCST006173,Biological process,#d53e4f
9592,European,17675.0,28941034.0,Smith CE,BMI x dairy intake interaction (1df interaction test),replication,2017-09-21,GCST006173,Body measurement,#d53e4f
9593,European,25513.0,28941034.0,Smith CE,BMI x dairy intake interaction (1df interaction test),initial,2017-09-21,GCST006173,Body measurement,#d53e4f
9594,Asian,4084.0,28931804.0,Benyamin B,Amyotrophic lateral sclerosis (sporadic),initial,2017-09-20,GCST004901,Neurological disorder,#3288bd
9595,European,36052.0,28931804.0,Benyamin B,Amyotrophic lateral sclerosis (sporadic),initial,2017-09-20,GCST004901,Neurological disorder,#d53e4f
9598,European,36052.0,28931804.0,Benyamin B,Amyotrophic lateral sclerosis (sporadic),initial,2017-09-20,GCST008472,Neurological disorder,#d53e4f
9599,Asian,4084.0,28931804.0,Benyamin B,Amyotrophic lateral sclerosis (sporadic),initial,2017-09-20,GCST008472,Neurological disorder,#3288bd
9600,European,4931.0,28979897.0,Zeller T,Coronary artery disease severity measurement,initial,2017-09-20,GCST004918,Cardiovascular disease,#d53e4f
9601,European,2283.0,28979897.0,Zeller T,Coronary artery disease severity measurement,replication,2017-09-20,GCST004918,Cardiovascular disease,#d53e4f
9605,European,130639.0,28928442.0,Tian C,Pneumonia,initial,2017-09-19,GCST005009,Other measurement,#d53e4f
9606,European,120649.0,28928442.0,Tian C,Scarlet fever,initial,2017-09-19,GCST005008,Other measurement,#d53e4f
9607,European,74504.0,28928442.0,Tian C,Strep throat,initial,2017-09-19,GCST005007,Other measurement,#d53e4f
9608,European,219605.0,28928442.0,Tian C,Hepatitis B,initial,2017-09-19,GCST005004,Other measurement,#d53e4f
9609,European,85903.0,28928442.0,Tian C,Mononucleosis,initial,2017-09-19,GCST005002,Other measurement,#d53e4f
9610,European,83597.0,28928442.0,Tian C,Rubella,initial,2017-09-19,GCST005020,Other measurement,#d53e4f
9611,European,121810.0,28928442.0,Tian C,Childhood ear infection,initial,2017-09-19,GCST005013,Other measurement,#d53e4f
9612,European,173421.0,28928442.0,Tian C,Tonsillectomy,initial,2017-09-19,GCST005014,Other measurement,#d53e4f
9613,European,68478.0,28928442.0,Tian C,Urinary tract infection frequency,initial,2017-09-19,GCST005012,Other measurement,#d53e4f
9614,European,84913.0,28928442.0,Tian C,Chronic sinus infection,initial,2017-09-19,GCST005021,Other measurement,#d53e4f
9615,European,59546.0,28928442.0,Tian C,Number of common colds,initial,2017-09-19,GCST005019,Other measurement,#d53e4f
9616,European,89191.0,28928442.0,Tian C,Rheumatic fever,initial,2017-09-19,GCST005018,Other measurement,#d53e4f
9617,European,219579.0,28928442.0,Tian C,Hepatitis A,initial,2017-09-19,GCST005017,Other measurement,#d53e4f
9618,European,85498.0,28928442.0,Tian C,Measles,initial,2017-09-19,GCST005016,Other measurement,#d53e4f
9619,European,89227.0,28928442.0,Tian C,Myringotomy,initial,2017-09-19,GCST005015,Other measurement,#d53e4f
9620,European,62453.0,28928442.0,Tian C,Yeast infection,initial,2017-09-19,GCST005011,Other measurement,#d53e4f
9621,European,83620.0,28928442.0,Tian C,Bacterial meningitis,initial,2017-09-19,GCST005010,Other measurement,#d53e4f
9622,European,88716.0,28928442.0,Tian C,Tuberculosis,initial,2017-09-19,GCST005006,Other measurement,#d53e4f
9623,European,62445.0,28928442.0,Tian C,Plantar warts,initial,2017-09-19,GCST005005,Other measurement,#d53e4f
9624,European,85380.0,28928442.0,Tian C,Mumps,initial,2017-09-19,GCST005003,Other measurement,#d53e4f
9625,European,88440.0,28928442.0,Tian C,Cold sores,initial,2017-09-19,GCST005000,Other measurement,#d53e4f
9626,European,134863.0,28928442.0,Tian C,Shingles,initial,2017-09-19,GCST005001,Other measurement,#d53e4f
9633,European,123751.0,28928442.0,Tian C,Chickenpox,initial,2017-09-19,GCST004999,Other measurement,#d53e4f
9637,European,315.0,28922980.0,Konte B,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia,initial,2017-09-19,GCST004953,Neurological disorder,#d53e4f
9638,European,315.0,28922980.0,Konte B,Disturbances of the gamma-frequency band of electroencephalography measures in schizophrenia,initial,2017-09-19,GCST004953,Other measurement,#d53e4f
9639,European,147.0,28935272.0,Moore KN,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2017-09-18,GCST004897,Other measurement,#d53e4f
9640,European,147.0,28935272.0,Moore KN,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2017-09-18,GCST004897,Cancer,#d53e4f
9641,European,147.0,28935272.0,Moore KN,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2017-09-18,GCST004897,Response to drug,#d53e4f
9642,European,147.0,28935272.0,Moore KN,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2017-09-18,GCST004897,Response to drug,#d53e4f
9643,European,5369.0,28924153.0,Chang X,Neuroblastoma (MYCN amplification),initial,2017-09-18,GCST004885,Cancer,#d53e4f
9644,European,5178.0,28924153.0,Chang X,Neuroblastoma (1p deletion),initial,2017-09-18,GCST004884,Cancer,#d53e4f
9645,European,395.0,28924153.0,Chang X,Neuroblastoma (11q deletion vs 11q undeleted and MYCN amplification),initial,2017-09-18,GCST004882,Cancer,#d53e4f
9646,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex),initial,2017-09-18,GCST004993,Neurological disorder,#3288bd
9647,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex),initial,2017-09-18,GCST004993,Other measurement,#3288bd
9648,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right anterior cingulate cortex),initial,2017-09-18,GCST004993,Other measurement,#3288bd
9649,European,289.0,28935272.0,Moore KN,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,initial,2017-09-18,GCST004896,Other measurement,#d53e4f
9650,European,289.0,28935272.0,Moore KN,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,initial,2017-09-18,GCST004896,Cancer,#d53e4f
9651,European,289.0,28935272.0,Moore KN,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,initial,2017-09-18,GCST004896,Response to drug,#d53e4f
9652,European,289.0,28935272.0,Moore KN,Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,initial,2017-09-18,GCST004896,Response to drug,#d53e4f
9653,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex),initial,2017-09-18,GCST004994,Neurological disorder,#3288bd
9654,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex),initial,2017-09-18,GCST004994,Other measurement,#3288bd
9655,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left anterior cingulate cortex),initial,2017-09-18,GCST004994,Other measurement,#3288bd
9656,European,5222.0,28924153.0,Chang X,Neuroblastoma (11q deletion),initial,2017-09-18,GCST004883,Cancer,#d53e4f
9657,European,1946.0,28924153.0,Chang X,Neuroblastoma (11q deletion),replication,2017-09-18,GCST004883,Cancer,#d53e4f
9658,Asian,227.0,28924203.0,Ren HY,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis),initial,2017-09-18,GCST004997,Other measurement,#3288bd
9659,Asian,227.0,28924203.0,Ren HY,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis),initial,2017-09-18,GCST004997,Neurological disorder,#3288bd
9660,Asian,227.0,28924203.0,Ren HY,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis),initial,2017-09-18,GCST004997,Other measurement,#3288bd
9661,Asian,227.0,28924203.0,Ren HY,Abnormal white matter microstructure in first episode schizophrenia (multivariate analysis),initial,2017-09-18,GCST004997,Other measurement,#3288bd
9662,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left inferior parietal cortex),initial,2017-09-18,GCST004991,Other measurement,#3288bd
9663,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left inferior parietal cortex),initial,2017-09-18,GCST004991,Neurological disorder,#3288bd
9664,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left inferior parietal cortex),initial,2017-09-18,GCST004991,Other measurement,#3288bd
9665,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex),initial,2017-09-18,GCST004995,Neurological disorder,#3288bd
9666,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex),initial,2017-09-18,GCST004995,Other measurement,#3288bd
9667,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (left posterior cingulate cortex),initial,2017-09-18,GCST004995,Other measurement,#3288bd
9668,Asian,227.0,28924203.0,Ren HY,Total mean fractional anisotropy measurement in first episode schizophrenia,initial,2017-09-18,GCST004996,Neurological disorder,#3288bd
9669,Asian,227.0,28924203.0,Ren HY,Total mean fractional anisotropy measurement in first episode schizophrenia,initial,2017-09-18,GCST004996,Other measurement,#3288bd
9670,Asian,227.0,28924203.0,Ren HY,Total mean fractional anisotropy measurement in first episode schizophrenia,initial,2017-09-18,GCST004996,Other measurement,#3288bd
9671,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex),initial,2017-09-18,GCST004992,Neurological disorder,#3288bd
9672,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex),initial,2017-09-18,GCST004992,Other measurement,#3288bd
9673,Asian,227.0,28924203.0,Ren HY,White matter microstructure in first episode schizophrenia (right posterior cingulate cortex),initial,2017-09-18,GCST004992,Other measurement,#3288bd
9674,Asian,1251.0,28921602.0,Lee MH,Hepatocellular carcinoma in hepatitis C infection,initial,2017-09-16,GCST006037,Cancer,#3288bd
9675,Asian,1098.0,28921602.0,Lee MH,Hepatocellular carcinoma in hepatitis C infection,replication,2017-09-16,GCST006037,Cancer,#3288bd
9676,Asian,1251.0,28921602.0,Lee MH,Hepatocellular carcinoma in hepatitis C infection,initial,2017-09-16,GCST006037,Digestive system disorder,#3288bd
9677,Asian,1098.0,28921602.0,Lee MH,Hepatocellular carcinoma in hepatitis C infection,replication,2017-09-16,GCST006037,Digestive system disorder,#3288bd
9678,Asian,10300.0,29212154.0,Lin E,Fasting blood glucose,initial,2017-09-16,GCST005877,Other measurement,#3288bd
9679,Asian,10300.0,29212154.0,Lin E,Systolic blood pressure,initial,2017-09-16,GCST005876,Other measurement,#3288bd
9680,Asian,10300.0,29212154.0,Lin E,Diastolic blood pressure,initial,2017-09-16,GCST005875,Other measurement,#3288bd
9681,Asian,10300.0,29212154.0,Lin E,HDL cholesterol,initial,2017-09-16,GCST005874,Lipid or lipoprotein measurement,#3288bd
9682,Asian,10300.0,29212154.0,Lin E,Triglyceride levels,initial,2017-09-16,GCST005873,Lipid or lipoprotein measurement,#3288bd
9683,Asian,10300.0,29212154.0,Lin E,Waist circumference,initial,2017-09-16,GCST005872,Body measurement,#3288bd
9684,Asian,10300.0,29212154.0,Lin E,Metabolic syndrome,initial,2017-09-16,GCST005871,Metabolic disorder,#3288bd
9685,European,1660.0,28927820.0,Sugier PE,Atopy,initial,2017-09-16,GCST006040,Immune system disorder,#d53e4f
9686,European,1138.0,28927820.0,Sugier PE,Atopy,replication,2017-09-16,GCST006040,Immune system disorder,#d53e4f
9687,European,446.0,28927820.0,Sugier PE,Atopy,replication,2017-09-16,GCST006040,Immune system disorder,#d53e4f
9688,African Am./Caribbean,954.0,28921760.0,Chenoweth MJ,nicotine metabolite ratio in current smokers,initial,2017-09-16,GCST004976,Biological process,#fee08b
9689,African Am./Caribbean,480.0,28921760.0,Chenoweth MJ,nicotine metabolite ratio in current smokers,replication,2017-09-16,GCST004976,Biological process,#fee08b
9690,African Am./Caribbean,954.0,28921760.0,Chenoweth MJ,nicotine metabolite ratio in current smokers,initial,2017-09-16,GCST004976,Other measurement,#fee08b
9691,African Am./Caribbean,480.0,28921760.0,Chenoweth MJ,nicotine metabolite ratio in current smokers,replication,2017-09-16,GCST004976,Other measurement,#fee08b
9692,African Am./Caribbean,1217.0,28916551.0,Liu Y,Knee osteoarthritis,initial,2017-09-15,GCST004881,Other disease,#fee08b
9693,Hispanic/Latin American,208.0,28918882.0,Wattacheril J,Pediatric non-alcoholic fatty liver disease activity score,initial,2017-09-14,GCST004942,Other measurement,#807dba
9694,Hispanic/Latin American,156.0,28918882.0,Wattacheril J,Pediatric nonalcoholic steatohepatitis,initial,2017-09-14,GCST004943,Digestive system disorder,#807dba
9695,Hispanic/Latin American,208.0,28918882.0,Wattacheril J,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease,initial,2017-09-14,GCST004938,Digestive system disorder,#807dba
9696,Hispanic/Latin American,208.0,28918882.0,Wattacheril J,Liver fibrosis in pediatric non-alcoholic fatty acid liver disease,initial,2017-09-14,GCST004938,Other trait,#807dba
9697,Hispanic/Latin American,149.0,28902444.0,Stein MB,Suicide attempts,replication,2017-09-13,GCST004893,Biological process,#807dba
9698,African,840.0,28902444.0,Stein MB,Suicide attempts,replication,2017-09-13,GCST004893,Biological process,#fc8d59
9699,European,4683.0,28902444.0,Stein MB,Suicide attempts,replication,2017-09-13,GCST004893,Biological process,#d53e4f
9700,Hispanic/Latin American,1940.0,28902444.0,Stein MB,Suicide attempts,initial,2017-09-13,GCST004893,Biological process,#807dba
9701,African,1772.0,28902444.0,Stein MB,Suicide attempts,initial,2017-09-13,GCST004893,Biological process,#fc8d59
9702,European,6539.0,28902444.0,Stein MB,Suicide attempts,initial,2017-09-13,GCST004893,Biological process,#d53e4f
9703,European,88355.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST004903,Other measurement,#d53e4f
9704,African Am./Caribbean,7564.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST004903,Other measurement,#fee08b
9705,Asian,7572.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST004903,Other measurement,#3288bd
9706,Asian,2366.0,28898252.0,Wheeler E,Glycated hemoglobin levels,replication,2017-09-12,GCST004903,Other measurement,#3288bd
9707,Asian,18472.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST004903,Other measurement,#3288bd
9708,Asian,1302.0,28898252.0,Wheeler E,Glycated hemoglobin levels,replication,2017-09-12,GCST004903,Other measurement,#3288bd
9709,European,33238.0,28898252.0,Wheeler E,Glycated hemoglobin levels,replication,2017-09-12,GCST004903,Other measurement,#d53e4f
9710,Asian,18472.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST007953,Other measurement,#3288bd
9711,African Am./Caribbean,7564.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST007952,Other measurement,#fee08b
9712,European,88355.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST007954,Other measurement,#d53e4f
9713,Asian,7572.0,28898252.0,Wheeler E,Glycated hemoglobin levels,initial,2017-09-12,GCST007951,Other measurement,#3288bd
9714,Asian,158284.0,28892062.0,Akiyama M,Body mass index,initial,2017-09-11,GCST004904,Body measurement,#3288bd
9715,Asian,15146.0,28892062.0,Akiyama M,Body mass index,replication,2017-09-11,GCST004904,Body measurement,#3288bd
9716,European,322154.0,28892062.0,Akiyama M,Body mass index,replication,2017-09-11,GCST004904,Body measurement,#d53e4f
9717,European,417508.0,28892059.0,Chang D,Parkinson's disease,initial,2017-09-11,GCST004902,Neurological disorder,#d53e4f
9718,European,11717.0,28892059.0,Chang D,Parkinson's disease,replication,2017-09-11,GCST004902,Neurological disorder,#d53e4f
9720,European,9888.0,28887542.0,Prins BP,Dehydroepiandrosterone sulphate levels,replication,2017-09-08,GCST004941,Other measurement,#d53e4f
9721,European,9722.0,28887542.0,Prins BP,Dehydroepiandrosterone sulphate levels,initial,2017-09-08,GCST004941,Other measurement,#d53e4f
9722,European,3473.0,29296818.0,Clay-Gilmour AI,Acute lymphoblastic leukemia (B-cell precursor),initial,2017-09-08,GCST005972,Cancer,#d53e4f
9724,European,9888.0,28887542.0,Prins BP,Glomerular filtration rate,replication,2017-09-08,GCST005063,Other measurement,#d53e4f
9725,European,9961.0,28887542.0,Prins BP,Glomerular filtration rate,initial,2017-09-08,GCST005063,Other measurement,#d53e4f
9727,European,9888.0,28887542.0,Prins BP,LDL cholesterol,replication,2017-09-08,GCST005068,Lipid or lipoprotein measurement,#d53e4f
9728,European,9961.0,28887542.0,Prins BP,LDL cholesterol,initial,2017-09-08,GCST005068,Lipid or lipoprotein measurement,#d53e4f
9729,European,9818.0,28887542.0,Prins BP,Urea levels,initial,2017-09-08,GCST005070,Other measurement,#d53e4f
9731,European,9888.0,28887542.0,Prins BP,Urea levels,replication,2017-09-08,GCST005070,Other measurement,#d53e4f
9732,European,9745.0,28887542.0,Prins BP,Triglyceride levels,initial,2017-09-08,GCST005073,Lipid or lipoprotein measurement,#d53e4f
9734,European,9888.0,28887542.0,Prins BP,Triglyceride levels,replication,2017-09-08,GCST005073,Lipid or lipoprotein measurement,#d53e4f
9735,European,4259.0,28887542.0,Prins BP,Testosterone levels,initial,2017-09-08,GCST005074,Other measurement,#d53e4f
9736,European,9888.0,28887542.0,Prins BP,Testosterone levels,replication,2017-09-08,GCST005074,Other measurement,#d53e4f
9739,European,9888.0,28887542.0,Prins BP,Ferritin levels,replication,2017-09-08,GCST005072,Other measurement,#d53e4f
9740,European,9818.0,28887542.0,Prins BP,Ferritin levels,initial,2017-09-08,GCST005072,Other measurement,#d53e4f
9742,European,9888.0,28887542.0,Prins BP,Insulin-like growth factor 1 levels,replication,2017-09-08,GCST005071,Other measurement,#d53e4f
9743,European,9732.0,28887542.0,Prins BP,Insulin-like growth factor 1 levels,initial,2017-09-08,GCST005071,Other measurement,#d53e4f
9744,European,9888.0,28887542.0,Prins BP,C-reactive protein levels,replication,2017-09-08,GCST005067,Inflammatory measurement,#d53e4f
9745,European,9541.0,28887542.0,Prins BP,C-reactive protein levels,initial,2017-09-08,GCST005067,Inflammatory measurement,#d53e4f
9747,European,9888.0,28887542.0,Prins BP,Hemoglobin levels,replication,2017-09-08,GCST005060,Hematological measurement,#d53e4f
9748,European,9667.0,28887542.0,Prins BP,Hemoglobin levels,initial,2017-09-08,GCST005060,Hematological measurement,#d53e4f
9751,European,9888.0,28887542.0,Prins BP,HDL cholesterol,replication,2017-09-08,GCST005058,Lipid or lipoprotein measurement,#d53e4f
9752,European,9796.0,28887542.0,Prins BP,HDL cholesterol,initial,2017-09-08,GCST005058,Lipid or lipoprotein measurement,#d53e4f
9753,European,3179.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia in adulthood,initial,2017-09-08,GCST005971,Cancer,#d53e4f
9754,European,3187.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia in young adulthood,initial,2017-09-08,GCST005970,Cancer,#d53e4f
9755,European,3161.0,29296818.0,Clay-Gilmour AI,Acute lymphoblastic leukemia in childhood (B cell precursor),initial,2017-09-08,GCST005969,Cancer,#d53e4f
9756,European,3280.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia (abnormal cytogenetics),initial,2017-09-08,GCST005968,Cancer,#d53e4f
9757,European,3360.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia (Philadelphia chromosome negative),initial,2017-09-08,GCST005967,Cancer,#d53e4f
9758,European,3437.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia (hyperdiploid negative),initial,2017-09-08,GCST005966,Cancer,#d53e4f
9759,European,3220.0,29296818.0,Clay-Gilmour AI,B cell acute lymphoblastic leukaemia (normal cytogenetics),initial,2017-09-08,GCST005965,Cancer,#d53e4f
9761,European,9888.0,28887542.0,Prins BP,Gamma glutamyl transferase levels,replication,2017-09-08,GCST005069,Liver enzyme measurement,#d53e4f
9762,European,9747.0,28887542.0,Prins BP,Gamma glutamyl transferase levels,initial,2017-09-08,GCST005069,Liver enzyme measurement,#d53e4f
9764,European,9888.0,28887542.0,Prins BP,Creatinine levels,replication,2017-09-08,GCST005066,Other measurement,#d53e4f
9765,European,9803.0,28887542.0,Prins BP,Creatinine levels,initial,2017-09-08,GCST005066,Other measurement,#d53e4f
9767,European,9888.0,28887542.0,Prins BP,"Cholesterol, total",replication,2017-09-08,GCST005065,Lipid or lipoprotein measurement,#d53e4f
9768,European,9817.0,28887542.0,Prins BP,"Cholesterol, total",initial,2017-09-08,GCST005065,Lipid or lipoprotein measurement,#d53e4f
9769,European,9463.0,28887542.0,Prins BP,Aspartate aminotransferase levels,initial,2017-09-08,GCST005064,Liver enzyme measurement,#d53e4f
9771,European,9888.0,28887542.0,Prins BP,Aspartate aminotransferase levels,replication,2017-09-08,GCST005064,Liver enzyme measurement,#d53e4f
9772,European,9762.0,28887542.0,Prins BP,Fibrinogen levels,initial,2017-09-08,GCST005062,Hematological measurement,#d53e4f
9773,European,9888.0,28887542.0,Prins BP,Fibrinogen levels,replication,2017-09-08,GCST005062,Hematological measurement,#d53e4f
9776,European,9888.0,28887542.0,Prins BP,Serum alkaline phosphatase levels,replication,2017-09-08,GCST005061,Liver enzyme measurement,#d53e4f
9777,European,9733.0,28887542.0,Prins BP,Serum alkaline phosphatase levels,initial,2017-09-08,GCST005061,Liver enzyme measurement,#d53e4f
9779,European,9888.0,28887542.0,Prins BP,Serum albumin level,replication,2017-09-08,GCST005059,Other measurement,#d53e4f
9780,European,9824.0,28887542.0,Prins BP,Serum albumin level,initial,2017-09-08,GCST005059,Other measurement,#d53e4f
9782,Asian,1249.0,28886140.0,Kwon YC,Kawasaki disease,initial,2017-09-08,GCST004859,Immune system disorder,#3288bd
9783,Asian,5514.0,28886140.0,Kwon YC,Kawasaki disease,replication,2017-09-08,GCST004859,Immune system disorder,#3288bd
9784,European,9888.0,28887542.0,Prins BP,Alanine transaminase levels,replication,2017-09-08,GCST004940,Liver enzyme measurement,#d53e4f
9785,European,9731.0,28887542.0,Prins BP,Alanine transaminase levels,initial,2017-09-08,GCST004940,Liver enzyme measurement,#d53e4f
9788,European,9888.0,28887542.0,Prins BP,Glycated hemoglobin levels,replication,2017-09-08,GCST004939,Other measurement,#d53e4f
9789,European,9436.0,28887542.0,Prins BP,Glycated hemoglobin levels,initial,2017-09-08,GCST004939,Other measurement,#d53e4f
9790,European,8599.0,28877031.0,Zhang G,Preterm birth (maternal effect),replication,2017-09-07,GCST004898,Other trait,#d53e4f
9791,European,43567.0,28877031.0,Zhang G,Preterm birth (maternal effect),initial,2017-09-07,GCST004898,Other trait,#d53e4f
9792,European,8599.0,28877031.0,Zhang G,Preterm birth (maternal effect),replication,2017-09-07,GCST004898,Other measurement,#d53e4f
9793,European,43567.0,28877031.0,Zhang G,Preterm birth (maternal effect),initial,2017-09-07,GCST004898,Other measurement,#d53e4f
9794,European,8643.0,28877031.0,Zhang G,Gestational age at birth (maternal effect),replication,2017-09-07,GCST004899,Other measurement,#d53e4f
9795,European,43568.0,28877031.0,Zhang G,Gestational age at birth (maternal effect),initial,2017-09-07,GCST004899,Other measurement,#d53e4f
9796,European,8643.0,28877031.0,Zhang G,Gestational age at birth (maternal effect),replication,2017-09-07,GCST004899,Other measurement,#d53e4f
9797,European,43568.0,28877031.0,Zhang G,Gestational age at birth (maternal effect),initial,2017-09-07,GCST004899,Other measurement,#d53e4f
9798,European,8557.0,28886342.0,Ng M,Dupuytren's disease,initial,2017-09-07,GCST004858,Other disease,#d53e4f
9800,European,1960.0,28878392.0,Shen X,IgG sialylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004930,Other measurement,#d53e4f
9801,European,1960.0,28878392.0,Shen X,IgG N-glycosylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004925,Other measurement,#d53e4f
9802,European,1960.0,28878392.0,Shen X,IgG digalactosylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004926,Other measurement,#d53e4f
9803,European,1960.0,28878392.0,Shen X,IgG monogalactosylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004924,Other measurement,#d53e4f
9804,European,1960.0,28878392.0,Shen X,IgG galactosylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004927,Other measurement,#d53e4f
9805,European,1960.0,28878392.0,Shen X,IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis),initial,2017-09-06,GCST004928,Other measurement,#d53e4f
9806,European,1960.0,28878392.0,Shen X,IgG fucosylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004929,Other measurement,#d53e4f
9807,European,1960.0,28878392.0,Shen X,IgG monosialylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004932,Other measurement,#d53e4f
9808,European,1960.0,28878392.0,Shen X,IgG disialylation phenotypes (multivariate analysis),initial,2017-09-06,GCST004931,Other measurement,#d53e4f
9809,African Am./Caribbean,22000.0,28871152.0,Sofer T,Diastolic blood pressure,replication,2017-09-04,GCST004890,Other measurement,#fee08b
9810,Hispanic/Latin American,2764.0,28871152.0,Sofer T,Diastolic blood pressure,replication,2017-09-04,GCST004890,Other measurement,#807dba
9811,Hispanic/Latin American,12278.0,28871152.0,Sofer T,Diastolic blood pressure,initial,2017-09-04,GCST004890,Other measurement,#807dba
9812,European,155786.0,28871152.0,Sofer T,Diastolic blood pressure,replication,2017-09-04,GCST004890,Other measurement,#d53e4f
9813,Hispanic/Latin American,2764.0,28871152.0,Sofer T,Hypertension,replication,2017-09-04,GCST004889,Cardiovascular disease,#807dba
9814,European,155786.0,28871152.0,Sofer T,Hypertension,replication,2017-09-04,GCST004889,Cardiovascular disease,#d53e4f
9815,African Am./Caribbean,22000.0,28871152.0,Sofer T,Hypertension,replication,2017-09-04,GCST004889,Cardiovascular disease,#fee08b
9816,Hispanic/Latin American,12278.0,28871152.0,Sofer T,Hypertension,initial,2017-09-04,GCST004889,Cardiovascular disease,#807dba
9817,European,155786.0,28871152.0,Sofer T,Pulse pressure,replication,2017-09-04,GCST004892,Cardiovascular measurement,#d53e4f
9818,Hispanic/Latin American,2764.0,28871152.0,Sofer T,Pulse pressure,replication,2017-09-04,GCST004892,Cardiovascular measurement,#807dba
9819,Hispanic/Latin American,12278.0,28871152.0,Sofer T,Pulse pressure,initial,2017-09-04,GCST004892,Cardiovascular measurement,#807dba
9820,African Am./Caribbean,22000.0,28871152.0,Sofer T,Pulse pressure,replication,2017-09-04,GCST004892,Cardiovascular measurement,#fee08b
9821,Asian,1050.0,28869801.0,Takahashi Y,Colorectal cancer,initial,2017-09-04,GCST004840,Cancer,#3288bd
9822,Asian,2798.0,28869801.0,Takahashi Y,Colorectal cancer,replication,2017-09-04,GCST004840,Cancer,#3288bd
9823,Hispanic/Latin American,12278.0,28871152.0,Sofer T,Systolic blood pressure,initial,2017-09-04,GCST004888,Other measurement,#807dba
9824,African Am./Caribbean,22000.0,28871152.0,Sofer T,Systolic blood pressure,replication,2017-09-04,GCST004888,Other measurement,#fee08b
9825,Hispanic/Latin American,2764.0,28871152.0,Sofer T,Systolic blood pressure,replication,2017-09-04,GCST004888,Other measurement,#807dba
9826,European,155786.0,28871152.0,Sofer T,Systolic blood pressure,replication,2017-09-04,GCST004888,Other measurement,#d53e4f
9827,European,142487.0,28869591.0,Kemp JP,Heel bone mineral density,initial,2017-09-04,GCST006288,Other measurement,#d53e4f
9828,European,20298.0,28869590.0,Zhao W,Type 2 diabetes,initial,2017-09-04,GCST004894,Metabolic disorder,#d53e4f
9829,European,2479.0,28869590.0,Zhao W,Type 2 diabetes,replication,2017-09-04,GCST004894,Metabolic disorder,#d53e4f
9830,Asian,28567.0,28869590.0,Zhao W,Type 2 diabetes,replication,2017-09-04,GCST004894,Metabolic disorder,#3288bd
9832,Asian,13532.0,28869590.0,Zhao W,Type 2 diabetes,initial,2017-09-04,GCST004894,Metabolic disorder,#3288bd
9833,Asian,50981.0,28869590.0,Zhao W,Type 2 diabetes,replication,2017-09-04,GCST004894,Metabolic disorder,#3288bd
9834,Asian,1050.0,28869801.0,Takahashi Y,Colorectal cancer,initial,2017-09-04,GCST004839,Cancer,#3288bd
9835,Asian,3373.0,28869801.0,Takahashi Y,Colorectal cancer,replication,2017-09-04,GCST004839,Cancer,#3288bd
9836,Hispanic/Latin American,2764.0,28871152.0,Sofer T,Mean arterial pressure,replication,2017-09-04,GCST004891,Other measurement,#807dba
9837,Hispanic/Latin American,12278.0,28871152.0,Sofer T,Mean arterial pressure,initial,2017-09-04,GCST004891,Other measurement,#807dba
9838,European,155786.0,28871152.0,Sofer T,Mean arterial pressure,replication,2017-09-04,GCST004891,Other measurement,#d53e4f
9839,African Am./Caribbean,22000.0,28871152.0,Sofer T,Mean arterial pressure,replication,2017-09-04,GCST004891,Other measurement,#fee08b
9840,European,3105.0,28881265.0,Sobalska-Kwapis M,Endometriosis,initial,2017-09-01,GCST004873,Other disease,#d53e4f
9848,Asian,3647.0,28776340.0,Son CN,Hyperuricemia,initial,2017-09-01,GCST004825,Cardiovascular measurement,#3288bd
9849,European,34174.0,28714976.0,Sims R,Alzheimer's disease (late onset),initial,2017-09-01,GCST005549,Neurological disorder,#d53e4f
9850,European,50959.0,28714976.0,Sims R,Alzheimer's disease (late onset),replication,2017-09-01,GCST005549,Neurological disorder,#d53e4f
9851,Asian,2025.0,29088834.0,Kimura M,Pulmonary arterial hypertension,initial,2017-08-24,GCST004947,Cardiovascular disease,#3288bd
9852,Asian,1012.0,29088834.0,Kimura M,Pulmonary arterial hypertension,replication,2017-08-24,GCST004947,Cardiovascular disease,#3288bd
9853,Hispanic/Latin American,8658.0,28838971.0,Mercader JM,Type 2 diabetes,initial,2017-08-24,GCST006145,Metabolic disorder,#807dba
9854,Hispanic/Latin American,7820.0,28838971.0,Mercader JM,Type 2 diabetes,replication,2017-08-24,GCST006145,Metabolic disorder,#807dba
9855,Other/Mixed,4377.0,28838971.0,Mercader JM,Type 2 diabetes,replication,2017-08-24,GCST006145,Metabolic disorder,#99d594
9856,European,867.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,replication,2017-08-24,GCST004783,Other disease,#d53e4f
9857,European,174.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,initial,2017-08-24,GCST004783,Other disease,#d53e4f
9858,African,76.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,replication,2017-08-24,GCST004783,Other disease,#fc8d59
9859,European,867.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,replication,2017-08-24,GCST004783,Other trait,#d53e4f
9860,European,174.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,initial,2017-08-24,GCST004783,Other trait,#d53e4f
9861,African,76.0,28839172.0,Mahlman M,Bronchopulmonary dysplasia in preterm infants,replication,2017-08-24,GCST004783,Other trait,#fc8d59
9862,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),initial,2017-08-23,GCST004801,Other measurement,#3288bd
9863,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),replication,2017-08-23,GCST004801,Other measurement,#3288bd
9864,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),initial,2017-08-23,GCST004801,Response to drug,#3288bd
9865,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),replication,2017-08-23,GCST004801,Response to drug,#3288bd
9866,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),initial,2017-08-23,GCST004801,Neurological disorder,#3288bd
9867,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (visual acuity),replication,2017-08-23,GCST004801,Neurological disorder,#3288bd
9868,European,249796.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),initial,2017-08-23,GCST004838,Body measurement,#d53e4f
9869,Other/Mixed,30482.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),initial,2017-08-23,GCST004838,Body measurement,#99d594
9870,European,86995.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),replication,2017-08-23,GCST004838,Body measurement,#d53e4f
9871,European,249796.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),initial,2017-08-23,GCST004838,Cardiovascular disease,#d53e4f
9872,Other/Mixed,30482.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),initial,2017-08-23,GCST004838,Cardiovascular disease,#99d594
9873,European,86995.0,28843344.0,Lv WQ,Coronary artery disease and/or body mass index (pleiotropy),replication,2017-08-23,GCST004838,Cardiovascular disease,#d53e4f
9874,African Am./Caribbean,8763.0,28836065.0,Hellwege JN,Uterine fibroids,initial,2017-08-23,GCST004779,Cancer,#fee08b
9875,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),initial,2017-08-23,GCST004802,Response to drug,#3288bd
9876,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),replication,2017-08-23,GCST004802,Response to drug,#3288bd
9877,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),initial,2017-08-23,GCST004802,Neurological disorder,#3288bd
9878,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),replication,2017-08-23,GCST004802,Neurological disorder,#3288bd
9879,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),initial,2017-08-23,GCST004802,Other measurement,#3288bd
9880,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (dry maculae),replication,2017-08-23,GCST004802,Other measurement,#3288bd
9881,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),initial,2017-08-23,GCST004803,Response to drug,#3288bd
9882,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),replication,2017-08-23,GCST004803,Response to drug,#3288bd
9883,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),initial,2017-08-23,GCST004803,Neurological disorder,#3288bd
9884,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),replication,2017-08-23,GCST004803,Neurological disorder,#3288bd
9885,Asian,256.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),initial,2017-08-23,GCST004803,Other measurement,#3288bd
9886,Asian,205.0,28835685.0,Yamashiro K,Response to ranibizumab in age-related macular degeneration (additional treatment requirement),replication,2017-08-23,GCST004803,Other measurement,#3288bd
9905,Other/Mixed,281.0,28828242.0,Dajani R,Type 2 diabetes,initial,2017-08-17,GCST004782,Metabolic disorder,#99d594
9906,European,4912.0,28828242.0,Dajani R,Type 2 diabetes,replication,2017-08-17,GCST004782,Metabolic disorder,#d53e4f
9907,Hispanic/Latin American,203.0,28817678.0,Archer NP,Acute lymphoblastic leukemia (childhood),initial,2017-08-17,GCST007727,Cancer,#807dba
9908,Other/Mixed,96.0,28817678.0,Archer NP,Acute lymphoblastic leukemia (childhood),initial,2017-08-17,GCST007727,Cancer,#99d594
9909,Asian,2888.0,28809852.0,Liu L,Attention deficit hyperactivity disorder,replication,2017-08-15,GCST004778,Neurological disorder,#3288bd
9910,Asian,1983.0,28809852.0,Liu L,Attention deficit hyperactivity disorder,initial,2017-08-15,GCST004778,Neurological disorder,#3288bd
9911,Asian,278.0,28808816.0,Xu C,Cognitive function,initial,2017-08-14,GCST004823,Other measurement,#3288bd
9912,European,9347.0,28806749.0,Leo PJ,Cervical cancer,initial,2017-08-14,GCST004833,Cancer,#d53e4f
9913,European,7703.0,28843169.0,Neumann A,Cortisol levels (saliva),initial,2017-08-12,GCST004780,Other measurement,#d53e4f
9914,European,7486.0,28800603.0,Arpawong TE,Verbal memory performance (delayed recall level),initial,2017-08-11,GCST004831,Other measurement,#d53e4f
9915,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),replication,2017-08-11,GCST005137,Response to drug,#99d594
9916,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),replication,2017-08-11,GCST005137,Response to drug,#d53e4f
9917,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),initial,2017-08-11,GCST005137,Response to drug,#99d594
9918,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),initial,2017-08-11,GCST005137,Response to drug,#d53e4f
9919,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),replication,2017-08-11,GCST005137,Cardiovascular measurement,#99d594
9920,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),replication,2017-08-11,GCST005137,Cardiovascular measurement,#d53e4f
9921,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),initial,2017-08-11,GCST005137,Cardiovascular measurement,#99d594
9922,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave morphology notching),initial,2017-08-11,GCST005137,Cardiovascular measurement,#d53e4f
9923,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Response to drug,#99d594
9924,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Response to drug,#d53e4f
9925,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Response to drug,#99d594
9926,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Response to drug,#d53e4f
9927,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9928,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9929,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9930,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9931,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9932,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9933,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9934,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9935,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9936,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9937,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),initial,2017-08-11,GCST005139,Cardiovascular measurement,#99d594
9938,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC1),replication,2017-08-11,GCST005139,Cardiovascular measurement,#d53e4f
9939,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Response to drug,#99d594
9940,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Response to drug,#d53e4f
9941,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Response to drug,#99d594
9942,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Response to drug,#d53e4f
9943,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9944,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9945,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9946,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9947,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9948,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9949,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9950,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9951,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9952,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),replication,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9953,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#99d594
9954,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC3),initial,2017-08-11,GCST005138,Cardiovascular measurement,#d53e4f
9955,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Response to drug,#d53e4f
9956,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Response to drug,#99d594
9957,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Response to drug,#d53e4f
9958,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Response to drug,#99d594
9959,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9960,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9961,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9962,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9963,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9964,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9965,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9966,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9967,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9968,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9969,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),initial,2017-08-11,GCST005136,Cardiovascular measurement,#d53e4f
9970,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (ventricular repolarization changes PC2),replication,2017-08-11,GCST005136,Cardiovascular measurement,#99d594
9971,European,7486.0,28800603.0,Arpawong TE,Verbal memory performance (delayed recall change),initial,2017-08-11,GCST004832,Other measurement,#d53e4f
9972,European,7486.0,28800603.0,Arpawong TE,Verbal memory performance (immediate recall level),initial,2017-08-11,GCST004828,Other measurement,#d53e4f
9973,European,6898.0,28800603.0,Arpawong TE,Verbal memory performance (immediate recall level),replication,2017-08-11,GCST004828,Other measurement,#d53e4f
9974,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),replication,2017-08-11,GCST005140,Response to drug,#99d594
9975,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),replication,2017-08-11,GCST005140,Response to drug,#d53e4f
9976,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),initial,2017-08-11,GCST005140,Response to drug,#99d594
9977,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),initial,2017-08-11,GCST005140,Response to drug,#d53e4f
9978,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),replication,2017-08-11,GCST005140,Cardiovascular measurement,#99d594
9979,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),replication,2017-08-11,GCST005140,Cardiovascular measurement,#d53e4f
9980,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),initial,2017-08-11,GCST005140,Cardiovascular measurement,#99d594
9981,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (ventricular repolarization duration change),initial,2017-08-11,GCST005140,Cardiovascular measurement,#d53e4f
9982,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),replication,2017-08-11,GCST005135,Response to drug,#99d594
9983,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),replication,2017-08-11,GCST005135,Response to drug,#d53e4f
9984,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),initial,2017-08-11,GCST005135,Response to drug,#99d594
9985,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),initial,2017-08-11,GCST005135,Response to drug,#d53e4f
9986,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),replication,2017-08-11,GCST005135,Cardiovascular measurement,#99d594
9987,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),replication,2017-08-11,GCST005135,Cardiovascular measurement,#d53e4f
9988,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),initial,2017-08-11,GCST005135,Cardiovascular measurement,#99d594
9989,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition (T wave maximal amplitude change),initial,2017-08-11,GCST005135,Cardiovascular measurement,#d53e4f
9990,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),replication,2017-08-11,GCST005134,Response to drug,#99d594
9991,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),replication,2017-08-11,GCST005134,Response to drug,#d53e4f
9992,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),initial,2017-08-11,GCST005134,Response to drug,#99d594
9993,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),initial,2017-08-11,GCST005134,Response to drug,#d53e4f
9994,Other/Mixed,64.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),replication,2017-08-11,GCST005134,Cardiovascular measurement,#99d594
9995,European,431.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),replication,2017-08-11,GCST005134,Cardiovascular measurement,#d53e4f
9996,Other/Mixed,47.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),initial,2017-08-11,GCST005134,Cardiovascular measurement,#99d594
9997,European,448.0,28800628.0,Salem JE,Sotalol-induced IKr potassium channel inhibition  (T wave peak and end interval change),initial,2017-08-11,GCST005134,Cardiovascular measurement,#d53e4f
9998,European,6898.0,28800603.0,Arpawong TE,Verbal memory performance (residualized delayed recall level),replication,2017-08-11,GCST004829,Other measurement,#d53e4f
9999,European,7486.0,28800603.0,Arpawong TE,Verbal memory performance (residualized delayed recall level),initial,2017-08-11,GCST004829,Other measurement,#d53e4f
10000,European,7486.0,28800603.0,Arpawong TE,Verbal memory performance (immediate recall change),initial,2017-08-11,GCST004827,Other measurement,#d53e4f
10001,European,6898.0,28800603.0,Arpawong TE,Verbal memory performance (immediate recall change),replication,2017-08-11,GCST004827,Other measurement,#d53e4f
10002,European,14384.0,28800603.0,Arpawong TE,Verbal memory performance (residualized delayed recall change),initial,2017-08-11,GCST004830,Other measurement,#d53e4f
10003,European,6898.0,28800603.0,Arpawong TE,Verbal memory performance (residualized delayed recall change),replication,2017-08-11,GCST004830,Other measurement,#d53e4f
10004,European,200.0,28783044.0,Ware JS,Thiazide-induced hyponatremia,replication,2017-08-07,GCST004786,Other trait,#d53e4f
10005,European,2953.0,28783044.0,Ware JS,Thiazide-induced hyponatremia,initial,2017-08-07,GCST004786,Other trait,#d53e4f
10006,European,183.0,28776448.0,Beaudoin JJ,Alcoholic hepatitis,initial,2017-08-04,GCST004784,Digestive system disorder,#d53e4f
10007,European,3006.0,28779025.0,Alberts R,Hepatocellular carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005858,Cancer,#d53e4f
10008,European,3006.0,28779025.0,Alberts R,Hepatocellular carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005858,Digestive system disorder,#d53e4f
10009,European,3007.0,28779025.0,Alberts R,Gallbladder carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005857,Cancer,#d53e4f
10010,European,3007.0,28779025.0,Alberts R,Gallbladder carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005857,Digestive system disorder,#d53e4f
10011,European,2949.0,28779025.0,Alberts R,Colorectal carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005856,Cancer,#d53e4f
10012,European,2949.0,28779025.0,Alberts R,Colorectal carcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005856,Digestive system disorder,#d53e4f
10013,European,3335.0,28779025.0,Alberts R,Cholangiocarcinoma in primary sclerosing cholangitis (time to event),initial,2017-08-04,GCST005860,Other measurement,#d53e4f
10014,European,3335.0,28779025.0,Alberts R,Cholangiocarcinoma in primary sclerosing cholangitis (time to event),initial,2017-08-04,GCST005860,Cancer,#d53e4f
10015,European,3335.0,28779025.0,Alberts R,Cholangiocarcinoma in primary sclerosing cholangitis (time to event),initial,2017-08-04,GCST005860,Digestive system disorder,#d53e4f
10016,European,3335.0,28779025.0,Alberts R,Cholangiocarcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005855,Cancer,#d53e4f
10017,European,3335.0,28779025.0,Alberts R,Cholangiocarcinoma in primary sclerosing cholangitis,initial,2017-08-04,GCST005855,Digestive system disorder,#d53e4f
10018,European,3316.0,28779025.0,Alberts R,Colectomy in primary sclerosing cholangitis,initial,2017-08-04,GCST005852,Digestive system disorder,#d53e4f
10019,European,3318.0,28779025.0,Alberts R,Liver transplant-free survival in primary sclerosing cholangitis (time to event),initial,2017-08-04,GCST005859,Other measurement,#d53e4f
10020,European,3318.0,28779025.0,Alberts R,Liver transplant-free survival in primary sclerosing cholangitis (time to event),initial,2017-08-04,GCST005859,Digestive system disorder,#d53e4f
10021,European,3234.0,28779025.0,Alberts R,Primary sclerosing cholangitis (small duct vs large duct),initial,2017-08-04,GCST005854,Digestive system disorder,#d53e4f
10022,European,3266.0,28779025.0,Alberts R,Autoimmune hepatitis in primary sclerosing cholangitis,initial,2017-08-04,GCST005853,Immune system disorder,#d53e4f
10023,European,3266.0,28779025.0,Alberts R,Autoimmune hepatitis in primary sclerosing cholangitis,initial,2017-08-04,GCST005853,Immune system disorder,#d53e4f
10024,European,3266.0,28779025.0,Alberts R,Autoimmune hepatitis in primary sclerosing cholangitis,initial,2017-08-04,GCST005853,Digestive system disorder,#d53e4f
10025,Hispanic/Latin American,411.0,28840121.0,Villalobos-Comparan M,Femoral neck bone geometry,initial,2017-08-03,GCST004835,Other measurement,#807dba
10026,Hispanic/Latin American,420.0,28840121.0,Villalobos-Comparan M,Femoral neck bone geometry,replication,2017-08-03,GCST004835,Other measurement,#807dba
10027,Hispanic/Latin American,411.0,28840121.0,Villalobos-Comparan M,Lumbar spine bone mineral density,initial,2017-08-03,GCST004834,Other measurement,#807dba
10028,Hispanic/Latin American,420.0,28840121.0,Villalobos-Comparan M,Lumbar spine bone mineral density,replication,2017-08-03,GCST004834,Other measurement,#807dba
10029,Asian,1124.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,initial,2017-08-03,GCST004813,Other measurement,#3288bd
10030,Asian,168.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,replication,2017-08-03,GCST004813,Other measurement,#3288bd
10031,Asian,102.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,replication,2017-08-03,GCST004813,Other measurement,#3288bd
10032,Asian,1124.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,initial,2017-08-03,GCST004813,Neurological disorder,#3288bd
10033,Asian,168.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,replication,2017-08-03,GCST004813,Neurological disorder,#3288bd
10034,Asian,102.0,28775256.0,Kawashima-Kumagai K,Laterality in neovascular age-related macular degeneration,replication,2017-08-03,GCST004813,Neurological disorder,#3288bd
10036,African,932.0,29117387.0,Conti DV,Prostate cancer,initial,2017-08-01,GCST004982,Cancer,#fc8d59
10037,African Am./Caribbean,11782.0,29117387.0,Conti DV,Prostate cancer,initial,2017-08-01,GCST004982,Cancer,#fee08b
10038,European,37776.0,28813576.0,Persad PJ,Age-related macular degeneration (SNP x mitochondrial C16069T interaction),initial,2017-08-01,GCST004872,Neurological disorder,#d53e4f
10039,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (intracranial brain volume),initial,2017-08-01,GCST004794,Other measurement,#99d594
10040,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (intracranial brain volume),initial,2017-08-01,GCST004794,Other measurement,#99d594
10041,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (intracranial brain volume),initial,2017-08-01,GCST004794,Other measurement,#99d594
10042,European,356.0,28763065.0,Xia K,Brain volume in infants (intracranial brain volume),initial,2017-08-01,GCST004794,Other measurement,#d53e4f
10043,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (intracranial brain volume),initial,2017-08-01,GCST004794,Other measurement,#99d594
10044,European,5206.0,28762467.0,Wadelius M,Sulfasalazine-induced agranulocytosis,initial,2017-08-01,GCST004781,Other trait,#d53e4f
10045,European,5206.0,28762467.0,Wadelius M,Sulfasalazine-induced agranulocytosis,initial,2017-08-01,GCST004781,Response to drug,#d53e4f
10046,African Am./Caribbean,6778.0,28794112.0,Christophersen IE,P wave duration,initial,2017-08-01,GCST004826,Cardiovascular measurement,#fee08b
10047,European,37678.0,28794112.0,Christophersen IE,P wave duration,initial,2017-08-01,GCST004826,Cardiovascular measurement,#d53e4f
10048,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (grey matter),initial,2017-08-01,GCST004797,Other measurement,#99d594
10049,European,356.0,28763065.0,Xia K,Brain volume in infants (grey matter),initial,2017-08-01,GCST004797,Other measurement,#d53e4f
10050,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (grey matter),initial,2017-08-01,GCST004797,Other measurement,#99d594
10051,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (grey matter),initial,2017-08-01,GCST004797,Other measurement,#99d594
10052,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (grey matter),initial,2017-08-01,GCST004797,Other measurement,#99d594
10053,European,123195.0,28870582.0,Wang XF,Alzheimer's disease or type 2 diabetes (pleiotropy),initial,2017-08-01,GCST004880,Neurological disorder,#d53e4f
10054,European,123195.0,28870582.0,Wang XF,Alzheimer's disease or type 2 diabetes (pleiotropy),initial,2017-08-01,GCST004880,Metabolic disorder,#d53e4f
10055,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (cerebrospinal fluid),initial,2017-08-01,GCST004796,Other measurement,#99d594
10056,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (cerebrospinal fluid),initial,2017-08-01,GCST004796,Other measurement,#99d594
10057,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (cerebrospinal fluid),initial,2017-08-01,GCST004796,Other measurement,#99d594
10058,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (cerebrospinal fluid),initial,2017-08-01,GCST004796,Other measurement,#99d594
10059,European,356.0,28763065.0,Xia K,Brain volume in infants (cerebrospinal fluid),initial,2017-08-01,GCST004796,Other measurement,#d53e4f
10060,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (white matter),initial,2017-08-01,GCST004795,Other measurement,#99d594
10061,European,356.0,28763065.0,Xia K,Brain volume in infants (white matter),initial,2017-08-01,GCST004795,Other measurement,#d53e4f
10062,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (white matter),initial,2017-08-01,GCST004795,Other measurement,#99d594
10063,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (white matter),initial,2017-08-01,GCST004795,Other measurement,#99d594
10064,Other/Mixed,205.0,28763065.0,Xia K,Brain volume in infants (white matter),initial,2017-08-01,GCST004795,Other measurement,#99d594
10065,African Am./Caribbean,6778.0,28794112.0,Christophersen IE,P wave terminal force,initial,2017-08-01,GCST004824,Cardiovascular measurement,#fee08b
10066,European,33955.0,28794112.0,Christophersen IE,P wave terminal force,initial,2017-08-01,GCST004824,Cardiovascular measurement,#d53e4f
10067,European,31764.0,28813576.0,Persad PJ,Age-related macular degeneration (SNP x mitochondrial G12771A interaction),initial,2017-08-01,GCST004871,Neurological disorder,#d53e4f
10068,European,33932.0,28813576.0,Persad PJ,Age-related macular degeneration (SNP x mitochondrial A4917G interaction),initial,2017-08-01,GCST004870,Neurological disorder,#d53e4f
10069,European,31757.0,28813576.0,Persad PJ,Age-related macular degeneration (SNP x mitochondrial T5004C interaction),initial,2017-08-01,GCST004869,Neurological disorder,#d53e4f
10070,European,33976.0,28813576.0,Persad PJ,Advanced age-related macular degeneration,initial,2017-08-01,GCST004868,Neurological disorder,#d53e4f
10071,European,391.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel in HER2+ breast cancer,initial,2017-07-31,GCST004789,Cardiovascular measurement,#d53e4f
10072,European,391.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel in HER2+ breast cancer,initial,2017-07-31,GCST004789,Response to drug,#d53e4f
10073,European,1191.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer,initial,2017-07-31,GCST004788,Response to drug,#d53e4f
10074,European,1191.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer,initial,2017-07-31,GCST004788,Cardiovascular measurement,#d53e4f
10075,European,1191.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and in response to paclitaxel and trastuzumab in HER+ breast cancer,initial,2017-07-31,GCST004788,Response to drug,#d53e4f
10077,Asian,5152.0,28761973.0,Peng C,Femoral neck bone mineral density or breast cancer (pleiotropy),initial,2017-07-31,GCST004836,Cancer,#3288bd
10079,Asian,5152.0,28761973.0,Peng C,Femoral neck bone mineral density or breast cancer (pleiotropy),initial,2017-07-31,GCST004836,Other measurement,#3288bd
10081,Asian,5152.0,28761973.0,Peng C,Lumbar spine bone mineral density or breast cancer (pleiotropy),initial,2017-07-31,GCST004837,Cancer,#3288bd
10083,Asian,5152.0,28761973.0,Peng C,Lumbar spine bone mineral density or breast cancer (pleiotropy),initial,2017-07-31,GCST004837,Other measurement,#3288bd
10084,European,800.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,initial,2017-07-31,GCST004790,Response to drug,#d53e4f
10085,European,800.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,initial,2017-07-31,GCST004790,Cardiovascular measurement,#d53e4f
10086,European,800.0,28763429.0,Serie DJ,Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,initial,2017-07-31,GCST004790,Response to drug,#d53e4f
10088,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline),initial,2017-07-28,GCST004968,Response to drug,#99d594
10090,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline),initial,2017-07-28,GCST004968,Cardiovascular disease,#99d594
10092,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline),initial,2017-07-28,GCST004968,Cardiovascular measurement,#99d594
10094,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease (adjusted for baseline),initial,2017-07-28,GCST004968,Cardiovascular disease,#99d594
10095,European,212.0,28753643.0,Yeo A,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004967,Response to drug,#d53e4f
10096,European,212.0,28753643.0,Yeo A,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004967,Other trait,#d53e4f
10097,European,212.0,28753643.0,Yeo A,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004967,Cardiovascular disease,#d53e4f
10098,European,212.0,28753643.0,Yeo A,Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004967,Cardiovascular disease,#d53e4f
10099,Hispanic/Latin American,390.0,28754176.0,Wang Z,Mental development (prenatal lead exposure interaction),initial,2017-07-28,GCST004769,Other measurement,#807dba
10100,Asian,490.0,28754176.0,Wang Z,Mental development (prenatal lead exposure interaction),initial,2017-07-28,GCST004769,Other measurement,#3288bd
10101,Hispanic/Latin American,390.0,28754176.0,Wang Z,Mental development (prenatal lead exposure interaction),initial,2017-07-28,GCST004769,Other measurement,#807dba
10102,Asian,490.0,28754176.0,Wang Z,Mental development (prenatal lead exposure interaction),initial,2017-07-28,GCST004769,Other measurement,#3288bd
10104,Other/Mixed,1573.0,28753643.0,Yeo A,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004959,Response to drug,#99d594
10106,Other/Mixed,1573.0,28753643.0,Yeo A,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004959,Cardiovascular disease,#99d594
10108,Other/Mixed,1573.0,28753643.0,Yeo A,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004959,Cardiovascular disease,#99d594
10110,Other/Mixed,1573.0,28753643.0,Yeo A,Myocardial infarction in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004959,Cardiovascular disease,#99d594
10112,Other/Mixed,22156.0,28753643.0,Yeo A,Lipoprotein phospholipase A2 activity in cardiovascular disease,initial,2017-07-28,GCST004963,Lipid or lipoprotein measurement,#99d594
10114,Other/Mixed,22156.0,28753643.0,Yeo A,Lipoprotein phospholipase A2 activity in cardiovascular disease,initial,2017-07-28,GCST004963,Cardiovascular disease,#99d594
10116,Other/Mixed,22156.0,28753643.0,Yeo A,Lipoprotein phospholipase A2 activity in cardiovascular disease,initial,2017-07-28,GCST004963,Cardiovascular disease,#99d594
10118,Other/Mixed,1318.0,28753643.0,Yeo A,Major coronary event in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004957,Response to drug,#99d594
10120,Other/Mixed,1318.0,28753643.0,Yeo A,Major coronary event in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004957,Cardiovascular disease,#99d594
10122,Other/Mixed,1318.0,28753643.0,Yeo A,Major coronary event in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004957,Cardiovascular disease,#99d594
10124,Other/Mixed,1318.0,28753643.0,Yeo A,Major coronary event in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004957,Cardiovascular measurement,#99d594
10125,Other/Mixed,1867.0,28753643.0,Yeo A,Odor events in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004960,Response to drug,#99d594
10127,Other/Mixed,1867.0,28753643.0,Yeo A,Odor events in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004960,Other measurement,#99d594
10129,Other/Mixed,1867.0,28753643.0,Yeo A,Odor events in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004960,Cardiovascular disease,#99d594
10131,Other/Mixed,1867.0,28753643.0,Yeo A,Odor events in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004960,Cardiovascular disease,#99d594
10133,Other/Mixed,2758.0,28753643.0,Yeo A,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004958,Response to drug,#99d594
10135,Other/Mixed,2758.0,28753643.0,Yeo A,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004958,Cardiovascular disease,#99d594
10137,Other/Mixed,2758.0,28753643.0,Yeo A,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004958,Cardiovascular disease,#99d594
10139,Other/Mixed,2758.0,28753643.0,Yeo A,Major coronary event in cardiovascular disease (time to event) (darapladib treatment interaction),initial,2017-07-28,GCST004958,Cardiovascular measurement,#99d594
10141,Other/Mixed,833.0,28753643.0,Yeo A,Myocardial infarction in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004965,Cardiovascular disease,#99d594
10143,Other/Mixed,833.0,28753643.0,Yeo A,Myocardial infarction in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004965,Cardiovascular disease,#99d594
10145,Other/Mixed,833.0,28753643.0,Yeo A,Myocardial infarction in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004965,Cardiovascular disease,#99d594
10147,Other/Mixed,833.0,28753643.0,Yeo A,Myocardial infarction in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004965,Biological process,#99d594
10149,Other/Mixed,740.0,28753643.0,Yeo A,Myocardial infarction in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004964,Response to drug,#99d594
10151,Other/Mixed,740.0,28753643.0,Yeo A,Myocardial infarction in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004964,Cardiovascular disease,#99d594
10153,Other/Mixed,740.0,28753643.0,Yeo A,Myocardial infarction in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004964,Cardiovascular disease,#99d594
10155,Other/Mixed,740.0,28753643.0,Yeo A,Myocardial infarction in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004964,Cardiovascular disease,#99d594
10157,European,481.0,28753643.0,Yeo A,Diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004962,Response to drug,#d53e4f
10158,European,481.0,28753643.0,Yeo A,Diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004962,Other trait,#d53e4f
10159,European,481.0,28753643.0,Yeo A,Diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004962,Cardiovascular disease,#d53e4f
10160,European,481.0,28753643.0,Yeo A,Diarrhoea in darapladib-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004962,Cardiovascular disease,#d53e4f
10161,Other/Mixed,1440.0,28753643.0,Yeo A,Major coronary event in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004961,Cardiovascular disease,#99d594
10163,Other/Mixed,1440.0,28753643.0,Yeo A,Major coronary event in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004961,Cardiovascular disease,#99d594
10165,Other/Mixed,1440.0,28753643.0,Yeo A,Major coronary event in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004961,Cardiovascular measurement,#99d594
10167,Other/Mixed,1440.0,28753643.0,Yeo A,Major coronary event in placebo-treated cardiovascular disease (time to event),initial,2017-07-28,GCST004961,Biological process,#99d594
10169,European,7999.0,28754779.0,Rosendahl J,Alcoholic chronic pancreatitis,initial,2017-07-28,GCST004860,Digestive system disorder,#d53e4f
10170,Asian,490.0,28754176.0,Wang Z,Motor development (prenatal lead exposure interaction),initial,2017-07-28,GCST004768,Other measurement,#3288bd
10171,Hispanic/Latin American,390.0,28754176.0,Wang Z,Motor development (prenatal lead exposure interaction),initial,2017-07-28,GCST004768,Other measurement,#807dba
10172,Asian,490.0,28754176.0,Wang Z,Motor development (prenatal lead exposure interaction),initial,2017-07-28,GCST004768,Other measurement,#3288bd
10173,Hispanic/Latin American,390.0,28754176.0,Wang Z,Motor development (prenatal lead exposure interaction),initial,2017-07-28,GCST004768,Other measurement,#807dba
10174,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,initial,2017-07-28,GCST004966,Response to drug,#99d594
10176,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,initial,2017-07-28,GCST004966,Cardiovascular disease,#99d594
10178,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,initial,2017-07-28,GCST004966,Cardiovascular measurement,#99d594
10180,Other/Mixed,10874.0,28753643.0,Yeo A,Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease,initial,2017-07-28,GCST004966,Cardiovascular disease,#99d594
10188,European,112117.0,28937693.0,Clarke TK,Alcohol consumption,initial,2017-07-25,GCST004886,Other measurement,#d53e4f
10189,European,108309.0,28937693.0,Clarke TK,Alcohol consumption in current drinkers,initial,2017-07-25,GCST004887,Other measurement,#d53e4f
10194,Asian,185.0,28744025.0,Woolston AL,Schizophrenia (age at onset),initial,2017-07-25,GCST004767,Neurological disorder,#3288bd
10197,European,150134.0,28739976.0,Wain LV,Diastolic blood pressure,initial,2017-07-24,GCST004777,Other measurement,#d53e4f
10199,European,87359.0,28739976.0,Wain LV,Diastolic blood pressure,replication,2017-07-24,GCST004777,Other measurement,#d53e4f
10200,European,781.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Lipid or lipoprotein measurement,#d53e4f
10201,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Lipid or lipoprotein measurement,#fee08b
10203,European,781.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Response to drug,#d53e4f
10204,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Response to drug,#fee08b
10206,European,781.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Metabolic disorder,#d53e4f
10207,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Metabolic disorder,#fee08b
10209,European,781.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Response to drug,#d53e4f
10210,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004766,Response to drug,#fee08b
10212,European,781.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Response to drug,#d53e4f
10213,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Response to drug,#fee08b
10215,European,781.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Metabolic disorder,#d53e4f
10216,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Metabolic disorder,#fee08b
10218,European,781.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Lipid or lipoprotein measurement,#d53e4f
10219,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Lipid or lipoprotein measurement,#fee08b
10221,European,781.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Response to drug,#d53e4f
10222,African Am./Caribbean,138.0,28736931.0,Rotroff DM,Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004765,Response to drug,#fee08b
10225,European,781.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Lipid or lipoprotein measurement,#d53e4f
10226,African Am./Caribbean,138.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Lipid or lipoprotein measurement,#fee08b
10228,European,781.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Response to drug,#d53e4f
10229,African Am./Caribbean,138.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Response to drug,#fee08b
10231,European,781.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Metabolic disorder,#d53e4f
10232,African Am./Caribbean,138.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Metabolic disorder,#fee08b
10234,European,781.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Response to drug,#d53e4f
10235,African Am./Caribbean,138.0,28736931.0,Rotroff DM,LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004764,Response to drug,#fee08b
10236,European,10817.0,28738859.0,de Jong K,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),initial,2017-07-24,GCST004800,Other measurement,#d53e4f
10238,European,1156.0,28738859.0,de Jong K,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),replication,2017-07-24,GCST004800,Other measurement,#d53e4f
10239,European,10817.0,28738859.0,de Jong K,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),initial,2017-07-24,GCST004800,Other measurement,#d53e4f
10241,European,1156.0,28738859.0,de Jong K,Forced expiratory volume in 1 second (environmental tobacco smoke interaction),replication,2017-07-24,GCST004800,Other measurement,#d53e4f
10242,European,150134.0,28739976.0,Wain LV,Pulse pressure,initial,2017-07-24,GCST004775,Cardiovascular measurement,#d53e4f
10243,European,87359.0,28739976.0,Wain LV,Pulse pressure,replication,2017-07-24,GCST004775,Cardiovascular measurement,#d53e4f
10245,European,150134.0,28739976.0,Wain LV,Systolic blood pressure,initial,2017-07-24,GCST004776,Other measurement,#d53e4f
10246,European,87359.0,28739976.0,Wain LV,Systolic blood pressure,replication,2017-07-24,GCST004776,Other measurement,#d53e4f
10252,European,781.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Lipid or lipoprotein measurement,#d53e4f
10254,African Am./Caribbean,138.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Lipid or lipoprotein measurement,#fee08b
10255,European,781.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Response to drug,#d53e4f
10257,African Am./Caribbean,138.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Response to drug,#fee08b
10258,European,781.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Metabolic disorder,#d53e4f
10260,African Am./Caribbean,138.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Metabolic disorder,#fee08b
10261,European,781.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Response to drug,#d53e4f
10263,African Am./Caribbean,138.0,28736931.0,Rotroff DM,HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,initial,2017-07-24,GCST004763,Response to drug,#fee08b
10265,European,40832.0,28757204.0,Manousaki D,Vitamin D levels,initial,2017-07-21,GCST004726,Other measurement,#d53e4f
10266,Asian,2350.0,28724990.0,Zillikens MC,Appendicular lean mass,replication,2017-07-19,GCST005037,Other measurement,#3288bd
10267,African Am./Caribbean,380.0,28724990.0,Zillikens MC,Appendicular lean mass,replication,2017-07-19,GCST005037,Other measurement,#fee08b
10268,European,42360.0,28724990.0,Zillikens MC,Appendicular lean mass,replication,2017-07-19,GCST005037,Other measurement,#d53e4f
10269,European,28330.0,28724990.0,Zillikens MC,Appendicular lean mass,initial,2017-07-19,GCST005037,Other measurement,#d53e4f
10270,Asian,7834.0,28724990.0,Zillikens MC,Lean body mass,replication,2017-07-19,GCST005036,Other measurement,#3288bd
10271,Asian,8034.0,28724990.0,Zillikens MC,Lean body mass,replication,2017-07-19,GCST005036,Other measurement,#3288bd
10272,African Am./Caribbean,380.0,28724990.0,Zillikens MC,Lean body mass,replication,2017-07-19,GCST005036,Other measurement,#fee08b
10273,European,47227.0,28724990.0,Zillikens MC,Lean body mass,replication,2017-07-19,GCST005036,Other measurement,#d53e4f
10274,European,38292.0,28724990.0,Zillikens MC,Lean body mass,initial,2017-07-19,GCST005036,Other measurement,#d53e4f
10275,European,3265.0,28714907.0,Treutlein J,Alcohol dependence,initial,2017-07-17,GCST004756,Neurological disorder,#d53e4f
10276,Hispanic/Latin American,3888.0,28714469.0,Langefeld CD,Systemic lupus erythematosus,initial,2017-07-17,GCST005752,Immune system disorder,#807dba
10277,European,18264.0,28714469.0,Langefeld CD,Systemic lupus erythematosus,initial,2017-07-17,GCST005752,Immune system disorder,#d53e4f
10278,African Am./Caribbean,5422.0,28714469.0,Langefeld CD,Systemic lupus erythematosus,initial,2017-07-17,GCST005752,Immune system disorder,#fee08b
10279,European,18264.0,28714469.0,Langefeld CD,Systemic lupus erythematosus,initial,2017-07-17,GCST007400,Immune system disorder,#d53e4f
10280,European,120286.0,28714974.0,Klarin D,Coronary artery disease,initial,2017-07-17,GCST007990,Cardiovascular disease,#d53e4f
10282,European,3260.0,28714907.0,Treutlein J,Chronic alcoholic pancreatitis or alcohol-related cirrhosis,initial,2017-07-17,GCST004755,Cancer,#d53e4f
10283,European,3260.0,28714907.0,Treutlein J,Chronic alcoholic pancreatitis or alcohol-related cirrhosis,initial,2017-07-17,GCST004755,Digestive system disorder,#d53e4f
10284,European,4775.0,28714907.0,Treutlein J,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis,initial,2017-07-17,GCST004757,Cancer,#d53e4f
10285,European,4775.0,28714907.0,Treutlein J,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis,initial,2017-07-17,GCST004757,Neurological disorder,#d53e4f
10286,European,4775.0,28714907.0,Treutlein J,Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis,initial,2017-07-17,GCST004757,Digestive system disorder,#d53e4f
10289,Asian,1451.0,28703135.0,Ruamviboonsuk P,Neovascular age-related macular degeneration,initial,2017-07-13,GCST004737,Neurological disorder,#3288bd
10290,Asian,845.0,28703135.0,Ruamviboonsuk P,Neovascular age-related macular degeneration,replication,2017-07-13,GCST004737,Neurological disorder,#3288bd
10291,Asian,1451.0,28703135.0,Ruamviboonsuk P,Neovascular age-related macular degeneration,initial,2017-07-13,GCST004737,Neurological disorder,#3288bd
10292,Asian,845.0,28703135.0,Ruamviboonsuk P,Neovascular age-related macular degeneration,replication,2017-07-13,GCST004737,Neurological disorder,#3288bd
10293,European,19108.0,28706201.0,Wei WH,Sero-negative rheumatoid arthritis,initial,2017-07-13,GCST005826,Immune system disorder,#d53e4f
10294,Asian,195.0,28700999.0,Yang CK,Hepatitis B virus-related hepatocellular carcinoma,initial,2017-07-13,GCST007514,Cancer,#3288bd
10295,Asian,97.0,28700999.0,Yang CK,Hepatitis B virus-related hepatocellular carcinoma,replication,2017-07-13,GCST007514,Cancer,#3288bd
10296,Asian,633.0,28703219.0,Son HY,Follicular thyroid cancer,replication,2017-07-13,GCST004754,Cancer,#3288bd
10297,Asian,8339.0,28703219.0,Son HY,Follicular thyroid cancer,initial,2017-07-13,GCST004754,Cancer,#3288bd
10298,Asian,8689.0,28703219.0,Son HY,Papillary thyroid cancer,initial,2017-07-13,GCST004753,Cancer,#3288bd
10299,Asian,1192.0,28703219.0,Son HY,Papillary thyroid cancer,replication,2017-07-13,GCST004753,Cancer,#3288bd
10300,Asian,8749.0,28703219.0,Son HY,Differentiated thyroid cancer,initial,2017-07-13,GCST004798,Cancer,#3288bd
10301,Asian,1220.0,28703219.0,Son HY,Differentiated thyroid cancer,replication,2017-07-13,GCST004798,Cancer,#3288bd
10302,European,53145.0,29313844.0,Willems SM,Hand grip strength,replication,2017-07-12,GCST005235,Other measurement,#d53e4f
10303,European,142035.0,29313844.0,Willems SM,Hand grip strength,initial,2017-07-12,GCST005235,Other measurement,#d53e4f
10306,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (remitter/non-remitter status),initial,2017-07-11,GCST004740,Neurological disorder,#d53e4f
10307,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (remitter/non-remitter status),initial,2017-07-11,GCST004740,Response to drug,#d53e4f
10308,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (% change in symptom score),initial,2017-07-11,GCST004739,Neurological disorder,#d53e4f
10309,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (% change in symptom score),initial,2017-07-11,GCST004739,Biological process,#d53e4f
10310,European,1291.0,28698626.0,Lopez-Mejias R,Immunoglobulin A vasculitis,initial,2017-07-11,GCST004745,Immune system disorder,#d53e4f
10311,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (% change in symptom score),initial,2017-07-11,GCST004738,Neurological disorder,#d53e4f
10312,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (% change in symptom score),initial,2017-07-11,GCST004738,Response to drug,#d53e4f
10313,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (responder/non-responder status),initial,2017-07-11,GCST004743,Neurological disorder,#d53e4f
10314,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (responder/non-responder status),initial,2017-07-11,GCST004743,Biological process,#d53e4f
10315,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (remitter/non-remitter status),initial,2017-07-11,GCST004742,Neurological disorder,#d53e4f
10316,European,205.0,28696415.0,Maciukiewicz M,Placebo response in major depressive disorder (remitter/non-remitter status),initial,2017-07-11,GCST004742,Biological process,#d53e4f
10317,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (responder/non-responder status),initial,2017-07-11,GCST004741,Neurological disorder,#d53e4f
10318,European,186.0,28696415.0,Maciukiewicz M,Duloxetine response in major depressive disorder (responder/non-responder status),initial,2017-07-11,GCST004741,Response to drug,#d53e4f
10319,African Am./Caribbean,330.0,28686080.0,Liu N,Warfarin maintenance dose (adjusted for clinical factors),replication,2017-07-07,GCST008374,Response to drug,#fee08b
10320,European,137.0,28686080.0,Liu N,Warfarin maintenance dose (adjusted for clinical factors),replication,2017-07-07,GCST008374,Response to drug,#d53e4f
10321,African Am./Caribbean,539.0,28686080.0,Liu N,Warfarin maintenance dose (adjusted for clinical factors),initial,2017-07-07,GCST008374,Response to drug,#fee08b
10322,European,701.0,28686080.0,Liu N,Warfarin maintenance dose (adjusted for clinical factors),initial,2017-07-07,GCST008374,Response to drug,#d53e4f
10323,Asian,5937.0,28680059.0,Song X,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma,replication,2017-07-05,GCST004799,Cancer,#3288bd
10324,Asian,3302.0,28680059.0,Song X,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma,initial,2017-07-05,GCST004799,Cancer,#3288bd
10325,Asian,5937.0,28680059.0,Song X,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma,replication,2017-07-05,GCST004799,Other trait,#3288bd
10326,Asian,3302.0,28680059.0,Song X,Family history of upper gastrointestinal cancer in esophageal squamous cell carcinoma,initial,2017-07-05,GCST004799,Other trait,#3288bd
10329,European,9410.0,29731509.0,Zabaneh D,Extremely high intelligence,initial,2017-07-04,GCST005626,Biological process,#d53e4f
10347,European,3394.0,28672053.0,Meng W,Foot ulcer in diabetes and neuropathy,initial,2017-07-03,GCST004724,Metabolic disorder,#d53e4f
10348,European,3394.0,28672053.0,Meng W,Foot ulcer in diabetes and neuropathy,initial,2017-07-03,GCST004724,Cancer,#d53e4f
10349,European,3394.0,28672053.0,Meng W,Foot ulcer in diabetes and neuropathy,initial,2017-07-03,GCST004724,Metabolic disorder,#d53e4f
10350,European,3394.0,28672053.0,Meng W,Foot ulcer in diabetes and neuropathy,initial,2017-07-03,GCST004724,Neurological disorder,#d53e4f
10351,European,4949.0,28672053.0,Meng W,Foot ulcer and neuropathy in diabetes,initial,2017-07-03,GCST004725,Metabolic disorder,#d53e4f
10352,European,4949.0,28672053.0,Meng W,Foot ulcer and neuropathy in diabetes,initial,2017-07-03,GCST004725,Cancer,#d53e4f
10353,European,4949.0,28672053.0,Meng W,Foot ulcer and neuropathy in diabetes,initial,2017-07-03,GCST004725,Metabolic disorder,#d53e4f
10354,European,4949.0,28672053.0,Meng W,Foot ulcer and neuropathy in diabetes,initial,2017-07-03,GCST004725,Neurological disorder,#d53e4f
10355,European,9896.0,28641744.0,Guo W,Obsessive-compulsive disorder or autism spectrum disorder,initial,2017-07-01,GCST004703,Neurological disorder,#d53e4f
10356,European,9896.0,28641744.0,Guo W,Obsessive-compulsive disorder or autism spectrum disorder,initial,2017-07-01,GCST004703,Neurological disorder,#d53e4f
10357,African,4758.0,28234671.0,Nandakumar P,Diastolic blood pressure,initial,2017-07-01,GCST007828,Other measurement,#fc8d59
10358,African Am./Caribbean,11156.0,28234671.0,Nandakumar P,Diastolic blood pressure,initial,2017-07-01,GCST007828,Other measurement,#fee08b
10359,African,4758.0,28234671.0,Nandakumar P,Systolic blood pressure,initial,2017-07-01,GCST007829,Other measurement,#fc8d59
10360,African Am./Caribbean,11156.0,28234671.0,Nandakumar P,Systolic blood pressure,initial,2017-07-01,GCST007829,Other measurement,#fee08b
10361,Asian,278.0,28662289.0,Lin YY,Familial hepatitis B virus-related hepatocellular carcinoma,initial,2017-06-29,GCST004736,Cancer,#3288bd
10362,Asian,278.0,28662289.0,Lin YY,Familial hepatitis B virus-related hepatocellular carcinoma,initial,2017-06-29,GCST004736,Digestive system disorder,#3288bd
10363,European,3103.0,28656603.0,Na R,Benign prostatic hyperplasia and/or lower urinary tract symptoms,initial,2017-06-28,GCST004638,Other trait,#d53e4f
10364,European,960.0,28656603.0,Na R,Benign prostatic hyperplasia and/or lower urinary tract symptoms,replication,2017-06-28,GCST004638,Other trait,#d53e4f
10366,European,3103.0,28656603.0,Na R,Benign prostatic hyperplasia and/or lower urinary tract symptoms,initial,2017-06-28,GCST004638,Other disease,#d53e4f
10367,European,960.0,28656603.0,Na R,Benign prostatic hyperplasia and/or lower urinary tract symptoms,replication,2017-06-28,GCST004638,Other disease,#d53e4f
10369,European,69603.0,28658209.0,Huang H,Inflammatory bowel disease,initial,2017-06-28,GCST005837,Immune system disorder,#d53e4f
10370,European,69603.0,28658209.0,Huang H,Inflammatory bowel disease,initial,2017-06-28,GCST005837,Digestive system disorder,#d53e4f
10371,European,69603.0,28658209.0,Huang H,Inflammatory bowel disease,initial,2017-06-28,GCST005837,Digestive system disorder,#d53e4f
10372,Asian,389.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#3288bd
10373,European,492.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#d53e4f
10374,Hispanic/Latin American,157.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#807dba
10375,African Am./Caribbean,59.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#fee08b
10376,African,467.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#fc8d59
10377,Asian,189.0,28654678.0,Mandage R,Epstein-Barr virus copy number in lymphoblastoid cell lines,initial,2017-06-27,GCST004735,Other disease,#3288bd
10382,European,2543.0,28632202.0,Witt SH,Borderline personality disorder,initial,2017-06-20,GCST004641,Other trait,#d53e4f
10385,European,4472.0,28627999.0,Ikram MA,Cerebral blood flow,initial,2017-06-19,GCST004376,Other measurement,#d53e4f
10386,European,1350.0,28627999.0,Ikram MA,Cerebral blood flow,replication,2017-06-19,GCST004376,Other measurement,#d53e4f
10387,European,2158.0,28628107.0,Jonsson S,IgG levels,replication,2017-06-19,GCST008576,Other measurement,#d53e4f
10388,European,15536.0,28628107.0,Jonsson S,IgG levels,initial,2017-06-19,GCST008576,Other measurement,#d53e4f
10389,European,2157.0,28628107.0,Jonsson S,IgM levels,replication,2017-06-19,GCST008575,Other measurement,#d53e4f
10390,European,14442.0,28628107.0,Jonsson S,IgM levels,initial,2017-06-19,GCST008575,Other measurement,#d53e4f
10391,European,2151.0,28628107.0,Jonsson S,IgA levels,replication,2017-06-19,GCST008568,Other measurement,#d53e4f
10392,European,16883.0,28628107.0,Jonsson S,IgA levels,initial,2017-06-19,GCST008568,Other measurement,#d53e4f
10393,European,3238.0,29296746.0,Ma Q,ADAMTS13 levels,initial,2017-06-19,GCST005945,Other measurement,#d53e4f
10396,European,4262.0,28630421.0,Li D,Anorexia nervosa (excluding migration to or from binge-eating disorder or bulimia nervosa),initial,2017-06-19,GCST004585,Metabolic disorder,#d53e4f
10399,European,1367.0,28701861.0,Randall CL,Fear of severe pain,initial,2017-06-15,GCST004709,Other measurement,#d53e4f
10400,African Am./Caribbean,159.0,28701861.0,Randall CL,Fear of severe pain,initial,2017-06-15,GCST004709,Other measurement,#fee08b
10401,Hispanic/Latin American,13.0,28701861.0,Randall CL,Fear of severe pain,initial,2017-06-15,GCST004709,Other measurement,#807dba
10402,Other/Mixed,23.0,28701861.0,Randall CL,Fear of severe pain,initial,2017-06-15,GCST004709,Other measurement,#99d594
10404,Hispanic/Latin American,13.0,28701861.0,Randall CL,Fear of pain,initial,2017-06-15,GCST004706,Other measurement,#807dba
10405,European,1367.0,28701861.0,Randall CL,Fear of pain,initial,2017-06-15,GCST004706,Other measurement,#d53e4f
10406,African Am./Caribbean,159.0,28701861.0,Randall CL,Fear of pain,initial,2017-06-15,GCST004706,Other measurement,#fee08b
10407,Other/Mixed,23.0,28701861.0,Randall CL,Fear of pain,initial,2017-06-15,GCST004706,Other measurement,#99d594
10409,European,1367.0,28701861.0,Randall CL,Fear of medical pain (dental),initial,2017-06-15,GCST004707,Other measurement,#d53e4f
10410,African Am./Caribbean,159.0,28701861.0,Randall CL,Fear of medical pain (dental),initial,2017-06-15,GCST004707,Other measurement,#fee08b
10411,Hispanic/Latin American,13.0,28701861.0,Randall CL,Fear of medical pain (dental),initial,2017-06-15,GCST004707,Other measurement,#807dba
10412,Other/Mixed,23.0,28701861.0,Randall CL,Fear of medical pain (dental),initial,2017-06-15,GCST004707,Other measurement,#99d594
10414,Other/Mixed,23.0,28701861.0,Randall CL,Fear of minor pain,initial,2017-06-15,GCST004708,Other measurement,#99d594
10415,European,1367.0,28701861.0,Randall CL,Fear of minor pain,initial,2017-06-15,GCST004708,Other measurement,#d53e4f
10416,African Am./Caribbean,159.0,28701861.0,Randall CL,Fear of minor pain,initial,2017-06-15,GCST004708,Other measurement,#fee08b
10417,Hispanic/Latin American,13.0,28701861.0,Randall CL,Fear of minor pain,initial,2017-06-15,GCST004708,Other measurement,#807dba
10419,African Am./Caribbean,6899.0,28613276.0,Nolte IM,Heart rate variability traits (SDNN),replication,2017-06-14,GCST004734,Cardiovascular measurement,#fee08b
10420,European,27850.0,28613276.0,Nolte IM,Heart rate variability traits (SDNN),initial,2017-06-14,GCST004734,Cardiovascular measurement,#d53e4f
10421,European,24125.0,28613276.0,Nolte IM,Heart rate variability traits (SDNN),replication,2017-06-14,GCST004734,Cardiovascular measurement,#d53e4f
10422,Hispanic/Latin American,11234.0,28613276.0,Nolte IM,Heart rate variability traits (SDNN),replication,2017-06-14,GCST004734,Cardiovascular measurement,#807dba
10423,European,24088.0,28613276.0,Nolte IM,Heart rate variability traits (pvRSA/HF),initial,2017-06-14,GCST004732,Cardiovascular measurement,#d53e4f
10424,Hispanic/Latin American,404.0,28613276.0,Nolte IM,Heart rate variability traits (pvRSA/HF),replication,2017-06-14,GCST004732,Cardiovascular measurement,#807dba
10425,African Am./Caribbean,1901.0,28613276.0,Nolte IM,Heart rate variability traits (pvRSA/HF),replication,2017-06-14,GCST004732,Cardiovascular measurement,#fee08b
10426,European,9377.0,28613276.0,Nolte IM,Heart rate variability traits (pvRSA/HF),replication,2017-06-14,GCST004732,Cardiovascular measurement,#d53e4f
10427,European,20429.0,28613276.0,Nolte IM,Heart rate variability traits (RMSSD),replication,2017-06-14,GCST004733,Cardiovascular measurement,#d53e4f
10428,European,26523.0,28613276.0,Nolte IM,Heart rate variability traits (RMSSD),initial,2017-06-14,GCST004733,Cardiovascular measurement,#d53e4f
10429,Hispanic/Latin American,11234.0,28613276.0,Nolte IM,Heart rate variability traits (RMSSD),replication,2017-06-14,GCST004733,Cardiovascular measurement,#807dba
10430,African Am./Caribbean,6895.0,28613276.0,Nolte IM,Heart rate variability traits (RMSSD),replication,2017-06-14,GCST004733,Cardiovascular measurement,#fee08b
10431,European,4097.0,28608620.0,Coleman JRI,Facial emotion recognition,initial,2017-06-13,GCST004727,Other measurement,#d53e4f
10432,European,4097.0,28608620.0,Coleman JRI,Facial emotion recognition (fearful faces),initial,2017-06-13,GCST004731,Other measurement,#d53e4f
10433,European,4097.0,28608620.0,Coleman JRI,Facial emotion recognition (angry faces),initial,2017-06-13,GCST004728,Other measurement,#d53e4f
10434,European,4097.0,28608620.0,Coleman JRI,Facial emotion recognition (sad faces),initial,2017-06-13,GCST004730,Other measurement,#d53e4f
10435,European,4097.0,28608620.0,Coleman JRI,Facial emotion recognition (happy faces),initial,2017-06-13,GCST004729,Other measurement,#d53e4f
10436,European,24573.0,28604728.0,Litchfield K,Testicular germ cell tumor,initial,2017-06-12,GCST004635,Cancer,#d53e4f
10437,European,5828.0,28604728.0,Litchfield K,Testicular germ cell tumor,replication,2017-06-12,GCST004635,Cancer,#d53e4f
10438,European,53639.0,28604731.0,Hammerschlag AR,Insomnia complaints,initial,2017-06-12,GCST006488,Neurological disorder,#d53e4f
10439,European,7565.0,28604731.0,Hammerschlag AR,Insomnia complaints,replication,2017-06-12,GCST006488,Neurological disorder,#d53e4f
10440,European,59367.0,28604731.0,Hammerschlag AR,Insomnia complaints,initial,2017-06-12,GCST006487,Neurological disorder,#d53e4f
10441,European,7565.0,28604731.0,Hammerschlag AR,Insomnia complaints,replication,2017-06-12,GCST006487,Neurological disorder,#d53e4f
10442,European,9859.0,28604730.0,McKay JD,Lung cancer in never smokers,initial,2017-06-12,GCST004747,Other measurement,#d53e4f
10443,European,9859.0,28604730.0,McKay JD,Lung cancer in never smokers,initial,2017-06-12,GCST004747,Cancer,#d53e4f
10444,European,40187.0,28604730.0,McKay JD,Lung cancer in ever smokers,initial,2017-06-12,GCST004749,Other measurement,#d53e4f
10445,European,40187.0,28604730.0,McKay JD,Lung cancer in ever smokers,initial,2017-06-12,GCST004749,Cancer,#d53e4f
10446,European,24108.0,28604730.0,McKay JD,Small cell lung carcinoma,initial,2017-06-12,GCST004746,Cancer,#d53e4f
10447,European,63053.0,28604730.0,McKay JD,Squamous cell lung carcinoma,initial,2017-06-12,GCST004750,Cancer,#d53e4f
10448,European,66756.0,28604730.0,McKay JD,Lung adenocarcinoma,initial,2017-06-12,GCST004744,Cancer,#d53e4f
10449,European,112717.0,28604731.0,Hammerschlag AR,Daytime sleepiness,initial,2017-06-12,GCST004699,Other measurement,#d53e4f
10450,European,105377.0,28604731.0,Hammerschlag AR,Snoring,initial,2017-06-12,GCST004698,Other measurement,#d53e4f
10451,European,113054.0,28604731.0,Hammerschlag AR,Daytime nap,initial,2017-06-12,GCST004693,Other measurement,#d53e4f
10452,European,112866.0,28604731.0,Hammerschlag AR,Ease of getting up in the morning,initial,2017-06-12,GCST004697,Other measurement,#d53e4f
10453,European,101185.0,28604731.0,Hammerschlag AR,Chronotype,initial,2017-06-12,GCST004696,Biological process,#d53e4f
10454,European,59512.0,28604731.0,Hammerschlag AR,Insomnia complaints (dichotomous),initial,2017-06-12,GCST004702,Neurological disorder,#d53e4f
10455,European,113006.0,28604731.0,Hammerschlag AR,Insomnia complaints (continuous),initial,2017-06-12,GCST004701,Neurological disorder,#d53e4f
10456,European,113006.0,28604731.0,Hammerschlag AR,Insomnia complaints (sex interaction),initial,2017-06-12,GCST004700,Neurological disorder,#d53e4f
10457,European,112411.0,28604731.0,Hammerschlag AR,Sleep duration,initial,2017-06-12,GCST004694,Other measurement,#d53e4f
10458,European,113006.0,28604731.0,Hammerschlag AR,Insomnia complaints,initial,2017-06-12,GCST004695,Neurological disorder,#d53e4f
10459,European,7565.0,28604731.0,Hammerschlag AR,Insomnia complaints,replication,2017-06-12,GCST004695,Neurological disorder,#d53e4f
10460,European,17528.0,28604732.0,Wang Z,Testicular germ cell tumor,initial,2017-06-12,GCST004713,Cancer,#d53e4f
10461,European,85716.0,28604730.0,McKay JD,Lung cancer,initial,2017-06-12,GCST004748,Cancer,#d53e4f
10462,Hispanic/Latin American,13184.0,28610988.0,Kerr KF,Heart rate,initial,2017-06-10,GCST004715,Cardiovascular measurement,#807dba
10463,European,7073.0,28610988.0,Kerr KF,Heart rate,replication,2017-06-10,GCST004715,Cardiovascular measurement,#d53e4f
10464,African Am./Caribbean,4771.0,28610988.0,Kerr KF,Heart rate,replication,2017-06-10,GCST004715,Cardiovascular measurement,#fee08b
10465,Hispanic/Latin American,13184.0,28610988.0,Kerr KF,Heart rate variability traits (SDNN),initial,2017-06-10,GCST004714,Cardiovascular measurement,#807dba
10466,African Am./Caribbean,2908.0,28610988.0,Kerr KF,Heart rate variability traits (SDNN),replication,2017-06-10,GCST004714,Cardiovascular measurement,#fee08b
10467,European,7073.0,28610988.0,Kerr KF,Heart rate variability traits (SDNN),replication,2017-06-10,GCST004714,Cardiovascular measurement,#d53e4f
10468,Hispanic/Latin American,13767.0,28610988.0,Kerr KF,Heart rate variability traits (RMSSD),initial,2017-06-10,GCST004716,Cardiovascular measurement,#807dba
10469,European,4730.0,28610988.0,Kerr KF,Heart rate variability traits (RMSSD),replication,2017-06-10,GCST004716,Cardiovascular measurement,#d53e4f
10470,African Am./Caribbean,2908.0,28610988.0,Kerr KF,Heart rate variability traits (RMSSD),replication,2017-06-10,GCST004716,Cardiovascular measurement,#fee08b
10471,African Am./Caribbean,1886.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004842,Body measurement,#fee08b
10472,African Am./Caribbean,1886.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004842,Other trait,#fee08b
10473,African Am./Caribbean,1886.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004842,Other measurement,#fee08b
10474,African Am./Caribbean,300.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Body measurement,#fee08b
10475,African Am./Caribbean,1586.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004843,Body measurement,#fee08b
10476,European,683.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Body measurement,#d53e4f
10477,African Am./Caribbean,300.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Other trait,#fee08b
10478,African Am./Caribbean,1586.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004843,Other trait,#fee08b
10479,European,683.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Other trait,#d53e4f
10480,African Am./Caribbean,300.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Other measurement,#fee08b
10481,African Am./Caribbean,1586.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),initial,2017-06-09,GCST004843,Other measurement,#fee08b
10482,European,683.0,28598419.0,Hong X,Preterm birth (maternal effect) (maternal pre-pregnancy BMI interaction),replication,2017-06-09,GCST004843,Other measurement,#d53e4f
10483,African Am./Caribbean,1733.0,28598419.0,Hong X,Gestational age at birth (maternal effect),initial,2017-06-09,GCST004844,Other measurement,#fee08b
10484,African Am./Caribbean,1733.0,28598419.0,Hong X,Gestational age at birth (maternal effect),initial,2017-06-09,GCST004844,Other measurement,#fee08b
10485,African Am./Caribbean,1496.0,28598419.0,Hong X,Spontaneous preterm birth (maternal effect),initial,2017-06-09,GCST004845,Other trait,#fee08b
10486,African Am./Caribbean,1496.0,28598419.0,Hong X,Spontaneous preterm birth (maternal effect),initial,2017-06-09,GCST004845,Other measurement,#fee08b
10487,European,9483.0,28598434.0,Scelo G,Renal cell carcinoma,replication,2017-06-09,GCST004710,Cancer,#d53e4f
10488,European,31190.0,28598434.0,Scelo G,Renal cell carcinoma,initial,2017-06-09,GCST004710,Cancer,#d53e4f
10489,European,683.0,28598419.0,Hong X,Preterm birth (maternal effect),replication,2017-06-09,GCST004841,Other trait,#d53e4f
10490,African Am./Caribbean,782.0,28598419.0,Hong X,Preterm birth (maternal effect),replication,2017-06-09,GCST004841,Other trait,#fee08b
10491,African Am./Caribbean,1733.0,28598419.0,Hong X,Preterm birth (maternal effect),initial,2017-06-09,GCST004841,Other trait,#fee08b
10492,European,683.0,28598419.0,Hong X,Preterm birth (maternal effect),replication,2017-06-09,GCST004841,Other measurement,#d53e4f
10493,African Am./Caribbean,782.0,28598419.0,Hong X,Preterm birth (maternal effect),replication,2017-06-09,GCST004841,Other measurement,#fee08b
10494,African Am./Caribbean,1733.0,28598419.0,Hong X,Preterm birth (maternal effect),initial,2017-06-09,GCST004841,Other measurement,#fee08b
10495,Hispanic/Latin American,1562.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Cardiovascular measurement,#807dba
10496,African Am./Caribbean,5707.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Cardiovascular measurement,#fee08b
10497,European,14889.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Cardiovascular measurement,#d53e4f
10498,Hispanic/Latin American,1562.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Other measurement,#807dba
10499,African Am./Caribbean,5707.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Other measurement,#fee08b
10500,European,14889.0,28749367.0,Gondalia R,QT interval (ambient particulate matter interaction),initial,2017-06-08,GCST004642,Other measurement,#d53e4f
10501,African Am./Caribbean,2030.0,28588231.0,Li M,"1,5-anhydroglucitol levels",replication,2017-06-06,GCST004643,Other measurement,#fee08b
10502,European,8790.0,28588231.0,Li M,"1,5-anhydroglucitol levels",replication,2017-06-06,GCST004643,Other measurement,#d53e4f
10503,European,7550.0,28588231.0,Li M,"1,5-anhydroglucitol levels",initial,2017-06-06,GCST004643,Other measurement,#d53e4f
10504,European,89553.0,28584286.0,Warrier V,Cognitive empathy,initial,2017-06-06,GCST005755,Other measurement,#d53e4f
10505,European,248715.0,28585551.0,Sigurdsson S,Diverticulitis,initial,2017-06-06,GCST008256,Digestive system disorder,#d53e4f
10506,European,251377.0,28585551.0,Sigurdsson S,Diverticular disease,initial,2017-06-06,GCST008257,Digestive system disorder,#d53e4f
10507,European,8990.0,28585551.0,Sigurdsson S,Diverticular disease,replication,2017-06-06,GCST008257,Digestive system disorder,#d53e4f
10508,African,1293.0,28584135.0,Chaturvedi S,Vaso-occlusive pain in sickle-cell anemia,initial,2017-06-05,GCST004644,Neurological disorder,#fc8d59
10509,African,1293.0,28584135.0,Chaturvedi S,Vaso-occlusive pain in sickle-cell anemia,initial,2017-06-05,GCST004644,Other measurement,#fc8d59
10510,European,47593.0,28552196.0,Tachmazidou I,Waist circumference,initial,2017-06-01,GCST008151,Body measurement,#d53e4f
10511,European,206737.0,28552196.0,Tachmazidou I,Waist circumference,replication,2017-06-01,GCST008151,Body measurement,#d53e4f
10513,European,111749.0,27864402.0,Harris SE,Self-rated health,initial,2017-06-01,GCST006620,Other trait,#d53e4f
10514,European,34004.0,28552196.0,Tachmazidou I,Hip circumference,initial,2017-06-01,GCST008162,Body measurement,#d53e4f
10516,European,205909.0,28552196.0,Tachmazidou I,Hip circumference,replication,2017-06-01,GCST008162,Body measurement,#d53e4f
10517,European,3357.0,28468790.0,Agopian AJ,Congenital heart disease (maternal effect),initial,2017-06-01,GCST004721,Cardiovascular disease,#d53e4f
10518,European,6739.0,28468790.0,Agopian AJ,Congenital heart disease (inherited effect),initial,2017-06-01,GCST004718,Cardiovascular disease,#d53e4f
10520,European,1317.0,28468790.0,Agopian AJ,Left ventricular obstructive tract defect (maternal effect),initial,2017-06-01,GCST004722,Cardiovascular disease,#d53e4f
10521,European,2514.0,28468790.0,Agopian AJ,Conotruncal heart defects (maternal effects),initial,2017-06-01,GCST004723,Cardiovascular disease,#d53e4f
10523,European,741.0,28468790.0,Agopian AJ,Left ventricular obstructive tract defect (inherited effect),initial,2017-06-01,GCST004719,Cardiovascular disease,#d53e4f
10524,European,47593.0,28552196.0,Tachmazidou I,Waist circumference,initial,2017-06-01,GCST008160,Body measurement,#d53e4f
10525,European,206737.0,28552196.0,Tachmazidou I,Waist circumference,replication,2017-06-01,GCST008160,Body measurement,#d53e4f
10527,European,47095.0,28552196.0,Tachmazidou I,Waist circumference adjusted for body mass index,initial,2017-06-01,GCST008161,Body measurement,#d53e4f
10529,European,206723.0,28552196.0,Tachmazidou I,Waist circumference adjusted for body mass index,replication,2017-06-01,GCST008161,Body measurement,#d53e4f
10530,European,33811.0,28552196.0,Tachmazidou I,Waist-to-hip ratio adjusted for BMI,initial,2017-06-01,GCST008159,Body measurement,#d53e4f
10532,European,206045.0,28552196.0,Tachmazidou I,Waist-to-hip ratio adjusted for BMI,replication,2017-06-01,GCST008159,Body measurement,#d53e4f
10533,European,53255.0,28552196.0,Tachmazidou I,Body mass index,initial,2017-06-01,GCST008158,Body measurement,#d53e4f
10535,European,209191.0,28552196.0,Tachmazidou I,Body mass index,replication,2017-06-01,GCST008158,Body measurement,#d53e4f
10536,European,10670.0,28552196.0,Tachmazidou I,Body fat mass,replication,2017-06-01,GCST008157,Other measurement,#d53e4f
10537,European,11802.0,28552196.0,Tachmazidou I,Body fat mass,initial,2017-06-01,GCST008157,Other measurement,#d53e4f
10540,European,205003.0,28552196.0,Tachmazidou I,Height,replication,2017-06-01,GCST008163,Body measurement,#d53e4f
10541,European,53588.0,28552196.0,Tachmazidou I,Height,initial,2017-06-01,GCST008163,Body measurement,#d53e4f
10542,European,4831.0,28468790.0,Agopian AJ,Conotruncal heart defects (inherited effects),initial,2017-06-01,GCST004720,Cardiovascular disease,#d53e4f
10547,European,33865.0,28552196.0,Tachmazidou I,Hip circumference adjusted for BMI,initial,2017-06-01,GCST008156,Body measurement,#d53e4f
10549,European,205905.0,28552196.0,Tachmazidou I,Hip circumference adjusted for BMI,replication,2017-06-01,GCST008156,Body measurement,#d53e4f
10550,European,34088.0,28552196.0,Tachmazidou I,Waist-hip ratio,initial,2017-06-01,GCST008155,Body measurement,#d53e4f
10552,European,206053.0,28552196.0,Tachmazidou I,Waist-hip ratio,replication,2017-06-01,GCST008155,Body measurement,#d53e4f
10553,European,12838.0,28552196.0,Tachmazidou I,Trunk fat mass,initial,2017-06-01,GCST008154,Other measurement,#d53e4f
10555,European,10667.0,28552196.0,Tachmazidou I,Trunk fat mass,replication,2017-06-01,GCST008154,Other measurement,#d53e4f
10556,European,11801.0,28552196.0,Tachmazidou I,Lean body mass,initial,2017-06-01,GCST008153,Other measurement,#d53e4f
10558,European,10676.0,28552196.0,Tachmazidou I,Lean body mass,replication,2017-06-01,GCST008153,Other measurement,#d53e4f
10559,European,53484.0,28552196.0,Tachmazidou I,Weight,initial,2017-06-01,GCST008152,Body measurement,#d53e4f
10561,European,179022.0,28552196.0,Tachmazidou I,Weight,replication,2017-06-01,GCST008152,Body measurement,#d53e4f
10562,European,53539.0,28566273.0,Scott RA,Type 2 diabetes,replication,2017-05-31,GCST004773,Metabolic disorder,#d53e4f
10563,European,159208.0,28566273.0,Scott RA,Type 2 diabetes,initial,2017-05-31,GCST004773,Metabolic disorder,#d53e4f
10564,European,159208.0,28566273.0,Scott RA,Type 2 diabetes,initial,2017-05-31,GCST004774,Metabolic disorder,#d53e4f
10565,European,79001.0,28566273.0,Scott RA,Type 2 diabetes,replication,2017-05-31,GCST004774,Metabolic disorder,#d53e4f
10566,European,1560.0,28577822.0,Deters KD,Language performance in older adults (adjusted for episodic memory),initial,2017-05-31,GCST004372,Other measurement,#d53e4f
10567,European,1560.0,28577822.0,Deters KD,Language performance in older adults (adjusted for episodic memory),initial,2017-05-31,GCST004372,Other measurement,#d53e4f
10568,European,1560.0,28577822.0,Deters KD,Language performance in older adults (adjusted for episodic memory),initial,2017-05-31,GCST004372,Other measurement,#d53e4f
10569,Asian,2875.0,27064256.0,Khor CC,Glaucoma (primary angle closure),initial,2016-04-04,GCST003467,Neurological disorder,#3288bd
10570,Asian,18063.0,27064256.0,Khor CC,Glaucoma (primary angle closure),initial,2016-04-04,GCST003467,Neurological disorder,#3288bd
10571,European,5516.0,27064256.0,Khor CC,Glaucoma (primary angle closure),initial,2016-04-04,GCST003467,Neurological disorder,#d53e4f
10572,European,3563.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#d53e4f
10573,Asian,295.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#3288bd
10574,Asian,6205.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#3288bd
10575,Asian,1180.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#3288bd
10576,Other/Mixed,2050.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#99d594
10577,Hispanic/Latin American,323.0,27064256.0,Khor CC,Glaucoma (primary angle closure),replication,2016-04-04,GCST003467,Neurological disorder,#807dba
10578,Hispanic/Latin American,1415.0,27036123.0,van Leeuwen EM,Triglycerides,initial,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#807dba
10579,African Am./Caribbean,6287.0,27036123.0,van Leeuwen EM,Triglycerides,initial,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#fee08b
10580,Asian,705.0,27036123.0,van Leeuwen EM,Triglycerides,initial,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#3288bd
10581,African Am./Caribbean,2710.0,27036123.0,van Leeuwen EM,Triglycerides,replication,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#fee08b
10582,Asian,9982.0,27036123.0,van Leeuwen EM,Triglycerides,replication,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#3288bd
10583,European,60827.0,27036123.0,van Leeuwen EM,Triglycerides,replication,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#d53e4f
10584,European,41142.0,27036123.0,van Leeuwen EM,Triglycerides,initial,2016-04-01,GCST003661,Lipid or lipoprotein measurement,#d53e4f
10585,Asian,703.0,27036123.0,van Leeuwen EM,HDL cholesterol,initial,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#3288bd
10586,African Am./Caribbean,2685.0,27036123.0,van Leeuwen EM,HDL cholesterol,replication,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#fee08b
10587,Asian,9992.0,27036123.0,van Leeuwen EM,HDL cholesterol,replication,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#3288bd
10588,European,71921.0,27036123.0,van Leeuwen EM,HDL cholesterol,replication,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#d53e4f
10589,African Am./Caribbean,6476.0,27036123.0,van Leeuwen EM,HDL cholesterol,initial,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#fee08b
10590,Hispanic/Latin American,1407.0,27036123.0,van Leeuwen EM,HDL cholesterol,initial,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#807dba
10591,European,50823.0,27036123.0,van Leeuwen EM,HDL cholesterol,initial,2016-04-01,GCST003660,Lipid or lipoprotein measurement,#d53e4f
10592,African Am./Caribbean,6480.0,27036123.0,van Leeuwen EM,"Cholesterol, total",initial,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#fee08b
10593,European,51430.0,27036123.0,van Leeuwen EM,"Cholesterol, total",initial,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#d53e4f
10594,Other/Mixed,71032.0,27036123.0,van Leeuwen EM,"Cholesterol, total",replication,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#99d594
10595,Asian,702.0,27036123.0,van Leeuwen EM,"Cholesterol, total",initial,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#3288bd
10596,Hispanic/Latin American,1412.0,27036123.0,van Leeuwen EM,"Cholesterol, total",initial,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#807dba
10597,African Am./Caribbean,2707.0,27036123.0,van Leeuwen EM,"Cholesterol, total",replication,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#fee08b
10598,Asian,10000.0,27036123.0,van Leeuwen EM,"Cholesterol, total",replication,2016-04-01,GCST003663,Lipid or lipoprotein measurement,#3288bd
10599,European,40473.0,27036123.0,van Leeuwen EM,LDL cholesterol,initial,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#d53e4f
10600,European,60078.0,27036123.0,van Leeuwen EM,LDL cholesterol,replication,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#d53e4f
10601,Hispanic/Latin American,1381.0,27036123.0,van Leeuwen EM,LDL cholesterol,initial,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#807dba
10602,African Am./Caribbean,6237.0,27036123.0,van Leeuwen EM,LDL cholesterol,initial,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#fee08b
10603,Asian,689.0,27036123.0,van Leeuwen EM,LDL cholesterol,initial,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#3288bd
10604,African Am./Caribbean,2679.0,27036123.0,van Leeuwen EM,LDL cholesterol,replication,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#fee08b
10605,Asian,9729.0,27036123.0,van Leeuwen EM,LDL cholesterol,replication,2016-04-01,GCST003662,Lipid or lipoprotein measurement,#3288bd
10606,European,24168.0,27029810.0,Joshi PK,Mortality,replication,2016-03-31,GCST005078,Other measurement,#d53e4f
10607,European,272081.0,27029810.0,Joshi PK,Mortality,initial,2016-03-31,GCST005078,Other measurement,#d53e4f
10608,African Am./Caribbean,962.0,27029810.0,Joshi PK,Mortality,replication,2016-03-31,GCST005078,Other measurement,#fee08b
10609,African,681.0,27029810.0,Joshi PK,Mortality,replication,2016-03-31,GCST005078,Other measurement,#fc8d59
10610,Asian,338.0,27029810.0,Joshi PK,Mortality,replication,2016-03-31,GCST005078,Other measurement,#3288bd
10611,Asian,1613.0,27029810.0,Joshi PK,Mortality,replication,2016-03-31,GCST005078,Other measurement,#3288bd
10612,African Am./Caribbean,6000.0,27028160.0,Sherva R,Cannabis dependence symptom count,initial,2016-03-30,GCST003465,Other measurement,#fee08b
10613,European,8754.0,27028160.0,Sherva R,Cannabis dependence symptom count,initial,2016-03-30,GCST003465,Other measurement,#d53e4f
10614,European,1893.0,27028160.0,Sherva R,Cannabis dependence symptom count,replication,2016-03-30,GCST003465,Other measurement,#d53e4f
10615,Asian,2088.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10616,Asian,2256.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10617,Asian,5971.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10618,European,40036.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#d53e4f
10619,Asian,2088.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10620,Asian,2256.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10621,Asian,5971.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#3288bd
10622,European,40036.0,27020472.0,Fan Q,Spherical equivalent (joint analysis main effects and education interaction),initial,2016-03-29,GCST003455,Other measurement,#d53e4f
10623,Asian,6467.0,27206850.0,Wang M,Bladder cancer,replication,2016-03-29,GCST003384,Cancer,#3288bd
10624,Asian,1584.0,27206850.0,Wang M,Bladder cancer,initial,2016-03-29,GCST003384,Cancer,#3288bd
10625,European,579.0,27023328.0,Kulkarni D,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia),initial,2016-03-29,GCST003456,Response to drug,#d53e4f
10626,European,579.0,27023328.0,Kulkarni D,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia),initial,2016-03-29,GCST003456,Other trait,#d53e4f
10627,European,579.0,27023328.0,Kulkarni D,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia),initial,2016-03-29,GCST003456,Cancer,#d53e4f
10628,European,579.0,27023328.0,Kulkarni D,Adverse response to dabrafenib or dabrafenib-trametinib treatment in melanoma (pyrexia),initial,2016-03-29,GCST003456,Response to drug,#d53e4f
10631,European,2967.0,27023175.0,Stringer S,Cannabis use,replication,2016-03-29,GCST003382,Biological process,#d53e4f
10632,African Am./Caribbean,2660.0,27023175.0,Stringer S,Cannabis use,replication,2016-03-29,GCST003382,Biological process,#fee08b
10633,European,32330.0,27023175.0,Stringer S,Cannabis use,initial,2016-03-29,GCST003382,Biological process,#d53e4f
10634,European,678.0,27021820.0,Roostaei T,Cognitive impairment (brain beta-amyloid deposition interaction),initial,2016-03-29,GCST003399,Other trait,#d53e4f
10635,European,949.0,27021820.0,Roostaei T,Cognitive impairment (brain beta-amyloid deposition interaction),replication,2016-03-29,GCST003399,Other trait,#d53e4f
10636,European,678.0,27021820.0,Roostaei T,Cognitive impairment (brain beta-amyloid deposition interaction),initial,2016-03-29,GCST003399,Other measurement,#d53e4f
10637,European,949.0,27021820.0,Roostaei T,Cognitive impairment (brain beta-amyloid deposition interaction),replication,2016-03-29,GCST003399,Other measurement,#d53e4f
10638,European,1060.0,27021288.0,Brevik EJ,Aggressiveness in attention deficit hyperactivity disorder,initial,2016-03-29,GCST003473,Neurological disorder,#d53e4f
10639,European,1060.0,27021288.0,Brevik EJ,Aggressiveness in attention deficit hyperactivity disorder,initial,2016-03-29,GCST003473,Other measurement,#d53e4f
10640,European,1060.0,27021288.0,Brevik EJ,Aggressiveness in attention deficit hyperactivity disorder,initial,2016-03-29,GCST003473,Other measurement,#d53e4f
10641,African Am./Caribbean,736.0,27022141.0,Liu L,High fetal hemoglobin in sickle cell disease,initial,2016-03-27,GCST006251,Hematological measurement,#fee08b
10642,African Am./Caribbean,736.0,27022141.0,Liu L,High fetal hemoglobin in sickle cell disease,initial,2016-03-27,GCST006251,Other disease,#fee08b
10648,European,63775.0,27015805.0,Pilling LC,Parental longevity (father's age at death),initial,2016-03-23,GCST003392,Other measurement,#d53e4f
10650,European,42273.0,27015805.0,Pilling LC,Parental extreme longevity (95 years and older),initial,2016-03-23,GCST003395,Other measurement,#d53e4f
10651,European,45627.0,27015805.0,Pilling LC,Parental longevity (combined parental age at death),initial,2016-03-23,GCST003394,Other measurement,#d53e4f
10652,European,52776.0,27015805.0,Pilling LC,Parental longevity (mother's age at death),initial,2016-03-23,GCST003393,Other measurement,#d53e4f
10653,European,16852.0,27008869.0,Chen MM,Endometrial cancer,initial,2016-03-23,GCST003436,Cancer,#d53e4f
10654,European,24925.0,27005778.0,Kettunen J,Metabolite levels (lipoprotein measures),initial,2016-03-23,GCST003665,Other measurement,#d53e4f
10655,European,24925.0,27005778.0,Kettunen J,Metabolite levels (lipoprotein measures),initial,2016-03-23,GCST003665,Other measurement,#d53e4f
10656,European,24925.0,27005778.0,Kettunen J,Metabolite levels (small molecules and protein measures),initial,2016-03-23,GCST003666,Other measurement,#d53e4f
10657,European,24925.0,27005778.0,Kettunen J,Metabolite levels (small molecules and protein measures),initial,2016-03-23,GCST003666,Other measurement,#d53e4f
10658,European,24925.0,27005778.0,Kettunen J,Metabolite levels (small molecules and protein measures),initial,2016-03-23,GCST003666,Other measurement,#d53e4f
10659,European,24925.0,27005778.0,Kettunen J,Metabolite levels (lipid measures),initial,2016-03-23,GCST003664,Other measurement,#d53e4f
10660,European,24925.0,27005778.0,Kettunen J,Metabolite levels (lipid measures),initial,2016-03-23,GCST003664,Other measurement,#d53e4f
10682,European,7778.0,27005825.0,Finkel TH,Arthritis (juvenile idiopathic),replication,2016-03-22,GCST003424,Immune system disorder,#d53e4f
10683,European,2888.0,27005825.0,Finkel TH,Arthritis (juvenile idiopathic),initial,2016-03-22,GCST003424,Immune system disorder,#d53e4f
10685,Asian,616.0,27001270.0,Vishal M,Glaucoma (primary open-angle),replication,2016-03-22,GCST003446,Neurological disorder,#3288bd
10686,Asian,701.0,27001270.0,Vishal M,Glaucoma (primary open-angle),initial,2016-03-22,GCST003446,Neurological disorder,#3288bd
10687,European,6813.0,26997408.0,Demirkan A,Depressive symptoms measurement (somatic complaints domain),replication,2016-03-21,GCST003667,Other measurement,#d53e4f
10688,European,32528.0,26997408.0,Demirkan A,Depressive symptoms measurement (somatic complaints domain),initial,2016-03-21,GCST003667,Other measurement,#d53e4f
10689,European,6813.0,26997408.0,Demirkan A,Depressive symptoms measurement (lack of positive affect domain),replication,2016-03-21,GCST003668,Other measurement,#d53e4f
10690,European,32528.0,26997408.0,Demirkan A,Depressive symptoms measurement (lack of positive affect domain),initial,2016-03-21,GCST003668,Other measurement,#d53e4f
10691,European,6813.0,26997408.0,Demirkan A,Depressive symptoms measurement (lack of negative affect domain),replication,2016-03-21,GCST003669,Other measurement,#d53e4f
10692,European,32528.0,26997408.0,Demirkan A,Depressive symptoms measurement (lack of negative affect domain),initial,2016-03-21,GCST003669,Other measurement,#d53e4f
10693,Asian,79.0,27001664.0,Yoo J,knee peak torque response,initial,2016-03-21,GCST003607,Other measurement,#3288bd
10694,Asian,79.0,27001664.0,Yoo J,Maximal oxygen uptake response,initial,2016-03-21,GCST003608,Other measurement,#3288bd
10696,European,902.0,26989097.0,Coleman JR,Response to cognitive-behavioural therapy in anxiety disorder,initial,2016-03-17,GCST003469,Neurological disorder,#d53e4f
10698,European,902.0,26989097.0,Coleman JR,Response to cognitive-behavioural therapy in anxiety disorder,initial,2016-03-17,GCST003469,Other trait,#d53e4f
10699,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Other measurement,#d53e4f
10700,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Other measurement,#fee08b
10701,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Other measurement,#3288bd
10702,Hispanic/Latin American,12558.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),initial,2016-03-15,GCST003674,Other measurement,#807dba
10703,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Neurological disorder,#d53e4f
10704,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Neurological disorder,#fee08b
10705,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),replication,2016-03-15,GCST003674,Neurological disorder,#3288bd
10706,Hispanic/Latin American,12558.0,26977737.0,Cade BE,Obstructive sleep apnea trait (apnea hypopnea index),initial,2016-03-15,GCST003674,Neurological disorder,#807dba
10707,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Other measurement,#fee08b
10708,Hispanic/Latin American,10238.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),initial,2016-03-15,GCST003675,Other measurement,#807dba
10709,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Other measurement,#d53e4f
10710,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Other measurement,#3288bd
10711,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Neurological disorder,#fee08b
10712,Hispanic/Latin American,10238.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),initial,2016-03-15,GCST003675,Neurological disorder,#807dba
10713,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Neurological disorder,#d53e4f
10714,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea trait (average respiratory event duration),replication,2016-03-15,GCST003675,Neurological disorder,#3288bd
10715,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Other measurement,#d53e4f
10716,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Other measurement,#fee08b
10717,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Other measurement,#3288bd
10718,Hispanic/Latin American,12557.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),initial,2016-03-15,GCST003673,Other measurement,#807dba
10719,European,5638.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Neurological disorder,#d53e4f
10720,African Am./Caribbean,1183.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Neurological disorder,#fee08b
10721,Asian,214.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),replication,2016-03-15,GCST003673,Neurological disorder,#3288bd
10722,Hispanic/Latin American,12557.0,26977737.0,Cade BE,Obstructive sleep apnea (average oxygen saturation during sleep),initial,2016-03-15,GCST003673,Neurological disorder,#807dba
10725,Asian,109.0,26980576.0,Kim K,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis,initial,2016-03-15,GCST003445,Response to drug,#3288bd
10726,Asian,109.0,26980576.0,Kim K,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis,initial,2016-03-15,GCST003445,Immune system disorder,#3288bd
10727,Asian,109.0,26980576.0,Kim K,Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis,initial,2016-03-15,GCST003445,Immune system disorder,#3288bd
10728,European,86475.0,26974007.0,Ellinghaus D,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",initial,2016-03-14,GCST005537,Immune system disorder,#d53e4f
10729,European,86475.0,26974007.0,Ellinghaus D,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",initial,2016-03-14,GCST005537,Immune system disorder,#d53e4f
10730,European,86475.0,26974007.0,Ellinghaus D,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",initial,2016-03-14,GCST005537,Immune system disorder,#d53e4f
10731,European,86475.0,26974007.0,Ellinghaus D,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",initial,2016-03-14,GCST005537,Digestive system disorder,#d53e4f
10732,European,86475.0,26974007.0,Ellinghaus D,"Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)",initial,2016-03-14,GCST005537,Digestive system disorder,#d53e4f
10733,European,23689.0,26969751.0,Parmar PG,Diastolic blood pressure,initial,2016-03-11,GCST003671,Other measurement,#d53e4f
10734,European,23689.0,26969751.0,Parmar PG,Systolic blood pressure,initial,2016-03-11,GCST003670,Other measurement,#d53e4f
10735,European,119688.0,26961502.0,Wood AR,Body mass index,initial,2016-03-10,GCST006802,Body measurement,#d53e4f
10736,European,117775.0,26961502.0,Wood AR,Type 2 diabetes,initial,2016-03-10,GCST006801,Metabolic disorder,#d53e4f
10737,European,11208.0,26959717.0,Nicoletti P,Drug-induced liver injury,initial,2016-03-09,GCST003426,Response to drug,#d53e4f
10738,European,11208.0,26959717.0,Nicoletti P,Drug-induced liver injury,initial,2016-03-09,GCST003426,Digestive system disorder,#d53e4f
10739,European,35672.0,26955885.0,Lane JM,Morning vs. evening chronotype,initial,2016-03-09,GCST003454,Biological process,#d53e4f
10740,European,437.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Biological process,#d53e4f
10741,African Am./Caribbean,364.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Biological process,#fee08b
10742,Other/Mixed,311.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Biological process,#99d594
10743,Hispanic/Latin American,453.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Biological process,#807dba
10744,Asian,674.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Biological process,#3288bd
10745,European,437.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Other measurement,#d53e4f
10746,African Am./Caribbean,364.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Other measurement,#fee08b
10747,Other/Mixed,311.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Other measurement,#99d594
10748,Hispanic/Latin American,453.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Other measurement,#807dba
10749,Asian,674.0,26959369.0,Haiman CA,S-phenylmercapturic acid levels in smokers,initial,2016-03-09,GCST003483,Other measurement,#3288bd
10750,European,10767.0,26956414.0,Berndt SI,Chronic lymphocytic leukemia,initial,2016-03-09,GCST003468,Cancer,#d53e4f
10752,European,100420.0,26955885.0,Lane JM,Chronotype,initial,2016-03-09,GCST003453,Biological process,#d53e4f
10753,European,3268.0,26965164.0,Hanchard NA,Congenital left-sided heart lesions,initial,2016-03-09,GCST003419,Cardiovascular disease,#d53e4f
10754,European,5526.0,26965164.0,Hanchard NA,Congenital left-sided heart lesions,replication,2016-03-09,GCST003419,Cardiovascular disease,#d53e4f
10755,European,975.0,26962152.0,Offenbacher S,Periodontal disease-related phenotype (Socransky),initial,2016-03-08,GCST003484,Other measurement,#d53e4f
10756,European,975.0,26962152.0,Offenbacher S,Periodontal disease related phenotype (PCT6),initial,2016-03-08,GCST008443,Other measurement,#d53e4f
10757,European,975.0,26962152.0,Offenbacher S,Periodontal disease related phenotype (PCT5),initial,2016-03-08,GCST008442,Other measurement,#d53e4f
10758,European,975.0,26962152.0,Offenbacher S,Periodontal disease related phenotype (PCT4),initial,2016-03-08,GCST008441,Other measurement,#d53e4f
10759,European,975.0,26962152.0,Offenbacher S,Periodontal disease related phenotype (PCT3),initial,2016-03-08,GCST008440,Other measurement,#d53e4f
10760,European,975.0,26962152.0,Offenbacher S,Periodontal disease related phenotype (PCT2),initial,2016-03-08,GCST008439,Other measurement,#d53e4f
10761,Asian,21096.0,26965516.0,Zeng C,Colorectal cancer,initial,2016-03-08,GCST003799,Cancer,#3288bd
10762,Asian,32599.0,26965516.0,Zeng C,Colorectal cancer,replication,2016-03-08,GCST003799,Cancer,#3288bd
10763,European,37561.0,26950853.0,Dehghan A,Incident myocardial infarction,replication,2016-03-07,GCST003430,Cardiovascular disease,#d53e4f
10764,African Am./Caribbean,8201.0,26950853.0,Dehghan A,Incident myocardial infarction,replication,2016-03-07,GCST003430,Cardiovascular disease,#fee08b
10765,European,23188.0,26950853.0,Dehghan A,Incident myocardial infarction,initial,2016-03-07,GCST003430,Cardiovascular disease,#d53e4f
10766,European,24024.0,26950853.0,Dehghan A,Incident coronary heart disease,initial,2016-03-07,GCST003431,Cardiovascular disease,#d53e4f
10767,European,31146.0,26950853.0,Dehghan A,Incident coronary heart disease,replication,2016-03-07,GCST003431,Cardiovascular disease,#d53e4f
10768,Hispanic/Latin American,6357.0,26926045.0,Adhikari K,Scalp hair shape,initial,2016-03-01,GCST003474,Other measurement,#807dba
10769,Hispanic/Latin American,6357.0,26926045.0,Adhikari K,Balding,initial,2016-03-01,GCST003480,Other measurement,#807dba
10770,Hispanic/Latin American,6357.0,26926045.0,Adhikari K,Hair color,initial,2016-03-01,GCST003479,Other measurement,#807dba
10771,Hispanic/Latin American,6357.0,26926045.0,Adhikari K,Hair greying,initial,2016-03-01,GCST003478,Other measurement,#807dba
10772,Hispanic/Latin American,2922.0,26926045.0,Adhikari K,Monobrow thickness,initial,2016-03-01,GCST003477,Other measurement,#807dba
10773,Hispanic/Latin American,2922.0,26926045.0,Adhikari K,Eyebrow thickness,initial,2016-03-01,GCST003476,Other measurement,#807dba
10774,Hispanic/Latin American,2922.0,26926045.0,Adhikari K,Beard thickness,initial,2016-03-01,GCST003475,Other measurement,#807dba
10775,European,215.0,26921259.0,Baurley JW,Nicotine metabolite ratio,initial,2016-02-27,GCST003376,Other measurement,#d53e4f
10776,Asian,51.0,26921259.0,Baurley JW,Nicotine metabolite ratio,initial,2016-02-27,GCST003376,Other measurement,#3288bd
10777,African Am./Caribbean,49.0,26921259.0,Baurley JW,Nicotine metabolite ratio,initial,2016-02-27,GCST003376,Other measurement,#fee08b
10794,Asian,4477.0,26912274.0,Zeng Y,Longevity,initial,2016-02-25,GCST003425,Other measurement,#3288bd
10795,European,5654.0,26911590.0,Mullin BH,Bone mineral density (femoral neck),replication,2016-02-25,GCST003381,Other measurement,#d53e4f
10796,European,1042.0,26911590.0,Mullin BH,Bone mineral density (femoral neck),initial,2016-02-25,GCST003381,Other measurement,#d53e4f
10797,European,5654.0,26911590.0,Mullin BH,Bone mineral density (hip),replication,2016-02-25,GCST003379,Other measurement,#d53e4f
10798,European,1042.0,26911590.0,Mullin BH,Bone mineral density (hip),initial,2016-02-25,GCST003379,Other measurement,#d53e4f
10799,European,5654.0,26911590.0,Mullin BH,Bone mineral density (spine),replication,2016-02-25,GCST003380,Other measurement,#d53e4f
10800,European,1042.0,26911590.0,Mullin BH,Bone mineral density (spine),initial,2016-02-25,GCST003380,Other measurement,#d53e4f
10801,European,2800.0,26910538.0,Choi SH,Vascular endothelial growth factor levels,replication,2016-02-24,GCST003403,Cardiovascular measurement,#d53e4f
10802,European,13312.0,26910538.0,Choi SH,Vascular endothelial growth factor levels,initial,2016-02-24,GCST003403,Cardiovascular measurement,#d53e4f
10803,Asian,3725.0,26902266.0,Giri AK,Serum uric acid levels,replication,2016-02-23,GCST003359,Cardiovascular measurement,#3288bd
10804,Asian,1109.0,26902266.0,Giri AK,Serum uric acid levels,initial,2016-02-23,GCST003359,Cardiovascular measurement,#3288bd
10807,European,116470.0,26913989.0,Traylor M,Alzheimer's disease or small vessel stroke,initial,2016-02-23,GCST003423,Neurological disorder,#d53e4f
10808,European,116470.0,26913989.0,Traylor M,Alzheimer's disease or small vessel stroke,initial,2016-02-23,GCST003423,Cardiovascular disease,#d53e4f
10809,Asian,1308.0,26891255.0,Jung ES,Crohn's disease,replication,2016-02-18,GCST003360,Digestive system disorder,#3288bd
10810,Asian,2644.0,26891255.0,Jung ES,Crohn's disease,initial,2016-02-18,GCST003360,Digestive system disorder,#3288bd
10811,Asian,1067.0,26887379.0,Tang W,Hirschsprung disease,initial,2016-02-18,GCST008016,Digestive system disorder,#3288bd
10812,African Am./Caribbean,159.0,26888256.0,Hernandez W,Venous thromboembolism,replication,2016-02-17,GCST003377,Cardiovascular disease,#fee08b
10813,African Am./Caribbean,578.0,26888256.0,Hernandez W,Venous thromboembolism,initial,2016-02-17,GCST003377,Cardiovascular disease,#fee08b
10814,Other/Mixed,1413.0,26879886.0,Wakil SM,Low high density lipoprotein cholesterol levels,replication,2016-02-16,GCST003391,Lipid or lipoprotein measurement,#99d594
10815,Other/Mixed,4082.0,26879886.0,Wakil SM,Low high density lipoprotein cholesterol levels,initial,2016-02-16,GCST003391,Lipid or lipoprotein measurement,#99d594
10816,European,1082.0,26908436.0,Siiskonen SJ,Squamous cell carcinoma,replication,2016-02-12,GCST003422,Cancer,#d53e4f
10817,European,13550.0,26908436.0,Siiskonen SJ,Squamous cell carcinoma,initial,2016-02-12,GCST003422,Cancer,#d53e4f
10818,Asian,2955.0,26876947.0,Saito T,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-02-11,GCST003450,Other trait,#3288bd
10819,Asian,2955.0,26876947.0,Saito T,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-02-11,GCST003450,Neurological disorder,#3288bd
10820,Asian,2955.0,26876947.0,Saito T,Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,initial,2016-02-11,GCST003450,Response to drug,#3288bd
10821,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Other trait,#d53e4f
10822,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Cardiovascular disease,#d53e4f
10823,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Cardiovascular disease,#d53e4f
10824,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Other trait,#d53e4f
10825,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Other trait,#d53e4f
10826,European,258962.0,26908601.0,Hinds DA,Thrombosis,initial,2016-02-09,GCST003390,Cardiovascular disease,#d53e4f
10828,European,86.0,26856250.0,Sacchetti E,Early response to risperidone in schizophrenia,initial,2016-02-09,GCST003432,Response to drug,#d53e4f
10829,Asian,2112.0,26853712.0,Zhang YB,Craniofacial microsomia,replication,2016-02-08,GCST004412,Other disease,#3288bd
10830,Asian,2951.0,26853712.0,Zhang YB,Craniofacial microsomia,initial,2016-02-08,GCST004412,Other disease,#3288bd
10831,European,441.0,26861389.0,D'Adamo CR,Serum lycopene concentrations,initial,2016-02-06,GCST003433,Other measurement,#d53e4f
10832,European,516.0,27333618.0,Sekula P,Membranous nephropathy,replication,2016-02-04,GCST003402,Other disease,#d53e4f
10833,European,668.0,27333618.0,Sekula P,Membranous nephropathy,initial,2016-02-04,GCST003402,Other disease,#d53e4f
10834,European,3524.0,26830138.0,Herold C,Alzheimer disease and age of onset,initial,2016-02-02,GCST003427,Neurological disorder,#d53e4f
10835,European,3524.0,26830138.0,Herold C,Alzheimer disease and age of onset,initial,2016-02-02,GCST003427,Other measurement,#d53e4f
10836,European,122125.0,26835600.0,Hu Y,Chronotype,initial,2016-02-02,GCST003428,Biological process,#d53e4f
10837,European,89283.0,26835600.0,Hu Y,Morning vs. evening chronotype,initial,2016-02-02,GCST003429,Biological process,#d53e4f
10838,European,33987.0,26833098.0,Kilpelainen TO,circulating leptin levels adjusted for BMI,initial,2016-02-01,GCST003368,Other measurement,#d53e4f
10839,European,18226.0,26833098.0,Kilpelainen TO,circulating leptin levels adjusted for BMI,replication,2016-02-01,GCST003368,Other measurement,#d53e4f
10840,Other/Mixed,4431.0,26708285.0,Wakil SM,Myocardial infarction,initial,2016-02-01,GCST003471,Cardiovascular disease,#99d594
10841,Other/Mixed,1237.0,26708285.0,Wakil SM,Myocardial infarction,replication,2016-02-01,GCST003471,Cardiovascular disease,#99d594
10842,Other/Mixed,5668.0,26708285.0,Wakil SM,Coronary artery disease,initial,2016-02-01,GCST003470,Cardiovascular disease,#99d594
10843,Other/Mixed,1273.0,26708285.0,Wakil SM,Coronary artery disease,replication,2016-02-01,GCST003470,Cardiovascular disease,#99d594
10844,European,23469.0,26833246.0,Lu Y,Body fat percentage,replication,2016-02-01,GCST003435,Body measurement,#d53e4f
10845,European,65831.0,26833246.0,Lu Y,Body fat percentage,initial,2016-02-01,GCST003435,Body measurement,#d53e4f
10846,Asian,9289.0,26833246.0,Lu Y,Body fat percentage,initial,2016-02-01,GCST003435,Body measurement,#3288bd
10847,African Am./Caribbean,1089.0,26833246.0,Lu Y,Body fat percentage,replication,2016-02-01,GCST003435,Body measurement,#fee08b
10848,African Am./Caribbean,416.0,26833246.0,Lu Y,Body fat percentage,initial,2016-02-01,GCST003435,Body measurement,#fee08b
10849,Asian,2333.0,26833246.0,Lu Y,Body fat percentage,initial,2016-02-01,GCST003435,Body measurement,#3288bd
10850,European,4548.0,26833182.0,Ware JJ,Cotinine levels in current smokers,initial,2016-02-01,GCST003466,Other measurement,#d53e4f
10851,European,755.0,26833182.0,Ware JJ,Cotinine levels in current smokers,replication,2016-02-01,GCST003466,Other measurement,#d53e4f
10852,European,33987.0,26833098.0,Kilpelainen TO,circulating leptin levels,initial,2016-02-01,GCST003367,Other measurement,#d53e4f
10853,European,18226.0,26833098.0,Kilpelainen TO,circulating leptin levels,replication,2016-02-01,GCST003367,Other measurement,#d53e4f
10854,European,965.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,replication,2016-01-31,GCST003328,Other measurement,#d53e4f
10855,European,279.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2016-01-31,GCST003328,Other measurement,#d53e4f
10856,European,965.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,replication,2016-01-31,GCST003328,Response to drug,#d53e4f
10857,European,279.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2016-01-31,GCST003328,Response to drug,#d53e4f
10858,European,965.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,replication,2016-01-31,GCST003328,Cancer,#d53e4f
10859,European,279.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2016-01-31,GCST003328,Cancer,#d53e4f
10860,European,965.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,replication,2016-01-31,GCST003328,Response to drug,#d53e4f
10861,European,279.0,26840454.0,French JD,Progression free survival in serous epithelial ovarian cancer treated with carboplatin and paclitaxel,initial,2016-01-31,GCST003328,Response to drug,#d53e4f
10866,African,618.0,26824906.0,Rankinen T,Endurance athleticism,replication,2016-01-29,GCST003459,Other measurement,#fc8d59
10867,Asian,825.0,26824906.0,Rankinen T,Endurance athleticism,replication,2016-01-29,GCST003459,Other measurement,#3288bd
10869,European,1815.0,26824906.0,Rankinen T,Endurance athleticism,replication,2016-01-29,GCST003459,Other measurement,#d53e4f
10870,Asian,176.0,26824906.0,Rankinen T,Endurance athleticism,initial,2016-01-29,GCST003459,Other measurement,#3288bd
10871,European,61457.0,26829030.0,Asgari MM,Squamous cell carcinoma,initial,2016-01-29,GCST003327,Cancer,#d53e4f
10872,European,6410.0,26829030.0,Asgari MM,Squamous cell carcinoma,replication,2016-01-29,GCST003327,Cancer,#d53e4f
10874,European,1815.0,26824906.0,Rankinen T,World class endurance athleticism,replication,2016-01-29,GCST003458,Other measurement,#d53e4f
10875,African,415.0,26824906.0,Rankinen T,World class endurance athleticism,replication,2016-01-29,GCST003458,Other measurement,#fc8d59
10876,Asian,688.0,26824906.0,Rankinen T,World class endurance athleticism,replication,2016-01-29,GCST003458,Other measurement,#3288bd
10877,Asian,176.0,26824906.0,Rankinen T,World class endurance athleticism,initial,2016-01-29,GCST003458,Other measurement,#3288bd
10878,Hispanic/Latin American,8214.0,26818947.0,Imamura M,Type 2 diabetes,replication,2016-01-28,GCST003400,Metabolic disorder,#807dba
10879,Asian,24965.0,26818947.0,Imamura M,Type 2 diabetes,replication,2016-01-28,GCST003400,Metabolic disorder,#3288bd
10880,European,160850.0,26818947.0,Imamura M,Type 2 diabetes,replication,2016-01-28,GCST003400,Metabolic disorder,#d53e4f
10881,Asian,43412.0,26818947.0,Imamura M,Type 2 diabetes,replication,2016-01-28,GCST003400,Metabolic disorder,#3288bd
10882,Asian,41646.0,26818947.0,Imamura M,Type 2 diabetes,initial,2016-01-28,GCST003400,Metabolic disorder,#3288bd
10883,European,79.0,26821981.0,Koga AT,antipsychotic drug dosage in schizophrenia or schizoaffective disorder,initial,2016-01-28,GCST003341,Neurological disorder,#d53e4f
10884,European,79.0,26821981.0,Koga AT,antipsychotic drug dosage in schizophrenia or schizoaffective disorder,initial,2016-01-28,GCST003341,Other measurement,#d53e4f
10885,European,79.0,26821981.0,Koga AT,antipsychotic drug dosage in schizophrenia or schizoaffective disorder,initial,2016-01-28,GCST003341,Neurological disorder,#d53e4f
10887,Hispanic/Latin American,1956.0,26819262.0,Zhou Y,Epstein Barr virus nuclear antigen 1 IgG levels,initial,2016-01-27,GCST003339,Other measurement,#807dba
10888,Hispanic/Latin American,1956.0,26819262.0,Zhou Y,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis,initial,2016-01-27,GCST003340,Immune system disorder,#807dba
10889,European,17698.0,26819262.0,Zhou Y,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis,initial,2016-01-27,GCST003340,Immune system disorder,#d53e4f
10891,Hispanic/Latin American,1956.0,26819262.0,Zhou Y,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis,initial,2016-01-27,GCST003340,Other measurement,#807dba
10892,European,17698.0,26819262.0,Zhou Y,Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis,initial,2016-01-27,GCST003340,Other measurement,#d53e4f
10894,European,662.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,replication,2016-01-27,GCST003330,Immune system disorder,#d53e4f
10895,European,1178.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,initial,2016-01-27,GCST003330,Immune system disorder,#d53e4f
10896,European,662.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,replication,2016-01-27,GCST003330,Other measurement,#d53e4f
10897,European,1178.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,initial,2016-01-27,GCST003330,Other measurement,#d53e4f
10898,European,662.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,replication,2016-01-27,GCST003330,Other measurement,#d53e4f
10899,European,1178.0,26815016.0,Julia A,Rheumatoid factor seropositivity in rheumatoid arthritis,initial,2016-01-27,GCST003330,Other measurement,#d53e4f
10900,European,1706.0,26818729.0,Weinsheimer S,Brain arteriovenous malformations (sporadic),initial,2016-01-27,GCST003318,Cancer,#d53e4f
10901,European,1352.0,26818729.0,Weinsheimer S,Brain arteriovenous malformations (sporadic),replication,2016-01-27,GCST003318,Cancer,#d53e4f
10902,European,331.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),initial,2016-01-25,GCST003300,Cancer,#d53e4f
10903,European,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cancer,#d53e4f
10904,Hispanic/Latin American,12.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cancer,#807dba
10905,Other/Mixed,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cancer,#99d594
10906,European,331.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),initial,2016-01-25,GCST003300,Response to drug,#d53e4f
10907,European,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Response to drug,#d53e4f
10908,Hispanic/Latin American,12.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Response to drug,#807dba
10909,Other/Mixed,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Response to drug,#99d594
10910,European,331.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),initial,2016-01-25,GCST003300,Cardiovascular disease,#d53e4f
10911,European,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cardiovascular disease,#d53e4f
10912,Hispanic/Latin American,12.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cardiovascular disease,#807dba
10913,Other/Mixed,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors (anthracycline treatment interaction),replication,2016-01-25,GCST003300,Cardiovascular disease,#99d594
10914,European,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cancer,#d53e4f
10915,Hispanic/Latin American,12.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cancer,#807dba
10916,Other/Mixed,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cancer,#99d594
10917,European,331.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,initial,2016-01-25,GCST003299,Cancer,#d53e4f
10918,European,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cardiovascular disease,#d53e4f
10919,Hispanic/Latin American,12.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cardiovascular disease,#807dba
10920,Other/Mixed,21.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,replication,2016-01-25,GCST003299,Cardiovascular disease,#99d594
10921,European,331.0,26811534.0,Wang X,Cardiomyopathy in childhood cancer survivors,initial,2016-01-25,GCST003299,Cardiovascular disease,#d53e4f
10922,European,522.0,27179730.0,Allen NB,Ideal cardiovascular health (clinical and behavioural),replication,2016-01-23,GCST003278,Other trait,#d53e4f
10923,European,11708.0,27179730.0,Allen NB,Ideal cardiovascular health (clinical and behavioural),initial,2016-01-23,GCST003278,Other trait,#d53e4f
10924,European,522.0,27179730.0,Allen NB,Ideal cardiovascular health (clinical),replication,2016-01-23,GCST003279,Other trait,#d53e4f
10925,European,11708.0,27179730.0,Allen NB,Ideal cardiovascular health (clinical),initial,2016-01-23,GCST003279,Other trait,#d53e4f
10926,Other/Mixed,2563.0,26806518.0,Hou L,Response to lithium treatment in bipolar disorder,initial,2016-01-22,GCST003378,Neurological disorder,#99d594
10927,Other/Mixed,2563.0,26806518.0,Hou L,Response to lithium treatment in bipolar disorder,initial,2016-01-22,GCST003378,Response to drug,#99d594
10928,European,3691.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,initial,2016-01-21,GCST003298,Cardiovascular measurement,#d53e4f
10929,European,5404.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,replication,2016-01-21,GCST003298,Cardiovascular measurement,#d53e4f
10930,Asian,54.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,replication,2016-01-21,GCST003298,Cardiovascular measurement,#3288bd
10931,Asian,29.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,initial,2016-01-21,GCST003298,Cardiovascular measurement,#3288bd
10932,African,33.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,replication,2016-01-21,GCST003298,Cardiovascular measurement,#fc8d59
10933,African,20.0,26908625.0,Johansson A,NT-proBNP levels in acute coronary syndrome,initial,2016-01-21,GCST003298,Cardiovascular measurement,#fc8d59
10934,European,133413.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003371,Other measurement,#d53e4f
10935,African,16840.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003371,Other measurement,#fc8d59
10936,European,133413.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003371,Other measurement,#d53e4f
10937,African,16840.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003371,Other measurement,#fc8d59
10938,Asian,42296.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#3288bd
10939,African,16471.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#fc8d59
10940,European,133413.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003372,Other measurement,#d53e4f
10941,European,42166.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#d53e4f
10942,Asian,42296.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#3288bd
10943,African,16471.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#fc8d59
10944,European,133413.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),initial,2016-01-21,GCST003372,Other measurement,#d53e4f
10945,European,42166.0,26831199.0,Pattaro C,Glomerular filtration rate (creatinine),replication,2016-01-21,GCST003372,Other measurement,#d53e4f
10946,European,117165.0,26831199.0,Pattaro C,Chronic kidney disease,initial,2016-01-21,GCST003374,Other disease,#d53e4f
10947,European,33972.0,26831199.0,Pattaro C,Chronic kidney disease,replication,2016-01-21,GCST003374,Other disease,#d53e4f
10948,European,32834.0,26831199.0,Pattaro C,Glomerular filtration rate (cystatin C),initial,2016-01-21,GCST003375,Other measurement,#d53e4f
10949,European,14930.0,26831199.0,Pattaro C,Glomerular filtration rate (cystatin C),replication,2016-01-21,GCST003375,Other measurement,#d53e4f
10950,European,32834.0,26831199.0,Pattaro C,Glomerular filtration rate (cystatin C),initial,2016-01-21,GCST003375,Other measurement,#d53e4f
10951,European,14930.0,26831199.0,Pattaro C,Glomerular filtration rate (cystatin C),replication,2016-01-21,GCST003375,Other measurement,#d53e4f
10952,European,11522.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),initial,2016-01-21,GCST003373,Other measurement,#d53e4f
10953,European,4955.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),replication,2016-01-21,GCST003373,Other measurement,#d53e4f
10954,European,11522.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),initial,2016-01-21,GCST003373,Metabolic disorder,#d53e4f
10955,European,4955.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),replication,2016-01-21,GCST003373,Metabolic disorder,#d53e4f
10956,European,11522.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),initial,2016-01-21,GCST003373,Other measurement,#d53e4f
10957,European,4955.0,26831199.0,Pattaro C,Glomerular filtration rate in diabetics (creatinine),replication,2016-01-21,GCST003373,Other measurement,#d53e4f
10958,Hispanic/Latin American,12491.0,26805783.0,Schick UM,Platelet count,initial,2016-01-21,GCST003383,Hematological measurement,#807dba
10959,Hispanic/Latin American,7170.0,26805783.0,Schick UM,Platelet count,replication,2016-01-21,GCST003383,Hematological measurement,#807dba
10960,European,118448.0,26831199.0,Pattaro C,Glomerular filtration rate in non diabetics (creatinine),initial,2016-01-21,GCST003401,Other measurement,#d53e4f
10961,European,36433.0,26831199.0,Pattaro C,Glomerular filtration rate in non diabetics (creatinine),replication,2016-01-21,GCST003401,Other measurement,#d53e4f
10962,European,118448.0,26831199.0,Pattaro C,Glomerular filtration rate in non diabetics (creatinine),initial,2016-01-21,GCST003401,Other measurement,#d53e4f
10963,European,36433.0,26831199.0,Pattaro C,Glomerular filtration rate in non diabetics (creatinine),replication,2016-01-21,GCST003401,Other measurement,#d53e4f
10964,Asian,44609.0,26785701.0,Wen W,Waist circumference,initial,2016-01-20,GCST003335,Body measurement,#3288bd
10965,Asian,25553.0,26785701.0,Wen W,Waist circumference,replication,2016-01-20,GCST003335,Body measurement,#3288bd
10967,Asian,25553.0,26785701.0,Wen W,Waist-hip ratio,replication,2016-01-20,GCST003337,Body measurement,#3288bd
10969,Asian,39869.0,26785701.0,Wen W,Waist-hip ratio,initial,2016-01-20,GCST003337,Body measurement,#3288bd
10970,Asian,24146.0,26785701.0,Wen W,Waist circumference adjusted for body mass index,replication,2016-01-20,GCST003336,Body measurement,#3288bd
10972,Asian,44609.0,26785701.0,Wen W,Waist circumference adjusted for body mass index,initial,2016-01-20,GCST003336,Body measurement,#3288bd
10973,Asian,20137.0,26785701.0,Wen W,Waist-to-hip ratio adjusted for body mass index,replication,2016-01-20,GCST003338,Body measurement,#3288bd
10974,Asian,39869.0,26785701.0,Wen W,Waist-to-hip ratio adjusted for body mass index,initial,2016-01-20,GCST003338,Body measurement,#3288bd
10976,Hispanic/Latin American,7876.0,26780889.0,Below JE,"Cholesterol, total",replication,2016-01-19,GCST003302,Lipid or lipoprotein measurement,#807dba
10977,Hispanic/Latin American,4383.0,26780889.0,Below JE,"Cholesterol, total",initial,2016-01-19,GCST003302,Lipid or lipoprotein measurement,#807dba
10978,Hispanic/Latin American,4383.0,26780889.0,Below JE,HDL cholesterol,initial,2016-01-19,GCST003304,Lipid or lipoprotein measurement,#807dba
10979,Hispanic/Latin American,7876.0,26780889.0,Below JE,HDL cholesterol,replication,2016-01-19,GCST003304,Lipid or lipoprotein measurement,#807dba
10980,Hispanic/Latin American,7876.0,26780889.0,Below JE,Triglycerides,replication,2016-01-19,GCST003301,Lipid or lipoprotein measurement,#807dba
10981,Hispanic/Latin American,4383.0,26780889.0,Below JE,Triglycerides,initial,2016-01-19,GCST003301,Lipid or lipoprotein measurement,#807dba
10982,Hispanic/Latin American,4383.0,26780889.0,Below JE,LDL cholesterol,initial,2016-01-19,GCST003303,Lipid or lipoprotein measurement,#807dba
10983,Hispanic/Latin American,7876.0,26780889.0,Below JE,LDL cholesterol,replication,2016-01-19,GCST003303,Lipid or lipoprotein measurement,#807dba
10984,Asian,444.0,26776603.0,Honne K,Response to anti-TNF therapy in rheumatoid arthritis,initial,2016-01-18,GCST003329,Immune system disorder,#3288bd
10985,Asian,444.0,26776603.0,Honne K,Response to anti-TNF therapy in rheumatoid arthritis,initial,2016-01-18,GCST003329,Response to drug,#3288bd
10986,European,3384.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (menopausal hormone therapy interaction),initial,2016-01-14,GCST003385,Cancer,#d53e4f
10987,European,3384.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (menopausal hormone therapy interaction),initial,2016-01-14,GCST003385,Other trait,#d53e4f
10988,Asian,2994.0,26763881.0,Kurano M,Phospholipid levels,initial,2016-01-14,GCST003362,Lipid or lipoprotein measurement,#3288bd
10989,Asian,6805.0,26763881.0,Kurano M,Phospholipid levels,replication,2016-01-14,GCST003362,Lipid or lipoprotein measurement,#3288bd
10990,Asian,2994.0,26763881.0,Kurano M,LDL cholesterol levels,initial,2016-01-14,GCST003361,Lipid or lipoprotein measurement,#3288bd
10991,Asian,6805.0,26763881.0,Kurano M,LDL cholesterol levels,replication,2016-01-14,GCST003361,Lipid or lipoprotein measurement,#3288bd
10992,Asian,2994.0,26763881.0,Kurano M,HDL cholesterol levels,initial,2016-01-14,GCST003363,Lipid or lipoprotein measurement,#3288bd
10993,Asian,6805.0,26763881.0,Kurano M,HDL cholesterol levels,replication,2016-01-14,GCST003363,Lipid or lipoprotein measurement,#3288bd
10994,European,1606.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (oestrogen hormone therapy interaction),initial,2016-01-14,GCST003387,Cancer,#d53e4f
10995,European,1606.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (oestrogen hormone therapy interaction),initial,2016-01-14,GCST003387,Other trait,#d53e4f
10996,European,1283.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (oestrogen-progestogen hormone therapy interaction),initial,2016-01-14,GCST003386,Cancer,#d53e4f
10997,European,1283.0,26766742.0,Garcia-Albeniz X,Colorectal cancer (oestrogen-progestogen hormone therapy interaction),initial,2016-01-14,GCST003386,Other trait,#d53e4f
10998,Other/Mixed,558.0,26767831.0,Grant AV,Tuberculosis,initial,2016-01-14,GCST003451,Other disease,#99d594
10999,Other/Mixed,967.0,26767831.0,Grant AV,Tuberculosis,replication,2016-01-14,GCST003451,Other disease,#99d594
11000,Asian,2994.0,26763881.0,Kurano M,Triglyceride levels,initial,2016-01-14,GCST003364,Lipid or lipoprotein measurement,#3288bd
11001,Asian,6805.0,26763881.0,Kurano M,Triglyceride levels,replication,2016-01-14,GCST003364,Lipid or lipoprotein measurement,#3288bd
11002,Asian,8842.0,26763874.0,Ryu D,Sex ratio,initial,2016-01-14,GCST003331,Other measurement,#3288bd
11003,Asian,935.0,26763874.0,Ryu D,Sex ratio,replication,2016-01-14,GCST003331,Other measurement,#3288bd
11004,European,17310.0,26754954.0,Otowa T,Anxiety disorder,initial,2016-01-12,GCST003370,Neurological disorder,#d53e4f
11005,European,18186.0,26754954.0,Otowa T,Anxiety disorder (factor score),initial,2016-01-12,GCST003369,Other measurement,#d53e4f
11006,Asian,391.0,26599303.0,Cheung CL,Antithyroid drug-induced agranulocytosis,replication,2016-01-12,GCST003580,Other trait,#3288bd
11007,Asian,795.0,26599303.0,Cheung CL,Antithyroid drug-induced agranulocytosis,initial,2016-01-12,GCST003580,Other trait,#3288bd
11008,Asian,391.0,26599303.0,Cheung CL,Antithyroid drug-induced agranulocytosis,replication,2016-01-12,GCST003580,Response to drug,#3288bd
11009,Asian,795.0,26599303.0,Cheung CL,Antithyroid drug-induced agranulocytosis,initial,2016-01-12,GCST003580,Response to drug,#3288bd
11010,African Am./Caribbean,1427.0,26752167.0,Taylor JY,Systolic blood pressure (cigarette smoking interaction),replication,2016-01-11,GCST003365,Other measurement,#fee08b
11011,African Am./Caribbean,1083.0,26752167.0,Taylor JY,Systolic blood pressure (cigarette smoking interaction),initial,2016-01-11,GCST003365,Other measurement,#fee08b
11012,African Am./Caribbean,1427.0,26752167.0,Taylor JY,Systolic blood pressure (cigarette smoking interaction),replication,2016-01-11,GCST003365,Other measurement,#fee08b
11013,African Am./Caribbean,1083.0,26752167.0,Taylor JY,Systolic blood pressure (cigarette smoking interaction),initial,2016-01-11,GCST003365,Other measurement,#fee08b
11014,African Am./Caribbean,1427.0,26752167.0,Taylor JY,Diastolic blood pressure (cigarette smoking interaction),replication,2016-01-11,GCST003366,Other measurement,#fee08b
11015,African Am./Caribbean,1083.0,26752167.0,Taylor JY,Diastolic blood pressure (cigarette smoking interaction),initial,2016-01-11,GCST003366,Other measurement,#fee08b
11016,African Am./Caribbean,1427.0,26752167.0,Taylor JY,Diastolic blood pressure (cigarette smoking interaction),replication,2016-01-11,GCST003366,Other measurement,#fee08b
11017,African Am./Caribbean,1083.0,26752167.0,Taylor JY,Diastolic blood pressure (cigarette smoking interaction),initial,2016-01-11,GCST003366,Other measurement,#fee08b
11018,European,33365.0,26752265.0,Bailey JN,Glaucoma (high intraocular pressure),initial,2016-01-11,GCST003344,Neurological disorder,#d53e4f
11019,European,363.0,26752265.0,Bailey JN,Glaucoma (low intraocular pressure),replication,2016-01-11,GCST003343,Neurological disorder,#d53e4f
11020,European,1870.0,26752265.0,Bailey JN,Glaucoma (low intraocular pressure),initial,2016-01-11,GCST003343,Neurological disorder,#d53e4f
11021,European,37333.0,26752265.0,Bailey JN,Glaucoma (primary open-angle),initial,2016-01-11,GCST003342,Neurological disorder,#d53e4f
11022,European,8836.0,26752265.0,Bailey JN,Glaucoma (primary open-angle),replication,2016-01-11,GCST003342,Neurological disorder,#d53e4f
11023,Asian,3580.0,26752265.0,Bailey JN,Glaucoma (primary open-angle),replication,2016-01-11,GCST003342,Neurological disorder,#3288bd
11024,Asian,465.0,26746183.0,Watanabe H,Rapid functional decline in sporadic amyotrophic lateral sclerosis,initial,2016-01-08,GCST003332,Other measurement,#3288bd
11025,Asian,465.0,26746183.0,Watanabe H,Rapid functional decline in sporadic amyotrophic lateral sclerosis,initial,2016-01-08,GCST003332,Neurological disorder,#3288bd
11026,Asian,465.0,26746183.0,Watanabe H,Moderate functional decline in sporadic amyotrophic lateral sclerosis,initial,2016-01-08,GCST003333,Other measurement,#3288bd
11027,Asian,465.0,26746183.0,Watanabe H,Moderate functional decline in sporadic amyotrophic lateral sclerosis,initial,2016-01-08,GCST003333,Neurological disorder,#3288bd
11028,African,528.0,26741287.0,Milet J,IgG1 response to Plasmodium falciparum antigen (GLURP),initial,2016-01-07,GCST003460,Other measurement,#fc8d59
11029,African,528.0,26741287.0,Milet J,IgG3 response to Plasmodium falciparum antigen (MSP2 FC27),initial,2016-01-07,GCST003464,Other measurement,#fc8d59
11030,African,528.0,26741287.0,Milet J,IgG3 response to Plasmodium falciparum antigen (MSP2 3D7),initial,2016-01-07,GCST003463,Other measurement,#fc8d59
11031,African,528.0,26741287.0,Milet J,IgG1 response to Plasmodium falciparum antigen (MSP1),initial,2016-01-07,GCST003462,Other measurement,#fc8d59
11032,African,528.0,26741287.0,Milet J,"IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7)",initial,2016-01-07,GCST003461,Other measurement,#fc8d59
11033,Other/Mixed,10092.0,26733130.0,Styrkarsdottir U,Bone mineral density (spine),replication,2016-01-06,GCST003388,Other measurement,#99d594
11034,European,20132.0,26733130.0,Styrkarsdottir U,Bone mineral density (spine),initial,2016-01-06,GCST003388,Other measurement,#d53e4f
11035,Other/Mixed,10037.0,26733130.0,Styrkarsdottir U,Bone mineral density (hip),replication,2016-01-06,GCST003389,Other measurement,#99d594
11036,European,20162.0,26733130.0,Styrkarsdottir U,Bone mineral density (hip),initial,2016-01-06,GCST003389,Other measurement,#d53e4f
11037,Asian,4746.0,26732560.0,Cheng YC,Ischemic stroke,initial,2016-01-05,GCST003324,Other trait,#3288bd
11038,African Am./Caribbean,426.0,26732560.0,Cheng YC,Ischemic stroke,initial,2016-01-05,GCST003324,Other trait,#fee08b
11039,European,17716.0,26732560.0,Cheng YC,Ischemic stroke,initial,2016-01-05,GCST003324,Other trait,#d53e4f
11040,European,8748.0,26732560.0,Cheng YC,Ischemic stroke,replication,2016-01-05,GCST003324,Other trait,#d53e4f
11041,European,17831.0,26732560.0,Cheng YC,Small vessel stroke,initial,2016-01-05,GCST003321,Cardiovascular disease,#d53e4f
11042,African Am./Caribbean,429.0,26732560.0,Cheng YC,Small vessel stroke,initial,2016-01-05,GCST003321,Cardiovascular disease,#fee08b
11043,Asian,4685.0,26732560.0,Cheng YC,Small vessel stroke,initial,2016-01-05,GCST003321,Cardiovascular disease,#3288bd
11044,European,17716.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Other trait,#d53e4f
11045,African Am./Caribbean,426.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Other trait,#fee08b
11046,Asian,4746.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Other trait,#3288bd
11047,European,17716.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Cardiovascular disease,#d53e4f
11048,African Am./Caribbean,426.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Cardiovascular disease,#fee08b
11049,Asian,4746.0,26732560.0,Cheng YC,Ischemic stroke (cardioembolic),initial,2016-01-05,GCST003323,Cardiovascular disease,#3288bd
11050,European,18186.0,26732560.0,Cheng YC,Ischemic stroke (undetermined subtype),initial,2016-01-05,GCST003320,Other trait,#d53e4f
11051,African Am./Caribbean,535.0,26732560.0,Cheng YC,Ischemic stroke (undetermined subtype),initial,2016-01-05,GCST003320,Other trait,#fee08b
11052,Asian,5207.0,26732560.0,Cheng YC,Ischemic stroke (undetermined subtype),initial,2016-01-05,GCST003320,Other trait,#3288bd
11053,European,17565.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Other trait,#d53e4f
11054,African Am./Caribbean,375.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Other trait,#fee08b
11055,Asian,4710.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Other trait,#3288bd
11056,European,17565.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Cardiovascular disease,#d53e4f
11057,African Am./Caribbean,375.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Cardiovascular disease,#fee08b
11058,Asian,4710.0,26732560.0,Cheng YC,Ischemic stroke (large artery atherosclerosis),initial,2016-01-05,GCST003322,Cardiovascular disease,#3288bd
11059,Asian,12924.0,26732429.0,Wang Z,Lung cancer,replication,2016-01-04,GCST003325,Cancer,#3288bd
11060,Asian,13154.0,26732429.0,Wang Z,Lung cancer,initial,2016-01-04,GCST003325,Cancer,#3288bd
11061,Asian,12924.0,26732429.0,Wang Z,Adenocarcinoma,replication,2016-01-04,GCST003326,Cancer,#3288bd
11062,Asian,13154.0,26732429.0,Wang Z,Adenocarcinoma,initial,2016-01-04,GCST003326,Cancer,#3288bd
11063,European,9534.0,26732621.0,Ruth KS,Length of menstrual cycle,initial,2016-01-04,GCST003334,Other measurement,#d53e4f
11064,Asian,1088.0,26845276.0,Ikeda M,Major depressive disorder (stressful life events interaction),initial,2016-01-01,GCST003319,Neurological disorder,#3288bd
11065,Asian,1088.0,26845276.0,Ikeda M,Major depressive disorder (stressful life events interaction),initial,2016-01-01,GCST003319,Other trait,#3288bd
11066,Asian,1088.0,26845276.0,Ikeda M,Major depressive disorder (stressful life events interaction),initial,2016-01-01,GCST003319,Other measurement,#3288bd
11067,Asian,1883.0,26398853.0,Ye BD,Ulcerative colitis,initial,2016-01-01,GCST008483,Immune system disorder,#3288bd
11068,Asian,3674.0,26398853.0,Ye BD,Ulcerative colitis,replication,2016-01-01,GCST008483,Immune system disorder,#3288bd
11069,Asian,5892.0,26545403.0,Bei JX,Nasopharyngeal carcinoma,initial,2016-01-01,GCST005113,Cancer,#3288bd
11070,Asian,10095.0,26545403.0,Bei JX,Nasopharyngeal carcinoma,replication,2016-01-01,GCST005113,Cancer,#3288bd
11071,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Liver enzyme measurement,#d53e4f
11072,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Liver enzyme measurement,#d53e4f
11073,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Other measurement,#d53e4f
11074,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Other measurement,#d53e4f
11075,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11076,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11077,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Other measurement,#d53e4f
11078,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Other measurement,#d53e4f
11079,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11080,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11081,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Other measurement,#d53e4f
11082,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Other measurement,#d53e4f
11083,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11084,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Hematological measurement,#d53e4f
11085,European,17348.0,27897004.0,Verma SS,Clinical laboratory measurements,replication,2016-01-01,GCST003540,Other measurement,#d53e4f
11086,European,17347.0,27897004.0,Verma SS,Clinical laboratory measurements,initial,2016-01-01,GCST003540,Other measurement,#d53e4f
11088,African,258.0,26718567.0,Williams SR,C-reactive protein levels in ischemic stroke,initial,2015-12-30,GCST003211,Other trait,#fc8d59
11089,European,1725.0,26718567.0,Williams SR,C-reactive protein levels in ischemic stroke,initial,2015-12-30,GCST003211,Other trait,#d53e4f
11091,African,258.0,26718567.0,Williams SR,C-reactive protein levels in ischemic stroke,initial,2015-12-30,GCST003211,Inflammatory measurement,#fc8d59
11092,European,1725.0,26718567.0,Williams SR,C-reactive protein levels in ischemic stroke,initial,2015-12-30,GCST003211,Inflammatory measurement,#d53e4f
11093,African,258.0,26718567.0,Williams SR,Prothrombin fragments F1+2 levels in ischemic stroke,initial,2015-12-30,GCST003235,Other trait,#fc8d59
11095,European,1725.0,26718567.0,Williams SR,Prothrombin fragments F1+2 levels in ischemic stroke,initial,2015-12-30,GCST003235,Other trait,#d53e4f
11096,African,258.0,26718567.0,Williams SR,Prothrombin fragments F1+2 levels in ischemic stroke,initial,2015-12-30,GCST003235,Other measurement,#fc8d59
11098,European,1725.0,26718567.0,Williams SR,Prothrombin fragments F1+2 levels in ischemic stroke,initial,2015-12-30,GCST003235,Other measurement,#d53e4f
11100,European,1725.0,26718567.0,Williams SR,Fibrinogen levels in ischemic stroke,initial,2015-12-30,GCST003212,Other trait,#d53e4f
11101,African,258.0,26718567.0,Williams SR,Fibrinogen levels in ischemic stroke,initial,2015-12-30,GCST003212,Other trait,#fc8d59
11103,European,1725.0,26718567.0,Williams SR,Fibrinogen levels in ischemic stroke,initial,2015-12-30,GCST003212,Hematological measurement,#d53e4f
11104,African,258.0,26718567.0,Williams SR,Fibrinogen levels in ischemic stroke,initial,2015-12-30,GCST003212,Hematological measurement,#fc8d59
11105,European,1725.0,26718567.0,Williams SR,Thrombin-antithrombin complex levels in ischemic stroke,initial,2015-12-30,GCST003233,Other trait,#d53e4f
11107,African,258.0,26718567.0,Williams SR,Thrombin-antithrombin complex levels in ischemic stroke,initial,2015-12-30,GCST003233,Other trait,#fc8d59
11108,European,1725.0,26718567.0,Williams SR,Thrombin-antithrombin complex levels in ischemic stroke,initial,2015-12-30,GCST003233,Other measurement,#d53e4f
11110,African,258.0,26718567.0,Williams SR,Thrombin-antithrombin complex levels in ischemic stroke,initial,2015-12-30,GCST003233,Other measurement,#fc8d59
11111,European,1725.0,26718567.0,Williams SR,Creatinine levels in ischemic stroke,initial,2015-12-30,GCST003213,Other trait,#d53e4f
11112,African,258.0,26718567.0,Williams SR,Creatinine levels in ischemic stroke,initial,2015-12-30,GCST003213,Other trait,#fc8d59
11114,European,1725.0,26718567.0,Williams SR,Creatinine levels in ischemic stroke,initial,2015-12-30,GCST003213,Other measurement,#d53e4f
11115,African,258.0,26718567.0,Williams SR,Creatinine levels in ischemic stroke,initial,2015-12-30,GCST003213,Other measurement,#fc8d59
11117,European,1725.0,26718567.0,Williams SR,Thrombomodulin levels in ischemic stroke,initial,2015-12-30,GCST003234,Other trait,#d53e4f
11118,African,258.0,26718567.0,Williams SR,Thrombomodulin levels in ischemic stroke,initial,2015-12-30,GCST003234,Other trait,#fc8d59
11120,European,1725.0,26718567.0,Williams SR,Thrombomodulin levels in ischemic stroke,initial,2015-12-30,GCST003234,Other measurement,#d53e4f
11121,African,258.0,26718567.0,Williams SR,Thrombomodulin levels in ischemic stroke,initial,2015-12-30,GCST003234,Other measurement,#fc8d59
11123,Asian,8201.0,26701879.0,Wang Z,Non-cardia gastric cancer,replication,2015-12-23,GCST003218,Cancer,#3288bd
11124,Asian,7001.0,26701879.0,Wang Z,Non-cardia gastric cancer,initial,2015-12-23,GCST003218,Cancer,#3288bd
11125,Asian,77.0,26865924.0,Lee M,Body mass index,initial,2015-12-21,GCST003248,Body measurement,#3288bd
11126,Asian,77.0,26865924.0,Lee M,Basal metabolic rate,initial,2015-12-21,GCST003249,Other measurement,#3288bd
11127,Asian,77.0,26782385.0,Zhou TQ,Atrophic age-related macular degeneration,initial,2015-12-21,GCST003199,Neurological disorder,#3288bd
11128,Asian,426.0,26782385.0,Zhou TQ,Atrophic age-related macular degeneration,replication,2015-12-21,GCST003199,Neurological disorder,#3288bd
11129,European,92444.0,26686553.0,Jorgenson E,Inguinal hernia,replication,2015-12-21,GCST003198,Other trait,#d53e4f
11130,European,72805.0,26686553.0,Jorgenson E,Inguinal hernia,initial,2015-12-21,GCST003198,Other trait,#d53e4f
11131,European,2267.0,26685716.0,Chang X,Magnesium levels,initial,2015-12-21,GCST003195,Other measurement,#d53e4f
11132,European,15623.0,26685716.0,Chang X,Magnesium levels,replication,2015-12-21,GCST003195,Other measurement,#d53e4f
11134,European,33976.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,initial,2015-12-21,GCST003219,Neurological disorder,#d53e4f
11135,Asian,1572.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#3288bd
11136,African,413.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#fc8d59
11138,European,33976.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,initial,2015-12-21,GCST003219,Neurological disorder,#d53e4f
11139,Asian,1572.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#3288bd
11140,African,413.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#fc8d59
11142,European,33976.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,initial,2015-12-21,GCST003219,Neurological disorder,#d53e4f
11143,Asian,1572.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#3288bd
11144,African,413.0,26691988.0,Fritsche LG,Advanced age-related macular degeneration,replication,2015-12-21,GCST003219,Neurological disorder,#fc8d59
11145,Other/Mixed,6807.0,26708676.0,Pulit SL,Ischemic stroke,replication,2015-12-18,GCST003258,Other trait,#99d594
11146,European,40990.0,26708676.0,Pulit SL,Ischemic stroke,initial,2015-12-18,GCST003258,Other trait,#d53e4f
11147,Other/Mixed,4963.0,26708676.0,Pulit SL,Ischemic stroke,initial,2015-12-18,GCST003258,Other trait,#99d594
11148,Hispanic/Latin American,2521.0,26708676.0,Pulit SL,Ischemic stroke,initial,2015-12-18,GCST003258,Other trait,#807dba
11149,Asian,7578.0,26708676.0,Pulit SL,Ischemic stroke,replication,2015-12-18,GCST003258,Other trait,#3288bd
11150,Hispanic/Latin American,1234.0,26708676.0,Pulit SL,Ischemic stroke,replication,2015-12-18,GCST003258,Other trait,#807dba
11151,European,368279.0,26708676.0,Pulit SL,Ischemic stroke,replication,2015-12-18,GCST003258,Other trait,#d53e4f
11152,Asian,548.0,26708676.0,Pulit SL,Ischemic stroke,replication,2015-12-18,GCST003258,Other trait,#3288bd
11153,Hispanic/Latin American,2791.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),initial,2015-12-18,GCST003261,Other trait,#807dba
11154,Other/Mixed,4440.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),initial,2015-12-18,GCST003261,Other trait,#99d594
11155,Hispanic/Latin American,835.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),replication,2015-12-18,GCST003261,Other trait,#807dba
11156,European,262805.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),replication,2015-12-18,GCST003261,Other trait,#d53e4f
11157,Other/Mixed,256.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),replication,2015-12-18,GCST003261,Other trait,#99d594
11158,European,34752.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),initial,2015-12-18,GCST003261,Other trait,#d53e4f
11159,Asian,346.0,26708676.0,Pulit SL,Ischemic stroke (undetermined subtype),replication,2015-12-18,GCST003261,Other trait,#3288bd
11160,European,219602.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Other trait,#d53e4f
11161,Asian,462.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Other trait,#3288bd
11162,Other/Mixed,286.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Other trait,#99d594
11163,European,28942.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Other trait,#d53e4f
11164,Asian,5507.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Other trait,#3288bd
11165,Hispanic/Latin American,771.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Other trait,#807dba
11166,Hispanic/Latin American,2981.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Other trait,#807dba
11167,Other/Mixed,3735.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Other trait,#99d594
11168,European,219602.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Cardiovascular disease,#d53e4f
11169,Asian,462.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Cardiovascular disease,#3288bd
11170,Other/Mixed,286.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Cardiovascular disease,#99d594
11171,European,28942.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Cardiovascular disease,#d53e4f
11172,Asian,5507.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Cardiovascular disease,#3288bd
11173,Hispanic/Latin American,771.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),replication,2015-12-18,GCST003260,Cardiovascular disease,#807dba
11174,Hispanic/Latin American,2981.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Cardiovascular disease,#807dba
11175,Other/Mixed,3735.0,26708676.0,Pulit SL,Ischemic stroke (small artery occlusion),initial,2015-12-18,GCST003260,Cardiovascular disease,#99d594
11176,Other/Mixed,3574.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Other trait,#99d594
11177,Asian,5548.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Other trait,#3288bd
11178,Hispanic/Latin American,726.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Other trait,#807dba
11179,European,178569.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Other trait,#d53e4f
11180,Asian,363.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Other trait,#3288bd
11181,Other/Mixed,272.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Other trait,#99d594
11182,European,29039.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Other trait,#d53e4f
11183,Hispanic/Latin American,2575.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Other trait,#807dba
11184,Other/Mixed,3574.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Cardiovascular disease,#99d594
11185,Asian,5548.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Cardiovascular disease,#3288bd
11186,Hispanic/Latin American,726.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Cardiovascular disease,#807dba
11187,European,178569.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Cardiovascular disease,#d53e4f
11188,Asian,363.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Cardiovascular disease,#3288bd
11189,Other/Mixed,272.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),replication,2015-12-18,GCST003259,Cardiovascular disease,#99d594
11190,European,29039.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Cardiovascular disease,#d53e4f
11191,Hispanic/Latin American,2575.0,26708676.0,Pulit SL,Ischemic stroke (large artery atherosclerosis),initial,2015-12-18,GCST003259,Cardiovascular disease,#807dba
11192,Hispanic/Latin American,2547.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Other trait,#807dba
11193,Other/Mixed,3562.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Other trait,#99d594
11194,Asian,5615.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Other trait,#3288bd
11195,Hispanic/Latin American,783.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Other trait,#807dba
11196,Asian,360.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Other trait,#3288bd
11197,Other/Mixed,3015.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Other trait,#99d594
11198,European,30090.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Other trait,#d53e4f
11199,European,277499.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Other trait,#d53e4f
11200,Hispanic/Latin American,2547.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Cardiovascular disease,#807dba
11201,Other/Mixed,3562.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Cardiovascular disease,#99d594
11202,Asian,5615.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Cardiovascular disease,#3288bd
11203,Hispanic/Latin American,783.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Cardiovascular disease,#807dba
11204,Asian,360.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Cardiovascular disease,#3288bd
11205,Other/Mixed,3015.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Cardiovascular disease,#99d594
11206,European,30090.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),initial,2015-12-18,GCST003257,Cardiovascular disease,#d53e4f
11207,European,277499.0,26708676.0,Pulit SL,Ischemic stroke (cardioembolic),replication,2015-12-18,GCST003257,Cardiovascular disease,#d53e4f
11208,European,3670.0,26674333.0,Traylor M,White matter hyperintensities in ischemic stroke,initial,2015-12-16,GCST003245,Other trait,#d53e4f
11209,European,3670.0,26674333.0,Traylor M,White matter hyperintensities in ischemic stroke,initial,2015-12-16,GCST003245,Other measurement,#d53e4f
11210,Asian,2252.0,26675016.0,Cha S,Thoracic-to-hip circumference ratio,replication,2015-12-16,GCST003197,Body measurement,#3288bd
11211,Asian,4988.0,26675016.0,Cha S,Thoracic-to-hip circumference ratio,initial,2015-12-16,GCST003197,Body measurement,#3288bd
11212,Asian,2151.0,26704534.0,Sapkota BR,Vitamin D levels,replication,2015-12-15,GCST003191,Other measurement,#3288bd
11213,Asian,1387.0,26704534.0,Sapkota BR,Vitamin D levels,initial,2015-12-15,GCST003191,Other measurement,#3288bd
11214,Asian,1895.0,26686025.0,Hwang JY,Calcaneal bone ultrasound measurement (speed of sound),initial,2015-12-12,GCST003196,Other measurement,#3288bd
11215,Asian,7263.0,26686025.0,Hwang JY,Calcaneal bone ultrasound measurement (speed of sound),replication,2015-12-12,GCST003196,Other measurement,#3288bd
11216,Asian,547.0,26656879.0,Yu H,Antipsychotic drug-induced weight gain in schizophrenia,replication,2015-12-09,GCST003579,Neurological disorder,#3288bd
11217,Asian,534.0,26656879.0,Yu H,Antipsychotic drug-induced weight gain in schizophrenia,initial,2015-12-09,GCST003579,Neurological disorder,#3288bd
11218,Asian,547.0,26656879.0,Yu H,Antipsychotic drug-induced weight gain in schizophrenia,replication,2015-12-09,GCST003579,Other trait,#3288bd
11219,Asian,534.0,26656879.0,Yu H,Antipsychotic drug-induced weight gain in schizophrenia,initial,2015-12-09,GCST003579,Other trait,#3288bd
11220,European,337.0,26644207.0,Clarelli F,Response to interferon beta in multiple sclerosis,initial,2015-12-08,GCST003193,Immune system disorder,#d53e4f
11221,European,337.0,26644207.0,Clarelli F,Response to interferon beta in multiple sclerosis,initial,2015-12-08,GCST003193,Response to drug,#d53e4f
11222,European,38199.0,26635082.0,Soler Artigas M,Lung function (FVC),initial,2015-12-04,GCST008482,Other measurement,#d53e4f
11223,European,54550.0,26635082.0,Soler Artigas M,Lung function (FVC),replication,2015-12-04,GCST008482,Other measurement,#d53e4f
11225,European,38199.0,26635082.0,Soler Artigas M,Lung function (FEV1),initial,2015-12-04,GCST008480,Other measurement,#d53e4f
11226,European,54550.0,26635082.0,Soler Artigas M,Lung function (FEV1),replication,2015-12-04,GCST008480,Other measurement,#d53e4f
11228,European,38199.0,26635082.0,Soler Artigas M,Lung function (FEV1/FVC),initial,2015-12-04,GCST008481,Other measurement,#d53e4f
11229,European,54550.0,26635082.0,Soler Artigas M,Lung function (FEV1/FVC),replication,2015-12-04,GCST008481,Other measurement,#d53e4f
11231,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Other measurement,#d53e4f
11232,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Other measurement,#fee08b
11233,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Response to drug,#d53e4f
11234,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Response to drug,#fee08b
11235,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Other disease,#d53e4f
11236,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1 in COPD,initial,2015-12-03,GCST003263,Other disease,#fee08b
11237,European,6659.0,26634245.0,Lutz SM,Pre bronchodilator FEV1/FVC ratio,initial,2015-12-03,GCST003267,Other measurement,#d53e4f
11238,European,6659.0,26634245.0,Lutz SM,Pre bronchodilator FEV1,initial,2015-12-03,GCST003266,Other measurement,#d53e4f
11239,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Response to drug,#d53e4f
11240,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Response to drug,#fee08b
11241,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Other disease,#d53e4f
11242,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Other disease,#fee08b
11243,European,5439.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Other measurement,#d53e4f
11244,African Am./Caribbean,821.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio in COPD,initial,2015-12-03,GCST003265,Other measurement,#fee08b
11245,European,10094.0,26634245.0,Lutz SM,Post bronchodilator FEV1,initial,2015-12-03,GCST003262,Other measurement,#d53e4f
11247,African Am./Caribbean,3260.0,26634245.0,Lutz SM,Post bronchodilator FEV1,initial,2015-12-03,GCST003262,Other measurement,#fee08b
11248,European,10094.0,26634245.0,Lutz SM,Post bronchodilator FEV1,initial,2015-12-03,GCST003262,Response to drug,#d53e4f
11250,African Am./Caribbean,3260.0,26634245.0,Lutz SM,Post bronchodilator FEV1,initial,2015-12-03,GCST003262,Response to drug,#fee08b
11251,African Am./Caribbean,3260.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio,initial,2015-12-03,GCST003264,Response to drug,#fee08b
11252,European,10094.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio,initial,2015-12-03,GCST003264,Response to drug,#d53e4f
11254,African Am./Caribbean,3260.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio,initial,2015-12-03,GCST003264,Other measurement,#fee08b
11255,European,10094.0,26634245.0,Lutz SM,Post bronchodilator FEV1/FVC ratio,initial,2015-12-03,GCST003264,Other measurement,#d53e4f
11257,European,1962.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio in diabetes,replication,2015-12-02,GCST003250,Metabolic disorder,#d53e4f
11258,European,5825.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio in diabetes,initial,2015-12-02,GCST003250,Metabolic disorder,#d53e4f
11259,European,1962.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio in diabetes,replication,2015-12-02,GCST003250,Other measurement,#d53e4f
11260,European,5825.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio in diabetes,initial,2015-12-02,GCST003250,Other measurement,#d53e4f
11261,European,54450.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio,initial,2015-12-02,GCST003255,Other measurement,#d53e4f
11262,European,54116.0,26631737.0,Teumer A,Microalbuminuria,initial,2015-12-02,GCST003253,Other trait,#d53e4f
11263,European,46051.0,26631737.0,Teumer A,Urinary albumin-to-creatinine ratio in non-diabetics,initial,2015-12-02,GCST003254,Other measurement,#d53e4f
11264,European,21333.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,initial,2015-12-01,GCST003209,Cancer,#d53e4f
11265,European,21333.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,initial,2015-12-01,GCST003209,Cancer,#d53e4f
11266,European,21333.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,initial,2015-12-01,GCST003208,Cancer,#d53e4f
11267,European,31179.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,replication,2015-12-01,GCST003208,Cancer,#d53e4f
11268,European,21333.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,initial,2015-12-01,GCST003208,Cancer,#d53e4f
11269,European,31179.0,26621817.0,Cheng TH,Colorectal or endometrial cancer,replication,2015-12-01,GCST003208,Cancer,#d53e4f
11270,European,6297.0,26626624.0,Stuart PE,Cutaneous psoriasis,initial,2015-11-28,GCST003269,Other measurement,#d53e4f
11271,European,17353.0,26626624.0,Stuart PE,Cutaneous psoriasis,replication,2015-11-28,GCST003269,Other measurement,#d53e4f
11272,European,6297.0,26626624.0,Stuart PE,Cutaneous psoriasis,initial,2015-11-28,GCST003269,Immune system disorder,#d53e4f
11273,European,17353.0,26626624.0,Stuart PE,Cutaneous psoriasis,replication,2015-11-28,GCST003269,Immune system disorder,#d53e4f
11274,European,6184.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,replication,2015-11-28,GCST003271,Other measurement,#d53e4f
11275,European,3309.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,initial,2015-11-28,GCST003271,Other measurement,#d53e4f
11276,European,6184.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,replication,2015-11-28,GCST003271,Immune system disorder,#d53e4f
11277,European,3309.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,initial,2015-11-28,GCST003271,Immune system disorder,#d53e4f
11278,European,6184.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,replication,2015-11-28,GCST003271,Immune system disorder,#d53e4f
11279,European,3309.0,26626624.0,Stuart PE,Psoriatic arthritis vs Cutaneous psoriasis,initial,2015-11-28,GCST003271,Immune system disorder,#d53e4f
11280,European,6880.0,26626624.0,Stuart PE,Psoriatic arthritis,initial,2015-11-28,GCST003270,Immune system disorder,#d53e4f
11281,European,17062.0,26626624.0,Stuart PE,Psoriatic arthritis,replication,2015-11-28,GCST003270,Immune system disorder,#d53e4f
11282,European,8941.0,26626624.0,Stuart PE,Psoriasis vulgaris,initial,2015-11-28,GCST003268,Immune system disorder,#d53e4f
11283,European,21801.0,26626624.0,Stuart PE,Psoriasis vulgaris,replication,2015-11-28,GCST003268,Immune system disorder,#d53e4f
11284,Other/Mixed,3710.0,26606652.0,Alarcon-Riquelme ME,Systemic lupus erythematosus,initial,2015-11-25,GCST003252,Immune system disorder,#99d594
11285,Asian,202.0,26600424.0,MacInnis MJ,Acute mountain sickness,replication,2015-11-24,GCST003188,Cardiovascular disease,#3288bd
11286,Asian,99.0,26600424.0,MacInnis MJ,Acute mountain sickness,initial,2015-11-24,GCST003188,Cardiovascular disease,#3288bd
11287,European,889.0,26620591.0,Barreto-Luis A,Asthma,initial,2015-11-24,GCST003176,Other disease,#d53e4f
11288,European,2206.0,26620591.0,Barreto-Luis A,Asthma,replication,2015-11-24,GCST003176,Other disease,#d53e4f
11289,European,11313.0,26604143.0,Felix JF,Childhood body mass index,replication,2015-11-24,GCST003177,Body measurement,#d53e4f
11290,European,34744.0,26604143.0,Felix JF,Childhood body mass index,initial,2015-11-24,GCST003177,Body measurement,#d53e4f
11291,Asian,560.0,26870257.0,Qu LS,Hepatocellular carcinoma in hepatitis B infection,replication,2015-11-23,GCST003189,Cancer,#3288bd
11292,Asian,100.0,26870257.0,Qu LS,Hepatocellular carcinoma in hepatitis B infection,initial,2015-11-23,GCST003189,Cancer,#3288bd
11293,Asian,560.0,26870257.0,Qu LS,Hepatocellular carcinoma in hepatitis B infection,replication,2015-11-23,GCST003189,Digestive system disorder,#3288bd
11294,Asian,100.0,26870257.0,Qu LS,Hepatocellular carcinoma in hepatitis B infection,initial,2015-11-23,GCST003189,Digestive system disorder,#3288bd
11295,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),initial,2015-11-19,GCST003241,Lipid or lipoprotein measurement,#3288bd
11296,European,462.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),initial,2015-11-19,GCST003230,Other measurement,#d53e4f
11297,European,435.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),replication,2015-11-19,GCST003230,Other measurement,#d53e4f
11298,European,462.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),initial,2015-11-19,GCST003230,Cancer,#d53e4f
11299,European,435.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),replication,2015-11-19,GCST003230,Cancer,#d53e4f
11300,European,462.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),initial,2015-11-19,GCST003230,Other measurement,#d53e4f
11301,European,435.0,26586795.0,Phipps AI,Survival in colorectal cancer (distant metastatic),replication,2015-11-19,GCST003230,Other measurement,#d53e4f
11302,European,2843.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),initial,2015-11-19,GCST003231,Other measurement,#d53e4f
11303,European,3205.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),replication,2015-11-19,GCST003231,Other measurement,#d53e4f
11304,European,2843.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),initial,2015-11-19,GCST003231,Cancer,#d53e4f
11305,European,3205.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),replication,2015-11-19,GCST003231,Cancer,#d53e4f
11306,European,2843.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),initial,2015-11-19,GCST003231,Other measurement,#d53e4f
11307,European,3205.0,26586795.0,Phipps AI,Survival in colorectal cancer (non-distant metastatic),replication,2015-11-19,GCST003231,Other measurement,#d53e4f
11308,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),initial,2015-11-19,GCST003242,Lipid or lipoprotein measurement,#3288bd
11309,European,3494.0,26586795.0,Phipps AI,Survival in colorectal cancer,initial,2015-11-19,GCST003229,Cancer,#d53e4f
11310,European,3764.0,26586795.0,Phipps AI,Survival in colorectal cancer,replication,2015-11-19,GCST003229,Cancer,#d53e4f
11311,European,3494.0,26586795.0,Phipps AI,Survival in colorectal cancer,initial,2015-11-19,GCST003229,Other measurement,#d53e4f
11312,European,3764.0,26586795.0,Phipps AI,Survival in colorectal cancer,replication,2015-11-19,GCST003229,Other measurement,#d53e4f
11313,Asian,1361.0,26584805.0,Dorajoo R,Delta-6 desaturase activity,initial,2015-11-19,GCST003244,Other measurement,#3288bd
11314,Asian,1361.0,26584805.0,Dorajoo R,Delta-5 desaturase activity,initial,2015-11-19,GCST003243,Other measurement,#3288bd
11315,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),initial,2015-11-19,GCST003236,Lipid or lipoprotein measurement,#3288bd
11316,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),initial,2015-11-19,GCST003237,Lipid or lipoprotein measurement,#3288bd
11317,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),initial,2015-11-19,GCST003238,Lipid or lipoprotein measurement,#3288bd
11318,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),initial,2015-11-19,GCST003239,Lipid or lipoprotein measurement,#3288bd
11319,Asian,1361.0,26584805.0,Dorajoo R,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),initial,2015-11-19,GCST003240,Lipid or lipoprotein measurement,#3288bd
11320,Asian,470.0,26580837.0,Chen CJ,Amyotrophic lateral sclerosis,initial,2015-11-18,GCST003175,Neurological disorder,#3288bd
11321,Asian,8344.0,26582766.0,Lu X,Triglycerides,initial,2015-11-18,GCST003217,Lipid or lipoprotein measurement,#3288bd
11322,Asian,14739.0,26582766.0,Lu X,Triglycerides,replication,2015-11-18,GCST003217,Lipid or lipoprotein measurement,#3288bd
11323,Asian,8344.0,26582766.0,Lu X,HDL cholesterol,initial,2015-11-18,GCST003215,Lipid or lipoprotein measurement,#3288bd
11324,Asian,14739.0,26582766.0,Lu X,HDL cholesterol,replication,2015-11-18,GCST003215,Lipid or lipoprotein measurement,#3288bd
11325,Asian,8344.0,26582766.0,Lu X,LDL cholesterol,initial,2015-11-18,GCST003216,Lipid or lipoprotein measurement,#3288bd
11326,Asian,14739.0,26582766.0,Lu X,LDL cholesterol,replication,2015-11-18,GCST003216,Lipid or lipoprotein measurement,#3288bd
11327,Asian,8344.0,26582766.0,Lu X,"Cholesterol, total",initial,2015-11-18,GCST003214,Lipid or lipoprotein measurement,#3288bd
11328,Asian,14739.0,26582766.0,Lu X,"Cholesterol, total",replication,2015-11-18,GCST003214,Lipid or lipoprotein measurement,#3288bd
11329,Hispanic/Latin American,761.0,26569114.0,Brown EL,Staphylococcus aureus nasal carriage (persistent),initial,2015-11-16,GCST003182,Other measurement,#807dba
11330,Hispanic/Latin American,717.0,26569114.0,Brown EL,Staphylococcus aureus nasal carriage (intermittent),initial,2015-11-16,GCST003181,Other measurement,#807dba
11331,Asian,1050.0,26531332.0,Kim LH,Schizophrenia,initial,2015-11-14,GCST003190,Neurological disorder,#3288bd
11332,Asian,914.0,26531332.0,Kim LH,Schizophrenia,replication,2015-11-14,GCST003190,Neurological disorder,#3288bd
11333,Asian,234.0,26566055.0,Mieda T,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours),replication,2015-11-13,GCST003200,Other measurement,#3288bd
11334,Asian,116.0,26566055.0,Mieda T,Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours),initial,2015-11-13,GCST003200,Other measurement,#3288bd
11335,European,120246.0,26561523.0,de Vries PS,Fibrinogen levels,initial,2015-11-10,GCST003194,Hematological measurement,#d53e4f
11342,European,6315.0,26553974.0,McLaren PJ,Setpoint viral load in HIV-1 infection,initial,2015-11-09,GCST003183,Other disease,#d53e4f
11343,European,6315.0,26553974.0,McLaren PJ,Setpoint viral load in HIV-1 infection,initial,2015-11-09,GCST003183,Other measurement,#d53e4f
11344,European,844.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Cancer,#d53e4f
11345,Asian,325.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Cancer,#3288bd
11346,European,811.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Cancer,#d53e4f
11347,Asian,114.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Cancer,#3288bd
11350,European,844.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Response to drug,#d53e4f
11351,Asian,325.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Response to drug,#3288bd
11352,European,811.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Response to drug,#d53e4f
11353,Asian,114.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Response to drug,#3288bd
11356,European,844.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Liver enzyme measurement,#d53e4f
11357,Asian,325.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),initial,2015-11-06,GCST003232,Liver enzyme measurement,#3288bd
11358,European,811.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Liver enzyme measurement,#d53e4f
11359,Asian,114.0,26546620.0,Xu CF,Response to Pazopanib in cancer (hepatotoxicity),replication,2015-11-06,GCST003232,Liver enzyme measurement,#3288bd
11362,African Am./Caribbean,1102.0,26545240.0,Giri A,Pelvic organ prolapse (moderate/severe),initial,2015-11-06,GCST003225,Other disease,#fee08b
11363,Hispanic/Latin American,468.0,26545240.0,Giri A,Pelvic organ prolapse (moderate/severe),initial,2015-11-06,GCST003225,Other disease,#807dba
11364,European,11181.0,26542096.0,Marenholz I,Atopic march,initial,2015-11-06,GCST003180,Other disease,#d53e4f
11365,European,8281.0,26542096.0,Marenholz I,Atopic march,replication,2015-11-06,GCST003180,Other disease,#d53e4f
11366,European,11181.0,26542096.0,Marenholz I,Atopic march,initial,2015-11-06,GCST003180,Immune system disorder,#d53e4f
11367,European,8281.0,26542096.0,Marenholz I,Atopic march,replication,2015-11-06,GCST003180,Immune system disorder,#d53e4f
11368,European,11181.0,26542096.0,Marenholz I,Atopic march,initial,2015-11-06,GCST003180,Biological process,#d53e4f
11369,European,8281.0,26542096.0,Marenholz I,Atopic march,replication,2015-11-06,GCST003180,Biological process,#d53e4f
11370,African Am./Caribbean,1741.0,26545240.0,Giri A,Pelvic organ prolapse,initial,2015-11-06,GCST003226,Other disease,#fee08b
11371,Hispanic/Latin American,911.0,26545240.0,Giri A,Pelvic organ prolapse,initial,2015-11-06,GCST003226,Other disease,#807dba
11372,European,4773.0,26589003.0,Federoff M,Multiple system atrophy,initial,2015-11-05,GCST003179,Neurological disorder,#d53e4f
11373,European,91.0,26528553.0,Davenport ER,Gut microbiome composition (summer),initial,2015-11-03,GCST003221,Other measurement,#d53e4f
11374,European,1335.0,26534935.0,Weng L,Nonobstructive coronary artery disease,initial,2015-11-03,GCST008436,Cardiovascular disease,#d53e4f
11375,European,93.0,26528553.0,Davenport ER,Gut microbiome composition (winter),initial,2015-11-03,GCST003223,Other measurement,#d53e4f
11376,European,127.0,26528553.0,Davenport ER,Gut microbiome composition (summer and winter),initial,2015-11-03,GCST003222,Other measurement,#d53e4f
11377,European,4216.0,26525574.0,Westerlind H,Collagenous colitis,initial,2015-11-02,GCST005879,Immune system disorder,#d53e4f
11378,European,397.0,26525574.0,Westerlind H,Collagenous colitis,replication,2015-11-02,GCST005879,Immune system disorder,#d53e4f
11379,Asian,262.0,26434682.0,Lin YJ,Coronary artery aneurysm in Kawasaki disease,initial,2015-11-01,GCST003192,Immune system disorder,#3288bd
11380,Asian,262.0,26434682.0,Lin YJ,Coronary artery aneurysm in Kawasaki disease,initial,2015-11-01,GCST003192,Cardiovascular disease,#3288bd
11381,European,46638.0,26414677.0,Day FR,Menopause (age at onset),replication,2015-11-01,GCST005560,Other measurement,#d53e4f
11382,European,2545.0,26414677.0,Day FR,Menopause (age at onset),initial,2015-11-01,GCST005560,Other measurement,#d53e4f
11383,European,6307.0,26366551.0,Zoledziewska M,Height,initial,2015-11-01,GCST005354,Body measurement,#d53e4f
11384,European,24367.0,26366551.0,Zoledziewska M,Height,replication,2015-11-01,GCST005354,Body measurement,#d53e4f
11385,European,69626.0,26414677.0,Day FR,Menopause (age at onset),initial,2015-11-01,GCST005312,Other measurement,#d53e4f
11386,European,6252.0,26632684.0,Dong J,Sense of smell,initial,2015-11-01,GCST003174,Biological process,#d53e4f
11387,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Cardiovascular disease,#fee08b
11388,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Cardiovascular disease,#d53e4f
11389,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003186,Cardiovascular disease,#d53e4f
11390,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Other disease,#fee08b
11391,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Other disease,#d53e4f
11392,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003186,Other disease,#d53e4f
11393,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Response to drug,#fee08b
11394,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003186,Response to drug,#d53e4f
11395,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003186,Response to drug,#d53e4f
11396,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),replication,2015-10-30,GCST003202,Response to drug,#d53e4f
11397,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),initial,2015-10-30,GCST003202,Response to drug,#d53e4f
11398,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),replication,2015-10-30,GCST003202,Cardiovascular disease,#d53e4f
11399,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),initial,2015-10-30,GCST003202,Cardiovascular disease,#d53e4f
11400,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),replication,2015-10-30,GCST003202,Cardiovascular disease,#d53e4f
11401,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (diuretic interaction),initial,2015-10-30,GCST003202,Cardiovascular disease,#d53e4f
11402,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),replication,2015-10-30,GCST003201,Cardiovascular disease,#d53e4f
11403,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),initial,2015-10-30,GCST003201,Cardiovascular disease,#d53e4f
11404,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),replication,2015-10-30,GCST003201,Response to drug,#d53e4f
11405,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),initial,2015-10-30,GCST003201,Response to drug,#d53e4f
11406,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),replication,2015-10-30,GCST003201,Cardiovascular disease,#d53e4f
11407,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (beta blocker interaction),initial,2015-10-30,GCST003201,Cardiovascular disease,#d53e4f
11408,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003187,Cardiovascular disease,#d53e4f
11409,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003187,Cardiovascular disease,#d53e4f
11410,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003187,Response to drug,#d53e4f
11411,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003187,Response to drug,#d53e4f
11412,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),initial,2015-10-30,GCST003187,Cardiovascular disease,#d53e4f
11413,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (ACE inhibitor interaction),replication,2015-10-30,GCST003187,Cardiovascular disease,#d53e4f
11414,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),initial,2015-10-30,GCST003203,Cardiovascular disease,#d53e4f
11415,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Cardiovascular disease,#d53e4f
11416,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Cardiovascular disease,#fee08b
11417,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),initial,2015-10-30,GCST003203,Response to drug,#d53e4f
11418,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Response to drug,#d53e4f
11419,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Response to drug,#fee08b
11420,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),initial,2015-10-30,GCST003203,Other disease,#d53e4f
11421,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Other disease,#d53e4f
11422,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (beta blocker interaction),replication,2015-10-30,GCST003203,Other disease,#fee08b
11423,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Response to drug,#d53e4f
11424,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Response to drug,#fee08b
11425,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),initial,2015-10-30,GCST003204,Response to drug,#d53e4f
11426,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Cardiovascular disease,#d53e4f
11427,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Cardiovascular disease,#fee08b
11428,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),initial,2015-10-30,GCST003204,Cardiovascular disease,#d53e4f
11429,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Other disease,#d53e4f
11430,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),replication,2015-10-30,GCST003204,Other disease,#fee08b
11431,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (diuretic interaction),initial,2015-10-30,GCST003204,Other disease,#d53e4f
11432,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003206,Cardiovascular disease,#d53e4f
11433,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003206,Cardiovascular disease,#d53e4f
11434,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003206,Response to drug,#d53e4f
11435,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003206,Response to drug,#d53e4f
11436,European,16375.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003206,Cardiovascular disease,#d53e4f
11437,European,1171.0,26516778.0,Bis JC,Myocardial infarction in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003206,Cardiovascular disease,#d53e4f
11438,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Cardiovascular disease,#d53e4f
11439,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003205,Cardiovascular disease,#d53e4f
11440,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Cardiovascular disease,#fee08b
11441,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Other disease,#d53e4f
11442,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003205,Other disease,#d53e4f
11443,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Other disease,#fee08b
11444,European,1751.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Response to drug,#d53e4f
11445,European,16375.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),initial,2015-10-30,GCST003205,Response to drug,#d53e4f
11446,African Am./Caribbean,4141.0,26516778.0,Bis JC,Cardiovascular disease in hypertension (calcium channel blocker interaction),replication,2015-10-30,GCST003205,Response to drug,#fee08b
11447,African Am./Caribbean,898.0,26519441.0,Kim S,Plasma homocysteine levels,initial,2015-10-30,GCST003157,Cardiovascular measurement,#fee08b
11448,African,960.0,26519441.0,Kim S,Plasma homocysteine levels,initial,2015-10-30,GCST003157,Cardiovascular measurement,#fc8d59
11449,European,5932.0,26503584.0,Litchfield K,Testicular germ cell tumor,initial,2015-10-27,GCST003247,Cancer,#d53e4f
11451,European,5932.0,26503584.0,Litchfield K,Testicular germ cell tumor,initial,2015-10-27,GCST003246,Cancer,#d53e4f
11453,European,11146.0,26503584.0,Litchfield K,Testicular germ cell tumor,replication,2015-10-27,GCST003246,Cancer,#d53e4f
11454,European,1176.0,26503763.0,Song J,Objective response to lithium treatment in bipolar disorder,initial,2015-10-27,GCST003161,Neurological disorder,#d53e4f
11455,European,1176.0,26503763.0,Song J,Objective response to lithium treatment in bipolar disorder,initial,2015-10-27,GCST003161,Response to drug,#d53e4f
11456,European,7007.0,26503763.0,Song J,Objective response to lithium treatment,initial,2015-10-27,GCST003159,Neurological disorder,#d53e4f
11457,European,7007.0,26503763.0,Song J,Objective response to lithium treatment,initial,2015-10-27,GCST003159,Response to drug,#d53e4f
11458,European,2698.0,26503763.0,Song J,Subjective response to lithium treatment in bipolar disorder,initial,2015-10-27,GCST003160,Neurological disorder,#d53e4f
11459,European,2698.0,26503763.0,Song J,Subjective response to lithium treatment in bipolar disorder,initial,2015-10-27,GCST003160,Response to drug,#d53e4f
11460,European,10538.0,26503763.0,Song J,Subjective response to lithium treatment,initial,2015-10-27,GCST003158,Neurological disorder,#d53e4f
11461,European,10538.0,26503763.0,Song J,Subjective response to lithium treatment,initial,2015-10-27,GCST003158,Response to drug,#d53e4f
11462,European,14267.0,26502338.0,Bentham J,Systemic lupus erythematosus,initial,2015-10-26,GCST003156,Immune system disorder,#d53e4f
11463,European,8943.0,26502338.0,Bentham J,Systemic lupus erythematosus,replication,2015-10-26,GCST003155,Immune system disorder,#d53e4f
11464,European,14267.0,26502338.0,Bentham J,Systemic lupus erythematosus,initial,2015-10-26,GCST003155,Immune system disorder,#d53e4f
11465,Asian,19131.0,26488411.0,Matsukura M,Peripheral artery disease,replication,2015-10-21,GCST003154,Cardiovascular disease,#3288bd
11466,Asian,4168.0,26488411.0,Matsukura M,Peripheral artery disease,initial,2015-10-21,GCST003154,Cardiovascular disease,#3288bd
11467,European,478.0,26491034.0,Sarzynski MA,Response to exercise (triglyceride level interaction),initial,2015-10-21,GCST003207,Lipid or lipoprotein measurement,#d53e4f
11468,European,478.0,26491034.0,Sarzynski MA,Response to exercise (triglyceride level interaction),initial,2015-10-21,GCST003207,Biological process,#d53e4f
11469,European,31149.0,26486471.0,van Loon J,Low vWF levels,initial,2015-10-21,GCST003210,Hematological measurement,#d53e4f
11470,African Am./Caribbean,772.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio,replication,2015-10-20,GCST003162,Other measurement,#fee08b
11471,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2015-10-20,GCST003162,Other measurement,#d53e4f
11472,European,2171.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio,replication,2015-10-20,GCST003162,Other measurement,#d53e4f
11473,African Am./Caribbean,772.0,26480920.0,Sung YJ,Subcutaneous adipose tissue,replication,2015-10-20,GCST003164,Other measurement,#fee08b
11474,European,2171.0,26480920.0,Sung YJ,Subcutaneous adipose tissue,replication,2015-10-20,GCST003164,Other measurement,#d53e4f
11475,European,2513.0,26480920.0,Sung YJ,Subcutaneous adipose tissue,initial,2015-10-20,GCST003164,Other measurement,#d53e4f
11476,African Am./Caribbean,772.0,26480920.0,Sung YJ,Total adipose tissue,replication,2015-10-20,GCST003168,Other measurement,#fee08b
11477,European,2513.0,26480920.0,Sung YJ,Total adipose tissue,initial,2015-10-20,GCST003168,Other measurement,#d53e4f
11478,European,2171.0,26480920.0,Sung YJ,Total adipose tissue,replication,2015-10-20,GCST003168,Other measurement,#d53e4f
11479,African Am./Caribbean,772.0,26480920.0,Sung YJ,Visceral adipose tissue,replication,2015-10-20,GCST003166,Other measurement,#fee08b
11480,European,2171.0,26480920.0,Sung YJ,Visceral adipose tissue,replication,2015-10-20,GCST003166,Other measurement,#d53e4f
11481,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue,initial,2015-10-20,GCST003166,Other measurement,#d53e4f
11482,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2015-10-20,GCST003173,Other measurement,#d53e4f
11483,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue adjusted for BMI,initial,2015-10-20,GCST003172,Other measurement,#d53e4f
11484,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue,initial,2015-10-20,GCST003171,Other measurement,#d53e4f
11485,European,2513.0,26480920.0,Sung YJ,Subcutaneous adipose tissue,initial,2015-10-20,GCST003170,Other measurement,#d53e4f
11486,European,2171.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,replication,2015-10-20,GCST003163,Other measurement,#d53e4f
11487,African Am./Caribbean,772.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,replication,2015-10-20,GCST003163,Other measurement,#fee08b
11488,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue/subcutaneous adipose tissue ratio adjusted for BMI,initial,2015-10-20,GCST003163,Other measurement,#d53e4f
11489,European,2513.0,26480920.0,Sung YJ,Total adipose tissue adjusted for BMI,initial,2015-10-20,GCST003169,Other measurement,#d53e4f
11490,European,2171.0,26480920.0,Sung YJ,Total adipose tissue adjusted for BMI,replication,2015-10-20,GCST003169,Other measurement,#d53e4f
11491,African Am./Caribbean,772.0,26480920.0,Sung YJ,Total adipose tissue adjusted for BMI,replication,2015-10-20,GCST003169,Other measurement,#fee08b
11492,European,2513.0,26480920.0,Sung YJ,Visceral adipose tissue adjusted for BMI,initial,2015-10-20,GCST003167,Other measurement,#d53e4f
11493,African Am./Caribbean,772.0,26480920.0,Sung YJ,Visceral adipose tissue adjusted for BMI,replication,2015-10-20,GCST003167,Other measurement,#fee08b
11494,European,2171.0,26480920.0,Sung YJ,Visceral adipose tissue adjusted for BMI,replication,2015-10-20,GCST003167,Other measurement,#d53e4f
11495,European,2513.0,26480920.0,Sung YJ,Subcutaneous adipose tissue adjusted for BMI,initial,2015-10-20,GCST003165,Other measurement,#d53e4f
11496,European,2171.0,26480920.0,Sung YJ,Subcutaneous adipose tissue adjusted for BMI,replication,2015-10-20,GCST003165,Other measurement,#d53e4f
11497,African Am./Caribbean,772.0,26480920.0,Sung YJ,Subcutaneous adipose tissue adjusted for BMI,replication,2015-10-20,GCST003165,Other measurement,#fee08b
11498,European,2138.0,26482880.0,Buch S,Cirrhosis (alcohol related),initial,2015-10-19,GCST003153,Cancer,#d53e4f
11499,European,2070.0,26482880.0,Buch S,Cirrhosis (alcohol related),replication,2015-10-19,GCST003153,Cancer,#d53e4f
11500,European,103066.0,26482879.0,Paternoster L,Atopic dermatitis,initial,2015-10-19,GCST003184,Immune system disorder,#d53e4f
11501,African Am./Caribbean,1266.0,26482879.0,Paternoster L,Atopic dermatitis,initial,2015-10-19,GCST003184,Immune system disorder,#fee08b
11502,Asian,9438.0,26482879.0,Paternoster L,Atopic dermatitis,initial,2015-10-19,GCST003184,Immune system disorder,#3288bd
11503,Hispanic/Latin American,1892.0,26482879.0,Paternoster L,Atopic dermatitis,initial,2015-10-19,GCST003184,Immune system disorder,#807dba
11504,Asian,2374.0,26482879.0,Paternoster L,Atopic dermatitis,replication,2015-10-19,GCST003184,Immune system disorder,#3288bd
11505,African Am./Caribbean,1288.0,26482879.0,Paternoster L,Atopic dermatitis,replication,2015-10-19,GCST003184,Immune system disorder,#fee08b
11507,European,257125.0,26482879.0,Paternoster L,Atopic dermatitis,replication,2015-10-19,GCST003184,Immune system disorder,#d53e4f
11508,European,6182.0,26490195.0,Cleynen I,Inflammatory bowel disease,replication,2015-10-18,GCST006960,Digestive system disorder,#d53e4f
11509,European,29838.0,26490195.0,Cleynen I,Inflammatory bowel disease,initial,2015-10-18,GCST006960,Digestive system disorder,#d53e4f
11510,European,685.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,replication,2015-10-12,GCST003178,Cancer,#d53e4f
11511,European,852.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,initial,2015-10-12,GCST003178,Cancer,#d53e4f
11512,European,685.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,replication,2015-10-12,GCST003178,Other measurement,#d53e4f
11513,European,852.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,initial,2015-10-12,GCST003178,Other measurement,#d53e4f
11514,European,685.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,replication,2015-10-12,GCST003178,Response to drug,#d53e4f
11515,European,852.0,26460308.0,Ghesquieres H,Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,initial,2015-10-12,GCST003178,Response to drug,#d53e4f
11516,European,2660.0,26562150.0,Seldin MF,Late-onset myasthenia gravis,initial,2015-10-10,GCST003251,Neurological disorder,#d53e4f
11517,European,7773.0,26451028.0,Hofer E,White matter lesion progression,initial,2015-10-08,GCST003151,Other measurement,#d53e4f
11518,European,47564.0,26450422.0,DeLorenze GN,Skin and soft tissue Staphylococcus aureus infection,initial,2015-10-08,GCST003149,Other disease,#d53e4f
11519,European,7773.0,26451028.0,Hofer E,White matter lesion progression (adjusted for white matter lesion burden at baseline),initial,2015-10-08,GCST003152,Other measurement,#d53e4f
11520,European,50045.0,26450422.0,DeLorenze GN,Staphylococcus aureus infection,initial,2015-10-08,GCST003150,Other disease,#d53e4f
11521,Asian,7394.0,26443449.0,Wang M,Prostate cancer,initial,2015-10-07,GCST003148,Cancer,#3288bd
11522,Asian,7524.0,26443449.0,Wang M,Prostate cancer,replication,2015-10-07,GCST003148,Cancer,#3288bd
11523,European,17074.0,26440539.0,Hancock DB,Nicotine dependence,initial,2015-10-06,GCST003185,Neurological disorder,#d53e4f
11524,European,7469.0,26440539.0,Hancock DB,Nicotine dependence,replication,2015-10-06,GCST003185,Neurological disorder,#d53e4f
11525,African Am./Caribbean,1671.0,26433129.0,Tin A,Plasma lactate levels,replication,2015-10-03,GCST003147,Other measurement,#fee08b
11526,European,6901.0,26433129.0,Tin A,Plasma lactate levels,initial,2015-10-03,GCST003147,Other measurement,#d53e4f
11527,European,9218.0,26424050.0,Kinnersley B,Glioblastoma,initial,2015-10-01,GCST003220,Cancer,#d53e4f
11528,European,3213.0,26424050.0,Kinnersley B,Glioblastoma,replication,2015-10-01,GCST003220,Cancer,#d53e4f
11529,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),initial,2015-10-01,GCST005962,Body measurement,#d53e4f
11530,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),initial,2015-10-01,GCST005962,Other measurement,#d53e4f
11531,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),initial,2015-10-01,GCST005962,Other measurement,#d53e4f
11532,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x age interaction,initial,2015-10-01,GCST005961,Body measurement,#d53e4f
11533,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x age interaction,initial,2015-10-01,GCST005961,Other measurement,#d53e4f
11534,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction,initial,2015-10-01,GCST005960,Body measurement,#d53e4f
11535,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction,initial,2015-10-01,GCST005960,Other measurement,#d53e4f
11536,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex x age interaction,initial,2015-10-01,GCST005960,Other measurement,#d53e4f
11537,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex interaction,initial,2015-10-01,GCST005959,Body measurement,#d53e4f
11538,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI x sex interaction,initial,2015-10-01,GCST005959,Other measurement,#d53e4f
11539,European,158073.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI (age >50),initial,2015-10-01,GCST005958,Body measurement,#d53e4f
11540,European,94302.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI (age <50),initial,2015-10-01,GCST005957,Body measurement,#d53e4f
11541,European,252375.0,26426971.0,Winkler TW,Waist-to-hip ratio adjusted for BMI,initial,2015-10-01,GCST005956,Body measurement,#d53e4f
11542,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction,initial,2015-10-01,GCST005955,Other measurement,#d53e4f
11543,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction,initial,2015-10-01,GCST005955,Body measurement,#d53e4f
11544,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction,initial,2015-10-01,GCST005955,Other measurement,#d53e4f
11545,European,309889.0,26426971.0,Winkler TW,Body mass index x age interaction,initial,2015-10-01,GCST005954,Body measurement,#d53e4f
11546,European,309889.0,26426971.0,Winkler TW,Body mass index x age interaction,initial,2015-10-01,GCST005954,Other measurement,#d53e4f
11547,European,112279.0,26426971.0,Winkler TW,Body mass index (age <50),initial,2015-10-01,GCST005953,Body measurement,#d53e4f
11548,European,197610.0,26426971.0,Winkler TW,Body mass index (age>50),initial,2015-10-01,GCST005952,Body measurement,#d53e4f
11549,European,309889.0,26426971.0,Winkler TW,Body mass index,initial,2015-10-01,GCST005951,Body measurement,#d53e4f
11550,European,8143.0,26367794.0,Zheng HF,Forearm bone mineral density,initial,2015-10-01,GCST005546,Other measurement,#d53e4f
11551,European,2662.0,26367794.0,Zheng HF,Forearm bone mineral density,replication,2015-10-01,GCST005546,Other measurement,#d53e4f
11552,European,33297.0,26367794.0,Zheng HF,Lumbar spine bone mineral density,initial,2015-10-01,GCST005545,Other measurement,#d53e4f
11553,European,16233.0,26367794.0,Zheng HF,Lumbar spine bone mineral density,replication,2015-10-01,GCST005545,Other measurement,#d53e4f
11554,European,32735.0,26367794.0,Zheng HF,Femoral neck bone mineral density,initial,2015-10-01,GCST005544,Other measurement,#d53e4f
11555,European,17253.0,26367794.0,Zheng HF,Femoral neck bone mineral density,replication,2015-10-01,GCST005544,Other measurement,#d53e4f
11556,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction (4df test),initial,2015-10-01,GCST005950,Other measurement,#d53e4f
11557,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction (4df test),initial,2015-10-01,GCST005950,Body measurement,#d53e4f
11558,European,309889.0,26426971.0,Winkler TW,Body mass index x sex x age interaction (4df test),initial,2015-10-01,GCST005950,Other measurement,#d53e4f
11559,European,309889.0,26426971.0,Winkler TW,Body mass index x sex interaction,initial,2015-10-01,GCST005949,Other measurement,#d53e4f
11560,European,309889.0,26426971.0,Winkler TW,Body mass index x sex interaction,initial,2015-10-01,GCST005949,Body measurement,#d53e4f
11561,European,3213.0,26424050.0,Kinnersley B,Glioma,replication,2015-10-01,GCST003228,Cancer,#d53e4f
11562,European,11582.0,26424050.0,Kinnersley B,Glioma,initial,2015-10-01,GCST003228,Cancer,#d53e4f
11563,Other/Mixed,11.0,26366535.0,Sood RF,Postburn hypertrophic scarring severity,initial,2015-10-01,GCST003146,Other measurement,#99d594
11565,African Am./Caribbean,19.0,26366535.0,Sood RF,Postburn hypertrophic scarring severity,initial,2015-10-01,GCST003146,Other measurement,#fee08b
11566,Other/Mixed,57.0,26366535.0,Sood RF,Postburn hypertrophic scarring severity,initial,2015-10-01,GCST003146,Other measurement,#99d594
11567,European,408.0,26366535.0,Sood RF,Postburn hypertrophic scarring severity,initial,2015-10-01,GCST003146,Other measurement,#d53e4f
11568,Asian,26.0,26366535.0,Sood RF,Postburn hypertrophic scarring severity,initial,2015-10-01,GCST003146,Other measurement,#3288bd
11569,European,3213.0,26424050.0,Kinnersley B,Non-glioblastoma glioma,replication,2015-10-01,GCST003227,Cancer,#d53e4f
11570,European,9799.0,26424050.0,Kinnersley B,Non-glioblastoma glioma,initial,2015-10-01,GCST003227,Cancer,#d53e4f
11571,African,15483.0,26416757.0,Band G,Severe malaria,replication,2015-09-30,GCST003145,Digestive system disorder,#fc8d59
11572,African,10421.0,26416757.0,Band G,Severe malaria,initial,2015-09-30,GCST003145,Digestive system disorder,#fc8d59
11574,European,6079.0,26417704.0,Corvol H,Lung disease severity in cystic fibrosis,initial,2015-09-29,GCST003143,Other disease,#d53e4f
11576,European,87943.0,26416764.0,Day FR,Polycystic ovary syndrome,initial,2015-09-29,GCST003144,Other disease,#d53e4f
11577,European,93055.0,26416764.0,Day FR,Polycystic ovary syndrome,replication,2015-09-29,GCST003144,Other disease,#d53e4f
11578,Other/Mixed,397.0,26420894.0,Wuttke M,Proteinuria in chronic kidney disease,initial,2015-09-28,GCST003142,Other disease,#99d594
11579,European,744.0,26420894.0,Wuttke M,Proteinuria in chronic kidney disease,initial,2015-09-28,GCST003142,Other disease,#d53e4f
11580,Other/Mixed,397.0,26420894.0,Wuttke M,Proteinuria in chronic kidney disease,initial,2015-09-28,GCST003142,Other trait,#99d594
11581,European,744.0,26420894.0,Wuttke M,Proteinuria in chronic kidney disease,initial,2015-09-28,GCST003142,Other trait,#d53e4f
11582,European,2064.0,26422391.0,Yellin JL,Juvenile osteochondritis dissecans,initial,2015-09-28,GCST003138,Other trait,#d53e4f
11583,European,744.0,26420894.0,Wuttke M,Glomerular filtration rate in chronic kidney disease,initial,2015-09-28,GCST003139,Other measurement,#d53e4f
11584,Other/Mixed,397.0,26420894.0,Wuttke M,Glomerular filtration rate in chronic kidney disease,initial,2015-09-28,GCST003139,Other measurement,#99d594
11585,European,744.0,26420894.0,Wuttke M,Glomerular filtration rate in chronic kidney disease,initial,2015-09-28,GCST003139,Other disease,#d53e4f
11586,Other/Mixed,397.0,26420894.0,Wuttke M,Glomerular filtration rate in chronic kidney disease,initial,2015-09-28,GCST003139,Other disease,#99d594
11587,European,1641.0,26420894.0,Wuttke M,Proteinuria and chronic kidney disease,initial,2015-09-28,GCST003141,Other disease,#d53e4f
11588,European,1641.0,26420894.0,Wuttke M,Proteinuria and chronic kidney disease,initial,2015-09-28,GCST003141,Other trait,#d53e4f
11589,European,2005.0,26420894.0,Wuttke M,Chronic kidney disease,initial,2015-09-28,GCST003140,Other disease,#d53e4f
11590,European,2190.0,26433762.0,Liu X,Eating disorder in bipolar disorder,initial,2015-09-25,GCST003132,Metabolic disorder,#d53e4f
11591,European,2190.0,26433762.0,Liu X,Eating disorder in bipolar disorder,initial,2015-09-25,GCST003132,Neurological disorder,#d53e4f
11597,European,3376.0,26433762.0,Liu X,Bipolar disorder,initial,2015-09-25,GCST003136,Neurological disorder,#d53e4f
11598,European,1554.0,26433762.0,Liu X,Bipolar disorder and eating disorder,initial,2015-09-25,GCST003135,Metabolic disorder,#d53e4f
11599,European,1554.0,26433762.0,Liu X,Bipolar disorder and eating disorder,initial,2015-09-25,GCST003135,Neurological disorder,#d53e4f
11601,European,923.0,26401656.0,Burkhardt R,Blood metabolite levels,replication,2015-09-24,GCST006879,Other measurement,#d53e4f
11602,European,2107.0,26401656.0,Burkhardt R,Blood metabolite levels,initial,2015-09-24,GCST006879,Other measurement,#d53e4f
11603,Asian,1430.0,26398136.0,Kuo PH,Autism spectrum disorder,initial,2015-09-23,GCST003130,Neurological disorder,#3288bd
11604,Asian,762.0,26398136.0,Kuo PH,Autism spectrum disorder,replication,2015-09-23,GCST003130,Neurological disorder,#3288bd
11605,European,13239.0,26394269.0,Cordell HJ,Primary biliary cholangitis,initial,2015-09-22,GCST003129,Cancer,#d53e4f
11606,European,7977.0,26394269.0,Cordell HJ,Primary biliary cholangitis,replication,2015-09-22,GCST003129,Cancer,#d53e4f
11607,Asian,7832.0,26394188.0,Zhu Z,Adolescent idiopathic scoliosis,replication,2015-09-22,GCST003128,Other disease,#3288bd
11608,Asian,2459.0,26394188.0,Zhu Z,Adolescent idiopathic scoliosis,initial,2015-09-22,GCST003128,Other disease,#3288bd
11609,European,68456.0,26390057.0,Kato N,Systolic blood pressure,replication,2015-09-21,GCST003272,Other measurement,#d53e4f
11611,Asian,16328.0,26390057.0,Kato N,Systolic blood pressure,replication,2015-09-21,GCST003272,Other measurement,#3288bd
11612,Asian,48268.0,26390057.0,Kato N,Systolic blood pressure,replication,2015-09-21,GCST003272,Other measurement,#3288bd
11613,European,35352.0,26390057.0,Kato N,Systolic blood pressure,initial,2015-09-21,GCST003272,Other measurement,#d53e4f
11614,Asian,33126.0,26390057.0,Kato N,Systolic blood pressure,initial,2015-09-21,GCST003272,Other measurement,#3288bd
11615,Asian,31516.0,26390057.0,Kato N,Systolic blood pressure,initial,2015-09-21,GCST003272,Other measurement,#3288bd
11616,Asian,16328.0,26390057.0,Kato N,Diastolic blood pressure,replication,2015-09-21,GCST003273,Other measurement,#3288bd
11617,European,68456.0,26390057.0,Kato N,Diastolic blood pressure,replication,2015-09-21,GCST003273,Other measurement,#d53e4f
11618,Asian,48268.0,26390057.0,Kato N,Diastolic blood pressure,replication,2015-09-21,GCST003273,Other measurement,#3288bd
11620,European,35352.0,26390057.0,Kato N,Diastolic blood pressure,initial,2015-09-21,GCST003273,Other measurement,#d53e4f
11621,Asian,33126.0,26390057.0,Kato N,Diastolic blood pressure,initial,2015-09-21,GCST003273,Other measurement,#3288bd
11622,Asian,31516.0,26390057.0,Kato N,Diastolic blood pressure,initial,2015-09-21,GCST003273,Other measurement,#3288bd
11623,Asian,33126.0,26390057.0,Kato N,Mean arterial pressure,initial,2015-09-21,GCST003275,Other measurement,#3288bd
11624,Asian,31516.0,26390057.0,Kato N,Mean arterial pressure,initial,2015-09-21,GCST003275,Other measurement,#3288bd
11625,European,35352.0,26390057.0,Kato N,Mean arterial pressure,initial,2015-09-21,GCST003275,Other measurement,#d53e4f
11627,European,68456.0,26390057.0,Kato N,Mean arterial pressure,replication,2015-09-21,GCST003275,Other measurement,#d53e4f
11628,Asian,48268.0,26390057.0,Kato N,Mean arterial pressure,replication,2015-09-21,GCST003275,Other measurement,#3288bd
11629,Asian,16328.0,26390057.0,Kato N,Mean arterial pressure,replication,2015-09-21,GCST003275,Other measurement,#3288bd
11630,European,35352.0,26390057.0,Kato N,Pulse pressure,initial,2015-09-21,GCST003274,Cardiovascular measurement,#d53e4f
11631,European,68456.0,26390057.0,Kato N,Pulse pressure,replication,2015-09-21,GCST003274,Cardiovascular measurement,#d53e4f
11632,Asian,48268.0,26390057.0,Kato N,Pulse pressure,replication,2015-09-21,GCST003274,Cardiovascular measurement,#3288bd
11634,Asian,33126.0,26390057.0,Kato N,Pulse pressure,initial,2015-09-21,GCST003274,Cardiovascular measurement,#3288bd
11635,Asian,31516.0,26390057.0,Kato N,Pulse pressure,initial,2015-09-21,GCST003274,Cardiovascular measurement,#3288bd
11636,Asian,16328.0,26390057.0,Kato N,Pulse pressure,replication,2015-09-21,GCST003274,Cardiovascular measurement,#3288bd
11637,Asian,16328.0,26390057.0,Kato N,Hypertension,replication,2015-09-21,GCST003276,Cardiovascular disease,#3288bd
11638,European,68456.0,26390057.0,Kato N,Hypertension,replication,2015-09-21,GCST003276,Cardiovascular disease,#d53e4f
11639,Asian,48268.0,26390057.0,Kato N,Hypertension,replication,2015-09-21,GCST003276,Cardiovascular disease,#3288bd
11641,Asian,33126.0,26390057.0,Kato N,Hypertension,initial,2015-09-21,GCST003276,Cardiovascular disease,#3288bd
11642,Asian,31516.0,26390057.0,Kato N,Hypertension,initial,2015-09-21,GCST003276,Cardiovascular disease,#3288bd
11643,European,35352.0,26390057.0,Kato N,Hypertension,initial,2015-09-21,GCST003276,Cardiovascular disease,#d53e4f
11644,African Am./Caribbean,2895.0,26377243.0,Li J,Lipoprotein (a) levels,initial,2015-09-17,GCST003127,Lipid or lipoprotein measurement,#fee08b
11645,European,49.0,26379185.0,Garcia-Etxebarria K,Severe influenza A (H1N1) infection,initial,2015-09-17,GCST003123,Other disease,#d53e4f
11646,European,549.0,26379185.0,Garcia-Etxebarria K,Severe influenza A (H1N1) infection,initial,2015-09-17,GCST003123,Other disease,#d53e4f
11647,European,107.0,26379185.0,Garcia-Etxebarria K,Mild influenza (H1N1) infection,initial,2015-09-17,GCST003124,Other disease,#d53e4f
11648,European,549.0,26379185.0,Garcia-Etxebarria K,Mild influenza (H1N1) infection,initial,2015-09-17,GCST003124,Other disease,#d53e4f
11649,European,156.0,26379185.0,Garcia-Etxebarria K,Influenza A (H1N1) infection,initial,2015-09-17,GCST003125,Other disease,#d53e4f
11650,European,549.0,26379185.0,Garcia-Etxebarria K,Influenza A (H1N1) infection,initial,2015-09-17,GCST003125,Other disease,#d53e4f
11651,European,156.0,26379185.0,Garcia-Etxebarria K,Influenza A (H1N1) severity,initial,2015-09-17,GCST003126,Other measurement,#d53e4f
11652,African Am./Caribbean,1657.0,26051272.0,Fischer A,Sarcoidosis,replication,2015-09-15,GCST005538,Other disease,#fee08b
11653,European,7850.0,26051272.0,Fischer A,Sarcoidosis,replication,2015-09-15,GCST005538,Other disease,#d53e4f
11654,European,7208.0,26051272.0,Fischer A,Sarcoidosis,initial,2015-09-15,GCST005538,Other disease,#d53e4f
11655,European,7842.0,26365420.0,Mbarek H,Alcohol dependence,initial,2015-09-14,GCST003121,Neurological disorder,#d53e4f
11656,European,4131.0,26366553.0,Danjou F,Hemoglobin levels,replication,2015-09-14,GCST003122,Hematological measurement,#d53e4f
11657,European,6602.0,26366553.0,Danjou F,Hemoglobin levels,initial,2015-09-14,GCST003122,Hematological measurement,#d53e4f
11658,European,63030.0,26362575.0,van den Berg SM,Extraversion,initial,2015-09-11,GCST003120,Biological process,#d53e4f
11659,European,9783.0,26362575.0,van den Berg SM,Extraversion,replication,2015-09-11,GCST003120,Biological process,#d53e4f
11660,European,18207.0,26362759.0,Rothwell S,Idiopathic inflammatory myopathy,initial,2015-09-11,GCST006051,Immune system disorder,#d53e4f
11661,European,16582.0,26362759.0,Rothwell S,Polymyositis,initial,2015-09-11,GCST006052,Neurological disorder,#d53e4f
11662,European,16530.0,26362759.0,Rothwell S,Dermatomyositis or juvenile dermatomyositis,initial,2015-09-11,GCST006053,Neurological disorder,#d53e4f
11663,European,16530.0,26362759.0,Rothwell S,Dermatomyositis or juvenile dermatomyositis,initial,2015-09-11,GCST006053,Neurological disorder,#d53e4f
11664,European,3861.0,26352407.0,Raffler J,Urinary metabolites,initial,2015-09-09,GCST003119,Other measurement,#d53e4f
11665,European,1691.0,26352407.0,Raffler J,Urinary metabolites,replication,2015-09-09,GCST003119,Other measurement,#d53e4f
11666,Asian,230.0,26348319.0,Myung W,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression,replication,2015-09-08,GCST003118,Neurological disorder,#3288bd
11667,Asian,481.0,26348319.0,Myung W,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression,initial,2015-09-08,GCST003118,Neurological disorder,#3288bd
11668,Asian,230.0,26348319.0,Myung W,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression,replication,2015-09-08,GCST003118,Response to drug,#3288bd
11669,Asian,481.0,26348319.0,Myung W,Response to serotonin reuptake inhibitors in non-psychotic unipolar depression,initial,2015-09-08,GCST003118,Response to drug,#3288bd
11670,Other/Mixed,2268.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#99d594
11671,Asian,25557.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#3288bd
11672,African Am./Caribbean,3139.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#fee08b
11673,Asian,11323.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#3288bd
11674,European,141217.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#d53e4f
11675,Hispanic/Latin American,4095.0,26343387.0,Nikpay M,Coronary artery disease,initial,2015-09-07,GCST003116,Cardiovascular disease,#807dba
11676,African Am./Caribbean,2908.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#fee08b
11677,European,126630.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#d53e4f
11678,Asian,23156.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#3288bd
11679,Other/Mixed,754.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#99d594
11680,Asian,9396.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#3288bd
11681,Hispanic/Latin American,3615.0,26343387.0,Nikpay M,Myocardial infarction,initial,2015-09-07,GCST003117,Cardiovascular disease,#807dba
11682,European,2952.0,26350878.0,Tashjian RZ,Rotator cuff tears,initial,2015-09-05,GCST003115,Other disease,#d53e4f
11683,Asian,810.0,26343869.0,Xie G,Carotid intima media thickness,initial,2015-09-05,GCST003114,Other measurement,#3288bd
11684,European,1032.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#d53e4f
11685,Asian,43.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#3288bd
11686,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#99d594
11687,Other/Mixed,78.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#99d594
11688,African Am./Caribbean,98.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#fee08b
11689,European,2484.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#d53e4f
11690,African Am./Caribbean,70.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#fee08b
11691,Asian,85.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#3288bd
11692,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#99d594
11693,Other/Mixed,4.0,26333835.0,Scheinfeldt LB,Sleep duration,replication,2015-09-03,GCST003112,Other measurement,#99d594
11694,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#99d594
11695,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003112,Other measurement,#99d594
11696,European,2484.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#d53e4f
11697,African Am./Caribbean,70.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#fee08b
11698,Asian,85.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#3288bd
11699,Other/Mixed,44.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#99d594
11700,Other/Mixed,7.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#99d594
11701,Other/Mixed,2.0,26333835.0,Scheinfeldt LB,Sleep duration,initial,2015-09-03,GCST003111,Other measurement,#99d594
11702,European,602.0,26421299.0,Li J,Cingulate cortical amyloid beta load,initial,2015-09-03,GCST003113,Other measurement,#d53e4f
11703,European,602.0,26421299.0,Li J,Cingulate cortical amyloid beta load,initial,2015-09-03,GCST003113,Other measurement,#d53e4f
11704,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other measurement,#99d594
11705,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),initial,2015-09-01,GCST003110,Other measurement,#807dba
11706,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other measurement,#807dba
11707,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other measurement,#99d594
11708,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),initial,2015-09-01,GCST003110,Other measurement,#807dba
11709,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other measurement,#807dba
11710,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Response to drug,#99d594
11711,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),initial,2015-09-01,GCST003110,Response to drug,#807dba
11712,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Response to drug,#807dba
11713,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other disease,#99d594
11714,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),initial,2015-09-01,GCST003110,Other disease,#807dba
11715,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1),replication,2015-09-01,GCST003110,Other disease,#807dba
11717,Asian,61.0,26177304.0,Waterman M,Ulcerative colitis,initial,2015-09-01,GCST006583,Immune system disorder,#3288bd
11718,European,507.0,26177304.0,Waterman M,Ulcerative colitis,initial,2015-09-01,GCST006583,Immune system disorder,#d53e4f
11719,African,7.0,26177304.0,Waterman M,Ulcerative colitis,initial,2015-09-01,GCST006583,Immune system disorder,#fc8d59
11720,Hispanic/Latin American,2.0,26177304.0,Waterman M,Ulcerative colitis,initial,2015-09-01,GCST006583,Immune system disorder,#807dba
11722,Hispanic/Latin American,100.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other measurement,#807dba
11723,European,243.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other measurement,#d53e4f
11724,African Am./Caribbean,149.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other measurement,#fee08b
11726,Hispanic/Latin American,100.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Response to drug,#807dba
11727,European,243.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Response to drug,#d53e4f
11728,African Am./Caribbean,149.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Response to drug,#fee08b
11730,Hispanic/Latin American,100.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other disease,#807dba
11731,European,243.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other disease,#d53e4f
11732,African Am./Caribbean,149.0,26148204.0,Wanga V,Bilirubin levels in tenofovir-treated HIV infection,initial,2015-09-01,GCST006074,Other disease,#fee08b
11734,Hispanic/Latin American,100.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Response to drug,#807dba
11735,African Am./Caribbean,149.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Response to drug,#fee08b
11736,European,243.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Response to drug,#d53e4f
11738,Hispanic/Latin American,100.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Other disease,#807dba
11739,African Am./Caribbean,149.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Other disease,#fee08b
11740,European,243.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection,initial,2015-09-01,GCST006073,Other disease,#d53e4f
11741,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other measurement,#99d594
11742,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),initial,2015-09-01,GCST003107,Other measurement,#807dba
11743,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other measurement,#807dba
11744,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Response to drug,#99d594
11745,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),initial,2015-09-01,GCST003107,Response to drug,#807dba
11746,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Response to drug,#807dba
11747,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other disease,#99d594
11748,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),initial,2015-09-01,GCST003107,Other disease,#807dba
11749,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other disease,#807dba
11750,Other/Mixed,568.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other measurement,#99d594
11751,Hispanic/Latin American,447.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),initial,2015-09-01,GCST003107,Other measurement,#807dba
11752,Hispanic/Latin American,2414.0,26325155.0,Brehm JM,Post-bronchodilator lung function in asthma (FEV1/FVC),replication,2015-09-01,GCST003107,Other measurement,#807dba
11753,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Response to drug,#d53e4f
11754,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Response to drug,#807dba
11756,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Response to drug,#fee08b
11757,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other disease,#d53e4f
11758,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other disease,#807dba
11760,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other disease,#fee08b
11761,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other measurement,#d53e4f
11762,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other measurement,#807dba
11764,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (treatment arm interaction),initial,2015-09-01,GCST006072,Other measurement,#fee08b
11765,European,486.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Response to drug,#d53e4f
11766,African Am./Caribbean,338.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Response to drug,#fee08b
11767,Hispanic/Latin American,202.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Response to drug,#807dba
11769,European,486.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other disease,#d53e4f
11770,African Am./Caribbean,338.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other disease,#fee08b
11771,Hispanic/Latin American,202.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other disease,#807dba
11773,European,486.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other measurement,#d53e4f
11774,African Am./Caribbean,338.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other measurement,#fee08b
11775,Hispanic/Latin American,202.0,26148204.0,Wanga V,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),initial,2015-09-01,GCST006069,Other measurement,#807dba
11778,African Am./Caribbean,149.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Response to drug,#fee08b
11779,Hispanic/Latin American,100.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Response to drug,#807dba
11780,European,243.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Response to drug,#d53e4f
11782,African Am./Caribbean,149.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Other disease,#fee08b
11783,Hispanic/Latin American,100.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Other disease,#807dba
11784,European,243.0,26148204.0,Wanga V,Tenofovir clearance in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006071,Other disease,#d53e4f
11785,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Response to drug,#807dba
11786,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Response to drug,#fee08b
11787,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Response to drug,#d53e4f
11789,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other disease,#807dba
11790,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other disease,#fee08b
11791,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other disease,#d53e4f
11793,Hispanic/Latin American,202.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other measurement,#807dba
11794,African Am./Caribbean,338.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other measurement,#fee08b
11795,European,486.0,26148204.0,Wanga V,6-month creatinine clearance change response to tenofovir treatment in HIV infection (concomitant antiretroviral treatment interaction),initial,2015-09-01,GCST006070,Other measurement,#d53e4f
11797,European,189.0,26323598.0,Brandl EJ,Antipsychotic drug-induced weight gain (time interaction),initial,2015-09-01,GCST003108,Body measurement,#d53e4f
11798,European,189.0,26323598.0,Brandl EJ,Antipsychotic drug-induced weight gain (time interaction),initial,2015-09-01,GCST003108,Other trait,#d53e4f
11799,European,86.0,26323598.0,Brandl EJ,Antipsychotic drug-induced weight gain,replication,2015-09-01,GCST003109,Other trait,#d53e4f
11800,European,189.0,26323598.0,Brandl EJ,Antipsychotic drug-induced weight gain,initial,2015-09-01,GCST003109,Other trait,#d53e4f
11801,European,209379.0,26235824.0,Styrkarsdottir U,Low bone mineral density (spine),initial,2015-08-29,GCST003106,Other measurement,#d53e4f
11802,European,209379.0,26235824.0,Styrkarsdottir U,Low bone mineral density (hip),initial,2015-08-29,GCST003105,Other measurement,#d53e4f
11803,Asian,1643.0,26314684.0,Liu X,Autism spectrum disorder,replication,2015-08-28,GCST003104,Neurological disorder,#3288bd
11804,Asian,776.0,26314684.0,Liu X,Autism spectrum disorder,initial,2015-08-28,GCST003104,Neurological disorder,#3288bd
11805,European,13581.0,26316170.0,Demirci FY,Systemic lupus erythematosus,replication,2015-08-28,GCST003103,Immune system disorder,#d53e4f
11806,European,1148.0,26316170.0,Demirci FY,Systemic lupus erythematosus,initial,2015-08-28,GCST003103,Immune system disorder,#d53e4f
11807,European,1728.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#d53e4f
11808,Asian,826.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,initial,2015-08-27,GCST003101,Other measurement,#3288bd
11809,African Am./Caribbean,709.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#fee08b
11810,Hispanic/Latin American,408.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#807dba
11811,European,1728.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#d53e4f
11812,Asian,826.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,initial,2015-08-27,GCST003101,Other measurement,#3288bd
11813,African Am./Caribbean,709.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#fee08b
11814,Hispanic/Latin American,408.0,26312577.0,Tan LJ,Bone mineral density (spine) and age at menarche,replication,2015-08-27,GCST003101,Other measurement,#807dba
11815,Asian,826.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,initial,2015-08-27,GCST003102,Other measurement,#3288bd
11816,African Am./Caribbean,709.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#fee08b
11817,Hispanic/Latin American,408.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#807dba
11818,European,1728.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#d53e4f
11819,Asian,826.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,initial,2015-08-27,GCST003102,Other measurement,#3288bd
11820,African Am./Caribbean,709.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#fee08b
11821,Hispanic/Latin American,408.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#807dba
11822,European,1728.0,26312577.0,Tan LJ,Bone mineral density (hip) and age at menarche,replication,2015-08-27,GCST003102,Other measurement,#d53e4f
11823,African Am./Caribbean,2887.0,26305897.0,Iyengar SK,Diabetic kidney disease,replication,2015-08-25,GCST003098,Metabolic disorder,#fee08b
11824,Other/Mixed,1297.0,26305897.0,Iyengar SK,Diabetic kidney disease,replication,2015-08-25,GCST003098,Metabolic disorder,#99d594
11825,European,3355.0,26305897.0,Iyengar SK,Diabetic kidney disease,replication,2015-08-25,GCST003098,Metabolic disorder,#d53e4f
11826,Other/Mixed,857.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003098,Metabolic disorder,#99d594
11827,European,746.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003098,Metabolic disorder,#d53e4f
11828,Hispanic/Latin American,1373.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003098,Metabolic disorder,#807dba
11829,African Am./Caribbean,3221.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003098,Metabolic disorder,#fee08b
11830,African Am./Caribbean,3221.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003099,Metabolic disorder,#fee08b
11831,European,746.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003099,Metabolic disorder,#d53e4f
11832,Hispanic/Latin American,1373.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003099,Metabolic disorder,#807dba
11833,Other/Mixed,857.0,26305897.0,Iyengar SK,Diabetic kidney disease,initial,2015-08-25,GCST003099,Metabolic disorder,#99d594
11835,European,18197.0,26307654.0,Szulkin R,Prostate cancer (survival),replication,2015-08-25,GCST003100,Other measurement,#d53e4f
11837,European,18197.0,26307654.0,Szulkin R,Prostate cancer (survival),replication,2015-08-25,GCST003100,Cancer,#d53e4f
11838,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11839,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Metabolic disorder,#d53e4f
11840,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11841,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11842,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11843,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11844,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11845,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Digestive system disorder,#d53e4f
11846,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11847,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11848,European,16753.0,26301688.0,Li YR,Pediatric autoimmune diseases,initial,2015-08-24,GCST003097,Immune system disorder,#d53e4f
11849,European,737.0,26299439.0,Li WD,Adiponectin levels (BMI-adjusted),initial,2015-08-24,GCST003095,Other measurement,#d53e4f
11850,European,737.0,26299439.0,Li WD,Adiponectin levels,initial,2015-08-24,GCST003096,Other measurement,#d53e4f
11851,European,8201.0,26301497.0,Dina C,Mitral valve prolapse,replication,2015-08-24,GCST003094,Cardiovascular disease,#d53e4f
11852,European,3881.0,26301497.0,Dina C,Mitral valve prolapse,initial,2015-08-24,GCST003094,Cardiovascular disease,#d53e4f
11853,European,706.0,26297903.0,Fabbri C,Manic episodes in bipolar disorder,initial,2015-08-20,GCST003089,Other trait,#d53e4f
11854,European,706.0,26297903.0,Fabbri C,Manic episodes in bipolar disorder,initial,2015-08-20,GCST003089,Neurological disorder,#d53e4f
11855,European,723.0,26297903.0,Fabbri C,Depressive and manic episodes in bipolar disorder,initial,2015-08-20,GCST003090,Other measurement,#d53e4f
11856,European,723.0,26297903.0,Fabbri C,Depressive and manic episodes in bipolar disorder,initial,2015-08-20,GCST003090,Other measurement,#d53e4f
11857,European,723.0,26297903.0,Fabbri C,Depressive and manic episodes in bipolar disorder,initial,2015-08-20,GCST003090,Neurological disorder,#d53e4f
11858,European,2964.0,26293465.0,Durda P,Soluble interleukin-2 receptor subunit alpha,initial,2015-08-20,GCST003088,Other measurement,#d53e4f
11859,African Am./Caribbean,683.0,26293465.0,Durda P,Soluble interleukin-2 receptor subunit alpha,initial,2015-08-20,GCST003088,Other measurement,#fee08b
11860,European,4464.0,26293465.0,Durda P,Soluble interleukin-2 receptor subunit alpha,replication,2015-08-20,GCST003088,Other measurement,#d53e4f
11861,European,6434.0,26291516.0,Miller FW,Myositis,initial,2015-08-20,GCST003092,Immune system disorder,#d53e4f
11862,Asian,148.0,26289589.0,Nishizawa D,Nicotine dependence,initial,2015-08-20,GCST003093,Neurological disorder,#3288bd
11863,Asian,374.0,26289589.0,Nishizawa D,Nicotine dependence,replication,2015-08-20,GCST003093,Neurological disorder,#3288bd
11864,European,723.0,26297903.0,Fabbri C,Depressive episodes in bipolar disorder,initial,2015-08-20,GCST003091,Other measurement,#d53e4f
11865,European,723.0,26297903.0,Fabbri C,Depressive episodes in bipolar disorder,initial,2015-08-20,GCST003091,Neurological disorder,#d53e4f
11866,European,645.0,26284813.0,Hayes MG,Luteinizing hormone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005269,Other measurement,#d53e4f
11867,European,607.0,26284813.0,Hayes MG,Luteinizing hormone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005269,Other measurement,#d53e4f
11868,European,645.0,26284813.0,Hayes MG,Luteinizing hormone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005269,Other disease,#d53e4f
11869,European,607.0,26284813.0,Hayes MG,Luteinizing hormone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005269,Other disease,#d53e4f
11870,European,2021.0,26284813.0,Hayes MG,DHEAS levels in polycystic ovary syndrome,replication,2015-08-18,GCST005274,Other measurement,#d53e4f
11871,European,984.0,26284813.0,Hayes MG,DHEAS levels in polycystic ovary syndrome,initial,2015-08-18,GCST005274,Other measurement,#d53e4f
11872,European,2021.0,26284813.0,Hayes MG,DHEAS levels in polycystic ovary syndrome,replication,2015-08-18,GCST005274,Other disease,#d53e4f
11873,European,984.0,26284813.0,Hayes MG,DHEAS levels in polycystic ovary syndrome,initial,2015-08-18,GCST005274,Other disease,#d53e4f
11874,European,3948.0,26284813.0,Hayes MG,Polycystic ovary syndrome,initial,2015-08-18,GCST005273,Other disease,#d53e4f
11875,European,4582.0,26284813.0,Hayes MG,Polycystic ovary syndrome,replication,2015-08-18,GCST005273,Other disease,#d53e4f
11876,European,1516.0,26284813.0,Hayes MG,Testosterone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005272,Other disease,#d53e4f
11877,European,957.0,26284813.0,Hayes MG,Testosterone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005272,Other disease,#d53e4f
11878,European,1516.0,26284813.0,Hayes MG,Testosterone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005272,Other measurement,#d53e4f
11879,European,957.0,26284813.0,Hayes MG,Testosterone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005272,Other measurement,#d53e4f
11880,European,903.0,26284813.0,Hayes MG,Sex hormone-binding globulin levels in polycystic ovary syndrome,initial,2015-08-18,GCST005271,Other disease,#d53e4f
11881,European,1156.0,26284813.0,Hayes MG,Sex hormone-binding globulin levels in polycystic ovary syndrome,replication,2015-08-18,GCST005271,Other disease,#d53e4f
11882,European,903.0,26284813.0,Hayes MG,Sex hormone-binding globulin levels in polycystic ovary syndrome,initial,2015-08-18,GCST005271,Other measurement,#d53e4f
11883,European,1156.0,26284813.0,Hayes MG,Sex hormone-binding globulin levels in polycystic ovary syndrome,replication,2015-08-18,GCST005271,Other measurement,#d53e4f
11884,European,647.0,26284813.0,Hayes MG,Follicule stimulating hormone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005270,Other disease,#d53e4f
11885,European,606.0,26284813.0,Hayes MG,Follicule stimulating hormone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005270,Other disease,#d53e4f
11886,European,647.0,26284813.0,Hayes MG,Follicule stimulating hormone levels in polycystic ovary syndrome,initial,2015-08-18,GCST005270,Other measurement,#d53e4f
11887,European,606.0,26284813.0,Hayes MG,Follicule stimulating hormone levels in polycystic ovary syndrome,replication,2015-08-18,GCST005270,Other measurement,#d53e4f
11888,Asian,14131.0,26278006.0,Ahmad S,Body mass index variance,initial,2015-08-17,GCST003087,Body measurement,#3288bd
11889,European,285019.0,26272126.0,Oddsson A,Kidney stones,initial,2015-08-14,GCST003086,Other disease,#d53e4f
11890,European,2573.0,26272072.0,Jiang X,ACPA-negative rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006807,Immune system disorder,#d53e4f
11891,European,2573.0,26272072.0,Jiang X,ACPA-negative rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006807,Other measurement,#d53e4f
11892,European,2573.0,26272072.0,Jiang X,ACPA-negative rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006807,Immune system disorder,#d53e4f
11893,European,1516.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),replication,2015-08-13,GCST006410,Immune system disorder,#d53e4f
11894,European,2573.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006410,Immune system disorder,#d53e4f
11895,European,1516.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),replication,2015-08-13,GCST006410,Other measurement,#d53e4f
11896,European,2573.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006410,Other measurement,#d53e4f
11897,European,1516.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),replication,2015-08-13,GCST006410,Immune system disorder,#d53e4f
11898,European,2573.0,26272072.0,Jiang X,ACPA-positive rheumatoid arthritis (smoking interaction),initial,2015-08-13,GCST006410,Immune system disorder,#d53e4f
11899,European,587.0,26268663.0,Nalls MA,Parkinson's disease,initial,2015-08-13,GCST005548,Neurological disorder,#d53e4f
11900,African Am./Caribbean,191.0,26265036.0,Parra EJ,Warfarin maintenance dose,replication,2015-08-12,GCST003085,Response to drug,#fee08b
11901,Asian,1611.0,26265036.0,Parra EJ,Warfarin maintenance dose,replication,2015-08-12,GCST003085,Response to drug,#3288bd
11902,European,798.0,26265036.0,Parra EJ,Warfarin maintenance dose,replication,2015-08-12,GCST003085,Response to drug,#d53e4f
11903,Hispanic/Latin American,367.0,26265036.0,Parra EJ,Warfarin maintenance dose,initial,2015-08-12,GCST003085,Response to drug,#807dba
11905,Asian,48.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Response to drug,#3288bd
11906,European,1275.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Response to drug,#d53e4f
11907,Hispanic/Latin American,601.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Response to drug,#807dba
11908,African Am./Caribbean,139.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Response to drug,#fee08b
11910,Asian,48.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Other disease,#3288bd
11911,European,1275.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Other disease,#d53e4f
11912,Hispanic/Latin American,601.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Other disease,#807dba
11913,African Am./Caribbean,139.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time dependent analysis),initial,2015-08-11,GCST003083,Other disease,#fee08b
11915,European,1751.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Response to drug,#d53e4f
11916,African Am./Caribbean,248.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Response to drug,#fee08b
11917,Hispanic/Latin American,640.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Response to drug,#807dba
11918,Asian,54.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Response to drug,#3288bd
11920,European,1751.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Other disease,#d53e4f
11921,African Am./Caribbean,248.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Other disease,#fee08b
11922,Hispanic/Latin American,640.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Other disease,#807dba
11923,Asian,54.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis,initial,2015-08-11,GCST003084,Other disease,#3288bd
11924,European,495.0,26268530.0,Ramanan VK,Longitudinal change in brain amyloid plaque burden,initial,2015-08-11,GCST003082,Other measurement,#d53e4f
11929,European,476.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Response to drug,#d53e4f
11930,African Am./Caribbean,109.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Response to drug,#fee08b
11931,Hispanic/Latin American,39.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Response to drug,#807dba
11932,Asian,6.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Response to drug,#3288bd
11935,European,476.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Other disease,#d53e4f
11936,African Am./Caribbean,109.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Other disease,#fee08b
11937,Hispanic/Latin American,39.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Other disease,#807dba
11938,Asian,6.0,26265699.0,Karol SE,Glucocorticoid-induced osteonecrosis (time independent analysis),replication,2015-08-11,GCST003080,Other disease,#3288bd
11956,European,472.0,26252872.0,Li QS,Cognitive decline rate in late mild cognitive impairment,initial,2015-08-07,GCST003075,Other trait,#d53e4f
11958,European,472.0,26252872.0,Li QS,Cognitive decline rate in late mild cognitive impairment,initial,2015-08-07,GCST003075,Other measurement,#d53e4f
11966,Asian,128.0,26242244.0,Ma Y,Exploratory eye movement dysfunction in schizophrenia (responsive search score),initial,2015-08-05,GCST003065,Other measurement,#3288bd
11967,Asian,128.0,26242244.0,Ma Y,Exploratory eye movement dysfunction in schizophrenia (cognitive search score),initial,2015-08-05,GCST003064,Other measurement,#3288bd
11968,Asian,128.0,26242244.0,Ma Y,Exploratory eye movement dysfunction in schizophrenia (number of eye fixations),initial,2015-08-05,GCST003068,Other measurement,#3288bd
11969,Asian,128.0,26242244.0,Ma Y,Exploratory eye movement dysfunction in schizophrenia (mean eye scanning length),initial,2015-08-05,GCST003067,Other measurement,#3288bd
11970,Asian,128.0,26242244.0,Ma Y,Exploratory eye movement dysfunction in schizophrenia (total eye scanning length),initial,2015-08-05,GCST003066,Other measurement,#3288bd
11973,European,1328.0,26239289.0,Nelson EC,Opioid dependence,initial,2015-08-04,GCST003614,Neurological disorder,#d53e4f
11974,European,1309.0,26239289.0,Nelson EC,Opioid dependence,replication,2015-08-04,GCST003614,Neurological disorder,#d53e4f
11975,European,280.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,initial,2015-08-03,GCST003062,Cancer,#d53e4f
11976,European,96.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cancer,#d53e4f
11977,Other/Mixed,15.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cancer,#99d594
11978,Asian,31.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cancer,#3288bd
11979,Hispanic/Latin American,23.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cancer,#807dba
11980,African Am./Caribbean,11.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cancer,#fee08b
11981,European,280.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,initial,2015-08-03,GCST003062,Cardiovascular disease,#d53e4f
11982,European,96.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cardiovascular disease,#d53e4f
11983,Other/Mixed,15.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cardiovascular disease,#99d594
11984,Asian,31.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cardiovascular disease,#3288bd
11985,Hispanic/Latin American,23.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cardiovascular disease,#807dba
11986,African Am./Caribbean,11.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Cardiovascular disease,#fee08b
11987,European,280.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,initial,2015-08-03,GCST003062,Response to drug,#d53e4f
11988,European,96.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Response to drug,#d53e4f
11989,Other/Mixed,15.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Response to drug,#99d594
11990,Asian,31.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Response to drug,#3288bd
11991,Hispanic/Latin American,23.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Response to drug,#807dba
11992,African Am./Caribbean,11.0,26237429.0,Aminkeng F,Anthracycline-induced cardiotoxicity in childhood cancer,replication,2015-08-03,GCST003062,Response to drug,#fee08b
11994,European,1576.0,26237428.0,Law MH,Cutaneous malignant melanoma,replication,2015-08-03,GCST003061,Cancer,#d53e4f
11995,European,36077.0,26237428.0,Law MH,Cutaneous malignant melanoma,initial,2015-08-03,GCST003061,Cancer,#d53e4f
11996,Other/Mixed,79.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),initial,2015-08-02,GCST003060,Neurological disorder,#99d594
11997,Other/Mixed,75.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),replication,2015-08-02,GCST003060,Neurological disorder,#99d594
11998,Other/Mixed,79.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),initial,2015-08-02,GCST003060,Other measurement,#99d594
11999,Other/Mixed,75.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),replication,2015-08-02,GCST003060,Other measurement,#99d594
12000,Other/Mixed,79.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),initial,2015-08-02,GCST003060,Other measurement,#99d594
12001,Other/Mixed,75.0,26233692.0,Gan-Or Z,Parkinson's disease in GBA mutation carriers (age at onset),replication,2015-08-02,GCST003060,Other measurement,#99d594
12002,Asian,500.0,26227905.0,Hu Y,Parkinson's disease,initial,2015-07-31,GCST003059,Neurological disorder,#3288bd
12003,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),initial,2015-07-29,GCST003058,Other measurement,#d53e4f
12004,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),initial,2015-07-29,GCST003058,Cancer,#d53e4f
12005,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),initial,2015-07-29,GCST003058,Response to drug,#d53e4f
12006,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab),initial,2015-07-29,GCST003058,Response to drug,#d53e4f
12007,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (chemotherapy interaction),initial,2015-07-29,GCST003057,Other measurement,#d53e4f
12008,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (chemotherapy interaction),initial,2015-07-29,GCST003057,Cancer,#d53e4f
12009,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (chemotherapy interaction),initial,2015-07-29,GCST003057,Response to drug,#d53e4f
12010,European,520.0,26222057.0,Pander J,Progression free survival in metastatic colorectal cancer (chemotherapy interaction),initial,2015-07-29,GCST003057,Response to drug,#d53e4f
12014,European,622.0,26209787.0,Barthold JS,Cryptorchidism,replication,2015-07-24,GCST003053,Other disease,#d53e4f
12015,European,3562.0,26209787.0,Barthold JS,Cryptorchidism,initial,2015-07-24,GCST003053,Other disease,#d53e4f
12016,Asian,6947.0,26211971.0,Ogura Y,Adolescent idiopathic scoliosis,replication,2015-07-23,GCST003052,Other disease,#3288bd
12017,Asian,13249.0,26211971.0,Ogura Y,Adolescent idiopathic scoliosis,initial,2015-07-23,GCST003052,Other disease,#3288bd
12018,Other/Mixed,24.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Other measurement,#99d594
12019,Hispanic/Latin American,27.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Other measurement,#807dba
12020,European,469.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Other measurement,#d53e4f
12021,African Am./Caribbean,25.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Other measurement,#fee08b
12022,European,1090.0,26198393.0,Ziv E,Multiple myeloma (survival),replication,2015-07-22,GCST003051,Other measurement,#d53e4f
12023,Other/Mixed,24.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Cancer,#99d594
12024,Hispanic/Latin American,27.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Cancer,#807dba
12025,European,469.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Cancer,#d53e4f
12026,African Am./Caribbean,25.0,26198393.0,Ziv E,Multiple myeloma (survival),initial,2015-07-22,GCST003051,Cancer,#fee08b
12027,European,1090.0,26198393.0,Ziv E,Multiple myeloma (survival),replication,2015-07-22,GCST003051,Cancer,#d53e4f
12028,Other/Mixed,4058.0,26198764.0,Goes FS,Schizophrenia,initial,2015-07-21,GCST003050,Neurological disorder,#99d594
12030,Other/Mixed,1097.0,26198764.0,Goes FS,Schizophrenia,initial,2015-07-21,GCST003048,Neurological disorder,#99d594
12031,European,5606.0,26199339.0,Liu CY,Lung cancer (asbestos exposure interaction),replication,2015-07-21,GCST003049,Cancer,#d53e4f
12032,European,1572.0,26199339.0,Liu CY,Lung cancer (asbestos exposure interaction),initial,2015-07-21,GCST003049,Cancer,#d53e4f
12033,European,5606.0,26199339.0,Liu CY,Lung cancer (asbestos exposure interaction),replication,2015-07-21,GCST003049,Other measurement,#d53e4f
12034,European,1572.0,26199339.0,Liu CY,Lung cancer (asbestos exposure interaction),initial,2015-07-21,GCST003049,Other measurement,#d53e4f
12035,Other/Mixed,739.0,26192919.0,Liu JZ,Ulcerative colitis,replication,2015-07-20,GCST003045,Immune system disorder,#99d594
12036,Asian,2229.0,26192919.0,Liu JZ,Ulcerative colitis,replication,2015-07-20,GCST003045,Immune system disorder,#3288bd
12037,Asian,4853.0,26192919.0,Liu JZ,Ulcerative colitis,replication,2015-07-20,GCST003045,Immune system disorder,#3288bd
12038,European,37394.0,26192919.0,Liu JZ,Ulcerative colitis,replication,2015-07-20,GCST003045,Immune system disorder,#d53e4f
12039,European,27432.0,26192919.0,Liu JZ,Ulcerative colitis,initial,2015-07-20,GCST003045,Immune system disorder,#d53e4f
12040,Asian,2413.0,26192919.0,Liu JZ,Inflammatory bowel disease,replication,2015-07-20,GCST003043,Digestive system disorder,#3288bd
12041,European,34652.0,26192919.0,Liu JZ,Inflammatory bowel disease,initial,2015-07-20,GCST003043,Digestive system disorder,#d53e4f
12042,European,51988.0,26192919.0,Liu JZ,Inflammatory bowel disease,replication,2015-07-20,GCST003043,Digestive system disorder,#d53e4f
12043,Other/Mixed,890.0,26192919.0,Liu JZ,Inflammatory bowel disease,replication,2015-07-20,GCST003043,Digestive system disorder,#99d594
12044,Asian,6543.0,26192919.0,Liu JZ,Inflammatory bowel disease,replication,2015-07-20,GCST003043,Digestive system disorder,#3288bd
12045,Asian,1735.0,26190474.0,Dai Y,Trichloroethylene-induced hypersensitivity syndrome,replication,2015-07-20,GCST003046,Biological process,#3288bd
12046,Asian,196.0,26190474.0,Dai Y,Trichloroethylene-induced hypersensitivity syndrome,initial,2015-07-20,GCST003046,Biological process,#3288bd
12047,European,452.0,26194203.0,Ramachandran D,Atrioventricular septal defects in Down syndrome,initial,2015-07-20,GCST003047,Other trait,#d53e4f
12048,European,452.0,26194203.0,Ramachandran D,Atrioventricular septal defects in Down syndrome,initial,2015-07-20,GCST003047,Cardiovascular disease,#d53e4f
12049,European,20883.0,26192919.0,Liu JZ,Crohn's disease,initial,2015-07-20,GCST003044,Digestive system disorder,#d53e4f
12050,European,41309.0,26192919.0,Liu JZ,Crohn's disease,replication,2015-07-20,GCST003044,Digestive system disorder,#d53e4f
12051,Other/Mixed,493.0,26192919.0,Liu JZ,Crohn's disease,replication,2015-07-20,GCST003044,Digestive system disorder,#99d594
12052,Asian,1174.0,26192919.0,Liu JZ,Crohn's disease,replication,2015-07-20,GCST003044,Digestive system disorder,#3288bd
12053,Asian,5409.0,26192919.0,Liu JZ,Crohn's disease,replication,2015-07-20,GCST003044,Digestive system disorder,#3288bd
12054,European,844.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,initial,2015-07-19,GCST003042,Metabolic disorder,#d53e4f
12055,Asian,699.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,replication,2015-07-19,GCST003042,Metabolic disorder,#3288bd
12056,European,583.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,replication,2015-07-19,GCST003042,Metabolic disorder,#d53e4f
12057,European,844.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,initial,2015-07-19,GCST003042,Metabolic disorder,#d53e4f
12058,Asian,699.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,replication,2015-07-19,GCST003042,Metabolic disorder,#3288bd
12059,European,583.0,26188370.0,Burdon KP,Sight-threatening diabetic retinopathy in type 2 diabetes,replication,2015-07-19,GCST003042,Metabolic disorder,#d53e4f
12060,European,2155.0,26188009.0,Vuckovic D,Hearing function (high tone),initial,2015-07-17,GCST003040,Other measurement,#d53e4f
12061,European,270.0,26188009.0,Vuckovic D,Hearing function (high tone),replication,2015-07-17,GCST003040,Other measurement,#d53e4f
12062,Asian,481.0,26188009.0,Vuckovic D,Hearing function (high tone),replication,2015-07-17,GCST003040,Other measurement,#3288bd
12063,European,2155.0,26188009.0,Vuckovic D,Hearing function (high tone),initial,2015-07-17,GCST003040,Other measurement,#d53e4f
12064,European,270.0,26188009.0,Vuckovic D,Hearing function (high tone),replication,2015-07-17,GCST003040,Other measurement,#d53e4f
12065,Asian,481.0,26188009.0,Vuckovic D,Hearing function (high tone),replication,2015-07-17,GCST003040,Other measurement,#3288bd
12066,European,2155.0,26188009.0,Vuckovic D,Hearing function (medium tone),initial,2015-07-17,GCST003033,Other measurement,#d53e4f
12067,European,270.0,26188009.0,Vuckovic D,Hearing function (medium tone),replication,2015-07-17,GCST003033,Other measurement,#d53e4f
12068,Asian,481.0,26188009.0,Vuckovic D,Hearing function (medium tone),replication,2015-07-17,GCST003033,Other measurement,#3288bd
12069,European,2155.0,26188009.0,Vuckovic D,Hearing function (medium tone),initial,2015-07-17,GCST003033,Other measurement,#d53e4f
12070,European,270.0,26188009.0,Vuckovic D,Hearing function (medium tone),replication,2015-07-17,GCST003033,Other measurement,#d53e4f
12071,Asian,481.0,26188009.0,Vuckovic D,Hearing function (medium tone),replication,2015-07-17,GCST003033,Other measurement,#3288bd
12072,European,2155.0,26188009.0,Vuckovic D,Hearing function (low tone),initial,2015-07-17,GCST003036,Other measurement,#d53e4f
12073,European,270.0,26188009.0,Vuckovic D,Hearing function (low tone),replication,2015-07-17,GCST003036,Other measurement,#d53e4f
12074,Asian,481.0,26188009.0,Vuckovic D,Hearing function (low tone),replication,2015-07-17,GCST003036,Other measurement,#3288bd
12075,European,2155.0,26188009.0,Vuckovic D,Hearing function (low tone),initial,2015-07-17,GCST003036,Other measurement,#d53e4f
12076,European,270.0,26188009.0,Vuckovic D,Hearing function (low tone),replication,2015-07-17,GCST003036,Other measurement,#d53e4f
12077,Asian,481.0,26188009.0,Vuckovic D,Hearing function (low tone),replication,2015-07-17,GCST003036,Other measurement,#3288bd
12078,European,2155.0,26188009.0,Vuckovic D,Hearing function (8 kHz),initial,2015-07-17,GCST003034,Other measurement,#d53e4f
12079,Asian,481.0,26188009.0,Vuckovic D,Hearing function (8 kHz),replication,2015-07-17,GCST003034,Other measurement,#3288bd
12080,European,270.0,26188009.0,Vuckovic D,Hearing function (8 kHz),replication,2015-07-17,GCST003034,Other measurement,#d53e4f
12081,European,2155.0,26188009.0,Vuckovic D,Hearing function (8 kHz),initial,2015-07-17,GCST003034,Other measurement,#d53e4f
12082,Asian,481.0,26188009.0,Vuckovic D,Hearing function (8 kHz),replication,2015-07-17,GCST003034,Other measurement,#3288bd
12083,European,270.0,26188009.0,Vuckovic D,Hearing function (8 kHz),replication,2015-07-17,GCST003034,Other measurement,#d53e4f
12084,European,2155.0,26188009.0,Vuckovic D,Hearing function (4 kHz),initial,2015-07-17,GCST003035,Other measurement,#d53e4f
12085,European,6162.0,26188009.0,Vuckovic D,Hearing function (4 kHz),replication,2015-07-17,GCST003035,Other measurement,#d53e4f
12086,Asian,481.0,26188009.0,Vuckovic D,Hearing function (4 kHz),replication,2015-07-17,GCST003035,Other measurement,#3288bd
12087,European,2155.0,26188009.0,Vuckovic D,Hearing function (4 kHz),initial,2015-07-17,GCST003035,Other measurement,#d53e4f
12088,European,6162.0,26188009.0,Vuckovic D,Hearing function (4 kHz),replication,2015-07-17,GCST003035,Other measurement,#d53e4f
12089,Asian,481.0,26188009.0,Vuckovic D,Hearing function (4 kHz),replication,2015-07-17,GCST003035,Other measurement,#3288bd
12090,European,2155.0,26188009.0,Vuckovic D,Hearing function (2 kHz),initial,2015-07-17,GCST003032,Other measurement,#d53e4f
12091,Asian,481.0,26188009.0,Vuckovic D,Hearing function (2 kHz),replication,2015-07-17,GCST003032,Other measurement,#3288bd
12092,European,270.0,26188009.0,Vuckovic D,Hearing function (2 kHz),replication,2015-07-17,GCST003032,Other measurement,#d53e4f
12093,European,2155.0,26188009.0,Vuckovic D,Hearing function (2 kHz),initial,2015-07-17,GCST003032,Other measurement,#d53e4f
12094,Asian,481.0,26188009.0,Vuckovic D,Hearing function (2 kHz),replication,2015-07-17,GCST003032,Other measurement,#3288bd
12095,European,270.0,26188009.0,Vuckovic D,Hearing function (2 kHz),replication,2015-07-17,GCST003032,Other measurement,#d53e4f
12096,Asian,481.0,26188009.0,Vuckovic D,Hearing function (1 kHz),replication,2015-07-17,GCST003041,Other measurement,#3288bd
12097,European,2155.0,26188009.0,Vuckovic D,Hearing function (1 kHz),initial,2015-07-17,GCST003041,Other measurement,#d53e4f
12098,European,6162.0,26188009.0,Vuckovic D,Hearing function (1 kHz),replication,2015-07-17,GCST003041,Other measurement,#d53e4f
12099,Asian,481.0,26188009.0,Vuckovic D,Hearing function (1 kHz),replication,2015-07-17,GCST003041,Other measurement,#3288bd
12100,European,2155.0,26188009.0,Vuckovic D,Hearing function (1 kHz),initial,2015-07-17,GCST003041,Other measurement,#d53e4f
12101,European,6162.0,26188009.0,Vuckovic D,Hearing function (1 kHz),replication,2015-07-17,GCST003041,Other measurement,#d53e4f
12102,European,270.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),replication,2015-07-17,GCST003037,Other measurement,#d53e4f
12103,European,2155.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),initial,2015-07-17,GCST003037,Other measurement,#d53e4f
12104,Asian,481.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),replication,2015-07-17,GCST003037,Other measurement,#3288bd
12105,European,270.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),replication,2015-07-17,GCST003037,Other measurement,#d53e4f
12106,European,2155.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),initial,2015-07-17,GCST003037,Other measurement,#d53e4f
12107,Asian,481.0,26188009.0,Vuckovic D,Hearing function (0.5 kHz),replication,2015-07-17,GCST003037,Other measurement,#3288bd
12108,European,270.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),replication,2015-07-17,GCST003039,Other measurement,#d53e4f
12109,Asian,481.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),replication,2015-07-17,GCST003039,Other measurement,#3288bd
12110,European,2155.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),initial,2015-07-17,GCST003039,Other measurement,#d53e4f
12111,European,270.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),replication,2015-07-17,GCST003039,Other measurement,#d53e4f
12112,Asian,481.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),replication,2015-07-17,GCST003039,Other measurement,#3288bd
12113,European,2155.0,26188009.0,Vuckovic D,Hearing function (0.25 kHz),initial,2015-07-17,GCST003039,Other measurement,#d53e4f
12114,European,192.0,26186006.0,Abrantes P,Intracranial aneurysm,initial,2015-07-17,GCST003038,Cardiovascular disease,#d53e4f
12115,European,507.0,26186006.0,Abrantes P,Intracranial aneurysm,replication,2015-07-17,GCST003038,Cardiovascular disease,#d53e4f
12116,European,750.0,26184070.0,Aebi M,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder,initial,2015-07-16,GCST003030,Neurological disorder,#d53e4f
12117,European,750.0,26184070.0,Aebi M,Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder,initial,2015-07-16,GCST003030,Other measurement,#d53e4f
12118,European,289.0,26183928.0,Leng S,MGMT methylation in smokers,replication,2015-07-16,GCST003031,Biological process,#d53e4f
12119,European,1163.0,26183928.0,Leng S,MGMT methylation in smokers,initial,2015-07-16,GCST003031,Biological process,#d53e4f
12120,Hispanic/Latin American,141.0,26183928.0,Leng S,MGMT methylation in smokers,replication,2015-07-16,GCST003031,Biological process,#807dba
12121,European,289.0,26183928.0,Leng S,MGMT methylation in smokers,replication,2015-07-16,GCST003031,Other measurement,#d53e4f
12122,European,1163.0,26183928.0,Leng S,MGMT methylation in smokers,initial,2015-07-16,GCST003031,Other measurement,#d53e4f
12123,Hispanic/Latin American,141.0,26183928.0,Leng S,MGMT methylation in smokers,replication,2015-07-16,GCST003031,Other measurement,#807dba
12124,Asian,6065.0,26174136.0,Setoh K,Serum alpha1-antitrypsin levels,replication,2015-07-15,GCST003028,Other measurement,#3288bd
12125,Asian,3294.0,26174136.0,Setoh K,Serum alpha1-antitrypsin levels,initial,2015-07-15,GCST003028,Other measurement,#3288bd
12126,European,612.0,26176695.0,Warrier V,Asperger syndrome,initial,2015-07-15,GCST003029,Neurological disorder,#d53e4f
12127,Asian,947.0,26169365.0,Huang KC,Yu-Zhi constitution type in type 2 diabetes,initial,2015-07-14,GCST003026,Other trait,#3288bd
12128,Asian,947.0,26169365.0,Huang KC,Yu-Zhi constitution type in type 2 diabetes,initial,2015-07-14,GCST003026,Metabolic disorder,#3288bd
12129,Asian,112.0,26174610.0,Kwak TJ,Ultraviolet-induced skin pigmentation (minimal erythema dose),replication,2015-07-14,GCST003024,Other measurement,#3288bd
12130,Asian,99.0,26174610.0,Kwak TJ,Ultraviolet-induced skin pigmentation (minimal erythema dose),initial,2015-07-14,GCST003024,Other measurement,#3288bd
12131,European,479.0,26174813.0,Alemany S,Attention function in attention deficit hyperactive disorder,initial,2015-07-14,GCST003025,Neurological disorder,#d53e4f
12132,European,479.0,26174813.0,Alemany S,Attention function in attention deficit hyperactive disorder,initial,2015-07-14,GCST003025,Other measurement,#d53e4f
12133,European,6007.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Response to drug,#d53e4f
12134,African,879.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Response to drug,#fc8d59
12135,European,5231.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,replication,2015-07-14,GCST003027,Response to drug,#d53e4f
12136,Other/Mixed,194.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Response to drug,#99d594
12137,European,6007.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Other trait,#d53e4f
12138,African,879.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Other trait,#fc8d59
12139,European,5231.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,replication,2015-07-14,GCST003027,Other trait,#d53e4f
12140,Other/Mixed,194.0,26169577.0,Mosley JD,Cough in response to angiotensin-converting enzyme inhibitor drugs,initial,2015-07-14,GCST003027,Other trait,#99d594
12141,European,7091.0,26184321.0,Lin BD,Blond vs non-blond hair color,initial,2015-07-13,GCST003023,Other trait,#d53e4f
12142,European,7091.0,26184321.0,Lin BD,Black vs. non-black hair color,initial,2015-07-13,GCST003019,Other trait,#d53e4f
12143,European,7091.0,26184321.0,Lin BD,Red vs non-red hair color,initial,2015-07-13,GCST003020,Other trait,#d53e4f
12144,European,7091.0,26184321.0,Lin BD,Light vs. dark hair color,initial,2015-07-13,GCST003022,Other trait,#d53e4f
12145,European,7091.0,26184321.0,Lin BD,Brown vs. non-brown hair color,initial,2015-07-13,GCST003021,Other trait,#d53e4f
12146,Asian,14694.0,26151821.0,Schumacher FR,Colorectal cancer,replication,2015-07-07,GCST003017,Cancer,#3288bd
12147,European,37955.0,26151821.0,Schumacher FR,Colorectal cancer,initial,2015-07-07,GCST003017,Cancer,#d53e4f
12148,Asian,567.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,replication,2015-07-07,GCST003018,Other trait,#3288bd
12149,Asian,683.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,initial,2015-07-07,GCST003018,Other trait,#3288bd
12150,Asian,567.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,replication,2015-07-07,GCST003018,Response to drug,#3288bd
12151,Asian,683.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,initial,2015-07-07,GCST003018,Response to drug,#3288bd
12152,Asian,567.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,replication,2015-07-07,GCST003018,Immune system disorder,#3288bd
12153,Asian,683.0,26151496.0,Chen PL,Thionamide-induced agranulocytosis in Graves' disease,initial,2015-07-07,GCST003018,Immune system disorder,#3288bd
12154,European,375.0,26207136.0,Cho CH,Hypersomnia during a major depressive episode in bipolar disorder,initial,2015-07-06,GCST003016,Other trait,#d53e4f
12155,European,375.0,26207136.0,Cho CH,Hypersomnia during a major depressive episode in bipolar disorder,initial,2015-07-06,GCST003016,Neurological disorder,#d53e4f
12156,European,375.0,26207136.0,Cho CH,Hypersomnia during a major depressive episode in bipolar disorder,initial,2015-07-06,GCST003016,Neurological disorder,#d53e4f
12157,European,619.0,26146898.0,Clark SL,Alcohol consumption,initial,2015-07-04,GCST003015,Biological process,#d53e4f
12158,European,730.0,26146898.0,Clark SL,Alcohol consumption,replication,2015-07-04,GCST003015,Biological process,#d53e4f
12159,European,872.0,26256467.0,Wojczynski MK,Postprandial triglyceride response to high fat diet meal,initial,2015-07-03,GCST003014,Biological process,#d53e4f
12160,European,843.0,26256467.0,Wojczynski MK,Postprandial triglyceride response to high fat diet meal,replication,2015-07-03,GCST003014,Biological process,#d53e4f
12161,European,872.0,26256467.0,Wojczynski MK,Postprandial triglyceride response to high fat diet meal,initial,2015-07-03,GCST003014,Lipid or lipoprotein measurement,#d53e4f
12162,European,843.0,26256467.0,Wojczynski MK,Postprandial triglyceride response to high fat diet meal,replication,2015-07-03,GCST003014,Lipid or lipoprotein measurement,#d53e4f
12163,European,17936.0,25663218.0,Verhaaren BF,White matter hyperintensity burden,initial,2015-07-02,GCST003013,Other measurement,#d53e4f
12164,African Am./Caribbean,1943.0,25663218.0,Verhaaren BF,White matter hyperintensity burden,initial,2015-07-02,GCST003013,Other measurement,#fee08b
12165,Asian,204.0,25663218.0,Verhaaren BF,White matter hyperintensity burden,initial,2015-07-02,GCST003013,Other measurement,#3288bd
12166,Asian,201.0,25663218.0,Verhaaren BF,White matter hyperintensity burden,initial,2015-07-02,GCST003013,Other measurement,#3288bd
12167,Hispanic/Latin American,795.0,25663218.0,Verhaaren BF,White matter hyperintensity burden,initial,2015-07-02,GCST003013,Other measurement,#807dba
12168,European,1357.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Neurological disorder,#d53e4f
12169,African Am./Caribbean,90.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Neurological disorder,#fee08b
12170,European,789.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Neurological disorder,#d53e4f
12171,African Am./Caribbean,213.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Neurological disorder,#fee08b
12172,European,1357.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Response to drug,#d53e4f
12173,African Am./Caribbean,90.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Response to drug,#fee08b
12174,European,789.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Response to drug,#d53e4f
12175,African Am./Caribbean,213.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Response to drug,#fee08b
12176,European,1357.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Cancer,#d53e4f
12177,African Am./Caribbean,90.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Cancer,#fee08b
12178,European,789.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Cancer,#d53e4f
12179,African Am./Caribbean,213.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Cancer,#fee08b
12180,European,1357.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Response to drug,#d53e4f
12181,African Am./Caribbean,90.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Response to drug,#fee08b
12182,European,789.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,replication,2015-07-02,GCST003627,Response to drug,#d53e4f
12183,African Am./Caribbean,213.0,26138065.0,Schneider BP,Neuropathy in taxane-treated breast cancer,initial,2015-07-02,GCST003627,Response to drug,#fee08b
12184,Asian,470.0,25325441.0,Baik I,Obstructive sleep apnea,initial,2015-07-01,GCST003012,Neurological disorder,#3288bd
12185,Other/Mixed,78.0,27186693.0,Aydin-Son Y,Arthritis (juvenile idiopathic),initial,2015-07-01,GCST003011,Immune system disorder,#99d594
12186,Asian,14956.0,26129866.0,Hu N,Gastric cancer,replication,2015-06-30,GCST003010,Cancer,#3288bd
12187,Asian,5058.0,26129866.0,Hu N,Gastric cancer,initial,2015-06-30,GCST003010,Cancer,#3288bd
12188,Asian,3735.0,26129866.0,Hu N,Non-cardia gastric cancer,initial,2015-06-30,GCST003007,Cancer,#3288bd
12189,Asian,11211.0,26129866.0,Hu N,Non-cardia gastric cancer,replication,2015-06-30,GCST003007,Cancer,#3288bd
12190,Asian,11286.0,26129866.0,Hu N,Cardia gastric cancer,replication,2015-06-30,GCST003009,Cancer,#3288bd
12191,Asian,3897.0,26129866.0,Hu N,Cardia gastric cancer,initial,2015-06-30,GCST003009,Cancer,#3288bd
12192,European,55.0,26121980.0,Chauhan L,Triptolide cytotoxicity,initial,2015-06-30,GCST003008,Response to drug,#d53e4f
12193,European,55.0,26121980.0,Chauhan L,Triptolide cytotoxicity,initial,2015-06-30,GCST003008,Other measurement,#d53e4f
12194,Hispanic/Latin American,10.0,26121033.0,Grondin Y,Noise-induced hearing loss,initial,2015-06-29,GCST003006,Neurological disorder,#807dba
12195,European,31.0,26121033.0,Grondin Y,Noise-induced hearing loss,initial,2015-06-29,GCST003006,Neurological disorder,#d53e4f
12196,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Ear protrusion,initial,2015-06-24,GCST002994,Other trait,#807dba
12197,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Folding of antihelix,initial,2015-06-24,GCST002996,Other trait,#807dba
12198,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Helix rolling,initial,2015-06-24,GCST002997,Other trait,#807dba
12199,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Lobe attachment,initial,2015-06-24,GCST002998,Other trait,#807dba
12200,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Lobe size,initial,2015-06-24,GCST002999,Other trait,#807dba
12201,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Ear morphology,initial,2015-06-24,GCST003001,Other trait,#807dba
12202,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Darwin's tubercle,initial,2015-06-24,GCST003000,Other trait,#807dba
12203,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Superior crus of antihelix expression,initial,2015-06-24,GCST003005,Other trait,#807dba
12204,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Crus helix expression,initial,2015-06-24,GCST003004,Other trait,#807dba
12205,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Antitragus size,initial,2015-06-24,GCST003003,Other trait,#807dba
12206,Hispanic/Latin American,4919.0,26105758.0,Adhikari K,Tragus size,initial,2015-06-24,GCST003002,Other trait,#807dba
12207,European,555.0,26116289.0,Raginis-Zborowska A,Dysphagia,initial,2015-06-24,GCST002995,Other trait,#d53e4f
12208,Asian,375.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,replication,2015-06-23,GCST002993,Response to drug,#3288bd
12209,Asian,329.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,initial,2015-06-23,GCST002993,Response to drug,#3288bd
12210,Asian,375.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,replication,2015-06-23,GCST002993,Cancer,#3288bd
12211,Asian,329.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,initial,2015-06-23,GCST002993,Cancer,#3288bd
12212,Asian,375.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,replication,2015-06-23,GCST002993,Digestive system disorder,#3288bd
12213,Asian,329.0,26100964.0,Cao S,Platinum-induced hepatotoxicity in non-small cell lung cancer,initial,2015-06-23,GCST002993,Digestive system disorder,#3288bd
12216,European,7320.0,26098869.0,Childs EJ,Pancreatic cancer,initial,2015-06-22,GCST002991,Cancer,#d53e4f
12218,European,204576.0,26098866.0,Helgason H,Gastric adenocarcinoma (histologically verified),initial,2015-06-22,GCST002990,Cancer,#d53e4f
12219,European,208152.0,26098866.0,Helgason H,Gastric cancer,initial,2015-06-22,GCST002992,Cancer,#d53e4f
12220,European,540.0,26112879.0,Rudkowska I,LDL peak particle diameter (total fat intake interaction),initial,2015-06-20,GCST002989,Lipid or lipoprotein measurement,#d53e4f
12221,European,540.0,26112879.0,Rudkowska I,LDL peak particle diameter (total fat intake interaction),initial,2015-06-20,GCST002989,Other measurement,#d53e4f
12222,European,15668.0,26087016.0,Pappa I,Early childhood aggressive behavior,initial,2015-06-18,GCST002984,Other measurement,#d53e4f
12223,African Am./Caribbean,14746.0,26089329.0,Carty CL,Stroke,initial,2015-06-18,GCST002987,Cardiovascular disease,#fee08b
12224,African Am./Caribbean,14519.0,26089329.0,Carty CL,Ischemic stroke,initial,2015-06-18,GCST002988,Other trait,#fee08b
12225,European,18988.0,26087016.0,Pappa I,Childhood and early adolescence aggressive behavior,initial,2015-06-18,GCST002986,Other measurement,#d53e4f
12226,Hispanic/Latin American,786.0,26339675.0,Tosto G,Alzheimer's disease (late onset),replication,2015-06-18,GCST002983,Neurological disorder,#807dba
12227,Hispanic/Latin American,4514.0,26339675.0,Tosto G,Alzheimer's disease (late onset),initial,2015-06-18,GCST002983,Neurological disorder,#807dba
12228,European,16311.0,26087016.0,Pappa I,Middle childhood and early adolescence aggressive behavior,initial,2015-06-18,GCST002985,Other measurement,#d53e4f
12229,Asian,538.0,26039976.0,Wei Z,HIV-1 viral setpoint,initial,2015-06-17,GCST002976,Other disease,#3288bd
12230,Asian,538.0,26039976.0,Wei Z,HIV-1 viral setpoint,initial,2015-06-17,GCST002976,Other measurement,#3288bd
12231,African,1737.0,26083729.0,Maruthur NM,Advanced glycation end-product levels,initial,2015-06-17,GCST002977,Other measurement,#fc8d59
12232,European,581.0,26083729.0,Maruthur NM,Advanced glycation end-product levels,initial,2015-06-17,GCST002977,Other measurement,#d53e4f
12233,Hispanic/Latin American,107.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#807dba
12234,African,61.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#fc8d59
12236,European,226.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#d53e4f
12237,Hispanic/Latin American,107.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#807dba
12238,African,61.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#fc8d59
12240,European,226.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Other measurement,#d53e4f
12241,Hispanic/Latin American,107.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Cancer,#807dba
12242,African,61.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Cancer,#fc8d59
12244,European,226.0,26084801.0,Mirabello L,Metastasis at diagnosis in osteosarcoma,replication,2015-06-17,GCST002978,Cancer,#d53e4f
12245,African,10.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other measurement,#fc8d59
12246,European,101.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other measurement,#d53e4f
12247,European,88.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other measurement,#d53e4f
12248,Asian,35.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other measurement,#3288bd
12249,Asian,50.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other measurement,#3288bd
12250,African,33.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other measurement,#fc8d59
12251,African,10.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Response to drug,#fc8d59
12252,European,101.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Response to drug,#d53e4f
12253,European,88.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Response to drug,#d53e4f
12254,Asian,35.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Response to drug,#3288bd
12255,Asian,50.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Response to drug,#3288bd
12256,African,33.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Response to drug,#fc8d59
12257,African,10.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other disease,#fc8d59
12258,European,101.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other disease,#d53e4f
12259,European,88.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other disease,#d53e4f
12260,Asian,35.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),initial,2015-06-17,GCST002979,Other disease,#3288bd
12261,Asian,50.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other disease,#3288bd
12262,African,33.0,26083242.0,Dahlin A,Response to montelukast in asthma (change in FEV1),replication,2015-06-17,GCST002979,Other disease,#fc8d59
12263,Asian,1206.0,26083723.0,Park S,Arterial stiffness (pulse-wave velocity),replication,2015-06-17,GCST002980,Cardiovascular measurement,#3288bd
12264,Asian,402.0,26083723.0,Park S,Arterial stiffness (pulse-wave velocity),initial,2015-06-17,GCST002980,Cardiovascular measurement,#3288bd
12266,European,873.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),initial,2015-06-17,GCST002982,Other trait,#d53e4f
12267,European,380.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),replication,2015-06-17,GCST002982,Other trait,#d53e4f
12268,European,873.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),initial,2015-06-17,GCST002982,Other trait,#d53e4f
12269,European,380.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),replication,2015-06-17,GCST002982,Other trait,#d53e4f
12270,European,873.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),initial,2015-06-17,GCST002982,Other measurement,#d53e4f
12271,European,380.0,26083657.0,Stafford-Smith M,Acute kidney injury in coronary artery bypass surgery (creatinine rise),replication,2015-06-17,GCST002982,Other measurement,#d53e4f
12272,European,877.0,26385043.0,Kertai MD,Postoperative atrial fibrillation in coronary artery bypass grafting surgery,initial,2015-06-17,GCST002975,Other trait,#d53e4f
12274,European,877.0,26385043.0,Kertai MD,Postoperative atrial fibrillation in coronary artery bypass grafting surgery,initial,2015-06-17,GCST002975,Cardiovascular disease,#d53e4f
12278,European,557.0,26079190.0,Galfalvy H,Suicide attempts in major depressive disorder,initial,2015-06-16,GCST002972,Neurological disorder,#d53e4f
12279,European,557.0,26079190.0,Galfalvy H,Suicide attempts in major depressive disorder,initial,2015-06-16,GCST002972,Biological process,#d53e4f
12280,European,1550.0,26079190.0,Galfalvy H,Suicide,initial,2015-06-16,GCST002973,Biological process,#d53e4f
12281,European,358.0,26079190.0,Galfalvy H,Suicide ideation score in major depressive disorder,initial,2015-06-16,GCST002974,Other measurement,#d53e4f
12282,European,358.0,26079190.0,Galfalvy H,Suicide ideation score in major depressive disorder,initial,2015-06-16,GCST002974,Neurological disorder,#d53e4f
12284,European,1810.0,26079190.0,Galfalvy H,Suicide behavior,initial,2015-06-16,GCST002969,Biological process,#d53e4f
12285,Asian,141.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),initial,2015-06-15,GCST002968,Other disease,#3288bd
12286,Asian,190.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),replication,2015-06-15,GCST002968,Other disease,#3288bd
12287,Asian,141.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),initial,2015-06-15,GCST002968,Response to drug,#3288bd
12288,Asian,190.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),replication,2015-06-15,GCST002968,Response to drug,#3288bd
12289,Asian,141.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),initial,2015-06-15,GCST002968,Other trait,#3288bd
12290,Asian,190.0,25950743.0,Uttayamakul S,Response to stavudine in HIV (lipoatrophy),replication,2015-06-15,GCST002968,Other trait,#3288bd
12291,European,23337.0,26075790.0,Kelemen LE,Mucinous ovarian carcinoma,initial,2015-06-15,GCST002967,Cancer,#d53e4f
12292,European,262.0,26077402.0,de Rooy DP,Joint damage progression in ACPA-negative rheumatoid arthritis,initial,2015-06-15,GCST003256,Immune system disorder,#d53e4f
12293,European,253.0,26077402.0,de Rooy DP,Joint damage progression in ACPA-negative rheumatoid arthritis,replication,2015-06-15,GCST003256,Immune system disorder,#d53e4f
12294,European,262.0,26077402.0,de Rooy DP,Joint damage progression in ACPA-negative rheumatoid arthritis,initial,2015-06-15,GCST003256,Other measurement,#d53e4f
12295,European,253.0,26077402.0,de Rooy DP,Joint damage progression in ACPA-negative rheumatoid arthritis,replication,2015-06-15,GCST003256,Other measurement,#d53e4f
12296,European,1182.0,26068415.0,Draisma HHM,Acylcarnitine levels,replication,2015-06-12,GCST002961,Other measurement,#d53e4f
12297,European,7478.0,26068415.0,Draisma HHM,Acylcarnitine levels,initial,2015-06-12,GCST002961,Other measurement,#d53e4f
12298,European,1182.0,26068415.0,Draisma HHM,Acylcarnitine levels,replication,2015-06-12,GCST002961,Other measurement,#d53e4f
12299,European,7478.0,26068415.0,Draisma HHM,Acylcarnitine levels,initial,2015-06-12,GCST002961,Other measurement,#d53e4f
12300,European,7478.0,26068415.0,Draisma HHM,Hexose levels,initial,2015-06-12,GCST002959,Other measurement,#d53e4f
12301,European,1182.0,26068415.0,Draisma HHM,Hexose levels,replication,2015-06-12,GCST002959,Other measurement,#d53e4f
12302,European,7478.0,26068415.0,Draisma HHM,Hexose levels,initial,2015-06-12,GCST002959,Other measurement,#d53e4f
12303,European,1182.0,26068415.0,Draisma HHM,Hexose levels,replication,2015-06-12,GCST002959,Other measurement,#d53e4f
12304,European,7478.0,26068415.0,Draisma HHM,Sphingolipid levels,initial,2015-06-12,GCST002964,Lipid or lipoprotein measurement,#d53e4f
12305,European,1182.0,26068415.0,Draisma HHM,Sphingolipid levels,replication,2015-06-12,GCST002964,Lipid or lipoprotein measurement,#d53e4f
12306,European,7478.0,26068415.0,Draisma HHM,Sphingolipid levels,initial,2015-06-12,GCST002964,Other measurement,#d53e4f
12307,European,1182.0,26068415.0,Draisma HHM,Sphingolipid levels,replication,2015-06-12,GCST002964,Other measurement,#d53e4f
12308,European,1182.0,26068415.0,Draisma HHM,Glycerophospholipid levels,replication,2015-06-12,GCST002965,Lipid or lipoprotein measurement,#d53e4f
12309,European,7478.0,26068415.0,Draisma HHM,Glycerophospholipid levels,initial,2015-06-12,GCST002965,Lipid or lipoprotein measurement,#d53e4f
12310,European,1182.0,26068415.0,Draisma HHM,Glycerophospholipid levels,replication,2015-06-12,GCST002965,Other measurement,#d53e4f
12311,European,7478.0,26068415.0,Draisma HHM,Glycerophospholipid levels,initial,2015-06-12,GCST002965,Other measurement,#d53e4f
12312,European,7478.0,26068415.0,Draisma HHM,Amino acid levels,initial,2015-06-12,GCST002966,Other measurement,#d53e4f
12313,European,1182.0,26068415.0,Draisma HHM,Amino acid levels,replication,2015-06-12,GCST002966,Other measurement,#d53e4f
12314,European,7478.0,26068415.0,Draisma HHM,Amino acid levels,initial,2015-06-12,GCST002966,Other measurement,#d53e4f
12315,European,1182.0,26068415.0,Draisma HHM,Amino acid levels,replication,2015-06-12,GCST002966,Other measurement,#d53e4f
12316,European,1456.0,26154020.0,Ferrari R,Frontotemporal dementia,initial,2015-06-12,GCST002960,Neurological disorder,#d53e4f
12317,African,949.0,26114229.0,Ashley-Koch AE,Post-traumatic stress disorder,initial,2015-06-12,GCST002963,Neurological disorder,#fc8d59
12318,European,759.0,26114229.0,Ashley-Koch AE,Post-traumatic stress disorder,initial,2015-06-12,GCST002963,Neurological disorder,#d53e4f
12320,European,581.0,26073756.0,McGeachie MJ,Asthma exacerbations,initial,2015-06-12,GCST002962,Other measurement,#d53e4f
12321,African Am./Caribbean,212.0,26073756.0,McGeachie MJ,Asthma exacerbations,replication,2015-06-12,GCST002962,Other measurement,#fee08b
12322,European,652.0,26073756.0,McGeachie MJ,Asthma exacerbations,replication,2015-06-12,GCST002962,Other measurement,#d53e4f
12323,European,52.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Biological process,#d53e4f
12324,African,13.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Biological process,#fc8d59
12325,Asian,1.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Biological process,#3288bd
12326,European,64.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Biological process,#d53e4f
12327,Other/Mixed,2.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Biological process,#99d594
12328,Asian,2.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Biological process,#3288bd
12329,Other/Mixed,17.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Biological process,#99d594
12330,African,17.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Biological process,#fc8d59
12331,European,52.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Immune system disorder,#d53e4f
12332,African,13.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Immune system disorder,#fc8d59
12333,Asian,1.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Immune system disorder,#3288bd
12334,European,64.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Immune system disorder,#d53e4f
12335,Other/Mixed,2.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,initial,2015-06-11,GCST002958,Immune system disorder,#99d594
12336,Asian,2.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Immune system disorder,#3288bd
12337,Other/Mixed,17.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Immune system disorder,#99d594
12338,African,17.0,26067905.0,Bari R,Acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation,replication,2015-06-11,GCST002958,Immune system disorder,#fc8d59
12339,African Am./Caribbean,362.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Biological process,#fee08b
12340,Other/Mixed,329.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Biological process,#99d594
12341,Hispanic/Latin American,449.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Biological process,#807dba
12342,Asian,704.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Biological process,#3288bd
12343,European,438.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Biological process,#d53e4f
12344,African Am./Caribbean,362.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Other measurement,#fee08b
12345,Other/Mixed,329.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Other measurement,#99d594
12346,Hispanic/Latin American,449.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Other measurement,#807dba
12347,Asian,704.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Other measurement,#3288bd
12348,European,438.0,26053186.0,Park SL,3-hydroxypropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002956,Other measurement,#d53e4f
12349,African Am./Caribbean,361.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Biological process,#fee08b
12350,European,440.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Biological process,#d53e4f
12351,Hispanic/Latin American,452.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Biological process,#807dba
12352,Asian,702.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Biological process,#3288bd
12353,Other/Mixed,329.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Biological process,#99d594
12354,African Am./Caribbean,361.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Other measurement,#fee08b
12355,European,440.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Other measurement,#d53e4f
12356,Hispanic/Latin American,452.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Other measurement,#807dba
12357,Asian,702.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Other measurement,#3288bd
12358,Other/Mixed,329.0,26053186.0,Park SL,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,initial,2015-06-08,GCST002957,Other measurement,#99d594
12359,Asian,8223.0,26049409.0,Hirano A,Alzheimer's disease (late onset),replication,2015-06-05,GCST002954,Neurological disorder,#3288bd
12360,Asian,8808.0,26049409.0,Hirano A,Alzheimer's disease (late onset),initial,2015-06-05,GCST002954,Neurological disorder,#3288bd
12369,European,908.0,26041818.0,Chesi A,Pediatric areal bone mineral density (radius),initial,2015-06-03,GCST002953,Other measurement,#d53e4f
12370,African Am./Caribbean,337.0,26041818.0,Chesi A,Pediatric areal bone mineral density (radius),initial,2015-06-03,GCST002953,Other measurement,#fee08b
12371,Other/Mixed,126.0,26041818.0,Chesi A,Pediatric areal bone mineral density (radius),initial,2015-06-03,GCST002953,Other measurement,#99d594
12372,European,481.0,26041818.0,Chesi A,Pediatric areal bone mineral density (radius),replication,2015-06-03,GCST002953,Other measurement,#d53e4f
12373,African Am./Caribbean,337.0,26041818.0,Chesi A,Pediatric bone mineral content (radius),initial,2015-06-03,GCST002952,Other measurement,#fee08b
12374,Other/Mixed,126.0,26041818.0,Chesi A,Pediatric bone mineral content (radius),initial,2015-06-03,GCST002952,Other measurement,#99d594
12375,European,481.0,26041818.0,Chesi A,Pediatric bone mineral content (radius),replication,2015-06-03,GCST002952,Other measurement,#d53e4f
12376,European,908.0,26041818.0,Chesi A,Pediatric bone mineral content (radius),initial,2015-06-03,GCST002952,Other measurement,#d53e4f
12378,European,187.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),replication,2015-06-02,GCST002951,Other measurement,#d53e4f
12380,European,259.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),initial,2015-06-02,GCST002951,Other measurement,#d53e4f
12382,European,187.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),replication,2015-06-02,GCST002951,Response to drug,#d53e4f
12384,European,259.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),initial,2015-06-02,GCST002951,Response to drug,#d53e4f
12386,European,187.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),replication,2015-06-02,GCST002951,Other disease,#d53e4f
12388,European,259.0,26031901.0,Dahlin A,Response to zileuton treatment in asthma (FEV1 change interaction),initial,2015-06-02,GCST002951,Other disease,#d53e4f
12389,Asian,1211.0,26220383.0,Jang HW,Epilepsy,initial,2015-06-02,GCST002950,Neurological disorder,#3288bd
12390,Asian,1114.0,26220383.0,Jang HW,Epilepsy and lamotrigine-induced maculopapular eruptions,initial,2015-06-02,GCST002949,Response to drug,#3288bd
12391,Asian,1114.0,26220383.0,Jang HW,Epilepsy and lamotrigine-induced maculopapular eruptions,initial,2015-06-02,GCST002949,Other disease,#3288bd
12392,Asian,1114.0,26220383.0,Jang HW,Epilepsy and lamotrigine-induced maculopapular eruptions,initial,2015-06-02,GCST002949,Neurological disorder,#3288bd
12393,European,6305.0,26030696.0,Cho MH,Percentage gas trapping,initial,2015-06-01,GCST002942,Other measurement,#d53e4f
12394,African Am./Caribbean,3033.0,26030696.0,Cho MH,Percentage gas trapping,initial,2015-06-01,GCST002942,Other measurement,#fee08b
12395,European,343.0,26030142.0,Van Driest SL,Renal elimination rate in vancomycin therapy,replication,2015-06-01,GCST002947,Other measurement,#d53e4f
12396,European,745.0,26030142.0,Van Driest SL,Renal elimination rate in vancomycin therapy,initial,2015-06-01,GCST002947,Other measurement,#d53e4f
12397,European,343.0,26030142.0,Van Driest SL,Renal elimination rate in vancomycin therapy,replication,2015-06-01,GCST002947,Response to drug,#d53e4f
12398,European,745.0,26030142.0,Van Driest SL,Renal elimination rate in vancomycin therapy,initial,2015-06-01,GCST002947,Response to drug,#d53e4f
12399,European,745.0,26030142.0,Van Driest SL,Vancomycin trough in vancomycin therapy,initial,2015-06-01,GCST002946,Other measurement,#d53e4f
12400,European,343.0,26030142.0,Van Driest SL,Vancomycin trough in vancomycin therapy,replication,2015-06-01,GCST002946,Other measurement,#d53e4f
12401,European,745.0,26030142.0,Van Driest SL,Vancomycin trough in vancomycin therapy,initial,2015-06-01,GCST002946,Response to drug,#d53e4f
12402,European,343.0,26030142.0,Van Driest SL,Vancomycin trough in vancomycin therapy,replication,2015-06-01,GCST002946,Response to drug,#d53e4f
12403,Asian,12095.0,26028593.0,Li M,IgA nephropathy,initial,2015-06-01,GCST002943,Other disease,#3288bd
12404,Asian,15898.0,26028593.0,Li M,IgA nephropathy,replication,2015-06-01,GCST002943,Other disease,#3288bd
12405,European,37272.0,26034056.0,Hoffmann TJ,Prostate cancer,initial,2015-06-01,GCST002944,Cancer,#d53e4f
12406,European,7539.0,26034056.0,Hoffmann TJ,Prostate cancer,replication,2015-06-01,GCST002944,Cancer,#d53e4f
12407,African Am./Caribbean,4679.0,26034056.0,Hoffmann TJ,Prostate cancer,replication,2015-06-01,GCST002944,Cancer,#fee08b
12408,African Am./Caribbean,2251.0,26034056.0,Hoffmann TJ,Prostate cancer,initial,2015-06-01,GCST002944,Cancer,#fee08b
12409,Hispanic/Latin American,3629.0,26034056.0,Hoffmann TJ,Prostate cancer,initial,2015-06-01,GCST002944,Cancer,#807dba
12410,Asian,3226.0,26034056.0,Hoffmann TJ,Prostate cancer,initial,2015-06-01,GCST002944,Cancer,#3288bd
12411,European,489.0,26030142.0,Van Driest SL,Peak creatinine levels in vancomycin therapy,initial,2015-06-01,GCST002948,Response to drug,#d53e4f
12412,European,439.0,26030142.0,Van Driest SL,Peak creatinine levels in vancomycin therapy,replication,2015-06-01,GCST002948,Response to drug,#d53e4f
12413,European,489.0,26030142.0,Van Driest SL,Peak creatinine levels in vancomycin therapy,initial,2015-06-01,GCST002948,Other measurement,#d53e4f
12414,European,439.0,26030142.0,Van Driest SL,Peak creatinine levels in vancomycin therapy,replication,2015-06-01,GCST002948,Other measurement,#d53e4f
12415,Asian,3559.0,26029870.0,Ye Z,Sporadic pituitary adenoma,initial,2015-06-01,GCST002940,Cancer,#3288bd
12416,Asian,6162.0,26029870.0,Ye Z,Sporadic pituitary adenoma,replication,2015-06-01,GCST002940,Cancer,#3288bd
12417,European,8998.0,26030696.0,Cho MH,Emphysema imaging phenotypes,initial,2015-06-01,GCST002945,Other measurement,#d53e4f
12418,African Am./Caribbean,3033.0,26030696.0,Cho MH,Emphysema imaging phenotypes,initial,2015-06-01,GCST002945,Other measurement,#fee08b
12419,European,8998.0,26030696.0,Cho MH,Airway imaging phenotypes,initial,2015-06-01,GCST002941,Other measurement,#d53e4f
12420,African Am./Caribbean,3033.0,26030696.0,Cho MH,Airway imaging phenotypes,initial,2015-06-01,GCST002941,Other measurement,#fee08b
12421,African Am./Caribbean,825.0,26024889.0,Qayyum R,Platelet aggregation,initial,2015-05-30,GCST002939,Biological process,#fee08b
12422,European,1221.0,26024889.0,Qayyum R,Platelet aggregation,replication,2015-05-30,GCST002939,Biological process,#d53e4f
12423,African Am./Caribbean,119.0,26024889.0,Qayyum R,Platelet aggregation,replication,2015-05-30,GCST002939,Biological process,#fee08b
12424,European,949.0,26025379.0,Ng E,Nickel levels,initial,2015-05-29,GCST002928,Other measurement,#d53e4f
12425,European,949.0,26025379.0,Ng E,Copper levels,initial,2015-05-29,GCST002938,Other measurement,#d53e4f
12426,African Am./Caribbean,2737.0,26058915.0,Tin A,Magnesium levels,initial,2015-05-29,GCST002933,Other measurement,#fee08b
12427,African Am./Caribbean,942.0,26058915.0,Tin A,Magnesium levels,replication,2015-05-29,GCST002933,Other measurement,#fee08b
12428,European,949.0,26025379.0,Ng E,Cadmium levels,initial,2015-05-29,GCST002936,Other measurement,#d53e4f
12429,European,949.0,26025379.0,Ng E,Mercury levels,initial,2015-05-29,GCST002927,Other measurement,#d53e4f
12430,European,949.0,26025379.0,Ng E,Zinc levels,initial,2015-05-29,GCST002934,Other measurement,#d53e4f
12431,European,949.0,26025379.0,Ng E,Lead levels,initial,2015-05-29,GCST002935,Other measurement,#d53e4f
12432,European,949.0,26025379.0,Ng E,Molybdenum levels,initial,2015-05-29,GCST002937,Other measurement,#d53e4f
12433,European,949.0,26025379.0,Ng E,Manganese levels,initial,2015-05-29,GCST002932,Other measurement,#d53e4f
12434,European,949.0,26025379.0,Ng E,Aluminium levels,initial,2015-05-29,GCST002931,Other measurement,#d53e4f
12435,European,949.0,26025379.0,Ng E,Cobalt levels,initial,2015-05-29,GCST002930,Other measurement,#d53e4f
12436,European,949.0,26025379.0,Ng E,Chromium levels,initial,2015-05-29,GCST002929,Other measurement,#d53e4f
12437,European,2913.0,26014426.0,Ruth KS,Sex hormone levels,initial,2015-05-27,GCST002925,Other measurement,#d53e4f
12438,European,489.0,26025128.0,Park HW,Bone mineral accretion in asthma (oral corticosteroid dose interaction),initial,2015-05-27,GCST002926,Other measurement,#d53e4f
12439,European,489.0,26025128.0,Park HW,Bone mineral accretion in asthma (oral corticosteroid dose interaction),initial,2015-05-27,GCST002926,Response to drug,#d53e4f
12440,European,489.0,26025128.0,Park HW,Bone mineral accretion in asthma (oral corticosteroid dose interaction),initial,2015-05-27,GCST002926,Other disease,#d53e4f
12441,European,2697.0,26007630.0,Swaminathan B,Multiple myeloma,replication,2015-05-26,GCST002921,Cancer,#d53e4f
12442,European,224749.0,26007630.0,Swaminathan B,Multiple myeloma,initial,2015-05-26,GCST002921,Cancer,#d53e4f
12443,Asian,116.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,initial,2015-05-26,GCST002924,Other measurement,#3288bd
12444,European,77.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Other measurement,#d53e4f
12445,African,87.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Other measurement,#fc8d59
12446,African,83.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Other measurement,#fc8d59
12447,Asian,116.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,initial,2015-05-26,GCST002924,Response to drug,#3288bd
12448,European,77.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Response to drug,#d53e4f
12449,African,87.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Response to drug,#fc8d59
12450,African,83.0,26015512.0,Komatsu M,Paclitaxel-induced cytotoxicity,replication,2015-05-26,GCST002924,Response to drug,#fc8d59
12451,European,2697.0,26007630.0,Swaminathan B,Multiple myeloma and monoclonal gammopathy,replication,2015-05-26,GCST002922,Cancer,#d53e4f
12452,European,296835.0,26007630.0,Swaminathan B,Multiple myeloma and monoclonal gammopathy,initial,2015-05-26,GCST002922,Cancer,#d53e4f
12453,European,2697.0,26007630.0,Swaminathan B,Multiple myeloma and monoclonal gammopathy,replication,2015-05-26,GCST002922,Other disease,#d53e4f
12454,European,296835.0,26007630.0,Swaminathan B,Multiple myeloma and monoclonal gammopathy,initial,2015-05-26,GCST002922,Other disease,#d53e4f
12455,Asian,145.0,26015512.0,Komatsu M,Paclitaxel-induced neuropathy,initial,2015-05-26,GCST002923,Neurological disorder,#3288bd
12456,Asian,145.0,26015512.0,Komatsu M,Paclitaxel-induced neuropathy,initial,2015-05-26,GCST002923,Response to drug,#3288bd
12457,European,17556.0,25990418.0,Al-Tassan NA,Colorectal cancer,initial,2015-05-20,GCST002919,Cancer,#d53e4f
12458,European,9786.0,25993607.0,de Moor MH,Neuroticism,replication,2015-05-20,GCST002920,Other measurement,#d53e4f
12459,European,63661.0,25993607.0,de Moor MH,Neuroticism,initial,2015-05-20,GCST002920,Other measurement,#d53e4f
12460,European,775.0,25987243.0,Parham LR,Lapatinib-induced hepatotoxicity,initial,2015-05-19,GCST002918,Response to drug,#d53e4f
12461,Asian,236.0,25987243.0,Parham LR,Lapatinib-induced hepatotoxicity,initial,2015-05-19,GCST002918,Response to drug,#3288bd
12463,European,775.0,25987243.0,Parham LR,Lapatinib-induced hepatotoxicity,initial,2015-05-19,GCST002918,Digestive system disorder,#d53e4f
12464,Asian,236.0,25987243.0,Parham LR,Lapatinib-induced hepatotoxicity,initial,2015-05-19,GCST002918,Digestive system disorder,#3288bd
12466,European,6744.0,25987507.0,Minica CC,Cannabis use (initiation),initial,2015-05-19,GCST002916,Biological process,#d53e4f
12467,European,5148.0,25987507.0,Minica CC,Cannabis use (age at onset),initial,2015-05-19,GCST002917,Biological process,#d53e4f
12468,European,5148.0,25987507.0,Minica CC,Cannabis use (age at onset),initial,2015-05-19,GCST002917,Other measurement,#d53e4f
12469,Asian,103.0,25985088.0,Oguchi T,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis,initial,2015-05-18,GCST002913,Other trait,#3288bd
12470,Asian,103.0,25985088.0,Oguchi T,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis,initial,2015-05-18,GCST002913,Immune system disorder,#3288bd
12471,Asian,103.0,25985088.0,Oguchi T,Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis,initial,2015-05-18,GCST002913,Other trait,#3288bd
12472,African Am./Caribbean,2868.0,25988933.0,Almli LM,Post-traumatic stress disorder,replication,2015-05-18,GCST002914,Neurological disorder,#fee08b
12473,Other/Mixed,4.0,25988933.0,Almli LM,Post-traumatic stress disorder,initial,2015-05-18,GCST002914,Neurological disorder,#99d594
12474,European,45.0,25988933.0,Almli LM,Post-traumatic stress disorder,initial,2015-05-18,GCST002914,Neurological disorder,#d53e4f
12475,African,35.0,25988933.0,Almli LM,Post-traumatic stress disorder,initial,2015-05-18,GCST002914,Neurological disorder,#fc8d59
12476,Asian,6.0,25988933.0,Almli LM,Post-traumatic stress disorder,initial,2015-05-18,GCST002914,Neurological disorder,#3288bd
12477,Hispanic/Latin American,57.0,25988933.0,Almli LM,Post-traumatic stress disorder,initial,2015-05-18,GCST002914,Neurological disorder,#807dba
12478,Other/Mixed,3126.0,25987655.0,Fernandez CA,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2015-05-18,GCST002915,Response to drug,#99d594
12479,Other/Mixed,182.0,25987655.0,Fernandez CA,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2015-05-18,GCST002915,Response to drug,#99d594
12480,Other/Mixed,3126.0,25987655.0,Fernandez CA,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2015-05-18,GCST002915,Cancer,#99d594
12481,Other/Mixed,182.0,25987655.0,Fernandez CA,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2015-05-18,GCST002915,Cancer,#99d594
12482,Asian,1971.0,25986216.0,Toyoda H,Narcolepsy with cataplexy,initial,2015-05-15,GCST002912,Neurological disorder,#3288bd
12483,Asian,1109.0,25986216.0,Toyoda H,Narcolepsy with cataplexy,replication,2015-05-15,GCST002912,Neurological disorder,#3288bd
12484,European,600.0,25914168.0,Esposito F,Response to interferon beta in multiple sclerosis,replication,2015-05-14,GCST002910,Immune system disorder,#d53e4f
12485,European,116.0,25914168.0,Esposito F,Response to interferon beta in multiple sclerosis,initial,2015-05-14,GCST002910,Immune system disorder,#d53e4f
12487,European,600.0,25914168.0,Esposito F,Response to interferon beta in multiple sclerosis,replication,2015-05-14,GCST002910,Response to drug,#d53e4f
12488,European,116.0,25914168.0,Esposito F,Response to interferon beta in multiple sclerosis,initial,2015-05-14,GCST002910,Response to drug,#d53e4f
12490,Asian,4093.0,25972035.0,Vinayagamoorthy N,Calcium levels,replication,2015-05-14,GCST002911,Other measurement,#3288bd
12491,Asian,4558.0,25972035.0,Vinayagamoorthy N,Calcium levels,initial,2015-05-14,GCST002911,Other measurement,#3288bd
12492,Asian,7444.0,25967671.0,Li C,Gout,replication,2015-05-13,GCST002909,Metabolic disorder,#3288bd
12493,Asian,3103.0,25967671.0,Li C,Gout,initial,2015-05-13,GCST002909,Metabolic disorder,#3288bd
12494,European,2158.0,25972531.0,Carter TC,Pyridoxal 5'-phosphate levels,initial,2015-05-13,GCST006799,Other measurement,#d53e4f
12495,European,2158.0,25972531.0,Carter TC,4-pyridoxic acid levels,initial,2015-05-13,GCST006798,Other measurement,#d53e4f
12496,European,2158.0,25972531.0,Carter TC,Pyridoxal levels,initial,2015-05-13,GCST006797,Other measurement,#d53e4f
12497,European,5857.0,25963972.0,Liu F,Skin colour saturation,initial,2015-05-12,GCST002906,Other trait,#d53e4f
12498,European,2668.0,25963972.0,Liu F,Skin sensitivity to sun,initial,2015-05-12,GCST002908,Immune system disorder,#d53e4f
12499,European,5278.0,25963972.0,Liu F,Perceived skin darkness,replication,2015-05-12,GCST002907,Other trait,#d53e4f
12500,European,9316.0,25963972.0,Liu F,Perceived skin darkness,initial,2015-05-12,GCST002907,Other trait,#d53e4f
12501,European,1563.0,25963331.0,Hatzimanolis A,Endophenotypes for schizophrenia in healthy individuals,replication,2015-05-12,GCST002905,Other trait,#d53e4f
12502,European,1079.0,25963331.0,Hatzimanolis A,Endophenotypes for schizophrenia in healthy individuals,initial,2015-05-12,GCST002905,Other trait,#d53e4f
12503,European,3372.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002903,Other measurement,#d53e4f
12504,European,639.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002903,Other measurement,#d53e4f
12505,European,3372.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002903,Cancer,#d53e4f
12506,European,639.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002903,Cancer,#d53e4f
12507,European,3372.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002903,Cancer,#d53e4f
12508,European,639.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002903,Cancer,#d53e4f
12509,European,62166.0,25961943.0,Surakka I,"Cholesterol, total",initial,2015-05-11,GCST002896,Lipid or lipoprotein measurement,#d53e4f
12510,European,58358.0,25961943.0,Surakka I,LDL cholesterol,initial,2015-05-11,GCST002898,Lipid or lipoprotein measurement,#d53e4f
12511,European,62166.0,25961943.0,Surakka I,Triglycerides,initial,2015-05-11,GCST002897,Lipid or lipoprotein measurement,#d53e4f
12514,European,62166.0,25961943.0,Surakka I,HDL cholesterol,initial,2015-05-11,GCST002899,Lipid or lipoprotein measurement,#d53e4f
12518,European,1236.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002901,Other measurement,#d53e4f
12519,European,4723.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002901,Other measurement,#d53e4f
12520,European,1236.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002901,Cancer,#d53e4f
12521,European,4723.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002901,Cancer,#d53e4f
12522,European,1236.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002901,Cancer,#d53e4f
12523,European,4723.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002901,Cancer,#d53e4f
12524,European,1236.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),initial,2015-05-11,GCST002901,Response to drug,#d53e4f
12525,European,4723.0,25964295.0,Khan S,Survival in endocrine treated breast cancer (estrogen-receptor positive),replication,2015-05-11,GCST002901,Response to drug,#d53e4f
12526,European,597.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),initial,2015-05-11,GCST002902,Cancer,#d53e4f
12527,European,1351.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),replication,2015-05-11,GCST002902,Cancer,#d53e4f
12528,European,597.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),initial,2015-05-11,GCST002902,Other measurement,#d53e4f
12529,European,1351.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),replication,2015-05-11,GCST002902,Other measurement,#d53e4f
12530,European,597.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),initial,2015-05-11,GCST002902,Cancer,#d53e4f
12531,European,1351.0,25964295.0,Khan S,Survival in breast cancer (estrogen-receptor negative),replication,2015-05-11,GCST002902,Cancer,#d53e4f
12532,European,3025.0,25956309.0,Palomba G,Breast cancer,initial,2015-05-10,GCST002895,Cancer,#d53e4f
12533,European,124013.0,25956309.0,Palomba G,Breast cancer,replication,2015-05-10,GCST002895,Cancer,#d53e4f
12535,European,3918.0,25953783.0,Warrington NM,Body mass index (age interaction),replication,2015-05-07,GCST002893,Body measurement,#d53e4f
12537,European,3918.0,25953783.0,Warrington NM,Body mass index,replication,2015-05-07,GCST002894,Body measurement,#d53e4f
12538,European,622.0,25948407.0,Kertai MD,Perioperative myocardial infarction in coronary artery bypass surgery,replication,2015-05-06,GCST002892,Other trait,#d53e4f
12540,European,622.0,25948407.0,Kertai MD,Perioperative myocardial infarction in coronary artery bypass surgery,replication,2015-05-06,GCST002892,Cardiovascular disease,#d53e4f
12542,European,20440.0,25939698.0,Tsoi LC,Psoriasis,replication,2015-05-05,GCST002889,Immune system disorder,#d53e4f
12543,European,11693.0,25939698.0,Tsoi LC,Psoriasis,initial,2015-05-05,GCST002889,Immune system disorder,#d53e4f
12545,European,290.0,25944848.0,Athanasiu L,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002885,Neurological disorder,#d53e4f
12546,European,290.0,25944848.0,Athanasiu L,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002885,Neurological disorder,#d53e4f
12547,European,290.0,25944848.0,Athanasiu L,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002885,Neurological disorder,#d53e4f
12548,European,290.0,25944848.0,Athanasiu L,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002885,Response to drug,#d53e4f
12549,European,290.0,25944848.0,Athanasiu L,Pharmacokinetics of olanzapine in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002885,Other measurement,#d53e4f
12550,European,829.0,25944848.0,Athanasiu L,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002888,Neurological disorder,#d53e4f
12551,European,829.0,25944848.0,Athanasiu L,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002888,Neurological disorder,#d53e4f
12552,European,829.0,25944848.0,Athanasiu L,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002888,Neurological disorder,#d53e4f
12553,European,829.0,25944848.0,Athanasiu L,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002888,Other measurement,#d53e4f
12554,European,829.0,25944848.0,Athanasiu L,Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002888,Response to drug,#d53e4f
12555,European,185.0,25944848.0,Athanasiu L,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002887,Neurological disorder,#d53e4f
12556,European,185.0,25944848.0,Athanasiu L,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002887,Neurological disorder,#d53e4f
12557,European,185.0,25944848.0,Athanasiu L,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002887,Neurological disorder,#d53e4f
12558,European,185.0,25944848.0,Athanasiu L,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002887,Other measurement,#d53e4f
12559,European,185.0,25944848.0,Athanasiu L,Pharmacokinetics of antiepileptic drugs in severe mental disorder (concentration drug ratio),initial,2015-05-05,GCST002887,Response to drug,#d53e4f
12560,European,4545.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,initial,2015-05-05,GCST002886,Other measurement,#d53e4f
12561,European,7973.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,replication,2015-05-05,GCST002886,Other measurement,#d53e4f
12562,European,4545.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,initial,2015-05-05,GCST002886,Other measurement,#d53e4f
12563,European,7973.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,replication,2015-05-05,GCST002886,Other measurement,#d53e4f
12564,European,4545.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,initial,2015-05-05,GCST002886,Cancer,#d53e4f
12565,European,7973.0,25939597.0,Berndt SI,Prostate cancer aggressiveness,replication,2015-05-05,GCST002886,Cancer,#d53e4f
12566,European,320.0,25944848.0,Athanasiu L,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002891,Neurological disorder,#d53e4f
12567,European,320.0,25944848.0,Athanasiu L,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002891,Neurological disorder,#d53e4f
12568,European,320.0,25944848.0,Athanasiu L,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002891,Neurological disorder,#d53e4f
12569,European,320.0,25944848.0,Athanasiu L,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002891,Other measurement,#d53e4f
12570,European,320.0,25944848.0,Athanasiu L,Pharmacokinetics of antidepressant drugs in severe mental disorder (concentration dose ratio),initial,2015-05-05,GCST002891,Response to drug,#d53e4f
12571,European,7541.0,25939597.0,Berndt SI,Prostate cancer,initial,2015-05-05,GCST002890,Cancer,#d53e4f
12572,European,15402.0,25939597.0,Berndt SI,Prostate cancer,replication,2015-05-05,GCST002890,Cancer,#d53e4f
12573,European,481.0,25827949.0,Kunz M,Cutaneous lupus erythematosus,replication,2015-05-04,GCST002884,Immune system disorder,#d53e4f
12574,European,1439.0,25827949.0,Kunz M,Cutaneous lupus erythematosus,initial,2015-05-04,GCST002884,Immune system disorder,#d53e4f
12575,European,1794.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002882,Other measurement,#d53e4f
12576,Other/Mixed,19.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002882,Other measurement,#99d594
12577,European,1922.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002882,Other measurement,#d53e4f
12578,Other/Mixed,18.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002882,Other measurement,#99d594
12579,European,1794.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002882,Cardiovascular disease,#d53e4f
12580,Other/Mixed,19.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002882,Cardiovascular disease,#99d594
12581,European,1922.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002882,Cardiovascular disease,#d53e4f
12582,Other/Mixed,18.0,25935875.0,Varenhorst C,Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002882,Cardiovascular disease,#99d594
12583,European,1794.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002883,Other measurement,#d53e4f
12584,Other/Mixed,18.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002883,Other measurement,#99d594
12585,Other/Mixed,19.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002883,Other measurement,#99d594
12586,European,1922.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002883,Other measurement,#d53e4f
12587,European,1794.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002883,Cardiovascular disease,#d53e4f
12588,Other/Mixed,18.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,initial,2015-05-02,GCST002883,Cardiovascular disease,#99d594
12589,Other/Mixed,19.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002883,Cardiovascular disease,#99d594
12590,European,1922.0,25935875.0,Varenhorst C,AR-C124910XX levels in individuals with acute coronary syndromes treated with ticagrelor,replication,2015-05-02,GCST002883,Cardiovascular disease,#d53e4f
12591,European,2025.0,25934476.0,de Vries PS,ADAMTS13 activity,replication,2015-05-01,GCST002881,Other measurement,#d53e4f
12592,European,3423.0,25934476.0,de Vries PS,ADAMTS13 activity,initial,2015-05-01,GCST002881,Other measurement,#d53e4f
12594,Hispanic/Latin American,85.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Response to drug,#807dba
12595,African Am./Caribbean,84.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Response to drug,#fee08b
12596,Asian,238.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Response to drug,#3288bd
12597,European,1607.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Response to drug,#d53e4f
12599,Hispanic/Latin American,85.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Metabolic disorder,#807dba
12600,African Am./Caribbean,84.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Metabolic disorder,#fee08b
12601,Asian,238.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Metabolic disorder,#3288bd
12602,European,1607.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Metabolic disorder,#d53e4f
12604,Hispanic/Latin American,85.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Cardiovascular measurement,#807dba
12605,African Am./Caribbean,84.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Cardiovascular measurement,#fee08b
12606,Asian,238.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Cardiovascular measurement,#3288bd
12607,European,1607.0,25676789.0,Wen CC,Serum uric acid levels in response to allopurinol in gout,initial,2015-05-01,GCST004751,Cardiovascular measurement,#d53e4f
12608,Asian,797.0,25935106.0,Kim KW,Recalcitrant atopic dermatitis,initial,2015-04-30,GCST002880,Immune system disorder,#3288bd
12609,Asian,620.0,25920553.0,Coleman C,Celiac disease,replication,2015-04-29,GCST008489,Immune system disorder,#3288bd
12610,European,23649.0,25920553.0,Coleman C,Celiac disease,replication,2015-04-29,GCST008489,Immune system disorder,#d53e4f
12611,European,878.0,25920553.0,Coleman C,Celiac disease,initial,2015-04-29,GCST008489,Immune system disorder,#d53e4f
12612,Asian,14727.0,25802187.0,Jiang DK,Chronic hepatitis B infection,replication,2015-04-28,GCST002879,Digestive system disorder,#3288bd
12613,Asian,3644.0,25802187.0,Jiang DK,Chronic hepatitis B infection,initial,2015-04-28,GCST002879,Digestive system disorder,#3288bd
12614,European,621.0,25918995.0,Salvatore JE,Adult antisocial behavior,initial,2015-04-28,GCST002877,Other measurement,#d53e4f
12615,European,498.0,25918995.0,Salvatore JE,Adult antisocial behavior,replication,2015-04-28,GCST002877,Other measurement,#d53e4f
12616,European,3373.0,25918841.0,Sanchez-Juan P,Creutzfeldt-Jakob disease (sporadic),replication,2015-04-28,GCST002878,Neurological disorder,#d53e4f
12617,European,2373.0,25918841.0,Sanchez-Juan P,Creutzfeldt-Jakob disease (sporadic),initial,2015-04-28,GCST002878,Neurological disorder,#d53e4f
12618,European,525.0,25936594.0,Tomer Y,Type 1 diabetes and autoimmune thyroid diseases,replication,2015-04-27,GCST002876,Immune system disorder,#d53e4f
12619,European,1073.0,25936594.0,Tomer Y,Type 1 diabetes and autoimmune thyroid diseases,initial,2015-04-27,GCST002876,Immune system disorder,#d53e4f
12620,European,525.0,25936594.0,Tomer Y,Type 1 diabetes and autoimmune thyroid diseases,replication,2015-04-27,GCST002876,Metabolic disorder,#d53e4f
12621,European,1073.0,25936594.0,Tomer Y,Type 1 diabetes and autoimmune thyroid diseases,initial,2015-04-27,GCST002876,Metabolic disorder,#d53e4f
12622,European,898.0,25918132.0,Yucesoy B,Diisocyanate-induced asthma,initial,2015-04-26,GCST002875,Biological process,#d53e4f
12623,European,898.0,25918132.0,Yucesoy B,Diisocyanate-induced asthma,initial,2015-04-26,GCST002875,Other disease,#d53e4f
12624,Asian,10303.0,25903422.0,Yin X,Psoriasis,replication,2015-04-23,GCST002874,Immune system disorder,#3288bd
12625,European,8682.0,25903422.0,Yin X,Psoriasis,initial,2015-04-23,GCST002874,Immune system disorder,#d53e4f
12626,Asian,5134.0,25903422.0,Yin X,Psoriasis,initial,2015-04-23,GCST002874,Immune system disorder,#3288bd
12627,European,10767.0,25903422.0,Yin X,Psoriasis,replication,2015-04-23,GCST002874,Immune system disorder,#d53e4f
12628,European,900.0,25855579.0,Mancikova V,Thyroid cancer,initial,2015-04-22,GCST002873,Cancer,#d53e4f
12629,European,3330.0,25855579.0,Mancikova V,Thyroid cancer,replication,2015-04-22,GCST002873,Cancer,#d53e4f
12630,European,3953.0,25898920.0,Korostishevsky M,Blood metabolite levels,initial,2015-04-22,GCST002872,Other measurement,#d53e4f
12631,European,3953.0,25898920.0,Korostishevsky M,Blood metabolite levels,initial,2015-04-22,GCST002872,Other measurement,#d53e4f
12632,European,3953.0,25898920.0,Korostishevsky M,Blood metabolite levels,initial,2015-04-22,GCST002872,Other measurement,#d53e4f
12633,European,3953.0,25898920.0,Korostishevsky M,Blood metabolite levels,initial,2015-04-22,GCST002872,Other measurement,#d53e4f
12635,European,298.0,25897834.0,Biernacka JM,Response to serotonin reuptake inhibitors in major depressive disorder,initial,2015-04-21,GCST002868,Neurological disorder,#d53e4f
12636,Asian,567.0,25897834.0,Biernacka JM,Response to serotonin reuptake inhibitors in major depressive disorder,initial,2015-04-21,GCST002868,Neurological disorder,#3288bd
12638,European,298.0,25897834.0,Biernacka JM,Response to serotonin reuptake inhibitors in major depressive disorder,initial,2015-04-21,GCST002868,Response to drug,#d53e4f
12639,Asian,567.0,25897834.0,Biernacka JM,Response to serotonin reuptake inhibitors in major depressive disorder,initial,2015-04-21,GCST002868,Response to drug,#3288bd
12640,European,1868.0,25898129.0,Shim H,Response to statin therapy (LDL cholesterol subfractions),initial,2015-04-21,GCST002865,Response to drug,#d53e4f
12641,European,6745.0,25898129.0,Shim H,Response to statin therapy (LDL cholesterol subfractions),replication,2015-04-21,GCST002865,Response to drug,#d53e4f
12642,European,1868.0,25898129.0,Shim H,Response to statin therapy (LDL cholesterol subfractions),initial,2015-04-21,GCST002865,Lipid or lipoprotein measurement,#d53e4f
12643,European,6745.0,25898129.0,Shim H,Response to statin therapy (LDL cholesterol subfractions),replication,2015-04-21,GCST002865,Lipid or lipoprotein measurement,#d53e4f
12656,European,1868.0,25898129.0,Shim H,LDL cholesterol subfractions,initial,2015-04-21,GCST002870,Lipid or lipoprotein measurement,#d53e4f
12657,European,6745.0,25898129.0,Shim H,LDL cholesterol subfractions,replication,2015-04-21,GCST002870,Lipid or lipoprotein measurement,#d53e4f
12658,European,361.0,25896534.0,Julia A,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis",initial,2015-04-21,GCST002869,Immune system disorder,#d53e4f
12659,European,245.0,25896534.0,Julia A,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis",replication,2015-04-21,GCST002869,Immune system disorder,#d53e4f
12660,European,361.0,25896534.0,Julia A,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis",initial,2015-04-21,GCST002869,Response to drug,#d53e4f
12661,European,245.0,25896534.0,Julia A,"Response to anti-TNF treatment (adalimumab, etanercept or infliximab) in rheumatoid arthritis",replication,2015-04-21,GCST002869,Response to drug,#d53e4f
12662,European,37954.0,25890600.0,Guo Q,Breast cancer (survival),initial,2015-04-18,GCST002861,Cancer,#d53e4f
12663,European,37954.0,25890600.0,Guo Q,Breast cancer (survival),initial,2015-04-18,GCST002861,Other measurement,#d53e4f
12664,European,37954.0,25890600.0,Guo Q,Breast cancer (survival),initial,2015-04-18,GCST002861,Cancer,#d53e4f
12665,European,37954.0,25890600.0,Guo Q,Breast cancer (survival),initial,2015-04-18,GCST002861,Cancer,#d53e4f
12666,European,2317.0,25886283.0,Chang X,Magnesium levels,initial,2015-04-17,GCST002860,Other measurement,#d53e4f
12667,African Am./Caribbean,1283.0,25886283.0,Chang X,Magnesium levels,initial,2015-04-17,GCST002860,Other measurement,#fee08b
12668,European,60.0,25896417.0,Nakada TA,Cytokine and corticosteroid-stimulated IL-6 production,initial,2015-04-17,GCST002858,Inflammatory measurement,#d53e4f
12669,European,60.0,25896417.0,Nakada TA,Cytokine and corticosteroid-stimulated IL-6 production,initial,2015-04-17,GCST002858,Response to drug,#d53e4f
12670,European,60.0,25896417.0,Nakada TA,Cytokine and corticosteroid-stimulated IL-6 production,initial,2015-04-17,GCST002858,Response to drug,#d53e4f
12671,European,5261.0,25886283.0,Chang X,Calcium levels,initial,2015-04-17,GCST002857,Other measurement,#d53e4f
12672,African Am./Caribbean,3817.0,25886283.0,Chang X,Calcium levels,initial,2015-04-17,GCST002857,Other measurement,#fee08b
12673,European,60.0,25896417.0,Nakada TA,Cytokine-stimulated IL-6 production,initial,2015-04-17,GCST002859,Inflammatory measurement,#d53e4f
12674,European,60.0,25896417.0,Nakada TA,Cytokine-stimulated IL-6 production,initial,2015-04-17,GCST002859,Response to drug,#d53e4f
12675,African Am./Caribbean,257.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),replication,2015-04-16,GCST002856,Other measurement,#fee08b
12676,European,153.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),replication,2015-04-16,GCST002856,Other measurement,#d53e4f
12677,Hispanic/Latin American,931.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),initial,2015-04-16,GCST002856,Other measurement,#807dba
12678,African Am./Caribbean,257.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),replication,2015-04-16,GCST002856,Other measurement,#fee08b
12679,European,153.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),replication,2015-04-16,GCST002856,Other measurement,#d53e4f
12680,Hispanic/Latin American,931.0,25898001.0,Dong C,Carotid artery intima media thickness (sex interaction),initial,2015-04-16,GCST002856,Other measurement,#807dba
12681,European,8013.0,25877299.0,Kristiansen W,Testicular germ cell tumor,initial,2015-04-15,GCST002855,Cancer,#d53e4f
12682,European,2709.0,25877299.0,Kristiansen W,Testicular germ cell tumor,replication,2015-04-15,GCST002855,Cancer,#d53e4f
12683,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Yang),replication,2015-04-15,GCST002851,Other trait,#3288bd
12684,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Yang),initial,2015-04-15,GCST002851,Other trait,#3288bd
12685,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Yang),replication,2015-04-15,GCST002851,Other trait,#3288bd
12686,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Yang),initial,2015-04-15,GCST002851,Other trait,#3288bd
12687,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Yang),initial,2015-04-15,GCST002852,Other trait,#3288bd
12688,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Yang),replication,2015-04-15,GCST002852,Other trait,#3288bd
12689,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Yang),initial,2015-04-15,GCST002852,Other trait,#3288bd
12690,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Yang),replication,2015-04-15,GCST002852,Other trait,#3288bd
12691,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Eum),replication,2015-04-15,GCST002853,Other trait,#3288bd
12692,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Eum),initial,2015-04-15,GCST002853,Other trait,#3288bd
12693,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Eum),replication,2015-04-15,GCST002853,Other trait,#3288bd
12694,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (Tae-Eum),initial,2015-04-15,GCST002853,Other trait,#3288bd
12695,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Eum),initial,2015-04-15,GCST002854,Other trait,#3288bd
12696,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Eum),replication,2015-04-15,GCST002854,Other trait,#3288bd
12697,Asian,3810.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Eum),initial,2015-04-15,GCST002854,Other trait,#3288bd
12698,Asian,1680.0,25888059.0,Cha S,Sasang constitutional medicine type (So-Eum),replication,2015-04-15,GCST002854,Other trait,#3288bd
12699,African Am./Caribbean,1444.0,25869804.0,Ibrahim-Verbaas CA,Information processing speed,replication,2015-04-14,GCST002850,Biological process,#fee08b
12700,European,33337.0,25869804.0,Ibrahim-Verbaas CA,Information processing speed,initial,2015-04-14,GCST002850,Biological process,#d53e4f
12701,European,8436.0,25869804.0,Ibrahim-Verbaas CA,Information processing speed,replication,2015-04-14,GCST002850,Biological process,#d53e4f
12702,European,20720.0,25869804.0,Ibrahim-Verbaas CA,Executive function,replication,2015-04-14,GCST002849,Biological process,#d53e4f
12703,European,13462.0,25869804.0,Ibrahim-Verbaas CA,Executive function,initial,2015-04-14,GCST002849,Biological process,#d53e4f
12704,African Am./Caribbean,3146.0,25869804.0,Ibrahim-Verbaas CA,Executive function,replication,2015-04-14,GCST002849,Biological process,#fee08b
12705,Asian,1494.0,25867717.0,Song N,Disease-free survival in breast cancer,replication,2015-04-13,GCST002847,Other measurement,#3288bd
12706,Asian,1732.0,25867717.0,Song N,Disease-free survival in breast cancer,initial,2015-04-13,GCST002847,Other measurement,#3288bd
12707,Asian,1494.0,25867717.0,Song N,Disease-free survival in breast cancer,replication,2015-04-13,GCST002847,Cancer,#3288bd
12708,Asian,1732.0,25867717.0,Song N,Disease-free survival in breast cancer,initial,2015-04-13,GCST002847,Cancer,#3288bd
12711,European,1358.0,25875332.0,Zayats T,Attention deficit hyperactivity disorder,initial,2015-04-13,GCST002848,Neurological disorder,#d53e4f
12712,European,3111.0,25865352.0,Schaarschmidt H,Atopic dermatitis,replication,2015-04-10,GCST002844,Immune system disorder,#d53e4f
12713,European,6163.0,25865352.0,Schaarschmidt H,Atopic dermatitis,initial,2015-04-10,GCST002844,Immune system disorder,#d53e4f
12714,Other/Mixed,891.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#99d594
12715,Asian,2949.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#3288bd
12716,African Am./Caribbean,801.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#fee08b
12717,Asian,837.0,25861811.0,Li Z,Glaucoma (primary open-angle),initial,2015-04-10,GCST008391,Neurological disorder,#3288bd
12718,European,16559.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#d53e4f
12719,Asian,11760.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#3288bd
12720,Asian,2993.0,25861811.0,Li Z,Glaucoma (primary open-angle),replication,2015-04-10,GCST008391,Neurological disorder,#3288bd
12721,Asian,2042.0,25861811.0,Li Z,Glaucoma (primary open-angle),initial,2015-04-10,GCST008391,Neurological disorder,#3288bd
12722,Asian,9145.0,25861811.0,Li Z,Glaucoma (primary open-angle),initial,2015-04-10,GCST008391,Neurological disorder,#3288bd
12723,African Am./Caribbean,1226.0,25861811.0,Li Z,Glaucoma (primary open-angle),initial,2015-04-10,GCST008391,Neurological disorder,#fee08b
12724,Asian,5050.0,25862617.0,Zhang Y,Systemic lupus erythematosus,initial,2015-04-10,GCST002845,Immune system disorder,#3288bd
12725,Asian,4628.0,25862617.0,Zhang Y,Systemic lupus erythematosus,replication,2015-04-10,GCST002845,Immune system disorder,#3288bd
12726,Asian,1425.0,25862617.0,Zhang Y,Systemic lupus erythematosus,replication,2015-04-10,GCST002845,Immune system disorder,#3288bd
12728,European,270930.0,25855136.0,Stacey SN,Basal cell carcinoma,initial,2015-04-09,GCST002842,Cancer,#d53e4f
12729,European,5170.0,25855136.0,Stacey SN,Basal cell carcinoma,replication,2015-04-09,GCST002842,Cancer,#d53e4f
12730,Asian,22422.0,25854761.0,Zuo X,Psoriasis,initial,2015-04-09,GCST008479,Immune system disorder,#3288bd
12731,Asian,20338.0,25854761.0,Zuo X,Psoriasis,replication,2015-04-09,GCST008479,Immune system disorder,#3288bd
12732,European,21590.0,25865494.0,Chan Y,Sitting height ratio,initial,2015-04-09,GCST002843,Body measurement,#d53e4f
12733,African Am./Caribbean,3545.0,25865494.0,Chan Y,Sitting height ratio,initial,2015-04-09,GCST002843,Body measurement,#fee08b
12734,Asian,1699.0,25848760.0,Sun Y,Developmental dysplasia of the hip,replication,2015-04-07,GCST002841,Other disease,#3288bd
12735,Asian,944.0,25848760.0,Sun Y,Developmental dysplasia of the hip,initial,2015-04-07,GCST002841,Other disease,#3288bd
12736,European,5992.0,25849990.0,Tapper W,Myeloproliferative neoplasms,replication,2015-04-07,GCST002840,Cancer,#d53e4f
12738,European,3198.0,25849990.0,Tapper W,Myeloproliferative neoplasms,initial,2015-04-07,GCST002840,Cancer,#d53e4f
12739,European,922.0,25839716.0,Ng E,Polychlorinated biphenyl levels,initial,2015-04-02,GCST002839,Other measurement,#d53e4f
12740,European,2949.0,25643325.0,Renton AE,Myasthenia gravis,initial,2015-04-01,GCST002838,Neurological disorder,#d53e4f
12741,European,890.0,25643325.0,Renton AE,Myasthenia gravis,replication,2015-04-01,GCST002838,Neurological disorder,#d53e4f
12742,European,89677.0,25751625.0,Michailidou K,Breast cancer,initial,2015-04-01,GCST007236,Cancer,#d53e4f
12743,European,33864.0,25751625.0,Michailidou K,Breast cancer,initial,2015-04-01,GCST004950,Cancer,#d53e4f
12744,European,89677.0,25751625.0,Michailidou K,Breast cancer,replication,2015-04-01,GCST004950,Cancer,#d53e4f
12745,European,29652.0,25751624.0,Onengut-Gumuscu S,Type 1 diabetes,initial,2015-04-01,GCST005536,Metabolic disorder,#d53e4f
12746,European,49.0,25813999.0,Jeong S,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),replication,2015-04-01,GCST002837,Response to drug,#d53e4f
12747,European,64.0,25813999.0,Jeong S,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),initial,2015-04-01,GCST002837,Response to drug,#d53e4f
12748,European,49.0,25813999.0,Jeong S,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),replication,2015-04-01,GCST002837,Other measurement,#d53e4f
12749,European,64.0,25813999.0,Jeong S,Change in intraocular pressure in response to steroid treatment (triamcinolone acetonide),initial,2015-04-01,GCST002837,Other measurement,#d53e4f
12750,Asian,328.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,initial,2015-03-31,GCST002833,Other trait,#3288bd
12751,Asian,876.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,replication,2015-03-31,GCST002833,Other trait,#3288bd
12752,Asian,328.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,initial,2015-03-31,GCST002833,Response to drug,#3288bd
12753,Asian,876.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,replication,2015-03-31,GCST002833,Response to drug,#3288bd
12754,Asian,328.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,initial,2015-03-31,GCST002833,Cancer,#3288bd
12755,Asian,876.0,25823687.0,Cao S,Platinum-induced myelosuppression in non-small cell lung cancer,replication,2015-03-31,GCST002833,Cancer,#3288bd
12757,Asian,6234.0,25823570.0,Miyake M,Corneal curvature,replication,2015-03-31,GCST002834,Other measurement,#3288bd
12758,European,2007.0,25823570.0,Miyake M,Corneal curvature,replication,2015-03-31,GCST002834,Other measurement,#d53e4f
12759,Asian,3248.0,25823570.0,Miyake M,Axial length,initial,2015-03-31,GCST002836,Other measurement,#3288bd
12760,Asian,3460.0,25823570.0,Miyake M,Axial length,replication,2015-03-31,GCST002836,Other measurement,#3288bd
12761,European,10871.0,25826619.0,Henrion MY,Renal cell carcinoma,initial,2015-03-31,GCST002835,Cancer,#d53e4f
12762,European,10114.0,25826619.0,Henrion MY,Renal cell carcinoma,replication,2015-03-31,GCST002835,Cancer,#d53e4f
12764,European,15282.0,25811787.0,Huffman JE,Urate levels in lean individuals,initial,2015-03-26,GCST002830,Other measurement,#d53e4f
12765,European,15282.0,25811787.0,Huffman JE,Urate levels in lean individuals,initial,2015-03-26,GCST002830,Body measurement,#d53e4f
12766,European,16957.0,25817017.0,Carmona FD,Giant cell arteritis,initial,2015-03-26,GCST006198,Cardiovascular disease,#d53e4f
12767,European,28610.0,25811787.0,Huffman JE,Urate levels (BMI interaction),initial,2015-03-26,GCST002827,Other measurement,#d53e4f
12768,European,13959.0,25811787.0,Huffman JE,Urate levels (BMI interaction),replication,2015-03-26,GCST002827,Other measurement,#d53e4f
12769,European,28610.0,25811787.0,Huffman JE,Urate levels (BMI interaction),initial,2015-03-26,GCST002827,Body measurement,#d53e4f
12770,European,13959.0,25811787.0,Huffman JE,Urate levels (BMI interaction),replication,2015-03-26,GCST002827,Body measurement,#d53e4f
12771,European,9445.0,25811787.0,Huffman JE,Urate levels in obese individuals,initial,2015-03-26,GCST002828,Body measurement,#d53e4f
12772,European,9445.0,25811787.0,Huffman JE,Urate levels in obese individuals,initial,2015-03-26,GCST002828,Other measurement,#d53e4f
12773,European,17078.0,25811787.0,Huffman JE,Urate levels in overweight individuals,initial,2015-03-26,GCST002829,Other measurement,#d53e4f
12774,European,17078.0,25811787.0,Huffman JE,Urate levels in overweight individuals,initial,2015-03-26,GCST002829,Body measurement,#d53e4f
12775,European,31950.0,25811787.0,Huffman JE,Urate levels (BMI interaction),initial,2015-03-26,GCST002826,Other measurement,#d53e4f
12776,European,31950.0,25811787.0,Huffman JE,Urate levels (BMI interaction),initial,2015-03-26,GCST002826,Body measurement,#d53e4f
12777,Other/Mixed,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#99d594
12778,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#3288bd
12779,Other/Mixed,241.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#99d594
12781,Hispanic/Latin American,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#807dba
12782,European,54.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#d53e4f
12783,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#3288bd
12784,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002823,Cardiovascular disease,#3288bd
12785,European,180.0,25799145.0,Kappen JH,Behcet's disease,replication,2015-03-23,GCST002823,Cardiovascular disease,#d53e4f
12786,Other/Mixed,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#99d594
12787,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#3288bd
12789,Hispanic/Latin American,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#807dba
12790,European,54.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#d53e4f
12791,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#3288bd
12792,Asian,1.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#3288bd
12793,Other/Mixed,3934.0,25799145.0,Kappen JH,Behcet's disease,replication,2015-03-23,GCST002824,Cardiovascular disease,#99d594
12794,Other/Mixed,241.0,25799145.0,Kappen JH,Behcet's disease,initial,2015-03-23,GCST002824,Cardiovascular disease,#99d594
12795,Hispanic/Latin American,1601.0,25798622.0,Knowles JW,Insulin resistance/response,replication,2015-03-23,GCST002825,Other trait,#807dba
12796,European,2764.0,25798622.0,Knowles JW,Insulin resistance/response,initial,2015-03-23,GCST002825,Other trait,#d53e4f
12797,European,1259.0,25798622.0,Knowles JW,Insulin resistance/response,replication,2015-03-23,GCST002825,Other trait,#d53e4f
12798,European,431.0,25866641.0,Xu W,Survival in microsatellite instability low/stable colorectal cancer,initial,2015-03-19,GCST002820,Other measurement,#d53e4f
12799,European,431.0,25866641.0,Xu W,Survival in microsatellite instability low/stable colorectal cancer,initial,2015-03-19,GCST002820,Cancer,#d53e4f
12800,European,431.0,25866641.0,Xu W,Survival in microsatellite instability low/stable colorectal cancer,initial,2015-03-19,GCST002820,Other measurement,#d53e4f
12801,European,431.0,25866641.0,Xu W,Survival in microsatellite instability low/stable colorectal cancer,initial,2015-03-19,GCST002820,Other measurement,#d53e4f
12802,European,171.0,25866641.0,Xu W,Survival in rectal cancer,initial,2015-03-19,GCST002821,Other measurement,#d53e4f
12803,European,171.0,25866641.0,Xu W,Survival in rectal cancer,initial,2015-03-19,GCST002821,Cancer,#d53e4f
12804,European,171.0,25866641.0,Xu W,Survival in rectal cancer,initial,2015-03-19,GCST002821,Other measurement,#d53e4f
12805,European,334.0,25866641.0,Xu W,Survival in colon cancer,initial,2015-03-19,GCST002822,Other measurement,#d53e4f
12806,European,334.0,25866641.0,Xu W,Survival in colon cancer,initial,2015-03-19,GCST002822,Cancer,#d53e4f
12807,European,334.0,25866641.0,Xu W,Survival in colon cancer,initial,2015-03-19,GCST002822,Other measurement,#d53e4f
12808,European,552.0,25784220.0,Sharma S,Adolescent idiopathic scoliosis,replication,2015-03-18,GCST002819,Other disease,#d53e4f
12809,Asian,2524.0,25784220.0,Sharma S,Adolescent idiopathic scoliosis,replication,2015-03-18,GCST002819,Other disease,#3288bd
12810,European,1184.0,25784220.0,Sharma S,Adolescent idiopathic scoliosis,initial,2015-03-18,GCST002819,Other disease,#d53e4f
12812,African Am./Caribbean,2004.0,25786224.0,Johnson EO,HIV-1 susceptibility,initial,2015-03-18,GCST002818,Other disease,#fee08b
12813,European,1132.0,25786224.0,Johnson EO,HIV-1 susceptibility,initial,2015-03-18,GCST002818,Other disease,#d53e4f
12814,European,681.0,25786224.0,Johnson EO,HIV-1 susceptibility,replication,2015-03-18,GCST002818,Other disease,#d53e4f
12815,African Am./Caribbean,1852.0,25786224.0,Johnson EO,HIV-1 susceptibility,replication,2015-03-18,GCST002818,Other disease,#fee08b
12816,African Am./Caribbean,2004.0,25786224.0,Johnson EO,HIV-1 susceptibility,initial,2015-03-18,GCST002818,Immune system disorder,#fee08b
12817,European,1132.0,25786224.0,Johnson EO,HIV-1 susceptibility,initial,2015-03-18,GCST002818,Immune system disorder,#d53e4f
12818,European,681.0,25786224.0,Johnson EO,HIV-1 susceptibility,replication,2015-03-18,GCST002818,Immune system disorder,#d53e4f
12819,African Am./Caribbean,1852.0,25786224.0,Johnson EO,HIV-1 susceptibility,replication,2015-03-18,GCST002818,Immune system disorder,#fee08b
12820,European,4203.0,25778476.0,Jun G,Alzheimer's disease (APOE e4 interaction),replication,2015-03-17,GCST002814,Neurological disorder,#d53e4f
12822,European,4203.0,25778476.0,Jun G,Alzheimer's disease (APOE e4 interaction),replication,2015-03-17,GCST002814,Other measurement,#d53e4f
12825,European,2417.0,25778476.0,Jun G,Alzheimer's disease in APOE e4- carriers,replication,2015-03-17,GCST002817,Neurological disorder,#d53e4f
12827,European,1786.0,25778476.0,Jun G,Alzheimer's disease in APOE e4+ carriers,replication,2015-03-17,GCST002813,Neurological disorder,#d53e4f
12828,Other/Mixed,638.0,25781172.0,Avramopoulos D,Bipolar disorder (inflammation and infection response interaction),initial,2015-03-17,GCST002815,Other measurement,#99d594
12829,Other/Mixed,638.0,25781172.0,Avramopoulos D,Bipolar disorder (inflammation and infection response interaction),initial,2015-03-17,GCST002815,Neurological disorder,#99d594
12830,Other/Mixed,638.0,25781172.0,Avramopoulos D,Bipolar disorder (inflammation and infection response interaction),initial,2015-03-17,GCST002815,Other measurement,#99d594
12831,European,17187.0,25781442.0,Nan H,Colorectal cancer (aspirin and/or NSAID use interaction),initial,2015-03-17,GCST002816,Other measurement,#d53e4f
12832,European,17187.0,25781442.0,Nan H,Colorectal cancer (aspirin and/or NSAID use interaction),initial,2015-03-17,GCST002816,Other measurement,#d53e4f
12833,European,17187.0,25781442.0,Nan H,Colorectal cancer (aspirin and/or NSAID use interaction),initial,2015-03-17,GCST002816,Other measurement,#d53e4f
12834,European,17187.0,25781442.0,Nan H,Colorectal cancer (aspirin and/or NSAID use interaction),initial,2015-03-17,GCST002816,Cancer,#d53e4f
12835,Other/Mixed,701.0,25781172.0,Avramopoulos D,Schizophrenia (inflammation and infection response interaction),initial,2015-03-17,GCST002812,Neurological disorder,#99d594
12836,Other/Mixed,701.0,25781172.0,Avramopoulos D,Schizophrenia (inflammation and infection response interaction),initial,2015-03-17,GCST002812,Other measurement,#99d594
12837,Other/Mixed,701.0,25781172.0,Avramopoulos D,Schizophrenia (inflammation and infection response interaction),initial,2015-03-17,GCST002812,Other measurement,#99d594
12838,Other/Mixed,701.0,25781172.0,Avramopoulos D,Schizophrenia (inflammation and infection response interaction),initial,2015-03-17,GCST002812,Other measurement,#99d594
12839,Asian,2106.0,25775280.0,Sun Y,Nonsyndromic cleft lip with or without cleft palate,initial,2015-03-16,GCST002811,Other trait,#3288bd
12840,Asian,3537.0,25775280.0,Sun Y,Nonsyndromic cleft lip with or without cleft palate,replication,2015-03-16,GCST002811,Other trait,#3288bd
12841,Asian,2106.0,25775280.0,Sun Y,Nonsyndromic cleft lip with or without cleft palate,initial,2015-03-16,GCST002811,Other trait,#3288bd
12842,Asian,3537.0,25775280.0,Sun Y,Nonsyndromic cleft lip with or without cleft palate,replication,2015-03-16,GCST002811,Other trait,#3288bd
12843,European,11137.0,25774636.0,Curtis J,Tuberculosis,initial,2015-03-16,GCST002810,Other disease,#d53e4f
12844,African,4637.0,25774636.0,Curtis J,Tuberculosis,replication,2015-03-16,GCST002810,Other disease,#fc8d59
12845,Other/Mixed,3950.0,25774636.0,Curtis J,Tuberculosis,replication,2015-03-16,GCST002810,Other disease,#99d594
12846,African Am./Caribbean,317.0,25827505.0,Swaminathan S,Bipolar disorder,initial,2015-03-14,GCST002809,Neurological disorder,#fee08b
12847,European,1237.0,25827505.0,Swaminathan S,Bipolar disorder,replication,2015-03-14,GCST002809,Neurological disorder,#d53e4f
12848,European,951.0,25827505.0,Swaminathan S,Bipolar disorder,initial,2015-03-14,GCST002809,Neurological disorder,#d53e4f
12849,European,5595.0,25772935.0,Germain M,Venous thromboembolism,replication,2015-03-12,GCST002808,Cardiovascular disease,#d53e4f
12850,European,60139.0,25772935.0,Germain M,Venous thromboembolism,initial,2015-03-12,GCST002808,Cardiovascular disease,#d53e4f
12851,European,1911.0,25763902.0,Draaken M,Classic bladder exstrophy,initial,2015-03-12,GCST002807,Other disease,#d53e4f
12852,European,1246.0,25758996.0,Pirastu N,Red wine liking,replication,2015-03-11,GCST002803,Other measurement,#d53e4f
12853,European,2271.0,25758996.0,Pirastu N,Red wine liking,initial,2015-03-11,GCST002803,Other measurement,#d53e4f
12854,Other/Mixed,353.0,25758996.0,Pirastu N,Red wine liking,replication,2015-03-11,GCST002803,Other measurement,#99d594
12855,European,2240.0,25758996.0,Pirastu N,White wine liking,initial,2015-03-11,GCST002802,Other measurement,#d53e4f
12856,European,1261.0,25758996.0,Pirastu N,White wine liking,replication,2015-03-11,GCST002802,Other measurement,#d53e4f
12857,Other/Mixed,335.0,25758996.0,Pirastu N,White wine liking,replication,2015-03-11,GCST002802,Other measurement,#99d594
12858,Other/Mixed,391.0,25760438.0,Anderson D,Type 2 diabetes,initial,2015-03-11,GCST002806,Metabolic disorder,#99d594
12859,Other/Mixed,361.0,25760438.0,Anderson D,Body mass index,initial,2015-03-11,GCST002805,Body measurement,#99d594
12860,Hispanic/Latin American,1932.0,25758998.0,Rubicz R,Antibody level in response to infection,initial,2015-03-11,GCST002804,Other measurement,#807dba
12861,European,16335.0,25743335.0,Taylor PN,Thyroid stimulating hormone levels,initial,2015-03-06,GCST008165,Other measurement,#d53e4f
12862,European,13651.0,25743335.0,Taylor PN,Free thyroxine concentration,initial,2015-03-06,GCST008164,Other measurement,#d53e4f
12863,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of children (6+ vs. 0 or 1),initial,2015-03-05,GCST002800,Other trait,#3288bd
12864,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of children (6+ vs. 0 or 1),initial,2015-03-05,GCST002800,Other measurement,#3288bd
12865,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of pregnancies,initial,2015-03-05,GCST002799,Other trait,#3288bd
12866,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of pregnancies,initial,2015-03-05,GCST002799,Other measurement,#3288bd
12867,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of children,initial,2015-03-05,GCST002801,Other trait,#3288bd
12868,Asian,1686.0,25742292.0,Aschebrook-Kilfoy B,Number of children,initial,2015-03-05,GCST002801,Other measurement,#3288bd
12869,European,439.0,25562107.0,Israel E,Bronchodilator response in asthma,replication,2015-03-01,GCST002796,Response to drug,#d53e4f
12870,European,724.0,25562107.0,Israel E,Bronchodilator response in asthma,initial,2015-03-01,GCST002796,Response to drug,#d53e4f
12871,European,439.0,25562107.0,Israel E,Bronchodilator response in asthma,replication,2015-03-01,GCST002796,Other disease,#d53e4f
12872,European,724.0,25562107.0,Israel E,Bronchodilator response in asthma,initial,2015-03-01,GCST002796,Other disease,#d53e4f
12873,European,2076.0,25337690.0,Redler S,Alopecia areata,replication,2015-03-01,GCST005539,Other disease,#d53e4f
12874,European,2242.0,25337690.0,Redler S,Alopecia areata,initial,2015-03-01,GCST005539,Other disease,#d53e4f
12875,European,5993.0,25101718.0,Lee JH,Chronic obstructive pulmonary disease,initial,2015-03-01,GCST002795,Other disease,#d53e4f
12876,African Am./Caribbean,2243.0,25101718.0,Lee JH,Chronic obstructive pulmonary disease,initial,2015-03-01,GCST002795,Other disease,#fee08b
12877,European,4287.0,25101718.0,Lee JH,Pulmonary artery enlargement in chronic obstructive pulmonary disease,initial,2015-03-01,GCST002797,Other trait,#d53e4f
12878,African Am./Caribbean,754.0,25101718.0,Lee JH,Pulmonary artery enlargement in chronic obstructive pulmonary disease,initial,2015-03-01,GCST002797,Other trait,#fee08b
12879,European,4287.0,25101718.0,Lee JH,Pulmonary artery enlargement in chronic obstructive pulmonary disease,initial,2015-03-01,GCST002797,Other disease,#d53e4f
12880,African Am./Caribbean,754.0,25101718.0,Lee JH,Pulmonary artery enlargement in chronic obstructive pulmonary disease,initial,2015-03-01,GCST002797,Other disease,#fee08b
12881,European,3718.0,25101718.0,Lee JH,Pulmonary artery enlargement and chronic obstructive pulmonary disease,initial,2015-03-01,GCST002798,Other trait,#d53e4f
12882,African Am./Caribbean,2009.0,25101718.0,Lee JH,Pulmonary artery enlargement and chronic obstructive pulmonary disease,initial,2015-03-01,GCST002798,Other trait,#fee08b
12883,European,3718.0,25101718.0,Lee JH,Pulmonary artery enlargement and chronic obstructive pulmonary disease,initial,2015-03-01,GCST002798,Other disease,#d53e4f
12884,African Am./Caribbean,2009.0,25101718.0,Lee JH,Pulmonary artery enlargement and chronic obstructive pulmonary disease,initial,2015-03-01,GCST002798,Other disease,#fee08b
12887,European,521.0,25881214.0,Shah AA,Vein graft stenosis in coronary artery bypass grafting,initial,2015-02-27,GCST002793,Other trait,#d53e4f
12888,European,521.0,25881214.0,Shah AA,Vein graft stenosis in coronary artery bypass grafting,initial,2015-02-27,GCST002793,Other trait,#d53e4f
12889,Hispanic/Latin American,36.0,25771307.0,Watson AL,Type 2 diabetes,initial,2015-02-26,GCST008434,Metabolic disorder,#807dba
12890,Hispanic/Latin American,44.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Neurological disorder,#807dba
12891,Asian,2.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Neurological disorder,#3288bd
12892,African,43.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Neurological disorder,#fc8d59
12893,European,209.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Neurological disorder,#d53e4f
12895,Hispanic/Latin American,44.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Cancer,#807dba
12896,Asian,2.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Cancer,#3288bd
12897,African,43.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Cancer,#fc8d59
12898,European,209.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Cancer,#d53e4f
12900,Hispanic/Latin American,44.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Response to drug,#807dba
12901,Asian,2.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Response to drug,#3288bd
12902,African,43.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Response to drug,#fc8d59
12903,European,209.0,25710658.0,Diouf B,Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,initial,2015-02-24,GCST002792,Response to drug,#d53e4f
12905,European,2197.0,25710614.0,Hong X,Food allergy,initial,2015-02-24,GCST002790,Other measurement,#d53e4f
12906,European,2197.0,25710614.0,Hong X,Egg allergy,initial,2015-02-24,GCST002789,Other measurement,#d53e4f
12907,European,2197.0,25710614.0,Hong X,Milk allergy,initial,2015-02-24,GCST002788,Other measurement,#d53e4f
12908,European,2197.0,25710614.0,Hong X,Peanut allergy,initial,2015-02-24,GCST002791,Other measurement,#d53e4f
12909,European,131.0,25710614.0,Hong X,Peanut allergy,replication,2015-02-24,GCST002791,Other measurement,#d53e4f
12911,European,718.0,25713168.0,Leng S,Gene methylation in lung tissue,replication,2015-02-23,GCST002786,Other measurement,#d53e4f
12912,European,1163.0,25713168.0,Leng S,Gene methylation in lung tissue,initial,2015-02-23,GCST002786,Other measurement,#d53e4f
12913,European,2844.0,25705849.0,Jacobs LC,Facial pigmentation,initial,2015-02-23,GCST002785,Other measurement,#d53e4f
12914,Other/Mixed,1455.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#99d594
12915,Other/Mixed,99.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#99d594
12916,Asian,4600.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#3288bd
12917,African,481.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#fc8d59
12918,Hispanic/Latin American,373.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#807dba
12920,European,12600.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#d53e4f
12921,Asian,7760.0,25706626.0,Aung T,Exfoliation syndrome,replication,2015-02-23,GCST002787,Neurological disorder,#3288bd
12922,Asian,2672.0,25706626.0,Aung T,Exfoliation syndrome,initial,2015-02-23,GCST002787,Neurological disorder,#3288bd
12923,European,1545.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,replication,2015-02-18,GCST002784,Response to drug,#d53e4f
12924,European,485.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,initial,2015-02-18,GCST002784,Response to drug,#d53e4f
12925,European,1545.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,replication,2015-02-18,GCST002784,Other measurement,#d53e4f
12926,European,485.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,initial,2015-02-18,GCST002784,Other measurement,#d53e4f
12927,European,1545.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,replication,2015-02-18,GCST002784,Cardiovascular disease,#d53e4f
12928,European,485.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,initial,2015-02-18,GCST002784,Cardiovascular disease,#d53e4f
12929,European,1545.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,replication,2015-02-18,GCST002784,Other measurement,#d53e4f
12930,European,485.0,25695618.0,Chittani M,Blood pressure response to hydrochlorothiazide in hypertension,initial,2015-02-18,GCST002784,Other measurement,#d53e4f
12931,Asian,1650.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,replication,2015-02-12,GCST002782,Body measurement,#3288bd
12932,African Am./Caribbean,8609.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,replication,2015-02-12,GCST002782,Body measurement,#fee08b
12933,Asian,2791.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,replication,2015-02-12,GCST002782,Body measurement,#3288bd
12934,European,67326.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,replication,2015-02-12,GCST002782,Body measurement,#d53e4f
12935,European,142762.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,initial,2015-02-12,GCST002782,Body measurement,#d53e4f
12936,African,461.0,25673412.0,Shungin D,Waist-to-hip ratio adjusted for body mass index,replication,2015-02-12,GCST002782,Body measurement,#fc8d59
12937,Asian,2791.0,25673412.0,Shungin D,Hip circumference,replication,2015-02-12,GCST004066,Body measurement,#3288bd
12938,Asian,1650.0,25673412.0,Shungin D,Hip circumference,replication,2015-02-12,GCST004066,Body measurement,#3288bd
12939,African Am./Caribbean,8609.0,25673412.0,Shungin D,Hip circumference,replication,2015-02-12,GCST004066,Body measurement,#fee08b
12940,European,67326.0,25673412.0,Shungin D,Hip circumference,replication,2015-02-12,GCST004066,Body measurement,#d53e4f
12941,African,461.0,25673412.0,Shungin D,Hip circumference,replication,2015-02-12,GCST004066,Body measurement,#fc8d59
12942,European,142762.0,25673412.0,Shungin D,Hip circumference,initial,2015-02-12,GCST004066,Body measurement,#d53e4f
12943,Asian,2791.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,replication,2015-02-12,GCST004063,Body measurement,#3288bd
12944,Asian,1650.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,replication,2015-02-12,GCST004063,Body measurement,#3288bd
12945,African Am./Caribbean,8609.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,replication,2015-02-12,GCST004063,Body measurement,#fee08b
12946,European,67326.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,replication,2015-02-12,GCST004063,Body measurement,#d53e4f
12947,African,461.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,replication,2015-02-12,GCST004063,Body measurement,#fc8d59
12948,European,142762.0,25673412.0,Shungin D,Waist circumference adjusted for body mass index,initial,2015-02-12,GCST004063,Body measurement,#d53e4f
12949,African Am./Caribbean,8609.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,replication,2015-02-12,GCST004067,Body measurement,#fee08b
12950,European,67326.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,replication,2015-02-12,GCST004067,Body measurement,#d53e4f
12951,African,461.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,replication,2015-02-12,GCST004067,Body measurement,#fc8d59
12952,European,142762.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,initial,2015-02-12,GCST004067,Body measurement,#d53e4f
12953,Asian,1650.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,replication,2015-02-12,GCST004067,Body measurement,#3288bd
12954,Asian,2791.0,25673412.0,Shungin D,Hip circumference adjusted for BMI,replication,2015-02-12,GCST004067,Body measurement,#3288bd
12955,African,461.0,25673412.0,Shungin D,Waist circumference,replication,2015-02-12,GCST004065,Body measurement,#fc8d59
12956,European,142762.0,25673412.0,Shungin D,Waist circumference,initial,2015-02-12,GCST004065,Body measurement,#d53e4f
12957,Asian,2791.0,25673412.0,Shungin D,Waist circumference,replication,2015-02-12,GCST004065,Body measurement,#3288bd
12958,Asian,1650.0,25673412.0,Shungin D,Waist circumference,replication,2015-02-12,GCST004065,Body measurement,#3288bd
12959,African Am./Caribbean,8609.0,25673412.0,Shungin D,Waist circumference,replication,2015-02-12,GCST004065,Body measurement,#fee08b
12960,European,67326.0,25673412.0,Shungin D,Waist circumference,replication,2015-02-12,GCST004065,Body measurement,#d53e4f
12961,Asian,1650.0,25673412.0,Shungin D,Waist-hip ratio,replication,2015-02-12,GCST004064,Body measurement,#3288bd
12962,Asian,2791.0,25673412.0,Shungin D,Waist-hip ratio,replication,2015-02-12,GCST004064,Body measurement,#3288bd
12963,African Am./Caribbean,8609.0,25673412.0,Shungin D,Waist-hip ratio,replication,2015-02-12,GCST004064,Body measurement,#fee08b
12964,European,67326.0,25673412.0,Shungin D,Waist-hip ratio,replication,2015-02-12,GCST004064,Body measurement,#d53e4f
12965,African,461.0,25673412.0,Shungin D,Waist-hip ratio,replication,2015-02-12,GCST004064,Body measurement,#fc8d59
12966,European,142762.0,25673412.0,Shungin D,Waist-hip ratio,initial,2015-02-12,GCST004064,Body measurement,#d53e4f
12967,Asian,1747.0,25673413.0,Locke AE,Body mass index,replication,2015-02-12,GCST002783,Body measurement,#3288bd
12968,Hispanic/Latin American,1276.0,25673413.0,Locke AE,Body mass index,initial,2015-02-12,GCST002783,Body measurement,#807dba
12969,African Am./Caribbean,887.0,25673413.0,Locke AE,Body mass index,initial,2015-02-12,GCST002783,Body measurement,#fee08b
12970,Asian,3622.0,25673413.0,Locke AE,Body mass index,replication,2015-02-12,GCST002783,Body measurement,#3288bd
12971,African Am./Caribbean,8755.0,25673413.0,Locke AE,Body mass index,replication,2015-02-12,GCST002783,Body measurement,#fee08b
12973,European,88138.0,25673413.0,Locke AE,Body mass index,replication,2015-02-12,GCST002783,Body measurement,#d53e4f
12974,European,236781.0,25673413.0,Locke AE,Body mass index,initial,2015-02-12,GCST002783,Body measurement,#d53e4f
12975,Asian,8345.0,25672891.0,Shimizu S,Periodontitis,replication,2015-02-11,GCST002781,Digestive system disorder,#3288bd
12976,Asian,9573.0,25672891.0,Shimizu S,Periodontitis,initial,2015-02-11,GCST002781,Digestive system disorder,#3288bd
12979,European,156.0,25665007.0,Xu H,Cisplatin-induced hearing loss in brain tumor patients,initial,2015-02-09,GCST002780,Other trait,#d53e4f
12982,European,156.0,25665007.0,Xu H,Cisplatin-induced hearing loss in brain tumor patients,initial,2015-02-09,GCST002780,Neurological disorder,#d53e4f
12985,European,156.0,25665007.0,Xu H,Cisplatin-induced hearing loss in brain tumor patients,initial,2015-02-09,GCST002780,Response to drug,#d53e4f
12986,Asian,321.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#3288bd
12987,Hispanic/Latin American,174.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#807dba
12988,Asian,76.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#3288bd
12989,Asian,808.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,initial,2015-02-08,GCST002779,Other disease,#3288bd
12990,Asian,321.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#3288bd
12991,Hispanic/Latin American,174.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#807dba
12992,Asian,76.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Other disease,#3288bd
12993,Asian,808.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,initial,2015-02-08,GCST002779,Other disease,#3288bd
12994,Asian,321.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Response to drug,#3288bd
12995,Hispanic/Latin American,174.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Response to drug,#807dba
12996,Asian,76.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,replication,2015-02-08,GCST002779,Response to drug,#3288bd
12997,Asian,808.0,25672763.0,Ueta M,Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe mucosal involvement,initial,2015-02-08,GCST002779,Response to drug,#3288bd
12998,European,1629.0,25663231.0,Beecham GW,Parkinson disease and lewy body pathology,initial,2015-02-06,GCST002778,Neurological disorder,#d53e4f
12999,European,1629.0,25663231.0,Beecham GW,Parkinson disease and lewy body pathology,initial,2015-02-06,GCST002778,Other measurement,#d53e4f
13000,European,90.0,25656473.0,de With SA,Clozapine-induced cytotoxicity,initial,2015-02-05,GCST002777,Other measurement,#d53e4f
13001,European,90.0,25656473.0,de With SA,Clozapine-induced cytotoxicity,initial,2015-02-05,GCST002777,Response to drug,#d53e4f
13002,European,547.0,25722978.0,Borghese B,Endometriosis,replication,2015-02-04,GCST002776,Other disease,#d53e4f
13003,European,80.0,25722978.0,Borghese B,Endometriosis,initial,2015-02-04,GCST002776,Other disease,#d53e4f
13006,European,53949.0,25644384.0,Davies G,Cognitive function,initial,2015-02-03,GCST002774,Biological process,#d53e4f
13007,Asian,2158.0,25646370.0,Matsuo H,Gout,initial,2015-02-02,GCST002773,Metabolic disorder,#3288bd
13008,Asian,2382.0,25646370.0,Matsuo H,Gout,replication,2015-02-02,GCST002773,Metabolic disorder,#3288bd
13009,Asian,16270.0,25642632.0,Liu H,Leprosy,replication,2015-02-02,GCST002772,Neurological disorder,#3288bd
13010,Asian,8060.0,25642632.0,Liu H,Leprosy,initial,2015-02-02,GCST002772,Neurological disorder,#3288bd
13011,European,737.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other disease,#d53e4f
13012,African,545.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other disease,#fc8d59
13013,Hispanic/Latin American,314.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other disease,#807dba
13014,European,737.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Response to drug,#d53e4f
13015,African,545.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Response to drug,#fc8d59
13016,Hispanic/Latin American,314.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Response to drug,#807dba
13017,European,737.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other measurement,#d53e4f
13018,African,545.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other measurement,#fc8d59
13019,Hispanic/Latin American,314.0,25461247.0,Lehmann DS,Response to efavirenz-containing treatment in HIV 1 infection (virologic failure),initial,2015-02-01,GCST002771,Other measurement,#807dba
13020,European,346.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other disease,#d53e4f
13021,African,265.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other disease,#fc8d59
13022,Hispanic/Latin American,175.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other disease,#807dba
13023,European,346.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other measurement,#d53e4f
13024,African,265.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other measurement,#fc8d59
13025,Hispanic/Latin American,175.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Other measurement,#807dba
13026,European,346.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Response to drug,#d53e4f
13027,African,265.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Response to drug,#fc8d59
13028,Hispanic/Latin American,175.0,25461247.0,Lehmann DS,Response to abacavir-containing treatment in HIV-1 infection (virologic failure),initial,2015-02-01,GCST002769,Response to drug,#807dba
13029,European,2088.0,25637336.0,Chan JP,Hand grip strength,initial,2015-02-01,GCST002770,Other measurement,#d53e4f
13030,European,541.0,25637336.0,Chan JP,Hand grip strength,replication,2015-02-01,GCST002770,Other measurement,#d53e4f
13031,European,3378.0,25637581.0,Derringer J,Behavioral disinhibition,replication,2015-01-31,GCST002768,Other measurement,#d53e4f
13033,Other/Mixed,40.0,25637581.0,Derringer J,Behavioral disinhibition,initial,2015-01-31,GCST002768,Other measurement,#99d594
13034,Other/Mixed,42.0,25637581.0,Derringer J,Behavioral disinhibition,initial,2015-01-31,GCST002768,Other measurement,#99d594
13035,African,114.0,25637581.0,Derringer J,Behavioral disinhibition,initial,2015-01-31,GCST002768,Other measurement,#fc8d59
13036,Hispanic/Latin American,477.0,25637581.0,Derringer J,Behavioral disinhibition,initial,2015-01-31,GCST002768,Other measurement,#807dba
13037,European,1129.0,25637581.0,Derringer J,Behavioral disinhibition,initial,2015-01-31,GCST002768,Other measurement,#d53e4f
13040,European,35380.0,25631608.0,Wessel J,Fasting blood insulin,initial,2015-01-29,GCST007898,Other measurement,#d53e4f
13041,African Am./Caribbean,12738.0,25631608.0,Wessel J,Fasting blood insulin,initial,2015-01-29,GCST007898,Other measurement,#fee08b
13042,European,50900.0,25631608.0,Wessel J,Fasting blood glucose,initial,2015-01-29,GCST007899,Other measurement,#d53e4f
13043,African Am./Caribbean,9664.0,25631608.0,Wessel J,Fasting blood glucose,initial,2015-01-29,GCST007899,Other measurement,#fee08b
13044,Asian,7810.0,25629512.0,Cheng CY,Exudative age-related macular degeneration,initial,2015-01-28,GCST002766,Neurological disorder,#3288bd
13045,Asian,14515.0,25629512.0,Cheng CY,Exudative age-related macular degeneration,replication,2015-01-28,GCST002766,Neurological disorder,#3288bd
13046,Asian,2131.0,25631615.0,Springelkamp H,Optic disc area,initial,2015-01-28,GCST002763,Other measurement,#3288bd
13047,Asian,2305.0,25631615.0,Springelkamp H,Optic disc area,initial,2015-01-28,GCST002763,Other measurement,#3288bd
13048,European,17248.0,25631615.0,Springelkamp H,Optic disc area,initial,2015-01-28,GCST002763,Other measurement,#d53e4f
13049,Asian,2405.0,25631615.0,Springelkamp H,Optic disc area,initial,2015-01-28,GCST002763,Other measurement,#3288bd
13050,Asian,2363.0,25631615.0,Springelkamp H,Optic cup area,replication,2015-01-28,GCST002762,Other measurement,#3288bd
13051,European,17218.0,25631615.0,Springelkamp H,Optic cup area,initial,2015-01-28,GCST002762,Other measurement,#d53e4f
13052,Asian,2225.0,25631615.0,Springelkamp H,Optic cup area,replication,2015-01-28,GCST002762,Other measurement,#3288bd
13053,Asian,2025.0,25631615.0,Springelkamp H,Optic cup area,replication,2015-01-28,GCST002762,Other measurement,#3288bd
13054,Asian,2363.0,25631615.0,Springelkamp H,Optic cup area,initial,2015-01-28,GCST002764,Other measurement,#3288bd
13055,Asian,2225.0,25631615.0,Springelkamp H,Optic cup area,initial,2015-01-28,GCST002764,Other measurement,#3288bd
13056,Asian,2025.0,25631615.0,Springelkamp H,Optic cup area,initial,2015-01-28,GCST002764,Other measurement,#3288bd
13057,European,17218.0,25631615.0,Springelkamp H,Optic cup area,initial,2015-01-28,GCST002764,Other measurement,#d53e4f
13058,Asian,2405.0,25631615.0,Springelkamp H,Optic disc area,replication,2015-01-28,GCST002765,Other measurement,#3288bd
13059,European,17248.0,25631615.0,Springelkamp H,Optic disc area,initial,2015-01-28,GCST002765,Other measurement,#d53e4f
13060,Asian,2305.0,25631615.0,Springelkamp H,Optic disc area,replication,2015-01-28,GCST002765,Other measurement,#3288bd
13061,Asian,2131.0,25631615.0,Springelkamp H,Optic disc area,replication,2015-01-28,GCST002765,Other measurement,#3288bd
13062,European,325.0,25625606.0,Mather KA,Hippocampal atrophy,initial,2015-01-27,GCST002760,Neurological disorder,#d53e4f
13063,European,33231.0,25625282.0,Mahajan A,Fasting blood glucose adjusted for BMI,initial,2015-01-27,GCST007858,Other measurement,#d53e4f
13064,European,30825.0,25625282.0,Mahajan A,Fasting blood insulin adjusted for BMI,initial,2015-01-27,GCST007857,Other measurement,#d53e4f
13065,European,498.0,25625606.0,Mather KA,Hippocampal volume,initial,2015-01-27,GCST002761,Other measurement,#d53e4f
13066,European,80494.0,25628336.0,Hromatka BS,Motion sickness,initial,2015-01-26,GCST002759,Other trait,#d53e4f
13069,European,2507.0,25616667.0,Goris A,Oligoclonal band status in multiple sclerosis,initial,2015-01-22,GCST002758,Immune system disorder,#d53e4f
13072,European,2507.0,25616667.0,Goris A,Oligoclonal band status in multiple sclerosis,initial,2015-01-22,GCST002758,Other measurement,#d53e4f
13073,European,7565.0,25608926.0,Betz RC,Alopecia areata,initial,2015-01-22,GCST004866,Other disease,#d53e4f
13074,European,3020.0,25608926.0,Betz RC,Alopecia areata,replication,2015-01-22,GCST004866,Other disease,#d53e4f
13076,European,773.0,25616667.0,Goris A,Immunoglobulin G index levels in multiple sclerosis,initial,2015-01-22,GCST002757,Immune system disorder,#d53e4f
13079,European,773.0,25616667.0,Goris A,Immunoglobulin G index levels in multiple sclerosis,initial,2015-01-22,GCST002757,Other measurement,#d53e4f
13081,Hispanic/Latin American,736.0,25607358.0,Hibar DP,Subcortical brain region volumes,replication,2015-01-21,GCST002756,Other measurement,#807dba
13082,Asian,545.0,25607358.0,Hibar DP,Subcortical brain region volumes,replication,2015-01-21,GCST002756,Other measurement,#3288bd
13083,European,15130.0,25607358.0,Hibar DP,Subcortical brain region volumes,replication,2015-01-21,GCST002756,Other measurement,#d53e4f
13084,European,13171.0,25607358.0,Hibar DP,Subcortical brain region volumes,initial,2015-01-21,GCST002756,Other measurement,#d53e4f
13094,European,1112.0,25604533.0,Renauer PA,Takayasu arteritis,initial,2015-01-20,GCST006575,Cardiovascular disease,#d53e4f
13095,Other/Mixed,978.0,25604533.0,Renauer PA,Takayasu arteritis,initial,2015-01-20,GCST006575,Cardiovascular disease,#99d594
13096,Other/Mixed,392.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm birth),replication,2015-01-19,GCST002751,Other measurement,#99d594
13097,Other/Mixed,1851.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm birth),initial,2015-01-19,GCST002751,Other measurement,#99d594
13098,Other/Mixed,392.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm birth),replication,2015-01-19,GCST002751,Other trait,#99d594
13099,Other/Mixed,1851.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm birth),initial,2015-01-19,GCST002751,Other trait,#99d594
13100,Other/Mixed,1881.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),initial,2015-01-19,GCST002752,Other measurement,#99d594
13101,African Am./Caribbean,194.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other measurement,#fee08b
13102,European,103.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other measurement,#d53e4f
13103,Other/Mixed,12.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other measurement,#99d594
13104,Hispanic/Latin American,184.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other measurement,#807dba
13105,Other/Mixed,1881.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),initial,2015-01-19,GCST002752,Other trait,#99d594
13106,African Am./Caribbean,194.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other trait,#fee08b
13107,European,103.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other trait,#d53e4f
13108,Other/Mixed,12.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other trait,#99d594
13109,Hispanic/Latin American,184.0,25599974.0,Zhang H,Spontaneous preterm birth (preterm delivery),replication,2015-01-19,GCST002752,Other trait,#807dba
13110,European,8683.0,25644374.0,Poirier JG,Lung cancer and family history of lung cancer,initial,2015-01-19,GCST002753,Cancer,#d53e4f
13111,European,8683.0,25644374.0,Poirier JG,Lung cancer and family history of lung cancer,initial,2015-01-19,GCST002753,Other measurement,#d53e4f
13112,Hispanic/Latin American,337.0,25584925.0,Chen W,Chronic obstructive pulmonary disease,replication,2015-01-13,GCST002750,Other disease,#807dba
13113,Hispanic/Latin American,1188.0,25584925.0,Chen W,Chronic obstructive pulmonary disease,initial,2015-01-13,GCST002750,Other disease,#807dba
13114,Asian,94.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Response to drug,#3288bd
13115,European,91.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Response to drug,#d53e4f
13116,African Am./Caribbean,93.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Response to drug,#fee08b
13117,Asian,94.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Other measurement,#3288bd
13118,European,91.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Other measurement,#d53e4f
13119,African Am./Caribbean,93.0,25628645.0,Tong Y,Response to Homoharringtonine (cytotoxicity),initial,2015-01-13,GCST002749,Other measurement,#fee08b
13120,European,13491.0,25581431.0,Kuchenbaecker KB,Epithelial ovarian cancer,initial,2015-01-12,GCST002748,Cancer,#d53e4f
13121,European,56254.0,25581431.0,Kuchenbaecker KB,Epithelial ovarian cancer,replication,2015-01-12,GCST002748,Cancer,#d53e4f
13122,European,2845.0,25583994.0,Tardif JC,Response to Dalcetrapib treatment in acute coronary syndrome,initial,2015-01-11,GCST002747,Response to drug,#d53e4f
13123,European,2845.0,25583994.0,Tardif JC,Response to Dalcetrapib treatment in acute coronary syndrome,initial,2015-01-11,GCST002747,Cardiovascular disease,#d53e4f
13124,European,2845.0,25583994.0,Tardif JC,Response to Dalcetrapib treatment in acute coronary syndrome,initial,2015-01-11,GCST002747,Cardiovascular measurement,#d53e4f
13125,Other/Mixed,1376.0,25575512.0,Lu W,Lipoprotein (a) - cholesterol levels,initial,2015-01-09,GCST002746,Lipid or lipoprotein measurement,#99d594
13126,Other/Mixed,2547.0,25884002.0,Moore CB,HDL Cholesterol in HIV-infection,initial,2015-01-09,GCST002744,Other disease,#99d594
13127,Other/Mixed,2547.0,25884002.0,Moore CB,HDL Cholesterol in HIV-infection,initial,2015-01-09,GCST002744,Lipid or lipoprotein measurement,#99d594
13128,Other/Mixed,2547.0,25884002.0,Moore CB,Neutrophil count in HIV-infection,initial,2015-01-09,GCST002743,Hematological measurement,#99d594
13129,Other/Mixed,2547.0,25884002.0,Moore CB,Neutrophil count in HIV-infection,initial,2015-01-09,GCST002743,Other disease,#99d594
13130,Other/Mixed,2547.0,25884002.0,Moore CB,Total bilirubin levels in HIV-1 infection,initial,2015-01-09,GCST002745,Other disease,#99d594
13131,Other/Mixed,2547.0,25884002.0,Moore CB,Total bilirubin levels in HIV-1 infection,initial,2015-01-09,GCST002745,Other measurement,#99d594
13132,European,1362.0,25569183.0,Vijai J,Marginal zone lymphoma,replication,2015-01-08,GCST002742,Cancer,#d53e4f
13133,European,7046.0,25569183.0,Vijai J,Marginal zone lymphoma,initial,2015-01-08,GCST002742,Cancer,#d53e4f
13134,European,12244.0,25574825.0,Baurecht H,Psoriasis,initial,2015-01-08,GCST002738,Immune system disorder,#d53e4f
13135,European,5946.0,25574825.0,Baurecht H,Atopic dermatitis,initial,2015-01-08,GCST002737,Immune system disorder,#d53e4f
13136,Asian,3080.0,25566987.0,Hosgood HD 3rd,Lung cancer (household air pollution interaction),initial,2015-01-08,GCST002739,Cancer,#3288bd
13137,Asian,3080.0,25566987.0,Hosgood HD 3rd,Lung cancer (household air pollution interaction),initial,2015-01-08,GCST002739,Other measurement,#3288bd
13138,European,18190.0,25574825.0,Baurecht H,Inflammatory skin disease,initial,2015-01-08,GCST002740,Other disease,#d53e4f
13139,Asian,1027.0,25574032.0,Lee H,Polycystic ovary syndrome,replication,2015-01-08,GCST002741,Other disease,#3288bd
13140,Asian,1922.0,25574032.0,Lee H,Polycystic ovary syndrome,initial,2015-01-08,GCST002741,Other disease,#3288bd
13141,African,2790.0,25561047.0,Musani SK,B-type natriuretic peptide levels,initial,2015-01-05,GCST002736,Cardiovascular measurement,#fc8d59
13142,Asian,135.0,25824743.0,Haryono SJ,Breast cancer,initial,2015-01-01,GCST002735,Cancer,#3288bd
13143,Asian,1183.0,25489960.0,Yang SK,Crohn's disease,initial,2015-01-01,GCST008485,Digestive system disorder,#3288bd
13144,Asian,1925.0,25489960.0,Yang SK,Crohn's disease,replication,2015-01-01,GCST008485,Digestive system disorder,#3288bd
13145,European,3184.0,25552591.0,Lieb W,Endothelial growth factor levels,replication,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13146,European,3574.0,25552591.0,Lieb W,Endothelial growth factor levels,initial,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13147,European,3184.0,25552591.0,Lieb W,Endothelial growth factor levels,replication,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13148,European,3574.0,25552591.0,Lieb W,Endothelial growth factor levels,initial,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13149,European,3184.0,25552591.0,Lieb W,Endothelial growth factor levels,replication,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13150,European,3574.0,25552591.0,Lieb W,Endothelial growth factor levels,initial,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13151,European,3184.0,25552591.0,Lieb W,Endothelial growth factor levels,replication,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13152,European,3574.0,25552591.0,Lieb W,Endothelial growth factor levels,initial,2014-12-31,GCST002731,Cardiovascular measurement,#d53e4f
13153,Asian,7861.0,25705162.0,Oh JH,Platelet count,replication,2014-12-31,GCST002733,Hematological measurement,#3288bd
13154,Asian,8842.0,25705162.0,Oh JH,Platelet count,initial,2014-12-31,GCST002733,Hematological measurement,#3288bd
13155,Asian,3000.0,25705159.0,Hong Y,Hepatitis,initial,2014-12-31,GCST002730,Other trait,#3288bd
13156,Asian,8842.0,25705158.0,Shim U,Metabolic syndrome,initial,2014-12-31,GCST002732,Metabolic disorder,#3288bd
13157,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Other trait,#d53e4f
13158,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Other trait,#d53e4f
13159,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Immune system disorder,#d53e4f
13160,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Immune system disorder,#d53e4f
13161,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Other trait,#d53e4f
13162,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Other trait,#d53e4f
13163,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Immune system disorder,#d53e4f
13164,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Immune system disorder,#d53e4f
13165,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Digestive system disorder,#d53e4f
13166,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Digestive system disorder,#d53e4f
13167,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Biological process,#d53e4f
13168,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Biological process,#d53e4f
13169,European,1296.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,replication,2014-12-31,GCST002729,Biological process,#d53e4f
13170,European,1090.0,25557950.0,Alonso A,Crohn's disease-related phenotypes,initial,2014-12-31,GCST002729,Biological process,#d53e4f
13171,European,80607.0,25551457.0,Baumert J,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)",initial,2014-12-31,GCST002734,Other measurement,#d53e4f
13172,European,80607.0,25551457.0,Baumert J,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)",initial,2014-12-31,GCST002734,Biological process,#d53e4f
13173,European,80607.0,25551457.0,Baumert J,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)",initial,2014-12-31,GCST002734,Hematological measurement,#d53e4f
13174,European,80607.0,25551457.0,Baumert J,"Fibrinogen levels (smoking status, alcohol consumption or body mass index interaction)",initial,2014-12-31,GCST002734,Body measurement,#d53e4f
13176,European,1523.0,25526632.0,Rafiq S,Breast cancer (survival),replication,2014-12-19,GCST002727,Other measurement,#d53e4f
13177,European,1341.0,25526632.0,Rafiq S,Breast cancer (survival),initial,2014-12-19,GCST002727,Other measurement,#d53e4f
13178,European,1523.0,25526632.0,Rafiq S,Breast cancer (survival),replication,2014-12-19,GCST002727,Cancer,#d53e4f
13179,European,1341.0,25526632.0,Rafiq S,Breast cancer (survival),initial,2014-12-19,GCST002727,Cancer,#d53e4f
13180,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13181,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13182,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13183,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13184,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13185,Hispanic/Latin American,4176.0,25524916.0,Palmer ND,Glucose homeostasis traits,initial,2014-12-18,GCST002726,Other measurement,#807dba
13187,European,2791.0,25521368.0,Tonjes A,Circulating chemerin levels,initial,2014-12-18,GCST004389,Cardiovascular measurement,#d53e4f
13188,European,538.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),replication,2014-12-18,GCST002725,Other measurement,#d53e4f
13189,European,1553.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),initial,2014-12-18,GCST002725,Other measurement,#d53e4f
13190,European,538.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),replication,2014-12-18,GCST002725,Other disease,#d53e4f
13191,European,1553.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),initial,2014-12-18,GCST002725,Other disease,#d53e4f
13192,European,538.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),replication,2014-12-18,GCST002725,Other trait,#d53e4f
13193,European,1553.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),initial,2014-12-18,GCST002725,Other trait,#d53e4f
13194,European,538.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),replication,2014-12-18,GCST002725,Other trait,#d53e4f
13195,European,1553.0,25533491.0,Rautanen A,Sepsis from pneumonia (survival),initial,2014-12-18,GCST002725,Other trait,#d53e4f
13196,European,4108.0,25514360.0,Hansel NN,Airway responsiveness in chronic obstructive pulmonary disease,initial,2014-12-16,GCST002724,Other measurement,#d53e4f
13197,European,4108.0,25514360.0,Hansel NN,Airway responsiveness in chronic obstructive pulmonary disease,initial,2014-12-16,GCST002724,Other disease,#d53e4f
13198,European,1504.0,25524241.0,Richter HE,Urgency urinary incontinence,replication,2014-12-15,GCST002723,Other trait,#d53e4f
13199,European,1507.0,25524241.0,Richter HE,Urgency urinary incontinence,initial,2014-12-15,GCST002723,Other trait,#d53e4f
13200,African Am./Caribbean,116.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Response to drug,#fee08b
13201,European,426.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,replication,2014-12-11,GCST002722,Response to drug,#d53e4f
13202,Asian,1.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Response to drug,#3288bd
13203,Hispanic/Latin American,8.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Response to drug,#807dba
13205,Other/Mixed,7.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Response to drug,#99d594
13206,European,811.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Response to drug,#d53e4f
13207,African Am./Caribbean,116.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Other trait,#fee08b
13208,European,426.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,replication,2014-12-11,GCST002722,Other trait,#d53e4f
13209,Asian,1.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Other trait,#3288bd
13210,Hispanic/Latin American,8.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Other trait,#807dba
13212,Other/Mixed,7.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Other trait,#99d594
13213,European,811.0,25503805.0,Karnes JH,Heparin-induced thrombocytopenia,initial,2014-12-11,GCST002722,Other trait,#d53e4f
13214,European,45530.0,25493955.0,Gorski M,Kidney function decline traits,initial,2014-12-10,GCST002720,Other disease,#d53e4f
13215,European,18028.0,25493955.0,Gorski M,Kidney function decline traits,replication,2014-12-10,GCST002720,Other disease,#d53e4f
13216,European,45530.0,25493955.0,Gorski M,Kidney function decline traits,initial,2014-12-10,GCST002720,Other trait,#d53e4f
13217,European,18028.0,25493955.0,Gorski M,Kidney function decline traits,replication,2014-12-10,GCST002720,Other trait,#d53e4f
13218,European,45530.0,25493955.0,Gorski M,Kidney function decline traits,initial,2014-12-10,GCST002720,Other measurement,#d53e4f
13219,European,18028.0,25493955.0,Gorski M,Kidney function decline traits,replication,2014-12-10,GCST002720,Other measurement,#d53e4f
13220,African Am./Caribbean,1082.0,25646338.0,Mozaffarian D,Trans fatty acid levels,replication,2014-12-10,GCST002721,Lipid or lipoprotein measurement,#fee08b
13221,European,8013.0,25646338.0,Mozaffarian D,Trans fatty acid levels,initial,2014-12-10,GCST002721,Lipid or lipoprotein measurement,#d53e4f
13222,Hispanic/Latin American,657.0,25646338.0,Mozaffarian D,Trans fatty acid levels,replication,2014-12-10,GCST002721,Lipid or lipoprotein measurement,#807dba
13223,Asian,669.0,25646338.0,Mozaffarian D,Trans fatty acid levels,replication,2014-12-10,GCST002721,Lipid or lipoprotein measurement,#3288bd
13224,European,887.0,25562672.0,Byrne EM,Seasonality,replication,2014-12-09,GCST002719,Other measurement,#d53e4f
13225,European,3269.0,25562672.0,Byrne EM,Seasonality,initial,2014-12-09,GCST002719,Other measurement,#d53e4f
13226,Other/Mixed,3286.0,25483131.0,Ghassibe-Sabbagh M,Type 2 diabetes,initial,2014-12-08,GCST002718,Metabolic disorder,#99d594
13227,European,6341.0,25476525.0,Germain M,Diabetic nephropathy in type 1 diabetes,replication,2014-12-06,GCST002716,Metabolic disorder,#d53e4f
13228,European,1462.0,25476525.0,Germain M,Diabetic nephropathy in type 1 diabetes,initial,2014-12-06,GCST002716,Metabolic disorder,#d53e4f
13229,European,6341.0,25476525.0,Germain M,Diabetic nephropathy in type 1 diabetes,replication,2014-12-06,GCST002716,Metabolic disorder,#d53e4f
13230,European,1462.0,25476525.0,Germain M,Diabetic nephropathy in type 1 diabetes,initial,2014-12-06,GCST002716,Metabolic disorder,#d53e4f
13231,Hispanic/Latin American,3334.0,25488688.0,Pino-Yanes M,Serum IgE levels,initial,2014-12-06,GCST002717,Other measurement,#807dba
13232,Hispanic/Latin American,454.0,25488688.0,Pino-Yanes M,Serum IgE levels,replication,2014-12-06,GCST002717,Other measurement,#807dba
13234,European,5275.0,25477429.0,Lieb W,Plasma renin activity levels,initial,2014-12-04,GCST002714,Cardiovascular measurement,#d53e4f
13241,Other/Mixed,558.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),replication,2014-12-02,GCST002713,Cancer,#99d594
13242,Other/Mixed,3027.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),initial,2014-12-02,GCST002713,Cancer,#99d594
13243,Hispanic/Latin American,1084.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),initial,2014-12-02,GCST002713,Cancer,#807dba
13244,African Am./Caribbean,1378.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),initial,2014-12-02,GCST002713,Cancer,#fee08b
13245,European,3739.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),replication,2014-12-02,GCST002713,Cancer,#d53e4f
13246,Hispanic/Latin American,535.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),replication,2014-12-02,GCST002713,Cancer,#807dba
13247,African Am./Caribbean,1085.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),replication,2014-12-02,GCST002713,Cancer,#fee08b
13248,European,1480.0,25468567.0,Perez-Andreu V,Acute lymphoblastic leukemia (adolescents and young adults),initial,2014-12-02,GCST002713,Cancer,#d53e4f
13249,African Am./Caribbean,4771.0,25469926.0,Gottlieb DJ,Sleep duration,replication,2014-12-02,GCST002711,Other measurement,#fee08b
13250,European,47180.0,25469926.0,Gottlieb DJ,Sleep duration,initial,2014-12-02,GCST002711,Other measurement,#d53e4f
13251,European,4424.0,25387706.0,Vaidyanathan U,Electrodermal activity,initial,2014-12-01,GCST002706,Other measurement,#d53e4f
13252,European,4424.0,25387706.0,Vaidyanathan U,Electrodermal activity,initial,2014-12-01,GCST002706,Other measurement,#d53e4f
13253,European,4424.0,25387706.0,Vaidyanathan U,Electrodermal activity,initial,2014-12-01,GCST002706,Other measurement,#d53e4f
13254,European,4424.0,25387706.0,Vaidyanathan U,Electrodermal activity,initial,2014-12-01,GCST002706,Other measurement,#d53e4f
13255,European,3323.0,25387708.0,Vaidyanathan U,Acoustic startle blink response,initial,2014-12-01,GCST002708,Other measurement,#d53e4f
13256,European,4469.0,25387707.0,Vaidyanathan U,Anti-saccade response,initial,2014-12-01,GCST002710,Other measurement,#d53e4f
13257,European,4501.0,25436638.0,Malinowski JR,Serum thyroid-stimulating hormone levels,initial,2014-12-01,GCST002707,Other measurement,#d53e4f
13258,African Am./Caribbean,351.0,25436638.0,Malinowski JR,Serum thyroid-stimulating hormone levels,initial,2014-12-01,GCST002707,Other measurement,#fee08b
13259,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13260,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13261,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13262,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13263,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13264,European,4026.0,25387704.0,Malone SM,Electroencephalogram traits,initial,2014-12-01,GCST002709,Other measurement,#d53e4f
13265,Asian,523.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,initial,2014-11-27,GCST002705,Immune system disorder,#3288bd
13266,Asian,467.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,replication,2014-11-27,GCST002705,Immune system disorder,#3288bd
13267,Asian,523.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,initial,2014-11-27,GCST002705,Immune system disorder,#3288bd
13268,Asian,467.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,replication,2014-11-27,GCST002705,Immune system disorder,#3288bd
13269,Asian,523.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,initial,2014-11-27,GCST002705,Immune system disorder,#3288bd
13270,Asian,467.0,25429627.0,Oryoji D,Hashimoto thyroiditis versus Graves' disease,replication,2014-11-27,GCST002705,Immune system disorder,#3288bd
13271,Asian,1575.0,25434496.0,Kim S,Prostate-specific antigen levels,replication,2014-11-27,GCST002703,Other measurement,#3288bd
13272,Asian,554.0,25434496.0,Kim S,Prostate-specific antigen levels,initial,2014-11-27,GCST002703,Other measurement,#3288bd
13273,European,1211.0,25431337.0,Bouzigon E,Fractional exhaled nitric oxide levels,initial,2014-11-27,GCST002704,Other measurement,#d53e4f
13274,European,9308.0,25431337.0,Bouzigon E,Fractional exhaled nitric oxide levels,replication,2014-11-27,GCST002704,Other measurement,#d53e4f
13275,Asian,57699.0,25429064.0,He M,Height,replication,2014-11-26,GCST002702,Body measurement,#3288bd
13276,Asian,36227.0,25429064.0,He M,Height,initial,2014-11-26,GCST002702,Body measurement,#3288bd
13277,African Am./Caribbean,3811.0,25648963.0,Debette S,Verbal declarative memory,replication,2014-11-25,GCST002701,Other measurement,#fee08b
13278,European,10617.0,25648963.0,Debette S,Verbal declarative memory,replication,2014-11-25,GCST002701,Other measurement,#d53e4f
13279,European,29076.0,25648963.0,Debette S,Verbal declarative memory,initial,2014-11-25,GCST002701,Other measurement,#d53e4f
13280,European,3307.0,25420145.0,Debette S,Cervical artery dissection,replication,2014-11-24,GCST002700,Cardiovascular disease,#d53e4f
13281,European,15809.0,25420145.0,Debette S,Cervical artery dissection,initial,2014-11-24,GCST002700,Cardiovascular disease,#d53e4f
13282,European,959.0,25917933.0,Zai CC,Suicide in bipolar disorder,initial,2014-11-20,GCST002699,Other measurement,#d53e4f
13283,European,959.0,25917933.0,Zai CC,Suicide in bipolar disorder,initial,2014-11-20,GCST002699,Neurological disorder,#d53e4f
13284,European,959.0,25917933.0,Zai CC,Suicide in bipolar disorder,initial,2014-11-20,GCST002699,Biological process,#d53e4f
13285,European,4240.0,25407941.0,Sleiman PM,Eosinophilic esophagitis,initial,2014-11-19,GCST002697,Digestive system disorder,#d53e4f
13286,European,1008.0,25407941.0,Sleiman PM,Eosinophilic esophagitis,replication,2014-11-19,GCST002697,Digestive system disorder,#d53e4f
13287,European,736.0,25411163.0,Maitland ML,Serum VEGFR2 concentration,initial,2014-11-19,GCST002698,Other measurement,#d53e4f
13288,European,1697.0,25390645.0,Otowa T,Anxiety disorder,initial,2014-11-12,GCST002696,Neurological disorder,#d53e4f
13289,African Am./Caribbean,597.0,25390645.0,Otowa T,Anxiety disorder,initial,2014-11-12,GCST002696,Neurological disorder,#fee08b
13290,Other/Mixed,363.0,25385369.0,Ramanan VK,Episodic memory,replication,2014-11-11,GCST002695,Biological process,#99d594
13291,African Am./Caribbean,711.0,25385369.0,Ramanan VK,Episodic memory,replication,2014-11-11,GCST002695,Biological process,#fee08b
13292,Other/Mixed,605.0,25385369.0,Ramanan VK,Episodic memory,initial,2014-11-11,GCST002695,Biological process,#99d594
13293,African Am./Caribbean,817.0,25385369.0,Ramanan VK,Episodic memory,initial,2014-11-11,GCST002695,Biological process,#fee08b
13294,European,6687.0,25385369.0,Ramanan VK,Episodic memory,replication,2014-11-11,GCST002695,Biological process,#d53e4f
13295,European,5283.0,25385369.0,Ramanan VK,Episodic memory,initial,2014-11-11,GCST002695,Biological process,#d53e4f
13296,Asian,981.0,25383971.0,Dunstan SJ,Enteric fever,replication,2014-11-10,GCST002693,Other disease,#3288bd
13297,Asian,819.0,25383971.0,Dunstan SJ,Enteric fever,replication,2014-11-10,GCST002693,Other disease,#3288bd
13298,Asian,2443.0,25383971.0,Dunstan SJ,Enteric fever,initial,2014-11-10,GCST002693,Other disease,#3288bd
13299,European,7100.0,25383866.0,Kirkpatrick RM,General cognitive ability,initial,2014-11-10,GCST002694,Biological process,#d53e4f
13300,Asian,73.0,25378290.0,McQueen MB,Body mass index (change over time),initial,2014-11-07,GCST002692,Body measurement,#3288bd
13301,African Am./Caribbean,677.0,25378290.0,McQueen MB,Body mass index (change over time),initial,2014-11-07,GCST002692,Body measurement,#fee08b
13302,Hispanic/Latin American,209.0,25378290.0,McQueen MB,Body mass index (change over time),initial,2014-11-07,GCST002692,Body measurement,#807dba
13303,Other/Mixed,8.0,25378290.0,McQueen MB,Body mass index (change over time),initial,2014-11-07,GCST002692,Body measurement,#99d594
13304,European,917.0,25378290.0,McQueen MB,Body mass index (change over time),initial,2014-11-07,GCST002692,Body measurement,#d53e4f
13306,African Am./Caribbean,94.0,25670933.0,Hanchard NA,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2014-11-07,GCST002691,Neurological disorder,#fee08b
13307,African Am./Caribbean,94.0,25670933.0,Hanchard NA,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2014-11-07,GCST002691,Biological process,#fee08b
13308,African Am./Caribbean,94.0,25670933.0,Hanchard NA,Alloimmunization response to red blood cell transfusion in sickle cell anemia,initial,2014-11-07,GCST002691,Biological process,#fee08b
13309,European,10129.0,25378659.0,Lemaitre RN,Very long-chain saturated fatty acid levels (fatty acid 20:0),initial,2014-11-06,GCST002690,Lipid or lipoprotein measurement,#d53e4f
13310,European,7915.0,25378659.0,Lemaitre RN,Very long-chain saturated fatty acid levels (fatty acid 24:0),initial,2014-11-06,GCST002689,Lipid or lipoprotein measurement,#d53e4f
13311,European,10129.0,25378659.0,Lemaitre RN,Very long-chain saturated fatty acid levels (fatty acid 22:0),initial,2014-11-06,GCST002688,Lipid or lipoprotein measurement,#d53e4f
13312,African Am./Caribbean,2701.0,25376901.0,Munir MS,Protein C levels,initial,2014-11-05,GCST002686,Hematological measurement,#fee08b
13313,African,321.0,25372704.0,Mtatiro SN,Fetal hemoglobin levels in sickle cell anemia,replication,2014-11-05,GCST002687,Hematological measurement,#fc8d59
13314,African,1213.0,25372704.0,Mtatiro SN,Fetal hemoglobin levels in sickle cell anemia,initial,2014-11-05,GCST002687,Hematological measurement,#fc8d59
13315,African,321.0,25372704.0,Mtatiro SN,Fetal hemoglobin levels in sickle cell anemia,replication,2014-11-05,GCST002687,Neurological disorder,#fc8d59
13316,African,1213.0,25372704.0,Mtatiro SN,Fetal hemoglobin levels in sickle cell anemia,initial,2014-11-05,GCST002687,Neurological disorder,#fc8d59
13317,Asian,2165.0,25367360.0,Li Q,Refractive astigmatism,initial,2014-11-04,GCST002685,Other trait,#3288bd
13318,Asian,1998.0,25367360.0,Li Q,Refractive astigmatism,initial,2014-11-04,GCST002685,Other trait,#3288bd
13319,Asian,6049.0,25367360.0,Li Q,Refractive astigmatism,initial,2014-11-04,GCST002685,Other trait,#3288bd
13320,European,37608.0,25367360.0,Li Q,Refractive astigmatism,initial,2014-11-04,GCST002685,Other trait,#d53e4f
13321,Asian,446.0,25364816.0,Awata T,Diabetic retinopathy in type 2 diabetes,initial,2014-11-03,GCST002684,Metabolic disorder,#3288bd
13322,Asian,1540.0,25364816.0,Awata T,Diabetic retinopathy in type 2 diabetes,replication,2014-11-03,GCST002684,Metabolic disorder,#3288bd
13323,Asian,446.0,25364816.0,Awata T,Diabetic retinopathy in type 2 diabetes,initial,2014-11-03,GCST002684,Metabolic disorder,#3288bd
13324,Asian,1540.0,25364816.0,Awata T,Diabetic retinopathy in type 2 diabetes,replication,2014-11-03,GCST002684,Metabolic disorder,#3288bd
13325,European,3889.0,25409777.0,Thyagarajan B,Pulmonary function,initial,2014-11-01,GCST002683,Other measurement,#d53e4f
13327,European,9260.0,25158072.0,Yu D,Tourette's syndrome or obsessive-compulsive disorder,initial,2014-10-31,GCST002682,Neurological disorder,#d53e4f
13328,European,9260.0,25158072.0,Yu D,Tourette's syndrome or obsessive-compulsive disorder,initial,2014-10-31,GCST002682,Neurological disorder,#d53e4f
13329,European,491.0,25456346.0,Nievergelt CM,Post-traumatic stress disorder,replication,2014-10-30,GCST002681,Neurological disorder,#d53e4f
13330,Asian,470.0,25456346.0,Nievergelt CM,Post-traumatic stress disorder,initial,2014-10-30,GCST002681,Neurological disorder,#3288bd
13331,African Am./Caribbean,205.0,25456346.0,Nievergelt CM,Post-traumatic stress disorder,initial,2014-10-30,GCST002681,Neurological disorder,#fee08b
13332,Other/Mixed,640.0,25456346.0,Nievergelt CM,Post-traumatic stress disorder,initial,2014-10-30,GCST002681,Neurological disorder,#99d594
13333,European,2179.0,25456346.0,Nievergelt CM,Post-traumatic stress disorder,initial,2014-10-30,GCST002681,Neurological disorder,#d53e4f
13334,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (ferritin levels),initial,2014-10-29,GCST002677,Other measurement,#d53e4f
13335,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (ferritin levels),replication,2014-10-29,GCST002677,Other measurement,#d53e4f
13336,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (ferritin levels),initial,2014-10-29,GCST002677,Other measurement,#d53e4f
13337,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (ferritin levels),replication,2014-10-29,GCST002677,Other measurement,#d53e4f
13338,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin levels),replication,2014-10-29,GCST002678,Other measurement,#d53e4f
13339,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin levels),initial,2014-10-29,GCST002678,Other measurement,#d53e4f
13340,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin levels),replication,2014-10-29,GCST002678,Other measurement,#d53e4f
13341,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin levels),initial,2014-10-29,GCST002678,Other measurement,#d53e4f
13342,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (iron levels),initial,2014-10-29,GCST002679,Other measurement,#d53e4f
13343,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (iron levels),replication,2014-10-29,GCST002679,Other measurement,#d53e4f
13344,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (iron levels),initial,2014-10-29,GCST002679,Other measurement,#d53e4f
13345,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (iron levels),replication,2014-10-29,GCST002679,Other measurement,#d53e4f
13346,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin saturation),replication,2014-10-29,GCST002680,Other measurement,#d53e4f
13347,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin saturation),initial,2014-10-29,GCST002680,Other measurement,#d53e4f
13348,European,24986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin saturation),replication,2014-10-29,GCST002680,Other measurement,#d53e4f
13349,European,23986.0,25352340.0,Benyamin B,Iron status biomarkers (transferrin saturation),initial,2014-10-29,GCST002680,Other measurement,#d53e4f
13350,European,478.0,25353672.0,Fernandez-Navarro P,Mammographic density,initial,2014-10-29,GCST002676,Other measurement,#d53e4f
13351,European,23279.0,25350695.0,Postmus I,Response to statins (LDL cholesterol change),replication,2014-10-28,GCST002675,Response to drug,#d53e4f
13352,European,18596.0,25350695.0,Postmus I,Response to statins (LDL cholesterol change),initial,2014-10-28,GCST002675,Response to drug,#d53e4f
13353,European,23279.0,25350695.0,Postmus I,Response to statins (LDL cholesterol change),replication,2014-10-28,GCST002675,Lipid or lipoprotein measurement,#d53e4f
13354,European,18596.0,25350695.0,Postmus I,Response to statins (LDL cholesterol change),initial,2014-10-28,GCST002675,Lipid or lipoprotein measurement,#d53e4f
13355,European,6117.0,25344690.0,Feenstra B,Febrile seizures,initial,2014-10-26,GCST002672,Other trait,#d53e4f
13356,European,3087.0,25344690.0,Feenstra B,Febrile seizures,replication,2014-10-26,GCST002672,Other trait,#d53e4f
13357,European,5047.0,25344690.0,Feenstra B,Febrile seizures (MMR vaccine-related),initial,2014-10-26,GCST002674,Other trait,#d53e4f
13358,European,3087.0,25344690.0,Feenstra B,Febrile seizures (MMR vaccine-related),replication,2014-10-26,GCST002674,Other trait,#d53e4f
13359,European,5118.0,25344690.0,Feenstra B,Febrile seizures (MMR vaccine-unrelated),initial,2014-10-26,GCST002673,Other trait,#d53e4f
13360,European,2679.0,25344690.0,Feenstra B,Febrile seizures (MMR vaccine-unrelated),replication,2014-10-26,GCST002673,Other trait,#d53e4f
13361,European,4162.0,25343990.0,Cornelis MC,Toenail selenium levels,initial,2014-10-24,GCST002671,Other measurement,#d53e4f
13362,European,9639.0,25343990.0,Cornelis MC,Blood and toenail selenium levels,initial,2014-10-24,GCST002670,Other measurement,#d53e4f
13363,European,343.0,25342443.0,Lindstrom S,Percent mammographic density,replication,2014-10-24,GCST002669,Other measurement,#d53e4f
13364,European,7916.0,25342443.0,Lindstrom S,Percent mammographic density,initial,2014-10-24,GCST002669,Other measurement,#d53e4f
13365,Other/Mixed,1472.0,25342443.0,Lindstrom S,Percent mammographic density,replication,2014-10-24,GCST002669,Other measurement,#99d594
13367,European,343.0,25342443.0,Lindstrom S,Percent mammographic density,replication,2014-10-24,GCST002669,Other measurement,#d53e4f
13368,European,7916.0,25342443.0,Lindstrom S,Percent mammographic density,initial,2014-10-24,GCST002669,Other measurement,#d53e4f
13369,Other/Mixed,1472.0,25342443.0,Lindstrom S,Percent mammographic density,replication,2014-10-24,GCST002669,Other measurement,#99d594
13371,European,343.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),replication,2014-10-24,GCST002668,Other measurement,#d53e4f
13372,European,7600.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),initial,2014-10-24,GCST002668,Other measurement,#d53e4f
13374,Other/Mixed,1472.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),replication,2014-10-24,GCST002668,Other measurement,#99d594
13375,European,343.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),replication,2014-10-24,GCST002668,Other measurement,#d53e4f
13376,European,7600.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),initial,2014-10-24,GCST002668,Other measurement,#d53e4f
13378,Other/Mixed,1472.0,25342443.0,Lindstrom S,Mammographic density (non-dense area),replication,2014-10-24,GCST002668,Other measurement,#99d594
13379,Other/Mixed,1472.0,25342443.0,Lindstrom S,Mammographic density (dense area),replication,2014-10-24,GCST002667,Other measurement,#99d594
13380,European,343.0,25342443.0,Lindstrom S,Mammographic density (dense area),replication,2014-10-24,GCST002667,Other measurement,#d53e4f
13381,European,7600.0,25342443.0,Lindstrom S,Mammographic density (dense area),initial,2014-10-24,GCST002667,Other measurement,#d53e4f
13383,Other/Mixed,1472.0,25342443.0,Lindstrom S,Mammographic density (dense area),replication,2014-10-24,GCST002667,Other measurement,#99d594
13384,European,343.0,25342443.0,Lindstrom S,Mammographic density (dense area),replication,2014-10-24,GCST002667,Other measurement,#d53e4f
13385,European,7600.0,25342443.0,Lindstrom S,Mammographic density (dense area),initial,2014-10-24,GCST002667,Other measurement,#d53e4f
13387,African Am./Caribbean,450.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,replication,2014-10-23,GCST002666,Other measurement,#fee08b
13388,European,715.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,replication,2014-10-23,GCST002666,Other measurement,#d53e4f
13389,European,410.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,initial,2014-10-23,GCST002666,Other measurement,#d53e4f
13390,African Am./Caribbean,450.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,replication,2014-10-23,GCST002666,Immune system disorder,#fee08b
13391,European,715.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,replication,2014-10-23,GCST002666,Immune system disorder,#d53e4f
13392,European,410.0,25338677.0,Kariuki SN,Interferon alpha levels in systemic lupus erythematosus,initial,2014-10-23,GCST002666,Immune system disorder,#d53e4f
13400,Asian,536.0,25335168.0,Hashimoto R,Superior frontal gyrus grey matter volume,initial,2014-10-21,GCST002663,Other measurement,#3288bd
13401,Other/Mixed,80.0,25729143.0,Ahmetov I,Maximal oxygen uptake response,initial,2014-10-21,GCST002664,Other measurement,#99d594
13402,Hispanic/Latin American,4710.0,25327703.0,Fejerman L,Breast cancer,initial,2014-10-20,GCST002662,Cancer,#807dba
13403,Hispanic/Latin American,6614.0,25327703.0,Fejerman L,Breast cancer,replication,2014-10-20,GCST002662,Cancer,#807dba
13404,European,15031.0,25329471.0,van Leeuwen EM,HDL cholesterol (SNP x SNP interaction),replication,2014-10-20,GCST002661,Lipid or lipoprotein measurement,#d53e4f
13405,European,2996.0,25329471.0,van Leeuwen EM,HDL cholesterol (SNP x SNP interaction),initial,2014-10-20,GCST002661,Lipid or lipoprotein measurement,#d53e4f
13407,European,746.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),replication,2014-10-18,GCST002660,Metabolic disorder,#d53e4f
13408,European,474.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),initial,2014-10-18,GCST002660,Metabolic disorder,#d53e4f
13409,European,746.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),replication,2014-10-18,GCST002660,Other measurement,#d53e4f
13410,European,474.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),initial,2014-10-18,GCST002660,Other measurement,#d53e4f
13411,European,746.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),replication,2014-10-18,GCST002660,Other measurement,#d53e4f
13412,European,474.0,25457201.0,de Tayrac M,Hereditary hemochromatosis-related traits (HFE mutation homozygotes),initial,2014-10-18,GCST002660,Other measurement,#d53e4f
13413,Asian,853.0,25328121.0,Lee JY,Coronary artery disease-related phenotypes,replication,2014-10-17,GCST002659,Cardiovascular disease,#3288bd
13414,Asian,667.0,25328121.0,Lee JY,Coronary artery disease-related phenotypes,initial,2014-10-17,GCST002659,Cardiovascular disease,#3288bd
13415,Asian,853.0,25328121.0,Lee JY,Coronary artery disease-related phenotypes,replication,2014-10-17,GCST002659,Cardiovascular measurement,#3288bd
13416,Asian,667.0,25328121.0,Lee JY,Coronary artery disease-related phenotypes,initial,2014-10-17,GCST002659,Cardiovascular measurement,#3288bd
13417,European,1983.0,25310577.0,Evans TJ,Acute lymphoblastic leukemia (childhood),replication,2014-10-13,GCST002657,Cancer,#d53e4f
13418,European,1550.0,25310577.0,Evans TJ,Acute lymphoblastic leukemia (childhood),initial,2014-10-13,GCST002657,Cancer,#d53e4f
13419,Asian,555.0,25310821.0,Kim JH,Hirschsprung disease,initial,2014-10-13,GCST002658,Digestive system disorder,#3288bd
13420,European,986.0,25451450.0,Jacobsen KK,Migraine in bipolar disorder,replication,2014-10-12,GCST002656,Neurological disorder,#d53e4f
13421,European,1374.0,25451450.0,Jacobsen KK,Migraine in bipolar disorder,initial,2014-10-12,GCST002656,Neurological disorder,#d53e4f
13422,European,986.0,25451450.0,Jacobsen KK,Migraine in bipolar disorder,replication,2014-10-12,GCST002656,Cardiovascular disease,#d53e4f
13423,European,1374.0,25451450.0,Jacobsen KK,Migraine in bipolar disorder,initial,2014-10-12,GCST002656,Cardiovascular disease,#d53e4f
13424,Asian,2096.0,25305756.0,Kiryluk K,IgA nephropathy,initial,2014-10-12,GCST002655,Other disease,#3288bd
13425,European,4603.0,25305756.0,Kiryluk K,IgA nephropathy,initial,2014-10-12,GCST002655,Other disease,#d53e4f
13426,European,9642.0,25305756.0,Kiryluk K,IgA nephropathy,replication,2014-10-12,GCST002655,Other disease,#d53e4f
13427,Asian,4271.0,25305756.0,Kiryluk K,IgA nephropathy,replication,2014-10-12,GCST002655,Other disease,#3288bd
13428,European,18423.0,25297839.0,Crosslin DR,Shingles,initial,2014-10-09,GCST002654,Other disease,#d53e4f
13429,Hispanic/Latin American,621.0,25297839.0,Crosslin DR,Shingles,initial,2014-10-09,GCST002654,Other disease,#807dba
13430,African,3485.0,25297839.0,Crosslin DR,Shingles,initial,2014-10-09,GCST002654,Other disease,#fc8d59
13431,European,2138.0,25411281.0,Dashti HS,Circulating phylloquinone levels,initial,2014-10-08,GCST002653,Other measurement,#d53e4f
13432,European,437.0,25293881.0,Patel YM,Cotinine glucuronidation,initial,2014-10-07,GCST002652,Other measurement,#d53e4f
13433,African Am./Caribbean,364.0,25293881.0,Patel YM,Cotinine glucuronidation,initial,2014-10-07,GCST002652,Other measurement,#fee08b
13434,Hispanic/Latin American,453.0,25293881.0,Patel YM,Cotinine glucuronidation,initial,2014-10-07,GCST002652,Other measurement,#807dba
13435,Asian,674.0,25293881.0,Patel YM,Cotinine glucuronidation,initial,2014-10-07,GCST002652,Other measurement,#3288bd
13436,Other/Mixed,311.0,25293881.0,Patel YM,Cotinine glucuronidation,initial,2014-10-07,GCST002652,Other measurement,#99d594
13437,European,437.0,25293881.0,Patel YM,Nicotine glucouronidation,initial,2014-10-07,GCST002649,Other measurement,#d53e4f
13438,African Am./Caribbean,364.0,25293881.0,Patel YM,Nicotine glucouronidation,initial,2014-10-07,GCST002649,Other measurement,#fee08b
13439,Hispanic/Latin American,453.0,25293881.0,Patel YM,Nicotine glucouronidation,initial,2014-10-07,GCST002649,Other measurement,#807dba
13440,Asian,674.0,25293881.0,Patel YM,Nicotine glucouronidation,initial,2014-10-07,GCST002649,Other measurement,#3288bd
13441,Other/Mixed,311.0,25293881.0,Patel YM,Nicotine glucouronidation,initial,2014-10-07,GCST002649,Other measurement,#99d594
13442,European,48528.0,25288136.0,Cornelis MC,Coffee consumption,initial,2014-10-07,GCST002651,Biological process,#d53e4f
13443,European,13469.0,25288136.0,Cornelis MC,Coffee consumption,replication,2014-10-07,GCST002651,Biological process,#d53e4f
13444,African Am./Caribbean,3845.0,25288136.0,Cornelis MC,Coffee consumption,replication,2014-10-07,GCST002651,Biological process,#fee08b
13445,European,91462.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),initial,2014-10-07,GCST002650,Biological process,#d53e4f
13446,European,30062.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),replication,2014-10-07,GCST002650,Biological process,#d53e4f
13447,African Am./Caribbean,7964.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),replication,2014-10-07,GCST002650,Biological process,#fee08b
13448,European,91462.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),initial,2014-10-07,GCST002650,Other measurement,#d53e4f
13449,European,30062.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),replication,2014-10-07,GCST002650,Other measurement,#d53e4f
13450,African Am./Caribbean,7964.0,25288136.0,Cornelis MC,Coffee consumption (cups per day),replication,2014-10-07,GCST002650,Other measurement,#fee08b
13451,European,4005.0,25284319.0,Sanchez-Mora C,Persistent attention-deficit hyperactivity disorder,replication,2014-10-06,GCST002648,Neurological disorder,#d53e4f
13452,European,1191.0,25284319.0,Sanchez-Mora C,Persistent attention-deficit hyperactivity disorder,initial,2014-10-06,GCST002648,Neurological disorder,#d53e4f
13453,European,80067.0,25282103.0,Wood AR,Height,replication,2014-10-05,GCST002647,Body measurement,#d53e4f
13454,European,253288.0,25282103.0,Wood AR,Height,initial,2014-10-05,GCST002647,Body measurement,#d53e4f
13455,Asian,7556.0,25281661.0,Matsuda K,Bladder cancer,replication,2014-10-03,GCST002645,Cancer,#3288bd
13456,Asian,6112.0,25281661.0,Matsuda K,Bladder cancer,initial,2014-10-03,GCST002645,Cancer,#3288bd
13457,European,8609.0,25281661.0,Matsuda K,Bladder cancer,replication,2014-10-03,GCST002645,Cancer,#d53e4f
13458,European,28238.0,25281659.0,van der Valk RJ,Infant length,initial,2014-10-03,GCST002646,Body measurement,#d53e4f
13459,European,28439.0,25281659.0,van der Valk RJ,Birth length,initial,2014-10-03,GCST002644,Body measurement,#d53e4f
13460,European,16145.0,25281659.0,van der Valk RJ,Birth length,replication,2014-10-03,GCST002644,Body measurement,#d53e4f
13461,Asian,651.0,25281659.0,van der Valk RJ,Birth length,replication,2014-10-03,GCST002644,Body measurement,#3288bd
13462,Other/Mixed,603.0,25281659.0,van der Valk RJ,Birth length,replication,2014-10-03,GCST002644,Body measurement,#99d594
13463,Other/Mixed,280.0,25281659.0,van der Valk RJ,Birth length,replication,2014-10-03,GCST002644,Body measurement,#99d594
13464,European,7381.0,25279986.0,Skibola CF,Follicular lymphoma,replication,2014-10-02,GCST002643,Cancer,#d53e4f
13465,European,10486.0,25279986.0,Skibola CF,Follicular lymphoma,initial,2014-10-02,GCST002643,Cancer,#d53e4f
13466,European,3157.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),replication,2014-10-01,GCST002641,Body measurement,#d53e4f
13467,Hispanic/Latin American,1250.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Body measurement,#807dba
13468,African Am./Caribbean,1547.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Body measurement,#fee08b
13469,Asian,548.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Body measurement,#3288bd
13470,European,2460.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Body measurement,#d53e4f
13471,European,3157.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),replication,2014-10-01,GCST002641,Other measurement,#d53e4f
13472,Hispanic/Latin American,1250.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Other measurement,#807dba
13473,African Am./Caribbean,1547.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Other measurement,#fee08b
13474,Asian,548.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Other measurement,#3288bd
13475,European,2460.0,25271088.0,Singh A,Hip circumference (psychosocial stress interaction),initial,2014-10-01,GCST002641,Other measurement,#d53e4f
13476,African Am./Caribbean,287.0,25089948.0,Theusch E,Response to simvastatin treatment (PCSK9 protein level change),replication,2014-10-01,GCST002642,Response to drug,#fee08b
13477,European,562.0,25089948.0,Theusch E,Response to simvastatin treatment (PCSK9 protein level change),initial,2014-10-01,GCST002642,Response to drug,#d53e4f
13478,African Am./Caribbean,287.0,25089948.0,Theusch E,Response to simvastatin treatment (PCSK9 protein level change),replication,2014-10-01,GCST002642,Other measurement,#fee08b
13479,European,562.0,25089948.0,Theusch E,Response to simvastatin treatment (PCSK9 protein level change),initial,2014-10-01,GCST002642,Other measurement,#d53e4f
13481,European,4899.0,25534755.0,Chaste P,Autism spectrum disorder-related traits,initial,2014-09-30,GCST002639,Neurological disorder,#d53e4f
13483,European,4899.0,25534755.0,Chaste P,Autism spectrum disorder-related traits,initial,2014-09-30,GCST002639,Neurological disorder,#d53e4f
13485,European,4899.0,25534755.0,Chaste P,Autism spectrum disorder-related traits,initial,2014-09-30,GCST002639,Other measurement,#d53e4f
13486,Asian,8738.0,25317112.0,Oh S,Gastritis,initial,2014-09-30,GCST002638,Digestive system disorder,#3288bd
13487,Asian,178.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,initial,2014-09-30,GCST002640,Immune system disorder,#3288bd
13488,Asian,473.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,replication,2014-09-30,GCST002640,Immune system disorder,#3288bd
13489,Asian,178.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,initial,2014-09-30,GCST002640,Other measurement,#3288bd
13490,Asian,473.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,replication,2014-09-30,GCST002640,Other measurement,#3288bd
13491,Asian,178.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,initial,2014-09-30,GCST002640,Inflammatory measurement,#3288bd
13492,Asian,473.0,25266886.0,Kim JJ,Inflammatory biomarkers in Kawasaki disease,replication,2014-09-30,GCST002640,Inflammatory measurement,#3288bd
13493,Asian,1302.0,25317111.0,Seo I,Medication adherence in chronic diseases,initial,2014-09-30,GCST002637,Metabolic disorder,#3288bd
13494,Asian,1302.0,25317111.0,Seo I,Medication adherence in chronic diseases,initial,2014-09-30,GCST002637,Cardiovascular disease,#3288bd
13495,Asian,1302.0,25317111.0,Seo I,Medication adherence in chronic diseases,initial,2014-09-30,GCST002637,Biological process,#3288bd
13496,European,5916.0,25261932.0,Cerhan JR,Diffuse large B cell lymphoma,replication,2014-09-28,GCST002636,Cancer,#d53e4f
13497,European,11523.0,25261932.0,Cerhan JR,Diffuse large B cell lymphoma,initial,2014-09-28,GCST002636,Cancer,#d53e4f
13498,European,6837.0,25256182.0,Foroud T,Intracranial aneurysm,replication,2014-09-25,GCST002633,Cardiovascular disease,#d53e4f
13499,European,5165.0,25256182.0,Foroud T,Intracranial aneurysm,initial,2014-09-25,GCST002633,Cardiovascular disease,#d53e4f
13500,European,1312.0,25256105.0,Freitag-Wolf S,Aggressive periodontitis (sex interaction),initial,2014-09-25,GCST002635,Other measurement,#d53e4f
13501,European,871.0,25256105.0,Freitag-Wolf S,Aggressive periodontitis (sex interaction),replication,2014-09-25,GCST002635,Other measurement,#d53e4f
13502,European,1312.0,25256105.0,Freitag-Wolf S,Aggressive periodontitis (sex interaction),initial,2014-09-25,GCST002635,Digestive system disorder,#d53e4f
13503,European,871.0,25256105.0,Freitag-Wolf S,Aggressive periodontitis (sex interaction),replication,2014-09-25,GCST002635,Digestive system disorder,#d53e4f
13504,Asian,1026.0,25303641.0,Zhang F,Kashin-Beck disease,replication,2014-09-25,GCST002634,Other disease,#3288bd
13505,Asian,1717.0,25303641.0,Zhang F,Kashin-Beck disease,initial,2014-09-25,GCST002634,Other disease,#3288bd
13506,Asian,69146.0,25249183.0,Lu X,Systolic blood pressure,replication,2014-09-23,GCST002630,Other measurement,#3288bd
13507,Asian,11816.0,25249183.0,Lu X,Systolic blood pressure,initial,2014-09-23,GCST002630,Other measurement,#3288bd
13508,Asian,9469.0,25249183.0,Lu X,Hypertension,initial,2014-09-23,GCST002627,Cardiovascular disease,#3288bd
13509,Asian,69146.0,25249183.0,Lu X,Hypertension,replication,2014-09-23,GCST002627,Cardiovascular disease,#3288bd
13510,Asian,11816.0,25249183.0,Lu X,Diastolic blood pressure,initial,2014-09-23,GCST002631,Other measurement,#3288bd
13511,Asian,69146.0,25249183.0,Lu X,Diastolic blood pressure,replication,2014-09-23,GCST002631,Other measurement,#3288bd
13512,European,1868.0,25246029.0,DiStefano JK,Bilirubin levels in extreme obesity,initial,2014-09-23,GCST002628,Other measurement,#d53e4f
13513,European,1868.0,25246029.0,DiStefano JK,Bilirubin levels in extreme obesity,initial,2014-09-23,GCST002628,Metabolic disorder,#d53e4f
13514,European,1868.0,25246029.0,DiStefano JK,Hepatic lipid content in extreme obesity,initial,2014-09-23,GCST002632,Lipid or lipoprotein measurement,#d53e4f
13515,European,1868.0,25246029.0,DiStefano JK,Hepatic lipid content in extreme obesity,initial,2014-09-23,GCST002632,Metabolic disorder,#d53e4f
13516,European,3511.0,25248455.0,Ek WE,Irritable bowel syndrome,replication,2014-09-23,GCST002629,Digestive system disorder,#d53e4f
13517,European,5466.0,25248455.0,Ek WE,Irritable bowel syndrome,initial,2014-09-23,GCST002629,Digestive system disorder,#d53e4f
13518,Asian,2305.0,25241763.0,Springelkamp H,Vertical cup-disc ratio,replication,2014-09-22,GCST002626,Other measurement,#3288bd
13519,Asian,2026.0,25241763.0,Springelkamp H,Vertical cup-disc ratio,replication,2014-09-22,GCST002626,Other measurement,#3288bd
13520,Asian,2453.0,25241763.0,Springelkamp H,Vertical cup-disc ratio,replication,2014-09-22,GCST002626,Other measurement,#3288bd
13521,European,21094.0,25241763.0,Springelkamp H,Vertical cup-disc ratio,initial,2014-09-22,GCST002626,Other measurement,#d53e4f
13523,European,3747.0,25245031.0,Luneburg N,L-arginine levels,initial,2014-09-21,GCST002623,Other measurement,#d53e4f
13524,European,1159.0,25245031.0,Luneburg N,L-arginine levels,replication,2014-09-21,GCST002623,Other measurement,#d53e4f
13525,European,5439.0,25241909.0,Lee JH,Chronic bronchitis in chronic obstructive pulmonary disease,initial,2014-09-21,GCST002621,Other disease,#d53e4f
13526,European,5439.0,25241909.0,Lee JH,Chronic bronchitis in chronic obstructive pulmonary disease,initial,2014-09-21,GCST002621,Other disease,#d53e4f
13527,European,5439.0,25241909.0,Lee JH,Chronic bronchitis and chronic obstructive pulmonary disease,initial,2014-09-21,GCST002625,Other disease,#d53e4f
13528,African Am./Caribbean,1931.0,25241909.0,Lee JH,Chronic bronchitis and chronic obstructive pulmonary disease,initial,2014-09-21,GCST002625,Other disease,#fee08b
13529,European,5439.0,25241909.0,Lee JH,Chronic bronchitis and chronic obstructive pulmonary disease,initial,2014-09-21,GCST002625,Other disease,#d53e4f
13530,African Am./Caribbean,1931.0,25241909.0,Lee JH,Chronic bronchitis and chronic obstructive pulmonary disease,initial,2014-09-21,GCST002625,Other disease,#fee08b
13532,European,3745.0,25245031.0,Luneburg N,Symmetrical dimethylarginine levels,initial,2014-09-21,GCST002622,Cardiovascular measurement,#d53e4f
13533,European,1152.0,25245031.0,Luneburg N,Symmetrical dimethylarginine levels,replication,2014-09-21,GCST002622,Cardiovascular measurement,#d53e4f
13534,European,3742.0,25245031.0,Luneburg N,Asymmetrical dimethylarginine levels,initial,2014-09-21,GCST002620,Cardiovascular measurement,#d53e4f
13535,European,1151.0,25245031.0,Luneburg N,Asymmetrical dimethylarginine levels,replication,2014-09-21,GCST002620,Cardiovascular measurement,#d53e4f
13537,European,7297.0,25241909.0,Lee JH,Chronic obstructive pulmonary disease,initial,2014-09-21,GCST002624,Other disease,#d53e4f
13538,European,7109.0,25352737.0,Ritchie MD,Age-related cataracts,initial,2014-09-19,GCST002619,Other trait,#d53e4f
13539,Other/Mixed,174.0,25352737.0,Ritchie MD,Age-related cataracts,initial,2014-09-19,GCST002619,Other trait,#99d594
13540,African,114.0,25352737.0,Ritchie MD,Age-related cataracts,initial,2014-09-19,GCST002619,Other trait,#fc8d59
13541,Other/Mixed,5503.0,25352737.0,Ritchie MD,Age-related cataracts (age at onset),initial,2014-09-19,GCST002618,Other measurement,#99d594
13542,Other/Mixed,5503.0,25352737.0,Ritchie MD,Age-related cataracts (age at onset),initial,2014-09-19,GCST002618,Other trait,#99d594
13543,European,386.0,25240745.0,Lopez S,Mitochondrial DNA levels,initial,2014-09-18,GCST002616,Other measurement,#d53e4f
13544,European,2443.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion,replication,2014-09-18,GCST002613,Other trait,#d53e4f
13545,European,1348.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion,initial,2014-09-18,GCST002613,Other trait,#d53e4f
13546,European,2036.0,25237182.0,Erickson SW,Multiple myeloma,initial,2014-09-18,GCST002614,Cancer,#d53e4f
13547,European,4581.0,25233373.0,Simpson CL,Myopia,replication,2014-09-18,GCST002615,Other trait,#d53e4f
13549,European,15619.0,25233373.0,Simpson CL,Myopia,initial,2014-09-18,GCST002615,Other trait,#d53e4f
13550,European,3106.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion in chronic obstructive pulmonary disease,replication,2014-09-18,GCST002612,Other disease,#d53e4f
13551,European,849.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion in chronic obstructive pulmonary disease,initial,2014-09-18,GCST002612,Other disease,#d53e4f
13552,European,3106.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion in chronic obstructive pulmonary disease,replication,2014-09-18,GCST002612,Other trait,#d53e4f
13553,European,849.0,25234806.0,Dijkstra AE,Chronic mucus hypersecretion in chronic obstructive pulmonary disease,initial,2014-09-18,GCST002612,Other trait,#d53e4f
13554,European,13912.0,25233373.0,Simpson CL,Hyperopia,initial,2014-09-18,GCST002617,Other trait,#d53e4f
13555,European,3208.0,25233373.0,Simpson CL,Hyperopia,replication,2014-09-18,GCST002617,Other trait,#d53e4f
13557,Asian,484.0,25223902.0,Go MJ,Fasting plasma glucose (childhood),initial,2014-09-16,GCST002610,Other measurement,#3288bd
13558,Asian,776.0,25223902.0,Go MJ,Fasting plasma glucose (childhood),replication,2014-09-16,GCST002610,Other measurement,#3288bd
13559,European,6558.0,25226531.0,St Pourcain B,Expressive vocabulary in infants,replication,2014-09-16,GCST002611,Biological process,#d53e4f
13560,European,13150.0,25226531.0,St Pourcain B,Expressive vocabulary in infants,initial,2014-09-16,GCST002611,Biological process,#d53e4f
13561,African Am./Caribbean,329.0,25224454.0,Li J,Iron status biomarkers,replication,2014-09-15,GCST002609,Other measurement,#fee08b
13562,African Am./Caribbean,2347.0,25224454.0,Li J,Iron status biomarkers,initial,2014-09-15,GCST002609,Other measurement,#fee08b
13563,European,510.0,25221879.0,Wu K,Pulmonary function in asthmatics,initial,2014-09-15,GCST002608,Other measurement,#d53e4f
13564,European,510.0,25221879.0,Wu K,Pulmonary function in asthmatics,initial,2014-09-15,GCST002608,Other disease,#d53e4f
13565,European,67543.0,25217961.0,Al Olama AA,Prostate cancer,initial,2014-09-14,GCST002606,Cancer,#d53e4f
13566,African,10463.0,25217961.0,Al Olama AA,Prostate cancer,initial,2014-09-14,GCST002606,Cancer,#fc8d59
13567,Asian,6954.0,25217961.0,Al Olama AA,Prostate cancer,initial,2014-09-14,GCST002606,Cancer,#3288bd
13568,Hispanic/Latin American,2080.0,25217961.0,Al Olama AA,Prostate cancer,initial,2014-09-14,GCST002606,Cancer,#807dba
13569,European,2207.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),initial,2014-09-14,GCST002607,Response to drug,#d53e4f
13571,European,78.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),replication,2014-09-14,GCST002607,Response to drug,#d53e4f
13572,European,2207.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),initial,2014-09-14,GCST002607,Digestive system disorder,#d53e4f
13574,European,78.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),replication,2014-09-14,GCST002607,Digestive system disorder,#d53e4f
13575,European,2207.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),initial,2014-09-14,GCST002607,Digestive system disorder,#d53e4f
13577,European,78.0,25217962.0,Heap GA,Response to thiopurine immunosuppressants in inflammatory bowel disease (pancreatitis) (azathioprine and mercaptopurine),replication,2014-09-14,GCST002607,Digestive system disorder,#d53e4f
13578,European,972.0,25218607.0,Coleman EA,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan),initial,2014-09-14,GCST002605,Cancer,#d53e4f
13579,European,972.0,25218607.0,Coleman EA,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan),initial,2014-09-14,GCST002605,Response to drug,#d53e4f
13580,European,972.0,25218607.0,Coleman EA,Response to chemotherapy in multiple myeloma (oral mucositis) (high-dose melphalan),initial,2014-09-14,GCST002605,Digestive system disorder,#d53e4f
13581,European,195.0,25223841.0,Li J,Schizophrenia (treatment resistant),replication,2014-09-13,GCST002604,Neurological disorder,#d53e4f
13582,European,174.0,25223841.0,Li J,Schizophrenia (treatment resistant),initial,2014-09-13,GCST002604,Neurological disorder,#d53e4f
13583,European,661.0,25224099.0,Gueant JL,beta-lactam allergy measurement,replication,2014-09-12,GCST007161,Other measurement,#d53e4f
13584,European,1611.0,25224099.0,Gueant JL,beta-lactam allergy measurement,initial,2014-09-12,GCST007161,Other measurement,#d53e4f
13585,European,3389.0,25214527.0,Dube MP,Creatine kinase in statin users,replication,2014-09-11,GCST002603,Response to drug,#d53e4f
13586,European,3412.0,25214527.0,Dube MP,Creatine kinase in statin users,initial,2014-09-11,GCST002603,Response to drug,#d53e4f
13587,European,3389.0,25214527.0,Dube MP,Creatine kinase in statin users,replication,2014-09-11,GCST002603,Cardiovascular measurement,#d53e4f
13588,European,3412.0,25214527.0,Dube MP,Creatine kinase in statin users,initial,2014-09-11,GCST002603,Cardiovascular measurement,#d53e4f
13590,European,1718.0,25208829.0,Anderson D,Vitamin D levels,initial,2014-09-11,GCST002602,Other measurement,#d53e4f
13591,European,3244.0,25208887.0,Ma Q,Plasma plasminogen levels,initial,2014-09-10,GCST002601,Other measurement,#d53e4f
13592,African Am./Caribbean,342.0,25201287.0,Del-Aguila JL,Response to thiazide diuretic treatment (hypokalemia),initial,2014-09-09,GCST002600,Response to drug,#fee08b
13593,European,425.0,25201287.0,Del-Aguila JL,Response to thiazide diuretic treatment (hypokalemia),initial,2014-09-09,GCST002600,Response to drug,#d53e4f
13594,African Am./Caribbean,342.0,25201287.0,Del-Aguila JL,Response to thiazide diuretic treatment (hypokalemia),initial,2014-09-09,GCST002600,Other trait,#fee08b
13595,European,425.0,25201287.0,Del-Aguila JL,Response to thiazide diuretic treatment (hypokalemia),initial,2014-09-09,GCST002600,Other trait,#d53e4f
13596,European,9793.0,25199915.0,Broer L,Longevity (90 years and older),initial,2014-09-08,GCST002599,Other measurement,#d53e4f
13597,European,2930.0,25200001.0,Robinson PC,Acute anterior uveitis in ankylosing spondylitis,initial,2014-09-08,GCST007361,Neurological disorder,#d53e4f
13598,European,2930.0,25200001.0,Robinson PC,Acute anterior uveitis in ankylosing spondylitis,initial,2014-09-08,GCST007361,Immune system disorder,#d53e4f
13599,European,11001.0,25200001.0,Robinson PC,Acute anterior uveitis (with or without ankylosing spondylitis),initial,2014-09-08,GCST007362,Neurological disorder,#d53e4f
13600,European,106736.0,25201988.0,Rietveld CA,Educational attainment,initial,2014-09-08,GCST002598,Other measurement,#d53e4f
13601,Asian,5202.0,25194280.0,Wei Q,Laryngeal squamous cell carcinoma,replication,2014-09-07,GCST002597,Cancer,#3288bd
13602,Asian,2988.0,25194280.0,Wei Q,Laryngeal squamous cell carcinoma,initial,2014-09-07,GCST002597,Cancer,#3288bd
13603,European,1784.0,25442119.0,McLaughlin RL,Amyotrophic lateral sclerosis,initial,2014-09-06,GCST007144,Neurological disorder,#d53e4f
13604,European,1784.0,25442119.0,McLaughlin RL,Amyotrophic lateral sclerosis (age of onset),initial,2014-09-06,GCST007145,Neurological disorder,#d53e4f
13605,European,1784.0,25442119.0,McLaughlin RL,Amyotrophic lateral sclerosis (age of onset),initial,2014-09-06,GCST007145,Other measurement,#d53e4f
13606,European,1204.0,25442119.0,McLaughlin RL,Amyotrophic lateral sclerosis,initial,2014-09-06,GCST007146,Neurological disorder,#d53e4f
13607,European,18509.0,25192705.0,Du M,Colorectal cancer (calcium intake interaction),initial,2014-09-05,GCST002596,Other measurement,#d53e4f
13608,European,18509.0,25192705.0,Du M,Colorectal cancer (calcium intake interaction),initial,2014-09-05,GCST002596,Cancer,#d53e4f
13609,European,1357.0,25187353.0,Goldstein JI,Clozapine-induced agranulocytosis,initial,2014-09-04,GCST002595,Other trait,#d53e4f
13610,European,1357.0,25187353.0,Goldstein JI,Clozapine-induced agranulocytosis,initial,2014-09-04,GCST002595,Response to drug,#d53e4f
13629,Asian,3963.0,25186300.0,Terao C,Antinuclear antibody levels,replication,2014-09-03,GCST002585,Other measurement,#3288bd
13630,Asian,3185.0,25186300.0,Terao C,Antinuclear antibody levels,initial,2014-09-03,GCST002585,Other measurement,#3288bd
13631,Asian,24740.0,25187374.0,Hwang JY,Fasting plasma glucose,initial,2014-09-03,GCST002586,Other measurement,#3288bd
13632,Asian,21345.0,25187374.0,Hwang JY,Fasting plasma glucose,replication,2014-09-03,GCST002586,Other measurement,#3288bd
13633,European,372.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),initial,2014-09-01,GCST002583,Other measurement,#d53e4f
13634,European,216.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),replication,2014-09-01,GCST002583,Other measurement,#d53e4f
13635,European,372.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),initial,2014-09-01,GCST002583,Other measurement,#d53e4f
13636,European,216.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),replication,2014-09-01,GCST002583,Other measurement,#d53e4f
13637,European,372.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),initial,2014-09-01,GCST002583,Response to drug,#d53e4f
13638,European,216.0,25410890.0,Frau F,Response to angiotensin II receptor blocker treatment (losartan) (change in systolic blood pressure levels),replication,2014-09-01,GCST002583,Response to drug,#d53e4f
13639,African Am./Caribbean,247.0,25072098.0,Bloom AJ,Exhaled carbon monoxide levels,initial,2014-09-01,GCST002584,Biological process,#fee08b
13640,European,1521.0,25072098.0,Bloom AJ,Exhaled carbon monoxide levels,initial,2014-09-01,GCST002584,Biological process,#d53e4f
13641,African Am./Caribbean,247.0,25072098.0,Bloom AJ,Exhaled carbon monoxide levels,initial,2014-09-01,GCST002584,Other measurement,#fee08b
13642,European,1521.0,25072098.0,Bloom AJ,Exhaled carbon monoxide levels,initial,2014-09-01,GCST002584,Other measurement,#d53e4f
13643,Asian,3377.0,25173107.0,Chen Y,Glaucoma (high intraocular pressure),replication,2014-08-31,GCST002581,Neurological disorder,#3288bd
13644,Asian,1971.0,25173107.0,Chen Y,Glaucoma (high intraocular pressure),initial,2014-08-31,GCST002581,Neurological disorder,#3288bd
13645,Asian,7738.0,25173106.0,Hysi PG,Intraocular pressure,initial,2014-08-31,GCST002580,Other measurement,#3288bd
13646,European,27558.0,25173106.0,Hysi PG,Intraocular pressure,initial,2014-08-31,GCST002580,Other measurement,#d53e4f
13647,European,3147.0,25173105.0,Gharahkhani P,Glaucoma (primary open-angle),initial,2014-08-31,GCST002582,Neurological disorder,#d53e4f
13648,European,13044.0,25173105.0,Gharahkhani P,Glaucoma (primary open-angle),replication,2014-08-31,GCST002582,Neurological disorder,#d53e4f
13649,European,1778.0,25130324.0,Cai DC,Heschl's gyrus morphology,initial,2014-08-29,GCST002579,Other measurement,#d53e4f
13651,Asian,1496.0,25162662.0,Liao M,Ferritin levels,replication,2014-08-27,GCST002578,Other measurement,#3288bd
13652,Asian,1999.0,25162662.0,Liao M,Ferritin levels,initial,2014-08-27,GCST002578,Other measurement,#3288bd
13653,Asian,327.0,25145502.0,Tang S,Non-small cell lung cancer (survival),replication,2014-08-22,GCST002577,Other measurement,#3288bd
13654,Asian,354.0,25145502.0,Tang S,Non-small cell lung cancer (survival),initial,2014-08-22,GCST002577,Other measurement,#3288bd
13655,Asian,327.0,25145502.0,Tang S,Non-small cell lung cancer (survival),replication,2014-08-22,GCST002577,Cancer,#3288bd
13656,Asian,354.0,25145502.0,Tang S,Non-small cell lung cancer (survival),initial,2014-08-22,GCST002577,Cancer,#3288bd
13657,Asian,4255.0,25134534.0,Chen K,Epithelial ovarian cancer,replication,2014-08-19,GCST002576,Cancer,#3288bd
13658,Asian,2216.0,25134534.0,Chen K,Epithelial ovarian cancer,initial,2014-08-19,GCST002576,Cancer,#3288bd
13659,European,716.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),initial,2014-08-18,GCST002574,Cardiovascular disease,#d53e4f
13660,European,648.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),replication,2014-08-18,GCST002574,Cardiovascular disease,#d53e4f
13661,Other/Mixed,24.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),replication,2014-08-18,GCST002574,Cardiovascular disease,#99d594
13662,Other/Mixed,207.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),initial,2014-08-18,GCST002574,Cardiovascular disease,#99d594
13663,European,716.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),initial,2014-08-18,GCST002574,Other measurement,#d53e4f
13664,European,648.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),replication,2014-08-18,GCST002574,Other measurement,#d53e4f
13665,Other/Mixed,24.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),replication,2014-08-18,GCST002574,Other measurement,#99d594
13666,Other/Mixed,207.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions (maternal effect),initial,2014-08-18,GCST002574,Other measurement,#99d594
13667,Asian,3244.0,25133637.0,Scannell Bryan M,Overweight status,initial,2014-08-18,GCST002570,Body measurement,#3288bd
13668,Asian,4474.0,25133637.0,Scannell Bryan M,Underweight status,initial,2014-08-18,GCST002569,Body measurement,#3288bd
13669,Asian,5344.0,25133637.0,Scannell Bryan M,Height,initial,2014-08-18,GCST002573,Body measurement,#3288bd
13670,Asian,4983.0,25133637.0,Scannell Bryan M,Body mass index (change over time),initial,2014-08-18,GCST002575,Body measurement,#3288bd
13671,European,716.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions,initial,2014-08-18,GCST002572,Cardiovascular disease,#d53e4f
13672,Other/Mixed,207.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions,initial,2014-08-18,GCST002572,Cardiovascular disease,#99d594
13673,Other/Mixed,24.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions,replication,2014-08-18,GCST002572,Cardiovascular disease,#99d594
13674,European,648.0,25138779.0,Mitchell LE,Congenital left-sided heart lesions,replication,2014-08-18,GCST002572,Cardiovascular disease,#d53e4f
13675,Asian,5354.0,25133637.0,Scannell Bryan M,Body mass index,initial,2014-08-18,GCST002571,Body measurement,#3288bd
13676,Asian,19712.0,25129146.0,Wu C,Esophageal squamous cell carcinoma,replication,2014-08-17,GCST002568,Cancer,#3288bd
13677,Asian,11124.0,25129146.0,Wu C,Esophageal squamous cell carcinoma,initial,2014-08-17,GCST002568,Cancer,#3288bd
13678,African,637.0,25014791.0,Govind N,Rheumatoid arthritis,initial,2014-08-14,GCST005562,Immune system disorder,#fc8d59
13679,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer (hypertension) (bevacizumab),initial,2014-08-12,GCST002567,Response to drug,#d53e4f
13680,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer (hypertension) (bevacizumab),initial,2014-08-12,GCST002567,Cancer,#d53e4f
13681,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer (hypertension) (bevacizumab),initial,2014-08-12,GCST002567,Cardiovascular disease,#d53e4f
13682,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),initial,2014-08-12,GCST002566,Response to drug,#d53e4f
13683,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),initial,2014-08-12,GCST002566,Cardiovascular disease,#d53e4f
13684,European,642.0,25117820.0,Schneider BP,Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),initial,2014-08-12,GCST002566,Cancer,#d53e4f
13686,European,1157.0,25111785.0,Jamain S,Bipolar disorder (early onset),replication,2014-08-11,GCST002564,Neurological disorder,#d53e4f
13687,European,1930.0,25111785.0,Jamain S,Bipolar disorder (early onset),initial,2014-08-11,GCST002564,Neurological disorder,#d53e4f
13688,European,6834.0,25109461.0,Ollila HM,Sleep duration,replication,2014-08-11,GCST002565,Other measurement,#d53e4f
13689,European,1941.0,25109461.0,Ollila HM,Sleep duration,initial,2014-08-11,GCST002565,Other measurement,#d53e4f
13690,European,6492.0,25108383.0,Geller F,Hypospadias,initial,2014-08-10,GCST002563,Other disease,#d53e4f
13691,European,3784.0,25108383.0,Geller F,Hypospadias,replication,2014-08-10,GCST002563,Other disease,#d53e4f
13692,Asian,358.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,replication,2014-08-10,GCST007229,Other trait,#3288bd
13693,Asian,340.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,initial,2014-08-10,GCST007229,Other trait,#3288bd
13694,Asian,358.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,replication,2014-08-10,GCST007229,Response to drug,#3288bd
13695,Asian,340.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,initial,2014-08-10,GCST007229,Response to drug,#3288bd
13696,Asian,358.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,replication,2014-08-10,GCST007229,Digestive system disorder,#3288bd
13697,Asian,340.0,25108385.0,Yang SK,Thiopurine-induced early leukopenia in Crohn's disease,initial,2014-08-10,GCST007229,Digestive system disorder,#3288bd
13698,Asian,2783.0,25108386.0,Hou S,Vogt-Koyanagi-Harada syndrome,initial,2014-08-10,GCST002562,Neurological disorder,#3288bd
13699,Asian,4358.0,25108386.0,Hou S,Vogt-Koyanagi-Harada syndrome,replication,2014-08-10,GCST002562,Neurological disorder,#3288bd
13700,European,35034.0,25105248.0,Wang H,Colorectal cancer,replication,2014-08-08,GCST002561,Cancer,#d53e4f
13701,African Am./Caribbean,6596.0,25105248.0,Wang H,Colorectal cancer,initial,2014-08-08,GCST002561,Cancer,#fee08b
13702,Asian,6424.0,25105248.0,Wang H,Colorectal cancer,initial,2014-08-08,GCST002561,Cancer,#3288bd
13703,European,47117.0,25102180.0,Ng MC,Type 2 diabetes,replication,2014-08-07,GCST002560,Metabolic disorder,#d53e4f
13704,African Am./Caribbean,11544.0,25102180.0,Ng MC,Type 2 diabetes,replication,2014-08-07,GCST002560,Metabolic disorder,#fee08b
13705,African Am./Caribbean,23827.0,25102180.0,Ng MC,Type 2 diabetes,initial,2014-08-07,GCST002560,Metabolic disorder,#fee08b
13706,Asian,472.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,initial,2014-08-06,GCST002558,Other disease,#3288bd
13707,Asian,380.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,replication,2014-08-06,GCST002558,Other disease,#3288bd
13708,Asian,3038.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,replication,2014-08-06,GCST002558,Other disease,#3288bd
13709,Asian,472.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,initial,2014-08-06,GCST002558,Response to drug,#3288bd
13710,Asian,380.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,replication,2014-08-06,GCST002558,Response to drug,#3288bd
13711,Asian,3038.0,25096692.0,Chung WH,Phenytoin-induced severe cutaneous adverse reactions,replication,2014-08-06,GCST002558,Response to drug,#3288bd
13712,Other/Mixed,117.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Cardiovascular disease,#99d594
13713,European,1725.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Cardiovascular disease,#d53e4f
13714,African,258.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Cardiovascular disease,#fc8d59
13715,Other/Mixed,117.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Other measurement,#99d594
13716,European,1725.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Other measurement,#d53e4f
13717,African,258.0,25147783.0,Keene KL,Vitamin B levels in ischemic stroke,initial,2014-08-06,GCST002559,Other measurement,#fc8d59
13718,Asian,16843.0,25096241.0,Keller MF,White blood cell count,initial,2014-08-05,GCST002556,Hematological measurement,#3288bd
13719,European,19509.0,25096241.0,Keller MF,White blood cell count,initial,2014-08-05,GCST002556,Hematological measurement,#d53e4f
13720,African Am./Caribbean,16388.0,25096241.0,Keller MF,White blood cell count,initial,2014-08-05,GCST002556,Hematological measurement,#fee08b
13721,Asian,9810.0,25096241.0,Keller MF,Monocyte count,initial,2014-08-05,GCST002555,Hematological measurement,#3288bd
13722,European,16550.0,25096241.0,Keller MF,Monocyte count,initial,2014-08-05,GCST002555,Hematological measurement,#d53e4f
13723,African Am./Caribbean,7369.0,25096241.0,Keller MF,Monocyte count,initial,2014-08-05,GCST002555,Hematological measurement,#fee08b
13724,Asian,9802.0,25096241.0,Keller MF,Neutrophil count,initial,2014-08-05,GCST002557,Hematological measurement,#3288bd
13725,European,16550.0,25096241.0,Keller MF,Neutrophil count,initial,2014-08-05,GCST002557,Hematological measurement,#d53e4f
13726,African Am./Caribbean,7391.0,25096241.0,Keller MF,Neutrophil count,initial,2014-08-05,GCST002557,Hematological measurement,#fee08b
13727,European,690.0,25140149.0,Hohman TJ,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction),initial,2014-08-04,GCST002554,Other measurement,#d53e4f
13728,European,690.0,25140149.0,Hohman TJ,Left inferior lateral ventricle volume (Cerebrospinal fluid biomarker status interaction),initial,2014-08-04,GCST002554,Other measurement,#d53e4f
13729,European,15295.0,25086665.0,Wolpin BM,Pancreatic cancer,replication,2014-08-03,GCST002553,Cancer,#d53e4f
13730,European,6785.0,25086665.0,Wolpin BM,Pancreatic cancer,initial,2014-08-03,GCST002553,Cancer,#d53e4f
13731,European,1111.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Immune system disorder,#d53e4f
13732,Hispanic/Latin American,1574.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Immune system disorder,#807dba
13733,Other/Mixed,561.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Immune system disorder,#99d594
13734,European,1111.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Other disease,#d53e4f
13735,Hispanic/Latin American,1574.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Other disease,#807dba
13736,Other/Mixed,561.0,25085501.0,Bunyavanich S,Allergic rhinitis in asthma,initial,2014-08-02,GCST002552,Other disease,#99d594
13737,European,2034.0,25085501.0,Bunyavanich S,Allergic rhinitis,initial,2014-08-02,GCST002550,Immune system disorder,#d53e4f
13738,Hispanic/Latin American,2326.0,25085501.0,Bunyavanich S,Allergic rhinitis,initial,2014-08-02,GCST002550,Immune system disorder,#807dba
13739,African Am./Caribbean,1273.0,25085501.0,Bunyavanich S,Allergic rhinitis,initial,2014-08-02,GCST002550,Immune system disorder,#fee08b
13740,European,923.0,25085501.0,Bunyavanich S,Allergic rhinitis in non-asthmatics,initial,2014-08-02,GCST002551,Immune system disorder,#d53e4f
13741,Hispanic/Latin American,752.0,25085501.0,Bunyavanich S,Allergic rhinitis in non-asthmatics,initial,2014-08-02,GCST002551,Immune system disorder,#807dba
13742,African Am./Caribbean,712.0,25085501.0,Bunyavanich S,Allergic rhinitis in non-asthmatics,initial,2014-08-02,GCST002551,Immune system disorder,#fee08b
13743,European,430.0,24528284.0,Ji Y,Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels),initial,2014-08-01,GCST002549,Response to drug,#d53e4f
13744,European,6631.0,24869959.0,Jacobs LC,Upper eyelid sagging severity,initial,2014-08-01,GCST006522,Other measurement,#d53e4f
13745,European,2352.0,25082827.0,Julia A,Ulcerative colitis,replication,2014-07-31,GCST002548,Immune system disorder,#d53e4f
13746,European,28694.0,25082827.0,Julia A,Ulcerative colitis,initial,2014-07-31,GCST002548,Immune system disorder,#d53e4f
13747,European,9634.0,25080503.0,Kwan JS,Osteoprotegerin levels,initial,2014-07-30,GCST002546,Cardiovascular measurement,#d53e4f
13748,Asian,702.0,25080503.0,Kwan JS,Osteoprotegerin levels,initial,2014-07-30,GCST002546,Cardiovascular measurement,#3288bd
13749,African Am./Caribbean,3273.0,25087078.0,Anney RJ,Epilepsy,initial,2014-07-30,GCST002547,Neurological disorder,#fee08b
13750,European,23453.0,25087078.0,Anney RJ,Epilepsy,initial,2014-07-30,GCST002547,Neurological disorder,#d53e4f
13752,Asian,3362.0,25087078.0,Anney RJ,Epilepsy,initial,2014-07-30,GCST002547,Neurological disorder,#3288bd
13753,Other/Mixed,1264.0,25087078.0,Anney RJ,Epilepsy,initial,2014-07-30,GCST002547,Neurological disorder,#99d594
13759,European,108990.0,25064009.0,Nalls MA,Parkinson's disease,initial,2014-07-27,GCST002544,Neurological disorder,#d53e4f
13760,European,10904.0,25064009.0,Nalls MA,Parkinson's disease,replication,2014-07-27,GCST002544,Neurological disorder,#d53e4f
13761,Asian,7922.0,25064007.0,Nakajima M,Ossification of the posterior longitudinal ligament of the spine,initial,2014-07-27,GCST002545,Other disease,#3288bd
13762,Asian,7017.0,25064007.0,Nakajima M,Ossification of the posterior longitudinal ligament of the spine,replication,2014-07-27,GCST002545,Other disease,#3288bd
13763,Other/Mixed,348.0,25060954.0,Wolber LE,Hearing function,initial,2014-07-24,GCST002543,Biological process,#99d594
13764,European,4591.0,25060954.0,Wolber LE,Hearing function,initial,2014-07-24,GCST002543,Biological process,#d53e4f
13765,European,964.0,25057126.0,Ramos YF,Osteoarthritis biomarkers,replication,2014-07-23,GCST002540,Other measurement,#d53e4f
13766,European,4654.0,25057126.0,Ramos YF,Osteoarthritis biomarkers,initial,2014-07-23,GCST002540,Other measurement,#d53e4f
13767,European,182413.0,25231870.0,Perry JR,Menarche (age at onset),initial,2014-07-23,GCST002541,Other measurement,#d53e4f
13768,Asian,6805.0,25055868.0,Sano M,Electrocardiographic traits,replication,2014-07-23,GCST002542,Cardiovascular measurement,#3288bd
13769,Asian,2994.0,25055868.0,Sano M,Electrocardiographic traits,initial,2014-07-23,GCST002542,Cardiovascular measurement,#3288bd
13770,Asian,5219.0,25056061.0,Ripke S,Schizophrenia,initial,2014-07-22,GCST002539,Neurological disorder,#3288bd
13771,European,82315.0,25056061.0,Ripke S,Schizophrenia,initial,2014-07-22,GCST002539,Neurological disorder,#d53e4f
13772,European,67749.0,25056061.0,Ripke S,Schizophrenia,replication,2014-07-22,GCST002539,Neurological disorder,#d53e4f
13774,European,2089.0,25044758.0,Stergiakouli E,Height adjusted BMI,replication,2014-07-21,GCST002538,Body measurement,#d53e4f
13775,European,57338.0,25038754.0,Cai Q,Breast cancer,replication,2014-07-20,GCST002537,Cancer,#d53e4f
13776,Asian,37511.0,25038754.0,Cai Q,Breast cancer,replication,2014-07-20,GCST002537,Cancer,#3288bd
13777,Asian,9450.0,25038754.0,Cai Q,Breast cancer,initial,2014-07-20,GCST002537,Cancer,#3288bd
13778,African Am./Caribbean,618.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,initial,2014-07-19,GCST002536,Neurological disorder,#fee08b
13779,Asian,398.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,replication,2014-07-19,GCST002536,Neurological disorder,#3288bd
13780,African Am./Caribbean,173.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,replication,2014-07-19,GCST002536,Neurological disorder,#fee08b
13781,African Am./Caribbean,618.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,initial,2014-07-19,GCST002536,Hematological measurement,#fee08b
13782,Asian,398.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,replication,2014-07-19,GCST002536,Hematological measurement,#3288bd
13783,African Am./Caribbean,173.0,25042611.0,Griffin PJ,Hemoglobin A2 levels in sickle cell anemia,replication,2014-07-19,GCST002536,Hematological measurement,#fee08b
13784,Asian,6085.0,25035420.0,Hong KW,PR interval,initial,2014-07-17,GCST002535,Cardiovascular measurement,#3288bd
13785,Asian,7295.0,25035420.0,Hong KW,PR interval,replication,2014-07-17,GCST002535,Cardiovascular measurement,#3288bd
13786,Asian,6085.0,25035420.0,Hong KW,QRS duration,initial,2014-07-17,GCST002533,Cardiovascular measurement,#3288bd
13787,Asian,7295.0,25035420.0,Hong KW,QRS duration,replication,2014-07-17,GCST002533,Cardiovascular measurement,#3288bd
13788,European,983.0,25030430.0,Zignego AL,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,initial,2014-07-17,GCST002534,Immune system disorder,#d53e4f
13789,European,271.0,25030430.0,Zignego AL,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,replication,2014-07-17,GCST002534,Immune system disorder,#d53e4f
13790,European,983.0,25030430.0,Zignego AL,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,initial,2014-07-17,GCST002534,Digestive system disorder,#d53e4f
13791,European,271.0,25030430.0,Zignego AL,Mixed cryoglobulinemia vasculitis in chronic hepatitis C infection,replication,2014-07-17,GCST002534,Digestive system disorder,#d53e4f
13792,African Am./Caribbean,7787.0,25027321.0,Hoffmann TJ,Glaucoma,initial,2014-07-15,GCST002529,Neurological disorder,#fee08b
13793,Hispanic/Latin American,3174.0,25027321.0,Hoffmann TJ,Glaucoma,initial,2014-07-15,GCST002529,Neurological disorder,#807dba
13794,European,3966.0,25028398.0,Weiss FU,High serum lipase activity,initial,2014-07-15,GCST002532,Other measurement,#d53e4f
13795,European,1444.0,25028398.0,Weiss FU,High serum lipase activity,replication,2014-07-15,GCST002532,Other measurement,#d53e4f
13796,European,363.0,25027320.0,Ramirez A,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,initial,2014-07-15,GCST002531,Neurological disorder,#d53e4f
13798,European,363.0,25027320.0,Ramirez A,Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,initial,2014-07-15,GCST002531,Other measurement,#d53e4f
13800,European,1444.0,25028398.0,Weiss FU,Serum lipase activity,replication,2014-07-15,GCST002530,Other measurement,#d53e4f
13801,European,3966.0,25028398.0,Weiss FU,Serum lipase activity,initial,2014-07-15,GCST002530,Other measurement,#d53e4f
13802,Other/Mixed,983.0,25023989.0,Schmit SL,Colorectal cancer,initial,2014-07-14,GCST002528,Cancer,#99d594
13803,Other/Mixed,1962.0,25023989.0,Schmit SL,Colorectal cancer,replication,2014-07-14,GCST002528,Cancer,#99d594
13804,European,2976.0,25023989.0,Schmit SL,Colorectal cancer,initial,2014-07-14,GCST002528,Cancer,#d53e4f
13805,European,9953.0,25017104.0,Kottyan LC,Eosinophilic esophagitis,initial,2014-07-13,GCST002527,Digestive system disorder,#d53e4f
13806,European,12597.0,25010111.0,Bolton JL,Cortisol levels (plasma),initial,2014-07-10,GCST002526,Other measurement,#d53e4f
13807,European,2795.0,25010111.0,Bolton JL,Cortisol levels (plasma),replication,2014-07-10,GCST002526,Other measurement,#d53e4f
13808,European,6456.0,25006744.0,Castaldi PJ,Local histogram emphysema pattern,initial,2014-07-09,GCST002525,Other measurement,#d53e4f
13809,African Am./Caribbean,3158.0,25006744.0,Castaldi PJ,Local histogram emphysema pattern,initial,2014-07-09,GCST002525,Other measurement,#fee08b
13810,African,343.0,25008200.0,Feng P,Chronic periodontitis,replication,2014-07-09,GCST002524,Digestive system disorder,#fc8d59
13811,European,1476.0,25008200.0,Feng P,Chronic periodontitis,replication,2014-07-09,GCST002524,Digestive system disorder,#d53e4f
13812,Other/Mixed,70.0,25008200.0,Feng P,Chronic periodontitis,initial,2014-07-09,GCST002524,Digestive system disorder,#99d594
13813,African Am./Caribbean,190.0,25008200.0,Feng P,Chronic periodontitis,initial,2014-07-09,GCST002524,Digestive system disorder,#fee08b
13814,European,606.0,25008200.0,Feng P,Chronic periodontitis,initial,2014-07-09,GCST002524,Digestive system disorder,#d53e4f
13815,European,2794.0,25003214.0,Davis OS,Reading or mathematical ability,initial,2014-07-08,GCST002522,Biological process,#d53e4f
13816,European,2153.0,25003214.0,Davis OS,Reading or mathematical ability,replication,2014-07-08,GCST002522,Biological process,#d53e4f
13817,European,2794.0,25003214.0,Davis OS,Reading or mathematical ability,initial,2014-07-08,GCST002522,Biological process,#d53e4f
13818,European,2153.0,25003214.0,Davis OS,Reading or mathematical ability,replication,2014-07-08,GCST002522,Biological process,#d53e4f
13819,Asian,1845.0,25043464.0,Jun G,Alzheimer's disease,replication,2014-07-08,GCST002523,Neurological disorder,#3288bd
13820,African Am./Caribbean,4896.0,25043464.0,Jun G,Alzheimer's disease,replication,2014-07-08,GCST002523,Neurological disorder,#fee08b
13821,European,18901.0,25043464.0,Jun G,Alzheimer's disease,replication,2014-07-08,GCST002523,Neurological disorder,#d53e4f
13824,European,2698.0,25044411.0,Liao SY,Lung function (forced expiratory volume in 1 second),initial,2014-07-08,GCST002521,Other measurement,#d53e4f
13825,European,4634.0,24999842.0,Garner C,Celiac disease,initial,2014-07-07,GCST002520,Immune system disorder,#d53e4f
13826,European,6535.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,initial,2014-07-03,GCST002519,Other disease,#d53e4f
13827,Other/Mixed,20912.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,replication,2014-07-03,GCST002519,Other disease,#99d594
13829,European,1235.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,replication,2014-07-03,GCST002519,Other disease,#d53e4f
13830,European,6535.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,initial,2014-07-03,GCST002519,Other disease,#d53e4f
13831,Other/Mixed,20912.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,replication,2014-07-03,GCST002519,Other disease,#99d594
13833,European,1235.0,24993907.0,Smolonska J,Asthma or chronic obstructive pulmonary disease,replication,2014-07-03,GCST002519,Other disease,#d53e4f
13834,European,27249.0,24983941.0,Tang W,Rate of change of FEV1 (time interaction),initial,2014-07-01,GCST002517,Other measurement,#d53e4f
13836,European,27249.0,24983941.0,Tang W,Rate of change of FEV1 (time interaction),initial,2014-07-01,GCST002517,Other measurement,#d53e4f
13838,Hispanic/Latin American,1367.0,24962563.0,Rubicz R,Food antigen IgG levels,initial,2014-07-01,GCST002518,Other measurement,#807dba
13839,Hispanic/Latin American,1367.0,24962563.0,Rubicz R,Food antigen IgG levels,initial,2014-07-01,GCST002518,Biological process,#807dba
13840,Asian,1031.0,24986923.0,Chu M,Pneumoconiosis in silica exposure,replication,2014-07-01,GCST002515,Other disease,#3288bd
13841,Asian,400.0,24986923.0,Chu M,Pneumoconiosis in silica exposure,initial,2014-07-01,GCST002515,Other disease,#3288bd
13842,Asian,1031.0,24986923.0,Chu M,Pneumoconiosis in silica exposure,replication,2014-07-01,GCST002515,Biological process,#3288bd
13843,Asian,400.0,24986923.0,Chu M,Pneumoconiosis in silica exposure,initial,2014-07-01,GCST002515,Biological process,#3288bd
13844,European,6462.0,24943344.0,Ferrari R,Frontotemporal dementia,initial,2014-07-01,GCST002516,Neurological disorder,#d53e4f
13845,European,6466.0,24943344.0,Ferrari R,Frontotemporal dementia,replication,2014-07-01,GCST002516,Neurological disorder,#d53e4f
13846,European,6122.0,24980573.0,Song F,Melanoma,initial,2014-06-30,GCST002514,Cancer,#d53e4f
13847,European,18416.0,24980573.0,Song F,Melanoma,replication,2014-06-30,GCST002514,Cancer,#d53e4f
13848,European,3354.0,24978480.0,Real LM,Colorectal cancer,replication,2014-06-30,GCST002512,Cancer,#d53e4f
13849,European,1281.0,24978480.0,Real LM,Colorectal cancer,initial,2014-06-30,GCST002512,Cancer,#d53e4f
13850,European,3354.0,24978480.0,Real LM,Colorectal cancer (SNP x SNP interaction),replication,2014-06-30,GCST002513,Cancer,#d53e4f
13851,European,1281.0,24978480.0,Real LM,Colorectal cancer (SNP x SNP interaction),initial,2014-06-30,GCST002513,Cancer,#d53e4f
13852,European,749.0,24974847.0,Fachal L,Response to radiotherapy in prostate cancer (toxicity),replication,2014-06-29,GCST002511,Biological process,#d53e4f
13853,European,652.0,24974847.0,Fachal L,Response to radiotherapy in prostate cancer (toxicity),initial,2014-06-29,GCST002511,Biological process,#d53e4f
13854,European,749.0,24974847.0,Fachal L,Response to radiotherapy in prostate cancer (toxicity),replication,2014-06-29,GCST002511,Cancer,#d53e4f
13855,European,652.0,24974847.0,Fachal L,Response to radiotherapy in prostate cancer (toxicity),initial,2014-06-29,GCST002511,Cancer,#d53e4f
13856,European,8014.0,24931836.0,Diekstra FP,Amyotrophic lateral sclerosis or frontotemporal dementia,replication,2014-06-27,GCST002510,Neurological disorder,#d53e4f
13857,European,19243.0,24931836.0,Diekstra FP,Amyotrophic lateral sclerosis or frontotemporal dementia,initial,2014-06-27,GCST002510,Neurological disorder,#d53e4f
13858,European,8014.0,24931836.0,Diekstra FP,Amyotrophic lateral sclerosis or frontotemporal dementia,replication,2014-06-27,GCST002510,Neurological disorder,#d53e4f
13859,European,19243.0,24931836.0,Diekstra FP,Amyotrophic lateral sclerosis or frontotemporal dementia,initial,2014-06-27,GCST002510,Neurological disorder,#d53e4f
13860,European,17394.0,24931836.0,Diekstra FP,Amyotrophic lateral sclerosis,initial,2014-06-27,GCST002509,Neurological disorder,#d53e4f
13861,European,1849.0,24931836.0,Diekstra FP,Frontotemporal dementia,initial,2014-06-27,GCST002508,Neurological disorder,#d53e4f
13862,European,3063.0,24974787.0,Meng W,Neuropathic pain in type 2 diabetes,initial,2014-06-26,GCST002507,Other trait,#d53e4f
13863,European,3063.0,24974787.0,Meng W,Neuropathic pain in type 2 diabetes,initial,2014-06-26,GCST002507,Metabolic disorder,#d53e4f
13864,European,34433.0,24975945.0,Ganesh SK,Blood pressure,replication,2014-06-26,GCST002506,Other measurement,#d53e4f
13865,Asian,5605.0,24975945.0,Ganesh SK,Blood pressure,replication,2014-06-26,GCST002506,Other measurement,#3288bd
13866,European,46553.0,24975945.0,Ganesh SK,Blood pressure,initial,2014-06-26,GCST002506,Other measurement,#d53e4f
13867,European,747.0,24964207.0,Mullins N,Suicidal ideation in depression or bipolar disorder,initial,2014-06-25,GCST002505,Neurological disorder,#d53e4f
13868,European,747.0,24964207.0,Mullins N,Suicidal ideation in depression or bipolar disorder,initial,2014-06-25,GCST002505,Biological process,#d53e4f
13869,European,747.0,24964207.0,Mullins N,Suicidal ideation in depression or bipolar disorder,initial,2014-06-25,GCST002505,Neurological disorder,#d53e4f
13870,European,3270.0,24964207.0,Mullins N,Suicide attempts in depression or bipolar disorder,initial,2014-06-25,GCST002503,Neurological disorder,#d53e4f
13871,European,3270.0,24964207.0,Mullins N,Suicide attempts in depression or bipolar disorder,initial,2014-06-25,GCST002503,Neurological disorder,#d53e4f
13872,European,3270.0,24964207.0,Mullins N,Suicide attempts in depression or bipolar disorder,initial,2014-06-25,GCST002503,Biological process,#d53e4f
13873,European,1791.0,25009551.0,Kullo IJ,Peripheral artery disease,replication,2014-06-25,GCST002504,Cardiovascular disease,#d53e4f
13874,European,3245.0,25009551.0,Kullo IJ,Peripheral artery disease,initial,2014-06-25,GCST002504,Cardiovascular disease,#d53e4f
13875,Asian,5220.0,24963161.0,Chen P,Corneal curvature,replication,2014-06-24,GCST002502,Other measurement,#3288bd
13876,Asian,2124.0,24963161.0,Chen P,Corneal curvature,initial,2014-06-24,GCST002502,Other measurement,#3288bd
13877,Asian,2138.0,24963161.0,Chen P,Corneal curvature,initial,2014-06-24,GCST002502,Other measurement,#3288bd
13878,Asian,3178.0,24963161.0,Chen P,Corneal curvature,initial,2014-06-24,GCST002502,Other measurement,#3288bd
13879,European,71061.0,24952745.0,Arking DE,QT interval,initial,2014-06-22,GCST002500,Cardiovascular measurement,#d53e4f
13880,European,33316.0,24952745.0,Arking DE,QT interval,replication,2014-06-22,GCST002500,Cardiovascular measurement,#d53e4f
13881,European,2823.0,24957906.0,Kuiper JJ,Birdshot chorioretinopathy,replication,2014-06-22,GCST002501,Cardiovascular disease,#d53e4f
13882,European,810.0,24957906.0,Kuiper JJ,Birdshot chorioretinopathy,initial,2014-06-22,GCST002501,Cardiovascular disease,#d53e4f
13883,Asian,2369.0,24951543.0,Liao J,Age-related nuclear cataracts,initial,2014-06-20,GCST002498,Other trait,#3288bd
13884,Asian,2200.0,24951543.0,Liao J,Age-related nuclear cataracts,initial,2014-06-20,GCST002498,Other trait,#3288bd
13885,Asian,2571.0,24951543.0,Liao J,Age-related nuclear cataracts,initial,2014-06-20,GCST002498,Other trait,#3288bd
13886,European,4593.0,24950379.0,Metrustry SJ,Birth weight,initial,2014-06-20,GCST002499,Body measurement,#d53e4f
13888,Other/Mixed,1177.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, upper limb)",initial,2014-06-19,GCST002496,Other measurement,#99d594
13889,Other/Mixed,232.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, upper limb)",initial,2014-06-19,GCST002496,Other measurement,#99d594
13890,European,8007.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, upper limb)",initial,2014-06-19,GCST002496,Other measurement,#d53e4f
13891,Other/Mixed,232.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, skull)",initial,2014-06-19,GCST002493,Other measurement,#99d594
13892,European,7976.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, skull)",initial,2014-06-19,GCST002493,Other measurement,#d53e4f
13893,Other/Mixed,1177.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, skull)",initial,2014-06-19,GCST002493,Other measurement,#99d594
13894,Asian,2502.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13895,Asian,1849.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13896,European,43445.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#d53e4f
13897,Asian,2476.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13898,Asian,1855.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13899,European,55796.0,24954895.0,Simino J,Blood pressure (age interaction),initial,2014-06-19,GCST002495,Other measurement,#d53e4f
13900,Asian,2502.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13901,Asian,1849.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13902,European,43445.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#d53e4f
13903,Asian,2476.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13904,Asian,1855.0,24954895.0,Simino J,Blood pressure (age interaction),replication,2014-06-19,GCST002495,Other measurement,#3288bd
13905,European,55796.0,24954895.0,Simino J,Blood pressure (age interaction),initial,2014-06-19,GCST002495,Other measurement,#d53e4f
13906,European,43445.0,24954895.0,Simino J,Blood pressure,replication,2014-06-19,GCST002497,Other measurement,#d53e4f
13907,European,55796.0,24954895.0,Simino J,Blood pressure,initial,2014-06-19,GCST002497,Other measurement,#d53e4f
13908,Asian,1855.0,24954895.0,Simino J,Blood pressure,replication,2014-06-19,GCST002497,Other measurement,#3288bd
13909,Asian,2476.0,24954895.0,Simino J,Blood pressure,replication,2014-06-19,GCST002497,Other measurement,#3288bd
13910,Asian,2502.0,24954895.0,Simino J,Blood pressure,replication,2014-06-19,GCST002497,Other measurement,#3288bd
13911,Asian,1849.0,24954895.0,Simino J,Blood pressure,replication,2014-06-19,GCST002497,Other measurement,#3288bd
13912,Other/Mixed,232.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, lower limb)",initial,2014-06-19,GCST002492,Other measurement,#99d594
13913,Other/Mixed,1177.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, lower limb)",initial,2014-06-19,GCST002492,Other measurement,#99d594
13914,European,8007.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, lower limb)",initial,2014-06-19,GCST002492,Other measurement,#d53e4f
13915,Other/Mixed,1177.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, total body less head)",initial,2014-06-19,GCST002494,Other measurement,#99d594
13916,European,8007.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, total body less head)",initial,2014-06-19,GCST002494,Other measurement,#d53e4f
13917,Other/Mixed,232.0,24945404.0,Kemp JP,"Bone mineral density (paediatric, total body less head)",initial,2014-06-19,GCST002494,Other measurement,#99d594
13918,Asian,625.0,24940741.0,Chang SW,Chronic hepatitis B infection,initial,2014-06-18,GCST002490,Digestive system disorder,#3288bd
13919,Asian,2063.0,24940741.0,Chang SW,Chronic hepatitis B infection,replication,2014-06-18,GCST002490,Digestive system disorder,#3288bd
13928,Asian,3170.0,24942650.0,Terao C,Anti-citrullinated peptide antibody,initial,2014-06-18,GCST002488,Other measurement,#3288bd
13929,European,1489.0,24939585.0,Fransen E,Age-related hearing impairment (SNP x SNP interaction),initial,2014-06-18,GCST002487,Neurological disorder,#d53e4f
13930,Asian,1999.0,24941225.0,Liang Y,Elevated serum carcinoembryonic antigen levels,initial,2014-06-18,GCST002485,Other measurement,#3288bd
13931,Asian,3170.0,24942650.0,Terao C,Rheumatoid factor,initial,2014-06-18,GCST002489,Other measurement,#3288bd
13932,Asian,898.0,24938310.0,Nakano M,Exfoliation glaucoma or exfoliation syndrome,initial,2014-06-18,GCST002486,Neurological disorder,#3288bd
13933,Asian,384.0,24938310.0,Nakano M,Exfoliation glaucoma or exfoliation syndrome,replication,2014-06-18,GCST002486,Neurological disorder,#3288bd
13934,European,1489.0,24939585.0,Fransen E,Age-related hearing impairment,initial,2014-06-18,GCST002491,Neurological disorder,#d53e4f
13935,European,1035.0,24934506.0,Eny KM,Skin fluorescence,replication,2014-06-17,GCST002484,Other measurement,#d53e4f
13936,European,9803.0,24934506.0,Eny KM,Skin fluorescence,initial,2014-06-17,GCST002484,Other measurement,#d53e4f
13937,Hispanic/Latin American,849.0,24929828.0,Loth DW,Lung function (forced vital capacity),replication,2014-06-15,GCST002483,Other measurement,#807dba
13938,African Am./Caribbean,6070.0,24929828.0,Loth DW,Lung function (forced vital capacity),replication,2014-06-15,GCST002483,Other measurement,#fee08b
13939,European,32917.0,24929828.0,Loth DW,Lung function (forced vital capacity),replication,2014-06-15,GCST002483,Other measurement,#d53e4f
13940,European,52253.0,24929828.0,Loth DW,Lung function (forced vital capacity),initial,2014-06-15,GCST002483,Other measurement,#d53e4f
13941,Asian,8637.0,24929828.0,Loth DW,Lung function (forced vital capacity),replication,2014-06-15,GCST002483,Other measurement,#3288bd
13942,Hispanic/Latin American,264.0,24954085.0,Della-Morte D,Carotid plaque burden (smoking interaction),replication,2014-06-14,GCST002482,Other measurement,#807dba
13943,Hispanic/Latin American,665.0,24954085.0,Della-Morte D,Carotid plaque burden (smoking interaction),initial,2014-06-14,GCST002482,Other measurement,#807dba
13944,Hispanic/Latin American,264.0,24954085.0,Della-Morte D,Carotid plaque burden (smoking interaction),replication,2014-06-14,GCST002482,Cardiovascular measurement,#807dba
13945,Hispanic/Latin American,665.0,24954085.0,Della-Morte D,Carotid plaque burden (smoking interaction),initial,2014-06-14,GCST002482,Cardiovascular measurement,#807dba
13946,European,7025.0,24927181.0,Navarini AA,Acne (severe),initial,2014-06-13,GCST002481,Other disease,#d53e4f
13947,European,4033.0,24927181.0,Navarini AA,Acne (severe),replication,2014-06-13,GCST002481,Other disease,#d53e4f
13948,European,2000.0,24925725.0,Chung SA,Lupus nephritis in systemic lupus erythematosus,initial,2014-06-12,GCST002479,Immune system disorder,#d53e4f
13949,European,2000.0,24925725.0,Chung SA,Lupus nephritis in systemic lupus erythematosus,initial,2014-06-12,GCST002479,Immune system disorder,#d53e4f
13950,European,4499.0,24920014.0,Cozen W,Hodgkin's lymphoma,replication,2014-06-12,GCST002480,Cancer,#d53e4f
13951,European,9693.0,24920014.0,Cozen W,Hodgkin's lymphoma,initial,2014-06-12,GCST002480,Cancer,#d53e4f
13952,Asian,1302.0,24919509.0,Terao C,Prostate-specific antigen levels,replication,2014-06-11,GCST002476,Other measurement,#3288bd
13953,Asian,1086.0,24919509.0,Terao C,Prostate-specific antigen levels,initial,2014-06-11,GCST002476,Other measurement,#3288bd
13954,Asian,39809.0,24916648.0,Hirokawa M,Myocardial infarction,replication,2014-06-11,GCST002475,Cardiovascular disease,#3288bd
13955,Asian,4864.0,24916648.0,Hirokawa M,Myocardial infarction,initial,2014-06-11,GCST002475,Cardiovascular disease,#3288bd
13956,European,1788.0,24962325.0,Kapoor M,Alcohol dependence (age at onset),initial,2014-06-11,GCST002477,Other measurement,#d53e4f
13957,European,1788.0,24962325.0,Kapoor M,Alcohol dependence (age at onset),initial,2014-06-11,GCST002477,Neurological disorder,#d53e4f
13958,European,2435.0,24916650.0,Versmissen J,Coronary heart disease in familial hypercholesterolemia,replication,2014-06-11,GCST002478,Metabolic disorder,#d53e4f
13959,European,466.0,24916650.0,Versmissen J,Coronary heart disease in familial hypercholesterolemia,initial,2014-06-11,GCST002478,Metabolic disorder,#d53e4f
13960,European,2435.0,24916650.0,Versmissen J,Coronary heart disease in familial hypercholesterolemia,replication,2014-06-11,GCST002478,Cardiovascular disease,#d53e4f
13961,European,466.0,24916650.0,Versmissen J,Coronary heart disease in familial hypercholesterolemia,initial,2014-06-11,GCST002478,Cardiovascular disease,#d53e4f
13962,European,1772.0,24908248.0,Walsh KM,Glioma (high-grade),replication,2014-06-08,GCST002474,Cancer,#d53e4f
13963,European,7608.0,24908248.0,Walsh KM,Glioma (high-grade),initial,2014-06-08,GCST002474,Cancer,#d53e4f
13968,African Am./Caribbean,241.0,24909733.0,Cook-Sather SD,Morphine dose requirement in tonsillectomy and adenoidectomy surgery,initial,2014-06-05,GCST002472,Response to drug,#fee08b
13969,European,277.0,24909733.0,Cook-Sather SD,Morphine dose requirement in tonsillectomy and adenoidectomy surgery,initial,2014-06-05,GCST002472,Response to drug,#d53e4f
13970,European,75.0,24909733.0,Cook-Sather SD,Morphine dose requirement in tonsillectomy and adenoidectomy surgery,replication,2014-06-05,GCST002472,Response to drug,#d53e4f
13971,African Am./Caribbean,70.0,24909733.0,Cook-Sather SD,Morphine dose requirement in tonsillectomy and adenoidectomy surgery,replication,2014-06-05,GCST002472,Response to drug,#fee08b
13972,Asian,7486.0,24903457.0,Kim YK,Blood pressure,initial,2014-06-05,GCST004705,Other measurement,#3288bd
13973,Asian,4544.0,24903457.0,Kim YK,Blood pressure,replication,2014-06-05,GCST004705,Other measurement,#3288bd
13974,Asian,7486.0,24903457.0,Kim YK,Blood pressure,initial,2014-06-05,GCST004705,Other measurement,#3288bd
13975,Asian,4544.0,24903457.0,Kim YK,Blood pressure,replication,2014-06-05,GCST004705,Other measurement,#3288bd
13976,Asian,7486.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),initial,2014-06-05,GCST002471,Other measurement,#3288bd
13977,Asian,4544.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),replication,2014-06-05,GCST002471,Other measurement,#3288bd
13978,Asian,7486.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),initial,2014-06-05,GCST002471,Other measurement,#3288bd
13979,Asian,4544.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),replication,2014-06-05,GCST002471,Other measurement,#3288bd
13980,Asian,7486.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),initial,2014-06-05,GCST002471,Other measurement,#3288bd
13981,Asian,4544.0,24903457.0,Kim YK,Blood pressure (anthropometric measures interaction),replication,2014-06-05,GCST002471,Other measurement,#3288bd
13986,Hispanic/Latin American,3701.0,24886709.0,Ko A,"Cholesterol, total",initial,2014-06-02,GCST002467,Lipid or lipoprotein measurement,#807dba
13987,Hispanic/Latin American,6017.0,24886709.0,Ko A,"Cholesterol, total",replication,2014-06-02,GCST002467,Lipid or lipoprotein measurement,#807dba
13988,Hispanic/Latin American,6017.0,24886709.0,Ko A,Triglycerides,replication,2014-06-02,GCST002468,Lipid or lipoprotein measurement,#807dba
13989,Hispanic/Latin American,3323.0,24886709.0,Ko A,Triglycerides,initial,2014-06-02,GCST002468,Lipid or lipoprotein measurement,#807dba
13990,Hispanic/Latin American,3701.0,24886709.0,Ko A,HDL cholesterol,initial,2014-06-02,GCST002469,Lipid or lipoprotein measurement,#807dba
13991,Hispanic/Latin American,6017.0,24886709.0,Ko A,HDL cholesterol,replication,2014-06-02,GCST002469,Lipid or lipoprotein measurement,#807dba
13992,European,96.0,24751813.0,Drago A,Response to haloperidol in psychosis,initial,2014-06-01,GCST002465,Neurological disorder,#d53e4f
13993,European,96.0,24751813.0,Drago A,Response to haloperidol in psychosis,initial,2014-06-01,GCST002465,Response to drug,#d53e4f
13994,European,48541.0,24880342.0,Wang Y,Lung cancer,replication,2014-06-01,GCST002466,Cancer,#d53e4f
13995,European,27209.0,24880342.0,Wang Y,Lung cancer,initial,2014-06-01,GCST002466,Cancer,#d53e4f
13996,European,48541.0,24880342.0,Wang Y,Lung cancer,replication,2014-06-01,GCST002466,Cancer,#d53e4f
13997,European,27209.0,24880342.0,Wang Y,Lung cancer,initial,2014-06-01,GCST002466,Cancer,#d53e4f
13998,European,48541.0,24880342.0,Wang Y,Lung cancer,replication,2014-06-01,GCST002466,Cancer,#d53e4f
13999,European,27209.0,24880342.0,Wang Y,Lung cancer,initial,2014-06-01,GCST002466,Cancer,#d53e4f
14000,European,3464.0,24871321.0,Sambo F,End-stage renal disease or diabetic nephropathy in type 1 diabetes,initial,2014-05-29,GCST002464,Metabolic disorder,#d53e4f
14002,European,3464.0,24871321.0,Sambo F,End-stage renal disease or diabetic nephropathy in type 1 diabetes,initial,2014-05-29,GCST002464,Other disease,#d53e4f
14004,European,3464.0,24871321.0,Sambo F,End-stage renal disease or diabetic nephropathy in type 1 diabetes,initial,2014-05-29,GCST002464,Metabolic disorder,#d53e4f
14006,European,3163.0,24871463.0,Armstrong DL,Systemic lupus erythematosus,initial,2014-05-29,GCST002463,Immune system disorder,#d53e4f
14008,European,8276.0,24958192.0,Gusareva ES,Alzheimer's disease (SNP x SNP interaction),initial,2014-05-28,GCST002462,Neurological disorder,#d53e4f
14009,European,7076.0,24958192.0,Gusareva ES,Alzheimer's disease (SNP x SNP interaction),replication,2014-05-28,GCST002462,Neurological disorder,#d53e4f
14010,European,15697.0,24861552.0,Rafnar T,Urinary bladder cancer,replication,2014-05-26,GCST002460,Cancer,#d53e4f
14011,European,91850.0,24861552.0,Rafnar T,Urinary bladder cancer,initial,2014-05-26,GCST002460,Cancer,#d53e4f
14012,Asian,47352.0,24861553.0,Wen W,Body mass index,replication,2014-05-26,GCST002461,Body measurement,#3288bd
14013,Asian,4301.0,24861553.0,Wen W,Body mass index,initial,2014-05-26,GCST002461,Body measurement,#3288bd
14014,Asian,82438.0,24861553.0,Wen W,Body mass index,initial,2014-05-26,GCST002461,Body measurement,#3288bd
14015,Asian,269.0,24863034.0,Urano T,Lean body mass,initial,2014-05-23,GCST002459,Other measurement,#3288bd
14016,Asian,1081.0,24863034.0,Urano T,Lean body mass,replication,2014-05-23,GCST002459,Other measurement,#3288bd
14017,Asian,3235.0,24852370.0,Zhan M,Serum thyroid-stimulating hormone levels,replication,2014-05-22,GCST002458,Other measurement,#3288bd
14018,Asian,1346.0,24852370.0,Zhan M,Serum thyroid-stimulating hormone levels,initial,2014-05-22,GCST002458,Other measurement,#3288bd
14019,European,16468.0,24850809.0,Verweij N,P wave duration,initial,2014-05-21,GCST002457,Cardiovascular measurement,#d53e4f
14020,European,16468.0,24850809.0,Verweij N,PR segment,initial,2014-05-21,GCST002456,Cardiovascular measurement,#d53e4f
14021,Other/Mixed,2889.0,24842889.0,Vacic V,Parkinson's disease,replication,2014-05-19,GCST002455,Neurological disorder,#99d594
14022,Other/Mixed,3741.0,24842889.0,Vacic V,Parkinson's disease,initial,2014-05-19,GCST002455,Neurological disorder,#99d594
14025,Asian,8270.0,24836286.0,Zhang B,Colorectal cancer,initial,2014-05-18,GCST002454,Cancer,#3288bd
14026,European,35246.0,24836286.0,Zhang B,Colorectal cancer,replication,2014-05-18,GCST002454,Cancer,#d53e4f
14027,Asian,38638.0,24836286.0,Zhang B,Colorectal cancer,replication,2014-05-18,GCST002454,Cancer,#3288bd
14028,European,2647.0,24832863.0,Wetherill L,Substance dependence phenotypes,replication,2014-05-16,GCST002452,Neurological disorder,#d53e4f
14029,European,2322.0,24832863.0,Wetherill L,Substance dependence phenotypes,initial,2014-05-16,GCST002452,Neurological disorder,#d53e4f
14030,Asian,1881.0,24837172.0,Juyal G,Ulcerative colitis,replication,2014-05-16,GCST002453,Immune system disorder,#3288bd
14031,Asian,1225.0,24837172.0,Juyal G,Ulcerative colitis,initial,2014-05-16,GCST002453,Immune system disorder,#3288bd
14032,European,8631.0,24823311.0,Guan W,Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),initial,2014-05-13,GCST002450,Lipid or lipoprotein measurement,#d53e4f
14033,European,8631.0,24823311.0,Guan W,Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),initial,2014-05-13,GCST002444,Lipid or lipoprotein measurement,#d53e4f
14035,European,3606.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other measurement,#d53e4f
14036,African Am./Caribbean,3015.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other measurement,#fee08b
14037,Hispanic/Latin American,2428.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other measurement,#807dba
14038,European,3606.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other disease,#d53e4f
14039,African Am./Caribbean,3015.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other disease,#fee08b
14040,Hispanic/Latin American,2428.0,24824216.0,Myers RA,Asthma (sex interaction),initial,2014-05-13,GCST002445,Other disease,#807dba
14041,European,8631.0,24823311.0,Guan W,Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),initial,2014-05-13,GCST002446,Lipid or lipoprotein measurement,#d53e4f
14042,African Am./Caribbean,820.0,24825563.0,McDonald ML,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry),initial,2014-05-13,GCST002447,Other measurement,#fee08b
14043,European,4658.0,24825563.0,McDonald ML,Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry),replication,2014-05-13,GCST002447,Other measurement,#d53e4f
14044,European,8631.0,24823311.0,Guan W,Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),initial,2014-05-13,GCST002448,Lipid or lipoprotein measurement,#d53e4f
14045,European,8631.0,24823311.0,Guan W,Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),initial,2014-05-13,GCST002449,Lipid or lipoprotein measurement,#d53e4f
14046,European,5591.0,24816252.0,Shin SY,Blood metabolite ratios,initial,2014-05-11,GCST002442,Other measurement,#d53e4f
14047,European,1767.0,24816252.0,Shin SY,Blood metabolite ratios,replication,2014-05-11,GCST002442,Other measurement,#d53e4f
14048,European,7824.0,24816252.0,Shin SY,Blood metabolite levels,initial,2014-05-11,GCST002443,Other measurement,#d53e4f
14049,European,3234.0,24847357.0,Ye Z,Staphylococcus aureus infection,initial,2014-05-09,GCST002440,Other disease,#d53e4f
14050,European,883.0,24811271.0,Kennedy RB,Immune response to measles-mumps-rubella vaccine,initial,2014-05-09,GCST002441,Response to drug,#d53e4f
14051,European,602.0,24801482.0,Baron-Cohen S,Mathematical ability,initial,2014-05-06,GCST002439,Biological process,#d53e4f
14052,Other/Mixed,1868.0,24800985.0,Agopian AJ,Conotruncal heart defects,initial,2014-05-06,GCST002438,Cardiovascular disease,#99d594
14053,Other/Mixed,30.0,24800985.0,Agopian AJ,Conotruncal heart defects,replication,2014-05-06,GCST002438,Cardiovascular disease,#99d594
14054,European,1044.0,24800985.0,Agopian AJ,Conotruncal heart defects,replication,2014-05-06,GCST002438,Cardiovascular disease,#d53e4f
14055,Asian,2397.0,24795349.0,Saxena R,Telomere length,replication,2014-05-03,GCST002437,Other measurement,#3288bd
14056,Asian,1616.0,24795349.0,Saxena R,Telomere length,initial,2014-05-03,GCST002437,Other measurement,#3288bd
14057,European,13285.0,24795349.0,Saxena R,Telomere length,replication,2014-05-03,GCST002437,Other measurement,#d53e4f
14058,Asian,2955.0,24827717.0,Yang F,Body mass index,replication,2014-05-01,GCST002435,Body measurement,#3288bd
14059,Asian,597.0,24827717.0,Yang F,Body mass index,initial,2014-05-01,GCST002435,Body measurement,#3288bd
14060,Asian,1895.0,24782177.0,Jiang L,Rheumatoid arthritis,initial,2014-05-01,GCST002434,Immune system disorder,#3288bd
14061,European,25708.0,24782177.0,Jiang L,Rheumatoid arthritis,replication,2014-05-01,GCST002434,Immune system disorder,#d53e4f
14062,Asian,4685.0,24782177.0,Jiang L,Rheumatoid arthritis,replication,2014-05-01,GCST002433,Immune system disorder,#3288bd
14063,Asian,1895.0,24782177.0,Jiang L,Rheumatoid arthritis,initial,2014-05-01,GCST002433,Immune system disorder,#3288bd
14064,European,1570.0,24797007.0,Holliday EG,Irritable bowel syndrome,initial,2014-05-01,GCST002436,Digestive system disorder,#d53e4f
14065,European,1201.0,24797007.0,Holliday EG,Irritable bowel syndrome,replication,2014-05-01,GCST002436,Digestive system disorder,#d53e4f
14066,Asian,189.0,24792382.0,Park TJ,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2014-04-30,GCST002432,Other measurement,#3288bd
14067,Asian,189.0,24792382.0,Park TJ,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2014-04-30,GCST002432,Response to drug,#3288bd
14068,Asian,189.0,24792382.0,Park TJ,Response to inhaled corticosteroid treatment in asthma (change in FEV1),initial,2014-04-30,GCST002432,Other disease,#3288bd
14069,European,516.0,24785509.0,Barnett GC,Response to radiotherapy in cancer (late toxicity),replication,2014-04-28,GCST002431,Cancer,#d53e4f
14070,European,1773.0,24785509.0,Barnett GC,Response to radiotherapy in cancer (late toxicity),initial,2014-04-28,GCST002431,Cancer,#d53e4f
14076,Other/Mixed,5244.0,24816038.0,Postmus I,Cardiovascular event reduction in the elderly at risk for vascular disease (statin therapy interaction),initial,2014-04-26,GCST002428,Response to drug,#99d594
14077,European,3769.0,24770850.0,Cousminer DL,Puberty onset (genital enlargement),initial,2014-04-25,GCST002426,Other measurement,#d53e4f
14078,European,208.0,24770850.0,Cousminer DL,Puberty onset (genital enlargement),replication,2014-04-25,GCST002426,Other measurement,#d53e4f
14079,European,9916.0,24770850.0,Cousminer DL,Puberty onset,initial,2014-04-25,GCST002425,Other measurement,#d53e4f
14080,European,1376.0,24770850.0,Cousminer DL,Puberty onset,replication,2014-04-25,GCST002425,Other measurement,#d53e4f
14081,European,6147.0,24770850.0,Cousminer DL,Puberty onset (breast development),initial,2014-04-25,GCST002427,Other measurement,#d53e4f
14082,Asian,903.0,24763700.0,Vinayagamoorthy N,C-reactive protein levels,replication,2014-04-24,GCST002424,Inflammatory measurement,#3288bd
14083,Asian,7626.0,24763700.0,Vinayagamoorthy N,C-reactive protein levels,initial,2014-04-24,GCST002424,Inflammatory measurement,#3288bd
14084,European,4554.0,24768677.0,de Boer YS,Autoimmune hepatitis type-1,replication,2014-04-23,GCST002423,Immune system disorder,#d53e4f
14085,European,14085.0,24768677.0,de Boer YS,Autoimmune hepatitis type-1,initial,2014-04-23,GCST002423,Immune system disorder,#d53e4f
14086,European,4554.0,24768677.0,de Boer YS,Autoimmune hepatitis type-1,replication,2014-04-23,GCST002423,Immune system disorder,#d53e4f
14087,European,14085.0,24768677.0,de Boer YS,Autoimmune hepatitis type-1,initial,2014-04-23,GCST002423,Immune system disorder,#d53e4f
14088,European,4569.0,24755620.0,Perez-Palma E,Alzheimer's disease,initial,2014-04-22,GCST002422,Neurological disorder,#d53e4f
14089,European,2950.0,24753544.0,Knipe DW,Prostate cancer,initial,2014-04-21,GCST002421,Cancer,#d53e4f
14090,European,3291.0,24753544.0,Knipe DW,Prostate cancer,replication,2014-04-21,GCST002421,Cancer,#d53e4f
14091,European,929.0,24882193.0,Winham SJ,Binge eating behaviour in bipolar disorder,initial,2014-04-19,GCST002420,Metabolic disorder,#d53e4f
14092,European,828.0,24882193.0,Winham SJ,Binge eating behaviour in bipolar disorder,replication,2014-04-19,GCST002420,Metabolic disorder,#d53e4f
14093,European,929.0,24882193.0,Winham SJ,Binge eating behaviour in bipolar disorder,initial,2014-04-19,GCST002420,Neurological disorder,#d53e4f
14094,European,828.0,24882193.0,Winham SJ,Binge eating behaviour in bipolar disorder,replication,2014-04-19,GCST002420,Neurological disorder,#d53e4f
14095,European,1963.0,24882193.0,Winham SJ,Binge eating behaviour and bipolar disorder,initial,2014-04-19,GCST002419,Metabolic disorder,#d53e4f
14096,European,1660.0,24882193.0,Winham SJ,Binge eating behaviour and bipolar disorder,replication,2014-04-19,GCST002419,Metabolic disorder,#d53e4f
14097,European,1963.0,24882193.0,Winham SJ,Binge eating behaviour and bipolar disorder,initial,2014-04-19,GCST002419,Neurological disorder,#d53e4f
14098,European,1660.0,24882193.0,Winham SJ,Binge eating behaviour and bipolar disorder,replication,2014-04-19,GCST002419,Neurological disorder,#d53e4f
14099,European,18404.0,24743840.0,Figueiredo JC,Colorectal cancer (diet interaction),initial,2014-04-17,GCST002415,Cancer,#d53e4f
14100,European,18404.0,24743840.0,Figueiredo JC,Colorectal cancer (diet interaction),initial,2014-04-17,GCST002415,Other measurement,#d53e4f
14101,Asian,2789.0,24722205.0,Kwak SH,Plasma thyroid-stimulating hormone levels,initial,2014-04-17,GCST002417,Other measurement,#3288bd
14102,Asian,829.0,24722205.0,Kwak SH,Plasma thyroid-stimulating hormone levels,replication,2014-04-17,GCST002417,Other measurement,#3288bd
14103,Asian,3396.0,24722205.0,Kwak SH,Thyroid peroxidase antibody positivity,initial,2014-04-17,GCST002416,Other measurement,#3288bd
14104,Asian,842.0,24722205.0,Kwak SH,Thyroid peroxidase antibody positivity,replication,2014-04-17,GCST002416,Other measurement,#3288bd
14105,Asian,2789.0,24722205.0,Kwak SH,Free thyroxine concentration,initial,2014-04-17,GCST002418,Other measurement,#3288bd
14106,Asian,829.0,24722205.0,Kwak SH,Free thyroxine concentration,replication,2014-04-17,GCST002418,Other measurement,#3288bd
14107,European,1380.0,24740207.0,Moy KA,Serum vitamin D-binding protein levels,initial,2014-04-16,GCST002414,Other measurement,#d53e4f
14108,European,5051.0,24740154.0,Lange EM,Prostate cancer (early onset),initial,2014-04-16,GCST002413,Cancer,#d53e4f
14109,European,3492.0,24740154.0,Lange EM,Prostate cancer (early onset),replication,2014-04-16,GCST002413,Cancer,#d53e4f
14110,Asian,308.0,24737549.0,Yoon KA,Non-small cell lung cancer (recurrence rate),replication,2014-04-15,GCST002412,Cancer,#3288bd
14111,Asian,250.0,24737549.0,Yoon KA,Non-small cell lung cancer (recurrence rate),initial,2014-04-15,GCST002412,Cancer,#3288bd
14112,European,29974.0,24737748.0,Whiffin N,Colorectal cancer,replication,2014-04-15,GCST002411,Cancer,#d53e4f
14113,European,13443.0,24737748.0,Whiffin N,Colorectal cancer,initial,2014-04-15,GCST002411,Cancer,#d53e4f
14114,Hispanic/Latin American,776.0,24736177.0,Sprooten E,White matter microstructure (global fractional anisotropy),initial,2014-04-13,GCST002409,Other measurement,#807dba
14115,European,8386.0,24728293.0,Styrkarsdottir U,"Osteoarthritis (hand, severe)",replication,2014-04-13,GCST002410,Other disease,#d53e4f
14116,European,69776.0,24728293.0,Styrkarsdottir U,"Osteoarthritis (hand, severe)",initial,2014-04-13,GCST002410,Other disease,#d53e4f
14117,European,3102.0,24714607.0,Dijkstra AE,Chronic mucus hypersecretion,initial,2014-04-08,GCST002407,Other trait,#d53e4f
14118,European,7816.0,24714607.0,Dijkstra AE,Chronic mucus hypersecretion,replication,2014-04-08,GCST002407,Other trait,#d53e4f
14119,European,890.0,24629169.0,Ising M,perceptual and visual search speed (trail making test A),initial,2014-04-08,GCST007693,Biological process,#d53e4f
14120,European,890.0,24629169.0,Ising M,perceptual and visual search speed and executive function (trail making test BA) (age interaction),initial,2014-04-08,GCST007698,Other measurement,#d53e4f
14121,European,890.0,24629169.0,Ising M,perceptual and visual search speed and executive function (trail making test BA) (age interaction),initial,2014-04-08,GCST007698,Biological process,#d53e4f
14122,European,890.0,24629169.0,Ising M,executive function (trail making test B) (age interaction),initial,2014-04-08,GCST007697,Other measurement,#d53e4f
14123,European,890.0,24629169.0,Ising M,perceptual and visual search speed (trail making test A) (age interaction),initial,2014-04-08,GCST007696,Biological process,#d53e4f
14124,European,890.0,24629169.0,Ising M,perceptual and visual search speed and executive function (trail making test BA),initial,2014-04-08,GCST007695,Other measurement,#d53e4f
14125,European,890.0,24629169.0,Ising M,perceptual and visual search speed and executive function (trail making test BA),initial,2014-04-08,GCST007695,Biological process,#d53e4f
14126,European,890.0,24629169.0,Ising M,executive function (trail making test B),initial,2014-04-08,GCST007694,Other measurement,#d53e4f
14127,European,694.0,24709693.0,Cobb J,Response to methotrexate in juvenile idiopathic arthritis,initial,2014-04-08,GCST002408,Response to drug,#d53e4f
14128,African,57.0,24952865.0,Akerblom A,Plasma cystastin c levels in acute coronary syndrome,initial,2014-04-04,GCST002406,Cardiovascular disease,#fc8d59
14129,Asian,90.0,24952865.0,Akerblom A,Plasma cystastin c levels in acute coronary syndrome,initial,2014-04-04,GCST002406,Cardiovascular disease,#3288bd
14130,European,9801.0,24952865.0,Akerblom A,Plasma cystastin c levels in acute coronary syndrome,initial,2014-04-04,GCST002406,Cardiovascular disease,#d53e4f
14132,Asian,412.0,24700089.0,Miura K,Cervical cancer,initial,2014-04-04,GCST002405,Cancer,#3288bd
14133,European,4789.0,24699409.0,Prokopenko I,Corrected insulin response adjusted for insulin sensitivity index,initial,2014-04-03,GCST005216,Other measurement,#d53e4f
14134,European,20461.0,24699409.0,Prokopenko I,Corrected insulin response adjusted for insulin sensitivity index,replication,2014-04-03,GCST005216,Other measurement,#d53e4f
14135,European,4789.0,24699409.0,Prokopenko I,Corrected insulin response adjusted for insulin sensitivity index,initial,2014-04-03,GCST005216,Other measurement,#d53e4f
14136,European,20461.0,24699409.0,Prokopenko I,Corrected insulin response adjusted for insulin sensitivity index,replication,2014-04-03,GCST005216,Other measurement,#d53e4f
14137,European,5130.0,24699409.0,Prokopenko I,Insulin disposition index,initial,2014-04-03,GCST005222,Other measurement,#d53e4f
14138,European,20461.0,24699409.0,Prokopenko I,Insulin disposition index,replication,2014-04-03,GCST005222,Other measurement,#d53e4f
14139,European,20620.0,24699409.0,Prokopenko I,Area under the curve of insulin levels,replication,2014-04-03,GCST005218,Other measurement,#d53e4f
14140,European,4324.0,24699409.0,Prokopenko I,Area under the curve of insulin levels,initial,2014-04-03,GCST005218,Other measurement,#d53e4f
14141,European,20722.0,24699409.0,Prokopenko I,Corrected insulin response,replication,2014-04-03,GCST005215,Other measurement,#d53e4f
14142,European,5318.0,24699409.0,Prokopenko I,Corrected insulin response,initial,2014-04-03,GCST005215,Other measurement,#d53e4f
14143,European,20706.0,24699409.0,Prokopenko I,Incremental insulin,replication,2014-04-03,GCST005219,Other measurement,#d53e4f
14144,European,4447.0,24699409.0,Prokopenko I,Incremental insulin,initial,2014-04-03,GCST005219,Other measurement,#d53e4f
14145,European,20513.0,24699409.0,Prokopenko I,Ratio of the area under the curve for insulin and the area under the curve for glucose,replication,2014-04-03,GCST005223,Other measurement,#d53e4f
14146,European,4231.0,24699409.0,Prokopenko I,Ratio of the area under the curve for insulin and the area under the curve for glucose,initial,2014-04-03,GCST005223,Other measurement,#d53e4f
14147,European,4409.0,24699409.0,Prokopenko I,Insulin levels adjusted for BMI,initial,2014-04-03,GCST005217,Other measurement,#d53e4f
14148,European,18535.0,24699409.0,Prokopenko I,Insulin levels adjusted for BMI,replication,2014-04-03,GCST005217,Other measurement,#d53e4f
14149,European,20792.0,24699409.0,Prokopenko I,Insulin levels,replication,2014-04-03,GCST005220,Other measurement,#d53e4f
14150,European,4483.0,24699409.0,Prokopenko I,Insulin levels,initial,2014-04-03,GCST005220,Other measurement,#d53e4f
14151,European,4768.0,24699409.0,Prokopenko I,Insulin sensitivity index,initial,2014-04-03,GCST005221,Other measurement,#d53e4f
14152,European,20514.0,24699409.0,Prokopenko I,Insulin sensitivity index,replication,2014-04-03,GCST005221,Other measurement,#d53e4f
14153,European,20518.0,24688116.0,Deelen J,Longevity (90 years and older),initial,2014-03-31,GCST002404,Other measurement,#d53e4f
14154,European,68486.0,24688116.0,Deelen J,Longevity (90 years and older),replication,2014-03-31,GCST002404,Other measurement,#d53e4f
14155,European,23850.0,24688116.0,Deelen J,Longevity (85 years and older),initial,2014-03-31,GCST002403,Other measurement,#d53e4f
14156,European,74216.0,24688116.0,Deelen J,Longevity (85 years and older),replication,2014-03-31,GCST002403,Other measurement,#d53e4f
14157,European,484.0,24677629.0,Wolf EJ,Post-traumatic stress disorder,initial,2014-03-27,GCST002401,Neurological disorder,#d53e4f
14158,European,9617.0,24676358.0,Viktorin A,Serum IgA levels,initial,2014-03-27,GCST002402,Other measurement,#d53e4f
14159,European,2785.0,24676358.0,Viktorin A,Serum IgA levels,replication,2014-03-27,GCST002402,Other measurement,#d53e4f
14160,European,1892.0,24675659.0,Hartiala J,Plasma trimethylamine N-oxide levels,replication,2014-03-27,GCST002400,Other measurement,#d53e4f
14161,European,1973.0,24675659.0,Hartiala J,Plasma trimethylamine N-oxide levels,initial,2014-03-27,GCST002400,Other measurement,#d53e4f
14162,European,733.0,24667120.0,Zhang TX,Clubfoot,replication,2014-03-25,GCST002399,Other disease,#d53e4f
14163,European,1396.0,24667120.0,Zhang TX,Clubfoot,initial,2014-03-25,GCST002399,Other disease,#d53e4f
14164,European,855.0,24680774.0,Mezzavilla M,Resting heart rate,initial,2014-03-25,GCST002398,Cardiovascular measurement,#d53e4f
14165,Asian,2035.0,24665060.0,Argos M,Smoking quantity,initial,2014-03-24,GCST002393,Other measurement,#3288bd
14166,European,8168.0,24662972.0,Figueroa JD,Bladder cancer (smoking interaction),replication,2014-03-24,GCST002397,Cancer,#d53e4f
14167,European,7413.0,24662972.0,Figueroa JD,Bladder cancer (smoking interaction),initial,2014-03-24,GCST002397,Cancer,#d53e4f
14168,Asian,2035.0,24665060.0,Argos M,Smoking cessation,initial,2014-03-24,GCST002395,Biological process,#3288bd
14169,Asian,2035.0,24665060.0,Argos M,Age of smoking initiation,initial,2014-03-24,GCST002394,Other measurement,#3288bd
14170,Asian,2035.0,24665060.0,Argos M,Age of smoking initiation,initial,2014-03-24,GCST002394,Biological process,#3288bd
14171,Asian,5354.0,24665060.0,Argos M,Smoking initiation,initial,2014-03-24,GCST002396,Biological process,#3288bd
14172,Asian,3023.0,24658283.0,Zhang R,Lung cancer (smoking interaction),replication,2014-03-22,GCST002392,Other measurement,#3288bd
14173,Asian,5408.0,24658283.0,Zhang R,Lung cancer (smoking interaction),initial,2014-03-22,GCST002392,Other measurement,#3288bd
14174,Asian,3023.0,24658283.0,Zhang R,Lung cancer (smoking interaction),replication,2014-03-22,GCST002392,Cancer,#3288bd
14175,Asian,5408.0,24658283.0,Zhang R,Lung cancer (smoking interaction),initial,2014-03-22,GCST002392,Cancer,#3288bd
14176,Other/Mixed,117.0,24651765.0,Williams SR,Plasma homocysteine levels (post-methionine load test),initial,2014-03-20,GCST002391,Cardiovascular measurement,#99d594
14177,European,1725.0,24651765.0,Williams SR,Plasma homocysteine levels (post-methionine load test),initial,2014-03-20,GCST002391,Cardiovascular measurement,#d53e4f
14178,African,258.0,24651765.0,Williams SR,Plasma homocysteine levels (post-methionine load test),initial,2014-03-20,GCST002391,Cardiovascular measurement,#fc8d59
14180,Asian,17290.0,24647736.0,Chen P,Glycated hemoglobin levels,initial,2014-03-19,GCST002390,Other measurement,#3288bd
14181,Asian,13585.0,24647736.0,Chen P,Glycated hemoglobin levels,replication,2014-03-19,GCST002390,Other measurement,#3288bd
14182,Asian,1727.0,24647736.0,Chen P,Glycated hemoglobin levels,initial,2014-03-19,GCST002390,Other measurement,#3288bd
14183,Hispanic/Latin American,794.0,24656865.0,Woo D,Intracerebral hemorrhage,replication,2014-03-18,GCST002389,Cardiovascular disease,#807dba
14184,African Am./Caribbean,1083.0,24656865.0,Woo D,Intracerebral hemorrhage,replication,2014-03-18,GCST002389,Cardiovascular disease,#fee08b
14185,European,2065.0,24656865.0,Woo D,Intracerebral hemorrhage,replication,2014-03-18,GCST002389,Cardiovascular disease,#d53e4f
14186,European,3026.0,24656865.0,Woo D,Intracerebral hemorrhage,initial,2014-03-18,GCST002389,Cardiovascular disease,#d53e4f
14187,African Am./Caribbean,1260.0,24625756.0,Yu B,Serum metabolite levels,initial,2014-03-13,GCST002388,Other measurement,#fee08b
14188,European,767.0,24614497.0,Oikkonen J,Musical aptitude,initial,2014-03-11,GCST002387,Biological process,#d53e4f
14190,European,24025.0,24618891.0,Muhleisen TW,Bipolar disorder,initial,2014-03-11,GCST002385,Neurological disorder,#d53e4f
14191,European,928.0,24604477.0,An P,NHDL cholesterol,initial,2014-03-07,GCST002384,Lipid or lipoprotein measurement,#d53e4f
14192,European,3313.0,24604477.0,An P,NHDL cholesterol,replication,2014-03-07,GCST002384,Lipid or lipoprotein measurement,#d53e4f
14193,Asian,1752.0,24603532.0,Nongpiur ME,Anterior chamber depth,initial,2014-03-06,GCST002383,Other measurement,#3288bd
14194,Asian,824.0,24603532.0,Nongpiur ME,Anterior chamber depth,replication,2014-03-06,GCST002383,Other measurement,#3288bd
14195,Asian,872.0,24603532.0,Nongpiur ME,Anterior chamber depth,initial,2014-03-06,GCST002383,Other measurement,#3288bd
14196,Asian,1860.0,24603532.0,Nongpiur ME,Anterior chamber depth,initial,2014-03-06,GCST002383,Other measurement,#3288bd
14197,European,3750.0,24595857.0,Sandholm N,Urinary albumin excretion rate in type 1 diabetes,replication,2014-03-05,GCST002382,Other measurement,#d53e4f
14198,European,1925.0,24595857.0,Sandholm N,Urinary albumin excretion rate in type 1 diabetes,initial,2014-03-05,GCST002382,Other measurement,#d53e4f
14199,Asian,559.0,24123702.0,Chung CM,Resistin levels,replication,2014-03-03,GCST002381,Other measurement,#3288bd
14200,Asian,382.0,24123702.0,Chung CM,Resistin levels,initial,2014-03-03,GCST002381,Other measurement,#3288bd
14201,European,5756.0,24487271.0,Weizman A,Pyoderma gangrenosum in inflammatory bowel disease,initial,2014-03-01,GCST002379,Other trait,#d53e4f
14202,European,5756.0,24487271.0,Weizman A,Pyoderma gangrenosum in inflammatory bowel disease,initial,2014-03-01,GCST002379,Digestive system disorder,#d53e4f
14203,European,5756.0,24487271.0,Weizman A,Erythema nodosum in inflammatory bowel disease,initial,2014-03-01,GCST002380,Other trait,#d53e4f
14204,European,5756.0,24487271.0,Weizman A,Erythema nodosum in inflammatory bowel disease,initial,2014-03-01,GCST002380,Digestive system disorder,#d53e4f
14205,European,10884.0,24578125.0,Olden M,Urinary uromodulin levels,initial,2014-02-27,GCST002376,Other measurement,#d53e4f
14206,European,4487.0,24578379.0,Huang J,Plasma plasminogen activator levels,replication,2014-02-27,GCST002374,Cardiovascular measurement,#d53e4f
14207,European,26929.0,24578379.0,Huang J,Plasma plasminogen activator levels,initial,2014-02-27,GCST002374,Cardiovascular measurement,#d53e4f
14208,European,466.0,24578207.0,Opherk C,White matter hyperintensity volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy,initial,2014-02-27,GCST002377,Other measurement,#d53e4f
14209,Asian,438.0,24583629.0,Senapati S,Response to methotrexate in rheumatoid arthritis,initial,2014-02-27,GCST002375,Response to drug,#3288bd
14210,European,12353.0,24586183.0,Medici M,Thyroid peroxidase antibody levels,initial,2014-02-27,GCST002373,Other measurement,#d53e4f
14211,European,8159.0,24586183.0,Medici M,Thyroid peroxidase antibody levels,replication,2014-02-27,GCST002373,Other measurement,#d53e4f
14212,European,18297.0,24586183.0,Medici M,Thyroid peroxidase antibody positivity,initial,2014-02-27,GCST002378,Other measurement,#d53e4f
14213,European,8990.0,24586183.0,Medici M,Thyroid peroxidase antibody positivity,replication,2014-02-27,GCST002378,Other measurement,#d53e4f
14214,European,609.0,24571439.0,Nudel R,Parent of origin effect on language impairment (paternal),initial,2014-02-26,GCST002371,Neurological disorder,#d53e4f
14215,European,503.0,24582949.0,Docampo E,Fibromyalgia,initial,2014-02-26,GCST002370,Immune system disorder,#d53e4f
14216,European,1541.0,24582949.0,Docampo E,Fibromyalgia,replication,2014-02-26,GCST002370,Immune system disorder,#d53e4f
14217,European,506.0,24571439.0,Nudel R,Parent of origin effect on language impairment (maternal),replication,2014-02-26,GCST002369,Neurological disorder,#d53e4f
14218,European,609.0,24571439.0,Nudel R,Parent of origin effect on language impairment (maternal),initial,2014-02-26,GCST002369,Neurological disorder,#d53e4f
14219,European,11388.0,24569950.0,Hatemi PK,Political ideology,initial,2014-02-26,GCST002372,Other trait,#d53e4f
14222,European,508.0,24574247.0,Yuan H,Maternal genotype effects in autism spectrum disorder families,initial,2014-02-25,GCST002368,Neurological disorder,#d53e4f
14225,European,508.0,24574247.0,Yuan H,Maternal genotype effects in autism spectrum disorder families,initial,2014-02-25,GCST002368,Other measurement,#d53e4f
14226,European,5628.0,24564958.0,St Pourcain B,Social communication problems,initial,2014-02-24,GCST002367,Other measurement,#d53e4f
14227,African Am./Caribbean,86.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy),initial,2014-02-20,GCST002366,Response to drug,#fee08b
14228,Hispanic/Latin American,43.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy),initial,2014-02-20,GCST002366,Response to drug,#807dba
14229,European,125.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy),initial,2014-02-20,GCST002366,Response to drug,#d53e4f
14230,Hispanic/Latin American,39.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),initial,2014-02-20,GCST002365,Response to drug,#807dba
14231,African Am./Caribbean,79.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),initial,2014-02-20,GCST002365,Response to drug,#fee08b
14232,European,104.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),initial,2014-02-20,GCST002365,Response to drug,#d53e4f
14233,Hispanic/Latin American,33.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy),initial,2014-02-20,GCST002363,Response to drug,#807dba
14234,African Am./Caribbean,61.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy),initial,2014-02-20,GCST002363,Response to drug,#fee08b
14235,European,93.0,24554482.0,Leger PD,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy),initial,2014-02-20,GCST002363,Response to drug,#d53e4f
14236,European,835.0,24586186.0,Rueedi R,Urinary metabolites (H-NMR features),initial,2014-02-20,GCST002364,Other measurement,#d53e4f
14237,Other/Mixed,601.0,24586186.0,Rueedi R,Urinary metabolites (H-NMR features),replication,2014-02-20,GCST002364,Other measurement,#99d594
14238,European,3121.0,24839885.0,Benke KS,Preschool internalizing problems,initial,2014-02-19,GCST002362,Other measurement,#d53e4f
14240,European,979.0,24556642.0,Zeng Z,Pit-and-Fissure caries,initial,2014-02-18,GCST002358,Digestive system disorder,#d53e4f
14241,European,3528.0,24535457.0,Chouraki V,Plasma amyloid beta peptide concentrations (ABx-42),initial,2014-02-18,GCST002359,Other measurement,#d53e4f
14242,European,1006.0,24556642.0,Zeng Z,Smooth-surface caries,initial,2014-02-18,GCST002361,Digestive system disorder,#d53e4f
14243,European,3528.0,24535457.0,Chouraki V,Plasma amyloid beta peptide concentrations (ABx-40),initial,2014-02-18,GCST002360,Other measurement,#d53e4f
14244,European,1853.0,24532677.0,Bossini-Castillo L,Rheumatoid arthritis (ACPA-negative),replication,2014-02-14,GCST002357,Immune system disorder,#d53e4f
14245,European,7156.0,24532677.0,Bossini-Castillo L,Rheumatoid arthritis (ACPA-negative),initial,2014-02-14,GCST002357,Immune system disorder,#d53e4f
14246,European,45790.0,24532676.0,Kim K,Rheumatoid arthritis (ACPA-positive),initial,2014-02-14,GCST006048,Immune system disorder,#d53e4f
14247,Asian,9299.0,24532676.0,Kim K,Rheumatoid arthritis (ACPA-positive),initial,2014-02-14,GCST006048,Immune system disorder,#3288bd
14248,Asian,8830.0,24513273.0,Yang B,Serum uric acid levels,replication,2014-02-11,GCST002355,Cardiovascular measurement,#3288bd
14249,Asian,3451.0,24513273.0,Yang B,Serum uric acid levels,initial,2014-02-11,GCST002355,Cardiovascular measurement,#3288bd
14250,European,22789.0,24518671.0,Nag A,Intraocular pressure,replication,2014-02-11,GCST002356,Other measurement,#d53e4f
14251,European,2774.0,24518671.0,Nag A,Intraocular pressure,initial,2014-02-11,GCST002356,Other measurement,#d53e4f
14252,Asian,879.0,24514567.0,Boraska V,Anorexia nervosa,replication,2014-02-11,GCST002354,Metabolic disorder,#3288bd
14253,European,11306.0,24514567.0,Boraska V,Anorexia nervosa,replication,2014-02-11,GCST002354,Metabolic disorder,#d53e4f
14254,European,17767.0,24514567.0,Boraska V,Anorexia nervosa,initial,2014-02-11,GCST002354,Metabolic disorder,#d53e4f
14255,European,3031.0,24511991.0,Hill-Burns EM,Parkinson's disease,replication,2014-02-10,GCST002353,Neurological disorder,#d53e4f
14256,European,3986.0,24511991.0,Hill-Burns EM,Parkinson's disease,initial,2014-02-10,GCST002353,Neurological disorder,#d53e4f
14257,European,69033.0,24509480.0,Mahajan A,Type 2 diabetes,initial,2014-02-09,GCST002352,Metabolic disorder,#d53e4f
14258,Asian,18817.0,24509480.0,Mahajan A,Type 2 diabetes,initial,2014-02-09,GCST002352,Metabolic disorder,#3288bd
14259,Asian,20019.0,24509480.0,Mahajan A,Type 2 diabetes,initial,2014-02-09,GCST002352,Metabolic disorder,#3288bd
14260,Hispanic/Latin American,2583.0,24509480.0,Mahajan A,Type 2 diabetes,initial,2014-02-09,GCST002352,Metabolic disorder,#807dba
14261,European,77138.0,24509480.0,Mahajan A,Type 2 diabetes,replication,2014-02-09,GCST002352,Metabolic disorder,#d53e4f
14263,European,9767.0,24621683.0,Cho MH,Chronic obstructive pulmonary disease (moderate to severe),initial,2014-02-07,GCST002351,Other disease,#d53e4f
14264,African Am./Caribbean,2570.0,24621683.0,Cho MH,Chronic obstructive pulmonary disease (moderate to severe),initial,2014-02-07,GCST002351,Other disease,#fee08b
14266,European,7100.0,24621683.0,Cho MH,Chronic obstructive pulmonary disease (severe),initial,2014-02-07,GCST002350,Other disease,#d53e4f
14267,African Am./Caribbean,2570.0,24621683.0,Cho MH,Chronic obstructive pulmonary disease (severe),initial,2014-02-07,GCST002350,Other disease,#fee08b
14268,European,176.0,24503447.0,Nelson D,Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity),initial,2014-02-06,GCST002347,Response to drug,#d53e4f
14269,European,176.0,24503447.0,Nelson D,Response to protease inhibitor treatment in hepatitis c (peak serum total bilirubin levels),initial,2014-02-06,GCST002349,Response to drug,#d53e4f
14270,Other/Mixed,57.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other trait,#99d594
14271,European,816.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other trait,#d53e4f
14272,Asian,777.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other trait,#3288bd
14273,Other/Mixed,57.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other measurement,#99d594
14274,European,816.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other measurement,#d53e4f
14275,Asian,777.0,24516586.0,Wu T,Cleft plate (environmental tobacco smoke interaction),initial,2014-02-06,GCST002348,Other measurement,#3288bd
14276,European,8945.0,24493630.0,Ahsan H,Breast cancer (early onset),replication,2014-02-03,GCST002346,Cancer,#d53e4f
14277,European,6225.0,24493630.0,Ahsan H,Breast cancer (early onset),initial,2014-02-03,GCST002346,Cancer,#d53e4f
14278,European,2329.0,24687471.0,Harlaar N,Receptive language ability,initial,2014-02-01,GCST002344,Biological process,#d53e4f
14279,European,2639.0,24687471.0,Harlaar N,Receptive language ability,replication,2014-02-01,GCST002344,Biological process,#d53e4f
14280,European,42208.0,24507774.0,Peloso GM,Triglycerides,initial,2014-02-01,GCST007849,Lipid or lipoprotein measurement,#d53e4f
14281,African,14330.0,24507774.0,Peloso GM,Triglycerides,initial,2014-02-01,GCST007849,Lipid or lipoprotein measurement,#fc8d59
14282,African,14330.0,24507774.0,Peloso GM,LDL cholesterol,initial,2014-02-01,GCST007848,Lipid or lipoprotein measurement,#fc8d59
14283,European,42208.0,24507774.0,Peloso GM,LDL cholesterol,initial,2014-02-01,GCST007848,Lipid or lipoprotein measurement,#d53e4f
14284,European,42208.0,24507774.0,Peloso GM,HDL cholesterol,initial,2014-02-01,GCST007850,Lipid or lipoprotein measurement,#d53e4f
14285,African,14330.0,24507774.0,Peloso GM,HDL cholesterol,initial,2014-02-01,GCST007850,Lipid or lipoprotein measurement,#fc8d59
14286,European,4896.0,24342994.0,Lencz T,General cognitive ability,initial,2014-02-01,GCST006523,Biological process,#d53e4f
14287,European,60.0,24483146.0,Li L,Response to cytadine analogues (cytosine arabinoside),initial,2014-02-01,GCST002345,Response to drug,#d53e4f
14288,African Am./Caribbean,54.0,24483146.0,Li L,Response to cytadine analogues (cytosine arabinoside),initial,2014-02-01,GCST002345,Response to drug,#fee08b
14289,Asian,60.0,24483146.0,Li L,Response to cytadine analogues (cytosine arabinoside),initial,2014-02-01,GCST002345,Response to drug,#3288bd
14290,Asian,60.0,24483146.0,Li L,Response to cytidine analogues (gemcitabine),initial,2014-02-01,GCST002343,Response to drug,#3288bd
14291,African Am./Caribbean,54.0,24483146.0,Li L,Response to cytidine analogues (gemcitabine),initial,2014-02-01,GCST002343,Response to drug,#fee08b
14292,European,60.0,24483146.0,Li L,Response to cytidine analogues (gemcitabine),initial,2014-02-01,GCST002343,Response to drug,#d53e4f
14293,European,297.0,24486069.0,Park HW,Asthma (corticosteroid response),replication,2014-01-31,GCST002342,Response to drug,#d53e4f
14294,European,124.0,24486069.0,Park HW,Asthma (corticosteroid response),initial,2014-01-31,GCST002342,Response to drug,#d53e4f
14295,Asian,4415.0,24448986.0,Zhang B,Colorectal cancer,initial,2014-01-21,GCST002340,Cancer,#3288bd
14296,Asian,14764.0,24448986.0,Zhang B,Colorectal cancer,replication,2014-01-21,GCST002340,Cancer,#3288bd
14297,Asian,3917.0,24465473.0,Liu Y,Telomere length,replication,2014-01-21,GCST002341,Other measurement,#3288bd
14298,European,696.0,24465473.0,Liu Y,Telomere length,replication,2014-01-21,GCST002341,Other measurement,#d53e4f
14299,Asian,2632.0,24465473.0,Liu Y,Telomere length,initial,2014-01-21,GCST002341,Other measurement,#3288bd
14300,Asian,200.0,24465431.0,Ma RC,Type 2 diabetes (young onset) and obesity,initial,2014-01-20,GCST002339,Metabolic disorder,#3288bd
14301,Asian,772.0,24444492.0,Kuo PH,Bipolar I disorder,replication,2014-01-18,GCST002338,Neurological disorder,#3288bd
14302,Asian,400.0,24444492.0,Kuo PH,Bipolar I disorder,initial,2014-01-18,GCST002338,Neurological disorder,#3288bd
14303,Asian,500.0,24529757.0,Xie T,Amyotrophic lateral sclerosis (sporadic),initial,2014-01-17,GCST002337,Neurological disorder,#3288bd
14304,European,4829.0,24478790.0,Lee JH,Telomere length,initial,2014-01-17,GCST002336,Other measurement,#d53e4f
14307,Asian,730.0,24430505.0,Moayyeri A,Bone properties (heel),initial,2014-01-14,GCST002335,Other measurement,#3288bd
14308,European,11058.0,24430505.0,Moayyeri A,Bone properties (heel),replication,2014-01-14,GCST002335,Other measurement,#d53e4f
14310,European,2380.0,24430505.0,Moayyeri A,Bone properties (heel),initial,2014-01-14,GCST002335,Other measurement,#d53e4f
14312,European,1885.0,24430505.0,Moayyeri A,Bone properties (heel),initial,2014-01-14,GCST002333,Other measurement,#d53e4f
14313,European,10074.0,24430505.0,Moayyeri A,Bone properties (heel),replication,2014-01-14,GCST002333,Other measurement,#d53e4f
14316,Asian,2483.0,24430505.0,Moayyeri A,Bone properties (heel),initial,2014-01-14,GCST002333,Other measurement,#3288bd
14317,European,2236.0,24430505.0,Moayyeri A,Bone properties (heel),replication,2014-01-14,GCST002334,Other measurement,#d53e4f
14318,European,4556.0,24430505.0,Moayyeri A,Bone properties (heel),initial,2014-01-14,GCST002334,Other measurement,#d53e4f
14319,European,5003.0,24413707.0,Chiang KM,Hypertension (young onset),replication,2014-01-11,GCST002332,Cardiovascular disease,#d53e4f
14320,Asian,1499.0,24413707.0,Chiang KM,Hypertension (young onset),replication,2014-01-11,GCST002332,Cardiovascular disease,#3288bd
14321,Asian,800.0,24413707.0,Chiang KM,Hypertension (young onset),initial,2014-01-11,GCST002332,Cardiovascular disease,#3288bd
14322,European,113616.0,24403052.0,Stacey SN,Basal cell carcinoma,initial,2014-01-08,GCST002331,Cancer,#d53e4f
14323,European,6090.0,24403052.0,Stacey SN,Basal cell carcinoma,replication,2014-01-08,GCST002331,Cancer,#d53e4f
14324,Asian,5520.0,24399259.0,He L,Acne (severe),replication,2014-01-07,GCST002329,Other disease,#3288bd
14325,Asian,2062.0,24399259.0,He L,Acne (severe),initial,2014-01-07,GCST002329,Other disease,#3288bd
14326,Hispanic/Latin American,3774.0,24406073.0,Galanter JM,Asthma,initial,2014-01-07,GCST002330,Other disease,#807dba
14327,Asian,6223.0,24387323.0,Kim WJ,Lung function,initial,2014-01-06,GCST002328,Other measurement,#3288bd
14328,Asian,2720.0,24387323.0,Kim WJ,Lung function,replication,2014-01-06,GCST002328,Other measurement,#3288bd
14330,European,1815.0,24387768.0,Xu W,Bipolar disorder,initial,2014-01-04,GCST002327,Neurological disorder,#d53e4f
14331,Hispanic/Latin American,2113.0,24383474.0,Manichaikul A,Pulmonary emphysema,initial,2014-01-02,GCST002326,Other disease,#807dba
14332,European,6023.0,24383474.0,Manichaikul A,Pulmonary emphysema,replication,2014-01-02,GCST002326,Other disease,#d53e4f
14333,European,2587.0,24383474.0,Manichaikul A,Pulmonary emphysema,initial,2014-01-02,GCST002326,Other disease,#d53e4f
14334,African Am./Caribbean,2510.0,24383474.0,Manichaikul A,Pulmonary emphysema,initial,2014-01-02,GCST002326,Other disease,#fee08b
14335,Asian,704.0,24383474.0,Manichaikul A,Pulmonary emphysema,initial,2014-01-02,GCST002326,Other disease,#3288bd
14336,European,8442.0,24387989.0,Mayes MD,Limited cutaneous systemic scleroderma,replication,2014-01-02,GCST005533,Neurological disorder,#d53e4f
14337,European,4593.0,24387989.0,Mayes MD,Limited cutaneous systemic scleroderma,initial,2014-01-02,GCST005533,Neurological disorder,#d53e4f
14338,European,5299.0,24387989.0,Mayes MD,Systemic sclerosis,initial,2014-01-02,GCST005534,Neurological disorder,#d53e4f
14339,European,9952.0,24387989.0,Mayes MD,Systemic sclerosis,replication,2014-01-02,GCST005534,Neurological disorder,#d53e4f
14340,European,7152.0,24387989.0,Mayes MD,Diffuse cutaneous systemic sclerosis,replication,2014-01-02,GCST005535,Neurological disorder,#d53e4f
14341,European,4040.0,24387989.0,Mayes MD,Diffuse cutaneous systemic sclerosis,initial,2014-01-02,GCST005535,Neurological disorder,#d53e4f
14342,European,1241.0,24392092.0,Luksys G,Memory performance,initial,2014-01-02,GCST002325,Other measurement,#d53e4f
14343,European,8305.0,24449572.0,Orozco G,Rheumatoid arthritis,initial,2014-01-01,GCST002323,Immune system disorder,#d53e4f
14344,European,7351.0,24449572.0,Orozco G,Rheumatoid arthritis,replication,2014-01-01,GCST002323,Immune system disorder,#d53e4f
14345,African Am./Caribbean,4213.0,24166409.0,Gelernter J,Alcohol dependence,initial,2014-01-01,GCST004712,Neurological disorder,#fee08b
14346,European,4671.0,24166409.0,Gelernter J,Alcohol dependence,initial,2014-01-01,GCST004712,Neurological disorder,#d53e4f
14347,African Am./Caribbean,651.0,24166409.0,Gelernter J,Alcohol dependence,replication,2014-01-01,GCST004712,Neurological disorder,#fee08b
14348,European,5244.0,24166409.0,Gelernter J,Alcohol dependence,replication,2014-01-01,GCST004712,Neurological disorder,#d53e4f
14349,African Am./Caribbean,4629.0,24166409.0,Gelernter J,Alcohol dependence,initial,2014-01-01,GCST004711,Other measurement,#fee08b
14350,European,1746.0,24166409.0,Gelernter J,Alcohol dependence,replication,2014-01-01,GCST004711,Other measurement,#d53e4f
14351,African Am./Caribbean,801.0,24166409.0,Gelernter J,Alcohol dependence,replication,2014-01-01,GCST004711,Other measurement,#fee08b
14352,European,5131.0,24166409.0,Gelernter J,Alcohol dependence,initial,2014-01-01,GCST004711,Other measurement,#d53e4f
14353,European,8747.0,24489884.0,Mick E,Anger,initial,2014-01-01,GCST002324,Biological process,#d53e4f
14354,Asian,8830.0,24386095.0,Zhou L,Lipid traits,replication,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14355,Asian,3451.0,24386095.0,Zhou L,Lipid traits,initial,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14356,Asian,8830.0,24386095.0,Zhou L,Lipid traits,replication,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14357,Asian,3451.0,24386095.0,Zhou L,Lipid traits,initial,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14358,Asian,8830.0,24386095.0,Zhou L,Lipid traits,replication,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14359,Asian,3451.0,24386095.0,Zhou L,Lipid traits,initial,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14360,Asian,8830.0,24386095.0,Zhou L,Lipid traits,replication,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14361,Asian,3451.0,24386095.0,Zhou L,Lipid traits,initial,2013-12-30,GCST002321,Lipid or lipoprotein measurement,#3288bd
14362,European,3333.0,24388013.0,Ferreira MA,Asthma and hay fever,replication,2013-12-30,GCST002322,Immune system disorder,#d53e4f
14363,European,20776.0,24388013.0,Ferreira MA,Asthma and hay fever,initial,2013-12-30,GCST002322,Immune system disorder,#d53e4f
14364,European,3333.0,24388013.0,Ferreira MA,Asthma and hay fever,replication,2013-12-30,GCST002322,Other disease,#d53e4f
14365,European,20776.0,24388013.0,Ferreira MA,Asthma and hay fever,initial,2013-12-30,GCST002322,Other disease,#d53e4f
14366,African Am./Caribbean,890.0,24468470.0,Zhang C,Cognitive decline (age-related),initial,2013-12-26,GCST002320,Other trait,#fee08b
14367,European,5765.0,24468470.0,Zhang C,Cognitive decline (age-related),initial,2013-12-26,GCST002320,Other trait,#d53e4f
14368,European,241.0,24375517.0,Lohmann K,Musician's dystonia,replication,2013-12-26,GCST002319,Neurological disorder,#d53e4f
14369,European,1111.0,24375517.0,Lohmann K,Musician's dystonia,initial,2013-12-26,GCST002319,Neurological disorder,#d53e4f
14370,European,58284.0,24390342.0,Okada Y,Rheumatoid arthritis,initial,2013-12-25,GCST002318,Immune system disorder,#d53e4f
14371,Asian,22515.0,24390342.0,Okada Y,Rheumatoid arthritis,initial,2013-12-25,GCST002318,Immune system disorder,#3288bd
14372,European,9576.0,24390342.0,Okada Y,Rheumatoid arthritis,replication,2013-12-25,GCST002318,Immune system disorder,#d53e4f
14373,Asian,13263.0,24390342.0,Okada Y,Rheumatoid arthritis,replication,2013-12-25,GCST002318,Immune system disorder,#3288bd
14374,Hispanic/Latin American,8214.0,24390345.0,Williams AL,Type 2 diabetes,initial,2013-12-25,GCST002317,Metabolic disorder,#807dba
14375,European,3207.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#d53e4f
14376,Asian,5648.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#3288bd
14377,Asian,2187.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#3288bd
14378,Asian,3968.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#3288bd
14379,African Am./Caribbean,4230.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#fee08b
14380,Other/Mixed,1277.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#99d594
14381,Hispanic/Latin American,1728.0,24390345.0,Williams AL,Type 2 diabetes,replication,2013-12-25,GCST002317,Metabolic disorder,#807dba
14382,Asian,368.0,24376627.0,Su WH,Nasopharyngeal carcinoma (SNP x SNP interaction),replication,2013-12-23,GCST006524,Cancer,#3288bd
14383,Asian,562.0,24376627.0,Su WH,Nasopharyngeal carcinoma (SNP x SNP interaction),initial,2013-12-23,GCST006524,Cancer,#3288bd
14384,Asian,32668.0,24376798.0,Miki D,Chronic hepatitis C infection,replication,2013-12-20,GCST002316,Digestive system disorder,#3288bd
14385,Asian,3444.0,24376798.0,Miki D,Chronic hepatitis C infection,initial,2013-12-20,GCST002316,Digestive system disorder,#3288bd
14386,European,1257.0,24357727.0,Rocanin-Arjo A,Thrombin generation potential phenotypes,replication,2013-12-19,GCST002315,Other measurement,#d53e4f
14387,European,1967.0,24357727.0,Rocanin-Arjo A,Thrombin generation potential phenotypes,initial,2013-12-19,GCST002315,Other measurement,#d53e4f
14388,Asian,577.0,24351856.0,Nanayakkara S,Chronic kidney disease,initial,2013-12-18,GCST002313,Other disease,#3288bd
14389,Asian,577.0,24351856.0,Nanayakkara S,Glomerular filtration rate,initial,2013-12-18,GCST002314,Other measurement,#3288bd
14390,European,673.0,24347629.0,Shaffer JR,Periodontal disease-related phenotype (Socransky),initial,2013-12-17,GCST002312,Digestive system disorder,#d53e4f
14391,Hispanic/Latin American,632.0,24379826.0,Voruganti VS,Serum uric acid levels,initial,2013-12-16,GCST002311,Cardiovascular measurement,#807dba
14392,European,6882.0,24376456.0,Simino J,Pulse pressure (alcohol consumption interaction),initial,2013-12-12,GCST002310,Cardiovascular measurement,#d53e4f
14393,European,6882.0,24376456.0,Simino J,Pulse pressure (alcohol consumption interaction),initial,2013-12-12,GCST002310,Biological process,#d53e4f
14394,European,6882.0,24376456.0,Simino J,Mean arterial pressure (alcohol consumption interaction),initial,2013-12-12,GCST002308,Other measurement,#d53e4f
14395,European,6882.0,24376456.0,Simino J,Mean arterial pressure (alcohol consumption interaction),initial,2013-12-12,GCST002308,Biological process,#d53e4f
14396,European,6882.0,24376456.0,Simino J,Diastolic blood pressure (alcohol consumption interaction),initial,2013-12-12,GCST002309,Other measurement,#d53e4f
14397,European,6882.0,24376456.0,Simino J,Diastolic blood pressure (alcohol consumption interaction),initial,2013-12-12,GCST002309,Biological process,#d53e4f
14398,European,6882.0,24376456.0,Simino J,Systolic blood pressure (alcohol consumption interaction),initial,2013-12-12,GCST002307,Other measurement,#d53e4f
14399,European,6882.0,24376456.0,Simino J,Systolic blood pressure (alcohol consumption interaction),initial,2013-12-12,GCST002307,Biological process,#d53e4f
14400,European,1408.0,24322204.0,Winham SJ,Bipolar disorder (body mass index interaction),initial,2013-12-10,GCST002306,Neurological disorder,#d53e4f
14401,European,1408.0,24322204.0,Winham SJ,Bipolar disorder (body mass index interaction),initial,2013-12-10,GCST002306,Body measurement,#d53e4f
14402,European,3457.0,24325915.0,Purrington KS,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)",replication,2013-12-09,GCST002305,Cancer,#d53e4f
14403,European,4928.0,24325915.0,Purrington KS,"Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative)",initial,2013-12-09,GCST002305,Cancer,#d53e4f
14404,Asian,5408.0,24325914.0,Chu M,Lung cancer (SNP x SNP interaction),initial,2013-12-09,GCST006866,Cancer,#3288bd
14405,Asian,7984.0,24325914.0,Chu M,Lung cancer (SNP x SNP interaction),replication,2013-12-09,GCST006866,Cancer,#3288bd
14406,Other/Mixed,2572.0,24315451.0,van der Valk RJ,Fractional exhaled nitric oxide (childhood),initial,2013-12-05,GCST002304,Other measurement,#99d594
14407,Hispanic/Latin American,1155.0,24315451.0,van der Valk RJ,Fractional exhaled nitric oxide (childhood),initial,2013-12-05,GCST002304,Other measurement,#807dba
14408,European,5131.0,24315451.0,van der Valk RJ,Fractional exhaled nitric oxide (childhood),initial,2013-12-05,GCST002304,Other measurement,#d53e4f
14409,European,47822.0,24405752.0,An P,Glycated hemoglobin levels,replication,2013-12-04,GCST002303,Other measurement,#d53e4f
14410,European,4088.0,24405752.0,An P,Glycated hemoglobin levels,initial,2013-12-04,GCST002303,Other measurement,#d53e4f
14411,Asian,2474.0,24324648.0,Yatagai Y,IgE levels,replication,2013-12-04,GCST002302,Other measurement,#3288bd
14412,Asian,1180.0,24324648.0,Yatagai Y,IgE levels,initial,2013-12-04,GCST002302,Other measurement,#3288bd
14413,European,2860.0,24348519.0,Namjou B,Body mass index,initial,2013-12-03,GCST002301,Body measurement,#d53e4f
14414,Asian,2075.0,23918589.0,Negi S,Rheumatoid arthritis,replication,2013-12-01,GCST002300,Immune system disorder,#3288bd
14415,Asian,1467.0,23918589.0,Negi S,Rheumatoid arthritis,initial,2013-12-01,GCST002300,Immune system disorder,#3288bd
14416,European,94.0,24778558.0,Domarkiene I,Coronary heart disease,initial,2013-12-01,GCST002298,Cardiovascular disease,#d53e4f
14417,European,6938.0,24292274.0,Speedy HE,Chronic lymphocytic leukemia,initial,2013-12-01,GCST002299,Cancer,#d53e4f
14418,European,4295.0,24292274.0,Speedy HE,Chronic lymphocytic leukemia,replication,2013-12-01,GCST002299,Cancer,#d53e4f
14419,Asian,1756.0,24282030.0,Pan L,Hepatitis B vaccine response,replication,2013-11-28,GCST002297,Response to drug,#3288bd
14420,Asian,185.0,24282030.0,Pan L,Hepatitis B vaccine response,initial,2013-11-28,GCST002297,Response to drug,#3288bd
14422,Asian,314.0,24277619.0,Quillen EE,Alcohol dependence,initial,2013-11-26,GCST002293,Neurological disorder,#3288bd
14423,European,23527.0,24280982.0,Ruderfer DM,Schizophrenia or bipolar disorder,initial,2013-11-26,GCST002295,Neurological disorder,#d53e4f
14426,European,23527.0,24280982.0,Ruderfer DM,Schizophrenia or bipolar disorder,initial,2013-11-26,GCST002295,Neurological disorder,#d53e4f
14429,Asian,272.0,24277619.0,Quillen EE,Alcohol consumption (max-drinks),initial,2013-11-26,GCST002294,Biological process,#3288bd
14430,Asian,298.0,24277619.0,Quillen EE,Response to alcohol consumption (flushing response),initial,2013-11-26,GCST002292,Biological process,#3288bd
14431,European,227.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),replication,2013-11-23,GCST002291,Response to drug,#d53e4f
14432,European,581.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),initial,2013-11-23,GCST002291,Response to drug,#d53e4f
14433,European,227.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),replication,2013-11-23,GCST002291,Response to drug,#d53e4f
14434,European,581.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),initial,2013-11-23,GCST002291,Response to drug,#d53e4f
14435,European,227.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),replication,2013-11-23,GCST002291,Other disease,#d53e4f
14436,European,581.0,24280104.0,Wu AC,Bronchodilator response in asthma (inhaled corticosteroid treatment interaction),initial,2013-11-23,GCST002291,Other disease,#d53e4f
14444,Hispanic/Latin American,580.0,24324551.0,Deng X,Parasitemia in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002282,Other measurement,#807dba
14445,Hispanic/Latin American,580.0,24324551.0,Deng X,Parasitemia in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002282,Other measurement,#807dba
14446,Hispanic/Latin American,580.0,24324551.0,Deng X,Ejection fraction in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002281,Other measurement,#807dba
14447,Hispanic/Latin American,580.0,24324551.0,Deng X,Ejection fraction in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002281,Cardiovascular measurement,#807dba
14448,Hispanic/Latin American,580.0,24324551.0,Deng X,QT interval in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002278,Cardiovascular measurement,#807dba
14449,Hispanic/Latin American,580.0,24324551.0,Deng X,QT interval in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002278,Other measurement,#807dba
14450,Hispanic/Latin American,580.0,24324551.0,Deng X,PR interval in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002279,Cardiovascular measurement,#807dba
14451,Hispanic/Latin American,580.0,24324551.0,Deng X,PR interval in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002279,Other measurement,#807dba
14452,Hispanic/Latin American,580.0,24324551.0,Deng X,Antibody status in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002280,Other measurement,#807dba
14453,Hispanic/Latin American,580.0,24324551.0,Deng X,Antibody status in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002280,Other measurement,#807dba
14454,Hispanic/Latin American,513.0,24324551.0,Deng X,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002285,Cardiovascular disease,#807dba
14455,Hispanic/Latin American,513.0,24324551.0,Deng X,Chagas cardiomyopathy in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002285,Other measurement,#807dba
14456,European,4630.0,24256812.0,Fogh I,Amyotrophic lateral sclerosis (sporadic),replication,2013-11-20,GCST002283,Neurological disorder,#d53e4f
14457,European,13225.0,24256812.0,Fogh I,Amyotrophic lateral sclerosis (sporadic),initial,2013-11-20,GCST002283,Neurological disorder,#d53e4f
14458,Hispanic/Latin American,580.0,24324551.0,Deng X,QRS duration in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002284,Cardiovascular measurement,#807dba
14459,Hispanic/Latin American,580.0,24324551.0,Deng X,QRS duration in Tripanosoma cruzi seropositivity,initial,2013-11-20,GCST002284,Other measurement,#807dba
14460,Asian,1080.0,24253340.0,Lencz T,Schizophrenia,replication,2013-11-19,GCST002277,Neurological disorder,#3288bd
14461,African Am./Caribbean,1875.0,24253340.0,Lencz T,Schizophrenia,replication,2013-11-19,GCST002277,Neurological disorder,#fee08b
14462,European,6993.0,24253340.0,Lencz T,Schizophrenia,replication,2013-11-19,GCST002277,Neurological disorder,#d53e4f
14463,European,2544.0,24253340.0,Lencz T,Schizophrenia,initial,2013-11-19,GCST002277,Neurological disorder,#d53e4f
14464,European,10732.0,24249740.0,Zhang L,Bone mineral density,replication,2013-11-17,GCST002276,Other measurement,#d53e4f
14465,European,8472.0,24249740.0,Zhang L,Bone mineral density,initial,2013-11-17,GCST002276,Other measurement,#d53e4f
14466,African Am./Caribbean,712.0,24249740.0,Zhang L,Bone mineral density,initial,2013-11-17,GCST002276,Other measurement,#fee08b
14467,Hispanic/Latin American,409.0,24249740.0,Zhang L,Bone mineral density,initial,2013-11-17,GCST002276,Other measurement,#807dba
14468,Asian,1547.0,24249740.0,Zhang L,Bone mineral density,initial,2013-11-17,GCST002276,Other measurement,#3288bd
14469,Asian,5139.0,24249740.0,Zhang L,Bone mineral density,replication,2013-11-17,GCST002276,Other measurement,#3288bd
14470,European,3684.0,24241537.0,Bonnelykke K,Asthma (childhood onset),initial,2013-11-17,GCST002275,Other disease,#d53e4f
14471,European,3058.0,24241537.0,Bonnelykke K,Asthma (childhood onset),replication,2013-11-17,GCST002275,Other disease,#d53e4f
14476,European,69230.0,24220699.0,Gudmundsson J,Renal cell carcinoma,initial,2013-11-13,GCST002273,Cancer,#d53e4f
14477,European,4678.0,24220699.0,Gudmundsson J,Renal cell carcinoma,replication,2013-11-13,GCST002273,Cancer,#d53e4f
14478,African Am./Caribbean,683.0,24220910.0,Purdue MP,Renal cell carcinoma,replication,2013-11-12,GCST002272,Cancer,#fee08b
14479,African Am./Caribbean,630.0,24220910.0,Purdue MP,Renal cell carcinoma,initial,2013-11-12,GCST002272,Cancer,#fee08b
14480,Asian,505.0,24265751.0,Li W,Delayed encephalopathy in acute carbon monoxide poisoning,replication,2013-11-12,GCST002271,Neurological disorder,#3288bd
14481,Asian,419.0,24265751.0,Li W,Delayed encephalopathy in acute carbon monoxide poisoning,initial,2013-11-12,GCST002271,Neurological disorder,#3288bd
14482,Asian,1529.0,24244560.0,Chen P,Glycated hemoglobin levels,initial,2013-11-07,GCST002270,Other measurement,#3288bd
14483,Asian,1735.0,24244560.0,Chen P,Glycated hemoglobin levels,initial,2013-11-07,GCST002270,Other measurement,#3288bd
14484,Asian,3427.0,24244560.0,Chen P,Glycated hemoglobin levels,initial,2013-11-07,GCST002270,Other measurement,#3288bd
14485,European,987.0,24223155.0,Behr ER,Drug-induced torsades de pointes,initial,2013-11-06,GCST002269,Cardiovascular disease,#d53e4f
14486,European,987.0,24223155.0,Behr ER,Drug-induced torsades de pointes,initial,2013-11-06,GCST002269,Biological process,#d53e4f
14487,European,3897.0,24189344.0,Xia K,Autism,replication,2013-11-05,GCST002268,Neurological disorder,#d53e4f
14488,Asian,1945.0,24189344.0,Xia K,Autism,initial,2013-11-05,GCST002268,Neurological disorder,#3288bd
14489,European,33689.0,24190013.0,Earp MA,Epithelial ovarian cancer,replication,2013-11-05,GCST002267,Cancer,#d53e4f
14490,European,943.0,24190013.0,Earp MA,Epithelial ovarian cancer,initial,2013-11-05,GCST002267,Cancer,#d53e4f
14491,European,2920.0,24080446.0,Rudolph A,Breast cancer (menopausal hormone therapy interaction),initial,2013-11-04,GCST002265,Cancer,#d53e4f
14492,European,16955.0,24080446.0,Rudolph A,Breast cancer (menopausal hormone therapy interaction),replication,2013-11-04,GCST002265,Cancer,#d53e4f
14493,European,2920.0,24080446.0,Rudolph A,Breast cancer (menopausal hormone therapy interaction),initial,2013-11-04,GCST002265,Other trait,#d53e4f
14494,European,16955.0,24080446.0,Rudolph A,Breast cancer (menopausal hormone therapy interaction),replication,2013-11-04,GCST002265,Other trait,#d53e4f
14495,European,541.0,24080446.0,Rudolph A,Lobular breast cancer (menopausal hormone therapy interaction),initial,2013-11-04,GCST002266,Cancer,#d53e4f
14496,European,9942.0,24080446.0,Rudolph A,Lobular breast cancer (menopausal hormone therapy interaction),replication,2013-11-04,GCST002266,Cancer,#d53e4f
14497,European,541.0,24080446.0,Rudolph A,Lobular breast cancer (menopausal hormone therapy interaction),initial,2013-11-04,GCST002266,Other trait,#d53e4f
14498,European,9942.0,24080446.0,Rudolph A,Lobular breast cancer (menopausal hormone therapy interaction),replication,2013-11-04,GCST002266,Other trait,#d53e4f
14499,African Am./Caribbean,10068.0,24185611.0,Cook MB,Prostate cancer,replication,2013-11-02,GCST002264,Cancer,#fee08b
14500,African,932.0,24185611.0,Cook MB,Prostate cancer,initial,2013-11-02,GCST002264,Cancer,#fc8d59
14501,European,236.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Other disease,#d53e4f
14502,Asian,221.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Other disease,#3288bd
14503,European,236.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Response to drug,#d53e4f
14504,Asian,221.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Response to drug,#3288bd
14505,European,236.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Cardiovascular disease,#d53e4f
14506,Asian,221.0,24236485.0,Cornejo-Garcia JA,Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),initial,2013-11-01,GCST002263,Cardiovascular disease,#3288bd
14507,European,41505.0,24076602.0,Beecham AH,Multiple sclerosis,replication,2013-11-01,GCST005531,Immune system disorder,#d53e4f
14508,European,38582.0,24076602.0,Beecham AH,Multiple sclerosis,initial,2013-11-01,GCST005531,Immune system disorder,#d53e4f
14509,European,4175.0,24097067.0,Lessard CJ,Sjögren's syndrome,initial,2013-11-01,GCST005532,Neurological disorder,#d53e4f
14510,European,4229.0,24097067.0,Lessard CJ,Sjögren's syndrome,replication,2013-11-01,GCST004879,Neurological disorder,#d53e4f
14511,European,2370.0,24097067.0,Lessard CJ,Sjögren's syndrome,initial,2013-11-01,GCST004879,Neurological disorder,#d53e4f
14512,European,2370.0,24097067.0,Lessard CJ,Sjögren's syndrome,initial,2013-11-01,GCST004878,Neurological disorder,#d53e4f
14513,European,6022.0,24097067.0,Lessard CJ,Sjögren's syndrome,replication,2013-11-01,GCST004878,Neurological disorder,#d53e4f
14514,Asian,265.0,24192120.0,Kamide K,Blood pressure (response to antihypertensive medication),initial,2013-11-01,GCST002262,Other measurement,#3288bd
14515,Asian,79.0,24192120.0,Kamide K,Blood pressure (response to antihypertensive medication),replication,2013-11-01,GCST002262,Other measurement,#3288bd
14516,Asian,265.0,24192120.0,Kamide K,Blood pressure (response to antihypertensive medication),initial,2013-11-01,GCST002262,Response to drug,#3288bd
14517,Asian,79.0,24192120.0,Kamide K,Blood pressure (response to antihypertensive medication),replication,2013-11-01,GCST002262,Response to drug,#3288bd
14518,Asian,487.0,24172245.0,Haga S,Tooth agenesis (maxillary third molar),initial,2013-10-31,GCST002257,Digestive system disorder,#3288bd
14519,Asian,487.0,24172245.0,Haga S,Tooth agenesis (third molar),initial,2013-10-31,GCST002256,Digestive system disorder,#3288bd
14520,Asian,1000.0,24204295.0,Han F,Narcolepsy (age of onset),initial,2013-10-31,GCST002261,Neurological disorder,#3288bd
14521,Asian,1000.0,24204295.0,Han F,Narcolepsy (age of onset),initial,2013-10-31,GCST002261,Other measurement,#3288bd
14522,Asian,1266.0,24204295.0,Han F,Narcolepsy (onset before 2009 H1N1 influenza pandemic),initial,2013-10-31,GCST002259,Neurological disorder,#3288bd
14523,Asian,3186.0,24204295.0,Han F,Narcolepsy,initial,2013-10-31,GCST002260,Neurological disorder,#3288bd
14524,European,14188.0,24204295.0,Han F,Narcolepsy,replication,2013-10-31,GCST002260,Neurological disorder,#d53e4f
14525,Asian,487.0,24172245.0,Haga S,Tooth agenesis (mandibular third molar),initial,2013-10-31,GCST002258,Digestive system disorder,#3288bd
14526,European,4443.0,24182552.0,Matteini AM,Inflammatory biomarkers,initial,2013-10-29,GCST002255,Inflammatory measurement,#d53e4f
14527,European,4443.0,24182552.0,Matteini AM,Inflammatory biomarkers,initial,2013-10-29,GCST002255,Inflammatory measurement,#d53e4f
14534,European,820.0,24204828.0,Zheng JS,Homeostasis model assessment of beta-cell function (dietary factor interaction),initial,2013-10-28,GCST002251,Other measurement,#d53e4f
14535,European,820.0,24204828.0,Zheng JS,Homeostasis model assessment of beta-cell function (dietary factor interaction),initial,2013-10-28,GCST002251,Other measurement,#d53e4f
14536,European,820.0,24204828.0,Zheng JS,Homeostasis model assessment of insulin resistance (dietary factor interaction),initial,2013-10-28,GCST002253,Other measurement,#d53e4f
14537,European,820.0,24204828.0,Zheng JS,Homeostasis model assessment of insulin resistance (dietary factor interaction),initial,2013-10-28,GCST002253,Other measurement,#d53e4f
14538,European,820.0,24204828.0,Zheng JS,Fasting insulin (dietary factor interaction),initial,2013-10-28,GCST002248,Other measurement,#d53e4f
14539,European,820.0,24204828.0,Zheng JS,Fasting insulin (dietary factor interaction),initial,2013-10-28,GCST002248,Other measurement,#d53e4f
14540,Asian,1840.0,24165912.0,He J,Blood pressure measurement (high sodium intervention),initial,2013-10-28,GCST002249,Other measurement,#3288bd
14541,Asian,659.0,24165912.0,He J,Blood pressure measurement (high sodium intervention),replication,2013-10-28,GCST002249,Other measurement,#3288bd
14542,Asian,1840.0,24165912.0,He J,Blood pressure measurement (high sodium intervention),initial,2013-10-28,GCST002249,Biological process,#3288bd
14543,Asian,659.0,24165912.0,He J,Blood pressure measurement (high sodium intervention),replication,2013-10-28,GCST002249,Biological process,#3288bd
14544,Asian,660.0,24165912.0,He J,Blood pressure measurement (low sodium intervention),replication,2013-10-28,GCST002250,Other measurement,#3288bd
14545,Asian,1850.0,24165912.0,He J,Blood pressure measurement (low sodium intervention),initial,2013-10-28,GCST002250,Other measurement,#3288bd
14546,Asian,660.0,24165912.0,He J,Blood pressure measurement (low sodium intervention),replication,2013-10-28,GCST002250,Biological process,#3288bd
14547,Asian,1850.0,24165912.0,He J,Blood pressure measurement (low sodium intervention),initial,2013-10-28,GCST002250,Biological process,#3288bd
14548,Asian,1836.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),initial,2013-10-28,GCST002252,Other measurement,#3288bd
14549,Asian,654.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),replication,2013-10-28,GCST002252,Other measurement,#3288bd
14550,Asian,1836.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),initial,2013-10-28,GCST002252,Biological process,#3288bd
14551,Asian,654.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),replication,2013-10-28,GCST002252,Biological process,#3288bd
14552,Asian,1836.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),initial,2013-10-28,GCST002252,Biological process,#3288bd
14553,Asian,654.0,24165912.0,He J,Blood pressure measurement (high sodium and potassium intervention),replication,2013-10-28,GCST002252,Biological process,#3288bd
14554,Asian,1881.0,24165912.0,He J,Blood pressure measurement (cold pressor test),initial,2013-10-28,GCST002247,Other measurement,#3288bd
14555,Asian,698.0,24165912.0,He J,Blood pressure measurement (cold pressor test),replication,2013-10-28,GCST002247,Other measurement,#3288bd
14556,Asian,1881.0,24165912.0,He J,Blood pressure measurement (cold pressor test),initial,2013-10-28,GCST002247,Biological process,#3288bd
14557,Asian,698.0,24165912.0,He J,Blood pressure measurement (cold pressor test),replication,2013-10-28,GCST002247,Biological process,#3288bd
14558,European,55134.0,24162737.0,Lambert JC,Alzheimer's disease (late onset),initial,2013-10-27,GCST002245,Neurological disorder,#d53e4f
14559,European,19884.0,24162737.0,Lambert JC,Alzheimer's disease (late onset),replication,2013-10-27,GCST002245,Neurological disorder,#d53e4f
14560,Asian,9903.0,24162738.0,Hu Z,Hepatitis B,replication,2013-10-27,GCST002246,Digestive system disorder,#3288bd
14561,Asian,1888.0,24162738.0,Hu Z,Hepatitis B,initial,2013-10-27,GCST002246,Digestive system disorder,#3288bd
14562,Asian,1294.0,24513584.0,Oei L,Fractures (vertebral),replication,2013-10-25,GCST002244,Other disease,#3288bd
14563,European,26217.0,24513584.0,Oei L,Fractures (vertebral),replication,2013-10-25,GCST002244,Other disease,#d53e4f
14564,European,2995.0,24513584.0,Oei L,Fractures (vertebral),initial,2013-10-25,GCST002244,Other disease,#d53e4f
14565,European,18729.0,24163127.0,Figueroa JD,Bladder cancer,initial,2013-10-24,GCST002243,Cancer,#d53e4f
14567,European,6206.0,24163127.0,Figueroa JD,Bladder cancer,initial,2013-10-24,GCST002240,Cancer,#d53e4f
14569,European,5110.0,24159190.0,Seppala I,Serum dimethylarginine levels (asymmetric/symetric ratio),initial,2013-10-24,GCST002242,Other measurement,#d53e4f
14570,European,5110.0,24159190.0,Seppala I,Symmetrical dimethylarginine levels,initial,2013-10-24,GCST002239,Other measurement,#d53e4f
14571,European,5110.0,24159190.0,Seppala I,Asymmetrical dimethylarginine levels,initial,2013-10-24,GCST002241,Cardiovascular measurement,#d53e4f
14572,European,5110.0,24159190.0,Seppala I,Asymmetrical dimethylarginine levels,initial,2013-10-24,GCST002241,Other measurement,#d53e4f
14573,European,985.0,24152035.0,Goodbourn PT,Contrast sensitivity,initial,2013-10-23,GCST002238,Other measurement,#d53e4f
14574,European,1071.0,24149102.0,Frampton M,Hodgkin's lymphoma,replication,2013-10-22,GCST002237,Cancer,#d53e4f
14575,European,7882.0,24149102.0,Frampton M,Hodgkin's lymphoma,initial,2013-10-22,GCST002237,Cancer,#d53e4f
14577,Other/Mixed,4344.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),initial,2013-10-20,GCST002236,Cancer,#99d594
14578,European,3647.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),replication,2013-10-20,GCST002236,Cancer,#d53e4f
14579,Hispanic/Latin American,1287.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),initial,2013-10-20,GCST002236,Cancer,#807dba
14580,European,1541.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),initial,2013-10-20,GCST002236,Cancer,#d53e4f
14581,Other/Mixed,171.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),replication,2013-10-20,GCST002236,Cancer,#99d594
14582,Other/Mixed,25.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),replication,2013-10-20,GCST002236,Cancer,#99d594
14583,Hispanic/Latin American,920.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),replication,2013-10-20,GCST002236,Cancer,#807dba
14584,African Am./Caribbean,1228.0,24141364.0,Perez-Andreu V,Acute lymphoblastic leukemia (childhood),replication,2013-10-20,GCST002236,Cancer,#fee08b
14585,African Am./Caribbean,2116.0,24143882.0,Gelernter J,Opioid sensitivity,replication,2013-10-19,GCST002235,Response to drug,#fee08b
14586,European,4496.0,24143882.0,Gelernter J,Opioid sensitivity,replication,2013-10-19,GCST002235,Response to drug,#d53e4f
14587,African Am./Caribbean,3318.0,24143882.0,Gelernter J,Opioid sensitivity,initial,2013-10-19,GCST002235,Response to drug,#fee08b
14588,European,2379.0,24143882.0,Gelernter J,Opioid sensitivity,initial,2013-10-19,GCST002235,Response to drug,#d53e4f
14589,Asian,4741.0,24143190.0,Low SK,Breast cancer,initial,2013-10-15,GCST002234,Cancer,#3288bd
14590,Asian,6280.0,24143190.0,Low SK,Breast cancer,replication,2013-10-15,GCST002234,Cancer,#3288bd
14591,Asian,10250.0,24105470.0,Wu Y,Adiponectin levels,replication,2013-10-14,GCST002233,Other measurement,#3288bd
14592,Asian,7827.0,24105470.0,Wu Y,Adiponectin levels,initial,2013-10-14,GCST002233,Other measurement,#3288bd
14593,European,5442.0,24121790.0,Levine DM,Esophageal adenocarcinoma,initial,2013-10-13,GCST002232,Cancer,#d53e4f
14594,European,7785.0,24121790.0,Levine DM,Esophageal adenocarcinoma,replication,2013-10-13,GCST002232,Cancer,#d53e4f
14595,European,7785.0,24121790.0,Levine DM,Barrett's esophagus,replication,2013-10-13,GCST002230,Digestive system disorder,#d53e4f
14596,European,5442.0,24121790.0,Levine DM,Barrett's esophagus,initial,2013-10-13,GCST002230,Digestive system disorder,#d53e4f
14597,European,8547.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),replication,2013-10-13,GCST002231,Cancer,#d53e4f
14598,European,7135.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),initial,2013-10-13,GCST002231,Cancer,#d53e4f
14599,European,8547.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),replication,2013-10-13,GCST002231,Other disease,#d53e4f
14600,European,7135.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),initial,2013-10-13,GCST002231,Other disease,#d53e4f
14601,European,8547.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),replication,2013-10-13,GCST002231,Digestive system disorder,#d53e4f
14602,European,7135.0,24121790.0,Levine DM,Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined),initial,2013-10-13,GCST002231,Digestive system disorder,#d53e4f
14603,European,1392.0,24114350.0,Zhang M,Acne (severe teenage),replication,2013-10-11,GCST002229,Other disease,#d53e4f
14604,European,928.0,24114350.0,Zhang M,Acne (severe teenage),initial,2013-10-11,GCST002229,Other disease,#d53e4f
14605,European,965.0,24133439.0,Jones RM,Social autistic-like traits,initial,2013-10-11,GCST002228,Other measurement,#d53e4f
14606,Asian,2740.0,24064335.0,Pei YF,Body mass index,replication,2013-10-08,GCST002227,Body measurement,#3288bd
14607,European,4979.0,24064335.0,Pei YF,Body mass index,replication,2013-10-08,GCST002227,Body measurement,#d53e4f
14608,Asian,1624.0,24064335.0,Pei YF,Body mass index,initial,2013-10-08,GCST002227,Body measurement,#3288bd
14609,Hispanic/Latin American,3348.0,24064335.0,Pei YF,Body mass index,initial,2013-10-08,GCST002227,Body measurement,#807dba
14610,African Am./Caribbean,7478.0,24064335.0,Pei YF,Body mass index,initial,2013-10-08,GCST002227,Body measurement,#fee08b
14611,European,8463.0,24064335.0,Pei YF,Body mass index,initial,2013-10-08,GCST002227,Body measurement,#d53e4f
14612,Asian,2740.0,24064335.0,Pei YF,Fat body mass,replication,2013-10-08,GCST002226,Other measurement,#3288bd
14613,European,4967.0,24064335.0,Pei YF,Fat body mass,replication,2013-10-08,GCST002226,Other measurement,#d53e4f
14614,Asian,1622.0,24064335.0,Pei YF,Fat body mass,initial,2013-10-08,GCST002226,Other measurement,#3288bd
14615,Hispanic/Latin American,408.0,24064335.0,Pei YF,Fat body mass,initial,2013-10-08,GCST002226,Other measurement,#807dba
14616,African Am./Caribbean,709.0,24064335.0,Pei YF,Fat body mass,initial,2013-10-08,GCST002226,Other measurement,#fee08b
14617,European,6433.0,24064335.0,Pei YF,Fat body mass,initial,2013-10-08,GCST002226,Other measurement,#d53e4f
14618,Asian,3697.0,24216480.0,Song YQ,Disc degeneration (lumbar),initial,2013-10-08,GCST002225,Other disease,#3288bd
14619,Asian,19097.0,24216480.0,Song YQ,Disc degeneration (lumbar),replication,2013-10-08,GCST002225,Other disease,#3288bd
14620,European,5434.0,24216480.0,Song YQ,Disc degeneration (lumbar),replication,2013-10-08,GCST002225,Other disease,#d53e4f
14621,Other/Mixed,2908.0,24101674.0,Hanson RL,Type 2 diabetes,replication,2013-10-07,GCST002224,Metabolic disorder,#99d594
14622,Other/Mixed,3926.0,24101674.0,Hanson RL,Type 2 diabetes,replication,2013-10-07,GCST002224,Metabolic disorder,#99d594
14623,Other/Mixed,840.0,24101674.0,Hanson RL,Type 2 diabetes,initial,2013-10-07,GCST002224,Metabolic disorder,#99d594
14624,Asian,4030.0,24097066.0,Li Y,Sjögren's syndrome,replication,2013-10-06,GCST002217,Neurological disorder,#3288bd
14625,Asian,1592.0,24097066.0,Li Y,Sjögren's syndrome,initial,2013-10-06,GCST002217,Neurological disorder,#3288bd
14626,European,94595.0,24097068.0,Willer CJ,Triglycerides,initial,2013-10-06,GCST002216,Lipid or lipoprotein measurement,#d53e4f
14627,European,93982.0,24097068.0,Willer CJ,Triglycerides,replication,2013-10-06,GCST002216,Lipid or lipoprotein measurement,#d53e4f
14628,European,94595.0,24097068.0,Willer CJ,"Cholesterol, total",initial,2013-10-06,GCST002221,Lipid or lipoprotein measurement,#d53e4f
14629,European,93982.0,24097068.0,Willer CJ,"Cholesterol, total",replication,2013-10-06,GCST002221,Lipid or lipoprotein measurement,#d53e4f
14630,European,94595.0,24097068.0,Willer CJ,LDL cholesterol,initial,2013-10-06,GCST002222,Lipid or lipoprotein measurement,#d53e4f
14631,European,93982.0,24097068.0,Willer CJ,LDL cholesterol,replication,2013-10-06,GCST002222,Lipid or lipoprotein measurement,#d53e4f
14632,European,93982.0,24097068.0,Willer CJ,HDL cholesterol,replication,2013-10-06,GCST002223,Lipid or lipoprotein measurement,#d53e4f
14633,European,94595.0,24097068.0,Willer CJ,HDL cholesterol,initial,2013-10-06,GCST002223,Lipid or lipoprotein measurement,#d53e4f
14634,European,5472.0,24096698.0,De Vivo I,Endometrial cancer,initial,2013-10-06,GCST002215,Cancer,#d53e4f
14635,European,4270.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002215,Cancer,#d53e4f
14636,African Am./Caribbean,262.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002215,Cancer,#fee08b
14637,Hispanic/Latin American,382.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002215,Cancer,#807dba
14638,Other/Mixed,81.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002215,Cancer,#99d594
14639,Asian,366.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002215,Cancer,#3288bd
14640,European,5472.0,24096698.0,De Vivo I,Endometrial cancer,initial,2013-10-06,GCST002218,Cancer,#d53e4f
14641,European,11369.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002218,Cancer,#d53e4f
14642,African Am./Caribbean,262.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002218,Cancer,#fee08b
14643,Asian,3136.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002218,Cancer,#3288bd
14644,Other/Mixed,81.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002218,Cancer,#99d594
14645,Hispanic/Latin American,382.0,24096698.0,De Vivo I,Endometrial cancer,replication,2013-10-06,GCST002218,Cancer,#807dba
14646,European,94595.0,24097068.0,Willer CJ,Triglycerides,initial,2013-10-06,GCST002219,Lipid or lipoprotein measurement,#d53e4f
14647,Asian,8743.0,24097068.0,Willer CJ,Triglycerides,replication,2013-10-06,GCST002219,Lipid or lipoprotein measurement,#3288bd
14648,European,94595.0,24097068.0,Willer CJ,LDL cholesterol,initial,2013-10-06,GCST002220,Lipid or lipoprotein measurement,#d53e4f
14649,African,4420.0,24097068.0,Willer CJ,LDL cholesterol,replication,2013-10-06,GCST002220,Lipid or lipoprotein measurement,#fc8d59
14650,Asian,8830.0,24094242.0,Li J,Serum alkaline phosphatase levels,replication,2013-10-05,GCST002214,Liver enzyme measurement,#3288bd
14651,Asian,1452.0,24094242.0,Li J,Serum alkaline phosphatase levels,initial,2013-10-05,GCST002214,Liver enzyme measurement,#3288bd
14652,European,1025.0,24098343.0,Polfus LM,Coronary artery calcification (smoking interaction),replication,2013-10-03,GCST002213,Other measurement,#d53e4f
14653,European,915.0,24098343.0,Polfus LM,Coronary artery calcification (smoking interaction),initial,2013-10-03,GCST002213,Other measurement,#d53e4f
14654,European,1025.0,24098343.0,Polfus LM,Coronary artery calcification (smoking interaction),replication,2013-10-03,GCST002213,Other trait,#d53e4f
14655,European,915.0,24098343.0,Polfus LM,Coronary artery calcification (smoking interaction),initial,2013-10-03,GCST002213,Other trait,#d53e4f
14656,European,9211.0,24084763.0,Wang J,Colorectal adenoma (advanced),replication,2013-10-01,GCST002212,Cancer,#d53e4f
14657,European,1406.0,24084763.0,Wang J,Colorectal adenoma (advanced),initial,2013-10-01,GCST002212,Cancer,#d53e4f
14658,Asian,118.0,24159609.0,Choi H,Acute myeloid leukemia,initial,2013-10-01,GCST002210,Cancer,#3288bd
14659,Asian,129.0,24159609.0,Choi H,Acute myeloid leukemia,replication,2013-10-01,GCST002210,Cancer,#3288bd
14660,Asian,929.0,24132900.0,Kanazawa T,Psychosis (atypical),initial,2013-10-01,GCST002211,Neurological disorder,#3288bd
14661,Asian,484.0,24124411.0,Park TJ,Liver enzyme levels (alanine transaminase),initial,2013-09-30,GCST002207,Liver enzyme measurement,#3288bd
14662,Asian,484.0,24124411.0,Park TJ,Liver enzyme levels (aspartate transaminase),initial,2013-09-30,GCST002208,Liver enzyme measurement,#3288bd
14663,Asian,6428.0,24124408.0,Hong KW,Orthostatic hypotension,initial,2013-09-30,GCST002209,Cardiovascular disease,#3288bd
14664,European,2355.0,24065183.0,Armour JA,Handedness,initial,2013-09-25,GCST002205,Other trait,#d53e4f
14665,European,1585.0,24065183.0,Armour JA,Handedness,initial,2013-09-25,GCST002206,Other trait,#d53e4f
14666,Other/Mixed,225.0,24065354.0,Al-Qahtani A,Liver disease in chronic hepatitis B virus infection,replication,2013-09-24,GCST002204,Digestive system disorder,#99d594
14667,Other/Mixed,648.0,24065354.0,Al-Qahtani A,Liver disease in chronic hepatitis B virus infection,initial,2013-09-24,GCST002204,Digestive system disorder,#99d594
14668,Other/Mixed,225.0,24065354.0,Al-Qahtani A,Liver disease in chronic hepatitis B virus infection,replication,2013-09-24,GCST002204,Digestive system disorder,#99d594
14669,Other/Mixed,648.0,24065354.0,Al-Qahtani A,Liver disease in chronic hepatitis B virus infection,initial,2013-09-24,GCST002204,Digestive system disorder,#99d594
14670,Asian,125.0,24086445.0,Wang Q,Gray matter volume (schizophrenia interaction),initial,2013-09-24,GCST002203,Neurological disorder,#3288bd
14671,Asian,125.0,24086445.0,Wang Q,Gray matter volume (schizophrenia interaction),initial,2013-09-24,GCST002203,Other measurement,#3288bd
14672,European,21679.0,24068962.0,O'Seaghdha CM,Calcium levels,replication,2013-09-19,GCST002201,Other measurement,#d53e4f
14673,European,39400.0,24068962.0,O'Seaghdha CM,Calcium levels,initial,2013-09-19,GCST002201,Other measurement,#d53e4f
14674,European,2668.0,24047446.0,Schosser A,Anxiety and major depressive disorder,initial,2013-09-19,GCST002200,Neurological disorder,#d53e4f
14675,European,2668.0,24047446.0,Schosser A,Anxiety and major depressive disorder,initial,2013-09-19,GCST002200,Other trait,#d53e4f
14676,European,1522.0,24047446.0,Schosser A,Anxiety in major depressive disorder,initial,2013-09-19,GCST002202,Neurological disorder,#d53e4f
14677,European,1522.0,24047446.0,Schosser A,Anxiety in major depressive disorder,initial,2013-09-19,GCST002202,Other trait,#d53e4f
14678,Asian,1496.0,24049095.0,Chen Z,Follicule stimulating hormone,replication,2013-09-18,GCST002199,Other measurement,#3288bd
14679,Asian,1999.0,24049095.0,Chen Z,Follicule stimulating hormone,initial,2013-09-18,GCST002199,Other measurement,#3288bd
14680,European,1474.0,24047826.0,Kleber ME,Homoarginine levels,replication,2013-09-18,GCST002196,Other measurement,#d53e4f
14681,European,5143.0,24047826.0,Kleber ME,Homoarginine levels,initial,2013-09-18,GCST002196,Other measurement,#d53e4f
14682,Asian,1496.0,24049095.0,Chen Z,Hormone measurements,replication,2013-09-18,GCST002195,Other measurement,#3288bd
14683,Asian,1999.0,24049095.0,Chen Z,Hormone measurements,initial,2013-09-18,GCST002195,Other measurement,#3288bd
14684,Asian,1496.0,24049095.0,Chen Z,Hormone measurements,replication,2013-09-18,GCST002195,Other measurement,#3288bd
14685,Asian,1999.0,24049095.0,Chen Z,Hormone measurements,initial,2013-09-18,GCST002195,Other measurement,#3288bd
14686,Asian,1496.0,24049095.0,Chen Z,Hormone measurements,replication,2013-09-18,GCST002195,Other measurement,#3288bd
14687,Asian,1999.0,24049095.0,Chen Z,Hormone measurements,initial,2013-09-18,GCST002195,Other measurement,#3288bd
14688,Other/Mixed,733.0,24057671.0,Chimusa ER,Tuberculosis,initial,2013-09-18,GCST002197,Other disease,#99d594
14689,Other/Mixed,733.0,24057671.0,Chimusa ER,Tuberculosis,initial,2013-09-18,GCST002198,Other disease,#99d594
14690,European,1364.0,24047820.0,St Pourcain B,Social communication problems,replication,2013-09-18,GCST002194,Other measurement,#d53e4f
14691,European,5584.0,24047820.0,St Pourcain B,Social communication problems,initial,2013-09-18,GCST002194,Other measurement,#d53e4f
14692,European,7069.0,24046328.0,Bradley DT,Abdominal aortic aneurysm,initial,2013-09-17,GCST002193,Cardiovascular disease,#d53e4f
14694,European,30620.0,24046328.0,Bradley DT,Abdominal aortic aneurysm,replication,2013-09-17,GCST002193,Cardiovascular disease,#d53e4f
14695,Asian,1827.0,24045676.0,Pyun JA,Menopause (age at onset),initial,2013-09-16,GCST002192,Other measurement,#3288bd
14696,Asian,2151.0,24043878.0,Wong EH,Schizophrenia,replication,2013-09-16,GCST002190,Neurological disorder,#3288bd
14697,Asian,2506.0,24043878.0,Wong EH,Schizophrenia,initial,2013-09-16,GCST002190,Neurological disorder,#3288bd
14698,Asian,3437.0,24045676.0,Pyun JA,Menarche (age at onset),initial,2013-09-16,GCST002191,Other measurement,#3288bd
14699,African Am./Caribbean,1617.0,24058526.0,Bhatnagar P,Systolic blood pressure in sickle cell anemia,initial,2013-09-13,GCST002187,Neurological disorder,#fee08b
14700,African Am./Caribbean,1617.0,24058526.0,Bhatnagar P,Systolic blood pressure in sickle cell anemia,initial,2013-09-13,GCST002187,Other measurement,#fee08b
14701,European,2246.0,24039173.0,McGrath LM,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia",initial,2013-09-13,GCST002188,Neurological disorder,#d53e4f
14702,European,2246.0,24039173.0,McGrath LM,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia",initial,2013-09-13,GCST002188,Neurological disorder,#d53e4f
14703,European,2246.0,24039173.0,McGrath LM,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia",initial,2013-09-13,GCST002188,Neurological disorder,#d53e4f
14704,European,2246.0,24039173.0,McGrath LM,"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia",initial,2013-09-13,GCST002188,Other measurement,#d53e4f
14705,Other/Mixed,807.0,24037343.0,Chang ALS,Skin youthfulness,replication,2013-09-13,GCST002189,Biological process,#99d594
14706,Other/Mixed,428.0,24037343.0,Chang ALS,Skin youthfulness,initial,2013-09-13,GCST002189,Biological process,#99d594
14707,European,728.0,24068947.0,Brandler WM,Relative hand skill in reading disability,initial,2013-09-12,GCST002183,Other trait,#d53e4f
14708,European,728.0,24068947.0,Brandler WM,Relative hand skill in reading disability,initial,2013-09-12,GCST002183,Neurological disorder,#d53e4f
14709,European,2235.0,24029427.0,Sandholm N,End-stage renal disease in Type 1 diabetics,initial,2013-09-12,GCST002182,Metabolic disorder,#d53e4f
14711,European,1517.0,24029427.0,Sandholm N,End-stage renal disease in Type 1 diabetics,replication,2013-09-12,GCST002182,Metabolic disorder,#d53e4f
14712,European,2235.0,24029427.0,Sandholm N,End-stage renal disease in Type 1 diabetics,initial,2013-09-12,GCST002182,Other disease,#d53e4f
14714,European,1517.0,24029427.0,Sandholm N,End-stage renal disease in Type 1 diabetics,replication,2013-09-12,GCST002182,Other disease,#d53e4f
14715,European,6219.0,24026423.0,Shameer K,Mean platelet volume,initial,2013-09-12,GCST002184,Hematological measurement,#d53e4f
14716,European,2666.0,24068947.0,Brandler WM,Relative hand skill,initial,2013-09-12,GCST002185,Other trait,#d53e4f
14717,European,13582.0,24026423.0,Shameer K,Platelet count,initial,2013-09-12,GCST002186,Hematological measurement,#d53e4f
14718,Asian,1183.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia),initial,2013-09-11,GCST002181,Other disease,#3288bd
14719,Asian,23.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia),replication,2013-09-11,GCST002181,Other disease,#3288bd
14720,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule),initial,2013-09-11,GCST002177,Other disease,#3288bd
14721,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule),initial,2013-09-11,GCST002177,Response to drug,#3288bd
14722,European,4291.0,24024963.0,Eicher JD,Reading disability and language impairment,initial,2013-09-11,GCST002175,Neurological disorder,#d53e4f
14723,European,440.0,24024963.0,Eicher JD,Reading disability and language impairment,replication,2013-09-11,GCST002175,Neurological disorder,#d53e4f
14724,European,4291.0,24024963.0,Eicher JD,Reading disability and language impairment,initial,2013-09-11,GCST002175,Neurological disorder,#d53e4f
14725,European,440.0,24024963.0,Eicher JD,Reading disability and language impairment,replication,2013-09-11,GCST002175,Neurological disorder,#d53e4f
14726,Asian,104.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel),initial,2013-09-11,GCST002180,Other disease,#3288bd
14727,Asian,104.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel),initial,2013-09-11,GCST002180,Response to drug,#3288bd
14728,Asian,120.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel),initial,2013-09-11,GCST002179,Other disease,#3288bd
14729,Asian,120.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel),initial,2013-09-11,GCST002179,Response to drug,#3288bd
14730,Asian,91.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),initial,2013-09-11,GCST002178,Response to drug,#3288bd
14731,Asian,91.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),initial,2013-09-11,GCST002178,Other disease,#3288bd
14732,Asian,91.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),initial,2013-09-11,GCST002178,Response to drug,#3288bd
14733,Asian,91.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU),initial,2013-09-11,GCST002178,Response to drug,#3288bd
14734,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU),initial,2013-09-11,GCST002176,Response to drug,#3288bd
14735,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU),initial,2013-09-11,GCST002176,Response to drug,#3288bd
14736,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU),initial,2013-09-11,GCST002176,Other disease,#3288bd
14737,Asian,224.0,24025145.0,Chung S,Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU),initial,2013-09-11,GCST002176,Response to drug,#3288bd
14738,Asian,1719.0,24023260.0,Wu Y,Lipid traits,replication,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14739,Asian,1782.0,24023260.0,Wu Y,Lipid traits,initial,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14740,Asian,1719.0,24023260.0,Wu Y,Lipid traits,replication,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14741,Asian,1782.0,24023260.0,Wu Y,Lipid traits,initial,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14742,Asian,1719.0,24023260.0,Wu Y,Lipid traits,replication,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14743,Asian,1782.0,24023260.0,Wu Y,Lipid traits,initial,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14744,Asian,1719.0,24023260.0,Wu Y,Lipid traits,replication,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14745,Asian,1782.0,24023260.0,Wu Y,Lipid traits,initial,2013-09-10,GCST002174,Lipid or lipoprotein measurement,#3288bd
14746,European,5248.0,24023261.0,Keller M,Lipid traits,replication,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14747,European,839.0,24023261.0,Keller M,Lipid traits,initial,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14748,European,5248.0,24023261.0,Keller M,Lipid traits,replication,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14749,European,839.0,24023261.0,Keller M,Lipid traits,initial,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14750,European,5248.0,24023261.0,Keller M,Lipid traits,replication,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14751,European,839.0,24023261.0,Keller M,Lipid traits,initial,2013-09-10,GCST002173,Lipid or lipoprotein measurement,#d53e4f
14752,European,2322.0,24015780.0,Wetherill L,Alcohol dependence,initial,2013-09-09,GCST002172,Neurological disorder,#d53e4f
14753,European,2647.0,24015780.0,Wetherill L,Alcohol dependence,replication,2013-09-09,GCST002172,Neurological disorder,#d53e4f
14754,European,2541.0,24080187.0,Guffanti G,Post-traumatic stress disorder,replication,2013-09-08,GCST002171,Neurological disorder,#d53e4f
14755,Other/Mixed,25.0,24080187.0,Guffanti G,Post-traumatic stress disorder,initial,2013-09-08,GCST002171,Neurological disorder,#99d594
14756,European,45.0,24080187.0,Guffanti G,Post-traumatic stress disorder,initial,2013-09-08,GCST002171,Neurological disorder,#d53e4f
14757,African Am./Caribbean,342.0,24080187.0,Guffanti G,Post-traumatic stress disorder,initial,2013-09-08,GCST002171,Neurological disorder,#fee08b
14758,European,8570.0,24014518.0,Kasperaviciute D,Mesial temporal lobe epilepsy with hippocampal sclerosis,initial,2013-09-06,GCST002170,Neurological disorder,#d53e4f
14759,European,4550.0,24014518.0,Kasperaviciute D,Mesial temporal lobe epilepsy with hippocampal sclerosis,replication,2013-09-06,GCST002170,Neurological disorder,#d53e4f
14760,Asian,10988.0,24023777.0,Miyake A,Adolescent idiopathic scoliosis (severe),replication,2013-09-04,GCST002169,Other disease,#3288bd
14761,Asian,2028.0,24023777.0,Miyake A,Adolescent idiopathic scoliosis (severe),initial,2013-09-04,GCST002169,Other disease,#3288bd
14762,European,6236.0,24002674.0,Ozel AB,Intraocular pressure,initial,2013-09-04,GCST002168,Other measurement,#d53e4f
14764,Asian,28783.0,24001895.0,Kelly TN,Blood pressure,replication,2013-09-03,GCST002167,Other measurement,#3288bd
14765,Asian,4325.0,24001895.0,Kelly TN,Blood pressure,initial,2013-09-03,GCST002167,Other measurement,#3288bd
14766,Asian,22275.0,24001895.0,Kelly TN,Blood pressure,initial,2013-09-03,GCST002167,Other measurement,#3288bd
14767,European,1015.0,24023788.0,Ong BA,Lung function (FEV1),initial,2013-09-02,GCST002165,Other measurement,#d53e4f
14768,African Am./Caribbean,541.0,24023788.0,Ong BA,Lung function (FEV1),initial,2013-09-02,GCST002165,Other measurement,#fee08b
14769,European,1015.0,24023788.0,Ong BA,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity),initial,2013-09-02,GCST002163,Other measurement,#d53e4f
14770,African Am./Caribbean,541.0,24023788.0,Ong BA,Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity),initial,2013-09-02,GCST002163,Other measurement,#fee08b
14771,African Am./Caribbean,541.0,24023788.0,Ong BA,Lung function (FVC),initial,2013-09-02,GCST002162,Other measurement,#fee08b
14772,European,1015.0,24023788.0,Ong BA,Lung function (FVC),initial,2013-09-02,GCST002162,Other measurement,#d53e4f
14773,European,1015.0,24023788.0,Ong BA,Lung function (FEV1/FVC),initial,2013-09-02,GCST002164,Other measurement,#d53e4f
14774,African Am./Caribbean,541.0,24023788.0,Ong BA,Lung function (FEV1/FVC),initial,2013-09-02,GCST002164,Other measurement,#fee08b
14775,European,608.0,23740775.0,Xie G,Wegener's granulomatosis,replication,2013-09-01,GCST002160,Cardiovascular disease,#d53e4f
14776,European,1962.0,23740775.0,Xie G,Wegener's granulomatosis,initial,2013-09-01,GCST002160,Cardiovascular disease,#d53e4f
14777,European,1756.0,23740775.0,Xie G,Wegener's granulomatosis,replication,2013-09-01,GCST002159,Cardiovascular disease,#d53e4f
14778,European,1962.0,23740775.0,Xie G,Wegener's granulomatosis,initial,2013-09-01,GCST002159,Cardiovascular disease,#d53e4f
14781,African Am./Caribbean,91.0,24009623.0,Jiang J,Response to mTOR inhibitor (everolimus),initial,2013-08-30,GCST002157,Response to drug,#fee08b
14782,European,87.0,24009623.0,Jiang J,Response to mTOR inhibitor (everolimus),initial,2013-08-30,GCST002157,Response to drug,#d53e4f
14783,Asian,94.0,24009623.0,Jiang J,Response to mTOR inhibitor (everolimus),initial,2013-08-30,GCST002157,Response to drug,#3288bd
14784,European,6381.0,23996088.0,Migliorini G,Acute lymphoblastic leukemia (B-cell precursor),initial,2013-08-30,GCST002158,Cancer,#d53e4f
14785,European,2937.0,23996088.0,Migliorini G,Acute lymphoblastic leukemia (B-cell precursor),replication,2013-08-30,GCST002158,Cancer,#d53e4f
14786,European,87.0,24009623.0,Jiang J,Response to mTOR inhibitor (rapamycin),initial,2013-08-30,GCST002156,Response to drug,#d53e4f
14787,African Am./Caribbean,91.0,24009623.0,Jiang J,Response to mTOR inhibitor (rapamycin),initial,2013-08-30,GCST002156,Response to drug,#fee08b
14788,Asian,94.0,24009623.0,Jiang J,Response to mTOR inhibitor (rapamycin),initial,2013-08-30,GCST002156,Response to drug,#3288bd
14789,European,27498.0,23989986.0,Evangelou E,Osteoarthritis (hip),replication,2013-08-29,GCST002155,Other disease,#d53e4f
14790,European,51537.0,23989986.0,Evangelou E,Osteoarthritis (hip),initial,2013-08-29,GCST002155,Other disease,#d53e4f
14791,Hispanic/Latin American,529.0,23992748.0,Drake KA,Asthma (bronchodilator response),replication,2013-08-29,GCST002154,Response to drug,#807dba
14792,Hispanic/Latin American,1782.0,23992748.0,Drake KA,Asthma (bronchodilator response),initial,2013-08-29,GCST002154,Response to drug,#807dba
14793,Hispanic/Latin American,529.0,23992748.0,Drake KA,Asthma (bronchodilator response),replication,2013-08-29,GCST002154,Other disease,#807dba
14794,Hispanic/Latin American,1782.0,23992748.0,Drake KA,Asthma (bronchodilator response),initial,2013-08-29,GCST002154,Other disease,#807dba
14795,European,1878.0,23982368.0,Qi L,Cardiovascular heart disease in diabetics,replication,2013-08-28,GCST002153,Other disease,#d53e4f
14796,European,2310.0,23982368.0,Qi L,Cardiovascular heart disease in diabetics,initial,2013-08-28,GCST002153,Other disease,#d53e4f
14797,European,1878.0,23982368.0,Qi L,Cardiovascular heart disease in diabetics,replication,2013-08-28,GCST002153,Metabolic disorder,#d53e4f
14798,European,2310.0,23982368.0,Qi L,Cardiovascular heart disease in diabetics,initial,2013-08-28,GCST002153,Metabolic disorder,#d53e4f
14799,European,4004.0,23984888.0,Himes BE,Airway hyperresponsiveness,replication,2013-08-28,GCST002152,Other trait,#d53e4f
14800,European,994.0,23984888.0,Himes BE,Airway hyperresponsiveness,initial,2013-08-28,GCST002152,Other trait,#d53e4f
14801,European,5902.0,23983088.0,Miller FW,Dermatomyositis,initial,2013-08-27,GCST002151,Neurological disorder,#d53e4f
14804,European,9542.0,23974872.0,Ripke S,Schizophrenia,replication,2013-08-25,GCST002149,Neurological disorder,#d53e4f
14808,European,11244.0,23974872.0,Ripke S,Schizophrenia,initial,2013-08-25,GCST002149,Neurological disorder,#d53e4f
14809,European,577.0,23974705.0,Allen EK,Otitis media (chronic/recurrent),initial,2013-08-23,GCST002148,Neurological disorder,#d53e4f
14810,Other/Mixed,25.0,23974705.0,Allen EK,Otitis media (chronic/recurrent),initial,2013-08-23,GCST002148,Neurological disorder,#99d594
14811,European,1584.0,23974705.0,Allen EK,Otitis media (chronic/recurrent),replication,2013-08-23,GCST002148,Neurological disorder,#d53e4f
14812,African Am./Caribbean,8423.0,23969696.0,Sabater-Lleal M,Fibrinogen,replication,2013-08-22,GCST002147,Hematological measurement,#fee08b
14813,European,91323.0,23969696.0,Sabater-Lleal M,Fibrinogen,initial,2013-08-22,GCST002147,Hematological measurement,#d53e4f
14814,Hispanic/Latin American,1447.0,23969696.0,Sabater-Lleal M,Fibrinogen,replication,2013-08-22,GCST002147,Hematological measurement,#807dba
14815,European,1392.0,23990791.0,Thun GA,Serum alpha1-antitrypsin levels,initial,2013-08-22,GCST002146,Other measurement,#d53e4f
14816,European,12518.0,23990791.0,Thun GA,Serum alpha1-antitrypsin levels,replication,2013-08-22,GCST002146,Other measurement,#d53e4f
14817,European,2546.0,23989729.0,Feenstra B,Infantile hypertrophic pyloric stenosis,replication,2013-08-21,GCST002145,Digestive system disorder,#d53e4f
14818,European,3372.0,23989729.0,Feenstra B,Infantile hypertrophic pyloric stenosis,initial,2013-08-21,GCST002145,Digestive system disorder,#d53e4f
14819,Other/Mixed,1435.0,23989729.0,Feenstra B,Infantile hypertrophic pyloric stenosis,replication,2013-08-21,GCST002145,Digestive system disorder,#99d594
14820,European,2379.0,23958962.0,Gelernter J,Cocaine dependence,initial,2013-08-20,GCST002142,Neurological disorder,#d53e4f
14821,African Am./Caribbean,3318.0,23958962.0,Gelernter J,Cocaine dependence,initial,2013-08-20,GCST002142,Neurological disorder,#fee08b
14822,European,4498.0,23958962.0,Gelernter J,Cocaine dependence,replication,2013-08-20,GCST002142,Neurological disorder,#d53e4f
14823,African Am./Caribbean,2114.0,23958962.0,Gelernter J,Cocaine dependence,replication,2013-08-20,GCST002142,Neurological disorder,#fee08b
14824,African Am./Caribbean,28190.0,23972371.0,Franceschini N,Blood pressure,initial,2013-08-20,GCST002143,Other measurement,#fee08b
14825,African Am./Caribbean,5266.0,23972371.0,Franceschini N,Blood pressure,replication,2013-08-20,GCST002143,Other measurement,#fee08b
14826,Asian,19601.0,23972371.0,Franceschini N,Blood pressure,replication,2013-08-20,GCST002143,Other measurement,#3288bd
14827,African,1188.0,23972371.0,Franceschini N,Blood pressure,initial,2013-08-20,GCST002143,Other measurement,#fc8d59
14828,African,5108.0,23972371.0,Franceschini N,Blood pressure,replication,2013-08-20,GCST002143,Other measurement,#fc8d59
14829,African,1389.0,23972371.0,Franceschini N,Blood pressure,replication,2013-08-20,GCST002143,Other measurement,#fc8d59
14830,European,69395.0,23972371.0,Franceschini N,Blood pressure,replication,2013-08-20,GCST002143,Other measurement,#d53e4f
14831,Hispanic/Latin American,503.0,23966204.0,Ledda M,Bitter taste perception,initial,2013-08-20,GCST002144,Biological process,#807dba
14832,Hispanic/Latin American,104.0,23966204.0,Ledda M,Bitter taste perception,replication,2013-08-20,GCST002144,Biological process,#807dba
14835,European,6041.0,23955597.0,Chubb D,Multiple myeloma,replication,2013-08-18,GCST002140,Cancer,#d53e4f
14836,European,9641.0,23955597.0,Chubb D,Multiple myeloma,initial,2013-08-18,GCST002140,Cancer,#d53e4f
14839,European,301.0,23956247.0,Knevel R,Joint damage progression in ACPA-positive rheumatoid arthritis,replication,2013-08-16,GCST002139,Immune system disorder,#d53e4f
14842,European,301.0,23956247.0,Knevel R,Joint damage progression in ACPA-positive rheumatoid arthritis,replication,2013-08-16,GCST002139,Other measurement,#d53e4f
14843,African Am./Caribbean,10027.0,23966867.0,Liu CT,Waist circumference,replication,2013-08-15,GCST002137,Body measurement,#fee08b
14844,African Am./Caribbean,23564.0,23966867.0,Liu CT,Waist circumference,initial,2013-08-15,GCST002137,Body measurement,#fee08b
14845,African Am./Caribbean,7606.0,23966867.0,Liu CT,Waist-hip ratio,replication,2013-08-15,GCST002138,Body measurement,#fee08b
14846,African Am./Caribbean,19744.0,23966867.0,Liu CT,Waist-hip ratio,initial,2013-08-15,GCST002138,Body measurement,#fee08b
14847,European,2501.0,24024966.0,Teumer A,Periodontitis (DPAL),initial,2013-08-14,GCST002129,Digestive system disorder,#d53e4f
14848,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Biological process,#d53e4f
14849,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Other measurement,#d53e4f
14850,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Biological process,#d53e4f
14851,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Biological process,#d53e4f
14852,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Biological process,#d53e4f
14853,European,7188.0,23942779.0,McGue M,Behavioural disinhibition (generation interaction),initial,2013-08-14,GCST002131,Neurological disorder,#d53e4f
14854,European,7188.0,23942779.0,McGue M,Non-substance related behavioral disinhibition,initial,2013-08-14,GCST002132,Biological process,#d53e4f
14855,European,7188.0,23942779.0,McGue M,Illicit drug use,initial,2013-08-14,GCST002133,Biological process,#d53e4f
14856,European,7188.0,23942779.0,McGue M,Alcohol dependence,initial,2013-08-14,GCST002134,Neurological disorder,#d53e4f
14857,European,7188.0,23942779.0,McGue M,Alcohol consumption,initial,2013-08-14,GCST002130,Biological process,#d53e4f
14858,European,3915.0,24024966.0,Teumer A,Periodontitis (CDC/AAP),initial,2013-08-14,GCST002126,Digestive system disorder,#d53e4f
14859,European,4032.0,24024966.0,Teumer A,Periodontitis (Mean PAL),initial,2013-08-14,GCST002127,Digestive system disorder,#d53e4f
14860,European,7188.0,23942779.0,McGue M,Nicotine use,initial,2013-08-14,GCST002135,Biological process,#d53e4f
14861,European,2969.0,24024966.0,Teumer A,Periodontitis (PAL4Q3),initial,2013-08-14,GCST002136,Digestive system disorder,#d53e4f
14862,Asian,26805.0,23945395.0,Hara K,Type 2 diabetes,initial,2013-08-14,GCST002128,Metabolic disorder,#3288bd
14863,Asian,38401.0,23945395.0,Hara K,Type 2 diabetes,replication,2013-08-14,GCST002128,Metabolic disorder,#3288bd
14864,Other/Mixed,315.0,23937595.0,Al Safar HS,Type 2 diabetes,replication,2013-08-13,GCST002123,Metabolic disorder,#99d594
14865,Other/Mixed,178.0,23937595.0,Al Safar HS,Type 2 diabetes,initial,2013-08-13,GCST002123,Metabolic disorder,#99d594
14866,European,3137.0,23953852.0,Pan Y,Alcohol consumption,replication,2013-08-13,GCST002121,Biological process,#d53e4f
14867,European,2687.0,23953852.0,Pan Y,Alcohol consumption,initial,2013-08-13,GCST002121,Biological process,#d53e4f
14868,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics (D.f. specific),initial,2013-08-13,GCST002125,Other measurement,#3288bd
14869,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics (D.f. specific),initial,2013-08-13,GCST002125,Other disease,#3288bd
14870,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics (D.p. specific),initial,2013-08-13,GCST002124,Other measurement,#3288bd
14871,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics (D.p. specific),initial,2013-08-13,GCST002124,Other disease,#3288bd
14872,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics,initial,2013-08-13,GCST002122,Other measurement,#3288bd
14873,Asian,877.0,23967269.0,Kim JH,IgE levels in asthmatics,initial,2013-08-13,GCST002122,Other disease,#3288bd
14874,African Am./Caribbean,1260.0,23934736.0,Yu B,Metabolite levels (Dihydroxy docosatrienoic acid),initial,2013-08-11,GCST002120,Other measurement,#fee08b
14875,African Am./Caribbean,1260.0,23934736.0,Yu B,Metabolite levels  (X-11787),initial,2013-08-11,GCST002119,Other measurement,#fee08b
14876,African Am./Caribbean,1260.0,23934736.0,Yu B,Metabolite levels (Pyroglutamine),initial,2013-08-11,GCST002118,Other measurement,#fee08b
14877,Asian,4800.0,23933737.0,Khor CC,Myopia (severe),replication,2013-08-09,GCST002117,Other trait,#3288bd
14878,Asian,5030.0,23933737.0,Khor CC,Myopia (severe),initial,2013-08-09,GCST002117,Other trait,#3288bd
14879,Asian,8216.0,24144296.0,Cheng CY,Axial length,replication,2013-08-08,GCST002115,Other measurement,#3288bd
14880,European,12531.0,24144296.0,Cheng CY,Axial length,initial,2013-08-08,GCST002115,Other measurement,#d53e4f
14881,European,3802.0,23929743.0,Yadav S,Blood pressure variability,initial,2013-08-08,GCST002116,Other measurement,#d53e4f
14882,European,3900.0,23929743.0,Yadav S,Blood pressure variability,replication,2013-08-08,GCST002116,Other measurement,#d53e4f
14883,European,668.0,23918034.0,Kuhnisch J,Molar-incisor hypomineralization,initial,2013-08-07,GCST002114,Other disease,#d53e4f
14884,European,1144.0,23932459.0,Yao TC,Pulmonary function,initial,2013-08-06,GCST002113,Other measurement,#d53e4f
14885,European,1144.0,23932459.0,Yao TC,Pulmonary function,initial,2013-08-06,GCST002113,Other measurement,#d53e4f
14886,European,1144.0,23932459.0,Yao TC,Pulmonary function,initial,2013-08-06,GCST002113,Other measurement,#d53e4f
14887,European,1144.0,23932459.0,Yao TC,Pulmonary function,initial,2013-08-06,GCST002113,Other measurement,#d53e4f
14888,European,618.0,23936387.0,Ostensson M,Celiac disease,initial,2013-08-02,GCST002112,Immune system disorder,#d53e4f
14889,Asian,2090.0,23903073.0,Kim HN,Personality dimensions,replication,2013-08-01,GCST002111,Other trait,#3288bd
14890,Asian,1089.0,23903073.0,Kim HN,Personality dimensions,initial,2013-08-01,GCST002111,Other trait,#3288bd
14891,European,187.0,23910658.0,McRae JF,Odorant perception (isobutyraldehyde),initial,2013-07-31,GCST002105,Biological process,#d53e4f
14892,Asian,109.0,23910658.0,McRae JF,Odorant perception (isobutyraldehyde),replication,2013-07-31,GCST002105,Biological process,#3288bd
14893,Asian,76.0,23921680.0,Kim DS,Allergic dermatitis (nickel),initial,2013-07-31,GCST002108,Immune system disorder,#3288bd
14894,European,187.0,23910658.0,McRae JF,Odorant perception (&beta;-ionone),initial,2013-07-31,GCST002107,Biological process,#d53e4f
14895,Asian,109.0,23910658.0,McRae JF,Odorant perception (&beta;-ionone),replication,2013-07-31,GCST002107,Biological process,#3288bd
14896,European,187.0,23910658.0,McRae JF,Odorant perception (&beta;-damascenone),initial,2013-07-31,GCST002106,Biological process,#d53e4f
14897,European,89.0,23910658.0,McRae JF,Odorant perception (&beta;-damascenone),replication,2013-07-31,GCST002106,Biological process,#d53e4f
14898,European,1664.0,23935956.0,Pistis G,Red blood cell traits,initial,2013-07-31,GCST002109,Hematological measurement,#d53e4f
14899,European,16764.0,23935956.0,Pistis G,Red blood cell traits,replication,2013-07-31,GCST002109,Hematological measurement,#d53e4f
14900,European,1664.0,23935956.0,Pistis G,Red blood cell traits,initial,2013-07-31,GCST002109,Hematological measurement,#d53e4f
14901,European,16764.0,23935956.0,Pistis G,Red blood cell traits,replication,2013-07-31,GCST002109,Hematological measurement,#d53e4f
14902,European,1367.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#d53e4f
14903,Hispanic/Latin American,817.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#807dba
14904,African Am./Caribbean,1075.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#fee08b
14905,Asian,1178.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#3288bd
14906,European,3026.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),replication,2013-07-31,GCST002110,Other measurement,#d53e4f
14907,European,1367.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#d53e4f
14908,Hispanic/Latin American,817.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#807dba
14909,African Am./Caribbean,1075.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#fee08b
14910,Asian,1178.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#3288bd
14911,European,3026.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),replication,2013-07-31,GCST002110,Other measurement,#d53e4f
14912,European,1367.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#d53e4f
14913,Hispanic/Latin American,817.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#807dba
14914,African Am./Caribbean,1075.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#fee08b
14915,Asian,1178.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),initial,2013-07-31,GCST002110,Other measurement,#3288bd
14916,European,3026.0,23903356.0,Hayes MG,Glycemic traits (pregnancy),replication,2013-07-31,GCST002110,Other measurement,#d53e4f
14917,European,2240.0,23900074.0,Pooley KA,Telomere length,initial,2013-07-29,GCST002103,Other measurement,#d53e4f
14919,European,390.0,23897914.0,Wang H,Bronchopulmonary dysplasia,initial,2013-07-29,GCST002104,Other disease,#d53e4f
14920,Other/Mixed,36.0,23897914.0,Wang H,Bronchopulmonary dysplasia,initial,2013-07-29,GCST002104,Other disease,#99d594
14921,Other/Mixed,167.0,23897914.0,Wang H,Bronchopulmonary dysplasia,initial,2013-07-29,GCST002104,Other disease,#99d594
14922,Hispanic/Latin American,908.0,23897914.0,Wang H,Bronchopulmonary dysplasia,initial,2013-07-29,GCST002104,Other disease,#807dba
14923,Other/Mixed,795.0,23897914.0,Wang H,Bronchopulmonary dysplasia,replication,2013-07-29,GCST002104,Other disease,#99d594
14924,African Am./Caribbean,225.0,23897914.0,Wang H,Bronchopulmonary dysplasia,initial,2013-07-29,GCST002104,Other disease,#fee08b
14925,European,1187.0,23894154.0,Kohler A,Thyroid cancer,initial,2013-07-26,GCST002102,Cancer,#d53e4f
14926,European,6685.0,23894154.0,Kohler A,Thyroid cancer,replication,2013-07-26,GCST002102,Cancer,#d53e4f
14927,European,13581.0,23935489.0,McLaren PJ,HIV-1 susceptibility,initial,2013-07-25,GCST002101,Other disease,#d53e4f
14928,European,5446.0,23886662.0,Weidinger S,Atopic dermatitis,replication,2013-07-25,GCST002100,Immune system disorder,#d53e4f
14929,European,5617.0,23886662.0,Weidinger S,Atopic dermatitis,initial,2013-07-25,GCST002100,Immune system disorder,#d53e4f
14930,Asian,379.0,23875689.0,Hong SN,Colorectal cancer,replication,2013-07-22,GCST002099,Cancer,#3288bd
14931,Asian,105.0,23875689.0,Hong SN,Colorectal cancer,initial,2013-07-22,GCST002099,Cancer,#3288bd
14932,Asian,1224.0,23872634.0,Bezzina CR,Brugada syndrome,replication,2013-07-21,GCST002098,Cardiovascular disease,#3288bd
14933,European,1400.0,23872634.0,Bezzina CR,Brugada syndrome,replication,2013-07-21,GCST002098,Cardiovascular disease,#d53e4f
14934,European,1427.0,23872634.0,Bezzina CR,Brugada syndrome,initial,2013-07-21,GCST002098,Cardiovascular disease,#d53e4f
14935,European,9992.0,23870195.0,Wojczynski MK,Coronary artery calcification,replication,2013-07-19,GCST002097,Other trait,#d53e4f
14936,African Am./Caribbean,5823.0,23870195.0,Wojczynski MK,Coronary artery calcification,initial,2013-07-19,GCST002097,Other trait,#fee08b
14938,European,4835.0,23871474.0,Psychosis Endophenotypes International Consortium,Psychosis,initial,2013-07-17,GCST002096,Neurological disorder,#d53e4f
14939,European,1610.0,23857890.0,Power RA,Major depressive disorder,initial,2013-07-15,GCST002095,Neurological disorder,#d53e4f
14940,Asian,1265.0,23850713.0,Yang SK,Crohn's disease,initial,2013-07-14,GCST002094,Digestive system disorder,#3288bd
14941,Asian,3488.0,23850713.0,Yang SK,Crohn's disease,replication,2013-07-14,GCST002094,Digestive system disorder,#3288bd
14942,European,8824.0,23853074.0,Meder B,Idiopathic dilated cardiomyopathy,replication,2013-07-12,GCST002093,Cardiovascular disease,#d53e4f
14943,European,3029.0,23853074.0,Meder B,Idiopathic dilated cardiomyopathy,initial,2013-07-12,GCST002093,Cardiovascular disease,#d53e4f
14944,European,2930.0,23874384.0,Viding E,Callous-unemotional behaviour,initial,2013-07-09,GCST002092,Biological process,#d53e4f
14947,Other/Mixed,76.0,23838604.0,Pare G,Angioedema in response to angiotensin-converting enzyme inhibitor,replication,2013-07-08,GCST002091,Response to drug,#99d594
14948,Other/Mixed,664.0,23838604.0,Pare G,Angioedema in response to angiotensin-converting enzyme inhibitor,initial,2013-07-08,GCST002091,Response to drug,#99d594
14949,Other/Mixed,76.0,23838604.0,Pare G,Angioedema in response to angiotensin-converting enzyme inhibitor,replication,2013-07-08,GCST002091,Cardiovascular disease,#99d594
14950,Other/Mixed,664.0,23838604.0,Pare G,Angioedema in response to angiotensin-converting enzyme inhibitor,initial,2013-07-08,GCST002091,Cardiovascular disease,#99d594
14951,European,4866.0,23836780.0,Blue Mountains Eye Study (BMES),Intraocular pressure,replication,2013-07-07,GCST002089,Other measurement,#d53e4f
14952,European,2175.0,23836780.0,Blue Mountains Eye Study (BMES),Intraocular pressure,initial,2013-07-07,GCST002089,Other measurement,#d53e4f
14953,European,1287.0,23829686.0,Ding L,Asthma (childhood onset),initial,2013-07-05,GCST002088,Other disease,#d53e4f
14954,Hispanic/Latin American,138.0,23829686.0,Ding L,Asthma (childhood onset),replication,2013-07-05,GCST002088,Other disease,#807dba
14955,African Am./Caribbean,156.0,23829686.0,Ding L,Asthma (childhood onset),replication,2013-07-05,GCST002088,Other disease,#fee08b
14956,European,44147.0,23824729.0,van Meurs JB,Homocysteine levels,initial,2013-07-03,GCST002087,Cardiovascular measurement,#d53e4f
14957,European,659.0,23830517.0,Saruhan-Direskeneli G,Takayasu arteritis,initial,2013-07-03,GCST006863,Cardiovascular disease,#d53e4f
14958,Other/Mixed,788.0,23830517.0,Saruhan-Direskeneli G,Takayasu arteritis,initial,2013-07-03,GCST006863,Cardiovascular disease,#99d594
14959,Asian,2275.0,23844046.0,Dorajoo R,C-reactive protein,initial,2013-07-02,GCST002086,Inflammatory measurement,#3288bd
14960,Asian,2238.0,23844046.0,Dorajoo R,C-reactive protein,initial,2013-07-02,GCST002086,Inflammatory measurement,#3288bd
14961,Asian,2179.0,23844046.0,Dorajoo R,C-reactive protein,initial,2013-07-02,GCST002086,Inflammatory measurement,#3288bd
14962,European,2475.0,23827383.0,Cadby G,Malignant mesothelioma,initial,2013-07-01,GCST002085,Cancer,#d53e4f
14963,European,759.0,23827383.0,Cadby G,Malignant mesothelioma,replication,2013-07-01,GCST002085,Cancer,#d53e4f
14964,European,22647.0,23749187.0,Cortes A,Ankylosing spondylitis (SNP x SNP interaction),initial,2013-07-01,GCST005530,Immune system disorder,#d53e4f
14965,Asian,3117.0,23749187.0,Cortes A,Ankylosing spondylitis,initial,2013-07-01,GCST005529,Immune system disorder,#3288bd
14966,European,22647.0,23749187.0,Cortes A,Ankylosing spondylitis,initial,2013-07-01,GCST005529,Immune system disorder,#d53e4f
14967,European,53862.0,23817569.0,Hinds DA,Self-reported allergy,initial,2013-06-30,GCST002083,Immune system disorder,#d53e4f
14968,European,16034.0,23817571.0,Bonnelykke K,Allergic sensitization,replication,2013-06-30,GCST002084,Other measurement,#d53e4f
14969,European,15845.0,23817571.0,Bonnelykke K,Allergic sensitization,initial,2013-06-30,GCST002084,Other measurement,#d53e4f
14970,Asian,11363.0,23817570.0,Shi Y,Cervical cancer,replication,2013-06-30,GCST002082,Cancer,#3288bd
14971,Asian,4392.0,23817570.0,Shi Y,Cervical cancer,initial,2013-06-30,GCST002082,Cancer,#3288bd
14972,European,76534.0,23793025.0,Anttila V,Migraine without aura,initial,2013-06-23,GCST002078,Cardiovascular disease,#d53e4f
14973,European,19147.0,23793025.0,Anttila V,Migraine - clinic-based,initial,2013-06-23,GCST002079,Cardiovascular disease,#d53e4f
14974,European,118710.0,23793025.0,Anttila V,Migraine,initial,2013-06-23,GCST002081,Cardiovascular disease,#d53e4f
14975,European,79357.0,23793025.0,Anttila V,Migraine with aura,initial,2013-06-23,GCST002080,Cardiovascular disease,#d53e4f
14976,European,9458.0,23805179.0,Hass J,Hippocampal volume in schizophrenia,replication,2013-06-21,GCST002076,Neurological disorder,#d53e4f
14977,European,170.0,23805179.0,Hass J,Hippocampal volume in schizophrenia,initial,2013-06-21,GCST002076,Neurological disorder,#d53e4f
14979,European,9458.0,23805179.0,Hass J,Hippocampal volume in schizophrenia,replication,2013-06-21,GCST002076,Other measurement,#d53e4f
14980,European,170.0,23805179.0,Hass J,Hippocampal volume in schizophrenia,initial,2013-06-21,GCST002076,Other measurement,#d53e4f
14982,European,798.0,23793441.0,Davis MF,Parkinson's disease,initial,2013-06-21,GCST002077,Neurological disorder,#d53e4f
14983,European,586.0,23823136.0,Larsen MH,Lipopolysaccharide induced cytokine levels,replication,2013-06-18,GCST002075,Other measurement,#d53e4f
14984,European,130.0,23823136.0,Larsen MH,Lipopolysaccharide induced cytokine levels,initial,2013-06-18,GCST002075,Other measurement,#d53e4f
14985,European,143.0,23776197.0,Leandro-Garcia LJ,Paclitaxel-induced neuropathy,initial,2013-06-17,GCST002074,Other measurement,#d53e4f
14986,European,143.0,23776197.0,Leandro-Garcia LJ,Paclitaxel-induced neuropathy,initial,2013-06-17,GCST002074,Response to drug,#d53e4f
14987,European,8027.0,23770605.0,Berndt SI,Chronic lymphocytic leukemia,replication,2013-06-16,GCST002073,Cancer,#d53e4f
14988,European,8400.0,23770605.0,Berndt SI,Chronic lymphocytic leukemia,initial,2013-06-16,GCST002073,Cancer,#d53e4f
14989,European,1884.0,23785401.0,Leone MA,Multiple sclerosis (OCB status),replication,2013-06-13,GCST002072,Immune system disorder,#d53e4f
14990,European,562.0,23785401.0,Leone MA,Multiple sclerosis (OCB status),initial,2013-06-13,GCST002072,Immune system disorder,#d53e4f
14991,European,3939.0,23776548.0,Sim X,Retinal arteriolar caliber,replication,2013-06-12,GCST002071,Other measurement,#d53e4f
14992,European,18722.0,23776548.0,Sim X,Retinal arteriolar caliber,initial,2013-06-12,GCST002071,Other measurement,#d53e4f
14993,European,5294.0,23752247.0,Loukola A,Smoking behavior,replication,2013-06-11,GCST002070,Biological process,#d53e4f
14994,European,1114.0,23752247.0,Loukola A,Smoking behavior,initial,2013-06-11,GCST002070,Biological process,#d53e4f
14995,Asian,1400.0,23760081.0,Kim YJ,Chronic hepatitis B infection,initial,2013-06-10,GCST002068,Digestive system disorder,#3288bd
14996,Asian,2909.0,23760081.0,Kim YJ,Chronic hepatitis B infection,replication,2013-06-10,GCST002068,Digestive system disorder,#3288bd
14997,European,10911.0,23740937.0,Martin JE,Systemic lupus erythematosus and Systemic sclerosis,initial,2013-06-10,GCST002069,Neurological disorder,#d53e4f
14998,European,10198.0,23740937.0,Martin JE,Systemic lupus erythematosus and Systemic sclerosis,replication,2013-06-10,GCST002069,Neurological disorder,#d53e4f
14999,European,10911.0,23740937.0,Martin JE,Systemic lupus erythematosus and Systemic sclerosis,initial,2013-06-10,GCST002069,Immune system disorder,#d53e4f
15000,European,10198.0,23740937.0,Martin JE,Systemic lupus erythematosus and Systemic sclerosis,replication,2013-06-10,GCST002069,Immune system disorder,#d53e4f
15001,European,424.0,23753411.0,Turner ST,Response to diuretic therapy in hypertension,initial,2013-06-10,GCST002067,Response to drug,#d53e4f
15002,European,841.0,23753411.0,Turner ST,Response to diuretic therapy in hypertension,replication,2013-06-10,GCST002067,Response to drug,#d53e4f
15003,Asian,6667.0,23749188.0,Tan DE,B cell non-Hodgkin lymphoma,replication,2013-06-09,GCST002066,Cancer,#3288bd
15004,Asian,1691.0,23749188.0,Tan DE,B cell non-Hodgkin lymphoma,initial,2013-06-09,GCST002066,Cancer,#3288bd
15005,European,4915.0,23743675.0,Kapoor M,Alcohol consumption,initial,2013-06-07,GCST002065,Biological process,#d53e4f
15006,European,133723.0,23754948.0,Randall JC,Sexual dimorphism in anthropometric traits,initial,2013-06-06,GCST002063,Other measurement,#d53e4f
15007,European,137052.0,23754948.0,Randall JC,Sexual dimorphism in anthropometric traits,replication,2013-06-06,GCST002063,Other measurement,#d53e4f
15008,European,133723.0,23754948.0,Randall JC,Sexual dimorphism in anthropometric traits,initial,2013-06-06,GCST002063,Other trait,#d53e4f
15009,European,137052.0,23754948.0,Randall JC,Sexual dimorphism in anthropometric traits,replication,2013-06-06,GCST002063,Other trait,#d53e4f
15010,European,2784.0,23761726.0,Yazar S,Corneal astigmatism,initial,2013-06-06,GCST002064,Other trait,#d53e4f
15011,African Am./Caribbean,533.0,23755828.0,Perera MA,Warfarin maintenance dose,initial,2013-06-05,GCST002061,Response to drug,#fee08b
15012,African Am./Caribbean,432.0,23755828.0,Perera MA,Warfarin maintenance dose,replication,2013-06-05,GCST002061,Response to drug,#fee08b
15013,European,6649.0,23738518.0,Luciano M,Non-word repetition,initial,2013-06-05,GCST002059,Biological process,#d53e4f
15014,European,6649.0,23738518.0,Luciano M,Reading and spelling,initial,2013-06-05,GCST002062,Biological process,#d53e4f
15015,European,6649.0,23738518.0,Luciano M,Word reading,initial,2013-06-05,GCST002060,Biological process,#d53e4f
15016,European,1024.0,23725790.0,Renteria ME,DNA methylation (parent-of-origin),initial,2013-06-03,GCST002057,Biological process,#d53e4f
15017,European,384.0,23725790.0,Renteria ME,DNA methylation (variation),replication,2013-06-03,GCST002058,Biological process,#d53e4f
15018,European,256.0,23725790.0,Renteria ME,DNA methylation (variation),initial,2013-06-03,GCST002058,Biological process,#d53e4f
15019,European,797.0,23727862.0,Savage SA,Osteosarcoma,replication,2013-06-02,GCST002056,Cancer,#d53e4f
15020,European,3397.0,23727862.0,Savage SA,Osteosarcoma,initial,2013-06-02,GCST002056,Cancer,#d53e4f
15022,Asian,489.0,23732972.0,Hashimoto R,Cognitive decline,initial,2013-06-01,GCST002055,Other trait,#3288bd
15023,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Immune system disorder,#d53e4f
15024,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Metabolic disorder,#d53e4f
15025,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Immune system disorder,#d53e4f
15026,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Other disease,#d53e4f
15027,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Immune system disorder,#d53e4f
15028,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Immune system disorder,#d53e4f
15029,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Digestive system disorder,#d53e4f
15030,European,143849.0,23603763.0,Liu JZ,"Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)",initial,2013-06-01,GCST005563,Digestive system disorder,#d53e4f
15031,European,28868.0,23603763.0,Liu JZ,Primary sclerosing cholangitis,initial,2013-06-01,GCST006670,Digestive system disorder,#d53e4f
15032,Asian,2003.0,23728934.0,Yang L,Attention deficit hyperactivity disorder,initial,2013-05-31,GCST002048,Neurological disorder,#3288bd
15033,European,2001.0,23728906.0,Byrne EM,Sleep latency,replication,2013-05-31,GCST002051,Other measurement,#d53e4f
15034,European,2280.0,23728906.0,Byrne EM,Sleep latency,initial,2013-05-31,GCST002051,Other measurement,#d53e4f
15035,European,2267.0,23728906.0,Byrne EM,Insomnia,initial,2013-05-31,GCST002052,Other measurement,#d53e4f
15036,European,2278.0,23728906.0,Byrne EM,Sleep duration,initial,2013-05-31,GCST002053,Other measurement,#d53e4f
15037,European,2314.0,23728906.0,Byrne EM,Sleep depth,initial,2013-05-31,GCST002054,Other measurement,#d53e4f
15038,European,2315.0,23728906.0,Byrne EM,Sleep quality,initial,2013-05-31,GCST002049,Other measurement,#d53e4f
15039,European,2322.0,23728906.0,Byrne EM,Sleep time,initial,2013-05-31,GCST002050,Other measurement,#d53e4f
15040,European,101069.0,23722424.0,Rietveld CA,Educational attainment,initial,2013-05-30,GCST002045,Other measurement,#d53e4f
15041,European,25490.0,23722424.0,Rietveld CA,Educational attainment,replication,2013-05-30,GCST002045,Other measurement,#d53e4f
15042,European,126559.0,23722424.0,Rietveld CA,Educational attainment (years of education),initial,2013-05-30,GCST008396,Other measurement,#d53e4f
15043,European,126559.0,23722424.0,Rietveld CA,Educational attainment (college completion),initial,2013-05-30,GCST002047,Other measurement,#d53e4f
15044,European,774.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),initial,2013-05-30,GCST002046,Response to drug,#d53e4f
15045,African Am./Caribbean,145.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),initial,2013-05-30,GCST002046,Response to drug,#fee08b
15046,Asian,16.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),initial,2013-05-30,GCST002046,Response to drug,#3288bd
15047,Other/Mixed,39.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),initial,2013-05-30,GCST002046,Response to drug,#99d594
15048,European,585.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),replication,2013-05-30,GCST002046,Response to drug,#d53e4f
15050,Hispanic/Latin American,126.0,23726668.0,Hunter AM,Response to antidepressant treatment (citalopram),initial,2013-05-30,GCST002046,Response to drug,#807dba
15051,European,5477.0,23720494.0,Evans DM,Blood trace element (Se levels),initial,2013-05-29,GCST002039,Other measurement,#d53e4f
15052,African Am./Caribbean,7917.0,23726366.0,Coram MA,HDL cholesterol,initial,2013-05-29,GCST002043,Lipid or lipoprotein measurement,#fee08b
15053,Hispanic/Latin American,3506.0,23726366.0,Coram MA,HDL cholesterol,initial,2013-05-29,GCST002043,Lipid or lipoprotein measurement,#807dba
15054,African Am./Caribbean,7138.0,23726366.0,Coram MA,HDL cholesterol,replication,2013-05-29,GCST002043,Lipid or lipoprotein measurement,#fee08b
15055,African Am./Caribbean,7601.0,23726366.0,Coram MA,Triglycerides,initial,2013-05-29,GCST002044,Lipid or lipoprotein measurement,#fee08b
15056,African Am./Caribbean,7138.0,23726366.0,Coram MA,Triglycerides,replication,2013-05-29,GCST002044,Lipid or lipoprotein measurement,#fee08b
15057,Hispanic/Latin American,3335.0,23726366.0,Coram MA,Triglycerides,initial,2013-05-29,GCST002044,Lipid or lipoprotein measurement,#807dba
15058,European,2603.0,23720494.0,Evans DM,Blood trace element (Zn levels),initial,2013-05-29,GCST002040,Other measurement,#d53e4f
15059,European,2603.0,23720494.0,Evans DM,Blood trace element (Cu levels),initial,2013-05-29,GCST002041,Other measurement,#d53e4f
15060,African Am./Caribbean,7138.0,23726366.0,Coram MA,LDL cholesterol,replication,2013-05-29,GCST002042,Other measurement,#fee08b
15061,African Am./Caribbean,7861.0,23726366.0,Coram MA,LDL cholesterol,initial,2013-05-29,GCST002042,Other measurement,#fee08b
15062,Hispanic/Latin American,3425.0,23726366.0,Coram MA,LDL cholesterol,initial,2013-05-29,GCST002042,Other measurement,#807dba
15063,European,1578.0,23726511.0,Xie P,Post-traumatic stress disorder,replication,2013-05-28,GCST002038,Neurological disorder,#d53e4f
15064,African Am./Caribbean,744.0,23726511.0,Xie P,Post-traumatic stress disorder,replication,2013-05-28,GCST002038,Neurological disorder,#fee08b
15065,African Am./Caribbean,3380.0,23726511.0,Xie P,Post-traumatic stress disorder,initial,2013-05-28,GCST002038,Neurological disorder,#fee08b
15066,European,1838.0,23726511.0,Xie P,Post-traumatic stress disorder,initial,2013-05-28,GCST002038,Neurological disorder,#d53e4f
15067,African Am./Caribbean,3392.0,23726511.0,Xie P,Post-traumatic stress disorder (asjusted for relatedness),initial,2013-05-28,GCST002037,Neurological disorder,#fee08b
15068,European,1846.0,23726511.0,Xie P,Post-traumatic stress disorder (asjusted for relatedness),initial,2013-05-28,GCST002037,Neurological disorder,#d53e4f
15069,Asian,6026.0,23708190.0,Hu Z,Congenital heart malformation,replication,2013-05-26,GCST002036,Cardiovascular disease,#3288bd
15070,Asian,2191.0,23708190.0,Hu Z,Congenital heart malformation,initial,2013-05-26,GCST002036,Cardiovascular disease,#3288bd
15071,Other/Mixed,320.0,23719583.0,Kerns SL,Adverse response to radiation therapy,initial,2013-05-26,GCST002034,Biological process,#99d594
15072,Other/Mixed,778.0,23719583.0,Kerns SL,Adverse response to radiation therapy,replication,2013-05-26,GCST002034,Biological process,#99d594
15073,European,6978.0,23708191.0,Cordell HJ,Congenital heart disease,initial,2013-05-26,GCST002035,Cardiovascular disease,#d53e4f
15074,European,3146.0,23708191.0,Cordell HJ,Congenital heart disease,replication,2013-05-26,GCST002035,Cardiovascular disease,#d53e4f
15075,European,11513.0,23704328.0,Fatemifar G,Primary tooth development (number of teeth),initial,2013-05-23,GCST002031,Biological process,#d53e4f
15076,African,12316.0,23717212.0,Band G,Malaria,initial,2013-05-23,GCST002033,Digestive system disorder,#fc8d59
15077,Asian,520.0,23746317.0,Yamaguchi T,Temporomandibular joint disorder,initial,2013-05-23,GCST002029,Other disease,#3288bd
15078,Asian,1256.0,23704207.0,Wu X,Non-small cell lung cancer (survival),replication,2013-05-23,GCST002032,Other measurement,#3288bd
15079,European,620.0,23704207.0,Wu X,Non-small cell lung cancer (survival),initial,2013-05-23,GCST002032,Other measurement,#d53e4f
15080,Asian,1256.0,23704207.0,Wu X,Non-small cell lung cancer (survival),replication,2013-05-23,GCST002032,Cancer,#3288bd
15081,European,620.0,23704207.0,Wu X,Non-small cell lung cancer (survival),initial,2013-05-23,GCST002032,Cancer,#d53e4f
15082,European,11118.0,23704328.0,Fatemifar G,Primary tooth development (time to first tooth eruption),initial,2013-05-23,GCST002030,Biological process,#d53e4f
15083,European,1203.0,23698163.0,Gong J,Serum selenium levels,initial,2013-05-21,GCST002028,Other measurement,#d53e4f
15084,European,621.0,23698163.0,Gong J,Serum selenium levels,replication,2013-05-21,GCST002028,Other measurement,#d53e4f
15085,African Am./Caribbean,1904.0,23696099.0,Ding K,Red blood cell traits,initial,2013-05-20,GCST002027,Hematological measurement,#fee08b
15086,African Am./Caribbean,411.0,23696099.0,Ding K,Red blood cell traits,replication,2013-05-20,GCST002027,Hematological measurement,#fee08b
15087,Asian,223.0,23677057.0,Kim JJ,Coronary arterial lesions in patients with Kawasaki disease,replication,2013-05-16,GCST002026,Immune system disorder,#3288bd
15088,Asian,140.0,23677057.0,Kim JJ,Coronary arterial lesions in patients with Kawasaki disease,initial,2013-05-16,GCST002026,Immune system disorder,#3288bd
15089,Asian,223.0,23677057.0,Kim JJ,Coronary arterial lesions in patients with Kawasaki disease,replication,2013-05-16,GCST002026,Cardiovascular disease,#3288bd
15090,Asian,140.0,23677057.0,Kim JJ,Coronary arterial lesions in patients with Kawasaki disease,initial,2013-05-16,GCST002026,Cardiovascular disease,#3288bd
15091,Other/Mixed,438.0,23668334.0,Shan J,Prostate cancer,replication,2013-05-13,GCST002024,Cancer,#99d594
15092,Other/Mixed,221.0,23668334.0,Shan J,Prostate cancer,initial,2013-05-13,GCST002024,Cancer,#99d594
15097,European,11146.0,23666240.0,Ruark E,Testicular germ cell tumor,replication,2013-05-12,GCST002022,Cancer,#d53e4f
15098,European,5932.0,23666240.0,Ruark E,Testicular germ cell tumor,initial,2013-05-12,GCST002022,Cancer,#d53e4f
15099,European,1638.0,23666239.0,Chung CC,Testicular germ cell tumor,initial,2013-05-12,GCST002023,Cancer,#d53e4f
15100,European,12070.0,23666239.0,Chung CC,Testicular germ cell tumor,replication,2013-05-12,GCST002023,Cancer,#d53e4f
15101,European,13627.0,23669352.0,Graff M,Body mass index,initial,2013-05-12,GCST002021,Body measurement,#d53e4f
15102,European,16253.0,23669352.0,Graff M,Body mass index,replication,2013-05-12,GCST002021,Body measurement,#d53e4f
15103,Asian,2506.0,23666238.0,Kou I,Scoliosis,initial,2013-05-12,GCST002020,Other disease,#3288bd
15104,Asian,27204.0,23666238.0,Kou I,Scoliosis,replication,2013-05-12,GCST002020,Other disease,#3288bd
15105,European,1184.0,23666238.0,Kou I,Scoliosis,replication,2013-05-12,GCST002020,Other disease,#d53e4f
15106,Asian,1999.0,23661040.0,Liao M,IgE levels,initial,2013-05-10,GCST002019,Other measurement,#3288bd
15107,Asian,1496.0,23661040.0,Liao M,IgE levels,replication,2013-05-10,GCST002019,Other measurement,#3288bd
15108,European,983.0,23665963.0,Dubinsky MC,Crohn's disease (time to surgery),initial,2013-05-09,GCST002018,Digestive system disorder,#d53e4f
15109,European,614.0,23665963.0,Dubinsky MC,Crohn's disease (need for surgery),initial,2013-05-09,GCST002017,Digestive system disorder,#d53e4f
15110,European,1287.0,23658558.0,Bae HT,Personality dimensions,replication,2013-05-08,GCST002015,Other trait,#d53e4f
15111,European,2631.0,23658558.0,Bae HT,Personality dimensions,initial,2013-05-08,GCST002015,Other trait,#d53e4f
15113,European,4595.0,23658558.0,Bae HT,Personality dimensions,initial,2013-05-08,GCST002016,Other trait,#d53e4f
15115,European,10485.0,23652523.0,Mayerle J,Helicobacter pylori serologic status,initial,2013-05-08,GCST002014,Other measurement,#d53e4f
15116,Asian,15495.0,23667675.0,Tanikawa C,Menarche (age at onset),initial,2013-05-07,GCST002013,Other measurement,#3288bd
15117,Asian,1962.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),replication,2013-05-05,GCST002010,Other measurement,#3288bd
15118,Asian,1331.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),initial,2013-05-05,GCST002010,Other measurement,#3288bd
15119,Asian,1962.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),replication,2013-05-05,GCST002010,Cancer,#3288bd
15120,Asian,1331.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),initial,2013-05-05,GCST002010,Cancer,#3288bd
15121,Asian,1962.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),replication,2013-05-05,GCST002010,Cancer,#3288bd
15122,Asian,1331.0,23644492.0,Wu C,Esophageal squamous cell cancer (length of survival),initial,2013-05-05,GCST002010,Cancer,#3288bd
15123,European,73965.0,23644456.0,Styrkarsdottir U,Bone mineral density,initial,2013-05-05,GCST002011,Other measurement,#d53e4f
15124,European,6767.0,23650146.0,Tang W,Venous thromboembolism,replication,2013-05-05,GCST002012,Cardiovascular disease,#d53e4f
15125,European,44499.0,23650146.0,Tang W,Venous thromboembolism,initial,2013-05-05,GCST002012,Cardiovascular disease,#d53e4f
15126,Asian,503.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide),initial,2013-05-04,GCST002002,Response to drug,#3288bd
15127,Asian,503.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide),initial,2013-05-04,GCST002002,Response to drug,#3288bd
15128,Asian,306.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine),initial,2013-05-04,GCST002003,Response to drug,#3288bd
15129,Asian,306.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine),initial,2013-05-04,GCST002003,Response to drug,#3288bd
15130,Asian,1171.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs),initial,2013-05-04,GCST001998,Response to drug,#3288bd
15131,Asian,1171.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs),initial,2013-05-04,GCST001998,Response to drug,#3288bd
15132,Asian,1129.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil),initial,2013-05-04,GCST001997,Response to drug,#3288bd
15133,Asian,1129.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil),initial,2013-05-04,GCST001997,Response to drug,#3288bd
15134,Asian,453.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin),initial,2013-05-04,GCST001996,Response to drug,#3288bd
15135,Asian,453.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin),initial,2013-05-04,GCST001996,Response to drug,#3288bd
15136,Asian,149.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin),initial,2013-05-04,GCST002009,Response to drug,#3288bd
15137,Asian,149.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin),initial,2013-05-04,GCST002009,Response to drug,#3288bd
15138,Asian,643.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),initial,2013-05-04,GCST002008,Response to drug,#3288bd
15139,Asian,643.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),initial,2013-05-04,GCST002008,Response to drug,#3288bd
15140,Asian,647.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin),initial,2013-05-04,GCST002007,Response to drug,#3288bd
15141,Asian,647.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin),initial,2013-05-04,GCST002007,Response to drug,#3288bd
15142,Asian,316.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin),initial,2013-05-04,GCST002006,Response to drug,#3288bd
15143,Asian,316.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin),initial,2013-05-04,GCST002006,Response to drug,#3288bd
15144,Asian,316.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin),initial,2013-05-04,GCST002006,Response to drug,#3288bd
15145,Asian,2543.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs),initial,2013-05-04,GCST002005,Response to drug,#3288bd
15146,Asian,2543.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs),initial,2013-05-04,GCST002005,Response to drug,#3288bd
15147,Asian,523.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin),initial,2013-05-04,GCST002004,Response to drug,#3288bd
15148,Asian,523.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin),initial,2013-05-04,GCST002004,Response to drug,#3288bd
15149,Asian,93.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide),initial,2013-05-04,GCST002000,Response to drug,#3288bd
15150,Asian,93.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide),initial,2013-05-04,GCST002000,Response to drug,#3288bd
15151,Asian,214.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),initial,2013-05-04,GCST001993,Response to drug,#3288bd
15152,Asian,214.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),initial,2013-05-04,GCST001993,Response to drug,#3288bd
15153,Asian,293.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors),initial,2013-05-04,GCST001994,Response to drug,#3288bd
15154,Asian,293.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors),initial,2013-05-04,GCST001994,Response to drug,#3288bd
15155,Asian,380.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel),initial,2013-05-04,GCST001995,Response to drug,#3288bd
15156,Asian,380.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel),initial,2013-05-04,GCST001995,Response to drug,#3288bd
15157,Asian,582.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel),initial,2013-05-04,GCST001999,Response to drug,#3288bd
15158,Asian,582.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel),initial,2013-05-04,GCST001999,Response to drug,#3288bd
15159,Asian,1196.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs),initial,2013-05-04,GCST002001,Response to drug,#3288bd
15160,Asian,1196.0,23648065.0,Low SK,Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs),initial,2013-05-04,GCST002001,Response to drug,#3288bd
15161,Asian,376.0,23678272.0,Cheong KA,Vitiligo (non-segmental),replication,2013-05-02,GCST001992,Immune system disorder,#3288bd
15162,Asian,212.0,23678272.0,Cheong KA,Vitiligo (non-segmental),initial,2013-05-02,GCST001992,Immune system disorder,#3288bd
15163,European,327.0,23643386.0,Hatoum IJ,Weight loss (gastric bypass surgery),replication,2013-05-02,GCST001991,Other trait,#d53e4f
15164,European,693.0,23643386.0,Hatoum IJ,Weight loss (gastric bypass surgery),initial,2013-05-02,GCST001991,Other trait,#d53e4f
15165,European,327.0,23643386.0,Hatoum IJ,Weight loss (gastric bypass surgery),replication,2013-05-02,GCST001991,Other trait,#d53e4f
15166,European,693.0,23643386.0,Hatoum IJ,Weight loss (gastric bypass surgery),initial,2013-05-02,GCST001991,Other trait,#d53e4f
15167,European,1893.0,23577725.0,Naj AC,Age-related macular degeneration,initial,2013-05-01,GCST001986,Neurological disorder,#d53e4f
15168,European,208.0,23577725.0,Naj AC,Age-related macular degeneration,replication,2013-05-01,GCST001986,Neurological disorder,#d53e4f
15169,European,1233.0,23577725.0,Naj AC,Age-related macular degeneration (extreme sampling),initial,2013-05-01,GCST001987,Neurological disorder,#d53e4f
15170,European,143.0,23577725.0,Naj AC,Age-related macular degeneration (extreme sampling),replication,2013-05-01,GCST001987,Neurological disorder,#d53e4f
15171,European,1419.0,23577725.0,Naj AC,Age-related macular degeneration (smoking status interaction),initial,2013-05-01,GCST001990,Other measurement,#d53e4f
15172,European,1419.0,23577725.0,Naj AC,Age-related macular degeneration (smoking status interaction),initial,2013-05-01,GCST001990,Neurological disorder,#d53e4f
15173,European,37537.0,23636237.0,Tanaka T,Dietary macronutrient intake,initial,2013-05-01,GCST001989,Biological process,#d53e4f
15174,European,41257.0,23636237.0,Tanaka T,Dietary macronutrient intake,replication,2013-05-01,GCST001989,Biological process,#d53e4f
15175,European,37537.0,23636237.0,Tanaka T,Dietary macronutrient intake,initial,2013-05-01,GCST001988,Biological process,#d53e4f
15176,European,33533.0,23636237.0,Tanaka T,Dietary macronutrient intake,replication,2013-05-01,GCST001988,Biological process,#d53e4f
15177,European,333.0,23633212.0,Rinella ES,Weight loss (gastric bypass surgery),replication,2013-04-30,GCST001985,Other trait,#d53e4f
15178,European,175.0,23633212.0,Rinella ES,Weight loss (gastric bypass surgery),initial,2013-04-30,GCST001985,Other trait,#d53e4f
15179,European,333.0,23633212.0,Rinella ES,Weight loss (gastric bypass surgery),replication,2013-04-30,GCST001985,Other trait,#d53e4f
15180,European,175.0,23633212.0,Rinella ES,Weight loss (gastric bypass surgery),initial,2013-04-30,GCST001985,Other trait,#d53e4f
15181,Asian,16242.0,23612905.0,Zhao SX,Graves' disease,replication,2013-04-29,GCST001984,Immune system disorder,#3288bd
15182,Asian,2910.0,23612905.0,Zhao SX,Graves' disease,initial,2013-04-29,GCST001984,Immune system disorder,#3288bd
15183,European,1256.0,23620144.0,Sulkava S,Job-related exhaustion,initial,2013-04-29,GCST001983,Neurological disorder,#d53e4f
15184,European,13864.0,23620144.0,Sulkava S,Job-related exhaustion,replication,2013-04-29,GCST001983,Neurological disorder,#d53e4f
15185,Asian,2910.0,23612905.0,Zhao SX,Graves' disease,initial,2013-04-29,GCST001982,Immune system disorder,#3288bd
15186,Asian,13080.0,23612905.0,Zhao SX,Graves' disease,replication,2013-04-29,GCST001982,Immune system disorder,#3288bd
15187,Asian,2483.0,23624525.0,Deng M,Amyotrophic lateral sclerosis,replication,2013-04-28,GCST001981,Neurological disorder,#3288bd
15188,Asian,2365.0,23624525.0,Deng M,Amyotrophic lateral sclerosis,initial,2013-04-28,GCST001981,Neurological disorder,#3288bd
15189,European,9305.0,23620142.0,Reiner AP,Circulating myeloperoxidase levels (serum),initial,2013-04-24,GCST001979,Cardiovascular measurement,#d53e4f
15190,European,9260.0,23620142.0,Reiner AP,Circulating myeloperoxidase levels (plasma),initial,2013-04-24,GCST001980,Cardiovascular measurement,#d53e4f
15191,European,1697.0,23626673.0,Matullo G,Malignant pleural mesothelioma,replication,2013-04-23,GCST001978,Cancer,#d53e4f
15192,European,759.0,23626673.0,Matullo G,Malignant pleural mesothelioma,initial,2013-04-23,GCST001978,Cancer,#d53e4f
15193,European,15872.0,23603761.0,Hinks A,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),initial,2013-04-21,GCST005528,Immune system disorder,#d53e4f
15194,European,15872.0,23603761.0,Hinks A,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),initial,2013-04-21,GCST005528,Immune system disorder,#d53e4f
15195,European,15872.0,23603761.0,Hinks A,Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),initial,2013-04-21,GCST005528,Immune system disorder,#d53e4f
15196,European,1180.0,23642732.0,Cox AJ,Bilirubin levels,initial,2013-04-19,GCST001976,Other measurement,#d53e4f
15197,Asian,1007.0,23562823.0,Sheu WH,Diabetic retinopathy,initial,2013-04-19,GCST001977,Metabolic disorder,#3288bd
15198,Hispanic/Latin American,585.0,23562823.0,Sheu WH,Diabetic retinopathy,replication,2013-04-19,GCST001977,Metabolic disorder,#807dba
15199,Asian,234.0,23594818.0,Ikeda M,Psychosis (methamphetamine induced),initial,2013-04-17,GCST001975,Neurological disorder,#3288bd
15200,European,2257.0,24429156.0,Noth I,Idiopathic pulmonary fibrosis,replication,2013-04-17,GCST001974,Cancer,#d53e4f
15201,European,1084.0,24429156.0,Noth I,Idiopathic pulmonary fibrosis,initial,2013-04-17,GCST001974,Cancer,#d53e4f
15202,Asian,1100.0,23594818.0,Ikeda M,Methamphetamine dependence,initial,2013-04-17,GCST001972,Neurological disorder,#3288bd
15203,European,87802.0,23599027.0,Demerath EW,Menarche (age at onset),replication,2013-04-17,GCST001973,Other measurement,#d53e4f
15204,African Am./Caribbean,2850.0,23599027.0,Demerath EW,Menarche (age at onset),replication,2013-04-17,GCST001973,Other measurement,#fee08b
15205,African Am./Caribbean,18089.0,23599027.0,Demerath EW,Menarche (age at onset),initial,2013-04-17,GCST001973,Other measurement,#fee08b
15206,Asian,687.0,23646285.0,Khor SS,Hypersomnia (HLA-DQB1*06:02 negative),initial,2013-04-16,GCST001971,Neurological disorder,#3288bd
15207,Other/Mixed,573.0,23592221.0,Rahmani M,Menopause (age at onset),replication,2013-04-16,GCST001970,Other measurement,#99d594
15208,European,38968.0,23592221.0,Rahmani M,Menopause (age at onset),replication,2013-04-16,GCST001970,Other measurement,#d53e4f
15209,Other/Mixed,352.0,23592221.0,Rahmani M,Menopause (age at onset),initial,2013-04-16,GCST001970,Other measurement,#99d594
15210,European,85787.0,23583979.0,den Hoed M,Heart rate,initial,2013-04-14,GCST001969,Cardiovascular measurement,#d53e4f
15211,European,88823.0,23583979.0,den Hoed M,Heart rate,replication,2013-04-14,GCST001969,Cardiovascular measurement,#d53e4f
15212,Asian,6568.0,23583979.0,den Hoed M,Heart rate,initial,2013-04-14,GCST001969,Cardiovascular measurement,#3288bd
15213,African,1188.0,23583978.0,Monda KL,Body mass index,initial,2013-04-14,GCST001967,Body measurement,#fc8d59
15214,African Am./Caribbean,37956.0,23583978.0,Monda KL,Body mass index,initial,2013-04-14,GCST001967,Body measurement,#fee08b
15215,African,4607.0,23583978.0,Monda KL,Body mass index,replication,2013-04-14,GCST001967,Body measurement,#fc8d59
15216,European,123706.0,23583978.0,Monda KL,Body mass index,replication,2013-04-14,GCST001967,Body measurement,#d53e4f
15217,African Am./Caribbean,27661.0,23583978.0,Monda KL,Body mass index,replication,2013-04-14,GCST001967,Body measurement,#fee08b
15218,European,2766.0,23583980.0,Fingerlin TE,Interstitial lung disease,replication,2013-04-14,GCST001968,Other disease,#d53e4f
15219,European,6299.0,23583980.0,Fingerlin TE,Interstitial lung disease,initial,2013-04-14,GCST001968,Other disease,#d53e4f
15220,European,7884.0,23585552.0,Kirin M,Rhegmatogenous retinal detachment,replication,2013-04-11,GCST001966,Neurological disorder,#d53e4f
15221,European,2820.0,23585552.0,Kirin M,Rhegmatogenous retinal detachment,initial,2013-04-11,GCST001966,Neurological disorder,#d53e4f
15222,Asian,6536.0,23575436.0,Go MJ,Glycemic traits,replication,2013-04-11,GCST001965,Metabolic disorder,#3288bd
15223,Asian,7696.0,23575436.0,Go MJ,Glycemic traits,initial,2013-04-11,GCST001965,Metabolic disorder,#3288bd
15224,African Am./Caribbean,5896.0,23571587.0,Reitz C,Alzheimer's disease (late onset),initial,2013-04-10,GCST001963,Neurological disorder,#fee08b
15225,European,2296.0,23575227.0,Urbanek M,Anthropometric traits in newborns,replication,2013-04-10,GCST001964,Other measurement,#d53e4f
15226,Asian,1207.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other measurement,#3288bd
15227,Hispanic/Latin American,616.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other measurement,#807dba
15228,European,1363.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other measurement,#d53e4f
15229,African Am./Caribbean,1095.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other measurement,#fee08b
15230,European,2296.0,23575227.0,Urbanek M,Anthropometric traits in newborns,replication,2013-04-10,GCST001964,Other trait,#d53e4f
15231,Asian,1207.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other trait,#3288bd
15232,Hispanic/Latin American,616.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other trait,#807dba
15233,European,1363.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other trait,#d53e4f
15234,African Am./Caribbean,1095.0,23575227.0,Urbanek M,Anthropometric traits in newborns,initial,2013-04-10,GCST001964,Other trait,#fee08b
15235,European,5866.0,23572186.0,Zheng HF,Bone mineral density,initial,2013-04-09,GCST001962,Other measurement,#d53e4f
15236,Hispanic/Latin American,715.0,23572186.0,Zheng HF,Bone mineral density,replication,2013-04-09,GCST001962,Other measurement,#807dba
15237,European,1659.0,23568457.0,Wade TD,Eating disorders,initial,2013-04-09,GCST001960,Metabolic disorder,#d53e4f
15238,European,2521.0,23568457.0,Wade TD,Eating disorders (purging via substances),initial,2013-04-09,GCST001959,Metabolic disorder,#d53e4f
15239,European,2442.0,23568457.0,Wade TD,Bulimia nervosa,initial,2013-04-09,GCST001958,Metabolic disorder,#d53e4f
15240,European,2524.0,23568457.0,Wade TD,Anorexia nervosa,initial,2013-04-09,GCST001961,Metabolic disorder,#d53e4f
15241,European,6889.0,23563609.0,Wheeler E,Obesity (early onset extreme),initial,2013-04-07,GCST001957,Metabolic disorder,#d53e4f
15242,European,2961.0,23563609.0,Wheeler E,Obesity (early onset extreme),replication,2013-04-07,GCST001957,Metabolic disorder,#d53e4f
15243,European,9703.0,23563607.0,Berndt SI,Height,replication,2013-04-07,GCST001956,Other measurement,#d53e4f
15244,European,16196.0,23563607.0,Berndt SI,Height,initial,2013-04-07,GCST001956,Other measurement,#d53e4f
15245,European,16068.0,23563607.0,Berndt SI,Body mass index,initial,2013-04-07,GCST001955,Body measurement,#d53e4f
15246,European,9791.0,23563607.0,Berndt SI,Body mass index,replication,2013-04-07,GCST001955,Body measurement,#d53e4f
15247,European,10255.0,23563607.0,Berndt SI,Waist-hip ratio,initial,2013-04-07,GCST001954,Other measurement,#d53e4f
15248,European,6703.0,23563607.0,Berndt SI,Waist-hip ratio,replication,2013-04-07,GCST001954,Other measurement,#d53e4f
15249,European,204498.0,23563607.0,Berndt SI,Obesity,initial,2013-04-07,GCST001953,Other measurement,#d53e4f
15250,European,133637.0,23563607.0,Berndt SI,Obesity,replication,2013-04-07,GCST001953,Other measurement,#d53e4f
15251,European,1278.0,23562540.0,Cruchaga C,Alzheimer's disease biomarkers,initial,2013-04-04,GCST001951,Neurological disorder,#d53e4f
15252,Asian,826.0,23593202.0,Ran S,Femoral neck bone geometry and menarche (age at onset),replication,2013-04-04,GCST001950,Other measurement,#3288bd
15253,European,501.0,23593202.0,Ran S,Femoral neck bone geometry and menarche (age at onset),replication,2013-04-04,GCST001950,Other measurement,#d53e4f
15254,European,1728.0,23593202.0,Ran S,Femoral neck bone geometry and menarche (age at onset),initial,2013-04-04,GCST001950,Other measurement,#d53e4f
15256,European,50627.0,23593239.0,van der Loos MJ,Self-employment,initial,2013-04-04,GCST001952,Other measurement,#d53e4f
15257,Asian,1735.0,23565137.0,Miyashita A,Alzheimer's disease (late onset),initial,2013-04-02,GCST001947,Neurological disorder,#3288bd
15258,Asian,3338.0,23565137.0,Miyashita A,Alzheimer's disease (late onset),replication,2013-04-02,GCST001947,Neurological disorder,#3288bd
15259,European,22771.0,23565137.0,Miyashita A,Alzheimer's disease (late onset),replication,2013-04-02,GCST001947,Neurological disorder,#d53e4f
15260,African Am./Caribbean,1031.0,23551011.0,Zhao L,Preeclampsia,initial,2013-04-02,GCST001949,Cardiovascular disease,#fee08b
15261,Hispanic/Latin American,720.0,23551011.0,Zhao L,Preeclampsia,initial,2013-04-02,GCST001949,Cardiovascular disease,#807dba
15262,European,1252.0,23551011.0,Zhao L,Preeclampsia,initial,2013-04-02,GCST001949,Cardiovascular disease,#d53e4f
15263,European,2810.0,23565138.0,Trzaskowski M,Anxiety,initial,2013-04-02,GCST001948,Other trait,#d53e4f
15264,European,4804.0,23565138.0,Trzaskowski M,Anxiety,replication,2013-04-02,GCST001948,Other trait,#d53e4f
15265,Other/Mixed,331.0,23517042.0,Melen E,Body mass index in non-asthmatics,initial,2013-04-01,GCST001935,Body measurement,#99d594
15267,European,12359.0,23517042.0,Melen E,Body mass index in non-asthmatics,initial,2013-04-01,GCST001935,Body measurement,#d53e4f
15268,Asian,1149.0,23511034.0,Yang SK,Ulcerative colitis,replication,2013-04-01,GCST001938,Immune system disorder,#3288bd
15269,Asian,1127.0,23511034.0,Yang SK,Ulcerative colitis,initial,2013-04-01,GCST001938,Immune system disorder,#3288bd
15270,European,1371.0,23555189.0,Chen Z,PCA3 expression level,initial,2013-04-01,GCST001946,Other measurement,#d53e4f
15276,Hispanic/Latin American,921.0,23517042.0,Melen E,Body mass index in asthmatics,replication,2013-04-01,GCST001945,Body measurement,#807dba
15277,European,4524.0,23517042.0,Melen E,Body mass index in asthmatics,initial,2013-04-01,GCST001945,Body measurement,#d53e4f
15278,European,979.0,23517042.0,Melen E,Body mass index in asthmatics,replication,2013-04-01,GCST001945,Body measurement,#d53e4f
15280,Other/Mixed,171.0,23517042.0,Melen E,Body mass index in asthmatics,initial,2013-04-01,GCST001945,Body measurement,#99d594
15282,Hispanic/Latin American,921.0,23517042.0,Melen E,Body mass index in asthmatics,replication,2013-04-01,GCST001945,Other disease,#807dba
15283,European,4524.0,23517042.0,Melen E,Body mass index in asthmatics,initial,2013-04-01,GCST001945,Other disease,#d53e4f
15284,European,979.0,23517042.0,Melen E,Body mass index in asthmatics,replication,2013-04-01,GCST001945,Other disease,#d53e4f
15286,Other/Mixed,171.0,23517042.0,Melen E,Body mass index in asthmatics,initial,2013-04-01,GCST001945,Other disease,#99d594
15287,European,9678.0,23548203.0,Zhang M,Tanning,initial,2013-04-01,GCST001939,Other trait,#d53e4f
15288,European,6747.0,23548203.0,Zhang M,Non-melanoma skin cancer,initial,2013-04-01,GCST001940,Other trait,#d53e4f
15289,European,2078.0,23548203.0,Zhang M,Non-melanoma skin cancer,replication,2013-04-01,GCST001940,Other trait,#d53e4f
15290,European,8165.0,23535730.0,Pharoah PD,Ovarian cancer,initial,2013-04-01,GCST001941,Cancer,#d53e4f
15291,European,39674.0,23535730.0,Pharoah PD,Ovarian cancer,replication,2013-04-01,GCST001941,Cancer,#d53e4f
15292,Asian,1183.0,23535730.0,Pharoah PD,Ovarian cancer,replication,2013-04-01,GCST001941,Cancer,#3288bd
15293,Asian,212.0,23535730.0,Pharoah PD,Ovarian cancer,replication,2013-04-01,GCST001941,Cancer,#3288bd
15294,European,39377.0,23535732.0,Eeles RA,Prostate cancer,replication,2013-04-01,GCST001942,Cancer,#d53e4f
15295,European,22548.0,23535732.0,Eeles RA,Prostate cancer,initial,2013-04-01,GCST001942,Cancer,#d53e4f
15296,European,10739.0,23535734.0,Codd V,Telomere length,replication,2013-04-01,GCST001936,Other measurement,#d53e4f
15297,European,37684.0,23535734.0,Codd V,Telomere length,initial,2013-04-01,GCST001936,Other measurement,#d53e4f
15298,European,87170.0,23535729.0,Michailidou K,Breast cancer,replication,2013-04-01,GCST001937,Cancer,#d53e4f
15299,European,22627.0,23535729.0,Michailidou K,Breast cancer,initial,2013-04-01,GCST001937,Cancer,#d53e4f
15300,European,4155.0,23548203.0,Zhang M,Hair color,replication,2013-04-01,GCST001932,Other trait,#d53e4f
15301,European,7070.0,23548203.0,Zhang M,Hair color,initial,2013-04-01,GCST001932,Other trait,#d53e4f
15302,European,2496.0,23548203.0,Zhang M,Eye color,replication,2013-04-01,GCST001929,Other trait,#d53e4f
15303,European,3871.0,23548203.0,Zhang M,Eye color,initial,2013-04-01,GCST001929,Other trait,#d53e4f
15304,European,47969.0,23535733.0,Garcia-Closas M,Breast cancer,replication,2013-04-01,GCST001930,Cancer,#d53e4f
15305,European,39387.0,23535733.0,Garcia-Closas M,Breast cancer,initial,2013-04-01,GCST001930,Cancer,#d53e4f
15308,European,9283.0,23548203.0,Zhang M,Sunburns,initial,2013-04-01,GCST001933,Other disease,#d53e4f
15309,European,4236.0,23548203.0,Zhang M,Sunburns,replication,2013-04-01,GCST001933,Other disease,#d53e4f
15310,Asian,2519.0,23511034.0,Yang SK,Ulcerative colitis,replication,2013-04-01,GCST001934,Immune system disorder,#3288bd
15311,Asian,1127.0,23511034.0,Yang SK,Ulcerative colitis,initial,2013-04-01,GCST001934,Immune system disorder,#3288bd
15312,Asian,3350.0,23539754.0,Yamada Y,Chronic kidney disease,replication,2013-03-28,GCST001924,Other disease,#3288bd
15313,Asian,501.0,23539754.0,Yamada Y,Chronic kidney disease,initial,2013-03-28,GCST001924,Other disease,#3288bd
15314,European,9049.0,23535967.0,Tin A,Glomerular filtration rate,initial,2013-03-28,GCST001923,Other measurement,#d53e4f
15315,African Am./Caribbean,455.0,23534349.0,Jeff JM,QRS duration,initial,2013-03-28,GCST001920,Cardiovascular measurement,#fee08b
15316,European,2706.0,23555300.0,Cui J,Response to anti-TNF therapy in rheumatoid arthritis,initial,2013-03-28,GCST001927,Immune system disorder,#d53e4f
15317,European,2706.0,23555300.0,Cui J,Response to anti-TNF therapy in rheumatoid arthritis,initial,2013-03-28,GCST001927,Response to drug,#d53e4f
15318,Asian,1184.0,23535911.0,Kitamoto T,Pediatric non-alcoholic fatty liver disease activity score,replication,2013-03-28,GCST001928,Digestive system disorder,#3288bd
15319,Asian,1326.0,23535911.0,Kitamoto T,Pediatric non-alcoholic fatty liver disease activity score,initial,2013-03-28,GCST001928,Digestive system disorder,#3288bd
15320,Asian,1184.0,23535911.0,Kitamoto T,Pediatric non-alcoholic fatty liver disease activity score,replication,2013-03-28,GCST001928,Cancer,#3288bd
15321,Asian,1326.0,23535911.0,Kitamoto T,Pediatric non-alcoholic fatty liver disease activity score,initial,2013-03-28,GCST001928,Cancer,#3288bd
15322,European,733.0,23555300.0,Cui J,Response to anti-TNF therapy in rheumatoid arthritis,initial,2013-03-28,GCST001926,Response to drug,#d53e4f
15323,Asian,151.0,23555300.0,Cui J,Response to anti-TNF therapy in rheumatoid arthritis,replication,2013-03-28,GCST001926,Response to drug,#3288bd
15324,European,139.0,23555300.0,Cui J,Response to anti-TNF therapy in rheumatoid arthritis,replication,2013-03-28,GCST001926,Response to drug,#d53e4f
15325,African Am./Caribbean,455.0,23534349.0,Jeff JM,PR interval,initial,2013-03-28,GCST001925,Cardiovascular measurement,#fee08b
15326,African Am./Caribbean,455.0,23534349.0,Jeff JM,Heart rate,initial,2013-03-28,GCST001921,Cardiovascular measurement,#fee08b
15327,African Am./Caribbean,455.0,23534349.0,Jeff JM,QT interval,initial,2013-03-28,GCST001922,Cardiovascular measurement,#fee08b
15328,European,1544.0,23541324.0,Li X,Pulmonary function in asthmatics,initial,2013-03-27,GCST001918,Other measurement,#d53e4f
15329,European,8211.0,23544012.0,Gaudet MM,Breast cancer in BRCA2 mutation carriers,initial,2013-03-27,GCST007302,Cancer,#d53e4f
15330,Asian,1639.0,23532257.0,Ma RC,Type 2 diabetes,initial,2013-03-27,GCST001919,Metabolic disorder,#3288bd
15331,Asian,38983.0,23532257.0,Ma RC,Type 2 diabetes,replication,2013-03-27,GCST001919,Metabolic disorder,#3288bd
15332,Asian,2146.0,23532257.0,Ma RC,Type 2 diabetes,replication,2013-03-27,GCST001919,Metabolic disorder,#3288bd
15333,European,47117.0,23532257.0,Ma RC,Type 2 diabetes,replication,2013-03-27,GCST001919,Metabolic disorder,#d53e4f
15334,Asian,1998.0,23532257.0,Ma RC,Type 2 diabetes,replication,2013-03-27,GCST001919,Metabolic disorder,#3288bd
15335,European,2727.0,23544013.0,Couch FJ,Breast Cancer in BRCA1 mutation carriers,initial,2013-03-27,GCST001916,Cancer,#d53e4f
15336,European,11964.0,23544013.0,Couch FJ,Breast Cancer in BRCA1 mutation carriers,replication,2013-03-27,GCST001916,Cancer,#d53e4f
15337,European,11964.0,23544013.0,Couch FJ,Ovarian cancer in BRCA1 mutation carriers,replication,2013-03-27,GCST001917,Cancer,#d53e4f
15338,European,2727.0,23544013.0,Couch FJ,Ovarian cancer in BRCA1 mutation carriers,initial,2013-03-27,GCST001917,Cancer,#d53e4f
15339,European,303.0,23535033.0,Sherva R,Alzheimer's disease (cognitive decline),initial,2013-03-24,GCST001915,Neurological disorder,#d53e4f
15340,Other/Mixed,5.0,23518928.0,Liu M,Estradiol plasma levels (breast cancer),initial,2013-03-21,GCST001914,Other measurement,#99d594
15341,Asian,17.0,23518928.0,Liu M,Estradiol plasma levels (breast cancer),initial,2013-03-21,GCST001914,Other measurement,#3288bd
15342,African,50.0,23518928.0,Liu M,Estradiol plasma levels (breast cancer),initial,2013-03-21,GCST001914,Other measurement,#fc8d59
15343,European,700.0,23518928.0,Liu M,Estradiol plasma levels (breast cancer),initial,2013-03-21,GCST001914,Other measurement,#d53e4f
15344,European,2652.0,23509962.0,Greliche N,Venous thromboembolism (SNP x SNP interaction),replication,2013-03-20,GCST001913,Cardiovascular disease,#d53e4f
15345,European,1639.0,23509962.0,Greliche N,Venous thromboembolism (SNP x SNP interaction),initial,2013-03-20,GCST001913,Cardiovascular disease,#d53e4f
15346,Hispanic/Latin American,1313.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),initial,2013-03-19,GCST001912,Cancer,#807dba
15347,African Am./Caribbean,1452.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),initial,2013-03-19,GCST001912,Cancer,#fee08b
15348,European,2358.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),initial,2013-03-19,GCST001912,Cancer,#d53e4f
15349,European,3175.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),replication,2013-03-19,GCST001912,Cancer,#d53e4f
15350,Hispanic/Latin American,783.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),replication,2013-03-19,GCST001912,Cancer,#807dba
15351,African Am./Caribbean,1203.0,23512250.0,Xu H,Acute lymphoblastic leukemia (childhood),replication,2013-03-19,GCST001912,Cancer,#fee08b
15352,Hispanic/Latin American,592.0,23508266.0,Duan QL,Asthma (bronchodilator response),replication,2013-03-19,GCST001911,Response to drug,#807dba
15353,European,403.0,23508266.0,Duan QL,Asthma (bronchodilator response),initial,2013-03-19,GCST001911,Response to drug,#d53e4f
15354,European,1220.0,23508266.0,Duan QL,Asthma (bronchodilator response),replication,2013-03-19,GCST001911,Response to drug,#d53e4f
15355,Hispanic/Latin American,592.0,23508266.0,Duan QL,Asthma (bronchodilator response),replication,2013-03-19,GCST001911,Other disease,#807dba
15356,European,403.0,23508266.0,Duan QL,Asthma (bronchodilator response),initial,2013-03-19,GCST001911,Other disease,#d53e4f
15357,European,1220.0,23508266.0,Duan QL,Asthma (bronchodilator response),replication,2013-03-19,GCST001911,Other disease,#d53e4f
15358,European,585.0,23496005.0,Luca G,Narcolepsy with cataplexy,initial,2013-03-18,GCST001909,Neurological disorder,#d53e4f
15359,European,387.0,23496005.0,Luca G,Narcolepsy with cataplexy,replication,2013-03-18,GCST001909,Neurological disorder,#d53e4f
15360,European,2054.0,23508960.0,Zhou G,Aspirin hydrolysis (plasma),initial,2013-03-18,GCST001910,Other measurement,#d53e4f
15362,European,1408.0,23502781.0,Germain M,Pulmonary arterial hypertension (without BMPR2 mutations),initial,2013-03-17,GCST001908,Cardiovascular disease,#d53e4f
15363,European,8966.0,23502783.0,Weinhold N,Multiple myeloma (IgH translocation),initial,2013-03-17,GCST001906,Cancer,#d53e4f
15364,European,8966.0,23502783.0,Weinhold N,Multiple myeloma (hyperdiploidy),initial,2013-03-17,GCST001907,Cancer,#d53e4f
15365,Hispanic/Latin American,2121.0,23505323.0,Weissglas-Volkov D,Hypertriglyceridemia,replication,2013-03-15,GCST001905,Lipid or lipoprotein measurement,#807dba
15366,Hispanic/Latin American,2240.0,23505323.0,Weissglas-Volkov D,Hypertriglyceridemia,initial,2013-03-15,GCST001905,Lipid or lipoprotein measurement,#807dba
15367,Hispanic/Latin American,2121.0,23505323.0,Weissglas-Volkov D,HDL cholesterol,replication,2013-03-15,GCST001904,Lipid or lipoprotein measurement,#807dba
15368,Hispanic/Latin American,2240.0,23505323.0,Weissglas-Volkov D,HDL cholesterol,initial,2013-03-15,GCST001904,Lipid or lipoprotein measurement,#807dba
15369,Hispanic/Latin American,1644.0,23493294.0,Gao X,Central corneal thickness,initial,2013-03-14,GCST001903,Other measurement,#807dba
15370,Hispanic/Latin American,124.0,23493294.0,Gao X,Central corneal thickness,replication,2013-03-14,GCST001903,Other measurement,#807dba
15371,European,2620.0,23561647.0,van Setten J,Coronary artery calcification,initial,2013-03-13,GCST001902,Other trait,#d53e4f
15372,European,2198.0,23482656.0,Chen D,Cervical cancer,replication,2013-03-12,GCST001900,Cancer,#d53e4f
15373,European,4982.0,23482656.0,Chen D,Cervical cancer,initial,2013-03-12,GCST001900,Cancer,#d53e4f
15380,European,996.0,23470693.0,Zeng Z,Pit-and-Fissure caries,initial,2013-03-07,GCST001897,Digestive system disorder,#d53e4f
15381,European,982.0,23470693.0,Zeng Z,Smooth-surface caries,initial,2013-03-07,GCST001896,Digestive system disorder,#d53e4f
15382,European,19763.0,23474815.0,Stambolian D,Refractive error,replication,2013-03-07,GCST001898,Other trait,#d53e4f
15383,European,7280.0,23474815.0,Stambolian D,Refractive error,initial,2013-03-07,GCST001898,Other trait,#d53e4f
15384,European,204.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#d53e4f
15385,Hispanic/Latin American,66.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#807dba
15386,Other/Mixed,1.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#99d594
15387,European,1490.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,initial,2013-03-06,GCST001895,Response to drug,#d53e4f
15388,Asian,25.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#3288bd
15389,Asian,9.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#3288bd
15390,Asian,15.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#3288bd
15392,African,6.0,23467860.0,Pare G,Response to dabigatran etexilate treatment,replication,2013-03-06,GCST001895,Response to drug,#fc8d59
15393,European,2316.0,23472165.0,Albertsen HM,Endometriosis,replication,2013-03-05,GCST001894,Other disease,#d53e4f
15394,European,14174.0,23472165.0,Albertsen HM,Endometriosis,initial,2013-03-05,GCST001894,Other disease,#d53e4f
15395,European,3403.0,23472185.0,Mero IL,Multiple sclerosis (OCB status),replication,2013-03-05,GCST001891,Immune system disorder,#d53e4f
15396,European,1528.0,23472185.0,Mero IL,Multiple sclerosis (OCB status),initial,2013-03-05,GCST001891,Immune system disorder,#d53e4f
15397,European,1528.0,23472185.0,Mero IL,Multiple sclerosis (OCB status),initial,2013-03-05,GCST001892,Immune system disorder,#d53e4f
15398,European,1528.0,23472185.0,Mero IL,Multiple sclerosis (OCB status),initial,2013-03-05,GCST001892,Other measurement,#d53e4f
15399,European,40407.0,23463857.0,Ritchie MD,Electrocardiographic conduction measures,replication,2013-03-05,GCST001893,Cardiovascular measurement,#d53e4f
15400,European,5272.0,23463857.0,Ritchie MD,Electrocardiographic conduction measures,initial,2013-03-05,GCST001893,Cardiovascular measurement,#d53e4f
15401,European,33781.0,23459443.0,Avery CL,QT interval (drug interaction),initial,2013-03-05,GCST001890,Cardiovascular measurement,#d53e4f
15402,European,331.0,23471985.0,Jahanshad N,Brain connectivity,initial,2013-03-05,GCST001889,Other measurement,#d53e4f
15403,European,4504.0,23459936.0,Divaris K,Periodontitis,initial,2013-03-04,GCST001888,Digestive system disorder,#d53e4f
15404,Other/Mixed,656.0,23459936.0,Divaris K,Periodontitis,replication,2013-03-04,GCST001888,Digestive system disorder,#99d594
15405,Asian,1008.0,23455636.0,Fritsche LG,Age-related macular degeneration,replication,2013-03-03,GCST001884,Neurological disorder,#3288bd
15406,European,16753.0,23455636.0,Fritsche LG,Age-related macular degeneration,replication,2013-03-03,GCST001884,Neurological disorder,#d53e4f
15407,Asian,4150.0,23455636.0,Fritsche LG,Age-related macular degeneration,initial,2013-03-03,GCST001884,Neurological disorder,#3288bd
15408,Asian,229.0,23455636.0,Fritsche LG,Age-related macular degeneration,initial,2013-03-03,GCST001884,Neurological disorder,#3288bd
15409,European,55115.0,23455636.0,Fritsche LG,Age-related macular degeneration,initial,2013-03-03,GCST001884,Neurological disorder,#d53e4f
15410,Asian,1881.0,23456168.0,Hao Y,Height,replication,2013-03-03,GCST001885,Body measurement,#3288bd
15411,Asian,6534.0,23456168.0,Hao Y,Height,initial,2013-03-03,GCST001885,Body measurement,#3288bd
15412,Other/Mixed,894.0,23314186.0,Crosslin DR,Monocyte count,initial,2013-03-03,GCST001887,Hematological measurement,#99d594
15413,European,9849.0,23314186.0,Crosslin DR,Monocyte count,initial,2013-03-03,GCST001887,Hematological measurement,#d53e4f
15414,Other/Mixed,271.0,23314186.0,Crosslin DR,Monocyte count,initial,2013-03-03,GCST001887,Hematological measurement,#99d594
15415,European,4919.0,23455637.0,Iles MM,Melanoma,initial,2013-03-03,GCST001886,Cancer,#d53e4f
15416,European,67980.0,23455637.0,Iles MM,Melanoma,replication,2013-03-03,GCST001886,Cancer,#d53e4f
15417,Asian,396.0,23456092.0,Park BL,Alcohol dependence,initial,2013-03-01,GCST001883,Neurological disorder,#3288bd
15418,Asian,975.0,23456092.0,Park BL,Alcohol dependence,replication,2013-03-01,GCST001883,Neurological disorder,#3288bd
15419,European,489.0,23281178.0,Hong MG,Metabolite levels,replication,2013-03-01,GCST001882,Other measurement,#d53e4f
15420,European,402.0,23281178.0,Hong MG,Metabolite levels,initial,2013-03-01,GCST001882,Other measurement,#d53e4f
15421,African Am./Caribbean,5761.0,23468962.0,Song C,Breast cancer,initial,2013-02-28,GCST001879,Cancer,#fee08b
15422,Asian,5811.0,23406873.0,Shi Y,Myopia (pathological),replication,2013-02-28,GCST001881,Other trait,#3288bd
15423,Asian,1625.0,23406873.0,Shi Y,Myopia (pathological),initial,2013-02-28,GCST001881,Other trait,#3288bd
15424,African,1103.0,23533358.0,Liu Z,Addiction,initial,2013-02-28,GCST001880,Neurological disorder,#fc8d59
15425,European,2524.0,23533358.0,Liu Z,Addiction,initial,2013-02-28,GCST001880,Neurological disorder,#d53e4f
15426,European,10799.0,23449627.0,Cousminer DL,Pubertal anthropometrics,initial,2013-02-27,GCST001876,Biological process,#d53e4f
15427,European,10799.0,23449627.0,Cousminer DL,Pubertal anthropometrics,initial,2013-02-27,GCST001876,Body measurement,#d53e4f
15428,European,61220.0,23453885.0,Smoller JW,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",initial,2013-02-27,GCST001877,Neurological disorder,#d53e4f
15429,European,61220.0,23453885.0,Smoller JW,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",initial,2013-02-27,GCST001877,Neurological disorder,#d53e4f
15430,European,61220.0,23453885.0,Smoller JW,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",initial,2013-02-27,GCST001877,Neurological disorder,#d53e4f
15431,European,61220.0,23453885.0,Smoller JW,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",initial,2013-02-27,GCST001877,Neurological disorder,#d53e4f
15432,European,61220.0,23453885.0,Smoller JW,"Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",initial,2013-02-27,GCST001877,Neurological disorder,#d53e4f
15433,Asian,134.0,23454411.0,Lin MT,Coronary arterial lesions in patients with Kawasaki disease,initial,2013-02-27,GCST001878,Immune system disorder,#3288bd
15434,Asian,245.0,23454411.0,Lin MT,Coronary arterial lesions in patients with Kawasaki disease,replication,2013-02-27,GCST001878,Immune system disorder,#3288bd
15435,Asian,134.0,23454411.0,Lin MT,Coronary arterial lesions in patients with Kawasaki disease,initial,2013-02-27,GCST001878,Cardiovascular disease,#3288bd
15436,Asian,245.0,23454411.0,Lin MT,Coronary arterial lesions in patients with Kawasaki disease,replication,2013-02-27,GCST001878,Cardiovascular disease,#3288bd
15437,European,6438.0,23455491.0,Zuo L,Alcohol dependence,replication,2013-02-27,GCST001874,Neurological disorder,#d53e4f
15438,European,2927.0,23455491.0,Zuo L,Alcohol dependence,initial,2013-02-27,GCST001874,Neurological disorder,#d53e4f
15439,European,14040.0,23449627.0,Cousminer DL,Pubertal anthropometrics,initial,2013-02-27,GCST001875,Body measurement,#d53e4f
15440,European,9710.0,23449627.0,Cousminer DL,Pubertal anthropometrics,replication,2013-02-27,GCST001875,Body measurement,#d53e4f
15441,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15442,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15443,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15444,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15445,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15446,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15447,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15448,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15449,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15450,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15451,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15452,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15453,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15454,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15455,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15456,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15457,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15458,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15459,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15460,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15461,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15462,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15463,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15464,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15465,Asian,14088.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#3288bd
15466,European,21020.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#d53e4f
15467,African Am./Caribbean,9692.0,23446634.0,Chen Z,Red blood cell traits,replication,2013-02-26,GCST001873,Hematological measurement,#fee08b
15468,African Am./Caribbean,16485.0,23446634.0,Chen Z,Red blood cell traits,initial,2013-02-26,GCST001873,Hematological measurement,#fee08b
15469,European,1874.0,23509613.0,Kamboh MI,Presence of antiphospholipid antibodies,initial,2013-02-24,GCST001872,Other measurement,#d53e4f
15470,European,5878.0,23437003.0,Paternoster L,Bone mineral density,initial,2013-02-21,GCST001870,Other measurement,#d53e4f
15471,European,1052.0,23437003.0,Paternoster L,Bone mineral density,replication,2013-02-21,GCST001870,Other measurement,#d53e4f
15472,European,263.0,23432519.0,O'Brien RP,Renal transplant outcome,initial,2013-02-21,GCST001871,Other measurement,#d53e4f
15473,Other/Mixed,16093.0,23423446.0,Hein R,Breast cancer (menopausal hormone therapy interaction),replication,2013-02-20,GCST001869,Cancer,#99d594
15474,European,731.0,23423446.0,Hein R,Breast cancer (menopausal hormone therapy interaction),initial,2013-02-20,GCST001869,Cancer,#d53e4f
15475,Other/Mixed,16093.0,23423446.0,Hein R,Breast cancer (menopausal hormone therapy interaction),replication,2013-02-20,GCST001869,Other trait,#99d594
15476,European,731.0,23423446.0,Hein R,Breast cancer (menopausal hormone therapy interaction),initial,2013-02-20,GCST001869,Other trait,#d53e4f
15477,Other/Mixed,169.0,23420232.0,Duggal P,Chronic hepatitis C infection,replication,2013-02-19,GCST001867,Digestive system disorder,#99d594
15478,African Am./Caribbean,284.0,23420232.0,Duggal P,Chronic hepatitis C infection,replication,2013-02-19,GCST001867,Digestive system disorder,#fee08b
15479,European,292.0,23420232.0,Duggal P,Chronic hepatitis C infection,replication,2013-02-19,GCST001867,Digestive system disorder,#d53e4f
15480,Other/Mixed,373.0,23420232.0,Duggal P,Chronic hepatitis C infection,initial,2013-02-19,GCST001867,Digestive system disorder,#99d594
15481,Other/Mixed,447.0,23420232.0,Duggal P,Chronic hepatitis C infection,initial,2013-02-19,GCST001867,Digestive system disorder,#99d594
15482,European,1581.0,23420232.0,Duggal P,Chronic hepatitis C infection,initial,2013-02-19,GCST001867,Digestive system disorder,#d53e4f
15483,European,200.0,23423138.0,Ludwig KU,Mathematical ability in children with dyslexia,initial,2013-02-19,GCST001866,Biological process,#d53e4f
15484,European,510.0,23423138.0,Ludwig KU,Mathematical ability in children with dyslexia,replication,2013-02-19,GCST001866,Biological process,#d53e4f
15485,European,555.0,23419831.0,Ramanan VK,Alzheimer's disease biomarkers,initial,2013-02-19,GCST001868,Neurological disorder,#d53e4f
15486,African Am./Caribbean,2497.0,23388002.0,Thanassoulis G,Mitral annular calcification,replication,2013-02-17,GCST001864,Other trait,#fee08b
15487,Hispanic/Latin American,2027.0,23388002.0,Thanassoulis G,Mitral annular calcification,replication,2013-02-17,GCST001864,Other trait,#807dba
15488,Asian,774.0,23388002.0,Thanassoulis G,Mitral annular calcification,replication,2013-02-17,GCST001864,Other trait,#3288bd
15489,European,745.0,23388002.0,Thanassoulis G,Mitral annular calcification,replication,2013-02-17,GCST001864,Other trait,#d53e4f
15490,European,3795.0,23388002.0,Thanassoulis G,Mitral annular calcification,initial,2013-02-17,GCST001864,Other trait,#d53e4f
15491,European,745.0,23388002.0,Thanassoulis G,Aortic-valve calcification,replication,2013-02-17,GCST001865,Cardiovascular disease,#d53e4f
15492,European,6942.0,23388002.0,Thanassoulis G,Aortic-valve calcification,initial,2013-02-17,GCST001865,Cardiovascular disease,#d53e4f
15493,African Am./Caribbean,2497.0,23388002.0,Thanassoulis G,Aortic-valve calcification,replication,2013-02-17,GCST001865,Cardiovascular disease,#fee08b
15494,Hispanic/Latin American,2027.0,23388002.0,Thanassoulis G,Aortic-valve calcification,replication,2013-02-17,GCST001865,Cardiovascular disease,#807dba
15495,Asian,774.0,23388002.0,Thanassoulis G,Aortic-valve calcification,replication,2013-02-17,GCST001865,Cardiovascular disease,#3288bd
15496,European,6728.0,23417110.0,Tin A,Beta-2 microglubulin plasma levels,initial,2013-02-16,GCST001863,Other measurement,#d53e4f
15497,Asian,939.0,23408455.0,Wakai K,Confectionary intake,initial,2013-02-14,GCST001861,Biological process,#3288bd
15498,Asian,4491.0,23408455.0,Wakai K,Confectionary intake,replication,2013-02-14,GCST001861,Biological process,#3288bd
15500,Other/Mixed,213.0,23406172.0,Milton JN,Sickle cell anemia (haemolysis),replication,2013-02-14,GCST001862,Neurological disorder,#99d594
15502,European,284.0,23412934.0,Gourraud PA,Multiple sclerosis,initial,2013-02-13,GCST001860,Immune system disorder,#d53e4f
15503,African Am./Caribbean,342.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Response to drug,#fee08b
15504,European,425.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Response to drug,#d53e4f
15505,African Am./Caribbean,342.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Lipid or lipoprotein measurement,#fee08b
15506,European,425.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Lipid or lipoprotein measurement,#d53e4f
15507,African Am./Caribbean,342.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Other measurement,#fee08b
15508,European,425.0,23400010.0,Del-Aguila JL,Thiazide-induced adverse metabolic effects in hypertensive patients,initial,2013-02-12,GCST001859,Other measurement,#d53e4f
15509,European,1195.0,23372042.0,Lane J,HIV-1 susceptibility,initial,2013-02-10,GCST001857,Other disease,#d53e4f
15510,European,37382.0,23396134.0,Verhoeven VJ,Refractive error,initial,2013-02-10,GCST001858,Other trait,#d53e4f
15511,Asian,2273.0,23396134.0,Verhoeven VJ,Refractive error,initial,2013-02-10,GCST001858,Other trait,#3288bd
15512,Asian,2108.0,23396134.0,Verhoeven VJ,Refractive error,initial,2013-02-10,GCST001858,Other trait,#3288bd
15513,Asian,3995.0,23396134.0,Verhoeven VJ,Refractive error,initial,2013-02-10,GCST001858,Other trait,#3288bd
15514,European,26420.0,23408906.0,Porcu E,Thyroid hormone levels,initial,2013-02-07,GCST001856,Other measurement,#d53e4f
15515,Hispanic/Latin American,276.0,23392654.0,Lewis JP,Response to antiplatelet therapy,replication,2013-02-07,GCST001855,Biological process,#807dba
15516,Other/Mixed,4.0,23392654.0,Lewis JP,Response to antiplatelet therapy,replication,2013-02-07,GCST001855,Biological process,#99d594
15517,African Am./Caribbean,237.0,23392654.0,Lewis JP,Response to antiplatelet therapy,replication,2013-02-07,GCST001855,Biological process,#fee08b
15518,European,710.0,23392654.0,Lewis JP,Response to antiplatelet therapy,replication,2013-02-07,GCST001855,Biological process,#d53e4f
15519,European,565.0,23392654.0,Lewis JP,Response to antiplatelet therapy,initial,2013-02-07,GCST001855,Biological process,#d53e4f
15520,European,19411.0,23393555.0,Jensen RA,Retinopathy in non-diabetics,initial,2013-02-05,GCST001854,Neurological disorder,#d53e4f
15521,European,3230.0,23381795.0,Verweij N,Circulating vasoactive peptide levels,replication,2013-02-04,GCST001853,Cardiovascular measurement,#d53e4f
15522,European,3444.0,23381795.0,Verweij N,Circulating vasoactive peptide levels,initial,2013-02-04,GCST001853,Cardiovascular measurement,#d53e4f
15523,European,21953.0,23894747.0,Aberg KA,Schizophrenia,initial,2013-02-01,GCST001851,Neurological disorder,#d53e4f
15524,Asian,2296.0,23894747.0,Aberg KA,Schizophrenia,replication,2013-02-01,GCST001851,Neurological disorder,#3288bd
15525,African Am./Caribbean,1262.0,23894747.0,Aberg KA,Schizophrenia,replication,2013-02-01,GCST001851,Neurological disorder,#fee08b
15526,European,2740.0,23894747.0,Aberg KA,Schizophrenia,replication,2013-02-01,GCST001851,Neurological disorder,#d53e4f
15527,European,339.0,23378610.0,Xie W,Metabolite levels,replication,2013-02-01,GCST001852,Other measurement,#d53e4f
15528,European,1004.0,23378610.0,Xie W,Metabolite levels,initial,2013-02-01,GCST001852,Other measurement,#d53e4f
15529,European,2256.0,23377640.0,GENDEP Investigators,Major depressive disorder,initial,2013-02-01,GCST001850,Neurological disorder,#d53e4f
15530,European,2247.0,23382691.0,Lauc G,IgG glycosylation,initial,2013-01-31,GCST001848,Other measurement,#d53e4f
15531,Asian,1452.0,23371916.0,Dai X,Bilirubin levels,initial,2013-01-31,GCST001846,Other measurement,#3288bd
15532,Asian,8830.0,23371916.0,Dai X,Bilirubin levels,replication,2013-01-31,GCST001846,Other measurement,#3288bd
15533,Asian,8028.0,23364394.0,Lee JY,Coronary heart disease,replication,2013-01-31,GCST001845,Cardiovascular disease,#3288bd
15534,Asian,5714.0,23364394.0,Lee JY,Coronary heart disease,initial,2013-01-31,GCST001845,Cardiovascular disease,#3288bd
15535,Other/Mixed,346.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,initial,2013-01-31,GCST001847,Biological process,#99d594
15536,Other/Mixed,377.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,replication,2013-01-31,GCST001847,Biological process,#99d594
15537,Other/Mixed,346.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,initial,2013-01-31,GCST001847,Other trait,#99d594
15538,Other/Mixed,377.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,replication,2013-01-31,GCST001847,Other trait,#99d594
15539,Other/Mixed,346.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,initial,2013-01-31,GCST001847,Cancer,#99d594
15540,Other/Mixed,377.0,23376709.0,Kerns SL,Urinary symptoms in response to radiotherapy in prostate cancer,replication,2013-01-31,GCST001847,Cancer,#99d594
15541,European,1848.0,23382691.0,Lauc G,IgG glycosylation,initial,2013-01-31,GCST001849,Other measurement,#d53e4f
15542,Asian,18189.0,23364009.0,Yang X,Drinking behavior,replication,2013-01-30,GCST001842,Biological process,#3288bd
15543,Asian,5010.0,23364009.0,Yang X,Drinking behavior,initial,2013-01-30,GCST001842,Biological process,#3288bd
15544,European,38360.0,23372041.0,Chu AY,Dietary macronutrient intake,replication,2013-01-30,GCST001844,Biological process,#d53e4f
15545,European,33533.0,23372041.0,Chu AY,Dietary macronutrient intake,initial,2013-01-30,GCST001844,Biological process,#d53e4f
15546,European,4771.0,23386860.0,Pasquale LR,Type 2 diabetes (dietary heme iron intake interaction),initial,2013-01-30,GCST001843,Metabolic disorder,#d53e4f
15547,European,4771.0,23386860.0,Pasquale LR,Type 2 diabetes (dietary heme iron intake interaction),initial,2013-01-30,GCST001843,Other measurement,#d53e4f
15548,European,5548.0,23358156.0,Benyamin B,Intelligence (childhood),replication,2013-01-29,GCST001837,Biological process,#d53e4f
15549,European,12441.0,23358156.0,Benyamin B,Intelligence (childhood),initial,2013-01-29,GCST001837,Biological process,#d53e4f
15550,European,8961.0,23362303.0,Wu JH,Oleic acid (18:1n-9) levels,initial,2013-01-29,GCST001834,Lipid or lipoprotein measurement,#d53e4f
15551,European,8961.0,23362303.0,Wu JH,Stearic acid (18:0) levels,initial,2013-01-29,GCST001840,Lipid or lipoprotein measurement,#d53e4f
15552,European,8961.0,23362303.0,Wu JH,Palmitoleic acid (16:1n-7) levels,initial,2013-01-29,GCST001841,Lipid or lipoprotein measurement,#d53e4f
15553,European,8025.0,23358160.0,Borglum AD,Schizophrenia,replication,2013-01-29,GCST001839,Neurological disorder,#d53e4f
15554,European,1770.0,23358160.0,Borglum AD,Schizophrenia,initial,2013-01-29,GCST001839,Neurological disorder,#d53e4f
15555,European,8025.0,23358160.0,Borglum AD,Schizophrenia (cytomegalovirus infection interaction),replication,2013-01-29,GCST001833,Neurological disorder,#d53e4f
15556,European,1770.0,23358160.0,Borglum AD,Schizophrenia (cytomegalovirus infection interaction),initial,2013-01-29,GCST001833,Neurological disorder,#d53e4f
15557,European,8025.0,23358160.0,Borglum AD,Schizophrenia (cytomegalovirus infection interaction),replication,2013-01-29,GCST001833,Other disease,#d53e4f
15558,European,1770.0,23358160.0,Borglum AD,Schizophrenia (cytomegalovirus infection interaction),initial,2013-01-29,GCST001833,Other disease,#d53e4f
15559,European,169.0,23374588.0,Martinelli-Boneschi F,Response to cholinesterase inhibitors in Alzheimer's disease,initial,2013-01-29,GCST001835,Response to drug,#d53e4f
15560,European,168.0,23374588.0,Martinelli-Boneschi F,Response to cholinesterase inhibitors in Alzheimer's disease,replication,2013-01-29,GCST001835,Response to drug,#d53e4f
15561,European,169.0,23374588.0,Martinelli-Boneschi F,Response to cholinesterase inhibitors in Alzheimer's disease,initial,2013-01-29,GCST001835,Neurological disorder,#d53e4f
15562,European,168.0,23374588.0,Martinelli-Boneschi F,Response to cholinesterase inhibitors in Alzheimer's disease,replication,2013-01-29,GCST001835,Neurological disorder,#d53e4f
15563,European,8961.0,23362303.0,Wu JH,Palmitic acid (16:0) levels,initial,2013-01-29,GCST001838,Lipid or lipoprotein measurement,#d53e4f
15564,European,4500.0,23382809.0,Xu C,Schizophrenia (negative symptoms),initial,2013-01-29,GCST001836,Neurological disorder,#d53e4f
15565,European,3216.0,23350875.0,Fernandez-Rozadilla C,Colorectal cancer,replication,2013-01-26,GCST001832,Cancer,#d53e4f
15566,European,1355.0,23350875.0,Fernandez-Rozadilla C,Colorectal cancer,initial,2013-01-26,GCST001832,Cancer,#d53e4f
15567,European,466.0,23354978.0,Rinella ES,Breast cancer,replication,2013-01-25,GCST001831,Cancer,#d53e4f
15568,European,1001.0,23354978.0,Rinella ES,Breast cancer,initial,2013-01-25,GCST001831,Cancer,#d53e4f
15569,Asian,3136.0,23349225.0,Hwang JY,Osteoporosis,replication,2013-01-24,GCST001830,Other disease,#3288bd
15570,Asian,1427.0,23349225.0,Hwang JY,Osteoporosis,initial,2013-01-24,GCST001830,Other disease,#3288bd
15571,European,490.0,23337944.0,Haghighi A,Fat intake,replication,2013-01-22,GCST001829,Biological process,#d53e4f
15572,European,598.0,23337944.0,Haghighi A,Fat intake,initial,2013-01-22,GCST001829,Biological process,#d53e4f
15573,Other/Mixed,68.0,23337848.0,Posti JP,Vascular constriction,replication,2013-01-18,GCST001828,Other disease,#99d594
15574,European,64.0,23337848.0,Posti JP,Vascular constriction,initial,2013-01-18,GCST001828,Other disease,#d53e4f
15575,European,3841.0,23349640.0,Vijai J,Lymphoma,replication,2013-01-17,GCST001826,Cancer,#d53e4f
15577,Asian,8632.0,23341777.0,Dong J,Squamous cell carcinoma,replication,2013-01-17,GCST001827,Cancer,#3288bd
15578,Asian,3927.0,23341777.0,Dong J,Squamous cell carcinoma,initial,2013-01-17,GCST001827,Cancer,#3288bd
15579,African Am./Caribbean,1734.0,23328707.0,Tin A,Beta-trace protein levels,replication,2013-01-16,GCST001825,Other measurement,#fee08b
15580,European,6720.0,23328707.0,Tin A,Beta-trace protein levels,initial,2013-01-16,GCST001825,Other measurement,#d53e4f
15581,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA/5-HIAA ratio),initial,2013-01-15,GCST001818,Other measurement,#d53e4f
15582,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA/5-HIAA ratio),initial,2013-01-15,GCST001818,Other measurement,#d53e4f
15583,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA/MHPG ratio),initial,2013-01-15,GCST001823,Other measurement,#d53e4f
15584,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA/MHPG ratio),initial,2013-01-15,GCST001823,Other measurement,#d53e4f
15585,European,22100.0,23322567.0,Lopes MC,Corneal astigmatism,initial,2013-01-15,GCST001819,Other trait,#d53e4f
15586,European,398.0,23319000.0,Luykx JJ,Metabolite levels (5-HIAA/ MHPG Ratio),initial,2013-01-15,GCST001821,Other measurement,#d53e4f
15587,European,398.0,23319000.0,Luykx JJ,Metabolite levels (5-HIAA/ MHPG Ratio),initial,2013-01-15,GCST001821,Other measurement,#d53e4f
15588,European,398.0,23319000.0,Luykx JJ,Metabolite levels (MHPG),initial,2013-01-15,GCST001822,Other measurement,#d53e4f
15589,European,398.0,23319000.0,Luykx JJ,Metabolite levels (5-HIAA),initial,2013-01-15,GCST001820,Other measurement,#d53e4f
15590,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA),initial,2013-01-15,GCST001824,Other measurement,#d53e4f
15591,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA-5-HIAA Factor score),initial,2013-01-15,GCST001817,Other measurement,#d53e4f
15592,European,398.0,23319000.0,Luykx JJ,Metabolite levels (HVA-5-HIAA Factor score),initial,2013-01-15,GCST001817,Other measurement,#d53e4f
15593,European,1516.0,23319801.0,Rafiq S,Breast cancer (prognosis),replication,2013-01-14,GCST001816,Cancer,#d53e4f
15594,European,536.0,23319801.0,Rafiq S,Breast cancer (prognosis),initial,2013-01-14,GCST001816,Cancer,#d53e4f
15595,Asian,1727.0,23321320.0,Urabe Y,Hepatitis C induced liver cirrhosis,initial,2013-01-12,GCST001815,Cancer,#3288bd
15596,Asian,4745.0,23321320.0,Urabe Y,Hepatitis C induced liver cirrhosis,replication,2013-01-12,GCST001815,Cancer,#3288bd
15597,Asian,4190.0,23326517.0,Holliday EG,Age-related macular degeneration,replication,2013-01-11,GCST001814,Neurological disorder,#3288bd
15598,European,19805.0,23326517.0,Holliday EG,Age-related macular degeneration,initial,2013-01-11,GCST001814,Neurological disorder,#d53e4f
15599,Asian,4637.0,23303382.0,Hong KW,Hematology traits,initial,2013-01-10,GCST001813,Cardiovascular measurement,#3288bd
15600,Asian,4205.0,23303382.0,Hong KW,Hematology traits,replication,2013-01-10,GCST001813,Cardiovascular measurement,#3288bd
15601,European,1147.0,23326512.0,Greenwood TA,Bipolar disorder (mania),replication,2013-01-10,GCST001811,Neurological disorder,#d53e4f
15602,European,1993.0,23326512.0,Greenwood TA,Bipolar disorder (mania),initial,2013-01-10,GCST001811,Neurological disorder,#d53e4f
15603,Hispanic/Latin American,1367.0,23326239.0,Rubicz R,Epstein-Barr virus immune response (EBNA-1),initial,2013-01-10,GCST001812,Other measurement,#807dba
15604,Hispanic/Latin American,589.0,23326239.0,Rubicz R,Epstein-Barr virus immune response (EBNA-1),replication,2013-01-10,GCST001812,Other measurement,#807dba
15605,Hispanic/Latin American,1367.0,23326239.0,Rubicz R,Epstein-Barr virus immune response (EBNA-1),initial,2013-01-10,GCST001812,Other disease,#807dba
15606,Hispanic/Latin American,589.0,23326239.0,Rubicz R,Epstein-Barr virus immune response (EBNA-1),replication,2013-01-10,GCST001812,Other disease,#807dba
15607,European,8340.0,23307926.0,Perry JR,Menopause (age at onset),replication,2013-01-09,GCST001810,Other measurement,#d53e4f
15608,European,17091.0,23307926.0,Perry JR,Menopause (age at onset),initial,2013-01-09,GCST001810,Other measurement,#d53e4f
15609,European,47117.0,23300278.0,Saxena R,Type 2 diabetes,replication,2013-01-08,GCST001809,Metabolic disorder,#d53e4f
15610,Asian,33707.0,23300278.0,Saxena R,Type 2 diabetes,replication,2013-01-08,GCST001809,Metabolic disorder,#3288bd
15611,Asian,45687.0,23300278.0,Saxena R,Type 2 diabetes,replication,2013-01-08,GCST001809,Metabolic disorder,#3288bd
15612,Asian,1616.0,23300278.0,Saxena R,Type 2 diabetes,initial,2013-01-08,GCST001809,Metabolic disorder,#3288bd
15613,Asian,3451.0,23300138.0,He M,Tumor biomarkers,initial,2013-01-07,GCST001808,Other measurement,#3288bd
15614,Asian,10326.0,23300138.0,He M,Tumor biomarkers,replication,2013-01-07,GCST001808,Other measurement,#3288bd
15615,European,3729.0,23297363.0,Cordell HJ,Tetralogy of Fallot,replication,2013-01-07,GCST001807,Other trait,#d53e4f
15616,European,5994.0,23297363.0,Cordell HJ,Tetralogy of Fallot,initial,2013-01-07,GCST001807,Other trait,#d53e4f
15617,Asian,2538.0,23291589.0,Lu Y,Corneal structure,initial,2013-01-06,GCST001806,Other measurement,#3288bd
15618,European,13057.0,23291589.0,Lu Y,Corneal structure,initial,2013-01-06,GCST001806,Other measurement,#d53e4f
15619,Asian,1883.0,23291589.0,Lu Y,Corneal structure,initial,2013-01-06,GCST001806,Other measurement,#3288bd
15620,Asian,2542.0,23291589.0,Lu Y,Corneal structure,initial,2013-01-06,GCST001806,Other measurement,#3288bd
15621,Asian,1941.0,23291585.0,Fakiola M,Leishmaniasis (visceral),replication,2013-01-06,GCST001805,Other disease,#3288bd
15622,Hispanic/Latin American,1970.0,23291585.0,Fakiola M,Leishmaniasis (visceral),initial,2013-01-06,GCST001805,Other disease,#807dba
15623,Asian,2078.0,23291585.0,Fakiola M,Leishmaniasis (visceral),initial,2013-01-06,GCST001805,Other disease,#3288bd
15624,Asian,1352.0,23291587.0,Kirino Y,Behcet's disease,replication,2013-01-06,GCST001804,Cardiovascular disease,#3288bd
15625,Other/Mixed,1468.0,23291587.0,Kirino Y,Behcet's disease,replication,2013-01-06,GCST001804,Cardiovascular disease,#99d594
15626,Other/Mixed,2493.0,23291587.0,Kirino Y,Behcet's disease,initial,2013-01-06,GCST001804,Cardiovascular disease,#99d594
15627,Asian,2937.0,23401653.0,Guggenheim JA,Corneal curvature,replication,2013-01-03,GCST001803,Other measurement,#3288bd
15628,Asian,2281.0,23401653.0,Guggenheim JA,Corneal curvature,replication,2013-01-03,GCST001803,Other measurement,#3288bd
15629,European,2023.0,23401653.0,Guggenheim JA,Corneal curvature,initial,2013-01-03,GCST001803,Other measurement,#d53e4f
15630,Asian,2142.0,23401653.0,Guggenheim JA,Corneal curvature,replication,2013-01-03,GCST001803,Other measurement,#3288bd
15632,European,487.0,23703922.0,Li WD,Uric acid levels,initial,2013-01-02,GCST001801,Cardiovascular measurement,#d53e4f
15633,European,34549.0,23290196.0,Hek K,Depression (quantitative trait),initial,2013-01-02,GCST001802,Neurological disorder,#d53e4f
15634,European,16709.0,23290196.0,Hek K,Depression (quantitative trait),replication,2013-01-02,GCST001802,Neurological disorder,#d53e4f
15635,European,306.0,23279374.0,Athanasiadis G,&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels,initial,2013-01-02,GCST001800,Other measurement,#d53e4f
15636,European,1722.0,23359319.0,Jin G,Prostate-specific antigen levels,replication,2013-01-01,GCST001799,Other measurement,#d53e4f
15637,European,3192.0,23359319.0,Jin G,Prostate-specific antigen levels,initial,2013-01-01,GCST001799,Other measurement,#d53e4f
15638,European,12307.0,23459209.0,Faraco J,Narcolepsy,initial,2013-01-01,GCST005522,Neurological disorder,#d53e4f
15639,European,2100.0,23381943.0,Williams FM,End-stage coagulation,initial,2013-01-01,GCST001798,Hematological measurement,#d53e4f
15640,European,2100.0,23381943.0,Williams FM,End-stage coagulation,initial,2013-01-01,GCST001798,Hematological measurement,#d53e4f
15641,European,2100.0,23381943.0,Williams FM,End-stage coagulation,initial,2013-01-01,GCST001798,Other measurement,#d53e4f
15642,African Am./Caribbean,6765.0,23275298.0,Fox ER,Cardiac structure and function,initial,2012-12-28,GCST001797,Other measurement,#fee08b
15643,European,12612.0,23275298.0,Fox ER,Cardiac structure and function,replication,2012-12-28,GCST001797,Other measurement,#d53e4f
15644,African Am./Caribbean,2468.0,23275298.0,Fox ER,Cardiac structure and function,replication,2012-12-28,GCST001797,Other measurement,#fee08b
15645,Asian,1999.0,23269536.0,Sun J,Prostate-specific antigen levels,initial,2012-12-27,GCST001796,Other measurement,#3288bd
15646,Asian,1496.0,23269536.0,Sun J,Prostate-specific antigen levels,replication,2012-12-27,GCST001796,Other measurement,#3288bd
15647,Asian,1416.0,23273568.0,Yang W,Systemic lupus erythematosus,replication,2012-12-27,GCST001795,Immune system disorder,#3288bd
15648,Asian,8923.0,23273568.0,Yang W,Systemic lupus erythematosus,replication,2012-12-27,GCST001795,Immune system disorder,#3288bd
15649,Asian,5050.0,23273568.0,Yang W,Systemic lupus erythematosus,initial,2012-12-27,GCST001795,Immune system disorder,#3288bd
15650,European,5185.0,23300701.0,Jiao S,Colorectal cancer (SNP x SNP interaction),replication,2012-12-26,GCST001794,Cancer,#d53e4f
15651,European,18938.0,23300701.0,Jiao S,Colorectal cancer (SNP x SNP interaction),initial,2012-12-26,GCST001794,Cancer,#d53e4f
15653,European,3250.0,23267103.0,Desch KC,Coagulation factor levels,initial,2012-12-24,GCST001793,Other measurement,#d53e4f
15654,European,110347.0,23263486.0,Kottgen A,Urate levels,initial,2012-12-23,GCST001791,Other measurement,#d53e4f
15655,European,32813.0,23263486.0,Kottgen A,Urate levels,replication,2012-12-23,GCST001791,Other measurement,#d53e4f
15656,European,8229.0,23263489.0,Huyghe JR,Proinsulin levels (early-phase conversion),initial,2012-12-23,GCST008112,Other measurement,#d53e4f
15657,European,8229.0,23263489.0,Huyghe JR,Proinsulin levels (late-phase conversion),initial,2012-12-23,GCST008113,Other measurement,#d53e4f
15658,European,8229.0,23263489.0,Huyghe JR,Insulin disposition index,initial,2012-12-23,GCST008111,Other measurement,#d53e4f
15659,European,8229.0,23263489.0,Huyghe JR,Insulinogenic index,initial,2012-12-23,GCST008110,Other measurement,#d53e4f
15660,European,8229.0,23263489.0,Huyghe JR,Fasting blood proinsulin levels,initial,2012-12-23,GCST008109,Other measurement,#d53e4f
15661,Asian,11280.0,23263487.0,Jia WH,Colorectal cancer,replication,2012-12-23,GCST001792,Cancer,#3288bd
15662,European,26060.0,23263487.0,Jia WH,Colorectal cancer,replication,2012-12-23,GCST001792,Cancer,#d53e4f
15663,Asian,7847.0,23263487.0,Jia WH,Colorectal cancer,initial,2012-12-23,GCST001792,Cancer,#3288bd
15664,European,69374.0,23263486.0,Kottgen A,Gout,initial,2012-12-23,GCST001790,Metabolic disorder,#d53e4f
15665,European,1036.0,23263486.0,Kottgen A,Gout,replication,2012-12-23,GCST001790,Metabolic disorder,#d53e4f
15666,Asian,758.0,23263444.0,Frazier-Wood AC,Lipoprotein diameter,replication,2012-12-22,GCST001789,Other disease,#3288bd
15667,European,817.0,23263444.0,Frazier-Wood AC,Lipoprotein diameter,initial,2012-12-22,GCST001789,Other disease,#d53e4f
15668,African Am./Caribbean,1594.0,23263444.0,Frazier-Wood AC,Lipoprotein diameter,replication,2012-12-22,GCST001789,Other disease,#fee08b
15669,Hispanic/Latin American,1422.0,23263444.0,Frazier-Wood AC,Lipoprotein diameter,replication,2012-12-22,GCST001789,Other disease,#807dba
15670,European,2430.0,23263444.0,Frazier-Wood AC,Lipoprotein diameter,replication,2012-12-22,GCST001789,Other disease,#d53e4f
15671,European,979.0,23263445.0,Lawrance-Owen AJ,Digit length ratio,initial,2012-12-22,GCST001788,Body measurement,#d53e4f
15672,Asian,3761.0,23266558.0,Yamazaki K,Crohn's disease,initial,2012-12-21,GCST001785,Digestive system disorder,#3288bd
15673,Asian,16951.0,23266558.0,Yamazaki K,Crohn's disease,replication,2012-12-21,GCST001785,Digestive system disorder,#3288bd
15674,European,27809.0,23266556.0,Peters U,Colorectal cancer,initial,2012-12-21,GCST001787,Cancer,#d53e4f
15675,European,1867.0,23266556.0,Peters U,Colorectal cancer,replication,2012-12-21,GCST001787,Cancer,#d53e4f
15676,Asian,7847.0,23266556.0,Peters U,Colorectal cancer,replication,2012-12-21,GCST001787,Cancer,#3288bd
15677,European,7443.0,23259602.0,Wang X,Dental caries,initial,2012-12-21,GCST001786,Digestive system disorder,#d53e4f
15678,European,50047.0,23284291.0,Hancock DB,Pulmonary function (smoking interaction),initial,2012-12-20,GCST001784,Other measurement,#d53e4f
15679,European,50047.0,23284291.0,Hancock DB,Pulmonary function (smoking interaction),initial,2012-12-20,GCST001784,Other measurement,#d53e4f
15680,European,6234.0,23263863.0,Li J,Platelet count,initial,2012-12-20,GCST001783,Hematological measurement,#d53e4f
15681,African Am./Caribbean,7943.0,23263863.0,Li J,Platelet count,initial,2012-12-20,GCST001783,Hematological measurement,#fee08b
15682,African Am./Caribbean,7943.0,23263863.0,Li J,Mean corpuscular volume,initial,2012-12-20,GCST001781,Hematological measurement,#fee08b
15683,European,6234.0,23263863.0,Li J,Mean corpuscular volume,initial,2012-12-20,GCST001781,Hematological measurement,#d53e4f
15684,European,6234.0,23263863.0,Li J,Mean corpuscular hemoglobin concentration,initial,2012-12-20,GCST001782,Hematological measurement,#d53e4f
15685,African Am./Caribbean,7943.0,23263863.0,Li J,Mean corpuscular hemoglobin concentration,initial,2012-12-20,GCST001782,Hematological measurement,#fee08b
15686,African Am./Caribbean,7943.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#fee08b
15687,European,6234.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#d53e4f
15688,African Am./Caribbean,7943.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#fee08b
15689,European,6234.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#d53e4f
15690,African Am./Caribbean,7943.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#fee08b
15691,European,6234.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#d53e4f
15692,African Am./Caribbean,7943.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#fee08b
15693,European,6234.0,23263863.0,Li J,Hematology traits,initial,2012-12-20,GCST001779,Hematological measurement,#d53e4f
15694,African Am./Caribbean,7943.0,23263863.0,Li J,Mean corpuscular hemoglobin,initial,2012-12-20,GCST001780,Hematological measurement,#fee08b
15695,European,6234.0,23263863.0,Li J,Mean corpuscular hemoglobin,initial,2012-12-20,GCST001780,Hematological measurement,#d53e4f
15696,European,2338.0,23255317.0,Wooten EC,Hypertrophic cardiomyopathy,replication,2012-12-19,GCST001778,Cardiovascular disease,#d53e4f
15697,European,997.0,23255317.0,Wooten EC,Hypertrophic cardiomyopathy,initial,2012-12-19,GCST001778,Cardiovascular disease,#d53e4f
15698,European,4238.0,23247145.0,Makela KM,LDL (oxidized),replication,2012-12-17,GCST001777,Lipid or lipoprotein measurement,#d53e4f
15699,European,2080.0,23247145.0,Makela KM,LDL (oxidized),initial,2012-12-17,GCST001777,Lipid or lipoprotein measurement,#d53e4f
15700,Asian,2514.0,23242368.0,Jiang DK,Hepatocellular carcinoma in hepatitis B infection,initial,2012-12-16,GCST001775,Cancer,#3288bd
15701,Asian,9285.0,23242368.0,Jiang DK,Hepatocellular carcinoma in hepatitis B infection,replication,2012-12-16,GCST001775,Cancer,#3288bd
15702,European,9491.0,23247143.0,Yu B,Cardiac Troponin-T levels,initial,2012-12-16,GCST001776,Cardiovascular measurement,#d53e4f
15703,African Am./Caribbean,2053.0,23247143.0,Yu B,Cardiac Troponin-T levels,initial,2012-12-16,GCST001776,Cardiovascular measurement,#fee08b
15704,European,1151.0,23237013.0,Power RA,Reporting of stressful life event,replication,2012-12-14,GCST001774,Other trait,#d53e4f
15705,European,2578.0,23237013.0,Power RA,Reporting of stressful life event,initial,2012-12-14,GCST001774,Other trait,#d53e4f
15706,European,1151.0,23237013.0,Power RA,Reporting of stressful life event,replication,2012-12-14,GCST001774,Other measurement,#d53e4f
15707,European,2578.0,23237013.0,Power RA,Reporting of stressful life event,initial,2012-12-14,GCST001774,Other measurement,#d53e4f
15708,European,421.0,23241943.0,Clark SL,Response to antipsychotic treatment,initial,2012-12-12,GCST001773,Response to drug,#d53e4f
15710,African Am./Caribbean,214.0,23241943.0,Clark SL,Response to antipsychotic treatment,initial,2012-12-12,GCST001773,Response to drug,#fee08b
15711,Asian,22.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),initial,2012-12-11,GCST001770,Response to drug,#3288bd
15712,African Am./Caribbean,58.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),initial,2012-12-11,GCST001770,Response to drug,#fee08b
15713,Hispanic/Latin American,266.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),initial,2012-12-11,GCST001770,Response to drug,#807dba
15714,European,806.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),initial,2012-12-11,GCST001770,Response to drug,#d53e4f
15715,European,699.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),replication,2012-12-11,GCST001770,Response to drug,#d53e4f
15716,Other/Mixed,127.0,23233662.0,Ramsey LB,Methotrexate clearance (acute lymphoblastic leukemia),initial,2012-12-11,GCST001770,Response to drug,#99d594
15717,European,2748.0,23229837.0,Aragam N,Neuroticism,initial,2012-12-11,GCST001771,Neurological disorder,#d53e4f
15718,European,882.0,23233654.0,Umicevic Mirkov M,Response to TNF-alpha inhibitors in rheumatoid arthritis,initial,2012-12-11,GCST001772,Immune system disorder,#d53e4f
15719,European,1821.0,23233654.0,Umicevic Mirkov M,Response to TNF-alpha inhibitors in rheumatoid arthritis,replication,2012-12-11,GCST001772,Immune system disorder,#d53e4f
15720,European,882.0,23233654.0,Umicevic Mirkov M,Response to TNF-alpha inhibitors in rheumatoid arthritis,initial,2012-12-11,GCST001772,Response to drug,#d53e4f
15721,European,1821.0,23233654.0,Umicevic Mirkov M,Response to TNF-alpha inhibitors in rheumatoid arthritis,replication,2012-12-11,GCST001772,Response to drug,#d53e4f
15722,European,502.0,23223146.0,Le Clerc S,Aging (facial),initial,2012-12-06,GCST001767,Biological process,#d53e4f
15723,African Am./Caribbean,929.0,23216389.0,Zuo L,Alcohol and nicotine co-dependence,replication,2012-12-06,GCST001769,Neurological disorder,#fee08b
15724,European,3737.0,23216389.0,Zuo L,Alcohol and nicotine co-dependence,replication,2012-12-06,GCST001769,Neurological disorder,#d53e4f
15725,European,2214.0,23216389.0,Zuo L,Alcohol and nicotine co-dependence,initial,2012-12-06,GCST001769,Neurological disorder,#d53e4f
15726,Asian,1713.0,23001997.0,Hou S,Behcet's disease,replication,2012-12-06,GCST001768,Cardiovascular disease,#3288bd
15727,Asian,1098.0,23001997.0,Hou S,Behcet's disease,initial,2012-12-06,GCST001768,Cardiovascular disease,#3288bd
15728,European,928.0,23213074.0,Adams LA,Non-alcoholic fatty liver disease histology (other),initial,2012-12-05,GCST001766,Digestive system disorder,#d53e4f
15729,European,63506.0,23222517.0,van der Harst P,Red blood cell traits,replication,2012-12-05,GCST001765,Hematological measurement,#d53e4f
15730,Asian,9308.0,23222517.0,van der Harst P,Red blood cell traits,initial,2012-12-05,GCST001765,Hematological measurement,#3288bd
15731,European,62553.0,23222517.0,van der Harst P,Red blood cell traits,initial,2012-12-05,GCST001765,Hematological measurement,#d53e4f
15732,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15733,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15734,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15735,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15736,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15737,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15738,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Lipid or lipoprotein measurement,#807dba
15739,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Inflammatory measurement,#807dba
15740,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15741,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Biological process,#807dba
15742,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15743,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15744,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15745,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15746,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15747,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Biological process,#807dba
15748,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Cardiovascular measurement,#807dba
15749,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15750,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15751,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15752,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Biological process,#807dba
15753,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Cardiovascular measurement,#807dba
15754,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15755,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15756,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15757,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15758,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Lipid or lipoprotein measurement,#807dba
15759,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Inflammatory measurement,#807dba
15760,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15761,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15762,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15763,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Inflammatory measurement,#807dba
15764,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15765,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15766,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15767,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Lipid or lipoprotein measurement,#807dba
15768,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Liver enzyme measurement,#807dba
15769,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15770,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Inflammatory measurement,#807dba
15771,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15772,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15773,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15774,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Body measurement,#807dba
15775,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15776,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Cardiovascular measurement,#807dba
15777,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15778,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Liver enzyme measurement,#807dba
15779,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Inflammatory measurement,#807dba
15780,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15781,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15782,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15783,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15784,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15785,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Lipid or lipoprotein measurement,#807dba
15786,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Lipid or lipoprotein measurement,#807dba
15787,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15788,Hispanic/Latin American,815.0,23251661.0,Comuzzie AG,Obesity-related traits,initial,2012-12-04,GCST001762,Other measurement,#807dba
15791,European,1367.0,23207651.0,Davies G,Cognitive decline,replication,2012-12-04,GCST001761,Other trait,#d53e4f
15792,European,3280.0,23207651.0,Davies G,Cognitive decline,initial,2012-12-04,GCST001761,Other trait,#d53e4f
15794,European,5640.0,23181788.0,Lasky-Su J,Asthma,replication,2012-12-04,GCST001763,Other disease,#d53e4f
15795,Hispanic/Latin American,1809.0,23181788.0,Lasky-Su J,Asthma,replication,2012-12-04,GCST001763,Other disease,#807dba
15796,European,3855.0,23181788.0,Lasky-Su J,Asthma,initial,2012-12-04,GCST001763,Other disease,#d53e4f
15798,Asian,8776.0,23209189.0,Tabassum R,Type 2 diabetes,replication,2012-12-03,GCST001759,Metabolic disorder,#3288bd
15799,European,22570.0,23209189.0,Tabassum R,Type 2 diabetes,replication,2012-12-03,GCST001759,Metabolic disorder,#d53e4f
15800,Asian,2128.0,23209189.0,Tabassum R,Type 2 diabetes,initial,2012-12-03,GCST001759,Metabolic disorder,#3288bd
15801,European,26836.0,23202124.0,Horikoshi M,Birth weight,initial,2012-12-02,GCST001758,Body measurement,#d53e4f
15802,European,42519.0,23202124.0,Horikoshi M,Birth weight,replication,2012-12-02,GCST001758,Body measurement,#d53e4f
15803,European,2454.0,23212062.0,Fanous AH,Schizophrenia,initial,2012-12-01,GCST001757,Neurological disorder,#d53e4f
15804,European,43327.0,23143596.0,Eyre S,Rheumatoid arthritis (ACPA-positive),initial,2012-12-01,GCST005568,Immune system disorder,#d53e4f
15805,European,19167.0,23143596.0,Eyre S,Rheumatoid arthritis (ACPA-negative),initial,2012-12-01,GCST005567,Immune system disorder,#d53e4f
15806,European,47580.0,23143596.0,Eyre S,Rheumatoid arthritis,initial,2012-12-01,GCST005569,Immune system disorder,#d53e4f
15807,European,12097.0,22922229.0,Cooper JD,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),initial,2012-12-01,GCST005524,Immune system disorder,#d53e4f
15808,European,12097.0,22922229.0,Cooper JD,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),initial,2012-12-01,GCST005524,Immune system disorder,#d53e4f
15809,European,12097.0,22922229.0,Cooper JD,Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),initial,2012-12-01,GCST005524,Immune system disorder,#d53e4f
15810,European,33394.0,23143594.0,Tsoi LC,Psoriasis,initial,2012-12-01,GCST005527,Immune system disorder,#d53e4f
15811,European,9826.0,22922229.0,Cooper JD,Hashimoto thyroiditis,initial,2012-12-01,GCST005525,Immune system disorder,#d53e4f
15812,European,11649.0,22922229.0,Cooper JD,Graves' disease,initial,2012-12-01,GCST005526,Immune system disorder,#d53e4f
15813,Asian,1627.0,23207799.0,Deng FY,Spine bone size,replication,2012-11-30,GCST001756,Other measurement,#3288bd
15814,European,2503.0,23207799.0,Deng FY,Spine bone size,replication,2012-11-30,GCST001756,Other measurement,#d53e4f
15815,European,2286.0,23207799.0,Deng FY,Spine bone size,initial,2012-11-30,GCST001756,Other measurement,#d53e4f
15816,African Am./Caribbean,83.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Response to drug,#fee08b
15817,European,77.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Response to drug,#d53e4f
15818,African,87.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Response to drug,#fc8d59
15819,African Am./Caribbean,83.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Neurological disorder,#fee08b
15820,European,77.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Neurological disorder,#d53e4f
15821,African,87.0,23204130.0,Wheeler HE,Paclitaxel-induced neuropathy,initial,2012-11-30,GCST001755,Neurological disorder,#fc8d59
15822,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (ever vs never smoking interaction),initial,2012-11-29,GCST001754,Other measurement,#807dba
15823,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (ever vs never smoking interaction),initial,2012-11-29,GCST001754,Other measurement,#fee08b
15824,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (ever vs never smoking interaction),initial,2012-11-29,GCST001754,Body measurement,#807dba
15825,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (ever vs never smoking interaction),initial,2012-11-29,GCST001754,Body measurement,#fee08b
15826,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (alcohol intake interaction),initial,2012-11-29,GCST004579,Other measurement,#fee08b
15827,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (alcohol intake interaction),initial,2012-11-29,GCST004579,Other measurement,#807dba
15828,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (alcohol intake interaction),initial,2012-11-29,GCST004579,Body measurement,#fee08b
15829,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (alcohol intake interaction),initial,2012-11-29,GCST004579,Body measurement,#807dba
15830,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (recreational physical activity interaction),initial,2012-11-29,GCST004583,Other measurement,#fee08b
15831,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (recreational physical activity interaction),initial,2012-11-29,GCST004583,Other measurement,#807dba
15832,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (recreational physical activity interaction),initial,2012-11-29,GCST004583,Body measurement,#fee08b
15833,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (recreational physical activity interaction),initial,2012-11-29,GCST004583,Body measurement,#807dba
15834,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (smoking years interaction),initial,2012-11-29,GCST004584,Other measurement,#fee08b
15835,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (smoking years interaction),initial,2012-11-29,GCST004584,Other measurement,#807dba
15836,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (smoking years interaction),initial,2012-11-29,GCST004584,Body measurement,#fee08b
15837,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (smoking years interaction),initial,2012-11-29,GCST004584,Body measurement,#807dba
15838,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (dietary energy interaction),initial,2012-11-29,GCST004582,Other measurement,#fee08b
15839,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (dietary energy interaction),initial,2012-11-29,GCST004582,Other measurement,#807dba
15840,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (dietary energy interaction),initial,2012-11-29,GCST004582,Body measurement,#fee08b
15841,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Waist-to-hip circumference ratio (dietary energy interaction),initial,2012-11-29,GCST004582,Body measurement,#807dba
15842,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index  (smoking years interaction),initial,2012-11-29,GCST004581,Other measurement,#fee08b
15843,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index  (smoking years interaction),initial,2012-11-29,GCST004581,Other measurement,#807dba
15844,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index  (smoking years interaction),initial,2012-11-29,GCST004581,Body measurement,#fee08b
15845,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index  (smoking years interaction),initial,2012-11-29,GCST004581,Body measurement,#807dba
15846,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (ever vs never smoking interaction),initial,2012-11-29,GCST004586,Other measurement,#fee08b
15847,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (ever vs never smoking interaction),initial,2012-11-29,GCST004586,Other measurement,#807dba
15848,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (ever vs never smoking interaction),initial,2012-11-29,GCST004586,Body measurement,#fee08b
15849,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (ever vs never smoking interaction),initial,2012-11-29,GCST004586,Body measurement,#807dba
15850,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (recreational physical activity interaction),initial,2012-11-29,GCST004580,Other measurement,#fee08b
15851,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (recreational physical activity interaction),initial,2012-11-29,GCST004580,Other measurement,#807dba
15852,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (recreational physical activity interaction),initial,2012-11-29,GCST004580,Body measurement,#fee08b
15853,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (recreational physical activity interaction),initial,2012-11-29,GCST004580,Body measurement,#807dba
15854,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (dietary energy interaction),initial,2012-11-29,GCST004587,Other measurement,#807dba
15855,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (dietary energy interaction),initial,2012-11-29,GCST004587,Other measurement,#fee08b
15856,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (dietary energy interaction),initial,2012-11-29,GCST004587,Body measurement,#807dba
15857,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (dietary energy interaction),initial,2012-11-29,GCST004587,Body measurement,#fee08b
15858,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (alcohol intake interaction),initial,2012-11-29,GCST001753,Other measurement,#807dba
15859,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (alcohol intake interaction),initial,2012-11-29,GCST001753,Other measurement,#fee08b
15860,Hispanic/Latin American,3484.0,23192594.0,Velez Edwards DR,Body mass index (alcohol intake interaction),initial,2012-11-29,GCST001753,Body measurement,#807dba
15861,African Am./Caribbean,8203.0,23192594.0,Velez Edwards DR,Body mass index (alcohol intake interaction),initial,2012-11-29,GCST001753,Body measurement,#fee08b
15862,Asian,985.0,23209447.0,Tang M,Nasopharyngeal carcinoma,replication,2012-11-29,GCST001752,Cancer,#3288bd
15863,Asian,4055.0,23209447.0,Tang M,Nasopharyngeal carcinoma,initial,2012-11-29,GCST001752,Cancer,#3288bd
15864,Asian,235.0,23183491.0,Nishizawa D,Opioid sensitivity,replication,2012-11-27,GCST001751,Response to drug,#3288bd
15865,Asian,118.0,23183491.0,Nishizawa D,Opioid sensitivity,initial,2012-11-27,GCST001751,Response to drug,#3288bd
15866,European,10781.0,23184150.0,Henrion M,Renal cell carcinoma,initial,2012-11-25,GCST001750,Cancer,#d53e4f
15867,European,12525.0,23184150.0,Henrion M,Renal cell carcinoma,replication,2012-11-25,GCST001750,Cancer,#d53e4f
15868,Asian,363.0,23180869.0,Wu C,Pancreatic cancer,replication,2012-11-24,GCST001749,Cancer,#3288bd
15869,European,642.0,23180869.0,Wu C,Pancreatic cancer,initial,2012-11-24,GCST001749,Cancer,#d53e4f
15870,African Am./Caribbean,13372.0,23183192.0,Deo R,Resting heart rate,initial,2012-11-23,GCST001748,Cardiovascular measurement,#fee08b
15871,Asian,1138.0,23180272.0,Park BL,Aspirin exacerbated respiratory disease in asthmatics,replication,2012-11-21,GCST001747,Other trait,#3288bd
15872,Asian,802.0,23180272.0,Park BL,Aspirin exacerbated respiratory disease in asthmatics,initial,2012-11-21,GCST001747,Other trait,#3288bd
15873,African Am./Caribbean,13105.0,23166209.0,Smith JG,QT interval,initial,2012-11-19,GCST001746,Cardiovascular measurement,#fee08b
15875,European,390.0,23160099.0,Justice CM,Sagittal craniosynostosis,initial,2012-11-18,GCST001745,Neurological disorder,#d53e4f
15876,Asian,182.0,23151678.0,Takata R,Serum tamsulosin hydrochloride concentration,initial,2012-11-15,GCST001744,Response to drug,#3288bd
15877,European,5069.0,23150908.0,Jonsson T,Alzheimer's disease,replication,2012-11-14,GCST001743,Neurological disorder,#d53e4f
15878,European,12438.0,23150908.0,Jonsson T,Alzheimer's disease,initial,2012-11-14,GCST001743,Neurological disorder,#d53e4f
15880,Asian,1190.0,23149450.0,Otowa T,Panic disorder,replication,2012-11-13,GCST001742,Neurological disorder,#3288bd
15881,Asian,2435.0,23149450.0,Otowa T,Panic disorder,initial,2012-11-13,GCST001742,Neurological disorder,#3288bd
15882,European,5080.0,23143602.0,Whitcomb DC,Pancreatitis,replication,2012-11-11,GCST001741,Digestive system disorder,#d53e4f
15883,European,5183.0,23143602.0,Whitcomb DC,Pancreatitis,initial,2012-11-11,GCST001741,Digestive system disorder,#d53e4f
15884,Asian,4012.0,23143601.0,Lan Q,Lung cancer,replication,2012-11-11,GCST001740,Cancer,#3288bd
15885,Asian,10054.0,23143601.0,Lan Q,Lung cancer,initial,2012-11-11,GCST001740,Cancer,#3288bd
15886,European,793.0,23149075.0,Aslibekyan S,Response to fenofibrate (adiponectin levels),initial,2012-11-10,GCST001738,Response to drug,#d53e4f
15887,African Am./Caribbean,2469.0,23146381.0,Levin AM,IgE levels,initial,2012-11-10,GCST001739,Other measurement,#fee08b
15888,Hispanic/Latin American,259.0,23146381.0,Levin AM,IgE levels,initial,2012-11-10,GCST001739,Other measurement,#807dba
15889,European,1564.0,23146381.0,Levin AM,IgE levels,initial,2012-11-10,GCST001739,Other measurement,#d53e4f
15890,Hispanic/Latin American,1477.0,23146381.0,Levin AM,IgE levels,replication,2012-11-10,GCST001739,Other measurement,#807dba
15891,European,1329.0,23146381.0,Levin AM,IgE levels,replication,2012-11-10,GCST001739,Other measurement,#d53e4f
15892,African Am./Caribbean,2961.0,23146381.0,Levin AM,IgE levels,replication,2012-11-10,GCST001739,Other measurement,#fee08b
15893,Asian,758.0,23137000.0,Lin HJ,Cataracts in type 2 diabetes,initial,2012-11-09,GCST001736,Neurological disorder,#3288bd
15894,Asian,758.0,23137000.0,Lin HJ,Cataracts in type 2 diabetes,initial,2012-11-09,GCST001736,Metabolic disorder,#3288bd
15895,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Inflammatory measurement,#d53e4f
15896,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Inflammatory measurement,#d53e4f
15897,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Other disease,#d53e4f
15898,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Inflammatory measurement,#d53e4f
15899,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Hematological measurement,#d53e4f
15900,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Inflammatory measurement,#d53e4f
15901,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Other measurement,#d53e4f
15902,European,1951.0,23144326.0,Kim DK,Chronic obstructive pulmonary disease-related biomarkers,initial,2012-11-09,GCST001737,Other measurement,#d53e4f
15903,Asian,348.0,23144319.0,Lee Y,Non-small cell lung cancer,initial,2012-11-08,GCST001734,Cancer,#3288bd
15904,African Am./Caribbean,13415.0,23139255.0,Butler AM,PR interval,initial,2012-11-08,GCST001735,Cardiovascular measurement,#fee08b
15905,European,564.0,23142968.0,Betcheva ET,Schizophrenia,initial,2012-11-07,GCST001733,Neurological disorder,#d53e4f
15906,European,427.0,23142968.0,Betcheva ET,Schizophrenia,replication,2012-11-07,GCST001733,Neurological disorder,#d53e4f
15907,Asian,756.0,23818313.0,Kim HJ,Obesity,initial,2012-11-06,GCST001732,Metabolic disorder,#3288bd
15908,Asian,1301.0,23818313.0,Kim HJ,Obesity,replication,2012-11-06,GCST001732,Metabolic disorder,#3288bd
15909,European,314.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),initial,2012-11-02,GCST001731,Other measurement,#d53e4f
15910,European,1261.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),replication,2012-11-02,GCST001731,Other measurement,#d53e4f
15911,European,314.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),initial,2012-11-02,GCST001731,Cancer,#d53e4f
15912,European,1261.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),replication,2012-11-02,GCST001731,Cancer,#d53e4f
15913,European,314.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),initial,2012-11-02,GCST001731,Other measurement,#d53e4f
15914,European,1261.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),replication,2012-11-02,GCST001731,Other measurement,#d53e4f
15915,European,314.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),initial,2012-11-02,GCST001731,Body measurement,#d53e4f
15916,European,1261.0,23114982.0,Siegert S,Colorectal cancer (environment interaction),replication,2012-11-02,GCST001731,Body measurement,#d53e4f
15917,European,5329.0,23118302.0,Chu AY,Lipoprotein-associated phospholipase A2 activity change in response to statin therapy,initial,2012-11-01,GCST001726,Lipid or lipoprotein measurement,#d53e4f
15918,European,42698.0,23128233.0,Jostins L,Inflammatory bowel disease,replication,2012-11-01,GCST001725,Digestive system disorder,#d53e4f
15919,European,34366.0,23128233.0,Jostins L,Inflammatory bowel disease,initial,2012-11-01,GCST001725,Digestive system disorder,#d53e4f
15920,European,516.0,23047291.0,Brown CC,Response to temozolomide,initial,2012-11-01,GCST001730,Response to drug,#d53e4f
15921,European,42698.0,23128233.0,Jostins L,Ulcerative colitis,replication,2012-11-01,GCST001728,Immune system disorder,#d53e4f
15922,European,34366.0,23128233.0,Jostins L,Ulcerative colitis,initial,2012-11-01,GCST001728,Immune system disorder,#d53e4f
15923,European,34366.0,23128233.0,Jostins L,Crohn's disease,initial,2012-11-01,GCST001729,Digestive system disorder,#d53e4f
15924,European,42698.0,23128233.0,Jostins L,Crohn's disease,replication,2012-11-01,GCST001729,Digestive system disorder,#d53e4f
15925,European,6851.0,23118302.0,Chu AY,Lipoprotein-associated phospholipase A2 activity and mass,initial,2012-11-01,GCST001727,Lipid or lipoprotein measurement,#d53e4f
15926,European,13664.0,23118302.0,Chu AY,Lipoprotein-associated phospholipase A2 activity and mass,replication,2012-11-01,GCST001727,Lipid or lipoprotein measurement,#d53e4f
15927,European,293.0,23118974.0,Candille SI,Eye color,replication,2012-10-31,GCST001723,Other trait,#d53e4f
15928,European,175.0,23118974.0,Candille SI,Eye color,initial,2012-10-31,GCST001723,Other trait,#d53e4f
15929,Asian,1496.0,23118916.0,Yang M,IgM levels,replication,2012-10-31,GCST001724,Other measurement,#3288bd
15930,Asian,1999.0,23118916.0,Yang M,IgM levels,initial,2012-10-31,GCST001724,Other measurement,#3288bd
15931,European,2286.0,23108985.0,Guo YF,Body mass (lean),replication,2012-10-30,GCST001722,Other measurement,#d53e4f
15932,Asian,1627.0,23108985.0,Guo YF,Body mass (lean),initial,2012-10-30,GCST001722,Other measurement,#3288bd
15933,European,1774.0,23108145.0,Wang LE,Lung Cancer (DNA repair capacity),initial,2012-10-29,GCST001721,Cancer,#d53e4f
15934,European,1374.0,23108145.0,Wang LE,Lung Cancer (DNA repair capacity),replication,2012-10-29,GCST001721,Cancer,#d53e4f
15935,European,59585.0,23104005.0,Gudmundsson J,Prostate cancer,initial,2012-10-28,GCST001719,Cancer,#d53e4f
15936,European,13053.0,23104005.0,Gudmundsson J,Prostate cancer,replication,2012-10-28,GCST001719,Cancer,#d53e4f
15937,Asian,2741.0,23104006.0,Nyholt DR,Endometriosis,initial,2012-10-28,GCST001720,Other disease,#3288bd
15938,Asian,5061.0,23104006.0,Nyholt DR,Endometriosis,replication,2012-10-28,GCST001720,Other disease,#3288bd
15939,European,11256.0,23104006.0,Nyholt DR,Endometriosis,initial,2012-10-28,GCST001720,Other disease,#d53e4f
15943,European,1402.0,23133572.0,Rye MS,Otitis media (chronic/recurrent),initial,2012-10-25,GCST001717,Neurological disorder,#d53e4f
15944,Asian,20437.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",replication,2012-10-25,GCST001718,Cancer,#3288bd
15945,Asian,9374.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",initial,2012-10-25,GCST001718,Cancer,#3288bd
15946,Asian,20437.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",replication,2012-10-25,GCST001718,Cancer,#3288bd
15947,Asian,9374.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",initial,2012-10-25,GCST001718,Cancer,#3288bd
15948,Asian,20437.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",replication,2012-10-25,GCST001718,Cancer,#3288bd
15949,Asian,9374.0,23103227.0,Jin G,"Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)",initial,2012-10-25,GCST001718,Cancer,#3288bd
15951,European,3895.0,23100282.0,Hopewell JC,Response to statin therapy,initial,2012-10-24,GCST001716,Response to drug,#d53e4f
15953,European,1678.0,23093944.0,Krumsiek J,Serum metabolite levels,initial,2012-10-18,GCST006249,Other measurement,#d53e4f
15954,European,22548.0,23065704.0,Amin Al Olama A,Prostate cancer,initial,2012-10-12,GCST001714,Cancer,#d53e4f
15955,European,49121.0,23065704.0,Amin Al Olama A,Prostate cancer,replication,2012-10-12,GCST001714,Cancer,#d53e4f
15956,European,920.0,23064961.0,Shaffer JR,Dental caries,initial,2012-10-11,GCST001713,Digestive system disorder,#d53e4f
15957,European,1716.0,23043469.0,Menzel S,HbA2 levels,replication,2012-10-09,GCST001710,Hematological measurement,#d53e4f
15958,European,2322.0,23043469.0,Menzel S,HbA2 levels,initial,2012-10-09,GCST001710,Hematological measurement,#d53e4f
15960,European,3776.0,23056639.0,de Boer RA,Protein biomarker,initial,2012-10-09,GCST001711,Other measurement,#d53e4f
15961,European,1251.0,23049088.0,Meng W,Myopia (pathological),initial,2012-10-09,GCST001712,Other trait,#d53e4f
15962,Asian,8877.0,23042114.0,Hirota T,Atopic dermatitis,replication,2012-10-07,GCST001709,Immune system disorder,#3288bd
15963,Asian,9443.0,23042114.0,Hirota T,Atopic dermatitis,initial,2012-10-07,GCST001709,Immune system disorder,#3288bd
15964,European,4948.0,23053960.0,Lee YH,Systemic lupus erythematosus,initial,2012-10-07,GCST001708,Immune system disorder,#d53e4f
15965,Asian,635.0,23041938.0,Lee YJ,Behcet's disease,replication,2012-10-06,GCST001707,Cardiovascular disease,#3288bd
15966,Asian,1167.0,23041938.0,Lee YJ,Behcet's disease,initial,2012-10-06,GCST001707,Cardiovascular disease,#3288bd
15967,European,39965.0,23041239.0,Traylor M,Stroke (ischemic),replication,2012-10-05,GCST001706,Cardiovascular disease,#d53e4f
15968,Asian,2465.0,23041239.0,Traylor M,Stroke (ischemic),replication,2012-10-05,GCST001706,Cardiovascular disease,#3288bd
15969,European,74393.0,23041239.0,Traylor M,Stroke (ischemic),initial,2012-10-05,GCST001706,Cardiovascular disease,#d53e4f
15970,European,289.0,23054467.0,Postula M,Platelet reactivity,initial,2012-10-04,GCST001705,Cardiovascular measurement,#d53e4f
15971,European,1720.0,23031429.0,Surakka I,Apolipoprotein Levels,initial,2012-10-03,GCST001703,Other measurement,#d53e4f
15972,European,1720.0,23031429.0,Surakka I,Cholesterol and Triglycerides,initial,2012-10-03,GCST001704,Lipid or lipoprotein measurement,#d53e4f
15973,European,1261.0,23031429.0,Surakka I,Cholesterol and Triglycerides,replication,2012-10-03,GCST001704,Lipid or lipoprotein measurement,#d53e4f
15974,European,1720.0,23031429.0,Surakka I,Cholesterol and Triglycerides,initial,2012-10-03,GCST001704,Lipid or lipoprotein measurement,#d53e4f
15975,European,1261.0,23031429.0,Surakka I,Cholesterol and Triglycerides,replication,2012-10-03,GCST001704,Lipid or lipoprotein measurement,#d53e4f
15976,European,11375.0,22961000.0,Liu JZ,Primary biliary cirrhosis,initial,2012-10-01,GCST005581,Cancer,#d53e4f
15977,Asian,2425.0,23023329.0,Xu J,Prostate cancer,initial,2012-09-30,GCST001702,Cancer,#3288bd
15978,Asian,10993.0,23023329.0,Xu J,Prostate cancer,replication,2012-09-30,GCST001702,Cancer,#3288bd
15979,European,18604.0,23028483.0,Ramasamy A,Asthma,initial,2012-09-28,GCST001701,Other disease,#d53e4f
15980,European,15286.0,23028483.0,Ramasamy A,Asthma,replication,2012-09-28,GCST001701,Other disease,#d53e4f
15981,Other/Mixed,230.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,replication,2012-09-26,GCST001700,Biological process,#99d594
15982,Other/Mixed,235.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2012-09-26,GCST001700,Biological process,#99d594
15983,Other/Mixed,230.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,replication,2012-09-26,GCST001700,Cancer,#99d594
15984,Other/Mixed,235.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2012-09-26,GCST001700,Cancer,#99d594
15985,Other/Mixed,230.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,replication,2012-09-26,GCST001700,Other disease,#99d594
15986,Other/Mixed,235.0,23021708.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2012-09-26,GCST001700,Other disease,#99d594
15987,Asian,9380.0,23022100.0,Franceschini N,Serum albumin level,initial,2012-09-26,GCST001699,Other measurement,#3288bd
15988,European,53190.0,23022100.0,Franceschini N,Serum albumin level,initial,2012-09-26,GCST001699,Other measurement,#d53e4f
15989,Asian,10168.0,23022100.0,Franceschini N,Serum total protein level,initial,2012-09-26,GCST001698,Hematological measurement,#3288bd
15990,European,25539.0,23022100.0,Franceschini N,Serum total protein level,initial,2012-09-26,GCST001698,Hematological measurement,#d53e4f
15991,European,2681.0,23010768.0,Meier S,Bipolar disorder (Negative mood delusions),replication,2012-09-25,GCST001695,Neurological disorder,#d53e4f
15992,European,3095.0,23010768.0,Meier S,Bipolar disorder (Negative mood delusions),initial,2012-09-25,GCST001695,Neurological disorder,#d53e4f
15993,Asian,11696.0,23049750.0,Kumasaka N,Smoking behavior,initial,2012-09-25,GCST001696,Biological process,#3288bd
15994,Asian,5462.0,23049750.0,Kumasaka N,Smoking behavior,replication,2012-09-25,GCST001696,Biological process,#3288bd
15995,European,9190.0,23001564.0,Mangino M,Telomere length,initial,2012-09-25,GCST001697,Other measurement,#d53e4f
15997,Hispanic/Latin American,815.0,23017229.0,Voruganti VS,Monocyte chemoattractant protein-1 levels,initial,2012-09-24,GCST001691,Other measurement,#807dba
15998,Asian,96.0,23006423.0,Niu N,Response to taxane treatment (docetaxel),initial,2012-09-24,GCST001692,Response to drug,#3288bd
15999,European,96.0,23006423.0,Niu N,Response to taxane treatment (docetaxel),initial,2012-09-24,GCST001692,Response to drug,#d53e4f
16000,African Am./Caribbean,96.0,23006423.0,Niu N,Response to taxane treatment (docetaxel),initial,2012-09-24,GCST001692,Response to drug,#fee08b
16001,Asian,96.0,23006423.0,Niu N,Response to taxane treatment (placlitaxel),initial,2012-09-24,GCST001694,Response to drug,#3288bd
16002,African Am./Caribbean,96.0,23006423.0,Niu N,Response to taxane treatment (placlitaxel),initial,2012-09-24,GCST001694,Response to drug,#fee08b
16003,European,96.0,23006423.0,Niu N,Response to taxane treatment (placlitaxel),initial,2012-09-24,GCST001694,Response to drug,#d53e4f
16004,Other/Mixed,1267.0,23007406.0,Yang JJ,Acute lymphoblastic leukemia (childhood),replication,2012-09-24,GCST001693,Cancer,#99d594
16005,Other/Mixed,1268.0,23007406.0,Yang JJ,Acute lymphoblastic leukemia (childhood),initial,2012-09-24,GCST001693,Cancer,#99d594
16006,European,912.0,23001122.0,Orr N,Breast cancer (male),replication,2012-09-23,GCST001690,Cancer,#d53e4f
16007,European,3618.0,23001122.0,Orr N,Breast cancer (male),initial,2012-09-23,GCST001690,Cancer,#d53e4f
16008,European,810.0,22990015.0,Arning A,Stroke (pediatric),initial,2012-09-20,GCST001689,Cardiovascular disease,#d53e4f
16009,European,3889.0,22997280.0,Ho JE,Growth differentiation factor-15 levels,initial,2012-09-20,GCST006519,Hematological measurement,#d53e4f
16010,European,6231.0,23028342.0,Sandholm N,Type 1 diabetes nephropathy,initial,2012-09-20,GCST001688,Metabolic disorder,#d53e4f
16011,European,4684.0,23028342.0,Sandholm N,Type 1 diabetes nephropathy,replication,2012-09-20,GCST001688,Metabolic disorder,#d53e4f
16012,European,4683.0,22993228.0,Williams FM,Disc degeneration (lumbar),initial,2012-09-19,GCST001687,Other disease,#d53e4f
16013,Asian,1402.0,23000144.0,Nakamura M,Primary biliary cholangitis,replication,2012-09-18,GCST001685,Cancer,#3288bd
16014,Asian,963.0,23000144.0,Nakamura M,Primary biliary cholangitis,initial,2012-09-18,GCST001685,Cancer,#3288bd
16015,European,19599.0,22990020.0,Huang J,Plasminogen activator inhibitor type 1 levels (PAI-1),initial,2012-09-18,GCST001684,Other measurement,#d53e4f
16016,European,10764.0,22990020.0,Huang J,Plasminogen activator inhibitor type 1 levels (PAI-1),replication,2012-09-18,GCST001684,Other measurement,#d53e4f
16017,European,4048.0,22986903.0,Hansel NN,Chronic obstructive pulmonary disease,initial,2012-09-18,GCST001686,Other disease,#d53e4f
16019,European,1772.0,22986903.0,Hansel NN,Chronic obstructive pulmonary disease,replication,2012-09-18,GCST001686,Other disease,#d53e4f
16020,European,2136.0,22982463.0,Tang WH,Paraoxonase activity,initial,2012-09-13,GCST001677,Cardiovascular measurement,#d53e4f
16021,European,1000.0,22981920.0,Weissflog L,Personality disorders,initial,2012-09-13,GCST001682,Neurological disorder,#d53e4f
16022,Asian,1999.0,23028341.0,Yang X,Complement C3 and C4 levels,initial,2012-09-13,GCST001679,Other measurement,#3288bd
16023,Asian,1496.0,23028341.0,Yang X,Complement C3 and C4 levels,replication,2012-09-13,GCST001679,Other measurement,#3288bd
16024,Asian,1999.0,23028341.0,Yang X,Complement C3 and C4 levels,initial,2012-09-13,GCST001679,Other measurement,#3288bd
16025,Asian,1496.0,23028341.0,Yang X,Complement C3 and C4 levels,replication,2012-09-13,GCST001679,Other measurement,#3288bd
16026,European,6972.0,22976474.0,Siddiq A,Breast cancer,replication,2012-09-13,GCST001683,Cancer,#d53e4f
16027,Hispanic/Latin American,1464.0,22976474.0,Siddiq A,Breast cancer,replication,2012-09-13,GCST001683,Cancer,#807dba
16028,Asian,914.0,22976474.0,Siddiq A,Breast cancer,replication,2012-09-13,GCST001683,Cancer,#3288bd
16029,African Am./Caribbean,3748.0,22976474.0,Siddiq A,Breast cancer,initial,2012-09-13,GCST001683,Cancer,#fee08b
16030,European,32530.0,22976474.0,Siddiq A,Breast cancer,initial,2012-09-13,GCST001683,Cancer,#d53e4f
16031,European,2801.0,22969067.0,Mishra A,Corneal curvature,initial,2012-09-13,GCST001680,Other measurement,#d53e4f
16032,Asian,5683.0,23028356.0,Myouzen K,Rheumatoid arthritis,initial,2012-09-13,GCST001681,Immune system disorder,#3288bd
16033,Asian,37586.0,23028356.0,Myouzen K,Rheumatoid arthritis,replication,2012-09-13,GCST001681,Immune system disorder,#3288bd
16034,European,5388.0,23028347.0,Liu F,Facial morphology,initial,2012-09-13,GCST001678,Other trait,#d53e4f
16035,European,4071.0,23028347.0,Liu F,Facial morphology,replication,2012-09-13,GCST001678,Other trait,#d53e4f
16036,European,59325.0,22982992.0,Yang J,Body mass index,replication,2012-09-12,GCST001676,Body measurement,#d53e4f
16037,European,133154.0,22982992.0,Yang J,Body mass index,initial,2012-09-12,GCST001676,Body measurement,#d53e4f
16038,Asian,16712.0,22960999.0,Wu C,Esophageal cancer (squamous cell),replication,2012-09-09,GCST001674,Cancer,#3288bd
16039,Asian,4075.0,22960999.0,Wu C,Esophageal cancer (squamous cell),initial,2012-09-09,GCST001674,Cancer,#3288bd
16040,Asian,16712.0,22960999.0,Wu C,Esophageal cancer (squamous cell),replication,2012-09-09,GCST001674,Cancer,#3288bd
16041,Asian,4075.0,22960999.0,Wu C,Esophageal cancer (squamous cell),initial,2012-09-09,GCST001674,Cancer,#3288bd
16042,European,7024.0,22961001.0,Su Z,Barrett's esophagus,initial,2012-09-09,GCST001675,Digestive system disorder,#d53e4f
16043,European,18811.0,22961001.0,Su Z,Barrett's esophagus,replication,2012-09-09,GCST001675,Digestive system disorder,#d53e4f
16044,Asian,16712.0,22960999.0,Wu C,Esophageal cancer  (alcohol interaction),replication,2012-09-09,GCST001672,Cancer,#3288bd
16045,Asian,4075.0,22960999.0,Wu C,Esophageal cancer  (alcohol interaction),initial,2012-09-09,GCST001672,Cancer,#3288bd
16046,European,3784.0,22968431.0,Urban TJ,Drug-induced liver injury,initial,2012-09-09,GCST001673,Digestive system disorder,#d53e4f
16047,European,2894.0,22968431.0,Urban TJ,Drug-induced liver injury,replication,2012-09-09,GCST001673,Digestive system disorder,#d53e4f
16048,European,229.0,23225573.0,Buck D,IgG levels,initial,2012-09-08,GCST001671,Other measurement,#d53e4f
16049,European,409.0,23225573.0,Buck D,IgG levels,replication,2012-09-08,GCST001671,Other measurement,#d53e4f
16050,Asian,2902.0,22951594.0,Elgazzar S,Breast cancer,initial,2012-09-06,GCST001667,Cancer,#3288bd
16051,Asian,4450.0,22951594.0,Elgazzar S,Breast cancer,replication,2012-09-06,GCST001667,Cancer,#3288bd
16052,Asian,2034.0,22961080.0,Li H,Type 2 diabetes,replication,2012-09-06,GCST001666,Metabolic disorder,#3288bd
16053,Asian,1783.0,22961080.0,Li H,Type 2 diabetes,replication,2012-09-06,GCST001666,Metabolic disorder,#3288bd
16054,Asian,35339.0,22961080.0,Li H,Type 2 diabetes,replication,2012-09-06,GCST001666,Metabolic disorder,#3288bd
16055,Asian,3712.0,22961080.0,Li H,Type 2 diabetes,initial,2012-09-06,GCST001666,Metabolic disorder,#3288bd
16056,European,9469.0,22956598.0,Peters MJ,Pain,replication,2012-09-06,GCST001668,Other trait,#d53e4f
16057,European,7099.0,22956598.0,Peters MJ,Pain,initial,2012-09-06,GCST001668,Other trait,#d53e4f
16058,European,3166.0,22961961.0,Foroud T,Intracranial aneurysm,initial,2012-09-06,GCST001665,Cardiovascular disease,#d53e4f
16059,Asian,16064.0,22951725.0,Tang XF,Vitiligo,replication,2012-09-06,GCST001670,Immune system disorder,#3288bd
16060,Asian,2818.0,22951725.0,Tang XF,Vitiligo,initial,2012-09-06,GCST001670,Immune system disorder,#3288bd
16061,Asian,2192.0,22951595.0,Hwang JY,Polycystic ovary syndrome,initial,2012-09-06,GCST001669,Other disease,#3288bd
16062,Asian,2192.0,22951595.0,Hwang JY,Polycystic ovary syndrome,replication,2012-09-06,GCST001669,Other disease,#3288bd
16063,European,4243.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis (age of onset),initial,2012-09-05,GCST001663,Neurological disorder,#d53e4f
16064,European,4243.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis (age of onset),initial,2012-09-05,GCST001663,Other measurement,#d53e4f
16065,European,9355.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals,initial,2012-09-05,GCST004792,Neurological disorder,#d53e4f
16066,European,9355.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals,initial,2012-09-05,GCST004793,Neurological disorder,#d53e4f
16067,European,4243.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis (C9orf72 mutation interaction),initial,2012-09-05,GCST004791,Neurological disorder,#d53e4f
16068,European,9355.0,22959728.0,Ahmeti KB,Amyotrophic lateral sclerosis,initial,2012-09-05,GCST001664,Neurological disorder,#d53e4f
16069,European,3590.0,22949513.0,EPICURE Consortium,Generalized epilepsy,replication,2012-09-04,GCST001662,Neurological disorder,#d53e4f
16070,European,3988.0,22949513.0,EPICURE Consortium,Generalized epilepsy,initial,2012-09-04,GCST001662,Neurological disorder,#d53e4f
16071,European,310.0,22945461.0,Rahmioglu N,CYP3A4 enzyme activity,initial,2012-09-04,GCST001661,Liver enzyme measurement,#d53e4f
16072,European,1131.0,22941191.0,Diskin SJ,Neuroblastoma,replication,2012-09-02,GCST001660,Cancer,#d53e4f
16073,African Am./Caribbean,2856.0,22941191.0,Diskin SJ,Neuroblastoma,replication,2012-09-02,GCST001660,Cancer,#fee08b
16074,European,6303.0,22941191.0,Diskin SJ,Neuroblastoma,initial,2012-09-02,GCST001660,Cancer,#d53e4f
16075,European,54410.0,22941190.0,Holliday EG,Stroke (ischemic),replication,2012-09-02,GCST001659,Cardiovascular disease,#d53e4f
16076,European,2406.0,22941190.0,Holliday EG,Stroke (ischemic),initial,2012-09-02,GCST001659,Cardiovascular disease,#d53e4f
16077,Other/Mixed,253.0,22885689.0,Levinson DF,Schizophrenia,initial,2012-09-01,GCST001657,Neurological disorder,#99d594
16078,European,3267.0,22885689.0,Levinson DF,Schizophrenia,initial,2012-09-01,GCST001657,Neurological disorder,#d53e4f
16079,Asian,3650.0,22885922.0,Morris AP,Type 2 diabetes,replication,2012-09-01,GCST005047,Metabolic disorder,#3288bd
16080,European,77138.0,22885922.0,Morris AP,Type 2 diabetes,replication,2012-09-01,GCST005047,Metabolic disorder,#d53e4f
16081,European,69033.0,22885922.0,Morris AP,Type 2 diabetes,initial,2012-09-01,GCST005047,Metabolic disorder,#d53e4f
16082,European,798.0,22881374.0,Cummings AC,Alzheimer's disease (late onset),initial,2012-09-01,GCST001658,Neurological disorder,#d53e4f
16083,Asian,1627.0,22960237.0,Han Y,Comprehensive strength and appendicular lean mass,initial,2012-08-31,GCST001656,Other measurement,#3288bd
16084,European,3286.0,22960237.0,Han Y,Comprehensive strength and appendicular lean mass,replication,2012-08-31,GCST001656,Other measurement,#d53e4f
16085,Asian,1627.0,22960237.0,Han Y,Comprehensive strength and appendicular lean mass,initial,2012-08-31,GCST001656,Other measurement,#3288bd
16086,European,3286.0,22960237.0,Han Y,Comprehensive strength and appendicular lean mass,replication,2012-08-31,GCST001656,Other measurement,#d53e4f
16088,Other/Mixed,2165.0,22935194.0,Connolly JJ,Autism,initial,2012-08-30,GCST001655,Neurological disorder,#99d594
16089,European,7405.0,22936702.0,Hofmann S,Sarcoidosis,replication,2012-08-30,GCST001654,Other disease,#d53e4f
16090,European,1870.0,22936702.0,Hofmann S,Sarcoidosis,initial,2012-08-30,GCST001654,Other disease,#d53e4f
16091,European,3225.0,22936694.0,Jin G,Androgen levels,initial,2012-08-30,GCST001653,Other measurement,#d53e4f
16092,European,3225.0,22936694.0,Jin G,Androgen levels,initial,2012-08-30,GCST001653,Other measurement,#d53e4f
16093,European,2761.0,22936669.0,Julia A,Crohn's disease,replication,2012-08-30,GCST001652,Digestive system disorder,#d53e4f
16094,European,2765.0,22936669.0,Julia A,Crohn's disease,initial,2012-08-30,GCST001652,Digestive system disorder,#d53e4f
16095,Other/Mixed,1.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#99d594
16096,European,325.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#d53e4f
16097,Asian,10.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#3288bd
16098,Other/Mixed,6.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#99d594
16100,Hispanic/Latin American,17.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#807dba
16101,African Am./Caribbean,18.0,22952603.0,Hart AB,Response to amphetamines,initial,2012-08-28,GCST001651,Biological process,#fee08b
16102,African Am./Caribbean,3787.0,22939635.0,Reiner AP,C-reactive protein,replication,2012-08-28,GCST001650,Inflammatory measurement,#fee08b
16103,African Am./Caribbean,8280.0,22939635.0,Reiner AP,C-reactive protein,initial,2012-08-28,GCST001650,Inflammatory measurement,#fee08b
16104,Hispanic/Latin American,3548.0,22939635.0,Reiner AP,C-reactive protein,initial,2012-08-28,GCST001650,Inflammatory measurement,#807dba
16105,Hispanic/Latin American,3548.0,22939635.0,Reiner AP,C-reactive protein,replication,2012-08-28,GCST001650,Inflammatory measurement,#807dba
16106,European,5656.0,22939635.0,Reiner AP,C-reactive protein,replication,2012-08-28,GCST001650,Inflammatory measurement,#d53e4f
16107,Asian,5319.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),initial,2012-08-26,GCST001649,Neurological disorder,#3288bd
16108,Asian,5301.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),replication,2012-08-26,GCST001649,Neurological disorder,#3288bd
16109,European,4830.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),replication,2012-08-26,GCST001649,Neurological disorder,#d53e4f
16110,Other/Mixed,340.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),replication,2012-08-26,GCST001649,Neurological disorder,#99d594
16111,Asian,389.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),replication,2012-08-26,GCST001649,Neurological disorder,#3288bd
16112,Asian,3268.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),initial,2012-08-26,GCST001649,Neurological disorder,#3288bd
16113,Asian,2875.0,22922875.0,Vithana EN,Glaucoma (primary angle closure),initial,2012-08-26,GCST001649,Neurological disorder,#3288bd
16114,African Am./Caribbean,5761.0,22923054.0,Chen F,Breast cancer,initial,2012-08-25,GCST001648,Cancer,#fee08b
16115,African Am./Caribbean,14579.0,22923054.0,Chen F,Breast cancer,replication,2012-08-25,GCST001648,Cancer,#fee08b
16116,European,3625.0,22925353.0,Lee HJ,Bipolar disorder,initial,2012-08-25,GCST001647,Neurological disorder,#d53e4f
16117,Asian,2075.0,22923026.0,Cheng I,Prostate cancer,initial,2012-08-24,GCST001646,Cancer,#3288bd
16118,Hispanic/Latin American,2100.0,22923026.0,Cheng I,Prostate cancer,initial,2012-08-24,GCST001646,Cancer,#807dba
16119,Asian,4969.0,22923026.0,Cheng I,Prostate cancer,replication,2012-08-24,GCST001646,Cancer,#3288bd
16120,European,5602.0,22923026.0,Cheng I,Prostate cancer,replication,2012-08-24,GCST001646,Cancer,#d53e4f
16121,African Am./Caribbean,1249.0,23067351.0,Rasmussen-Torvik LJ,LDL cholesterol,initial,2012-08-23,GCST001645,Lipid or lipoprotein measurement,#fee08b
16122,European,767.0,22911880.0,Boraska V,Eating disorders,replication,2012-08-22,GCST001644,Neurological disorder,#d53e4f
16123,European,2567.0,22911880.0,Boraska V,Eating disorders,initial,2012-08-22,GCST001644,Neurological disorder,#d53e4f
16124,European,2786.0,22915352.0,Power RA,Depression (age of onset),replication,2012-08-22,GCST001643,Neurological disorder,#d53e4f
16125,European,4330.0,22915352.0,Power RA,Depression (age of onset),initial,2012-08-22,GCST001643,Neurological disorder,#d53e4f
16126,European,2786.0,22915352.0,Power RA,Depression (age of onset),replication,2012-08-22,GCST001643,Other measurement,#d53e4f
16127,European,4330.0,22915352.0,Power RA,Depression (age of onset),initial,2012-08-22,GCST001643,Other measurement,#d53e4f
16128,European,499.0,22907730.0,Ji Y,Response to antidepressants,initial,2012-08-21,GCST001641,Response to drug,#d53e4f
16129,European,1207.0,22907730.0,Ji Y,Response to antidepressants,replication,2012-08-21,GCST001641,Response to drug,#d53e4f
16130,European,1806.0,22907691.0,Breitfeld J,Vaspin levels,replication,2012-08-21,GCST001642,Other measurement,#d53e4f
16131,European,826.0,22907691.0,Breitfeld J,Vaspin levels,initial,2012-08-21,GCST001642,Other measurement,#d53e4f
16132,European,1345.0,22903471.0,Hibar DP,Lentiform nucleus volume,initial,2012-08-18,GCST001640,Other measurement,#d53e4f
16133,Asian,5415.0,22899653.0,Timofeeva MN,Lung cancer,replication,2012-08-16,GCST001638,Cancer,#3288bd
16134,European,44385.0,22899653.0,Timofeeva MN,Lung cancer,initial,2012-08-16,GCST001638,Cancer,#d53e4f
16135,European,6608.0,22916037.0,Inouye M,Metabolite levels,initial,2012-08-16,GCST001639,Other trait,#d53e4f
16136,African,2153.0,22895189.0,Timmann C,Malaria,initial,2012-08-15,GCST001637,Digestive system disorder,#fc8d59
16137,African,5755.0,22895189.0,Timmann C,Malaria,replication,2012-08-15,GCST001637,Digestive system disorder,#fc8d59
16138,Hispanic/Latin American,496.0,22889924.0,Scharf JM,Tourette syndrome,replication,2012-08-14,GCST001635,Neurological disorder,#807dba
16139,European,6249.0,22889924.0,Scharf JM,Tourette syndrome,initial,2012-08-14,GCST001635,Neurological disorder,#d53e4f
16141,European,7919.0,22889921.0,Stewart SE,Obsessive-compulsive disorder,initial,2012-08-14,GCST001636,Neurological disorder,#d53e4f
16142,Asian,5255.0,22885925.0,Shi Y,Polycystic ovary syndrome,initial,2012-08-12,GCST001634,Other disease,#3288bd
16143,Asian,15804.0,22885925.0,Shi Y,Polycystic ovary syndrome,replication,2012-08-12,GCST001634,Other disease,#3288bd
16144,European,6811.0,22886559.0,Rajaraman P,Glioma,initial,2012-08-11,GCST001633,Cancer,#d53e4f
16145,European,16616.0,22886559.0,Rajaraman P,Glioma,replication,2012-08-11,GCST001633,Cancer,#d53e4f
16146,European,817.0,22890011.0,Frazier-Wood AC,Response to fenofibrate,initial,2012-08-09,GCST001632,Response to drug,#d53e4f
16147,European,3400.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Schizophrenia,initial,2012-08-07,GCST001631,Neurological disorder,#d53e4f
16148,European,44216.0,22883433.0,Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2,Schizophrenia,replication,2012-08-07,GCST001631,Neurological disorder,#d53e4f
16149,Asian,340.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2012-08-07,GCST001629,Response to drug,#3288bd
16150,Asian,528.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,initial,2012-08-07,GCST001629,Response to drug,#3288bd
16151,European,409.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2012-08-07,GCST001629,Response to drug,#d53e4f
16152,Asian,340.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2012-08-07,GCST001629,Cancer,#3288bd
16153,Asian,528.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,initial,2012-08-07,GCST001629,Cancer,#3288bd
16154,European,409.0,22872573.0,Hu L,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2012-08-07,GCST001629,Cancer,#d53e4f
16155,European,491.0,22869035.0,Logue MW,Post-traumatic stress disorder,initial,2012-08-07,GCST001630,Neurological disorder,#d53e4f
16156,African Am./Caribbean,605.0,22869035.0,Logue MW,Post-traumatic stress disorder,replication,2012-08-07,GCST001630,Neurological disorder,#fee08b
16157,Asian,2385.0,22863734.0,Ludwig KU,Orofacial clefts,replication,2012-08-05,GCST001628,Other trait,#3288bd
16158,European,3715.0,22863734.0,Ludwig KU,Orofacial clefts,initial,2012-08-05,GCST001628,Other trait,#d53e4f
16159,Asian,1239.0,22863731.0,Cheung CL,Thyrotoxic hypokalemic periodic paralysis,initial,2012-08-05,GCST001627,Metabolic disorder,#3288bd
16160,Asian,454.0,22863731.0,Cheung CL,Thyrotoxic hypokalemic periodic paralysis,replication,2012-08-05,GCST001627,Metabolic disorder,#3288bd
16161,Asian,1496.0,22864923.0,Yang C,IgA levels,replication,2012-08-03,GCST001626,Other measurement,#3288bd
16162,Asian,1999.0,22864923.0,Yang C,IgA levels,initial,2012-08-03,GCST001626,Other measurement,#3288bd
16163,African Am./Caribbean,117.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,replication,2012-07-27,GCST001624,Response to drug,#fee08b
16164,European,154.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,replication,2012-07-27,GCST001624,Response to drug,#d53e4f
16165,European,855.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,initial,2012-07-27,GCST001624,Response to drug,#d53e4f
16166,African Am./Caribbean,117.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,replication,2012-07-27,GCST001624,Neurological disorder,#fee08b
16167,European,154.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,replication,2012-07-27,GCST001624,Neurological disorder,#d53e4f
16168,European,855.0,22843789.0,Baldwin RM,Paclitaxel-induced neuropathy,initial,2012-07-27,GCST001624,Neurological disorder,#d53e4f
16169,European,114863.0,22843499.0,Boraska V,Sex ratio at birth,initial,2012-07-27,GCST001625,Other measurement,#d53e4f
16170,European,32875.0,22837378.0,Wilk JB,Airflow obstruction,initial,2012-07-26,GCST001621,Other measurement,#d53e4f
16171,European,2881.0,22837378.0,Wilk JB,Airflow obstruction,replication,2012-07-26,GCST001621,Other measurement,#d53e4f
16172,Other/Mixed,1314.0,22843504.0,Anney R,Autism,replication,2012-07-26,GCST001619,Neurological disorder,#99d594
16173,Other/Mixed,1419.0,22843504.0,Anney R,Autism,initial,2012-07-26,GCST001619,Neurological disorder,#99d594
16174,European,3248.0,22843503.0,Qi Q,Resistin levels,initial,2012-07-26,GCST001620,Other measurement,#d53e4f
16175,European,659.0,22843503.0,Qi Q,Resistin levels,replication,2012-07-26,GCST001620,Other measurement,#d53e4f
16177,European,246.0,22828495.0,Brown AA,Neural processing (facial expression),initial,2012-07-24,GCST001618,Other measurement,#d53e4f
16178,European,85.0,22828495.0,Brown AA,Neural processing (facial expression),replication,2012-07-24,GCST001618,Other measurement,#d53e4f
16179,European,883.0,22911860.0,Hernandez DG,Parkinson's disease,initial,2012-07-24,GCST001617,Neurological disorder,#d53e4f
16180,European,4356.0,22821403.0,Ellinghaus D,Sclerosing cholangitis and ulcerative colitis (combined),initial,2012-07-23,GCST001615,Immune system disorder,#d53e4f
16182,European,4356.0,22821403.0,Ellinghaus D,Sclerosing cholangitis and ulcerative colitis (combined),initial,2012-07-23,GCST001615,Digestive system disorder,#d53e4f
16184,European,1418.0,22814818.0,Hoehn R,Central corneal thickness,replication,2012-07-20,GCST001614,Other measurement,#d53e4f
16185,European,3931.0,22814818.0,Hoehn R,Central corneal thickness,initial,2012-07-20,GCST001614,Other measurement,#d53e4f
16186,European,3120.0,22808956.0,Lyons PA,Antineutrophil cytoplasmic antibody-associated vasculitis,replication,2012-07-19,GCST001613,Immune system disorder,#d53e4f
16187,European,6173.0,22808956.0,Lyons PA,Antineutrophil cytoplasmic antibody-associated vasculitis,initial,2012-07-19,GCST001613,Immune system disorder,#d53e4f
16188,European,8175.0,22829776.0,Coviello AD,Sex hormone-binding globulin levels,replication,2012-07-19,GCST001612,Other measurement,#d53e4f
16189,European,21791.0,22829776.0,Coviello AD,Sex hormone-binding globulin levels,initial,2012-07-19,GCST001612,Other measurement,#d53e4f
16190,European,3664.0,23055271.0,Gregersen PK,Myasthenia gravis,replication,2012-07-16,GCST001611,Other disease,#d53e4f
16191,European,5905.0,23055271.0,Gregersen PK,Myasthenia gravis,initial,2012-07-16,GCST001611,Other disease,#d53e4f
16192,Asian,39717.0,22797727.0,Okada Y,Renal function-related traits (BUN),initial,2012-07-15,GCST001610,Other measurement,#3288bd
16193,Asian,17461.0,22797727.0,Okada Y,Renal function-related traits (BUN),replication,2012-07-15,GCST001610,Other measurement,#3288bd
16194,Asian,39717.0,22797727.0,Okada Y,Renal function-related traits (BUN),initial,2012-07-15,GCST001610,Other measurement,#3288bd
16195,Asian,17461.0,22797727.0,Okada Y,Renal function-related traits (BUN),replication,2012-07-15,GCST001610,Other measurement,#3288bd
16196,Asian,7028.0,22797724.0,Shiraishi K,Lung adenocarcinoma,initial,2012-07-15,GCST001609,Cancer,#3288bd
16197,Asian,12536.0,22797724.0,Shiraishi K,Lung adenocarcinoma,replication,2012-07-15,GCST001609,Cancer,#3288bd
16198,Asian,21417.0,22797727.0,Okada Y,Renal function-related traits (urea),initial,2012-07-15,GCST001608,Other measurement,#3288bd
16199,Asian,11657.0,22797727.0,Okada Y,Renal function-related traits (urea),replication,2012-07-15,GCST001608,Other measurement,#3288bd
16200,Asian,21417.0,22797727.0,Okada Y,Renal function-related traits (urea),initial,2012-07-15,GCST001608,Cardiovascular measurement,#3288bd
16201,Asian,11657.0,22797727.0,Okada Y,Renal function-related traits (urea),replication,2012-07-15,GCST001608,Cardiovascular measurement,#3288bd
16202,Asian,42451.0,22797727.0,Okada Y,Renal function-related traits (eGRFcrea),initial,2012-07-15,GCST001607,Other measurement,#3288bd
16203,Asian,19636.0,22797727.0,Okada Y,Renal function-related traits (eGRFcrea),replication,2012-07-15,GCST001607,Other measurement,#3288bd
16204,Asian,42257.0,22797727.0,Okada Y,Renal function-related traits (sCR),initial,2012-07-15,GCST001606,Other measurement,#3288bd
16205,Asian,19662.0,22797727.0,Okada Y,Renal function-related traits (sCR),replication,2012-07-15,GCST001606,Other measurement,#3288bd
16208,Asian,9156.0,22807686.0,Li S,Hepatocellular carcinoma,replication,2012-07-12,GCST001603,Cancer,#3288bd
16209,Asian,3003.0,22807686.0,Li S,Hepatocellular carcinoma,initial,2012-07-12,GCST001603,Cancer,#3288bd
16210,African Am./Caribbean,927.0,22791750.0,Chen G,Insulin-related traits,initial,2012-07-12,GCST001604,Other measurement,#fee08b
16211,African,570.0,22791750.0,Chen G,Insulin-related traits,replication,2012-07-12,GCST001604,Other measurement,#fc8d59
16212,European,1312.0,22780124.0,Lind PA,Gambling,initial,2012-07-11,GCST001601,Biological process,#d53e4f
16213,European,282.0,22785395.0,Gaj P,Alzheimer's disease,initial,2012-07-11,GCST001602,Neurological disorder,#d53e4f
16214,European,263.0,22773346.0,Edwards DR,Aging,initial,2012-07-07,GCST001599,Biological process,#d53e4f
16215,Asian,1496.0,22673310.0,Liao M,IgG levels,replication,2012-07-07,GCST001600,Other measurement,#3288bd
16216,Asian,1999.0,22673310.0,Liao M,IgG levels,initial,2012-07-07,GCST001600,Other measurement,#3288bd
16217,Asian,126.0,22763476.0,Zhang D,Blood pressure,initial,2012-07-05,GCST001598,Other measurement,#3288bd
16218,European,5878.0,22792071.0,Zheng HF,Cortical thickness,initial,2012-07-05,GCST001593,Other measurement,#d53e4f
16219,European,1032.0,22792071.0,Zheng HF,Cortical thickness,replication,2012-07-05,GCST001593,Other measurement,#d53e4f
16220,European,1644.0,22792082.0,Himes BE,Asthma (bronchodilator response),initial,2012-07-05,GCST001597,Response to drug,#d53e4f
16221,European,1051.0,22792082.0,Himes BE,Asthma (bronchodilator response),replication,2012-07-05,GCST001597,Response to drug,#d53e4f
16222,European,1644.0,22792082.0,Himes BE,Asthma (bronchodilator response),initial,2012-07-05,GCST001597,Other disease,#d53e4f
16223,European,1051.0,22792082.0,Himes BE,Asthma (bronchodilator response),replication,2012-07-05,GCST001597,Other disease,#d53e4f
16224,European,1834.0,22792070.0,Medina-Gomez C,Bone mineral density,initial,2012-07-05,GCST001594,Other measurement,#d53e4f
16226,European,11052.0,22792070.0,Medina-Gomez C,Bone mineral density,replication,2012-07-05,GCST001594,Other measurement,#d53e4f
16227,European,5672.0,22792071.0,Zheng HF,Bone mineral density,initial,2012-07-05,GCST001595,Other measurement,#d53e4f
16228,Asian,1035.0,22792221.0,Takamoto M,Glaucoma,replication,2012-07-05,GCST001596,Neurological disorder,#3288bd
16229,Asian,843.0,22792221.0,Takamoto M,Glaucoma,initial,2012-07-05,GCST001596,Neurological disorder,#3288bd
16230,European,1392.0,22760553.0,Adkins DE,Response to citalopram treatment,initial,2012-07-03,GCST001591,Response to drug,#d53e4f
16231,African Am./Caribbean,264.0,22760553.0,Adkins DE,Response to citalopram treatment,initial,2012-07-03,GCST001591,Response to drug,#fee08b
16232,Other/Mixed,106.0,22760553.0,Adkins DE,Response to citalopram treatment,initial,2012-07-03,GCST001591,Response to drug,#99d594
16233,European,18419.0,22763110.0,Zeggini E,Osteoarthritis,initial,2012-07-03,GCST001592,Other disease,#d53e4f
16234,European,50411.0,22763110.0,Zeggini E,Osteoarthritis,replication,2012-07-03,GCST001592,Other disease,#d53e4f
16235,European,1163.0,22764253.0,Thier S,Essential tremor,replication,2012-07-03,GCST001590,Other trait,#d53e4f
16236,European,1364.0,22764253.0,Thier S,Essential tremor,initial,2012-07-03,GCST001590,Other trait,#d53e4f
16237,European,1020.0,22699663.0,Divaris K,Periodontal microbiota,initial,2012-07-01,GCST001588,Digestive system disorder,#d53e4f
16238,European,2402.0,22754043.0,Byrne EM,Insomnia (caffeine-induced),initial,2012-07-01,GCST001586,Other measurement,#d53e4f
16239,Asian,26932.0,22751097.0,Lu X,Coronary heart disease,replication,2012-07-01,GCST001587,Cardiovascular disease,#3288bd
16240,Asian,6534.0,22751097.0,Lu X,Coronary heart disease,initial,2012-07-01,GCST001587,Cardiovascular disease,#3288bd
16241,European,11617.0,22794196.0,Lu Y,Ovarian cancer,replication,2012-07-01,GCST001589,Cancer,#d53e4f
16242,European,985.0,22794196.0,Lu Y,Ovarian cancer,initial,2012-07-01,GCST001589,Cancer,#d53e4f
16243,European,16175.0,22747683.0,Eriksson N,Breast size,initial,2012-06-30,GCST001585,Body measurement,#d53e4f
16244,Asian,801.0,22744181.0,Hai R,Lean body mass and age at menarche (combined),initial,2012-06-29,GCST001584,Body measurement,#3288bd
16245,European,1692.0,22744181.0,Hai R,Lean body mass and age at menarche (combined),replication,2012-06-29,GCST001584,Body measurement,#d53e4f
16246,Asian,801.0,22744181.0,Hai R,Lean body mass and age at menarche (combined),initial,2012-06-29,GCST001584,Other measurement,#3288bd
16247,European,1692.0,22744181.0,Hai R,Lean body mass and age at menarche (combined),replication,2012-06-29,GCST001584,Other measurement,#d53e4f
16248,Other/Mixed,928.0,23505185.0,Plourde M,Adiposity,initial,2012-06-28,GCST001583,Metabolic disorder,#99d594
16249,Asian,21043.0,22737229.0,Nishida N,Hepatitis B (viral clearance),replication,2012-06-21,GCST001582,Digestive system disorder,#3288bd
16250,Asian,550.0,22737229.0,Nishida N,Hepatitis B (viral clearance),initial,2012-06-21,GCST001582,Digestive system disorder,#3288bd
16251,Asian,6805.0,22726844.0,Kim JW,QT interval,initial,2012-06-20,GCST001580,Cardiovascular measurement,#3288bd
16252,Asian,7373.0,22726844.0,Kim JW,QT interval,replication,2012-06-20,GCST001580,Cardiovascular measurement,#3288bd
16253,Other/Mixed,2547.0,22745674.0,Hager J,Coronary heart disease,replication,2012-06-20,GCST001581,Cardiovascular disease,#99d594
16254,Other/Mixed,1949.0,22745674.0,Hager J,Coronary heart disease,initial,2012-06-20,GCST001581,Cardiovascular disease,#99d594
16256,European,5909.0,22705344.0,Sobrin L,Age-related macular degeneration (choroidal neovascularisation),initial,2012-06-15,GCST001579,Neurological disorder,#d53e4f
16258,European,2594.0,22705344.0,Sobrin L,Age-related macular degeneration (CNV vs. GA),initial,2012-06-15,GCST001577,Neurological disorder,#d53e4f
16260,European,2594.0,22705344.0,Sobrin L,Age-related macular degeneration (CNV vs. GA),initial,2012-06-15,GCST001577,Neurological disorder,#d53e4f
16261,European,4953.0,22705344.0,Sobrin L,Age-related macular degeneration (geographic atrophy),initial,2012-06-15,GCST001578,Neurological disorder,#d53e4f
16262,European,658.0,22701019.0,Sabater-Lleal M,Factor XI,replication,2012-06-14,GCST001575,Hematological measurement,#d53e4f
16263,European,339.0,22701019.0,Sabater-Lleal M,Factor XI,initial,2012-06-14,GCST001575,Hematological measurement,#d53e4f
16264,Asian,1461.0,22719876.0,Kawaguchi T,Nonalcoholic fatty liver disease,initial,2012-06-14,GCST001576,Digestive system disorder,#3288bd
16265,European,986.0,22703881.0,Tang W,Prothrombin time,replication,2012-06-14,GCST001573,Hematological measurement,#d53e4f
16266,European,2583.0,22703881.0,Tang W,Prothrombin time,initial,2012-06-14,GCST001573,Hematological measurement,#d53e4f
16267,European,2611.0,22703881.0,Tang W,Activated partial thromboplastin time,replication,2012-06-14,GCST001574,Hematological measurement,#d53e4f
16268,European,9240.0,22703881.0,Tang W,Activated partial thromboplastin time,initial,2012-06-14,GCST001574,Hematological measurement,#d53e4f
16269,European,2842.0,22694956.0,Cipriani V,Age-related macular degeneration,replication,2012-06-13,GCST001571,Neurological disorder,#d53e4f
16270,European,3092.0,22694956.0,Cipriani V,Age-related macular degeneration,initial,2012-06-13,GCST001571,Neurological disorder,#d53e4f
16271,European,528.0,22704111.0,Hotaling JM,Erectile dysfunction in type 1 diabetes,initial,2012-06-13,GCST001572,Metabolic disorder,#d53e4f
16272,European,528.0,22704111.0,Hotaling JM,Erectile dysfunction in type 1 diabetes,initial,2012-06-13,GCST001572,Other disease,#d53e4f
16273,European,4866.0,22700719.0,Slager SL,Chronic lymphocytic leukemia,initial,2012-06-13,GCST001570,Cancer,#d53e4f
16274,European,2894.0,22700719.0,Slager SL,Chronic lymphocytic leukemia,replication,2012-06-13,GCST001570,Cancer,#d53e4f
16275,European,4646.0,22688191.0,Bergen SE,Schizophrenia,initial,2012-06-12,GCST001565,Neurological disorder,#d53e4f
16277,European,2929.0,22688191.0,Bergen SE,Bipolar disorder,initial,2012-06-12,GCST001569,Neurological disorder,#d53e4f
16278,Other/Mixed,24763.0,22692763.0,Liu CT,Bone mineral density (sex interaction),replication,2012-06-12,GCST001566,Other measurement,#99d594
16279,European,25353.0,22692763.0,Liu CT,Bone mineral density (sex interaction),initial,2012-06-12,GCST001566,Other measurement,#d53e4f
16280,Other/Mixed,24763.0,22692763.0,Liu CT,Bone mineral density (sex interaction),replication,2012-06-12,GCST001566,Other measurement,#99d594
16281,European,25353.0,22692763.0,Liu CT,Bone mineral density (sex interaction),initial,2012-06-12,GCST001566,Other measurement,#d53e4f
16282,European,5482.0,22688191.0,Bergen SE,Bipolar disorder and schizophrenia,initial,2012-06-12,GCST001567,Neurological disorder,#d53e4f
16283,European,5482.0,22688191.0,Bergen SE,Bipolar disorder and schizophrenia,initial,2012-06-12,GCST001567,Neurological disorder,#d53e4f
16284,Asian,51.0,22693232.0,Zhou J,Influenza (severity),initial,2012-06-12,GCST001568,Biological process,#3288bd
16285,Asian,374.0,22693232.0,Zhou J,Influenza (severity),replication,2012-06-12,GCST001568,Biological process,#3288bd
16286,European,1824.0,22694930.0,Li X,Asthma,initial,2012-06-11,GCST001564,Other disease,#d53e4f
16288,European,5160.0,22683712.0,Freilinger T,Migraine,replication,2012-06-10,GCST001563,Cardiovascular disease,#d53e4f
16289,European,25713.0,22678113.0,Cox HC,Migraine,replication,2012-06-08,GCST001562,Cardiovascular disease,#d53e4f
16290,Other/Mixed,285.0,22678113.0,Cox HC,Migraine,initial,2012-06-08,GCST001562,Cardiovascular disease,#99d594
16291,Asian,2789.0,22685421.0,Fan Q,Myopia (pathological),initial,2012-06-07,GCST001561,Other trait,#3288bd
16292,Asian,2155.0,22685421.0,Fan Q,Myopia (pathological),initial,2012-06-07,GCST001561,Other trait,#3288bd
16293,European,1416.0,22673963.0,Lasky-Su J,Vitamin D levels,initial,2012-06-07,GCST001560,Other measurement,#d53e4f
16294,Hispanic/Latin American,1108.0,22673963.0,Lasky-Su J,Vitamin D levels,replication,2012-06-07,GCST001560,Other measurement,#807dba
16295,European,7151.0,22683750.0,Sinner MF,Cardiac repolarization,replication,2012-06-06,GCST001559,Cardiovascular measurement,#d53e4f
16296,European,7482.0,22683750.0,Sinner MF,Cardiac repolarization,initial,2012-06-06,GCST001559,Cardiovascular measurement,#d53e4f
16298,Other/Mixed,2962.0,22672568.0,Heit JA,Venous thromboembolism,initial,2012-06-05,GCST001557,Cardiovascular disease,#99d594
16303,European,1598.0,22675492.0,Prescott J,Sex hormone-binding globulin levels,initial,2012-06-04,GCST001554,Other measurement,#d53e4f
16304,European,1589.0,22675492.0,Prescott J,Testosterone levels,initial,2012-06-04,GCST001555,Other measurement,#d53e4f
16305,European,1583.0,22675492.0,Prescott J,Estradiol levels,initial,2012-06-04,GCST001553,Other measurement,#d53e4f
16306,Asian,10.0,22665904.0,Willis JA,Pancreatic cancer,replication,2012-06-04,GCST001556,Cancer,#3288bd
16307,Asian,4.0,22665904.0,Willis JA,Pancreatic cancer,replication,2012-06-04,GCST001556,Cancer,#3288bd
16308,European,798.0,22665904.0,Willis JA,Pancreatic cancer,replication,2012-06-04,GCST001556,Cancer,#d53e4f
16309,African Am./Caribbean,21.0,22665904.0,Willis JA,Pancreatic cancer,replication,2012-06-04,GCST001556,Cancer,#fee08b
16310,European,252.0,22665904.0,Willis JA,Pancreatic cancer,initial,2012-06-04,GCST001556,Cancer,#d53e4f
16311,Other/Mixed,7.0,22856363.0,Ousdal OT,Amygdala reactivity,replication,2012-06-01,GCST001551,Other measurement,#99d594
16312,Asian,29.0,22856363.0,Ousdal OT,Amygdala reactivity,replication,2012-06-01,GCST001551,Other measurement,#3288bd
16313,European,50.0,22856363.0,Ousdal OT,Amygdala reactivity,replication,2012-06-01,GCST001551,Other measurement,#d53e4f
16314,African Am./Caribbean,13.0,22856363.0,Ousdal OT,Amygdala reactivity,replication,2012-06-01,GCST001551,Other measurement,#fee08b
16315,European,224.0,22856363.0,Ousdal OT,Amygdala reactivity,initial,2012-06-01,GCST001551,Other measurement,#d53e4f
16316,European,1117.0,22661486.0,Ulmer M,Central corneal thickness,initial,2012-06-01,GCST001552,Other measurement,#d53e4f
16317,European,3529.0,22648509.0,Wang KS,Formal thought disorder in schizophrenia,initial,2012-05-31,GCST001549,Other trait,#d53e4f
16320,European,12806.0,22693459.0,Li R,Male-pattern baldness,initial,2012-05-31,GCST001548,Other disease,#d53e4f
16321,European,726.0,22658931.0,Pajewski NM,Immune response to anthrax vaccine,initial,2012-05-30,GCST001547,Response to drug,#d53e4f
16322,Other/Mixed,2427.0,22666496.0,Shiffman D,Coronary heart disease event reduction (statin therapy interaction),replication,2012-05-30,GCST001545,Response to drug,#99d594
16323,Other/Mixed,682.0,22666496.0,Shiffman D,Coronary heart disease event reduction (statin therapy interaction),initial,2012-05-30,GCST001545,Response to drug,#99d594
16326,Other/Mixed,2427.0,22666496.0,Shiffman D,Coronary heart disease event reduction (statin therapy interaction),replication,2012-05-30,GCST001545,Cardiovascular disease,#99d594
16327,Other/Mixed,682.0,22666496.0,Shiffman D,Coronary heart disease event reduction (statin therapy interaction),initial,2012-05-30,GCST001545,Cardiovascular disease,#99d594
16330,European,443.0,22658654.0,Chung SJ,Parkinson's disease (motor and cognition),initial,2012-05-30,GCST001546,Neurological disorder,#d53e4f
16331,European,2291.0,22637743.0,Wei S,Lung cancer (asbestos exposure interaction),initial,2012-05-27,GCST001543,Cancer,#d53e4f
16332,European,2291.0,22637743.0,Wei S,Lung cancer (asbestos exposure interaction),initial,2012-05-27,GCST001543,Other measurement,#d53e4f
16333,European,17780.0,22634755.0,Dunlop MG,Colorectal cancer,initial,2012-05-27,GCST001544,Cancer,#d53e4f
16334,European,37170.0,22634755.0,Dunlop MG,Colorectal cancer,replication,2012-05-27,GCST001544,Cancer,#d53e4f
16335,Asian,3481.0,22634755.0,Dunlop MG,Colorectal cancer,replication,2012-05-27,GCST001544,Cancer,#3288bd
16336,European,9244.0,22628180.0,Luciano M,Personality dimensions,replication,2012-05-24,GCST001541,Other trait,#d53e4f
16337,European,6268.0,22628180.0,Luciano M,Personality dimensions,initial,2012-05-24,GCST001541,Other trait,#d53e4f
16338,European,1287.0,22628157.0,Levine AJ,HIV-associated dementia,initial,2012-05-24,GCST001542,Neurological disorder,#d53e4f
16339,European,269.0,22633400.0,Kosova G,Male fertility,initial,2012-05-23,GCST001540,Other measurement,#d53e4f
16340,European,269.0,22633400.0,Kosova G,Male fertility,initial,2012-05-23,GCST001540,Other trait,#d53e4f
16341,European,269.0,22633400.0,Kosova G,Male fertility,initial,2012-05-23,GCST001540,Other measurement,#d53e4f
16342,African Am./Caribbean,32389.0,22832964.0,David SP,Smoking behavior,initial,2012-05-22,GCST001539,Biological process,#fee08b
16343,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-12p40),initial,2012-05-19,GCST001537,Response to drug,#d53e4f
16344,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-12p40),initial,2012-05-19,GCST001537,Response to drug,#fee08b
16345,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-12p40),initial,2012-05-19,GCST001537,Other measurement,#d53e4f
16346,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-12p40),initial,2012-05-19,GCST001537,Other measurement,#fee08b
16347,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IFN-alpha),initial,2012-05-19,GCST001538,Response to drug,#d53e4f
16348,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IFN-alpha),initial,2012-05-19,GCST001538,Response to drug,#fee08b
16349,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IFN-alpha),initial,2012-05-19,GCST001538,Other measurement,#d53e4f
16350,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IFN-alpha),initial,2012-05-19,GCST001538,Other measurement,#fee08b
16351,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted TNF-alpha),initial,2012-05-19,GCST001536,Response to drug,#d53e4f
16352,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted TNF-alpha),initial,2012-05-19,GCST001536,Response to drug,#fee08b
16353,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted TNF-alpha),initial,2012-05-19,GCST001536,Other measurement,#d53e4f
16354,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted TNF-alpha),initial,2012-05-19,GCST001536,Other measurement,#fee08b
16355,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune response to smallpox vaccine (IL-6),initial,2012-05-19,GCST001532,Response to drug,#fee08b
16356,European,512.0,22610502.0,Kennedy RB,Immune response to smallpox vaccine (IL-6),initial,2012-05-19,GCST001532,Response to drug,#d53e4f
16357,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune response to smallpox vaccine (IL-6),initial,2012-05-19,GCST001532,Other measurement,#fee08b
16358,European,512.0,22610502.0,Kennedy RB,Immune response to smallpox vaccine (IL-6),initial,2012-05-19,GCST001532,Other measurement,#d53e4f
16359,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-1beta),initial,2012-05-19,GCST001533,Response to drug,#fee08b
16360,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-1beta),initial,2012-05-19,GCST001533,Response to drug,#d53e4f
16361,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-1beta),initial,2012-05-19,GCST001533,Other measurement,#fee08b
16362,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-1beta),initial,2012-05-19,GCST001533,Other measurement,#d53e4f
16363,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-10),initial,2012-05-19,GCST001534,Response to drug,#fee08b
16364,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-10),initial,2012-05-19,GCST001534,Response to drug,#d53e4f
16365,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-10),initial,2012-05-19,GCST001534,Other measurement,#fee08b
16366,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-10),initial,2012-05-19,GCST001534,Other measurement,#d53e4f
16367,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-2),initial,2012-05-19,GCST001535,Response to drug,#d53e4f
16368,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-2),initial,2012-05-19,GCST001535,Response to drug,#fee08b
16369,European,512.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-2),initial,2012-05-19,GCST001535,Other measurement,#d53e4f
16370,African Am./Caribbean,199.0,22610502.0,Kennedy RB,Immune reponse to smallpox (secreted IL-2),initial,2012-05-19,GCST001535,Other measurement,#fee08b
16371,African Am./Caribbean,419.0,22745009.0,Melville SA,Hippocampal atrophy,replication,2012-05-15,GCST001530,Neurological disorder,#fee08b
16372,European,1673.0,22745009.0,Melville SA,Hippocampal atrophy,initial,2012-05-15,GCST001530,Neurological disorder,#d53e4f
16373,European,12433.0,22832960.0,Service SK,Temperament,initial,2012-05-15,GCST001531,Other measurement,#d53e4f
16374,Asian,136.0,22584459.0,Sasayama D,Response to antidepressants,replication,2012-05-15,GCST001528,Response to drug,#3288bd
16375,Asian,92.0,22584459.0,Sasayama D,Response to antidepressants,initial,2012-05-15,GCST001528,Response to drug,#3288bd
16376,European,2229.0,22832961.0,Kamboh MI,Alzheimer's disease,initial,2012-05-15,GCST001529,Neurological disorder,#d53e4f
16377,European,1262.0,22832961.0,Kamboh MI,Alzheimer's disease,replication,2012-05-15,GCST001529,Neurological disorder,#d53e4f
16379,European,51750.0,22581228.0,Manning AK,Fasting blood insulin (BMI interaction),initial,2012-05-13,GCST001526,Body measurement,#d53e4f
16380,European,33823.0,22581228.0,Manning AK,Fasting blood insulin (BMI interaction),replication,2012-05-13,GCST001526,Body measurement,#d53e4f
16381,European,51750.0,22581228.0,Manning AK,Fasting blood insulin (BMI interaction),initial,2012-05-13,GCST001526,Other measurement,#d53e4f
16382,European,33823.0,22581228.0,Manning AK,Fasting blood insulin (BMI interaction),replication,2012-05-13,GCST001526,Other measurement,#d53e4f
16383,European,58074.0,22581228.0,Manning AK,Fasting blood glucose,initial,2012-05-13,GCST005186,Other measurement,#d53e4f
16384,European,38422.0,22581228.0,Manning AK,Fasting blood glucose,replication,2012-05-13,GCST005186,Other measurement,#d53e4f
16385,European,51750.0,22581228.0,Manning AK,Fasting blood insulin,initial,2012-05-13,GCST005185,Other measurement,#d53e4f
16386,European,33823.0,22581228.0,Manning AK,Fasting blood insulin,replication,2012-05-13,GCST005185,Other measurement,#d53e4f
16387,European,58074.0,22581228.0,Manning AK,Fasting blood glucose (BMI interaction),initial,2012-05-13,GCST001527,Body measurement,#d53e4f
16388,European,38422.0,22581228.0,Manning AK,Fasting blood glucose (BMI interaction),replication,2012-05-13,GCST001527,Body measurement,#d53e4f
16389,European,58074.0,22581228.0,Manning AK,Fasting blood glucose (BMI interaction),initial,2012-05-13,GCST001527,Other measurement,#d53e4f
16390,European,38422.0,22581228.0,Manning AK,Fasting blood glucose (BMI interaction),replication,2012-05-13,GCST001527,Other measurement,#d53e4f
16391,European,10557.0,22589738.0,Fox CS,Subcutaneous adipose tissue,initial,2012-05-10,GCST001521,Other measurement,#d53e4f
16392,European,10557.0,22589738.0,Fox CS,Visceral adipose tissue adjusted for BMI,initial,2012-05-10,GCST001523,Other measurement,#d53e4f
16393,European,10557.0,22589738.0,Fox CS,Visceral adipose tissue adjusted for BMI,initial,2012-05-10,GCST001523,Body measurement,#d53e4f
16394,European,10557.0,22589738.0,Fox CS,Visceral adipose tissue/subcutaneous adipose tissue ratio,initial,2012-05-10,GCST001524,Other measurement,#d53e4f
16395,European,10557.0,22589738.0,Fox CS,Visceral fat,initial,2012-05-10,GCST001525,Other measurement,#d53e4f
16396,Hispanic/Latin American,1399.0,22589742.0,Fox CS,Pericardial fat,replication,2012-05-10,GCST001522,Other measurement,#807dba
16397,European,5487.0,22589742.0,Fox CS,Pericardial fat,initial,2012-05-10,GCST001522,Other measurement,#d53e4f
16398,African Am./Caribbean,1442.0,22589742.0,Fox CS,Pericardial fat,replication,2012-05-10,GCST001522,Other measurement,#fee08b
16399,Asian,761.0,22589742.0,Fox CS,Pericardial fat,replication,2012-05-10,GCST001522,Other measurement,#3288bd
16400,European,198.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy,initial,2012-05-07,GCST001520,Response to drug,#d53e4f
16401,African Am./Caribbean,193.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy,initial,2012-05-07,GCST001520,Response to drug,#fee08b
16402,European,198.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy,initial,2012-05-07,GCST001520,Cardiovascular disease,#d53e4f
16403,African Am./Caribbean,193.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy,initial,2012-05-07,GCST001520,Cardiovascular disease,#fee08b
16404,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences (time),initial,2012-05-07,GCST001511,Other trait,#d53e4f
16405,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences (immigration/crime),initial,2012-05-07,GCST001515,Other trait,#d53e4f
16406,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences (feminism/equality),initial,2012-05-07,GCST001514,Other trait,#d53e4f
16407,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences (fairness),initial,2012-05-07,GCST001513,Other trait,#d53e4f
16408,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences (environmentalism),initial,2012-05-07,GCST001512,Other trait,#d53e4f
16409,European,394.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),initial,2012-05-07,GCST001518,Response to drug,#d53e4f
16410,European,196.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),replication,2012-05-07,GCST001518,Response to drug,#d53e4f
16411,African Am./Caribbean,194.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),replication,2012-05-07,GCST001518,Response to drug,#fee08b
16412,African Am./Caribbean,193.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),initial,2012-05-07,GCST001518,Response to drug,#fee08b
16413,European,394.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),initial,2012-05-07,GCST001518,Cardiovascular disease,#d53e4f
16414,European,196.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),replication,2012-05-07,GCST001518,Cardiovascular disease,#d53e4f
16415,African Am./Caribbean,194.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),replication,2012-05-07,GCST001518,Cardiovascular disease,#fee08b
16416,African Am./Caribbean,193.0,22566498.0,Turner ST,Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),initial,2012-05-07,GCST001518,Cardiovascular disease,#fee08b
16417,European,77.0,22566560.0,Malhotra AK,Antipsychotic drug-induced weight gain,initial,2012-05-07,GCST001517,Other trait,#d53e4f
16418,European,183.0,22566560.0,Malhotra AK,Antipsychotic drug-induced weight gain,replication,2012-05-07,GCST001517,Other trait,#d53e4f
16419,African Am./Caribbean,22.0,22566560.0,Malhotra AK,Antipsychotic drug-induced weight gain,replication,2012-05-07,GCST001517,Other trait,#fee08b
16420,African Am./Caribbean,32.0,22566560.0,Malhotra AK,Antipsychotic drug-induced weight gain,initial,2012-05-07,GCST001517,Other trait,#fee08b
16422,European,6523.0,22566624.0,Castano Betancourt MC,Osteoarthritis,initial,2012-05-07,GCST001516,Other disease,#d53e4f
16423,European,4442.0,22566624.0,Castano Betancourt MC,Osteoarthritis,replication,2012-05-07,GCST001516,Other disease,#d53e4f
16424,European,9617.0,22566634.0,Benjamin DJ,Economic and political preferences,initial,2012-05-07,GCST001519,Other trait,#d53e4f
16425,European,3228.0,22561518.0,Jin Y,Vitiligo,initial,2012-05-06,GCST001509,Immune system disorder,#d53e4f
16426,European,2661.0,22561518.0,Jin Y,Vitiligo,replication,2012-05-06,GCST001509,Immune system disorder,#d53e4f
16427,European,196.0,22569225.0,Krintel SB,Response to TNF-alpha inhibitors in rheumatoid arthritis,initial,2012-05-06,GCST001510,Immune system disorder,#d53e4f
16428,European,196.0,22569225.0,Krintel SB,Response to TNF-alpha inhibitors in rheumatoid arthritis,initial,2012-05-06,GCST001510,Response to drug,#d53e4f
16429,European,1576.0,22561531.0,Wan YI,Asthma,replication,2012-05-05,GCST001508,Other disease,#d53e4f
16430,European,4279.0,22561531.0,Wan YI,Asthma,initial,2012-05-05,GCST001508,Other disease,#d53e4f
16431,Other/Mixed,85.0,22556244.0,Kenny EE,Hair color,initial,2012-05-04,GCST001507,Other trait,#99d594
16432,European,1560.0,22554406.0,Kang SJ,Electroencephalographic traits in alcoholism,initial,2012-05-03,GCST001503,Other measurement,#d53e4f
16433,European,1560.0,22554406.0,Kang SJ,Electroencephalographic traits in alcoholism,initial,2012-05-03,GCST001503,Neurological disorder,#d53e4f
16434,European,7482.0,22570627.0,van Koolwijk LM,Intraocular pressure,replication,2012-05-03,GCST001506,Other measurement,#d53e4f
16435,European,11972.0,22570627.0,van Koolwijk LM,Intraocular pressure,initial,2012-05-03,GCST001506,Other measurement,#d53e4f
16436,Asian,1122.0,22551897.0,Mahasirimongkol S,Tuberculosis,initial,2012-05-03,GCST001504,Other disease,#3288bd
16437,Asian,1201.0,22551897.0,Mahasirimongkol S,Tuberculosis,replication,2012-05-03,GCST001504,Other disease,#3288bd
16438,Asian,728.0,22551897.0,Mahasirimongkol S,Tuberculosis,initial,2012-05-03,GCST001504,Other disease,#3288bd
16439,Asian,808.0,22551897.0,Mahasirimongkol S,Tuberculosis,replication,2012-05-03,GCST001504,Other disease,#3288bd
16440,European,5725.0,22570697.0,Matesanz F,Multiple sclerosis,replication,2012-05-03,GCST001505,Immune system disorder,#d53e4f
16441,European,6685.0,22570697.0,Matesanz F,Multiple sclerosis,initial,2012-05-03,GCST001505,Immune system disorder,#d53e4f
16443,European,107.0,22560479.0,Forno E,Asthma (childhood onset),replication,2012-05-02,GCST001502,Other disease,#d53e4f
16444,European,573.0,22560479.0,Forno E,Asthma (childhood onset),initial,2012-05-02,GCST001502,Other disease,#d53e4f
16445,Hispanic/Latin American,591.0,22560479.0,Forno E,Asthma (childhood onset),replication,2012-05-02,GCST001502,Other disease,#807dba
16446,African Am./Caribbean,116.0,22550155.0,Edelstein LC,Platelet thrombus formation,initial,2012-05-01,GCST001501,Cardiovascular measurement,#fee08b
16447,European,125.0,22550155.0,Edelstein LC,Platelet thrombus formation,initial,2012-05-01,GCST001501,Cardiovascular measurement,#d53e4f
16448,African Am./Caribbean,116.0,22550155.0,Edelstein LC,Platelet thrombus formation,initial,2012-05-01,GCST001501,Hematological measurement,#fee08b
16449,European,125.0,22550155.0,Edelstein LC,Platelet thrombus formation,initial,2012-05-01,GCST001501,Hematological measurement,#d53e4f
16450,European,5339.0,22544364.0,Turnbull C,Wilms tumor,replication,2012-04-29,GCST001500,Cancer,#d53e4f
16451,European,2636.0,22544364.0,Turnbull C,Wilms tumor,initial,2012-04-29,GCST001500,Cancer,#d53e4f
16452,European,15411.0,22544366.0,Ellinor PT,Atrial fibrillation,replication,2012-04-29,GCST001499,Cardiovascular disease,#d53e4f
16453,European,59133.0,22544366.0,Ellinor PT,Atrial fibrillation,initial,2012-04-29,GCST001499,Cardiovascular disease,#d53e4f
16454,European,344.0,22605921.0,Gibson J,Glaucoma (primary open-angle),replication,2012-04-28,GCST001498,Neurological disorder,#d53e4f
16455,European,5767.0,22605921.0,Gibson J,Glaucoma (primary open-angle),initial,2012-04-28,GCST001498,Neurological disorder,#d53e4f
16456,Asian,1629.0,22558069.0,Osman W,Non-albumin protein levels,replication,2012-04-27,GCST001496,Other measurement,#3288bd
16457,Asian,9103.0,22558069.0,Osman W,Non-albumin protein levels,initial,2012-04-27,GCST001496,Other measurement,#3288bd
16458,African Am./Caribbean,2152.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,replication,2012-04-27,GCST001497,Neurological disorder,#fee08b
16459,African Am./Caribbean,905.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,initial,2012-04-27,GCST001497,Neurological disorder,#fee08b
16460,African Am./Caribbean,2152.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,replication,2012-04-27,GCST001497,Digestive system disorder,#fee08b
16461,African Am./Caribbean,905.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,initial,2012-04-27,GCST001497,Digestive system disorder,#fee08b
16462,African Am./Caribbean,2152.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,replication,2012-04-27,GCST001497,Other measurement,#fee08b
16463,African Am./Caribbean,905.0,22558097.0,Milton JN,Cholelithiasis-related traits in sickle cell anemia,initial,2012-04-27,GCST001497,Other measurement,#fee08b
16464,European,407.0,22538805.0,Tantisira KG,Asthma,replication,2012-04-26,GCST001495,Other disease,#d53e4f
16465,European,418.0,22538805.0,Tantisira KG,Asthma,initial,2012-04-26,GCST001495,Other disease,#d53e4f
16466,European,6633.0,22570617.0,Wiggs JL,Glaucoma (primary open-angle),initial,2012-04-26,GCST001493,Neurological disorder,#d53e4f
16467,Asian,4137.0,22541561.0,Zhao H,Non-obstructive azoospermia,replication,2012-04-26,GCST001494,Other disease,#3288bd
16468,Asian,2665.0,22541561.0,Zhao H,Non-obstructive azoospermia,initial,2012-04-26,GCST001494,Other disease,#3288bd
16469,European,580.0,22542470.0,Ovsyannikova IG,Immune response to smallpox vaccine (IL-6),initial,2012-04-25,GCST001491,Response to drug,#d53e4f
16470,Hispanic/Latin American,217.0,22542470.0,Ovsyannikova IG,Immune response to smallpox vaccine (IL-6),initial,2012-04-25,GCST001491,Response to drug,#807dba
16471,African Am./Caribbean,217.0,22542470.0,Ovsyannikova IG,Immune response to smallpox vaccine (IL-6),initial,2012-04-25,GCST001491,Response to drug,#fee08b
16473,Hispanic/Latin American,99.0,22524403.0,Rice JP,Nicotine dependence,initial,2012-04-24,GCST001490,Neurological disorder,#807dba
16474,European,2267.0,22524403.0,Rice JP,Nicotine dependence,initial,2012-04-24,GCST001490,Neurological disorder,#d53e4f
16476,African Am./Caribbean,999.0,22524403.0,Rice JP,Nicotine dependence,initial,2012-04-24,GCST001490,Neurological disorder,#fee08b
16477,European,9126.0,22532574.0,Stevens KN,Percent mammographic density,replication,2012-04-24,GCST001489,Cancer,#d53e4f
16478,European,1241.0,22532574.0,Stevens KN,Percent mammographic density,initial,2012-04-24,GCST001489,Cancer,#d53e4f
16479,Asian,8834.0,22513714.0,Shin J,Gout,initial,2012-04-19,GCST001488,Metabolic disorder,#3288bd
16480,African Am./Caribbean,1366.0,22508271.0,Rasmussen-Torvik LJ,Fasting plasma glucose,initial,2012-04-16,GCST001486,Other measurement,#fee08b
16481,Asian,664.0,22508271.0,Rasmussen-Torvik LJ,Fasting plasma glucose,initial,2012-04-16,GCST001486,Other measurement,#3288bd
16482,European,2349.0,22508271.0,Rasmussen-Torvik LJ,Fasting plasma glucose,initial,2012-04-16,GCST001486,Other measurement,#d53e4f
16483,Hispanic/Latin American,1171.0,22508271.0,Rasmussen-Torvik LJ,Fasting plasma glucose,initial,2012-04-16,GCST001486,Other measurement,#807dba
16484,European,3727.0,22494929.0,Rawal R,Thyroid function,replication,2012-04-16,GCST001487,Other trait,#d53e4f
16485,European,3736.0,22494929.0,Rawal R,Thyroid function,initial,2012-04-16,GCST001487,Other trait,#d53e4f
16486,European,10768.0,22504419.0,Taal HR,Head circumference (infant),initial,2012-04-15,GCST001484,Body measurement,#d53e4f
16487,European,8321.0,22504419.0,Taal HR,Head circumference (infant),replication,2012-04-15,GCST001484,Body measurement,#d53e4f
16488,European,50933.0,22504420.0,Estrada K,Femoral neck bone mineral density,replication,2012-04-15,GCST007691,Other measurement,#d53e4f
16489,Other/Mixed,32961.0,22504420.0,Estrada K,Femoral neck bone mineral density,initial,2012-04-15,GCST007691,Other measurement,#99d594
16490,European,7795.0,22504417.0,Stein JL,Brain structure,initial,2012-04-15,GCST001481,Other measurement,#d53e4f
16491,Other/Mixed,237.0,22504417.0,Stein JL,Brain structure,replication,2012-04-15,GCST001481,Other measurement,#99d594
16492,European,12514.0,22504417.0,Stein JL,Brain structure,replication,2012-04-15,GCST001481,Other measurement,#d53e4f
16493,Hispanic/Latin American,605.0,22504417.0,Stein JL,Brain structure,replication,2012-04-15,GCST001481,Other measurement,#807dba
16494,Other/Mixed,8175.0,22504418.0,Ikram MA,Intracranial volume,initial,2012-04-15,GCST001483,Other measurement,#99d594
16495,European,1752.0,22504418.0,Ikram MA,Intracranial volume,replication,2012-04-15,GCST001483,Other measurement,#d53e4f
16496,Other/Mixed,32961.0,22504420.0,Estrada K,Lumbar spine bone mineral density,initial,2012-04-15,GCST001482,Other measurement,#99d594
16497,European,50933.0,22504420.0,Estrada K,Lumbar spine bone mineral density,replication,2012-04-15,GCST001482,Other measurement,#d53e4f
16498,European,2318.0,22504421.0,Bis JC,Hippocampal volume,replication,2012-04-15,GCST001485,Other measurement,#d53e4f
16499,European,9232.0,22504421.0,Bis JC,Hippocampal volume,initial,2012-04-15,GCST001485,Other measurement,#d53e4f
16500,European,2142.0,22526605.0,Howson JM,Type 1 diabetes autoantibodies,initial,2012-04-12,GCST001479,Metabolic disorder,#d53e4f
16501,European,855.0,22526605.0,Howson JM,Type 1 diabetes autoantibodies,replication,2012-04-12,GCST001479,Metabolic disorder,#d53e4f
16502,European,2142.0,22526605.0,Howson JM,Type 1 diabetes autoantibodies,initial,2012-04-12,GCST001479,Other measurement,#d53e4f
16503,European,855.0,22526605.0,Howson JM,Type 1 diabetes autoantibodies,replication,2012-04-12,GCST001479,Other measurement,#d53e4f
16504,Asian,147.0,22503698.0,Bhatnagar R,Oral cancers (chewing tobacco related),initial,2012-04-12,GCST001480,Other measurement,#3288bd
16505,Asian,147.0,22503698.0,Bhatnagar R,Oral cancers (chewing tobacco related),initial,2012-04-12,GCST001480,Cancer,#3288bd
16507,European,1104.0,22509378.0,Burri A,Sexual dysfunction (female),initial,2012-04-11,GCST001477,Other trait,#d53e4f
16508,Other/Mixed,1157.0,22491018.0,Wang J,Response to tocilizumab in rheumatoid arthritis,initial,2012-04-10,GCST001476,Immune system disorder,#99d594
16509,Other/Mixed,526.0,22491018.0,Wang J,Response to tocilizumab in rheumatoid arthritis,replication,2012-04-10,GCST001476,Immune system disorder,#99d594
16510,Other/Mixed,1157.0,22491018.0,Wang J,Response to tocilizumab in rheumatoid arthritis,initial,2012-04-10,GCST001476,Biological process,#99d594
16511,Other/Mixed,526.0,22491018.0,Wang J,Response to tocilizumab in rheumatoid arthritis,replication,2012-04-10,GCST001476,Biological process,#99d594
16512,European,4888.0,22484627.0,Bradfield JP,Obesity,replication,2012-04-08,GCST001475,Metabolic disorder,#d53e4f
16513,European,13848.0,22484627.0,Bradfield JP,Obesity,initial,2012-04-08,GCST001475,Metabolic disorder,#d53e4f
16514,European,39282.0,22493691.0,Eriksson N,Hypothyroidism,initial,2012-04-06,GCST001474,Other disease,#d53e4f
16515,European,15131.0,22482804.0,Ellinghaus D,Crohn's disease and psoriasis,initial,2012-04-06,GCST001473,Immune system disorder,#d53e4f
16516,European,17360.0,22482804.0,Ellinghaus D,Crohn's disease and psoriasis,replication,2012-04-06,GCST001473,Immune system disorder,#d53e4f
16517,European,15131.0,22482804.0,Ellinghaus D,Crohn's disease and psoriasis,initial,2012-04-06,GCST001473,Digestive system disorder,#d53e4f
16518,European,17360.0,22482804.0,Ellinghaus D,Crohn's disease and psoriasis,replication,2012-04-06,GCST001473,Digestive system disorder,#d53e4f
16519,African,486.0,22492993.0,Doumatey AP,C-reactive protein,replication,2012-04-05,GCST001472,Inflammatory measurement,#fc8d59
16520,African Am./Caribbean,837.0,22492993.0,Doumatey AP,C-reactive protein,initial,2012-04-05,GCST001472,Inflammatory measurement,#fee08b
16521,African Am./Caribbean,929.0,22488850.0,Zuo L,Alcohol and nicotine co-dependence,initial,2012-04-04,GCST001471,Neurological disorder,#fee08b
16522,European,2214.0,22488850.0,Zuo L,Alcohol and nicotine co-dependence,initial,2012-04-04,GCST001471,Neurological disorder,#d53e4f
16523,European,434.0,22472174.0,Xiao Y,Glioblastoma,replication,2012-04-03,GCST001470,Cancer,#d53e4f
16524,European,315.0,22472174.0,Xiao Y,Glioblastoma,initial,2012-04-03,GCST001470,Cancer,#d53e4f
16525,European,18759.0,22472876.0,Sullivan PF,Major depressive disorder,initial,2012-04-03,GCST001469,Neurological disorder,#d53e4f
16526,European,57478.0,22472876.0,Sullivan PF,Major depressive disorder,replication,2012-04-03,GCST001469,Neurological disorder,#d53e4f
16527,European,2372.0,22466613.0,Sun L,Cystic fibrosis (meconium ileus),replication,2012-04-01,GCST001468,Digestive system disorder,#d53e4f
16528,European,3763.0,22466613.0,Sun L,Cystic fibrosis (meconium ileus),initial,2012-04-01,GCST001468,Digestive system disorder,#d53e4f
16529,European,18753.0,22479309.0,Boraska V,Brachial circumference,initial,2012-03-29,GCST001462,Body measurement,#d53e4f
16530,European,3623.0,22479309.0,Boraska V,Brachial circumference,replication,2012-03-29,GCST001462,Body measurement,#d53e4f
16531,European,5003.0,22479346.0,Yang HC,Hypertension,replication,2012-03-29,GCST001467,Cardiovascular disease,#d53e4f
16532,Asian,800.0,22479346.0,Yang HC,Hypertension,initial,2012-03-29,GCST001467,Cardiovascular disease,#3288bd
16533,Asian,315.0,22479346.0,Yang HC,Hypertension,replication,2012-03-29,GCST001467,Cardiovascular disease,#3288bd
16534,African,397.0,22455414.0,Tekola Ayele F,Podoconiosis,initial,2012-03-29,GCST001464,Immune system disorder,#fc8d59
16535,African,606.0,22455414.0,Tekola Ayele F,Podoconiosis,replication,2012-03-29,GCST001464,Immune system disorder,#fc8d59
16536,European,29347.0,22479202.0,Dastani Z,Adiponectin levels,initial,2012-03-29,GCST001465,Other measurement,#d53e4f
16537,European,10536.0,22479202.0,Dastani Z,Adiponectin levels,replication,2012-03-29,GCST001465,Other measurement,#d53e4f
16538,Asian,1776.0,22479202.0,Dastani Z,Adiponectin levels,initial,2012-03-29,GCST001463,Other measurement,#3288bd
16539,African Am./Caribbean,4232.0,22479202.0,Dastani Z,Adiponectin levels,initial,2012-03-29,GCST001463,Other measurement,#fee08b
16540,European,29347.0,22479202.0,Dastani Z,Adiponectin levels,initial,2012-03-29,GCST001463,Other measurement,#d53e4f
16541,European,74354.0,22479191.0,Pattaro C,Chronic kidney disease,initial,2012-03-29,GCST001466,Other disease,#d53e4f
16542,European,56246.0,22479191.0,Pattaro C,Chronic kidney disease,replication,2012-03-29,GCST001466,Other disease,#d53e4f
16543,Asian,11139.0,22456796.0,Imamura M,Type 2 diabetes,replication,2012-03-28,GCST001461,Metabolic disorder,#3288bd
16544,Asian,7541.0,22456796.0,Imamura M,Type 2 diabetes,initial,2012-03-28,GCST001461,Metabolic disorder,#3288bd
16545,European,1144.0,22470424.0,Kwee LC,Amyotrophic lateral sclerosis,replication,2012-03-28,GCST001460,Neurological disorder,#d53e4f
16546,European,6896.0,22470424.0,Kwee LC,Amyotrophic lateral sclerosis,initial,2012-03-28,GCST001460,Neurological disorder,#d53e4f
16547,European,431.0,22457343.0,Martinelli-Boneschi F,Multiple sclerosis,initial,2012-03-28,GCST001459,Immune system disorder,#d53e4f
16548,European,777.0,22457343.0,Martinelli-Boneschi F,Multiple sclerosis,replication,2012-03-28,GCST001459,Immune system disorder,#d53e4f
16549,Asian,7894.0,22452962.0,Kim HC,Breast cancer,replication,2012-03-27,GCST001457,Cancer,#3288bd
16550,Asian,4325.0,22452962.0,Kim HC,Breast cancer,initial,2012-03-27,GCST001457,Cancer,#3288bd
16551,Asian,273.0,22479419.0,Liou YJ,Schizophrenia (treatment resistant),replication,2012-03-27,GCST001458,Neurological disorder,#3288bd
16552,Asian,1328.0,22479419.0,Liou YJ,Schizophrenia (treatment resistant),initial,2012-03-27,GCST001458,Neurological disorder,#3288bd
16553,Asian,20965.0,22446963.0,Okada Y,Rheumatoid arthritis,initial,2012-03-25,GCST001454,Immune system disorder,#3288bd
16554,Asian,26961.0,22446963.0,Okada Y,Rheumatoid arthritis,replication,2012-03-25,GCST001454,Immune system disorder,#3288bd
16555,Asian,811.0,22446961.0,Lee YC,Kawasaki disease,replication,2012-03-25,GCST001456,Immune system disorder,#3288bd
16556,Asian,1729.0,22446961.0,Lee YC,Kawasaki disease,initial,2012-03-25,GCST001456,Immune system disorder,#3288bd
16558,Asian,3807.0,22446962.0,Onouchi Y,Kawasaki disease,initial,2012-03-25,GCST001455,Immune system disorder,#3288bd
16559,Asian,201.0,22445761.0,Kurose K,Sexual dysfunction (SSRI/SNRI-related),initial,2012-03-23,GCST001453,Other trait,#3288bd
16560,Asian,9014.0,22419738.0,Osman W,Glaucoma (primary open-angle),replication,2012-03-22,GCST001451,Neurological disorder,#3288bd
16561,Asian,7993.0,22419738.0,Osman W,Glaucoma (primary open-angle),initial,2012-03-22,GCST001451,Neurological disorder,#3288bd
16562,European,399.0,22437316.0,Sarig O,Pemphigus vulgaris,replication,2012-03-22,GCST001452,Immune system disorder,#d53e4f
16565,Other/Mixed,372.0,22437316.0,Sarig O,Pemphigus vulgaris,replication,2012-03-22,GCST001452,Immune system disorder,#99d594
16566,European,2112.0,22437554.0,Major JM,Response to Vitamin E supplementation,initial,2012-03-21,GCST001450,Biological process,#d53e4f
16567,European,18330.0,22430674.0,Lambert JC,Alzheimer's disease,replication,2012-03-20,GCST001449,Neurological disorder,#d53e4f
16568,European,7353.0,22430674.0,Lambert JC,Alzheimer's disease,initial,2012-03-20,GCST001449,Neurological disorder,#d53e4f
16569,Asian,3514.0,22426144.0,Long J,Endometrial cancer,initial,2012-03-16,GCST001447,Cancer,#3288bd
16570,Asian,1774.0,22426144.0,Long J,Endometrial cancer,replication,2012-03-16,GCST001447,Cancer,#3288bd
16571,European,19800.0,22426144.0,Long J,Endometrial cancer,replication,2012-03-16,GCST001447,Cancer,#d53e4f
16572,Other/Mixed,762.0,22446040.0,Wang KS,Body mass index,replication,2012-03-16,GCST001448,Body measurement,#99d594
16573,European,5218.0,22446040.0,Wang KS,Body mass index,initial,2012-03-16,GCST001448,Body measurement,#d53e4f
16574,European,12018.0,22424883.0,Imboden M,Pulmonary function decline,replication,2012-03-15,GCST001444,Other measurement,#d53e4f
16575,European,4118.0,22424883.0,Imboden M,Pulmonary function decline,initial,2012-03-15,GCST001444,Other measurement,#d53e4f
16576,European,12018.0,22424883.0,Imboden M,Pulmonary function decline,replication,2012-03-15,GCST001444,Other measurement,#d53e4f
16577,European,4118.0,22424883.0,Imboden M,Pulmonary function decline,initial,2012-03-15,GCST001444,Other measurement,#d53e4f
16579,Other/Mixed,98080.0,22438815.0,Lill CM,Parkinson's disease,replication,2012-03-15,GCST001445,Neurological disorder,#99d594
16580,European,535.0,22425255.0,Lopez LM,White matter integrity,initial,2012-03-15,GCST001446,Other measurement,#d53e4f
16581,European,1094.0,22419666.0,Shi M,Orofacial clefts,initial,2012-03-14,GCST001442,Other disease,#d53e4f
16583,Other/Mixed,1277.0,22419666.0,Shi M,Orofacial clefts,initial,2012-03-14,GCST001442,Other disease,#99d594
16584,European,4916.0,22432041.0,Johnson MP,Preeclampsia,replication,2012-03-14,GCST001443,Cardiovascular disease,#d53e4f
16585,European,1078.0,22432041.0,Johnson MP,Preeclampsia,initial,2012-03-14,GCST001443,Cardiovascular disease,#d53e4f
16586,Asian,700.0,22428042.0,Nakano M,Glaucoma (primary open-angle),replication,2012-03-12,GCST001441,Neurological disorder,#3288bd
16587,Asian,1519.0,22428042.0,Nakano M,Glaucoma (primary open-angle),initial,2012-03-12,GCST001441,Neurological disorder,#3288bd
16588,European,594.0,22417934.0,Athanasiu L,Body mass index and cholesterol (psychopharmacological treatment),initial,2012-03-12,GCST001440,Lipid or lipoprotein measurement,#d53e4f
16589,European,594.0,22417934.0,Athanasiu L,Body mass index and cholesterol (psychopharmacological treatment),initial,2012-03-12,GCST001440,Biological process,#d53e4f
16590,European,594.0,22417934.0,Athanasiu L,Body mass index and cholesterol (psychopharmacological treatment),initial,2012-03-12,GCST001440,Body measurement,#d53e4f
16591,African Am./Caribbean,16388.0,22423221.0,Qayyum R,Mean platelet volume,initial,2012-03-08,GCST001439,Hematological measurement,#fee08b
16592,African Am./Caribbean,16388.0,22423221.0,Qayyum R,Platelet count,initial,2012-03-08,GCST008047,Hematological measurement,#fee08b
16593,Asian,76.0,22399142.0,Jongjaroenprasert W,Thyrotoxic hypokalemic periodic paralysis,replication,2012-03-08,GCST001437,Metabolic disorder,#3288bd
16594,Asian,152.0,22399142.0,Jongjaroenprasert W,Thyrotoxic hypokalemic periodic paralysis,initial,2012-03-08,GCST001437,Metabolic disorder,#3288bd
16595,European,2994.0,22412388.0,Kenny EE,Crohn's disease,initial,2012-03-08,GCST001438,Digestive system disorder,#d53e4f
16596,European,3095.0,22412388.0,Kenny EE,Crohn's disease,replication,2012-03-08,GCST001438,Digestive system disorder,#d53e4f
16597,European,10564.0,22399527.0,Kristiansson K,Metabolic syndrome,initial,2012-03-07,GCST001436,Metabolic disorder,#d53e4f
16598,European,4391.0,22403646.0,Froguel P,Haptoglobin levels,replication,2012-03-05,GCST001435,Hematological measurement,#d53e4f
16599,European,631.0,22403646.0,Froguel P,Haptoglobin levels,initial,2012-03-05,GCST001435,Hematological measurement,#d53e4f
16600,Other/Mixed,100.0,22391508.0,Jiang R,Naphthyl-keratin adduct levels,initial,2012-03-05,GCST001434,Other measurement,#99d594
16601,Asian,9621.0,22387998.0,Tanikawa C,Duodenal ulcer,replication,2012-03-04,GCST001433,Digestive system disorder,#3288bd
16602,Asian,22737.0,22387998.0,Tanikawa C,Duodenal ulcer,initial,2012-03-04,GCST001433,Digestive system disorder,#3288bd
16603,European,5849.0,22451204.0,Pankratz N,Parkinson's disease,replication,2012-03-01,GCST001430,Neurological disorder,#d53e4f
16604,European,8477.0,22451204.0,Pankratz N,Parkinson's disease,initial,2012-03-01,GCST001430,Neurological disorder,#d53e4f
16605,European,1372.0,22379998.0,McCormack M,Adverse response to lamotrigine and phenytoin,initial,2012-03-01,GCST001431,Response to drug,#d53e4f
16606,Asian,14765.0,22396660.0,Urabe Y,Nephrolithiasis,replication,2012-03-01,GCST001432,Other disease,#3288bd
16607,Asian,8375.0,22396660.0,Urabe Y,Nephrolithiasis,initial,2012-03-01,GCST001432,Other disease,#3288bd
16608,European,2733.0,22613542.0,Chen XD,Drinking behavior,replication,2012-03-01,GCST001429,Biological process,#d53e4f
16609,European,904.0,22613542.0,Chen XD,Drinking behavior,initial,2012-03-01,GCST001429,Biological process,#d53e4f
16610,Asian,2955.0,22613542.0,Chen XD,Drinking behavior,replication,2012-03-01,GCST001429,Biological process,#3288bd
16611,European,656.0,22449649.0,Loo SK,Intelligence,initial,2012-02-28,GCST001428,Biological process,#d53e4f
16612,European,3304.0,22377092.0,Wang KS,Nicotine dependence,replication,2012-02-27,GCST001427,Neurological disorder,#d53e4f
16613,European,2420.0,22377092.0,Wang KS,Nicotine dependence,initial,2012-02-27,GCST001427,Neurological disorder,#d53e4f
16614,European,5136.0,22367438.0,Tao S,Prostate cancer (SNP x SNP interaction),replication,2012-02-26,GCST001426,Cancer,#d53e4f
16616,Asian,1496.0,22367966.0,Lin X,Vitamin B12 levels,replication,2012-02-24,GCST001424,Other measurement,#3288bd
16617,Asian,1999.0,22367966.0,Lin X,Vitamin B12 levels,initial,2012-02-24,GCST001424,Other measurement,#3288bd
16618,Asian,315.0,22384028.0,Guo Y,Hypertension,initial,2012-02-24,GCST001423,Cardiovascular disease,#3288bd
16619,European,2550.0,22368281.0,Deshmukh HA,Response to statin therapy,replication,2012-02-24,GCST001425,Response to drug,#d53e4f
16620,European,2702.0,22368281.0,Deshmukh HA,Response to statin therapy,initial,2012-02-24,GCST001425,Response to drug,#d53e4f
16621,Asian,5242.0,22383897.0,Long J,Breast cancer,initial,2012-02-23,GCST001420,Cancer,#3288bd
16622,Asian,34455.0,22383897.0,Long J,Breast cancer,replication,2012-02-23,GCST001420,Cancer,#3288bd
16623,European,1573.0,22362865.0,Knaapila A,Odorant perception,initial,2012-02-23,GCST001422,Biological process,#d53e4f
16624,European,226.0,22362865.0,Knaapila A,Odorant perception,replication,2012-02-23,GCST001422,Biological process,#d53e4f
16625,Asian,1313.0,22383894.0,Pierce BL,Arsenic metabolism,initial,2012-02-23,GCST001421,Other measurement,#3288bd
16626,European,2697.0,22365631.0,Greenwood TA,Temperament (bipolar disorder),initial,2012-02-22,GCST001419,Other measurement,#d53e4f
16627,European,2697.0,22365631.0,Greenwood TA,Temperament (bipolar disorder),initial,2012-02-22,GCST001419,Other trait,#d53e4f
16628,European,2697.0,22365631.0,Greenwood TA,Temperament (bipolar disorder),initial,2012-02-22,GCST001419,Neurological disorder,#d53e4f
16629,African Am./Caribbean,207.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Digestive system disorder,#fee08b
16630,European,1017.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Digestive system disorder,#d53e4f
16631,Hispanic/Latin American,95.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Digestive system disorder,#807dba
16632,African Am./Caribbean,207.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Lipid or lipoprotein measurement,#fee08b
16633,European,1017.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Lipid or lipoprotein measurement,#d53e4f
16634,Hispanic/Latin American,95.0,22497812.0,Clark PJ,Lipid levels in hepatitis C treatment,initial,2012-02-22,GCST001418,Lipid or lipoprotein measurement,#807dba
16636,European,8754.0,22354554.0,Thompson SD,Arthritis (juvenile idiopathic),replication,2012-02-21,GCST001417,Immune system disorder,#d53e4f
16637,European,1472.0,22354554.0,Thompson SD,Arthritis (juvenile idiopathic),initial,2012-02-21,GCST001417,Immune system disorder,#d53e4f
16638,Asian,2118.0,22344219.0,Wen W,Body mass index,replication,2012-02-19,GCST001415,Body measurement,#3288bd
16639,Asian,2431.0,22344219.0,Wen W,Body mass index,initial,2012-02-19,GCST001415,Body measurement,#3288bd
16640,Asian,2522.0,22344219.0,Wen W,Body mass index,initial,2012-02-19,GCST001415,Body measurement,#3288bd
16641,Asian,22762.0,22344219.0,Wen W,Body mass index,initial,2012-02-19,GCST001415,Body measurement,#3288bd
16642,Asian,53215.0,22344219.0,Wen W,Body mass index,replication,2012-02-19,GCST001415,Body measurement,#3288bd
16643,Asian,35625.0,22344221.0,Okada Y,Body mass index (SNP x SNP interaction),replication,2012-02-19,GCST001416,Body measurement,#3288bd
16644,Asian,26620.0,22344221.0,Okada Y,Body mass index (SNP x SNP interaction),initial,2012-02-19,GCST001416,Body measurement,#3288bd
16645,European,4034.0,22359512.0,Demirkan A,Phospholipid levels (plasma),initial,2012-02-16,GCST001414,Lipid or lipoprotein measurement,#d53e4f
16646,European,1622.0,22341974.0,Paternoster L,Facial morphology,replication,2012-02-16,GCST001412,Other trait,#d53e4f
16647,European,2185.0,22341974.0,Paternoster L,Facial morphology,initial,2012-02-16,GCST001412,Other trait,#d53e4f
16648,European,760.0,22343285.0,Bakken TE,Occipital cortical area (total cortical area interaction),replication,2012-02-16,GCST001411,Other measurement,#d53e4f
16649,European,421.0,22343285.0,Bakken TE,Occipital cortical area (total cortical area interaction),initial,2012-02-16,GCST001411,Other measurement,#d53e4f
16650,European,760.0,22343285.0,Bakken TE,Occipital cortical area (total cortical area interaction),replication,2012-02-16,GCST001411,Other measurement,#d53e4f
16651,European,421.0,22343285.0,Bakken TE,Occipital cortical area (total cortical area interaction),initial,2012-02-16,GCST001411,Other measurement,#d53e4f
16652,European,4034.0,22359512.0,Demirkan A,Sphingolipid levels,initial,2012-02-16,GCST001413,Lipid or lipoprotein measurement,#d53e4f
16653,European,5071.0,22333899.0,Wei WH,Body mass index (SNP x SNP interaction),replication,2012-02-15,GCST001409,Body measurement,#d53e4f
16654,European,3653.0,22333899.0,Wei WH,Body mass index (SNP x SNP interaction),initial,2012-02-15,GCST001409,Body measurement,#d53e4f
16655,European,3745.0,22342860.0,Marjamaa A,Cardiac repolarization,replication,2012-02-15,GCST001410,Cardiovascular measurement,#d53e4f
16656,European,1870.0,22342860.0,Marjamaa A,Cardiac repolarization,initial,2012-02-15,GCST001410,Cardiovascular measurement,#d53e4f
16657,European,6989.0,22331829.0,Chasman DI,Response to statins (LDL cholesterol change),initial,2012-02-13,GCST001408,Response to drug,#d53e4f
16658,European,6989.0,22331829.0,Chasman DI,Response to statins (LDL cholesterol change),initial,2012-02-13,GCST001408,Lipid or lipoprotein measurement,#d53e4f
16659,European,1960.0,22327514.0,Postel-Vinay S,Ewing sarcoma,replication,2012-02-12,GCST001407,Cancer,#d53e4f
16660,European,4779.0,22327514.0,Postel-Vinay S,Ewing sarcoma,initial,2012-02-12,GCST001407,Cancer,#d53e4f
16663,Asian,928.0,22318345.0,Cha PC,Gallbladder cancer,replication,2012-02-09,GCST001404,Cancer,#3288bd
16664,Asian,907.0,22318345.0,Cha PC,Gallbladder cancer,initial,2012-02-09,GCST001404,Cancer,#3288bd
16665,Asian,4965.0,22322875.0,Kim SJ,Hypertension risk in short sleep duration,initial,2012-02-09,GCST001405,Cardiovascular disease,#3288bd
16666,Asian,4965.0,22322875.0,Kim SJ,Hypertension risk in short sleep duration,initial,2012-02-09,GCST001405,Other measurement,#3288bd
16668,European,11032.0,22319020.0,Davies RW,Coronary heart disease,replication,2012-02-07,GCST001401,Cardiovascular disease,#d53e4f
16669,European,13949.0,22319020.0,Davies RW,Coronary heart disease,initial,2012-02-07,GCST001401,Cardiovascular disease,#d53e4f
16670,European,791.0,22310351.0,Fernandez-Rozadilla C,Fluorouracil treatment response in colorectal cancer,replication,2012-02-07,GCST001403,Response to drug,#d53e4f
16671,European,203.0,22310351.0,Fernandez-Rozadilla C,Fluorouracil treatment response in colorectal cancer,initial,2012-02-07,GCST001403,Response to drug,#d53e4f
16672,European,3402.0,22306654.0,Feenstra B,Infantile hypertrophic pyloric stenosis,initial,2012-02-05,GCST001399,Digestive system disorder,#d53e4f
16673,European,1672.0,22306654.0,Feenstra B,Infantile hypertrophic pyloric stenosis,replication,2012-02-05,GCST001399,Digestive system disorder,#d53e4f
16674,African,3176.0,22306650.0,Thye T,Tuberculosis,initial,2012-02-05,GCST001398,Other disease,#fc8d59
16675,African,7178.0,22306650.0,Thye T,Tuberculosis,replication,2012-02-05,GCST001398,Other disease,#fc8d59
16676,European,10315.0,22306650.0,Thye T,Tuberculosis,replication,2012-02-05,GCST001398,Other disease,#d53e4f
16678,European,9520.0,22306652.0,Bellenguez C,Stroke,initial,2012-02-05,GCST001400,Cardiovascular disease,#d53e4f
16679,European,41458.0,22306652.0,Bellenguez C,Stroke,replication,2012-02-05,GCST001400,Cardiovascular disease,#d53e4f
16680,European,16179.0,22293688.0,Huang J,Type 1 diabetes,initial,2012-02-01,GCST001394,Metabolic disorder,#d53e4f
16681,European,16179.0,22293688.0,Huang J,Crohn's disease,initial,2012-02-01,GCST001396,Digestive system disorder,#d53e4f
16682,European,16179.0,22293688.0,Huang J,Type 2 diabetes,initial,2012-02-01,GCST001397,Metabolic disorder,#d53e4f
16683,European,1142.0,22420046.0,Stergiakouli E,Attention deficit hyperactivity disorder,replication,2012-02-01,GCST001395,Neurological disorder,#d53e4f
16684,European,5808.0,22420046.0,Stergiakouli E,Attention deficit hyperactivity disorder,initial,2012-02-01,GCST001395,Neurological disorder,#d53e4f
16686,Asian,3782.0,22290723.0,Ryu J,Glycated hemoglobin levels,replication,2012-01-30,GCST001393,Other measurement,#3288bd
16687,Asian,4275.0,22290723.0,Ryu J,Glycated hemoglobin levels,initial,2012-01-30,GCST001393,Other measurement,#3288bd
16688,European,8330.0,22286219.0,Kettunen J,Metabolite levels,initial,2012-01-29,GCST001391,Other measurement,#d53e4f
16689,European,8330.0,22286219.0,Kettunen J,Lipid metabolism phenotypes,initial,2012-01-29,GCST001392,Other measurement,#d53e4f
16690,Asian,95.0,22293537.0,Kiyotani K,Response to gemcitabine in pancreatic cancer,replication,2012-01-29,GCST001390,Response to drug,#3288bd
16691,Asian,79.0,22293537.0,Kiyotani K,Response to gemcitabine in pancreatic cancer,initial,2012-01-29,GCST001390,Response to drug,#3288bd
16692,Asian,95.0,22293537.0,Kiyotani K,Response to gemcitabine in pancreatic cancer,replication,2012-01-29,GCST001390,Cancer,#3288bd
16693,Asian,79.0,22293537.0,Kiyotani K,Response to gemcitabine in pancreatic cancer,initial,2012-01-29,GCST001390,Cancer,#3288bd
16694,European,462.0,22286170.0,Cusanovich DA,Lymphocyte counts,initial,2012-01-27,GCST001389,Hematological measurement,#d53e4f
16695,Asian,6867.0,22286173.0,Low SK,Intracranial aneurysm,initial,2012-01-27,GCST001388,Cardiovascular disease,#3288bd
16696,Asian,8260.0,22286173.0,Low SK,Intracranial aneurysm,replication,2012-01-27,GCST001388,Cardiovascular disease,#3288bd
16697,European,7617.0,22286212.0,Urayama KY,Hodgkin's lymphoma,initial,2012-01-27,GCST001387,Cancer,#d53e4f
16698,European,1176.0,22286212.0,Urayama KY,Hodgkin's lymphoma,replication,2012-01-27,GCST001387,Cancer,#d53e4f
16699,Asian,29951.0,22291604.0,Okada Y,Systemic lupus erythematosus,replication,2012-01-26,GCST001384,Immune system disorder,#3288bd
16700,Asian,4275.0,22291604.0,Okada Y,Systemic lupus erythematosus,initial,2012-01-26,GCST001384,Immune system disorder,#3288bd
16701,European,1392.0,22291609.0,Naitza S,Inflammatory biomarkers,replication,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16702,European,4694.0,22291609.0,Naitza S,Inflammatory biomarkers,initial,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16703,European,1392.0,22291609.0,Naitza S,Inflammatory biomarkers,replication,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16704,European,4694.0,22291609.0,Naitza S,Inflammatory biomarkers,initial,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16705,European,1392.0,22291609.0,Naitza S,Inflammatory biomarkers,replication,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16706,European,4694.0,22291609.0,Naitza S,Inflammatory biomarkers,initial,2012-01-26,GCST001385,Inflammatory measurement,#d53e4f
16707,European,1392.0,22291609.0,Naitza S,Inflammatory biomarkers,replication,2012-01-26,GCST001385,Other measurement,#d53e4f
16708,European,4694.0,22291609.0,Naitza S,Inflammatory biomarkers,initial,2012-01-26,GCST001385,Other measurement,#d53e4f
16710,European,495.0,22295056.0,Christie JD,Acute lung injury,replication,2012-01-25,GCST001383,Other disease,#d53e4f
16711,European,2866.0,22295056.0,Christie JD,Acute lung injury,initial,2012-01-25,GCST001383,Other disease,#d53e4f
16712,European,43773.0,22267200.0,Gudmundsson J,Thyroid cancer,replication,2012-01-22,GCST001382,Cancer,#d53e4f
16713,European,27758.0,22267200.0,Gudmundsson J,Thyroid cancer,initial,2012-01-22,GCST001382,Cancer,#d53e4f
16714,European,14435.0,22267201.0,Stolk L,Menopause (age at onset),replication,2012-01-22,GCST001381,Other measurement,#d53e4f
16715,European,38968.0,22267201.0,Stolk L,Menopause (age at onset),initial,2012-01-22,GCST001381,Other measurement,#d53e4f
16716,European,139.0,22388998.0,Zhang CK,Gaucher disease severity,initial,2012-01-19,GCST001380,Metabolic disorder,#d53e4f
16718,European,1715.0,22279548.0,Sebastiani P,Longevity,initial,2012-01-18,GCST001379,Other measurement,#d53e4f
16719,European,292.0,22279548.0,Sebastiani P,Longevity,replication,2012-01-18,GCST001379,Other measurement,#d53e4f
16720,European,951.0,22443383.0,Oudot-Mellakh T,Hemostatic factors and hematological phenotypes,initial,2012-01-16,GCST001378,Other measurement,#d53e4f
16721,Asian,223.0,22239941.0,Png E,Tuberculosis,initial,2012-01-13,GCST001377,Other disease,#3288bd
16722,Asian,1140.0,22239941.0,Png E,Tuberculosis,replication,2012-01-13,GCST001377,Other disease,#3288bd
16723,European,3616.0,22239941.0,Png E,Tuberculosis,replication,2012-01-13,GCST001377,Other disease,#d53e4f
16724,European,904.0,22247754.0,Murray SS,Life threatening arrhythmia,initial,2012-01-11,GCST001376,Cardiovascular disease,#d53e4f
16725,Asian,1714.0,22233651.0,Kwak SH,Diabetes (gestational),replication,2012-01-10,GCST001375,Metabolic disorder,#3288bd
16726,Asian,1710.0,22233651.0,Kwak SH,Diabetes (gestational),initial,2012-01-10,GCST001375,Metabolic disorder,#3288bd
16727,European,1300.0,22229870.0,Karns R,Uric acid levels,initial,2012-01-09,GCST001374,Cardiovascular measurement,#d53e4f
16728,Asian,4160.0,22232737.0,Shu XO,Breast cancer (survival),replication,2012-01-09,GCST001373,Other measurement,#3288bd
16729,Asian,1950.0,22232737.0,Shu XO,Breast cancer (survival),initial,2012-01-09,GCST001373,Other measurement,#3288bd
16730,Asian,4160.0,22232737.0,Shu XO,Breast cancer (survival),replication,2012-01-09,GCST001373,Other measurement,#3288bd
16731,Asian,1950.0,22232737.0,Shu XO,Breast cancer (survival),initial,2012-01-09,GCST001373,Other measurement,#3288bd
16732,Asian,4160.0,22232737.0,Shu XO,Breast cancer (survival),replication,2012-01-09,GCST001373,Cancer,#3288bd
16733,Asian,1950.0,22232737.0,Shu XO,Breast cancer (survival),initial,2012-01-09,GCST001373,Cancer,#3288bd
16734,European,757.0,22245343.0,Meda SA,Alzheimer's disease,initial,2012-01-08,GCST001372,Neurological disorder,#d53e4f
16735,European,1092.0,22228203.0,Aslibekyan S,Inflammatory biomarkers,initial,2012-01-05,GCST001371,Response to drug,#d53e4f
16736,European,9515.0,22219177.0,Tao S,Prostate cancer (SNP x SNP interaction),initial,2012-01-04,GCST001370,Other measurement,#d53e4f
16737,European,9515.0,22219177.0,Tao S,Prostate cancer (SNP x SNP interaction),initial,2012-01-04,GCST001370,Cancer,#d53e4f
16738,African Am./Caribbean,1994.0,22238593.0,Palmer ND,Type 2 diabetes,initial,2012-01-04,GCST001369,Metabolic disorder,#fee08b
16739,African Am./Caribbean,4455.0,22238593.0,Palmer ND,Type 2 diabetes,replication,2012-01-04,GCST001369,Metabolic disorder,#fee08b
16740,African Am./Caribbean,82.0,22864933.0,O'Donnell PH,Capecitabine sensitivity,initial,2012-01-03,GCST001368,Response to drug,#fee08b
16741,African,173.0,22864933.0,O'Donnell PH,Capecitabine sensitivity,initial,2012-01-03,GCST001368,Response to drug,#fc8d59
16742,European,164.0,22864933.0,O'Donnell PH,Capecitabine sensitivity,initial,2012-01-03,GCST001368,Response to drug,#d53e4f
16743,Asian,84.0,22864933.0,O'Donnell PH,Capecitabine sensitivity,initial,2012-01-03,GCST001368,Response to drug,#3288bd
16744,Other/Mixed,576.0,22210626.0,Mead S,Prion diseases,initial,2011-12-30,GCST001366,Neurological disorder,#99d594
16745,European,7296.0,22210626.0,Mead S,Prion diseases,initial,2011-12-30,GCST001366,Neurological disorder,#d53e4f
16746,Asian,1496.0,22171074.0,Tan A,Triglycerides,replication,2011-12-30,GCST001367,Lipid or lipoprotein measurement,#3288bd
16747,Asian,1999.0,22171074.0,Tan A,Triglycerides,initial,2011-12-30,GCST001367,Lipid or lipoprotein measurement,#3288bd
16748,African,425.0,22205395.0,Tekola Ayele F,Interleukin-10 levels,replication,2011-12-29,GCST006102,Inflammatory measurement,#fc8d59
16749,African Am./Caribbean,704.0,22205395.0,Tekola Ayele F,Interleukin-10 levels,initial,2011-12-29,GCST006102,Inflammatory measurement,#fee08b
16750,African Am./Caribbean,706.0,22205395.0,Tekola Ayele F,Interleukin-1-receptor antagonist levels,initial,2011-12-29,GCST006104,Inflammatory measurement,#fee08b
16751,African Am./Caribbean,704.0,22205395.0,Tekola Ayele F,Interleukin-6 levels,initial,2011-12-29,GCST006103,Inflammatory measurement,#fee08b
16752,European,397.0,22216198.0,Athanasiadis G,Anticoagulant levels,initial,2011-12-28,GCST001365,Other measurement,#d53e4f
16753,Asian,6023.0,22197933.0,Hu Z,Non-obstructive azoospermia,replication,2011-12-25,GCST001362,Other disease,#3288bd
16754,Asian,2638.0,22197933.0,Hu Z,Non-obstructive azoospermia,initial,2011-12-25,GCST001362,Other disease,#3288bd
16755,Asian,5704.0,22197929.0,Yu XQ,IgA nephropathy,initial,2011-12-25,GCST001364,Other disease,#3288bd
16756,Asian,6167.0,22197929.0,Yu XQ,IgA nephropathy,replication,2011-12-25,GCST001364,Other disease,#3288bd
16757,European,25252.0,22197932.0,Paternoster L,Atopic dermatitis,replication,2011-12-25,GCST001363,Immune system disorder,#d53e4f
16758,European,26171.0,22197932.0,Paternoster L,Atopic dermatitis,initial,2011-12-25,GCST001363,Immune system disorder,#d53e4f
16759,European,16717.0,22199011.0,Murabito JM,Ankle-brachial index,replication,2011-12-23,GCST001361,Cardiovascular measurement,#d53e4f
16760,European,41692.0,22199011.0,Murabito JM,Ankle-brachial index,initial,2011-12-23,GCST001361,Cardiovascular measurement,#d53e4f
16761,European,2034.0,22205951.0,Kerner B,Bipolar disorder,initial,2011-12-21,GCST001359,Neurological disorder,#d53e4f
16762,Asian,980.0,22188591.0,Anantharaman R,Asthma,initial,2011-12-21,GCST001360,Other disease,#3288bd
16763,Asian,1045.0,22188591.0,Anantharaman R,Asthma,replication,2011-12-21,GCST001360,Other disease,#3288bd
16764,European,3843.0,22182935.0,Chen DT,Bipolar disorder,replication,2011-12-20,GCST001358,Neurological disorder,#d53e4f
16765,Asian,2000.0,22182935.0,Chen DT,Bipolar disorder,initial,2011-12-20,GCST001358,Neurological disorder,#3288bd
16766,European,12755.0,22182935.0,Chen DT,Bipolar disorder,initial,2011-12-20,GCST001358,Neurological disorder,#d53e4f
16767,Asian,240.0,22180457.0,Kiyotani K,Response to tamoxifen in breast cancer,initial,2011-12-16,GCST001357,Response to drug,#3288bd
16768,Asian,222.0,22180457.0,Kiyotani K,Response to tamoxifen in breast cancer,replication,2011-12-16,GCST001357,Response to drug,#3288bd
16769,Asian,62.0,22179738.0,Lai HM,Gout,initial,2011-12-16,GCST001356,Metabolic disorder,#3288bd
16770,European,472.0,22174390.0,Rankinen T,Heart rate variability traits,initial,2011-12-15,GCST001354,Cardiovascular measurement,#d53e4f
16771,European,3367.0,21908519.0,Huffman JE,N-glycan levels,initial,2011-12-15,GCST005046,Other measurement,#d53e4f
16772,European,8716.0,22170493.0,Ellinghaus E,Psoriatic arthritis,replication,2011-12-15,GCST001355,Immune system disorder,#d53e4f
16773,European,3967.0,22170493.0,Ellinghaus E,Psoriatic arthritis,initial,2011-12-15,GCST001355,Immune system disorder,#d53e4f
16774,African,496.0,22174851.0,Lingappa JR,HIV-1 viral setpoint,initial,2011-12-12,GCST001352,Other measurement,#fc8d59
16775,African,798.0,22174851.0,Lingappa JR,HIV-1 susceptibility,initial,2011-12-12,GCST001353,Other disease,#fc8d59
16776,African,798.0,22174851.0,Lingappa JR,HIV-1 susceptibility,initial,2011-12-12,GCST001353,Immune system disorder,#fc8d59
16777,Asian,5480.0,22158540.0,Wu C,Pancreatic cancer,replication,2011-12-11,GCST001350,Cancer,#3288bd
16778,Asian,2972.0,22158540.0,Wu C,Pancreatic cancer,initial,2011-12-11,GCST001350,Cancer,#3288bd
16779,Asian,1783.0,22158537.0,Cho YS,Type 2 diabetes,initial,2011-12-11,GCST001351,Metabolic disorder,#3288bd
16780,Asian,2034.0,22158537.0,Cho YS,Type 2 diabetes,initial,2011-12-11,GCST001351,Metabolic disorder,#3288bd
16781,Asian,35873.0,22158537.0,Cho YS,Type 2 diabetes,replication,2011-12-11,GCST001351,Metabolic disorder,#3288bd
16782,Asian,15000.0,22158537.0,Cho YS,Type 2 diabetes,initial,2011-12-11,GCST001351,Metabolic disorder,#3288bd
16783,European,2601.0,22156575.0,Paus T,Brain development,replication,2011-12-09,GCST001349,Body measurement,#d53e4f
16784,European,557.0,22156575.0,Paus T,Brain development,initial,2011-12-09,GCST001349,Body measurement,#d53e4f
16785,Asian,1228.0,22174901.0,Chan KY,Hepatocellular carcinoma,replication,2011-12-08,GCST001348,Cancer,#3288bd
16786,Asian,192.0,22174901.0,Chan KY,Hepatocellular carcinoma,initial,2011-12-08,GCST001348,Cancer,#3288bd
16787,European,6032.0,22144573.0,O'Donnell CJ,Coronary artery calcification,replication,2011-12-05,GCST001347,Other trait,#d53e4f
16788,European,9961.0,22144573.0,O'Donnell CJ,Coronary artery calcification,initial,2011-12-05,GCST001347,Other trait,#d53e4f
16789,European,294.0,22142827.0,Innocenti F,Response to gemcitabine in pancreatic cancer,initial,2011-12-05,GCST001346,Response to drug,#d53e4f
16790,European,294.0,22142827.0,Innocenti F,Response to gemcitabine in pancreatic cancer,initial,2011-12-05,GCST001346,Cancer,#d53e4f
16791,Asian,5596.0,22138694.0,Lin Z,Ankylosing spondylitis,replication,2011-12-04,GCST001345,Immune system disorder,#3288bd
16792,Asian,6068.0,22138694.0,Lin Z,Ankylosing spondylitis,initial,2011-12-04,GCST001345,Immune system disorder,#3288bd
16793,European,927.0,22140272.0,Dalgaard MD,Testicular dysgenesis syndrome,initial,2011-12-03,GCST001344,Other disease,#d53e4f
16794,European,671.0,22140272.0,Dalgaard MD,Testicular dysgenesis syndrome,replication,2011-12-03,GCST001344,Other disease,#d53e4f
16795,Other/Mixed,129.0,22130093.0,Nam RK,Prostate cancer,replication,2011-12-01,GCST001338,Cancer,#99d594
16797,European,2810.0,22130093.0,Nam RK,Prostate cancer,replication,2011-12-01,GCST001338,Cancer,#d53e4f
16798,Asian,189.0,22130093.0,Nam RK,Prostate cancer,replication,2011-12-01,GCST001338,Cancer,#3288bd
16799,African,311.0,22130093.0,Nam RK,Prostate cancer,replication,2011-12-01,GCST001338,Cancer,#fc8d59
16800,European,192.0,21897333.0,Irvin MR,Fat distribution (HIV),initial,2011-12-01,GCST001343,Other disease,#d53e4f
16801,European,192.0,21897333.0,Irvin MR,Fat distribution (HIV),initial,2011-12-01,GCST001343,Body measurement,#d53e4f
16802,African Am./Caribbean,1009.0,22159054.0,Logue MW,Alzheimer's disease,initial,2011-12-01,GCST001342,Neurological disorder,#fee08b
16803,European,17698.0,22190364.0,Patsopoulos NA,Multiple sclerosis,initial,2011-12-01,GCST001341,Immune system disorder,#d53e4f
16804,European,3091.0,22105264.0,Allen-Brady K,Pelvic organ prolapse,initial,2011-12-01,GCST001340,Other disease,#d53e4f
16805,European,76.0,22105264.0,Allen-Brady K,Pelvic organ prolapse,replication,2011-12-01,GCST001340,Other disease,#d53e4f
16806,Asian,2238.0,22144915.0,Fan Q,Corneal astigmatism,initial,2011-12-01,GCST001339,Other trait,#3288bd
16807,Asian,2120.0,22144915.0,Fan Q,Corneal astigmatism,replication,2011-12-01,GCST001339,Other trait,#3288bd
16808,Asian,2016.0,22144915.0,Fan Q,Corneal astigmatism,initial,2011-12-01,GCST001339,Other trait,#3288bd
16809,Asian,2139.0,22144915.0,Fan Q,Corneal astigmatism,replication,2011-12-01,GCST001339,Other trait,#3288bd
16810,European,42.0,22137330.0,Sanchez-Juan P,Creutzfeldt-Jakob disease (variant),replication,2011-11-30,GCST001334,Neurological disorder,#d53e4f
16811,European,1597.0,22137330.0,Sanchez-Juan P,Creutzfeldt-Jakob disease (variant),initial,2011-11-30,GCST001334,Neurological disorder,#d53e4f
16812,European,18838.0,22139419.0,Gieger C,Platelet count,replication,2011-11-30,GCST001337,Hematological measurement,#d53e4f
16813,European,48666.0,22139419.0,Gieger C,Platelet count,initial,2011-11-30,GCST001337,Hematological measurement,#d53e4f
16814,European,18838.0,22139419.0,Gieger C,Mean platelet volume,replication,2011-11-30,GCST001335,Hematological measurement,#d53e4f
16815,European,18600.0,22139419.0,Gieger C,Mean platelet volume,initial,2011-11-30,GCST001335,Hematological measurement,#d53e4f
16816,Hispanic/Latin American,3468.0,22131368.0,Chen CT,Menarche and menopause (age at onset),initial,2011-11-30,GCST001336,Other measurement,#807dba
16817,Hispanic/Latin American,3468.0,22131368.0,Chen CT,Menarche and menopause (age at onset),initial,2011-11-30,GCST001336,Other measurement,#807dba
16818,Asian,182.0,22118420.0,Datta S,Bilirubin levels,initial,2011-11-28,GCST001333,Other measurement,#3288bd
16819,European,700.0,22126837.0,LeBlanc M,Cognitive function,initial,2011-11-28,GCST001332,Biological process,#d53e4f
16820,European,1096.0,22120009.0,Broderick P,Multiple myeloma,replication,2011-11-27,GCST001331,Cancer,#d53e4f
16821,European,7578.0,22120009.0,Broderick P,Multiple myeloma,initial,2011-11-27,GCST001331,Cancer,#d53e4f
16822,Asian,1080.0,22116939.0,Guo Y,Epilepsy,replication,2011-11-24,GCST001329,Neurological disorder,#3288bd
16823,Asian,3451.0,22116939.0,Guo Y,Epilepsy,initial,2011-11-24,GCST001329,Neurological disorder,#3288bd
16824,European,232.0,22116950.0,Schuh-Huerta SM,Ovarian reserve,initial,2011-11-24,GCST001330,Other measurement,#d53e4f
16825,African Am./Caribbean,200.0,22116950.0,Schuh-Huerta SM,Ovarian reserve,initial,2011-11-24,GCST001330,Other measurement,#fee08b
16826,European,6095.0,22116812.0,Schrijvers EM,Vascular dementia,replication,2011-11-23,GCST001328,Cardiovascular disease,#d53e4f
16827,European,5700.0,22116812.0,Schrijvers EM,Vascular dementia,initial,2011-11-23,GCST001328,Cardiovascular disease,#d53e4f
16829,European,1073.0,22105620.0,Papassotiropoulos A,Memory performance,initial,2011-11-22,GCST001327,Other measurement,#d53e4f
16830,African Am./Caribbean,1683.0,22101970.0,Kho AN,Type 2 diabetes,initial,2011-11-19,GCST001326,Metabolic disorder,#fee08b
16831,European,4805.0,22101970.0,Kho AN,Type 2 diabetes,initial,2011-11-19,GCST001326,Metabolic disorder,#d53e4f
16832,European,707.0,22095909.0,Lange CM,Response to hepatitis C treatment,initial,2011-11-16,GCST001325,Digestive system disorder,#d53e4f
16833,African Am./Caribbean,619.0,22085899.0,Chen G,Bilirubin levels,initial,2011-11-16,GCST001324,Other measurement,#fee08b
16834,European,3708.0,22086417.0,Cozen W,Nodular sclerosis Hodgkin lymphoma,initial,2011-11-15,GCST001323,Cancer,#d53e4f
16835,European,327.0,22086417.0,Cozen W,Nodular sclerosis Hodgkin lymphoma,replication,2011-11-15,GCST001323,Cancer,#d53e4f
16836,European,822.0,22833209.0,Hu X,Rate of cognitive decline in mild cognitive impairment (time interaction),initial,2011-11-15,GCST004371,Other trait,#d53e4f
16837,European,822.0,22833209.0,Hu X,Rate of cognitive decline in mild cognitive impairment (time interaction),initial,2011-11-15,GCST004371,Other measurement,#d53e4f
16838,European,822.0,22833209.0,Hu X,Rate of cognitive decline in mild cognitive impairment (time interaction),initial,2011-11-15,GCST004371,Other measurement,#d53e4f
16839,Asian,2540.0,22081228.0,Khor CC,Kawasaki disease,replication,2011-11-13,GCST001322,Immune system disorder,#3288bd
16840,European,1954.0,22081228.0,Khor CC,Kawasaki disease,replication,2011-11-13,GCST001322,Immune system disorder,#d53e4f
16841,European,6657.0,22081228.0,Khor CC,Kawasaki disease,initial,2011-11-13,GCST001322,Immune system disorder,#d53e4f
16842,Other/Mixed,405.0,22081228.0,Khor CC,Kawasaki disease,replication,2011-11-13,GCST001322,Immune system disorder,#99d594
16843,European,869.0,22072270.0,Wang KS,Alcohol withdrawal symptoms,initial,2011-11-11,GCST001319,Neurological disorder,#d53e4f
16844,European,825.0,22072270.0,Wang KS,Alcohol withdrawal symptoms,replication,2011-11-11,GCST001319,Neurological disorder,#d53e4f
16845,European,893.0,22076464.0,Ellinghaus E,Acute lymphoblastic leukemia (childhood),initial,2011-11-11,GCST001320,Cancer,#d53e4f
16846,European,4338.0,22076464.0,Ellinghaus E,Acute lymphoblastic leukemia (childhood),replication,2011-11-11,GCST001320,Cancer,#d53e4f
16847,European,5421.0,22080838.0,Cho MH,Chronic obstructive pulmonary disease,initial,2011-11-11,GCST001321,Other disease,#d53e4f
16849,European,2050.0,22075249.0,Tang WH,Serum ceruloplasmin levels,replication,2011-11-10,GCST001318,Other measurement,#d53e4f
16850,European,2647.0,22075249.0,Tang WH,Serum ceruloplasmin levels,initial,2011-11-10,GCST001318,Other measurement,#d53e4f
16851,European,7809.0,22075330.0,Granada M,IgE levels,replication,2011-11-08,GCST001316,Other measurement,#d53e4f
16852,European,6819.0,22075330.0,Granada M,IgE levels,initial,2011-11-08,GCST001316,Other measurement,#d53e4f
16853,European,20634.0,22068335.0,Mitchell GF,Aortic stiffness,initial,2011-11-08,GCST001317,Cardiovascular measurement,#d53e4f
16854,European,5306.0,22068335.0,Mitchell GF,Aortic stiffness,replication,2011-11-08,GCST001317,Cardiovascular measurement,#d53e4f
16855,European,2286.0,22087292.0,Sun L,Femoral neck bone geometry,replication,2011-11-07,GCST001315,Other measurement,#d53e4f
16856,Asian,1627.0,22087292.0,Sun L,Femoral neck bone geometry,initial,2011-11-07,GCST001315,Other measurement,#3288bd
16857,Asian,3310.0,22065538.0,Morisaki H,Adiponectin levels,initial,2011-11-07,GCST001314,Other measurement,#3288bd
16858,Asian,620.0,22057235.0,Trynka G,Celiac disease,initial,2011-11-06,GCST005523,Immune system disorder,#3288bd
16859,European,23649.0,22057235.0,Trynka G,Celiac disease,initial,2011-11-06,GCST005523,Immune system disorder,#d53e4f
16860,European,874.0,22064162.0,Edwards AC,Depression and alcohol dependence,initial,2011-11-05,GCST001313,Neurological disorder,#d53e4f
16863,European,40011.0,22055160.0,Bown MJ,Abdominal aortic aneurysm,replication,2011-11-04,GCST001312,Cardiovascular disease,#d53e4f
16864,European,7172.0,22055160.0,Bown MJ,Abdominal aortic aneurysm,initial,2011-11-04,GCST001312,Cardiovascular disease,#d53e4f
16865,Other/Mixed,717.0,22054870.0,De Jager PL,Cognitive decline,replication,2011-11-03,GCST001311,Biological process,#99d594
16866,European,1562.0,22054870.0,De Jager PL,Cognitive decline,replication,2011-11-03,GCST001311,Biological process,#d53e4f
16867,European,749.0,22054870.0,De Jager PL,Cognitive decline,initial,2011-11-03,GCST001311,Biological process,#d53e4f
16868,European,12347.0,22036096.0,Ramasamy A,IgE grass sensitization,initial,2011-11-01,GCST001303,Immune system disorder,#d53e4f
16869,European,12898.0,22036096.0,Ramasamy A,Allergic rhinitis,initial,2011-11-01,GCST001310,Immune system disorder,#d53e4f
16870,Other/Mixed,418.0,22295569.0,Karunas AS,Asthma,replication,2011-11-01,GCST001306,Other disease,#99d594
16871,Other/Mixed,678.0,22295569.0,Karunas AS,Asthma,initial,2011-11-01,GCST001306,Other disease,#99d594
16872,European,12526.0,22010049.0,Middelberg RP,Gamma glutamyl transferase levels,initial,2011-11-01,GCST001307,Liver enzyme measurement,#d53e4f
16873,European,1151.0,22041458.0,Clark SL,Response to anti-depressant treatment in major depressive disorder,initial,2011-11-01,GCST001308,Response to drug,#d53e4f
16874,African Am./Caribbean,288.0,22041458.0,Clark SL,Response to anti-depressant treatment in major depressive disorder,initial,2011-11-01,GCST001308,Response to drug,#fee08b
16875,European,395.0,22051697.0,Du R,Asthma,initial,2011-11-01,GCST001309,Other disease,#d53e4f
16876,Hispanic/Latin American,584.0,22051697.0,Du R,Asthma,replication,2011-11-01,GCST001309,Other disease,#807dba
16877,European,2809.0,22044751.0,Foster MC,Renal sinus fat,initial,2011-11-01,GCST001304,Other measurement,#d53e4f
16878,Asian,3279.0,22037551.0,Shi Y,Gastric cancer,initial,2011-10-30,GCST001300,Cancer,#3288bd
16879,Asian,6897.0,22037551.0,Shi Y,Gastric cancer,replication,2011-10-30,GCST001300,Cancer,#3288bd
16880,African Am./Caribbean,3749.0,22037553.0,Haiman CA,Breast cancer,initial,2011-10-30,GCST001298,Cancer,#fee08b
16881,European,5388.0,22037553.0,Haiman CA,Breast cancer,initial,2011-10-30,GCST001298,Cancer,#d53e4f
16882,European,19193.0,22037553.0,Haiman CA,Breast cancer,replication,2011-10-30,GCST001298,Cancer,#d53e4f
16883,Asian,2345.0,22037552.0,Yue WH,Schizophrenia,initial,2011-10-30,GCST001299,Neurological disorder,#3288bd
16884,Asian,9630.0,22037552.0,Yue WH,Schizophrenia,replication,2011-10-30,GCST001299,Neurological disorder,#3288bd
16885,European,12046.0,22037903.0,Crosslin DR,White blood cell count,initial,2011-10-30,GCST001302,Hematological measurement,#d53e4f
16886,African,1487.0,22037903.0,Crosslin DR,White blood cell count,initial,2011-10-30,GCST001302,Hematological measurement,#fc8d59
16887,Asian,10218.0,22037555.0,Shi Y,Schizophrenia,initial,2011-10-30,GCST001301,Neurological disorder,#3288bd
16888,Asian,8922.0,22037555.0,Shi Y,Schizophrenia,replication,2011-10-30,GCST001301,Neurological disorder,#3288bd
16889,European,612.0,22032556.0,Brockschmidt FF,Male-pattern baldness,replication,2011-10-27,GCST001297,Other disease,#d53e4f
16890,European,1198.0,22032556.0,Brockschmidt FF,Male-pattern baldness,initial,2011-10-27,GCST001297,Other disease,#d53e4f
16891,European,3012.0,22027810.0,Forstbauer LM,Alopecia areata,replication,2011-10-26,GCST001295,Other disease,#d53e4f
16892,European,1385.0,22027810.0,Forstbauer LM,Alopecia areata,initial,2011-10-26,GCST001295,Other disease,#d53e4f
16893,European,501.0,22030708.0,Menke A,Suicidal ideation,replication,2011-10-26,GCST001296,Other measurement,#d53e4f
16894,European,397.0,22030708.0,Menke A,Suicidal ideation,initial,2011-10-26,GCST001296,Other measurement,#d53e4f
16895,Other/Mixed,1772.0,22029572.0,Simonson MA,Cardiovascular disease risk factors,initial,2011-10-26,GCST001294,Other measurement,#99d594
16896,Asian,6287.0,22019778.0,Zhang F,Leprosy,initial,2011-10-23,GCST001292,Neurological disorder,#3288bd
16897,Asian,8600.0,22019778.0,Zhang F,Leprosy,replication,2011-10-23,GCST001292,Neurological disorder,#3288bd
16898,Asian,2506.0,22019779.0,Takahashi Y,Scoliosis,initial,2011-10-23,GCST001293,Other disease,#3288bd
16899,Asian,10149.0,22019779.0,Takahashi Y,Scoliosis,replication,2011-10-23,GCST001293,Other disease,#3288bd
16900,African Am./Caribbean,20809.0,22021425.0,Carty CL,Height,replication,2011-10-21,GCST001290,Body measurement,#fee08b
16901,African Am./Caribbean,8149.0,22021425.0,Carty CL,Height,initial,2011-10-21,GCST001290,Body measurement,#fee08b
16904,Other/Mixed,11163.0,22028671.0,Surakka I,Lipid traits,replication,2011-10-20,GCST001289,Lipid or lipoprotein measurement,#99d594
16905,European,11509.0,22028671.0,Surakka I,Lipid traits,replication,2011-10-20,GCST001289,Lipid or lipoprotein measurement,#d53e4f
16906,European,32225.0,22028671.0,Surakka I,Lipid traits,initial,2011-10-20,GCST001289,Lipid or lipoprotein measurement,#d53e4f
16907,European,598.0,22013104.0,Melka MG,Obesity-related traits,initial,2011-10-19,GCST001288,Other measurement,#d53e4f
16908,European,598.0,22013104.0,Melka MG,Obesity-related traits,initial,2011-10-19,GCST001288,Body measurement,#d53e4f
16909,European,598.0,22013104.0,Melka MG,Obesity-related traits,initial,2011-10-19,GCST001288,Metabolic disorder,#d53e4f
16910,European,4374.0,22012869.0,Hinney A,Attention deficit hyperactivity disorder,replication,2011-10-19,GCST001287,Neurological disorder,#d53e4f
16911,European,1795.0,22012869.0,Hinney A,Attention deficit hyperactivity disorder,initial,2011-10-19,GCST001287,Neurological disorder,#d53e4f
16912,European,2410.0,22010048.0,Wu X,Renal cell carcinoma,initial,2011-10-18,GCST001283,Cancer,#d53e4f
16913,European,12277.0,22010048.0,Wu X,Renal cell carcinoma,replication,2011-10-18,GCST001283,Cancer,#d53e4f
16915,European,7860.0,22833195.0,Terracciano A,Excitement-seeking behaviour,initial,2011-10-18,GCST006796,Other measurement,#d53e4f
16916,European,2062.0,22833195.0,Terracciano A,Excitement-seeking behaviour,replication,2011-10-18,GCST006796,Other measurement,#d53e4f
16918,European,1190.0,22005931.0,Kamboh MI,Alzheimer's disease (age of onset),initial,2011-10-18,GCST001280,Neurological disorder,#d53e4f
16920,European,1190.0,22005931.0,Kamboh MI,Alzheimer's disease (age of onset),initial,2011-10-18,GCST001280,Other measurement,#d53e4f
16921,Asian,1286.0,21989058.0,Qin Y,Premature ovarian failure,initial,2011-10-18,GCST001284,Other disease,#3288bd
16922,Asian,1200.0,21989058.0,Qin Y,Premature ovarian failure,replication,2011-10-18,GCST001284,Other disease,#3288bd
16923,European,3501.0,22004471.0,Frank J,Alcohol dependence,initial,2011-10-18,GCST001281,Neurological disorder,#d53e4f
16924,European,2020.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Neurological disorder,#d53e4f
16925,Other/Mixed,2.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Neurological disorder,#99d594
16926,African Am./Caribbean,12.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Neurological disorder,#fee08b
16927,European,2020.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Other trait,#d53e4f
16928,Other/Mixed,2.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Other trait,#99d594
16929,African Am./Caribbean,12.0,22005930.0,Hollingworth P,Psychosis in Alzheimer's disease,initial,2011-10-18,GCST001282,Other trait,#fee08b
16930,European,6944.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Neurological disorder,#d53e4f
16931,African Am./Caribbean,12.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Neurological disorder,#fee08b
16932,Other/Mixed,2.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Neurological disorder,#99d594
16933,European,6944.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Other trait,#d53e4f
16934,African Am./Caribbean,12.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Other trait,#fee08b
16935,Other/Mixed,2.0,22005930.0,Hollingworth P,Psychosis and Alzheimer's disease,initial,2011-10-18,GCST001285,Other trait,#99d594
16936,African Am./Caribbean,1366.0,22006218.0,Yoon D,Smoking behavior,replication,2011-10-18,GCST001286,Biological process,#fee08b
16937,European,671.0,22006218.0,Yoon D,Smoking behavior,replication,2011-10-18,GCST001286,Biological process,#d53e4f
16938,Asian,8842.0,22006218.0,Yoon D,Smoking behavior,initial,2011-10-18,GCST001286,Biological process,#3288bd
16939,Asian,2805.0,22004975.0,Li R,Systemic lupus erythematosus,initial,2011-10-17,GCST001279,Immune system disorder,#3288bd
16940,Asian,7674.0,22004975.0,Li R,Systemic lupus erythematosus,replication,2011-10-17,GCST001279,Immune system disorder,#3288bd
16941,Asian,1443.0,22004975.0,Li R,Systemic lupus erythematosus,replication,2011-10-17,GCST001279,Immune system disorder,#3288bd
16942,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme levels (alanine transaminase),initial,2011-10-16,GCST001275,Liver enzyme measurement,#3288bd
16943,European,52350.0,22001757.0,Chambers JC,Liver enzyme levels (alanine transaminase),initial,2011-10-16,GCST001275,Liver enzyme measurement,#d53e4f
16944,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme levels (gamma-glutamyl transferase),initial,2011-10-16,GCST001277,Liver enzyme measurement,#3288bd
16945,European,52350.0,22001757.0,Chambers JC,Liver enzyme levels (gamma-glutamyl transferase),initial,2011-10-16,GCST001277,Liver enzyme measurement,#d53e4f
16946,Asian,8739.0,22001757.0,Chambers JC,Liver enzyme levels (alkaline phosphatase),initial,2011-10-16,GCST001276,Liver enzyme measurement,#3288bd
16947,European,52350.0,22001757.0,Chambers JC,Liver enzyme levels (alkaline phosphatase),initial,2011-10-16,GCST001276,Liver enzyme measurement,#d53e4f
16948,Asian,4671.0,22001756.0,Khor CC,Dengue shock syndrome,replication,2011-10-16,GCST001278,Other disease,#3288bd
16949,Asian,4026.0,22001756.0,Khor CC,Dengue shock syndrome,initial,2011-10-16,GCST001278,Other disease,#3288bd
16950,European,12126.0,22003152.0,Grallert H,Lipoprotein-associated phospholipase A2 activity and mass,initial,2011-10-14,GCST001273,Lipid or lipoprotein measurement,#d53e4f
16952,European,1317.0,22003120.0,Burdon KP,Corneal structure,replication,2011-10-14,GCST001274,Neurological disorder,#d53e4f
16953,European,3781.0,22003120.0,Burdon KP,Corneal structure,initial,2011-10-14,GCST001274,Neurological disorder,#d53e4f
16954,European,2133.0,21993531.0,Kuparinen T,Cytomegalovirus antibody response,initial,2011-10-13,GCST001272,Biological process,#d53e4f
16955,European,977.0,21996601.0,Das K,Blood pressure,initial,2011-10-11,GCST001270,Other measurement,#d53e4f
16956,Other/Mixed,409.0,21990027.0,Drago A,Response to antipsychotic therapy (extrapyramidal side effects),initial,2011-10-11,GCST001271,Response to drug,#99d594
16957,European,6555.0,21983785.0,Macgregor S,Melanoma,initial,2011-10-09,GCST001266,Cancer,#d53e4f
16958,European,20337.0,21983785.0,Macgregor S,Melanoma,replication,2011-10-09,GCST001266,Cancer,#d53e4f
16959,European,15506.0,21983786.0,Sulem P,Serum uric acid levels,initial,2011-10-09,GCST001269,Cardiovascular measurement,#d53e4f
16960,European,40968.0,21983786.0,Sulem P,Gout,initial,2011-10-09,GCST001268,Metabolic disorder,#d53e4f
16961,European,10422.0,21983787.0,Barrett JH,Melanoma,initial,2011-10-09,GCST001267,Cancer,#d53e4f
16962,European,13000.0,21983787.0,Barrett JH,Melanoma,replication,2011-10-09,GCST001267,Cancer,#d53e4f
16963,European,1879.0,21981779.0,Denny JC,Hypothyroidism,replication,2011-10-07,GCST001265,Other disease,#d53e4f
16964,European,6370.0,21981779.0,Denny JC,Hypothyroidism,initial,2011-10-07,GCST001265,Other disease,#d53e4f
16966,European,5244.0,21977987.0,Trompet S,LDL cholesterol,initial,2011-10-06,GCST001262,Lipid or lipoprotein measurement,#d53e4f
16967,European,1129.0,21979947.0,Li X,Corneal structure,replication,2011-10-06,GCST001261,Neurological disorder,#d53e4f
16968,European,3546.0,21979947.0,Li X,Corneal structure,initial,2011-10-06,GCST001261,Neurological disorder,#d53e4f
16969,European,5491.0,21998597.0,Ohlsson C,Testosterone levels,replication,2011-10-06,GCST001264,Other measurement,#d53e4f
16970,European,8938.0,21998597.0,Ohlsson C,Testosterone levels,initial,2011-10-06,GCST001264,Other measurement,#d53e4f
16971,African Am./Caribbean,16436.0,21998595.0,N'Diaye A,Height,replication,2011-10-06,GCST001263,Body measurement,#fee08b
16972,Other/Mixed,20427.0,21998595.0,N'Diaye A,Height,initial,2011-10-06,GCST001263,Body measurement,#99d594
16973,Asian,9928.0,21971053.0,Takeuchi F,Coronary heart disease,replication,2011-10-05,GCST001260,Cardiovascular disease,#3288bd
16974,Asian,3648.0,21971053.0,Takeuchi F,Coronary heart disease,initial,2011-10-05,GCST001260,Cardiovascular disease,#3288bd
16975,European,152.0,21961650.0,Squassina A,Response to lithium treatment in bipolar disorder,replication,2011-10-03,GCST001259,Response to drug,#d53e4f
16976,European,52.0,21961650.0,Squassina A,Response to lithium treatment in bipolar disorder,initial,2011-10-03,GCST001259,Response to drug,#d53e4f
16977,European,42247.0,21964575.0,Rafnar T,Ovarian cancer,initial,2011-10-02,GCST001258,Cancer,#d53e4f
16978,Asian,2798.0,22004137.0,Liu L,Hepatitis B,initial,2011-10-01,GCST001257,Digestive system disorder,#3288bd
16979,European,1388.0,21980348.0,Fox AA,Postoperative ventricular dysfunction,replication,2011-09-30,GCST001256,Cardiovascular disease,#d53e4f
16980,European,1199.0,21980348.0,Fox AA,Postoperative ventricular dysfunction,initial,2011-09-30,GCST001256,Cardiovascular disease,#d53e4f
16981,European,3360.0,21980299.0,Bradfield JP,Type 1 diabetes,replication,2011-09-29,GCST001255,Metabolic disorder,#d53e4f
16982,European,26890.0,21980299.0,Bradfield JP,Type 1 diabetes,initial,2011-09-29,GCST001255,Metabolic disorder,#d53e4f
16983,African Am./Caribbean,1189.0,21956439.0,Zuo L,Alcohol dependence,initial,2011-09-28,GCST001254,Neurological disorder,#fee08b
16984,European,2927.0,21956439.0,Zuo L,Alcohol dependence,initial,2011-09-28,GCST001254,Neurological disorder,#d53e4f
16985,European,2652.0,21980494.0,Germain M,Venous thromboembolism,initial,2011-09-27,GCST001253,Cardiovascular disease,#d53e4f
16986,European,935.0,21991891.0,Tantisira KG,Asthma treatment response,replication,2011-09-26,GCST001252,Response to drug,#d53e4f
16987,European,1169.0,21991891.0,Tantisira KG,Asthma treatment response,initial,2011-09-26,GCST001252,Response to drug,#d53e4f
16988,European,48201.0,21946350.0,Soler Artigas M,Pulmonary function,initial,2011-09-25,GCST001248,Other measurement,#d53e4f
16989,European,46411.0,21946350.0,Soler Artigas M,Pulmonary function,replication,2011-09-25,GCST001248,Other measurement,#d53e4f
16990,European,41735.0,21946351.0,Stacey SN,Basal cell carcinoma,initial,2011-09-25,GCST001250,Cancer,#d53e4f
16991,Other/Mixed,17607.0,21946351.0,Stacey SN,Basal cell carcinoma,replication,2011-09-25,GCST001250,Cancer,#99d594
16992,European,48201.0,21946350.0,Soler Artigas M,Pulmonary function,initial,2011-09-25,GCST001251,Other measurement,#d53e4f
16993,European,46411.0,21946350.0,Soler Artigas M,Pulmonary function,replication,2011-09-25,GCST001251,Other measurement,#d53e4f
16994,European,1728.0,21947420.0,Lei SF,Spine bone size,replication,2011-09-25,GCST001249,Other measurement,#d53e4f
16995,Asian,1627.0,21947420.0,Lei SF,Spine bone size,initial,2011-09-25,GCST001249,Other measurement,#3288bd
16996,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Liver enzyme measurement,#d53e4f
16997,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Liver enzyme measurement,#d53e4f
16998,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Lipid or lipoprotein measurement,#d53e4f
16999,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Other measurement,#d53e4f
17000,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Liver enzyme measurement,#d53e4f
17001,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Lipid or lipoprotein measurement,#d53e4f
17002,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Inflammatory measurement,#d53e4f
17003,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Cardiovascular measurement,#d53e4f
17004,European,11683.0,21943158.0,Middelberg RP,Cardiovascular disease risk factors,initial,2011-09-24,GCST001247,Lipid or lipoprotein measurement,#d53e4f
17006,Other/Mixed,29807.0,21926416.0,Amos CI,Melanoma,replication,2011-09-22,GCST001245,Cancer,#99d594
17007,European,2830.0,21926416.0,Amos CI,Melanoma,initial,2011-09-22,GCST001245,Cancer,#d53e4f
17008,European,3402.0,21957438.0,Meschia JF,Stroke,initial,2011-09-21,GCST001243,Cardiovascular disease,#d53e4f
17009,European,1695.0,21940522.0,Shaffer JR,Dental caries,replication,2011-09-21,GCST001244,Digestive system disorder,#d53e4f
17010,European,1305.0,21940522.0,Shaffer JR,Dental caries,initial,2011-09-21,GCST001244,Digestive system disorder,#d53e4f
17011,European,16731.0,21926972.0,Sklar P,Bipolar disorder,initial,2011-09-18,GCST001241,Neurological disorder,#d53e4f
17012,European,46918.0,21926972.0,Sklar P,Bipolar disorder,replication,2011-09-18,GCST001241,Neurological disorder,#d53e4f
17013,European,21856.0,21926974.0,Ripke S,Schizophrenia,initial,2011-09-18,GCST001242,Neurological disorder,#d53e4f
17014,European,29839.0,21926974.0,Ripke S,Schizophrenia,replication,2011-09-18,GCST001242,Neurological disorder,#d53e4f
17015,European,29181.0,21935397.0,Paternoster L,Obesity (extreme),replication,2011-09-15,GCST001240,Metabolic disorder,#d53e4f
17016,European,5373.0,21935397.0,Paternoster L,Obesity (extreme),initial,2011-09-15,GCST001240,Metabolic disorder,#d53e4f
17017,Asian,1005.0,21912425.0,Tohkin M,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN),initial,2011-09-13,GCST001239,Other disease,#3288bd
17018,Asian,1005.0,21912425.0,Tohkin M,Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN),initial,2011-09-13,GCST001239,Other disease,#3288bd
17019,Asian,12545.0,21909109.0,Kim YJ,Gamma glutamyl transpeptidase,initial,2011-09-11,GCST001234,Liver enzyme measurement,#3288bd
17020,Asian,30395.0,21909109.0,Kim YJ,Gamma glutamyl transpeptidase,replication,2011-09-11,GCST001234,Liver enzyme measurement,#3288bd
17021,European,133661.0,21909115.0,Ehret GB,Diastolic blood pressure,replication,2011-09-11,GCST001228,Other measurement,#d53e4f
17022,European,69395.0,21909115.0,Ehret GB,Diastolic blood pressure,initial,2011-09-11,GCST001228,Other measurement,#d53e4f
17023,European,1174.0,21909107.0,LeMaire SA,Thoracic aortic aneurysms and dissections,replication,2011-09-11,GCST001229,Cardiovascular disease,#d53e4f
17024,European,1639.0,21909107.0,LeMaire SA,Thoracic aortic aneurysms and dissections,initial,2011-09-11,GCST001229,Cardiovascular disease,#d53e4f
17025,Asian,12545.0,21909109.0,Kim YJ,Triglycerides,initial,2011-09-11,GCST001230,Lipid or lipoprotein measurement,#3288bd
17026,Asian,30395.0,21909109.0,Kim YJ,Triglycerides,replication,2011-09-11,GCST001230,Lipid or lipoprotein measurement,#3288bd
17028,Other/Mixed,687.0,21909108.0,Bis JC,Carotid intima media thickness,replication,2011-09-11,GCST001231,Cardiovascular disease,#99d594
17029,European,31211.0,21909108.0,Bis JC,Carotid intima media thickness,initial,2011-09-11,GCST001231,Cardiovascular disease,#d53e4f
17030,Asian,16280.0,21909106.0,Arakawa S,Age-related macular degeneration,replication,2011-09-11,GCST001232,Neurological disorder,#3288bd
17031,Asian,4150.0,21909106.0,Arakawa S,Age-related macular degeneration,initial,2011-09-11,GCST001232,Neurological disorder,#3288bd
17032,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Other measurement,#3288bd
17033,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Other measurement,#3288bd
17034,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Other measurement,#3288bd
17035,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Other measurement,#3288bd
17036,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Liver enzyme measurement,#3288bd
17037,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Liver enzyme measurement,#3288bd
17038,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Lipid or lipoprotein measurement,#3288bd
17039,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Lipid or lipoprotein measurement,#3288bd
17040,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Other measurement,#3288bd
17041,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Other measurement,#3288bd
17042,Asian,12545.0,21909109.0,Kim YJ,Metabolite levels,initial,2011-09-11,GCST001233,Cardiovascular measurement,#3288bd
17043,Asian,30395.0,21909109.0,Kim YJ,Metabolite levels,replication,2011-09-11,GCST001233,Cardiovascular measurement,#3288bd
17044,European,133661.0,21909115.0,Ehret GB,Hypertension,replication,2011-09-11,GCST001238,Cardiovascular disease,#d53e4f
17045,European,69395.0,21909115.0,Ehret GB,Hypertension,initial,2011-09-11,GCST001238,Cardiovascular disease,#d53e4f
17046,European,133661.0,21909115.0,Ehret GB,Systolic blood pressure,replication,2011-09-11,GCST001227,Other measurement,#d53e4f
17047,European,69395.0,21909115.0,Ehret GB,Systolic blood pressure,initial,2011-09-11,GCST001227,Other measurement,#d53e4f
17048,European,74064.0,21909110.0,Wain LV,Blood pressure,initial,2011-09-11,GCST001235,Other measurement,#d53e4f
17049,European,48607.0,21909110.0,Wain LV,Blood pressure,replication,2011-09-11,GCST001235,Other measurement,#d53e4f
17050,Asian,12545.0,21909109.0,Kim YJ,HDL cholesterol,initial,2011-09-11,GCST001237,Lipid or lipoprotein measurement,#3288bd
17051,Asian,30395.0,21909109.0,Kim YJ,HDL cholesterol,replication,2011-09-11,GCST001237,Lipid or lipoprotein measurement,#3288bd
17052,European,74064.0,21909110.0,Wain LV,Blood pressure,initial,2011-09-11,GCST001236,Other measurement,#d53e4f
17053,European,48607.0,21909110.0,Wain LV,Blood pressure,replication,2011-09-11,GCST001236,Other measurement,#d53e4f
17054,European,4811.0,21896673.0,Chen D,HPV seropositivity,initial,2011-09-10,GCST001225,Other measurement,#d53e4f
17055,Hispanic/Latin American,2344.0,21896673.0,Chen D,HPV seropositivity,replication,2011-09-10,GCST001225,Other measurement,#807dba
17056,European,25358.0,21907864.0,Ferreira MA,Asthma,replication,2011-09-10,GCST001226,Other disease,#d53e4f
17057,European,32442.0,21907864.0,Ferreira MA,Asthma,initial,2011-09-10,GCST001226,Other disease,#d53e4f
17058,European,80.0,21912186.0,Smith AK,Chronic fatigue syndrome,initial,2011-09-09,GCST001223,Immune system disorder,#d53e4f
17059,Asian,29968.0,21908515.0,Cai Q,Breast cancer,replication,2011-09-09,GCST001224,Cancer,#3288bd
17060,Asian,4128.0,21908515.0,Cai Q,Breast cancer,initial,2011-09-09,GCST001224,Cancer,#3288bd
17062,European,2994.0,21931568.0,Geller F,Permanent tooth development,replication,2011-09-08,GCST001221,Biological process,#d53e4f
17063,European,5088.0,21931568.0,Geller F,Permanent tooth development,initial,2011-09-08,GCST001221,Biological process,#d53e4f
17064,European,866.0,21900944.0,Shen H,Aspartate aminotransferase levels,initial,2011-09-08,GCST001222,Liver enzyme measurement,#d53e4f
17065,Asian,3837.0,21900946.0,Nakabayashi K,Graves' disease,initial,2011-09-08,GCST001219,Immune system disorder,#3288bd
17066,Asian,1589.0,21900946.0,Nakabayashi K,Graves' disease,replication,2011-09-08,GCST001219,Immune system disorder,#3288bd
17067,European,142.0,21931564.0,Nicholson G,Metabolite levels,initial,2011-09-08,GCST001220,Other measurement,#d53e4f
17068,European,202.0,21931564.0,Nicholson G,Metabolite levels,replication,2011-09-08,GCST001220,Other measurement,#d53e4f
17069,European,1450.0,21900290.0,Qi Q,Lp (a) levels,initial,2011-09-06,GCST001218,Lipid or lipoprotein measurement,#d53e4f
17070,European,2820.0,21886157.0,Suhre K,Metabolic traits,initial,2011-08-31,GCST001217,Other measurement,#d53e4f
17071,European,7929.0,21876539.0,Amin N,Coffee consumption,replication,2011-08-30,GCST001215,Biological process,#d53e4f
17072,European,18716.0,21876539.0,Amin N,Coffee consumption,initial,2011-08-30,GCST001215,Biological process,#d53e4f
17074,European,5006.0,21878437.0,Mondul AM,Retinol levels,initial,2011-08-30,GCST001216,Other measurement,#d53e4f
17075,European,1124.0,21878437.0,Mondul AM,Retinol levels,replication,2011-08-30,GCST001216,Other measurement,#d53e4f
17076,European,3335.0,21878436.0,Sampietro ML,Coronary restenosis,replication,2011-08-30,GCST001214,Cardiovascular disease,#d53e4f
17077,European,866.0,21878436.0,Sampietro ML,Coronary restenosis,initial,2011-08-30,GCST001214,Cardiovascular disease,#d53e4f
17078,Asian,38568.0,21874001.0,Kooner JS,Type 2 diabetes,replication,2011-08-28,GCST001213,Metabolic disorder,#3288bd
17079,Asian,20019.0,21874001.0,Kooner JS,Type 2 diabetes,initial,2011-08-28,GCST001213,Metabolic disorder,#3288bd
17080,European,1016.0,21876473.0,Lydall GJ,Alcohol dependence,initial,2011-08-26,GCST001211,Neurological disorder,#d53e4f
17081,European,16378.0,21873549.0,Strawbridge RJ,Proinsulin levels,replication,2011-08-26,GCST001212,Other measurement,#d53e4f
17082,European,10701.0,21873549.0,Strawbridge RJ,Proinsulin levels,initial,2011-08-26,GCST001212,Other measurement,#d53e4f
17083,Asian,1394.0,21866343.0,Ahn MJ,Non-small cell lung cancer,replication,2011-08-25,GCST001210,Cancer,#3288bd
17084,Asian,942.0,21866343.0,Ahn MJ,Non-small cell lung cancer,initial,2011-08-25,GCST001210,Cancer,#3288bd
17085,European,35474.0,21871595.0,Day-Williams AG,Osteoarthritis,replication,2011-08-25,GCST001209,Other disease,#d53e4f
17086,European,8071.0,21871595.0,Day-Williams AG,Osteoarthritis,initial,2011-08-25,GCST001209,Other disease,#d53e4f
17087,African Am./Caribbean,1040.0,21901158.0,Irvin MR,Insulin resistance/response,initial,2011-08-25,GCST001208,Other trait,#fee08b
17088,European,1912.0,21862451.0,Benyamin B,Butyrylcholinesterase levels,replication,2011-08-23,GCST001207,Liver enzyme measurement,#d53e4f
17089,European,6879.0,21862451.0,Benyamin B,Butyrylcholinesterase levels,initial,2011-08-23,GCST001207,Liver enzyme measurement,#d53e4f
17090,European,4641.0,21886828.0,Wei W,Uric acid levels (SNP x SNP interaction),replication,2011-08-19,GCST001206,Cardiovascular measurement,#d53e4f
17091,European,1201.0,21886828.0,Wei W,Uric acid levels (SNP x SNP interaction),initial,2011-08-19,GCST001206,Cardiovascular measurement,#d53e4f
17092,European,2931.0,21876681.0,Hamza TH,Parkinson's disease (coffee consumption interaction),replication,2011-08-18,GCST001205,Neurological disorder,#d53e4f
17093,European,2389.0,21876681.0,Hamza TH,Parkinson's disease (coffee consumption interaction),initial,2011-08-18,GCST001205,Neurological disorder,#d53e4f
17094,European,2931.0,21876681.0,Hamza TH,Parkinson's disease (coffee consumption interaction),replication,2011-08-18,GCST001205,Biological process,#d53e4f
17095,European,2389.0,21876681.0,Hamza TH,Parkinson's disease (coffee consumption interaction),initial,2011-08-18,GCST001205,Biological process,#d53e4f
17096,Asian,700.0,21844665.0,Hu HJ,Rheumatoid arthritis,initial,2011-08-16,GCST001203,Immune system disorder,#3288bd
17097,Asian,1289.0,21844665.0,Hu HJ,Rheumatoid arthritis,replication,2011-08-16,GCST001203,Immune system disorder,#3288bd
17098,African,83.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (cisplatin),initial,2011-08-16,GCST001201,Response to drug,#fc8d59
17099,African,176.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (cisplatin),initial,2011-08-16,GCST001201,Response to drug,#fc8d59
17100,European,174.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (cisplatin),initial,2011-08-16,GCST001201,Response to drug,#d53e4f
17101,Asian,175.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (cisplatin),initial,2011-08-16,GCST001201,Response to drug,#3288bd
17102,African,176.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (carboplatin),initial,2011-08-16,GCST001204,Response to drug,#fc8d59
17103,African,83.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (carboplatin),initial,2011-08-16,GCST001204,Response to drug,#fc8d59
17104,Asian,175.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (carboplatin),initial,2011-08-16,GCST001204,Response to drug,#3288bd
17105,European,174.0,21844884.0,Wheeler HE,Response to platinum-based chemotherapy (carboplatin),initial,2011-08-16,GCST001204,Response to drug,#d53e4f
17106,Asian,7504.0,21841780.0,Chu X,Graves' disease,replication,2011-08-14,GCST001200,Immune system disorder,#3288bd
17107,Asian,2958.0,21841780.0,Chu X,Graves' disease,initial,2011-08-14,GCST001200,Immune system disorder,#3288bd
17108,European,572.0,21835309.0,Larsson M,Iris characteristics,replication,2011-08-12,GCST001199,Other measurement,#d53e4f
17109,European,2121.0,21835309.0,Larsson M,Iris characteristics,initial,2011-08-12,GCST001199,Other measurement,#d53e4f
17110,European,11514.0,21833088.0,Sawcer S,Multiple sclerosis,replication,2011-08-11,GCST001198,Immune system disorder,#d53e4f
17111,European,26621.0,21833088.0,Sawcer S,Multiple sclerosis,initial,2011-08-11,GCST001198,Immune system disorder,#d53e4f
17112,European,98.0,21836138.0,Hadchouel A,Bronchopulmonary dysplasia,initial,2011-08-11,GCST001197,Other disease,#d53e4f
17113,European,351.0,21836138.0,Hadchouel A,Bronchopulmonary dysplasia,replication,2011-08-11,GCST001197,Other disease,#d53e4f
17114,African,107.0,21836138.0,Hadchouel A,Bronchopulmonary dysplasia,initial,2011-08-11,GCST001197,Other disease,#fc8d59
17115,African,47.0,21836138.0,Hadchouel A,Bronchopulmonary dysplasia,replication,2011-08-11,GCST001197,Other disease,#fc8d59
17116,European,3511.0,21826061.0,Davies G,Intelligence,initial,2011-08-09,GCST001195,Biological process,#d53e4f
17117,European,670.0,21826061.0,Davies G,Intelligence,replication,2011-08-09,GCST001195,Biological process,#d53e4f
17118,Asian,122.0,21826085.0,Tanaka S,Tardive dyskinesia,initial,2011-08-09,GCST001196,Neurological disorder,#3288bd
17119,Asian,174.0,21826085.0,Tanaka S,Tardive dyskinesia,replication,2011-08-09,GCST001196,Neurological disorder,#3288bd
17120,European,4773.0,21827660.0,Yang TH,Glioma,initial,2011-08-09,GCST001194,Cancer,#d53e4f
17121,European,10577.0,21824976.0,Garcia-Closas M,Bladder cancer,initial,2011-08-08,GCST001193,Cancer,#d53e4f
17122,European,3583.0,21824976.0,Garcia-Closas M,Bladder cancer,replication,2011-08-08,GCST001193,Cancer,#d53e4f
17123,European,109.0,21826682.0,Isackson PJ,Response to statin therapy,replication,2011-08-08,GCST001192,Response to drug,#d53e4f
17124,European,79.0,21826682.0,Isackson PJ,Response to statin therapy,initial,2011-08-08,GCST001192,Response to drug,#d53e4f
17125,African Am./Caribbean,8155.0,21829389.0,Barbalic M,Coronary heart disease,replication,2011-08-04,GCST001190,Cardiovascular disease,#fee08b
17126,African Am./Caribbean,2905.0,21829389.0,Barbalic M,Coronary heart disease,initial,2011-08-04,GCST001190,Cardiovascular disease,#fee08b
17127,European,8300.0,21829393.0,Plagnol V,Thyroid peroxidase autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004383,Metabolic disorder,#d53e4f
17128,European,8300.0,21829393.0,Plagnol V,Thyroid peroxidase autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004383,Other measurement,#d53e4f
17129,European,4328.0,21829393.0,Plagnol V,Gastric parietal cell autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004382,Metabolic disorder,#d53e4f
17130,European,4328.0,21829393.0,Plagnol V,Gastric parietal cell autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004382,Other measurement,#d53e4f
17132,European,2498.0,21829393.0,Plagnol V,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004381,Metabolic disorder,#d53e4f
17134,European,2498.0,21829393.0,Plagnol V,Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004381,Other measurement,#d53e4f
17135,European,2506.0,21829393.0,Plagnol V,Glutamate decarboxylase autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004380,Metabolic disorder,#d53e4f
17136,European,2506.0,21829393.0,Plagnol V,Glutamate decarboxylase autoantibody levels in type 1 diabetes,initial,2011-08-04,GCST004380,Other measurement,#d53e4f
17137,European,19102.0,21829393.0,Plagnol V,Type 1 diabetes,initial,2011-08-04,GCST001191,Metabolic disorder,#d53e4f
17138,European,3440.0,21812969.0,Liu X,Parkinson's disease,replication,2011-08-03,GCST001189,Neurological disorder,#d53e4f
17139,European,446.0,21812969.0,Liu X,Parkinson's disease,initial,2011-08-03,GCST001189,Neurological disorder,#d53e4f
17140,European,1624.0,21810271.0,Antoni G,vWF and FVIII levels,initial,2011-08-02,GCST001188,Other measurement,#d53e4f
17141,Asian,149.0,21810746.0,Chantarangsu S,Nevirapine-induced rash,initial,2011-08-01,GCST001186,Response to drug,#3288bd
17142,Asian,233.0,21810746.0,Chantarangsu S,Nevirapine-induced rash,replication,2011-08-01,GCST001186,Response to drug,#3288bd
17143,Asian,6996.0,21846871.0,Mehta NN,Coronary heart disease,initial,2011-08-01,GCST001185,Cardiovascular disease,#3288bd
17144,European,8424.0,21846871.0,Mehta NN,Coronary heart disease,initial,2011-08-01,GCST001185,Cardiovascular disease,#d53e4f
17147,European,1054.0,21810643.0,Bakken TE,Cortical thickness,initial,2011-08-01,GCST001187,Other measurement,#d53e4f
17148,Asian,4836.0,21804548.0,Hirota T,Asthma,initial,2011-07-31,GCST001183,Other disease,#3288bd
17149,Asian,30247.0,21804548.0,Hirota T,Asthma,replication,2011-07-31,GCST001183,Other disease,#3288bd
17150,European,2727.0,21804549.0,Torgerson DG,Asthma,replication,2011-07-31,GCST001182,Other disease,#d53e4f
17151,African Am./Caribbean,1612.0,21804549.0,Torgerson DG,Asthma,initial,2011-07-31,GCST001182,Other disease,#fee08b
17152,Hispanic/Latin American,2299.0,21804549.0,Torgerson DG,Asthma,replication,2011-07-31,GCST001182,Other disease,#807dba
17153,European,2088.0,21804549.0,Torgerson DG,Asthma,initial,2011-07-31,GCST001182,Other disease,#d53e4f
17154,Hispanic/Latin American,1688.0,21804549.0,Torgerson DG,Asthma,initial,2011-07-31,GCST001182,Other disease,#807dba
17155,African Am./Caribbean,2147.0,21804549.0,Torgerson DG,Asthma,replication,2011-07-31,GCST001182,Other disease,#fee08b
17156,European,2538.0,21804547.0,Dobbins SE,Meningioma,replication,2011-07-31,GCST001184,Cancer,#d53e4f
17157,European,1563.0,21804547.0,Dobbins SE,Meningioma,initial,2011-07-31,GCST001184,Cancer,#d53e4f
17158,European,2305.0,21801394.0,Genin E,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2011-07-29,GCST001181,Other disease,#d53e4f
17159,European,2305.0,21801394.0,Genin E,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2011-07-29,GCST001181,Other disease,#d53e4f
17160,European,8866.0,21829377.0,Lemaitre RN,Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),initial,2011-07-28,GCST001180,Lipid or lipoprotein measurement,#d53e4f
17161,European,8866.0,21829377.0,Lemaitre RN,Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),initial,2011-07-28,GCST001179,Lipid or lipoprotein measurement,#d53e4f
17162,European,8866.0,21829377.0,Lemaitre RN,Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid),initial,2011-07-28,GCST001177,Lipid or lipoprotein measurement,#d53e4f
17163,European,8866.0,21829377.0,Lemaitre RN,Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),initial,2011-07-28,GCST001178,Lipid or lipoprotein measurement,#d53e4f
17164,Asian,270.0,21799462.0,Srinivasan Y,Epirubicin-induced leukopenia,initial,2011-07-27,GCST001175,Other trait,#3288bd
17165,Asian,48.0,21799462.0,Srinivasan Y,Epirubicin-induced leukopenia,replication,2011-07-27,GCST001175,Other trait,#3288bd
17166,European,1168.0,21795503.0,Alkelai A,Schizophrenia,replication,2011-07-27,GCST001176,Neurological disorder,#d53e4f
17167,Other/Mixed,189.0,21795503.0,Alkelai A,Schizophrenia,initial,2011-07-27,GCST001176,Neurological disorder,#99d594
17168,European,1657.0,21785125.0,Traglia M,Hepcidin levels,initial,2011-07-25,GCST001174,Other measurement,#d53e4f
17169,Asian,8903.0,21799836.0,Cui B,Type 2 diabetes,replication,2011-07-22,GCST001173,Metabolic disorder,#3288bd
17170,Asian,1599.0,21799836.0,Cui B,Type 2 diabetes,initial,2011-07-22,GCST001173,Metabolic disorder,#3288bd
17172,Hispanic/Latin American,63.0,21777205.0,Dumitrescu L,Lipid traits,initial,2011-07-21,GCST001170,Other measurement,#807dba
17173,Hispanic/Latin American,1443.0,21777205.0,Dumitrescu L,Lipid traits,replication,2011-07-21,GCST001170,Other measurement,#807dba
17174,African,1478.0,21777205.0,Dumitrescu L,Lipid traits,replication,2011-07-21,GCST001170,Other measurement,#fc8d59
17175,European,1627.0,21777205.0,Dumitrescu L,Lipid traits,replication,2011-07-21,GCST001170,Other measurement,#d53e4f
17176,African Am./Caribbean,66.0,21777205.0,Dumitrescu L,Lipid traits,initial,2011-07-21,GCST001170,Other measurement,#fee08b
17177,European,282.0,21777205.0,Dumitrescu L,Lipid traits,initial,2011-07-21,GCST001170,Other measurement,#d53e4f
17178,Asian,3106.0,21814517.0,Noguchi E,Asthma,initial,2011-07-21,GCST001172,Other disease,#3288bd
17179,Asian,3106.0,21814517.0,Noguchi E,Asthma,replication,2011-07-21,GCST001172,Other disease,#3288bd
17180,European,1183.0,21775533.0,Tan XL,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers,replication,2011-07-20,GCST001169,Response to drug,#d53e4f
17181,African Am./Caribbean,91.0,21775533.0,Tan XL,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers,initial,2011-07-20,GCST001169,Response to drug,#fee08b
17182,European,96.0,21775533.0,Tan XL,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers,initial,2011-07-20,GCST001169,Response to drug,#d53e4f
17183,Asian,96.0,21775533.0,Tan XL,Response to platinum-based chemotherapy in small cell and non-small cell lung cancers,initial,2011-07-20,GCST001169,Response to drug,#3288bd
17184,European,16995.0,21782286.0,Walter S,Aging (time to event),initial,2011-07-20,GCST001166,Biological process,#d53e4f
17185,African Am./Caribbean,30033.0,21775986.0,Hinch AG,Recombination measurement,initial,2011-07-20,GCST001168,Other measurement,#fee08b
17186,European,10411.0,21782286.0,Walter S,Aging (time to death),replication,2011-07-20,GCST001167,Other measurement,#d53e4f
17187,European,25007.0,21782286.0,Walter S,Aging (time to death),initial,2011-07-20,GCST001167,Other measurement,#d53e4f
17188,European,10411.0,21782286.0,Walter S,Aging (time to death),replication,2011-07-20,GCST001167,Biological process,#d53e4f
17189,European,25007.0,21782286.0,Walter S,Aging (time to death),initial,2011-07-20,GCST001167,Biological process,#d53e4f
17190,Other/Mixed,564.0,21771265.0,Yosifova A,Bipolar disorder,initial,2011-07-19,GCST001164,Neurological disorder,#99d594
17191,Other/Mixed,450.0,21771265.0,Yosifova A,Bipolar disorder,replication,2011-07-19,GCST001164,Neurological disorder,#99d594
17192,Asian,559.0,21771975.0,Chung CM,Adiponectin levels,replication,2011-07-19,GCST001165,Other measurement,#3288bd
17193,Asian,382.0,21771975.0,Chung CM,Adiponectin levels,initial,2011-07-19,GCST001165,Other measurement,#3288bd
17194,African Am./Caribbean,1996.0,21768215.0,Tin A,Urate levels,replication,2011-07-18,GCST001163,Other measurement,#fee08b
17195,African Am./Caribbean,8651.0,21768215.0,Tin A,Urate levels,initial,2011-07-18,GCST001163,Other measurement,#fee08b
17196,Asian,1931.0,21764829.0,Png E,Hepatitis B vaccine response,replication,2011-07-15,GCST001162,Response to drug,#3288bd
17197,Asian,1683.0,21764829.0,Png E,Hepatitis B vaccine response,initial,2011-07-15,GCST001162,Response to drug,#3288bd
17198,European,6322.0,21761138.0,Peters U,Colorectal cancer,initial,2011-07-15,GCST001161,Cancer,#d53e4f
17199,European,17262.0,21761138.0,Peters U,Colorectal cancer,replication,2011-07-15,GCST001161,Cancer,#d53e4f
17201,European,7385.0,21779181.0,Gorlova O,Systemic sclerosis,replication,2011-07-14,GCST001156,Neurological disorder,#d53e4f
17202,European,7468.0,21779181.0,Gorlova O,Systemic sclerosis,initial,2011-07-14,GCST001156,Neurological disorder,#d53e4f
17203,European,3527.0,21757650.0,Debette S,Vascular endothelial growth factor levels,initial,2011-07-14,GCST001155,Cardiovascular measurement,#d53e4f
17204,European,1727.0,21757650.0,Debette S,Vascular endothelial growth factor levels,replication,2011-07-14,GCST001155,Cardiovascular measurement,#d53e4f
17205,European,7385.0,21779181.0,Gorlova O,Systemic sclerosis,replication,2011-07-14,GCST001160,Neurological disorder,#d53e4f
17206,European,7468.0,21779181.0,Gorlova O,Systemic sclerosis,initial,2011-07-14,GCST001160,Neurological disorder,#d53e4f
17207,European,5122.0,21779381.0,Schurks M,Cardiovascular disease risk factors,initial,2011-07-14,GCST001157,Other disease,#d53e4f
17208,European,2448.0,21779176.0,Winkelmann J,Restless legs syndrome,initial,2011-07-14,GCST001159,Neurological disorder,#d53e4f
17209,European,9689.0,21779176.0,Winkelmann J,Restless legs syndrome,replication,2011-07-14,GCST001159,Neurological disorder,#d53e4f
17211,European,4883.0,21747397.0,Rietschel M,Schizophrenia,initial,2011-07-12,GCST001152,Neurological disorder,#d53e4f
17212,European,33577.0,21747397.0,Rietschel M,Schizophrenia,replication,2011-07-12,GCST001152,Neurological disorder,#d53e4f
17213,European,3313.0,21752600.0,Chen J,Schizophrenia,initial,2011-07-12,GCST001151,Neurological disorder,#d53e4f
17214,European,12352.0,21752600.0,Chen J,Schizophrenia,replication,2011-07-12,GCST001151,Neurological disorder,#d53e4f
17215,African Am./Caribbean,2127.0,21752600.0,Chen J,Schizophrenia,replication,2011-07-12,GCST001151,Neurological disorder,#fee08b
17216,Asian,6649.0,21750111.0,Mbarek H,Hepatitis B,replication,2011-07-12,GCST001150,Digestive system disorder,#3288bd
17217,Asian,2514.0,21750111.0,Mbarek H,Hepatitis B,initial,2011-07-12,GCST001150,Digestive system disorder,#3288bd
17218,European,13632.0,21750109.0,Rafnar T,Bladder cancer,replication,2011-07-12,GCST001153,Cancer,#d53e4f
17219,European,43837.0,21750109.0,Rafnar T,Bladder cancer,initial,2011-07-12,GCST001153,Cancer,#d53e4f
17220,Other/Mixed,515.0,21750109.0,Rafnar T,Bladder cancer,replication,2011-07-12,GCST001153,Cancer,#99d594
17221,European,6594.0,21743469.0,Evans DM,Ankylosing spondylitis,replication,2011-07-10,GCST001149,Immune system disorder,#d53e4f
17222,European,11802.0,21743469.0,Evans DM,Ankylosing spondylitis,initial,2011-07-10,GCST001149,Immune system disorder,#d53e4f
17223,African Am./Caribbean,410.0,21743467.0,Kote-Jarai Z,Prostate cancer,replication,2011-07-10,GCST001148,Cancer,#fee08b
17224,Asian,853.0,21743467.0,Kote-Jarai Z,Prostate cancer,replication,2011-07-10,GCST001148,Cancer,#3288bd
17225,European,46191.0,21743467.0,Kote-Jarai Z,Prostate cancer,replication,2011-07-10,GCST001148,Cancer,#d53e4f
17226,European,13560.0,21743467.0,Kote-Jarai Z,Prostate cancer,initial,2011-07-10,GCST001148,Cancer,#d53e4f
17227,Other/Mixed,12595.0,21743467.0,Kote-Jarai Z,Prostate cancer,replication,2011-07-10,GCST001148,Cancer,#99d594
17228,European,14090.0,21743057.0,Schumacher FR,Prostate cancer,replication,2011-07-08,GCST001147,Cancer,#d53e4f
17229,European,7240.0,21743057.0,Schumacher FR,Prostate cancer,initial,2011-07-08,GCST001147,Cancer,#d53e4f
17230,European,2340.0,21750679.0,Allanore Y,Systemic sclerosis,initial,2011-07-07,GCST001146,Neurological disorder,#d53e4f
17231,European,5608.0,21750679.0,Allanore Y,Systemic sclerosis,replication,2011-07-07,GCST001146,Neurological disorder,#d53e4f
17232,European,8434.0,21732829.0,Dolmans GH,Dupuytren's disease,replication,2011-07-06,GCST001144,Other disease,#d53e4f
17233,European,3692.0,21732829.0,Dolmans GH,Dupuytren's disease,initial,2011-07-06,GCST001144,Other disease,#d53e4f
17234,African,176.0,21755009.0,Wheeler HE,Chemotherapeutic susceptibility,initial,2011-07-06,GCST001145,Response to drug,#fc8d59
17235,African Am./Caribbean,83.0,21755009.0,Wheeler HE,Chemotherapeutic susceptibility,initial,2011-07-06,GCST001145,Response to drug,#fee08b
17236,European,992.0,21729881.0,Major JM,Vitamin E levels,replication,2011-07-05,GCST001142,Other measurement,#d53e4f
17237,European,4014.0,21729881.0,Major JM,Vitamin E levels,initial,2011-07-05,GCST001142,Other measurement,#d53e4f
17238,Other/Mixed,2775.0,21729881.0,Major JM,Vitamin E levels,replication,2011-07-05,GCST001142,Other measurement,#99d594
17239,European,869.0,22303337.0,Wang K,HDL cholesterol,replication,2011-07-05,GCST001143,Lipid or lipoprotein measurement,#d53e4f
17240,European,1437.0,22303337.0,Wang K,HDL cholesterol,initial,2011-07-05,GCST001143,Lipid or lipoprotein measurement,#d53e4f
17241,European,2154.0,21750702.0,Schosser A,Suicidal ideation,initial,2011-07-05,GCST001141,Other measurement,#d53e4f
17242,European,1531.0,21750702.0,Schosser A,Suicidal ideation,replication,2011-07-05,GCST001141,Other measurement,#d53e4f
17243,Asian,5408.0,21725308.0,Hu Z,Lung cancer,initial,2011-07-03,GCST001140,Cancer,#3288bd
17244,Asian,12722.0,21725308.0,Hu Z,Lung cancer,replication,2011-07-03,GCST001140,Cancer,#3288bd
17245,Asian,977.0,21725309.0,Miki D,Chronic hepatitis C infection,initial,2011-07-03,GCST001139,Digestive system disorder,#3288bd
17246,Asian,2335.0,21725309.0,Miki D,Chronic hepatitis C infection,replication,2011-07-03,GCST001139,Digestive system disorder,#3288bd
17247,Asian,274.0,21787189.0,Nyberg F,Interstitial lung disease,initial,2011-07-01,GCST001136,Other disease,#3288bd
17248,European,11823.0,21738480.0,Nalls MA,White blood cell count,replication,2011-07-01,GCST001137,Hematological measurement,#d53e4f
17249,European,19509.0,21738480.0,Nalls MA,White blood cell count,initial,2011-07-01,GCST001137,Hematological measurement,#d53e4f
17250,European,208.0,21694509.0,Janicki PK,Postoperative nausea and vomiting,replication,2011-07-01,GCST001138,Other trait,#d53e4f
17251,European,251.0,21694509.0,Janicki PK,Postoperative nausea and vomiting,initial,2011-07-01,GCST001138,Other trait,#d53e4f
17254,European,21283.0,21738491.0,Arking DE,Sudden cardiac arrest,initial,2011-06-30,GCST001132,Cardiovascular disease,#d53e4f
17255,European,14265.0,21738491.0,Arking DE,Sudden cardiac arrest,replication,2011-06-30,GCST001132,Cardiovascular disease,#d53e4f
17256,Asian,14767.0,21738479.0,Reiner AP,White blood cell count,replication,2011-06-30,GCST001133,Hematological measurement,#3288bd
17257,European,19509.0,21738479.0,Reiner AP,White blood cell count,replication,2011-06-30,GCST001133,Hematological measurement,#d53e4f
17258,Hispanic/Latin American,3551.0,21738479.0,Reiner AP,White blood cell count,replication,2011-06-30,GCST001133,Hematological measurement,#807dba
17259,African Am./Caribbean,16388.0,21738479.0,Reiner AP,White blood cell count,initial,2011-06-30,GCST001133,Hematological measurement,#fee08b
17260,Asian,8794.0,21738478.0,Okada Y,White blood cell types,initial,2011-06-30,GCST001134,Hematological measurement,#3288bd
17261,Asian,5998.0,21738478.0,Okada Y,White blood cell types,replication,2011-06-30,GCST001134,Hematological measurement,#3288bd
17262,European,1821.0,21740922.0,Nebel A,Longevity,initial,2011-06-29,GCST001131,Other measurement,#d53e4f
17263,European,1614.0,21740922.0,Nebel A,Longevity,replication,2011-06-29,GCST001131,Other measurement,#d53e4f
17264,European,10337.0,21708048.0,Jiao H,Obesity,replication,2011-06-28,GCST001130,Metabolic disorder,#d53e4f
17265,European,327.0,21708048.0,Jiao H,Obesity,initial,2011-06-28,GCST001130,Metabolic disorder,#d53e4f
17266,Asian,7557.0,21706003.0,Kilpelainen TO,Adiposity,initial,2011-06-26,GCST001128,Metabolic disorder,#3288bd
17267,European,39576.0,21706003.0,Kilpelainen TO,Adiposity,replication,2011-06-26,GCST001128,Metabolic disorder,#d53e4f
17268,European,29069.0,21706003.0,Kilpelainen TO,Adiposity,initial,2011-06-26,GCST001128,Metabolic disorder,#d53e4f
17269,European,2306.0,21706340.0,Teerlink C,Melanoma,initial,2011-06-26,GCST001129,Cancer,#d53e4f
17270,European,52.0,21705454.0,Huang RS,Response to platinum-based agents,replication,2011-06-24,GCST001127,Response to drug,#d53e4f
17271,European,87.0,21705454.0,Huang RS,Response to platinum-based agents,initial,2011-06-24,GCST001127,Response to drug,#d53e4f
17272,European,6271.0,21700618.0,Nan H,Basal cell carcinoma,replication,2011-06-23,GCST001124,Cancer,#d53e4f
17273,European,8058.0,21700618.0,Nan H,Basal cell carcinoma,initial,2011-06-23,GCST001124,Cancer,#d53e4f
17274,Other/Mixed,2133.0,21701565.0,Malhotra A,Body mass index,replication,2011-06-23,GCST001123,Body measurement,#99d594
17275,Other/Mixed,1120.0,21701565.0,Malhotra A,Body mass index,initial,2011-06-23,GCST001123,Body measurement,#99d594
17276,African Am./Caribbean,3724.0,21701570.0,Ng MC,Body mass index,replication,2011-06-23,GCST001125,Body measurement,#fee08b
17277,African Am./Caribbean,1715.0,21701570.0,Ng MC,Body mass index,initial,2011-06-23,GCST001125,Body measurement,#fee08b
17278,European,33050.0,21738487.0,Do CB,Parkinson's disease,initial,2011-06-23,GCST001126,Neurological disorder,#d53e4f
17279,European,626.0,21700879.0,Qi L,Adiponectin levels,replication,2011-06-23,GCST001122,Other measurement,#d53e4f
17280,European,1591.0,21700879.0,Qi L,Adiponectin levels,initial,2011-06-23,GCST001122,Other measurement,#d53e4f
17281,European,5628.0,21700265.0,Kullo IJ,Erythrocyte sedimentation rate,replication,2011-06-22,GCST001120,Inflammatory measurement,#d53e4f
17282,European,1979.0,21700265.0,Kullo IJ,Erythrocyte sedimentation rate,initial,2011-06-22,GCST001120,Inflammatory measurement,#d53e4f
17283,European,3334.0,21703634.0,Wang KS,Alcohol dependence,replication,2011-06-22,GCST001121,Neurological disorder,#d53e4f
17284,European,2699.0,21703634.0,Wang KS,Alcohol dependence,initial,2011-06-22,GCST001121,Neurological disorder,#d53e4f
17285,Asian,744.0,21699788.0,Okada Y,Ulcerative colitis or Crohn's disease,initial,2011-06-20,GCST001118,Immune system disorder,#3288bd
17286,Asian,983.0,21699788.0,Okada Y,Ulcerative colitis or Crohn's disease,replication,2011-06-20,GCST001118,Immune system disorder,#3288bd
17287,Asian,744.0,21699788.0,Okada Y,Ulcerative colitis or Crohn's disease,initial,2011-06-20,GCST001118,Digestive system disorder,#3288bd
17288,Asian,983.0,21699788.0,Okada Y,Ulcerative colitis or Crohn's disease,replication,2011-06-20,GCST001118,Digestive system disorder,#3288bd
17289,European,331.0,21682944.0,Alkelai A,Schizophrenia,initial,2011-06-20,GCST001119,Neurological disorder,#d53e4f
17290,Other/Mixed,189.0,21682944.0,Alkelai A,Schizophrenia,replication,2011-06-20,GCST001119,Neurological disorder,#99d594
17291,Other/Mixed,138.0,21696813.0,Schauberger EM,Asthma (childhood onset),replication,2011-06-20,GCST001117,Other disease,#99d594
17292,Hispanic/Latin American,3693.0,21696813.0,Schauberger EM,Asthma (childhood onset),replication,2011-06-20,GCST001117,Other disease,#807dba
17293,European,277.0,21696813.0,Schauberger EM,Asthma (childhood onset),initial,2011-06-20,GCST001117,Other disease,#d53e4f
17294,European,9243.0,21696813.0,Schauberger EM,Asthma (childhood onset),replication,2011-06-20,GCST001117,Other disease,#d53e4f
17295,African Am./Caribbean,156.0,21696813.0,Schauberger EM,Asthma (childhood onset),replication,2011-06-20,GCST001117,Other disease,#fee08b
17297,European,4611.0,21685912.0,Hoglinger GU,Progressive supranuclear palsy,replication,2011-06-19,GCST001116,Neurological disorder,#d53e4f
17298,European,4027.0,21685912.0,Hoglinger GU,Progressive supranuclear palsy,initial,2011-06-19,GCST001116,Neurological disorder,#d53e4f
17299,Other/Mixed,329.0,21685912.0,Hoglinger GU,Progressive supranuclear palsy,initial,2011-06-19,GCST001116,Neurological disorder,#99d594
17300,European,1162.0,21688384.0,Wang KS,Schizophrenia (age at onset),initial,2011-06-17,GCST001115,Neurological disorder,#d53e4f
17301,European,1068.0,21688384.0,Wang KS,Schizophrenia (age at onset),replication,2011-06-17,GCST001115,Neurological disorder,#d53e4f
17302,European,1162.0,21688384.0,Wang KS,Schizophrenia (age at onset),initial,2011-06-17,GCST001115,Other measurement,#d53e4f
17303,European,1068.0,21688384.0,Wang KS,Schizophrenia (age at onset),replication,2011-06-17,GCST001115,Other measurement,#d53e4f
17304,European,1162.0,21688384.0,Wang KS,Schizophrenia (age at onset) (sex interaction),initial,2011-06-17,GCST001114,Neurological disorder,#d53e4f
17305,European,1068.0,21688384.0,Wang KS,Schizophrenia (age at onset) (sex interaction),replication,2011-06-17,GCST001114,Neurological disorder,#d53e4f
17306,European,1162.0,21688384.0,Wang KS,Schizophrenia (age at onset) (sex interaction),initial,2011-06-17,GCST001114,Other measurement,#d53e4f
17307,European,1068.0,21688384.0,Wang KS,Schizophrenia (age at onset) (sex interaction),replication,2011-06-17,GCST001114,Other measurement,#d53e4f
17308,African Am./Caribbean,1323.0,21698141.0,Freedman BI,End-stage renal disease,replication,2011-06-16,GCST001107,Other disease,#fee08b
17309,African Am./Caribbean,1940.0,21698141.0,Freedman BI,End-stage renal disease,initial,2011-06-16,GCST001107,Other disease,#fee08b
17310,European,3440.0,21685187.0,Siedlinski M,Lifetime average cigarettes per day in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001112,Other disease,#d53e4f
17311,European,3440.0,21685187.0,Siedlinski M,Lifetime average cigarettes per day in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001112,Other measurement,#d53e4f
17312,European,1113.0,21685187.0,Siedlinski M,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001111,Other disease,#d53e4f
17313,European,1113.0,21685187.0,Siedlinski M,Current cigarettes per day in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001111,Other measurement,#d53e4f
17314,European,3071.0,21685187.0,Siedlinski M,Smoking cessation in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001108,Other disease,#d53e4f
17315,European,3071.0,21685187.0,Siedlinski M,Smoking cessation in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001108,Biological process,#d53e4f
17316,European,9361.0,21681796.0,Fornage M,White matter hyperintensity burden,initial,2011-06-16,GCST001109,Other measurement,#d53e4f
17317,European,3024.0,21681796.0,Fornage M,White matter hyperintensity burden,replication,2011-06-16,GCST001109,Other measurement,#d53e4f
17318,Asian,158.0,21679298.0,Ma X,Schizophrenia,initial,2011-06-16,GCST001110,Neurological disorder,#3288bd
17319,European,3397.0,21685187.0,Siedlinski M,Age at smoking initiation in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001113,Other disease,#d53e4f
17320,European,3397.0,21685187.0,Siedlinski M,Age at smoking initiation in chronic obstructive pulmonary disease,initial,2011-06-16,GCST001113,Biological process,#d53e4f
17321,European,5062.0,21666691.0,Sun LD,Atopic dermatitis,replication,2011-06-13,GCST001106,Immune system disorder,#d53e4f
17322,Asian,15821.0,21666691.0,Sun LD,Atopic dermatitis,replication,2011-06-13,GCST001106,Immune system disorder,#3288bd
17323,Asian,2374.0,21666691.0,Sun LD,Atopic dermatitis,initial,2011-06-13,GCST001106,Immune system disorder,#3288bd
17324,European,17777.0,21666692.0,Chasman DI,Migraine,replication,2011-06-12,GCST001105,Cardiovascular disease,#d53e4f
17325,European,23230.0,21666692.0,Chasman DI,Migraine,initial,2011-06-12,GCST001105,Cardiovascular disease,#d53e4f
17326,European,605.0,21658281.0,Aouizerat BE,Sudden cardiac arrest,initial,2011-06-10,GCST001102,Cardiovascular disease,#d53e4f
17327,European,605.0,21658281.0,Aouizerat BE,Sudden cardiac arrest,initial,2011-06-10,GCST001099,Cardiovascular disease,#d53e4f
17328,Asian,2008.0,21665993.0,Han S,Corneal curvature,initial,2011-06-10,GCST001101,Other measurement,#3288bd
17329,Asian,2281.0,21665993.0,Han S,Corneal curvature,initial,2011-06-10,GCST001101,Other measurement,#3288bd
17330,Asian,929.0,21665993.0,Han S,Corneal curvature,replication,2011-06-10,GCST001101,Other measurement,#3288bd
17331,Asian,2142.0,21665993.0,Han S,Corneal curvature,replication,2011-06-10,GCST001101,Other measurement,#3288bd
17332,European,605.0,21658281.0,Aouizerat BE,Sudden cardiac arrest,initial,2011-06-10,GCST001104,Cardiovascular disease,#d53e4f
17333,European,6728.0,21665990.0,Yu Y,Age-related macular degeneration,initial,2011-06-10,GCST001100,Neurological disorder,#d53e4f
17334,European,57814.0,21665990.0,Yu Y,Age-related macular degeneration,replication,2011-06-10,GCST001100,Neurological disorder,#d53e4f
17335,Other/Mixed,5.0,21665988.0,Horne BD,Peripartum cardiomyopathy,initial,2011-06-10,GCST001098,Cardiovascular disease,#99d594
17336,European,362.0,21665988.0,Horne BD,Peripartum cardiomyopathy,replication,2011-06-10,GCST001098,Cardiovascular disease,#d53e4f
17337,European,739.0,21665988.0,Horne BD,Peripartum cardiomyopathy,initial,2011-06-10,GCST001098,Cardiovascular disease,#d53e4f
17338,European,5181.0,21665994.0,Kutalik Z,Alcohol consumption (transferrin glycosylation),initial,2011-06-10,GCST001103,Biological process,#d53e4f
17340,European,1470.0,21654844.0,Briggs FB,Multiple sclerosis,initial,2011-06-09,GCST001096,Immune system disorder,#d53e4f
17341,European,9538.0,21694764.0,Martin NW,Educational attainment,initial,2011-06-09,GCST001097,Other measurement,#d53e4f
17342,European,968.0,21694764.0,Martin NW,Educational attainment,replication,2011-06-09,GCST001097,Other measurement,#d53e4f
17343,European,380.0,21659360.0,Wade R,Response to antineoplastic agents,replication,2011-06-09,GCST001095,Response to drug,#d53e4f
17344,European,356.0,21659360.0,Wade R,Response to antineoplastic agents,initial,2011-06-09,GCST001095,Response to drug,#d53e4f
17345,Asian,303.0,21659334.0,Tanaka Y,Response to hepatitis C treatment,initial,2011-06-09,GCST001094,Digestive system disorder,#3288bd
17346,Asian,391.0,21659334.0,Tanaka Y,Response to hepatitis C treatment,replication,2011-06-09,GCST001094,Digestive system disorder,#3288bd
17347,Asian,1709.0,21647738.0,Wu Y,C-reactive protein,initial,2011-06-07,GCST001093,Inflammatory measurement,#3288bd
17348,Hispanic/Latin American,1310.0,21647700.0,Below JE,Type 2 diabetes,replication,2011-06-07,GCST001092,Metabolic disorder,#807dba
17349,Hispanic/Latin American,1273.0,21647700.0,Below JE,Type 2 diabetes,initial,2011-06-07,GCST001092,Metabolic disorder,#807dba
17350,Asian,360.0,21674006.0,Yamada K,Schizophrenia,initial,2011-06-06,GCST001090,Neurological disorder,#3288bd
17351,Asian,2175.0,21674006.0,Yamada K,Schizophrenia,replication,2011-06-06,GCST001090,Neurological disorder,#3288bd
17352,European,6307.0,21646302.0,Bielinski SJ,Bilirubin levels,initial,2011-06-06,GCST001091,Other measurement,#d53e4f
17353,Asian,8143.0,21642993.0,Wu C,Esophageal cancer,replication,2011-06-05,GCST001089,Cancer,#3288bd
17354,Asian,4075.0,21642993.0,Wu C,Esophageal cancer,initial,2011-06-05,GCST001089,Cancer,#3288bd
17355,Asian,1088.0,21640322.0,Shi Y,Myopia (pathological),initial,2011-06-02,GCST001088,Other trait,#3288bd
17356,Asian,8445.0,21640322.0,Shi Y,Myopia (pathological),replication,2011-06-02,GCST001088,Other trait,#3288bd
17358,European,12943.0,21627779.0,Antunez C,Alzheimer's disease,replication,2011-05-31,GCST001087,Neurological disorder,#d53e4f
17360,European,1088.0,21627779.0,Antunez C,Alzheimer's disease,initial,2011-05-31,GCST001087,Neurological disorder,#d53e4f
17361,European,3440.0,21623375.0,Albagha OM,Paget's disease,initial,2011-05-29,GCST001086,Other disease,#d53e4f
17362,European,3145.0,21623375.0,Albagha OM,Paget's disease,replication,2011-05-29,GCST001086,Other disease,#d53e4f
17363,European,5000.0,21626137.0,Slavin TP,Hypertension (SNP x SNP interaction),initial,2011-05-28,GCST001085,Cardiovascular disease,#d53e4f
17364,European,5000.0,21626137.0,Slavin TP,Coronary heart disease (SNP X SNP interaction),initial,2011-05-28,GCST001084,Cardiovascular disease,#d53e4f
17365,Other/Mixed,57.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other measurement,#99d594
17366,Asian,777.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other measurement,#3288bd
17367,European,816.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other measurement,#d53e4f
17368,Other/Mixed,57.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other disease,#99d594
17369,Asian,777.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other disease,#3288bd
17370,European,816.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other disease,#d53e4f
17371,Other/Mixed,57.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other trait,#99d594
17372,Asian,777.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other trait,#3288bd
17373,European,816.0,21618603.0,Beaty TH,Orofacial clefts (maternal alcohol consumption interaction),initial,2011-05-26,GCST001082,Other trait,#d53e4f
17375,European,276.0,21612516.0,Malovini A,Longevity,replication,2011-05-25,GCST001081,Other measurement,#d53e4f
17376,European,963.0,21612516.0,Malovini A,Longevity,initial,2011-05-25,GCST001081,Other measurement,#d53e4f
17378,European,5031.0,21606135.0,Wild PS,Coronary heart disease,initial,2011-05-23,GCST001079,Cardiovascular disease,#d53e4f
17379,European,54758.0,21606135.0,Wild PS,Coronary heart disease,replication,2011-05-23,GCST001079,Cardiovascular disease,#d53e4f
17380,African Am./Caribbean,6715.0,21602798.0,Haiman CA,Prostate cancer,initial,2011-05-22,GCST001078,Cancer,#fee08b
17381,African Am./Caribbean,3408.0,21602798.0,Haiman CA,Prostate cancer,replication,2011-05-22,GCST001078,Cancer,#fee08b
17382,African,1705.0,21602798.0,Haiman CA,Prostate cancer,replication,2011-05-22,GCST001078,Cancer,#fc8d59
17384,European,2317.0,21602797.0,Wright FA,Cystic fibrosis severity,initial,2011-05-22,GCST001077,Digestive system disorder,#d53e4f
17386,European,898.0,21602797.0,Wright FA,Cystic fibrosis severity,replication,2011-05-22,GCST001077,Digestive system disorder,#d53e4f
17387,Asian,2834.0,21625490.0,Andiappan AK,Atopy,replication,2011-05-20,GCST001075,Immune system disorder,#3288bd
17388,Asian,1001.0,21625490.0,Andiappan AK,Atopy,initial,2011-05-20,GCST001075,Immune system disorder,#3288bd
17389,Hispanic/Latin American,99.0,21703177.0,Thompson AJ,IFN-related cytopenia,initial,2011-05-20,GCST001076,Digestive system disorder,#807dba
17390,African Am./Caribbean,201.0,21703177.0,Thompson AJ,IFN-related cytopenia,initial,2011-05-20,GCST001076,Digestive system disorder,#fee08b
17391,European,984.0,21703177.0,Thompson AJ,IFN-related cytopenia,initial,2011-05-20,GCST001076,Digestive system disorder,#d53e4f
17392,Asian,30765.0,21572416.0,Kato N,Blood pressure,replication,2011-05-15,GCST001072,Other measurement,#3288bd
17393,Asian,19608.0,21572416.0,Kato N,Blood pressure,initial,2011-05-15,GCST001072,Other measurement,#3288bd
17394,Hispanic/Latin American,2584.0,21573907.0,Parra EJ,Type 2 diabetes,initial,2011-05-15,GCST001070,Metabolic disorder,#807dba
17395,Asian,5203.0,21573128.0,Kou I,Osteoporosis,replication,2011-05-15,GCST001071,Other disease,#3288bd
17396,Asian,1747.0,21573128.0,Kou I,Osteoporosis,initial,2011-05-15,GCST001071,Other disease,#3288bd
17397,European,1862.0,21572414.0,Suhre K,Urinary metabolites,replication,2011-05-15,GCST001073,Other measurement,#d53e4f
17399,Asian,19608.0,21572416.0,Kato N,Blood pressure,initial,2011-05-15,GCST001074,Other measurement,#3288bd
17400,Asian,30765.0,21572416.0,Kato N,Blood pressure,replication,2011-05-15,GCST001074,Other measurement,#3288bd
17401,European,3620.0,21565293.0,Teumer A,Thyroid volume,initial,2011-05-13,GCST001069,Other measurement,#d53e4f
17402,European,1290.0,21565293.0,Teumer A,Thyroid volume,replication,2011-05-13,GCST001069,Other measurement,#d53e4f
17403,European,2460.0,21573004.0,Prescott J,Telomere length,replication,2011-05-10,GCST001068,Other measurement,#d53e4f
17404,European,3554.0,21573004.0,Prescott J,Telomere length,initial,2011-05-10,GCST001068,Other measurement,#d53e4f
17405,European,1399.0,21551455.0,Kanetsky PA,Testicular cancer,replication,2011-05-06,GCST001067,Cancer,#d53e4f
17406,European,1268.0,21551455.0,Kanetsky PA,Testicular cancer,initial,2011-05-06,GCST001067,Cancer,#d53e4f
17407,African Am./Caribbean,610.0,21546767.0,Murea M,Dialysis-related mortality,initial,2011-05-05,GCST001066,Other disease,#fee08b
17408,European,3365.0,21540310.0,Hofmann S,Sarcoidosis,replication,2011-05-03,GCST001064,Other disease,#d53e4f
17409,European,773.0,21540310.0,Hofmann S,Sarcoidosis,initial,2011-05-03,GCST001064,Other disease,#d53e4f
17410,European,808.0,21540461.0,Kim DH,Chronic myeloid leukemia,replication,2011-05-03,GCST001063,Cancer,#d53e4f
17411,Asian,1237.0,21540461.0,Kim DH,Chronic myeloid leukemia,replication,2011-05-03,GCST001063,Cancer,#3288bd
17412,Asian,698.0,21540461.0,Kim DH,Chronic myeloid leukemia,initial,2011-05-03,GCST001063,Cancer,#3288bd
17415,African,115.0,21507922.0,Ramsuran V,Platelet count,initial,2011-05-01,GCST001061,Hematological measurement,#fc8d59
17416,African,115.0,21507922.0,Ramsuran V,Neutrophil count,initial,2011-05-01,GCST001059,Hematological measurement,#fc8d59
17417,European,4446.0,21532571.0,Burdon KP,Glaucoma,initial,2011-05-01,GCST001062,Neurological disorder,#d53e4f
17418,European,5474.0,21532571.0,Burdon KP,Glaucoma,replication,2011-05-01,GCST001062,Neurological disorder,#d53e4f
17419,European,755.0,21502085.0,Troyer JL,AIDS progression,initial,2011-05-01,GCST001060,Immune system disorder,#d53e4f
17420,European,11582.0,21531791.0,Sanson M,Glioma,initial,2011-04-29,GCST001058,Cancer,#d53e4f
17421,European,1196.0,21552555.0,Wang K,Obesity,replication,2011-04-28,GCST001057,Metabolic disorder,#d53e4f
17422,European,1060.0,21552555.0,Wang K,Obesity,initial,2011-04-28,GCST001057,Metabolic disorder,#d53e4f
17423,African Am./Caribbean,991.0,21521612.0,Kohli MA,Major depressive disorder,replication,2011-04-28,GCST001056,Neurological disorder,#fee08b
17424,European,13969.0,21521612.0,Kohli MA,Major depressive disorder,replication,2011-04-28,GCST001056,Neurological disorder,#d53e4f
17425,European,719.0,21521612.0,Kohli MA,Major depressive disorder,initial,2011-04-28,GCST001056,Neurological disorder,#d53e4f
17426,European,8754.0,21529783.0,Heath AC,Alcoholism (heaviness of drinking),initial,2011-04-27,GCST001052,Neurological disorder,#d53e4f
17427,European,3393.0,21529783.0,Heath AC,Alcoholism (heaviness of drinking),replication,2011-04-27,GCST001052,Neurological disorder,#d53e4f
17428,European,8754.0,21529783.0,Heath AC,Alcoholism (alcohol dependence factor score),initial,2011-04-27,GCST001054,Neurological disorder,#d53e4f
17429,European,3393.0,21529783.0,Heath AC,Alcoholism (alcohol dependence factor score),replication,2011-04-27,GCST001054,Neurological disorder,#d53e4f
17430,European,8754.0,21529783.0,Heath AC,Alcoholism (alcohol use disorder factor score),initial,2011-04-27,GCST001053,Neurological disorder,#d53e4f
17431,European,3393.0,21529783.0,Heath AC,Alcoholism (alcohol use disorder factor score),replication,2011-04-27,GCST001053,Neurological disorder,#d53e4f
17432,European,8754.0,21529783.0,Heath AC,Alcoholism (12-month weekly alcohol consumption),initial,2011-04-27,GCST001055,Neurological disorder,#d53e4f
17433,European,3393.0,21529783.0,Heath AC,Alcoholism (12-month weekly alcohol consumption),replication,2011-04-27,GCST001055,Neurological disorder,#d53e4f
17434,European,1654.0,21493818.0,Shaw SY,Monocyte early outgrowth colony forming units,initial,2011-04-21,GCST001048,Other measurement,#d53e4f
17435,European,20898.0,21533022.0,Duncan EL,Bone mineral density,replication,2011-04-21,GCST001050,Other measurement,#d53e4f
17436,European,1955.0,21533022.0,Duncan EL,Bone mineral density,initial,2011-04-21,GCST001050,Other measurement,#d53e4f
17437,European,21052.0,21502573.0,Smith NL,D-dimer levels,initial,2011-04-21,GCST001049,Cardiovascular measurement,#d53e4f
17438,European,5001.0,21533074.0,Smedby KE,Follicular lymphoma,replication,2011-04-21,GCST001051,Cancer,#d53e4f
17439,European,1170.0,21533074.0,Smedby KE,Follicular lymphoma,initial,2011-04-21,GCST001051,Cancer,#d53e4f
17441,European,22435.0,21533024.0,Pare G,Soluble ICAM-1,initial,2011-04-21,GCST001047,Cardiovascular measurement,#d53e4f
17442,Asian,2733.0,21505073.0,Terao C,Rheumatoid arthritis,initial,2011-04-19,GCST001042,Immune system disorder,#3288bd
17443,Asian,9171.0,21505073.0,Terao C,Rheumatoid arthritis,replication,2011-04-19,GCST001042,Immune system disorder,#3288bd
17444,Asian,437.0,21505071.0,Li Z,Myopia (pathological),initial,2011-04-19,GCST001044,Other trait,#3288bd
17445,Asian,12962.0,21505071.0,Li Z,Myopia (pathological),replication,2011-04-19,GCST001044,Other trait,#3288bd
17446,European,464.0,21502949.0,Stein JL,Caudate nucleus volume,replication,2011-04-19,GCST001045,Other measurement,#d53e4f
17447,European,734.0,21502949.0,Stein JL,Caudate nucleus volume,initial,2011-04-19,GCST001045,Other measurement,#d53e4f
17448,Asian,2531.0,21544081.0,Dorajoo R,Obesity,initial,2011-04-19,GCST001046,Metabolic disorder,#3288bd
17449,Asian,5429.0,21544081.0,Dorajoo R,Obesity,initial,2011-04-19,GCST001046,Metabolic disorder,#3288bd
17450,Asian,2431.0,21544081.0,Dorajoo R,Obesity,initial,2011-04-19,GCST001046,Metabolic disorder,#3288bd
17451,European,818.0,21502966.0,Weber F,Response to interferon beta therapy,replication,2011-04-19,GCST001043,Response to drug,#d53e4f
17452,European,362.0,21502966.0,Weber F,Response to interferon beta therapy,initial,2011-04-19,GCST001043,Response to drug,#d53e4f
17453,Asian,3269.0,21499248.0,Kumar V,Hepatocellular carcinoma,replication,2011-04-17,GCST001041,Cancer,#3288bd
17454,Asian,3611.0,21499248.0,Kumar V,Hepatocellular carcinoma,initial,2011-04-17,GCST001041,Cancer,#3288bd
17455,European,10843.0,21499250.0,Spurdle AB,Endometrial cancer,replication,2011-04-17,GCST001040,Cancer,#d53e4f
17456,European,6455.0,21499250.0,Spurdle AB,Endometrial cancer,initial,2011-04-17,GCST001040,Cancer,#d53e4f
17457,European,2096.0,21497890.0,Orange JS,Common variable immunodeficiency,initial,2011-04-15,GCST001039,Immune system disorder,#d53e4f
17458,European,1223.0,21497890.0,Orange JS,Common variable immunodeficiency,replication,2011-04-15,GCST001039,Immune system disorder,#d53e4f
17459,European,14846.0,21533175.0,Zhai G,Dehydroepiandrosterone sulphate levels,initial,2011-04-14,GCST001038,Other measurement,#d53e4f
17460,Hispanic/Latin American,857.0,21483430.0,Carless MA,Neuranatomic and neurocognitive phenotypes,initial,2011-04-12,GCST001037,Other measurement,#807dba
17461,Hispanic/Latin American,857.0,21483430.0,Carless MA,Neuranatomic and neurocognitive phenotypes,initial,2011-04-12,GCST001037,Other measurement,#807dba
17462,European,733.0,21570397.0,Lucena MI,Drug-induced liver injury (amoxicillin-clavulanate),initial,2011-04-12,GCST001036,Digestive system disorder,#d53e4f
17463,European,735.0,21483023.0,Wu X,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2011-04-11,GCST001035,Response to drug,#d53e4f
17464,European,327.0,21483023.0,Wu X,Response to platinum-based chemotherapy in non-small-cell lung cancer,initial,2011-04-11,GCST001035,Response to drug,#d53e4f
17465,European,735.0,21483023.0,Wu X,Response to platinum-based chemotherapy in non-small-cell lung cancer,replication,2011-04-11,GCST001035,Cancer,#d53e4f
17466,European,327.0,21483023.0,Wu X,Response to platinum-based chemotherapy in non-small-cell lung cancer,initial,2011-04-11,GCST001035,Cancer,#d53e4f
17467,European,3581.0,21478494.0,Nan H,Cutaneous nevi,replication,2011-04-09,GCST001034,Cancer,#d53e4f
17468,European,9136.0,21478494.0,Nan H,Cutaneous nevi,initial,2011-04-09,GCST001034,Cancer,#d53e4f
17469,European,296.0,21473668.0,Fliers EA,Attention deficit hyperactivity disorder motor coordination,replication,2011-04-07,GCST001030,Neurological disorder,#d53e4f
17470,European,890.0,21473668.0,Fliers EA,Attention deficit hyperactivity disorder motor coordination,initial,2011-04-07,GCST001030,Neurological disorder,#d53e4f
17471,European,47431.0,21490707.0,Cornelis MC,Caffeine consumption,initial,2011-04-07,GCST001032,Biological process,#d53e4f
17472,Asian,2034.0,21490949.0,Sim X,Type 2 diabetes,initial,2011-04-07,GCST001033,Metabolic disorder,#3288bd
17473,Asian,3955.0,21490949.0,Sim X,Type 2 diabetes,initial,2011-04-07,GCST001033,Metabolic disorder,#3288bd
17474,Asian,2146.0,21490949.0,Sim X,Type 2 diabetes,initial,2011-04-07,GCST001033,Metabolic disorder,#3288bd
17475,Asian,3634.0,21471979.0,Kumar V,Large B-cell lymphoma,replication,2011-04-07,GCST001031,Cancer,#3288bd
17476,Asian,1008.0,21471979.0,Kumar V,Large B-cell lymphoma,initial,2011-04-07,GCST001031,Cancer,#3288bd
17477,European,26316.0,21471458.0,Schumann G,Alcohol consumption,initial,2011-04-06,GCST001029,Biological process,#d53e4f
17478,European,21185.0,21471458.0,Schumann G,Alcohol consumption,replication,2011-04-06,GCST001029,Biological process,#d53e4f
17479,European,2289.0,21467234.0,FitzGerald LM,Prostate cancer,replication,2011-04-05,GCST001028,Cancer,#d53e4f
17480,European,302.0,21467234.0,FitzGerald LM,Prostate cancer,initial,2011-04-05,GCST001028,Cancer,#d53e4f
17481,European,20373.0,21460840.0,Hollingworth P,Alzheimer's disease,initial,2011-04-03,GCST001025,Neurological disorder,#d53e4f
17482,European,39342.0,21460840.0,Hollingworth P,Alzheimer's disease,replication,2011-04-03,GCST001025,Neurological disorder,#d53e4f
17483,European,38754.0,21460841.0,Naj AC,Alzheimer's disease (late onset),replication,2011-04-03,GCST001026,Neurological disorder,#d53e4f
17484,European,15675.0,21460841.0,Naj AC,Alzheimer's disease (late onset),initial,2011-04-03,GCST001026,Neurological disorder,#d53e4f
17485,Asian,6683.0,21460842.0,Cha PC,Uterine fibroids,replication,2011-04-03,GCST001027,Cancer,#3288bd
17486,Asian,3035.0,21460842.0,Cha PC,Uterine fibroids,initial,2011-04-03,GCST001027,Cancer,#3288bd
17489,Asian,1558.0,21452313.0,Freudenberg J,Rheumatoid arthritis,initial,2011-04-01,GCST001022,Immune system disorder,#3288bd
17490,Asian,1437.0,21452313.0,Freudenberg J,Rheumatoid arthritis,replication,2011-04-01,GCST001022,Immune system disorder,#3288bd
17491,European,2287.0,21459883.0,Villard E,Idiopathic dilated cardiomyopathy,initial,2011-04-01,GCST001023,Cardiovascular disease,#d53e4f
17492,European,2467.0,21459883.0,Villard E,Idiopathic dilated cardiomyopathy,replication,2011-04-01,GCST001023,Cardiovascular disease,#d53e4f
17493,European,679.0,21483845.0,McLaren CE,Iron status biomarkers,initial,2011-03-31,GCST001021,Other measurement,#d53e4f
17494,European,232.0,21483845.0,McLaren CE,Iron status biomarkers,replication,2011-03-31,GCST001021,Other measurement,#d53e4f
17495,European,679.0,21483845.0,McLaren CE,Iron deficiency,initial,2011-03-31,GCST001020,Other trait,#d53e4f
17496,European,232.0,21483845.0,McLaren CE,Iron deficiency,replication,2011-03-31,GCST001020,Other trait,#d53e4f
17497,European,10980.0,21448238.0,Ligthart L,Migraine,initial,2011-03-30,GCST001019,Cardiovascular disease,#d53e4f
17498,European,8731.0,21448238.0,Ligthart L,Migraine,replication,2011-03-30,GCST001019,Cardiovascular disease,#d53e4f
17499,Asian,1741.0,21441931.0,Okamoto K,Nephrotic syndrome (acquired),initial,2011-03-27,GCST001018,Other disease,#3288bd
17500,Asian,5581.0,21441931.0,Okamoto K,Nephrotic syndrome (acquired),replication,2011-03-27,GCST001018,Other disease,#3288bd
17501,European,2829.0,21441570.0,Grassi MA,Diabetic retinopathy,initial,2011-03-26,GCST001017,Metabolic disorder,#d53e4f
17502,European,67.0,21396408.0,Miller EK,Vaccine-related adverse events,initial,2011-03-25,GCST001016,Response to drug,#d53e4f
17504,European,2698.0,21423239.0,Willour VL,Suicide attempts in bipolar disorder,initial,2011-03-25,GCST001015,Neurological disorder,#d53e4f
17506,European,2698.0,21423239.0,Willour VL,Suicide attempts in bipolar disorder,initial,2011-03-25,GCST001015,Biological process,#d53e4f
17507,European,337.0,21428769.0,McCormack M,Adverse response to carbamazepine,replication,2011-03-24,GCST001014,Response to drug,#d53e4f
17508,European,4052.0,21428769.0,McCormack M,Adverse response to carbamazepine,initial,2011-03-24,GCST001014,Response to drug,#d53e4f
17509,European,2073.0,21418511.0,Deelen J,Longevity,initial,2011-03-21,GCST001013,Other measurement,#d53e4f
17511,European,3575.0,21418511.0,Deelen J,Longevity,replication,2011-03-21,GCST001013,Other measurement,#d53e4f
17512,Other/Mixed,3298.0,21418511.0,Deelen J,Longevity,replication,2011-03-21,GCST001013,Other measurement,#99d594
17513,European,2368.0,21424380.0,Sehrawat B,Breast cancer,replication,2011-03-19,GCST001012,Cancer,#d53e4f
17514,European,623.0,21424380.0,Sehrawat B,Breast cancer,initial,2011-03-19,GCST001012,Cancer,#d53e4f
17515,European,20726.0,21437268.0,McKay JD,Oral cavity and pharyngeal cancer,replication,2011-03-17,GCST001011,Cancer,#d53e4f
17516,European,10425.0,21437268.0,McKay JD,Oral cavity and pharyngeal cancer,initial,2011-03-17,GCST001011,Cancer,#d53e4f
17517,European,7003.0,21399635.0,Mells GF,Primary biliary cholangitis,initial,2011-03-13,GCST001010,Cancer,#d53e4f
17518,European,3134.0,21399635.0,Mells GF,Primary biliary cholangitis,replication,2011-03-13,GCST001010,Cancer,#d53e4f
17519,Asian,2096.0,21399633.0,Gharavi AG,Nephropathy,initial,2011-03-13,GCST001009,Other disease,#3288bd
17520,Asian,1460.0,21399633.0,Gharavi AG,Nephropathy,replication,2011-03-13,GCST001009,Other disease,#3288bd
17521,European,2410.0,21399633.0,Gharavi AG,Nephropathy,replication,2011-03-13,GCST001009,Other disease,#d53e4f
17522,European,1997.0,21423719.0,Speliotes EK,Nonalcoholic fatty liver disease,replication,2011-03-10,GCST001008,Digestive system disorder,#d53e4f
17523,European,7176.0,21423719.0,Speliotes EK,Nonalcoholic fatty liver disease,initial,2011-03-10,GCST001008,Digestive system disorder,#d53e4f
17524,European,22161.0,21386085.0,Kraja AT,Metabolic syndrome (bivariate traits),initial,2011-03-08,GCST001007,Metabolic disorder,#d53e4f
17525,European,22161.0,21386085.0,Kraja AT,Triglycerides-Blood Pressure (TG-BP),initial,2011-03-08,GCST001004,Lipid or lipoprotein measurement,#d53e4f
17526,European,22161.0,21386085.0,Kraja AT,Triglycerides-Blood Pressure (TG-BP),initial,2011-03-08,GCST001004,Other measurement,#d53e4f
17527,European,22161.0,21386085.0,Kraja AT,HDL Cholesterol - Triglycerides (HDLC-TG),initial,2011-03-08,GCST001005,Lipid or lipoprotein measurement,#d53e4f
17528,European,22161.0,21386085.0,Kraja AT,HDL Cholesterol - Triglycerides (HDLC-TG),initial,2011-03-08,GCST001005,Lipid or lipoprotein measurement,#d53e4f
17529,European,22161.0,21386085.0,Kraja AT,Waist Circumference - Triglycerides (WC-TG),initial,2011-03-08,GCST001006,Lipid or lipoprotein measurement,#d53e4f
17530,European,22161.0,21386085.0,Kraja AT,Waist Circumference - Triglycerides (WC-TG),initial,2011-03-08,GCST001006,Metabolic disorder,#d53e4f
17531,European,22161.0,21386085.0,Kraja AT,Metabolic syndrome,initial,2011-03-08,GCST001003,Metabolic disorder,#d53e4f
17532,Asian,6187.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Coronary heart disease,replication,2011-03-06,GCST000999,Cardiovascular disease,#3288bd
17533,Asian,14790.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Coronary heart disease,initial,2011-03-06,GCST000999,Cardiovascular disease,#3288bd
17534,European,15682.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Coronary heart disease,initial,2011-03-06,GCST000999,Cardiovascular disease,#d53e4f
17535,European,34406.0,21378988.0,Coronary Artery Disease (C4D) Genetics Consortium,Coronary heart disease,replication,2011-03-06,GCST000999,Cardiovascular disease,#d53e4f
17536,European,1654.0,21378987.0,Holm H,Sick sinus syndrome,replication,2011-03-06,GCST001001,Cardiovascular disease,#d53e4f
17537,European,38384.0,21378987.0,Holm H,Sick sinus syndrome,initial,2011-03-06,GCST001001,Cardiovascular disease,#d53e4f
17538,Asian,7593.0,21378986.0,Wang F,Coronary heart disease,replication,2011-03-06,GCST001000,Cardiovascular disease,#3288bd
17539,Asian,460.0,21378986.0,Wang F,Coronary heart disease,initial,2011-03-06,GCST001000,Cardiovascular disease,#3288bd
17540,European,804.0,21386754.0,Marciante KD,Cerivastatin-induced rhabdomyolysis,initial,2011-03-06,GCST001002,Response to drug,#d53e4f
17542,European,804.0,21386754.0,Marciante KD,Cerivastatin-induced rhabdomyolysis,initial,2011-03-06,GCST001002,Other disease,#d53e4f
17544,European,86995.0,21378990.0,Schunkert H,Coronary heart disease,initial,2011-03-06,GCST000998,Cardiovascular disease,#d53e4f
17545,European,56682.0,21378990.0,Schunkert H,Coronary heart disease,replication,2011-03-06,GCST000998,Cardiovascular disease,#d53e4f
17546,African Am./Caribbean,10694.0,21378095.0,Fox ER,Blood pressure,replication,2011-03-04,GCST000997,Other measurement,#fee08b
17547,European,69899.0,21378095.0,Fox ER,Blood pressure,replication,2011-03-04,GCST000997,Other measurement,#d53e4f
17548,African,1188.0,21378095.0,Fox ER,Blood pressure,replication,2011-03-04,GCST000997,Other measurement,#fc8d59
17549,African Am./Caribbean,7473.0,21378095.0,Fox ER,Blood pressure,initial,2011-03-04,GCST000997,Other measurement,#fee08b
17550,European,6530.0,21408207.0,Chung SA,Systemic lupus erythematosus,initial,2011-03-03,GCST000996,Immune system disorder,#d53e4f
17551,European,1951.0,21368711.0,Alliey-Rodriguez N,Personality traits in bipolar disorder,initial,2011-03-02,GCST000995,Other trait,#d53e4f
17552,European,1951.0,21368711.0,Alliey-Rodriguez N,Personality traits in bipolar disorder,initial,2011-03-02,GCST000995,Neurological disorder,#d53e4f
17553,Asian,5666.0,21372407.0,Takeuchi F,Drinking behavior,replication,2011-03-01,GCST000994,Biological process,#3288bd
17554,Asian,1462.0,21372407.0,Takeuchi F,Drinking behavior,initial,2011-03-01,GCST000994,Biological process,#3288bd
17555,European,6611.0,21357676.0,Sulem P,Coffee consumption,initial,2011-02-28,GCST000992,Biological process,#d53e4f
17556,European,4050.0,21357676.0,Sulem P,Coffee consumption,replication,2011-02-28,GCST000992,Biological process,#d53e4f
17557,Asian,368.0,23480133.0,Kim Y,Vascular dementia,replication,2011-02-28,GCST000993,Cardiovascular disease,#3288bd
17558,Asian,284.0,23480133.0,Kim Y,Vascular dementia,initial,2011-02-28,GCST000993,Cardiovascular disease,#3288bd
17559,European,31277.0,21355061.0,Boger CA,Urinary albumin excretion,replication,2011-02-25,GCST000988,Other trait,#d53e4f
17560,European,31580.0,21355061.0,Boger CA,Urinary albumin excretion,initial,2011-02-25,GCST000988,Other trait,#d53e4f
17561,European,2190.0,21357381.0,Figueiredo JC,Colorectal cancer,initial,2011-02-25,GCST000989,Cancer,#d53e4f
17562,European,1682.0,21357381.0,Figueiredo JC,Colorectal cancer,replication,2011-02-25,GCST000989,Cancer,#d53e4f
17563,European,191.0,21364930.0,Bol SM,HIV-1 replication,initial,2011-02-25,GCST000990,Other disease,#d53e4f
17565,Asian,126.0,21519539.0,Cho SC,Autism spectrum disorders (language delay),initial,2011-02-25,GCST000991,Neurological disorder,#3288bd
17567,European,3595.0,21390209.0,Hu X,Alzheimer's disease (late onset),initial,2011-02-24,GCST000986,Neurological disorder,#d53e4f
17568,European,38053.0,21383967.0,Zhernakova A,Celiac disease or Rheumatoid arthritis,initial,2011-02-24,GCST000987,Other disease,#d53e4f
17569,European,12213.0,21383967.0,Zhernakova A,Celiac disease or Rheumatoid arthritis,replication,2011-02-24,GCST000987,Other disease,#d53e4f
17570,European,41821.0,21353194.0,Cichon S,Bipolar disorder,replication,2011-02-23,GCST000985,Neurological disorder,#d53e4f
17571,European,1982.0,21353194.0,Cichon S,Bipolar disorder,initial,2011-02-23,GCST000985,Neurological disorder,#d53e4f
17572,African Am./Caribbean,13.0,21339755.0,Liu X,5-HTT brain serotonin transporter levels,initial,2011-02-22,GCST000983,Other measurement,#fee08b
17573,European,13.0,21339755.0,Liu X,5-HTT brain serotonin transporter levels,initial,2011-02-22,GCST000983,Other measurement,#d53e4f
17574,Hispanic/Latin American,7.0,21339755.0,Liu X,5-HTT brain serotonin transporter levels,initial,2011-02-22,GCST000983,Other measurement,#807dba
17575,European,51.0,21339755.0,Liu X,5-HTT brain serotonin transporter levels,replication,2011-02-22,GCST000983,Other measurement,#d53e4f
17576,European,2894.0,21323541.0,Stanescu HC,Idiopathic membranous nephropathy,initial,2011-02-22,GCST000984,Other disease,#d53e4f
17577,European,677.0,21326295.0,Jin Y,Vitiligo,replication,2011-02-17,GCST000981,Immune system disorder,#d53e4f
17578,European,1339.0,21326295.0,Jin Y,Vitiligo,initial,2011-02-17,GCST000981,Immune system disorder,#d53e4f
17579,European,772.0,21379329.0,Wijsman EM,Alzheimer's disease (late onset),replication,2011-02-17,GCST000980,Neurological disorder,#d53e4f
17580,Hispanic/Latin American,418.0,21379329.0,Wijsman EM,Alzheimer's disease (late onset),replication,2011-02-17,GCST000980,Neurological disorder,#807dba
17581,European,3839.0,21379329.0,Wijsman EM,Alzheimer's disease (late onset),initial,2011-02-17,GCST000980,Neurological disorder,#d53e4f
17582,African Am./Caribbean,440.0,21326311.0,Bhatnagar P,F-cell distribution in sickle cell anaemia,initial,2011-02-17,GCST000982,Hematological measurement,#fee08b
17583,African Am./Caribbean,440.0,21326311.0,Bhatnagar P,F-cell distribution in sickle cell anaemia,initial,2011-02-17,GCST000982,Neurological disorder,#fee08b
17584,European,269.0,21359210.0,Ricci G,Asthma (childhood onset),initial,2011-02-16,GCST000979,Other disease,#d53e4f
17586,European,2357.0,21314694.0,Kendler KS,Alcohol dependence,initial,2011-02-11,GCST000977,Neurological disorder,#d53e4f
17587,African Am./Caribbean,812.0,21314694.0,Kendler KS,Alcohol dependence,initial,2011-02-11,GCST000977,Neurological disorder,#fee08b
17588,European,1711.0,21316860.0,Velders FP,Cortisol secretion,initial,2011-02-11,GCST000978,Other measurement,#d53e4f
17589,European,2836.0,21316860.0,Velders FP,Cortisol secretion,replication,2011-02-11,GCST000978,Other measurement,#d53e4f
17590,African Am./Caribbean,5313.0,21347282.0,Lettre G,Coronary heart disease,initial,2011-02-10,GCST000972,Cardiovascular disease,#fee08b
17591,African Am./Caribbean,2250.0,21347282.0,Lettre G,Coronary heart disease,replication,2011-02-10,GCST000972,Cardiovascular disease,#fee08b
17592,African Am./Caribbean,2854.0,21347282.0,Lettre G,Hypertension,replication,2011-02-10,GCST000973,Cardiovascular disease,#fee08b
17593,African Am./Caribbean,7917.0,21347282.0,Lettre G,Hypertension,initial,2011-02-10,GCST000973,Cardiovascular disease,#fee08b
17594,African Am./Caribbean,7813.0,21347282.0,Lettre G,HDL cholesterol,initial,2011-02-10,GCST000974,Lipid or lipoprotein measurement,#fee08b
17595,African Am./Caribbean,4323.0,21347282.0,Lettre G,HDL cholesterol,replication,2011-02-10,GCST000974,Lipid or lipoprotein measurement,#fee08b
17596,African Am./Caribbean,3789.0,21347282.0,Lettre G,LDL cholesterol,replication,2011-02-10,GCST000975,Lipid or lipoprotein measurement,#fee08b
17597,African Am./Caribbean,7565.0,21347282.0,Lettre G,LDL cholesterol,initial,2011-02-10,GCST000975,Lipid or lipoprotein measurement,#fee08b
17598,African Am./Caribbean,2159.0,21347282.0,Lettre G,Type 2 diabetes,replication,2011-02-10,GCST000976,Metabolic disorder,#fee08b
17599,African Am./Caribbean,6942.0,21347282.0,Lettre G,Type 2 diabetes,initial,2011-02-10,GCST000976,Metabolic disorder,#fee08b
17600,African Am./Caribbean,6247.0,21347284.0,Smith JG,PR interval,initial,2011-02-10,GCST000971,Cardiovascular measurement,#fee08b
17601,African Am./Caribbean,2022.0,21347284.0,Smith JG,PR interval,replication,2011-02-10,GCST000971,Cardiovascular measurement,#fee08b
17602,European,9326.0,21307088.0,Khor CC,Optic disc area,replication,2011-02-09,GCST000970,Other measurement,#d53e4f
17603,Asian,2132.0,21307088.0,Khor CC,Optic disc area,initial,2011-02-09,GCST000970,Other measurement,#3288bd
17604,Asian,2313.0,21307088.0,Khor CC,Optic disc area,initial,2011-02-09,GCST000970,Other measurement,#3288bd
17605,European,5580.0,21305692.0,Belmonte Mahon P,Bipolar disorder (age of onset and psychotic symptoms),initial,2011-02-08,GCST000969,Other measurement,#d53e4f
17607,European,5580.0,21305692.0,Belmonte Mahon P,Bipolar disorder (age of onset and psychotic symptoms),initial,2011-02-08,GCST000969,Other trait,#d53e4f
17609,European,5580.0,21305692.0,Belmonte Mahon P,Bipolar disorder (age of onset and psychotic symptoms),initial,2011-02-08,GCST000969,Neurological disorder,#d53e4f
17611,European,90.0,21497773.0,Ziliak D,Response to platinum-based chemotherapy in head and neck cancers,initial,2011-02-08,GCST000967,Response to drug,#d53e4f
17612,Asian,849.0,21310492.0,Huang YC,Diabetic retinopathy,initial,2011-02-08,GCST000966,Metabolic disorder,#3288bd
17613,Asian,90.0,21497773.0,Ziliak D,Response to platinum-based chemotherapy in head and neck cancers,initial,2011-02-08,GCST000968,Response to drug,#3288bd
17614,African,59.0,21497773.0,Ziliak D,Response to platinum-based chemotherapy in head and neck cancers,replication,2011-02-08,GCST000968,Response to drug,#fc8d59
17615,European,90.0,21497773.0,Ziliak D,Response to platinum-based chemotherapy in head and neck cancers,replication,2011-02-08,GCST000968,Response to drug,#d53e4f
17616,European,66185.0,21300955.0,Dehghan A,C-reactive protein levels,initial,2011-02-07,GCST000965,Inflammatory measurement,#d53e4f
17617,European,16540.0,21300955.0,Dehghan A,C-reactive protein levels,replication,2011-02-07,GCST000965,Inflammatory measurement,#d53e4f
17618,European,22545.0,21297633.0,Anderson CA,Ulcerative colitis,replication,2011-02-06,GCST000964,Immune system disorder,#d53e4f
17619,European,26405.0,21297633.0,Anderson CA,Ulcerative colitis,initial,2011-02-06,GCST000964,Immune system disorder,#d53e4f
17620,Asian,574.0,21326860.0,Tsai FJ,Kawasaki disease,replication,2011-02-04,GCST000962,Immune system disorder,#3288bd
17621,Asian,696.0,21326860.0,Tsai FJ,Kawasaki disease,initial,2011-02-04,GCST000962,Immune system disorder,#3288bd
17622,African Am./Caribbean,1017.0,21294900.0,Charles BA,Uric acid levels,initial,2011-02-04,GCST000963,Cardiovascular measurement,#fee08b
17623,European,4806.0,21254220.0,Jiang Y,Bipolar disorder,initial,2011-02-01,GCST000961,Neurological disorder,#d53e4f
17624,European,17352.0,21292315.0,Nalls MA,Parkinson's disease,initial,2011-02-01,GCST000959,Neurological disorder,#d53e4f
17626,European,851.0,21348951.0,Parsa A,Cardiac hypertrophy,initial,2011-02-01,GCST000960,Other trait,#d53e4f
17628,European,4877.0,21278746.0,Lindstrom S,Percent mammographic density,initial,2011-01-30,GCST000958,Other measurement,#d53e4f
17629,European,1145.0,21278746.0,Lindstrom S,Percent mammographic density,replication,2011-01-30,GCST000958,Other measurement,#d53e4f
17630,European,1325.0,21273288.0,Del Greco M F,Natriuretic peptide levels,initial,2011-01-27,GCST000957,Cardiovascular measurement,#d53e4f
17631,European,1746.0,21273288.0,Del Greco M F,Natriuretic peptide levels,replication,2011-01-27,GCST000957,Cardiovascular measurement,#d53e4f
17632,African,1103.0,21298047.0,Chen X,Substance dependence,initial,2011-01-27,GCST000956,Neurological disorder,#fc8d59
17633,European,2524.0,21298047.0,Chen X,Substance dependence,initial,2011-01-27,GCST000956,Neurological disorder,#d53e4f
17634,European,10249.0,21298027.0,Festen EA,Crohn's disease and celiac disease,initial,2011-01-27,GCST000955,Immune system disorder,#d53e4f
17635,European,11367.0,21298027.0,Festen EA,Crohn's disease and celiac disease,replication,2011-01-27,GCST000955,Immune system disorder,#d53e4f
17636,European,10249.0,21298027.0,Festen EA,Crohn's disease and celiac disease,initial,2011-01-27,GCST000955,Digestive system disorder,#d53e4f
17637,European,11367.0,21298027.0,Festen EA,Crohn's disease and celiac disease,replication,2011-01-27,GCST000955,Digestive system disorder,#d53e4f
17638,Asian,1721.0,21270382.0,Baik I,Alcohol consumption,initial,2011-01-26,GCST000954,Biological process,#3288bd
17639,Asian,1113.0,21270382.0,Baik I,Alcohol consumption,replication,2011-01-26,GCST000954,Biological process,#3288bd
17640,Other/Mixed,87.0,21245432.0,Spraggs CF,Lapatinib-induced hepatotoxicity in breast cancer,initial,2011-01-24,GCST000953,Response to drug,#99d594
17642,Other/Mixed,31.0,21245432.0,Spraggs CF,Lapatinib-induced hepatotoxicity in breast cancer,replication,2011-01-24,GCST000953,Response to drug,#99d594
17643,European,222.0,21245432.0,Spraggs CF,Lapatinib-induced hepatotoxicity in breast cancer,initial,2011-01-24,GCST000953,Response to drug,#d53e4f
17645,European,144.0,21245432.0,Spraggs CF,Lapatinib-induced hepatotoxicity in breast cancer,replication,2011-01-24,GCST000953,Response to drug,#d53e4f
17646,European,18021.0,21263130.0,Fletcher O,Breast cancer,replication,2011-01-24,GCST000952,Cancer,#d53e4f
17647,European,6346.0,21263130.0,Fletcher O,Breast cancer,initial,2011-01-24,GCST000952,Cancer,#d53e4f
17648,European,282.0,21283782.0,Tore S,Nephrolithiasis,replication,2011-01-20,GCST000951,Other disease,#d53e4f
17649,European,174.0,21283782.0,Tore S,Nephrolithiasis,initial,2011-01-20,GCST000951,Other disease,#d53e4f
17650,European,2796.0,21248740.0,Simon-Sanchez J,Parkinson's disease,initial,2011-01-19,GCST000950,Neurological disorder,#d53e4f
17653,European,317.0,21242121.0,Frullanti E,Lung adenocarcinoma (clinical stage),replication,2011-01-17,GCST000947,Cancer,#d53e4f
17654,European,600.0,21242121.0,Frullanti E,Lung adenocarcinoma (clinical stage),initial,2011-01-17,GCST000947,Cancer,#d53e4f
17655,Asian,7782.0,21242260.0,Cui R,Colorectal cancer,replication,2011-01-17,GCST000948,Cancer,#3288bd
17656,Asian,3481.0,21242260.0,Cui R,Colorectal cancer,initial,2011-01-17,GCST000948,Cancer,#3288bd
17657,European,17053.0,21239051.0,Reilly MP,Coronary artery disease,replication,2011-01-14,GCST000945,Cardiovascular disease,#d53e4f
17658,European,2723.0,21239051.0,Reilly MP,Coronary artery disease,initial,2011-01-14,GCST000945,Cardiovascular disease,#d53e4f
17659,European,7311.0,21239051.0,Reilly MP,Myocardial infarction in coronary artery disease,initial,2011-01-14,GCST000946,Cardiovascular disease,#d53e4f
17660,European,2116.0,21239051.0,Reilly MP,Myocardial infarction in coronary artery disease,replication,2011-01-14,GCST000946,Cardiovascular disease,#d53e4f
17661,European,7311.0,21239051.0,Reilly MP,Myocardial infarction in coronary artery disease,initial,2011-01-14,GCST000946,Cardiovascular disease,#d53e4f
17662,European,2116.0,21239051.0,Reilly MP,Myocardial infarction in coronary artery disease,replication,2011-01-14,GCST000946,Cardiovascular disease,#d53e4f
17663,Asian,2383.0,21228123.0,Ochi H,Response to hepatitis C treatment,initial,2011-01-12,GCST000944,Digestive system disorder,#3288bd
17664,African Am./Caribbean,1086.0,21223598.0,Wineinger NE,Aortic root size,initial,2011-01-11,GCST000943,Cardiovascular measurement,#fee08b
17665,African Am./Caribbean,734.0,22384361.0,Cheng YC,Stroke,initial,2011-01-11,GCST000940,Cardiovascular disease,#fee08b
17666,Asian,93.0,22384361.0,Cheng YC,Stroke,initial,2011-01-11,GCST000940,Cardiovascular disease,#3288bd
17667,European,989.0,22384361.0,Cheng YC,Stroke,initial,2011-01-11,GCST000940,Cardiovascular disease,#d53e4f
17668,European,4276.0,22384361.0,Cheng YC,Stroke,replication,2011-01-11,GCST000940,Cardiovascular disease,#d53e4f
17669,Asian,320.0,21155030.0,Cheong MY,Stroke (ischemic),initial,2011-01-11,GCST000941,Cardiovascular disease,#3288bd
17670,Asian,940.0,21155030.0,Cheong MY,Stroke (ischemic),replication,2011-01-11,GCST000941,Cardiovascular disease,#3288bd
17671,European,5074.0,21221126.0,Shen Y,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2011-01-11,GCST000942,Other disease,#d53e4f
17672,European,5074.0,21221126.0,Shen Y,Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),initial,2011-01-11,GCST000942,Other disease,#d53e4f
17673,Asian,1556.0,21221998.0,Kim JJ,Kawasaki disease,replication,2011-01-09,GCST000939,Immune system disorder,#3288bd
17674,Asian,786.0,21221998.0,Kim JJ,Kawasaki disease,initial,2011-01-09,GCST000939,Immune system disorder,#3288bd
17675,European,10280.0,21216879.0,Kaplan RC,Insulin-like growth factors,initial,2011-01-07,GCST000937,Other measurement,#d53e4f
17677,Other/Mixed,1113.0,21216876.0,Sharma S,Adolescent idiopathic scoliosis,initial,2011-01-07,GCST000938,Other disease,#99d594
17678,European,1228.0,21216876.0,Sharma S,Adolescent idiopathic scoliosis,replication,2011-01-07,GCST000938,Other disease,#d53e4f
17679,African Am./Caribbean,1258.0,21212386.0,Arnett DK,Cardiac muscle measurement,initial,2011-01-06,GCST000936,Other measurement,#fee08b
17680,European,1316.0,21212386.0,Arnett DK,Cardiac muscle measurement,replication,2011-01-06,GCST000936,Other measurement,#d53e4f
17681,African Am./Caribbean,989.0,21212386.0,Arnett DK,Cardiac muscle measurement,replication,2011-01-06,GCST000936,Other measurement,#fee08b
17682,African Am./Caribbean,1258.0,21212386.0,Arnett DK,Cardiac muscle measurement,initial,2011-01-06,GCST000936,Other trait,#fee08b
17683,European,1316.0,21212386.0,Arnett DK,Cardiac muscle measurement,replication,2011-01-06,GCST000936,Other trait,#d53e4f
17684,African Am./Caribbean,989.0,21212386.0,Arnett DK,Cardiac muscle measurement,replication,2011-01-06,GCST000936,Other trait,#fee08b
17685,European,5633.0,21208937.0,Pichler I,Iron status biomarkers,initial,2011-01-04,GCST000935,Other measurement,#d53e4f
17686,European,3457.0,21208937.0,Pichler I,Iron status biomarkers,replication,2011-01-04,GCST000935,Other measurement,#d53e4f
17687,European,1708.0,21211648.0,Ege MJ,Asthma or atopy (farm exposure interaction),initial,2011-01-01,GCST000934,Other measurement,#d53e4f
17688,European,1708.0,21211648.0,Ege MJ,Asthma or atopy (farm exposure interaction),initial,2011-01-01,GCST000934,Other disease,#d53e4f
17689,Asian,2742.0,21196492.0,Okada Y,C-reactive protein,replication,2010-12-31,GCST000933,Inflammatory measurement,#3288bd
17690,Asian,10112.0,21196492.0,Okada Y,C-reactive protein,initial,2010-12-31,GCST000933,Inflammatory measurement,#3288bd
17691,European,3304.0,21302353.0,Perroud N,Hoarding,initial,2010-12-28,GCST000932,Neurological disorder,#d53e4f
17692,European,2896.0,21186350.0,Zhou K,Response to metformin in type 2 diabetes (glycemic),replication,2010-12-26,GCST000927,Response to drug,#d53e4f
17693,European,1024.0,21186350.0,Zhou K,Response to metformin in type 2 diabetes (glycemic),initial,2010-12-26,GCST000927,Response to drug,#d53e4f
17694,European,2314.0,21253498.0,Benjamin AM,Waist-to-hip ratio (sex interaction),initial,2010-12-26,GCST000928,Other measurement,#d53e4f
17695,European,2314.0,21253498.0,Benjamin AM,Waist-to-hip ratio (sex interaction),initial,2010-12-26,GCST000928,Body measurement,#d53e4f
17696,European,2872.0,21253498.0,Benjamin AM,Body mass index,replication,2010-12-26,GCST000929,Body measurement,#d53e4f
17697,European,9091.0,21253498.0,Benjamin AM,Body mass index,initial,2010-12-26,GCST000929,Body measurement,#d53e4f
17698,European,2872.0,21253498.0,Benjamin AM,Waist circumference (sex interaction),replication,2010-12-26,GCST000931,Body measurement,#d53e4f
17699,European,2314.0,21253498.0,Benjamin AM,Waist circumference (sex interaction),initial,2010-12-26,GCST000931,Body measurement,#d53e4f
17700,European,2872.0,21253498.0,Benjamin AM,Waist circumference (sex interaction),replication,2010-12-26,GCST000931,Other measurement,#d53e4f
17701,European,2314.0,21253498.0,Benjamin AM,Waist circumference (sex interaction),initial,2010-12-26,GCST000931,Other measurement,#d53e4f
17702,European,2872.0,21253498.0,Benjamin AM,Body mass index (sex interaction),replication,2010-12-26,GCST000930,Other measurement,#d53e4f
17703,European,9091.0,21253498.0,Benjamin AM,Body mass index (sex interaction),initial,2010-12-26,GCST000930,Other measurement,#d53e4f
17704,European,2872.0,21253498.0,Benjamin AM,Body mass index (sex interaction),replication,2010-12-26,GCST000930,Body measurement,#d53e4f
17705,European,9091.0,21253498.0,Benjamin AM,Body mass index (sex interaction),initial,2010-12-26,GCST000930,Body measurement,#d53e4f
17706,European,2559.0,21203500.0,Lauc G,N-glycan levels,initial,2010-12-23,GCST000925,Other measurement,#d53e4f
17707,European,470.0,21183627.0,Bouchard C,Maximal oxygen uptake response,initial,2010-12-23,GCST000926,Other measurement,#d53e4f
17708,African,247.0,21183627.0,Bouchard C,Maximal oxygen uptake response,replication,2010-12-23,GCST000926,Other measurement,#fc8d59
17710,Asian,60.0,21177773.0,Moyer AM,Response to acetaminophen (hepatotoxicity),initial,2010-12-22,GCST000924,Response to drug,#3288bd
17711,African Am./Caribbean,56.0,21177773.0,Moyer AM,Response to acetaminophen (hepatotoxicity),initial,2010-12-22,GCST000924,Response to drug,#fee08b
17712,European,60.0,21177773.0,Moyer AM,Response to acetaminophen (hepatotoxicity),initial,2010-12-22,GCST000924,Response to drug,#d53e4f
17713,Other/Mixed,2744.0,21177295.0,Panoutsopoulou K,Osteoarthritis,replication,2010-12-21,GCST000923,Other disease,#99d594
17714,European,56173.0,21177295.0,Panoutsopoulou K,Osteoarthritis,replication,2010-12-21,GCST000923,Other disease,#d53e4f
17715,European,8071.0,21177295.0,Panoutsopoulou K,Osteoarthritis,initial,2010-12-21,GCST000923,Other disease,#d53e4f
17716,European,17375.0,21173776.0,de Moor MH,Agreeableness,initial,2010-12-21,GCST006329,Other measurement,#d53e4f
17717,European,3294.0,21173776.0,de Moor MH,Agreeableness,replication,2010-12-21,GCST006329,Other measurement,#d53e4f
17718,European,17375.0,21173776.0,de Moor MH,Extraversion,initial,2010-12-21,GCST006328,Other measurement,#d53e4f
17719,European,3294.0,21173776.0,de Moor MH,Extraversion,replication,2010-12-21,GCST006328,Other measurement,#d53e4f
17720,European,17375.0,21173776.0,de Moor MH,Neuroticism,initial,2010-12-21,GCST006327,Other measurement,#d53e4f
17721,European,3294.0,21173776.0,de Moor MH,Neuroticism,replication,2010-12-21,GCST006327,Other measurement,#d53e4f
17722,European,17375.0,21173776.0,de Moor MH,Conscientiousness,initial,2010-12-21,GCST006326,Other measurement,#d53e4f
17723,European,3294.0,21173776.0,de Moor MH,Conscientiousness,replication,2010-12-21,GCST006326,Other measurement,#d53e4f
17724,European,17375.0,21173776.0,de Moor MH,Openness,initial,2010-12-21,GCST000922,Other measurement,#d53e4f
17725,European,3294.0,21173776.0,de Moor MH,Openness,replication,2010-12-21,GCST000922,Other measurement,#d53e4f
17726,Other/Mixed,2.0,21197116.0,Ryu E,Age-related macular degeneration,initial,2010-12-17,GCST000921,Neurological disorder,#99d594
17727,African,12.0,21197116.0,Ryu E,Age-related macular degeneration,initial,2010-12-17,GCST000921,Neurological disorder,#fc8d59
17728,Other/Mixed,744.0,21197116.0,Ryu E,Age-related macular degeneration,replication,2010-12-17,GCST000921,Neurological disorder,#99d594
17729,European,576.0,21197116.0,Ryu E,Age-related macular degeneration,initial,2010-12-17,GCST000921,Neurological disorder,#d53e4f
17730,European,2373.0,21160077.0,Gudmundsson J,Serum prostate-specific antigen levels,replication,2010-12-15,GCST000919,Other measurement,#d53e4f
17731,European,7538.0,21160077.0,Gudmundsson J,Serum prostate-specific antigen levels,initial,2010-12-15,GCST000919,Other measurement,#d53e4f
17732,Asian,271.0,21211798.0,Yamada Y,Myocardial infarction,initial,2010-12-15,GCST000920,Cardiovascular disease,#3288bd
17733,Asian,17176.0,21211798.0,Yamada Y,Myocardial infarction,replication,2010-12-15,GCST000920,Cardiovascular disease,#3288bd
17734,African,1379.0,21160409.0,Petrovski S,HIV-1 susceptibility,initial,2010-12-14,GCST000918,Other disease,#fc8d59
17735,European,3000.0,21156761.0,Padyukov L,Rheumatoid arthritis,initial,2010-12-14,GCST000917,Immune system disorder,#d53e4f
17736,European,2105.0,21156761.0,Padyukov L,Rheumatoid arthritis,replication,2010-12-14,GCST000917,Immune system disorder,#d53e4f
17737,Asian,9130.0,21151128.0,Chen ZJ,Polycystic ovary syndrome,replication,2010-12-12,GCST000914,Other disease,#3288bd
17738,Asian,1639.0,21151128.0,Chen ZJ,Polycystic ovary syndrome,initial,2010-12-12,GCST000914,Other disease,#3288bd
17739,European,3199.0,21151127.0,Melum E,Primary sclerosing cholangitis,replication,2010-12-12,GCST000915,Digestive system disorder,#d53e4f
17740,European,3677.0,21151127.0,Melum E,Primary sclerosing cholangitis,initial,2010-12-12,GCST000915,Digestive system disorder,#d53e4f
17741,European,4663.0,21151130.0,Painter JN,Endometriosis,replication,2010-12-12,GCST000916,Other disease,#d53e4f
17742,European,10254.0,21151130.0,Painter JN,Endometriosis,initial,2010-12-12,GCST000916,Other disease,#d53e4f
17743,European,6616.0,21149283.0,Oexle K,Iron status biomarkers,initial,2010-12-10,GCST000913,Other measurement,#d53e4f
17744,Asian,934.0,21149285.0,Ozeki T,Adverse response to carbamazepine,initial,2010-12-10,GCST000912,Response to drug,#3288bd
17745,Asian,67.0,21149285.0,Ozeki T,Adverse response to carbamazepine,replication,2010-12-10,GCST000912,Response to drug,#3288bd
17746,European,459.0,21087763.0,Carrasquillo MM,Progranulin levels,replication,2010-12-10,GCST000911,Other measurement,#d53e4f
17747,European,518.0,21087763.0,Carrasquillo MM,Progranulin levels,initial,2010-12-10,GCST000911,Other measurement,#d53e4f
17748,African Am./Caribbean,1399.0,21150874.0,McDonough CW,Type 2 diabetes nephropathy,replication,2010-12-08,GCST000909,Metabolic disorder,#fee08b
17749,African Am./Caribbean,1994.0,21150874.0,McDonough CW,Type 2 diabetes nephropathy,initial,2010-12-08,GCST000909,Metabolic disorder,#fee08b
17750,European,2832.0,21150878.0,Ferreira MA,Asthma,initial,2010-12-08,GCST000910,Other disease,#d53e4f
17751,European,604.0,21150878.0,Ferreira MA,Asthma,replication,2010-12-08,GCST000910,Other disease,#d53e4f
17752,European,346.0,21139019.0,Walsh KM,Ileal carcinoids,initial,2010-12-07,GCST000908,Cancer,#d53e4f
17753,European,7116.0,21131975.0,Purdue MP,Renal cell carcinoma,replication,2010-12-05,GCST000907,Cancer,#d53e4f
17754,European,12277.0,21131975.0,Purdue MP,Renal cell carcinoma,initial,2010-12-05,GCST000907,Cancer,#d53e4f
17755,European,4039.0,21130836.0,Luciano M,Information processing speed,initial,2010-12-03,GCST000905,Biological process,#d53e4f
17756,European,703.0,21131588.0,Slager SL,Chronic lymphocytic leukemia,initial,2010-12-03,GCST000906,Cancer,#d53e4f
17757,European,1217.0,21131588.0,Slager SL,Chronic lymphocytic leukemia,replication,2010-12-03,GCST000906,Cancer,#d53e4f
17759,European,3467.0,21124317.0,Wang K,Neuroblastoma,replication,2010-12-01,GCST000901,Cancer,#d53e4f
17760,European,4881.0,21124317.0,Wang K,Neuroblastoma,initial,2010-12-01,GCST000901,Cancer,#d53e4f
17761,Asian,622.0,21105107.0,Clifford RJ,Hepatocellular carcinoma,replication,2010-12-01,GCST000902,Cancer,#3288bd
17762,Asian,451.0,21105107.0,Clifford RJ,Hepatocellular carcinoma,initial,2010-12-01,GCST000902,Cancer,#3288bd
17763,European,374.0,21123754.0,Kim S,Alzheimer's disease biomarkers,initial,2010-12-01,GCST000900,Neurological disorder,#d53e4f
17764,Other/Mixed,140.0,21130132.0,Mick E,Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure),initial,2010-12-01,GCST000903,Response to drug,#99d594
17765,Asian,245.0,21118971.0,Wu C,Small-cell lung cancer (survival),initial,2010-11-30,GCST000896,Cancer,#3288bd
17766,Asian,305.0,21118971.0,Wu C,Small-cell lung cancer (survival),replication,2010-11-30,GCST000896,Cancer,#3288bd
17767,European,939.0,21116278.0,Furney SJ,Hippocampal volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000897,Neurological disorder,#d53e4f
17768,European,939.0,21116278.0,Furney SJ,Hippocampal volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000897,Other measurement,#d53e4f
17769,European,963.0,21116278.0,Furney SJ,Whole-brain volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000895,Neurological disorder,#d53e4f
17770,European,963.0,21116278.0,Furney SJ,Whole-brain volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000895,Other measurement,#d53e4f
17771,European,939.0,21116278.0,Furney SJ,Total ventricular volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000892,Neurological disorder,#d53e4f
17772,European,939.0,21116278.0,Furney SJ,Total ventricular volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000892,Other measurement,#d53e4f
17773,European,939.0,21116278.0,Furney SJ,Entorhinal cortical volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000893,Neurological disorder,#d53e4f
17774,European,939.0,21116278.0,Furney SJ,Entorhinal cortical volume (Alzheimer's disease interaction),initial,2010-11-30,GCST000893,Other measurement,#d53e4f
17775,European,939.0,21116278.0,Furney SJ,Total ventricular volume,initial,2010-11-30,GCST000898,Other measurement,#d53e4f
17776,European,939.0,21116278.0,Furney SJ,Entorhinal cortical thickness (Alzheimer's disease interaction),initial,2010-11-30,GCST000889,Neurological disorder,#d53e4f
17777,European,939.0,21116278.0,Furney SJ,Entorhinal cortical thickness (Alzheimer's disease interaction),initial,2010-11-30,GCST000889,Other measurement,#d53e4f
17778,European,939.0,21116278.0,Furney SJ,Hippocampal volume,initial,2010-11-30,GCST000890,Other measurement,#d53e4f
17779,European,963.0,21116278.0,Furney SJ,Whole-brain volume,initial,2010-11-30,GCST000891,Other measurement,#d53e4f
17780,European,939.0,21116278.0,Furney SJ,Entorhinal cortical volume,initial,2010-11-30,GCST000899,Other measurement,#d53e4f
17781,European,939.0,21116278.0,Furney SJ,Entorhinal cortical thickness,initial,2010-11-30,GCST000894,Other measurement,#d53e4f
17782,European,1067.0,21113153.0,van der Zanden LF,Hypospadias,replication,2010-11-28,GCST000888,Other disease,#d53e4f
17783,European,930.0,21113153.0,van der Zanden LF,Hypospadias,initial,2010-11-28,GCST000888,Other disease,#d53e4f
17784,Asian,1733.0,21107343.0,Aoki A,Myocardial infarction,initial,2010-11-25,GCST000887,Cardiovascular disease,#3288bd
17785,Asian,11397.0,21107343.0,Aoki A,Myocardial infarction,replication,2010-11-25,GCST000887,Cardiovascular disease,#3288bd
17786,Other/Mixed,266.0,21098978.0,Sherva R,Alzheimer's disease,initial,2010-11-25,GCST000886,Neurological disorder,#99d594
17787,European,5277.0,21098978.0,Sherva R,Alzheimer's disease,replication,2010-11-25,GCST000886,Neurological disorder,#d53e4f
17788,Other/Mixed,738.0,21107309.0,McClay JL,Response to antipsychotic treatment in schizophrenia (working memory),initial,2010-11-24,GCST000883,Biological process,#99d594
17789,Other/Mixed,738.0,21107309.0,McClay JL,Response to antipsychotic treatment in schizophrenia (reasoning),initial,2010-11-24,GCST000885,Biological process,#99d594
17790,Other/Mixed,738.0,21107309.0,McClay JL,Response to antipsychotic treatment,initial,2010-11-24,GCST000884,Response to drug,#99d594
17791,European,834.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),replication,2010-11-24,GCST000882,Response to drug,#d53e4f
17792,European,673.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),initial,2010-11-24,GCST000882,Response to drug,#d53e4f
17793,European,834.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),replication,2010-11-24,GCST000882,Other measurement,#d53e4f
17794,European,673.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),initial,2010-11-24,GCST000882,Other measurement,#d53e4f
17795,European,834.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),replication,2010-11-24,GCST000882,Response to drug,#d53e4f
17796,European,673.0,21106707.0,Gu J,Response to bleomycin (chromatid breaks),initial,2010-11-24,GCST000882,Response to drug,#d53e4f
17797,Asian,1628.0,21104366.0,Tan L,Bone mineral density (wrist),replication,2010-11-23,GCST000881,Other measurement,#3288bd
17798,European,1000.0,21104366.0,Tan L,Bone mineral density (wrist),initial,2010-11-23,GCST000881,Other measurement,#d53e4f
17799,European,21389.0,21102463.0,Franke A,Crohn's disease,initial,2010-11-21,GCST000879,Digestive system disorder,#d53e4f
17800,European,30962.0,21102463.0,Franke A,Crohn's disease,replication,2010-11-21,GCST000879,Digestive system disorder,#d53e4f
17801,European,87802.0,21102462.0,Elks CE,Menarche (age at onset),initial,2010-11-21,GCST000880,Other measurement,#d53e4f
17802,European,14731.0,21102462.0,Elks CE,Menarche (age at onset),replication,2010-11-21,GCST000880,Other measurement,#d53e4f
17803,Asian,3087.0,21095009.0,Li YJ,Myopia (pathological),replication,2010-11-20,GCST000878,Other trait,#3288bd
17804,Asian,980.0,21095009.0,Li YJ,Myopia (pathological),initial,2010-11-20,GCST000878,Other trait,#3288bd
17805,European,1934.0,21124946.0,Paternoster L,Bone mineral density,initial,2010-11-18,GCST000877,Other measurement,#d53e4f
17806,European,3835.0,21124946.0,Paternoster L,Bone mineral density,replication,2010-11-18,GCST000877,Other measurement,#d53e4f
17807,European,2136.0,21124955.0,Marzi C,Amyloid A serum levels,replication,2010-11-18,GCST000876,Lipid or lipoprotein measurement,#d53e4f
17808,European,4212.0,21124955.0,Marzi C,Amyloid A serum levels,initial,2010-11-18,GCST000876,Lipid or lipoprotein measurement,#d53e4f
17809,European,2905.0,21088011.0,Erdmann J,Coronary heart disease,initial,2010-11-18,GCST000875,Cardiovascular disease,#d53e4f
17810,European,16131.0,21088011.0,Erdmann J,Coronary heart disease,replication,2010-11-18,GCST000875,Cardiovascular disease,#d53e4f
17811,European,10296.0,21084426.0,Saad M,Parkinson's disease,replication,2010-11-17,GCST000874,Neurological disorder,#d53e4f
17812,European,3023.0,21084426.0,Saad M,Parkinson's disease,initial,2010-11-17,GCST000874,Neurological disorder,#d53e4f
17813,European,4766.0,21079607.0,Wang K,Anorexia nervosa,initial,2010-11-16,GCST000873,Metabolic disorder,#d53e4f
17814,European,40407.0,21076409.0,Sotoodehnia N,QRS duration,initial,2010-11-14,GCST000872,Cardiovascular measurement,#d53e4f
17815,European,7170.0,21076409.0,Sotoodehnia N,QRS duration,replication,2010-11-14,GCST000872,Cardiovascular measurement,#d53e4f
17816,Asian,105.0,21079520.0,Sato Y,Non-small cell lung cancer (survival),initial,2010-11-12,GCST000871,Other measurement,#3288bd
17817,Asian,105.0,21079520.0,Sato Y,Non-small cell lung cancer (survival),initial,2010-11-12,GCST000871,Cancer,#3288bd
17818,,,,,Atopy,,,GCST000870,Immune system disorder,black
17819,Asian,2428.0,21068099.0,Evangelou E,Osteoarthritis,replication,2010-11-10,GCST000869,Other disease,#3288bd
17820,European,12868.0,21068099.0,Evangelou E,Osteoarthritis,replication,2010-11-10,GCST000869,Other disease,#d53e4f
17821,European,38280.0,21068099.0,Evangelou E,Osteoarthritis,initial,2010-11-10,GCST000869,Other disease,#d53e4f
17823,European,5200.0,21062454.0,Li J,Breast cancer (estrogen-receptor negative),initial,2010-11-09,GCST000867,Cancer,#d53e4f
17824,European,573.0,21051773.0,Scerri TS,Handedness in dyslexia,replication,2010-11-09,GCST000868,Other trait,#d53e4f
17826,European,573.0,21051773.0,Scerri TS,Handedness in dyslexia,replication,2010-11-09,GCST000868,Neurological disorder,#d53e4f
17828,European,566.0,21061259.0,Plant D,Response to anti-TNF therapy in rheumatoid arthritis,initial,2010-11-08,GCST000865,Response to drug,#d53e4f
17829,European,720.0,21061259.0,Plant D,Response to anti-TNF therapy in rheumatoid arthritis,replication,2010-11-08,GCST000865,Response to drug,#d53e4f
17830,Other/Mixed,186.0,21059989.0,Lee JH,Alzheimer's disease,replication,2010-11-08,GCST000864,Neurological disorder,#99d594
17831,African Am./Caribbean,401.0,21059989.0,Lee JH,Alzheimer's disease,initial,2010-11-08,GCST000864,Neurological disorder,#fee08b
17832,Hispanic/Latin American,34.0,21059989.0,Lee JH,Alzheimer's disease,initial,2010-11-08,GCST000864,Neurological disorder,#807dba
17833,European,658.0,21059989.0,Lee JH,Alzheimer's disease,initial,2010-11-08,GCST000864,Neurological disorder,#d53e4f
17834,European,3839.0,21059989.0,Lee JH,Alzheimer's disease,replication,2010-11-08,GCST000864,Neurological disorder,#d53e4f
17835,European,663.0,21059979.0,Shen H,LDL cholesterol,replication,2010-11-08,GCST000866,Lipid or lipoprotein measurement,#d53e4f
17836,European,841.0,21059979.0,Shen H,LDL cholesterol,initial,2010-11-08,GCST000866,Lipid or lipoprotein measurement,#d53e4f
17837,European,1534.0,21057379.0,Curtis D,Bipolar disorder and schizophrenia,initial,2010-11-04,GCST000862,Neurological disorder,#d53e4f
17838,African Am./Caribbean,1035.0,21668797.0,Agrawal A,Cannabis dependence,initial,2010-11-04,GCST000861,Neurological disorder,#fee08b
17839,European,2019.0,21668797.0,Agrawal A,Cannabis dependence,initial,2010-11-04,GCST000861,Neurological disorder,#d53e4f
17840,Asian,108.0,21048783.0,Kamada F,Moyamoya disease,replication,2010-11-04,GCST000860,Cardiovascular disease,#3288bd
17841,Asian,117.0,21048783.0,Kamada F,Moyamoya disease,initial,2010-11-04,GCST000860,Cardiovascular disease,#3288bd
17842,Hispanic/Latin American,677.0,21051598.0,Pereyra F,HIV-1 control,initial,2010-11-04,GCST000863,Other disease,#807dba
17843,African Am./Caribbean,1233.0,21051598.0,Pereyra F,HIV-1 control,initial,2010-11-04,GCST000863,Other disease,#fee08b
17844,European,1712.0,21051598.0,Pereyra F,HIV-1 control,initial,2010-11-04,GCST000863,Other disease,#d53e4f
17845,Asian,592.0,21072201.0,Kim JH,Aspirin intolerance in asthmatics,replication,2010-11-03,GCST000859,Other trait,#3288bd
17846,Asian,180.0,21072201.0,Kim JH,Aspirin intolerance in asthmatics,initial,2010-11-03,GCST000859,Other trait,#3288bd
17847,Asian,1413.0,21044949.0,Yang J,Systemic lupus erythematosus,replication,2010-11-02,GCST000858,Immune system disorder,#3288bd
17848,Asian,1772.0,21044949.0,Yang J,Systemic lupus erythematosus,initial,2010-11-02,GCST000858,Immune system disorder,#3288bd
17849,Asian,4071.0,21044949.0,Yang J,Systemic lupus erythematosus,replication,2010-11-02,GCST000858,Immune system disorder,#3288bd
17850,European,6880.0,21044948.0,Spencer CC,Parkinson's disease,initial,2010-11-02,GCST000855,Neurological disorder,#d53e4f
17851,European,3023.0,21044948.0,Spencer CC,Parkinson's disease,replication,2010-11-02,GCST000855,Neurological disorder,#d53e4f
17852,European,6560.0,21042317.0,Wray NR,Major depressive disorder,replication,2010-11-02,GCST000856,Neurological disorder,#d53e4f
17853,European,6104.0,21042317.0,Wray NR,Major depressive disorder,initial,2010-11-02,GCST000856,Neurological disorder,#d53e4f
17854,European,862.0,21184583.0,Zlojutro M,Event-related brain oscillations,replication,2010-11-02,GCST000857,Other measurement,#d53e4f
17855,African Am./Caribbean,153.0,21184583.0,Zlojutro M,Event-related brain oscillations,replication,2010-11-02,GCST000857,Other measurement,#fee08b
17856,African Am./Caribbean,293.0,21184583.0,Zlojutro M,Event-related brain oscillations,initial,2010-11-02,GCST000857,Other measurement,#fee08b
17857,Other/Mixed,80.0,21184583.0,Zlojutro M,Event-related brain oscillations,replication,2010-11-02,GCST000857,Other measurement,#99d594
17858,European,771.0,21184583.0,Zlojutro M,Event-related brain oscillations,initial,2010-11-02,GCST000857,Other measurement,#d53e4f
17859,European,4390.0,21041247.0,Perlis RH,Suicide risk,initial,2010-11-01,GCST000854,Neurological disorder,#d53e4f
17861,European,2698.0,21041247.0,Perlis RH,Suicide risk,replication,2010-11-01,GCST000854,Neurological disorder,#d53e4f
17862,European,4390.0,21041247.0,Perlis RH,Suicide risk,initial,2010-11-01,GCST000854,Biological process,#d53e4f
17864,European,2698.0,21041247.0,Perlis RH,Suicide risk,replication,2010-11-01,GCST000854,Biological process,#d53e4f
17865,European,3462.0,20848476.0,Haritunians T,Ulcerative colitis,initial,2010-11-01,GCST000853,Immune system disorder,#d53e4f
17866,European,2334.0,21041692.0,Denny JC,Atrioventricular conduction,initial,2010-11-01,GCST000852,Cardiovascular measurement,#d53e4f
17867,European,5473.0,21037568.0,Enciso-Mora V,Hodgkin's lymphoma,replication,2010-10-31,GCST000851,Cancer,#d53e4f
17868,European,5788.0,21037568.0,Enciso-Mora V,Hodgkin's lymphoma,initial,2010-10-31,GCST000851,Cancer,#d53e4f
17869,European,502.0,21037115.0,Wan ES,Body mass in chronic obstructive pulmonary disease,replication,2010-10-29,GCST000850,Other disease,#d53e4f
17870,European,2950.0,21037115.0,Wan ES,Body mass in chronic obstructive pulmonary disease,initial,2010-10-29,GCST000850,Other disease,#d53e4f
17871,European,502.0,21037115.0,Wan ES,Body mass in chronic obstructive pulmonary disease,replication,2010-10-29,GCST000850,Body measurement,#d53e4f
17872,European,2950.0,21037115.0,Wan ES,Body mass in chronic obstructive pulmonary disease,initial,2010-10-29,GCST000850,Body measurement,#d53e4f
17873,European,6652.0,21060863.0,Ikram MK,Retinal vascular caliber,replication,2010-10-28,GCST000847,Other measurement,#d53e4f
17874,European,15358.0,21060863.0,Ikram MK,Retinal vascular caliber,initial,2010-10-28,GCST000847,Other measurement,#d53e4f
17875,European,4389.0,20981099.0,Kong A,Recombination measurement (males),initial,2010-10-28,GCST000845,Other measurement,#d53e4f
17876,European,6041.0,20981099.0,Kong A,Recombination measurement (females),initial,2010-10-28,GCST000848,Other measurement,#d53e4f
17877,European,1703.0,21060860.0,Gaudet MM,Breast cancer in BRCA2 mutation carriers,initial,2010-10-28,GCST000846,Cancer,#d53e4f
17878,European,2486.0,21060860.0,Gaudet MM,Breast cancer in BRCA2 mutation carriers,replication,2010-10-28,GCST000846,Cancer,#d53e4f
17879,European,36386.0,21082022.0,Padmanabhan S,Hypertension,replication,2010-10-28,GCST000849,Cardiovascular disease,#d53e4f
17880,European,3320.0,21082022.0,Padmanabhan S,Hypertension,initial,2010-10-28,GCST000849,Cardiovascular disease,#d53e4f
17881,European,655.0,20978177.0,Penney KL,Prostate cancer mortality,replication,2010-10-26,GCST000844,Other measurement,#d53e4f
17882,European,564.0,20978177.0,Penney KL,Prostate cancer mortality,initial,2010-10-26,GCST000844,Other measurement,#d53e4f
17883,European,655.0,20978177.0,Penney KL,Prostate cancer mortality,replication,2010-10-26,GCST000844,Cancer,#d53e4f
17884,European,564.0,20978177.0,Penney KL,Prostate cancer mortality,initial,2010-10-26,GCST000844,Cancer,#d53e4f
17885,European,7962.0,20972440.0,Houlston RS,Colorectal cancer,initial,2010-10-24,GCST000843,Cancer,#d53e4f
17886,European,30420.0,20972440.0,Houlston RS,Colorectal cancer,initial,2010-10-24,GCST000843,Cancer,#d53e4f
17887,European,56656.0,20972438.0,Rothman N,Bladder cancer,replication,2010-10-24,GCST000842,Cancer,#d53e4f
17888,European,8652.0,20972438.0,Rothman N,Bladder cancer,initial,2010-10-24,GCST000842,Cancer,#d53e4f
17889,European,73.0,20971583.0,Ojwang JO,Dupuytren's disease,initial,2010-10-22,GCST000841,Other disease,#d53e4f
17892,Asian,1780.0,20966902.0,Croteau-Chonka DC,Body mass index,initial,2010-10-21,GCST000840,Body measurement,#3288bd
17896,European,1460.0,20953186.0,Huffmeier U,Psoriatic arthritis,initial,2010-10-17,GCST000835,Immune system disorder,#d53e4f
17897,European,5488.0,20953186.0,Huffmeier U,Psoriatic arthritis,replication,2010-10-17,GCST000835,Immune system disorder,#d53e4f
17898,European,7909.0,20953188.0,Ellinghaus E,Psoriasis,replication,2010-10-17,GCST000836,Immune system disorder,#d53e4f
17900,European,1618.0,20953188.0,Ellinghaus E,Psoriasis,initial,2010-10-17,GCST000836,Immune system disorder,#d53e4f
17901,European,7353.0,20953190.0,Strange A,Psoriasis,initial,2010-10-17,GCST000833,Immune system disorder,#d53e4f
17902,European,8638.0,20953190.0,Strange A,Psoriasis,replication,2010-10-17,GCST000833,Immune system disorder,#d53e4f
17904,Asian,360.0,20947153.0,Ueta M,Stevens-Johnson syndrome,initial,2010-10-12,GCST000832,Other disease,#3288bd
17905,European,217.0,20939080.0,Greenbaum L,Tardive dyskinesia in schizophrenia,initial,2010-10-11,GCST000831,Neurological disorder,#d53e4f
17906,Other/Mixed,8.0,20939080.0,Greenbaum L,Tardive dyskinesia in schizophrenia,initial,2010-10-11,GCST000831,Neurological disorder,#99d594
17907,Other/Mixed,170.0,20939080.0,Greenbaum L,Tardive dyskinesia in schizophrenia,replication,2010-10-11,GCST000831,Neurological disorder,#99d594
17908,African Am./Caribbean,102.0,20939080.0,Greenbaum L,Tardive dyskinesia in schizophrenia,initial,2010-10-11,GCST000831,Neurological disorder,#fee08b
17909,European,113636.0,20935629.0,Heid IM,Waist-hip ratio,replication,2010-10-10,GCST000829,Body measurement,#d53e4f
17910,European,77167.0,20935629.0,Heid IM,Waist-hip ratio,initial,2010-10-10,GCST000829,Body measurement,#d53e4f
17911,European,125931.0,20935630.0,Speliotes EK,Body mass index,replication,2010-10-10,GCST000830,Body measurement,#d53e4f
17912,European,123865.0,20935630.0,Speliotes EK,Body mass index,initial,2010-10-10,GCST000830,Body measurement,#d53e4f
17913,European,390.0,20932310.0,Han MR,Cerebrospinal T-tau levels,initial,2010-10-08,GCST000826,Other measurement,#d53e4f
17914,European,390.0,20932310.0,Han MR,Cerebrospinal fluid AB1-42 levels,initial,2010-10-08,GCST000827,Other measurement,#d53e4f
17915,Asian,4001.0,20887962.0,Jee SH,Adiponectin levels,initial,2010-10-08,GCST000828,Other measurement,#3288bd
17916,Asian,2304.0,20887962.0,Jee SH,Adiponectin levels,replication,2010-10-08,GCST000828,Other measurement,#3288bd
17917,European,390.0,20932310.0,Han MR,Cerebrospinal P-tau181p levels,initial,2010-10-08,GCST000825,Other measurement,#d53e4f
17918,African Am./Caribbean,79.0,20932654.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2010-10-05,GCST000824,Biological process,#fee08b
17919,African Am./Caribbean,79.0,20932654.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2010-10-05,GCST000824,Cancer,#fee08b
17920,African Am./Caribbean,79.0,20932654.0,Kerns SL,Erectile dysfunction and prostate cancer treatment,initial,2010-10-05,GCST000824,Other disease,#fee08b
17921,Other/Mixed,738.0,20921969.0,Aberg K,Antipsychotic drug-induced QTc interval prolongation,initial,2010-10-05,GCST000822,Response to drug,#99d594
17922,African Am./Caribbean,93.0,20923822.0,Niu N,Radiation response,initial,2010-10-05,GCST000823,Biological process,#fee08b
17923,European,89.0,20923822.0,Niu N,Radiation response,initial,2010-10-05,GCST000823,Biological process,#d53e4f
17924,Asian,95.0,20923822.0,Niu N,Radiation response,initial,2010-10-05,GCST000823,Biological process,#3288bd
17925,European,13844.0,20801717.0,Shatunov A,Amyotrophic lateral sclerosis,initial,2010-10-01,GCST000820,Neurological disorder,#d53e4f
17926,Hispanic/Latin American,34.0,20920776.0,DeWan AT,Asthma,replication,2010-10-01,GCST000819,Other disease,#807dba
17927,Other/Mixed,51.0,20920776.0,DeWan AT,Asthma,replication,2010-10-01,GCST000819,Other disease,#99d594
17928,European,47.0,20920776.0,DeWan AT,Asthma,initial,2010-10-01,GCST000819,Other disease,#d53e4f
17929,Hispanic/Latin American,32.0,20920776.0,DeWan AT,Asthma,initial,2010-10-01,GCST000819,Other disease,#807dba
17930,African Am./Caribbean,29.0,20920776.0,DeWan AT,Asthma,replication,2010-10-01,GCST000819,Other disease,#fee08b
17931,Other/Mixed,14.0,20920776.0,DeWan AT,Asthma,initial,2010-10-01,GCST000819,Other disease,#99d594
17932,European,385.0,20920776.0,DeWan AT,Asthma,replication,2010-10-01,GCST000819,Other disease,#d53e4f
17933,African Am./Caribbean,15.0,20920776.0,DeWan AT,Asthma,initial,2010-10-01,GCST000819,Other disease,#fee08b
17934,European,4234.0,20889312.0,Wang KS,Bipolar disorder and schizophrenia,initial,2010-10-01,GCST000821,Neurological disorder,#d53e4f
17935,European,22054.0,20884846.0,Yang Q,Urate levels,replication,2010-09-30,GCST000818,Other measurement,#d53e4f
17936,European,28283.0,20884846.0,Yang Q,Urate levels,initial,2010-09-30,GCST000818,Other measurement,#d53e4f
17937,European,50074.0,20881960.0,Lango Allen H,Height,replication,2010-09-29,GCST000817,Body measurement,#d53e4f
17938,European,133653.0,20881960.0,Lango Allen H,Height,initial,2010-09-29,GCST000817,Body measurement,#d53e4f
17939,European,706.0,20877300.0,Perroud N,Suicidal ideation,initial,2010-09-28,GCST000816,Biological process,#d53e4f
17940,European,3012.0,20927387.0,Kullo IJ,Red blood cell traits,initial,2010-09-28,GCST000814,Hematological measurement,#d53e4f
17941,European,3012.0,20927387.0,Kullo IJ,Red blood cell traits,initial,2010-09-28,GCST000814,Hematological measurement,#d53e4f
17942,European,3012.0,20927387.0,Kullo IJ,Red blood cell traits,initial,2010-09-28,GCST000814,Hematological measurement,#d53e4f
17943,European,3012.0,20927387.0,Kullo IJ,Red blood cell traits,initial,2010-09-28,GCST000814,Hematological measurement,#d53e4f
17944,Asian,2274.0,20876614.0,Yoon KA,Non-small cell lung cancer,replication,2010-09-28,GCST000815,Cancer,#3288bd
17945,Asian,2162.0,20876614.0,Yoon KA,Non-small cell lung cancer,initial,2010-09-28,GCST000815,Cancer,#3288bd
17948,European,878.0,20876420.0,Ingle JN,Adverse response to aromatase inhibitors,initial,2010-09-27,GCST000813,Response to drug,#d53e4f
17949,Asian,10242.0,20871597.0,Miki D,Lung adenocarcinoma,replication,2010-09-26,GCST000810,Cancer,#3288bd
17950,Asian,2904.0,20871597.0,Miki D,Lung adenocarcinoma,initial,2010-09-26,GCST000810,Cancer,#3288bd
17952,European,8428.0,20872241.0,Li J,Breast cancer,initial,2010-09-26,GCST000811,Cancer,#d53e4f
17953,European,17723.0,20864672.0,Waterworth DM,Triglycerides,initial,2010-09-23,GCST000809,Lipid or lipoprotein measurement,#d53e4f
17954,European,37774.0,20864672.0,Waterworth DM,Triglycerides,replication,2010-09-23,GCST000809,Lipid or lipoprotein measurement,#d53e4f
17955,Asian,9665.0,20864672.0,Waterworth DM,Triglycerides,replication,2010-09-23,GCST000809,Lipid or lipoprotein measurement,#3288bd
17956,European,872.0,20861866.0,Kopplin LJ,Age-related macular degeneration,initial,2010-09-23,GCST000806,Neurological disorder,#d53e4f
17957,European,3762.0,20861866.0,Kopplin LJ,Age-related macular degeneration,replication,2010-09-23,GCST000806,Neurological disorder,#d53e4f
17958,Other/Mixed,2035.0,20885792.0,Naj AC,Alzheimer's disease (late onset),initial,2010-09-23,GCST000808,Neurological disorder,#99d594
17960,Other/Mixed,26475.0,20860503.0,Moffatt MF,Asthma,initial,2010-09-23,GCST000804,Other disease,#99d594
17961,European,17723.0,20864672.0,Waterworth DM,HDL cholesterol,initial,2010-09-23,GCST000805,Lipid or lipoprotein measurement,#d53e4f
17962,European,37774.0,20864672.0,Waterworth DM,HDL cholesterol,replication,2010-09-23,GCST000805,Lipid or lipoprotein measurement,#d53e4f
17963,Asian,9665.0,20864672.0,Waterworth DM,HDL cholesterol,replication,2010-09-23,GCST000805,Lipid or lipoprotein measurement,#3288bd
17964,European,17723.0,20864672.0,Waterworth DM,LDL cholesterol,initial,2010-09-23,GCST000807,Lipid or lipoprotein measurement,#d53e4f
17965,European,37774.0,20864672.0,Waterworth DM,LDL cholesterol,replication,2010-09-23,GCST000807,Lipid or lipoprotein measurement,#d53e4f
17966,Asian,9665.0,20864672.0,Waterworth DM,LDL cholesterol,replication,2010-09-23,GCST000807,Lipid or lipoprotein measurement,#3288bd
17967,European,46368.0,20858683.0,Soranzo N,Glycated hemoglobin levels,initial,2010-09-21,GCST000803,Other measurement,#d53e4f
17968,European,19570.0,20852633.0,Bolton KL,Ovarian cancer,replication,2010-09-19,GCST000800,Cancer,#d53e4f
17969,European,4121.0,20852633.0,Bolton KL,Ovarian cancer,initial,2010-09-19,GCST000800,Cancer,#d53e4f
17970,European,5986.0,20852631.0,Antoniou AC,Breast cancer,replication,2010-09-19,GCST000801,Cancer,#d53e4f
17971,European,2383.0,20852631.0,Antoniou AC,Breast cancer,initial,2010-09-19,GCST000801,Cancer,#d53e4f
17972,European,60473.0,20852632.0,Goode EL,Ovarian cancer,replication,2010-09-19,GCST000802,Cancer,#d53e4f
17973,European,4122.0,20852632.0,Goode EL,Ovarian cancer,initial,2010-09-19,GCST000802,Cancer,#d53e4f
17974,Asian,936.0,20877124.0,Hiura Y,Hypertension,initial,2010-09-18,GCST000799,Cardiovascular disease,#3288bd
17975,Asian,6132.0,20877124.0,Hiura Y,Hypertension,replication,2010-09-18,GCST000799,Cardiovascular disease,#3288bd
17976,Other/Mixed,21680.0,20862305.0,Shu XO,Type 2 diabetes,replication,2010-09-16,GCST000796,Metabolic disorder,#99d594
17977,Asian,2729.0,20862305.0,Shu XO,Type 2 diabetes,initial,2010-09-16,GCST000796,Metabolic disorder,#3288bd
17978,European,1782.0,20849430.0,Franklin CS,Glycated hemoglobin levels,initial,2010-09-16,GCST000798,Other measurement,#d53e4f
17979,Asian,1521.0,20844546.0,Adachi S,Endometriosis,initial,2010-09-16,GCST000797,Other disease,#3288bd
17980,European,5328.0,20835239.0,Solouki AM,Refractive error,initial,2010-09-12,GCST000795,Other trait,#d53e4f
17981,European,10280.0,20835239.0,Solouki AM,Refractive error,replication,2010-09-12,GCST000795,Other trait,#d53e4f
17982,European,4270.0,20835236.0,Hysi PG,Refractive error,initial,2010-09-12,GCST000794,Other trait,#d53e4f
17983,European,13414.0,20835236.0,Hysi PG,Refractive error,replication,2010-09-12,GCST000794,Other trait,#d53e4f
17984,European,4239.0,20835238.0,Thorleifsson G,Glaucoma (primary open-angle),replication,2010-09-12,GCST000793,Neurological disorder,#d53e4f
17985,European,36140.0,20835238.0,Thorleifsson G,Glaucoma (primary open-angle),initial,2010-09-12,GCST000793,Neurological disorder,#d53e4f
17986,Asian,444.0,20833655.0,Cha PC,Warfarin maintenance dose,replication,2010-09-10,GCST000792,Response to drug,#3288bd
17987,Asian,1508.0,20833655.0,Cha PC,Warfarin maintenance dose,initial,2010-09-10,GCST000792,Response to drug,#3288bd
17988,European,2014.0,20826269.0,Panicker V,Thyroid function,initial,2010-09-10,GCST000791,Other trait,#d53e4f
17989,European,1093.0,20826269.0,Panicker V,Thyroid function,replication,2010-09-10,GCST000791,Other trait,#d53e4f
17991,European,290.0,20825314.0,Baratz KH,Fuchs's corneal dystrophy,initial,2010-09-09,GCST000790,Neurological disorder,#d53e4f
17992,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors,initial,2010-09-09,GCST004704,Body measurement,#d53e4f
17993,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors,replication,2010-09-09,GCST004704,Body measurement,#d53e4f
17994,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors,initial,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
17995,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors,replication,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
17996,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors,initial,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
17997,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors,replication,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
17998,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors,initial,2010-09-09,GCST004704,Other disease,#d53e4f
17999,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors,replication,2010-09-09,GCST004704,Other disease,#d53e4f
18000,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors,initial,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
18001,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors,replication,2010-09-09,GCST004704,Lipid or lipoprotein measurement,#d53e4f
18002,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Body measurement,#d53e4f
18003,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Body measurement,#d53e4f
18004,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18005,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18006,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18007,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18008,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Other disease,#d53e4f
18009,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Other disease,#d53e4f
18010,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18011,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Lipid or lipoprotein measurement,#d53e4f
18012,European,2442.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),replication,2010-09-09,GCST000789,Other measurement,#d53e4f
18013,European,525.0,20838585.0,Smith EN,Cardiovascular risk factors (age interaction),initial,2010-09-09,GCST000789,Other measurement,#d53e4f
18014,European,3417.0,20832056.0,Ikeda M,Schizophrenia,replication,2010-09-08,GCST000788,Neurological disorder,#d53e4f
18015,Asian,3962.0,20832056.0,Ikeda M,Schizophrenia,replication,2010-09-08,GCST000788,Neurological disorder,#3288bd
18016,Asian,1108.0,20832056.0,Ikeda M,Schizophrenia,initial,2010-09-08,GCST000788,Neurological disorder,#3288bd
18017,European,15595.0,20818381.0,Yamauchi T,Type 2 diabetes,replication,2010-09-05,GCST000787,Metabolic disorder,#d53e4f
18018,Asian,20289.0,20818381.0,Yamauchi T,Type 2 diabetes,replication,2010-09-05,GCST000787,Metabolic disorder,#3288bd
18019,Asian,7541.0,20818381.0,Yamauchi T,Type 2 diabetes,initial,2010-09-05,GCST000787,Metabolic disorder,#3288bd
18020,Hispanic/Latin American,286.0,20871662.0,Fu YP,Diabetic retinopathy,initial,2010-09-02,GCST000786,Metabolic disorder,#807dba
18023,European,1413.0,20808326.0,Krumbiegel M,Pseudoexfoliation syndrome,replication,2010-09-01,GCST000784,Neurological disorder,#d53e4f
18024,European,240.0,20808326.0,Krumbiegel M,Pseudoexfoliation syndrome,initial,2010-09-01,GCST000784,Neurological disorder,#d53e4f
18025,European,43264.0,20802479.0,Anttila V,Migraine,replication,2010-08-29,GCST000782,Cardiovascular disease,#d53e4f
18026,European,13478.0,20802479.0,Anttila V,Migraine,initial,2010-08-29,GCST000782,Cardiovascular disease,#d53e4f
18027,European,8048.0,20802025.0,Tang W,Protein C levels,initial,2010-08-27,GCST000780,Hematological measurement,#d53e4f
18028,European,1376.0,20802025.0,Tang W,Protein C levels,replication,2010-08-27,GCST000780,Hematological measurement,#d53e4f
18029,European,902.0,20801718.0,Laaksovirta H,Amyotrophic lateral sclerosis,initial,2010-08-27,GCST000781,Neurological disorder,#d53e4f
18030,European,4811.0,20800221.0,Terracciano A,Depression (quantitative trait),initial,2010-08-25,GCST000779,Neurological disorder,#d53e4f
18031,European,369.0,20811658.0,Uhl GR,Smoking cessation,initial,2010-08-24,GCST000778,Biological process,#d53e4f
18032,Asian,2810.0,20729853.0,Wang LD,Esophageal cancer,initial,2010-08-22,GCST000776,Cancer,#3288bd
18033,Asian,19526.0,20729853.0,Wang LD,Esophageal cancer,replication,2010-08-22,GCST000776,Cancer,#3288bd
18034,Asian,5623.0,20729852.0,Abnet CC,Esophageal cancer and gastric cancer,initial,2010-08-22,GCST000777,Cancer,#3288bd
18035,Asian,5623.0,20729852.0,Abnet CC,Esophageal cancer and gastric cancer,initial,2010-08-22,GCST000777,Cancer,#3288bd
18036,European,5882.0,20719862.0,Vitart V,Central corneal thickness,replication,2010-08-18,GCST000775,Other measurement,#d53e4f
18037,European,1445.0,20719862.0,Vitart V,Central corneal thickness,initial,2010-08-18,GCST000775,Other measurement,#d53e4f
18038,European,4186.0,20713499.0,Huang J,"Schizophrenia, bipolar disorder and depression (combined)",initial,2010-08-16,GCST000774,Neurological disorder,#d53e4f
18039,European,4186.0,20713499.0,Huang J,"Schizophrenia, bipolar disorder and depression (combined)",initial,2010-08-16,GCST000774,Neurological disorder,#d53e4f
18040,European,4186.0,20713499.0,Huang J,"Schizophrenia, bipolar disorder and depression (combined)",initial,2010-08-16,GCST000774,Neurological disorder,#d53e4f
18042,European,3986.0,20711177.0,Hamza TH,Parkinson's disease,initial,2010-08-15,GCST000772,Neurological disorder,#d53e4f
18043,European,865.0,20711174.0,Hor H,Narcolepsy,replication,2010-08-15,GCST000771,Neurological disorder,#d53e4f
18044,European,1264.0,20711174.0,Hor H,Narcolepsy,initial,2010-08-15,GCST000771,Neurological disorder,#d53e4f
18045,Asian,2892.0,20711176.0,Nakashima M,Keloid,replication,2010-08-15,GCST000773,Other disease,#3288bd
18046,Asian,1122.0,20711176.0,Nakashima M,Keloid,initial,2010-08-15,GCST000773,Other disease,#3288bd
18047,European,2383.0,20709820.0,Kong X,Emphysema-related traits,initial,2010-08-13,GCST000770,Other disease,#d53e4f
18048,European,20611.0,20705733.0,O'Seaghdha CM,Calcium levels,initial,2010-08-12,GCST000769,Other measurement,#d53e4f
18049,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (lobular),initial,2010-08-10,GCST000766,Digestive system disorder,#d53e4f
18050,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (lobular),initial,2010-08-10,GCST000766,Cancer,#d53e4f
18051,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (AST),initial,2010-08-10,GCST000767,Digestive system disorder,#d53e4f
18052,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (AST),initial,2010-08-10,GCST000767,Cancer,#d53e4f
18053,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (other),initial,2010-08-10,GCST000765,Liver enzyme measurement,#d53e4f
18054,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (other),initial,2010-08-10,GCST000765,Digestive system disorder,#d53e4f
18055,European,236.0,20708005.0,Chalasani N,Non-alcoholic fatty liver disease histology (other),initial,2010-08-10,GCST000765,Cancer,#d53e4f
18056,,,,,Asthma,,,GCST000768,Other disease,black
18057,African,6066.0,20694014.0,Thye T,Tuberculosis,replication,2010-08-08,GCST000764,Other disease,#fc8d59
18058,African,5359.0,20694014.0,Thye T,Tuberculosis,initial,2010-08-08,GCST000764,Other disease,#fc8d59
18059,European,5178.0,20694013.0,Davila S,Meningococcal disease,initial,2010-08-08,GCST000762,Other disease,#d53e4f
18060,European,2280.0,20694013.0,Davila S,Meningococcal disease,replication,2010-08-08,GCST000762,Other disease,#d53e4f
18061,European,1228.0,20694011.0,Ferreira RC,Immunoglobulin A,replication,2010-08-08,GCST000763,Other measurement,#d53e4f
18062,European,1520.0,20694011.0,Ferreira RC,Immunoglobulin A,initial,2010-08-08,GCST000763,Other measurement,#d53e4f
18063,European,96598.0,20686565.0,Teslovich TM,Triglycerides,initial,2010-08-05,GCST000758,Lipid or lipoprotein measurement,#d53e4f
18064,European,3351.0,20732627.0,Neale BM,Attention deficit hyperactivity disorder,initial,2010-08-05,GCST000757,Neurological disorder,#d53e4f
18065,European,99900.0,20686565.0,Teslovich TM,HDL cholesterol,initial,2010-08-05,GCST000755,Lipid or lipoprotein measurement,#d53e4f
18066,Asian,1169.0,20700438.0,Hsiung CA,Lung adenocarcinoma,initial,2010-08-05,GCST000761,Cancer,#3288bd
18067,Asian,4699.0,20700438.0,Hsiung CA,Lung adenocarcinoma,replication,2010-08-05,GCST000761,Cancer,#3288bd
18068,European,95454.0,20686565.0,Teslovich TM,LDL cholesterol,initial,2010-08-05,GCST000759,Lipid or lipoprotein measurement,#d53e4f
18069,European,100184.0,20686565.0,Teslovich TM,"Cholesterol, total",initial,2010-08-05,GCST000760,Lipid or lipoprotein measurement,#d53e4f
18070,European,15366.0,20700443.0,Meyer TE,Magnesium levels,initial,2010-08-05,GCST000756,Other measurement,#d53e4f
18071,European,8463.0,20700443.0,Meyer TE,Magnesium levels,replication,2010-08-05,GCST000756,Other measurement,#d53e4f
18072,Asian,2240.0,20694148.0,Zabaneh D,Metabolic syndrome,replication,2010-08-04,GCST000753,Metabolic disorder,#3288bd
18073,Asian,2554.0,20694148.0,Zabaneh D,Metabolic syndrome,initial,2010-08-04,GCST000753,Metabolic disorder,#3288bd
18074,European,5117.0,20691247.0,Verweij KJ,Personality dimensions,initial,2010-08-04,GCST000754,Other trait,#d53e4f
18075,Asian,8.0,20670164.0,Horinouchi M,Acute lymphoblastic leukemia (childhood),initial,2010-08-01,GCST000749,Cancer,#3288bd
18076,Asian,16.0,20670164.0,Horinouchi M,Acute lymphoblastic leukemia (childhood),replication,2010-08-01,GCST000749,Cancer,#3288bd
18077,European,5415.0,20732625.0,Neale BM,Attention deficit hyperactivity disorder,initial,2010-08-01,GCST000751,Neurological disorder,#d53e4f
18078,Asian,3869.0,20676096.0,Zhang H,Hepatocellular carcinoma,replication,2010-08-01,GCST000752,Cancer,#3288bd
18079,Asian,707.0,20676096.0,Zhang H,Hepatocellular carcinoma,initial,2010-08-01,GCST000752,Cancer,#3288bd
18080,European,6707.0,20707712.0,Mosing MA,Self-rated health,initial,2010-08-01,GCST000747,Other trait,#d53e4f
18082,Asian,4969.0,20676098.0,Takata R,Prostate cancer,initial,2010-08-01,GCST000750,Cancer,#3288bd
18083,Asian,8416.0,20676098.0,Takata R,Prostate cancer,replication,2010-08-01,GCST000750,Cancer,#3288bd
18084,European,73.0,20675712.0,Reed DR,Bitter taste response,replication,2010-07-31,GCST000746,Biological process,#d53e4f
18085,European,1457.0,20675712.0,Reed DR,Bitter taste response,initial,2010-07-31,GCST000746,Biological process,#d53e4f
18086,European,950.0,20673876.0,Rietschel M,Major depressive disorder,replication,2010-07-29,GCST000743,Neurological disorder,#d53e4f
18087,European,1892.0,20673876.0,Rietschel M,Major depressive disorder,initial,2010-07-29,GCST000743,Neurological disorder,#d53e4f
18088,European,8097.0,20686651.0,Gudbjartsson DF,Chronic kidney disease and serum creatinine levels,replication,2010-07-29,GCST000742,Other disease,#d53e4f
18089,European,38765.0,20686651.0,Gudbjartsson DF,Chronic kidney disease and serum creatinine levels,initial,2010-07-29,GCST000742,Other disease,#d53e4f
18090,European,8097.0,20686651.0,Gudbjartsson DF,Chronic kidney disease and serum creatinine levels,replication,2010-07-29,GCST000742,Other measurement,#d53e4f
18091,European,38765.0,20686651.0,Gudbjartsson DF,Chronic kidney disease and serum creatinine levels,initial,2010-07-29,GCST000742,Other measurement,#d53e4f
18092,Asian,6200.0,20686608.0,Low SK,Pancreatic cancer,initial,2010-07-29,GCST000745,Cancer,#3288bd
18093,Asian,518.0,20668459.0,Kim HN,Height,initial,2010-07-29,GCST000744,Body measurement,#3288bd
18094,European,299.0,20668430.0,Genovese G,Glomerulosclerosis,replication,2010-07-28,GCST000741,Other disease,#d53e4f
18095,European,1592.0,20668430.0,Genovese G,Glomerulosclerosis,initial,2010-07-28,GCST000741,Other disease,#d53e4f
18096,African Am./Caribbean,1815.0,20668430.0,Genovese G,Glomerulosclerosis,initial,2010-07-28,GCST000741,Other disease,#fee08b
18097,Other/Mixed,1965.0,20663923.0,Anney R,Autism,replication,2010-07-27,GCST000740,Neurological disorder,#99d594
18099,Other/Mixed,155.0,20663923.0,Anney R,Autism,initial,2010-07-27,GCST000740,Neurological disorder,#99d594
18100,European,1230.0,20663923.0,Anney R,Autism,initial,2010-07-27,GCST000740,Neurological disorder,#d53e4f
18102,European,783.0,20663923.0,Anney R,Autism,replication,2010-07-27,GCST000740,Neurological disorder,#d53e4f
18103,European,3467.0,20662065.0,Clancy RM,Neonatal lupus,initial,2010-07-26,GCST000738,Immune system disorder,#d53e4f
18104,Hispanic/Latin American,85.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,replication,2010-07-26,GCST000739,Immune system disorder,#807dba
18105,European,173.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,replication,2010-07-26,GCST000739,Immune system disorder,#d53e4f
18106,African Am./Caribbean,20.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,initial,2010-07-26,GCST000739,Immune system disorder,#fee08b
18107,Hispanic/Latin American,32.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,initial,2010-07-26,GCST000739,Immune system disorder,#807dba
18108,European,36.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,initial,2010-07-26,GCST000739,Immune system disorder,#d53e4f
18109,Asian,16.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,initial,2010-07-26,GCST000739,Immune system disorder,#3288bd
18110,African Am./Caribbean,280.0,20659327.0,Kariuki SN,Serologic markers in systemic lupus erythematosus,replication,2010-07-26,GCST000739,Immune system disorder,#fee08b
18111,European,1660.0,20657596.0,Johansen CT,Hypertriglyceridemia,initial,2010-07-25,GCST000737,Metabolic disorder,#d53e4f
18112,European,8919.0,20661308.0,Kapur K,Calcium levels,initial,2010-07-22,GCST000736,Other measurement,#d53e4f
18113,Asian,3947.0,20661308.0,Kapur K,Calcium levels,initial,2010-07-22,GCST000736,Other measurement,#3288bd
18114,European,4126.0,20661308.0,Kapur K,Calcium levels,replication,2010-07-22,GCST000736,Other measurement,#d53e4f
18115,European,9372.0,20639881.0,Conde L,Follicular lymphoma,replication,2010-07-18,GCST000734,Cancer,#d53e4f
18116,European,1431.0,20639881.0,Conde L,Follicular lymphoma,initial,2010-07-18,GCST000734,Cancer,#d53e4f
18117,European,79.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,replication,2010-07-18,GCST000735,Digestive system disorder,#d53e4f
18118,European,37.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,initial,2010-07-18,GCST000735,Digestive system disorder,#d53e4f
18119,Hispanic/Latin American,3.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,initial,2010-07-18,GCST000735,Digestive system disorder,#807dba
18120,Other/Mixed,1.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,initial,2010-07-18,GCST000735,Digestive system disorder,#99d594
18121,Other/Mixed,176.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,initial,2010-07-18,GCST000735,Digestive system disorder,#99d594
18122,Hispanic/Latin American,16.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,replication,2010-07-18,GCST000735,Digestive system disorder,#807dba
18123,Other/Mixed,1.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,replication,2010-07-18,GCST000735,Digestive system disorder,#99d594
18124,Other/Mixed,405.0,20639878.0,Singer JB,Lumiracoxib-related liver injury,replication,2010-07-18,GCST000735,Digestive system disorder,#99d594
18125,European,1398.0,20639880.0,Liu X,Primary biliary cholangitis,initial,2010-07-18,GCST000733,Cancer,#d53e4f
18126,European,4187.0,20639880.0,Liu X,Primary biliary cholangitis,replication,2010-07-18,GCST000733,Cancer,#d53e4f
18127,European,5127.0,20602913.0,Duffy DL,Nevus count,replication,2010-07-17,GCST000732,Other measurement,#d53e4f
18128,European,1810.0,20602913.0,Duffy DL,Nevus count,initial,2010-07-17,GCST000732,Other measurement,#d53e4f
18129,European,38991.0,20639392.0,Eijgelsheim M,Resting heart rate,initial,2010-07-16,GCST000731,Cardiovascular measurement,#d53e4f
18130,Asian,8841.0,20639394.0,Kang TW,Bilirubin levels,initial,2010-07-16,GCST000730,Other measurement,#3288bd
18131,Asian,1096.0,20639394.0,Kang TW,Bilirubin levels,replication,2010-07-16,GCST000730,Other measurement,#3288bd
18132,Asian,453.0,20637204.0,Ochi H,Ribavirin-induced anemia,initial,2010-07-13,GCST000729,Other trait,#3288bd
18133,Asian,470.0,20637204.0,Ochi H,Ribavirin-induced anemia,replication,2010-07-13,GCST000729,Other trait,#3288bd
18134,Asian,453.0,20637204.0,Ochi H,Ribavirin-induced anemia,initial,2010-07-13,GCST000729,Response to drug,#3288bd
18135,Asian,470.0,20637204.0,Ochi H,Ribavirin-induced anemia,replication,2010-07-13,GCST000729,Response to drug,#3288bd
18136,Other/Mixed,2493.0,20622878.0,Remmers EF,Behcet's disease,initial,2010-07-11,GCST000726,Cardiovascular disease,#99d594
18137,Asian,1479.0,20622878.0,Remmers EF,Behcet's disease,replication,2010-07-11,GCST000726,Cardiovascular disease,#3288bd
18138,Other/Mixed,336.0,20622878.0,Remmers EF,Behcet's disease,replication,2010-07-11,GCST000726,Cardiovascular disease,#99d594
18139,Other/Mixed,352.0,20622878.0,Remmers EF,Behcet's disease,replication,2010-07-11,GCST000726,Cardiovascular disease,#99d594
18140,European,430.0,20622878.0,Remmers EF,Behcet's disease,replication,2010-07-11,GCST000726,Cardiovascular disease,#d53e4f
18141,European,537.0,20622880.0,Bezzina CR,Ventricular fibrillation,replication,2010-07-11,GCST000725,Cardiovascular disease,#d53e4f
18142,European,972.0,20622880.0,Bezzina CR,Ventricular fibrillation,initial,2010-07-11,GCST000725,Cardiovascular disease,#d53e4f
18143,Asian,1348.0,20622879.0,Mizuki N,Behcet's disease,initial,2010-07-11,GCST000728,Cardiovascular disease,#3288bd
18144,Other/Mixed,2494.0,20622879.0,Mizuki N,Behcet's disease,replication,2010-07-11,GCST000728,Cardiovascular disease,#99d594
18145,Asian,259.0,20622879.0,Mizuki N,Behcet's disease,replication,2010-07-11,GCST000728,Cardiovascular disease,#3288bd
18146,European,10718.0,20622881.0,Gretarsdottir S,Abdominal aortic aneurysm,replication,2010-07-11,GCST000727,Cardiovascular disease,#d53e4f
18147,European,31795.0,20622881.0,Gretarsdottir S,Abdominal aortic aneurysm,initial,2010-07-11,GCST000727,Cardiovascular disease,#d53e4f
18148,European,2235.0,20634892.0,Calboli FC,Neuroticism (age interaction),initial,2010-07-09,GCST000724,Neurological disorder,#d53e4f
18149,European,2235.0,20634892.0,Calboli FC,Neuroticism (age interaction),initial,2010-07-09,GCST000724,Other measurement,#d53e4f
18150,European,2235.0,20634892.0,Calboli FC,Neuroticism,initial,2010-07-09,GCST004569,Neurological disorder,#d53e4f
18151,Asian,1398.0,20613766.0,Akiyama K,Intracranial aneurysm,replication,2010-07-08,GCST000723,Cardiovascular disease,#3288bd
18152,Asian,482.0,20613766.0,Akiyama K,Intracranial aneurysm,initial,2010-07-08,GCST000723,Cardiovascular disease,#3288bd
18153,European,13074.0,20610541.0,Lascorz J,Colorectal cancer,replication,2010-07-07,GCST000722,Cancer,#d53e4f
18154,European,1634.0,20610541.0,Lascorz J,Colorectal cancer,initial,2010-07-07,GCST000722,Cancer,#d53e4f
18155,Asian,2741.0,20601957.0,Uno S,Endometriosis,initial,2010-07-04,GCST000721,Other disease,#3288bd
18156,Asian,4458.0,20601957.0,Uno S,Endometriosis,replication,2010-07-04,GCST000721,Other disease,#3288bd
18157,Asian,1553.0,20610895.0,Koriyama H,Peripheral artery disease,initial,2010-07-02,GCST000720,Cardiovascular disease,#3288bd
18158,Asian,2239.0,20610895.0,Koriyama H,Peripheral artery disease,replication,2010-07-02,GCST000720,Cardiovascular disease,#3288bd
18159,Asian,758.0,20664687.0,Lin HJ,Cataracts in type 2 diabetes,initial,2010-07-01,GCST000717,Neurological disorder,#3288bd
18160,European,5411.0,20595679.0,Feehally J,Nephropathy,initial,2010-07-01,GCST000718,Other disease,#d53e4f
18161,European,4332.0,20596022.0,Petukhova L,Alopecia areata,initial,2010-07-01,GCST000719,Other disease,#d53e4f
18162,European,211.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2010-06-30,GCST000715,Response to drug,#d53e4f
18163,African,40.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2010-06-30,GCST000715,Response to drug,#fc8d59
18164,Hispanic/Latin American,46.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2010-06-30,GCST000715,Response to drug,#807dba
18165,Asian,4.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2010-06-30,GCST000715,Response to drug,#3288bd
18166,European,99.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2010-06-30,GCST000715,Response to drug,#d53e4f
18167,Other/Mixed,21.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,initial,2010-06-30,GCST000715,Response to drug,#99d594
18168,Hispanic/Latin American,24.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2010-06-30,GCST000715,Response to drug,#807dba
18169,Asian,2.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2010-06-30,GCST000715,Response to drug,#3288bd
18170,Other/Mixed,5.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2010-06-30,GCST000715,Response to drug,#99d594
18171,African,33.0,20592726.0,Chen SH,Asparaginase hypersensitivity in acute lymphoblastic leukemia,replication,2010-06-30,GCST000715,Response to drug,#fc8d59
18172,European,1415.0,20598377.0,Nischwitz S,Multiple sclerosis,initial,2010-06-30,GCST000716,Immune system disorder,#d53e4f
18173,European,47117.0,20581827.0,Voight BF,Type 2 diabetes,initial,2010-06-27,GCST000712,Metabolic disorder,#d53e4f
18174,European,94337.0,20581827.0,Voight BF,Type 2 diabetes,replication,2010-06-27,GCST000712,Metabolic disorder,#d53e4f
18175,African Am./Caribbean,1257.0,20585324.0,Dick DM,Conduct disorder,initial,2010-06-27,GCST000714,Neurological disorder,#fee08b
18176,Other/Mixed,8.0,20585324.0,Dick DM,Conduct disorder,initial,2010-06-27,GCST000714,Neurological disorder,#99d594
18177,European,2698.0,20585324.0,Dick DM,Conduct disorder,initial,2010-06-27,GCST000714,Neurological disorder,#d53e4f
18178,African Am./Caribbean,1257.0,20585324.0,Dick DM,Conduct disorder (symptom count),initial,2010-06-27,GCST000713,Neurological disorder,#fee08b
18179,Other/Mixed,8.0,20585324.0,Dick DM,Conduct disorder (symptom count),initial,2010-06-27,GCST000713,Neurological disorder,#99d594
18180,European,2698.0,20585324.0,Dick DM,Conduct disorder (symptom count),initial,2010-06-27,GCST000713,Neurological disorder,#d53e4f
18181,Hispanic/Latin American,961.0,20600896.0,Engelman CD,Vitamin D levels,replication,2010-06-26,GCST000711,Other measurement,#807dba
18182,Hispanic/Latin American,229.0,20600896.0,Engelman CD,Vitamin D levels,initial,2010-06-26,GCST000711,Other measurement,#807dba
18183,European,9126.0,20585627.0,Eriksson N,Hair color,initial,2010-06-24,GCST000707,Other trait,#d53e4f
18184,European,9126.0,20585627.0,Eriksson N,Eye color,initial,2010-06-24,GCST000710,Other trait,#d53e4f
18185,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Biological process,#d53e4f
18186,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18187,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18188,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Biological process,#d53e4f
18189,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18190,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18191,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Biological process,#d53e4f
18192,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18193,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18194,European,9126.0,20585627.0,Eriksson N,Common traits (Other),initial,2010-06-24,GCST000706,Other trait,#d53e4f
18195,European,9126.0,20585627.0,Eriksson N,Freckling,initial,2010-06-24,GCST000708,Other trait,#d53e4f
18196,European,5459.0,20585626.0,Long J,Breast cancer,replication,2010-06-24,GCST000709,Cancer,#d53e4f
18197,Asian,28152.0,20585626.0,Long J,Breast cancer,replication,2010-06-24,GCST000709,Cancer,#3288bd
18198,Asian,4157.0,20585626.0,Long J,Breast cancer,initial,2010-06-24,GCST000709,Cancer,#3288bd
18199,Asian,161.0,20534544.0,Beall CM,Hemoglobin levels,replication,2010-06-22,GCST000704,Hematological measurement,#3288bd
18200,Asian,35.0,20534544.0,Beall CM,Hemoglobin levels,initial,2010-06-22,GCST000704,Hematological measurement,#3288bd
18201,European,1531.0,20570966.0,McGovern DP,Crohn's disease,replication,2010-06-22,GCST000705,Digestive system disorder,#d53e4f
18202,European,4099.0,20570966.0,McGovern DP,Crohn's disease,initial,2010-06-22,GCST000705,Digestive system disorder,#d53e4f
18203,European,37.0,20558996.0,Ott J,Schizophrenia,initial,2010-06-17,GCST000702,Neurological disorder,#d53e4f
18204,European,16264.0,20558539.0,Kestenbaum B,Phosphorus levels,initial,2010-06-17,GCST000703,Other measurement,#d53e4f
18205,European,5444.0,20558539.0,Kestenbaum B,Phosphorus levels,replication,2010-06-17,GCST000703,Other measurement,#d53e4f
18206,European,4120.0,20543847.0,Turnbull C,Testicular germ cell cancer,replication,2010-06-13,GCST000701,Cancer,#d53e4f
18207,European,5926.0,20543847.0,Turnbull C,Testicular germ cell cancer,initial,2010-06-13,GCST000701,Cancer,#d53e4f
18208,European,7360.0,20548946.0,Ramdas WD,Vertical cup-disc ratio,initial,2010-06-10,GCST000700,Other measurement,#d53e4f
18209,European,4455.0,20548946.0,Ramdas WD,Vertical cup-disc ratio,replication,2010-06-10,GCST000700,Other measurement,#d53e4f
18210,European,7721.0,20548944.0,Hsu YH,Osteoporosis-related phenotypes,replication,2010-06-10,GCST000698,Other disease,#d53e4f
18211,European,3569.0,20548944.0,Hsu YH,Osteoporosis-related phenotypes,initial,2010-06-10,GCST000698,Other disease,#d53e4f
18212,European,4455.0,20548946.0,Ramdas WD,Optic disc parameters,replication,2010-06-10,GCST000699,Other measurement,#d53e4f
18213,European,7360.0,20548946.0,Ramdas WD,Optic disc parameters,initial,2010-06-10,GCST000699,Other measurement,#d53e4f
18214,European,17871.0,20541252.0,Wang TJ,Vitamin D insufficiency,replication,2010-06-09,GCST000697,Other trait,#d53e4f
18215,European,16125.0,20541252.0,Wang TJ,Vitamin D insufficiency,initial,2010-06-09,GCST000697,Other trait,#d53e4f
18216,African Am./Caribbean,699.0,20532800.0,Bostrom MA,End-stage renal disease (non-diabetic),replication,2010-06-08,GCST000696,Other disease,#fee08b
18217,African Am./Caribbean,942.0,20532800.0,Bostrom MA,End-stage renal disease (non-diabetic),initial,2010-06-08,GCST000696,Other disease,#fee08b
18218,European,755.0,20528957.0,Oedegaard KJ,Migraine in psychiatric disorder,initial,2010-06-07,GCST000695,Neurological disorder,#d53e4f
18219,European,455.0,20528957.0,Oedegaard KJ,Migraine in psychiatric disorder,replication,2010-06-07,GCST000695,Neurological disorder,#d53e4f
18220,European,755.0,20528957.0,Oedegaard KJ,Migraine in psychiatric disorder,initial,2010-06-07,GCST000695,Cardiovascular disease,#d53e4f
18221,European,455.0,20528957.0,Oedegaard KJ,Migraine in psychiatric disorder,replication,2010-06-07,GCST000695,Cardiovascular disease,#d53e4f
18222,European,2917.0,20529992.0,Teupser D,Phytosterol levels,replication,2010-06-07,GCST000694,Other measurement,#d53e4f
18223,European,1495.0,20529992.0,Teupser D,Phytosterol levels,initial,2010-06-07,GCST000694,Other measurement,#d53e4f
18224,Asian,17363.0,20526339.0,Quan C,Vitiligo,replication,2010-06-06,GCST000692,Immune system disorder,#3288bd
18225,Asian,2546.0,20526339.0,Quan C,Vitiligo,initial,2010-06-06,GCST000692,Immune system disorder,#3288bd
18226,African Am./Caribbean,840.0,20526338.0,Johnson AD,Platelet aggregation,replication,2010-06-06,GCST000693,Biological process,#fee08b
18227,European,3991.0,20526338.0,Johnson AD,Platelet aggregation,initial,2010-06-06,GCST000693,Biological process,#d53e4f
18228,European,10380.0,20522523.0,Kasperaviciute D,Partial epilepsies,initial,2010-06-03,GCST000691,Neurological disorder,#d53e4f
18229,Asian,245.0,20463552.0,Wu C,Response to platinum-based chemotherapy in small-cell lung cancer,initial,2010-06-01,GCST000688,Response to drug,#3288bd
18230,Asian,183.0,20463552.0,Wu C,Response to platinum-based chemotherapy in small-cell lung cancer,replication,2010-06-01,GCST000688,Response to drug,#3288bd
18231,European,3230.0,20516156.0,Lewis CM,Major depressive disorder,initial,2010-06-01,GCST000689,Neurological disorder,#d53e4f
18232,European,3336.0,20516156.0,Lewis CM,Major depressive disorder,replication,2010-06-01,GCST000689,Neurological disorder,#d53e4f
18233,African Am./Caribbean,225.0,20520587.0,Nielsen DA,Heroin addiction,initial,2010-06-01,GCST000690,Neurological disorder,#fee08b
18234,European,350.0,20520587.0,Nielsen DA,Heroin addiction,initial,2010-06-01,GCST000690,Neurological disorder,#d53e4f
18235,Asian,3477.0,20512145.0,Bei JX,Nasopharyngeal carcinoma,initial,2010-05-30,GCST000687,Cancer,#3288bd
18236,Asian,7407.0,20512145.0,Bei JX,Nasopharyngeal carcinoma,replication,2010-05-30,GCST000687,Cancer,#3288bd
18237,European,190.0,20484958.0,Diergaarde B,Pancreatic cancer,initial,2010-05-17,GCST000686,Cancer,#d53e4f
18238,European,142.0,20484958.0,Diergaarde B,Pancreatic cancer,replication,2010-05-17,GCST000686,Cancer,#d53e4f
18239,European,5951.0,20463881.0,Liu F,Eye color traits,initial,2010-05-16,GCST000685,Other trait,#d53e4f
18240,European,3543.0,20463881.0,Liu F,Eye color traits,replication,2010-05-16,GCST000685,Other trait,#d53e4f
18242,European,4075.0,20485516.0,Lu Y,Central corneal thickness,initial,2010-05-13,GCST000683,Other measurement,#d53e4f
18243,Other/Mixed,25610.0,20460622.0,Seshadri S,Alzheimer's disease,initial,2010-05-12,GCST000682,Neurological disorder,#99d594
18244,European,20037.0,20460622.0,Seshadri S,Alzheimer's disease,replication,2010-05-12,GCST000682,Neurological disorder,#d53e4f
18245,Asian,214.0,20460270.0,Garcia-Barcelo MM,Biliary atresia,replication,2010-05-11,GCST000681,Digestive system disorder,#3288bd
18246,Asian,762.0,20460270.0,Garcia-Barcelo MM,Biliary atresia,initial,2010-05-11,GCST000681,Digestive system disorder,#3288bd
18247,European,8556.0,20453838.0,Turnbull C,Breast cancer,initial,2010-05-09,GCST000678,Cancer,#d53e4f
18248,European,24799.0,20453838.0,Turnbull C,Breast cancer,replication,2010-05-09,GCST000678,Cancer,#d53e4f
18249,European,25708.0,20453842.0,Stahl EA,Rheumatoid arthritis,initial,2010-05-09,GCST000679,Immune system disorder,#d53e4f
18250,European,15574.0,20453842.0,Stahl EA,Rheumatoid arthritis,replication,2010-05-09,GCST000679,Immune system disorder,#d53e4f
18251,Asian,22127.0,20453841.0,Kochi Y,Rheumatoid arthritis,replication,2010-05-09,GCST000677,Immune system disorder,#3288bd
18252,Asian,5683.0,20453841.0,Kochi Y,Rheumatoid arthritis,initial,2010-05-09,GCST000677,Immune system disorder,#3288bd
18253,European,1754.0,20453840.0,Sanna S,Multiple sclerosis,initial,2010-05-09,GCST000680,Immune system disorder,#d53e4f
18254,European,3780.0,20453840.0,Sanna S,Multiple sclerosis,replication,2010-05-09,GCST000680,Immune system disorder,#d53e4f
18255,European,299.0,20452100.0,Kramer PL,Alzheimer's disease,initial,2010-05-06,GCST000676,Neurological disorder,#d53e4f
18256,European,10693.0,20451256.0,Djurovic S,Bipolar disorder,replication,2010-05-05,GCST000674,Neurological disorder,#d53e4f
18257,European,760.0,20451256.0,Djurovic S,Bipolar disorder,initial,2010-05-05,GCST000674,Neurological disorder,#d53e4f
18258,African Am./Caribbean,2895.0,20445134.0,Smith NL,Heart failure,initial,2010-05-05,GCST000675,Cardiovascular disease,#fee08b
18259,European,20926.0,20445134.0,Smith NL,Heart failure,initial,2010-05-05,GCST000675,Cardiovascular disease,#d53e4f
18260,Asian,1038.0,20436469.0,Beaty TH,Cleft lip,initial,2010-05-02,GCST000673,Other trait,#3288bd
18261,European,825.0,20436469.0,Beaty TH,Cleft lip,initial,2010-05-02,GCST000673,Other trait,#d53e4f
18262,European,3830.0,20436469.0,Beaty TH,Cleft lip,replication,2010-05-02,GCST000673,Other trait,#d53e4f
18263,Other/Mixed,1769.0,20436469.0,Beaty TH,Cleft lip,replication,2010-05-02,GCST000673,Other trait,#99d594
18264,Asian,322.0,20436469.0,Beaty TH,Cleft lip,replication,2010-05-02,GCST000673,Other trait,#3288bd
18265,Asian,2194.0,20436469.0,Beaty TH,Cleft lip,replication,2010-05-02,GCST000673,Other trait,#3288bd
18266,European,1693.0,20436471.0,Albagha OM,Paget's disease,initial,2010-05-02,GCST000672,Other disease,#d53e4f
18267,European,744.0,20436471.0,Albagha OM,Paget's disease,replication,2010-05-02,GCST000672,Other disease,#d53e4f
18268,European,6668.0,20442857.0,Suchindran S,Lipoprotein-associated phospholipase A2 activity and mass,initial,2010-04-29,GCST000671,Lipid or lipoprotein measurement,#d53e4f
18269,Other/Mixed,322.0,20421487.0,Hodgkinson CA,Electroencephalogram traits,initial,2010-04-26,GCST000670,Other measurement,#99d594
18270,European,185.0,20421487.0,Hodgkinson CA,Electroencephalogram traits,replication,2010-04-26,GCST000670,Other measurement,#d53e4f
18271,Other/Mixed,1893.0,20421499.0,Levy D,Telomere length,replication,2010-04-26,GCST000669,Other measurement,#99d594
18272,European,2876.0,20421499.0,Levy D,Telomere length,replication,2010-04-26,GCST000669,Other measurement,#d53e4f
18273,European,3417.0,20421499.0,Levy D,Telomere length,initial,2010-04-26,GCST000669,Other measurement,#d53e4f
18274,European,54731.0,20418888.0,Thorgeirsson TE,Smoking behavior,replication,2010-04-25,GCST000667,Biological process,#d53e4f
18275,European,31266.0,20418888.0,Thorgeirsson TE,Smoking behavior,initial,2010-04-25,GCST000667,Biological process,#d53e4f
18276,European,120516.0,20418889.0,Liu JZ,Smoking behavior,replication,2010-04-25,GCST000668,Biological process,#d53e4f
18277,European,41150.0,20418889.0,Liu JZ,Smoking behavior,initial,2010-04-25,GCST000668,Biological process,#d53e4f
18279,European,74035.0,20418890.0,Tobacco and Genetics Consortium,Smoking behavior,initial,2010-04-25,GCST000666,Biological process,#d53e4f
18280,European,4501.0,20418485.0,Ahn J,Vitamin D levels,initial,2010-04-23,GCST000664,Other measurement,#d53e4f
18281,European,2221.0,20418485.0,Ahn J,Vitamin D levels,replication,2010-04-23,GCST000664,Other measurement,#d53e4f
18282,European,5643.0,20418489.0,Qi L,Type 2 diabetes,initial,2010-04-23,GCST000665,Metabolic disorder,#d53e4f
18283,European,84605.0,20418489.0,Qi L,Type 2 diabetes,replication,2010-04-23,GCST000665,Metabolic disorder,#d53e4f
18284,European,5552.0,20421936.0,Scherag A,Obesity (early onset extreme),replication,2010-04-22,GCST000663,Metabolic disorder,#d53e4f
18285,European,2258.0,20421936.0,Scherag A,Obesity (early onset extreme),initial,2010-04-22,GCST000663,Metabolic disorder,#d53e4f
18286,European,3635.0,20410501.0,Jin Y,Vitiligo,replication,2010-04-21,GCST000662,Immune system disorder,#d53e4f
18287,European,4021.0,20410501.0,Jin Y,Vitiligo,initial,2010-04-21,GCST000662,Immune system disorder,#d53e4f
18288,African,466.0,20400778.0,Morrison AC,Mortality in heart failure,initial,2010-04-17,GCST000661,Cardiovascular disease,#fc8d59
18289,European,2562.0,20400778.0,Morrison AC,Mortality in heart failure,initial,2010-04-17,GCST000661,Cardiovascular disease,#d53e4f
18290,African,466.0,20400778.0,Morrison AC,Mortality in heart failure,initial,2010-04-17,GCST000661,Other measurement,#fc8d59
18291,European,2562.0,20400778.0,Morrison AC,Mortality in heart failure,initial,2010-04-17,GCST000661,Other measurement,#d53e4f
18292,African Am./Caribbean,4175.0,20400458.0,Kang SJ,Anthropometric traits,replication,2010-04-16,GCST000660,Other measurement,#fee08b
18293,African Am./Caribbean,743.0,20400458.0,Kang SJ,Anthropometric traits,initial,2010-04-16,GCST000660,Other measurement,#fee08b
18294,African,1188.0,20400458.0,Kang SJ,Anthropometric traits,initial,2010-04-16,GCST000660,Other measurement,#fc8d59
18295,European,1368.0,20395239.0,Macgregor S,Optic nerve measurement (cup area),initial,2010-04-15,GCST000659,Other measurement,#d53e4f
18296,European,848.0,20395239.0,Macgregor S,Optic nerve measurement (cup area),replication,2010-04-15,GCST000659,Other measurement,#d53e4f
18297,European,1368.0,20395239.0,Macgregor S,Optic nerve measurement (cup-to-disc ratio),initial,2010-04-15,GCST000655,Other measurement,#d53e4f
18298,European,848.0,20395239.0,Macgregor S,Optic nerve measurement (cup-to-disc ratio),replication,2010-04-15,GCST000655,Other measurement,#d53e4f
18299,European,848.0,20395239.0,Macgregor S,Optic nerve measurement (disc area),replication,2010-04-15,GCST000657,Other measurement,#d53e4f
18300,European,1368.0,20395239.0,Macgregor S,Optic nerve measurement (disc area),initial,2010-04-15,GCST000657,Other measurement,#d53e4f
18301,African Am./Caribbean,515.0,20205591.0,Pelak K,HIV-1 viral setpoint,initial,2010-04-15,GCST000656,Other disease,#fee08b
18302,European,848.0,20395239.0,Macgregor S,Optic nerve measurement (rim area),replication,2010-04-15,GCST000658,Other measurement,#d53e4f
18303,European,1368.0,20395239.0,Macgregor S,Optic nerve measurement (rim area),initial,2010-04-15,GCST000658,Other measurement,#d53e4f
18304,Asian,2000.0,20386566.0,Lee MT,Bipolar I disorder,initial,2010-04-13,GCST000654,Neurological disorder,#3288bd
18305,Asian,1409.0,20386566.0,Lee MT,Bipolar I disorder,replication,2010-04-13,GCST000654,Neurological disorder,#3288bd
18308,European,1278.0,20385826.0,Neale BM,Age-related macular degeneration,replication,2010-04-12,GCST000653,Neurological disorder,#d53e4f
18309,Asian,1014.0,20385819.0,Chen W,Age-related macular degeneration,replication,2010-04-12,GCST000652,Neurological disorder,#3288bd
18310,European,13890.0,20385819.0,Chen W,Age-related macular degeneration,replication,2010-04-12,GCST000652,Neurological disorder,#d53e4f
18311,European,3307.0,20385819.0,Chen W,Age-related macular degeneration,initial,2010-04-12,GCST000652,Neurological disorder,#d53e4f
18312,European,7322.0,20383147.0,Radstake TR,Systemic sclerosis,replication,2010-04-11,GCST000650,Neurological disorder,#d53e4f
18313,European,7467.0,20383147.0,Radstake TR,Systemic sclerosis,initial,2010-04-11,GCST000650,Neurological disorder,#d53e4f
18314,European,23812.0,20383145.0,Chambers JC,Creatinine levels,initial,2010-04-11,GCST000651,Other measurement,#d53e4f
18315,European,16626.0,20383145.0,Chambers JC,Creatinine levels,replication,2010-04-11,GCST000651,Other measurement,#d53e4f
18316,European,22982.0,20383146.0,Kottgen A,Chronic kidney disease,replication,2010-04-11,GCST000649,Other measurement,#d53e4f
18317,European,67093.0,20383146.0,Kottgen A,Chronic kidney disease,initial,2010-04-11,GCST000649,Other measurement,#d53e4f
18318,European,22982.0,20383146.0,Kottgen A,Chronic kidney disease,replication,2010-04-11,GCST000649,Other disease,#d53e4f
18319,European,67093.0,20383146.0,Kottgen A,Chronic kidney disease,initial,2010-04-11,GCST000649,Other disease,#d53e4f
18320,European,22982.0,20383146.0,Kottgen A,Chronic kidney disease,replication,2010-04-11,GCST000649,Other measurement,#d53e4f
18321,European,67093.0,20383146.0,Kottgen A,Chronic kidney disease,initial,2010-04-11,GCST000649,Other measurement,#d53e4f
18322,Other/Mixed,746.0,20372150.0,Freathy RM,Birth weight,replication,2010-04-06,GCST000648,Body measurement,#99d594
18323,European,10623.0,20372150.0,Freathy RM,Birth weight,initial,2010-04-06,GCST000648,Body measurement,#d53e4f
18324,European,27591.0,20372150.0,Freathy RM,Birth weight,replication,2010-04-06,GCST000648,Body measurement,#d53e4f
18325,Other/Mixed,1748.0,20372150.0,Freathy RM,Birth weight,replication,2010-04-06,GCST000648,Body measurement,#99d594
18326,European,1231.0,20370913.0,Ma L,Cholesterol,replication,2010-04-06,GCST000647,Lipid or lipoprotein measurement,#d53e4f
18328,Asian,4777.0,20364137.0,Yasuno K,Intracranial aneurysm,replication,2010-04-04,GCST000646,Cardiovascular disease,#3288bd
18329,European,15295.0,20364137.0,Yasuno K,Intracranial aneurysm,initial,2010-04-04,GCST000646,Cardiovascular disease,#d53e4f
18330,Asian,660.0,20363506.0,Meguro A,Glaucoma,initial,2010-04-02,GCST000645,Neurological disorder,#3288bd
18331,European,11536.0,20397748.0,Liu JZ,Body mass index,initial,2010-04-01,GCST000642,Body measurement,#d53e4f
18332,European,706.0,20360315.0,Uher R,Response to antidepressants,initial,2010-04-01,GCST000643,Response to drug,#d53e4f
18333,European,11536.0,20397748.0,Liu JZ,Height,initial,2010-04-01,GCST000644,Body measurement,#d53e4f
18335,European,1021.0,20350937.0,Takahashi M,"Thyroid cancer (Papillary, radiation-related)",initial,2010-03-29,GCST000640,Cancer,#d53e4f
18336,European,9029.0,20348956.0,Kiemeney LA,Urinary bladder cancer,replication,2010-03-28,GCST000639,Cancer,#d53e4f
18337,European,41199.0,20348956.0,Kiemeney LA,Urinary bladder cancer,initial,2010-03-28,GCST000639,Cancer,#d53e4f
18338,Other/Mixed,19611.0,20360844.0,Arking DE,Sudden cardiac arrest,replication,2010-03-25,GCST000638,Cardiovascular disease,#99d594
18339,European,650.0,20360844.0,Arking DE,Sudden cardiac arrest,initial,2010-03-25,GCST000638,Cardiovascular disease,#d53e4f
18340,European,56.0,20308991.0,Kim S,Brain cytoarchitecture,initial,2010-03-23,GCST000636,Other measurement,#d53e4f
18342,European,4335.0,20332263.0,Azzato EM,Breast cancer (prognosis),replication,2010-03-23,GCST000637,Cancer,#d53e4f
18343,European,3928.0,20339536.0,Barber MJ,Response to statin therapy,initial,2010-03-22,GCST000635,Response to drug,#d53e4f
18344,European,2619.0,20306291.0,Davis OS,Cognitive ability,replication,2010-03-21,GCST000634,Biological process,#d53e4f
18345,European,860.0,20306291.0,Davis OS,Cognitive ability,initial,2010-03-21,GCST000634,Biological process,#d53e4f
18346,European,728.0,20304703.0,Li Y,Lung cancer,initial,2010-03-19,GCST000633,Cancer,#d53e4f
18347,European,1299.0,20304703.0,Li Y,Lung cancer,replication,2010-03-19,GCST000633,Cancer,#d53e4f
18348,Other/Mixed,219.0,20304703.0,Li Y,Lung cancer,replication,2010-03-19,GCST000633,Cancer,#99d594
18349,Other/Mixed,26.0,20304703.0,Li Y,Lung cancer,initial,2010-03-19,GCST000633,Cancer,#99d594
18350,European,1431.0,20303064.0,Houlihan LM,Activated partial thromboplastin time,initial,2010-03-18,GCST000631,Hematological measurement,#d53e4f
18351,Asian,4295.0,20305777.0,Nakajima M,Knee osteoarthritis,initial,2010-03-18,GCST000629,Other disease,#3288bd
18352,European,1884.0,20305777.0,Nakajima M,Knee osteoarthritis,replication,2010-03-18,GCST000629,Other disease,#d53e4f
18353,Asian,514.0,20305777.0,Nakajima M,Knee osteoarthritis,replication,2010-03-18,GCST000629,Other disease,#3288bd
18354,European,2889.0,20303062.0,Medland SE,Digit length ratio,initial,2010-03-18,GCST000630,Body measurement,#d53e4f
18355,European,3659.0,20303062.0,Medland SE,Digit length ratio,replication,2010-03-18,GCST000630,Body measurement,#d53e4f
18356,European,6025.0,20304771.0,Newman AB,Longevity,replication,2010-03-18,GCST000632,Other measurement,#d53e4f
18357,European,3791.0,20304771.0,Newman AB,Longevity,initial,2010-03-18,GCST000632,Other measurement,#d53e4f
18358,Hispanic/Latin American,858.0,20237162.0,Bozaoglu K,Chemerin levels,initial,2010-03-17,GCST000628,Cardiovascular measurement,#807dba
18359,European,7604.0,20231535.0,Smith NL,Factor VIII levels,replication,2010-03-15,GCST000626,Hematological measurement,#d53e4f
18360,European,15279.0,20231535.0,Smith NL,Factor VIII levels,initial,2010-03-15,GCST000626,Hematological measurement,#d53e4f
18361,European,23608.0,20231535.0,Smith NL,vWF levels,initial,2010-03-15,GCST000627,Hematological measurement,#d53e4f
18362,European,7604.0,20231535.0,Smith NL,vWF levels,replication,2010-03-15,GCST000627,Hematological measurement,#d53e4f
18363,European,15422.0,20231535.0,Smith NL,Factor VII levels,initial,2010-03-15,GCST000625,Other measurement,#d53e4f
18364,European,7604.0,20231535.0,Smith NL,Factor VII levels,replication,2010-03-15,GCST000625,Other measurement,#d53e4f
18365,European,7967.0,20228798.0,Franke A,Ulcerative colitis,replication,2010-03-14,GCST000623,Immune system disorder,#d53e4f
18366,European,2746.0,20228798.0,Franke A,Ulcerative colitis,initial,2010-03-14,GCST000623,Immune system disorder,#d53e4f
18367,European,3589.0,20228799.0,McGovern DP,Ulcerative colitis,replication,2010-03-14,GCST000624,Immune system disorder,#d53e4f
18368,European,9484.0,20228799.0,McGovern DP,Ulcerative colitis,initial,2010-03-14,GCST000624,Immune system disorder,#d53e4f
18369,European,2035.0,20222955.0,Pattaro C,Creatinine levels,replication,2010-03-11,GCST000622,Other measurement,#d53e4f
18370,European,4006.0,20222955.0,Pattaro C,Creatinine levels,initial,2010-03-11,GCST000622,Other measurement,#d53e4f
18371,European,352.0,20212171.0,Buil A,C4b binding protein levels,initial,2010-03-08,GCST000621,Cardiovascular measurement,#d53e4f
18372,European,1300.0,20208534.0,Rothenberg ME,Eosinophilic esophagitis (pediatric),replication,2010-03-07,GCST000620,Digestive system disorder,#d53e4f
18373,European,2155.0,20208534.0,Rothenberg ME,Eosinophilic esophagitis (pediatric),initial,2010-03-07,GCST000620,Digestive system disorder,#d53e4f
18374,European,1845.0,20202923.0,Bierut LJ,Alcohol dependence,replication,2010-03-02,GCST000619,Neurological disorder,#d53e4f
18375,African Am./Caribbean,1161.0,20202923.0,Bierut LJ,Alcohol dependence,initial,2010-03-02,GCST000619,Neurological disorder,#fee08b
18376,European,2668.0,20202923.0,Bierut LJ,Alcohol dependence,initial,2010-03-02,GCST000619,Neurological disorder,#d53e4f
18377,European,421.0,20195266.0,Adkins DE,Response to antipsychotic treatment,initial,2010-03-02,GCST000618,Response to drug,#d53e4f
18378,Other/Mixed,103.0,20195266.0,Adkins DE,Response to antipsychotic treatment,initial,2010-03-02,GCST000618,Response to drug,#99d594
18379,African Am./Caribbean,214.0,20195266.0,Adkins DE,Response to antipsychotic treatment,initial,2010-03-02,GCST000618,Response to drug,#fee08b
18380,European,742.0,20197096.0,Stein JL,Brain structure (hippocampal volume),initial,2010-03-01,GCST000615,Other measurement,#d53e4f
18381,European,742.0,20197096.0,Stein JL,Brain structure (hippocampal volume),initial,2010-03-01,GCST000615,Other measurement,#d53e4f
18382,European,324.0,20235792.0,Uhl GR,Smoking cessation,initial,2010-03-01,GCST000616,Biological process,#d53e4f
18383,European,742.0,20197096.0,Stein JL,Brain structure (temporal lobe volume),initial,2010-03-01,GCST000614,Neurological disorder,#d53e4f
18384,African Am./Caribbean,485.0,20201924.0,Edenberg HJ,Alcohol dependence,initial,2010-03-01,GCST000617,Neurological disorder,#fee08b
18385,European,1399.0,20201924.0,Edenberg HJ,Alcohol dependence,initial,2010-03-01,GCST000617,Neurological disorder,#d53e4f
18386,African,226.0,20487506.0,Joubert BR,HIV (mother-to-child transmission),initial,2010-03-01,GCST000613,Biological process,#fc8d59
18387,European,10602.0,20190752.0,Dubois PC,Celiac disease,replication,2010-02-28,GCST000612,Immune system disorder,#d53e4f
18388,European,15283.0,20190752.0,Dubois PC,Celiac disease,initial,2010-02-28,GCST000612,Immune system disorder,#d53e4f
18389,Asian,19633.0,20189936.0,Okada Y,Height,initial,2010-02-26,GCST000611,Body measurement,#3288bd
18390,European,5919.0,20195514.0,Pillas D,Primary tooth development (time to first tooth eruption),initial,2010-02-26,GCST000609,Biological process,#d53e4f
18391,European,5752.0,20195514.0,Pillas D,Primary tooth development (number of teeth),initial,2010-02-26,GCST000610,Biological process,#d53e4f
18392,Asian,93.0,20189245.0,Han S,Acute lymphoblastic leukemia (childhood),initial,2010-02-25,GCST000608,Cancer,#3288bd
18393,European,16443.0,20185149.0,Athanasiu L,Schizophrenia,replication,2010-02-23,GCST000607,Neurological disorder,#d53e4f
18394,European,506.0,20185149.0,Athanasiu L,Schizophrenia,initial,2010-02-23,GCST000607,Neurological disorder,#d53e4f
18395,European,518.0,20147318.0,Qi L,E-selectin levels,replication,2010-02-22,GCST000606,Inflammatory measurement,#d53e4f
18396,European,1005.0,20147318.0,Qi L,E-selectin levels,initial,2010-02-22,GCST000606,Inflammatory measurement,#d53e4f
18397,European,875.0,20167575.0,Sun Q,Soluble leptin receptor levels,replication,2010-02-22,GCST000605,Other measurement,#d53e4f
18398,European,1504.0,20167575.0,Sun Q,Soluble leptin receptor levels,initial,2010-02-22,GCST000605,Other measurement,#d53e4f
18400,European,1006.0,20173748.0,Cho MH,Chronic obstructive pulmonary disease,replication,2010-02-21,GCST000603,Other disease,#d53e4f
18401,European,4320.0,20173748.0,Cho MH,Chronic obstructive pulmonary disease,initial,2010-02-21,GCST000603,Other disease,#d53e4f
18403,African,198.0,20173735.0,Fellay J,Chronic hepatitis C infection,initial,2010-02-21,GCST000604,Digestive system disorder,#fc8d59
18404,European,988.0,20173735.0,Fellay J,Chronic hepatitis C infection,initial,2010-02-21,GCST000604,Digestive system disorder,#d53e4f
18405,European,4771.0,20173747.0,Ellinor PT,Atrial fibrillation,replication,2010-02-21,GCST000602,Cardiovascular disease,#d53e4f
18406,European,14179.0,20173747.0,Ellinor PT,Atrial fibrillation,initial,2010-02-21,GCST000602,Cardiovascular disease,#d53e4f
18407,Asian,3276.0,20174558.0,Tsai FJ,Type 2 diabetes,replication,2010-02-19,GCST000601,Metabolic disorder,#3288bd
18408,Asian,1889.0,20174558.0,Tsai FJ,Type 2 diabetes,initial,2010-02-19,GCST000601,Metabolic disorder,#3288bd
18409,Asian,1894.0,20172861.0,Okada Y,Neutrophil count,replication,2010-02-18,GCST000600,Hematological measurement,#3288bd
18410,Asian,5771.0,20172861.0,Okada Y,Neutrophil count,initial,2010-02-18,GCST000600,Hematological measurement,#3288bd
18411,European,9813.0,20167578.0,Barbalic M,Soluble levels of adhesion molecules,initial,2010-02-18,GCST000599,Other measurement,#d53e4f
18412,European,740.0,20171287.0,Stein JL,Brain structure,initial,2010-02-17,GCST000597,Other measurement,#d53e4f
18413,European,669.0,20164292.0,Koller DL,Bone mineral density,replication,2010-02-17,GCST000598,Other measurement,#d53e4f
18414,European,1524.0,20164292.0,Koller DL,Bone mineral density,initial,2010-02-17,GCST000598,Other measurement,#d53e4f
18415,European,590.0,20064070.0,Herbeck JT,HIV-1 progression,replication,2010-02-15,GCST000596,Other disease,#d53e4f
18416,European,156.0,20064070.0,Herbeck JT,HIV-1 progression,initial,2010-02-15,GCST000596,Other disease,#d53e4f
18417,European,642.0,20154673.0,Van Deerlin VM,Frontotemporal lobar degeneration,replication,2010-02-14,GCST000595,Neurological disorder,#d53e4f
18418,European,3024.0,20154673.0,Van Deerlin VM,Frontotemporal lobar degeneration,initial,2010-02-14,GCST000595,Neurological disorder,#d53e4f
18421,European,204.0,20159113.0,Jakkula E,Multiple sclerosis,initial,2010-02-12,GCST000593,Immune system disorder,#d53e4f
18423,European,10112.0,20159113.0,Jakkula E,Multiple sclerosis,replication,2010-02-12,GCST000593,Immune system disorder,#d53e4f
18424,Asian,4785.0,20169177.0,Yang W,Systemic lupus erythematosus,replication,2010-02-12,GCST000592,Immune system disorder,#3288bd
18425,Asian,833.0,20169177.0,Yang W,Systemic lupus erythematosus,replication,2010-02-12,GCST000592,Immune system disorder,#3288bd
18426,Asian,1798.0,20169177.0,Yang W,Systemic lupus erythematosus,initial,2010-02-12,GCST000592,Immune system disorder,#3288bd
18427,European,1523.0,20150558.0,He M,Interleukin-18 levels,initial,2010-02-11,GCST000590,Inflammatory measurement,#d53e4f
18428,European,435.0,20150558.0,He M,Interleukin-18 levels,replication,2010-02-11,GCST000590,Inflammatory measurement,#d53e4f
18429,European,3825.0,20152958.0,Xing C,Fasting plasma glucose,replication,2010-02-11,GCST000591,Other measurement,#d53e4f
18430,African Am./Caribbean,1571.0,20152958.0,Xing C,Fasting plasma glucose,replication,2010-02-11,GCST000591,Other measurement,#fee08b
18431,European,7428.0,20152958.0,Xing C,Fasting plasma glucose,initial,2010-02-11,GCST000591,Other measurement,#d53e4f
18432,African Am./Caribbean,2029.0,20152958.0,Xing C,Fasting plasma glucose,initial,2010-02-11,GCST000591,Other measurement,#fee08b
18433,European,9492.0,20139977.0,Codd V,Telomere length,replication,2010-02-07,GCST000586,Other measurement,#d53e4f
18434,European,2917.0,20139977.0,Codd V,Telomere length,initial,2010-02-07,GCST000586,Other measurement,#d53e4f
18435,Asian,14364.0,20139978.0,Kamatani Y,Mean corpuscular volume,initial,2010-02-07,GCST000585,Hematological measurement,#3288bd
18436,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Other measurement,#3288bd
18437,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Liver enzyme measurement,#3288bd
18438,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Liver enzyme measurement,#3288bd
18439,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Hematological measurement,#3288bd
18440,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Liver enzyme measurement,#3288bd
18441,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Liver enzyme measurement,#3288bd
18442,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Hematological measurement,#3288bd
18443,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Cardiovascular measurement,#3288bd
18444,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Other measurement,#3288bd
18445,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Cardiovascular measurement,#3288bd
18446,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Lipid or lipoprotein measurement,#3288bd
18447,Asian,14402.0,20139978.0,Kamatani Y,Hematological and biochemical traits,initial,2010-02-07,GCST000583,Other measurement,#3288bd
18448,Asian,8868.0,20139978.0,Kamatani Y,Urate levels,initial,2010-02-07,GCST000581,Other measurement,#3288bd
18449,Asian,14362.0,20139978.0,Kamatani Y,Mean corpuscular hemoglobin,initial,2010-02-07,GCST000587,Hematological measurement,#3288bd
18450,Asian,14362.0,20139978.0,Kamatani Y,Mean corpuscular hemoglobin,initial,2010-02-07,GCST000587,Hematological measurement,#3288bd
18451,Asian,14806.0,20139978.0,Kamatani Y,Platelet count,initial,2010-02-07,GCST000580,Hematological measurement,#3288bd
18452,Asian,8993.0,20139978.0,Kamatani Y,Triglycerides,initial,2010-02-07,GCST000584,Lipid or lipoprotein measurement,#3288bd
18453,Asian,14377.0,20139978.0,Kamatani Y,Mean corpuscular hemoglobin concentration,initial,2010-02-07,GCST000582,Hematological measurement,#3288bd
18454,Asian,14377.0,20139978.0,Kamatani Y,Mean corpuscular hemoglobin concentration,initial,2010-02-07,GCST000582,Hematological measurement,#3288bd
18455,Asian,14677.0,20139978.0,Kamatani Y,White blood cell count,initial,2010-02-07,GCST000589,Hematological measurement,#3288bd
18456,Asian,14392.0,20139978.0,Kamatani Y,Red blood cell count,initial,2010-02-07,GCST000588,Hematological measurement,#3288bd
18457,Asian,74.0,20125193.0,Cirulli ET,Cognitive performance,initial,2010-02-03,GCST000579,Other measurement,#3288bd
18458,Hispanic/Latin American,7.0,20125193.0,Cirulli ET,Cognitive performance,initial,2010-02-03,GCST000579,Other measurement,#807dba
18459,Asian,167.0,20125193.0,Cirulli ET,Cognitive performance,initial,2010-02-03,GCST000579,Other measurement,#3288bd
18460,European,813.0,20125193.0,Cirulli ET,Cognitive performance,initial,2010-02-03,GCST000579,Other measurement,#d53e4f
18461,European,2656.0,20125088.0,Shi J,Major depressive disorder,initial,2010-02-02,GCST000578,Neurological disorder,#d53e4f
18462,European,3901.0,20159242.0,Li X,Asthma,initial,2010-02-01,GCST000576,Other disease,#d53e4f
18463,European,1040.0,20117844.0,Brynedal B,Multiple sclerosis (severity),initial,2010-02-01,GCST000577,Immune system disorder,#d53e4f
18464,European,873.0,20117844.0,Brynedal B,Multiple sclerosis (severity),replication,2010-02-01,GCST000577,Immune system disorder,#d53e4f
18466,Asian,126.0,20101243.0,Petersen GM,Pancreatic cancer,initial,2010-01-24,GCST000574,Cancer,#3288bd
18467,Other/Mixed,369.0,20101243.0,Petersen GM,Pancreatic cancer,initial,2010-01-24,GCST000574,Cancer,#99d594
18468,European,7416.0,20101243.0,Petersen GM,Pancreatic cancer,initial,2010-01-24,GCST000574,Cancer,#d53e4f
18469,European,733.0,20100581.0,Shen L,Brain imaging,initial,2010-01-22,GCST000573,Other measurement,#d53e4f
18470,Asian,4185.0,20096396.0,Kung AW,Bone mineral density,replication,2010-01-20,GCST000572,Other measurement,#3288bd
18471,European,13913.0,20096396.0,Kung AW,Bone mineral density,replication,2010-01-20,GCST000572,Other measurement,#d53e4f
18472,Asian,785.0,20096396.0,Kung AW,Bone mineral density,initial,2010-01-20,GCST000572,Other measurement,#3288bd
18473,European,62264.0,20081858.0,Dupuis J,Fasting blood insulin,replication,2010-01-17,GCST000571,Other measurement,#d53e4f
18474,European,38238.0,20081858.0,Dupuis J,Fasting blood insulin,initial,2010-01-17,GCST000571,Other measurement,#d53e4f
18475,European,62264.0,20081858.0,Dupuis J,Homeostasis model assessment of beta-cell function,replication,2010-01-17,GCST005180,Other measurement,#d53e4f
18476,European,36466.0,20081858.0,Dupuis J,Homeostasis model assessment of beta-cell function,initial,2010-01-17,GCST005180,Other measurement,#d53e4f
18477,European,62264.0,20081858.0,Dupuis J,Homeostasis model assessment of insulin resistance,replication,2010-01-17,GCST005179,Other measurement,#d53e4f
18478,European,37037.0,20081858.0,Dupuis J,Homeostasis model assessment of insulin resistance,initial,2010-01-17,GCST005179,Other measurement,#d53e4f
18479,European,76558.0,20081858.0,Dupuis J,Fasting blood glucose,replication,2010-01-17,GCST000568,Other measurement,#d53e4f
18480,European,46186.0,20081858.0,Dupuis J,Fasting blood glucose,initial,2010-01-17,GCST000568,Other measurement,#d53e4f
18481,European,30620.0,20081857.0,Saxena R,Two-hour glucose challenge,replication,2010-01-17,GCST000569,Other measurement,#d53e4f
18482,Other/Mixed,15234.0,20081857.0,Saxena R,Two-hour glucose challenge,initial,2010-01-17,GCST000569,Other measurement,#99d594
18483,European,15754.0,20081856.0,McMahon FJ,Major mood disorders,initial,2010-01-17,GCST000570,Neurological disorder,#d53e4f
18484,European,4677.0,20081856.0,McMahon FJ,Major mood disorders,replication,2010-01-17,GCST000570,Neurological disorder,#d53e4f
18485,European,3497.0,20070850.0,Edwards TL,Parkinson's disease,initial,2010-01-13,GCST000567,Neurological disorder,#d53e4f
18486,European,347.0,20068591.0,Van Laer L,Hearing impairment,initial,2010-01-13,GCST000566,Neurological disorder,#d53e4f
18487,Asian,623.0,20066004.0,Chung CM,Angiotensin-converting enzyme activity,replication,2010-01-12,GCST000565,Other measurement,#3288bd
18488,Asian,400.0,20066004.0,Chung CM,Angiotensin-converting enzyme activity,initial,2010-01-12,GCST000565,Other measurement,#3288bd
18489,European,2416.0,20062062.0,Reveille JD,Ankylosing spondylitis,replication,2010-01-10,GCST000563,Immune system disorder,#d53e4f
18490,European,7193.0,20062062.0,Reveille JD,Ankylosing spondylitis,initial,2010-01-10,GCST000563,Immune system disorder,#d53e4f
18491,European,28517.0,20062060.0,Pfeufer A,PR interval,initial,2010-01-10,GCST000562,Cardiovascular measurement,#d53e4f
18492,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18493,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18494,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18495,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18496,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18497,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18498,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18499,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18500,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18501,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18502,European,10352.0,20062063.0,Holm H,Electrocardiographic traits,replication,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18503,European,12670.0,20062063.0,Holm H,Electrocardiographic traits,initial,2010-01-10,GCST000561,Cardiovascular measurement,#d53e4f
18504,Asian,6243.0,20062061.0,Chambers JC,Electrocardiographic traits,replication,2010-01-10,GCST000564,Cardiovascular measurement,#3288bd
18505,Asian,6543.0,20062061.0,Chambers JC,Electrocardiographic traits,initial,2010-01-10,GCST000564,Cardiovascular measurement,#3288bd
18506,European,5370.0,20062061.0,Chambers JC,Electrocardiographic traits,replication,2010-01-10,GCST000564,Cardiovascular measurement,#d53e4f
18507,Asian,700.0,20072603.0,Guo Y,Osteoporosis,initial,2010-01-08,GCST000560,Other disease,#3288bd
18508,Asian,906.0,20072603.0,Guo Y,Osteoporosis,replication,2010-01-08,GCST000560,Other disease,#3288bd
18509,European,656.0,20066028.0,Igl W,Cholesterol,initial,2010-01-08,GCST000559,Lipid or lipoprotein measurement,#d53e4f
18510,European,3282.0,20066028.0,Igl W,Cholesterol,replication,2010-01-08,GCST000559,Lipid or lipoprotein measurement,#d53e4f
18512,Other/Mixed,7397.0,20112360.0,Kerkhof HJ,Osteoarthritis,replication,2010-01-07,GCST000558,Other disease,#99d594
18513,European,41597.0,20112360.0,Kerkhof HJ,Osteoarthritis,replication,2010-01-07,GCST000558,Other disease,#d53e4f
18514,European,4837.0,20112360.0,Kerkhof HJ,Osteoarthritis,initial,2010-01-07,GCST000558,Other disease,#d53e4f
18515,European,1362.0,20060832.0,Rauch A,Chronic hepatitis C infection,initial,2010-01-07,GCST000557,Digestive system disorder,#d53e4f
18516,African Am./Caribbean,6.0,20215924.0,Liu X,Functional MRI,initial,2010-01-01,GCST000556,Other measurement,#fee08b
18517,Other/Mixed,5.0,20215924.0,Liu X,Functional MRI,initial,2010-01-01,GCST000556,Other measurement,#99d594
18518,European,57.0,20215924.0,Liu X,Functional MRI,initial,2010-01-01,GCST000556,Other measurement,#d53e4f
18519,European,177.0,20009918.0,Shrestha S,Carotid atherosclerosis in HIV infection,initial,2010-01-01,GCST000555,Other disease,#d53e4f
18520,European,177.0,20009918.0,Shrestha S,Carotid atherosclerosis in HIV infection,initial,2010-01-01,GCST000555,Cardiovascular measurement,#d53e4f
18521,European,177.0,20009918.0,Shrestha S,Carotid atherosclerosis in HIV infection,initial,2010-01-01,GCST000555,Cardiovascular measurement,#d53e4f
18522,European,177.0,20009918.0,Shrestha S,Carotid atherosclerosis in HIV infection,initial,2010-01-01,GCST000555,Cardiovascular disease,#d53e4f
18523,African Am./Caribbean,644.0,20044523.0,Debette S,Subclinical brain infarct,replication,2009-12-31,GCST000554,Cardiovascular disease,#fee08b
18524,European,1822.0,20044523.0,Debette S,Subclinical brain infarct,replication,2009-12-31,GCST000554,Cardiovascular disease,#d53e4f
18525,European,9401.0,20044523.0,Debette S,Subclinical brain infarct,initial,2009-12-31,GCST000554,Cardiovascular disease,#d53e4f
18526,European,2538.0,20045101.0,Ferreira MA,CD4:CD8 lymphocyte ratio,initial,2009-12-31,GCST000553,Inflammatory measurement,#d53e4f
18527,European,988.0,20045101.0,Ferreira MA,CD4:CD8 lymphocyte ratio,replication,2009-12-31,GCST000553,Inflammatory measurement,#d53e4f
18528,European,1699.0,20038948.0,Papassotiropoulos A,Memory (short-term),replication,2009-12-29,GCST000552,Biological process,#d53e4f
18529,European,333.0,20038948.0,Papassotiropoulos A,Memory (short-term),initial,2009-12-29,GCST000552,Biological process,#d53e4f
18530,European,7385.0,20038947.0,Shyn SI,Major depressive disorder (broad),initial,2009-12-29,GCST000551,Neurological disorder,#d53e4f
18531,European,1202.0,20037589.0,Illig T,Metabolite levels,replication,2009-12-27,GCST000550,Other measurement,#d53e4f
18532,European,1029.0,20037589.0,Illig T,Metabolite levels,initial,2009-12-27,GCST000550,Other measurement,#d53e4f
18533,European,2362.0,20041166.0,Fellay J,HIV-1 control,initial,2009-12-24,GCST000549,Other disease,#d53e4f
18534,European,2781.0,20032318.0,Sleiman PM,Asthma,initial,2009-12-23,GCST000548,Other disease,#d53e4f
18535,African Am./Caribbean,3712.0,20032318.0,Sleiman PM,Asthma,replication,2009-12-23,GCST000548,Other disease,#fee08b
18536,European,2463.0,20032318.0,Sleiman PM,Asthma,replication,2009-12-23,GCST000548,Other disease,#d53e4f
18537,European,655.0,20023658.0,Mangold E,Orofacial clefts,replication,2009-12-20,GCST000547,Other trait,#d53e4f
18538,European,1717.0,20023658.0,Mangold E,Orofacial clefts,initial,2009-12-20,GCST000547,Other trait,#d53e4f
18539,Asian,9209.0,20018961.0,Zhang FR,Leprosy,replication,2009-12-16,GCST000546,Neurological disorder,#3288bd
18540,Asian,1931.0,20018961.0,Zhang FR,Leprosy,initial,2009-12-16,GCST000546,Neurological disorder,#3288bd
18541,Asian,113.0,20018918.0,Solovieff N,Fetal hemoglobin levels,replication,2009-12-16,GCST000545,Hematological measurement,#3288bd
18542,African,305.0,20018918.0,Solovieff N,Fetal hemoglobin levels,replication,2009-12-16,GCST000545,Hematological measurement,#fc8d59
18543,African,848.0,20018918.0,Solovieff N,Fetal hemoglobin levels,initial,2009-12-16,GCST000545,Hematological measurement,#fc8d59
18544,Asian,406.0,20018918.0,Solovieff N,Fetal hemoglobin levels,replication,2009-12-16,GCST000545,Hematological measurement,#3288bd
18545,European,20288.0,20010834.0,Repapi E,Pulmonary function,initial,2009-12-13,GCST000544,Other measurement,#d53e4f
18546,European,54276.0,20010834.0,Repapi E,Pulmonary function,replication,2009-12-13,GCST000544,Other measurement,#d53e4f
18547,European,16178.0,20010835.0,Hancock DB,Pulmonary function,replication,2009-12-13,GCST000542,Other measurement,#d53e4f
18548,European,20890.0,20010835.0,Hancock DB,Pulmonary function,initial,2009-12-13,GCST000542,Other measurement,#d53e4f
18549,European,1462.0,20012890.0,Ronald A,Social and non-social autistic-like traits,initial,2009-12-13,GCST000543,Other measurement,#d53e4f
18550,European,3494.0,20012890.0,Ronald A,Social and non-social autistic-like traits,replication,2009-12-13,GCST000543,Other measurement,#d53e4f
18551,European,1488.0,20175129.0,Zhao LJ,Femoral neck bone geometry,replication,2009-12-11,GCST000541,Other measurement,#d53e4f
18552,Asian,2118.0,20175129.0,Zhao LJ,Femoral neck bone geometry,replication,2009-12-11,GCST000541,Other measurement,#3288bd
18553,European,987.0,20175129.0,Zhao LJ,Femoral neck bone geometry,initial,2009-12-11,GCST000541,Other measurement,#d53e4f
18554,European,651.0,19961619.0,Castro-Giner F,Atopy,replication,2009-12-06,GCST000540,Immune system disorder,#d53e4f
18555,European,225.0,19961619.0,Castro-Giner F,Atopy,initial,2009-12-06,GCST000540,Immune system disorder,#d53e4f
18556,European,13276.0,19966805.0,Wallace C,Type 1 diabetes,replication,2009-12-06,GCST000539,Metabolic disorder,#d53e4f
18557,European,16559.0,19966805.0,Wallace C,Type 1 diabetes,initial,2009-12-06,GCST000539,Metabolic disorder,#d53e4f
18558,European,6202.0,20011104.0,Richards JB,Adiponectin levels,replication,2009-12-05,GCST000538,Other measurement,#d53e4f
18559,European,8531.0,20011104.0,Richards JB,Adiponectin levels,initial,2009-12-05,GCST000538,Other measurement,#d53e4f
18560,European,4659.0,20018283.0,Heid IM,Adiponectin levels,initial,2009-12-02,GCST000537,Other measurement,#d53e4f
18561,European,13795.0,20018283.0,Heid IM,Adiponectin levels,replication,2009-12-02,GCST000537,Other measurement,#d53e4f
18562,Asian,60.0,19954339.0,Yin CS,Sasang constitutional medicine type,initial,2009-12-01,GCST000536,Other trait,#3288bd
18563,Asian,690.0,19950302.0,Zhou X,Systemic sclerosis,initial,2009-11-30,GCST000535,Neurological disorder,#3288bd
18564,European,3854.0,19950302.0,Zhou X,Systemic sclerosis,replication,2009-11-30,GCST000535,Neurological disorder,#d53e4f
18565,European,3701.0,19944697.0,Karlsen TH,Primary sclerosing cholangitis,replication,2009-11-25,GCST000534,Digestive system disorder,#d53e4f
18566,European,583.0,19944697.0,Karlsen TH,Primary sclerosing cholangitis,initial,2009-11-25,GCST000534,Digestive system disorder,#d53e4f
18568,European,2000.0,19936222.0,Chasman DI,Lipid metabolism phenotypes,replication,2009-11-20,GCST000533,Other measurement,#d53e4f
18569,European,17296.0,19936222.0,Chasman DI,Lipid metabolism phenotypes,initial,2009-11-20,GCST000533,Other measurement,#d53e4f
18570,Asian,174.0,20183929.0,Nuinoon M,Beta thalassemia/hemoglobin E disease,replication,2009-11-19,GCST000532,Other disease,#3288bd
18571,Asian,618.0,20183929.0,Nuinoon M,Beta thalassemia/hemoglobin E disease,initial,2009-11-19,GCST000532,Other disease,#3288bd
18572,European,7934.0,19915575.0,Simon-Sanchez J,Parkinson's disease,replication,2009-11-15,GCST000528,Neurological disorder,#d53e4f
18573,European,5691.0,19915575.0,Simon-Sanchez J,Parkinson's disease,initial,2009-11-15,GCST000528,Neurological disorder,#d53e4f
18574,European,8571.0,19915574.0,Imielinski M,Inflammatory bowel disease (early onset),initial,2009-11-15,GCST000531,Digestive system disorder,#d53e4f
18575,European,6818.0,19915574.0,Imielinski M,Inflammatory bowel disease (early onset),replication,2009-11-15,GCST000531,Digestive system disorder,#d53e4f
18576,European,7139.0,19915572.0,Barrett JC,Ulcerative colitis,replication,2009-11-15,GCST000527,Immune system disorder,#d53e4f
18577,European,7778.0,19915572.0,Barrett JC,Ulcerative colitis,initial,2009-11-15,GCST000527,Immune system disorder,#d53e4f
18578,Asian,1310.0,19915573.0,Asano K,Ulcerative colitis,initial,2009-11-15,GCST000529,Immune system disorder,#3288bd
18579,Asian,1473.0,19915573.0,Asano K,Ulcerative colitis,replication,2009-11-15,GCST000529,Immune system disorder,#3288bd
18580,Asian,3509.0,19915576.0,Satake W,Parkinson's disease,initial,2009-11-15,GCST000530,Neurological disorder,#3288bd
18581,Asian,16686.0,19915576.0,Satake W,Parkinson's disease,replication,2009-11-15,GCST000530,Neurological disorder,#3288bd
18582,European,1954.0,20039944.0,Docherty SJ,Mathematical ability,replication,2009-11-10,GCST000524,Biological process,#d53e4f
18583,European,1200.0,20039944.0,Docherty SJ,Mathematical ability,initial,2009-11-10,GCST000524,Biological process,#d53e4f
18584,African Am./Caribbean,1864.0,19910028.0,Mathias RA,Asthma,initial,2009-11-10,GCST000525,Other disease,#fee08b
18585,European,2237.0,19910028.0,Mathias RA,Asthma,replication,2009-11-10,GCST000525,Other disease,#d53e4f
18586,African Am./Caribbean,5205.0,19910028.0,Mathias RA,Asthma,replication,2009-11-10,GCST000525,Other disease,#fee08b
18587,Hispanic/Latin American,229.0,19902172.0,Palmer ND,Insulin-related traits,initial,2009-11-10,GCST000526,Other measurement,#807dba
18588,Hispanic/Latin American,814.0,19902172.0,Palmer ND,Insulin-related traits,replication,2009-11-10,GCST000526,Other measurement,#807dba
18589,European,315.0,19901119.0,Trevino LR,Methotrexate phramacokinetics (acute lymphoblastic leukemia),initial,2009-11-09,GCST000523,Response to drug,#d53e4f
18590,Asian,5.0,19901119.0,Trevino LR,Methotrexate phramacokinetics (acute lymphoblastic leukemia),initial,2009-11-09,GCST000523,Response to drug,#3288bd
18592,African Am./Caribbean,73.0,19901119.0,Trevino LR,Methotrexate phramacokinetics (acute lymphoblastic leukemia),initial,2009-11-09,GCST000523,Response to drug,#fee08b
18593,Other/Mixed,41.0,19901119.0,Trevino LR,Methotrexate phramacokinetics (acute lymphoblastic leukemia),initial,2009-11-09,GCST000523,Response to drug,#99d594
18594,Asian,8842.0,19893584.0,Kim JJ,Height,initial,2009-11-06,GCST000522,Body measurement,#3288bd
18595,European,1255.0,19897590.0,Schaefer AS,Periodontitis,initial,2009-11-06,GCST000521,Digestive system disorder,#d53e4f
18596,European,496.0,19897590.0,Schaefer AS,Periodontitis,replication,2009-11-06,GCST000521,Digestive system disorder,#d53e4f
18597,European,76.0,19890347.0,Birlea SA,Vitiligo,initial,2009-11-05,GCST000520,Immune system disorder,#d53e4f
18598,European,20985.0,19896111.0,Medland SE,Hair morphology,initial,2009-11-04,GCST000519,Other trait,#d53e4f
18599,European,1096.0,19929986.0,Craig DW,End-stage renal disease,initial,2009-11-01,GCST000518,Other disease,#d53e4f
18600,European,6292.0,19838195.0,Gateva V,Systemic lupus erythematosus,replication,2009-11-01,GCST004867,Immune system disorder,#d53e4f
18601,European,9169.0,19838195.0,Gateva V,Systemic lupus erythematosus,initial,2009-11-01,GCST004867,Immune system disorder,#d53e4f
18603,European,1919.0,19880490.0,Tanaka T,Iron levels,initial,2009-10-30,GCST000517,Other measurement,#d53e4f
18604,European,2557.0,19874204.0,Guo Y,Bone mineral density,replication,2009-10-29,GCST000515,Other measurement,#d53e4f
18605,European,983.0,19874204.0,Guo Y,Bone mineral density,initial,2009-10-29,GCST000515,Other measurement,#d53e4f
18606,European,1304.0,19875614.0,Paterson AD,Glycemic control in type 1 diabetes (HbA1c),initial,2009-10-29,GCST000516,Other measurement,#d53e4f
18607,European,1382.0,19875614.0,Paterson AD,Glycemic control in type 1 diabetes (HbA1c),replication,2009-10-29,GCST000516,Other measurement,#d53e4f
18608,African Am./Caribbean,214.0,19875103.0,Aberg K,Response to antipsychotic therapy (extrapyramidal side effects),initial,2009-10-27,GCST000514,Response to drug,#fee08b
18609,European,421.0,19875103.0,Aberg K,Response to antipsychotic therapy (extrapyramidal side effects),initial,2009-10-27,GCST000514,Response to drug,#d53e4f
18610,Other/Mixed,103.0,19875103.0,Aberg K,Response to antipsychotic therapy (extrapyramidal side effects),initial,2009-10-27,GCST000514,Response to drug,#99d594
18611,African Am./Caribbean,1265.0,20029952.0,Sebastiani P,Sickle cell anemia (severity),initial,2009-10-23,GCST000513,Neurological disorder,#fee08b
18612,African Am./Caribbean,163.0,20029952.0,Sebastiani P,Sickle cell anemia (severity),replication,2009-10-23,GCST000513,Neurological disorder,#fee08b
18613,European,3925.0,19851299.0,Johansson A,Weight,initial,2009-10-22,GCST000511,Body measurement,#d53e4f
18615,European,2538.0,19853236.0,Ferreira MA,White blood cell count,initial,2009-10-22,GCST008419,Hematological measurement,#d53e4f
18616,European,1543.0,19853236.0,Ferreira MA,White blood cell count,replication,2009-10-22,GCST008419,Hematological measurement,#d53e4f
18617,European,2538.0,19853236.0,Ferreira MA,Red blood cell count,initial,2009-10-22,GCST008426,Hematological measurement,#d53e4f
18619,European,1543.0,19853236.0,Ferreira MA,Red blood cell count,replication,2009-10-22,GCST008426,Hematological measurement,#d53e4f
18620,European,2538.0,19853236.0,Ferreira MA,Neutrophil count,initial,2009-10-22,GCST008425,Hematological measurement,#d53e4f
18622,European,1543.0,19853236.0,Ferreira MA,Neutrophil count,replication,2009-10-22,GCST008425,Hematological measurement,#d53e4f
18623,European,2538.0,19853236.0,Ferreira MA,Monocyte count,initial,2009-10-22,GCST008421,Hematological measurement,#d53e4f
18624,European,1543.0,19853236.0,Ferreira MA,Monocyte count,replication,2009-10-22,GCST008421,Hematological measurement,#d53e4f
18626,European,2538.0,19853236.0,Ferreira MA,Mean corpuscular volume,initial,2009-10-22,GCST008420,Hematological measurement,#d53e4f
18628,European,1543.0,19853236.0,Ferreira MA,Mean corpuscular volume,replication,2009-10-22,GCST008420,Hematological measurement,#d53e4f
18629,European,2538.0,19853236.0,Ferreira MA,Mean corpuscular hemoglobin concentration,initial,2009-10-22,GCST008418,Hematological measurement,#d53e4f
18631,European,1543.0,19853236.0,Ferreira MA,Mean corpuscular hemoglobin concentration,replication,2009-10-22,GCST008418,Hematological measurement,#d53e4f
18632,European,2538.0,19853236.0,Ferreira MA,Mean corpuscular hemoglobin,initial,2009-10-22,GCST008432,Hematological measurement,#d53e4f
18634,European,1543.0,19853236.0,Ferreira MA,Mean corpuscular hemoglobin,replication,2009-10-22,GCST008432,Hematological measurement,#d53e4f
18636,European,2538.0,19853236.0,Ferreira MA,Lymphocyte counts,initial,2009-10-22,GCST008431,Hematological measurement,#d53e4f
18637,European,1543.0,19853236.0,Ferreira MA,Lymphocyte counts,replication,2009-10-22,GCST008431,Hematological measurement,#d53e4f
18638,European,2538.0,19853236.0,Ferreira MA,Hematocrit,initial,2009-10-22,GCST008430,Hematological measurement,#d53e4f
18640,European,1543.0,19853236.0,Ferreira MA,Hematocrit,replication,2009-10-22,GCST008430,Hematological measurement,#d53e4f
18641,European,2538.0,19853236.0,Ferreira MA,Hemoglobin levels,initial,2009-10-22,GCST008429,Hematological measurement,#d53e4f
18643,European,1543.0,19853236.0,Ferreira MA,Hemoglobin levels,replication,2009-10-22,GCST008429,Hematological measurement,#d53e4f
18644,European,1543.0,19853236.0,Ferreira MA,Eosinophil counts,replication,2009-10-22,GCST008428,Hematological measurement,#d53e4f
18646,European,2538.0,19853236.0,Ferreira MA,Eosinophil counts,initial,2009-10-22,GCST008428,Hematological measurement,#d53e4f
18647,European,1543.0,19853236.0,Ferreira MA,Basophil count,replication,2009-10-22,GCST008427,Inflammatory measurement,#d53e4f
18649,European,2538.0,19853236.0,Ferreira MA,Basophil count,initial,2009-10-22,GCST008427,Inflammatory measurement,#d53e4f
18650,European,3925.0,19851299.0,Johansson A,Body mass index,initial,2009-10-22,GCST000512,Body measurement,#d53e4f
18651,European,1543.0,19853236.0,Ferreira MA,Platelet count,replication,2009-10-22,GCST000510,Hematological measurement,#d53e4f
18653,European,2538.0,19853236.0,Ferreira MA,Platelet count,initial,2009-10-22,GCST000510,Hematological measurement,#d53e4f
18654,Asian,37.0,19850125.0,Kim HJ,Neuromyelitis optica,replication,2009-10-19,GCST000508,Immune system disorder,#3288bd
18655,Asian,293.0,19850125.0,Kim HJ,Neuromyelitis optica,initial,2009-10-19,GCST000508,Immune system disorder,#3288bd
18656,European,1067.0,19846067.0,Garriock HA,Response to citalopram treatment,initial,2009-10-19,GCST000509,Response to drug,#d53e4f
18657,African Am./Caribbean,241.0,19846067.0,Garriock HA,Response to citalopram treatment,initial,2009-10-19,GCST000509,Response to drug,#fee08b
18658,Hispanic/Latin American,183.0,19846067.0,Garriock HA,Response to citalopram treatment,initial,2009-10-19,GCST000509,Response to drug,#807dba
18659,Asian,10202.0,19838193.0,Han JW,Systemic lupus erythematosus,replication,2009-10-18,GCST000507,Immune system disorder,#3288bd
18660,Asian,2252.0,19838193.0,Han JW,Systemic lupus erythematosus,initial,2009-10-18,GCST000507,Immune system disorder,#3288bd
18661,European,11587.0,19836008.0,Landi MT,Lung adenocarcinoma,initial,2009-10-15,GCST000506,Cancer,#d53e4f
18662,European,21379.0,19836008.0,Landi MT,Lung adenocarcinoma,replication,2009-10-15,GCST000506,Cancer,#d53e4f
18663,European,9456.0,19862010.0,Ganesh SK,Mean corpuscular hemoglobin,replication,2009-10-11,GCST000504,Hematological measurement,#d53e4f
18664,European,24167.0,19862010.0,Ganesh SK,Mean corpuscular hemoglobin,initial,2009-10-11,GCST000504,Hematological measurement,#d53e4f
18665,European,4627.0,19820697.0,Soranzo N,Hematological parameters,initial,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18666,European,9316.0,19820697.0,Soranzo N,Hematological parameters,replication,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18667,European,4627.0,19820697.0,Soranzo N,Hematological parameters,initial,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18668,European,9316.0,19820697.0,Soranzo N,Hematological parameters,replication,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18669,European,4627.0,19820697.0,Soranzo N,Hematological parameters,initial,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18670,European,9316.0,19820697.0,Soranzo N,Hematological parameters,replication,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18671,European,4627.0,19820697.0,Soranzo N,Hematological parameters,initial,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18672,European,9316.0,19820697.0,Soranzo N,Hematological parameters,replication,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18673,European,4627.0,19820697.0,Soranzo N,Hematological parameters,initial,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18674,European,9316.0,19820697.0,Soranzo N,Hematological parameters,replication,2009-10-11,GCST000498,Hematological measurement,#d53e4f
18675,European,9316.0,19820697.0,Soranzo N,Mean platelet volume,replication,2009-10-11,GCST000497,Hematological measurement,#d53e4f
18676,European,4627.0,19820697.0,Soranzo N,Mean platelet volume,initial,2009-10-11,GCST000497,Hematological measurement,#d53e4f
18677,European,9456.0,19862010.0,Ganesh SK,Other erythrocyte phenotypes,replication,2009-10-11,GCST000500,Hematological measurement,#d53e4f
18678,European,24167.0,19862010.0,Ganesh SK,Other erythrocyte phenotypes,initial,2009-10-11,GCST000500,Hematological measurement,#d53e4f
18679,European,9456.0,19862010.0,Ganesh SK,Other erythrocyte phenotypes,replication,2009-10-11,GCST000500,Hematological measurement,#d53e4f
18680,European,24167.0,19862010.0,Ganesh SK,Other erythrocyte phenotypes,initial,2009-10-11,GCST000500,Hematological measurement,#d53e4f
18681,European,24167.0,19862010.0,Ganesh SK,Hemoglobin,initial,2009-10-11,GCST000499,Hematological measurement,#d53e4f
18682,European,9456.0,19862010.0,Ganesh SK,Hemoglobin,replication,2009-10-11,GCST000499,Hematological measurement,#d53e4f
18683,European,24167.0,19862010.0,Ganesh SK,Mean corpuscular volume,initial,2009-10-11,GCST000503,Hematological measurement,#d53e4f
18684,European,9456.0,19862010.0,Ganesh SK,Mean corpuscular volume,replication,2009-10-11,GCST000503,Hematological measurement,#d53e4f
18685,European,24167.0,19862010.0,Ganesh SK,Hematocrit,initial,2009-10-11,GCST000502,Hematological measurement,#d53e4f
18686,European,9456.0,19862010.0,Ganesh SK,Hematocrit,replication,2009-10-11,GCST000502,Hematological measurement,#d53e4f
18687,European,6316.0,19820698.0,Chambers JC,Hemoglobin,initial,2009-10-11,GCST000501,Hematological measurement,#d53e4f
18688,Asian,9685.0,19820698.0,Chambers JC,Hemoglobin,initial,2009-10-11,GCST000501,Hematological measurement,#3288bd
18689,European,5187.0,19820698.0,Chambers JC,Hemoglobin,replication,2009-10-11,GCST000501,Hematological measurement,#d53e4f
18690,Asian,6721.0,19820698.0,Chambers JC,Hemoglobin,replication,2009-10-11,GCST000501,Hematological measurement,#3288bd
18691,European,3470.0,19820699.0,Benyamin B,Iron status biomarkers,replication,2009-10-11,GCST000505,Other measurement,#d53e4f
18692,European,4818.0,19820699.0,Benyamin B,Iron status biomarkers,initial,2009-10-11,GCST000505,Other measurement,#d53e4f
18694,Other/Mixed,5265.0,19812673.0,Weiss LA,Autism,replication,2009-10-08,GCST000496,Neurological disorder,#99d594
18695,Other/Mixed,1553.0,19812673.0,Weiss LA,Autism,initial,2009-10-08,GCST000496,Neurological disorder,#99d594
18696,European,19195.0,19801982.0,Rivadeneira F,Bone mineral density (hip),initial,2009-10-04,GCST000495,Other measurement,#d53e4f
18697,European,19195.0,19801982.0,Rivadeneira F,Bone mineral density (spine),initial,2009-10-04,GCST000494,Other measurement,#d53e4f
18698,European,4110.0,19798445.0,Hicks AA,Sphingolipid levels,initial,2009-10-02,GCST000493,Lipid or lipoprotein measurement,#d53e4f
18699,European,186.0,19786962.0,Roeske D,Speech perception in dyslexia,replication,2009-09-29,GCST000492,Biological process,#d53e4f
18700,European,200.0,19786962.0,Roeske D,Speech perception in dyslexia,initial,2009-09-29,GCST000492,Biological process,#d53e4f
18701,Asian,1510.0,19779542.0,Nakanishi H,Myopia (pathological),replication,2009-09-25,GCST000491,Other trait,#3288bd
18702,Asian,1231.0,19779542.0,Nakanishi H,Myopia (pathological),initial,2009-09-25,GCST000491,Other trait,#3288bd
18704,European,747.0,19772629.0,Latourelle JC,Parkinson's disease (age of onset),replication,2009-09-22,GCST000490,Neurological disorder,#d53e4f
18705,European,857.0,19772629.0,Latourelle JC,Parkinson's disease (age of onset),initial,2009-09-22,GCST000490,Neurological disorder,#d53e4f
18707,European,747.0,19772629.0,Latourelle JC,Parkinson's disease (age of onset),replication,2009-09-22,GCST000490,Other measurement,#d53e4f
18708,European,857.0,19772629.0,Latourelle JC,Parkinson's disease (age of onset),initial,2009-09-22,GCST000490,Other measurement,#d53e4f
18709,European,3748.0,19767753.0,Eeles RA,Prostate cancer,initial,2009-09-20,GCST000488,Cancer,#d53e4f
18710,Other/Mixed,38640.0,19767753.0,Eeles RA,Prostate cancer,replication,2009-09-20,GCST000488,Cancer,#99d594
18711,European,24193.0,19767754.0,Gudmundsson J,Prostate cancer,replication,2009-09-20,GCST000489,Cancer,#d53e4f
18712,European,37350.0,19767754.0,Gudmundsson J,Prostate cancer,initial,2009-09-20,GCST000489,Cancer,#d53e4f
18713,European,2134.0,19754311.0,Le Clerc S,AIDS,initial,2009-09-15,GCST000487,Immune system disorder,#d53e4f
18714,Asian,172.0,19749757.0,Tanaka Y,Response to hepatitis C treatment,replication,2009-09-13,GCST000486,Digestive system disorder,#3288bd
18715,Asian,142.0,19749757.0,Tanaka Y,Response to hepatitis C treatment,initial,2009-09-13,GCST000486,Digestive system disorder,#3288bd
18716,European,555.0,19749758.0,Suppiah V,Response to hepatitis C treatment,replication,2009-09-13,GCST000485,Digestive system disorder,#d53e4f
18717,European,293.0,19749758.0,Suppiah V,Response to hepatitis C treatment,initial,2009-09-13,GCST000485,Digestive system disorder,#d53e4f
18718,European,699.0,20061627.0,Heinzen EL,Alzheimer's disease,initial,2009-09-11,GCST000484,Neurological disorder,#d53e4f
18719,European,4763.0,19744961.0,Hazra A,Folate pathway vitamin levels,initial,2009-09-10,GCST000483,Other measurement,#d53e4f
18720,European,547.0,19740415.0,Sha Q,Amyotrophic lateral sclerosis (SNP x SNP interaction),initial,2009-09-09,GCST000482,Neurological disorder,#d53e4f
18721,European,11336.0,19734901.0,van Es MA,Amyotrophic lateral sclerosis,initial,2009-09-06,GCST000481,Neurological disorder,#d53e4f
18722,European,8472.0,19734901.0,van Es MA,Amyotrophic lateral sclerosis,replication,2009-09-06,GCST000481,Neurological disorder,#d53e4f
18723,European,7275.0,19734903.0,Lambert JC,Alzheimer's disease,replication,2009-09-06,GCST000480,Neurological disorder,#d53e4f
18724,European,7360.0,19734903.0,Lambert JC,Alzheimer's disease,initial,2009-09-06,GCST000480,Neurological disorder,#d53e4f
18725,European,12676.0,19734900.0,Rung J,Type 2 diabetes,replication,2009-09-06,GCST000478,Metabolic disorder,#d53e4f
18726,European,1376.0,19734900.0,Rung J,Type 2 diabetes,initial,2009-09-06,GCST000478,Metabolic disorder,#d53e4f
18727,European,4363.0,19734902.0,Harold D,Alzheimer's disease,replication,2009-09-06,GCST000479,Neurological disorder,#d53e4f
18728,European,11789.0,19734902.0,Harold D,Alzheimer's disease,initial,2009-09-06,GCST000479,Neurological disorder,#d53e4f
18729,European,958.0,19734545.0,Need AC,Cognitive performance,initial,2009-09-04,GCST000477,Other measurement,#d53e4f
18730,Asian,207.0,19734545.0,Need AC,Cognitive performance,initial,2009-09-04,GCST000477,Other measurement,#3288bd
18731,Asian,104.0,19734545.0,Need AC,Cognitive performance,initial,2009-09-04,GCST000477,Other measurement,#3288bd
18733,European,477.0,19729612.0,Paterson AD,Soluble E-selectin levels,replication,2009-09-03,GCST000476,Inflammatory measurement,#d53e4f
18734,European,685.0,19729612.0,Paterson AD,Soluble E-selectin levels,initial,2009-09-03,GCST000476,Inflammatory measurement,#d53e4f
18735,European,5758.0,19729412.0,Tonjes A,Height,replication,2009-09-03,GCST000475,Body measurement,#d53e4f
18736,European,929.0,19729412.0,Tonjes A,Height,initial,2009-09-03,GCST000475,Body measurement,#d53e4f
18737,European,2622.0,19727025.0,De Moor MH,Leisure-time exercise behaviour,initial,2009-09-02,GCST000474,Biological process,#d53e4f
18738,European,1198.0,19736353.0,Ising M,Response to antidepressant treatment,replication,2009-09-01,GCST000471,Response to drug,#d53e4f
18739,European,700.0,19736353.0,Ising M,Response to antidepressant treatment,initial,2009-09-01,GCST000471,Response to drug,#d53e4f
18740,European,2649.0,19723657.0,Spain SL,Colorectal cancer,replication,2009-09-01,GCST000472,Cancer,#d53e4f
18741,European,1850.0,19723657.0,Spain SL,Colorectal cancer,initial,2009-09-01,GCST000472,Cancer,#d53e4f
18742,Other/Mixed,244.0,19721433.0,McClay JL,Response to antipsychotic treatment,initial,2009-09-01,GCST000473,Response to drug,#99d594
18743,European,494.0,19721433.0,McClay JL,Response to antipsychotic treatment,initial,2009-09-01,GCST000473,Response to drug,#d53e4f
18744,Other/Mixed,1682.0,19724244.0,Laje G,Response to antidepressant treatment,replication,2009-08-31,GCST000470,Response to drug,#99d594
18745,Other/Mixed,180.0,19724244.0,Laje G,Response to antidepressant treatment,initial,2009-08-31,GCST000470,Response to drug,#99d594
18746,Hispanic/Latin American,531.0,19714205.0,Hancock DB,Asthma (childhood onset),replication,2009-08-28,GCST000468,Other disease,#807dba
18747,Hispanic/Latin American,1476.0,19714205.0,Hancock DB,Asthma (childhood onset),initial,2009-08-28,GCST000468,Other disease,#807dba
18748,European,1000.0,19714249.0,Liu YZ,Obesity and osteoporosis,initial,2009-08-28,GCST000469,Metabolic disorder,#d53e4f
18749,European,3355.0,19714249.0,Liu YZ,Obesity and osteoporosis,replication,2009-08-28,GCST000469,Metabolic disorder,#d53e4f
18750,European,1000.0,19714249.0,Liu YZ,Obesity and osteoporosis,initial,2009-08-28,GCST000469,Other disease,#d53e4f
18751,European,3355.0,19714249.0,Liu YZ,Obesity and osteoporosis,replication,2009-08-28,GCST000469,Other disease,#d53e4f
18752,Other/Mixed,4.0,19706858.0,Shuldiner AR,Response to clopidogrel therapy,replication,2009-08-26,GCST000467,Response to drug,#99d594
18753,African Am./Caribbean,83.0,19706858.0,Shuldiner AR,Response to clopidogrel therapy,replication,2009-08-26,GCST000467,Response to drug,#fee08b
18754,European,140.0,19706858.0,Shuldiner AR,Response to clopidogrel therapy,replication,2009-08-26,GCST000467,Response to drug,#d53e4f
18755,European,429.0,19706858.0,Shuldiner AR,Response to clopidogrel therapy,initial,2009-08-26,GCST000467,Response to drug,#d53e4f
18756,Asian,2680.0,19698717.0,Cui R,Esophageal cancer,replication,2009-08-18,GCST000466,Cancer,#3288bd
18757,Asian,1109.0,19698717.0,Cui R,Esophageal cancer,initial,2009-08-18,GCST000466,Cancer,#3288bd
18758,Hispanic/Latin American,75.0,19684573.0,Ge D,Response to hepatitis C treatment,initial,2009-08-16,GCST000465,Digestive system disorder,#807dba
18759,African Am./Caribbean,191.0,19684573.0,Ge D,Response to hepatitis C treatment,initial,2009-08-16,GCST000465,Digestive system disorder,#fee08b
18760,European,871.0,19684573.0,Ge D,Response to hepatitis C treatment,initial,2009-08-16,GCST000465,Digestive system disorder,#d53e4f
18761,European,19275.0,19684603.0,Trevino LR,Acute lymphoblastic leukemia (childhood),initial,2009-08-16,GCST000464,Cancer,#d53e4f
18762,European,3305.0,19684604.0,Papaemmanuil E,Acute lymphoblastic leukemia (childhood),initial,2009-08-16,GCST000463,Cancer,#d53e4f
18763,Other/Mixed,11.0,19680635.0,Alkelai A,Response to antipsychotic treatment,initial,2009-08-13,GCST000462,Response to drug,#99d594
18764,European,257.0,19680635.0,Alkelai A,Response to antipsychotic treatment,initial,2009-08-13,GCST000462,Response to drug,#d53e4f
18765,African Am./Caribbean,129.0,19680635.0,Alkelai A,Response to antipsychotic treatment,initial,2009-08-13,GCST000462,Response to drug,#fee08b
18766,Other/Mixed,2.0,19668339.0,Potkin SG,Hippocampal atrophy,initial,2009-08-07,GCST000461,Neurological disorder,#99d594
18767,African Am./Caribbean,21.0,19668339.0,Potkin SG,Hippocampal atrophy,initial,2009-08-07,GCST000461,Neurological disorder,#fee08b
18768,Asian,4.0,19668339.0,Potkin SG,Hippocampal atrophy,initial,2009-08-07,GCST000461,Neurological disorder,#3288bd
18769,European,354.0,19668339.0,Potkin SG,Hippocampal atrophy,initial,2009-08-07,GCST000461,Neurological disorder,#d53e4f
18770,Asian,2275.0,19664746.0,Tse KP,Nasopharyngeal carcinoma,replication,2009-08-05,GCST000460,Cancer,#3288bd
18771,Asian,562.0,19664746.0,Tse KP,Nasopharyngeal carcinoma,initial,2009-08-05,GCST000460,Cancer,#3288bd
18773,European,5470.0,19654303.0,Broderick P,Lung cancer,replication,2009-08-04,GCST000459,Cancer,#d53e4f
18774,European,3390.0,19654303.0,Broderick P,Lung cancer,initial,2009-08-04,GCST000459,Cancer,#d53e4f
18775,European,6062.0,19656524.0,Grant SF,Orofacial clefts,initial,2009-08-03,GCST000458,Other trait,#d53e4f
18776,European,4462.0,19651812.0,Chambers JC,Fasting plasma glucose,replication,2009-08-03,GCST000457,Other measurement,#d53e4f
18777,Asian,7474.0,19651812.0,Chambers JC,Fasting plasma glucose,initial,2009-08-03,GCST000457,Other measurement,#3288bd
18778,European,16421.0,19648919.0,Song H,Ovarian cancer,replication,2009-08-02,GCST000455,Cancer,#d53e4f
18779,European,4170.0,19648919.0,Song H,Ovarian cancer,initial,2009-08-02,GCST000455,Cancer,#d53e4f
18780,European,4247.0,19648918.0,Amundadottir L,Pancreatic cancer,replication,2009-08-02,GCST000456,Cancer,#d53e4f
18781,European,3576.0,19648918.0,Amundadottir L,Pancreatic cancer,initial,2009-08-02,GCST000456,Cancer,#d53e4f
18782,European,1926.0,19648920.0,Wu X,Bladder cancer,initial,2009-08-02,GCST000454,Cancer,#d53e4f
18783,European,44331.0,19648920.0,Wu X,Bladder cancer,replication,2009-08-02,GCST000454,Cancer,#d53e4f
18784,European,2325.0,20031603.0,Marroni F,QT interval,initial,2009-08-01,GCST000452,Cardiovascular measurement,#d53e4f
18785,European,94.0,19667218.0,Comabella M,Response to interferon beta therapy,replication,2009-08-01,GCST000453,Response to drug,#d53e4f
18786,European,106.0,19667218.0,Comabella M,Response to interferon beta therapy,initial,2009-08-01,GCST000453,Response to drug,#d53e4f
18787,European,778.0,20031604.0,Cheng YC,Matrix metalloproteinase levels,initial,2009-08-01,GCST000450,Other measurement,#d53e4f
18788,European,2325.0,20031603.0,Marroni F,RR interval (heart rate),initial,2009-08-01,GCST000451,Cardiovascular measurement,#d53e4f
18789,Asian,857.0,19625618.0,Nakano M,Glaucoma (primary open-angle),replication,2009-07-22,GCST000449,Neurological disorder,#3288bd
18790,Asian,718.0,19625618.0,Nakano M,Glaucoma (primary open-angle),initial,2009-07-22,GCST000449,Neurological disorder,#3288bd
18791,European,3241.0,19620980.0,Skibola CF,Follicular lymphoma,replication,2009-07-20,GCST000448,Cancer,#d53e4f
18792,European,781.0,19620980.0,Skibola CF,Follicular lymphoma,initial,2009-07-20,GCST000448,Cancer,#d53e4f
18793,African,980.0,19609347.0,Adeyemo A,Hypertension,replication,2009-07-17,GCST000447,Cardiovascular disease,#fc8d59
18794,African Am./Caribbean,1017.0,19609347.0,Adeyemo A,Hypertension,initial,2009-07-17,GCST000447,Cardiovascular disease,#fee08b
18795,European,6218.0,19597492.0,Benjamin EJ,Atrial fibrillation,replication,2009-07-13,GCST000445,Cardiovascular disease,#d53e4f
18796,European,40518.0,19597492.0,Benjamin EJ,Atrial fibrillation,initial,2009-07-13,GCST000445,Cardiovascular disease,#d53e4f
18797,Asian,3049.0,19597491.0,Gudbjartsson DF,Atrial fibrillation,replication,2009-07-13,GCST000446,Cardiovascular disease,#3288bd
18798,European,5806.0,19597491.0,Gudbjartsson DF,Atrial fibrillation,replication,2009-07-13,GCST000446,Cardiovascular disease,#d53e4f
18799,European,36137.0,19597491.0,Gudbjartsson DF,Atrial fibrillation,initial,2009-07-13,GCST000446,Cardiovascular disease,#d53e4f
18800,European,29527.0,19587794.0,Nolte IM,QT interval,replication,2009-07-09,GCST000444,Cardiovascular measurement,#d53e4f
18801,European,3558.0,19587794.0,Nolte IM,QT interval,initial,2009-07-09,GCST000444,Cardiovascular measurement,#d53e4f
18802,European,4094.0,19584346.0,Vasan RS,Aortic root size,replication,2009-07-08,GCST000442,Cardiovascular measurement,#d53e4f
18803,European,12612.0,19584346.0,Vasan RS,Aortic root size,initial,2009-07-08,GCST000442,Cardiovascular measurement,#d53e4f
18804,European,948.0,19584900.0,Tonjes A,Body mass index and fat mass,initial,2009-07-08,GCST000443,Other measurement,#d53e4f
18805,European,948.0,19584900.0,Tonjes A,Body mass index and fat mass,initial,2009-07-08,GCST000443,Body measurement,#d53e4f
18806,European,4094.0,19584346.0,Vasan RS,Cardiac structure and function,replication,2009-07-08,GCST000441,Other measurement,#d53e4f
18807,European,12612.0,19584346.0,Vasan RS,Cardiac structure and function,initial,2009-07-08,GCST000441,Other measurement,#d53e4f
18808,Other/Mixed,2.0,19578366.0,Wrensch M,Glioma (high-grade),replication,2009-07-05,GCST000440,Cancer,#99d594
18809,European,174.0,19578366.0,Wrensch M,Glioma (high-grade),replication,2009-07-05,GCST000440,Cancer,#d53e4f
18810,European,4684.0,19578366.0,Wrensch M,Glioma (high-grade),initial,2009-07-05,GCST000440,Cancer,#d53e4f
18811,Other/Mixed,174.0,19578366.0,Wrensch M,Glioma (high-grade),replication,2009-07-05,GCST000440,Cancer,#99d594
18812,European,4179.0,19578364.0,Bishop DT,Melanoma,replication,2009-07-05,GCST000437,Cancer,#d53e4f
18813,European,5456.0,19578364.0,Bishop DT,Melanoma,initial,2009-07-05,GCST000437,Cancer,#d53e4f
18814,European,11514.0,19578365.0,Falchi M,Cutaneous nevi,replication,2009-07-05,GCST000438,Cancer,#d53e4f
18815,European,1524.0,19578365.0,Falchi M,Cutaneous nevi,initial,2009-07-05,GCST000438,Cancer,#d53e4f
18816,European,5548.0,19578367.0,Shete S,Glioma,initial,2009-07-05,GCST000439,Cancer,#d53e4f
18817,European,5498.0,19578367.0,Shete S,Glioma,replication,2009-07-05,GCST000439,Cancer,#d53e4f
18819,European,1451.0,19578179.0,Teichert M,Acenocoumarol maintenance dosage,initial,2009-07-04,GCST000436,Response to drug,#d53e4f
18820,European,20185.0,19571811.0,Purcell SM,Schizophrenia,replication,2009-07-01,GCST000434,Neurological disorder,#d53e4f
18821,European,6909.0,19571811.0,Purcell SM,Schizophrenia,initial,2009-07-01,GCST000434,Neurological disorder,#d53e4f
18822,Other/Mixed,13615.0,19567438.0,Elliott P,C-reactive protein,replication,2009-07-01,GCST000430,Inflammatory measurement,#99d594
18823,Other/Mixed,17967.0,19567438.0,Elliott P,C-reactive protein,initial,2009-07-01,GCST000430,Inflammatory measurement,#99d594
18824,European,2020.0,19581569.0,Treutlein J,Alcohol dependence,replication,2009-07-01,GCST000432,Neurological disorder,#d53e4f
18825,European,1834.0,19581569.0,Treutlein J,Alcohol dependence,initial,2009-07-01,GCST000432,Neurological disorder,#d53e4f
18826,European,21751.0,19571809.0,Shi J,Schizophrenia,replication,2009-07-01,GCST000433,Neurological disorder,#d53e4f
18827,African Am./Caribbean,2259.0,19571809.0,Shi J,Schizophrenia,initial,2009-07-01,GCST000433,Neurological disorder,#fee08b
18828,European,5334.0,19571809.0,Shi J,Schizophrenia,initial,2009-07-01,GCST000433,Neurological disorder,#d53e4f
18829,European,6912.0,19570815.0,Estrada K,Height,replication,2009-07-01,GCST000431,Body measurement,#d53e4f
18830,European,10074.0,19570815.0,Estrada K,Height,initial,2009-07-01,GCST000431,Body measurement,#d53e4f
18831,European,31375.0,19571808.0,Stefansson H,Schizophrenia,replication,2009-07-01,GCST000435,Neurological disorder,#d53e4f
18832,European,16161.0,19571808.0,Stefansson H,Schizophrenia,initial,2009-07-01,GCST000435,Neurological disorder,#d53e4f
18833,European,10743.0,19561606.0,Thorleifsson G,Kidney stones,replication,2009-06-28,GCST000429,Other disease,#d53e4f
18834,European,35540.0,19561606.0,Thorleifsson G,Kidney stones,initial,2009-06-28,GCST000429,Other disease,#d53e4f
18835,European,38580.0,19557161.0,Lindgren CM,Adiposity,initial,2009-06-26,GCST000428,Metabolic disorder,#d53e4f
18836,European,102064.0,19557161.0,Lindgren CM,Adiposity,replication,2009-06-26,GCST000428,Metabolic disorder,#d53e4f
18837,European,31373.0,19557197.0,Heard-Costa NL,Waist circumference,initial,2009-06-26,GCST000427,Body measurement,#d53e4f
18838,European,3972.0,19553259.0,Cotsapas C,Obesity (extreme),initial,2009-06-24,GCST000426,Metabolic disorder,#d53e4f
18839,European,9844.0,19525953.0,De Jager PL,Multiple sclerosis,initial,2009-06-14,GCST000424,Immune system disorder,#d53e4f
18840,European,4331.0,19525953.0,De Jager PL,Multiple sclerosis,replication,2009-06-14,GCST000424,Immune system disorder,#d53e4f
18841,European,4566.0,19525955.0,Bahlo M,Multiple sclerosis,replication,2009-06-14,GCST000425,Immune system disorder,#d53e4f
18842,European,5031.0,19525955.0,Bahlo M,Multiple sclerosis,initial,2009-06-14,GCST000425,Immune system disorder,#d53e4f
18843,European,1238.0,19525478.0,Malarstig A,Homocysteine levels,replication,2009-06-12,GCST000423,Cardiovascular measurement,#d53e4f
18844,European,387.0,19525478.0,Malarstig A,Homocysteine levels,initial,2009-06-12,GCST000423,Cardiovascular measurement,#d53e4f
18845,European,150.0,19508998.0,Knauff EA,Premature ovarian failure,replication,2009-06-09,GCST000422,Other disease,#d53e4f
18846,European,334.0,19508998.0,Knauff EA,Premature ovarian failure,initial,2009-06-09,GCST000422,Other disease,#d53e4f
18847,European,1804.0,19508968.0,Zhai G,Osteoarthritis,initial,2009-06-08,GCST000421,Other disease,#d53e4f
18848,European,3266.0,19508968.0,Zhai G,Osteoarthritis,replication,2009-06-08,GCST000421,Other disease,#d53e4f
18849,Other/Mixed,5486.0,19503088.0,Gregersen PK,Rheumatoid arthritis,replication,2009-06-07,GCST000420,Immune system disorder,#99d594
18850,European,6922.0,19503088.0,Gregersen PK,Rheumatoid arthritis,initial,2009-06-07,GCST000420,Immune system disorder,#d53e4f
18851,Other/Mixed,1861.0,19497516.0,Elmore JR,Abdominal aortic aneurysm,replication,2009-06-06,GCST000419,Cardiovascular disease,#99d594
18853,European,28141.0,19503597.0,Kolz M,Uric acid levels,initial,2009-06-05,GCST000418,Cardiovascular measurement,#d53e4f
18854,European,3244.0,19488044.0,Smith EN,Bipolar disorder,replication,2009-06-02,GCST000417,Neurological disorder,#d53e4f
18855,European,2034.0,19488044.0,Smith EN,Bipolar disorder,initial,2009-06-02,GCST000417,Neurological disorder,#d53e4f
18856,African Am./Caribbean,1015.0,19488044.0,Smith EN,Bipolar disorder,initial,2009-06-02,GCST000417,Neurological disorder,#fee08b
18857,European,2377.0,19483681.0,Rapley EA,Testicular germ cell tumor,replication,2009-05-31,GCST000414,Cancer,#d53e4f
18858,European,2165.0,19483681.0,Rapley EA,Testicular germ cell tumor,initial,2009-05-31,GCST000414,Cancer,#d53e4f
18859,European,1196.0,19483682.0,Kanetsky PA,Testicular cancer,initial,2009-05-31,GCST000416,Cancer,#d53e4f
18860,European,1639.0,19483682.0,Kanetsky PA,Testicular cancer,replication,2009-05-31,GCST000416,Cancer,#d53e4f
18861,European,350.0,19483685.0,Daly AK,Drug-induced liver injury (flucloxacillin),initial,2009-05-31,GCST000415,Digestive system disorder,#d53e4f
18862,Asian,420.0,19478819.0,Ng CC,Nasopharyngeal carcinoma,replication,2009-05-29,GCST000413,Cancer,#3288bd
18863,Asian,371.0,19478819.0,Ng CC,Nasopharyngeal carcinoma,initial,2009-05-29,GCST000413,Cancer,#3288bd
18864,European,172.0,19478329.0,Aston KI,Male infertility,initial,2009-05-28,GCST000412,Other disease,#d53e4f
18865,European,2390.0,19456320.0,Ma D,Autism,replication,2009-05-28,GCST000411,Neurological disorder,#d53e4f
18866,European,1390.0,19456320.0,Ma D,Autism,initial,2009-05-28,GCST000411,Neurological disorder,#d53e4f
18867,African,3463.0,19465909.0,Jallow M,Malaria,replication,2009-05-24,GCST000410,Digestive system disorder,#fc8d59
18868,African,2040.0,19465909.0,Jallow M,Malaria,initial,2009-05-24,GCST000410,Digestive system disorder,#fc8d59
18869,Hispanic/Latin American,961.0,19461586.0,Norris JM,Obesity-related traits,replication,2009-05-21,GCST000409,Other measurement,#807dba
18870,Hispanic/Latin American,229.0,19461586.0,Norris JM,Obesity-related traits,initial,2009-05-21,GCST000409,Other measurement,#807dba
18871,European,2012.0,19458352.0,Hirschfield GM,Primary biliary cholangitis,initial,2009-05-20,GCST000408,Cancer,#d53e4f
18872,European,1732.0,19458352.0,Hirschfield GM,Primary biliary cholangitis,replication,2009-05-20,GCST000408,Cancer,#d53e4f
18873,European,704.0,19454037.0,Arnett DK,Left ventricular mass,replication,2009-05-19,GCST000407,Cardiovascular measurement,#d53e4f
18874,African Am./Caribbean,1467.0,19454037.0,Arnett DK,Left ventricular mass,replication,2009-05-19,GCST000407,Cardiovascular measurement,#fee08b
18875,European,202.0,19454037.0,Arnett DK,Left ventricular mass,initial,2009-05-19,GCST000407,Cardiovascular measurement,#d53e4f
18876,Other/Mixed,4079.0,19451621.0,Landers JE,Amyotrophic lateral sclerosis,initial,2009-05-18,GCST000406,Neurological disorder,#99d594
18877,Other/Mixed,1094.0,19451621.0,Landers JE,Amyotrophic lateral sclerosis,replication,2009-05-18,GCST000406,Neurological disorder,#99d594
18878,European,4714.0,19448623.0,Ong KK,Menarche (age at onset),initial,2009-05-17,GCST000405,Other measurement,#d53e4f
18879,European,16373.0,19448623.0,Ong KK,Menarche (age at onset),replication,2009-05-17,GCST000405,Other measurement,#d53e4f
18880,European,17438.0,19448621.0,He C,Menarche and menopause (age at onset),initial,2009-05-17,GCST000403,Other measurement,#d53e4f
18881,European,17438.0,19448621.0,He C,Menarche and menopause (age at onset),initial,2009-05-17,GCST000403,Other measurement,#d53e4f
18882,European,17510.0,19448620.0,Perry JR,Menarche (age at onset),initial,2009-05-17,GCST000404,Other measurement,#d53e4f
18883,European,15297.0,19448622.0,Sulem P,Menarche (age at onset),initial,2009-05-15,GCST000400,Other measurement,#d53e4f
18884,European,10040.0,19448622.0,Sulem P,Menarche (age at onset),replication,2009-05-15,GCST000400,Other measurement,#d53e4f
18885,European,2560.0,19448619.0,Stolk L,Menopause (age at onset),replication,2009-05-15,GCST000401,Other measurement,#d53e4f
18886,European,2979.0,19448619.0,Stolk L,Menopause (age at onset),initial,2009-05-15,GCST000401,Other measurement,#d53e4f
18887,Other/Mixed,1177.0,19448189.0,Perlis RH,Response to lithium treatment in bipolar disorder,initial,2009-05-15,GCST000402,Response to drug,#99d594
18888,European,359.0,19448189.0,Perlis RH,Response to lithium treatment in bipolar disorder,replication,2009-05-15,GCST000402,Response to drug,#d53e4f
18889,Other/Mixed,322.0,19442274.0,Fei Y,Behcet's disease,initial,2009-05-14,GCST000399,Cardiovascular disease,#99d594
18890,European,29136.0,19430479.0,Levy D,Hypertension,initial,2009-05-10,GCST000398,Cardiovascular disease,#d53e4f
18891,European,34433.0,19430479.0,Levy D,Hypertension,replication,2009-05-10,GCST000398,Cardiovascular disease,#d53e4f
18892,European,19877.0,19430482.0,Kottgen A,Renal function and chronic kidney disease,initial,2009-05-10,GCST000397,Other measurement,#d53e4f
18894,European,3219.0,19430482.0,Kottgen A,Renal function and chronic kidney disease,replication,2009-05-10,GCST000397,Other measurement,#d53e4f
18895,European,19877.0,19430482.0,Kottgen A,Renal function and chronic kidney disease,initial,2009-05-10,GCST000397,Other disease,#d53e4f
18897,European,3219.0,19430482.0,Kottgen A,Renal function and chronic kidney disease,replication,2009-05-10,GCST000397,Other disease,#d53e4f
18898,European,16559.0,19430480.0,Barrett JC,Type 1 diabetes,initial,2009-05-10,GCST000392,Metabolic disorder,#d53e4f
18899,European,13279.0,19430480.0,Barrett JC,Type 1 diabetes,replication,2009-05-10,GCST000392,Metabolic disorder,#d53e4f
18900,European,34433.0,19430483.0,Newton-Cheh C,Diastolic blood pressure,initial,2009-05-10,GCST000394,Other measurement,#d53e4f
18901,European,100347.0,19430483.0,Newton-Cheh C,Diastolic blood pressure,replication,2009-05-10,GCST000394,Other measurement,#d53e4f
18902,Asian,12889.0,19430483.0,Newton-Cheh C,Diastolic blood pressure,replication,2009-05-10,GCST000394,Other measurement,#3288bd
18903,European,34433.0,19430483.0,Newton-Cheh C,Systolic blood pressure,initial,2009-05-10,GCST000395,Other measurement,#d53e4f
18904,European,100347.0,19430483.0,Newton-Cheh C,Systolic blood pressure,replication,2009-05-10,GCST000395,Other measurement,#d53e4f
18905,Asian,12889.0,19430483.0,Newton-Cheh C,Systolic blood pressure,replication,2009-05-10,GCST000395,Other measurement,#3288bd
18906,European,34433.0,19430479.0,Levy D,Diastolic blood pressure,replication,2009-05-10,GCST000396,Other measurement,#d53e4f
18907,European,29136.0,19430479.0,Levy D,Diastolic blood pressure,initial,2009-05-10,GCST000396,Other measurement,#d53e4f
18908,European,34433.0,19430479.0,Levy D,Systolic blood pressure,replication,2009-05-10,GCST000393,Other measurement,#d53e4f
18909,European,29136.0,19430479.0,Levy D,Systolic blood pressure,initial,2009-05-10,GCST000393,Other measurement,#d53e4f
18910,Hispanic/Latin American,229.0,19430760.0,Rich SS,Insulin resistance/response,initial,2009-05-09,GCST000391,Other trait,#807dba
18911,Hispanic/Latin American,961.0,19430760.0,Rich SS,Insulin resistance/response,replication,2009-05-09,GCST000391,Other trait,#807dba
18912,European,1205.0,19426955.0,Himes BE,Asthma,initial,2009-05-07,GCST000389,Other disease,#d53e4f
18913,African Am./Caribbean,5264.0,19426955.0,Himes BE,Asthma,replication,2009-05-07,GCST000389,Other disease,#fee08b
18914,Hispanic/Latin American,1776.0,19426955.0,Himes BE,Asthma,replication,2009-05-07,GCST000389,Other disease,#807dba
18915,Other/Mixed,1776.0,19426955.0,Himes BE,Asthma,replication,2009-05-07,GCST000389,Other disease,#99d594
18916,European,15339.0,19426955.0,Himes BE,Asthma,replication,2009-05-07,GCST000389,Other disease,#d53e4f
18917,Asian,1666.0,19421330.0,Yang HC,Hypertension (young onset),replication,2009-05-07,GCST000390,Cardiovascular disease,#3288bd
18918,Asian,350.0,19421330.0,Yang HC,Hypertension (young onset),initial,2009-05-07,GCST000390,Cardiovascular disease,#3288bd
18919,European,2692.0,19419973.0,Sanna S,Bilirubin levels,replication,2009-05-06,GCST000388,Other measurement,#d53e4f
18920,European,4300.0,19419973.0,Sanna S,Bilirubin levels,initial,2009-05-06,GCST000388,Other measurement,#d53e4f
18921,European,18190.0,19416921.0,Scott LJ,Bipolar disorder,initial,2009-05-05,GCST000387,Neurological disorder,#d53e4f
18922,Other/Mixed,9464.0,19414484.0,Johnson AD,Bilirubin levels,initial,2009-05-04,GCST000386,Other measurement,#99d594
18923,European,2490.0,19412175.0,Capasso M,Neuroblastoma (high-risk),replication,2009-05-03,GCST000384,Cancer,#d53e4f
18924,European,2440.0,19412175.0,Capasso M,Neuroblastoma (high-risk),initial,2009-05-03,GCST000384,Cancer,#d53e4f
18925,European,1881.0,19412176.0,Hallmayer J,Narcolepsy,initial,2009-05-03,GCST000385,Neurological disorder,#d53e4f
18926,African Am./Caribbean,277.0,19412176.0,Hallmayer J,Narcolepsy,replication,2009-05-03,GCST000385,Neurological disorder,#fee08b
18927,European,718.0,19412176.0,Hallmayer J,Narcolepsy,replication,2009-05-03,GCST000385,Neurological disorder,#d53e4f
18928,Asian,1166.0,19412176.0,Hallmayer J,Narcolepsy,replication,2009-05-03,GCST000385,Neurological disorder,#3288bd
18929,Asian,4631.0,19330027.0,Ahmed S,Breast cancer,replication,2009-05-01,GCST004948,Cancer,#3288bd
18930,European,80356.0,19330027.0,Ahmed S,Breast cancer,replication,2009-05-01,GCST004948,Cancer,#d53e4f
18931,European,754.0,19330027.0,Ahmed S,Breast cancer,initial,2009-05-01,GCST004948,Cancer,#d53e4f
18932,European,23660.0,19330027.0,Ahmed S,Breast cancer,replication,2009-05-01,GCST004949,Cancer,#d53e4f
18933,European,754.0,19330027.0,Ahmed S,Breast cancer,initial,2009-05-01,GCST004949,Cancer,#d53e4f
18934,Asian,1022.0,19401414.0,Takeuchi F,Type 2 diabetes,initial,2009-04-29,GCST000383,Metabolic disorder,#3288bd
18935,Asian,11977.0,19401414.0,Takeuchi F,Type 2 diabetes,replication,2009-04-29,GCST000383,Metabolic disorder,#3288bd
18936,European,2038.0,19404256.0,Wang K,Autism,replication,2009-04-28,GCST000382,Neurological disorder,#d53e4f
18937,European,10796.0,19404256.0,Wang K,Autism,initial,2009-04-28,GCST000382,Neurological disorder,#d53e4f
18938,Asian,7861.0,19396169.0,Cho YS,Height,replication,2009-04-26,GCST000380,Body measurement,#3288bd
18939,Asian,8842.0,19396169.0,Cho YS,Height,initial,2009-04-26,GCST000380,Body measurement,#3288bd
18940,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Other measurement,#3288bd
18941,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Other measurement,#3288bd
18942,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Other measurement,#3288bd
18943,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Other measurement,#3288bd
18944,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Other measurement,#3288bd
18945,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Other measurement,#3288bd
18946,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Cardiovascular measurement,#3288bd
18947,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Cardiovascular measurement,#3288bd
18948,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Body measurement,#3288bd
18949,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Body measurement,#3288bd
18950,Asian,7861.0,19396169.0,Cho YS,Biomedical quantitative traits,replication,2009-04-26,GCST000381,Body measurement,#3288bd
18951,Asian,8842.0,19396169.0,Cho YS,Biomedical quantitative traits,initial,2009-04-26,GCST000381,Body measurement,#3288bd
18952,European,4265.0,19369658.0,Ikram MA,Stroke,replication,2009-04-15,GCST000379,Cardiovascular disease,#d53e4f
18953,African Am./Caribbean,3004.0,19369658.0,Ikram MA,Stroke,replication,2009-04-15,GCST000379,Cardiovascular disease,#fee08b
18954,European,19602.0,19369658.0,Ikram MA,Stroke,initial,2009-04-15,GCST000379,Cardiovascular disease,#d53e4f
18955,African Am./Caribbean,2.0,19367585.0,Poduslo SE,Aging,initial,2009-04-14,GCST000378,Biological process,#fee08b
18956,European,314.0,19367585.0,Poduslo SE,Aging,initial,2009-04-14,GCST000378,Biological process,#d53e4f
18957,Asian,1810.0,19359809.0,Hiura Y,HDL cholesterol,replication,2009-04-10,GCST000377,Lipid or lipoprotein measurement,#3288bd
18958,Asian,900.0,19359809.0,Hiura Y,HDL cholesterol,initial,2009-04-10,GCST000377,Lipid or lipoprotein measurement,#3288bd
18959,European,1165.0,19359265.0,Mangino M,Telomere length,replication,2009-04-08,GCST000376,Other measurement,#d53e4f
18960,European,1625.0,19359265.0,Mangino M,Telomere length,initial,2009-04-08,GCST000376,Other measurement,#d53e4f
18961,Asian,854.0,19349983.0,Kamatani Y,Hepatitis B,replication,2009-04-06,GCST000375,Digestive system disorder,#3288bd
18962,Asian,4420.0,19349983.0,Kamatani Y,Hepatitis B,replication,2009-04-06,GCST000375,Digestive system disorder,#3288bd
18963,Asian,1113.0,19349983.0,Kamatani Y,Hepatitis B,initial,2009-04-06,GCST000375,Digestive system disorder,#3288bd
18964,European,3011.0,19349984.0,Esparza-Gordillo J,Atopic dermatitis,initial,2009-04-06,GCST000374,Immune system disorder,#d53e4f
18965,European,6594.0,19349984.0,Esparza-Gordillo J,Atopic dermatitis,replication,2009-04-06,GCST000374,Immune system disorder,#d53e4f
18966,Asian,5981.0,19403135.0,Yamada Y,Stroke (ischemic),replication,2009-04-05,GCST000373,Cardiovascular disease,#3288bd
18967,Asian,266.0,19403135.0,Yamada Y,Stroke (ischemic),initial,2009-04-05,GCST000373,Cardiovascular disease,#3288bd
18968,European,7187.0,19343178.0,Soranzo N,Height,replication,2009-04-03,GCST000372,Body measurement,#d53e4f
18969,European,12611.0,19343178.0,Soranzo N,Height,initial,2009-04-03,GCST000372,Body measurement,#d53e4f
18970,European,870.0,19340012.0,Nan H,Tanning,replication,2009-04-02,GCST000371,Other trait,#d53e4f
18971,European,2287.0,19340012.0,Nan H,Tanning,initial,2009-04-02,GCST000371,Other trait,#d53e4f
18972,European,22096.0,20031576.0,Dehghan A,Fibrinogen,initial,2009-04-01,GCST000366,Hematological measurement,#d53e4f
18973,European,17686.0,20031576.0,Dehghan A,Fibrinogen,replication,2009-04-01,GCST000366,Hematological measurement,#d53e4f
18974,European,13974.0,20031578.0,Pare G,Homocysteine levels,initial,2009-04-01,GCST000367,Cardiovascular measurement,#d53e4f
18975,European,840.0,20031578.0,Pare G,Homocysteine levels,replication,2009-04-01,GCST000367,Cardiovascular measurement,#d53e4f
18976,European,17686.0,20031577.0,Danik JS,Fibrinogen,initial,2009-04-01,GCST000368,Hematological measurement,#d53e4f
18977,European,4221.0,20031579.0,Tarasov KV,Arterial stiffness,initial,2009-04-01,GCST000370,Cardiovascular measurement,#d53e4f
18978,European,2654.0,20031579.0,Tarasov KV,Arterial stiffness,replication,2009-04-01,GCST000370,Cardiovascular measurement,#d53e4f
18979,European,3761.0,20031582.0,Thompson JF,Response to statin therapy,replication,2009-04-01,GCST000369,Response to drug,#d53e4f
18980,European,1984.0,20031582.0,Thompson JF,Response to statin therapy,initial,2009-04-01,GCST000369,Response to drug,#d53e4f
18982,European,18282.0,19330030.0,Thomas G,Breast cancer,replication,2009-03-29,GCST000365,Cancer,#d53e4f
18983,European,2287.0,19330030.0,Thomas G,Breast cancer,initial,2009-03-29,GCST000365,Cancer,#d53e4f
18985,European,15842.0,19305409.0,Pfeufer A,QT interval,initial,2009-03-22,GCST000364,Cardiovascular measurement,#d53e4f
18986,European,15854.0,19305408.0,Newton-Cheh C,QT interval,replication,2009-03-22,GCST000363,Cardiovascular measurement,#d53e4f
18987,European,13685.0,19305408.0,Newton-Cheh C,QT interval,initial,2009-03-22,GCST000363,Cardiovascular measurement,#d53e4f
18988,European,7691.0,19300500.0,Wilk JB,Pulmonary function,initial,2009-03-20,GCST000362,Other measurement,#d53e4f
18989,European,835.0,19300500.0,Wilk JB,Pulmonary function,replication,2009-03-20,GCST000362,Other measurement,#d53e4f
18990,European,1053.0,19300499.0,Takeuchi F,Warfarin maintenance dose,initial,2009-03-20,GCST000360,Response to drug,#d53e4f
18991,European,588.0,19300499.0,Takeuchi F,Warfarin maintenance dose,replication,2009-03-20,GCST000360,Response to drug,#d53e4f
18992,European,2752.0,19300482.0,Pillai SG,Chronic obstructive pulmonary disease,replication,2009-03-20,GCST000359,Other disease,#d53e4f
18994,European,1633.0,19300482.0,Pillai SG,Chronic obstructive pulmonary disease,initial,2009-03-20,GCST000359,Other disease,#d53e4f
18995,European,954.0,19304780.0,Org E,Hypertension,initial,2009-03-20,GCST000361,Cardiovascular disease,#d53e4f
18996,European,2812.0,19304780.0,Org E,Hypertension,replication,2009-03-20,GCST000361,Cardiovascular disease,#d53e4f
18997,European,686.0,19303062.0,Tanaka T,Folate pathway vitamin levels,replication,2009-03-18,GCST000358,Other measurement,#d53e4f
18998,European,2934.0,19303062.0,Tanaka T,Folate pathway vitamin levels,initial,2009-03-18,GCST000358,Other measurement,#d53e4f
18999,European,686.0,19303062.0,Tanaka T,Folate pathway vitamin levels,replication,2009-03-18,GCST000358,Other measurement,#d53e4f
19000,European,2934.0,19303062.0,Tanaka T,Folate pathway vitamin levels,initial,2009-03-18,GCST000358,Other measurement,#d53e4f
19001,European,686.0,19303062.0,Tanaka T,Folate pathway vitamin levels,replication,2009-03-18,GCST000358,Other measurement,#d53e4f
19002,European,2934.0,19303062.0,Tanaka T,Folate pathway vitamin levels,initial,2009-03-18,GCST000358,Other measurement,#d53e4f
19003,European,3323.0,19287384.0,Kilpivaara O,Myeloproliferative neoplasms,initial,2009-03-15,GCST000357,Cancer,#d53e4f
19004,European,849.0,19287509.0,Cui J,Anti-cyclic Citrullinated Peptide Antibody,replication,2009-03-14,GCST000356,Other measurement,#d53e4f
19005,European,531.0,19287509.0,Cui J,Anti-cyclic Citrullinated Peptide Antibody,initial,2009-03-14,GCST000356,Other measurement,#d53e4f
19006,Asian,1387.0,19282985.0,Liu YZ,Menarche (age at onset),replication,2009-03-13,GCST000355,Other measurement,#3288bd
19007,European,1616.0,19282985.0,Liu YZ,Menarche (age at onset),replication,2009-03-13,GCST000355,Other measurement,#d53e4f
19008,European,477.0,19282985.0,Liu YZ,Menarche (age at onset),initial,2009-03-13,GCST000355,Other measurement,#d53e4f
19009,European,3237.0,19278955.0,Tregouet DA,Venous thromboembolism,replication,2009-03-10,GCST000354,Cardiovascular disease,#d53e4f
19010,European,1647.0,19278955.0,Tregouet DA,Venous thromboembolism,initial,2009-03-10,GCST000354,Cardiovascular disease,#d53e4f
19012,European,607.0,19270707.0,Birnbaum S,Orofacial clefts,initial,2009-03-08,GCST000353,Other trait,#d53e4f
19013,Asian,2955.0,19268274.0,Liu XG,Body mass (lean),replication,2009-03-04,GCST000352,Other measurement,#3288bd
19014,European,3460.0,19268274.0,Liu XG,Body mass (lean),replication,2009-03-04,GCST000352,Other measurement,#d53e4f
19015,European,973.0,19268274.0,Liu XG,Body mass (lean),initial,2009-03-04,GCST000352,Other measurement,#d53e4f
19016,Other/Mixed,249.0,19268276.0,Vink JM,Smoking behavior,replication,2009-03-04,GCST000351,Biological process,#99d594
19017,European,7614.0,19268276.0,Vink JM,Smoking behavior,replication,2009-03-04,GCST000351,Biological process,#d53e4f
19018,European,3497.0,19268276.0,Vink JM,Smoking behavior,initial,2009-03-04,GCST000351,Biological process,#d53e4f
19019,Asian,804.0,19259986.0,Hattori E,Bipolar disorder,replication,2009-03-02,GCST000350,Neurological disorder,#3288bd
19020,Asian,214.0,19259986.0,Hattori E,Bipolar disorder,initial,2009-03-02,GCST000350,Neurological disorder,#3288bd
19021,European,1304.0,19252134.0,Pezzolesi MG,Type 2 diabetes nephropathy,replication,2009-02-27,GCST000348,Metabolic disorder,#d53e4f
19022,European,1705.0,19252134.0,Pezzolesi MG,Type 2 diabetes nephropathy,initial,2009-02-27,GCST000348,Metabolic disorder,#d53e4f
19023,European,4342.0,19247474.0,Caporaso N,Smoking behavior,initial,2009-02-27,GCST000349,Biological process,#d53e4f
19024,European,1000.0,19249006.0,Xiong DH,Bone mineral density,initial,2009-02-25,GCST000347,Other measurement,#d53e4f
19025,European,4925.0,19249006.0,Xiong DH,Bone mineral density,replication,2009-02-25,GCST000347,Other measurement,#d53e4f
19026,African,908.0,19249006.0,Xiong DH,Bone mineral density,replication,2009-02-25,GCST000347,Other measurement,#fc8d59
19027,Asian,3655.0,19249006.0,Xiong DH,Bone mineral density,replication,2009-02-25,GCST000347,Other measurement,#3288bd
19028,European,320.0,19242412.0,Gu Y,Cystic fibrosis severity,initial,2009-02-25,GCST000346,Digestive system disorder,#d53e4f
19029,European,485.0,19242412.0,Gu Y,Cystic fibrosis severity,replication,2009-02-25,GCST000346,Digestive system disorder,#d53e4f
19031,Other/Mixed,604.0,19230858.0,Schrauwen I,Otosclerosis,initial,2009-02-18,GCST000345,Neurological disorder,#99d594
19032,Other/Mixed,1719.0,19230858.0,Schrauwen I,Otosclerosis,replication,2009-02-18,GCST000345,Neurological disorder,#99d594
19033,European,3057.0,19219042.0,Zheng W,Breast cancer,replication,2009-02-15,GCST000343,Cancer,#d53e4f
19034,Asian,3027.0,19219042.0,Zheng W,Breast cancer,initial,2009-02-15,GCST000343,Cancer,#3288bd
19035,Asian,7502.0,19219042.0,Zheng W,Breast cancer,replication,2009-02-15,GCST000343,Cancer,#3288bd
19036,Other/Mixed,1262.0,19389651.0,Smith JG,Electrocardiographic conduction measures,initial,2009-02-15,GCST000344,Cardiovascular measurement,#99d594
19037,European,1601.0,19221038.0,Soranzo N,Mean platelet volume,replication,2009-02-12,GCST000342,Hematological measurement,#d53e4f
19040,European,4864.0,19198611.0,Tregouet DA,Coronary heart disease,initial,2009-02-08,GCST000341,Cardiovascular disease,#d53e4f
19041,European,14398.0,19198611.0,Tregouet DA,Coronary heart disease,replication,2009-02-08,GCST000341,Cardiovascular disease,#d53e4f
19042,European,2520.0,19198612.0,Erdmann J,Coronary heart disease,initial,2009-02-08,GCST000338,Cardiovascular disease,#d53e4f
19043,European,38253.0,19198612.0,Erdmann J,Coronary heart disease,replication,2009-02-08,GCST000338,Cardiovascular disease,#d53e4f
19044,European,19492.0,19198609.0,Kathiresan S,Myocardial infarction (early onset),replication,2009-02-08,GCST000340,Cardiovascular disease,#d53e4f
19045,European,6042.0,19198609.0,Kathiresan S,Myocardial infarction (early onset),initial,2009-02-08,GCST000340,Cardiovascular disease,#d53e4f
19046,European,9392.0,19198610.0,Gudbjartsson DF,Eosinophil counts,initial,2009-02-08,GCST000339,Hematological measurement,#d53e4f
19047,European,12118.0,19198610.0,Gudbjartsson DF,Eosinophil counts,replication,2009-02-08,GCST000339,Hematological measurement,#d53e4f
19048,Asian,5212.0,19198610.0,Gudbjartsson DF,Eosinophil counts,replication,2009-02-08,GCST000339,Hematological measurement,#3288bd
19049,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Body measurement,#99d594
19050,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Lipid or lipoprotein measurement,#99d594
19051,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Body measurement,#99d594
19052,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Inflammatory measurement,#99d594
19053,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Body measurement,#99d594
19054,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Lipid or lipoprotein measurement,#99d594
19055,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Body measurement,#99d594
19056,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Other measurement,#99d594
19057,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Lipid or lipoprotein measurement,#99d594
19058,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Other measurement,#99d594
19059,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Lipid or lipoprotein measurement,#99d594
19060,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Body measurement,#99d594
19061,Other/Mixed,2906.0,19197348.0,Lowe JK,Quantitative traits,initial,2009-02-06,GCST000337,Other measurement,#99d594
19062,European,2159.0,19198613.0,Gudmundsson J,Thyroid cancer,replication,2009-02-06,GCST000335,Cancer,#d53e4f
19063,European,37388.0,19198613.0,Gudmundsson J,Thyroid cancer,initial,2009-02-06,GCST000335,Cancer,#d53e4f
19064,European,14455.0,19197363.0,Need AC,Schizophrenia,replication,2009-02-06,GCST000336,Neurological disorder,#d53e4f
19065,European,1734.0,19197363.0,Need AC,Schizophrenia,initial,2009-02-06,GCST000336,Neurological disorder,#d53e4f
19066,Asian,700.0,19196962.0,Garcia-Barcelo MM,Hirschsprung disease,replication,2009-02-05,GCST000334,Digestive system disorder,#3288bd
19067,Asian,527.0,19196962.0,Garcia-Barcelo MM,Hirschsprung disease,initial,2009-02-05,GCST000334,Digestive system disorder,#3288bd
19068,European,5616.0,19193627.0,Chio A,Amyotrophic lateral sclerosis,replication,2009-02-04,GCST000333,Neurological disorder,#d53e4f
19069,European,2521.0,19193627.0,Chio A,Amyotrophic lateral sclerosis,initial,2009-02-04,GCST000333,Neurological disorder,#d53e4f
19070,African Am./Caribbean,1251.0,19188921.0,Liu YZ,Smoking behavior,replication,2009-02-03,GCST000332,Biological process,#fee08b
19071,European,7623.0,19188921.0,Liu YZ,Smoking behavior,replication,2009-02-03,GCST000332,Biological process,#d53e4f
19072,European,840.0,19188921.0,Liu YZ,Smoking behavior,initial,2009-02-03,GCST000332,Biological process,#d53e4f
19073,European,898.0,19260139.0,Polasek O,Anthropometric traits,initial,2009-02-01,GCST000327,Other measurement,#d53e4f
19074,European,18245.0,20031564.0,Ridker PM,HDL cholesterol,initial,2009-02-01,GCST000331,Lipid or lipoprotein measurement,#d53e4f
19075,Asian,347.0,19187332.0,Kim SH,Asthma (toluene diisocyanate-induced),initial,2009-02-01,GCST000330,Other disease,#3288bd
19076,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Other measurement,#d53e4f
19077,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Lipid or lipoprotein measurement,#d53e4f
19078,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Lipid or lipoprotein measurement,#d53e4f
19079,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Lipid or lipoprotein measurement,#d53e4f
19080,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Hematological measurement,#d53e4f
19081,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Cardiovascular measurement,#d53e4f
19082,European,898.0,19260141.0,Zemunik T,Biochemical measures,initial,2009-02-01,GCST000328,Lipid or lipoprotein measurement,#d53e4f
19083,European,112.0,19207018.0,Kim H,Pain,initial,2009-02-01,GCST000326,Other trait,#d53e4f
19084,European,14830.0,19182806.0,Stefansson H,Essential tremor,initial,2009-02-01,GCST000329,Other trait,#d53e4f
19085,European,1720.0,19182806.0,Stefansson H,Essential tremor,replication,2009-02-01,GCST000329,Other trait,#d53e4f
19086,European,1552.0,19181680.0,Timpson NJ,Bone mineral density,initial,2009-01-30,GCST000325,Other measurement,#d53e4f
19087,European,3875.0,19181680.0,Timpson NJ,Bone mineral density,replication,2009-01-30,GCST000325,Other measurement,#d53e4f
19089,European,2540.0,19185284.0,Ferrucci L,Carotenoid and tocopherol levels,replication,2009-01-29,GCST000324,Other measurement,#d53e4f
19090,European,1191.0,19185284.0,Ferrucci L,Carotenoid and tocopherol levels,initial,2009-01-29,GCST000324,Other measurement,#d53e4f
19092,European,2540.0,19185284.0,Ferrucci L,Carotenoid and tocopherol levels,replication,2009-01-29,GCST000324,Other measurement,#d53e4f
19093,European,1191.0,19185284.0,Ferrucci L,Carotenoid and tocopherol levels,initial,2009-01-29,GCST000324,Other measurement,#d53e4f
19094,African,53.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Cancer,#fc8d59
19095,Other/Mixed,78.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Cancer,#99d594
19096,European,356.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Cancer,#d53e4f
19097,African,53.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Response to drug,#fc8d59
19098,Other/Mixed,78.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Response to drug,#99d594
19099,European,356.0,19176441.0,Yang JJ,Response to treatment for acute lymphoblastic leukemia,initial,2009-01-28,GCST000323,Response to drug,#d53e4f
19100,European,2759.0,19169254.0,Nair RP,Psoriasis,initial,2009-01-25,GCST000322,Immune system disorder,#d53e4f
19101,European,10089.0,19169254.0,Nair RP,Psoriasis,replication,2009-01-25,GCST000322,Immune system disorder,#d53e4f
19102,Asian,13061.0,19169255.0,Zhang XJ,Psoriasis,replication,2009-01-25,GCST000321,Immune system disorder,#3288bd
19103,Asian,2271.0,19169255.0,Zhang XJ,Psoriasis,initial,2009-01-25,GCST000321,Immune system disorder,#3288bd
19104,Asian,400.0,19165232.0,Otowa T,Panic disorder,initial,2009-01-23,GCST000320,Neurological disorder,#3288bd
19105,European,1986.0,19165155.0,Ling H,Adiponectin levels,initial,2009-01-22,GCST000319,Other measurement,#d53e4f
19106,European,2796.0,19151714.0,Meyre D,Obesity,initial,2009-01-18,GCST000317,Metabolic disorder,#d53e4f
19107,European,14186.0,19151714.0,Meyre D,Obesity,replication,2009-01-18,GCST000317,Metabolic disorder,#d53e4f
19108,European,1575.0,19151717.0,Rafnar T,Basal cell carcinoma,replication,2009-01-18,GCST000318,Cancer,#d53e4f
19109,European,30395.0,19151717.0,Rafnar T,Basal cell carcinoma,initial,2009-01-18,GCST000318,Cancer,#d53e4f
19110,European,1076.0,19148276.0,Tanaka T,Polyunsaturated fatty acid levels,replication,2009-01-16,GCST000316,Other measurement,#d53e4f
19111,European,1075.0,19148276.0,Tanaka T,Polyunsaturated fatty acid levels,initial,2009-01-16,GCST000316,Other measurement,#d53e4f
19112,European,2099.0,19136949.0,Carrasquillo MM,Alzheimer's disease,initial,2009-01-11,GCST000315,Neurological disorder,#d53e4f
19113,European,2756.0,19136949.0,Carrasquillo MM,Alzheimer's disease,replication,2009-01-11,GCST000315,Neurological disorder,#d53e4f
19114,European,241.0,19132087.0,Burgner D,Kawasaki disease,initial,2009-01-09,GCST000314,Immune system disorder,#d53e4f
19115,European,1940.0,19132087.0,Burgner D,Kawasaki disease,replication,2009-01-09,GCST000314,Immune system disorder,#d53e4f
19116,European,1054.0,19124843.0,Ober C,Lp (a) levels,replication,2009-01-07,GCST000312,Lipid or lipoprotein measurement,#d53e4f
19117,Other/Mixed,357.0,19124843.0,Ober C,Lp (a) levels,initial,2009-01-07,GCST000312,Lipid or lipoprotein measurement,#99d594
19118,European,970.0,19125160.0,Feulner TM,Alzheimer's disease,initial,2009-01-07,GCST000313,Neurological disorder,#d53e4f
19119,European,2502.0,19122664.0,Silverberg MS,Ulcerative colitis,replication,2009-01-04,GCST000311,Immune system disorder,#d53e4f
19120,European,3525.0,19122664.0,Silverberg MS,Ulcerative colitis,initial,2009-01-04,GCST000311,Immune system disorder,#d53e4f
19121,European,458.0,19118814.0,Beecham GW,Alzheimer's disease,replication,2009-01-03,GCST000310,Neurological disorder,#d53e4f
19122,European,988.0,19118814.0,Beecham GW,Alzheimer's disease,initial,2009-01-03,GCST000310,Neurological disorder,#d53e4f
19123,European,463.0,19116933.0,Hinks A,Arthritis (juvenile idiopathic),initial,2009-01-01,GCST000309,Immune system disorder,#d53e4f
19124,European,2678.0,19116933.0,Hinks A,Arthritis (juvenile idiopathic),replication,2009-01-01,GCST000309,Immune system disorder,#d53e4f
19125,European,4636.0,19117981.0,Sun J,Prostate cancer,replication,2009-01-01,GCST000307,Cancer,#d53e4f
19127,European,2834.0,19117981.0,Sun J,Prostate cancer,initial,2009-01-01,GCST000307,Cancer,#d53e4f
19128,European,1627.0,19115949.0,Limou S,AIDS progression,initial,2009-01-01,GCST000308,Immune system disorder,#d53e4f
19130,European,542.0,19114657.0,Wang Y,Blood pressure,initial,2008-12-29,GCST000306,Other measurement,#d53e4f
19131,Other/Mixed,575.0,19114657.0,Wang Y,Blood pressure,replication,2008-12-29,GCST000306,Other measurement,#99d594
19132,European,6361.0,19114657.0,Wang Y,Blood pressure,replication,2008-12-29,GCST000306,Other measurement,#d53e4f
19133,European,8617.0,19110211.0,Meisinger C,Mean platelet volume,replication,2008-12-24,GCST000305,Hematological measurement,#d53e4f
19134,European,1606.0,19110211.0,Meisinger C,Mean platelet volume,initial,2008-12-24,GCST000305,Hematological measurement,#d53e4f
19135,European,3141.0,19107115.0,Muglia P,Major depressive disorder,initial,2008-12-23,GCST000304,Neurological disorder,#d53e4f
19136,European,455.0,19096518.0,Pare G,Glycated hemoglobin levels,replication,2008-12-19,GCST000303,Other measurement,#d53e4f
19137,European,14618.0,19096518.0,Pare G,Glycated hemoglobin levels,initial,2008-12-19,GCST000303,Other measurement,#d53e4f
19138,European,411.0,19084217.0,Benyamin B,Iron status biomarkers,initial,2008-12-17,GCST000302,Other measurement,#d53e4f
19139,European,918.0,19084217.0,Benyamin B,Iron status biomarkers,initial,2008-12-17,GCST000301,Other measurement,#d53e4f
19140,Other/Mixed,809.0,19074352.0,Pollin TI,Triglycerides,initial,2008-12-17,GCST000300,Lipid or lipoprotein measurement,#99d594
19141,Other/Mixed,698.0,19074352.0,Pollin TI,Triglycerides,replication,2008-12-17,GCST000300,Lipid or lipoprotein measurement,#99d594
19143,European,11036.0,19079260.0,Thorleifsson G,Weight,replication,2008-12-14,GCST000299,Body measurement,#d53e4f
19144,African Am./Caribbean,1160.0,19079260.0,Thorleifsson G,Weight,initial,2008-12-14,GCST000299,Body measurement,#fee08b
19145,European,72598.0,19079260.0,Thorleifsson G,Weight,initial,2008-12-14,GCST000299,Body measurement,#d53e4f
19146,European,8510.0,19079262.0,Styrkarsdottir U,Bone mineral density (spine),replication,2008-12-14,GCST000295,Other measurement,#d53e4f
19147,European,6865.0,19079262.0,Styrkarsdottir U,Bone mineral density (spine),initial,2008-12-14,GCST000295,Other measurement,#d53e4f
19148,European,8510.0,19079262.0,Styrkarsdottir U,Bone mineral density (hip),replication,2008-12-14,GCST000297,Other measurement,#d53e4f
19149,European,6865.0,19079262.0,Styrkarsdottir U,Bone mineral density (hip),initial,2008-12-14,GCST000297,Other measurement,#d53e4f
19150,European,11036.0,19079260.0,Thorleifsson G,Body mass index,replication,2008-12-14,GCST000296,Body measurement,#d53e4f
19151,European,72598.0,19079260.0,Thorleifsson G,Body mass index,initial,2008-12-14,GCST000296,Body measurement,#d53e4f
19153,African Am./Caribbean,1160.0,19079260.0,Thorleifsson G,Body mass index,initial,2008-12-14,GCST000296,Body measurement,#fee08b
19154,European,32387.0,19079261.0,Willer CJ,Body mass index,initial,2008-12-14,GCST000298,Body measurement,#d53e4f
19155,European,59082.0,19079261.0,Willer CJ,Body mass index,replication,2008-12-14,GCST000298,Body measurement,#d53e4f
19156,Other/Mixed,810.0,19081515.0,Mead S,Creutzfeldt-Jakob disease,replication,2008-12-11,GCST000294,Neurological disorder,#99d594
19157,European,3610.0,19081515.0,Mead S,Creutzfeldt-Jakob disease,replication,2008-12-11,GCST000294,Neurological disorder,#d53e4f
19158,European,3200.0,19081515.0,Mead S,Creutzfeldt-Jakob disease,initial,2008-12-11,GCST000294,Neurological disorder,#d53e4f
19159,European,11972.0,19065144.0,Sullivan PF,Major depressive disorder,replication,2008-12-09,GCST000293,Neurological disorder,#d53e4f
19160,European,3540.0,19065144.0,Sullivan PF,Major depressive disorder,initial,2008-12-09,GCST000293,Neurological disorder,#d53e4f
19161,European,19840.0,19060906.0,Kathiresan S,HDL cholesterol,initial,2008-12-07,GCST000290,Lipid or lipoprotein measurement,#d53e4f
19162,European,20623.0,19060906.0,Kathiresan S,HDL cholesterol,replication,2008-12-07,GCST000290,Lipid or lipoprotein measurement,#d53e4f
19163,European,2151.0,19060909.0,Bouatia-Naji N,Fasting plasma glucose,initial,2008-12-07,GCST000291,Other measurement,#d53e4f
19164,European,16094.0,19060909.0,Bouatia-Naji N,Fasting plasma glucose,replication,2008-12-07,GCST000291,Other measurement,#d53e4f
19165,European,4763.0,19060910.0,Sabatti C,Metabolic traits,initial,2008-12-07,GCST000292,Biological process,#d53e4f
19166,European,4763.0,19060910.0,Sabatti C,Metabolic traits,initial,2008-12-07,GCST000292,Lipid or lipoprotein measurement,#d53e4f
19167,European,4763.0,19060910.0,Sabatti C,Metabolic traits,initial,2008-12-07,GCST000292,Other measurement,#d53e4f
19168,European,4763.0,19060910.0,Sabatti C,Metabolic traits,initial,2008-12-07,GCST000292,Other measurement,#d53e4f
19169,European,4763.0,19060910.0,Sabatti C,LDL cholesterol,initial,2008-12-07,GCST000283,Lipid or lipoprotein measurement,#d53e4f
19170,European,21412.0,19060911.0,Aulchenko YS,HDL cholesterol,initial,2008-12-07,GCST000288,Lipid or lipoprotein measurement,#d53e4f
19171,European,4763.0,19060910.0,Sabatti C,HDL cholesterol,initial,2008-12-07,GCST000284,Lipid or lipoprotein measurement,#d53e4f
19172,European,17815.0,19060911.0,Aulchenko YS,Triglycerides,initial,2008-12-07,GCST000289,Lipid or lipoprotein measurement,#d53e4f
19173,European,17797.0,19060911.0,Aulchenko YS,LDL cholesterol,initial,2008-12-07,GCST000282,Lipid or lipoprotein measurement,#d53e4f
19174,European,22562.0,19060911.0,Aulchenko YS,"Cholesterol, total",initial,2008-12-07,GCST000285,Lipid or lipoprotein measurement,#d53e4f
19175,European,19840.0,19060906.0,Kathiresan S,Triglycerides,initial,2008-12-07,GCST000286,Lipid or lipoprotein measurement,#d53e4f
19176,European,20623.0,19060906.0,Kathiresan S,Triglycerides,replication,2008-12-07,GCST000286,Lipid or lipoprotein measurement,#d53e4f
19177,European,19840.0,19060906.0,Kathiresan S,LDL cholesterol,initial,2008-12-07,GCST000287,Lipid or lipoprotein measurement,#d53e4f
19178,European,20623.0,19060906.0,Kathiresan S,LDL cholesterol,replication,2008-12-07,GCST000287,Lipid or lipoprotein measurement,#d53e4f
19179,European,2790.0,18821565.0,Lasky-Su J,Inattentive symptoms,initial,2008-12-05,GCST000279,Biological process,#d53e4f
19180,European,2790.0,18821565.0,Lasky-Su J,Attention deficit hyperactivity disorder,initial,2008-12-05,GCST000281,Neurological disorder,#d53e4f
19181,European,2790.0,18821565.0,Lasky-Su J,Hyperactive-impulsive symptoms,initial,2008-12-05,GCST000278,Biological process,#d53e4f
19182,European,2790.0,18937294.0,Lasky-Su J,Attention deficit hyperactivity disorder (time to onset),initial,2008-12-05,GCST000280,Neurological disorder,#d53e4f
19183,European,9103.0,19056611.0,Timpson NJ,Type 2 diabetes,replication,2008-12-03,GCST000277,Metabolic disorder,#d53e4f
19184,European,4862.0,19056611.0,Timpson NJ,Type 2 diabetes,initial,2008-12-03,GCST000277,Metabolic disorder,#d53e4f
19185,European,1692.0,19047183.0,Friedman RA,Hearing impairment,initial,2008-12-01,GCST000275,Neurological disorder,#d53e4f
19186,European,130.0,19047183.0,Friedman RA,Hearing impairment,replication,2008-12-01,GCST000275,Neurological disorder,#d53e4f
19187,European,35812.0,19060907.0,Prokopenko I,Fasting plasma glucose,initial,2008-12-01,GCST000276,Other measurement,#d53e4f
19188,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19189,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19190,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19191,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19192,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Lipid or lipoprotein measurement,#d53e4f
19193,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19194,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19195,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Lipid or lipoprotein measurement,#d53e4f
19196,European,284.0,19043545.0,Gieger C,Metabolite levels,initial,2008-11-28,GCST000274,Other measurement,#d53e4f
19198,European,3972.0,18957941.0,Terracciano A,Personality dimensions,initial,2008-11-24,GCST000273,Other trait,#d53e4f
19199,Asian,2953.0,19030899.0,Lei SF,Height,replication,2008-11-23,GCST000272,Body measurement,#3288bd
19200,Asian,618.0,19030899.0,Lei SF,Height,initial,2008-11-23,GCST000272,Body measurement,#3288bd
19202,European,106.0,19023125.0,Potkin SG,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction),initial,2008-11-20,GCST000271,Neurological disorder,#d53e4f
19204,European,106.0,19023125.0,Potkin SG,Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction),initial,2008-11-20,GCST000271,Other measurement,#d53e4f
19205,European,37210.0,19011631.0,Houlston RS,Colorectal cancer,replication,2008-11-16,GCST000270,Cancer,#d53e4f
19206,European,3831.0,19011631.0,Houlston RS,Colorectal cancer,initial,2008-11-16,GCST000270,Cancer,#d53e4f
19207,European,1861.0,19010793.0,Baranzini SE,Multiple sclerosis,initial,2008-11-14,GCST000269,Immune system disorder,#d53e4f
19208,European,1677.0,19010793.0,Baranzini SE,Multiple sclerosis (severity),initial,2008-11-14,GCST000266,Immune system disorder,#d53e4f
19209,European,1674.0,19010793.0,Baranzini SE,Brain lesion load,initial,2008-11-14,GCST000265,Immune system disorder,#d53e4f
19210,European,1636.0,19010793.0,Baranzini SE,Normalized brain volume,initial,2008-11-14,GCST000268,Immune system disorder,#d53e4f
19211,European,1861.0,19010793.0,Baranzini SE,Multiple sclerosis (age of onset),initial,2008-11-14,GCST000267,Immune system disorder,#d53e4f
19212,European,1861.0,19010793.0,Baranzini SE,Multiple sclerosis (age of onset),initial,2008-11-14,GCST000267,Other measurement,#d53e4f
19213,Asian,1171.0,18997786.0,Bilguvar K,Intracranial aneurysm,replication,2008-11-09,GCST000262,Cardiovascular disease,#3288bd
19214,European,7856.0,18997786.0,Bilguvar K,Intracranial aneurysm,initial,2008-11-09,GCST000262,Cardiovascular disease,#d53e4f
19215,European,480.0,19009022.0,Drgon T,Nicotine dependence,initial,2008-11-09,GCST000264,Neurological disorder,#d53e4f
19217,European,2739.0,18997785.0,Aulchenko YS,Multiple sclerosis,replication,2008-11-09,GCST000263,Immune system disorder,#d53e4f
19218,European,240.0,18997785.0,Aulchenko YS,Multiple sclerosis,initial,2008-11-09,GCST000263,Immune system disorder,#d53e4f
19219,European,2246.0,18985386.0,Pankratz N,Parkinson's disease (familial),initial,2008-11-06,GCST000261,Neurological disorder,#d53e4f
19221,European,1890.0,18987618.0,Cronin S,Amyotrophic lateral sclerosis,initial,2008-11-05,GCST000260,Neurological disorder,#d53e4f
19222,European,2803.0,18980221.0,Neale BM,Attention deficit hyperactivity disorder,initial,2008-11-03,GCST000259,Neurological disorder,#d53e4f
19223,European,16235.0,18978792.0,Cooper JD,Type 1 diabetes,replication,2008-11-02,GCST000258,Metabolic disorder,#d53e4f
19224,European,8207.0,18978792.0,Cooper JD,Type 1 diabetes,initial,2008-11-02,GCST000258,Metabolic disorder,#d53e4f
19225,European,5431.0,18978787.0,Wang Y,Lung cancer,replication,2008-11-02,GCST000257,Cancer,#d53e4f
19226,European,10295.0,18978787.0,Wang Y,Lung cancer,initial,2008-11-02,GCST000257,Cancer,#d53e4f
19227,European,8472.0,18978790.0,McKay JD,Lung cancer,replication,2008-11-02,GCST000256,Cancer,#d53e4f
19228,European,6717.0,18978790.0,McKay JD,Lung cancer,initial,2008-11-02,GCST000256,Cancer,#d53e4f
19229,European,2605.0,18976728.0,Bertram L,Alzheimer's disease,replication,2008-10-29,GCST000255,Neurological disorder,#d53e4f
19230,European,1345.0,18976728.0,Bertram L,Alzheimer's disease,initial,2008-10-29,GCST000255,Neurological disorder,#d53e4f
19231,European,39859.0,18952825.0,Johansson A,Height,replication,2008-10-24,GCST000254,Body measurement,#d53e4f
19232,African Am./Caribbean,1148.0,18952825.0,Johansson A,Height,replication,2008-10-24,GCST000254,Body measurement,#fee08b
19233,European,3925.0,18952825.0,Johansson A,Height,initial,2008-10-24,GCST000254,Body measurement,#d53e4f
19234,European,2814.0,18951430.0,Anney RJ,Attention deficit hyperactivity disorder and conduct disorder,initial,2008-10-24,GCST000253,Neurological disorder,#d53e4f
19235,European,2814.0,18951430.0,Anney RJ,Attention deficit hyperactivity disorder and conduct disorder,initial,2008-10-24,GCST000253,Neurological disorder,#d53e4f
19236,European,1586.0,18941528.0,Comabella M,Multiple sclerosis,replication,2008-10-22,GCST000252,Immune system disorder,#d53e4f
19237,European,484.0,18941528.0,Comabella M,Multiple sclerosis,initial,2008-10-22,GCST000252,Immune system disorder,#d53e4f
19238,European,34047.0,18849993.0,Stacey SN,Basal cell carcinoma,initial,2008-10-12,GCST000249,Cancer,#d53e4f
19239,European,4060.0,18849993.0,Stacey SN,Basal cell carcinoma,replication,2008-10-12,GCST000249,Cancer,#d53e4f
19240,European,553.0,18849994.0,Hillmer AM,Male-pattern baldness,replication,2008-10-12,GCST000251,Other disease,#d53e4f
19241,European,808.0,18849994.0,Hillmer AM,Male-pattern baldness,initial,2008-10-12,GCST000251,Other disease,#d53e4f
19242,European,3836.0,18849991.0,Richards JB,Male-pattern baldness,replication,2008-10-12,GCST000250,Other disease,#d53e4f
19243,European,1125.0,18849991.0,Richards JB,Male-pattern baldness,initial,2008-10-12,GCST000250,Other disease,#d53e4f
19244,Asian,3669.0,18940312.0,Yuan X,Liver enzyme levels,replication,2008-10-10,GCST000248,Other measurement,#3288bd
19245,European,1005.0,18940312.0,Yuan X,Liver enzyme levels,replication,2008-10-10,GCST000248,Other measurement,#d53e4f
19246,European,7751.0,18940312.0,Yuan X,Liver enzyme levels,initial,2008-10-10,GCST000248,Other measurement,#d53e4f
19248,European,593.0,18839057.0,Lesch KP,Attention deficit hyperactivity disorder,initial,2008-10-07,GCST000246,Neurological disorder,#d53e4f
19249,European,2803.0,18846501.0,Sonuga-Barke EJ,Conduct disorder (maternal expressed emotions interaction),initial,2008-10-07,GCST000245,Other measurement,#d53e4f
19250,European,2803.0,18846501.0,Sonuga-Barke EJ,Conduct disorder (maternal expressed emotions interaction),initial,2008-10-07,GCST000245,Neurological disorder,#d53e4f
19251,European,2803.0,18846501.0,Sonuga-Barke EJ,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction),initial,2008-10-07,GCST000247,Neurological disorder,#d53e4f
19252,European,2803.0,18846501.0,Sonuga-Barke EJ,Attention deficit hyperactivity disorder symptoms (maternal expressed emotions interaction),initial,2008-10-07,GCST000247,Other measurement,#d53e4f
19253,European,7976.0,18840781.0,Grant SF,Type 1 diabetes,replication,2008-10-07,GCST000244,Metabolic disorder,#d53e4f
19254,European,3158.0,18840781.0,Grant SF,Type 1 diabetes,initial,2008-10-07,GCST000244,Metabolic disorder,#d53e4f
19255,European,4946.0,18836448.0,Franke A,Ulcerative colitis,replication,2008-10-05,GCST000243,Immune system disorder,#d53e4f
19256,European,1944.0,18836448.0,Franke A,Ulcerative colitis,initial,2008-10-05,GCST000243,Immune system disorder,#d53e4f
19257,European,11024.0,18834626.0,Dehghan A,Urate levels,replication,2008-10-01,GCST000242,Other measurement,#d53e4f
19258,African Am./Caribbean,3843.0,18834626.0,Dehghan A,Urate levels,replication,2008-10-01,GCST000242,Other measurement,#fee08b
19259,European,11847.0,18834626.0,Dehghan A,Urate levels,initial,2008-10-01,GCST000242,Other measurement,#d53e4f
19260,European,23919.0,18991354.0,Gretarsdottir S,Stroke (ischemic),replication,2008-10-01,GCST000239,Cardiovascular disease,#d53e4f
19261,European,12476.0,18991354.0,Gretarsdottir S,Stroke (ischemic),initial,2008-10-01,GCST000239,Cardiovascular disease,#d53e4f
19262,European,970.0,19802338.0,Chasman DI,Lipid traits,replication,2008-10-01,GCST000241,Other measurement,#d53e4f
19263,European,6382.0,19802338.0,Chasman DI,Lipid traits,initial,2008-10-01,GCST000241,Other measurement,#d53e4f
19264,European,15873.0,20031538.0,Heid IM,HDL cholesterol,replication,2008-10-01,GCST000240,Lipid or lipoprotein measurement,#d53e4f
19265,European,4274.0,20031538.0,Heid IM,HDL cholesterol,initial,2008-10-01,GCST000240,Lipid or lipoprotein measurement,#d53e4f
19266,Asian,618.0,18835860.0,Mushiroda T,Idiopathic pulmonary fibrosis,replication,2008-10-01,GCST000238,Cancer,#3288bd
19267,Asian,1093.0,18835860.0,Mushiroda T,Idiopathic pulmonary fibrosis,initial,2008-10-01,GCST000238,Cancer,#3288bd
19269,European,2321.0,18823527.0,Abraham R,Alzheimer's disease,initial,2008-09-29,GCST000237,Neurological disorder,#d53e4f
19270,African Am./Caribbean,184.0,18820697.0,Miyagawa T,Narcolepsy,replication,2008-09-28,GCST000236,Neurological disorder,#fee08b
19271,Asian,611.0,18820697.0,Miyagawa T,Narcolepsy,initial,2008-09-28,GCST000236,Neurological disorder,#3288bd
19272,Asian,773.0,18820697.0,Miyagawa T,Narcolepsy,replication,2008-09-28,GCST000236,Neurological disorder,#3288bd
19273,European,785.0,18820697.0,Miyagawa T,Narcolepsy,replication,2008-09-28,GCST000236,Neurological disorder,#d53e4f
19274,European,105.0,18821564.0,Mick E,Attention deficit hyperactivity disorder,initial,2008-09-26,GCST000235,Neurological disorder,#d53e4f
19275,Hispanic/Latin American,34.0,18821564.0,Mick E,Attention deficit hyperactivity disorder,initial,2008-09-26,GCST000235,Neurological disorder,#807dba
19276,African Am./Caribbean,26.0,18821564.0,Mick E,Attention deficit hyperactivity disorder,initial,2008-09-26,GCST000235,Neurological disorder,#fee08b
19277,Other/Mixed,22.0,18821564.0,Mick E,Attention deficit hyperactivity disorder,initial,2008-09-26,GCST000235,Neurological disorder,#99d594
19278,Other/Mixed,2346.0,18802019.0,Burkhardt R,LDL cholesterol,initial,2008-09-18,GCST000234,Lipid or lipoprotein measurement,#99d594
19279,European,413.0,18780872.0,Liu P,Lung cancer,initial,2008-09-17,GCST000233,Cancer,#d53e4f
19281,European,5965.0,18794855.0,Kiemeney LA,Urinary bladder cancer,replication,2008-09-14,GCST000231,Cancer,#d53e4f
19282,European,36139.0,18794855.0,Kiemeney LA,Urinary bladder cancer,initial,2008-09-14,GCST000231,Cancer,#d53e4f
19283,European,15853.0,18794853.0,Raychaudhuri S,Rheumatoid arthritis,initial,2008-09-14,GCST000232,Immune system disorder,#d53e4f
19284,European,9736.0,18794853.0,Raychaudhuri S,Rheumatoid arthritis,replication,2008-09-14,GCST000232,Immune system disorder,#d53e4f
19285,European,1081.0,18760390.0,Huyghe JR,Hearing impairment,initial,2008-09-12,GCST000230,Neurological disorder,#d53e4f
19286,European,1216.0,18776929.0,Liu YZ,Hip bone size,replication,2008-09-08,GCST000229,Body measurement,#d53e4f
19287,European,1000.0,18776929.0,Liu YZ,Hip bone size,initial,2008-09-08,GCST000229,Body measurement,#d53e4f
19288,European,1059.0,18776911.0,Hazra A,Vitamin B12 levels,replication,2008-09-07,GCST000228,Other measurement,#d53e4f
19289,European,1658.0,18776911.0,Hazra A,Vitamin B12 levels,initial,2008-09-07,GCST000228,Other measurement,#d53e4f
19290,Other/Mixed,868.0,18759275.0,McArdle PF,Uric acid levels,initial,2008-09-01,GCST000227,Cardiovascular measurement,#99d594
19291,European,1880.0,18762592.0,van den Oord EJ,Neuroticism,replication,2008-09-01,GCST000226,Neurological disorder,#d53e4f
19292,European,1227.0,18762592.0,van den Oord EJ,Neuroticism,initial,2008-09-01,GCST000226,Neurological disorder,#d53e4f
19293,European,1943.0,18758461.0,Di Bernardo MC,Chronic lymphocytic leukemia,initial,2008-08-31,GCST000224,Cancer,#d53e4f
19294,European,2701.0,18758461.0,Di Bernardo MC,Chronic lymphocytic leukemia,replication,2008-08-31,GCST000224,Cancer,#d53e4f
19295,European,16046.0,18758464.0,Kugathasan S,Inflammatory bowel disease,replication,2008-08-31,GCST000225,Digestive system disorder,#d53e4f
19296,European,5261.0,18758464.0,Kugathasan S,Inflammatory bowel disease,initial,2008-08-31,GCST000225,Digestive system disorder,#d53e4f
19297,European,1004.0,18729187.0,Galvan A,Lung adenocarcinoma,initial,2008-08-26,GCST000223,Cancer,#d53e4f
19298,European,9769.0,18846228.0,Weidinger S,IgE levels,replication,2008-08-22,GCST000222,Other measurement,#d53e4f
19299,European,1530.0,18846228.0,Weidinger S,IgE levels,initial,2008-08-22,GCST000222,Other measurement,#d53e4f
19300,Asian,13173.0,18711367.0,Yasuda K,Type 2 diabetes,replication,2008-08-17,GCST000219,Metabolic disorder,#3288bd
19301,European,6570.0,18711367.0,Yasuda K,Type 2 diabetes,replication,2008-08-17,GCST000219,Metabolic disorder,#d53e4f
19302,Asian,1691.0,18711367.0,Yasuda K,Type 2 diabetes,initial,2008-08-17,GCST000219,Metabolic disorder,#3288bd
19303,European,10596.0,18711365.0,Ferreira MA,Bipolar disorder,initial,2008-08-17,GCST000220,Neurological disorder,#d53e4f
19304,Asian,12361.0,18711366.0,Unoki H,Type 2 diabetes,replication,2008-08-17,GCST000221,Metabolic disorder,#3288bd
19305,Asian,1752.0,18711366.0,Unoki H,Type 2 diabetes,initial,2008-08-17,GCST000221,Metabolic disorder,#3288bd
19306,European,9387.0,18711366.0,Unoki H,Type 2 diabetes,replication,2008-08-17,GCST000221,Metabolic disorder,#d53e4f
19307,,,,,Sarcoidosis,,,GCST000218,Other disease,black
19308,European,800.0,18668548.0,Julia A,Rheumatoid arthritis,initial,2008-08-01,GCST000217,Immune system disorder,#d53e4f
19309,European,804.0,18668548.0,Julia A,Rheumatoid arthritis,replication,2008-08-01,GCST000217,Immune system disorder,#d53e4f
19310,European,2586.0,19165918.0,Graham RR,Systemic lupus erythematosus,initial,2008-08-01,GCST000216,Immune system disorder,#d53e4f
19311,European,1341.0,19165918.0,Graham RR,Systemic lupus erythematosus,replication,2008-08-01,GCST000216,Immune system disorder,#d53e4f
19314,Asian,3647.0,18677311.0,O'Donovan MC,Schizophrenia,replication,2008-07-30,GCST000215,Neurological disorder,#3288bd
19315,European,10658.0,18677311.0,O'Donovan MC,Schizophrenia,replication,2008-07-30,GCST000215,Neurological disorder,#d53e4f
19316,European,3416.0,18677311.0,O'Donovan MC,Schizophrenia,initial,2008-07-30,GCST000215,Neurological disorder,#d53e4f
19317,European,4946.0,18660810.0,Schormair B,Restless legs syndrome,replication,2008-07-27,GCST000214,Neurological disorder,#d53e4f
19318,European,2272.0,18660810.0,Schormair B,Restless legs syndrome,initial,2008-07-27,GCST000214,Neurological disorder,#d53e4f
19319,European,16664.0,18650507.0,Link E,Response to statin therapy,replication,2008-07-23,GCST000213,Response to drug,#d53e4f
19320,European,175.0,18650507.0,Link E,Response to statin therapy,initial,2008-07-23,GCST000213,Response to drug,#d53e4f
19321,European,1174.0,18723019.0,Franke A,Crohn's disease and sarcoidosis (combined),initial,2008-07-21,GCST000212,Other disease,#d53e4f
19322,European,2408.0,18723019.0,Franke A,Crohn's disease and sarcoidosis (combined),replication,2008-07-21,GCST000212,Other disease,#d53e4f
19323,European,1174.0,18723019.0,Franke A,Crohn's disease and sarcoidosis (combined),initial,2008-07-21,GCST000212,Digestive system disorder,#d53e4f
19324,European,2408.0,18723019.0,Franke A,Crohn's disease and sarcoidosis (combined),replication,2008-07-21,GCST000212,Digestive system disorder,#d53e4f
19325,European,89.0,18615156.0,Liu C,Response to TNF antagonist treatment,initial,2008-07-10,GCST000211,Response to drug,#d53e4f
19326,European,2008.0,18604267.0,Pare G,Soluble ICAM-1,replication,2008-07-04,GCST000210,Cardiovascular measurement,#d53e4f
19327,European,4570.0,18604267.0,Pare G,Soluble ICAM-1,initial,2008-07-04,GCST000210,Cardiovascular measurement,#d53e4f
19328,European,87.0,18594024.0,Sarasquete ME,Osteonecrosis of the jaw,initial,2008-07-01,GCST000209,Other disease,#d53e4f
19329,African Am./Caribbean,194.0,18591461.0,Turner ST,Response to diuretic therapy,initial,2008-06-30,GCST000208,Response to drug,#fee08b
19330,European,195.0,18591461.0,Turner ST,Response to diuretic therapy,initial,2008-06-30,GCST000208,Response to drug,#d53e4f
19331,European,8151.0,18587394.0,Barrett JC,Crohn's disease,replication,2008-06-29,GCST000207,Digestive system disorder,#d53e4f
19332,European,9541.0,18587394.0,Barrett JC,Crohn's disease,initial,2008-06-29,GCST000207,Digestive system disorder,#d53e4f
19334,European,2019.0,18576341.0,Behrens EM,Arthritis (juvenile idiopathic),initial,2008-06-24,GCST000206,Immune system disorder,#d53e4f
19335,European,654.0,18451265.0,Bouatia-Naji N,Fasting plasma glucose,initial,2008-06-19,GCST000205,Other measurement,#d53e4f
19336,European,9353.0,18451265.0,Bouatia-Naji N,Fasting plasma glucose,replication,2008-06-19,GCST000205,Other measurement,#d53e4f
19337,European,374.0,18535201.0,Cooper GM,Warfarin maintenance dose,replication,2008-06-05,GCST000204,Response to drug,#d53e4f
19338,European,181.0,18535201.0,Cooper GM,Warfarin maintenance dose,initial,2008-06-05,GCST000204,Response to drug,#d53e4f
19339,European,18436.0,18521185.0,Chen WM,Fasting plasma glucose,replication,2008-06-04,GCST000202,Other measurement,#d53e4f
19340,European,5088.0,18521185.0,Chen WM,Fasting plasma glucose,initial,2008-06-04,GCST000202,Other measurement,#d53e4f
19341,European,550.0,18519826.0,Uhl GR,Smoking cessation,initial,2008-06-04,GCST000203,Biological process,#d53e4f
19342,Other/Mixed,104.0,18521090.0,Lavedan C,Response to iloperidone treatment (PANSS-T score),replication,2008-06-03,GCST000200,Response to drug,#99d594
19343,Other/Mixed,106.0,18521090.0,Lavedan C,Response to iloperidone treatment (PANSS-T score),initial,2008-06-03,GCST000200,Response to drug,#99d594
19344,African Am./Caribbean,91.0,18521091.0,Volpi S,Response to iloperidone treatment (QT prolongation),initial,2008-06-03,GCST000201,Response to drug,#fee08b
19345,Other/Mixed,7.0,18521091.0,Volpi S,Response to iloperidone treatment (QT prolongation),initial,2008-06-03,GCST000201,Response to drug,#99d594
19346,Asian,16.0,18521091.0,Volpi S,Response to iloperidone treatment (QT prolongation),initial,2008-06-03,GCST000201,Response to drug,#3288bd
19347,European,69.0,18521091.0,Volpi S,Response to iloperidone treatment (QT prolongation),initial,2008-06-03,GCST000201,Response to drug,#d53e4f
19348,European,4305.0,18514160.0,Arnaud-Lopez L,Thyroid stimulating hormone levels,initial,2008-06-01,GCST000199,Other trait,#d53e4f
19349,European,4158.0,18514160.0,Arnaud-Lopez L,Thyroid stimulating hormone levels,replication,2008-06-01,GCST000199,Other trait,#d53e4f
19350,European,5130.0,18488028.0,Sulem P,Blue vs. green eyes,initial,2008-05-18,GCST000192,Other trait,#d53e4f
19351,European,3330.0,18488028.0,Sulem P,Blue vs. green eyes,replication,2008-05-18,GCST000192,Other trait,#d53e4f
19352,European,5130.0,18488028.0,Sulem P,Red vs. non-red hair color,initial,2008-05-18,GCST000193,Other trait,#d53e4f
19353,European,3330.0,18488028.0,Sulem P,Red vs. non-red hair color,replication,2008-05-18,GCST000193,Other trait,#d53e4f
19354,European,5130.0,18488028.0,Sulem P,Blond vs. brown hair color,initial,2008-05-18,GCST000194,Other trait,#d53e4f
19355,European,3330.0,18488028.0,Sulem P,Blond vs. brown hair color,replication,2008-05-18,GCST000194,Other trait,#d53e4f
19356,European,5130.0,18488028.0,Sulem P,Skin sensitivity to sun,initial,2008-05-18,GCST000195,Immune system disorder,#d53e4f
19357,European,3330.0,18488028.0,Sulem P,Skin sensitivity to sun,replication,2008-05-18,GCST000195,Immune system disorder,#d53e4f
19358,European,5130.0,18488028.0,Sulem P,Freckles,initial,2008-05-18,GCST000197,Other trait,#d53e4f
19359,European,3330.0,18488028.0,Sulem P,Freckles,replication,2008-05-18,GCST000197,Other trait,#d53e4f
19360,European,3330.0,18488028.0,Sulem P,Burning and freckling,replication,2008-05-18,GCST000196,Other trait,#d53e4f
19361,European,5130.0,18488028.0,Sulem P,Burning and freckling,initial,2008-05-18,GCST000196,Other trait,#d53e4f
19362,European,3330.0,18488028.0,Sulem P,Burning and freckling,replication,2008-05-18,GCST000196,Other disease,#d53e4f
19363,European,5130.0,18488028.0,Sulem P,Burning and freckling,initial,2008-05-18,GCST000196,Other disease,#d53e4f
19364,European,1728.0,18488026.0,Brown KM,Melanoma,initial,2008-05-18,GCST000198,Cancer,#d53e4f
19365,European,2481.0,18488026.0,Brown KM,Melanoma,replication,2008-05-18,GCST000198,Cancer,#d53e4f
19366,European,2287.0,18483556.0,Han J,Black vs. blond hair color,initial,2008-05-16,GCST000190,Other trait,#d53e4f
19367,European,8465.0,18483556.0,Han J,Black vs. blond hair color,replication,2008-05-16,GCST000190,Other trait,#d53e4f
19368,European,8465.0,18483556.0,Han J,Black vs. red hair color,replication,2008-05-16,GCST000191,Other trait,#d53e4f
19369,European,2287.0,18483556.0,Han J,Black vs. red hair color,initial,2008-05-16,GCST000191,Other trait,#d53e4f
19370,European,4590.0,18464913.0,Melzer D,Protein quantitative trait loci,replication,2008-05-09,GCST000189,Other measurement,#d53e4f
19371,European,1200.0,18464913.0,Melzer D,Protein quantitative trait loci,initial,2008-05-09,GCST000189,Other measurement,#d53e4f
19372,European,2848.0,18463370.0,Maris JM,Neuroblastoma,replication,2008-05-09,GCST000188,Cancer,#d53e4f
19373,European,3075.0,18463370.0,Maris JM,Neuroblastoma,initial,2008-05-09,GCST000188,Cancer,#d53e4f
19374,Hispanic/Latin American,6.0,18463975.0,Kibriya MG,Breast cancer,initial,2008-05-08,GCST000187,Cancer,#807dba
19375,European,52.0,18463975.0,Kibriya MG,Breast cancer,initial,2008-05-08,GCST000187,Cancer,#d53e4f
19376,African Am./Caribbean,2.0,18463975.0,Kibriya MG,Breast cancer,initial,2008-05-08,GCST000187,Cancer,#fee08b
19377,European,642.0,18471798.0,Valdes AM,Knee osteoarthritis,initial,2008-05-08,GCST000186,Other disease,#d53e4f
19378,European,3549.0,18471798.0,Valdes AM,Knee osteoarthritis,replication,2008-05-08,GCST000186,Other disease,#d53e4f
19379,Asian,2684.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,initial,2008-05-04,GCST000184,Body measurement,#3288bd
19380,European,4561.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Body measurement,#d53e4f
19381,Asian,7394.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Body measurement,#3288bd
19382,Asian,2684.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,initial,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#3288bd
19383,European,4561.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#d53e4f
19384,Asian,7394.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#3288bd
19385,Asian,2684.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,initial,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#3288bd
19386,European,4561.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#d53e4f
19387,Asian,7394.0,18454146.0,Chambers JC,Waist circumference and related phenotypes,replication,2008-05-04,GCST000184,Lipid or lipoprotein measurement,#3288bd
19388,European,66340.0,18454148.0,Loos RJ,Body mass index,replication,2008-05-04,GCST000185,Body measurement,#d53e4f
19389,European,16876.0,18454148.0,Loos RJ,Body mass index,initial,2008-05-04,GCST000185,Body measurement,#d53e4f
19390,European,284.0,18449908.0,Poduslo SE,Alzheimer's disease,replication,2008-04-30,GCST000183,Neurological disorder,#d53e4f
19392,European,30.0,18449908.0,Poduslo SE,Alzheimer's disease,initial,2008-04-30,GCST000183,Neurological disorder,#d53e4f
19393,European,6463.0,18455228.0,Richards JB,Bone mineral density,replication,2008-04-29,GCST000182,Other measurement,#d53e4f
19394,European,2094.0,18455228.0,Richards JB,Bone mineral density,initial,2008-04-29,GCST000182,Other measurement,#d53e4f
19395,European,7925.0,18445777.0,Styrkarsdottir U,Bone mineral density (spine),replication,2008-04-29,GCST000180,Other measurement,#d53e4f
19396,European,5861.0,18445777.0,Styrkarsdottir U,Bone mineral density (spine),initial,2008-04-29,GCST000180,Other measurement,#d53e4f
19397,European,5861.0,18445777.0,Styrkarsdottir U,Bone mineral density (hip),initial,2008-04-29,GCST000181,Other measurement,#d53e4f
19398,European,7925.0,18445777.0,Styrkarsdottir U,Bone mineral density (hip),replication,2008-04-29,GCST000181,Other measurement,#d53e4f
19399,European,5106.0,18439552.0,Reiner AP,C-reactive protein,replication,2008-04-24,GCST000179,Inflammatory measurement,#d53e4f
19400,European,909.0,18439552.0,Reiner AP,C-reactive protein,initial,2008-04-24,GCST000179,Inflammatory measurement,#d53e4f
19401,European,6345.0,18439548.0,Ridker PM,C-reactive protein,initial,2008-04-24,GCST000178,Inflammatory measurement,#d53e4f
19402,European,1140.0,18403759.0,Ober C,YKL-40 levels,replication,2008-04-09,GCST000177,Inflammatory measurement,#d53e4f
19403,European,632.0,18403759.0,Ober C,YKL-40 levels,initial,2008-04-09,GCST000177,Inflammatory measurement,#d53e4f
19404,European,17801.0,18391950.0,Lettre G,Height,replication,2008-04-06,GCST000176,Body measurement,#d53e4f
19405,European,15821.0,18391950.0,Lettre G,Height,initial,2008-04-06,GCST000176,Body measurement,#d53e4f
19406,European,13665.0,18391952.0,Weedon MN,Height,initial,2008-04-06,GCST000174,Body measurement,#d53e4f
19407,European,16482.0,18391952.0,Weedon MN,Height,replication,2008-04-06,GCST000174,Body measurement,#d53e4f
19408,European,30968.0,18391951.0,Gudbjartsson DF,Height,initial,2008-04-06,GCST000175,Body measurement,#d53e4f
19409,European,8541.0,18391951.0,Gudbjartsson DF,Height,replication,2008-04-06,GCST000175,Body measurement,#d53e4f
19410,European,737.0,18369459.0,Liu Y,Psoriasis,initial,2008-04-04,GCST000173,Immune system disorder,#d53e4f
19411,European,2370.0,18369459.0,Liu Y,Psoriasis,replication,2008-04-04,GCST000173,Immune system disorder,#d53e4f
19412,European,4848.0,18385739.0,Thorgeirsson TE,Nicotine dependence,replication,2008-04-03,GCST000171,Neurological disorder,#d53e4f
19413,European,10995.0,18385739.0,Thorgeirsson TE,Nicotine dependence,initial,2008-04-03,GCST000171,Neurological disorder,#d53e4f
19414,European,6418.0,18385676.0,Amos CI,Lung cancer,replication,2008-04-03,GCST000172,Cancer,#d53e4f
19415,European,2291.0,18385676.0,Amos CI,Lung cancer,initial,2008-04-03,GCST000172,Cancer,#d53e4f
19416,European,794.0,18385738.0,Hung RJ,Lung cancer,replication,2008-04-03,GCST000170,Cancer,#d53e4f
19417,Other/Mixed,4448.0,18385738.0,Hung RJ,Lung cancer,initial,2008-04-03,GCST000170,Cancer,#99d594
19418,Other/Mixed,6471.0,18385738.0,Hung RJ,Lung cancer,replication,2008-04-03,GCST000170,Cancer,#99d594
19419,European,10128.0,18372903.0,Zeggini E,Type 2 diabetes,initial,2008-03-30,GCST000167,Metabolic disorder,#d53e4f
19420,European,79792.0,18372903.0,Zeggini E,Type 2 diabetes,replication,2008-03-30,GCST000167,Metabolic disorder,#d53e4f
19422,European,20688.0,18372901.0,Tenesa A,Colorectal cancer,replication,2008-03-30,GCST000168,Cancer,#d53e4f
19423,Asian,7579.0,18372901.0,Tenesa A,Colorectal cancer,replication,2008-03-30,GCST000168,Cancer,#3288bd
19424,European,1983.0,18372901.0,Tenesa A,Colorectal cancer,initial,2008-03-30,GCST000168,Cancer,#d53e4f
19426,European,1849.0,18372905.0,Tomlinson IP,Colorectal cancer,initial,2008-03-30,GCST000169,Cancer,#d53e4f
19427,European,33951.0,18372905.0,Tomlinson IP,Colorectal cancer,replication,2008-03-30,GCST000169,Cancer,#d53e4f
19428,European,3529.0,18360741.0,Butcher LM,Environmental confusion in the home,replication,2008-03-25,GCST000166,Other measurement,#d53e4f
19429,European,838.0,18360741.0,Butcher LM,Environmental confusion in the home,initial,2008-03-25,GCST000166,Other measurement,#d53e4f
19430,European,4288.0,18364390.0,Capon F,Psoriasis,replication,2008-03-25,GCST000165,Immune system disorder,#d53e4f
19431,European,606.0,18364390.0,Capon F,Psoriasis,initial,2008-03-25,GCST000165,Immune system disorder,#d53e4f
19432,African Am./Caribbean,436.0,18347602.0,Sullivan PF,Schizophrenia,initial,2008-03-18,GCST000164,Neurological disorder,#fee08b
19433,Other/Mixed,207.0,18347602.0,Sullivan PF,Schizophrenia,initial,2008-03-18,GCST000164,Neurological disorder,#99d594
19434,European,828.0,18347602.0,Sullivan PF,Schizophrenia,initial,2008-03-18,GCST000164,Neurological disorder,#d53e4f
19435,European,2327.0,18332876.0,Kirov G,Schizophrenia,initial,2008-03-11,GCST000163,Neurological disorder,#d53e4f
19436,European,2359.0,18326623.0,Gold B,Breast cancer,replication,2008-03-11,GCST000162,Cancer,#d53e4f
19437,European,548.0,18326623.0,Gold B,Breast cancer,initial,2008-03-11,GCST000162,Cancer,#d53e4f
19438,European,9947.0,18327256.0,Doring A,Urate levels,replication,2008-03-09,GCST000161,Other measurement,#d53e4f
19439,European,1644.0,18327256.0,Doring A,Urate levels,initial,2008-03-09,GCST000161,Other measurement,#d53e4f
19440,European,706.0,18327257.0,Vitart V,Urate levels,replication,2008-03-09,GCST000160,Other measurement,#d53e4f
19441,European,794.0,18327257.0,Vitart V,Urate levels,initial,2008-03-09,GCST000160,Other measurement,#d53e4f
19442,European,1000.0,18325910.0,Liu YJ,Obesity,initial,2008-03-05,GCST000159,Metabolic disorder,#d53e4f
19443,European,3812.0,18325910.0,Liu YJ,Obesity,replication,2008-03-05,GCST000159,Metabolic disorder,#d53e4f
19444,European,1943.0,18317468.0,Sklar P,Bipolar disorder,replication,2008-03-04,GCST000158,Neurological disorder,#d53e4f
19445,European,3469.0,18317468.0,Sklar P,Bipolar disorder,initial,2008-03-04,GCST000158,Neurological disorder,#d53e4f
19446,European,5049.0,18311140.0,Hunt KA,Celiac disease,replication,2008-03-02,GCST000157,Immune system disorder,#d53e4f
19447,European,2189.0,18311140.0,Hunt KA,Celiac disease,initial,2008-03-02,GCST000157,Immune system disorder,#d53e4f
19448,Asian,580.0,18316681.0,Uhl GR,Methamphetamine dependence,initial,2008-03-01,GCST000156,Neurological disorder,#3288bd
19449,Other/Mixed,2931.0,18282107.0,Shifman S,Schizophrenia,initial,2008-02-15,GCST000155,Neurological disorder,#99d594
19450,Other/Mixed,4148.0,18282107.0,Shifman S,Schizophrenia,replication,2008-02-15,GCST000155,Neurological disorder,#99d594
19451,Asian,873.0,18282107.0,Shifman S,Schizophrenia,replication,2008-02-15,GCST000155,Neurological disorder,#3288bd
19452,European,5802.0,18282107.0,Shifman S,Schizophrenia,replication,2008-02-15,GCST000155,Neurological disorder,#d53e4f
19453,European,23226.0,18264098.0,Gudmundsson J,Prostate cancer,initial,2008-02-10,GCST000153,Cancer,#d53e4f
19454,European,15829.0,18264098.0,Gudmundsson J,Prostate cancer,replication,2008-02-10,GCST000153,Cancer,#d53e4f
19455,European,6634.0,18264097.0,Eeles RA,Prostate cancer,replication,2008-02-10,GCST000152,Cancer,#d53e4f
19456,European,3748.0,18264097.0,Eeles RA,Prostate cancer,initial,2008-02-10,GCST000152,Cancer,#d53e4f
19457,European,2329.0,18264096.0,Thomas G,Prostate cancer,initial,2008-02-10,GCST000154,Cancer,#d53e4f
19458,European,7905.0,18264096.0,Thomas G,Prostate cancer,replication,2008-02-10,GCST000154,Cancer,#d53e4f
19459,European,4979.0,18262040.0,Sandhu MS,LDL cholesterol,replication,2008-02-09,GCST000151,Lipid or lipoprotein measurement,#d53e4f
19460,European,11685.0,18262040.0,Sandhu MS,LDL cholesterol,initial,2008-02-09,GCST000151,Lipid or lipoprotein measurement,#d53e4f
19461,European,521.0,18245381.0,Uda M,Fetal hemoglobin levels,replication,2008-02-05,GCST000150,Hematological measurement,#d53e4f
19462,European,4305.0,18245381.0,Uda M,Fetal hemoglobin levels,initial,2008-02-05,GCST000150,Hematological measurement,#d53e4f
19467,European,2000.0,18227835.0,Berrettini W,Nicotine dependence,replication,2008-01-29,GCST000147,Neurological disorder,#d53e4f
19468,European,7481.0,18227835.0,Berrettini W,Nicotine dependence,initial,2008-01-29,GCST000147,Neurological disorder,#d53e4f
19469,European,1406.0,18252221.0,Kayser M,Iris color,initial,2008-01-24,GCST000146,Other trait,#d53e4f
19470,European,6867.0,18252221.0,Kayser M,Iris color,replication,2008-01-24,GCST000146,Other trait,#d53e4f
19471,European,3195.0,18067574.0,Butcher LM,General cognitive ability,replication,2008-01-22,GCST000145,Biological process,#d53e4f
19472,European,860.0,18067574.0,Butcher LM,General cognitive ability,initial,2008-01-22,GCST000145,Biological process,#d53e4f
19473,European,3671.0,18204446.0,Harley JB,Systemic lupus erythematosus,replication,2008-01-20,GCST000142,Immune system disorder,#d53e4f
19474,European,3037.0,18204446.0,Harley JB,Systemic lupus erythematosus,initial,2008-01-20,GCST000142,Immune system disorder,#d53e4f
19475,European,3297.0,18204447.0,Kozyrev SV,Systemic lupus erythematosus,replication,2008-01-20,GCST000143,Immune system disorder,#d53e4f
19476,European,794.0,18204447.0,Kozyrev SV,Systemic lupus erythematosus,initial,2008-01-20,GCST000143,Immune system disorder,#d53e4f
19477,European,1650.0,18204098.0,Hom G,Systemic lupus erythematosus,replication,2008-01-20,GCST000144,Immune system disorder,#d53e4f
19478,European,4651.0,18204098.0,Hom G,Systemic lupus erythematosus,initial,2008-01-20,GCST000144,Immune system disorder,#d53e4f
19479,European,3136.0,18198356.0,Hakonarson H,Type 1 diabetes,replication,2008-01-15,GCST000141,Metabolic disorder,#d53e4f
19480,European,3105.0,18198356.0,Hakonarson H,Type 1 diabetes,initial,2008-01-15,GCST000141,Metabolic disorder,#d53e4f
19481,European,206.0,18195134.0,Byun E,Response to interferon beta therapy,initial,2008-01-14,GCST000140,Response to drug,#d53e4f
19482,European,81.0,18195134.0,Byun E,Response to interferon beta therapy,replication,2008-01-14,GCST000140,Response to drug,#d53e4f
19483,European,18554.0,18193044.0,Kathiresan S,Triglycerides,replication,2008-01-13,GCST000138,Lipid or lipoprotein measurement,#d53e4f
19484,European,2758.0,18193044.0,Kathiresan S,Triglycerides,initial,2008-01-13,GCST000138,Lipid or lipoprotein measurement,#d53e4f
19485,European,8684.0,18193043.0,Willer CJ,Triglycerides,initial,2008-01-13,GCST000139,Lipid or lipoprotein measurement,#d53e4f
19486,European,9741.0,18193043.0,Willer CJ,Triglycerides,replication,2008-01-13,GCST000139,Lipid or lipoprotein measurement,#d53e4f
19487,European,8589.0,18193043.0,Willer CJ,LDL cholesterol,initial,2008-01-13,GCST000132,Lipid or lipoprotein measurement,#d53e4f
19488,European,12981.0,18193043.0,Willer CJ,LDL cholesterol,replication,2008-01-13,GCST000132,Lipid or lipoprotein measurement,#d53e4f
19489,European,2758.0,18193044.0,Kathiresan S,HDL cholesterol,initial,2008-01-13,GCST000133,Lipid or lipoprotein measurement,#d53e4f
19490,European,18554.0,18193044.0,Kathiresan S,HDL cholesterol,replication,2008-01-13,GCST000133,Lipid or lipoprotein measurement,#d53e4f
19491,European,18544.0,18193044.0,Kathiresan S,LDL cholesterol,replication,2008-01-13,GCST000134,Lipid or lipoprotein measurement,#d53e4f
19492,European,2758.0,18193044.0,Kathiresan S,LDL cholesterol,initial,2008-01-13,GCST000134,Lipid or lipoprotein measurement,#d53e4f
19493,European,11437.0,18193043.0,Willer CJ,HDL cholesterol,replication,2008-01-13,GCST000135,Lipid or lipoprotein measurement,#d53e4f
19494,European,8656.0,18193043.0,Willer CJ,HDL cholesterol,initial,2008-01-13,GCST000135,Lipid or lipoprotein measurement,#d53e4f
19495,European,23684.0,18193045.0,Sanna S,Height,replication,2008-01-13,GCST000136,Body measurement,#d53e4f
19496,European,6669.0,18193045.0,Sanna S,Height,initial,2008-01-13,GCST000136,Body measurement,#d53e4f
19497,African Am./Caribbean,3860.0,18193045.0,Sanna S,Height,replication,2008-01-13,GCST000136,Body measurement,#fee08b
19498,Asian,1181.0,18193046.0,Kooner JS,Triglycerides,replication,2008-01-13,GCST000137,Lipid or lipoprotein measurement,#3288bd
19499,European,1005.0,18193046.0,Kooner JS,Triglycerides,initial,2008-01-13,GCST000137,Lipid or lipoprotein measurement,#d53e4f
19500,Asian,1006.0,18193046.0,Kooner JS,Triglycerides,initial,2008-01-13,GCST000137,Lipid or lipoprotein measurement,#3288bd
19501,European,6827.0,18193046.0,Kooner JS,Triglycerides,replication,2008-01-13,GCST000137,Lipid or lipoprotein measurement,#d53e4f
19502,Other/Mixed,2528.0,18193046.0,Kooner JS,Triglycerides,replication,2008-01-13,GCST000137,Lipid or lipoprotein measurement,#99d594
19503,European,4955.0,18179892.0,Wallace C,LDL cholesterol,replication,2008-01-10,GCST000131,Lipid or lipoprotein measurement,#d53e4f
19504,European,1955.0,18179892.0,Wallace C,LDL cholesterol,initial,2008-01-10,GCST000131,Lipid or lipoprotein measurement,#d53e4f
19505,European,4955.0,18179892.0,Wallace C,Urate levels,replication,2008-01-10,GCST000130,Other measurement,#d53e4f
19506,European,1955.0,18179892.0,Wallace C,Urate levels,initial,2008-01-10,GCST000130,Other measurement,#d53e4f
19507,European,2269.0,18159244.0,Hinney A,Obesity (early onset extreme),replication,2007-12-26,GCST000129,Metabolic disorder,#d53e4f
19508,European,929.0,18159244.0,Hinney A,Obesity (early onset extreme),initial,2007-12-26,GCST000129,Metabolic disorder,#d53e4f
19509,European,1603.0,18073375.0,Duggan D,Prostate cancer,replication,2007-12-19,GCST000128,Cancer,#d53e4f
19510,African Am./Caribbean,556.0,18073375.0,Duggan D,Prostate cancer,replication,2007-12-19,GCST000128,Cancer,#fee08b
19511,European,2834.0,18073375.0,Duggan D,Prostate cancer,initial,2007-12-19,GCST000128,Cancer,#d53e4f
19512,European,1458.0,18084291.0,van Es MA,Amyotrophic lateral sclerosis,initial,2007-12-16,GCST000127,Neurological disorder,#d53e4f
19513,European,2225.0,18084291.0,van Es MA,Amyotrophic lateral sclerosis,replication,2007-12-16,GCST000127,Neurological disorder,#d53e4f
19514,European,432.0,18057069.0,Cronin S,Amyotrophic lateral sclerosis,initial,2007-12-07,GCST000126,Neurological disorder,#d53e4f
19515,European,1458.0,18057069.0,Cronin S,Amyotrophic lateral sclerosis,replication,2007-12-07,GCST000126,Neurological disorder,#d53e4f
19516,Asian,311.0,18075462.0,Suzuki S,Coronary spasm,replication,2007-11-17,GCST000125,Cardiovascular disease,#3288bd
19517,Asian,100.0,18075462.0,Suzuki S,Coronary spasm,initial,2007-11-17,GCST000125,Cardiovascular disease,#3288bd
19518,European,667.0,17998437.0,Li H,Alzheimer's disease,replication,2007-11-12,GCST000124,Neurological disorder,#d53e4f
19519,European,1489.0,17998437.0,Li H,Alzheimer's disease,initial,2007-11-12,GCST000124,Neurological disorder,#d53e4f
19520,European,4305.0,17997608.0,Li S,Urate levels,initial,2007-11-09,GCST000123,Other measurement,#d53e4f
19521,European,1301.0,17997608.0,Li S,Urate levels,replication,2007-11-09,GCST000123,Other measurement,#d53e4f
19522,European,1707.0,17982456.0,Plenge RM,Rheumatoid arthritis,replication,2007-11-04,GCST000122,Immune system disorder,#d53e4f
19524,European,397.0,17982456.0,Plenge RM,Rheumatoid arthritis,initial,2007-11-04,GCST000122,Immune system disorder,#d53e4f
19527,,,,,Skin sensitivity to sun,,,GCST000116,Immune system disorder,black
19528,,,,,Blue vs. brown eyes,,,GCST000120,Other trait,black
19529,,,,,Blue vs. green eyes,,,GCST000117,Other trait,black
19530,European,2986.0,17952075.0,Sulem P,Blond vs. brown hair color,initial,2007-10-21,GCST000118,Other trait,#d53e4f
19531,European,3932.0,17952075.0,Sulem P,Blond vs. brown hair color,replication,2007-10-21,GCST000118,Other trait,#d53e4f
19532,,,,,Freckles,,,GCST000119,Other trait,black
19533,,,,,Red vs non-red hair color,,,GCST000115,Other trait,black
19534,Asian,737.0,17999355.0,Stokowski RP,Skin pigmentation,initial,2007-10-15,GCST000114,Other trait,#3288bd
19535,Asian,231.0,17999355.0,Stokowski RP,Skin pigmentation,replication,2007-10-15,GCST000114,Other trait,#3288bd
19536,European,13475.0,17934461.0,Broderick P,Colorectal cancer,replication,2007-10-14,GCST000113,Cancer,#d53e4f
19537,European,1890.0,17934461.0,Broderick P,Colorectal cancer,initial,2007-10-14,GCST000113,Cancer,#d53e4f
19538,European,165.0,17911428.0,Cervino AC,Lupus,initial,2007-10-08,GCST000112,Immune system disorder,#d53e4f
19539,European,886.0,17903294.0,Yang Q,Factor VII,initial,2007-09-19,GCST000082,Other measurement,#d53e4f
19541,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Biological process,#d53e4f
19542,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Hematological measurement,#d53e4f
19543,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Hematological measurement,#d53e4f
19544,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Hematological measurement,#d53e4f
19545,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Inflammatory measurement,#d53e4f
19546,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Cardiovascular measurement,#d53e4f
19547,European,1062.0,17903294.0,Yang Q,Hemostatic factors and hematological phenotypes,initial,2007-09-19,GCST000080,Other measurement,#d53e4f
19549,European,8100.0,17903299.0,Kathiresan S,Lipid traits,replication,2007-09-19,GCST000078,Other measurement,#d53e4f
19550,European,1087.0,17903299.0,Kathiresan S,Lipid traits,initial,2007-09-19,GCST000078,Other measurement,#d53e4f
19555,European,1238.0,17903301.0,Vasan RS,Endothelial function traits,initial,2007-09-19,GCST000102,Other measurement,#d53e4f
19562,European,1951.0,17903306.0,Newton-Cheh C,Electrocardiographic traits,initial,2007-09-19,GCST000111,Cardiovascular measurement,#d53e4f
19563,European,1238.0,17903301.0,Vasan RS,Echocardiographic traits,initial,2007-09-19,GCST000110,Other measurement,#d53e4f
19564,European,1238.0,17903301.0,Vasan RS,Echocardiographic traits,initial,2007-09-19,GCST000110,Other trait,#d53e4f
19565,European,1238.0,17903301.0,Vasan RS,Echocardiographic traits,initial,2007-09-19,GCST000110,Other trait,#d53e4f
19570,European,694.0,17903297.0,Seshadri S,Cognitive test performance,initial,2007-09-19,GCST000098,Other measurement,#d53e4f
19581,European,1341.0,17903300.0,Fox CS,Body mass index,initial,2007-09-19,GCST000090,Body measurement,#d53e4f
19582,European,1238.0,17903301.0,Vasan RS,Exercise treadmill test traits,initial,2007-09-19,GCST000089,Cardiovascular measurement,#d53e4f
19583,European,705.0,17903297.0,Seshadri S,Volumetric brain MRI,initial,2007-09-19,GCST000088,Other measurement,#d53e4f
19585,European,747.0,17903306.0,Newton-Cheh C,Heart rate variability traits,initial,2007-09-19,GCST000086,Cardiovascular measurement,#d53e4f
19587,European,1079.0,17903300.0,Fox CS,Waist circumference,initial,2007-09-19,GCST000084,Body measurement,#d53e4f
19588,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Other measurement,#d53e4f
19589,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Liver enzyme measurement,#d53e4f
19590,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Inflammatory measurement,#d53e4f
19591,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Inflammatory measurement,#d53e4f
19592,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Liver enzyme measurement,#d53e4f
19593,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Cardiovascular measurement,#d53e4f
19594,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Inflammatory measurement,#d53e4f
19595,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Other measurement,#d53e4f
19596,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Other measurement,#d53e4f
19597,European,1012.0,17903293.0,Benjamin EJ,Select biomarker traits,initial,2007-09-19,GCST000083,Other measurement,#d53e4f
19598,European,4815.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#d53e4f
19599,Other/Mixed,634.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#99d594
19600,Hispanic/Latin American,603.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#807dba
19601,European,1087.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,initial,2007-09-10,GCST000073,Other measurement,#d53e4f
19602,European,4815.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#d53e4f
19603,Other/Mixed,634.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#99d594
19604,Hispanic/Latin American,603.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Other measurement,#807dba
19605,European,1087.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,initial,2007-09-10,GCST000073,Other measurement,#d53e4f
19606,European,4815.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Metabolic disorder,#d53e4f
19607,Other/Mixed,634.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Metabolic disorder,#99d594
19608,Hispanic/Latin American,603.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,replication,2007-09-10,GCST000073,Metabolic disorder,#807dba
19609,European,1087.0,17848626.0,Florez JC,Type 2 diabetes and 6 quantitative traits,initial,2007-09-10,GCST000073,Metabolic disorder,#d53e4f
19610,European,3022.0,17846126.0,Rampersaud E,Type 2 diabetes,replication,2007-09-10,GCST000076,Metabolic disorder,#d53e4f
19611,European,419.0,17846126.0,Rampersaud E,Type 2 diabetes,initial,2007-09-10,GCST000076,Metabolic disorder,#d53e4f
19612,Other/Mixed,634.0,17846126.0,Rampersaud E,Type 2 diabetes,replication,2007-09-10,GCST000076,Metabolic disorder,#99d594
19613,Hispanic/Latin American,603.0,17846126.0,Rampersaud E,Type 2 diabetes,replication,2007-09-10,GCST000076,Metabolic disorder,#807dba
19614,Hispanic/Latin American,561.0,17846124.0,Hayes MG,Type 2 diabetes,initial,2007-09-10,GCST000075,Metabolic disorder,#807dba
19615,Other/Mixed,895.0,17846124.0,Hayes MG,Type 2 diabetes,replication,2007-09-10,GCST000075,Metabolic disorder,#99d594
19616,European,1506.0,17846124.0,Hayes MG,Type 2 diabetes,replication,2007-09-10,GCST000075,Metabolic disorder,#d53e4f
19617,European,1892.0,17846125.0,Hanson RL,Type 2 diabetes,replication,2007-09-10,GCST000074,Metabolic disorder,#d53e4f
19618,Other/Mixed,2834.0,17846125.0,Hanson RL,Type 2 diabetes,replication,2007-09-10,GCST000074,Metabolic disorder,#99d594
19619,Other/Mixed,895.0,17846125.0,Hanson RL,Type 2 diabetes,initial,2007-09-10,GCST000074,Metabolic disorder,#99d594
19620,Hispanic/Latin American,760.0,17846125.0,Hanson RL,Type 2 diabetes,replication,2007-09-10,GCST000074,Metabolic disorder,#807dba
19621,European,911.0,17827064.0,van Es MA,Amyotrophic lateral sclerosis,initial,2007-09-07,GCST000072,Neurological disorder,#d53e4f
19622,European,1782.0,17827064.0,van Es MA,Amyotrophic lateral sclerosis,replication,2007-09-07,GCST000072,Neurological disorder,#d53e4f
19623,European,2911.0,17804836.0,Plenge RM,Rheumatoid arthritis,replication,2007-09-05,GCST000070,Immune system disorder,#d53e4f
19624,European,3380.0,17804836.0,Plenge RM,Rheumatoid arthritis,initial,2007-09-05,GCST000070,Immune system disorder,#d53e4f
19625,European,1146.0,17804789.0,Raelson JV,Crohn's disease,initial,2007-09-05,GCST000071,Digestive system disorder,#d53e4f
19626,European,3141.0,17804789.0,Raelson JV,Crohn's disease,replication,2007-09-05,GCST000071,Digestive system disorder,#d53e4f
19627,European,179.0,17767159.0,Menzel S,F-cell distribution,initial,2007-09-02,GCST000069,Hematological measurement,#d53e4f
19628,European,90.0,17767159.0,Menzel S,F-cell distribution,replication,2007-09-02,GCST000069,Hematological measurement,#d53e4f
19629,European,29098.0,17767157.0,Weedon MN,Height,replication,2007-09-02,GCST000068,Body measurement,#d53e4f
19630,European,4921.0,17767157.0,Weedon MN,Height,initial,2007-09-02,GCST000068,Body measurement,#d53e4f
19631,European,397.0,17690259.0,Thorleifsson G,Glaucoma (exfoliation),replication,2007-08-09,GCST000067,Neurological disorder,#d53e4f
19632,European,14649.0,17690259.0,Thorleifsson G,Glaucoma (exfoliation),initial,2007-08-09,GCST000067,Neurological disorder,#d53e4f
19633,European,792.0,17684544.0,Franke A,Crohn's disease,initial,2007-08-08,GCST000066,Digestive system disorder,#d53e4f
19634,European,6309.0,17684544.0,Franke A,Crohn's disease,replication,2007-08-08,GCST000066,Digestive system disorder,#d53e4f
19635,Other/Mixed,3.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#99d594
19636,Other/Mixed,192.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#99d594
19637,Other/Mixed,3.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#99d594
19638,African,35.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#fc8d59
19639,Asian,8.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#3288bd
19640,Hispanic/Latin American,87.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#807dba
19641,European,438.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,replication,2007-08-01,GCST000065,Neurological disorder,#d53e4f
19642,European,928.0,17671248.0,Dunckley T,Amyotrophic lateral sclerosis,initial,2007-08-01,GCST000065,Neurological disorder,#d53e4f
19643,Asian,188.0,17653210.0,Maeda S,Type 2 diabetes nephropathy,initial,2007-08-01,GCST000064,Metabolic disorder,#3288bd
19644,European,2054.0,17667963.0,Shifman S,Neuroticism,initial,2007-07-31,GCST000063,Neurological disorder,#d53e4f
19645,European,1533.0,17667963.0,Shifman S,Neuroticism,replication,2007-07-31,GCST000063,Neurological disorder,#d53e4f
19646,European,7136.0,17660530.0,Hafler DA,Multiple sclerosis,replication,2007-07-29,GCST000062,Immune system disorder,#d53e4f
19647,European,5224.0,17660530.0,Hafler DA,Multiple sclerosis,initial,2007-07-29,GCST000062,Immune system disorder,#d53e4f
19648,European,2320.0,17611496.0,Moffatt MF,Asthma,replication,2007-07-26,GCST000061,Other disease,#d53e4f
19649,European,2187.0,17611496.0,Moffatt MF,Asthma,initial,2007-07-26,GCST000061,Other disease,#d53e4f
19650,European,4741.0,17658951.0,Scuteri A,Obesity-related traits,initial,2007-07-20,GCST000060,Body measurement,#d53e4f
19651,European,1471.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#d53e4f
19652,African Am./Caribbean,968.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#fee08b
19653,Hispanic/Latin American,824.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#807dba
19654,European,4741.0,17658951.0,Scuteri A,Obesity-related traits,initial,2007-07-20,GCST000060,Body measurement,#d53e4f
19655,European,1471.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#d53e4f
19656,African Am./Caribbean,968.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#fee08b
19657,Hispanic/Latin American,824.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#807dba
19658,European,4741.0,17658951.0,Scuteri A,Obesity-related traits,initial,2007-07-20,GCST000060,Body measurement,#d53e4f
19659,European,1471.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#d53e4f
19660,African Am./Caribbean,968.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#fee08b
19661,Hispanic/Latin American,824.0,17658951.0,Scuteri A,Obesity-related traits,replication,2007-07-20,GCST000060,Body measurement,#807dba
19662,European,2206.0,17634447.0,Stefansson H,Restless legs syndrome,replication,2007-07-19,GCST000058,Neurological disorder,#d53e4f
19663,European,15970.0,17634447.0,Stefansson H,Restless legs syndrome,initial,2007-07-19,GCST000058,Neurological disorder,#d53e4f
19664,European,140.0,17641165.0,Fellay J,HIV-1 viral setpoint,replication,2007-07-19,GCST000059,Biological process,#d53e4f
19665,European,486.0,17641165.0,Fellay J,HIV-1 viral setpoint,initial,2007-07-19,GCST000059,Biological process,#d53e4f
19666,European,2519.0,17634449.0,Samani NJ,Coronary heart disease,replication,2007-07-18,GCST000057,Cardiovascular disease,#d53e4f
19667,European,4864.0,17634449.0,Samani NJ,Coronary heart disease,initial,2007-07-18,GCST000057,Cardiovascular disease,#d53e4f
19668,European,2336.0,17637780.0,Winkelmann J,Restless legs syndrome,replication,2007-07-18,GCST000056,Neurological disorder,#d53e4f
19669,European,2045.0,17637780.0,Winkelmann J,Restless legs syndrome,initial,2007-07-18,GCST000056,Neurological disorder,#d53e4f
19670,Hispanic/Latin American,334.0,17632509.0,Buch S,Gallstone disease,replication,2007-07-15,GCST000055,Digestive system disorder,#807dba
19671,European,640.0,17632509.0,Buch S,Gallstone disease,initial,2007-07-15,GCST000055,Digestive system disorder,#d53e4f
19672,European,2868.0,17632509.0,Buch S,Gallstone disease,replication,2007-07-15,GCST000055,Digestive system disorder,#d53e4f
19673,European,2503.0,17632545.0,Hakonarson H,Type 1 diabetes,replication,2007-07-15,GCST000054,Metabolic disorder,#d53e4f
19674,European,3105.0,17632545.0,Hakonarson H,Type 1 diabetes,initial,2007-07-15,GCST000054,Metabolic disorder,#d53e4f
19675,European,12580.0,17618284.0,Tomlinson I,Colorectal cancer,replication,2007-07-08,GCST000053,Cancer,#d53e4f
19676,European,1890.0,17618284.0,Tomlinson I,Colorectal cancer,initial,2007-07-08,GCST000053,Cancer,#d53e4f
19678,European,10472.0,17618283.0,Zanke BW,Colorectal cancer,replication,2007-07-08,GCST000052,Cancer,#d53e4f
19680,European,5026.0,17603472.0,Gudbjartsson DF,Atrial fibrillation/atrial flutter,initial,2007-07-01,GCST000051,Cardiovascular disease,#d53e4f
19681,European,17810.0,17603472.0,Gudbjartsson DF,Atrial fibrillation/atrial flutter,replication,2007-07-01,GCST000051,Cardiovascular disease,#d53e4f
19682,Asian,3169.0,17603472.0,Gudbjartsson DF,Atrial fibrillation/atrial flutter,replication,2007-07-01,GCST000051,Cardiovascular disease,#3288bd
19683,European,5050.0,17603485.0,Gudmundsson J,Prostate cancer,replication,2007-07-01,GCST000050,Cancer,#d53e4f
19684,European,12791.0,17603485.0,Gudmundsson J,Prostate cancer,initial,2007-07-01,GCST000050,Cancer,#d53e4f
19685,European,5349.0,17668382.0,Salonen JT,Type 2 diabetes,replication,2007-06-26,GCST000049,Metabolic disorder,#d53e4f
19686,European,997.0,17668382.0,Salonen JT,Type 2 diabetes,initial,2007-06-26,GCST000049,Metabolic disorder,#d53e4f
19687,European,2480.0,17558408.0,van Heel DA,Celiac disease,replication,2007-06-10,GCST000048,Immune system disorder,#d53e4f
19688,European,2200.0,17558408.0,van Heel DA,Celiac disease,initial,2007-06-10,GCST000048,Immune system disorder,#d53e4f
19689,European,4686.0,17554300.0,Wellcome Trust Case Control Consortium,Crohn's disease,initial,2007-06-07,GCST000042,Digestive system disorder,#d53e4f
19690,European,4901.0,17554300.0,Wellcome Trust Case Control Consortium,Type 1 diabetes,initial,2007-06-07,GCST000043,Metabolic disorder,#d53e4f
19691,European,4806.0,17554300.0,Wellcome Trust Case Control Consortium,Bipolar disorder,initial,2007-06-07,GCST000044,Neurological disorder,#d53e4f
19692,European,4864.0,17554300.0,Wellcome Trust Case Control Consortium,Coronary heart disease,initial,2007-06-07,GCST000045,Cardiovascular disease,#d53e4f
19693,European,4798.0,17554300.0,Wellcome Trust Case Control Consortium,Rheumatoid arthritis,initial,2007-06-07,GCST000040,Immune system disorder,#d53e4f
19696,European,4862.0,17554300.0,Wellcome Trust Case Control Consortium,Type 2 diabetes,initial,2007-06-07,GCST000047,Metabolic disorder,#d53e4f
19697,European,4890.0,17554300.0,Wellcome Trust Case Control Consortium,Hypertension,initial,2007-06-07,GCST000041,Cardiovascular disease,#d53e4f
19698,European,3206.0,17554261.0,Parkes M,Crohn's disease,replication,2007-06-06,GCST000039,Digestive system disorder,#d53e4f
19700,European,17991.0,17554260.0,Todd JA,Type 1 diabetes,replication,2007-06-06,GCST000038,Metabolic disorder,#d53e4f
19701,European,5000.0,17554260.0,Todd JA,Type 1 diabetes,initial,2007-06-06,GCST000038,Metabolic disorder,#d53e4f
19702,European,2287.0,17529973.0,Hunter DJ,Breast cancer,initial,2007-05-27,GCST000036,Cancer,#d53e4f
19703,European,2352.0,17529973.0,Hunter DJ,Breast cancer,replication,2007-05-27,GCST000036,Cancer,#d53e4f
19704,Other/Mixed,896.0,17529973.0,Hunter DJ,Breast cancer,replication,2007-05-27,GCST000036,Cancer,#99d594
19705,European,48565.0,17529967.0,Easton DF,Breast cancer,replication,2007-05-27,GCST000035,Cancer,#d53e4f
19706,European,754.0,17529967.0,Easton DF,Breast cancer,initial,2007-05-27,GCST000035,Cancer,#d53e4f
19707,Asian,7928.0,17529967.0,Easton DF,Breast cancer,replication,2007-05-27,GCST000035,Cancer,#3288bd
19708,Other/Mixed,441.0,17529974.0,Stacey SN,Breast cancer,replication,2007-05-27,GCST000037,Cancer,#99d594
19709,Hispanic/Latin American,840.0,17529974.0,Stacey SN,Breast cancer,replication,2007-05-27,GCST000037,Cancer,#807dba
19710,European,13145.0,17529974.0,Stacey SN,Breast cancer,initial,2007-05-27,GCST000037,Cancer,#d53e4f
19711,European,8921.0,17529974.0,Stacey SN,Breast cancer,replication,2007-05-27,GCST000037,Cancer,#d53e4f
19712,Asian,1126.0,17529974.0,Stacey SN,Breast cancer,replication,2007-05-27,GCST000037,Cancer,#3288bd
19713,African Am./Caribbean,870.0,17529974.0,Stacey SN,Breast cancer,replication,2007-05-27,GCST000037,Cancer,#fee08b
19714,European,204.0,17505501.0,Kindmark A,Response to ximelagatran treatment (increased serum alanine aminotransferase levels),initial,2007-05-15,GCST000034,Liver enzyme measurement,#d53e4f
19715,European,26.0,17505501.0,Kindmark A,Response to ximelagatran treatment (increased serum alanine aminotransferase levels),replication,2007-05-15,GCST000034,Liver enzyme measurement,#d53e4f
19716,European,204.0,17505501.0,Kindmark A,Response to ximelagatran treatment (increased serum alanine aminotransferase levels),initial,2007-05-15,GCST000034,Response to drug,#d53e4f
19717,European,26.0,17505501.0,Kindmark A,Response to ximelagatran treatment (increased serum alanine aminotransferase levels),replication,2007-05-15,GCST000034,Response to drug,#d53e4f
19718,European,1648.0,17486107.0,Baum AE,Bipolar disorder,replication,2007-05-08,GCST000033,Neurological disorder,#d53e4f
19719,European,1024.0,17486107.0,Baum AE,Bipolar disorder,initial,2007-05-08,GCST000033,Neurological disorder,#d53e4f
19720,European,517.0,17434096.0,Matarin M,Stroke,initial,2007-05-06,GCST000032,Cardiovascular disease,#d53e4f
19721,European,23791.0,17478681.0,McPherson R,Coronary heart disease,replication,2007-05-03,GCST000031,Cardiovascular disease,#d53e4f
19722,European,634.0,17478681.0,McPherson R,Coronary heart disease,initial,2007-05-03,GCST000031,Cardiovascular disease,#d53e4f
19723,European,9289.0,17478679.0,Helgadottir A,Myocardial infarction,replication,2007-05-03,GCST000030,Cardiovascular disease,#d53e4f
19724,European,8335.0,17478679.0,Helgadottir A,Myocardial infarction,initial,2007-05-03,GCST000030,Cardiovascular disease,#d53e4f
19725,European,472.0,17470457.0,Huentelman MJ,Episodic memory,replication,2007-04-30,GCST000029,Biological process,#d53e4f
19726,European,341.0,17470457.0,Huentelman MJ,Episodic memory,initial,2007-04-30,GCST000029,Biological process,#d53e4f
19727,European,4862.0,17463249.0,Zeggini E,Type 2 diabetes,initial,2007-04-26,GCST000025,Metabolic disorder,#d53e4f
19728,European,9103.0,17463249.0,Zeggini E,Type 2 diabetes,replication,2007-04-26,GCST000025,Metabolic disorder,#d53e4f
19729,European,1451.0,17463246.0,Saxena R,Apolipoprotein A1 levels,initial,2007-04-26,GCST004921,Lipid or lipoprotein measurement,#d53e4f
19730,European,2601.0,17463246.0,Saxena R,LDL cholesterol levels,initial,2007-04-26,GCST004920,Lipid or lipoprotein measurement,#d53e4f
19731,European,2623.0,17463246.0,Saxena R,HDL cholesterol levels,initial,2007-04-26,GCST004919,Lipid or lipoprotein measurement,#d53e4f
19732,European,2659.0,17463246.0,Saxena R,Triglycerides,initial,2007-04-26,GCST000026,Lipid or lipoprotein measurement,#d53e4f
19733,European,5217.0,17463246.0,Saxena R,Triglycerides,replication,2007-04-26,GCST000026,Lipid or lipoprotein measurement,#d53e4f
19734,European,8686.0,17460697.0,Steinthorsdottir V,Type 2 diabetes,initial,2007-04-26,GCST000027,Metabolic disorder,#d53e4f
19735,European,9461.0,17460697.0,Steinthorsdottir V,Type 2 diabetes,replication,2007-04-26,GCST000027,Metabolic disorder,#d53e4f
19736,European,2335.0,17463248.0,Scott LJ,Type 2 diabetes,initial,2007-04-26,GCST000024,Metabolic disorder,#d53e4f
19737,European,2473.0,17463248.0,Scott LJ,Type 2 diabetes,replication,2007-04-26,GCST000024,Metabolic disorder,#d53e4f
19738,European,2931.0,17463246.0,Saxena R,Type 2 diabetes,initial,2007-04-26,GCST000028,Metabolic disorder,#d53e4f
19739,European,10850.0,17463246.0,Saxena R,Type 2 diabetes,replication,2007-04-26,GCST000028,Metabolic disorder,#d53e4f
19743,European,10657.0,17434869.0,Frayling TM,Body mass index,initial,2007-04-12,GCST000022,Body measurement,#d53e4f
19744,European,29596.0,17434869.0,Frayling TM,Body mass index,replication,2007-04-12,GCST000022,Body measurement,#d53e4f
19745,European,454.0,17407593.0,Uhl GR,Nicotine dependence,initial,2007-04-03,GCST000021,Neurological disorder,#d53e4f
19746,African Am./Caribbean,745.0,17401366.0,Gudmundsson J,Prostate cancer,replication,2007-04-01,GCST000019,Cancer,#fee08b
19747,European,3655.0,17401366.0,Gudmundsson J,Prostate cancer,replication,2007-04-01,GCST000019,Cancer,#d53e4f
19748,European,4517.0,17401366.0,Gudmundsson J,Prostate cancer,initial,2007-04-01,GCST000019,Cancer,#d53e4f
19749,Other/Mixed,207.0,17395743.0,Hanson RL,End-stage renal disease,initial,2007-04-01,GCST000020,Other disease,#99d594
19750,European,2329.0,17401363.0,Yeager M,Prostate cancer,initial,2007-04-01,GCST000017,Cancer,#d53e4f
19751,European,6266.0,17401363.0,Yeager M,Prostate cancer,replication,2007-04-01,GCST000017,Cancer,#d53e4f
19752,European,1086.0,17474819.0,Coon KD,Alzheimer's disease (late onset),initial,2007-04-01,GCST000018,Neurological disorder,#d53e4f
19753,European,322.0,17522711.0,Lencz T,Schizophrenia,initial,2007-03-20,GCST000016,Neurological disorder,#d53e4f
19754,European,604.0,17357082.0,Melquist S,Progressive supranuclear palsy,replication,2007-03-08,GCST000015,Neurological disorder,#d53e4f
19755,European,632.0,17357082.0,Melquist S,Progressive supranuclear palsy,initial,2007-03-08,GCST000015,Neurological disorder,#d53e4f
19756,European,3109.0,17447842.0,Libioulle C,Crohn's disease,replication,2007-03-05,GCST000014,Digestive system disorder,#d53e4f
19757,European,1475.0,17447842.0,Libioulle C,Crohn's disease,initial,2007-03-05,GCST000014,Digestive system disorder,#d53e4f
19758,European,547.0,17362836.0,Schymick JC,Amyotrophic lateral sclerosis,initial,2007-02-20,GCST000013,Neurological disorder,#d53e4f
19759,European,5511.0,17293876.0,Sladek R,Type 2 diabetes,replication,2007-02-11,GCST000012,Metabolic disorder,#d53e4f
19760,European,1275.0,17293876.0,Sladek R,Type 2 diabetes,initial,2007-02-11,GCST000012,Metabolic disorder,#d53e4f
19761,European,673.0,17223258.0,Spinola M,Lung cancer,initial,2007-01-16,GCST000011,Cancer,#d53e4f
19762,European,621.0,17223258.0,Spinola M,Lung cancer,replication,2007-01-16,GCST000011,Cancer,#d53e4f
19763,European,981.0,17158188.0,Bierut LJ,Nicotine dependence,replication,2006-12-07,GCST000010,Neurological disorder,#d53e4f
19764,European,948.0,17158188.0,Bierut LJ,Nicotine dependence,initial,2006-12-07,GCST000010,Neurological disorder,#d53e4f
19765,African Am./Caribbean,920.0,17099884.0,Liu QR,Addiction,initial,2006-12-05,GCST000009,Neurological disorder,#fee08b
19766,European,740.0,17099884.0,Liu QR,Addiction,initial,2006-12-05,GCST000009,Neurological disorder,#d53e4f
19767,Other/Mixed,1584.0,17068223.0,Duerr RH,Inflammatory bowel disease,replication,2006-10-26,GCST000008,Digestive system disorder,#99d594
19768,European,1095.0,17068223.0,Duerr RH,Inflammatory bowel disease,initial,2006-10-26,GCST000008,Digestive system disorder,#d53e4f
19769,Other/Mixed,18.0,17053149.0,Papassotiropoulos A,Memory performance,replication,2006-10-20,GCST000007,Other measurement,#99d594
19770,European,662.0,17053149.0,Papassotiropoulos A,Memory performance,replication,2006-10-20,GCST000007,Other measurement,#d53e4f
19771,European,341.0,17053149.0,Papassotiropoulos A,Memory performance,initial,2006-10-20,GCST000007,Other measurement,#d53e4f
19772,Asian,226.0,17053108.0,Dewan A,Age-related macular degeneration (wet),initial,2006-10-19,GCST000006,Neurological disorder,#3288bd
19773,European,537.0,17052657.0,Fung HC,Parkinson's disease,initial,2006-09-28,GCST000005,Neurological disorder,#d53e4f
19774,European,4851.0,16648850.0,Arking DE,QT interval,replication,2006-04-30,GCST000004,Cardiovascular measurement,#d53e4f
19775,European,200.0,16648850.0,Arking DE,QT interval,initial,2006-04-30,GCST000004,Cardiovascular measurement,#d53e4f
19777,African Am./Caribbean,866.0,16614226.0,Herbert A,Obesity,replication,2006-04-14,GCST000003,Metabolic disorder,#fee08b
19778,European,10527.0,16614226.0,Herbert A,Obesity,replication,2006-04-14,GCST000003,Metabolic disorder,#d53e4f
19780,European,744.0,16252231.0,Maraganore DM,Parkinson's disease,initial,2005-09-09,GCST000002,Neurological disorder,#d53e4f
19781,Other/Mixed,141.0,16252231.0,Maraganore DM,Parkinson's disease,initial,2005-09-09,GCST000002,Neurological disorder,#99d594
19782,Asian,1.0,16252231.0,Maraganore DM,Parkinson's disease,replication,2005-09-09,GCST000002,Neurological disorder,#3288bd
19783,European,541.0,16252231.0,Maraganore DM,Parkinson's disease,replication,2005-09-09,GCST000002,Neurological disorder,#d53e4f
19784,Other/Mixed,122.0,16252231.0,Maraganore DM,Parkinson's disease,replication,2005-09-09,GCST000002,Neurological disorder,#99d594
19785,Asian,1.0,16252231.0,Maraganore DM,Parkinson's disease,initial,2005-09-09,GCST000002,Neurological disorder,#3288bd
19786,European,146.0,15761122.0,Klein RJ,Age-related macular degeneration,initial,2005-03-10,GCST000001,Neurological disorder,#d53e4f
19787,European,3213.0,28548082.0,Southam L,Fasting blood insulin,initial,2017-05-26,GCST004533,Other measurement,#d53e4f
19788,European,3213.0,28548082.0,Southam L,C-reactive protein levels,initial,2017-05-26,GCST004530,Inflammatory measurement,#d53e4f
19789,European,3213.0,28548082.0,Southam L,Diastolic blood pressure,initial,2017-05-26,GCST004531,Other measurement,#d53e4f
19790,European,3213.0,28548082.0,Southam L,Fasting blood glucose,initial,2017-05-26,GCST004532,Other measurement,#d53e4f
19791,European,3213.0,28548082.0,Southam L,Fasting blood insulin adjusted for BMI,initial,2017-05-26,GCST004762,Other measurement,#d53e4f
19792,European,3213.0,28548082.0,Southam L,Height,initial,2017-05-26,GCST004534,Body measurement,#d53e4f
19793,European,3213.0,28548082.0,Southam L,Mean corpuscular hemoglobin concentration,initial,2017-05-26,GCST004543,Hematological measurement,#d53e4f
19794,European,3213.0,28548082.0,Southam L,Mean corpuscular volume,initial,2017-05-26,GCST004544,Hematological measurement,#d53e4f
19795,European,3213.0,28548082.0,Southam L,Hematocrit,initial,2017-05-26,GCST004535,Hematological measurement,#d53e4f
19796,European,3213.0,28548082.0,Southam L,Very low density lipoprotein cholesterol levels,initial,2017-05-26,GCST004759,Lipid or lipoprotein measurement,#d53e4f
19797,European,3213.0,28548082.0,Southam L,Waist circumference,initial,2017-05-26,GCST004551,Body measurement,#d53e4f
19798,European,3213.0,28548082.0,Southam L,Waist circumference adjusted for body mass index,initial,2017-05-26,GCST004552,Body measurement,#d53e4f
19799,European,3213.0,28548082.0,Southam L,Weight,initial,2017-05-26,GCST004554,Body measurement,#d53e4f
19800,European,3213.0,28548082.0,Southam L,Waist-hip ratio,initial,2017-05-26,GCST004555,Body measurement,#d53e4f
19801,European,3213.0,28548082.0,Southam L,Waist-to-hip ratio adjusted for body mass index,initial,2017-05-26,GCST004556,Body measurement,#d53e4f
19802,European,3213.0,28548082.0,Southam L,Hemoglobin,initial,2017-05-26,GCST004536,Hematological measurement,#d53e4f
19803,European,3213.0,28548082.0,Southam L,Homeostasis model assessment of insulin resistance,initial,2017-05-26,GCST004539,Other measurement,#d53e4f
19804,European,3213.0,28548082.0,Southam L,Homeostasis model assessment of insulin resistance adjusted for BMI,initial,2017-05-26,GCST004540,Other measurement,#d53e4f
19805,European,3213.0,28548082.0,Southam L,Low density lipoprotein cholesterol levels,initial,2017-05-26,GCST004541,Lipid or lipoprotein measurement,#d53e4f
19806,European,3213.0,28548082.0,Southam L,Mean corpuscular hemoglobin,initial,2017-05-26,GCST004542,Hematological measurement,#d53e4f
19807,European,3213.0,28548082.0,Southam L,Platelet count,initial,2017-05-26,GCST004545,Hematological measurement,#d53e4f
19808,European,3213.0,28548082.0,Southam L,Red blood cell count,initial,2017-05-26,GCST004546,Hematological measurement,#d53e4f
19809,European,3213.0,28548082.0,Southam L,Systolic blood pressure,initial,2017-05-26,GCST004547,Other measurement,#d53e4f
19810,European,3213.0,28548082.0,Southam L,Total cholesterol levels,initial,2017-05-26,GCST004548,Lipid or lipoprotein measurement,#d53e4f
19811,European,3213.0,28548082.0,Southam L,Triglyceride levels,initial,2017-05-26,GCST004550,Lipid or lipoprotein measurement,#d53e4f
19812,European,3213.0,28548082.0,Southam L,White blood cell count,initial,2017-05-26,GCST004553,Hematological measurement,#d53e4f
19813,European,3213.0,28548082.0,Southam L,Body mass index,initial,2017-05-26,GCST004529,Body measurement,#d53e4f
19814,European,3213.0,28548082.0,Southam L,High density lipoprotein cholesterol levels,initial,2017-05-26,GCST004537,Lipid or lipoprotein measurement,#d53e4f
19815,European,3213.0,28548082.0,Southam L,Hip bone size,initial,2017-05-26,GCST004538,Body measurement,#d53e4f
19816,European,3213.0,28548082.0,Southam L,Hip bone size adjusted for BMI,initial,2017-05-26,GCST004760,Body measurement,#d53e4f
19817,European,3213.0,28548082.0,Southam L,Fasting blood glucose adjusted for BMI,initial,2017-05-26,GCST004761,Other measurement,#d53e4f
19824,European,33431.0,29615537.0,Kulminski AM,Death,initial,2018-03-01,GCST005762,Other trait,#d53e4f
19825,European,33431.0,29615537.0,Kulminski AM,Body mass index,initial,2018-03-01,GCST005769,Body measurement,#d53e4f
19826,European,33431.0,29615537.0,Kulminski AM,C-reactive protein levels,initial,2018-03-01,GCST005770,Inflammatory measurement,#d53e4f
19827,European,33431.0,29615537.0,Kulminski AM,Creatinine levels,initial,2018-03-01,GCST005771,Other measurement,#d53e4f
19828,European,33431.0,29615537.0,Kulminski AM,Diastolic blood pressure,initial,2018-03-01,GCST005772,Other measurement,#d53e4f
19829,European,33431.0,29615537.0,Kulminski AM,Lung function (forced vital capacity),initial,2018-03-01,GCST005773,Other measurement,#d53e4f
19830,European,33431.0,29615537.0,Kulminski AM,Heart rate,initial,2018-03-01,GCST005774,Cardiovascular measurement,#d53e4f
19831,European,33431.0,29615537.0,Kulminski AM,Hematocrit,initial,2018-03-01,GCST005775,Hematological measurement,#d53e4f
19832,European,33431.0,29615537.0,Kulminski AM,High density lipoprotein cholesterol levels,initial,2018-03-01,GCST005776,Lipid or lipoprotein measurement,#d53e4f
19833,European,33431.0,29615537.0,Kulminski AM,Systolic blood pressure,initial,2018-03-01,GCST005777,Other measurement,#d53e4f
19834,European,33431.0,29615537.0,Kulminski AM,Total cholesterol levels,initial,2018-03-01,GCST005781,Lipid or lipoprotein measurement,#d53e4f
19835,European,33431.0,29615537.0,Kulminski AM,Triglyceride levels,initial,2018-03-01,GCST005780,Lipid or lipoprotein measurement,#d53e4f
19836,European,33431.0,29615537.0,Kulminski AM,Alzheimer's disease,initial,2018-03-01,GCST005779,Neurological disorder,#d53e4f
19837,European,33431.0,29615537.0,Kulminski AM,Atrial fibrillation,initial,2018-03-01,GCST005778,Cardiovascular disease,#d53e4f
19838,European,33431.0,29615537.0,Kulminski AM,Cancer,initial,2018-03-01,GCST005768,Cancer,#d53e4f
19839,European,33431.0,29615537.0,Kulminski AM,Coronary heart disease,initial,2018-03-01,GCST005767,Cardiovascular disease,#d53e4f
19840,European,33431.0,29615537.0,Kulminski AM,Diabetes mellitus,initial,2018-03-01,GCST005766,Metabolic disorder,#d53e4f
19841,European,33431.0,29615537.0,Kulminski AM,Heart failure,initial,2018-03-01,GCST005765,Cardiovascular disease,#d53e4f
19842,European,33431.0,29615537.0,Kulminski AM,Stroke,initial,2018-03-01,GCST005764,Cardiovascular disease,#d53e4f
19843,European,33431.0,29615537.0,Kulminski AM,Blood glucose levels,initial,2018-03-01,GCST005763,Other measurement,#d53e4f
19844,Asian,2413.0,29503163.0,Yu H,Response to antipsychotic treatment in schizophrenia,initial,2018-03-01,GCST006292,Neurological disorder,#3288bd
19845,Asian,1379.0,29503163.0,Yu H,Response to antipsychotic treatment in schizophrenia,replication,2018-03-01,GCST006292,Neurological disorder,#3288bd
19846,Asian,2413.0,29503163.0,Yu H,Response to antipsychotic treatment in schizophrenia,initial,2018-03-01,GCST006292,Response to drug,#3288bd
19847,Asian,1379.0,29503163.0,Yu H,Response to antipsychotic treatment in schizophrenia,replication,2018-03-01,GCST006292,Response to drug,#3288bd
19848,Asian,192.0,29503163.0,Yu H,Response to haloperidol in schizophrenia,initial,2018-03-01,GCST006298,Neurological disorder,#3288bd
19849,Asian,192.0,29503163.0,Yu H,Response to haloperidol in schizophrenia,initial,2018-03-01,GCST006298,Response to drug,#3288bd
19850,Asian,193.0,29503163.0,Yu H,Response to perphenazine in schizophrenia,initial,2018-03-01,GCST006297,Neurological disorder,#3288bd
19851,Asian,193.0,29503163.0,Yu H,Response to perphenazine in schizophrenia,initial,2018-03-01,GCST006297,Response to drug,#3288bd
19852,Asian,408.0,29503163.0,Yu H,Response to ziprazidone in schizophrenia,initial,2018-03-01,GCST006296,Neurological disorder,#3288bd
19853,Asian,408.0,29503163.0,Yu H,Response to ziprazidone in schizophrenia,initial,2018-03-01,GCST006296,Response to drug,#3288bd
19854,Asian,386.0,29503163.0,Yu H,Response to quetiapine in schizophrenia,initial,2018-03-01,GCST006295,Neurological disorder,#3288bd
19855,Asian,386.0,29503163.0,Yu H,Response to quetiapine in schizophrenia,initial,2018-03-01,GCST006295,Response to drug,#3288bd
19856,Asian,405.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,replication,2018-03-01,GCST006285,Neurological disorder,#3288bd
19857,Asian,397.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,initial,2018-03-01,GCST006285,Neurological disorder,#3288bd
19858,Asian,405.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,replication,2018-03-01,GCST006285,Response to drug,#3288bd
19859,Asian,397.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,initial,2018-03-01,GCST006285,Response to drug,#3288bd
19860,Asian,405.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,replication,2018-03-01,GCST006285,Response to drug,#3288bd
19861,Asian,397.0,29503163.0,Yu H,Response to aripiprazole in schizophrenia,initial,2018-03-01,GCST006285,Response to drug,#3288bd
19862,Asian,559.0,29503163.0,Yu H,Response to risperidone in schizophrenia,replication,2018-03-01,GCST006294,Neurological disorder,#3288bd
19863,Asian,425.0,29503163.0,Yu H,Response to risperidone in schizophrenia,initial,2018-03-01,GCST006294,Neurological disorder,#3288bd
19864,Asian,559.0,29503163.0,Yu H,Response to risperidone in schizophrenia,replication,2018-03-01,GCST006294,Response to drug,#3288bd
19865,Asian,425.0,29503163.0,Yu H,Response to risperidone in schizophrenia,initial,2018-03-01,GCST006294,Response to drug,#3288bd
19866,Asian,415.0,29503163.0,Yu H,Response to olanzapine in schizophrenia,replication,2018-03-01,GCST006293,Neurological disorder,#3288bd
19867,Asian,412.0,29503163.0,Yu H,Response to olanzapine in schizophrenia,initial,2018-03-01,GCST006293,Neurological disorder,#3288bd
19868,Asian,415.0,29503163.0,Yu H,Response to olanzapine in schizophrenia,replication,2018-03-01,GCST006293,Response to drug,#3288bd
19869,Asian,412.0,29503163.0,Yu H,Response to olanzapine in schizophrenia,initial,2018-03-01,GCST006293,Response to drug,#3288bd
19874,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Immune system disorder,#fc8d59
19875,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Immune system disorder,#3288bd
19876,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Immune system disorder,#807dba
19877,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Immune system disorder,#d53e4f
19879,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Response to drug,#fc8d59
19880,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Response to drug,#3288bd
19881,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Response to drug,#807dba
19882,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Response to drug,#d53e4f
19884,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Other measurement,#fc8d59
19885,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Other measurement,#3288bd
19886,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Other measurement,#807dba
19887,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (presence of antibodies),initial,2018-03-01,GCST005706,Other measurement,#d53e4f
19889,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Immune system disorder,#fc8d59
19890,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Immune system disorder,#3288bd
19891,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Immune system disorder,#807dba
19892,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Immune system disorder,#d53e4f
19894,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Response to drug,#fc8d59
19895,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Response to drug,#3288bd
19896,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Response to drug,#807dba
19897,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Response to drug,#d53e4f
19899,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Other measurement,#fc8d59
19900,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Other measurement,#3288bd
19901,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Other measurement,#807dba
19902,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (mean antibody levels),initial,2018-03-01,GCST005707,Other measurement,#d53e4f
19904,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Immune system disorder,#fc8d59
19905,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Immune system disorder,#3288bd
19906,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Immune system disorder,#807dba
19907,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Immune system disorder,#d53e4f
19909,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Response to drug,#fc8d59
19910,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Response to drug,#3288bd
19911,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Response to drug,#807dba
19912,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Response to drug,#d53e4f
19914,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Other measurement,#fc8d59
19915,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Other measurement,#3288bd
19916,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Other measurement,#807dba
19917,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (area under the curve for the first two years),initial,2018-03-01,GCST005708,Other measurement,#d53e4f
19918,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Immune system disorder,#fc8d59
19919,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Immune system disorder,#3288bd
19920,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Immune system disorder,#807dba
19921,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Immune system disorder,#d53e4f
19923,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Response to drug,#fc8d59
19924,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Response to drug,#3288bd
19925,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Response to drug,#807dba
19926,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Response to drug,#d53e4f
19928,African,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Other measurement,#fc8d59
19929,Asian,1.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Other measurement,#3288bd
19930,Hispanic/Latin American,7.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Other measurement,#807dba
19931,European,926.0,29521573.0,Buck D,Neutralising antibody response to interferon beta therapy in multiple sclerosis (maximum antibody levels),initial,2018-03-01,GCST005709,Other measurement,#d53e4f
19933,European,1161.0,22841784.0,Patin E,Hepatitis C induced liver fibrosis,initial,2012-07-26,GCST001623,Digestive system disorder,#d53e4f
19934,European,1181.0,22841784.0,Patin E,Hepatitis C induced liver fibrosis,replication,2012-07-26,GCST001623,Digestive system disorder,#d53e4f
19935,European,1161.0,22841784.0,Patin E,Hepatitis C induced liver fibrosis,initial,2012-07-26,GCST001623,Cancer,#d53e4f
19936,European,1181.0,22841784.0,Patin E,Hepatitis C induced liver fibrosis,replication,2012-07-26,GCST001623,Cancer,#d53e4f
19937,European,2565.0,29562276.0,Venkateswaran S,Childhood onset ulcerative colitis,initial,2018-03-01,GCST005815,Immune system disorder,#d53e4f
19938,European,356.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),replication,2018-03-01,GCST007358,Response to drug,#d53e4f
19939,European,181.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),initial,2018-03-01,GCST007358,Response to drug,#d53e4f
19940,European,356.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),replication,2018-03-01,GCST007358,Other measurement,#d53e4f
19941,European,181.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),initial,2018-03-01,GCST007358,Other measurement,#d53e4f
19942,European,356.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),replication,2018-03-01,GCST007358,Cancer,#d53e4f
19943,European,181.0,30207284.0,Galvan-Femenia I,Response to platinum-based chemotherapy in non-small-cell lung cancer (progression),initial,2018-03-01,GCST007358,Cancer,#d53e4f
19944,European,6739.0,22837380.0,Fischer A,Sarcoidosis,replication,2012-07-26,GCST001622,Other disease,#d53e4f
19945,European,2139.0,22837380.0,Fischer A,Sarcoidosis,initial,2012-07-26,GCST001622,Other disease,#d53e4f
